
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
        <link rel="canonical" href="https://vimbook.beauhilton.com/print_page/">
      
      <link rel="icon" href="../images/vumc-favicon.png">
      <meta name="generator" content="mkdocs-1.3.0, mkdocs-material-8.3.6">
    
    
      
        <title>Print Site - VUMC IM Residency Handbook</title>
      
    
    
      <link rel="stylesheet" href="../assets/stylesheets/main.4a0965b7.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.cbb835fc.min.css">
        
      
      
    
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=IBM+Plex+Sans:300,300i,400,400i,700,700i%7CIBM+Plex+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"IBM Plex Sans";--md-code-font:"IBM Plex Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../css/print-site-enum-headings2.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings3.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings4.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings5.css">
    
      <link rel="stylesheet" href="../css/print-site-enum-headings6.css">
    
      <link rel="stylesheet" href="../css/print-site.css">
    
      <link rel="stylesheet" href="../css/print-site-material.css">
    
      <link rel="stylesheet" href="../stylesheets/extra.css">
    
    <script>__md_scope=new URL("/",location),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      
  


  
  


  <script>window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)},ga.l=+new Date,ga("create","UA-105678972-1","auto"),ga("set","anonymizeIp",!0),ga("send","pageview"),document.addEventListener("DOMContentLoaded",function(){document.forms.search&&document.forms.search.query.addEventListener("blur",function(){var e;this.value&&(e=document.location.pathname,ga("send","pageview",e+"?q="+this.value))}),"undefined"!=typeof location$&&location$.subscribe(function(e){ga("send","pageview",e.pathname)})})</script>
  <script async src="https://www.google-analytics.com/analytics.js"></script>


    
    
 <link rel="apple-touch-icon" sizes="256x256" href="/images/apple-touch-icon.png">

  
        <script type="text/javascript">
        document.addEventListener('DOMContentLoaded', function () {
            remove_material_navigation();remove_mkdocs_theme_navigation();generate_toc();
        })
        </script>
        </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="black" data-md-color-accent="amber">
  
    
    
      <script>var palette=__md_get("__palette");if(palette&&"object"==typeof palette.color)for(var key of Object.keys(palette.color))document.body.setAttribute("data-md-color-"+key,palette.color[key])</script>
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="VUMC IM Residency Handbook" class="md-header__button md-logo" aria-label="VUMC IM Residency Handbook" data-md-component="logo">
      
  <img src="../images/vumc-favicon.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            VUMC IM Residency Handbook
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Print Site
            
          </span>
        </div>
      </div>
    </div>
    
      <form class="md-header__option" data-md-component="palette">
        
          
          
          <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="black" data-md-color-accent="amber"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_1">
          
            <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_2" hidden>
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
            </label>
          
        
          
          
          <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="black" data-md-color-accent="amber"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_2">
          
            <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_1" hidden>
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
            </label>
          
        
      </form>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
          <a href="javascript:void(0)" class="md-search__icon md-icon" aria-label="Share" data-clipboard data-clipboard-text="" data-md-component="search-share" tabindex="-1">
            <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M18 16.08c-.76 0-1.44.3-1.96.77L8.91 12.7c.05-.23.09-.46.09-.7 0-.24-.04-.47-.09-.7l7.05-4.11c.54.5 1.25.81 2.04.81a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3c0 .24.04.47.09.7L8.04 9.81C7.5 9.31 6.79 9 6 9a3 3 0 0 0-3 3 3 3 0 0 0 3 3c.79 0 1.5-.31 2.04-.81l7.12 4.15c-.05.21-.08.43-.08.66 0 1.61 1.31 2.91 2.92 2.91 1.61 0 2.92-1.3 2.92-2.91A2.92 2.92 0 0 0 18 16.08Z"/></svg>
          </a>
        
        <button type="reset" class="md-search__icon md-icon" aria-label="Clear" tabindex="-1">
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/vanderbilt-internal-medicine/vimbook" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--! Font Awesome Free 6.1.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2022 Fonticons, Inc.--><path d="M439.55 236.05 244 40.45a28.87 28.87 0 0 0-40.81 0l-40.66 40.63 51.52 51.52c27.06-9.14 52.68 16.77 43.39 43.68l49.66 49.66c34.23-11.8 61.18 31 35.47 56.69-26.49 26.49-70.21-2.87-56-37.34L240.22 199v121.85c25.3 12.54 22.26 41.85 9.08 55a34.34 34.34 0 0 1-48.55 0c-17.57-17.6-11.07-46.91 11.25-56v-123c-20.8-8.51-24.6-30.74-18.64-45L142.57 101 8.45 235.14a28.86 28.86 0 0 0 0 40.81l195.61 195.6a28.86 28.86 0 0 0 40.8 0l194.69-194.69a28.86 28.86 0 0 0 0-40.81z"/></svg>
  </div>
  <div class="md-source__repository">
    GitHub
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="VUMC IM Residency Handbook" class="md-nav__button md-logo" aria-label="VUMC IM Residency Handbook" data-md-component="logo">
      
  <img src="../images/vumc-favicon.png" alt="logo">

    </a>
    VUMC IM Residency Handbook
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/vanderbilt-internal-medicine/vimbook" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--! Font Awesome Free 6.1.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2022 Fonticons, Inc.--><path d="M439.55 236.05 244 40.45a28.87 28.87 0 0 0-40.81 0l-40.66 40.63 51.52 51.52c27.06-9.14 52.68 16.77 43.39 43.68l49.66 49.66c34.23-11.8 61.18 31 35.47 56.69-26.49 26.49-70.21-2.87-56-37.34L240.22 199v121.85c25.3 12.54 22.26 41.85 9.08 55a34.34 34.34 0 0 1-48.55 0c-17.57-17.6-11.07-46.91 11.25-56v-123c-20.8-8.51-24.6-30.74-18.64-45L142.57 101 8.45 235.14a28.86 28.86 0 0 0 0 40.81l195.61 195.6a28.86 28.86 0 0 0 40.8 0l194.69-194.69a28.86 28.86 0 0 0 0-40.81z"/></svg>
  </div>
  <div class="md-source__repository">
    GitHub
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
      

  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        Home
      </a>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_2" type="checkbox" id="__nav_2" >
      
      
      
      
        <label class="md-nav__link" for="__nav_2">
          Introduction
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Introduction" data-md-level="1">
        <label class="md-nav__title" for="__nav_2">
          <span class="md-nav__icon md-icon"></span>
          Introduction
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-acknowledgements/" class="md-nav__link">
        Acknowledgements
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-authors-editors-reviewers/" class="md-nav__link">
        Editors, Authors, and Reviewers
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-disclaimers/" class="md-nav__link">
        Disclaimers
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-rationale/" class="md-nav__link">
        Rationale
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../introduction/introduction-web-app-setup/" class="md-nav__link">
        Web App Setup
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_3" type="checkbox" id="__nav_3" >
      
      
      
      
        <label class="md-nav__link" for="__nav_3">
          Cardiology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Cardiology" data-md-level="1">
        <label class="md-nav__title" for="__nav_3">
          <span class="md-nav__icon md-icon"></span>
          Cardiology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-acs/" class="md-nav__link">
        Acute Coronary Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-arrhythmias/" class="md-nav__link">
        Arrhythmias
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-atrial-fibrillation-and-flutter/" class="md-nav__link">
        Atrial Fibrillation & Flutter
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-autonomics-and-orthostatics/" class="md-nav__link">
        Autonomics and Orthostatic Hypotension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-bedside-echocardiography/" class="md-nav__link">
        Bedside Echocardiography
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-cardiac-devices/" class="md-nav__link">
        Cardiac Devices
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-chest-pain/" class="md-nav__link">
        Chest Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-chf/" class="md-nav__link">
        Heart Failure
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-ekg/" class="md-nav__link">
        Approach to the ECG
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-inpatient-hypertension/" class="md-nav__link">
        Inpatient Hypertension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-pe/" class="md-nav__link">
        Pulmonary Embolism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-rhc/" class="md-nav__link">
        Right Heart Catheterization
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-shock/" class="md-nav__link">
        Cardiogenic Shock
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-syncope/" class="md-nav__link">
        Syncope
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../cardiology/cardiology-valvular-heart-disease/" class="md-nav__link">
        Valvular Heart Disease
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_4" type="checkbox" id="__nav_4" >
      
      
      
      
        <label class="md-nav__link" for="__nav_4">
          Critical care
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Critical care" data-md-level="1">
        <label class="md-nav__title" for="__nav_4">
          <span class="md-nav__icon md-icon"></span>
          Critical care
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-abcdef-a2f-bundle/" class="md-nav__link">
        ABCDEF (A2F) Bundle
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-ards/" class="md-nav__link">
        Acute Respiratory Distress Syndrome (ARDS)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-brain-death/" class="md-nav__link">
        Brain Death
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-codes/" class="md-nav__link">
        Running Codes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-drips/" class="md-nav__link">
        MICU/CCU Drips
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-intubation-extubation/" class="md-nav__link">
        Intubation and Extubation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-modes-oxygen-delivery/" class="md-nav__link">
        Modes of Oxygen Delivery
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-refractory-hypercapnia/" class="md-nav__link">
        Refractory Hypercapnia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-refractory-hypoxemia/" class="md-nav__link">
        Refractory Hypoxemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-sepsis/" class="md-nav__link">
        Sepsis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-shock/" class="md-nav__link">
        Management of Shock
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-temperature-abnormalities/" class="md-nav__link">
        Temperature Abnormalities
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-tracheostomy/" class="md-nav__link">
        Tracheostomy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-ultrasound/" class="md-nav__link">
        Ultrasound in Critical Care
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../critical-care/critical-care-vent-settings/" class="md-nav__link">
        Introduction to Vent Management
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_5" type="checkbox" id="__nav_5" >
      
      
      
      
        <label class="md-nav__link" for="__nav_5">
          Demo
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Demo" data-md-level="1">
        <label class="md-nav__title" for="__nav_5">
          <span class="md-nav__icon md-icon"></span>
          Demo
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../demo/demo-lights/" class="md-nav__link">
        Pleural Effusions
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_6" type="checkbox" id="__nav_6" >
      
      
      
      
        <label class="md-nav__link" for="__nav_6">
          Endocrinology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Endocrinology" data-md-level="1">
        <label class="md-nav__title" for="__nav_6">
          <span class="md-nav__icon md-icon"></span>
          Endocrinology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-adrenal-incidentalomas/" class="md-nav__link">
        Adrenal Incidentalomas
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-adrenal-insufficiency/" class="md-nav__link">
        Adrenal Insufficiency
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-diabetes-inpatient-management/" class="md-nav__link">
        Inpatient Diabetes Mellitus (DM)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-dka/" class="md-nav__link">
        Diabetic Ketoacidosis (DKA)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-hyperthyroidism/" class="md-nav__link">
        Hyperthyroidism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-hypoglycemia/" class="md-nav__link">
        Hypoglycemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-hypothyroidism/" class="md-nav__link">
        Hypothyroidism
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-severe-hypertriglyceridemia/" class="md-nav__link">
        Severe Hypertriglyceridemia (HTG)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-steroid-conversions/" class="md-nav__link">
        Steroid Conversions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-stress-dose-steroids/" class="md-nav__link">
        Stress Dose Steroids
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-thyroid-nodules/" class="md-nav__link">
        Thyroid Nodules
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/endocrinology-thyroid-storm/" class="md-nav__link">
        Thyroid Storm
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../endocrinology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_7" type="checkbox" id="__nav_7" >
      
      
      
      
        <label class="md-nav__link" for="__nav_7">
          Gastroenterology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Gastroenterology" data-md-level="1">
        <label class="md-nav__title" for="__nav_7">
          <span class="md-nav__icon md-icon"></span>
          Gastroenterology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-acute-abdominal-pain/" class="md-nav__link">
        Acute Abdominal Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-acute-diverticulitis/" class="md-nav__link">
        Acute Diverticulitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-acute-pancreatitis/" class="md-nav__link">
        Acute Pancreatitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-biliary-disease/" class="md-nav__link">
        Biliary Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-c-diff/" class="md-nav__link">
        Clostridioides Difficile Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-chronic-pancreatitis/" class="md-nav__link">
        Chronic Pancreatitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-constipation/" class="md-nav__link">
        Constipation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-diarrhea/" class="md-nav__link">
        Diarrhea
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-esophageal-disorders/" class="md-nav__link">
        Esophageal Disorders
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-gastroparesis/" class="md-nav__link">
        Gastroparesis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-gi-bleeding/" class="md-nav__link">
        GI Bleeding
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-gi-covid/" class="md-nav__link">
        GI Manifestations of COVID
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-ibs/" class="md-nav__link">
        Irritable Bowel Syndrome
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-inflammatory-bowel-disease/" class="md-nav__link">
        Inflammatory Bowel Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-intestinal-ischemia/" class="md-nav__link">
        Intestinal Ischemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-nausea-vomiting/" class="md-nav__link">
        Nausea & Vomiting
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-peptic-ulcer-disease/" class="md-nav__link">
        Peptic Ulcer Disease
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../gastroenterology/gastroenterology-small-bowel-obstruction/" class="md-nav__link">
        Small Bowel Obstruction (SBO)
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_8" type="checkbox" id="__nav_8" >
      
      
      
      
        <label class="md-nav__link" for="__nav_8">
          Geriatrics
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Geriatrics" data-md-level="1">
        <label class="md-nav__title" for="__nav_8">
          <span class="md-nav__icon md-icon"></span>
          Geriatrics
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-dementia/" class="md-nav__link">
        Dementia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-falls/" class="md-nav__link">
        Falls
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-frailty/" class="md-nav__link">
        Frailty
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-functional-status/" class="md-nav__link">
        Functional Status
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-malnutrition/" class="md-nav__link">
        Malnutrition
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-medication-management/" class="md-nav__link">
        Medication Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-overview/" class="md-nav__link">
        Geriatrics Overview
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../geriatrics/geriatrics-urinary-incontinence-and-foley-catheter/" class="md-nav__link">
        Urinary Incontinence and Foley Catheters
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_9" type="checkbox" id="__nav_9" >
      
      
      
      
        <label class="md-nav__link" for="__nav_9">
          Hematology oncology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hematology oncology" data-md-level="1">
        <label class="md-nav__title" for="__nav_9">
          <span class="md-nav__icon md-icon"></span>
          Hematology oncology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-anemia/" class="md-nav__link">
        Anemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-anticoagulation/" class="md-nav__link">
        Anticoagulation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-bone-marrow-transplant/" class="md-nav__link">
        Bone Marrow Transplant
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-chemotherapy-toxicity/" class="md-nav__link">
        Chemotherapy Toxicity
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-coagulopathies/" class="md-nav__link">
        Coagulopathies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-dic/" class="md-nav__link">
        DIC
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-dvts/" class="md-nav__link">
        DVTs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-hypercoagulable-states/" class="md-nav__link">
        Hypercoagulable States
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-leukemia/" class="md-nav__link">
        Leukemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-lymphoma/" class="md-nav__link">
        Lymphoma
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-medical-oncology-resources/" class="md-nav__link">
        Medical Oncology Resources
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-myelodysplastic-syndromes/" class="md-nav__link">
        Myelodysplastic Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-myeloproliferative-neoplasms/" class="md-nav__link">
        Myeloproliferative Neoplasms
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-neutropenia-and-neutropenic-fever/" class="md-nav__link">
        Neutropenia and Neutropenic Fever
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-oncologic-emergencies/" class="md-nav__link">
        Oncologic Emergencies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-paraneoplastic-syndromes/" class="md-nav__link">
        Paraneoplastic Syndromes
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-plasma-cell-dyscrasias/" class="md-nav__link">
        Plasma Cell Dyscrasias
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-sickle-cell-crisis/" class="md-nav__link">
        Sickle Cell Crisis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-thrombocytopenia/" class="md-nav__link">
        Thrombocytopenia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/hematologyoncology-transfusion-medicine/" class="md-nav__link">
        Transfusion Medicine
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hematology-oncology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_10" type="checkbox" id="__nav_10" >
      
      
      
      
        <label class="md-nav__link" for="__nav_10">
          Hepatology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hepatology" data-md-level="1">
        <label class="md-nav__title" for="__nav_10">
          <span class="md-nav__icon md-icon"></span>
          Hepatology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-acute-liver-failure/" class="md-nav__link">
        Acute Liver Injury and Failure
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-alcoholic-hepatitis/" class="md-nav__link">
        Alcoholic Hepatitis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-ascites/" class="md-nav__link">
        Ascites and Hepatic Hydrothorax
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-cirrhosis/" class="md-nav__link">
        Cirrhosis Overview
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-coagulopathy/" class="md-nav__link">
        Coagulopathy in Cirrhosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-hepatic-encephalopathy/" class="md-nav__link">
        Hepatic Encephalopathy (HE)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-hepatocellular-carcinoma/" class="md-nav__link">
        Hepatocellular Carcinoma (HCC)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-hepatorenal-syndrome/" class="md-nav__link">
        Hepatorenal Syndrome
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-hyponatremia-cirrhosis/" class="md-nav__link">
        Hyponatremia in Cirrhosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-liver-transplantation/" class="md-nav__link">
        Liver Transplant (LT) Workup
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-medication-pearls/" class="md-nav__link">
        Medication Pearls
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-nash-and-nafld/" class="md-nav__link">
        NASH and NAFLD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-portal-vein-thrombosis/" class="md-nav__link">
        Portal Vein Thrombosis (PVT)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-post-liver-transplant-management/" class="md-nav__link">
        Post-Liver Transplant Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-sbp/" class="md-nav__link">
        Spontaneous Bacterial Peritonitis (SBP)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-tips/" class="md-nav__link">
        Transjugular Intrahepatic Portosystemic Shunt (TIPS)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/hepatology-upper-gi-bleed-cirrhosis/" class="md-nav__link">
        Gastroesophageal Varices and Hemorrhage
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hepatology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_11" type="checkbox" id="__nav_11" >
      
      
      
      
        <label class="md-nav__link" for="__nav_11">
          Hospital medicine
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Hospital medicine" data-md-level="1">
        <label class="md-nav__title" for="__nav_11">
          <span class="md-nav__icon md-icon"></span>
          Hospital medicine
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-enteral-nutrition/" class="md-nav__link">
        Enteral Nutrition
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-guidelines-pregnant-patients/" class="md-nav__link">
        Guidelines for Pregnant Patients
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-lines-and-catheters/" class="md-nav__link">
        Lines and Catheters
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-mobility-and-hospital-therapy/" class="md-nav__link">
        Mobility and In-Hospital Therapy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-telemetry/" class="md-nav__link">
        Telemetry
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-transitions-of-care/" class="md-nav__link">
        Transitions of Care: Tips for Safe Discharges
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/hospital-medicine-wounds/" class="md-nav__link">
        Wounds − Adapted from Dr. Duggan’s Geriatrics Guide
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../hospital-medicine/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_12" type="checkbox" id="__nav_12" >
      
      
      
      
        <label class="md-nav__link" for="__nav_12">
          Infectious diseases
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Infectious diseases" data-md-level="1">
        <label class="md-nav__title" for="__nav_12">
          <span class="md-nav__icon md-icon"></span>
          Infectious diseases
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-disease-sexually-transmitted-diseases/" class="md-nav__link">
        Sexually Transmitted Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-aids-defining-conditions/" class="md-nav__link">
        AIDS Defining Conditions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-antimicrobial-prophylaxis/" class="md-nav__link">
        Antimicrobial prophylaxis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-bacteremia/" class="md-nav__link">
        Bacteremia: Interpreting GenMark ePlex® Results – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-brief-overview-art/" class="md-nav__link">
        Brief Overview of ART
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-cns-infection/" class="md-nav__link">
        Central Nervous System Infection – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-community-acquired-pneumonia/" class="md-nav__link">
        Community Acquired Pneumonia (CAP)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-diabetic-foot-infection/" class="md-nav__link">
        Diabetic Foot Infection – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-endocarditis/" class="md-nav__link">
        Endocarditis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-febrile-neutropenia/" class="md-nav__link">
        Febrile Neutropenia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-fungal-infections/" class="md-nav__link">
        Fungal Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-general-tips/" class="md-nav__link">
        General Tips
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-gu-infection/" class="md-nav__link">
        Genitourinary Infection – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-hap-and-vap/" class="md-nav__link">
        Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-hiv-art-general-concepts/" class="md-nav__link">
        HIV/AIDS and ART
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-inpatient-covid19/" class="md-nav__link">
        Inpatient COVID-19 Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-orthopedic-infection/" class="md-nav__link">
        Joint Infections and Osteomyelitis – VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-pulmonary-infections/" class="md-nav__link">
        Pulmonary Infections
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/infectious-diseases-ssti/" class="md-nav__link">
        Skin and Soft Tissue Infection (SSTI) - VASP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../infectious-diseases/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_13" type="checkbox" id="__nav_13" >
      
      
      
      
        <label class="md-nav__link" for="__nav_13">
          Nephrology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Nephrology" data-md-level="1">
        <label class="md-nav__title" for="__nav_13">
          <span class="md-nav__icon md-icon"></span>
          Nephrology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-acute-rejection/" class="md-nav__link">
        Acute Rejection
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-aki/" class="md-nav__link">
        AKI
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-approach-ckd/" class="md-nav__link">
        Approach to CKD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-common-side-effects-renal-transplant-immune-suppresants/" class="md-nav__link">
        Common Side Effects of Renal Transplant Immune Suppresants
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hematuria/" class="md-nav__link">
        Hematuria
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypercalcemia/" class="md-nav__link">
        Hypercalcemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hyperkalemia/" class="md-nav__link">
        Hyperkalemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypernatremia/" class="md-nav__link">
        Hypernatremia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hyperphosphatemia/" class="md-nav__link">
        Hyperphosphatemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypokalemia/" class="md-nav__link">
        Hypokalemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypomagnesemia/" class="md-nav__link">
        Hypomagnesemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hyponatremia/" class="md-nav__link">
        Hyponatremia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-hypophosphatemia/" class="md-nav__link">
        Hypophosphatemia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-metabolic-acidosis/" class="md-nav__link">
        Metabolic acidosis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-peritonitis-patients-pd/" class="md-nav__link">
        Peritonitis in patients on PD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-renal-replacement-therapy/" class="md-nav__link">
        Renal Replacement Therapy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-transplant-aki/" class="md-nav__link">
        Transplant AKI
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-ua/" class="md-nav__link">
        UA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../nephrology/nephrology-uti-renal-transplant/" class="md-nav__link">
        UTI in Renal Transplant
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_14" type="checkbox" id="__nav_14" >
      
      
      
      
        <label class="md-nav__link" for="__nav_14">
          Neurology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Neurology" data-md-level="1">
        <label class="md-nav__title" for="__nav_14">
          <span class="md-nav__icon md-icon"></span>
          Neurology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-aidp/" class="md-nav__link">
        AIDP
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-als/" class="md-nav__link">
        ALS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-ams/" class="md-nav__link">
        AMS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-basic-seizures/" class="md-nav__link">
        Seizures
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-brain-masses/" class="md-nav__link">
        Brain Masses
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-elevated-icp-and-hydrocephalus/" class="md-nav__link">
        Elevated ICP and Hydrocephalus
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-inpatient-headache/" class="md-nav__link">
        Inpatient Headache
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-ms/" class="md-nav__link">
        MS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-myasthenia-etc/" class="md-nav__link">
        Myasthenia etc
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-outpatient-headache/" class="md-nav__link">
        Outpatient Headache
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-parkinson/" class="md-nav__link">
        Parkinson
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-status-epilepticus/" class="md-nav__link">
        Status Epilepticus
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-stroke-0/" class="md-nav__link">
        Stroke
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../neurology/neurology-vertigo/" class="md-nav__link">
        Vertigo
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_15" type="checkbox" id="__nav_15" >
      
      
      
      
        <label class="md-nav__link" for="__nav_15">
          Ophthalmology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Ophthalmology" data-md-level="1">
        <label class="md-nav__title" for="__nav_15">
          <span class="md-nav__icon md-icon"></span>
          Ophthalmology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../ophthalmology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_16" type="checkbox" id="__nav_16" >
      
      
      
      
        <label class="md-nav__link" for="__nav_16">
          Outpatient medicine
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Outpatient medicine" data-md-level="1">
        <label class="md-nav__title" for="__nav_16">
          <span class="md-nav__icon md-icon"></span>
          Outpatient medicine
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-asthma/" class="md-nav__link">
        Asthma
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-coding-and-informatics/" class="md-nav__link">
        Coding and Informatics
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-hypertension/" class="md-nav__link">
        Hypertension
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-lipids/" class="md-nav__link">
        Lipids
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-obesitynutrition/" class="md-nav__link">
        Obesity/Nutrition
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../outpatient-medicine/outpatient-medicine-preventative-medicine/" class="md-nav__link">
        Preventative Medicine
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_17" type="checkbox" id="__nav_17" >
      
      
      
      
        <label class="md-nav__link" for="__nav_17">
          Pain and palliative
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Pain and palliative" data-md-level="1">
        <label class="md-nav__title" for="__nav_17">
          <span class="md-nav__icon md-icon"></span>
          Pain and palliative
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-acute-and-chronic-pain/" class="md-nav__link">
        Acute and Chronic Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-code-status-discussion/" class="md-nav__link">
        Code Status Discussion
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-death-pronouncement/" class="md-nav__link">
        The Death Pronouncement
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-medications-dying-patients/" class="md-nav__link">
        Medications for Dying Patients
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-opiate-principles/" class="md-nav__link">
        Opiate Principles
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pain-and-palliative/pain-and-palliative-video-examples-navigating-difficult-conversations/" class="md-nav__link">
        Video Examples for Navigating Difficult Conversations
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_18" type="checkbox" id="__nav_18" >
      
      
      
      
        <label class="md-nav__link" for="__nav_18">
          Physical medicine rehabilitation
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Physical medicine rehabilitation" data-md-level="1">
        <label class="md-nav__title" for="__nav_18">
          <span class="md-nav__icon md-icon"></span>
          Physical medicine rehabilitation
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-back-pain/" class="md-nav__link">
        Back Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-knee-pain/" class="md-nav__link">
        Knee Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-neck-pain/" class="md-nav__link">
        Neck Pain
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-pmr-consultation/" class="md-nav__link">
        PM&R Consultation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-rehabilitation-options/" class="md-nav__link">
        Rehabilitation Options
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../physical-medicine-rehabilitation/physical-medicine-rehabilitation-shoulder-pain/" class="md-nav__link">
        Shoulder Pain
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_19" type="checkbox" id="__nav_19" >
      
      
      
      
        <label class="md-nav__link" for="__nav_19">
          Procedures
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Procedures" data-md-level="1">
        <label class="md-nav__title" for="__nav_19">
          <span class="md-nav__icon md-icon"></span>
          Procedures
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/main/" class="md-nav__link">
        About
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-anesthesia/" class="md-nav__link">
        Anesthesia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-anticoagulation-parameters/" class="md-nav__link">
        Anticoagulation Parameters
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-arterial-line/" class="md-nav__link">
        Arterial Line
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-central-line/" class="md-nav__link">
        Central line
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-consent/" class="md-nav__link">
        Consent
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-dht/" class="md-nav__link">
        DHT
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-lumbar-puncture/" class="md-nav__link">
        Lumbar Puncture
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-paracentesis/" class="md-nav__link">
        Paracentesis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-thoracentesis/" class="md-nav__link">
        Thoracentesis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../procedures/procedures-ultrasound-guided-peripheral-iv/" class="md-nav__link">
        Ultrasound-Guided Peripheral IV
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_20" type="checkbox" id="__nav_20" >
      
      
      
      
        <label class="md-nav__link" for="__nav_20">
          Psychiatry
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Psychiatry" data-md-level="1">
        <label class="md-nav__title" for="__nav_20">
          <span class="md-nav__icon md-icon"></span>
          Psychiatry
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-agitation-management/" class="md-nav__link">
        Agitation Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-inpatient-insomnia/" class="md-nav__link">
        Inpatient Insomnia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-medical-decision-making-capacity/" class="md-nav__link">
        Medical Decision-Making Capacity
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-medical-hold/" class="md-nav__link">
        Medical Hold
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-motivational-interviewing/" class="md-nav__link">
        Motivational Interviewing
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-personality-disorders/" class="md-nav__link">
        Personality Disorders
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../psychiatry/psychiatry-substance-use-disorder/" class="md-nav__link">
        Substance Use Disorder
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_21" type="checkbox" id="__nav_21" >
      
      
      
      
        <label class="md-nav__link" for="__nav_21">
          Pulmonary
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Pulmonary" data-md-level="1">
        <label class="md-nav__title" for="__nav_21">
          <span class="md-nav__icon md-icon"></span>
          Pulmonary
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-acute-asthma-exacerbation/" class="md-nav__link">
        Acute Asthma Exacerbation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-blood-gases/" class="md-nav__link">
        Blood Gases
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-cf-exacerbation/" class="md-nav__link">
        CF Exacerbation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-copd-exacerbation-management/" class="md-nav__link">
        COPD Exacerbation Management
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-cxrs/" class="md-nav__link">
        CXRs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-hemoptysis/" class="md-nav__link">
        Hemoptysis
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-home-oxygen-therapies/" class="md-nav__link">
        Home Oxygen Therapies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-hypoxia/" class="md-nav__link">
        Hypoxia
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-ild/" class="md-nav__link">
        ILD
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-pfts/" class="md-nav__link">
        PFTs
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-pleural-effusions/" class="md-nav__link">
        Pleural Effusions
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../pulmonary/pulmonary-pulmonary-hypertension/" class="md-nav__link">
        Pulmonary Hypertension
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_22" type="checkbox" id="__nav_22" >
      
      
      
      
        <label class="md-nav__link" for="__nav_22">
          Radiology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Radiology" data-md-level="1">
        <label class="md-nav__title" for="__nav_22">
          <span class="md-nav__icon md-icon"></span>
          Radiology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../radiology/radiology-consults-radiology-procedures/" class="md-nav__link">
        Consults for Radiology Procedures
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../radiology/radiology-cxr/" class="md-nav__link">
        Basic Chest X-ray Interpretation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../radiology/radiology-kub/" class="md-nav__link">
        Basic Abdominal X-ray Interpretation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../radiology/radiology-radiology-exams-diagnosis/" class="md-nav__link">
        Common Radiology Exams by Suspected Diagnosis
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_23" type="checkbox" id="__nav_23" >
      
      
      
      
        <label class="md-nav__link" for="__nav_23">
          Rheumatology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Rheumatology" data-md-level="1">
        <label class="md-nav__title" for="__nav_23">
          <span class="md-nav__icon md-icon"></span>
          Rheumatology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/main/" class="md-nav__link">
        Main
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-biologic-overview/" class="md-nav__link">
        Biologic Overview
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-common-rheumatologic-diseases/" class="md-nav__link">
        Common Rheumatologic Diseases
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-crystal-arthropathy/" class="md-nav__link">
        Crystal Arthropathy
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-inflammatory-myopathies/" class="md-nav__link">
        Inflammatory Myopathies
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-rheumatology-lab-testing/" class="md-nav__link">
        Rheumatology Lab Testing
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../rheumatology/rheumatology-vasculitis/" class="md-nav__link">
        Vasculitis
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_24" type="checkbox" id="__nav_24" >
      
      
      
      
        <label class="md-nav__link" for="__nav_24">
          Toxicology
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Toxicology" data-md-level="1">
        <label class="md-nav__title" for="__nav_24">
          <span class="md-nav__icon md-icon"></span>
          Toxicology
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../toxicology/toxicology-brown-recluse-loxoscelism/" class="md-nav__link">
        Brown Recluse Bites (Loxoscelism)
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../toxicology/toxicology-overdose-management/" class="md-nav__link">
        Management of Specific Overdoses
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../toxicology/toxicology-qtc/" class="md-nav__link">
        Drug-Induced QTc Prolongation
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../toxicology/toxicology-toxidrome-overview/" class="md-nav__link">
        Toxidrome Overview
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_25" type="checkbox" id="__nav_25" >
      
      
      
      
        <label class="md-nav__link" for="__nav_25">
          zCBH
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="zCBH" data-md-level="1">
        <label class="md-nav__title" for="__nav_25">
          <span class="md-nav__icon md-icon"></span>
          zCBH
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../zCBH/cprs/" class="md-nav__link">
        CPRS
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../zCBH/va-notes/" class="md-nav__link">
        VA notes
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    
    <li class="md-nav__item md-nav__item--nested">
      
      
        <input class="md-nav__toggle md-toggle" data-md-toggle="__nav_26" type="checkbox" id="__nav_26" >
      
      
      
      
        <label class="md-nav__link" for="__nav_26">
          Appendices
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <nav class="md-nav" aria-label="Appendices" data-md-level="1">
        <label class="md-nav__title" for="__nav_26">
          <span class="md-nav__icon md-icon"></span>
          Appendices
        </label>
        <ul class="md-nav__list" data-md-scrollfix>
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-how-discharges-va/" class="md-nav__link">
        "How to" on Discharges at VA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-how-discharges-vumc/" class="md-nav__link">
        "How to" on Discharges at VUMC
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-interns-guide-rotations-va/" class="md-nav__link">
        Interns' Guide to Rotations at VA
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-interns-guide-rotations-vumc/" class="md-nav__link">
        Interns' Guide to Rotations
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-staging-wounds/" class="md-nav__link">
        Staging Wounds
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-uploading-records/" class="md-nav__link">
        Uploading Records to EPIC
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-va-phone-numbers/" class="md-nav__link">
        VA Phone Numbers
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/appendices-vumc-phone-directory/" class="md-nav__link">
        VUMC Phone Directory
      </a>
    </li>
  

            
          
            
              
  
  
  
    <li class="md-nav__item">
      <a href="../appendices/main/" class="md-nav__link">
        VUMC Rotations
      </a>
    </li>
  

            
          
        </ul>
      </nav>
    </li>
  

    
      
      
      

  
  
  
    <li class="md-nav__item">
      
      <input class="md-nav__toggle md-toggle" data-md-toggle="toc" type="checkbox" id="__toc">
      
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          Print Site
          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="./" class="md-nav__link md-nav__link--active">
        Print Site
      </a>
      
        

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#" class="md-nav__link">
    Home
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-introduction" class="md-nav__link">
    Introduction
  </a>
  
    <nav class="md-nav" aria-label="Introduction">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-acknowledgements" class="md-nav__link">
    Acknowledgements
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-authors-editors-reviewers" class="md-nav__link">
    Editors, Authors, and Reviewers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-disclaimers" class="md-nav__link">
    Disclaimers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-rationale" class="md-nav__link">
    Rationale
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-web-app-setup" class="md-nav__link">
    Web App Setup
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-cardiology" class="md-nav__link">
    Cardiology
  </a>
  
    <nav class="md-nav" aria-label="Cardiology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-acs" class="md-nav__link">
    Acute Coronary Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-arrhythmias" class="md-nav__link">
    Arrhythmias
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-atrial-fibrillation-and-flutter" class="md-nav__link">
    Atrial Fibrillation & Flutter
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-autonomics-and-orthostatics" class="md-nav__link">
    Autonomics and Orthostatic Hypotension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-bedside-echocardiography" class="md-nav__link">
    Bedside Echocardiography
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-cardiac-devices" class="md-nav__link">
    Cardiac Devices
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-chest-pain" class="md-nav__link">
    Chest Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-chf" class="md-nav__link">
    Heart Failure
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-ekg" class="md-nav__link">
    Approach to the ECG
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-inpatient-hypertension" class="md-nav__link">
    Inpatient Hypertension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-pe" class="md-nav__link">
    Pulmonary Embolism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-rhc" class="md-nav__link">
    Right Heart Catheterization
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-shock" class="md-nav__link">
    Cardiogenic Shock
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-syncope" class="md-nav__link">
    Syncope
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-valvular-heart-disease" class="md-nav__link">
    Valvular Heart Disease
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-critical-care" class="md-nav__link">
    Critical care
  </a>
  
    <nav class="md-nav" aria-label="Critical care">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-abcdef-a2f-bundle" class="md-nav__link">
    ABCDEF (A2F) Bundle
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-ards" class="md-nav__link">
    Acute Respiratory Distress Syndrome (ARDS)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-brain-death" class="md-nav__link">
    Brain Death
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-codes" class="md-nav__link">
    Running Codes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-drips" class="md-nav__link">
    MICU/CCU Drips
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-intubation-extubation" class="md-nav__link">
    Intubation and Extubation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-modes-oxygen-delivery" class="md-nav__link">
    Modes of Oxygen Delivery
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-refractory-hypercapnia" class="md-nav__link">
    Refractory Hypercapnia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-refractory-hypoxemia" class="md-nav__link">
    Refractory Hypoxemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-sepsis" class="md-nav__link">
    Sepsis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-shock" class="md-nav__link">
    Management of Shock
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-temperature-abnormalities" class="md-nav__link">
    Temperature Abnormalities
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-tracheostomy" class="md-nav__link">
    Tracheostomy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-ultrasound" class="md-nav__link">
    Ultrasound in Critical Care
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-vent-settings" class="md-nav__link">
    Introduction to Vent Management
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-demo" class="md-nav__link">
    Demo
  </a>
  
    <nav class="md-nav" aria-label="Demo">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#demo-demo-lights" class="md-nav__link">
    Pleural Effusions
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-endocrinology" class="md-nav__link">
    Endocrinology
  </a>
  
    <nav class="md-nav" aria-label="Endocrinology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-adrenal-incidentalomas" class="md-nav__link">
    Adrenal Incidentalomas
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-adrenal-insufficiency" class="md-nav__link">
    Adrenal Insufficiency
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-diabetes-inpatient-management" class="md-nav__link">
    Inpatient Diabetes Mellitus (DM)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-dka" class="md-nav__link">
    Diabetic Ketoacidosis (DKA)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hyperthyroidism" class="md-nav__link">
    Hyperthyroidism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hypoglycemia" class="md-nav__link">
    Hypoglycemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hypothyroidism" class="md-nav__link">
    Hypothyroidism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-severe-hypertriglyceridemia" class="md-nav__link">
    Severe Hypertriglyceridemia (HTG)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-steroid-conversions" class="md-nav__link">
    Steroid Conversions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-stress-dose-steroids" class="md-nav__link">
    Stress Dose Steroids
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-thyroid-nodules" class="md-nav__link">
    Thyroid Nodules
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-thyroid-storm" class="md-nav__link">
    Thyroid Storm
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-gastroenterology" class="md-nav__link">
    Gastroenterology
  </a>
  
    <nav class="md-nav" aria-label="Gastroenterology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-abdominal-pain" class="md-nav__link">
    Acute Abdominal Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-diverticulitis" class="md-nav__link">
    Acute Diverticulitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-pancreatitis" class="md-nav__link">
    Acute Pancreatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-biliary-disease" class="md-nav__link">
    Biliary Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-c-diff" class="md-nav__link">
    Clostridioides Difficile Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-chronic-pancreatitis" class="md-nav__link">
    Chronic Pancreatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-constipation" class="md-nav__link">
    Constipation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-diarrhea" class="md-nav__link">
    Diarrhea
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-esophageal-disorders" class="md-nav__link">
    Esophageal Disorders
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-gastroparesis" class="md-nav__link">
    Gastroparesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-gi-bleeding" class="md-nav__link">
    GI Bleeding
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-gi-covid" class="md-nav__link">
    GI Manifestations of COVID
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-ibs" class="md-nav__link">
    Irritable Bowel Syndrome
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-inflammatory-bowel-disease" class="md-nav__link">
    Inflammatory Bowel Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-intestinal-ischemia" class="md-nav__link">
    Intestinal Ischemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-nausea-vomiting" class="md-nav__link">
    Nausea & Vomiting
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-peptic-ulcer-disease" class="md-nav__link">
    Peptic Ulcer Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-small-bowel-obstruction" class="md-nav__link">
    Small Bowel Obstruction (SBO)
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-geriatrics" class="md-nav__link">
    Geriatrics
  </a>
  
    <nav class="md-nav" aria-label="Geriatrics">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-dementia" class="md-nav__link">
    Dementia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-falls" class="md-nav__link">
    Falls
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-frailty" class="md-nav__link">
    Frailty
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-functional-status" class="md-nav__link">
    Functional Status
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-malnutrition" class="md-nav__link">
    Malnutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-medication-management" class="md-nav__link">
    Medication Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-overview" class="md-nav__link">
    Geriatrics Overview
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter" class="md-nav__link">
    Urinary Incontinence and Foley Catheters
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hematology-oncology" class="md-nav__link">
    Hematology oncology
  </a>
  
    <nav class="md-nav" aria-label="Hematology oncology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-anemia" class="md-nav__link">
    Anemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-anticoagulation" class="md-nav__link">
    Anticoagulation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-bone-marrow-transplant" class="md-nav__link">
    Bone Marrow Transplant
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-chemotherapy-toxicity" class="md-nav__link">
    Chemotherapy Toxicity
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-coagulopathies" class="md-nav__link">
    Coagulopathies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-dic" class="md-nav__link">
    DIC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-dvts" class="md-nav__link">
    DVTs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-hypercoagulable-states" class="md-nav__link">
    Hypercoagulable States
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-leukemia" class="md-nav__link">
    Leukemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-lymphoma" class="md-nav__link">
    Lymphoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-medical-oncology-resources" class="md-nav__link">
    Medical Oncology Resources
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-myelodysplastic-syndromes" class="md-nav__link">
    Myelodysplastic Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-myeloproliferative-neoplasms" class="md-nav__link">
    Myeloproliferative Neoplasms
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever" class="md-nav__link">
    Neutropenia and Neutropenic Fever
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-oncologic-emergencies" class="md-nav__link">
    Oncologic Emergencies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-paraneoplastic-syndromes" class="md-nav__link">
    Paraneoplastic Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-plasma-cell-dyscrasias" class="md-nav__link">
    Plasma Cell Dyscrasias
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-sickle-cell-crisis" class="md-nav__link">
    Sickle Cell Crisis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-thrombocytopenia" class="md-nav__link">
    Thrombocytopenia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-transfusion-medicine" class="md-nav__link">
    Transfusion Medicine
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hepatology" class="md-nav__link">
    Hepatology
  </a>
  
    <nav class="md-nav" aria-label="Hepatology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-acute-liver-failure" class="md-nav__link">
    Acute Liver Injury and Failure
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-alcoholic-hepatitis" class="md-nav__link">
    Alcoholic Hepatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-ascites" class="md-nav__link">
    Ascites and Hepatic Hydrothorax
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-cirrhosis" class="md-nav__link">
    Cirrhosis Overview
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-coagulopathy" class="md-nav__link">
    Coagulopathy in Cirrhosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatic-encephalopathy" class="md-nav__link">
    Hepatic Encephalopathy (HE)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatocellular-carcinoma" class="md-nav__link">
    Hepatocellular Carcinoma (HCC)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatorenal-syndrome" class="md-nav__link">
    Hepatorenal Syndrome
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hyponatremia-cirrhosis" class="md-nav__link">
    Hyponatremia in Cirrhosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-liver-transplantation" class="md-nav__link">
    Liver Transplant (LT) Workup
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-medication-pearls" class="md-nav__link">
    Medication Pearls
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-nash-and-nafld" class="md-nav__link">
    NASH and NAFLD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-portal-vein-thrombosis" class="md-nav__link">
    Portal Vein Thrombosis (PVT)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-post-liver-transplant-management" class="md-nav__link">
    Post-Liver Transplant Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-sbp" class="md-nav__link">
    Spontaneous Bacterial Peritonitis (SBP)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-tips" class="md-nav__link">
    Transjugular Intrahepatic Portosystemic Shunt (TIPS)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-upper-gi-bleed-cirrhosis" class="md-nav__link">
    Gastroesophageal Varices and Hemorrhage
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hospital-medicine" class="md-nav__link">
    Hospital medicine
  </a>
  
    <nav class="md-nav" aria-label="Hospital medicine">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-enteral-nutrition" class="md-nav__link">
    Enteral Nutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients" class="md-nav__link">
    Guidelines for Pregnant Patients
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-lines-and-catheters" class="md-nav__link">
    Lines and Catheters
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-mobility-and-hospital-therapy" class="md-nav__link">
    Mobility and In-Hospital Therapy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-telemetry" class="md-nav__link">
    Telemetry
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-transitions-of-care" class="md-nav__link">
    Transitions of Care: Tips for Safe Discharges
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-wounds" class="md-nav__link">
    Wounds − Adapted from Dr. Duggan’s Geriatrics Guide
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-infectious-diseases" class="md-nav__link">
    Infectious diseases
  </a>
  
    <nav class="md-nav" aria-label="Infectious diseases">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases" class="md-nav__link">
    Sexually Transmitted Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-aids-defining-conditions" class="md-nav__link">
    AIDS Defining Conditions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-antimicrobial-prophylaxis" class="md-nav__link">
    Antimicrobial prophylaxis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-bacteremia" class="md-nav__link">
    Bacteremia: Interpreting GenMark ePlex® Results – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-brief-overview-art" class="md-nav__link">
    Brief Overview of ART
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-cns-infection" class="md-nav__link">
    Central Nervous System Infection – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-community-acquired-pneumonia" class="md-nav__link">
    Community Acquired Pneumonia (CAP)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-diabetic-foot-infection" class="md-nav__link">
    Diabetic Foot Infection – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-endocarditis" class="md-nav__link">
    Endocarditis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-febrile-neutropenia" class="md-nav__link">
    Febrile Neutropenia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-fungal-infections" class="md-nav__link">
    Fungal Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-general-tips" class="md-nav__link">
    General Tips
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-gu-infection" class="md-nav__link">
    Genitourinary Infection – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-hap-and-vap" class="md-nav__link">
    Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-hiv-art-general-concepts" class="md-nav__link">
    HIV/AIDS and ART
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-inpatient-covid19" class="md-nav__link">
    Inpatient COVID-19 Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-orthopedic-infection" class="md-nav__link">
    Joint Infections and Osteomyelitis – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-pulmonary-infections" class="md-nav__link">
    Pulmonary Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-ssti" class="md-nav__link">
    Skin and Soft Tissue Infection (SSTI) - VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-nephrology" class="md-nav__link">
    Nephrology
  </a>
  
    <nav class="md-nav" aria-label="Nephrology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#nephrology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-acute-rejection" class="md-nav__link">
    Acute Rejection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-aki" class="md-nav__link">
    AKI
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-approach-ckd" class="md-nav__link">
    Approach to CKD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants" class="md-nav__link">
    Common Side Effects of Renal Transplant Immune Suppresants
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hematuria" class="md-nav__link">
    Hematuria
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypercalcemia" class="md-nav__link">
    Hypercalcemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyperkalemia" class="md-nav__link">
    Hyperkalemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypernatremia" class="md-nav__link">
    Hypernatremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyperphosphatemia" class="md-nav__link">
    Hyperphosphatemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypokalemia" class="md-nav__link">
    Hypokalemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypomagnesemia" class="md-nav__link">
    Hypomagnesemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyponatremia" class="md-nav__link">
    Hyponatremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypophosphatemia" class="md-nav__link">
    Hypophosphatemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-metabolic-acidosis" class="md-nav__link">
    Metabolic acidosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-peritonitis-patients-pd" class="md-nav__link">
    Peritonitis in patients on PD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-renal-replacement-therapy" class="md-nav__link">
    Renal Replacement Therapy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-transplant-aki" class="md-nav__link">
    Transplant AKI
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-ua" class="md-nav__link">
    UA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-uti-renal-transplant" class="md-nav__link">
    UTI in Renal Transplant
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-neurology" class="md-nav__link">
    Neurology
  </a>
  
    <nav class="md-nav" aria-label="Neurology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#neurology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-aidp" class="md-nav__link">
    AIDP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-als" class="md-nav__link">
    ALS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-ams" class="md-nav__link">
    AMS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-basic-seizures" class="md-nav__link">
    Seizures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-brain-masses" class="md-nav__link">
    Brain Masses
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-elevated-icp-and-hydrocephalus" class="md-nav__link">
    Elevated ICP and Hydrocephalus
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-inpatient-headache" class="md-nav__link">
    Inpatient Headache
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-ms" class="md-nav__link">
    MS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-myasthenia-etc" class="md-nav__link">
    Myasthenia etc
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-outpatient-headache" class="md-nav__link">
    Outpatient Headache
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-parkinson" class="md-nav__link">
    Parkinson
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-status-epilepticus" class="md-nav__link">
    Status Epilepticus
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-stroke-0" class="md-nav__link">
    Stroke
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-vertigo" class="md-nav__link">
    Vertigo
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-ophthalmology" class="md-nav__link">
    Ophthalmology
  </a>
  
    <nav class="md-nav" aria-label="Ophthalmology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#ophthalmology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-outpatient-medicine" class="md-nav__link">
    Outpatient medicine
  </a>
  
    <nav class="md-nav" aria-label="Outpatient medicine">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-asthma" class="md-nav__link">
    Asthma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-coding-and-informatics" class="md-nav__link">
    Coding and Informatics
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-hypertension" class="md-nav__link">
    Hypertension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-lipids" class="md-nav__link">
    Lipids
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-obesitynutrition" class="md-nav__link">
    Obesity/Nutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-preventative-medicine" class="md-nav__link">
    Preventative Medicine
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-pain-and-palliative" class="md-nav__link">
    Pain and palliative
  </a>
  
    <nav class="md-nav" aria-label="Pain and palliative">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-acute-and-chronic-pain" class="md-nav__link">
    Acute and Chronic Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-code-status-discussion" class="md-nav__link">
    Code Status Discussion
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-death-pronouncement" class="md-nav__link">
    The Death Pronouncement
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-medications-dying-patients" class="md-nav__link">
    Medications for Dying Patients
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-opiate-principles" class="md-nav__link">
    Opiate Principles
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations" class="md-nav__link">
    Video Examples for Navigating Difficult Conversations
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-physical-medicine-rehabilitation" class="md-nav__link">
    Physical medicine rehabilitation
  </a>
  
    <nav class="md-nav" aria-label="Physical medicine rehabilitation">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain" class="md-nav__link">
    Back Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain" class="md-nav__link">
    Knee Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain" class="md-nav__link">
    Neck Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation" class="md-nav__link">
    PM&R Consultation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options" class="md-nav__link">
    Rehabilitation Options
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain" class="md-nav__link">
    Shoulder Pain
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-procedures" class="md-nav__link">
    Procedures
  </a>
  
    <nav class="md-nav" aria-label="Procedures">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#procedures-main" class="md-nav__link">
    About
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-anesthesia" class="md-nav__link">
    Anesthesia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-anticoagulation-parameters" class="md-nav__link">
    Anticoagulation Parameters
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-arterial-line" class="md-nav__link">
    Arterial Line
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-central-line" class="md-nav__link">
    Central line
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-consent" class="md-nav__link">
    Consent
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-dht" class="md-nav__link">
    DHT
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-lumbar-puncture" class="md-nav__link">
    Lumbar Puncture
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-paracentesis" class="md-nav__link">
    Paracentesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-thoracentesis" class="md-nav__link">
    Thoracentesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-ultrasound-guided-peripheral-iv" class="md-nav__link">
    Ultrasound-Guided Peripheral IV
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-psychiatry" class="md-nav__link">
    Psychiatry
  </a>
  
    <nav class="md-nav" aria-label="Psychiatry">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#psychiatry-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-agitation-management" class="md-nav__link">
    Agitation Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-inpatient-insomnia" class="md-nav__link">
    Inpatient Insomnia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-medical-decision-making-capacity" class="md-nav__link">
    Medical Decision-Making Capacity
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-medical-hold" class="md-nav__link">
    Medical Hold
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-motivational-interviewing" class="md-nav__link">
    Motivational Interviewing
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-personality-disorders" class="md-nav__link">
    Personality Disorders
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-substance-use-disorder" class="md-nav__link">
    Substance Use Disorder
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-pulmonary" class="md-nav__link">
    Pulmonary
  </a>
  
    <nav class="md-nav" aria-label="Pulmonary">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#pulmonary-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-acute-asthma-exacerbation" class="md-nav__link">
    Acute Asthma Exacerbation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-blood-gases" class="md-nav__link">
    Blood Gases
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-cf-exacerbation" class="md-nav__link">
    CF Exacerbation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-copd-exacerbation-management" class="md-nav__link">
    COPD Exacerbation Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-cxrs" class="md-nav__link">
    CXRs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-hemoptysis" class="md-nav__link">
    Hemoptysis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-home-oxygen-therapies" class="md-nav__link">
    Home Oxygen Therapies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-hypoxia" class="md-nav__link">
    Hypoxia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-ild" class="md-nav__link">
    ILD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pfts" class="md-nav__link">
    PFTs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pleural-effusions" class="md-nav__link">
    Pleural Effusions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pulmonary-hypertension" class="md-nav__link">
    Pulmonary Hypertension
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-radiology" class="md-nav__link">
    Radiology
  </a>
  
    <nav class="md-nav" aria-label="Radiology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-consults-radiology-procedures" class="md-nav__link">
    Consults for Radiology Procedures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-cxr" class="md-nav__link">
    Basic Chest X-ray Interpretation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-kub" class="md-nav__link">
    Basic Abdominal X-ray Interpretation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-radiology-exams-diagnosis" class="md-nav__link">
    Common Radiology Exams by Suspected Diagnosis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-rheumatology" class="md-nav__link">
    Rheumatology
  </a>
  
    <nav class="md-nav" aria-label="Rheumatology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#rheumatology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-biologic-overview" class="md-nav__link">
    Biologic Overview
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-common-rheumatologic-diseases" class="md-nav__link">
    Common Rheumatologic Diseases
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-crystal-arthropathy" class="md-nav__link">
    Crystal Arthropathy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-inflammatory-myopathies" class="md-nav__link">
    Inflammatory Myopathies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-rheumatology-lab-testing" class="md-nav__link">
    Rheumatology Lab Testing
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-vasculitis" class="md-nav__link">
    Vasculitis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-toxicology" class="md-nav__link">
    Toxicology
  </a>
  
    <nav class="md-nav" aria-label="Toxicology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#toxicology-toxicology-brown-recluse-loxoscelism" class="md-nav__link">
    Brown Recluse Bites (Loxoscelism)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#toxicology-toxicology-overdose-management" class="md-nav__link">
    Management of Specific Overdoses
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#toxicology-toxicology-qtc" class="md-nav__link">
    Drug-Induced QTc Prolongation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#toxicology-toxicology-toxidrome-overview" class="md-nav__link">
    Toxidrome Overview
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-zcbh" class="md-nav__link">
    zCBH
  </a>
  
    <nav class="md-nav" aria-label="zCBH">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#zcbh-cprs" class="md-nav__link">
    CPRS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#zcbh-va-notes" class="md-nav__link">
    VA notes
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-appendices" class="md-nav__link">
    Appendices
  </a>
  
    <nav class="md-nav" aria-label="Appendices">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-how-discharges-va" class="md-nav__link">
    "How to" on Discharges at VA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-how-discharges-vumc" class="md-nav__link">
    "How to" on Discharges at VUMC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-interns-guide-rotations-va" class="md-nav__link">
    Interns' Guide to Rotations at VA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-interns-guide-rotations-vumc" class="md-nav__link">
    Interns' Guide to Rotations
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-staging-wounds" class="md-nav__link">
    Staging Wounds
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-uploading-records" class="md-nav__link">
    Uploading Records to EPIC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-va-phone-numbers" class="md-nav__link">
    VA Phone Numbers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-vumc-phone-directory" class="md-nav__link">
    VUMC Phone Directory
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-main" class="md-nav__link">
    VUMC Rotations
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#" class="md-nav__link">
    Home
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-introduction" class="md-nav__link">
    Introduction
  </a>
  
    <nav class="md-nav" aria-label="Introduction">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-acknowledgements" class="md-nav__link">
    Acknowledgements
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-authors-editors-reviewers" class="md-nav__link">
    Editors, Authors, and Reviewers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-disclaimers" class="md-nav__link">
    Disclaimers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-rationale" class="md-nav__link">
    Rationale
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#introduction-introduction-web-app-setup" class="md-nav__link">
    Web App Setup
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-cardiology" class="md-nav__link">
    Cardiology
  </a>
  
    <nav class="md-nav" aria-label="Cardiology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-acs" class="md-nav__link">
    Acute Coronary Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-arrhythmias" class="md-nav__link">
    Arrhythmias
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-atrial-fibrillation-and-flutter" class="md-nav__link">
    Atrial Fibrillation & Flutter
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-autonomics-and-orthostatics" class="md-nav__link">
    Autonomics and Orthostatic Hypotension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-bedside-echocardiography" class="md-nav__link">
    Bedside Echocardiography
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-cardiac-devices" class="md-nav__link">
    Cardiac Devices
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-chest-pain" class="md-nav__link">
    Chest Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-chf" class="md-nav__link">
    Heart Failure
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-ekg" class="md-nav__link">
    Approach to the ECG
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-inpatient-hypertension" class="md-nav__link">
    Inpatient Hypertension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-pe" class="md-nav__link">
    Pulmonary Embolism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-rhc" class="md-nav__link">
    Right Heart Catheterization
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-shock" class="md-nav__link">
    Cardiogenic Shock
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-syncope" class="md-nav__link">
    Syncope
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#cardiology-cardiology-valvular-heart-disease" class="md-nav__link">
    Valvular Heart Disease
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-critical-care" class="md-nav__link">
    Critical care
  </a>
  
    <nav class="md-nav" aria-label="Critical care">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-abcdef-a2f-bundle" class="md-nav__link">
    ABCDEF (A2F) Bundle
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-ards" class="md-nav__link">
    Acute Respiratory Distress Syndrome (ARDS)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-brain-death" class="md-nav__link">
    Brain Death
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-codes" class="md-nav__link">
    Running Codes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-drips" class="md-nav__link">
    MICU/CCU Drips
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-intubation-extubation" class="md-nav__link">
    Intubation and Extubation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-modes-oxygen-delivery" class="md-nav__link">
    Modes of Oxygen Delivery
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-refractory-hypercapnia" class="md-nav__link">
    Refractory Hypercapnia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-refractory-hypoxemia" class="md-nav__link">
    Refractory Hypoxemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-sepsis" class="md-nav__link">
    Sepsis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-shock" class="md-nav__link">
    Management of Shock
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-temperature-abnormalities" class="md-nav__link">
    Temperature Abnormalities
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-tracheostomy" class="md-nav__link">
    Tracheostomy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-ultrasound" class="md-nav__link">
    Ultrasound in Critical Care
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#critical-care-critical-care-vent-settings" class="md-nav__link">
    Introduction to Vent Management
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-demo" class="md-nav__link">
    Demo
  </a>
  
    <nav class="md-nav" aria-label="Demo">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#demo-demo-lights" class="md-nav__link">
    Pleural Effusions
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-endocrinology" class="md-nav__link">
    Endocrinology
  </a>
  
    <nav class="md-nav" aria-label="Endocrinology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-adrenal-incidentalomas" class="md-nav__link">
    Adrenal Incidentalomas
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-adrenal-insufficiency" class="md-nav__link">
    Adrenal Insufficiency
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-diabetes-inpatient-management" class="md-nav__link">
    Inpatient Diabetes Mellitus (DM)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-dka" class="md-nav__link">
    Diabetic Ketoacidosis (DKA)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hyperthyroidism" class="md-nav__link">
    Hyperthyroidism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hypoglycemia" class="md-nav__link">
    Hypoglycemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-hypothyroidism" class="md-nav__link">
    Hypothyroidism
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-severe-hypertriglyceridemia" class="md-nav__link">
    Severe Hypertriglyceridemia (HTG)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-steroid-conversions" class="md-nav__link">
    Steroid Conversions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-stress-dose-steroids" class="md-nav__link">
    Stress Dose Steroids
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-thyroid-nodules" class="md-nav__link">
    Thyroid Nodules
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-endocrinology-thyroid-storm" class="md-nav__link">
    Thyroid Storm
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#endocrinology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-gastroenterology" class="md-nav__link">
    Gastroenterology
  </a>
  
    <nav class="md-nav" aria-label="Gastroenterology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-abdominal-pain" class="md-nav__link">
    Acute Abdominal Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-diverticulitis" class="md-nav__link">
    Acute Diverticulitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-acute-pancreatitis" class="md-nav__link">
    Acute Pancreatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-biliary-disease" class="md-nav__link">
    Biliary Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-c-diff" class="md-nav__link">
    Clostridioides Difficile Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-chronic-pancreatitis" class="md-nav__link">
    Chronic Pancreatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-constipation" class="md-nav__link">
    Constipation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-diarrhea" class="md-nav__link">
    Diarrhea
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-esophageal-disorders" class="md-nav__link">
    Esophageal Disorders
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-gastroparesis" class="md-nav__link">
    Gastroparesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-gi-bleeding" class="md-nav__link">
    GI Bleeding
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-gi-covid" class="md-nav__link">
    GI Manifestations of COVID
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-ibs" class="md-nav__link">
    Irritable Bowel Syndrome
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-inflammatory-bowel-disease" class="md-nav__link">
    Inflammatory Bowel Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-intestinal-ischemia" class="md-nav__link">
    Intestinal Ischemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-nausea-vomiting" class="md-nav__link">
    Nausea & Vomiting
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-peptic-ulcer-disease" class="md-nav__link">
    Peptic Ulcer Disease
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#gastroenterology-gastroenterology-small-bowel-obstruction" class="md-nav__link">
    Small Bowel Obstruction (SBO)
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-geriatrics" class="md-nav__link">
    Geriatrics
  </a>
  
    <nav class="md-nav" aria-label="Geriatrics">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-dementia" class="md-nav__link">
    Dementia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-falls" class="md-nav__link">
    Falls
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-frailty" class="md-nav__link">
    Frailty
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-functional-status" class="md-nav__link">
    Functional Status
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-malnutrition" class="md-nav__link">
    Malnutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-medication-management" class="md-nav__link">
    Medication Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-overview" class="md-nav__link">
    Geriatrics Overview
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter" class="md-nav__link">
    Urinary Incontinence and Foley Catheters
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hematology-oncology" class="md-nav__link">
    Hematology oncology
  </a>
  
    <nav class="md-nav" aria-label="Hematology oncology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-anemia" class="md-nav__link">
    Anemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-anticoagulation" class="md-nav__link">
    Anticoagulation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-bone-marrow-transplant" class="md-nav__link">
    Bone Marrow Transplant
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-chemotherapy-toxicity" class="md-nav__link">
    Chemotherapy Toxicity
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-coagulopathies" class="md-nav__link">
    Coagulopathies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-dic" class="md-nav__link">
    DIC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-dvts" class="md-nav__link">
    DVTs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-hypercoagulable-states" class="md-nav__link">
    Hypercoagulable States
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-leukemia" class="md-nav__link">
    Leukemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-lymphoma" class="md-nav__link">
    Lymphoma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-medical-oncology-resources" class="md-nav__link">
    Medical Oncology Resources
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-myelodysplastic-syndromes" class="md-nav__link">
    Myelodysplastic Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-myeloproliferative-neoplasms" class="md-nav__link">
    Myeloproliferative Neoplasms
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever" class="md-nav__link">
    Neutropenia and Neutropenic Fever
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-oncologic-emergencies" class="md-nav__link">
    Oncologic Emergencies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-paraneoplastic-syndromes" class="md-nav__link">
    Paraneoplastic Syndromes
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-plasma-cell-dyscrasias" class="md-nav__link">
    Plasma Cell Dyscrasias
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-sickle-cell-crisis" class="md-nav__link">
    Sickle Cell Crisis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-thrombocytopenia" class="md-nav__link">
    Thrombocytopenia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-hematologyoncology-transfusion-medicine" class="md-nav__link">
    Transfusion Medicine
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hematology-oncology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hepatology" class="md-nav__link">
    Hepatology
  </a>
  
    <nav class="md-nav" aria-label="Hepatology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-acute-liver-failure" class="md-nav__link">
    Acute Liver Injury and Failure
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-alcoholic-hepatitis" class="md-nav__link">
    Alcoholic Hepatitis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-ascites" class="md-nav__link">
    Ascites and Hepatic Hydrothorax
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-cirrhosis" class="md-nav__link">
    Cirrhosis Overview
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-coagulopathy" class="md-nav__link">
    Coagulopathy in Cirrhosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatic-encephalopathy" class="md-nav__link">
    Hepatic Encephalopathy (HE)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatocellular-carcinoma" class="md-nav__link">
    Hepatocellular Carcinoma (HCC)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hepatorenal-syndrome" class="md-nav__link">
    Hepatorenal Syndrome
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-hyponatremia-cirrhosis" class="md-nav__link">
    Hyponatremia in Cirrhosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-liver-transplantation" class="md-nav__link">
    Liver Transplant (LT) Workup
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-medication-pearls" class="md-nav__link">
    Medication Pearls
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-nash-and-nafld" class="md-nav__link">
    NASH and NAFLD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-portal-vein-thrombosis" class="md-nav__link">
    Portal Vein Thrombosis (PVT)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-post-liver-transplant-management" class="md-nav__link">
    Post-Liver Transplant Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-sbp" class="md-nav__link">
    Spontaneous Bacterial Peritonitis (SBP)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-tips" class="md-nav__link">
    Transjugular Intrahepatic Portosystemic Shunt (TIPS)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-hepatology-upper-gi-bleed-cirrhosis" class="md-nav__link">
    Gastroesophageal Varices and Hemorrhage
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hepatology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-hospital-medicine" class="md-nav__link">
    Hospital medicine
  </a>
  
    <nav class="md-nav" aria-label="Hospital medicine">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-enteral-nutrition" class="md-nav__link">
    Enteral Nutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients" class="md-nav__link">
    Guidelines for Pregnant Patients
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-lines-and-catheters" class="md-nav__link">
    Lines and Catheters
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-mobility-and-hospital-therapy" class="md-nav__link">
    Mobility and In-Hospital Therapy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-telemetry" class="md-nav__link">
    Telemetry
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-transitions-of-care" class="md-nav__link">
    Transitions of Care: Tips for Safe Discharges
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-hospital-medicine-wounds" class="md-nav__link">
    Wounds − Adapted from Dr. Duggan’s Geriatrics Guide
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#hospital-medicine-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-infectious-diseases" class="md-nav__link">
    Infectious diseases
  </a>
  
    <nav class="md-nav" aria-label="Infectious diseases">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases" class="md-nav__link">
    Sexually Transmitted Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-aids-defining-conditions" class="md-nav__link">
    AIDS Defining Conditions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-antimicrobial-prophylaxis" class="md-nav__link">
    Antimicrobial prophylaxis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-bacteremia" class="md-nav__link">
    Bacteremia: Interpreting GenMark ePlex® Results – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-brief-overview-art" class="md-nav__link">
    Brief Overview of ART
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-cns-infection" class="md-nav__link">
    Central Nervous System Infection – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-community-acquired-pneumonia" class="md-nav__link">
    Community Acquired Pneumonia (CAP)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-diabetic-foot-infection" class="md-nav__link">
    Diabetic Foot Infection – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-endocarditis" class="md-nav__link">
    Endocarditis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-febrile-neutropenia" class="md-nav__link">
    Febrile Neutropenia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-fungal-infections" class="md-nav__link">
    Fungal Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-general-tips" class="md-nav__link">
    General Tips
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-gu-infection" class="md-nav__link">
    Genitourinary Infection – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-hap-and-vap" class="md-nav__link">
    Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-hiv-art-general-concepts" class="md-nav__link">
    HIV/AIDS and ART
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-inpatient-covid19" class="md-nav__link">
    Inpatient COVID-19 Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-orthopedic-infection" class="md-nav__link">
    Joint Infections and Osteomyelitis – VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-pulmonary-infections" class="md-nav__link">
    Pulmonary Infections
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-infectious-diseases-ssti" class="md-nav__link">
    Skin and Soft Tissue Infection (SSTI) - VASP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#infectious-diseases-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-nephrology" class="md-nav__link">
    Nephrology
  </a>
  
    <nav class="md-nav" aria-label="Nephrology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#nephrology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-acute-rejection" class="md-nav__link">
    Acute Rejection
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-aki" class="md-nav__link">
    AKI
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-approach-ckd" class="md-nav__link">
    Approach to CKD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants" class="md-nav__link">
    Common Side Effects of Renal Transplant Immune Suppresants
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hematuria" class="md-nav__link">
    Hematuria
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypercalcemia" class="md-nav__link">
    Hypercalcemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyperkalemia" class="md-nav__link">
    Hyperkalemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypernatremia" class="md-nav__link">
    Hypernatremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyperphosphatemia" class="md-nav__link">
    Hyperphosphatemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypokalemia" class="md-nav__link">
    Hypokalemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypomagnesemia" class="md-nav__link">
    Hypomagnesemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hyponatremia" class="md-nav__link">
    Hyponatremia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-hypophosphatemia" class="md-nav__link">
    Hypophosphatemia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-metabolic-acidosis" class="md-nav__link">
    Metabolic acidosis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-peritonitis-patients-pd" class="md-nav__link">
    Peritonitis in patients on PD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-renal-replacement-therapy" class="md-nav__link">
    Renal Replacement Therapy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-transplant-aki" class="md-nav__link">
    Transplant AKI
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-ua" class="md-nav__link">
    UA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#nephrology-nephrology-uti-renal-transplant" class="md-nav__link">
    UTI in Renal Transplant
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-neurology" class="md-nav__link">
    Neurology
  </a>
  
    <nav class="md-nav" aria-label="Neurology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#neurology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-aidp" class="md-nav__link">
    AIDP
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-als" class="md-nav__link">
    ALS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-ams" class="md-nav__link">
    AMS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-basic-seizures" class="md-nav__link">
    Seizures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-brain-masses" class="md-nav__link">
    Brain Masses
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-elevated-icp-and-hydrocephalus" class="md-nav__link">
    Elevated ICP and Hydrocephalus
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-inpatient-headache" class="md-nav__link">
    Inpatient Headache
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-ms" class="md-nav__link">
    MS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-myasthenia-etc" class="md-nav__link">
    Myasthenia etc
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-outpatient-headache" class="md-nav__link">
    Outpatient Headache
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-parkinson" class="md-nav__link">
    Parkinson
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-status-epilepticus" class="md-nav__link">
    Status Epilepticus
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-stroke-0" class="md-nav__link">
    Stroke
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#neurology-neurology-vertigo" class="md-nav__link">
    Vertigo
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-ophthalmology" class="md-nav__link">
    Ophthalmology
  </a>
  
    <nav class="md-nav" aria-label="Ophthalmology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#ophthalmology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-outpatient-medicine" class="md-nav__link">
    Outpatient medicine
  </a>
  
    <nav class="md-nav" aria-label="Outpatient medicine">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-asthma" class="md-nav__link">
    Asthma
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-coding-and-informatics" class="md-nav__link">
    Coding and Informatics
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-hypertension" class="md-nav__link">
    Hypertension
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-lipids" class="md-nav__link">
    Lipids
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-obesitynutrition" class="md-nav__link">
    Obesity/Nutrition
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#outpatient-medicine-outpatient-medicine-preventative-medicine" class="md-nav__link">
    Preventative Medicine
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-pain-and-palliative" class="md-nav__link">
    Pain and palliative
  </a>
  
    <nav class="md-nav" aria-label="Pain and palliative">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-acute-and-chronic-pain" class="md-nav__link">
    Acute and Chronic Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-code-status-discussion" class="md-nav__link">
    Code Status Discussion
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-death-pronouncement" class="md-nav__link">
    The Death Pronouncement
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-medications-dying-patients" class="md-nav__link">
    Medications for Dying Patients
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-opiate-principles" class="md-nav__link">
    Opiate Principles
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations" class="md-nav__link">
    Video Examples for Navigating Difficult Conversations
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-physical-medicine-rehabilitation" class="md-nav__link">
    Physical medicine rehabilitation
  </a>
  
    <nav class="md-nav" aria-label="Physical medicine rehabilitation">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain" class="md-nav__link">
    Back Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain" class="md-nav__link">
    Knee Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain" class="md-nav__link">
    Neck Pain
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation" class="md-nav__link">
    PM&R Consultation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options" class="md-nav__link">
    Rehabilitation Options
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain" class="md-nav__link">
    Shoulder Pain
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-procedures" class="md-nav__link">
    Procedures
  </a>
  
    <nav class="md-nav" aria-label="Procedures">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#procedures-main" class="md-nav__link">
    About
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-anesthesia" class="md-nav__link">
    Anesthesia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-anticoagulation-parameters" class="md-nav__link">
    Anticoagulation Parameters
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-arterial-line" class="md-nav__link">
    Arterial Line
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-central-line" class="md-nav__link">
    Central line
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-consent" class="md-nav__link">
    Consent
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-dht" class="md-nav__link">
    DHT
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-lumbar-puncture" class="md-nav__link">
    Lumbar Puncture
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-paracentesis" class="md-nav__link">
    Paracentesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-thoracentesis" class="md-nav__link">
    Thoracentesis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#procedures-procedures-ultrasound-guided-peripheral-iv" class="md-nav__link">
    Ultrasound-Guided Peripheral IV
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-psychiatry" class="md-nav__link">
    Psychiatry
  </a>
  
    <nav class="md-nav" aria-label="Psychiatry">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#psychiatry-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-agitation-management" class="md-nav__link">
    Agitation Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-inpatient-insomnia" class="md-nav__link">
    Inpatient Insomnia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-medical-decision-making-capacity" class="md-nav__link">
    Medical Decision-Making Capacity
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-medical-hold" class="md-nav__link">
    Medical Hold
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-motivational-interviewing" class="md-nav__link">
    Motivational Interviewing
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-personality-disorders" class="md-nav__link">
    Personality Disorders
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#psychiatry-psychiatry-substance-use-disorder" class="md-nav__link">
    Substance Use Disorder
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-pulmonary" class="md-nav__link">
    Pulmonary
  </a>
  
    <nav class="md-nav" aria-label="Pulmonary">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#pulmonary-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-acute-asthma-exacerbation" class="md-nav__link">
    Acute Asthma Exacerbation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-blood-gases" class="md-nav__link">
    Blood Gases
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-cf-exacerbation" class="md-nav__link">
    CF Exacerbation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-copd-exacerbation-management" class="md-nav__link">
    COPD Exacerbation Management
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-cxrs" class="md-nav__link">
    CXRs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-hemoptysis" class="md-nav__link">
    Hemoptysis
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-home-oxygen-therapies" class="md-nav__link">
    Home Oxygen Therapies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-hypoxia" class="md-nav__link">
    Hypoxia
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-ild" class="md-nav__link">
    ILD
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pfts" class="md-nav__link">
    PFTs
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pleural-effusions" class="md-nav__link">
    Pleural Effusions
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#pulmonary-pulmonary-pulmonary-hypertension" class="md-nav__link">
    Pulmonary Hypertension
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-radiology" class="md-nav__link">
    Radiology
  </a>
  
    <nav class="md-nav" aria-label="Radiology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-consults-radiology-procedures" class="md-nav__link">
    Consults for Radiology Procedures
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-cxr" class="md-nav__link">
    Basic Chest X-ray Interpretation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-kub" class="md-nav__link">
    Basic Abdominal X-ray Interpretation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#radiology-radiology-radiology-exams-diagnosis" class="md-nav__link">
    Common Radiology Exams by Suspected Diagnosis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-rheumatology" class="md-nav__link">
    Rheumatology
  </a>
  
    <nav class="md-nav" aria-label="Rheumatology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#rheumatology-main" class="md-nav__link">
    Main
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-biologic-overview" class="md-nav__link">
    Biologic Overview
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-common-rheumatologic-diseases" class="md-nav__link">
    Common Rheumatologic Diseases
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-crystal-arthropathy" class="md-nav__link">
    Crystal Arthropathy
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-inflammatory-myopathies" class="md-nav__link">
    Inflammatory Myopathies
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-rheumatology-lab-testing" class="md-nav__link">
    Rheumatology Lab Testing
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#rheumatology-rheumatology-vasculitis" class="md-nav__link">
    Vasculitis
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-toxicology" class="md-nav__link">
    Toxicology
  </a>
  
    <nav class="md-nav" aria-label="Toxicology">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#toxicology-toxicology-brown-recluse-loxoscelism" class="md-nav__link">
    Brown Recluse Bites (Loxoscelism)
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#toxicology-toxicology-overdose-management" class="md-nav__link">
    Management of Specific Overdoses
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#toxicology-toxicology-qtc" class="md-nav__link">
    Drug-Induced QTc Prolongation
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#toxicology-toxicology-toxidrome-overview" class="md-nav__link">
    Toxidrome Overview
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-zcbh" class="md-nav__link">
    zCBH
  </a>
  
    <nav class="md-nav" aria-label="zCBH">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#zcbh-cprs" class="md-nav__link">
    CPRS
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#zcbh-va-notes" class="md-nav__link">
    VA notes
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
        <li class="md-nav__item">
  <a href="#section-appendices" class="md-nav__link">
    Appendices
  </a>
  
    <nav class="md-nav" aria-label="Appendices">
      <ul class="md-nav__list">
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-how-discharges-va" class="md-nav__link">
    "How to" on Discharges at VA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-how-discharges-vumc" class="md-nav__link">
    "How to" on Discharges at VUMC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-interns-guide-rotations-va" class="md-nav__link">
    Interns' Guide to Rotations at VA
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-interns-guide-rotations-vumc" class="md-nav__link">
    Interns' Guide to Rotations
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-staging-wounds" class="md-nav__link">
    Staging Wounds
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-uploading-records" class="md-nav__link">
    Uploading Records to EPIC
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-va-phone-numbers" class="md-nav__link">
    VA Phone Numbers
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-appendices-vumc-phone-directory" class="md-nav__link">
    VUMC Phone Directory
  </a>
  
</li>
        
          <li class="md-nav__item">
  <a href="#appendices-main" class="md-nav__link">
    VUMC Rotations
  </a>
  
</li>
        
      </ul>
    </nav>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          <div class="md-content" data-md-component="content">
            <article class="md-content__inner md-typeset">
              
                


<div id="print-site-page" class="">
        <div id="print-site-banner">
            <p>
    <em>This box will disappear when printing</em>
    <span style="float: right"><a href="https://timvink.github.io/mkdocs-print-site-plugin/">mkdocs-print-site-plugin</a></span>
</p>
<p>
    This page has combined all site pages into one. You can export to PDF using <b>File > Print > Save as PDF</b>.
</p>
<p>
    See also <a href="https://timvink.github.io/mkdocs-print-site-plugin/how-to/export-PDF.html">export to PDF</a> and <a href="https://timvink.github.io/mkdocs-print-site-plugin/how-to/export-HTML.html">export to standalone HTML</a>.
</p>
        </div>
        
        <section class="print-page">
            <div id="print-page-toc" data-toc-depth="3">
                <nav role='navigation' class='print-page-toc-nav'>
                <h1 class='print-page-toc-title'>Table of Contents</h1>
                </nav>
            </div>
        </section>
        <section class="print-page" id="index"><h1 id="index-home">Home<a class="headerlink" href="#index-home" title="Permanent link">&para;</a></h1>
<p>This is the online home of the Vanderbilt Internal Medicine Residency Handbook.</p>
<h1 id="index-dedication">Dedication<a class="headerlink" href="#index-dedication" title="Permanent link">&para;</a></h1>
<p>The authors and editors dedicate the fourth edition of the Housestaff
Handbook to the memory of Dr. Michael Fowler, whose compassion,
sincerity, and commitment to education continue to guide and inspire
us. </p>
<p>Michael J. Fowler, MD, Associate Professor of Medicine and Associate
Professor, Office of Teaching and Learning in Medicine in the Vanderbilt
University School of Medicine, was an inspiring teacher and educator, an
outstanding physician, and a wonderful colleague who passed away on
February 20, 2022. As a Master Clinical Teacher at Vanderbilt, Mike was
the Course Director for Physical Diagnosis and taught physical diagnosis
to more than 1500 Vanderbilt medical students. As Co-director of the
Shade Tree Clinic, he touched the lives of many patients and inspired
Vanderbilt medical students to understand how to be a physician who
cared for the entire patient. He was a wonderful, passionate teacher and
advocate for all students in the clinical setting, in the classroom and
in life, and touched many, many people with his kindness, humor,
intellect, humility, and medical and teaching skills.</p>
<p>– Alvin C. Powers, MD, Nashville, TN, May 2022</p>
<figure>
<p><img alt="QR code for vimbook.org" src="../images/qr-light.svg#only-light" width="300" />
<img alt="QR code for vimbook.org" src="../images/qr-dark.svg#only-dark" width="300" /></p>
<figcaption>QR code link for this online VIMBook</figcaption>
</figure></section>
                        <h1 class='nav-section-title' id='section-introduction'>
                            Introduction <a class='headerlink' href='#section-introduction' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="introduction-introduction-acknowledgements"><h1 id="introduction-introduction-acknowledgements-acknowledgements">Acknowledgements<a class="headerlink" href="#introduction-introduction-acknowledgements-acknowledgements" title="Permanent link">&para;</a></h1>
<p>The Vanderbilt University Medical Center (VUMC) Internal Medicine
Housestaff Handbook began with an Internal Medicine Resident Quality
Improvement Project which was led by Michael J. Neuss, MD, PhD, under
the guidance of Jennifer K. Green, MD, MPH in 2019.</p>
<p>We would like to thank the following individuals for their contributions
to the 4<sup>th</sup> edition of the Housestaff Handbook:</p>
<ul>
<li>The many VUMC residents (past and present) who have meticulously
    authored each section of this handbook.</li>
<li>The VUMC faculty who carefully reviewed each topic for its accuracy.</li>
<li>Leah Brown, MD and Joseph Quintana, MD, the 3<sup>rd</sup> edition's
    co-editors-in-chief, whose guidance was instrumental in the
    transition between editions.</li>
<li>Chase Webber, DO, who was a sounding board for our new ideas
    throughout the year as the Handbook’s faculty advisor.</li>
<li>C. Beau Hilton, MD for his work in updating and improving the online
    version of this handbook.</li>
<li>John McPherson, MD, Kim Rathmell, MD PhD, Kristy Braden and Maria
    Kasel, for their unwavering support.</li>
</ul></section><section class="print-page" id="introduction-introduction-authors-editors-reviewers"><h1 id="introduction-introduction-authors-editors-reviewers-editors-authors-and-reviewers">Editors, Authors, and Reviewers<a class="headerlink" href="#introduction-introduction-authors-editors-reviewers-editors-authors-and-reviewers" title="Permanent link">&para;</a></h1>
<hr />
<h1 id="introduction-introduction-authors-editors-reviewers-editors-in-chief">Editors-in-Chief<a class="headerlink" href="#introduction-introduction-authors-editors-reviewers-editors-in-chief" title="Permanent link">&para;</a></h1>
<p>Soibhan Kelley, MD &amp; Jennifer Marvin-Peek, MD</p>
<hr />
<h1 id="introduction-introduction-authors-editors-reviewers-resident-editors">Resident Editors<a class="headerlink" href="#introduction-introduction-authors-editors-reviewers-resident-editors" title="Permanent link">&para;</a></h1>
<p>Cardiology: Nicholas King, MD </p>
<p>Critical Care: Raymond Dieter, MD</p>
<p>Endocrinology: Kinsley Ojukwu, MD </p>
<p>Gastroenterology: Taylor Riggs, MD </p>
<p>Geriatrics: Thomas Horton, MD </p>
<p>Hematology/Oncology: Michael LaPelusa, MD</p>
<p>Hepatology: Julie Cui, MD </p>
<p>Hospital Medicine: Soibhan Kelley, MD</p>
<p>Infectious Diseases: Kaitlyn Reasoner, MD</p>
<p>Nephrology: Trey Richardson, MD</p>
<p>Neurology: Hunter Hewitt, MD</p>
<p>Ophthalmology: Jonathan Barnett, MD</p>
<p>Outpatient Medicine: Christina Snider, MD</p>
<p>Palliative Care: Eli Cohen, MD</p>
<p>Physical Medicine &amp; Rehabilitation: 
Jakob Dovgan, MD,
Douglas Bryant, MD,
William Galbraith, DO,
and Nicholas Abramson, MD</p>
<p>Procedures: Katherine Heckman, MD </p>
<p>Psychiatry: Soibhan Kelley, MD</p>
<p>Pulmonary: Taryn Boyle, MD</p>
<p>Radiology: Janesh Lakhoo, MD, MS</p>
<p>Rheumatology: Raeann Whitney, MD  </p>
<p>Toxicology: Jennifer Marvin-Peek, MD</p>
<hr />
<h1 id="introduction-introduction-authors-editors-reviewers-faculty-reviewers">Faculty Reviewers<a class="headerlink" href="#introduction-introduction-authors-editors-reviewers-faculty-reviewers" title="Permanent link">&para;</a></h1>
<p>Cardiology:  David Meoli, MD PhD </p>
<p>Critical Care: Todd Rice, MD</p>
<p>Endocrinology: Laura Heller, MD</p>
<p>Gastroenterology: Patrick Yachimski, MD </p>
<p>Geriatrics: Mariu Duggan, MD, MPH</p>
<p>Hematology/Oncology: Rajiv Agarwal, MD and Benjamin Tillman, MD</p>
<p>Hepatology: Manhal J. Izzy, MD</p>
<p>Hospital Medicine: Chase J. Webber, DO</p>
<p>Infectious Diseases: Milner Staub, MD, MPH and Sean Kelly, MD</p>
<p>Nephrology: JP Arroyo, MD PhD, Edward Gould, MD, and Beatrice Concepcion, MD</p>
<p>Neurology: Christopher Lee, MD</p>
<p>Ophthalmology: John Bond, MD</p>
<p>Outpatient: Jennifer K. Green, MD, MPH</p>
<p>Palliative Care: Mohana Karlekar, MD</p>
<p>Physical Medicine &amp; Rehabilitation: C. J. Plummer, MD</p>
<p>Procedures: Garren Montgomery, MD</p>
<p>Psychiatry: Jonathan Smith, MD and Jose Arriola Vigo MD, MPH</p>
<p>Pulmonary: Meredith Pugh, MD</p>
<p>Radiology: Virginia Planz, MD</p>
<p>Rheumatology: Kevin Byram, MD</p>
<p>Toxicology:  Rebecca E. Bruccoleri, MD and Saralyn R. Williams, MD</p></section><section class="print-page" id="introduction-introduction-disclaimers"><h1 id="introduction-introduction-disclaimers-disclaimers">Disclaimers<a class="headerlink" href="#introduction-introduction-disclaimers-disclaimers" title="Permanent link">&para;</a></h1>
<p>The handbook is not a substitute for clinical judgment and is intended
as an educational guide. Content reflects current national guidelines,
as well as practice at VUMC and the Nashville VA. The handbook is not
intended to replace more comprehensive references or guides.</p>
<p>Images are used sparingly, but when used are created by the
authors themselves, available by public domain, or reproduced under fair
use.</p></section><section class="print-page" id="introduction-introduction-rationale"><h1 id="introduction-introduction-rationale-rationale">Rationale<a class="headerlink" href="#introduction-introduction-rationale-rationale" title="Permanent link">&para;</a></h1>
<p>The aim of this handbook is to provide specific, systems-based guidance
on practice at VUMC and the Nashville VA. We hope to provide readers with direct
and actionable guidance, consolidating the combined wisdom of
generations of residents and faculty experts.</p>
<p>The Handbook represents a coordinated effort to disseminate details of
our practice in a standardized, peer-reviewed format. The guidance
provided by the handbook makes legible evidence-based practice as well
as the oral tradition of a resident guiding an intern, or an attending a
resident. We hope that this handbook will inspire confidence and
learning, whether the reader is an intern on July 1 or a senior resident
who wishes to refresh their memory of a topic.</p></section><section class="print-page" id="introduction-introduction-web-app-setup"><h1 id="introduction-introduction-web-app-setup-web-app-setup">Web App Setup<a class="headerlink" href="#introduction-introduction-web-app-setup-web-app-setup" title="Permanent link">&para;</a></h1>
<p>This site is optimized for use on mobile devices. It is possible to set
up a link from your device's home screen that gives it the look and feel
of a web app.</p>
<ul>
<li>iOS users: Go to <a href="http://vimbook.org/">VIMBook.org</a> . At the bottom
    of the screen, hit the "Share" icon (box with upward facing arrow).
    Hit "Add to Home Screen." Rename it to your liking. The gold
    Vanderbilt icon will appear on your home screen, and you can click
    this icon to be taken directly to the website!</li>
<li>Android users:  Go to <a href="http://vimbook.org/">VIMBook.org</a> . Press
    Menu, then select "Bookmarks." Hold it down until "Add Shortcut to
    Home Screen" appears, and click it. This will place an icon on your
    home screen, and you can click this icon to be taken directly to the
    website!</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Introduction</h1>
                        <h1 class='nav-section-title' id='section-cardiology'>
                            Cardiology <a class='headerlink' href='#section-cardiology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="cardiology-cardiology-acs"><h1 id="cardiology-cardiology-acs-acute-coronary-syndromes">Acute Coronary Syndromes<a class="headerlink" href="#cardiology-cardiology-acs-acute-coronary-syndromes" title="Permanent link">&para;</a></h1>
<p>Anna Berry</p>
<hr />
<h2 id="cardiology-cardiology-acs-background">Background<a class="headerlink" href="#cardiology-cardiology-acs-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Completely or partially occluding thrombus on a disrupted
    atherothrombotic coronary plaque leading to myocardial
    ischemia/infarction</li>
<li>STEMI: Elevated troponin &amp; elevation in ST segment or new LBBB with
    symptoms<ul>
<li>> 0.1 mV in at least 2 contiguous leads</li>
<li>Exception, in V2-V3:</li>
<li>> 0.2 mV in men older than 40 y/o</li>
<li>> 0.25 in men younger than 40 y/o</li>
<li>> 0.15 mV in women</li>
</ul>
</li>
<li>NSTEMI: Evidence of myocardial necrosis (elevated troponin) w/o ST
    segment elevation</li>
<li>Unstable Angina: Angina without evidence of myocardial necrosis
    (normal troponin)</li>
<li>Other causes of myocardial injury: coronary spasm, embolism,
    imbalance of oxygen demand and supply 2/2 fever, tachycardia,
    hypo-/hypertension</li>
</ul>
<h2 id="cardiology-cardiology-acs-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-acs-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Classic Angina: dyspnea on exertion, substernal, pressure or
    vice-like quality, improved with rest. Note that response
    nitroglycerin is no longer in the guidelines.</li>
<li>Anginal Equivalents: nausea, weakness, epigastric pain (esp. in age
    > 65 y/o, women, diabetics)</li>
<li>Change in patient’s baseline angina, especially onset at rest</li>
<li>Physical Exam: sinus tachycardia, diaphoresis</li>
<li>If large infarct, can present with symptoms of acute heart failure</li>
</ul>
<h2 id="cardiology-cardiology-acs-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-acs-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>EKG: Compare to prior EKG and assess for<ul>
<li>New ST elevations or ST depressions</li>
<li>T wave inversions: not specific but more concerning if deep (>
    0.3mV)</li>
<li>Biphasic T waves and deep T wave inversions in leads V2 &amp; V3
    (Wellens' sign [LAD])</li>
</ul>
</li>
<li>Cardiac biomarkers: troponin I is most sensitive for myocardial
    injury</li>
<li>ACC/AHA guidelines recommend both EKG and trop q2-6 hours<ul>
<li>Consider this if high suspicion for ACS despite normal initial
    markers</li>
<li>If negative x2, OK to stop trending</li>
</ul>
</li>
<li>Other labs: lipid panel, TSH, A1C</li>
</ul>
<h2 id="cardiology-cardiology-acs-management">Management<a class="headerlink" href="#cardiology-cardiology-acs-management" title="Permanent link">&para;</a></h2>
<h3 id="cardiology-cardiology-acs-stemi">STEMI<a class="headerlink" href="#cardiology-cardiology-acs-stemi" title="Permanent link">&para;</a></h3>
<ul>
<li>STAT page Cardiology on call via Synergy (whether in VA or
    Vanderbilt)</li>
<li>ASAP: aspirin 325mg, heparin drip (high nomogram, with bolus)</li>
<li>Hold P2Y12 receptor blocker until discussed with cards fellow</li>
</ul>
<h3 id="cardiology-cardiology-acs-nstemi">NSTEMI<a class="headerlink" href="#cardiology-cardiology-acs-nstemi" title="Permanent link">&para;</a></h3>
<ul>
<li>Medical management followed by left-heart catheterization within 48
    hours</li>
<li>General: bedrest, telemetry, repeat EKG with recurrent chest pain,
    NPO at midnight</li>
<li>Place cath case request (see “pre-catheterization” management below)</li>
</ul>
<h3 id="cardiology-cardiology-acs-anti-thrombotic-therapy">Anti-thrombotic therapy<a class="headerlink" href="#cardiology-cardiology-acs-anti-thrombotic-therapy" title="Permanent link">&para;</a></h3>
<p>Antiplatelet agents</p>
<ul>
<li>ASA 325 mg loading dose then 81 mg daily after</li>
<li>Do not give P2Y12 receptor blocker until discussed with
        cardiology fellow</li>
<li>Clopidogrel: prodrug that is metabolized to active form (can
            have undermetabolizers), irreversible inhibition</li>
<li>Ticagrelor: reversible inhibitor</li>
<li>Prasugrel: prodrug but more rapidly metabolized than
            clopidogrel with less variation, irreversible inhibition, do
            not use w/ age > 75 or weight \&lt; 60 kg</li>
<li>Prasugrel and ticagrelor are superior to clopidogrel but
            have higher bleeding risk</li>
<li>Cangrelor: IV, rarely used</li>
</ul>
<p>Anti-coagulants</p>
<ul>
<li>Unfractionated heparin drip</li>
<li>Type this in Epic and select “nursing managed” protocol for
        “ACS”</li>
<li>VA: it can be found under the “Orders” tab along the left-hand
        column.</li>
<li>Enoxaparin (LMWH) can be used but requires preserved renal
        function (CrCl > 30) and most interventionalists prefer heparin
        prior to LHC</li>
</ul>
<h3 id="cardiology-cardiology-acs-pre-catheterization-care">Pre-Catheterization Care<a class="headerlink" href="#cardiology-cardiology-acs-pre-catheterization-care" title="Permanent link">&para;</a></h3>
<ul>
<li>Ensure pt. is NPO at MN for planned cath</li>
<li>Continue anticoagulation with heparin gtt</li>
<li>Place cardiac catheterization request (must be in cardiology
    context). Can also call cath lab to ensure pt. is scheduled
    appropriately</li>
</ul>
<h3 id="cardiology-cardiology-acs-post-catheterization-care-catheterization-documentation">Post-Catheterization Care Catheterization Documentation<a class="headerlink" href="#cardiology-cardiology-acs-post-catheterization-care-catheterization-documentation" title="Permanent link">&para;</a></h3>
<ul>
<li>The most appropriate guidance for post-cath care is in the cardiac
    catheterization report</li>
<li>VUMC: Epic Cardiac tab Cardiac Catheterization/Intervention Report</li>
<li>VA: Note tab Post-Procedure note and Cardiac Catheterization note</li>
<li>If there is a delay in filing the final report at VUMC: Review the
    Cardiac Catheterization Nursing Documentation which shows if stents
    were deployed</li>
</ul>
<h3 id="cardiology-cardiology-acs-post-catheterization-heparin">Post-Catheterization Heparin<a class="headerlink" href="#cardiology-cardiology-acs-post-catheterization-heparin" title="Permanent link">&para;</a></h3>
<ul>
<li>Medical management w/o intervention: stop heparin unless directed in
    report</li>
<li>If indication for CABG (ex: Left main, proximal LAD), continue
    heparin gtt until surgery</li>
<li>PCI placed: stop heparin and continue/start DAPT as directed by
    cardiology</li>
<li>Other medical indication for anticoagulation (DVT/PE, atrial
    fibrillation): restart ~ six hours after catheterization</li>
</ul>
<h3 id="cardiology-cardiology-acs-cath-site-checks">Cath Site Checks<a class="headerlink" href="#cardiology-cardiology-acs-cath-site-checks" title="Permanent link">&para;</a></h3>
<ul>
<li>6 - 8 hours post catheterization (typically can be signed out as
    0000 cath check), only needed for femoral arterial access</li>
<li>Look, listen, feel: evaluate for hematoma &amp; pseudoaneurysm; call
    fellow if concerned</li>
<li>Small amount of bruising and mild tenderness at the site is normal</li>
<li>Listen above and below the site for a bruit; the area should be soft</li>
<li>Hypotension after femoral access is concerning for RP bleed<ul>
<li>STAT CBC, CT A/P &amp; call the cardiology fellow</li>
</ul>
</li>
<li>Femoral oozing: Cardiology fellow, will need to hold pressure</li>
<li>Radial oozing: instruct nurse to re-inflate the TR band and restart
    the clock on deflation</li>
</ul>
<h3 id="cardiology-cardiology-acs-post-acs-care">Post ACS Care<a class="headerlink" href="#cardiology-cardiology-acs-post-acs-care" title="Permanent link">&para;</a></h3>
<ul>
<li>Echo prior to discharge</li>
<li>DAPT: Aspirin 81 mg daily and P2Y12 agent</li>
<li>Beta blocker in all patients within 24 hours</li>
<li>Metoprolol, carvedilol &amp; bisoprolol have proven mortality benefit
      with reduced EF</li>
<li>High intensity statin (ex: rosuvastatin 40 or atorvastatin 80). See
    outpatient lipids section</li>
<li>ACEi/ARB if anterior STEMI</li>
<li>Lifestyle Modification: weight loss, smoking cessation, diabetes
    control</li>
<li>See heart failure section for management of HFrEF</li>
</ul>
<h3 id="cardiology-cardiology-acs-acs-complications">ACS Complications<a class="headerlink" href="#cardiology-cardiology-acs-acs-complications" title="Permanent link">&para;</a></h3>
<ul>
<li>VT/VF, sinus bradycardia, third-degree heart block, new VSD, LV
    perforation, acute mitral regurgitation, pericarditis and
    cardiogenic shock; More common with STEMI CCU post-cath</li>
</ul>
<h3 id="cardiology-cardiology-acs-additional-information">Additional Information<a class="headerlink" href="#cardiology-cardiology-acs-additional-information" title="Permanent link">&para;</a></h3>
<ul>
<li>Initiate treatment if there is true concern for ACS and bleeding
    risk acceptable, medications can always be discontinued</li>
<li>TIMI score: >2 correlates with ↑ mortality, indicating a need for
    aggressive treatment</li>
<li>ACC Guideline Clinical App is a useful resource with summaries of
    guideline-based recs</li>
</ul></section><section class="print-page" id="cardiology-cardiology-arrhythmias"><h1 id="cardiology-cardiology-arrhythmias-arrhythmias">Arrhythmias<a class="headerlink" href="#cardiology-cardiology-arrhythmias-arrhythmias" title="Permanent link">&para;</a></h1>
<p>Kunal Patel, Madeline Rukavina</p>
<hr />
<h2 id="cardiology-cardiology-arrhythmias-acute-management-of-arrhythmias">Acute management of arrhythmias<a class="headerlink" href="#cardiology-cardiology-arrhythmias-acute-management-of-arrhythmias" title="Permanent link">&para;</a></h2>
<ul>
<li>12-lead EKG if possible and have defib pads on patient</li>
<li>Is the patient unstable (hypotensive, signs/symptoms of
    hypoperfusion)?</li>
<li>Is the information real?</li>
<li>Review tele strips if stable: VUMC Web Resources -> VUH PIICiX
    Philips Web -> patient selection -> alarm review
    (vuhphilipsweb.app.vumc.org)</li>
<li>Review past EKGs to determine if patient has had this rhythm before</li>
<li>Ensure pt has good IV access</li>
<li>Labs: BMP, Mg, TSH, and &plusmn; troponin, tox screen</li>
</ul>
<hr />
<h2 id="cardiology-cardiology-arrhythmias-bradyarrhythmias">Bradyarrhythmias<a class="headerlink" href="#cardiology-cardiology-arrhythmias-bradyarrhythmias" title="Permanent link">&para;</a></h2>
<p>Kunal Patel</p>
<hr />
<h3 id="cardiology-cardiology-arrhythmias-background">Background<a class="headerlink" href="#cardiology-cardiology-arrhythmias-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Broadly classified as sinus node dysfunction (pacing defect) or
    atrioventricular block (conduction defect)</li>
<li>Clinical presentation varies widely based on underlying cause,
    timing, degree of block/dysfunction</li>
<li>Unlikely to cause symptoms if HR >50</li>
<li>Symptoms include syncope/presyncope, dyspnea, angina</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-etiologies">Etiologies<a class="headerlink" href="#cardiology-cardiology-arrhythmias-etiologies" title="Permanent link">&para;</a></h3>
<ul>
<li>Infection/sepsis</li>
<li>Ischemia</li>
<li>Rheumatologic/Inflammatory</li>
<li>Post-cardiac surgery</li>
<li>Hypothyroidism</li>
<li>Sleep apnea</li>
<li>Infiltration (amyloid, hemochromatosis)</li>
<li>High vagal tone (pain, nausea)</li>
<li>Medications: Antihypertensives, antiarrhythmics, psychoactive meds,
    anesthetics, cannabis, muscle relaxants, etc.</li>
</ul>
<p>Sinus node dysfunction</p>
<ul>
<li>Symptomatic sinus bradycardia, tachy-brady syndrome, chronotropic
    incompetence, sinus pause, SA exit block</li>
<li>Asymptomatic sinus bradycardia (esp in young/healthy patient) is
    unlikely to be true bradyarrhythmia</li>
</ul>
<p>AV Block</p>
<p><img alt="AV block" src="../images/image2.png" /></p>
<h3 id="cardiology-cardiology-arrhythmias-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-arrhythmias-evaluation" title="Permanent link">&para;</a></h3>
<ul>
<li>TTE if structural disease suspected</li>
<li>Ambulatory cardiac monitoring if frequently symptomatic</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-management">Management<a class="headerlink" href="#cardiology-cardiology-arrhythmias-management" title="Permanent link">&para;</a></h3>
<ul>
<li>Avoid nodal blocking agents – Adenosine, Beta-blockers, CCBs,
    Digoxin</li>
<li>Observation if asymptomatic</li>
<li>Treat identified underlying causes</li>
<li>If symptomatic or high-grade block (Mobitz II or complete heart
    block), EP consult for pacemaker evaluation</li>
<li>If unstable:</li>
<li>Atropine (0.5 mg every 3 to 5 minutes; maximum total dose: 3 mg)<ul>
<li>Do NOT use in heart transplant</li>
<li>Call CCU Fellow</li>
<li>Dopamine (5 to 20 mcg/kg/minute) OR Epi (2 to 10 mcg/min)</li>
<li>Transvenous pacing
  (Pacer pads on the defib device are capable of pacing,
  but don’t forget to sedate!)</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-arrhythmias-tachyarrhythmias-narrow-complex">Tachyarrhythmias - Narrow complex<a class="headerlink" href="#cardiology-cardiology-arrhythmias-tachyarrhythmias-narrow-complex" title="Permanent link">&para;</a></h2>
<p>Kunal Patel</p>
<hr />
<h3 id="cardiology-cardiology-arrhythmias-background_1">Background<a class="headerlink" href="#cardiology-cardiology-arrhythmias-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Three causes of tachyarrhythmias<ul>
<li>Re-entry: patient with structural heart disease (ex post-infarction
scar)</li>
<li>Abnormal Automaticity: electrolyte abnormalities or acute ischemia
(Purkinje fibers)</li>
<li>Triggered Activity: early and late after depolarizations. Ex:
Hypokalemia, ischemia, infracts, excess calcium and drug toxicity</li>
</ul>
</li>
</ul>
<p>Tachyarrhythmia differential</p>
<p><img alt="tachyarrhythmia" src="../images/image3.png" /></p>
<h3 id="cardiology-cardiology-arrhythmias-evaluation_1">Evaluation<a class="headerlink" href="#cardiology-cardiology-arrhythmias-evaluation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Unstable tachyarrhythmia</li>
<li>Start with treatment, determine type later</li>
<li>Synchronized cardioversion: place defibrillator pads, consider
    0.5-2mg IV midazolam for sedation, prepare for synchronized
    cardioversion at 200J (can ↑ to 300-360 J)</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-management_1">Management<a class="headerlink" href="#cardiology-cardiology-arrhythmias-management_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Sinus tachycardia<ul>
<li>Almost always secondary</li>
<li>Address underlying causes: fever/sepsis, hypo/hypervolemia, anxiety,
  anemia, PE, ACS, hypoxia, pain, urinary retention, withdrawal</li>
</ul>
</li>
<li>Atrial Fibrillation/Flutter – See Atrial fibrillation section</li>
<li>AVNRT/Orthodromic AVRT<ul>
<li>Look for p buried in QRS, rate 150-250, AVRT will have delta waves
when NSR</li>
<li>Vagal maneuvers (1<sup>st</sup> line): Sit patient upright have them blow into
tip of 10cc syringe for 10-15 seconds rapidly lay supine and raise
legs</li>
<li>Adenosine (2<sup>nd</sup> line): therapeutic (break AVRT/AVNRT) and diagnostic
(allows visualization of underlying rhythm)<ul>
<li>Do NOT give in heart transplant, severe COPD, pre-excitation
causing wide complex tachycardia (WPW antidromic AVRT)</li>
<li>Peripheral line at AC or above w/ arm elevated:
  6mg x1, 6mg x1 (if not effective after 1-2 min),
  12mg x1 (if refractory to 6mg)</li>
<li>Central line: cut dose in half to 3mg x1, 3mg x1, 6mg x1</li>
</ul>
</li>
</ul>
</li>
<li>Multifocal atrial tachycardia<ul>
<li>3 or more p wave morphologies. Seen in cardiac and pulmonary disease</li>
<li>Usually does not cause hemodynamic instability</li>
<li>BBs and non-DHP CCBs can be effective, need to address underlying
  issue</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 24%" />
<col style="width: 31%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Dosing</th>
<th>Benefits</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Metoprolol</td>
<td><p>5mg IV q5m x3</p>
<p>PO metoprolol tartrate 12.5mg q6 hours ↑ every 6 hr to
target</p></td>
<td><p>Good 1st line agent</p>
<p>Less BP effect than dilt</p></td>
<td><p>Hypotension,</p>
<p>Negative inotropy</p></td>
</tr>
<tr class="even">
<td>Diltiazem</td>
<td><p>10-20 mg IV over 2m q15m x2</p>
<p>drip = 5-15 mg/hr</p></td>
<td>Good 1st line w/ normal EF with drip needed</td>
<td><p>Hypotension</p>
<p>Avoid in HFrEF</p></td>
</tr>
<tr class="odd">
<td>Esmolol</td>
<td><p>500 mcg/kg bolus</p>
<p>drip = 50-200 mcg/kg/min</p></td>
<td><p>Rapid onset/offset</p>
<p>RBC metabolism</p></td>
<td>Hypotension</td>
</tr>
<tr class="even">
<td>Amiodarone</td>
<td>150 IV over 10-30m, then 1 mg/m for 6h, then 0.5mg/m for 18h</td>
<td><p>Minimal BP effects</p>
<p>Long lasting; Relatively fast onset (acute effect is mostly beta
blockade)</p></td>
<td><p>Pulmonary and thyroid toxicity</p>
<p>Cardioversion</p></td>
</tr>
<tr class="odd">
<td>Digoxin</td>
<td>500mcg IV x1, then 250mcg IV q6h x2-3</td>
<td>Great for reduced EF, positive inotropy</td>
<td><p>Slow onset</p>
<p>Depends on vagal tone – poor in hyper- adrenergic states</p></td>
</tr>
<tr class="even">
<td>Procainamide</td>
<td>20-50 mg/min loading, 1-4 mg/min maintenance</td>
<td>Use in pre-excitation syndromes (i.e. WPW), does not inhibit AV nodal
conduction</td>
<td><p>Lupus-like syndrome</p>
<p>Hypotension</p></td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-arrhythmias-tachyarrhythmias-wide-complex">Tachyarrhythmias - Wide Complex<a class="headerlink" href="#cardiology-cardiology-arrhythmias-tachyarrhythmias-wide-complex" title="Permanent link">&para;</a></h2>
<p>Madeline Rukavina</p>
<hr />
<h3 id="cardiology-cardiology-arrhythmias-definitions">Definitions<a class="headerlink" href="#cardiology-cardiology-arrhythmias-definitions" title="Permanent link">&para;</a></h3>
<p>Ventricular tachycardia (VT): a run of 3+ PVCs</p>
<ul>
<li>Sustained VT: VT for 30 seconds or shorter if it requires
    intervention</li>
<li>Nonsustained VT (NSVT): VT for \&lt; 30 seconds</li>
<li>VT storm: 3+ separate episodes of sustained VT within 24 hrs.</li>
</ul>
<p>VT Morphologies</p>
<ul>
<li>Monomorphic VT: similar QRS configuration from beat to beat<ul>
<li>Usually 2/2 scar-mediated VT from prior infarction</li>
</ul>
</li>
<li>Polymorphic VT: a continuously changing QRS configuration from beat
    to beat<ul>
<li>Ischemia until proven otherwise</li>
</ul>
</li>
<li>Torsades de Pointes (TdP): a form of polymorphic VT with a continually
    varying QRS that appears to spiral around the baseline of the ECG in
    a sinusoidal pattern</li>
<li>Ventricular fibrillation (VF): chaotic rhythm characterized by
    undulations that are irregular in timing and morphology, without
    discrete QRS complexes</li>
</ul>
<p>Ventricular Tachycardia vs. SVT with aberrancy</p>
<ul>
<li>VT: The action potential originated in the ventricles (ex: VT)</li>
<li>Supraventricular tachycardia with aberrancy: the action potential
    originates from a focus above the ventricles &amp; conducts through the
    AV node with a delay or block resulting in a wide QRS (mimics VT)</li>
<li>Ex: sinus tachycardia w/ bundle branch block (block may be rate
    dependent), AF w/ LBBB</li>
</ul>
<p>Many ways to differentiate VT vs. SVT w/ aberrancy</p>
<ul>
<li>Consult cardiology for assistance</li>
<li>Look for ECG features suggestive of VT</li>
<li>Very broad complexes >160 ms</li>
<li>RsR’ complex with a taller left rabbit ear In V&frac12;</li>
<li>AV dissociation (P/QRS dissociation)</li>
<li>Capture Beats: native QRS complexes making a cameo during the VT</li>
<li>Fusion Beats: QRS which appears like a signal average of VT and
        native complex</li>
</ul>
<p><img alt="capture beat" src="../images/image4.png" />
<img alt="fusion beat" src="../images/image5.png" /></p>
<ul>
<li>There are more advanced criteria to help distinguish. The aVR
    (Vereckie) criteria is one example that is fast and accurate</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-management_2">Management<a class="headerlink" href="#cardiology-cardiology-arrhythmias-management_2" title="Permanent link">&para;</a></h3>
<p>Unstable</p>
<ul>
<li>Sedate with midazolam 1-2mg</li>
<li>Cardioversion for monomorphic VT. Synchronized shock at 100-200J</li>
<li>Defibrillation if VF/polyVT</li>
</ul>
<p>Stable</p>
<ul>
<li>Medications (as below)</li>
</ul>
<table>
<colgroup>
<col style="width: 24%" />
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 24%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug Name</th>
<th>Dosing</th>
<th>Mechanism</th>
<th>Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Amiodarone</td>
<td>150mg IV over 10 min, then 1mg/min for 6 hours; repeat bolus if VT
recurs</td>
<td><p>Class III</p>
<p>-K+ channel blocker; has class Ia, II, &amp; IV effects</p></td>
<td>Bradycardia, hypotension (acutely)</td>
</tr>
<tr class="even">
<td>Lidocaine</td>
<td>1-1.5 mg/kg (usually 75-100 mg) at a rate of 25-50mg/min; lower
doses of .5-.75mg/kg can be repeated every 5-10 min as needed</td>
<td><p>Class IB</p>
<p>-fast Na+ channel blocker-&gt; slows conduction</p></td>
<td>Slurred speech, AMS, seizures, bradycardia</td>
</tr>
<tr class="odd">
<td>Procainamide</td>
<td>20-50mg/min until arrhythmia terminates or max dose 17mg/kg is
reached</td>
<td><p>Class IA</p>
<p>-fast Na+ channel blocker -&gt; slows conduction</p>
<p>-K+ channel blocker-&gt; prolongs repolarization</p></td>
<td><p>Bradycardia, hypotension, torsades, drug-induced lupus</p>
<p>Avoid in HF pts, prolonged QT</p></td>
</tr>
</tbody>
</table>

<ul>
<li>
<p>Cardioversion If refractory to medical management</p>
</li>
<li>
<p>Treatment of underlying cause if identifiable</p>
<ul>
<li>Ischemia, electrolyte disturbances, heart failure, drugs</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-arrhythmias-premature-ventricular-complexes-pvcs">Premature Ventricular Complexes (PVCs)<a class="headerlink" href="#cardiology-cardiology-arrhythmias-premature-ventricular-complexes-pvcs" title="Permanent link">&para;</a></h2>
<p>Madeline Rukavina</p>
<hr />
<h3 id="cardiology-cardiology-arrhythmias-background_2">Background<a class="headerlink" href="#cardiology-cardiology-arrhythmias-background_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Premature Ventricular Complex (PVC): early ventricular
    depolarization &plusmn; mechanical contraction</li>
<li>PVC burden: % of beats of ventricular origin / total beats over a
    24h period</li>
<li>PVCs are common: Up to 80% of apparently healthy people have PVCs</li>
<li>Normal number of PVCs in an adult is \&lt;500 in 24h</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-etiologies_1">Etiologies<a class="headerlink" href="#cardiology-cardiology-arrhythmias-etiologies_1" title="Permanent link">&para;</a></h3>
<ul>
<li>HTN with LVH, prior MI/scar, HF, myocarditis, ARVC, HCM, idiopathic
    VT, OSA, pHTN, COPD, thyroid disease, substance use (EtOH, nicotine,
    stimulants, caffeine)</li>
</ul>
<h3 id="cardiology-cardiology-arrhythmias-inpatient-evaluation-management">Inpatient Evaluation &amp; Management<a class="headerlink" href="#cardiology-cardiology-arrhythmias-inpatient-evaluation-management" title="Permanent link">&para;</a></h3>
<ul>
<li>12 lead EKG: conduction disease, long QT syndrome, Brugada syndrome,
    ARVC</li>
<li>Labs: K, Mg, TSH, drug screen</li>
<li>Evaluate for QT prolonging agents (risk of Torsades)</li>
<li>Evaluate tele for PVC burden</li>
<li>Inpt consult to EP for PVCs rarely warranted unless significant PVC
    burden (>5 PVC/min, consistently) in setting of reduced LVEF.</li>
<li>For pts with >5 PVC/min or pts with symptoms, discharge with
    Ziopatch (VA) or mobile cardiac telemetry (VU) and obtain TTE if
    none recent.</li>
</ul></section><section class="print-page" id="cardiology-cardiology-atrial-fibrillation-and-flutter"><h1 id="cardiology-cardiology-atrial-fibrillation-and-flutter-atrial-fibrillation-flutter">Atrial Fibrillation &amp; Flutter<a class="headerlink" href="#cardiology-cardiology-atrial-fibrillation-and-flutter-atrial-fibrillation-flutter" title="Permanent link">&para;</a></h1>
<p>Brittany Saldivar</p>
<hr />
<h2 id="cardiology-cardiology-atrial-fibrillation-and-flutter-background">Background<a class="headerlink" href="#cardiology-cardiology-atrial-fibrillation-and-flutter-background" title="Permanent link">&para;</a></h2>
<ul>
<li>AF: 12-lead EKG with absence of p-waves and irregularly irregular
    QRS complexes</li>
<li>Flutter: sawtooth atrial F waves (300 BPM) with regular or regularly
    irregular QRS complexes</li>
<li>Ventricular rate ratio of F waves: V waves ~150 (2:1), ~100 (3:1),
    or ~75 (4:1)</li>
<li>3 classifications<ul>
<li>Paroxysmal (terminates within 7 days)</li>
<li>Persistent (persisting beyond 7 days)</li>
<li>Permanent (normal rhythm cannot be restored)</li>
</ul>
</li>
<li>Rapid ventricular response (RVR) is HR > 100 (ie AF/Flutter w/
    tachycardia)</li>
<li>AF/RVR is far more often a consequence of hypotension than the cause
    of it</li>
</ul>
<h2 id="cardiology-cardiology-atrial-fibrillation-and-flutter-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-atrial-fibrillation-and-flutter-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Causes: Mnemonic “H PIRATES”<ul>
<li>Hypertension</li>
<li>Pneumonia, Pericarditis, Post-op</li>
<li>Ischemia (rare)</li>
<li>Rheumatic Valve</li>
<li>Atrial Myxoma or Accessory Pathway</li>
<li>Thyrotoxicosis</li>
<li>Ethanol or Excess Volume</li>
<li>Sick sinus, Sepsis</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-atrial-fibrillation-and-flutter-management">Management<a class="headerlink" href="#cardiology-cardiology-atrial-fibrillation-and-flutter-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Treatment goals<ul>
<li>Rate control, Goal HR \&lt; 110 (RACE II)</li>
<li>Rhythm control (if indicated)</li>
<li>Stroke prevention</li>
</ul>
</li>
</ul>
<p>Rate control (inpatient)</p>
<ul>
<li>RVR ~ sinus tach of AF; Always work to address the underlying cause
    (infection, volume overload, etc). Rate control is rarely an
    emergency unless the patient is unstable</li>
<li>If stable with RVR (SBP >90)<ul>
<li>IV if HR > 130 or symptomatic (metop 5 mg IV or dilt 15-20 mg
    IV), otherwise do PO</li>
<li>AV nodal blocking agents<ul>
<li>B-blockers: Start with metop tartrate (titratable)
  consolidate to succinate. Avoid in decompensated or
  borderline HF</li>
<li>Calcium channel blockers (diltiazem): avoid in HFrEF</li>
</ul>
</li>
</ul>
</li>
<li>Peri stable (SBPs 80s-90 with preserved perfusion)<ul>
<li>Amiodarone: Consider if decompensated HF, accessory pathway,
    anti-coagulated. Caution that you may cardiovert pt (stroke
    risk)</li>
</ul>
</li>
<li>Unstable (SBPs \&lt;80)<ul>
<li>Cardioversion</li>
</ul>
</li>
</ul>
<p>Rate control (outpatient)</p>
<ul>
<li>typically achieved with beta blocker therapy,
  metoprolol is most frequently used</li>
</ul>
<p>Rhythm control (inpatient)</p>
<ul>
<li>New onset a-fib (first time diagnosis): most pts will be a candidate
    for trial of cardioversion</li>
<li>If onset clearly within 48 hours, can proceed without TEE. Often TEE
    is done anyway (pt may have had intermittent asymp AF)</li>
<li>If onset >48 hours or unclear, will need TEE to rule out LAA
    thrombus</li>
<li>Pharmacologic options include class 1C: flecainide, propafenone
    (avoid in structural heart disease) and class 3: Amiodarone,
    dronedarone, sotalol, ibutilide, dofetilide (some require loading
    inpt)<ul>
<li>Caution using antiarrhythmics in any pt you wouldn't
    electrically cardiovert without TEE</li>
</ul>
</li>
</ul>
<p>Rhythm control (outpatient)</p>
<ul>
<li>Consider EP consult for ablation in symptomatic paroxysmal or
    persistent AF refractory to anti-arrhythmic drugs, AF in HFrEF, or
    flutter</li>
<li>Stroke Prevention (for AF and flutter)<ul>
<li>CHA2DS2-VASc risk score >2 in M or >3 in F should prompt long term
AC in AF persisting >48 hours</li>
<li>NOACs (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred to
warfarin except in moderate to severe MS or mechanical valve</li>
</ul>
</li>
<li>If cardioversion planned for new onset AF, start AC as soon as
    possible<ul>
<li>Post-cardioversion, anticoagulate for at least 4 weeks due to
    atrial stunning and stroke risk</li>
</ul>
</li>
<li>If no contraindications or procedures, continue anticoagulation
    while inpatient</li>
<li>Typically do not need to bridge AC for AF in the setting of
    procedures unless mechanical valve is present. Decide on a case
    by-case basis</li>
<li>Left atrial appendage closure can be considered in those with
    increased risk of bleeding</li>
</ul></section><section class="print-page" id="cardiology-cardiology-autonomics-and-orthostatics"><h1 id="cardiology-cardiology-autonomics-and-orthostatics-autonomics-and-orthostatic-hypotension">Autonomics and Orthostatic Hypotension<a class="headerlink" href="#cardiology-cardiology-autonomics-and-orthostatics-autonomics-and-orthostatic-hypotension" title="Permanent link">&para;</a></h1>
<p>Leonard Chiu</p>
<hr />
<h2 id="cardiology-cardiology-autonomics-and-orthostatics-background">Background<a class="headerlink" href="#cardiology-cardiology-autonomics-and-orthostatics-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Orthostatic Hypotension: SBP ↓ > 20 mmHg, DBP ↓ > 10 mmHg), or HR
    Increase > 30 within 3 min of standing up or head-up tilt to 60% on
    a tilt table</li>
<li>Etiologies: Neurogenic OH (nOH) vs non-neurogenic OH</li>
<li>nOH associated with autonomic failure<ul>
<li>Blunted tachycardia during hypotension characteristic of
    autonomic failure</li>
<li>nOH: If HR rise is \&lt;15</li>
<li>nOH also associated with periods of high BP (supine
    hypertension)</li>
<li>Ex: Neurodegenerative disease, neuropathy (diabetes, amyloid,
    paraneoplastic, etc)</li>
</ul>
</li>
<li>Other causes: volume depletion (most common), medications
    (diuretics, alpha-1 blockers, BB, etc), pump failure (severe AS,
    arrhythmia)</li>
</ul>
<h2 id="cardiology-cardiology-autonomics-and-orthostatics-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-autonomics-and-orthostatics-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Orthostatic vitals signs (checking supine, sitting, and standing
    with 5-minute wait in each position)</li>
<li>Volume status exam</li>
<li>Labs: CBC, CMP, EKG, TSH, B12, , LFTs,</li>
<li>Consider SPEP/UPEP, paraneoplastic panel, autonomic function testing
    depending on clinical context</li>
<li>Autonomic Function Testing: Available at 4:15pm Tues, Wed, Thurs NPO
    4 hours prior</li>
<li>Hold oral pressors and antihypertensives 12 hours prior</li>
</ul>
<h2 id="cardiology-cardiology-autonomics-and-orthostatics-management">Management<a class="headerlink" href="#cardiology-cardiology-autonomics-and-orthostatics-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Conservative:</li>
<li>TED hose and abdominal binder for ambulation</li>
<li>Drink 16oz of fluid 15 min prior to standing</li>
<li>If they have supine HTN, keep HOB 30-45 degrees at all times</li>
<li>Add 2.3-4.6g of salt per day to diet (if no contraindications)</li>
<li>Avoid high temperatures (which cause peripheral vasodilation)</li>
<li>Supine HTN therapies: transdermal nitroglycerin (preferred);
    minoxidil, hydralazine, or clonidine in select patients</li>
</ul>
<p>Orthostatic hypotension pharmacologic therapies</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 22%" />
<col style="width: 28%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Dose</th>
<th>Mechanism</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Fludocortisone (Florinef)</td>
<td><p>0.1mg QD</p>
<p>↑ by 0.1 mg</p>
<p>Max: 0.3 mg QD</p></td>
<td>Mineralocorticoid increase blood volume. Enhances sensitivity to
circulating catecholamines</td>
<td><p>Edema</p>
<p>HTN</p>
<p>HypoK</p>
<p>Do not use in CHF</p></td>
</tr>
<tr class="even">
<td>Midodrine</td>
<td><p>2.5mg TID</p>
<p>↑ by 2.5mg</p>
<p>Up to 10mg TID</p></td>
<td>Peripheral-selective α1 agonist → constricts both aa &amp; vv</td>
<td><p>Supine HTN</p>
<p>Pilomotor reactions</p>
<p>Pruritus</p>
<p>GI upset</p>
<p>Avoid in uncontrolled HTN, urinary retention, heart disease</p></td>
</tr>
<tr class="odd">
<td>Droxidopa</td>
<td><p>100mg</p>
<p>↑ by 100mg</p>
<p>Up to 600mg TID</p></td>
<td>NE precursor → carboxylated to NE. Can cross BBB.</td>
<td>Supine HTN, less than midodrine</td>
</tr>
<tr class="even">
<td>Atomoxetine</td>
<td>10mg or 18mg</td>
<td>SNRI</td>
<td>Do not use w/ glaucoma or MAOI</td>
</tr>
</tbody>
</table></section><section class="print-page" id="cardiology-cardiology-bedside-echocardiography"><h1 id="cardiology-cardiology-bedside-echocardiography-bedside-echocardiography">Bedside Echocardiography<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-bedside-echocardiography" title="Permanent link">&para;</a></h1>
<p>Jamie Pfaff</p>
<hr />
<h2 id="cardiology-cardiology-bedside-echocardiography-finding-an-ultrasound">Finding an Ultrasound<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-finding-an-ultrasound" title="Permanent link">&para;</a></h2>
<ul>
<li>MICU: radiology room behind charge nurse’s desk in middle hallway</li>
<li>VA ICU: In front of resident workspace</li>
<li>8N: Behind nurses station before entering cleaning supply room</li>
<li>8S: In supply closet to left as your walk toward nursing station -
    (door code is 1-3-5)</li>
<li>6MCE: COVID restricted (ask nurses)</li>
<li>CCU/5N only: supply room on left as entering CCU</li>
<li>Round wing: 5<sup>th</sup> floor, ask nurses</li>
</ul>
<h2 id="cardiology-cardiology-bedside-echocardiography-tte-standard-views">TTE Standard Views<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-tte-standard-views" title="Permanent link">&para;</a></h2>
<p><img alt="image" src="../images/image10.jpeg" /></p>
<h3 id="cardiology-cardiology-bedside-echocardiography-parasternal-long">Parasternal long<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-parasternal-long" title="Permanent link">&para;</a></h3>
<p><img alt="image" src="../images/image9.png" />
<img alt="image" src="../images/image8.png" /></p>
<ul>
<li>Probe position: Rotate probe 180 degrees with right edge of
    probe/probe marker pointing toward patient’s left shoulder</li>
<li>
<p>Make sure probe is centered over mitral valve (In right spot if you
    can see MV and AV)</p>
<ul>
<li>Distance separating the anterior MV leaflet from the septal wall
    as measure of LV systolic function (easy evaluation of systolic
    function)</li>
<li>Place M mode spike at tip of mitral leaflet and hit M mode
    (perpendicular to septum)</li>
<li>Identify E point (passive filling of LV) and determine distance
    from interventricular septum (IVS)<ul>
<li>\&lt;7mm = Normal</li>
<li>>10mm = HF</li>
</ul>
</li>
<li>Confounders that elevate EPSS: AR, MS</li>
</ul>
</li>
</ul>
<h3 id="cardiology-cardiology-bedside-echocardiography-parasternal-short">Parasternal short<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-parasternal-short" title="Permanent link">&para;</a></h3>
<ul>
<li>Probe position: Rotate probe 180 degrees with right edge of
    probe/probe marker pointing toward patient’s left shoulder</li>
<li>Good position to assess EF by visualizing wall thickening</li>
</ul>
<p>Apical four chamber</p>
<ul>
<li>Probe position: Slide down and look near patient’s left nipple (or
    in the intermammary fold after lifting up breast tissue if needed -
    at PMI if able to palpate)</li>
<li>Good to assess EF by visualizing cardiac shortening</li>
</ul>
<h3 id="cardiology-cardiology-bedside-echocardiography-subxiphoid">Subxiphoid<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-subxiphoid" title="Permanent link">&para;</a></h3>
<ul>
<li>Probe position: Push probe head into patient’s abdomen just below
    xiphoid and flatten probe to make nearly parallel to patient’s
    position, marker to pt’s left</li>
<li>Troubleshooting: shift probe slightly left of midline (toward
    patient’s right) and angle toward heart/right to use liver as
    acoustic window or ask patient to take big breath (moves heart
    closer to probe)</li>
<li>Best window to visualize pericardial effusion</li>
</ul>
<h3 id="cardiology-cardiology-bedside-echocardiography-ivc">IVC<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-ivc" title="Permanent link">&para;</a></h3>
<figure>
<p><img alt="image" src="../images/image11.jpeg" /></p>
</figure>
<ul>
<li>Probe position: subxiphoid area with probe marker facing toward
    patient’s head tilted slightly left of midline, trace IVC into RA to
    verify correct vessel (vs aorta)</li>
<li>IVC size and collapsibility used as a surrogate for CVP and RAP<ul>
<li>\&lt;2.1 cm and >50% collapse: RAP ~3mmHg</li>
<li>\&lt;2.1 cm and \&lt; 50% collapse or >2.1cm and >50% collapse: RAP
    ~8mmHg</li>
<li>>2.1cm, \&lt;50% collapse: RAP ~ >15mmHg</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-bedside-echocardiography-resources">Resources<a class="headerlink" href="#cardiology-cardiology-bedside-echocardiography-resources" title="Permanent link">&para;</a></h2>
<ul>
<li><a href="https://www.coreultrasound.com/basic-cardiac-function/">https://www.coreultrasound.com/basic-cardiac-function/</a></li>
<li><a href="http://pie.med.utoronto.ca/tte">http://pie.med.utoronto.ca/tte</a></li>
<li><a href="https://www.echocardiographer.org/TTE.html">https://www.echocardiographer.org/TTE.html</a></li>
<li>App: FATE CARD (Focus Assessed Transthoracic Echocardiography)</li>
</ul></section><section class="print-page" id="cardiology-cardiology-cardiac-devices"><h1 id="cardiology-cardiology-cardiac-devices-cardiac-devices">Cardiac Devices<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-cardiac-devices" title="Permanent link">&para;</a></h1>
<p>Marcus Threadcraft</p>
<hr />
<h2 id="cardiology-cardiology-cardiac-devices-types-of-cardiac-implantable-electronic-devices-cied">Types of Cardiac Implantable Electronic Devices (CIED)<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-types-of-cardiac-implantable-electronic-devices-cied" title="Permanent link">&para;</a></h2>
<ul>
<li>For Controlling Arrhythmias: Implantable Pulse Generators</li>
<li>Pacemakers: Anti-bradycardia pacing</li>
<li>ICDs: Anti-tachycardia pacing and defibrillation</li>
<li>Biventricular Pacemakers: CRT for ventricular dyssynchrony (LBBB &amp;
    Heart Failure)</li>
<li>Loop Recorders: implantable devices for monitoring arrhythmias (most
    often Afib)</li>
<li>LVADs: augment cardiac output for end-stage heart failure (not
    covered here)</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-pacemakers">Pacemakers<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-pacemakers" title="Permanent link">&para;</a></h3>
<ul>
<li>Provide anti-bradycardia pacing by stimulating myocardium</li>
<li>Peripheral permanent pacemakers (PPMs)</li>
<li>SubQ generator, transvenous leads<ul>
<li>Single chamber RV lead</li>
<li>Dual chamber RV and RA leads</li>
<li>BiV: RV, RA, and LV (coronary sinus) leads</li>
</ul>
</li>
<li>Leadless pacemaker<ul>
<li>Implanted generator in RV</li>
</ul>
</li>
</ul>
<p>Indications</p>
<ul>
<li>Symptomatic Bradycardia</li>
<li>Heart Block: 2<sup>nd</sup> Degree Type II w/ sx or 3<sup>rd</sup> Degree</li>
<li>Sick Sinus Syndrome</li>
<li>Carotid Sinus Syndrome</li>
<li>After catheter ablation of AV node for AF</li>
<li>CRT</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-implantable-cardioverterdefibrillators-icds">Implantable Cardioverter/Defibrillators (ICDs)<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-implantable-cardioverterdefibrillators-icds" title="Permanent link">&para;</a></h3>
<ul>
<li>Pacing lead + defibrillation coil</li>
<li>Detect and treat VT/VF v<ul>
<li>Anti-tachycardia pacing (ATP)- attempts to entrain and terminate
    VT</li>
<li>Defibrillation If ATP unsuccessful</li>
</ul>
</li>
</ul>
<p>Indications</p>
<ul>
<li>Primary prevention<ul>
<li>HFrEF<ul>
<li>EF \&lt;35% and NYHA II-III or EF \&lt;30% and NYHA I</li>
<li>Must be >90d from revasc, >40d from MI, and on GDMT</li>
</ul>
</li>
<li>Arrhythmogenic syndromes<ul>
<li>Arrhythmogenic RV cardiomyopathy, Brugada syndrome, HCM and
    cardiac sarcoid with specific risk factors</li>
</ul>
</li>
</ul>
</li>
<li>Secondary prevention<ul>
<li>Hx VF arrest or VT</li>
<li>Inducible VT on EP study with history of syncope</li>
</ul>
</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-cardiac-resynchronization-therapy-crt">Cardiac Resynchronization Therapy (CRT)<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-cardiac-resynchronization-therapy-crt" title="Permanent link">&para;</a></h3>
<ul>
<li>BiV pacer that coordinates LV/RV contraction through synchronized
    activation of each ventricle following atrial contraction.</li>
<li>-P: CRT pacing only</li>
<li>-D: ICD function</li>
</ul>
<p>Indications</p>
<ul>
<li>Class I: LBBB and QRS≥150 with EF\&lt;35%, NYHA II- IV, on GDMT, NSR</li>
<li>Class IIa: EF\&lt;35%, NYHA II- IV, on GDMT, NSR AND<ul>
<li>LBBB &amp; QRS 120-149, non-LBBB &amp; QRS≥150, or EF\&lt;35% and expected
    to require >40% ventricular pacing</li>
</ul>
</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-interpreting-pacemaker-codes">Interpreting Pacemaker Codes<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-interpreting-pacemaker-codes" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th></th>
<th>1<sup>st</sup> Letter</th>
<th>2<sup>nd</sup> Letter</th>
<th>3<sup>rd</sup> Letter</th>
<th>4<sup>th</sup> Letter</th>
</tr>
</thead>
<tbody>
<tr>
<td>A: atrial, V: ventricular, D: dual, O: none, I: inhibition, R: rate-adaptive</td>
<td>Chamber Paced</td>
<td>Chamber Sensed</td>
<td>Response to Sensed Beat</td>
<td>Program Features</td>
</tr>
</tbody>
</table>
<h3 id="cardiology-cardiology-cardiac-devices-examples-of-common-pacing-modes">Examples of Common Pacing Modes<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-examples-of-common-pacing-modes" title="Permanent link">&para;</a></h3>
<ul>
<li>VVI: Single RV lead that delivers a beat if no beat sensed. Often
    used with chronic AF with bradycardia</li>
<li>DDDR: Senses and paces both the atria and ventricle. If beat not
    sensed within a predefined interval, beat delivered. R indicates
    rate responsivity (changes rate based on changes in patient
    activity)</li>
<li>Magnet: Paces at a fixed rate without respect to native electrical
    activity (AOO,VOO,DOO). Deactivates ICD shock. Often used in surgery
    or at end of life to avoid ICD shocks</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-additional-configurations">Additional Configurations<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-additional-configurations" title="Permanent link">&para;</a></h3>
<ul>
<li>Epicardial Leads- pacemaker/defibrillator leads attached to outside
    of the heart (requires OR) vs traditional transvenous lead
    placement, which are inserted in the Cath Lab<ul>
<li>Epicardial Leads generally placed in smaller children or during
    cardiac surgery with expected need for pacing/defibrillation</li>
</ul>
</li>
<li>Abandoned leads<ul>
<li>Absolute contraindication to MRI (ungrounded, produces heat and
    thermal Injury In setting of magnetic field)</li>
</ul>
</li>
</ul>
<h3 id="cardiology-cardiology-cardiac-devices-placement-complications">Placement Complications<a class="headerlink" href="#cardiology-cardiology-cardiac-devices-placement-complications" title="Permanent link">&para;</a></h3>
<ul>
<li>Acute: pocket hematoma, pneumothorax, myocardial perforation,
    cardiac tamponade, infection, lead displacement or disconnection</li>
<li>Long-term: secondary device infection, lead fracture (lead lifetime
    10-15 years), insulation failure</li>
</ul>
<p><img alt="image" src="../images/image6.tiff" /></p></section><section class="print-page" id="cardiology-cardiology-chest-pain"><h1 id="cardiology-cardiology-chest-pain-chest-pain">Chest Pain<a class="headerlink" href="#cardiology-cardiology-chest-pain-chest-pain" title="Permanent link">&para;</a></h1>
<p>Nicholas King</p>
<hr />
<h2 id="cardiology-cardiology-chest-pain-chest-pain-angina-framework">Chest Pain / Angina Framework<a class="headerlink" href="#cardiology-cardiology-chest-pain-chest-pain-angina-framework" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Determining likelihood that chest pain has a cardiac etiology
    depends on symptoms and lies on a spectrum</p>
</li>
<li>
<p>Cardiac > possible cardiac > noncardiac is more useful than
    typical vs atypical angina</p>
</li>
</ul>
<h2 id="cardiology-cardiology-chest-pain-diagnoses-not-to-miss-the-serious-six">Diagnoses Not to Miss: “The Serious Six”<a class="headerlink" href="#cardiology-cardiology-chest-pain-diagnoses-not-to-miss-the-serious-six" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute Coronary Syndrome</li>
<li>Mediastinitis (e.g, esophageal perforation)</li>
<li>Aortic Dissection/Aneurysm</li>
<li>Cardiac Tamponade</li>
<li>Pulmonary Embolus</li>
<li>Pneumothorax</li>
</ul>
<h2 id="cardiology-cardiology-chest-pain-other-differential-diagnoses">Other Differential Diagnoses<a class="headerlink" href="#cardiology-cardiology-chest-pain-other-differential-diagnoses" title="Permanent link">&para;</a></h2>
<ul>
<li>Skin: Laceration, herpes zoster</li>
<li>Subcutaneous: cellulitis, abscess</li>
<li>Musculoskeletal: Costochondritis, fracture, myositis, sprain/strain</li>
<li>Pleural space (no pain receptors in the lung): PNA, tumor, pleuritis</li>
<li>Pericardium: Pericarditis</li>
<li>Heart: Myocarditis, spontaneous coronary artery dissection (SCAD),
    coronary vasospasm, aortic stenosis, stress-induced cardiomyopathy
    (Takotsubo), decompensated heart failure</li>
<li>Esophagus: GERD, esophagitis</li>
<li>Trachea: Tracheitis, tracheal tear</li>
</ul>
<h2 id="cardiology-cardiology-chest-pain-physical-exam">Physical Exam<a class="headerlink" href="#cardiology-cardiology-chest-pain-physical-exam" title="Permanent link">&para;</a></h2>
<ul>
<li>Vitals: BP in both arms (do while interviewing - quick, easy,
    inexpensive)</li>
<li>Hemodynamic profile (warm/dry, warm/wet, cold/dry, cold/wet)</li>
<li>Palpate chest: evaluate costochondral junction, subcutaneous
    emphysema, examine skin</li>
<li>Cardiac: murmurs, rub for pericarditis, JVD for heart failure or PE
    with RV strain</li>
<li>Pulm: absent breath sounds for PTX, crackles for left heart failure,
    PNA</li>
<li>Abdomen: abdominal pain mistaken or referred as chest pain</li>
<li>Extremities: asymmetric leg swelling (>2 cm difference) for DVT/PE</li>
</ul>
<h2 id="cardiology-cardiology-chest-pain-diagnostic-studies">Diagnostic Studies<a class="headerlink" href="#cardiology-cardiology-chest-pain-diagnostic-studies" title="Permanent link">&para;</a></h2>
<ul>
<li>EKG: ACS (STEMI, new LBBB, ST depressions, T wave Inversions,
    Wellens' sign), pericarditis, pericardial effusion</li>
<li>Labs: Troponin (ACS, PE, myocarditis), CBC, BNP, lactate</li>
<li>CXR: PTX, PNA, dissection, esophageal rupture</li>
<li>Bedside ultrasound: pericardial effusion, R heart strain for PE,
    wall motion abnormality for infarct/ischemia or stress-induced CM,
    valvular disease, lung sliding/PTX</li>
<li>CTA: gold standard for PE. Dissection can be diagnosed w/ CTA, MRA,
    or TEE</li>
</ul>
<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 19%" />
<col style="width: 19%" />
<col style="width: 20%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="5"><br />
Evaluation for Coronary Disease</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Test</td>
<td>Indications</td>
<td>Benefits</td>
<td>Risks</td>
<td>Considerations</td>
</tr>
<tr class="even">
<td>EKG Stress</td>
<td rowspan="6"><p>Low to Intermediate risk patients</p>
<p><em>Do not stress active or suspected ACS</em></p>
<p>Serves as screening with high NPV</p></td>
<td>Functional status w/ Bruce treadmill protocol</td>
<td><p>Exercise tolerance</p>
<p>limits use</p></td>
<td><p>Cannot have LBBB,</p>
<p>nondiagnostic if 85% target HR not achieved</p></td>
</tr>
<tr class="odd">
<td>Dobutamine Echo Stress</td>
<td>More sensitive than EKG</td>
<td>Contraindicated: arrhythmias, LVOT obstruction, HTN, AS</td>
<td><p>Can be useful to eval low grade low flow AS</p>
<p>Hold BB</p></td>
</tr>
<tr class="even">
<td>SPECT stress</td>
<td><p>More sensitive than echo,</p>
<p>Assess viability</p></td>
<td>Adenosine or Regadenason contraindicated in reactive airway
disease</td>
<td>No caffeine or theophylline prior</td>
</tr>
<tr class="odd">
<td>PET stress</td>
<td><p>Better PPV than Echo</p>
<p>Assess viability</p></td>
<td colspan="2">Better for pts with larger abdominal girth (less
diaphragmatic attenuation)</td>
</tr>
<tr class="even">
<td>Cardiac MRI</td>
<td>Assesses viability</td>
<td colspan="2">Can assess nonischemic vs ischemic cardiomyopathy; HR
must be &lt; 70, gold standard for structure and function</td>
</tr>
<tr class="odd">
<td>Coronary CT</td>
<td>Very high NPV for stenosis</td>
<td><p>Contrast media reactions</p>
<p>CIN lower risk than cath</p></td>
<td><p>Might have poor lumen visualization if heavy calcium burden</p>
<p>HR &lt; 70</p></td>
</tr>
<tr class="even">
<td>Coronary Angiogram</td>
<td><p>STEMI</p>
<p>High risk NSTEMI:</p>
<p>Refractory angina, new arrhythmia, cardiogenic shock (HF)</p>
<p>Suspected true ACS</p>
<p>Diagnostic and Therapeutic</p></td>
<td><p>Direct visualization of lumen</p>
<p>Therapeutic PCI</p></td>
<td><p>CIN with contrast</p>
<p>Cath site complications</p>
<p>Rare: SCAD, cholesterol emboli</p></td>
<td><p>Positive Screen (above) necessitates LHC</p>
<p>Case request cath lab</p>
<p>NPO MN prior</p>
<p>Groin check if femoral access</p></td>
</tr>
</tbody>
</table></section><section class="print-page" id="cardiology-cardiology-chf"><h1 id="cardiology-cardiology-chf-heart-failure">Heart Failure<a class="headerlink" href="#cardiology-cardiology-chf-heart-failure" title="Permanent link">&para;</a></h1>
<p>Brittany Saldivar</p>
<hr />
<h2 id="cardiology-cardiology-chf-background">Background<a class="headerlink" href="#cardiology-cardiology-chf-background" title="Permanent link">&para;</a></h2>
<p>ACC/AHA Stages of HF</p>
<ul>
<li>Stage A: At risk but without structural heart disease or symptoms</li>
<li>Stage B: + structural HD, - symptoms</li>
<li>Stage C: + structural HD, + prior or current symptoms</li>
<li>Stage D: refractory HF requiring specialized intervention</li>
</ul>
<p>NY Heart Association (NYHA) Functional Classes of HF</p>
<ul>
<li>Class I: Normal physical activity is not limited</li>
<li>Class II: Comfortable at rest; normal physical activity results in
    HF symptoms</li>
<li>Class III: Comfortable at rest; less than normal activity leads to
    HF symptoms</li>
<li>Class IV: Inability to perform any physical activity without
    symptoms</li>
</ul>
<h2 id="cardiology-cardiology-chf-etiologies">Etiologies<a class="headerlink" href="#cardiology-cardiology-chf-etiologies" title="Permanent link">&para;</a></h2>
<ul>
<li>HFrEF (Clinical diagnosis + LVEF \&lt; 40%)<ul>
<li>Ischemic: Obstructive CAD, previous/current myocardial
    infarction</li>
<li>Non-ischemic:<ul>
<li>Load: HTN, valvulopathy</li>
<li>Arrhythmia: tachyarrhythmia, pacemaker induced</li>
<li>Myocardium</li>
</ul>
</li>
<li>Toxins (EtOH, drugs, chemo, radiation),</li>
<li>Inflammatory (infections, AI),</li>
<li>Metabolic (thyroid, thiamine deficiency),</li>
<li>Infiltrative (amyloid, sarcoid, hemochromatosis)</li>
<li>Stress induced/takotsubo CM<ul>
<li>Genetic</li>
<li>Idiopathic</li>
</ul>
</li>
</ul>
</li>
<li>HFpEF: HTN, CAD, obesity, DM, infiltrative, hypertrophic
    cardiomyopathy</li>
</ul>
<p>Causes of Heart Failure Exacerbations (FAILURES)</p>
<ul>
<li>Forgetting medications or taking drugs that can worsen HF (e.g. BB,
    CCB, NSAIDs, TZDs), chemo (anthracyclines, trastuzumab)</li>
<li>Arrhythmia/Anemia: AF, VT, PVCs; Increased arrhythmia burden on
    device check?</li>
<li>Ischemia/Infarction/Infection: myocarditis; Acute vascular
    dysfunction (e.g. endocarditis), especially mitral or aortic
    regurgitation.</li>
<li>Lifestyle choices: Dietary indiscretions - high salt, EtOH,
    excessive fluid intake. Obesity.</li>
<li>Upregulation (of CO): pregnancy and hyperthyroidism</li>
<li>Renal failure: acute, progression of CKD, or insufficient dialysis
    (Increased preload)</li>
<li>Embolus (pulmonary) or COPD (leads to increase right-sided
    afterload)</li>
<li>Stenosis (worsening AS, RAS) leading to hypertensive crisis high
    left-sided afterload</li>
</ul>
<h2 id="cardiology-cardiology-chf-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-chf-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Volume overload: shortness of breath, dyspnea on exertion,
    Orthopnea, PND</li>
<li>Nausea/poor po intake (hepatic and gut congestion)</li>
<li>Confusion (decreased CO)</li>
<li>Exam: Edema (legs, sacrum), rales, S3, S4, murmur (AS, MR), elevated
    JVD, + hepatojugular reflex, ascites</li>
</ul>
<h2 id="cardiology-cardiology-chf-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-chf-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>CBC, CMP, Magnesium, Lactate, TSH, iron studies</li>
<li>Troponin, ECG</li>
<li>BNP (Pro-BNP if on Entresto) – high negative predictive value for HF
    (false negative can occur in obese patients)</li>
<li>CXR – differentiate other causes of dyspnea</li>
<li>TTE</li>
<li>Determine hemodynamic and volume profile<ul>
<li>Cold vs warm</li>
<li>Dry vs wet</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 23%" />
<col style="width: 25%" />
<col style="width: 31%" />
</colgroup>
<thead>
<tr class="header">
<th>Cardiac Index</th>
<th></th>
<th>Euvolemia</th>
<th>Hypervolemia</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Low</td>
<td><p>Warm Extremities</p>
<p>Adequate UOP</p>
<p>Normal PPP</p></td>
<td><p>Warm and Dry</p>
<p>Forrester Class I</p>
<p>Tx: GDMT as tolerated</p></td>
<td><p>Warm and Wet</p>
<p>Forrester Class II</p>
<p>Tx: Diuresis, Vasodilators</p></td>
</tr>
<tr class="even">
<td>Normal</td>
<td><p>Cardiogenic Shock</p>
<p>Cool Extremities</p>
<p>Renal Failure</p>
<p>Narrow PP</p></td>
<td><p>Cold and Dry</p>
<p>Forrester Class III</p>
<p>Tx: Inotropes</p></td>
<td><p>Cold and Wet</p>
<p>Forrester Class IV</p>
<p>Tx: Diuresis +Tailored therapy (+/- vasodilators, inotropes)</p></td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-chf-management">Management<a class="headerlink" href="#cardiology-cardiology-chf-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Telemetry, Daily STANDING weights, 2 L fluid restriction, 2g sodium
    diet, strict I/Os</li>
<li>Diuresis: Place on 2.5 x home dose of IV diuretic, dose BID-TID
    (DOSE Trial)</li>
<li>Goal is to be net negative (generally 1-2 L per day but patient
    dependent)</li>
<li>Check BMP BID and Mg QD, keep K>4 and Mg>2</li>
<li>Low threshold for substantial increase (double) in loop vs
    transition to drip if not diuresing adequately</li>
<li>Can also augment with sequential nephron blockade (thiazides,
    acetazolamide)</li>
<li>Continuation/optimization of GDMT (below)</li>
</ul>
<hr />
<h1 id="cardiology-cardiology-chf-guideline-directed-medical-therapy-for-hfref">Guideline-Directed Medical Therapy for HFrEF<a class="headerlink" href="#cardiology-cardiology-chf-guideline-directed-medical-therapy-for-hfref" title="Permanent link">&para;</a></h1>
<p>Brittany Saldivar</p>
<hr />
<h2 id="cardiology-cardiology-chf-general-principles">General Principles<a class="headerlink" href="#cardiology-cardiology-chf-general-principles" title="Permanent link">&para;</a></h2>
<ul>
<li>Starting patients on low dose of multiple agents preferred to max
    dose of single agent</li>
<li>D/C summary should have discharge weight, diuretic regimen, and
    renal function</li>
<li>Daily weights at home with rescue diuretic plan (pm dose for 3 lbs
    in 1 day, 5 lbs in 3 days</li>
</ul>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 26%" />
<col style="width: 26%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Indication</th>
<th>Mechanism/ Benefits</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td colspan="4">Beta Blockers</td>
</tr>
<tr class="even">
<td><p>Carvedilol</p>
<p>Metoprolol succinate</p>
<p>Bisoprolol</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>Reduces catecholamine stimulation. Decreased HR, myocardial energy
demand, less adverse remodeling.</td>
<td><p>Avoid if pt is decompensated (cold); “start low and go slow”</p>
<p>Can continue during exacerbation if patient compensated</p></td>
</tr>
<tr class="odd">
<td colspan="4">ARNIs</td>
</tr>
<tr class="even">
<td>Sacubitril/ valsartan</td>
<td><p>HFrEF &lt; 40%</p>
<p>NYHA class II – IV</p>
<p>Used in place of ACE/ARB</p></td>
<td>Prevents vasoactive natriuretic peptide degradation involved in
pathogenesis of HF (+ action of ARB)</td>
<td><p>Need a 36 hr wash-out period if transitioning from ACEi to
ARNI</p>
<p>Hypotension</p>
<p>Risk of angioedema</p></td>
</tr>
<tr class="odd">
<td colspan="4">ACEIs</td>
</tr>
<tr class="even">
<td><p>Lisinopril</p>
<p>Enalapril</p>
<p>Captopril</p>
<p>Ramipril</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>Blocks harmful effects of RAAS activation and attenuates adverse
cardiac and vascular remodeling</td>
<td><p>Risk of angioedema</p>
<p>Monitor renal function and K</p></td>
</tr>
<tr class="odd">
<td colspan="4">ARBs</td>
</tr>
<tr class="even">
<td><p>Losartan</p>
<p>Valsartan</p>
<p>Candesartan</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>See ACEIs</td>
<td><p>See ACEIs</p>
<p>Preference for ARB &gt; ACEi if plans to start ARNI</p></td>
</tr>
<tr class="odd">
<td colspan="4">MRAs</td>
</tr>
<tr class="even">
<td><p>Eplerenone</p>
<p>Spironolactone</p></td>
<td><p>NYHA class II-IV and</p>
<p>GFR &gt;30</p></td>
<td>Diuretic and blood pressure lowering effects and blocks deleterious
effects of aldosterone on the heart (including hypertrophy and
fibrosis)</td>
<td>Hyperkalemia – avoid if CrCl &lt;30 or K &gt;5</td>
</tr>
<tr class="odd">
<td colspan="4">SGLT2i</td>
</tr>
<tr class="even">
<td><p>Dapagliflozin</p>
<p>Empagliflozin</p></td>
<td><p>HFrEF &lt;40% with and without DM</p>
<p>NYHA class II-IV</p>
<p>In conjunction with background GDMT</p></td>
<td>Osmotic diuresis and natriuresis, improve myocardial metabolism,
inhibit sodium-hydrogen exchange in myocardium, reduce cardiac
fibrosis</td>
<td><p>UTI/ GU infections</p>
<p>Risk of ketoacidosis (both DKA and euglycemic)</p></td>
</tr>
<tr class="odd">
<td colspan="4">Vasodilators</td>
</tr>
<tr class="even">
<td><p>Hydralazine</p>
<p>Isosorbide Dinitrate</p></td>
<td><p>Persistently symptomatic black patients despite ARNI/ BB/ MRA/
SGLT2i</p>
<p>NYHA class III-IV</p></td>
<td><p>Reduces cardiac afterload and preload and may also enhance nitric
oxide bioavailability</p>
<p>Reduction in mortality for African American patients</p></td>
<td>Hypotension</td>
</tr>
<tr class="odd">
<td colspan="4">Ivabradine</td>
</tr>
<tr class="even">
<td>Ivabradine</td>
<td><p>HFrEF &lt;35%, on maximally tolerated BB, sinus rhythm with HR
&gt; 70</p>
<p>NYHA class II or III</p></td>
<td><p>If current inhibitor involved in SA node activity</p>
<p>Decr HR associated with improved outcomes</p></td>
<td><p>Need sinus rhythm</p>
<p>Caution in sinus node disease and conduction defects</p></td>
</tr>
<tr class="odd">
<td colspan="4">Iron Repletion (IV)</td>
</tr>
<tr class="even">
<td><p>Iron sucrose</p>
<p>Ferric carboxymaltose</p>
<p>Iron dextran</p></td>
<td>Ferritin &lt;100 µg/L or ferritin 100-299 µg/L AND transferrin
saturation &lt;20%</td>
<td><p>Decreases HF hospitalizations</p>
<p>Improves exercise function and QOL</p></td>
<td>Risk of anaphylaxis higher in iron dextran</td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-chf-device-therapies-after-optimization-of-medical-gdmt">Device therapies (after optimization of medical GDMT)<a class="headerlink" href="#cardiology-cardiology-chf-device-therapies-after-optimization-of-medical-gdmt" title="Permanent link">&para;</a></h2>
<ul>
<li>Cardiac resynchronization therapy (CRT)<ul>
<li>Class I indication: NYHA class II to IV, LVEF ≤35% with QRS ≥150 ms
and left bundle branch block (LBBB)</li>
<li>Class II (consider) If EF \&lt; 35% and:<ul>
<li>QRSd > 150, without LBBB</li>
<li>AF that requires ventricular pacing and AVN ablation</li>
<li>Undergoing placement of device with anticipation of >40%
ventricular pacing</li>
</ul>
</li>
</ul>
</li>
<li>ICD<ul>
<li>Class I indication: NYHA class II – VI with LVEF \&lt;35% (must have
>1yr expected survival and 40+ days from MI)</li>
</ul>
</li>
<li>Mitra Clip<ul>
<li>Criteria: moderate to severe mitral regurgitation (3-4+), on
maximally tolerated GDMT, an ejection fraction >20%, and a left
ventricle end-systolic dimension of less than 7 cm</li>
</ul>
</li>
</ul></section><section class="print-page" id="cardiology-cardiology-ekg"><h1 id="cardiology-cardiology-ekg-approach-to-the-ecg">Approach to the ECG<a class="headerlink" href="#cardiology-cardiology-ekg-approach-to-the-ecg" title="Permanent link">&para;</a></h1>
<p>Melis Sahinoz</p>
<hr />
<p>Method = mastery, approach each EKG the same.</p>
<h2 id="cardiology-cardiology-ekg-rate">Rate<a class="headerlink" href="#cardiology-cardiology-ekg-rate" title="Permanent link">&para;</a></h2>
<ul>
<li>Regular rhythms = “Rule of 300” = 300 ÷ (large boxes between QRS
    complexes)</li>
<li>300, 150, 100, 75, 60, 50</li>
<li>Irregular rhythms or severe bradycardia = (total number of QRS
    complexes on ECG) x 6</li>
</ul>
<h2 id="cardiology-cardiology-ekg-rhythm">Rhythm<a class="headerlink" href="#cardiology-cardiology-ekg-rhythm" title="Permanent link">&para;</a></h2>
<ul>
<li>Determine regular vs irregular: calipers or march out QRS complexes
    on paper</li>
<li>Criteria for Sinus rhythm: P before every QRS; Upright P in Lead I,
    II; Negative in aVr</li>
</ul>
<h2 id="cardiology-cardiology-ekg-axis">Axis<a class="headerlink" href="#cardiology-cardiology-ekg-axis" title="Permanent link">&para;</a></h2>
<ul>
<li>Normal: - 30<sup>o</sup> to + 90<sup>o</sup></li>
<li>Quick method: Leads I and II</li>
<li>Normal Axis: Upright in I and II</li>
<li>Left Axis Deviation: Upright in I, down in II<ul>
<li>Causes: LVH, LBBB, Left anterior fascicular block, prior
    inferior MI</li>
</ul>
</li>
<li>Right Axis Deviation: Down in I, up in II<ul>
<li>Causes: RVH, RBBB, Left posterior fascicular block, prior
    lateral MI, PE</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-ekg-intervals">Intervals<a class="headerlink" href="#cardiology-cardiology-ekg-intervals" title="Permanent link">&para;</a></h2>
<ul>
<li>PR Interval: normal 120 – 200 ms<ul>
<li>If \&lt; 120 ms, consider pre-excitation with accessory pathway (i.e.
    WPW)</li>
<li>If > 200 ms, first degree AV block</li>
</ul>
</li>
<li>QRS Complex: 60 – 100 ms (normal)<ul>
<li>100-120 ms: Incomplete BBB or non-specific intraventricular
    conduction delay (IVCD)</li>
<li>> 120ms: complete BBB, ventricular tachycardia, hyperkalemia</li>
</ul>
</li>
<li>QT interval: Normal duration \&lt; 450ms in men and \&lt; 460ms in women<ul>
<li>QT is inversely proportional to HR (QT interval shortens at faster
    HRs)</li>
<li>Quick estimate: normal QT is less than half the preceding RR
    interval</li>
<li>QTc estimates the QT interval at a HR of 60 bpm (to allow for
    comparison across HRs)</li>
<li>A couple formulas exist to calculate QTc:<ul>
<li>QTcB= most commonly used due to simplicity, most accurate HR of
    60</li>
<li>QTcF= more accurate when HR is outside the range of 60-100</li>
</ul>
</li>
<li>Clinically significant when generally QTc > 500 ms</li>
<li>Causes of Prolonged QTc: hereditary, medication-induced
    (anti-emetics, ABX, psychiatric meds), hypokalemia, hypomagnesemia,
    hypocalcemia, ischemia</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-ekg-morphology">Morphology<a class="headerlink" href="#cardiology-cardiology-ekg-morphology" title="Permanent link">&para;</a></h2>
<ul>
<li>P wave: P waves in limb leads should be ≤2.5 small box high and ≤2.5
    small box wide<ul>
<li>Right Atrial Enlargement: Peaked P Wave in Lead II that measures
    >2.5 mm</li>
<li>Left Atrial Enlargement<ul>
<li>Lead II: Bifid P Wave (two humps) with total duration > 110 ms</li>
<li>Lead V1: Biphasic P wave, terminal deflection > 1mm wide and
    deep</li>
</ul>
</li>
<li>If ≥ 3 different P wave morphologies in same lead: wandering atrial
    pacemaker (HR \&lt; 100) or multifocal atrial tachycardia (HR > 100)</li>
</ul>
</li>
<li>QRS complex<ul>
<li>Voltage<ul>
<li>Low voltage: QRS amplitude \&lt; 5mm in limb leads or \&lt; 10mm in
    precordial<ul>
<li>Causes: pericardial effusion, infiltrative cardiomyopathy,
    obesity</li>
</ul>
</li>
<li>Right Ventricular Hypertrophy: Tall R Waves in V1 (> 7mm) and
    right axis deviation</li>
<li>Left Ventricular Hypertrophy: multiple criteria exist<ul>
<li>Sokolow-Lyon criteria is a common example: S in V1 + R in V5
    or V6 >35mm, R in aVL <u>></u>1.1 mV</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Conduction delays<ul>
<li>RBBB: Wide QRS and RSR’ in V1 or V2; deep broad S In lateral
    leads</li>
<li>LBBB: Wide QRS, large S in V1, broad monophasic R wave in
    lateral leads (I, aVL, V6)</li>
</ul>
</li>
<li>R wave progression<ul>
<li>R wave normally gets progressively larger from V1 to V6</li>
<li>If the transition does not occur by V4, this is called "poor R
    wave progression". This is seen in chronic lung disease, LVH,
    left anterior fascicular block, and anterior MI.</li>
</ul>
</li>
<li>Q-wave: Small Q waves are normal in most leads<ul>
<li>Never normal in V1-V3</li>
<li>Pathologic Q waves: > 1 box wide and 2 boxes deep or > 25% height
    of R wave</li>
</ul>
</li>
<li>ST Segment<ul>
<li>ST Elevation: STEMI, LBBB (ST elevation in leads with deep S waves),
    LVH, Ventricular paced rhythm, Pericarditis (associated with PR
    depression), coronary vasospasm, Brugada syndrome</li>
<li>ST Depression: ischemia, reciprocal change in STEMI, posterior
    myocardial infarction (V1-V3), digoxin, hypokalemia</li>
<li>See ACS section for STEMI criteria, Wellens Syndrome</li>
</ul>
</li>
<li>T wave<ul>
<li>Normal T waves are upright in all leads except aVR and V1</li>
<li>Inverted T Waves<ul>
<li>Acute ischemia (if present in contiguous leads), LBBB (in
    lateral leads), RBBB (V1-V3), LVH (‘strain’ pattern similar to
    LBBB), RVH (RV ‘strain’ in V1-V3 or inferior leads), PE (right
    heart strain or part of S1,Q3,T3), intracranial pathology</li>
</ul>
</li>
<li>Peaked T Waves<ul>
<li>Hyperkalemia vs ‘hyperacute’ T waves that precede ST elevation
    and Q waves in STEMI</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="cardiology-cardiology-inpatient-hypertension"><h1 id="cardiology-cardiology-inpatient-hypertension-inpatient-hypertension">Inpatient Hypertension<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-inpatient-hypertension" title="Permanent link">&para;</a></h1>
<p>Lee Richardson</p>
<hr />
<h2 id="cardiology-cardiology-inpatient-hypertension-background">Background<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Hypertensive urgency: SBP > 180mmHg/DBP > 120mmHg</li>
<li>Hypertensive emergency: SBP > 180mmHg/DBP > 120mmHg + end organ
    damage</li>
</ul>
<h2 id="cardiology-cardiology-inpatient-hypertension-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Are there signs/symptoms of end organ damage?</li>
<li>Neurologic symptoms: agitation, delirium, stupor, seizures, visual
    disturbances</li>
<li>Focal neurologic deficits</li>
<li>Chest pain</li>
<li>Back pain (consider aortic dissection)</li>
<li>Dyspnea (consider pulmonary edema)</li>
<li>BMP, LFTs, Troponin, BNP: Lab findings suggestive of end-organ
    damage</li>
</ul>
<h2 id="cardiology-cardiology-inpatient-hypertension-management">Management<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Goal is to lower BP back to normal over 24-48 hours</li>
<li>Initial lowering should be 10-20% in minutes if HTN emergency; goal
    should be 10-20% in 2-4 hours if HTN urgency</li>
<li>Typically aim for initial goal BP near 160/110</li>
<li>Exceptions to gradual lowering include:<ul>
<li>Acute stroke: call code stroke, lower ONLY if BP > 185/110 in
    pts under consideration for reperfusion therapy; or BP >
    220/120 in pts not candidates for reperfusion therapy</li>
<li>Aortic dissection: Goal = rapidly lower BP in minutes to target
    of 100-120 systolic to avoid aortic shearing forces</li>
</ul>
</li>
<li>Pharmacologic therapy<ul>
<li>If pt was previously on anti-HTN meds, ensure their home medicines
    have been restarted at appropriate doses, formulation (long acting
    vs. short), and dosing intervals</li>
<li>If pt has a rapid acting anti-HTN med, can consider giving a dose
    early or an “extra dose” and then up titrating their overall daily
    dose</li>
</ul>
</li>
<li>Rescue therapies<ul>
<li>Captopril PO (12.5mg or 25mg dosed Q8H; conversion ratio of
    captopril:lisinopril = 5:1)</li>
<li>Hydralazine PO (10-20mg initial dosing Q6H)</li>
<li>Isosorbide dinitrate PO (5-20mg TID)</li>
<li>Nifedipine XL PO (dose at 30mg initially, max 90 mg BID; NOT
    sublingual)</li>
<li>Labetalol IV (10-40mg initially; dosed up to every 20-30mins)</li>
<li>Hydralazine IV (10-20mg initially; dosed up to every 30 mins).</li>
<li>Nitropaste 1” (can add/wipe away for titration; dose Q6H until
    oral meds can be started for better long-acting control)</li>
</ul>
</li>
<li>Dialysis if missed session</li>
</ul>
<h2 id="cardiology-cardiology-inpatient-hypertension-additional-information">Additional Information<a class="headerlink" href="#cardiology-cardiology-inpatient-hypertension-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Refractory HTN: try additional agents listed above vs. escalation of
    care for drip (nicardipine, nitroglycerin, nitroprusside, esmolol).</p>
</li>
<li>
<p>Most drips that can be done for this indication are done in stepdown
    and usually require no-titration of the infusion and occasionally
    the MD to be bedside to initiate the infusion.</p>
</li>
<li>
<p>This includes diltiazem, labetalol, nitroglycerin, and verapamil
    drips. Nicardipine, esmolol, and nitroprusside drips are not allowed
    on step down.</p>
</li>
</ul></section><section class="print-page" id="cardiology-cardiology-pe"><h1 id="cardiology-cardiology-pe-pulmonary-embolism">Pulmonary Embolism<a class="headerlink" href="#cardiology-cardiology-pe-pulmonary-embolism" title="Permanent link">&para;</a></h1>
<p>Anna Berry</p>
<hr />
<h2 id="cardiology-cardiology-pe-background">Background<a class="headerlink" href="#cardiology-cardiology-pe-background" title="Permanent link">&para;</a></h2>
<p>A thrombus originating in a deep vein (LE > UE) embolizing to the
    pulmonary arterial circulation.</p>
<ul>
<li>Risk Factors = Virchow’s Triad<ul>
<li>Stasis: immobilization, hospitalization, spinal cord injury, or long
    travel</li>
<li>Hypercoagulable state: cancer, prothrombotic genetic conditions such
    as Factor V Leiden, OCPs, antiphospholipid syndrome, nephrotic
    syndrome, pregnancy, infection, etc.</li>
<li>Endothelial Injury: surgery, trauma</li>
</ul>
</li>
</ul>
<p>Most originate from a DVT in the iliac, femoral, and popliteal veins</p>
<h2 id="cardiology-cardiology-pe-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-pe-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Dyspnea and tachypnea</li>
<li>Respiratory alkalosis on blood gas from hyperventilation</li>
<li>Hypoxemia</li>
<li>Sinus Tachycardia or atrial arrhythmias</li>
<li>Hemoptysis</li>
<li>Lower extremity pain, swelling, and redness – occurs in 50% of pts
    with DVT</li>
<li>RV Failure (large PE) – elevated JVP, hypotension, syncope, R
    parasternal heave, accentuated P2, hepatomegaly</li>
</ul>
<h2 id="cardiology-cardiology-pe-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-pe-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>If hemodynamically unstable and PE suspected, provide hemodynamic
    support (ie. O2, pressors, etc.) and perform emergent bedside TTE</li>
<li>
<p>If no RV strain evident on TTE, low likelihood of hemodynamically
    significant PE. Consider other causes of shock.</p>
</li>
<li>
<p>Hemodynamically stable</p>
<ul>
<li>EKG<ul>
<li>Most commonly sinus tachycardia</li>
<li>Less commonly and indicative of large PE: RAD, RVH, RBBB, RA
    enlargement, S1Q3T3 (deep S in lead I, deep Q and inverted T in
    lead III), TWI in V1-V3</li>
</ul>
</li>
<li>CXR: Typically normal. May see linear atelectasis, pleural effusion,
    PA cutoff sign</li>
<li>Labs: ABG, troponin, BNP</li>
<li>May consider lower extremity dopplers</li>
<li>Imaging vs d-dimer based on pre-test probability:<ul>
<li>Low pre-test probability (use Wells Criteria) d-dimer</li>
<li>For moderate to high pre-test probability CTA Chest PE protocol<ul>
<li>If high pre-test probability or moderate pre-test
    probability with >4 hour delay in work-up, start empiric
    anticoagulation if bleeding risk is acceptable while work-up
    is ongoing</li>
</ul>
</li>
</ul>
</li>
<li>TTE</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-pe-management">Management<a class="headerlink" href="#cardiology-cardiology-pe-management" title="Permanent link">&para;</a></h2>
<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 26%" />
<col style="width: 26%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th>PE Class:</th>
<th>Low risk</th>
<th>Submassive</th>
<th>Massive</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Definition</td>
<td><p>Hemodynamically stable</p>
<p>No evidence of right heart strain or myocardial necrosis on labs or
TTE</p></td>
<td><p>Hemodynamically stable</p>
<p>Evidence of right heart strain or myocardial necrosis: RV strain on
TTE (ex: D-sign), BNP &gt;150, trop &gt;0.05</p></td>
<td><p>Hemodynamically unstable (ex: SBP&lt;90)</p>
<p>Evidence of RV strain</p></td>
</tr>
<tr class="even">
<td>Management</td>
<td><p>Start anticoagulation</p>
<p>LWH or heparin gtt (if renal impairment)</p>
<p>Can also use NOAC. Rivaroxaban &amp; apixaban can be used as initial
management. Edoxaban &amp; dabigatran can be used after 5-10 days of
parenteral therapy</p></td>
<td><p>Provide hemodynamic support, monitor for decompensation</p>
<p>Start anticoagulation with unfractionated heparin gtt</p>
<p>STAT consult cardiology for consideration of catheter directed
thrombolysis (EKOS) or embolectomy</p></td>
<td><p>Provide hemodynamic support.</p>
<p>Start anticoagulation with unfractionated heparin gtt</p>
<p>Page CCU fellow STAT. Consider systemic tPA (this is a
fellow/attending level decision).</p>
<p>Discuss with cardiology catheter directed thrombolysis (EKOS) or
embolectomy</p></td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-pe-tpa-considerations">tPA Considerations<a class="headerlink" href="#cardiology-cardiology-pe-tpa-considerations" title="Permanent link">&para;</a></h2>
<ul>
<li>Dose is 100mg tPA over 2hrs</li>
<li>Most effective within 24 hours but effective up to 14d</li>
<li>Contraindications:<ul>
<li>Absolute:<ul>
<li>CNS Pathology: hemorrhagic or ischemic CVA within 3 mo, AVM,
    CNS neoplasm, recent surgery</li>
<li>Trauma: Recent head trauma w/ fx or injury</li>
</ul>
</li>
<li>Relative<ul>
<li>Surgery: surgery w/in 3 wks</li>
<li>Heme: active bleeding, bleeding diathesis, plt \&lt; 100, oral
    AC</li>
<li>Age: >75 yo, dementia</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-pe-long-term-management">Long-term management<a class="headerlink" href="#cardiology-cardiology-pe-long-term-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Anticoagulation: see “Venous Thromboembolism” in Hematology/Oncology</li>
</ul></section><section class="print-page" id="cardiology-cardiology-rhc"><h1 id="cardiology-cardiology-rhc-right-heart-catheterization">Right Heart Catheterization<a class="headerlink" href="#cardiology-cardiology-rhc-right-heart-catheterization" title="Permanent link">&para;</a></h1>
<p>Pakinam Mekki</p>
<hr />
<h2 id="cardiology-cardiology-rhc-background">Background<a class="headerlink" href="#cardiology-cardiology-rhc-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Pulmonary artery catheter (PAC): Multilumen catheter that sits in
    the right heart to provide invasive measurement of hemodynamic
    parameters</li>
<li>Indications for PAC placement<ul>
<li>Diagnose undifferentiated shock</li>
<li>Severe cardiogenic shock</li>
<li>Diagnose pulmonary hypertension</li>
<li>Diagnose left -> right shunting</li>
<li>Diagnose valvular and pericardial disease</li>
<li>Titrating medications, specifically inotropes, pulmonary
    vasodilators, diuresis</li>
</ul>
</li>
<li>Contraindications to PAC placement<ul>
<li>RA/RV mass or thrombi</li>
<li>Tricuspid or pulmonic valve endocarditis</li>
<li>Mechanical tricuspid or pulmonic valves</li>
<li>Presence of RV assist device</li>
</ul>
</li>
<li>Complications of PAC placement<ul>
<li>Arrythmias: VT, RBBB, 3<sup>rd</sup> degree AV block if preexisting LBBB</li>
<li>Infection (endocarditis of the pulmonary valve)</li>
<li>Bleeding</li>
<li>Pulmonary embolism and pulmonary Infarct</li>
<li>Pneumothorax</li>
<li>Air embolism</li>
<li>Pulmonary artery perforation / rupture</li>
<li>Endocardial/valvular damage</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-rhc-pac-pressure-tracings">PAC Pressure Tracings<a class="headerlink" href="#cardiology-cardiology-rhc-pac-pressure-tracings" title="Permanent link">&para;</a></h2>
<figure>
<p><img alt="image" src="../images/image7.png" /></p>
</figure>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 23%" />
<col style="width: 17%" />
<col style="width: 37%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Definition</th>
<th>Normal "Rule of 5s"</th>
<th><blockquote>
<p>Interpretation</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Central Venous Pressure</p>
<p>(CVP)</p></td>
<td>Pressure in superior vena cava, often an indicator of volume
status</td>
<td>0 - 5 mmHg</td>
<td>Elevated CVP is indicative of cardiac dysfunction and/or fluid
retention<br />
<br />
Low CVP is indicative of volume depletion or decreased venous tone</td>
</tr>
<tr class="even">
<td>Right Atrial Pressure (RAP)</td>
<td>Surrogate for preload, should be same as CVP</td>
<td>0 - 5 mmHg</td>
<td>Elevated with disruption in forward cardiac flow or increase in
intravascular volume</td>
</tr>
<tr class="odd">
<td>Right Ventricle Pressure (</td>
<td>Right ventricular systolic and diastolic pressures; RVSP can be
surrogate for PASP</td>
<td>25/5 mmHg</td>
<td>Elevated with diseases that elevate PA pressure and pulmonic valve
disorders. Severe RVP elevations are generally chronic while acute
conditions typically have RVSP &lt;40-50.</td>
</tr>
<tr class="even">
<td>Pulmonary Artery Pressure (PAP)</td>
<td>Measured as systolic, diastolic, and mean pressures. Diagnoses
pHTN.</td>
<td><p>25/10 mmHg</p>
<p>Mean: 10 - 19 mmHg</p></td>
<td>Elevated In acute conditions (PE, hypoxemia induced pulmonary
vasoconstriction) or pHTN (mean PAP &gt; 20 mm Hg)</td>
</tr>
<tr class="odd">
<td>Pulmonary Artery Wedge Pressure (PAWP or wedge)</td>
<td>Pressure measured by wedging the PAC into a small pulmonary arterial
branch; surrogate for left atrial pressures and LVEDP</td>
<td>10 mm Hg</td>
<td>Increased with elevated LVEDP: systolic or diastolic heart failure,
mitral and aortic valve disorders, hypervolemia, R to L shunts,
tamponade, constrictive/restrictive cardiomyopathy</td>
</tr>
<tr class="even">
<td>Thermodilution Cardiac Output &amp; Index</td>
<td>Amount of blood pumped in one min. CI is the cardiac output divided
by body surface area (to standardize for body size)</td>
<td><p>CO: 3.4-15 L/min</p>
<p>CI: 2.8-4.2 L/min/m^2</p></td>
<td><p>Low CI: systolic/diastolic heart failure, severe valvular
disorder (MR, AS), RV failure, pHTN, cardiogenic shock.</p>
<p>Elevated CI (high-output state): sepsis, anemia, thyrotoxicosis, A-V
shunt</p></td>
</tr>
<tr class="odd">
<td><p>Mixed central venous oxyhemoglobin</p>
<p>saturation (SvO2)</p></td>
<td>% of oxygen bound to Hgb in blood returning to the right side of the
heart, reflects total body O2 extraction</td>
<td>65-70%</td>
<td><p>High SvO2 (&gt; 65%) = decreased O2 demand or “high flow” states
seen in distributive shock (sepsis)</p>
<p>Low SvO2 (&lt; 50%) = decreased O2 delivery seen in cardiogenic or
hypovolemic shock. In low SvO2 states, there is less O2 supply to same
demand)</p></td>
</tr>
</tbody>
</table>

<h2 id="cardiology-cardiology-rhc-calculating-hemodynamic-parameters-from-pac-pressures">Calculating Hemodynamic Parameters from PAC Pressures<a class="headerlink" href="#cardiology-cardiology-rhc-calculating-hemodynamic-parameters-from-pac-pressures" title="Permanent link">&para;</a></h2>
<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 29%" />
<col style="width: 19%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Definition</th>
<th>Normal Values</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Fick CO and CI</td>
<td>Calculated CO based on Oxygen consumption (VO2), Hbg, and O2 sats of
arterial and venous blood</td>
<td><p>4-7 L/min</p>
<p>2.5-4 L/min/m<sup>2</sup></p></td>
<td>See "Cardiac Index" above.</td>
</tr>
<tr class="even">
<td>Systemic Vascular Resistance (SVR)</td>
<td>Measurement of afterload; helpful in delineating the etiology of
shock as well as guiding afterload-reduction therapy in HFrEF</td>
<td>700-1200 dynes*s*cm<sup>-5</sup></td>
<td><p>Elevated SVR is seen in hypovolemic, cardiogenic, and obstructive
shock</p>
<p>Decreased SVR is seen in distributive shock (sepsis, anaphylaxis,
neurogenic)</p></td>
</tr>
<tr class="odd">
<td>Transpulmonary gradient (TPG)</td>
<td>Differentiates between pre- and post-capillary pulmonary
hypertension.</td>
<td>&lt; 12 mmHg</td>
<td>A TPG value greater than 12 mmHg indicates that a component of the
pHTN is secondary to pulmonary vascular disease</td>
</tr>
<tr class="even">
<td>Pulmonary Vascular Resistance (PVR)</td>
<td>Gold standard in the estimation of the severity of pre-capillary
pHTN<br />
<br />
Reflects the pressure drop across the pulmonary system only and is
independent of the LA, mitral valve and the LV</td>
<td><p>&lt; 3 Wood Units</p>
<p>30-90 dynes*sec*cm<sup>5</sup></p></td>
<td><p>Elevated PVR (&gt;3 Wood units) suggests pre-capillary pHTN</p>
<p>Normal PVR seen in pulmonary venous hypertension (diastolic
dysfunction)</p></td>
</tr>
<tr class="odd">
<td>Pulmonary artery pulsatility index (PAPi)</td>
<td>Pulmonary pulse pressure relative to preload (RAP), Indicator of RV
function</td>
<td>&gt; 0.9</td>
<td>PAPi &lt; 0.9 predicts in-hospital mortality and/or need for RVAD in
acute MI. Can be decreased in pure RV failure or biventricular
failure</td>
</tr>
<tr class="even">
<td>Cardiac Power</td>
<td>Cardiac output relative to afterload, a measure of LV contractile
reserve</td>
<td>Normal &gt; 1</td>
<td><p>CP&lt; 0.6 strongly suggestive of LV failure</p>
<p>Found to be a strong independent hemodynamic correlate in pts with
cardiogenic shock. Predictor of mortality in CCU</p></td>
</tr>
</tbody>
</table></section><section class="print-page" id="cardiology-cardiology-shock"><h1 id="cardiology-cardiology-shock-cardiogenic-shock">Cardiogenic Shock<a class="headerlink" href="#cardiology-cardiology-shock-cardiogenic-shock" title="Permanent link">&para;</a></h1>
<p>Ashley Cozart</p>
<hr />
<h2 id="cardiology-cardiology-shock-definition">Definition<a class="headerlink" href="#cardiology-cardiology-shock-definition" title="Permanent link">&para;</a></h2>
<p>Impairment of cardiac output due to primary cardiac disorder that
    results in end-organ hypoperfusion and hypoxia</p>
<h2 id="cardiology-cardiology-shock-etiology">Etiology<a class="headerlink" href="#cardiology-cardiology-shock-etiology" title="Permanent link">&para;</a></h2>
<ul>
<li>Cardiomyopathic: myocardial infarction with LV dysfunction,
    exacerbation of heart failure, myocarditis, myocardial contusion,
    drug-induced</li>
<li>Arrhythmic: atrial tachycardias (atrial fibrillation/flutter, AVRT,
    AVNRT), ventricular tachycardia and fibrillation, complete heart
    block, second degree heart block</li>
<li>Mechanical: valvular insufficiency, valvular rupture, critical
    valvular stenosis, ventricular septal wall defect, ruptures
    ventricular wall aneurysm, atrial myxoma</li>
</ul>
<h2 id="cardiology-cardiology-shock-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-shock-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Cold (decreased perfusion) due to reduced cardiac output (can be
    wet- increased PCWP OR dry normal PCWP)</li>
<li>Symptoms of volume overload + end-organ hypoperfusion (altered
    mental status, nausea, abdominal pain, decreased urine output)</li>
<li>Hypotension; narrow pulse pressure</li>
</ul>
<h2 id="cardiology-cardiology-shock-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-shock-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>EKG</li>
<li>Labs: CBC, CMP, BNP, troponin, lactate</li>
<li>Evidence of end organ damage: lactic acidosis, acute kidney injury,
    acute liver injury</li>
<li>Echocardiogram: assess EF and valves</li>
<li>LHC If ischemia (see ACS)</li>
<li>Hemodynamic monitoring via Swan-Ganz or PA catheter:<ul>
<li>No benefit for general shock but does improve in-hospital mortality
for those with cardiogenic shock</li>
<li>PA catheter hemodynamic profile:<ul>
<li>Cardiac index \&lt; 2.2, cardiac power \&lt;0.6, SVR 800-1600, SVO2
\&lt;60%</li>
<li>LV-dominant: RA (CVP) \&lt;15, PCWP >18, PAPi >1.5 (pulmonary
artery pulsatility index)</li>
<li>RV-dominant: RA >15, PCWP \&lt;18, PAPi >1.5</li>
<li>Bi-V-dominant: RA >15, PCWP >18, PAPi >1.5</li>
<li>PAPi \&lt; 1 indicates that patient will likely need RV support</li>
<li>CP \&lt; 0.5 strongest independent hemodynamic correlate of
mortality in CS</li>
<li>See right heart cath section for interpreting PA catheter
profiles</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-shock-management-medical-mechanical-circulatory-support">Management (medical &amp; mechanical circulatory support)<a class="headerlink" href="#cardiology-cardiology-shock-management-medical-mechanical-circulatory-support" title="Permanent link">&para;</a></h2>
<h3 id="cardiology-cardiology-shock-medical-management">Medical management<a class="headerlink" href="#cardiology-cardiology-shock-medical-management" title="Permanent link">&para;</a></h3>
<p>Focus on optimizing preload, afterload, and contractility.</p>
<ul>
<li>Preload: IV diuresis</li>
<li>Afterload: IV – nitroglycerine, nitroprusside; PO – hydralazine,
    isosorbide dinitrate; vasoconstricting pressors (phenylephrine,
    vasopressin) if needing BP support</li>
<li>Contractility - Inodilators (increase contractility, decrease
    afterload – milrinone, dobutamine) or inoconstrictors (increase
    contractility and afterload – epinephrine, norepinephrine)</li>
</ul>
<h3 id="cardiology-cardiology-shock-mechanical-circulatory-support-indications">Mechanical circulatory support indications<a class="headerlink" href="#cardiology-cardiology-shock-mechanical-circulatory-support-indications" title="Permanent link">&para;</a></h3>
<ul>
<li>Shock refractory to >1 pressor</li>
<li>Shock 2/2 MI (physiology: unloads LV, increases systemic perfusion,
    increases myocardial perfusion, and provides hemodynamic support
    during PCI)</li>
</ul>
<p>Types of mechanical circulatory support (MCS)</p>
<table>
<colgroup>
<col style="width: 6%" />
<col style="width: 25%" />
<col style="width: 22%" />
<col style="width: 22%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Intra-aortic Balloon Pump</th>
<th>V-A ECMO</th>
<th>Tandem Heart</th>
<th>Impella</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Dynamics</td>
<td>Inflates during diastole, deflates during systole</td>
<td>Blood from femoral vein is oxygenated and pumped to femoral
artery</td>
<td><p>LV: blood aspirated from LA to femoral artery</p>
<p>RV: blood aspirate from RA to PA</p></td>
<td><p>Impella 2.5, 5.0 &amp; CP: Blood aspirated from LV to aortic
root</p>
<p>Impella RP: Blood aspirated from IVC and delivered to PA</p></td>
</tr>
<tr class="even">
<td>Flow</td>
<td>1 LMP</td>
<td>4.5 LPM</td>
<td>4-5 LPM</td>
<td><p>2.5: 2.5 L/min</p>
<p>CP: 3.33 L/min</p>
<p>5.0: 5 L/min</p>
<p>RP: 4 L/min</p></td>
</tr>
<tr class="odd">
<td>Support</td>
<td>LV</td>
<td>BiV</td>
<td>LV, RV, or BiV</td>
<td>LV or RV (RP)</td>
</tr>
<tr class="even">
<td>Effects</td>
<td><p>Reduces afterload</p>
<p>Increases stroke volume (SV)</p>
<p>Increases coronary perfusion</p>
<p>Reduces LV preload and PCWP</p></td>
<td><p>Increases afterload</p>
<p>Reduces SV</p>
<p>Reduces LV preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
<td><p>Increases afterload</p>
<p>Reduces SV</p>
<p>Reduces LV preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
<td><p>Reduces SV</p>
<p>Reduces preload and PCWP</p>
<p>Improves tissue perfusion</p></td>
</tr>
<tr class="odd">
<td>Complications</td>
<td><p>Thrombocytopenia</p>
<p>Thrombosis</p>
<p>Arterial obstruction</p>
<p>Aortic rupture or dissection</p>
<p>Air embolism</p></td>
<td><p>Circuit thrombosis</p>
<p>LV dilation</p>
<p>Hypothermia</p>
<p>Gas embolism</p></td>
<td><p>Tamponade d/t perforation</p>
<p>Thrombosis</p>
<p>Embolism (gas or thrombus)</p>
<p>Arterial Shunt</p></td>
<td><p>Pump migration</p>
<p>Hemolysis</p>
<p>Aortic regurg</p>
<p>LV perf</p>
<p>VT/VF</p></td>
</tr>
</tbody>
</table>

<p>Daily management of MCS devices:</p>
<ul>
<li>Ensure optimal placement of device with daily CXR</li>
<li>Anticoagulation (based on device)</li>
<li>Hematoma monitoring at device site</li>
<li>Check distal pulses to monitor for limb ischemia</li>
</ul>
<p>Pearls for MCS</p>
<ul>
<li>MCS devices are contraindicated in following situations: aortic
    regurgitation or metallic aortic valve, aortic aneurysm or
    dissection, severe aortic or peripheral artery disease, left
    ventricular or left atrial thrombi, bleeding diathesis, uncontrolled
    sepsis</li>
<li>ECMO is placed by the cardiac surgery team, once a patient is
    cannulated they will move onto the cardiac surgery team</li>
<li>Impella, tandem heart, and IABPs are placed in the cath lab</li>
<li>MCS is a bridge to recovery/definitive therapy, durable cardiac
    support (VAD), or transplant</li>
</ul></section><section class="print-page" id="cardiology-cardiology-syncope"><h1 id="cardiology-cardiology-syncope-syncope">Syncope<a class="headerlink" href="#cardiology-cardiology-syncope-syncope" title="Permanent link">&para;</a></h1>
<p>Sarah Myers</p>
<hr />
<h2 id="cardiology-cardiology-syncope-background">Background<a class="headerlink" href="#cardiology-cardiology-syncope-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Definition: abrupt, transient loss of consciousness with rapid &amp;
    spontaneous recovery  </li>
<li>Presyncope – symptoms occurring before syncope including
    lightheadedness, tunnel vision/other visual disturbances</li>
</ul>
<h2 id="cardiology-cardiology-syncope-classification">Classification<a class="headerlink" href="#cardiology-cardiology-syncope-classification" title="Permanent link">&para;</a></h2>
<ul>
<li>Cardiac syncope </li>
<li>Tachyarrhythmias: VT, SVT </li>
<li>Bradyarrhythmias: sinus node dysfunction, AV blocks (high grade) </li>
<li>Structural: Aortic Stenosis, HCM, cardiac tamponade, congenital
    anomalies, masses/tumors </li>
<li>Vascular: Pulmonary embolism, aortic dissection, severe pHTN </li>
<li>Noncardiac syncope</li>
<li>Reflex mediated<ul>
<li>Vasovagal; most common form of reflex mediated syncope<ul>
<li>Can occur sitting/standing or with trigger (stress, pain,
    medical settings)</li>
<li>Classically has prodrome of nausea, diaphoresis, tunnel
    vision followed by hypotension and/or bradycardia</li>
</ul>
</li>
<li>Situational (micturition/defecation/coughing)</li>
<li>Carotid sinus sensitivity syndrome</li>
</ul>
</li>
<li>Orthostatic</li>
<li>Medications (diuretics, nitrates/CCB/alpha blockers, TCAs)</li>
<li>Volume depletion (hemorrhage, dehydration)</li>
<li>Autonomic dysfunction</li>
</ul>
<h2 id="cardiology-cardiology-syncope-differential-diagnosis">Differential diagnosis<a class="headerlink" href="#cardiology-cardiology-syncope-differential-diagnosis" title="Permanent link">&para;</a></h2>
<ul>
<li>Seizure, stroke, metabolic derangements, Intoxication/withdrawal,
    hypoglycemia, head trauma</li>
<li>With rare exceptions, these do not result In complete LOC with
    spontaneous recovery</li>
</ul>
<h2 id="cardiology-cardiology-syncope-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-syncope-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>History and physical are essential for evaluation of a syncopal
    event </li>
<li>Characteristics associated with cardiac syncope </li>
<li>Male, >60, known structural/ischemic heart disease, brief/no
    prodrome, syncope while supine/at rest or during exercise, family hx
    of SCD/premature death, abnormal exam </li>
<li>Characteristics associated with noncardiac syncope</li>
<li>Younger age, syncope while standing or with positional changes,
    prodrome (nausea, vomiting, warmth), specific triggers, previous
    episodes that have been similar  </li>
</ul>
<h2 id="cardiology-cardiology-syncope-workup">Workup<a class="headerlink" href="#cardiology-cardiology-syncope-workup" title="Permanent link">&para;</a></h2>
<ul>
<li>EKG on all patients with syncope, monitor those who are admitted on
    telemetry</li>
<li>CBC, CMP, troponin, BNP (If cardiac cause suspected), POC glucose,
    UDS, orthostatic VS</li>
<li>EEG and neuroimaging if concern for seizure activity or focal neuro
    deficit  </li>
<li>TTE and consider stress testing particularly in exertional syncope  </li>
</ul>
<h2 id="cardiology-cardiology-syncope-management">Management<a class="headerlink" href="#cardiology-cardiology-syncope-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Cardiac: managed as indicated based on pathology </li>
<li>
<p>If arrhythmia is suspected but not captured on admission, consider
    discharge with event monitor  </p>
</li>
<li>
<p>Noncardiac</p>
</li>
<li>
<p>Reflex</p>
<ul>
<li>Vasovagal- consider tilt table testing If recurrent or diagnosis
    not clear</li>
<li>Situational- mainly avoiding triggers</li>
<li>Carotid sinus syndrome- may require PPM</li>
</ul>
</li>
<li>
<p>Orthostatic</p>
<ul>
<li>Medication related<ul>
<li>Appropriate to hold potentially offending medications
    (diuretics, vasodilators) during evaluation</li>
<li>Monitor for worsening supine hypertension, arrhythmias, or
    heart failure when holding</li>
</ul>
</li>
<li>Volume depletion; resuscitate as appropriate</li>
<li>Autonomic dysfunction: see autonomics section</li>
</ul>
</li>
<li>
<p>Driving: TN law does not require any MD to inform the state of TLOC </p>
</li>
<li>Should still recommend patients not drive while work-up ongoing.
    Document all conversations about driving with patients</li>
</ul></section><section class="print-page" id="cardiology-cardiology-valvular-heart-disease"><h1 id="cardiology-cardiology-valvular-heart-disease-valvular-heart-disease">Valvular Heart Disease<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-valvular-heart-disease" title="Permanent link">&para;</a></h1>
<p>Jonathan Napper, Marcus Threadcraft</p>
<hr />
<h1 id="cardiology-cardiology-valvular-heart-disease-aortic-stenosis">Aortic stenosis<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-aortic-stenosis" title="Permanent link">&para;</a></h1>
<p>Jonathan Napper </p>
<hr />
<h2 id="cardiology-cardiology-valvular-heart-disease-etiology">Etiology<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-etiology" title="Permanent link">&para;</a></h2>
<ul>
<li>Degenerative calcification of the aortic cusps</li>
<li>Congenital bicuspid aortic valve</li>
<li>Chronic deterioration (calcific)</li>
<li>Prior rheumatic fever/inflammation</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-presentation">Presentation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Angina, syncope, exertional dyspnea, heart failure (HF carries worse
    prognosis)</li>
<li>Typically aged 70 – 80 y/o; if bicuspid aortic valve expect 10-20
    yrs earlier</li>
<li>Physical exam: Systolic crescendo-decrescendo murmur that radiates
    towards the carotids</li>
<li>Late peaking murmur, faint or absent S2, or delayed carotid upstroke
    suggest severe AS</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-evaluation">Evaluation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>TTE with doppler is test of choice</li>
</ul>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 19%" />
<col style="width: 20%" />
<col style="width: 20%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr class="header">
<th>Severity  </th>
<th>Valve Area (cm<sup>2</sup>) </th>
<th>Mean Gradient (mmHg) </th>
<th><p>Velocity  </p>
<p>(m/s) </p></th>
<th>Indexed Valve Area (cm<sup>2</sup>/m<sup>2</sup>)  </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Mild  </td>
<td>&gt;1.5 </td>
<td>&lt;20 </td>
<td>2.0-2.9 </td>
<td>&gt;0.85 </td>
</tr>
<tr class="even">
<td>Moderate  </td>
<td>1.0-1.5 </td>
<td>20-39 </td>
<td>3.0-3.9 </td>
<td>0.60-0.85 </td>
</tr>
<tr class="odd">
<td>Severe </td>
<td>&lt;1.0 </td>
<td>&gt;40 </td>
<td>&gt;4.0 </td>
<td>&lt;0.6 </td>
</tr>
<tr class="even">
<td>Critical  </td>
<td>&lt;0.5 </td>
<td>-- </td>
<td>-- </td>
<td>-- </td>
</tr>
</tbody>
</table>

<p>AS stages</p>
<ul>
<li>A: at risk of AS (those with bicuspid anatomy or calcification</li>
<li>B: Asymptomatic non-severe AS</li>
<li>C: asymptomatic AS<ul>
<li>C1: normal EF</li>
<li>C2: abnormal EF<ul>
<li>This stage might benefit from exercise or stress testing to
  elicit symptoms</li>
</ul>
</li>
</ul>
</li>
<li>
<p>D: Symptomatic AS</p>
</li>
<li>
<p>Some with symptomatic AS might not have enough LV reserve to produce
    high velocities and gradients (ex EF of 10% w/ critical valve area)
    = low flow/low gradient AS; consider dobutamine to unmask AS</p>
</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-management">Management<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-management" title="Permanent link">&para;</a></h2>
<ul>
<li>No proven effective medical therapy</li>
<li>Definitive treatment is valve replacement for:<ul>
<li>Stage D</li>
<li>Stage C with inducible symptoms on stress testing, low EF, or
    undergoing other cardiac procedure</li>
<li>Rapid progression (increase in velocity >0.3m/sec per year)</li>
</ul>
</li>
<li>Consult cardiac surgery for determination of SAVR vs TAVR<ul>
<li>In general, high risk surgical patients benefit most from TAVR</li>
<li>At VUMC: If determined to be intermediate to high operative risk by
    Cardiac Surgery, they will often recommend contacting the TAVR team
    for evaluation</li>
</ul>
</li>
<li>Avoid rapid hemodynamic shifts and aggressive changes in preload or
    afterload</li>
<li>Aim for normotension<ul>
<li>Avoid preferential vasodilators such as
hydralazine or nitroglycerin</li>
<li>Significant vasodilation may ↓ coronary filling pressures ->
myocardial ischemia</li>
</ul>
</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-monitoring">Monitoring<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-monitoring" title="Permanent link">&para;</a></h2>
<ul>
<li>Severe AS: TTE q 6-12 months</li>
<li>Moderate AS: TTE q 1-2 years</li>
<li>Mild AS: TTE q 3-5 years</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-post-avr-anticoagulation">Post AVR anticoagulation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-post-avr-anticoagulation" title="Permanent link">&para;</a></h2>
<ul>
<li>All patients will get 3-6 months of AC s/p AVR</li>
<li>Continued duration based on type of AVR<ul>
<li>Bioprosthetic (TAVR and some SAVRs): antiplatelets alone after
    Initial AC</li>
<li>Mechanical: lifelong AC with warfarin only</li>
</ul>
</li>
</ul>
<h1 id="cardiology-cardiology-valvular-heart-disease-aortic-regurgitation">Aortic Regurgitation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-aortic-regurgitation" title="Permanent link">&para;</a></h1>
<p>Jonathan Napper </p>
<hr />
<h2 id="cardiology-cardiology-valvular-heart-disease-etiology_1">Etiology<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-etiology_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Primary valve disease (rheumatic disease, bicuspid aortic valve,
    infective endocarditis, syphilis)</li>
<li>Primary aortic root disease (medial degeneration, aortic dissection,
    Marfan’s syndrome, bicuspid aortic valve, syphilis, non-syndromic
    familial)</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-presentation_1">Presentation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-presentation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute AR: LV cannot respond to increased volume to maintain stroke
    volume pulmonary edema and cardiogenic shock</li>
<li>Chronic AR: indolent presentation, often patient will develop
    symptoms of heart failure including DoE, orthopnea, PND</li>
<li>Physical exam: “Water-hammer” pulses, wide pulse pressure, laterally
    displaced PMI, high pitched “blowing” decrescendo murmur best heard
    at third intercostal space at left sternal border, S3</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-management_1">Management<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute severe AR<ul>
<li>Prompt surgical repair</li>
<li>Vasodilators such as nitroprusside and diuretics can be used to
    stabilize patient</li>
</ul>
</li>
<li>
<p>Chronic severe AR</p>
<ul>
<li>Medical management</li>
<li>Early symptoms of exercise intolerance can be treated with
    diuretics</li>
<li>Systolic BP should also be controlled with goal SBP \&lt; 140 in
    chronic AR</li>
</ul>
</li>
<li>
<p>Repeat imaging should be performed 3-6 month to assess for depressed
    LVEF or LV dilation</p>
</li>
<li>
<p>Stages of Chronic AR: Ranging from Stage (A): Asymptomatic but “At
    Risk” AR to Stage (D) Symptomatic Severe AR</p>
<ul>
<li>If symptoms are present, automatically Stage D, otherwise
    Progression through stages is determined by AR Jet Width</li>
</ul>
</li>
<li>Class I indications for Valve Repair:<ul>
<li>Stage D (Symptomatic) or Stage C (Asymptomatic Severe AR)
  with LVEF \&lt; 55%, or are undergoing other
  cardiac surgery</li>
<li>If LVEF > or equal 55%, patients should be considered for
        surgery if LV is dilated (LVESD > 50 mm (class IIa) or LVEDD >
        65 mm (class IIb))</li>
<li>Any patient with progressive AR, even if they do not meet criteria
    for severe AR, should consider valve replacement if undergoing
    cardiac surgery for other reasons</li>
<li>Note: TAVI for isolated chronic AR is challenging 2/2 dilation
        of the aortic annulus and root</li>
</ul>
</li>
</ul>
<h1 id="cardiology-cardiology-valvular-heart-disease-mitral-regurgitation">Mitral Regurgitation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-mitral-regurgitation" title="Permanent link">&para;</a></h1>
<p>Marcus Threadcraft</p>
<hr />
<h2 id="cardiology-cardiology-valvular-heart-disease-etiology_2">Etiology<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-etiology_2" title="Permanent link">&para;</a></h2>
<ul>
<li>Primary MR – caused by direct involvement of the valve apparatus
    (leaflets or chordae tendineae)</li>
<li>Degenerative/myxomatous mitral valve disease (mitral valve prolapse
    with flail leaflet, mitral annular calcification, chordal rupture)</li>
<li>Rheumatic fever</li>
<li>Infective endocarditis</li>
<li>Papillary muscle rupture following acute (inferior) MI</li>
<li>Secondary MR- caused by changes of the LV that lead to valvular
    incompetence</li>
<li>Dilated Cardiomyopathy</li>
<li>HOCM with systolic anterior motion</li>
<li>Coronary Artery Disease or prior MI leading to papillary muscle
    tethering</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-presentation_2">Presentation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-presentation_2" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute MR- sudden onset reduction in forward cardiac flow and left
    atrial/pulmonary vein volume overload</li>
<li>Dyspnea with flash pulmonary edema</li>
<li>Left-sided heart failure</li>
<li>Chronic MR- progressive symptoms d/t cardiac remodeling to
    compensate for mitral flow reversal</li>
<li>Progressively worsening heart failure: dyspnea, orthopnea, PND</li>
<li>LV dilation from volume overload</li>
<li>LA remodeling/dilation leading to afib</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-auscultation">Auscultation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-auscultation" title="Permanent link">&para;</a></h2>
<ul>
<li>Holosystolic Murmur</li>
<li>Best heard at Apex</li>
<li>Radiation to the Axilla</li>
<li>Frequently associated with S3</li>
<li>Murmur may be absent in acute MR due to large regurgitant
    orifice/low velocity regurgitant jet</li>
<li>Increases w/ increased preload or afterload</li>
<li>Pulmonary Rales</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-evaluation_1">Evaluation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-evaluation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>CXR: assess for pulmonary edema, r/o other causes of acute dyspnea</li>
<li>ECG: often non-specific, LVH</li>
<li>Echocardiography: assess valve apparatus, size, and function of
    LA/LV, grade severity of MR</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-chronic-mr-stages">Chronic MR stages<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-chronic-mr-stages" title="Permanent link">&para;</a></h2>
<ul>
<li>A: No symptoms</li>
<li>B: >mild MR w/o hemodynamic changes or symptoms</li>
<li>C: Severe MR w/o symptoms<ul>
<li>C1: preserved EF and normal LV size</li>
<li>C2: reduced EF (\&lt;60%), dilated LV (LVESD > 40mm)</li>
</ul>
</li>
<li>D: Severe/symptomatic</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-management_2">Management<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-management_2" title="Permanent link">&para;</a></h2>
<p>Acute hemodynamically significant MR</p>
<ul>
<li>Urgent surgical repair or replacement</li>
<li>Medical stabilization as a bridge to surgery<ul>
<li>Afterload reduction is key to promote forward flow</li>
<li>Vasodilators (nitroprusside, nitroglycerin) reduce afterload</li>
<li>Diuresis to reduce preload and improve pulmonary edema</li>
<li>IABP placement can be used as mechanical afterload reduction</li>
</ul>
</li>
</ul>
<p>Chronic severe primary MR</p>
<ul>
<li>Surgical repair favored over valve replacement</li>
<li>Class I:<ul>
<li>Asymptomatic patients w/ LVEF 30-59% or LVESD > or equal 40mm</li>
<li>Symptomatic patients w/ EF > 30%</li>
</ul>
</li>
<li>Class II:<ul>
<li>A: asymptomatic patients with progressive EF decline or LV
    dilation on serial monitoring; or very severe MR</li>
<li>B: new onset AF</li>
</ul>
</li>
<li>Secondary MR can consider MV repair with persistent class III-IV
    symptoms while on guideline directed medical therapy</li>
<li>In HFrEF, consider MitraClip after volume optimization (see Heart
    Failure section)</li>
</ul>
<h1 id="cardiology-cardiology-valvular-heart-disease-mitral-stenosis">Mitral Stenosis<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-mitral-stenosis" title="Permanent link">&para;</a></h1>
<p>Marcus Threadcraft</p>
<hr />
<h1 id="cardiology-cardiology-valvular-heart-disease-etiology_3">Etiology<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-etiology_3" title="Permanent link">&para;</a></h1>
<p>Characterized by thickened mitral valve leaflets and fused
leaflet tips.</p>
<ul>
<li>Rheumatic Fever (leading cause worldwide)</li>
<li>Calcification of the mitral valve annulus (common in high income
    countries)</li>
<li>Autoimmune Diseases: SLE, Rheumatoid arthritis</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-presentation_3">Presentation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-presentation_3" title="Permanent link">&para;</a></h2>
<ul>
<li>Progressive symptoms: Asymptomatic Heart Failure</li>
<li>Orthopnea</li>
<li>PND</li>
<li>Hoarseness/Dysphagia (compression of recurrent laryngeal
    nerve/esophagus by enlarged left atrium from pressure overload)</li>
<li>Symptoms of Right Heart Failure</li>
<li>Acute Symptoms may present in settings of increased cardiac output
    (pregnancy, sepsis, or exercise) or tachyarrhythmias</li>
<li>Dyspnea</li>
<li>Fatigue</li>
<li>Palpitations</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-physical-exam">Physical exam<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-physical-exam" title="Permanent link">&para;</a></h2>
<ul>
<li>Low-pitched rumbling, diastolic Murmur, best heard at apex,
    low-pitched, rum<ul>
<li>Loud S1, opening snap after S2</li>
<li>Prominent P2 if pulmonary HTN develops</li>
</ul>
</li>
<li>Pulmonary Rales</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-evaluation_2">Evaluation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-evaluation_2" title="Permanent link">&para;</a></h2>
<ul>
<li>CXR: LA enlargement, increased pulmonary vasculature</li>
<li>Echocardiography: thickening of mitral valve leaflets, decreased
    area of valve leaflets, left atrial enlargement</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-management_3">Management<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-management_3" title="Permanent link">&para;</a></h2>
<ul>
<li>Varies between rheumatic MS and calcific MS (in general,
    intervention of calcific MS is very challenging and high risk)</li>
<li>Severe, symptomatic rheumatic MS:<ul>
<li>Percutaneous mitral balloon commissurotomy (PMBC)</li>
<li>Surgical repair/replacement if patient failed PMBC or undergoing
other cardiac surgery</li>
</ul>
</li>
<li>
<p>Calcific MS has a poor prognosis with 5-year survival \&lt;50%,
    Intervention is higher risk and should be reserved for severely
    symptomatic patients</p>
</li>
<li>
<p>No role for commissurotomy with calcific MS</p>
</li>
<li>Surgical valve replacement may be considered for severely
    symptomatic patients (technically challenging)</li>
</ul>
<h2 id="cardiology-cardiology-valvular-heart-disease-anti-coagulation">Anti-Coagulation<a class="headerlink" href="#cardiology-cardiology-valvular-heart-disease-anti-coagulation" title="Permanent link">&para;</a></h2>
<ul>
<li>Anti-coagulation is indicated if:<ul>
<li>Mechanical prosthetic mitral valve<ul>
<li>Warfarin, goal INR 3-4 lifelong</li>
</ul>
</li>
<li>Bioprosthetic mitral valve replacement<ul>
<li>Warfarin, goal INR 2-3 for first 3-6 months</li>
</ul>
</li>
<li>Atrial Fibrillation regardless of CHADS2VASC score</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Cardiology</h1>
                        <h1 class='nav-section-title' id='section-critical-care'>
                            Critical care <a class='headerlink' href='#section-critical-care' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="critical-care-critical-care-abcdef-a2f-bundle"><h1 id="critical-care-critical-care-abcdef-a2f-bundle-abcdef-a2f-bundle">ABCDEF (A2F) Bundle<a class="headerlink" href="#critical-care-critical-care-abcdef-a2f-bundle-abcdef-a2f-bundle" title="Permanent link">&para;</a></h1>
<p>Kaele Leonard</p>
<hr />
<h2 id="critical-care-critical-care-abcdef-a2f-bundle-background">Background<a class="headerlink" href="#critical-care-critical-care-abcdef-a2f-bundle-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Post-Intensive Care Syndrome (PICS): complex constellation of
    cognitive, physical, and psychological impairments that impact most
    survivors of critical illness, leading to disability, frailty, and
    poor quality of life</li>
<li>Predicted by (1) duration of immobility and (2) delirium</li>
<li>Both are reduced by >80% compliance with ABCDEF (A2F) Bundle
    concepts</li>
<li>ABCDEF (A2F) Bundle: Interprofessional, evidence-based safety bundle
    of care principles to help reduce LOS, mortality, bounce-backs, and
    the duration of ICU delirium and coma</li>
<li>Goal: allow pt to “prove us wrong” about readiness for liberation
    from devices, sedatives, etc.</li>
</ul>
<p>**A**ssess, prevent, and manage pain</p>
<ul>
<li>Tools to assess pain using facial expressions, body movements,
    muscle tension, compliance with ventilator, or vocalization for
    extubated pts</li>
<li>Ex: Critical Care Pain Observation Tool (CPOT): scale 0-8,
    uncontrolled pain 3</li>
<li>Uncontrolled pain increases risk for delirium, limits inspiratory
    effort &amp; weaning from ventilator, and limits ability to mobilize</li>
<li>Treatment: multi-modal: parenteral opioids, neuropathic meds (e.g.,
    gabapentin, ketamine), adjunctive non-opioids analgesics (e.g.,
    acetaminophen, NSAIDs), nonpharmacologic interventions
    (repositioning, heat/cold)</li>
</ul>
<p>**B**oth spontaneous awakening trials (SATs) and spontaneous breathing
trials (SBTs)</p>
<ul>
<li>SATs = daily sedative interruptions</li>
<li>RN-driven protocol involving safety checklist: no active seizures,
    alcohol withdrawal, agitation, paralytics, myocardial infarction, or
    increased ICP</li>
<li>If pass SAT, then proceed to SBT</li>
<li>If fail SAT (anxiety, agitation, pain, resp distress) restart
    sedation at ½ doses</li>
<li>SBTs = PS ventilation (Fi02 ≤ 50%, PEEP ≤ 7.5; typically 40% and
    5/5) for ≥ 30 minutes</li>
<li>RT or physician/APP-driven protocol with safety screen: passed SAT,
    O2 sat ≥ 88%, inspiratory efforts, no myocardial ischemia, no/low
    vasopressor support</li>
<li>If pass SBT, physician/APP judgment on extubation</li>
<li>If fail SBT (RR > 35 or \&lt; 8, O2 sat \&lt; 88%, resp distress, mental
    status change) restart full ventilatory support</li>
<li>Evidence:<ul>
<li>Liberated pts from mechanical ventilation 3 days sooner, decreased
    ICU and hospital length of stay by 4 days, and 14% absolute
    reduction in mortality at 1 year</li>
</ul>
</li>
</ul>
<p>**C**hoice of analgesia and sedation</p>
<ul>
<li>Richmond Agitation-Sedation Scale (RASS): sedation &amp; level of
    arousal assessment tool (Figure 1)</li>
<li>Target light sedation of RASS -1 to 0 with goal of (1) pt following
    commands without agitation and (2) limiting immobilization</li>
<li>Over-sedation: hold sedatives till target, then restart at ½ prior
    dose</li>
<li>Analgosedation with focus on treating pain first and then adding
    sedation meds PRN</li>
<li>Sedatives: dexmedetomidine (dex) or propofol >>> benzodiazepines</li>
<li>Benzodiazepines increase risk of delirium in a dose-dependent
    fashion</li>
</ul>
<figure>
<p><img alt="Richmond Agitation-Sedation Scale" src="../images/image12.png" />
  </p>
<figcaption> Figure 1: Richmond Agitation-Sedation Scale (RASS) Delirium - assess, prevent, and manage</figcaption>
</figure>
<p>**D**elirium- assess, prevent, and manage</p>
<ul>
<li>Screening for delirium: q4hr using CAM-ICU (Figure 2)</li>
<li>Affects 60-80% of ventilated pts and associated with increased
    morbidity and mortality, longer ICU and hospital length of stay,
    long-term cognitive dysfunction</li>
<li>Risk factors and treatment: see Delirium section in Psychiatry</li>
</ul>
<p>**E**arly mobility and exercise</p>
<ul>
<li>Prolonged immobilization during critical illness leads to
    ICU-acquired weakness, associated with worse outcomes: ↑ mechanical
    ventilation, increased hosp length of stay, greater mortality, and
    greater disability</li>
<li>Consult PT/OT to initiate rehab at the beginning of critical illness</li>
<li>Can be done safely in pts receiving advanced support</li>
</ul>
<p>**F**amily engagement and empowerment</p>
<ul>
<li>Especially important when pts are unable to communicate themselves</li>
<li>Incorporate family at the bedside and on rounds to learn pt
    preferences and values, engage in shared-decision making, and
    address questions and concerns</li>
</ul>
<figure>
<p><img alt="ABCDEF" src="../images/image13.png" />
  </p>
<figcaption></figcaption>
</figure></section><section class="print-page" id="critical-care-critical-care-ards"><h1 id="critical-care-critical-care-ards-acute-respiratory-distress-syndrome-ards">Acute Respiratory Distress Syndrome (ARDS)<a class="headerlink" href="#critical-care-critical-care-ards-acute-respiratory-distress-syndrome-ards" title="Permanent link">&para;</a></h1>
<p>Judd Heideman</p>
<hr />
<h2 id="critical-care-critical-care-ards-background">Background<a class="headerlink" href="#critical-care-critical-care-ards-background" title="Permanent link">&para;</a></h2>
<ul>
<li>A syndrome of diffuse inflammation and injury of the alveoli and
    capillary endothelium leading to fluid and protein accumulation in
    the interstitium and alveoli, pulmonary edema, and hypoxemic
    respiratory failure; 30-50% mortality rate</li>
<li>Triggers:</li>
<li>Pulmonary<ul>
<li>Pneumonia (viral and bacterial) • Lung contusion</li>
<li>Direct inhalation injury • Aspiration</li>
<li>Primary graft dysfunction of pulmonary transplant</li>
</ul>
</li>
<li>Extra-pulmonary<ul>
<li>Sepsis (most common cause) • HSCT</li>
<li>Trauma • Burns</li>
<li>Massive blood transfusions/TRALI • Pancreatitis</li>
<li>Drugs (amiodarone, chemotherapy, cocaine, opioids)</li>
</ul>
</li>
</ul>
<h2 id="critical-care-critical-care-ards-evaluation">Evaluation<a class="headerlink" href="#critical-care-critical-care-ards-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Diagnosis: Berlin Criteria</li>
<li>New or worsening respiratory symptoms beginning within one week of
    diagnosis</li>
<li>New bilateral opacities present on chest radiograph or CT chest<ul>
<li>Not explained by effusions, collapse of lobe/lung, or nodules</li>
</ul>
</li>
<li>Absence of left heart failure or volume overload</li>
<li>Severity: based on PaO2/FiO2 ratio with a PEEP ≥ 5 cm H2O</li>
<li>PaO2 = arterial partial pressure of O2 (requires ABG)</li>
<li>FiO2 = fraction of inspired oxygen (expressed as a decimal between
    0.21 and 1.0)</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th>PaO2/FiO2 ratio</th>
<th>PEEP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>201-300</td>
<td>≥5</td>
</tr>
<tr>
<td>Moderate</td>
<td>101-200</td>
<td>≥5</td>
</tr>
<tr>
<td>Severe</td>
<td>\&lt;100</td>
<td>≥5</td>
</tr>
</tbody>
</table>
<h2 id="critical-care-critical-care-ards-management">Management<a class="headerlink" href="#critical-care-critical-care-ards-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Frequently requires intubation; non-invasive ventilation not a great
    treatment</li>
<li>Low tidal volume (Vt) ventilation mortality benefit</li>
<li>Goal Vt = 4-8 mL/kg of <em>predicted</em> body weight (obese patients don’t
    have bigger lungs)</li>
<li>Plateau pressure goal: ≤30 cm H2O</li>
<li>Oxygenation goal: PaO2 55-80 or SpO2 88-95%</li>
<li>pH goal: ≥7.20, “permissive hypercapnia”</li>
<li>Treat the underlying cause (see “Triggers” above)</li>
</ul></section><section class="print-page" id="critical-care-critical-care-brain-death"><h1 id="critical-care-critical-care-brain-death-brain-death">Brain Death<a class="headerlink" href="#critical-care-critical-care-brain-death-brain-death" title="Permanent link">&para;</a></h1>
<p>Anna Berry</p>
<hr />
<h2 id="critical-care-critical-care-brain-death-background">Background<a class="headerlink" href="#critical-care-critical-care-brain-death-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Brain death= complete and permanent loss of brain function. Defined
    by coma with loss of capacity for consciousness, brainstem reflexes,
    and the ability to breathe independently</li>
</ul>
<p>Checklist for Determination of Brain Death (American Academy of
Neurology)</p>
<ol>
<li>Prerequisites (all must be checked)<ul>
<li>Coma, irreversible and cause known</li>
<li>Neuroimaging explains coma – usually CT or MRI</li>
<li>Absence of CNS depressing drugs</li>
<li>No evidence of residual paralytics (electrical stimulation if
    paralytics used)</li>
<li>Absence of severe acid-base, electrolyte, endocrine abnormality</li>
<li>Normothermia or mild hypothermia (core temp >36°C)</li>
<li>SBP ≥100 mm Hg</li>
<li>No spontaneous respirations</li>
</ul>
</li>
<li>Examination (all must be checked) – Attending MUST be present for
brain death exam</li>
</ol>
<figure>
<p><img alt="brain death" src="../images/image14.png" />
  </p>
<figcaption>Greer DM, Determination of Brain Death. NEJM. 2021;385;2554-61. DOI:
0.1056/NEJMcp2025326</figcaption>
</figure>
<ol>
<li>Apnea testing (all must be checked) – Attending MUST be present<ul>
<li>Pt is hemodynamically stable</li>
<li>Ventilator adjusted to provide normocarbia (PaCO2 35–45 mm Hg)</li>
<li>Preoxygenate with 100% FiO2 and PEEP of 5 cm water for >10 minutes
    to PaO2 >200 mmHg</li>
<li>Provide oxygen via a suction catheter to the level of the carina at
    6 L/min or attach T-piece with continuous positive airway pressure
    (CPAP) at 10 cm H2O</li>
<li>Disconnect ventilator</li>
<li>Spontaneous respirations absent</li>
<li>Arterial blood gas drawn at 8–10 minutes, patient reconnected to
    ventilator</li>
<li>PCO2 ≥60 mm Hg, or 20 mm Hg rise from normal baseline value; OR:</li>
<li>Apnea test aborted due to spontaneous respirations present,
    hemodynamic instability, or hypoxia</li>
</ul>
</li>
<li>Ancillary testing (Order one test if clinical examination cannot be
fully performed due to patient factors or if apnea testing
inconclusive/aborted)<ul>
<li>Cerebral angiogram</li>
<li>HMPAO SPECT (Single photon emission computed tomography)</li>
<li>EEG &amp; TCD (transcranial Doppler)</li>
</ul>
</li>
</ol>
<h2 id="critical-care-critical-care-brain-death-organ-donation-caveats">Organ donation caveats<a class="headerlink" href="#critical-care-critical-care-brain-death-organ-donation-caveats" title="Permanent link">&para;</a></h2>
<ul>
<li>Discussions about organ donation should take place between Tennessee
    Donor Services (TDS) and the surrogate. You SHOULD NOT be having
    conversations with the surrogate about donation. Direct questions to
    TDS.</li>
</ul></section><section class="print-page" id="critical-care-critical-care-codes"><h1 id="critical-care-critical-care-codes-running-codes">Running Codes<a class="headerlink" href="#critical-care-critical-care-codes-running-codes" title="Permanent link">&para;</a></h1>
<p>Jacqueline Visina</p>
<hr />
<h2 id="critical-care-critical-care-codes-arrival-to-a-code">Arrival to a Code<a class="headerlink" href="#critical-care-critical-care-codes-arrival-to-a-code" title="Permanent link">&para;</a></h2>
<ul>
<li>Questions to answer when you arrive: Is someone running the code?
    Who is doing compressions? Do we have pads on the patient? What is
    our IV access?</li>
<li>Take charge: establish if anyone is actively running the code, if
    someone is running the code, introduce yourself and ask how you may
    be helpful. If someone is NOT, have someone begin chest compressions
    IMMEDIATELY and assume responsibility for the running the code</li>
<li>IV access: IV access preferred, if no immediate IV access, place IO</li>
<li>Obtain a brief medical history and events surrounding the code and
    the patient’s code status</li>
<li>Have someone find the nearest crash cart and get pads on the patient
    as soon as possible</li>
</ul>
<h2 id="critical-care-critical-care-codes-running-the-code">Running the Code<a class="headerlink" href="#critical-care-critical-care-codes-running-the-code" title="Permanent link">&para;</a></h2>
<ul>
<li>Assess the rhythm</li>
<li>If Vfib/VT- immediately shock</li>
<li>For polymorphic VT, this is ischemia until proven otherwise unless
    the patient is on a large amount of QTc prolonging medications.</li>
<li>If PEA/Asystole- resume compressions, give Epi 1mg ASAP</li>
<li>Strong ACLS</li>
<li>Q2min- pulse check, rhythm check, shock?</li>
<li>Remember the two interventions with proven mortality benefit are
    high quality chest compressions and early defibrillation. Do not
    interrupt these actions for other things</li>
<li>Monitor the quality of chest compressions</li>
<li>Warn resuscitators when shock is being delivered</li>
<li>Consider Advanced Airway</li>
<li>Remember chest compressions save lives. Not intubation. Do not stop
    compressions for intubation</li>
<li>Stay Calm</li>
<li>Closed Loop communication- continue giving instructions, use names,
    minimize interruptions</li>
<li>Do not move from foot of bed if you are running the code</li>
<li>Ensure delivery of adequate compressions. Avoid excessive
    ventilation</li>
<li>If you are running the code, it is helpful to maintain a constant
    verbal running summary of interventions that have been tried and the
    course of the code</li>
<li>Have a member of the team locate an ultrasound for line placement
    and diagnostics</li>
<li>Allow family to be present</li>
<li>H’s and T’s: Treat Reversible Factors</li>
<li>Some of the fellows here will empirically give 2 grams of magnesium,
    1 amp of D50, 1 amp of bicarb, and 1g calcium chloride at the onset
    of the code irrespective of presenting rhythm</li>
<li>Can send Labs – ask for a “loaded gas”. This will usually be a
    VBG/ABG with lactate, K, Ca, and Hgb. Often information does not
    result quick enough to change immediate management. Have someone
    look up most recent labs in Epic (looking for recent hyperK,
    acidosis)</li>
</ul>
<h2 id="critical-care-critical-care-codes-terminating-a-code">Terminating a Code<a class="headerlink" href="#critical-care-critical-care-codes-terminating-a-code" title="Permanent link">&para;</a></h2>
<ul>
<li>Consider initial rhythm, patient comorbidities, cardiac vs
    non-cardiac arrest, bedside echo findings. ROSC or rhythm changes
    during code?</li>
<li>Persistent ETCO2\&lt; 10mmHg after 20min CPR has minimal survival</li>
<li>Ask your team if they have any other therapies that they feel would
    be indicated</li>
<li>Ask if anyone remains in favor of continuing CPR</li>
<li>When unanimous, terminate the code and announce time of death. Thank
    your team. Take a moment of silence for the deceased patient</li>
</ul>
<h2 id="critical-care-critical-care-codes-post-arrest-care">Post-Arrest Care<a class="headerlink" href="#critical-care-critical-care-codes-post-arrest-care" title="Permanent link">&para;</a></h2>
<ul>
<li>Immediately following ROSC is the most dangerous point of ACLS</li>
<li>Airway: Secure airway if not done during code, ensure RT avoids
    hypoxia or hyperoxia</li>
<li>BP: MAPs>65, IVF and/or pressors if needed</li>
<li>If on floor, prioritize moving patient to a unit for ongoing care
    once hemodynamically stable enough for transfer. Would not delay for
    other diagnostics/interventions (lines, CXR, etc)</li>
<li>Cardiac: obtain EKG. Assess if urgent cardiac intervention is
    required for STEMI vs unstable cardiogenic shock vs VT storm or Vfib</li>
<li>Neuro: if not following commands, consider TTM. TTM is still
    performed at VUMC with a strict protocol and inclusion criteria. If
    there is any question about TTM eligibility, page the CCU fellow</li>
<li>Send rainbow labs (CBC, CMP, Mg, coags, trop, lactate, VBG/ABG).
    Treat rapidly reversible causes</li>
<li>CXR</li>
<li>Propofol/fentanyl infusion if the patient is intubated. Pressor of
    choice post ROSC is usually levophed</li>
<li>If not done during the code, usually central access will be obtained
    and an arterial line will be placed</li>
</ul>
<h2 id="critical-care-critical-care-codes-intern-role-during-codes">Intern role during codes<a class="headerlink" href="#critical-care-critical-care-codes-intern-role-during-codes" title="Permanent link">&para;</a></h2>
<ul>
<li>maintain hand on femoral pulse</li>
<li>place IO if needed</li>
<li>have access to the patient’s chart to answer questions that arise during the code.</li>
<li>If family is not available, looking up primary contact information is invaluable.</li>
<li>In the MICU, your role is to grab the yellow IO kit prior to leaving for the code</li>
</ul>
<h2 id="critical-care-critical-care-codes-family-presence-during-cpr">Family presence during CPR<a class="headerlink" href="#critical-care-critical-care-codes-family-presence-during-cpr" title="Permanent link">&para;</a></h2>
<p>Studies show that it reduces the frequency of
PTSD-related symptoms and does not interfere with medical efforts</p>
<table>
<thead>
<tr>
<th>Treatable Causes of Cardiac Arrest: The H’s and T’s</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>H’s</td>
<td>T’s</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>Toxins</td>
</tr>
<tr>
<td>Hypovolemia</td>
<td>Tamponade</td>
</tr>
<tr>
<td>H+</td>
<td>Tension Pneumothorax</td>
</tr>
<tr>
<td>Hypo/Hyper K</td>
<td>Thrombosis: Pulmonary</td>
</tr>
<tr>
<td>Hypothermia</td>
<td>Thrombosis: Coronary</td>
</tr>
</tbody>
</table></section><section class="print-page" id="critical-care-critical-care-drips"><h1 id="critical-care-critical-care-drips-micuccu-drips">MICU/CCU Drips<a class="headerlink" href="#critical-care-critical-care-drips-micuccu-drips" title="Permanent link">&para;</a></h1>
<p>Patrick Barney</p>
<hr />
<p>Most have order sets in Epic. Typically choose “Titration Allowed” in
ICU</p>
<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 17%" />
<col style="width: 16%" />
<col style="width: 23%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="5">Vasopressors:</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td>Dose</td>
<td>Receptors</td>
<td>Indications</td>
<td>Considerations</td>
</tr>
<tr class="even">
<td><strong>Norepinephrine (Levophed)</strong></td>
<td>1 – 100 mcg/min</td>
<td>αα1 &gt; β1</td>
<td>1st line septic shock</td>
<td>Peripheral ischemia, skin necrosis</td>
</tr>
<tr class="odd">
<td><strong>Phenylephrine (Neosynephrine)</strong></td>
<td><p>Bolus: 0.05 – 0.5 mg q 10-15 min</p>
<p>Infusion: 40-360 mcg/min</p></td>
<td>αα1</td>
<td>Periprocedural hypotension (Neostick), pts w/ tachyarrhythmias,
Critical AS or HOCM with severe LVOT obstruction and shock</td>
<td>Reflex bradycardia, Peripheral ischemia, skin necrosis</td>
</tr>
<tr class="even">
<td><strong>Epinephrine</strong></td>
<td>1 – 40 mcg/min</td>
<td>αα1=β1=β2</td>
<td>Post PEA arrest, Anaphylaxis, Septic shock (severe), Cardiogenic
shock</td>
<td>Tachy-arrhythmias, Peripheral ischemia, skin necrosis</td>
</tr>
<tr class="odd">
<td><strong>Vasopressin</strong></td>
<td>0.04 U/min (no titration)</td>
<td>V1, V2, V3</td>
<td>2nd line septic shock, Right heart failure</td>
<td>Hyponatremia, Bradycardia</td>
</tr>
<tr class="even">
<td><p><strong>ANG II</strong></p>
<p><strong>needs approval from MICU leadership</strong></p></td>
<td>20 – 40 ng/kg/min</td>
<td>ANG II</td>
<td>Refractory vasodilatory shock</td>
<td>Thrombosis pt MUST have chemical DVT ppx. Contraindicated in heart
failure</td>
</tr>
<tr class="odd">
<td><strong>Dopamine</strong></td>
<td>2 – 20 mcg/kg/min</td>
<td>Dopamine (1-5 mcg) &gt; β1 (5-10 mcg) &gt;α1 (&gt;10mcg)</td>
<td>Hypotension, Cardiogenic shock</td>
<td>Tachy-arrhythmias, peripheral ischemia, skin necrosis</td>
</tr>
<tr class="even">
<td><strong>Dobutamine</strong></td>
<td>2.5 – 20 mcg/kg/min</td>
<td>β1 &gt;&gt;&gt; β2</td>
<td>Cardiogenic shock</td>
<td>Vasodilation Hypotension, Tachycardia, Tachyphylaxis</td>
</tr>
<tr class="odd">
<td><strong>Milrinone</strong></td>
<td>0.375 – 0.75 mcg/kg/min</td>
<td>PDE-3</td>
<td>Cardiogenic shock</td>
<td>Hypotension, renally cleared</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 10%" />
<col style="width: 10%" />
<col style="width: 11%" />
<col style="width: 9%" />
<col style="width: 12%" />
<col style="width: 11%" />
<col style="width: 11%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="8">Sedatives/Anxiolytics:</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td colspan="2">Dose</td>
<td colspan="2">Class</td>
<td colspan="3">Side effects</td>
</tr>
<tr class="even">
<td><strong>Propofol</strong></td>
<td colspan="2">Infusion: 5 – 150 mcg/kg/min</td>
<td colspan="2">General anesthetic (GABA R agonist)</td>
<td colspan="3"><p>Severe hypotension, bradycardia,
hypertriglyceridemia, propofol infusion syndrome (rare)</p>
<p>Monitor for toxicity with q4 day TGs and CK</p></td>
</tr>
<tr class="odd">
<td><strong>Dexmedetomidine (Precedex)</strong></td>
<td colspan="2">Infusion: 0.1 – 1.5 mcg/kg/h</td>
<td colspan="2">Central αα2 agonist</td>
<td colspan="3">Hypotension, bradycardia</td>
</tr>
<tr class="even">
<td><strong>Midazolam (Versed)</strong></td>
<td colspan="2"><p>Push: 0.5 – 5 mg</p>
<p>Infusion: 0.25 – 5 mg/h (no max dose)</p></td>
<td colspan="2">Benzodiazepine</td>
<td colspan="3">Hypotension, risk of BNZ withdrawal if used for long
periods with sudden discontinuation</td>
</tr>
<tr class="odd">
<td><strong>Lorazepam (Ativan)</strong></td>
<td colspan="2"><p>Push: 0.5 – 10 mg</p>
<p>Infusion: 0.5 – 5 mg/h (no max dose)</p></td>
<td colspan="2">Benzodiazepine</td>
<td colspan="3">Hypotension, propylene glycol carrier - AGMA</td>
</tr>
<tr class="even">
<td><strong>Ketamine</strong></td>
<td colspan="2"><p>Push: 1-2mg/kg</p>
<p>Infusion: 0.2mg/kg/hr, titrate by 0.1 q15min</p></td>
<td colspan="2">NDMA antagonist</td>
<td colspan="3"><p>Delirium/hallucination – use caution in patients with
psychiatric hx, hypertension, tachycardia</p>
<p>Pretreat with 0.4mg IV glycopyrrolate to avoid
hyper-salivation</p></td>
</tr>
<tr class="odd">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 29%" />
<col style="width: 48%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Analgesic:</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td>Dose</td>
<td>Side effects</td>
</tr>
<tr class="even">
<td><strong>Fentanyl</strong></td>
<td><p>Push: 25 – 100 mcg</p>
<p>Infusion: 25 – 400 mcg/h</p></td>
<td>Hypotension, Serotonin syndrome, chest wall rigidity at high
doses</td>
</tr>
<tr class="odd">
<td><strong>Morphine</strong></td>
<td><p>Push: 1 – 5 mg q1-2h prn</p>
<p>Infusion: 1 – 5 mg/h</p></td>
<td>Hypotension (profound), itching, constipation, HA; avoid in renal
failure</td>
</tr>
<tr class="even">
<td><strong>Hydromorphone (Dilaudid)</strong></td>
<td><p>Push: 0.25 – 1 q1-2h prn</p>
<p>Infusion: 0.5 – 3 mg/h</p></td>
<td>Hypotension, respiratory depression, itching</td>
</tr>
</tbody>
</table>

<table style="width:100%;">
<colgroup>
<col style="width: 16%" />
<col style="width: 15%" />
<col style="width: 19%" />
<col style="width: 13%" />
<col style="width: 16%" />
<col style="width: 18%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="6">Anti-hypertensives</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td>Class/MOA</td>
<td>Dose</td>
<td>Indications</td>
<td>Side effects</td>
<td>Comments</td>
</tr>
<tr class="even">
<td><strong>Esmolol</strong></td>
<td>Beta blocker</td>
<td><p>Bolus: 1mg/kg over 30s</p>
<p>Infusion: 50-300mcg/kg/min (max 300)</p></td>
<td>Aortic dissection, HTN emergency</td>
<td>Bradycardia, hypotension</td>
<td>Titrate to desired BP or HR. Caution in HFrEF</td>
</tr>
<tr class="odd">
<td><strong>Nicardipine</strong></td>
<td>CCB</td>
<td>Infusion: 5-15mg/hr (max 15)</td>
<td>HTN emergency</td>
<td>Bradycardia, hypotension</td>
<td>Titrate to desired BP, avoid in HFrEF</td>
</tr>
<tr class="even">
<td><strong>Nitroprusside</strong></td>
<td>Metabolized to NO vasodilatory effect (arterial roughly =
venous)</td>
<td>Infusion: 0.3mcg/kg/min; titrate q2min to max 10mcg/kg/min</td>
<td>HTN E, flash pulmonary edema, HFrEF for afterload reduction</td>
<td>Hypotension, cyanide toxicity</td>
<td>Contraindicated in hepatic and renal failure</td>
</tr>
<tr class="odd">
<td><strong>Nitroglycerin</strong></td>
<td>NO mediated venous &gt; arterial vasodilation</td>
<td>Infusion: start 0.25mcg/kg/min, titrate by 1mcg/kg/min q15min (max
10mcg/kg/min)</td>
<td>Refractory angina, flash pulmonary edema, HTN emergency</td>
<td>Hypotension, headache, palpitations</td>
<td>Contraindicated in severe RHF and concurrent use of PDE-5
inhibitor</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 17%" />
<col style="width: 15%" />
<col style="width: 20%" />
<col style="width: 30%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="5">Anti-Arrhythmics:</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Drug</td>
<td>Dose</td>
<td>Indications</td>
<td>Side effects</td>
<td>Comments</td>
</tr>
<tr class="even">
<td><strong>Adenosine</strong></td>
<td>6 – 12 mg IV rapid push and flush; may repeat x2</td>
<td>PSVT conversion</td>
<td>Complete AV nodal blockade</td>
<td><p>10 second half-life</p>
<p> Must have continuous EKG/tele monitor</p></td>
</tr>
<tr class="odd">
<td><strong>Amiodarone</strong></td>
<td><p>ACLS: 300 mg IV push</p>
<p>Non-emergent: 150 mg over 10 min then 0.5 mg/min</p></td>
<td>Vtach/Vfib, Afib</td>
<td>Pulm, ophthalmic and thyroid toxicity w/ chronic use</td>
<td>Less hypotension than other agents, safe in heart failure. May
chemically cardiovert patients, caution if off therapeutic AC</td>
</tr>
<tr class="even">
<td><strong>Diltiazem</strong></td>
<td><p>Push: 10 – 20 mg q15 min x 2 if no response</p>
<p>Infusion: 5 – 15 mg/h</p></td>
<td>Afib, Aflutter, PSVT</td>
<td>Bradycardia, hypotension</td>
<td>Avoid use in pts with HFrEF</td>
</tr>
<tr class="odd">
<td><strong>Lidocaine</strong></td>
<td><p>ACLS: 1 mg/kg x 1</p>
<p>Infusion: 1 – 4 mg/min</p></td>
<td>Vtach</td>
<td>Bradycardia, Heart block</td>
<td>Avoid use in liver failure/ Okay for HFrEF. Often 1<sup>st</sup>
line CCU med for VT/ May need to check levels if using for longer than
24 hours</td>
</tr>
<tr class="even">
<td><strong>Procainamide</strong></td>
<td>15 mg/kg over 30 min then 1 – 6 mg/min</td>
<td>Vtach, refractory afib</td>
<td>Bradycardia, hypotension</td>
<td>Drug-induced lupus, cytopenias</td>
</tr>
</tbody>
</table></section><section class="print-page" id="critical-care-critical-care-intubation-extubation"><h1 id="critical-care-critical-care-intubation-extubation-intubation-and-extubation">Intubation and Extubation<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-intubation-and-extubation" title="Permanent link">&para;</a></h1>
<p>Daniel Motta-Calderon</p>
<hr />
<h2 id="critical-care-critical-care-intubation-extubation-intubation">Intubation<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-intubation" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-critical-care-intubation-extubation-background">Background<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Intubation is the definitive therapy for patients with worsening
    respiratory failure</li>
<li>Indications for intubation- hypoxic or hypercarbic respiratory
    failure, airway protection</li>
</ul>
<h3 id="critical-care-critical-care-intubation-extubation-intubation-checklist">Intubation checklist<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-intubation-checklist" title="Permanent link">&para;</a></h3>
<ul>
<li>Prepare the patient<ul>
<li>IV access: at least two large bore IV access sites.</li>
<li>Optimize position: Supine sniffing position</li>
<li>Assess the airway: Assess for difficult intubation predictors
    (opening mouth \&lt;3cm, Mallampati ≥ III, neck circumference >40cm,
    thyromental distance \&lt;6cm, head-neck extension \&lt;30 degrees)</li>
<li>Optimal pre-oxygenation: using FiO2 100% (facemask, high flow
    nasal cannula)</li>
<li>Optimize medical status: resuscitation, temporize hyperkalemia,
    Hb >7</li>
</ul>
</li>
<li>Prepare the equipment<ul>
<li>Monitoring: SpO2, capnography, telemetry, BP</li>
<li>Equipment: bag valve mask, 2 endotracheal tubes (ETT) with cuffs
    checked, direct laryngoscope, videolaryngoscope, bougie/stylet,
    working suction, supraglottic airway, oropharyngeal airway</li>
<li>Medications: paralytic (ex: rocuronium, succinylcholine),
    induction sedative (ex: etomidate, ketamine, propofol), analgesics
    (ex: fentanyl), maintenance sedative, IVF hanging in room, pressors
    (ex: Neostick)</li>
</ul>
</li>
<li>Prepare the team<ul>
<li>First and second intubators, RT, RN, someone to monitor hemodynamics</li>
</ul>
</li>
</ul>
<h3 id="critical-care-critical-care-intubation-extubation-rapid-sequence-intubation-rsi">Rapid-sequence intubation (RSI)<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-rapid-sequence-intubation-rsi" title="Permanent link">&para;</a></h3>
<ul>
<li>Preferred method of induction, associated with increased
    first-attempt success and fewer intubation-related complications</li>
<li>Simultaneous IV administration of rapidly acting paralytic and
    induction agents to achieve sedation and paralysis</li>
</ul>
<h3 id="critical-care-critical-care-intubation-extubation-post-intubation">Post-intubation<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-post-intubation" title="Permanent link">&para;</a></h3>
<ul>
<li>Ensure correct placement of ETT with capnography and confirming
    bilateral breath sounds</li>
<li>Secure ETT with taping, tying or tube holder</li>
<li>Obtain post-placement CXR</li>
</ul>
<h3 id="critical-care-critical-care-intubation-extubation-immediate-complications-of-intubation">Immediate complications of intubation<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-immediate-complications-of-intubation" title="Permanent link">&para;</a></h3>
<ul>
<li>Aspiration: Suction airway, ideally prior to initiation of positive
    pressure ventilation to prevent distal movement of aspirated
    contents. Cricoid pressure maneuver historically used to reduce risk
    but unclear if it works so often not performed</li>
<li>Cardiovascular collapse: May be hypotension or sympathetic surge
    (hypertension, tachycardia, arrhythmias). Manage with
    fluids/pressors if need, rule out other causes (ex: hypoxia, PTX)</li>
<li>Hypoxemia: Preoxygenate with 100% FiO2 to minimize risk. Rescue
    maneuvers with bag mask ventilation if needed</li>
<li>Mechanical injury: Dental, soft tissue, tracheal, laryngeal.
    Retrieve any dislodged teeth, suction blood</li>
</ul>
<h2 id="critical-care-critical-care-intubation-extubation-extubation">Extubation<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-extubation" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-critical-care-intubation-extubation-is-the-patient-ready-to-be-extubated">Is the patient ready to be extubated?<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-is-the-patient-ready-to-be-extubated" title="Permanent link">&para;</a></h3>
<ul>
<li>Are they oxygenating well? SpO2 ≥90% with FiO2 ≤50% and PEEP ≤8cm
    H20</li>
<li>Has the underlying cause of their respiratory failure improved?</li>
<li>Did patient pass their SBT?<ul>
<li>See ABCDEF Bundle section for details on SBT</li>
</ul>
</li>
<li>Is patient able to protect their airway?</li>
<li>Is the patient on a stable pressor requirement or no pressors?</li>
<li>Is patient coughing and clearing secretions?</li>
<li>Is patient off sedation, alert and following commands?</li>
<li>Positive cuff leak? (See below for steps)</li>
<li>Consider calculating the rapid shallow breathing index (RSBI):
    RR/tidal volume (L)<ul>
<li>Set PS at 0cm H2O, and PEEP at 5cm H2O and, measure VT &amp; RR for
    one minute.</li>
<li>RSBI ≥ 105 predicts likely failure to wean. The use of a RSBI is
    attending dependent at Vanderbilt and is not frequently
    calculated when assessing readiness for extubation</li>
</ul>
</li>
</ul>
<h3 id="critical-care-critical-care-intubation-extubation-post-extubation-complications">Post-extubation complications<a class="headerlink" href="#critical-care-critical-care-intubation-extubation-post-extubation-complications" title="Permanent link">&para;</a></h3>
<ul>
<li>Post-extubation stridor: 2/2 laryngeal edema</li>
<li>Positive cuff leak test= high risk methylprednisolone 20 mg IV q4h
    x 4 prior to extubation to prevent</li>
<li>If after extubation: Methylprednisolone 40 mg IV x1 dose + inhaled
    racemic epinephrine. If stridor >60minutes, consider reintubation</li>
<li>Cuff leak test:<ul>
<li>Suction secretions and set the ventilator into the AC mode</li>
<li>Inflate the cuff and record inspiratory and expiratory VT to
    evaluate for differences between the two volumes</li>
<li>Deflate the cuff record the expiratory VT over the next six
    breathing cycles. Average the three lowest expiratory VT values</li>
<li>The cuff leak volume is the difference between the inspiratory
    VT (measured before the cuff was deflated) and the averaged
    expiratory VT. If the difference is \&lt;100cc, this is considered
    failure but is not an absolute contradiction to extubation</li>
</ul>
</li>
<li>Post-extubation respiratory failure<ul>
<li>Recurrent hypoxic or hypercarbic respiratory failure</li>
<li>Assess for aggravating factors (volume overload, shock, AMS, etc)</li>
<li>For hypercarbic respiratory failure, may trial BiPAP. If
    unsuccessful reintubate</li>
<li>Preventative post-extubation BiPAP not routinely used in all
    patients but <em>consider</em> in select populations at high risk for
    failure: severe COPD with preexisting chronic hypercarbia during
    SBT, patients intubated for cardiogenic pulmonary edema</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-critical-care-modes-oxygen-delivery"><h1 id="critical-care-critical-care-modes-oxygen-delivery-modes-of-oxygen-delivery">Modes of Oxygen Delivery<a class="headerlink" href="#critical-care-critical-care-modes-oxygen-delivery-modes-of-oxygen-delivery" title="Permanent link">&para;</a></h1>
<p>Blake Funke</p>
<hr />
<table>
<thead>
<tr>
<th>System</th>
<th>L/min</th>
<th>% O2</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blow by (ex: Trach collar)</td>
<td></td>
<td>21-100%</td>
<td></td>
</tr>
<tr>
<td>Nasal cannula</td>
<td>1-8</td>
<td>25 – 45%</td>
<td></td>
</tr>
<tr>
<td>Large bore nasal cannula</td>
<td>Up to 15</td>
<td>Up to 65%</td>
<td>Can be identified by larger bore tubing (often green) and nose piece. Colloquially referred to as HFNC at VUMC, but true HFNC = optiflow</td>
</tr>
<tr>
<td>Venturi mask</td>
<td>4 to 15</td>
<td>24 – 50%</td>
<td>Actual FiO2 is dependent on patient effort</td>
</tr>
<tr>
<td>Non-rebreather</td>
<td>10 to 15</td>
<td>65-95%</td>
<td>Often used as a bridge to higher level of O2 therapy</td>
</tr>
<tr>
<td>HFNC: Optiflow (VUMC), AirVo (NAVA)</td>
<td>Up to 60</td>
<td>30-100%</td>
<td>Delivers 0.5-1 cm/H2O of PEEP per 10L of flow</td>
</tr>
<tr>
<td><em>Use of all of these modes requires a spontaneously breathing patient</em></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h2 id="critical-care-critical-care-modes-oxygen-delivery-non-invasive-positive-pressure-ventilation">Non-invasive positive pressure ventilation<a class="headerlink" href="#critical-care-critical-care-modes-oxygen-delivery-non-invasive-positive-pressure-ventilation" title="Permanent link">&para;</a></h2>
<ul>
<li>CPAP<ul>
<li>Indications: obstructive sleep apnea, tracheomalacia</li>
<li>Settings: CPAP, FiO2</li>
</ul>
</li>
<li>BiPAP<ul>
<li>Indications: hypercapnic respiratory failure (RF), hypoxic RF,
    pulmonary edema, obstructive sleep apnea, obesity hypoventilation
    syndrome, RF 2/2 neuromuscular disease</li>
<li>Settings: IPAP, EPAP, FiO2, RR (sometimes)</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 19%" />
<col style="width: 16%" />
<col style="width: 44%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="4">Invasive positive-pressure ventilation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Mode</td>
<td>You set</td>
<td>Not set</td>
<td>Comments</td>
</tr>
<tr class="even">
<td>Pressure support (PS)</td>
<td><p>PEEP</p>
<p>PS above PEEP</p>
<p>FiO2</p></td>
<td><p>TV</p>
<p>RR</p>
<p>Inspiratory flow</p></td>
<td>Similar to Bipap. Frequently used for vent weaning / SBT. Requires
spontaneously breathing pt</td>
</tr>
<tr class="odd">
<td>Volume Control (AC/VC)</td>
<td><p>PEEP</p>
<p>RR</p>
<p>TV</p>
<p>Inspiratory flow</p>
<p>FiO2</p></td>
<td>Inspiratory pressure</td>
<td><p>Mandates a minute ventilation; limits volutrauma (i.e. can
guarantee low tidal volume ventilation)</p>
<p>Primary mode used in MICU (mode used in major ARDS trials)</p></td>
</tr>
<tr class="even">
<td><p>SIMV</p>
<p>Synchronized Intermittent Mandatory Ventilation</p></td>
<td><p>PEEP</p>
<p>RR</p>
<p>TV</p>
<p>PS above PEEP</p>
<p>FiO2</p></td>
<td></td>
<td>Pt gets VC breath for set rate, but if tries to breath over this
will get PS breath; VC and PS breaths are synchronized when able</td>
</tr>
<tr class="odd">
<td>Pressure Control (AC/PC)</td>
<td><p>RR</p>
<p>Inspiratory Pressure</p>
<p>PEEP</p>
<p>Inspiratory Time (or I:E ratio)</p>
<p>FiO2</p></td>
<td>TV</td>
<td><p>Minimizes barotrauma (i.e. sets a max inspiratory pressure) does
not guarantee a specific minute ventilation (must monitor PCO2 with
blood gases)</p>
<p>Does not have natural ventilator alarms for protection – need to
increase low minute ventilation alarm threshold</p></td>
</tr>
<tr class="even">
<td><p>PRVC</p>
<p>Pressure Regulated Volume Control</p></td>
<td><p>PEEP</p>
<p>RR</p>
<p>TV</p>
<p>Inspiratory flow</p>
<p>Pressure max</p>
<p>FiO2</p></td>
<td></td>
<td><p>Adaptive pressure control (NOT actually a volume control mode);
tries to limit both barotrauma and volutrauma but if in conflict, minute
ventilation will drop (i.e. need to monitor PCO2 with blood gases like
any other PC mode)</p>
<p>Con: More the pt works, the less the ventilator does</p></td>
</tr>
<tr class="odd">
<td>APRV / Bilevel</td>
<td><p>PEEP (PLow)</p>
<p>Pressure High</p>
<p>Time Low</p>
<p>Time High</p>
<p>FiO2</p></td>
<td>TV</td>
<td><p>Long periods of inspiratory holds and very brief expirations
(i.e. releases), for refractory hypoxemia.</p>
<p>Often difficult to ventilate pts on this mode</p></td>
</tr>
</tbody>
</table></section><section class="print-page" id="critical-care-critical-care-refractory-hypercapnia"><h1 id="critical-care-critical-care-refractory-hypercapnia-refractory-hypercapnia">Refractory Hypercapnia<a class="headerlink" href="#critical-care-critical-care-refractory-hypercapnia-refractory-hypercapnia" title="Permanent link">&para;</a></h1>
<p>Amelia Muhs</p>
<hr />
<h2 id="critical-care-critical-care-refractory-hypercapnia-background">Background<a class="headerlink" href="#critical-care-critical-care-refractory-hypercapnia-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Inadequate clearance of CO2 leading to respiratory acidosis (pH ≤
    7.20) despite maximum RR&amp;TV (i.e. minute ventilation) tolerated
    without causing barotrauma or autoPEEP</li>
<li>Common causes:<ul>
<li>Obstructive lung disease (COPD, emphysema, asthma)</li>
<li>Hypoventilation (sleep apnea, obesity, sedative medications (ie
    opiates), neuromuscular weakness, chest wall trauma, ascites/pleural
    effusion)</li>
<li>Increased CO2 load (shock, sepsis, malignant hyperthermia)</li>
</ul>
</li>
<li>Presentation:<ul>
<li>Shortness of breath</li>
<li>AMS, somnolence</li>
<li>Hypoxemia</li>
<li>Tachycardia, hypertension (in some cases)</li>
</ul>
</li>
</ul>
<h2 id="critical-care-critical-care-refractory-hypercapnia-evaluation">Evaluation<a class="headerlink" href="#critical-care-critical-care-refractory-hypercapnia-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Physical exam, mental status, recent medications</li>
<li>ABG or VBG – if increased PCO2 and normal pH, always treat the pH
    and not the PCO2 (i.e., may be compensated chronic hypercarbia and
    blowing off more CO2 may be harmful)</li>
</ul>
<h2 id="critical-care-critical-care-refractory-hypercapnia-management-algorithm">Management Algorithm<a class="headerlink" href="#critical-care-critical-care-refractory-hypercapnia-management-algorithm" title="Permanent link">&para;</a></h2>
<ul>
<li>Special considerations<ul>
<li>If history of OSA, make sure they are on home CPAP/BiPAP</li>
<li>If opiate related trial narcan</li>
<li>Bronchodilators for reactive airway diseases</li>
</ul>
</li>
<li>BiPAP<ul>
<li>Contraindicated if pt unable to remove BiPAP mask on their own</li>
<li>Increase MV by increasing Δ between IPAP/EPAP or increasing RR</li>
</ul>
</li>
<li>Mechanical ventilation<ul>
<li>Allows you to control rate and tidal volume (in Volume Control
    modes)</li>
<li>NOTE: some pts have higher minute ventilation on their own compared
    to mechanical ventilation (e.g., DKA); pt-specific considerations
    regarding intubation</li>
<li>To increase minute ventilation and CO2 clearance:<ul>
<li>Increase RR<ul>
<li>30-35 is about as high as you can go</li>
<li>Need to keep in mind I/E time to avoid breath
    stacking/autoPEEP (gas trapped in lungs)</li>
<li>Some signs of autoPEEP include worsening hypotension and the
    expiratory limb on the flow waveform on the vent not
    returning to zero</li>
</ul>
</li>
<li>Increase TV we usually start at 4-6mL/kg IBW. You can consider
    increasing to 8mL/kg IBW as long as plateau pressures remain \&lt;
    30 cm H2O<ul>
<li>Goal peak pressures ≤ 35 cm H2O / plateau pressures ≤ 30 cm
    H2O</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>ARDS permissive hypercapnia (goal pH ≥ 7.2)</li>
<li>V-V ECMO / Extracorporeal carbon dioxide removal (ECCO2R)</li>
<li>Indications for hypercapnia:<ul>
<li>Severe dynamic hyperinflation and/or severe respiratory acidosis</li>
<li>pH ≤ 7.25 with PaCO2 ≥ 60 for 6 hr with RR at 35/min and TV
    increased to target maximum MV while keeping plateau pressure ≤
    32 cm H2O</li>
<li>Similar considerations and contraindications as refractory hypoxemia
(see above)</li>
<li>Benefits: Reduces work of breathing, promotes early ventilator
    weaning/extubating allows early mobilization and recovery</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-critical-care-refractory-hypoxemia"><h1 id="critical-care-critical-care-refractory-hypoxemia-refractory-hypoxemia">Refractory Hypoxemia<a class="headerlink" href="#critical-care-critical-care-refractory-hypoxemia-refractory-hypoxemia" title="Permanent link">&para;</a></h1>
<p>Amelia Muhs</p>
<hr />
<h2 id="critical-care-critical-care-refractory-hypoxemia-background">Background<a class="headerlink" href="#critical-care-critical-care-refractory-hypoxemia-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Inadequate arterial oxygenation despite high levels of inspired O2
    or the development of barotrauma in mechanically ventilated pts</li>
<li>Generally start to consider the interventions below if needing FiO2
    >80%</li>
<li>Differential:<ul>
<li>Worsening underlying primary process (e.g. progressive ARDS)</li>
<li>PE</li>
<li>Pneumothorax</li>
<li>Fluid overload</li>
<li>Ventilator-associated Pneumonia</li>
<li>New ARDS</li>
</ul>
</li>
</ul>
<h2 id="critical-care-critical-care-refractory-hypoxemia-evaluation">Evaluation<a class="headerlink" href="#critical-care-critical-care-refractory-hypoxemia-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Always get CXR STAT if pt has new or worsening O2 requirement</li>
<li>ABG is frequently helpful as well</li>
<li>Can use POCUS to check for lung sliding (pneumothorax) or RV
    enlargement/septal bowing/McConnell’s sign (RV strain in PE)</li>
</ul>
<h2 id="critical-care-critical-care-refractory-hypoxemia-initial-management">Initial management<a class="headerlink" href="#critical-care-critical-care-refractory-hypoxemia-initial-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Remember – if at any point the pt is rapidly decompensating, you can
    always disconnect them from the vent and bag them until they
    recover/while calling for help</li>
<li>Early consideration of ECMO consult in appropriate pts (discuss with
    MICU fellow)</li>
<li>Optimize fluid status consider diuresis/dialysis if not making urine</li>
<li>Consider higher PEEP strategy</li>
<li>Increased PEEP higher mean airway pressure, generally improves
    oxygenation especially with diffuse pulmonary pathologies<ul>
<li>Exceptions may include certain focal/shunt pathologies (e.g.
    dense lobar PNA)</li>
<li>Worsening oxygenation may occur with overdistension of alveoli
    increase dead space ventilation; generally determined
    empirically at the bedside</li>
</ul>
</li>
<li>Titrate up slowly; generally do not exceed PEEP 18<ul>
<li>Limited by high plateau pressures/barotrauma,
    overdistension/dead space ventilation, decreased preload/venous
    return</li>
</ul>
</li>
<li>
<p>ARDSnet FiO2/PEEP Tables: At VUMC we typically use the Lower PEEP
    table</p>
</li>
<li>
<p>Other recruitment maneuvers</p>
<ul>
<li>Reposition pt – can try elevating HOB or positioning so “good lung”
    is down</li>
<li>If concern for mucus plug, consider need for bronch</li>
<li>If concern for significant atelectasis can try recruitment maneuvers
    with the vent including sustained inflation (setting expiratory
    pressure to ~30 for ~30 seconds) and PEEP titration (setting PEEP
    to 20-25 and decreasing by 2cm at a time) – call the fellow before
    attempting</li>
</ul>
</li>
</ul>
<h2 id="critical-care-critical-care-refractory-hypoxemia-management-algorithm-for-refractory-hypoxemia">Management Algorithm for Refractory Hypoxemia<a class="headerlink" href="#critical-care-critical-care-refractory-hypoxemia-management-algorithm-for-refractory-hypoxemia" title="Permanent link">&para;</a></h2>
<ul>
<li>Inhaled vasodilators: Distribute preferentially to well-ventilated
    alveoli local vasodilation improved V/Q matching</li>
<li>VUMC formulary preference: inhaled epoprostenol (aka Flolan)</li>
<li>Alternatives: inhaled milrinone, inhaled nitric oxide</li>
<li>Data suggest improved PaO2/FiO2; large RCT without evidence for
    mortality benefit</li>
<li>Deep sedation (RASS -4 or -5)<ul>
<li>Promotes ventilator synchrony</li>
</ul>
</li>
<li>Neuromuscular blockade (paralysis) – call your fellow before doing
    this<ul>
<li>Rationale: maximal vent synchrony (eliminates residual chest
    wall/diaphragm tone)</li>
<li>Pt MUST be RASS -5 (need analgesia + sedation)</li>
<li>Trial one time IV push of vecuronium 0.1 mg/kg</li>
<li>If improved vent synchrony/oxygenation, consider cisatracurium
    (Nimbex) drip</li>
<li>Data are mixed ACURASYS 2010 (improved 90-day mortality but
    underpowered likely overestimating benefit); ROSE 2019 (no
    difference in 90-day mortality)</li>
</ul>
</li>
<li>Prone positioning (Need attending approval)<ul>
<li>Pts with moderate to severe ARDS (PaO2/FiO2 ratio \&lt; 150)</li>
<li>At VUMC, we use regular ICU beds and manually flip pts; cycle prone
    16 hrs/supine 8 hrs</li>
<li>When proning or supining a pt, always have a provider who can
    intubate in the room in case unplanned extubation occurs</li>
<li>Considerations: need a team of people to reposition, high risk of ET
    tube malposition, difficult to access lines/perform procedures, high
    risk of pressure injuries</li>
<li>Data: PROSEVA 2013 proning improved 28-day mortality; study
    complicated by imbalances between groups</li>
</ul>
</li>
<li>Alternative ventilator modes (usually Pressure Control or
    APRV/BiLevel/BiVent)</li>
<li>APRV/BiVent should be avoided in people with bad obstructive lung
    disease, hemodynamic instability, refractory hypercarbia</li>
<li>Venovenous (V-V) ECMO<ul>
<li>Indications for hypoxemia:<ul>
<li>PaO2/FiO2 \&lt; 50 with FiO2 >80% for >3 hrs OR</li>
<li>PaO2/FiO2 \&lt; 80 with FiO2 >80% for >6 hrs AND</li>
<li>Mechanical ventilation ≤ 1 week</li>
</ul>
</li>
<li>Absolute Contraindications:<ul>
<li>Poor short-term prognosis (e.g. metastatic cancer)</li>
<li>Irreversible, devastating neurologic pathology</li>
<li>Chronic respiratory insufficiency without the possibility for
    transplant</li>
</ul>
</li>
<li>Can calculate RESP score predicts in-hospital survival with ECMO</li>
<li>CONSULT EARLY if a pt may be a candidate; allows ECMO team to assist
    with evaluation</li>
<li>Data:<ul>
<li>CESAR 2009: improved 6-month survival without severe disability</li>
<li>EOLIA 2018 : no mortality benefit but 28% crossover from control
    to ECMO arm dilutes potential effects</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-critical-care-sepsis"><h1 id="critical-care-critical-care-sepsis-sepsis">Sepsis<a class="headerlink" href="#critical-care-critical-care-sepsis-sepsis" title="Permanent link">&para;</a></h1>
<p>Charlie Oertli</p>
<hr />
<h2 id="critical-care-critical-care-sepsis-background">Background<a class="headerlink" href="#critical-care-critical-care-sepsis-background" title="Permanent link">&para;</a></h2>
<p>Most recent definition (Sepsis-3): organ dysfunction from
    dysregulated host response to infection</p>
<ul>
<li>2021 Surviving Sepsis Guidelines: SIRS, MEWS, NEWS superior to qSOFA
    for <u>screening</u> sepsis</li>
<li>SIRS ≥2 of any of: 1) RR>20, 2) T \&lt;36 or >38, 3) HR >90, 4) WBC
    \&lt;4 or >12 or >10% bands</li>
<li>Septic Shock = sepsis + vasopressors + lactate >2 meq/dL (Sepsis 3
    definition)</li>
<li>Alternate screening systems you may see which are more
    <u>specific</u> and better at prognosis of in hospital mortality
    than SIRS:<ul>
<li>Acute change in baseline SOFA score ≥2: P/F ratio, Plts, Tbili, SBP,
    GCS, Cr</li>
<li>"Quick" SOFA (qSOFA): ≥2 of AMS (GCS≤13), SBP≤100 mmHg, RR≥22/min</li>
</ul>
</li>
</ul>
<h2 id="critical-care-critical-care-sepsis-evaluation">Evaluation<a class="headerlink" href="#critical-care-critical-care-sepsis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Cultures prior to antibiotics if possible (but don’t delay
    antibiotics just to get cultures)</li>
<li>Consider sputum Cx, paracentesis, thoracentesis, wound Cx, LP, joint
    aspiration</li>
<li>Lactate (even if not hypotensive)</li>
<li>Imaging: x-ray, CT, or US of potential source</li>
</ul>
<h2 id="critical-care-critical-care-sepsis-management">Management<a class="headerlink" href="#critical-care-critical-care-sepsis-management" title="Permanent link">&para;</a></h2>
<p>Source control: Remove old lines, chest tube for empyema, drain
    abscesses, etc</p>
<p>Antibiotics</p>
<ul>
<li>Early antibiotics: within 1 hour if septic shock, within 3 hours if
    sepsis</li>
<li>Target organisms most likely to cause infection in suspected organ;
    if source unknown, start empiric broad-spectrum</li>
<li>MRSA coverage - vancomycin/daptomycin/linezolid/ceftaroline</li>
<li>Pseudomonas coverage - zosyn/cefepime/meropenem /cipro/gentamicin</li>
<li>Pneumonia: add atypical coverage (azithromycin/levaquin; 2<sup>nd</sup> line
    doxycycline if prolonged QTC or elderly) if severe or being admitted
    to the ICU</li>
<li>Fungal coverage for Candida: if neutropenic, TPN, abdominal surgery,
    prior antibiotics</li>
<li>De-escalation: Once source is controlled, if abx duration is unknown
    use procalcitonin, culture susceptibilities, and clinical evaluation
    to help guide de-escalation</li>
</ul>
<p>Resuscitation</p>
<ul>
<li>Give 1-3 L (≥30 mL/kg of body weight) of IV balanced crystalloid
    within first 3 hours</li>
<li>Only give blood if Hb \&lt; 7, unless evidence of bleeding or
    myocardial ischemia</li>
<li>Monitor HR, BP, mental status, urine output – do NOT give
    beta-blockers to slow HR in the setting of sepsis unless dangerously
    high and limiting diastolic filling (discuss with fellow), this is
    an appropriate stress response</li>
<li>Assess fluid responsiveness by leg raise (if BP improves with leg
    raise, give more fluids). Other options US IVC (mixed data), pulse
    pressure</li>
</ul>
<p>Vasopressors</p>
<ul>
<li>Start if MAP not responsive to fluid resuscitation</li>
<li>Target MAP > 65mmHg, also monitor mental status, serum lactate, and
    urine output; may need higher goal for pts with chronic HTN</li>
<li>Start with norepinephrine -- via central line, PICC, or port. Can
    run through peripheral IV (at least 18g, proximal to wrist) up to 15
    mcg/min for up to 48 hours if no central access<ul>
<li>SOAP II trial: norepinephrine > dopamine (less arrhythmias)</li>
<li>No upper limit of NE but can cause peripheral ischemia with
    prolonged use</li>
</ul>
</li>
<li>Add vasopressin at fixed dose of 0.04 units/min when NE dose >= 50
    mcg/min<ul>
<li>VASST trial: possible benefit for pts on 5-15 of NE; however,
    this was opposite of hypothesis and vasopressin is expensive</li>
</ul>
</li>
<li>Add epinephrine or dobutamine if low cardiac output</li>
<li>Add phenylephrine for pts with tachyarrhythmias (reflex bradycardia)</li>
<li>Consider Angiotensin II (discuss with fellow, needs MICU leadership
    approval) contraindicated with CHF and
    DVT/PE/clots/hypercoagulability</li>
<li>Consider steroids if vasopressors failing or on steroids chronically
    hydrocortisone 100mg IV q8hr or 50mg IV q6hr for 5 to 7 days</li>
</ul></section><section class="print-page" id="critical-care-critical-care-shock"><h1 id="critical-care-critical-care-shock-management-of-shock">Management of Shock<a class="headerlink" href="#critical-care-critical-care-shock-management-of-shock" title="Permanent link">&para;</a></h1>
<p>Alex Toporex, Soibhan Kelley</p>
<hr />
<h2 id="critical-care-critical-care-shock-distributive-shock">Distributive Shock<a class="headerlink" href="#critical-care-critical-care-shock-distributive-shock" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-critical-care-shock-background">Background<a class="headerlink" href="#critical-care-critical-care-shock-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Pathophysiology: severe, peripheral vasodilation</li>
<li>CO/CI increased, SVR decreased, PCWP and RAP normal to low</li>
<li>Etiologies: sepsis (most common), anaphylaxis, neurogenic, adrenal
    insufficiency, pancreatitis</li>
<li>Signs/symptoms:<ul>
<li>Sepsis: localizing signs of infection; tachycardia, tachypnea, may
    be hypo/hyperthermic; POCUS with hyperdynamic cardiac function</li>
<li>Anaphylaxis: history of anaphylaxis; urticaria, edema, diarrhea,
    wheezing on exam</li>
<li>Neurogenic: history of CNS trauma; focal neurologic deficits on exam</li>
<li>Adrenal insufficiency: hx chronic steroid use, may have GI symptoms,
    hyponatremia (common), hyperkalemia (rare), hypoglycemia,
    hypo/hyperthermia, NAGMA</li>
<li>Pancreatitis: abdominal pain, elevated lipase, evidence on CT scan</li>
</ul>
</li>
</ul>
<h3 id="critical-care-critical-care-shock-management">Management<a class="headerlink" href="#critical-care-critical-care-shock-management" title="Permanent link">&para;</a></h3>
<ul>
<li>Sepsis: see sepsis section</li>
<li>Anaphylaxis: 0.3mg IM epinephrine ASAP to be repeated q5-15min x 3;
    after third IM epi, consider IVF and epi gtt if persistent
    hypotension. Adjuncts: albuterol nebs for bronchospasm, H1 and H2
    blockers, &plusmn; glucocorticoids (methylprednisolone 1mg/kg).
    EPINEPHRINE SAVES LIVES.</li>
<li>Neurogenic: caution with IVF resuscitation, can worsen cerebral and
    spinal cord edema; preferred pressors are norepinephrine and
    phenylephrine; for neurogenic shock 2/2 spinal cord pathology,
    consider higher MAP goal 85-90 mmHg</li>
<li>Adrenal insufficiency: stress dose steroids with hydrocortisone
    100mg IV q8hr or 50mg q6hr</li>
<li>Pancreatitis: IVF + pressors; trend H/H and Ca; treat complications
    (necrotizing pancreatitis, abdominal compartment syndrome); address
    underlying etiology (see GI section)</li>
</ul>
<h2 id="critical-care-critical-care-shock-cardiogenic-shock">Cardiogenic Shock<a class="headerlink" href="#critical-care-critical-care-shock-cardiogenic-shock" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-critical-care-shock-background_1">Background<a class="headerlink" href="#critical-care-critical-care-shock-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Pathophysiology: CO/CI decreased, SVR increased, PCWP and RAP
    elevated (left heart failure) or PCWP low/normal and RAP elevated
    (right heart failure)</li>
<li>Etiologies: Cardiomyopathy (LHF, RHF or biventricular), arrhythmia,
    mechanical such as acute AR (ex: dissection) or MR (ex: ruptured
    papillary muscle)</li>
</ul>
<h3 id="critical-care-critical-care-shock-presentation">Presentation<a class="headerlink" href="#critical-care-critical-care-shock-presentation" title="Permanent link">&para;</a></h3>
<ul>
<li>Edematous, elevated JVP, “cold and wet”; hypoxia w/crackles and pulm
    edema; mixed venous sat \&lt; 50-60%; POCUS with plump,
    non-compressible IVC, reduced EF, and B-lines</li>
</ul>
<h3 id="critical-care-critical-care-shock-management_1">Management<a class="headerlink" href="#critical-care-critical-care-shock-management_1" title="Permanent link">&para;</a></h3>
<p>See cardiogenic shock in cardiology section</p>
<h2 id="critical-care-critical-care-shock-hypovolemic-shock">Hypovolemic Shock<a class="headerlink" href="#critical-care-critical-care-shock-hypovolemic-shock" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-critical-care-shock-background_2">Background<a class="headerlink" href="#critical-care-critical-care-shock-background_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Etiologies: Hemorrhagic and non-hemorrhagic</li>
<li>Signs/symptoms:<ul>
<li>Hemorrhagic: Common sources include GI, retroperitoneal (*needs
    high index of suspicion), traumatic, intraabdominal, thighs, thorax</li>
<li>Non-hemorrhagic: 2/2 GI losses or decreased PO intake</li>
</ul>
</li>
<li>POCUS with thin, collapsible IVC</li>
</ul>
<h3 id="critical-care-critical-care-shock-management-hemorrhagic">Management (Hemorrhagic)<a class="headerlink" href="#critical-care-critical-care-shock-management-hemorrhagic" title="Permanent link">&para;</a></h3>
<ul>
<li>Ensure good access with two large-bore (at least 18G) IVs ideally in
    AC or above; Cordis or MAC CVC (can also use dialysis catheter, if
    necessary)</li>
<li>Hyperacute bleed:<ul>
<li>1:1:1 ratio FFP:Plt:RBC (balanced resuscitation), massive
    transfusion protocol (MTP)</li>
<li>Monitor iCa and replete (citrated blood products will deplete Ca)</li>
<li>Minimize crystalloid if possible, w/primary use to prevent immediate
    hemodynamic collapse (contributes to coagulopathy, hypothermia,
    acidemia, trauma/surgery)</li>
<li>Permissive hypotension until source control/transfusions with
    arterial bleeds (high MAP/SBP -> clot destabilization); trend POC
    lactate/exam to guide</li>
<li>Acute traumatic arterial bleed or post-partum hemorrhage consider
    TXA (1-2 gm bolus)</li>
<li>Reverse anticoagulation, if applicable</li>
<li>Vasopressors -> generally poorly effective, would start with
    norepinephrine</li>
<li>Source control -> GI, IR, or EGS</li>
</ul>
</li>
<li>Variceal bleed: See GI Bleeding section for specific management</li>
</ul>
<h3 id="critical-care-critical-care-shock-management-non-hemorrhagic">Management (Non-Hemorrhagic)<a class="headerlink" href="#critical-care-critical-care-shock-management-non-hemorrhagic" title="Permanent link">&para;</a></h3>
<ul>
<li>Aggressive IVF resuscitation (balanced crystalloid); target MAP ≥65</li>
<li>Can support BP during resuscitation with pressors (usually
    norepinephrine)</li>
</ul>
<h2 id="critical-care-critical-care-shock-obstructive-shock">Obstructive Shock<a class="headerlink" href="#critical-care-critical-care-shock-obstructive-shock" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-critical-care-shock-background_3">Background<a class="headerlink" href="#critical-care-critical-care-shock-background_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Etiologies: Massive pulmonary embolism, tension pneumothorax, and cardiac
    tamponade</li>
<li>Signs/symptoms:<ul>
<li>Pulmonary embolism: acute hypotension, known DVT, evidence of R
    heart strain on EKG, POCUS w/enlarged RV, septal bowing, McConnell’s
    sign, ↑ BNP, PE on CTA</li>
<li>Tension pneumothorax: history of COPD or fibrotic lung disease,
    ventilated pts w/ high peak pressures, unilateral decreased BS on
    auscultation and tympany on percussion, POCUS without lung sliding,
    CXR w/ PTX and mediastinal shift</li>
<li>Cardiac tamponade: elevated JVP, muffled heart sounds, pulsus
    paradoxus, POCUS with diastolic collapse of RV and large pericardial
    effusion (best in subcostal window)</li>
</ul>
</li>
</ul>
<h3 id="critical-care-critical-care-shock-management_2">Management<a class="headerlink" href="#critical-care-critical-care-shock-management_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Massive pulmonary embolism: see Pulmonary Embolism Section for
    specific management</li>
<li>Tension PTX: needle decompression using 14-16G needle into the
    second intercostal space at the midclavicular line; call trauma
    surgery or fellow for chest tube ASAP</li>
<li>Cardiac tamponade: STAT page cardiology or cardiothoracic surgery;
    can temporize hypotension with IVF resuscitation—500-1L IVF boluses
    (may not work if pt is euvolemic or hypervolemic); no proven benefit
    from inotropy (e.g., dobutamine)</li>
</ul></section><section class="print-page" id="critical-care-critical-care-temperature-abnormalities"><h1 id="critical-care-critical-care-temperature-abnormalities-temperature-abnormalities">Temperature Abnormalities<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-temperature-abnormalities" title="Permanent link">&para;</a></h1>
<p>Soibhan Kelley</p>
<hr />
<h2 id="critical-care-critical-care-temperature-abnormalities-hypothermia">Hypothermia<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-hypothermia" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-critical-care-temperature-abnormalities-background">Background<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Core temperature \&lt;35°C (95°F). Mild 32-35C (90-95F), moderate
    28-32C (82-90F), or severe \&lt;28C (82F) &plusmn; pulseless</li>
<li>Ensure thermometer is “low-reading,” standard thermometers not
    accurate</li>
<li>Core temperature can be measured w/ bladder catheter probe or
    esophageal probe (may be falsely ↑ if heated oxygen being
    delivered). Rectal temp can be used but is less accurate</li>
<li>Etiologies:<ul>
<li>Heat loss: Environmental, burns, iatrogenic (CRRT, cold IVF, massive
    transfusion protocol), vasodilatory drugs/toxins</li>
<li>Decreased heat production: endocrinopathies (hypothyroidism, adrenal
    insufficiency, hypopituitarism, hypoglycemia), thiamine deficiency</li>
<li>Impaired regulation: Spinal cord injury, hypothalamic lesions, drugs
    (classes including antihyperglycemics, beta blockers, sedatives,
    ETOH, alpha agonists, general anesthetics)</li>
<li>Multiple mechanisms: sepsis, pancreatitis, DKA</li>
</ul>
</li>
</ul>
<h3 id="critical-care-critical-care-temperature-abnormalities-evaluation">Evaluation<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-evaluation" title="Permanent link">&para;</a></h3>
<ul>
<li>Infectious work-up</li>
<li>POC blood glucose, TSH/FT4, cortisol, lipase, UA, UDS, EtOH level,
    additional tox as appropriate, DKA work-up if relevant</li>
<li>Physical exam + history for exposures and trauma</li>
<li>CBC, CMP, Lactate, ABG, CK, PT/PTT, Fibrinogen</li>
<li>EKG</li>
</ul>
<h3 id="critical-care-critical-care-temperature-abnormalities-management">Management<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-management" title="Permanent link">&para;</a></h3>
<ul>
<li>Treat underlying cause [see appropriate sections]</li>
<li>Mild hypothermia:<ul>
<li>Passive external rewarming (PER): blankets, increase ambient
    temperature</li>
<li>Note that PER requires sufficient underlying physiologic reserve to
    generate heat. This is often impaired in elderly pts, malnutrition,
    sepsis</li>
</ul>
</li>
<li>Moderate hypothermia, refractory mild hypothermia, or cardiovascular
    instability:<ul>
<li>Active external rewarming (AER): forced warm air (ie Bair Hugger),
    heated blankets, heat lamps, hot packs (consider burn risk)</li>
</ul>
</li>
<li>Severe hypothermia or refractory moderate hypothermia:<ul>
<li>Active core rewarming: Warmed IV crystalloid (limited rewarming
    potential unless large volume but will decrease ongoing losses),
    warmed humidified inspired air, warmed bladder lavage</li>
<li>More extreme methods such as peritoneal/thoracic lavage more likely
    to be used in severe environmental cases in ED</li>
</ul>
</li>
<li>Pulseless severe hypothermia (“You aren't dead unless you are warm
    and dead”)<ul>
<li>Continue CPR until re-warmed as severe hypothermia is
    neuroprotective and pts can have good neurologic outcomes despite
    hours of CPR</li>
<li>ACLS medications and shocks will have poor effectiveness; prioritize
    circulation (i.e. chest compressions) and rewarming</li>
<li>Consider ECMO (likely venoarterial if pulseless); would need
    transfer to CVICU</li>
</ul>
</li>
<li>Identify and manage complications: bradycardia/heart block,
    arrhythmias, shock, coagulopathy/DIC, rhabdo; rebound
    hyperkalemia/hypoglycemia with rewarming</li>
</ul>
<h2 id="critical-care-critical-care-temperature-abnormalities-fever-and-hyperthermia">Fever and Hyperthermia<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-fever-and-hyperthermia" title="Permanent link">&para;</a></h2>
<h3 id="critical-care-critical-care-temperature-abnormalities-background_1">Background<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Fever: T >38.0°C (100.4°F) driven by hypothalamus activity in
    response to systemic triggers (i.e. cytokines); may use lower
    threshold for immunocompromised pts</li>
<li>Hyperthermia: T >41.0 C (105.8°F) uncontrolled heat production with
    failure of thermoregulation</li>
<li>Infectious etiologies:<ul>
<li>Considerations in the ICU include central-line associated blood
stream infection, catheter-associated UTI, pneumonia (including
ventilator-associated), sinusitis (esp in pts with NGT or ETT),
<em>clostridium difficile</em>, acalculous cholecystitis</li>
</ul>
</li>
<li>Non-infectious etiologies:</li>
<li>Drug fever<ul>
<li>Difficult to distinguish from other causes; Can begin hrs-wks
    after starting a drug</li>
<li>Sources: antibiotics (penicillins, cephalosporins,
    sulfonamides), anticonvulsants (phenytoin, carbamazepine,
    phenobarbital), allopurinol, heparin, dexmedetomidine</li>
<li>Drugs of abuse with sympathomimetic activity (cocaine, meth,
    ecstasy)</li>
<li>Anticholinergic or salicylate intoxication</li>
</ul>
</li>
<li>Idiosyncratic drug reactions<ul>
<li>Serotonin syndrome</li>
<li>Neuroleptic malignant syndrome</li>
<li>Malignant hyperthermia</li>
</ul>
</li>
<li>Transfusion reactions</li>
<li>PE/DVT</li>
<li>Endocrine: hyperthyroidism/thyroid storm, adrenal insufficiency</li>
<li>CNS pathology (intracranial bleed/stroke, particularly hypothalamic
    region)</li>
<li>Malignancy</li>
<li>Heat stroke (exertional or non-exertional)</li>
<li>Other inflammatory states: Pancreatitis, gout, pericarditis,
    pneumonitis</li>
</ul>
<h3 id="critical-care-critical-care-temperature-abnormalities-evaluation_1">Evaluation<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-evaluation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Infectious work-up &plusmn; LP; may consider pan-scan if unable to
    identify source</li>
<li>POC glucose, BMP, LFT, Mg/Phos, CBC w/diff</li>
<li>Consider coags + fibrinogen (DIC), CK/UA (rhabdo), UDS,
    acetaminophen and salicylate levels, TSH/FT4, cortisol, lipase, ABG</li>
<li>Review medication list: antibiotics, serotonergic drugs,
    anti-psychotics, recent sedation for OR or recently intubated with
    succinylcholine, dexmedetomidine</li>
<li>Consider CT/MRI head</li>
</ul>
<h3 id="critical-care-critical-care-temperature-abnormalities-management_1">Management<a class="headerlink" href="#critical-care-critical-care-temperature-abnormalities-management_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Treat underlying etiology [see appropriate sections]</li>
<li>Serotonin syndrome -> stop serotonergic drugs; add cyproheptadine</li>
<li>Malignant hyperthermia ->activate malignant hyperthermia team; add
    dantrolene</li>
<li>Cooling<ul>
<li>Target \&lt;38.0°C (100.4°F)</li>
<li>Surface cooling: Ice (bath, or ice packs more likely in our MICU),
    evaporative cooling with misted lukewarm water and fan</li>
<li>Internal cooling:
    Cold IV fluids
    (pharmacy keeps ~3L of cold LR on-hand, they will cool more if you call down and ask),
    dry ventilation (evaporative) with non-humidified nasal cannula or vent circuit</li>
<li>Avoid shivering -> give opiates (except in serotonin syndrome),
    precedex, propofol, benzos, ketamine</li>
</ul>
</li>
<li>Antipyretics<ul>
<li>Acetaminophen, NSAIDs</li>
<li>Block prostaglandin-mediated temperature elevations</li>
<li>Effective for most causes of fever- infection, pancreatitis, DVT/PE,
    pneumonitis</li>
<li>AVOID for true hyperthermia (ineffective and potentially harmful)
    -> neuroleptic malignant syndrome, malignant hyperthermia,
    serotonin syndrome, heat stroke</li>
</ul>
</li>
<li>Monitor for complications<ul>
<li>Rhabdo, DIC, arrhythmias</li>
</ul>
</li>
<li>If high suspicion for infection and not improving on antibiotics,
    consider other infectious etiologies including fungal (ex: candida)</li>
</ul></section><section class="print-page" id="critical-care-critical-care-tracheostomy"><h1 id="critical-care-critical-care-tracheostomy-tracheostomy">Tracheostomy<a class="headerlink" href="#critical-care-critical-care-tracheostomy-tracheostomy" title="Permanent link">&para;</a></h1>
<p>Jared Freitas</p>
<hr />
<h2 id="critical-care-critical-care-tracheostomy-indications">Indications<a class="headerlink" href="#critical-care-critical-care-tracheostomy-indications" title="Permanent link">&para;</a></h2>
<ul>
<li>Prolonged mechanical intubation and weaning</li>
<li>Tracheal stenosis</li>
<li>Acute airway obstructions (head and neck cancers)</li>
<li>Trauma</li>
<li>Neuromuscular disease</li>
</ul>
<h2 id="critical-care-critical-care-tracheostomy-benefits-of-tracheostomy-vs-et-tube">Benefits of Tracheostomy vs ET tube<a class="headerlink" href="#critical-care-critical-care-tracheostomy-benefits-of-tracheostomy-vs-et-tube" title="Permanent link">&para;</a></h2>
<ul>
<li>Improved pt comfort and decreased need for sedation</li>
<li>Reduced laryngeal damage</li>
<li>Increased ability to communicate (i.e. speaking valve)</li>
<li>May decrease risk of developing ventilator associated pneumonia
    (mixed data)</li>
<li>May reduce time to wean from the vent and decrease time in the
    hospital (mixed data)</li>
</ul>
<h2 id="critical-care-critical-care-tracheostomy-timing">Timing<a class="headerlink" href="#critical-care-critical-care-tracheostomy-timing" title="Permanent link">&para;</a></h2>
<ul>
<li>No mortality difference or ↓ in hospital length of stay for early
    (day 4) vs late (day 10)</li>
<li>Generally performed after 2 weeks of intubation, but not backed by
    data</li>
<li>Pts that might get tracheostomy earlier: anticipated prolonged
    mechanical ventilation (i.e. those with acute neurologic injury
    affecting spinal cord)</li>
</ul>
<h2 id="critical-care-critical-care-tracheostomy-types-of-tracheostomy-tubes">Types of Tracheostomy Tubes<a class="headerlink" href="#critical-care-critical-care-tracheostomy-types-of-tracheostomy-tubes" title="Permanent link">&para;</a></h2>
<ul>
<li>Different brands: most common in hospital = Shiley</li>
<li>Components:<ul>
<li>Faceplate: keeps tube in place, has the model and size on it</li>
<li>Inner cannula: can be removed, cleaned and replaced in case of
    obstruction</li>
<li>Cuff (may or may not have): allows for pt to be ventilated; may
    prevent some aspiration</li>
<li>Fenestration (may or may not have): allow speaking without valve</li>
</ul>
</li>
<li>Common sizes:<ul>
<li>Initial: 8-0; Standard downsizing: 6-0</li>
<li>Lengths: standard vs larger XLT (P = longer proximal end, D =
    longer distal end)</li>
</ul>
</li>
<li>Presenting on ICU rounds = size/cuff status/brand (e.g. 8-0 cuffed
    shiley)</li>
</ul>
<h2 id="critical-care-critical-care-tracheostomy-speaking-valves">Speaking Valves<a class="headerlink" href="#critical-care-critical-care-tracheostomy-speaking-valves" title="Permanent link">&para;</a></h2>
<ul>
<li>Passy Muir Valve (PMV): one-way valve placed on the outer portion of
    the trach; air moves in with inspiration but is blocked and thus
    funneled up through the vocal cords during exhalation allowing for
    phonation</li>
<li>Contraindication: severe upper airway obstruction or aspiration
    risk, copious secretions, decreased cognitive status, severe medical
    instability, or inability to tolerate cuff deflation</li>
<li>IMPORTANT SAFETY PRINCIPLE: cuff must be deflated, since air needs
    to be able to travel back up the airway, if the cuff is not deflated
    and you put the PMV on, then pt cannot exhale</li>
</ul>
<h2 id="critical-care-critical-care-tracheostomy-maintenance-of-tracheostomy-tubes">Maintenance of Tracheostomy Tubes<a class="headerlink" href="#critical-care-critical-care-tracheostomy-maintenance-of-tracheostomy-tubes" title="Permanent link">&para;</a></h2>
<ul>
<li>Inner cannula should be cleaned 2-3 times per day</li>
<li>Daily stoma care should be initiated to prevent pressure ulcers and
    stoma infections</li>
<li>As needed suctioning for secretions</li>
</ul>
<h2 id="critical-care-critical-care-tracheostomy-complications-and-airway-emergencies-in-a-tracheostomy-pt">Complications and airway emergencies in a tracheostomy pt<a class="headerlink" href="#critical-care-critical-care-tracheostomy-complications-and-airway-emergencies-in-a-tracheostomy-pt" title="Permanent link">&para;</a></h2>
<ul>
<li>Hemorrhage (mild bleeding from surface vessels and granulation
    tissue is common, major bleeding is rare think erosion into
    brachiocephalic [innominate] artery)</li>
<li>Airway damage subglottic or tracheal stenosis; tracheobronchitis</li>
<li>Fistulas (tracheoarterial, tracheoesophageal)</li>
<li>Unintended tracheostomy tube dislodgement:<ul>
<li>Bag mask (use hand/gauze to occlude stoma) or intubate from above
    (i.e. through the mouth); if complete laryngectomy then must use
    stoma</li>
<li>Fresh trach (≤ 14 days): do NOT replace due to risk of misplacement
    into the mediastinum and loss of airway; airway management from
    above</li>
<li>Older trach: can be replaced at bedside with obturator by trained
    staff</li>
<li>All pts with trachs have a yellow sign above bed with date, type,
    size of trach as well as a replacement trach with obturator in the
    room</li>
</ul>
</li>
</ul>
<h2 id="critical-care-critical-care-tracheostomy-secretion-management">Secretion Management<a class="headerlink" href="#critical-care-critical-care-tracheostomy-secretion-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Respiratory hygiene (“pulmonary toilet”): heated vent, guaifenesin,
    hypertonic saline, duonebs, cough assist device, appropriate
    suctioning (too much = worsen secretions), acapella, inspiratory
    spirometer</li>
</ul></section><section class="print-page" id="critical-care-critical-care-ultrasound"><h1 id="critical-care-critical-care-ultrasound-ultrasound-in-critical-care">Ultrasound in Critical Care<a class="headerlink" href="#critical-care-critical-care-ultrasound-ultrasound-in-critical-care" title="Permanent link">&para;</a></h1>
<p>Audrey White</p>
<hr />
<h2 id="critical-care-critical-care-ultrasound-volume-assessment">Volume assessment<a class="headerlink" href="#critical-care-critical-care-ultrasound-volume-assessment" title="Permanent link">&para;</a></h2>
<ul>
<li>IVC measurements</li>
<li>Clinical Questions: Will the patient respond to fluid resuscitation?
    Is CVP low or high?</li>
<li>Protocol: See cardiology POCUS section</li>
<li>Limitations: Non applicable in patients with elevated abdominal
    pressure or abdominal contractions during measurement</li>
<li>Troubleshooting: Use the liver as a window to the IVC to avoid bowel
    gas. Start at the right mid-axillary line with the leading edge
    toward the head of the patient, and fan to view the IVC in
    longitudinal axis.</li>
</ul>
<h2 id="critical-care-critical-care-ultrasound-lung-assessment">Lung Assessment<a class="headerlink" href="#critical-care-critical-care-ultrasound-lung-assessment" title="Permanent link">&para;</a></h2>
<ul>
<li>Lung ultrasound relies on recognition of ultrasound artifacts to
    identify normal and pathologic findings.</li>
<li>Normal findings<ul>
<li>“Bat sign”: Ultrasound cannot penetrate reflective rib surface,
    casting a vertical shadow</li>
<li>A- lines: hyperechoic horizontal lines descending from the
    pleural line at regular intervals. This reverberation artifact
    occurs in normal aerated lung</li>
</ul>
</li>
<li>Pathologic findings<ul>
<li>B-lines, comet tails: Vertical hyperechoic lines which (1)
    extend from the pleural line through the depth of the image, (2)
    move with lung sliding, and (3) obliterate A lines. Multiple B
    lines indicates excess interstitial fluid</li>
<li>Lung rockets: >3 B lines indicates interstitial syndrome. Most
    common cause is acute pulmonary edema, also consider ARDS, PNA,
    pulmonary fibrosis, &amp; pulmonary contusion. Helps distinguish CHF
    vs COPD exacerbation in patients with dyspnea</li>
<li>Loss of lung sliding, barcode sign: The shimmering, twinkling
    appearance of the dynamic aerated lung is lost. Can confirm in
    M-mode with barcode sign- smooth homogenous lines indicating no
    movement of lung tissue. Lung sliding=suspicion for PTX but NOT
    specific unless can identify lung point</li>
<li>Lung Point: The precise location where the lung detaches from
    the pleura can sometimes be identified. Can confirm in M-mode
    which will show “barcode” and “seashore” patterns adjacent. 100%
    specific for pneumothorax</li>
<li>Pleural effusion, jellyfish sign: Anechoic fluid is visualized
    between the diaphragm and dynamic lung</li>
</ul>
</li>
<li>Probe: linear or phased array</li>
<li>Protocol<ul>
<li>Adjust the depth to ~10cm to start. Position the probe vertically
    on the midclavicular line. Slide the probe so that the hyperechoic
    pleural line is visualized between rib shadows. Note
    presence/absence of A lines, B lines, lung sliding, and alveolar
    consolidation</li>
<li>Repeat on the opposite side and lower anterior lung fields</li>
<li>Repeat on the right and left mid-axillary line, upper and lower
        lung fields. Look for pleural effusion between the diaphragm and
        lung</li>
<li>Repeat on the posterior lung fields if indicated to complete a
        12-zone lung examination</li>
</ul>
</li>
</ul>
<h2 id="critical-care-critical-care-ultrasound-cardiovascular">Cardiovascular<a class="headerlink" href="#critical-care-critical-care-ultrasound-cardiovascular" title="Permanent link">&para;</a></h2>
<p>Goal-directed echocardiography for acute shock</p>
<ul>
<li>Pericardial tamponade<ul>
<li>Apical 4 chamber (A4C): pericardial effusion, may see end diastolic
    collapse of right atrium</li>
<li>Parasternal long (PLAX): pericardial effusion will appear anterior
    to thoracic descending aorta, may see collapsing right ventricle</li>
<li>False positives: pericardial cyst, pericardial fat pad, pleural
    effusion (posterior to thoracic descending aorta on PLAX)</li>
</ul>
</li>
<li>Acute cor pulmonale<ul>
<li>PLAX, PSAX: paradoxical septal motion, D shaped left ventricle,
    dilated RV</li>
<li>A4C: end-diastolic RV area : LV area > 1</li>
<li>Subxiphoid (SUX): dilated IVC</li>
</ul>
</li>
<li>LVEF- see cardiology section</li>
</ul>
<h2 id="critical-care-critical-care-ultrasound-abdominal-assessments">Abdominal assessments<a class="headerlink" href="#critical-care-critical-care-ultrasound-abdominal-assessments" title="Permanent link">&para;</a></h2>
<ul>
<li>FAST exam</li>
<li>Clinical questions: Is there fluid in the peritoneal or pericardial
    spaces?</li>
<li>Probe: curvilinear or phased array</li>
<li>Protocol<ul>
<li>Start on abdominal mode at depth 21-25cm. Assess for pericardial
    effusion in SUX view</li>
<li>Reduce depth to 12-16cm and place probe on the right anterior
    axillary line between ribs 8-12 with the indicator toward the
    patient’s head. Sweep medially to identify the right kidney.
    Assess for anechoic fluid in Morrison’s pouch between the kidney
    and liver, subdiaphragmatic space, and paracolic gutter. Rock
    the probe to assess for fluid cephalad to the diaphragm. Slide
    inferiorly to confirm no fluid around the inferior pole of the
    kidney</li>
<li>Place probe on the left anterior axillary line between ribs 8-11
    with the leading edge toward the patient’s head. Sweep medially
    to identify the left kidney. Assess for anechoic fluid in the
    splenorenal interface, subdiaphragmatic space, pleural space,
    paracolic gutter, and left kidney inferior pole</li>
<li>Place probe midline just superior to the pubic symphysis.
    Identify the bladder in longitudinal and transverse view. Assess
    for fluid outside the bladder wall and in the pouch of Douglas
    (females) or rectovesicular space (males)</li>
</ul>
</li>
<li>Limitations: Cannot detect retroperitoneal bleed. False positives
    from ascites, pleural effusion, subcapsular hematoma, ruptured
    cysts, physiologic fluid in pouch of Douglas, epicardial fat pad.
    Exam may be indeterminant if significant bowel gas or obesity</li>
<li>Small bowel obstruction assessment<ul>
<li>Overall SBO ultrasound has ~92% sensitivity and ~97% specificity
    to detect SBO and greater diagnostic accuracy than abdominal XR</li>
<li>Probe: curvilinear</li>
<li>Protocol: Have the patient lie supine and relax the abdominal wall.
    Place the probe vertically on the abdomen and sweep across all four
    quadrants in sagittal view. Repeat in transverse view. Measure small
    bowel wall thickness and diameter using the caliper tool</li>
<li>Signs of SBO:<ul>
<li>Diameter > 2cm • Decreased peristalsis</li>
<li>Wall thickness > 4mm • Back and forth stool movement</li>
<li>Tanga sign: In severe SBO, may see triangular pocket hypoechoic
    free fluid surrounding the small bowel near the obstruction</li>
</ul>
</li>
</ul>
</li>
<li>Renal ultrasound<ul>
<li>Protocol is similar to FAST exam. Fan the probe through each kidney
    in sagittal and transverse view to assess for dilation of the
    collecting ducts. To move the kidney inferiorly, ask the patient to
    take a deep breath</li>
<li>Bilateral hydronephrosis and full bladder suggests urinary
    obstruction distal to the ureter</li>
<li>Unilateral hydronephrosis suggests nephrolithiasis or ureteral
    obstruction</li>
<li>Limitations: Renal US has a reported sensitivity of 70% and
    specificity of 75% to detect nephrolithiasis compared to CT</li>
</ul>
</li>
</ul></section><section class="print-page" id="critical-care-critical-care-vent-settings"><h1 id="critical-care-critical-care-vent-settings-introduction-to-vent-management">Introduction to Vent Management<a class="headerlink" href="#critical-care-critical-care-vent-settings-introduction-to-vent-management" title="Permanent link">&para;</a></h1>
<p>Jared Freitas</p>
<hr />
<h2 id="critical-care-critical-care-vent-settings-ventilator-settings">Ventilator Settings<a class="headerlink" href="#critical-care-critical-care-vent-settings-ventilator-settings" title="Permanent link">&para;</a></h2>
<ul>
<li>See table in Modes of Oxygen Delivery for variables adjusted
    in each ventilator mode</li>
<li>Trigger: what initiates a breath; time, flow, or pressure (pt
    triggers are flow and pressure)</li>
</ul>
<h2 id="critical-care-critical-care-vent-settings-static-ventilator-readouts">Static Ventilator Readouts<a class="headerlink" href="#critical-care-critical-care-vent-settings-static-ventilator-readouts" title="Permanent link">&para;</a></h2>
<ul>
<li>Plateau pressure (Pplat): measure with inspiratory hold, assesses
    static lung compliance</li>
<li>Auto-PEEP: measure with expiratory hold; occurs when volume of
    previous breath is not entirely expelled before the next breath is
    initiated</li>
</ul>
<h2 id="critical-care-critical-care-vent-settings-dynamic-ventilator-readouts">Dynamic Ventilator Readouts<a class="headerlink" href="#critical-care-critical-care-vent-settings-dynamic-ventilator-readouts" title="Permanent link">&para;</a></h2>
<ul>
<li>Measured RR: in most modes, pt may trigger breaths above set RR; if
    set and measured RR match consider ↓ respiratory drive (sedation,
    neurologic injury) or iatrogenic over-ventilation</li>
<li>VTi / VTe: tidal volume of inspiration (VTi) and expiration (VTe)</li>
<li>VTi should approximately equal VTe, if not then concern for air leak
    (e.g. cuff leak or pneumothorax) or auto-PEEP</li>
<li>Minute ventilation: calculated from VTe x RR; higher MV = more CO2
    clearance</li>
<li>Peak pressure: highest pressure reached in the entire ventilator
    cycle</li>
</ul>
<h2 id="critical-care-critical-care-vent-settings-critical-non-ventilator-hemodynamic-readouts">Critical Non-ventilator hemodynamic readouts<a class="headerlink" href="#critical-care-critical-care-vent-settings-critical-non-ventilator-hemodynamic-readouts" title="Permanent link">&para;</a></h2>
<ul>
<li>SpO2: if poor waveform or discordant with PaO2, may need serial ABG</li>
<li>HR: quickest indicator of emergencies such as pneumothorax, PE,
    ventilator disconnection</li>
<li>Blood pressure: positive pressure ventilation decreases preload and
    afterload; depending on the underlying pt physiology, increases in
    positive pressure may be detrimental or beneficial for BP</li>
</ul>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 21%" />
<col style="width: 57%" />
</colgroup>
<thead>
<tr class="header">
<th>Alarm Type</th>
<th>What is causing the alarm?</th>
<th>Troubleshooting</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>High Peak Pressure</td>
<td>Static compliance issue (stretch of the lung - doesn't change with
airflow) versus dynamic compliance issue (resistance of the circuit when
there is air flowing)</td>
<td><p>Step 1: Check plateau pressure by performing inspiratory hold.
Must be in VC mode.</p>
<p><strong>High Peak and Low Plateau</strong> = Dynamic compliance issue
High Resistance</p>
<ul>
<li><p>Check circuit tubing for excess water condensation or a kink. Ask
RT to disconnect and clear circuit</p></li>
<li><p>Check if patient is biting ETT bite block, pain
control/sedation</p></li>
<li><p>Incline suction to clear secretions or proximal mucous
plug</p></li>
<li><p>Auscultate for wheezing or stridor to indicate bronchospasm or
airway obstruction-&gt;give bronchodilators</p></li>
</ul>
<p><strong>High Peak and High Plateau</strong> = Static compliance issue
Worsening alveolar process</p>
<ul>
<li><p>Emergencies to quickly assess for:</p></li>
</ul>
<ul>
<li><p>Tension pneumothorax (exam, US for lung sliding, CXR)</p></li>
<li><p>Main stem intubation (ask about any tube migration, listen to
breath sounds, CXR)</p></li>
</ul>
<ul>
<li><p>Consider worsening alveolar process leading to decreased lung
compliance: worsening pulmonary edema, PNA, DAH, ARDS or other
non-alveolar process such as new pleural effusion, obesity,
intraabdominal hypertension/compartment syndrome</p></li>
</ul>
<ul>
<li><p>CXR, US to assess for b-lines, tracheal aspirate, bronch,
etc</p></li>
<li><p>Treat according to etiology (chest tube, reposition ETT,
diuresis, abx, etc)</p></li>
</ul></td>
</tr>
<tr class="even">
<td>Low Tidal Volume/Low Minute Ventilation (VE)</td>
<td>Pt is not getting the desired tidal volume/VE that was set in the
vent parameters. The alarm reports exhaled VE. May cause inadequate
ventilation, CO2 retention, potentially hypoxia</td>
<td><p><strong>Compare inspiratory tidal volumes (Vti) with expiratory
tidal volumes (Vte) on the ventilator. If Vti&gt;Vte, check for a leak
in the system</strong></p>
<ul>
<li><p>Have RT check all connections</p></li>
<li><p>Listen for a cuff leak – can have RT check a cuff pressure and if
low then re-inflate-&gt;sometimes need to do an ETT exchange</p></li>
<li></li>
</ul>
<p><strong>If low tidal volumes and no leak (ie. Vti = Vte) and RR
WNL</strong></p>
<ul>
<li><p>Pt may need more support, ie switching to a different vent mode
(PS to PRVC). Discuss with RT or fellow</p></li>
</ul>
<p><strong>If low RR and no leak and Vt at goal</strong></p>
<ul>
<li><p>Patient may be oversedated</p></li>
<li><p>Ensure pt has a back-up rate in case they aren't triggering the
vent-&gt;may need to switch vent modes for this (i.e. take off pressure
support) or increase set/ventilator respiratory rate</p></li>
</ul></td>
</tr>
<tr class="odd">
<td>Apnea</td>
<td>No breaths are being triggered by the vent your patient is NOT
breathing this is an emergency</td>
<td><p>***<strong>Check that patient hasn't self-extubated, trach hasn't
fallen out, or been unhooked from vent***</strong></p>
<p>If self-extubated or tracheostomy decannulated, then immediately
start bagging the patient (may need to bag from trach stoma if s/p
laryngectomy). Have nurse call staff assist so that patient can be
re-intubated if necessary or have trach team called to replace a fresh
(&lt;7 days old) trach</p></td>
</tr>
</tbody>
</table></section><h1 class='nav-section-title-end'>Ended: Critical care</h1>
                        <h1 class='nav-section-title' id='section-demo'>
                            Demo <a class='headerlink' href='#section-demo' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="demo-demo-lights"><h1 id="demo-demo-lights-pleural-effusions">Pleural Effusions<a class="headerlink" href="#demo-demo-lights-pleural-effusions" title="Permanent link">&para;</a></h1>
<p>Author: Eddie Qian</p>
<h2 id="demo-demo-lights-background">Background<a class="headerlink" href="#demo-demo-lights-background" title="Permanent link">&para;</a></h2>
<p>There is a normal influx of fluid into the pleural space due to
leaky capillary membranes and the pleural space’s negative pressure.
This fluid is constantly reabsorbed by lymphatics. An imbalance in
the system will result in accumulation.</p>
<p>Some examples:</p>
<ul>
<li>Increased Influx: increased filtration from the capillaries from
        high intravascular hydrostatic pressure (i.e., heart failure,
        renal failure, volume overload) or low intravascular oncotic
        pressure</li>
<li>Other liquid entry into the pleural space through anatomic
        deficits: <abbr title="Cerebrospinal Fluid">CSF</abbr>, chyle, urine, blood, ascites (the diaphragm is
        naturally porous and pleural effusions with ascites are not uncommon)</li>
<li>Decreased Efflux: obstruction of the parietal pleural stoma
        (from protein or cellular debris in exudative pleural effusions)</li>
<li>Increased systemic venous pressure (lymphatic system drains into
        systemic venous circulation, so if there is high venous
        pressure this prevents the lymphatics from draining
        appropriately)</li>
</ul>
<h2 id="demo-demo-lights-evaluation">Evaluation<a class="headerlink" href="#demo-demo-lights-evaluation" title="Permanent link">&para;</a></h2>
<h3 id="demo-demo-lights-imaging">Imaging<a class="headerlink" href="#demo-demo-lights-imaging" title="Permanent link">&para;</a></h3>
<ul>
<li>CXR: lateral decubitus position (if effusion moves with gravity,
        suggests free flowing)</li>
<li>Ultrasound: assess size, location, loculations (fibrinous
        septations which may prevent simple drainage)</li>
<li>CT Chest with contrast (not always indicated; helpful to eval
        septations)</li>
</ul>
<h3 id="demo-demo-lights-thoracentesis-see-procedures-section">Thoracentesis (see <a href="#procedures-procedures-thoracentesis">Procedures section</a>)<a class="headerlink" href="#demo-demo-lights-thoracentesis-see-procedures-section" title="Permanent link">&para;</a></h3>
<p>Will it change management?</p>
<p>If septated or empyema,  consider pulm consult for chest tube.</p>
<p>Orders:</p>
<ul>
<li>Always: Pleural <abbr title="Lactate Dehydrogenase">LDH</abbr>, protein, cell count/diff, culture</li>
<li>Don’t forget serum <abbr title="Lactate Dehydrogenase">LDH</abbr> &amp; protein!</li>
<li>Consider: pleural cytology, hematocrit, triglycerides, glucose,
        amylase</li>
</ul>
<p>Interpretation:</p>
<table>
<thead>
<tr>
<th>Lights Criteria</th>
<th>&gt;=1 of the following = exudative</th>
</tr>
</thead>
<tbody>
<tr>
<td>pleural protein : serum protein</td>
<td>&gt; 0.50</td>
</tr>
<tr>
<td>pleural <abbr title="Lactate Dehydrogenase">LDH</abbr> : serum <abbr title="Lactate Dehydrogenase">LDH</abbr></td>
<td>&gt; 0.60</td>
</tr>
<tr>
<td>pleural <abbr title="Lactate Dehydrogenase">LDH</abbr> : upper limit of normal of serum <abbr title="Lactate Dehydrogenase">LDH</abbr></td>
<td>&gt; 0.66</td>
</tr>
</tbody>
</table>
<ul>
<li>Lights criteria: &gt;=1 of the following to be considered an
        exudative effusion</li>
<li>Pleural to serum protein ratio &gt; 0.5</li>
<li>Pleural to serum <abbr title="Lactate Dehydrogenase">LDH</abbr> ratio &gt; 0.6</li>
<li>Pleural <abbr title="Lactate Dehydrogenase">LDH</abbr> &gt; &#8532; upper limit of normal range of serum <abbr title="Lactate Dehydrogenase">LDH</abbr></li>
<li>Transudative: CHF exacerbation, hepatic hydrothorax, atelectasis
        (caused by increased intrapleural negative pressure),
        hypoalbuminemia, renal failure</li>
<li>Exudative: infections (bacterial, TB, fungal), malignant,
        rheumatologic, PE</li>
</ul>
<p>Pearls about initial tests:</p>
<ul>
<li>Protein: &gt;5 think TB or malignancy, =&lt; 0.5 think urine, <abbr title="Cerebrospinal Fluid">CSF</abbr>,
            peritoneal dialysate</li>
<li>Glucose: =&lt; 60 think about malignancy, TB,
                rheumatologic, and less specific hemothorax or
                parapneumonic</li>
<li>Cell count/differential: polys represent an acute
                process, monocytes represent a chronic process,
                lymphocytes think about TB or malignancy, eosinophils
                think about air/blood, TB, malignancy, asbestos, drugs</li>
<li>Two separate processes may co-occur and a transudate may mask an
                exudative effusion; if  concerned for this and you have clinical
                stability, trial diuresis prior to thoracentesis.</li>
</ul>
<details class="info">
<summary>References</summary>
<p><a href="https://doi.org/10.7326/0003-4819-77-4-507">Lights Criteria Original Paper</a></p>
</details></section><h1 class='nav-section-title-end'>Ended: Demo</h1>
                        <h1 class='nav-section-title' id='section-endocrinology'>
                            Endocrinology <a class='headerlink' href='#section-endocrinology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="endocrinology-endocrinology-adrenal-incidentalomas"><h1 id="endocrinology-endocrinology-adrenal-incidentalomas-adrenal-incidentalomas">Adrenal Incidentalomas<a class="headerlink" href="#endocrinology-endocrinology-adrenal-incidentalomas-adrenal-incidentalomas" title="Permanent link">&para;</a></h1>
<p>Matthew Gonzalez</p>
<hr />
<h2 id="endocrinology-endocrinology-adrenal-incidentalomas-background">Background<a class="headerlink" href="#endocrinology-endocrinology-adrenal-incidentalomas-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Adrenal mass &gt;1cm, discovered by chance on radiographic imaging</p>
</li>
<li>
<p>Less than 1% are malignant</p>
</li>
<li>
<p>Supportive of benign: &lt;4 cm in size, smooth borders, homogenous appearance, &lt;10 HU (Hounsfield units), rapid contrast washout (on "adrenal phase" imaging)</p>
</li>
<li>
<p>Supportive of malignancy: &gt;4 cm in size, irregular borders, &gt; 20 HU on unenhanced CT, delayed contrast washout, tumor calcifications, increase in size over time, presence in young pts and hx cancer</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-adrenal-incidentalomas-evaluation">Evaluation<a class="headerlink" href="#endocrinology-endocrinology-adrenal-incidentalomas-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>All incidentalomas should be screened for pheochromocytoma (~3% incidence) before operative intervention </p>
</li>
<li>
<p>Cortisol secreting adenoma (~6% incidence) causing Cushing's syndrome: baseline serum DHEAS, low dose (1mg) overnight dexamethasone suppression test</p>
</li>
<li>
<p>Aldosterone secreting adenoma (&lt;1% incidence) causing hyperaldosteronism: if hypertensive (HTN) or hypokalemic order plasma aldosterone and renin, confirmatory testing with sodium loading (oral vs IV) and 24-hour urine aldosterone, sodium, and creatinine</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-adrenal-incidentalomas-management">Management<a class="headerlink" href="#endocrinology-endocrinology-adrenal-incidentalomas-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>If benign appearing and not hormone producing: interval imaging in ~1 year, and repeat hormone work up</p>
</li>
<li>
<p>Unilateral adrenal incidentaloma</p>
<ul>
<li>If progression free (stable size, and not hormone producing) can consider monitoring cessation after 4 years</li>
</ul>
</li>
<li>
<p>Pheochromocytomas should undergo surgical evaluation for removal</p>
<ul>
<li>Alpha blockade (phenoxybenzamine) + propranolol prior to resection to avoid HTN crisis</li>
</ul>
</li>
<li>
<p>Aldosteronoma: should undergo surgical evaluation for definitive treatment; if unable to undergo surgery can treat with medical management with long term mineralocorticoid antagonist (e.g. spironolactone)</p>
</li>
<li>
<p>Cortisoloma: if clinically significant should undergo surgical removal, will need perioperative glucocorticoid administration to avoid iatrogenic adrenal insufficiency</p>
</li>
<li>
<p>Macroadenomas (masses &gt;4 cm) are usually malignant and should be considered for surgical resection due to higher risk of carcinoma</p>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-adrenal-insufficiency"><h1 id="endocrinology-endocrinology-adrenal-insufficiency-adrenal-insufficiency">Adrenal Insufficiency<a class="headerlink" href="#endocrinology-endocrinology-adrenal-insufficiency-adrenal-insufficiency" title="Permanent link">&para;</a></h1>
<p>Griffin Bullock</p>
<hr />
<h2 id="endocrinology-endocrinology-adrenal-insufficiency-background">Background<a class="headerlink" href="#endocrinology-endocrinology-adrenal-insufficiency-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Differential: Primary (Adrenals) vs Secondary (Pituitary):<ul>
<li>Exogenous steroid use (&gt;10 mg for &gt;3wks) undergoing severe physiologic stress or sudden discontinuation of steroid</li>
<li>Autoimmune adrenal insufficiency</li>
<li>Infection/Infiltration: tuberculosis, sarcoidosis, malignancy</li>
<li>Hemorrhage (Waterhouse-Friderichsen syndrome)</li>
<li>Pituitary mass/tumor, infarct, infiltration, surgery, trauma </li>
</ul>
</li>
</ul>
<h2 id="endocrinology-endocrinology-adrenal-insufficiency-presentation">Presentation<a class="headerlink" href="#endocrinology-endocrinology-adrenal-insufficiency-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Generalized weakness, lightheaded, abdominal pain, nausea, weight loss, fatigue</p>
</li>
<li>
<p>Lab Abnormalities: hyponatremia, hyperkalemia, hypoglycemia</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-adrenal-insufficiency-evaluation">Evaluation<a class="headerlink" href="#endocrinology-endocrinology-adrenal-insufficiency-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Inpatient Setting</p>
<ul>
<li>Draw AM cortisol and ACTH (ideally 8am) -&gt; 0.25mg cosyntropin -&gt; cortisol 1 hour after <ul>
<li>Cortisol level ≥18-20 rules out primary adrenal insufficiency (and most secondary)</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Outpatient Setting</p>
<ul>
<li>Draw AM cortisol level for screening (&gt;15 rules typically rules out adrenal insufficiency)</li>
<li>ACTH stimulation for confirmation</li>
</ul>
</li>
</ul>
<h2 id="endocrinology-endocrinology-adrenal-insufficiency-management">Management<a class="headerlink" href="#endocrinology-endocrinology-adrenal-insufficiency-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Consult endocrine if ACTH stimulation test is abnormal</li>
<li>Adrenal crisis (if concerned, treat first, test later)<ul>
<li>BMP, glucose monitoring, ACTH level, serum cortisol</li>
<li>Fluid resuscitation: NS or D5NS. Do not use hypotonic saline</li>
<li>Hydrocortisone 100mg x1 followed by 50mg q8h </li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-diabetes-inpatient-management"><h1 id="endocrinology-endocrinology-diabetes-inpatient-management-inpatient-diabetes-mellitus-dm">Inpatient Diabetes Mellitus (DM)<a class="headerlink" href="#endocrinology-endocrinology-diabetes-inpatient-management-inpatient-diabetes-mellitus-dm" title="Permanent link">&para;</a></h1>
<p>Will Bassett</p>
<hr />
<h2 id="endocrinology-endocrinology-diabetes-inpatient-management-background">Background<a class="headerlink" href="#endocrinology-endocrinology-diabetes-inpatient-management-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Blood glucose (BG) goal</p>
<ul>
<li>Wards: &lt;140 mg/dL fasting; &lt;180 mg/dL random; increase for elderly, “sicker” patients</li>
<li>ICU: 140-180 mg/dL (NICE-SUGAR Trial)</li>
<li>Avoiding hypoglycemia in critically ill patients is more important than targeting ideal BG</li>
</ul>
</li>
</ul>
<h2 id="endocrinology-endocrinology-diabetes-inpatient-management-management">Management<a class="headerlink" href="#endocrinology-endocrinology-diabetes-inpatient-management-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Initial orders</p>
<ul>
<li>HOLD all home oral diabetes medications (except consider continuing empagliflozin in heart failure pts)</li>
<li>Typically recommend dose reducing home insulin (usually 50% of home dose for type 2; varies for type 1) for changes in diet. If AKI present, consider reducing by more.<ul>
<li>Patients with Type 1 DM <em>always need basal insulin</em>, even if NPO or else will lead to DKA</li>
<li>If patients with Type 1 DM are eating, they will need prandial insulin as well </li>
</ul>
</li>
<li>Order set “SUBCUTANEOUS INSULIN ORDER(S)”<ul>
<li>Hemoglobin A1c. Can consider if none in last 3 months and concern for poor outpatient control. A1c does not routinely affect inpatient management</li>
<li>Fingerstick blood glucose: Typically AC/HS (before meals and nightly)</li>
<li>Hypoglycemia management: Select all of these</li>
<li>Basal insulin:<ul>
<li>Type 2 DM, consider ↓ home dose (50-60% to home dose) as often inpatients have reduced PO intake and ↓ renal function</li>
<li>Type 1 DM, DO NOT hold basal insulin, and avoid ↓ &lt; 80% of home dose</li>
<li>Unnecessary if no home basal insulin</li>
</ul>
</li>
<li>Insulin lispro meal: ↓ home dose by &frac12;, do not give while NPO</li>
<li>Lispro insulin correction scale: Start with Low or Medium sliding scale and ↑ prn</li>
<li>Carb-controlled or carb-restricted diet</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Insulin adjustments</p>
<ul>
<li>If BGs persistently &gt;200<ul>
<li>Calculate all insulin needs over 24h (basal + mealtime + sliding scale)<ul>
<li>Give 50% as basal and other 50% as 3 divided mealtime doses</li>
<li>E.g. 10 basal + 0 mealtime + 14 sliding scale total = 24 units total daily = 12u basal + 4u TID with meals</li>
<li>If new to basal, safe start is 0.2 u/kg daily if normal GFR</li>
</ul>
</li>
</ul>
</li>
<li>If BGs &lt; 70<ul>
<li>If overnight/AM, reduce basal insulin dose</li>
<li>If daytime/post-prandial hypoglycemia, reduce mealtime and sliding scale</li>
<li>Less is more! Blood glucose in the low 200s is better than the 50s</li>
<li>If endocrine consulted for inpatient glucose management, please notify &gt;24h prior to discharge if you want recommended discharge regimen</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="endocrinology-endocrinology-diabetes-inpatient-management-steroid-induced-hyperglycemia">Steroid-induced Hyperglycemia<a class="headerlink" href="#endocrinology-endocrinology-diabetes-inpatient-management-steroid-induced-hyperglycemia" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Steroids increase insulin resistance causing elevated postprandial BG</p>
</li>
<li>
<p>Insulin adjustments</p>
<ul>
<li>Double mealtime + correction dose with leaving the basal the same</li>
<li>Modified basal bolus regimen (30% basal, 70% bolus)</li>
<li>Add NPH once daily (weight + dose based, per below*) if on daily prednisone<ul>
<li>Prednisone 10 mg = 0.1 u/kg NPH</li>
<li>Prednisone 20 mg = 0.2 u/kg NPH up to 0.4 u/kg daily</li>
<li><em>lower dose if AKI, administer at the same time as prednisone dosing</em></li>
</ul>
</li>
<li>On discharge, if steroids will be longstanding, increase home insulin regimen per inpatient requirements. If steroids will be tapered or discontinued soon after, either continue hospital regimen for remainder of steroid course or return to home regimen (hyperglycemia is better than hypoglycemia)</li>
</ul>
</li>
</ul>
<h2 id="endocrinology-endocrinology-diabetes-inpatient-management-additional-information">Additional Information<a class="headerlink" href="#endocrinology-endocrinology-diabetes-inpatient-management-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Tube feeds</p>
<ul>
<li>Dose regular insulin q6h (not TID AC as they don’t have distinct “meals”)</li>
<li>Consolidate for bolus feedings based on 24-hour insulin needs prior to discharge</li>
</ul>
</li>
<li>
<p>Insulin pumps</p>
<ul>
<li>If a patient has a pump and supplies, reasonably controlled BG, is willing and able to manage pump then s/he can keep the pump on. <em>This requires a Diabetes Consult</em>.</li>
<li>Still order POC BG checks AC/HS for nurse to chart and fill out MedEx pump contract</li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-dka"><h1 id="endocrinology-endocrinology-dka-diabetic-ketoacidosis-dka">Diabetic Ketoacidosis (DKA)<a class="headerlink" href="#endocrinology-endocrinology-dka-diabetic-ketoacidosis-dka" title="Permanent link">&para;</a></h1>
<p>Will Bassett, Matthew Gonzalez</p>
<hr />
<h2 id="endocrinology-endocrinology-dka-background">Background<a class="headerlink" href="#endocrinology-endocrinology-dka-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Classically in type 1 diabetes but can also occur in insulin-dependent type 2 diabetes</p>
</li>
<li>
<p>Definition: ↑ blood glucose (typically &gt;350) w/ high anion gap and ketones in blood/urine</p>
</li>
<li>
<p>If glucose is significantly elevated but little to no ketones/anion gap present, you likely have HHS, which is typically associated with ↑ serum osm and BG &gt; 600</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-dka-evaluation">Evaluation<a class="headerlink" href="#endocrinology-endocrinology-dka-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Labs: BMP with anion gap (AG), CBC, phos, blood gas, serum osms, UA, consider beta-hydroxybutyrate</p>
</li>
<li>
<p>Workup aimed at discovering the underlying cause (The "I’s"):</p>
<ul>
<li>
<p>Infection/ Inflammation: CBC, CXR, UA/UCx, LFTs; consider BCx, lipase (pancreatitis). Note: Leukocytosis will be present in DKA, even if infection isn’t the precipitating factor</p>
</li>
<li>
<p>Ischemia (MI, CVA, mesenteric ischemia): EKG, Troponin, CT(A) if clinical suspicion</p>
</li>
<li>
<p>Intoxication - Ethanol (can cause ketosis with or without acidosis), cocaine, MDMA</p>
</li>
<li>
<p>Impregnation - Beta HCG if appropriate</p>
</li>
<li>
<p>Insulin-openia/Iatrogenic: steroids, SGLT2 inhibitors, other meds, insulin delivery failure (pump failure, insulin degraded by heat, etc.)</p>
</li>
</ul>
</li>
</ul>
<p>Remember to correct sodium for hyperglycemia (Na + 2.4 mEq * (BG-100))</p>
<h2 id="endocrinology-endocrinology-dka-management">Management<a class="headerlink" href="#endocrinology-endocrinology-dka-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Initial monitoring: q2-4h BMPs (monitor K closely), q1h BG fingersticks</p>
<ul>
<li>Can space less frequently once gap is closed x 2 and patient off insulin infusion</li>
</ul>
</li>
<li>
<p>Ensure IV access</p>
</li>
<li>
<p>Start IV fluids, insulin, and potassium as below</p>
<ul>
<li>
<p>Start insulin gtt</p>
</li>
<li>
<p>Start subcutaneous long-acting insulin as soon as insulin drip/IV insulin is started</p>
<ul>
<li>Either start home long-acting (dose reduce as needed) or if insulin naïve, lantus 0.2-0.3u/kg/day</li>
</ul>
</li>
<li>
<p>Lactated ringers’ preferred fluid if no contraindication</p>
</li>
<li>
<p>Dextrose should be added when BG &lt;200 (or clear liquid diet)</p>
</li>
<li>
<p>Turn off insulin drip when anion gap is closed on two consecutive BMPs. Make sure your long acting insulin has been given at least four hours prior to drip being turned off</p>
</li>
</ul>
</li>
<li>
<p>Consult endocrinology early</p>
</li>
<li>
<p>Management algorithm below (Diabetes Care. 2009 Jul; 32(7): 1335–1343)</p>
</li>
<li>
<p>Note: pts are usually deficient in total body potassium even if their serum potassium is high</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-dka-additional-information">Additional Information<a class="headerlink" href="#endocrinology-endocrinology-dka-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Pts on insulin drip can be admitted to stepdown (8MCE) with order set</p>
</li>
<li>
<p>Pts can be admitted to stepdown on a subcutaneous insulin protocol with mild DKA with endocrinology guiding insulin management</p>
</li>
<li>
<p>Avoid ordering C-peptide if concern for new type 1 diabetes, beta islet cells can be "stunned" with recent hyperglycemic states and may be falsely low</p>
</li>
<li>
<p>SGLT2 inhibitors are being prescribed much more often and can cause a euglycemic DKA, where acidosis and ketosis present but no elevated BG. These patients still require an insulin gtt until their acidosis has improved and their gap closed, regardless of BG level</p>
</li>
</ul>
<hr />
<p><img alt="initial management of dka" src="../images/dka-management.jpg" /></p></section><section class="print-page" id="endocrinology-endocrinology-hyperthyroidism"><h1 id="endocrinology-endocrinology-hyperthyroidism-hyperthyroidism">Hyperthyroidism<a class="headerlink" href="#endocrinology-endocrinology-hyperthyroidism-hyperthyroidism" title="Permanent link">&para;</a></h1>
<p>Griffin Bullock</p>
<hr />
<h2 id="endocrinology-endocrinology-hyperthyroidism-background">Background<a class="headerlink" href="#endocrinology-endocrinology-hyperthyroidism-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Low TSH and High T4 and/or T3 (primary): Graves’ disease, Toxic goiter, TSH-producing adenoma, hyperemesis gravidarum, subacute granulomatous thyroiditis, amiodarone, radiation, excessive replacement, struma ovarii</p>
</li>
<li>
<p>Low TSH/Normal T4 and T3: Subclinical hyperthyroidism, central hypothyroidism, non-thyroidal illness, recovery from hyperthyroidism, pregnancy (physiologic)</p>
</li>
<li>
<p>Subclinical Hyperthyroidism: repeat testing to verify abnormality is not transient</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-hyperthyroidism-presentation">Presentation<a class="headerlink" href="#endocrinology-endocrinology-hyperthyroidism-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Anxiety, emotional lability, heat intolerance, tremor, palpitations, increased appetite, unexplained weight loss, new onset atrial fibrillation, myopathy, menstrual disorder, exophthalmos, tachycardia, pretibial myxedema, hyperreflexia, lid lag, changes to hair or skin</li>
</ul>
<h2 id="endocrinology-endocrinology-hyperthyroidism-evaluation">Evaluation<a class="headerlink" href="#endocrinology-endocrinology-hyperthyroidism-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>TSH, free T4, free T3 (only T3 or T4 may be elevated, though both often are)</p>
</li>
<li>
<p>Biotin affects assay, causes falsely ↓ TSH and falsely ↑ FT4/FT3</p>
</li>
<li>
<p>CBC: May have a normocytic anemia due to increased plasma volume</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-hyperthyroidism-management">Management<a class="headerlink" href="#endocrinology-endocrinology-hyperthyroidism-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Thyrotropin antibodies (Graves-specific test, not sensitive)</p>
</li>
<li>
<p>Radioiodine uptake scan if thyrotropin antibodies negative</p>
<ul>
<li>Note: if pt has had a contrasted study wtih radioactive iodine in the past 6 weeks, the RAI update scan will not be helpful </li>
</ul>
</li>
<li>
<p>Treatment: methimazole, PTU, beta blockers, radioiodine ablation, surgery</p>
</li>
<li>
<p>Pts should be referred to endocrinology for treatment plan based on work up</p>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-hypoglycemia"><h1 id="endocrinology-endocrinology-hypoglycemia-hypoglycemia">Hypoglycemia<a class="headerlink" href="#endocrinology-endocrinology-hypoglycemia-hypoglycemia" title="Permanent link">&para;</a></h1>
<p>Will Bassett</p>
<hr />
<h2 id="endocrinology-endocrinology-hypoglycemia-background">Background<a class="headerlink" href="#endocrinology-endocrinology-hypoglycemia-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Definition: BG &lt;70 mg/dL in a patient on insulin or an oral hypoglycemic; &lt;55 mg/dL for other patients</p>
<ul>
<li>Generally worse outcomes than hyperglycemia</li>
</ul>
</li>
<li>
<p>Causes: infection, liver failure, iatrogenic (e.g. insulin not adjusted for AKI or being NPO)</p>
</li>
<li>
<p>Symptoms vary from tremor, palpitations, delirium, dizziness, AMS, coma</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-hypoglycemia-management">Management<a class="headerlink" href="#endocrinology-endocrinology-hypoglycemia-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Give PO carbohydrate load (15-20g oral glucose) if pt is alert and tolerates PO</p>
</li>
<li>
<p>Give IV D50 if severe (&lt;50), or cannot take PO</p>
</li>
<li>
<p>Repeat measurements after 15 minutes and treat again as needed</p>
<ul>
<li>As a rule of thumb, 15g of carbs should raise BG within 15 minutes</li>
</ul>
</li>
<li>
<p>Give glucagon 0.5-1mg SQ/IM if no IV access and impaired consciousness</p>
<ul>
<li>Effect is transient and IV access should be obtained ASAP for glucose infusion</li>
</ul>
</li>
<li>
<p>Do NOT hold basal insulin for T1DM: treat the low, then reduce dose if needed</p>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-hypothyroidism"><h1 id="endocrinology-endocrinology-hypothyroidism-hypothyroidism">Hypothyroidism<a class="headerlink" href="#endocrinology-endocrinology-hypothyroidism-hypothyroidism" title="Permanent link">&para;</a></h1>
<p>Griffin Bullock</p>
<hr />
<h2 id="endocrinology-endocrinology-hypothyroidism-background">Background<a class="headerlink" href="#endocrinology-endocrinology-hypothyroidism-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Elevated TSH and low FT4 (primary hypothyroidism)<ul>
<li>Hashimoto’s (autoimmune) thyroiditis, iodine deficiency, drugs (amiodarone, dopamine antagonists), adrenal insufficiency, thyroid hormone resistance (genetic), non-thyroidal illness (recovery phase), post-surgery or ablation for hyperthyroidism</li>
</ul>
</li>
<li>
<p>Elevated TSH and normal FT4: subclinical hypothyroidism</p>
</li>
<li>
<p>Low-Normal TSH, low FT4: central hypothyroidism, sick euthyroid</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-hypothyroidism-presentation">Presentation<a class="headerlink" href="#endocrinology-endocrinology-hypothyroidism-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Often non-specific and vague: fatigue, cold intolerance, weight gain, constipation, dry skin, myalgia, edema menstrual irregularities, depression, mental dysfunction</p>
</li>
<li>
<p>Goiter, bradycardia, diastolic hypertension, delayed relaxation following reflex testing</p>
</li>
<li>
<p>Lab abnormalities: microcytic anemia, hypercholesterolemia, hyponatremia, elevated CK</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-hypothyroidism-evaluation">Evaluation<a class="headerlink" href="#endocrinology-endocrinology-hypothyroidism-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>TSH: If elevated repeat TSH and obtain T4</p>
</li>
<li>
<p>Lipid panel, CBC, BMP</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-hypothyroidism-management">Management<a class="headerlink" href="#endocrinology-endocrinology-hypothyroidism-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Treatment required if ↓ T4, significantly ↑ TSH (&gt;10), or symptoms with any lab abnormality</p>
</li>
<li>
<p>Titrate therapy to a normal TSH (unless central hypothyroidism, then target free T4 levels)</p>
</li>
<li>
<p>Observation of asymptomatic pts with subclinical hypothyroidism (normal T4, mild ↑ TSH)</p>
</li>
<li>
<p>Treatment is with formulation of T4 (full replacement is approximately 1.6 mcg/kg/day)</p>
</li>
<li>
<p>Initial Dose:</p>
<ul>
<li>
<p>Young/healthy patients: full anticipated dose</p>
</li>
<li>
<p>Older patients or patients with CAD: 25-50 mcg daily</p>
</li>
</ul>
</li>
<li>
<p>Increased doses required for: pregnancy, estrogen therapy, weight gain, PPI therapy, GI disorders (↓ absorption), ferrous sulfate therapy</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-hypothyroidism-additional-information">Additional information<a class="headerlink" href="#endocrinology-endocrinology-hypothyroidism-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Pts should take Levothyroxine alone, 1 hr prior to eating to ensure appropriate absorption</p>
</li>
<li>
<p>Of note, missed doses can be taken along with the next dose</p>
</li>
<li>
<p>Symptoms improve in 2-3 weeks. TSH steady state requires 6 weeks</p>
</li>
<li>
<p>Dose can be titrated every 6 weeks based on TSH</p>
</li>
<li>
<p>Pregnancy: Pregnancy causes lab changes due to differing levels thyroid binding globulin. Use tables based on trimester to interpret values</p>
<ul>
<li>TPO antibody testing should be conducted if abnormal as this affects risk of complications</li>
</ul>
</li>
<li>
<p>Hypothyroid pts are at increased risk for preeclampsia, placental abruption, preterm labor/delivery</p>
</li>
<li>
<p>Refer to endocrine for close monitoring and adjustment to avoid fetal complications</p>
</li>
<li>
<p>Inpatients who are pregnant and have abnormal TFTs warrant endocine consult. </p>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-severe-hypertriglyceridemia"><h1 id="endocrinology-endocrinology-severe-hypertriglyceridemia-severe-hypertriglyceridemia-htg">Severe Hypertriglyceridemia (HTG)<a class="headerlink" href="#endocrinology-endocrinology-severe-hypertriglyceridemia-severe-hypertriglyceridemia-htg" title="Permanent link">&para;</a></h1>
<p>Chloe de Crecy</p>
<hr />
<h2 id="endocrinology-endocrinology-severe-hypertriglyceridemia-background">Background<a class="headerlink" href="#endocrinology-endocrinology-severe-hypertriglyceridemia-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Elevated triglycerides (TG) on a <em>fasting</em> lipid panel</p>
<ul>
<li>Normal: &lt;150 mg/dL</li>
<li>Moderate HTG: 150-499 mg/dL</li>
<li>Moderate to severe HTG: 500-999 mg/dL</li>
<li>Severe HTG: &gt;1000 mg/dL</li>
</ul>
</li>
<li>
<p>Nearly all patients with severe HTG have a genetic predisposition and an additional factor known to raise serum TGs (e.g. diabetes, alcohol abuse, oral estrogen therapy, hypothyroidism, nephrotic syndrome, propofol, ART, pregnancy)</p>
</li>
<li>
<p>Risks of hypertriglyceridemia: pancreatitis (can occur if serum TG &gt;500 mg/dL), ASCVD</p>
</li>
<li>
<p>Signs: xanthomas, hepatosplenomegaly, lipemia retinalis, milky appearance of plasma</p>
</li>
<li>
<p>Symptoms: short-term memory loss, abdominal pain, flushing with alcohol</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-severe-hypertriglyceridemia-evaluation">Evaluation<a class="headerlink" href="#endocrinology-endocrinology-severe-hypertriglyceridemia-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Order lipid panel for: usual outpatient screening, acute pancreatitis, cutaneous xanthomas, family members with familial HTG, monitoring HTG treatment</p>
</li>
<li>
<p>Note: Sodium, glucose, amylase, LDL readings can be affected by HTG</p>
</li>
<li>
<p>Consider sending A1c, Cr, TSH</p>
</li>
<li>
<p>Assess medication list for secondary causes</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-severe-hypertriglyceridemia-management">Management<a class="headerlink" href="#endocrinology-endocrinology-severe-hypertriglyceridemia-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>HTG induced pancreatitis</p>
<ul>
<li>
<p>If pt has hypocalcemia, lactic acidosis, or multi-organ dysfunction</p>
<ul>
<li>Initiate plasmapheresis and monitor serum TG after each cycle until &lt;500</li>
<li>Severe dietary fat restriction (&lt;5%) until TG &lt;1000</li>
</ul>
</li>
<li>
<p>If none of the above and pt is hyperglycemic</p>
<ul>
<li>Start insulin gtt, IVF, monitor q1h BG and q12h TG</li>
<li>Discontinue insulin when serum TG &lt;500</li>
<li>Severe dietary fat restriction (&lt;5%) until TG &lt;1000</li>
</ul>
</li>
<li>
<p>If none of the above and patient is euglycemic</p>
<ul>
<li>Monitor q12h TG until &lt;500</li>
<li>Severe dietary fat restriction (&lt;5%) until TG &lt;1000</li>
<li>Consider initiation of insulin gtt as well (regardless of BG level) as insulin will help metabolize TG particles</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Long-term Management (once TG &lt;1000, otherwise decreased efficacy)</p>
<ul>
<li>Pharmacologic: fibrates (most commonly fenofibrate), statins, niacin, omega-3 fatty acids</li>
<li>Nonpharmacologic: discontinue alcohol use, dietary fat and sugar restriction (target fat intake at &lt;10% of calorie intake), exercise</li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-steroid-conversions"><h1 id="endocrinology-endocrinology-steroid-conversions-steroid-conversions">Steroid Conversions<a class="headerlink" href="#endocrinology-endocrinology-steroid-conversions-steroid-conversions" title="Permanent link">&para;</a></h1>
<p>Steroid Conversion Chart – Neil Phillips</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Name</td>
<td>Equivalent doses (mg)</td>
<td>Anti-inflammatory activity relative to hydrocortisone</td>
<td>Duration of action (hrs)</td>
</tr>
<tr>
<td>Hydrocortisone (cortisol)</td>
<td>20</td>
<td>1</td>
<td>8 to 12</td>
</tr>
<tr>
<td>Cortisone acetate</td>
<td>25</td>
<td>0.8</td>
<td>8 to 12</td>
</tr>
<tr>
<td>Prednisone</td>
<td>5</td>
<td>4</td>
<td>12 to 36</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>5</td>
<td>4</td>
<td>12 to 36</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>4</td>
<td>5</td>
<td>12 to 36</td>
</tr>
<tr>
<td>Triamcinolone</td>
<td>4</td>
<td>5</td>
<td>12 to 36</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>0.75</td>
<td>30</td>
<td>36 to 72</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>0.6</td>
<td>30</td>
<td>36 to 72</td>
</tr>
</tbody>
</table></section><section class="print-page" id="endocrinology-endocrinology-stress-dose-steroids"><h1 id="endocrinology-endocrinology-stress-dose-steroids-stress-dose-steroids">Stress Dose Steroids<a class="headerlink" href="#endocrinology-endocrinology-stress-dose-steroids-stress-dose-steroids" title="Permanent link">&para;</a></h1>
<p>Griffin Bullock</p>
<hr />
<h2 id="endocrinology-endocrinology-stress-dose-steroids-primary-options">Primary Options<a class="headerlink" href="#endocrinology-endocrinology-stress-dose-steroids-primary-options" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Dexamethasone 4 mg IV: does not affect cortisol assays, ideal if diagnosis uncertain</p>
</li>
<li>
<p>Hydrocortisone 100 mg IV bolus then 50 mg q8h until stable: greater mineralocorticoid activity. Ideal if adrenal insufficiency known/confirmed or if hyperkalemic (K&gt;6.0)</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-stress-dose-steroids-when-to-use">When to Use<a class="headerlink" href="#endocrinology-endocrinology-stress-dose-steroids-when-to-use" title="Permanent link">&para;</a></h2>
<ul>
<li>Concern for adrenal crisis</li>
<li>Patients with known adrenal insufficiency:<ul>
<li>Minor Illness: ↑ dose x3 for 3 d or until clinically improved &amp; acute stress resolved</li>
</ul>
</li>
<li>Surgery: dependent on severity of operation<ul>
<li>Minor (e.g. hernia repair): hydrocortisone 25 mg for 1 day</li>
<li>Moderate (e.g. cholecystectomy): 50-75 mg day of surgery and post-op day 1</li>
<li>Major (e.g. CABG): 100-150 mg daily 2-3 days (would consult endocrine in this setting)</li>
<li>Trauma, critical illness, or unclear give stress dose</li>
</ul>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-thyroid-nodules"><h1 id="endocrinology-endocrinology-thyroid-nodules-thyroid-nodules">Thyroid Nodules<a class="headerlink" href="#endocrinology-endocrinology-thyroid-nodules-thyroid-nodules" title="Permanent link">&para;</a></h1>
<p>Terra Swanson</p>
<hr />
<h2 id="endocrinology-endocrinology-thyroid-nodules-background">Background<a class="headerlink" href="#endocrinology-endocrinology-thyroid-nodules-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>~50% of adults will have a thyroid nodule on ultrasound</p>
</li>
<li>
<p>Benign: goiter, cyst, inflammatory, Hashimoto’s, follicular adenoma (microadenoma)</p>
</li>
<li>
<p>Malignant: follicular, papillary, medullary, anaplastic, metastatic, thyroid lymphoma</p>
</li>
<li>
<p>Risk factors for malignancy: age &lt;30, head or neck radiation, family history of thyroid cancer</p>
</li>
</ul>
<h2 id="endocrinology-endocrinology-thyroid-nodules-evaluation">Evaluation<a class="headerlink" href="#endocrinology-endocrinology-thyroid-nodules-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>TSH, Free T4, Thyroid U/S</li>
</ul>
<h2 id="endocrinology-endocrinology-thyroid-nodules-management">Management<a class="headerlink" href="#endocrinology-endocrinology-thyroid-nodules-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>If Low TSH: Likely a hyperfunctioning "hot" nodule (benign in 95% of cases)</p>
<ul>
<li>
<p>Order Iodine-123 or technetium-99m thyroid scan</p>
<ul>
<li>
<p>If hyperfunctioning → measure T3/free T4 if ↑, treat for hyperthyroidism</p>
</li>
<li>
<p>If non-functioning → proceed as if TSH were normal</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Normal or elevated TSH:</p>
<ul>
<li>
<p>FNA indicated based on U/S findings listed below (determined by TI-RADS system)</p>
<ul>
<li>
<p>Nodules &gt;1 cm that have high- or intermediate-suspicion pattern</p>
</li>
<li>
<p>Nodules &gt;1.5 cm that have low-suspicion pattern</p>
</li>
<li>
<p>Nodules &gt;2 cm that have very-low-suspicion pattern</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>FNA cytology determines the plan of action:</p>
<ul>
<li>
<p>Benign → periodic US monitoring at 12-24 months, then at increasing intervals</p>
</li>
<li>
<p>Indeterminate → repeat FNA in 3-12 months</p>
</li>
<li>
<p>Malignant → surgical referral</p>
</li>
</ul>
</li>
<li>
<p>Nodules that do not meet FNA criteria, US findings determine the timing for follow-up imaging:</p>
<ul>
<li>
<p>High suspicion: 6-12 months</p>
</li>
<li>
<p>Low to intermediate suspicion: 12-24 months</p>
</li>
<li>
<p>Nodules &gt;1 cm with very ↓ suspicion OR pure cyst: &gt;24 months if at all</p>
</li>
</ul>
</li>
<li>
<p>Nodules &lt;1 cm with very ↓ suspicion OR pure cyst: no further imaging necessary</p>
</li>
</ul></section><section class="print-page" id="endocrinology-endocrinology-thyroid-storm"><h1 id="endocrinology-endocrinology-thyroid-storm-thyroid-storm">Thyroid Storm<a class="headerlink" href="#endocrinology-endocrinology-thyroid-storm-thyroid-storm" title="Permanent link">&para;</a></h1>
<p>Gaby Schroeder</p>
<hr />
<h2 id="endocrinology-endocrinology-thyroid-storm-background">Background<a class="headerlink" href="#endocrinology-endocrinology-thyroid-storm-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Diagnosis is based on recognition of exaggerated signs/symptoms of thyrotoxicosis leading to multi-organ dysfunction in the setting of precipitating event</p>
</li>
<li>
<p>Common Precipitants: Grave’s Disease, surgery, trauma, pregnancy, stress, infection, MI/PE, medication non-compliance, iodine loads</p>
</li>
<li>
<p>Use Burch-Wartofsky Point Scale (BWPS); available on MD Calc</p>
<ul>
<li>
<p>> 45: highly suggestive</p>
</li>
<li>
<p>25-44: impending storm</p>
</li>
<li>
<p>\&lt; Less than 25: unlikely to represent storm</p>
</li>
</ul>
</li>
</ul>
<h2 id="endocrinology-endocrinology-thyroid-storm-management">Management<a class="headerlink" href="#endocrinology-endocrinology-thyroid-storm-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>ENDOCRINE EMERGENCY - if suspected consult Endocrine ASAP</p>
</li>
<li>
<p>Therapies directed towards thyroid gland</p>
<ul>
<li>PTU: Preferred because it inhibits peripheral conversion of T4 -&gt; T3 as well as production of T4, 500-1000mg loading dose, followed by 250mg q4 -6 hours (PO, rectal)</li>
<li>Methimazole: q4-6 hours, dose varies (PO, rectal, IV)</li>
</ul>
</li>
<li>
<p>Therapies directed toward decreasing T4 to T3 conversion</p>
<ul>
<li>Propranolol (60-80mg PO q4)</li>
<li>Hydrocortisone (300mg x1, 100mg q8) - treats high incidence of co-existing adrenal insufficiency</li>
</ul>
</li>
<li>
<p>Cholestyramine 4g QID can be considered to reduce enteric recirculation</p>
</li>
<li>
<p>Refractory Storm: plasmapheresis and plasma exchange</p>
</li>
<li>
<p>Close hemodynamic monitoring, may need vasopressors (consider transfer to ICU)</p>
</li>
</ul></section><section class="print-page" id="endocrinology-main"><p>Inpatient Diabetes Mellitus (DM) – Will Bassett</p>
<p>Background</p>
<ul>
<li>Blood glucose (BG) goal</li>
</ul>
<!-- -->

<ul>
<li>
<p>Wards: \&lt;140 mg/dL fasting; \&lt;180 mg/dL random; increase for
    elderly, “sicker” patients</p>
</li>
<li>
<p>ICU: 140-180 mg/dL (NICE-SUGAR Trial)</p>
</li>
<li>
<p>Avoiding hypoglycemia in critically ill patients is more important
    than targeting ideal BG</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Initial orders</li>
</ul>
<!-- -->

<ul>
<li>
<p>HOLD all home oral diabetes medications (except empagliflozin in
    heart failure pts)</p>
</li>
<li>
<p>Always dose reduce home insulin (typically 50-60% of home dose for
    type 2; 80% for type 1) for changes in diet. If AKI present,
    consider reducing by more.</p>
<ul>
<li>Patients with Type 1 DM always need basal insulin, even if NPO
    or else will lead to DKA</li>
</ul>
</li>
<li>
<p>Order set “SUBCUTANEOUS INSULIN ORDER(S)”</p>
<ul>
<li>
<p>Hemoglobin A1c. Can consider if none in last 3 months and
    concern for poor outpatient control. A1c does not routinely
    affect inpatient management</p>
</li>
<li>
<p>Fingerstick blood glucose: Typically AC/HS (before meals and
    nightly)</p>
</li>
<li>
<p>Hypoglycemia management: Select all of these</p>
</li>
<li>
<p>Basal insulin:</p>
<ul>
<li>
<p>Type 2 DM, consider ↓ home dose (50-60% to home dose) as
    often inpatients have reduced PO intake and ↓ renal function</p>
</li>
<li>
<p>Type 1 DM, DO NOT hold basal insulin, and avoid ↓ \&lt; 80% of
    home dose</p>
</li>
<li>
<p>Unnecessary if no home basal insulin</p>
</li>
</ul>
</li>
<li>
<p>Insulin lispro meal: ↓ home dose by &frac12;, do not give while NPO</p>
</li>
<li>
<p>Lispro insulin correction scale: Start with Low or Medium
    sliding scale and ↑ prn</p>
</li>
</ul>
</li>
<li>
<p>Carb-controlled or carb-restricted diet</p>
</li>
</ul>
<!-- -->

<ul>
<li>Insulin adjustments</li>
</ul>
<!-- -->

<ul>
<li>
<p>If BGs persistently >200</p>
<ul>
<li>
<p>Calculate all insulin needs over 24h (basal + mealtime + sliding
    scale)</p>
<ul>
<li>
<p>Give 50% as basal and other 50% as 3 divided mealtime doses</p>
</li>
<li>
<p>E.g. 10 basal + 0 mealtime + 14 sliding scale total = 24
    units total daily = 12u basal + 4u TID with meals</p>
</li>
<li>
<p>If new to basal, safe start is 0.2 u/kg daily if normal GFR</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>If BGs \&lt; 70</p>
<ul>
<li>
<p>If overnight/AM, reduce basal insulin dose</p>
</li>
<li>
<p>If daytime/post-prandial hypoglycemia, reduce mealtime and
    sliding scale</p>
</li>
<li>
<p>Less is more! Blood glucose in the low 200s is better than the
    50s</p>
</li>
<li>
<p>If endocrine consulted for inpatient glucose management, please
    notify >24h prior to discharge if you want recommended
    discharge regimen</p>
</li>
</ul>
</li>
</ul>
<p>Steroid-induced Hyperglycemia</p>
<ul>
<li>
<p>Steroids increase insulin resistance causing elevated postprandial
    BG</p>
</li>
<li>
<p>Insulin adjustments</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Double mealtime + correction dose with leaving the basal the same</p>
</li>
<li>
<p>Modified basal bolus regimen (30% basal, 70% bolus)</p>
</li>
<li>
<p>Add NPH once daily (weight + dose based, per below*) if on daily
    prednisone</p>
<ul>
<li>
<p>Prednisone 10 mg = 0.1 u/kg NPH</p>
</li>
<li>
<p>Prednisone 20 mg = 0.2 u/kg NPH up to 0.4 u/kg daily</p>
</li>
<li>
<p>*lower dose if AKI, administer at the same time as prednisone
    dosing</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>On discharge, if steroids will be longstanding, increase home
    insulin regimen per inpatient requirements. If steroids will be
    tapered or discontinued soon after, either continue hospital regimen
    for remainder of steroid course or return to home regimen
    (hyperglycemia is better than hypoglycemia)</li>
</ul>
<p>Additional Information</p>
<ul>
<li>At the VA, NPH is formulary</li>
</ul>
<!-- -->

<ul>
<li>
<p>If a pt takes Lantus at home, this can be continued; otherwise, a
    PADR is needed.</p>
</li>
<li>
<p>NPH’s duration of action is shorter than Lantus and, in most cases,
    should be dosed q12h. The conversion is done by taking total Lantus
    dose and dividing it two doses.</p>
</li>
</ul>
<!-- -->

<ul>
<li>Tube feeds</li>
</ul>
<!-- -->

<ul>
<li>
<p>Dose regular insulin q6h (not TID AC as they don’t have distinct
    “meals”)</p>
</li>
<li>
<p>Consolidate for bolus feedings based on 24-hour insulin needs prior
    to discharge</p>
</li>
</ul>
<!-- -->

<ul>
<li>Insulin pumps</li>
</ul>
<!-- -->

<ul>
<li>
<p>If a patient has a pump and supplies, reasonably controlled BG, is
    willing and able to manage pump then s/he can keep the pump on.
    <u>This requires a Diabetes Consult.</u></p>
</li>
<li>
<p>Still order POC BG checks AC/HS for nurse to chart and fill out
    MedEx pump contract</p>
</li>
</ul>
<p>Hypoglycemia – Will Bassett</p>
<p>Background</p>
<ul>
<li>Definition: BG \&lt;70 mg/dL</li>
</ul>
<!-- -->

<ul>
<li>Generally worse outcomes than hyperglycemia</li>
</ul>
<!-- -->

<ul>
<li>
<p>Causes: infection, liver failure, iatrogenic (e.g. insulin not
    adjusted for AKI or being NPO)</p>
</li>
<li>
<p>Symptoms vary from tremor, palpitations, delirium, dizziness, AMS,
    coma</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Give PO carbohydrate load (15-20g oral glucose) if pt is alert and
    tolerates PO</p>
</li>
<li>
<p>Give IV D50 if severe (\&lt;50), or cannot take PO</p>
</li>
<li>
<p>Repeat measurements after 15 minutes and treat again as needed</p>
</li>
<li>
<p>Give glucagon 0.5-1mg SQ/IM if no IV access and impaired
    consciousness</p>
</li>
</ul>
<!-- -->

<ul>
<li>Effect is transient and IV access should be obtained ASAP for
    glucose infusion</li>
</ul>
<!-- -->

<ul>
<li>Do NOT hold basal insulin for T1DM: treat the low, then reduce dose
    if needed</li>
</ul>
<p>Diabetic Ketoacidosis (DKA) – Will Bassett, Matthew Gonzalez</p>
<p>Background</p>
<ul>
<li>
<p>Classically in type 1 diabetes but can also occur in
    insulin-dependent type 2 diabetes</p>
</li>
<li>
<p>Definition: ↑ blood glucose (typically >350) w/ high anion gap and
    ketones in blood/urine</p>
</li>
<li>
<p>If glucose is significantly elevated but little to no ketones/anion
    gap present, you likely have HHS, which is typically associated with
    ↑ serum osm and BG > 600</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Labs: BMP with anion gap (AG), CBC, phos, blood gas, serum osms, UA,
    consider beta-hydroxybutyrate</p>
</li>
<li>
<p>Workup aimed at discovering the underlying cause (The "I’s"):</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Infection/ Inflammation: CBC, CXR, UA/UCx, LFTs; consider BCx,
    lipase (pancreatitis). Note: Leukocytosis will be present in DKA,
    even if infection isn’t the precipitating factor</p>
</li>
<li>
<p>Ischemia (MI, CVA, mesenteric ischemia): EKG, Troponin, CT(A) if
    clinical suspicion</p>
</li>
<li>
<p>Intoxication - Ethanol (can cause ketosis with or without acidosis),
    cocaine, MDMA</p>
</li>
<li>
<p>Impregnation - Beta HCG if appropriate</p>
</li>
<li>
<p>Insulin-openia/Iatrogenic: steroids, SGLT2 inhibitors, other meds,
    insulin delivery failure (pump failure, insulin degraded by heat,
    etc.)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Remember to correct sodium for hyperglycemia (Na + 2.4 mEq *
    (BG-100))</li>
</ul>
<p>Management</p>
<ul>
<li>Initial monitoring: q2-4h BMPs (monitor K closely), q1h BG
    fingersticks</li>
</ul>
<!-- -->

<ul>
<li>Can space less frequently once gap is closed x 2 and patient off
    insulin infusion</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ensure IV access</p>
</li>
<li>
<p>Start IV fluids, insulin, and potassium as below</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Start insulin gtt</p>
</li>
<li>
<p>Start subcutaneous long-acting insulin as soon as insulin drip/IV
    insulin is started</p>
<ul>
<li>Either start home long-acting (dose reduce as needed) or if
    insulin naïve, lantus 0.2-0.3u/kg/day</li>
</ul>
</li>
<li>
<p>Lactated ringers’ preferred fluid if no contraindication</p>
</li>
<li>
<p>Dextrose should be added when BG \&lt;200 (or clear liquid diet)</p>
</li>
<li>
<p>Turn off insulin drip when anion gap is closed on two consecutive
    BMPs</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consult endocrinology early</p>
</li>
<li>
<p>Management algorithm on next page (Diabetes Care. 2009 Jul; 32(7):
    1335–1343)</p>
</li>
<li>
<p>Note: pts are usually deficient in total body potassium even if
    their serum potassium is high</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>Pts on insulin drip can be admitted to stepdown (8MCE) with order
    set</p>
</li>
<li>
<p>Pts can be admitted to stepdown on a subcutaneous insulin protocol
    with mild DKA with endocrinology guiding insulin management</p>
</li>
<li>
<p>Avoid ordering C-peptide if concern for new type 1 diabetes, beta
    islet cells can be "stunned" with recent hyperglycemic states and
    may be falsely low</p>
</li>
<li>
<p>SGLT2 inhibitors, are being prescribed much more often and can cause
    a euglycemic DKA, where acidosis and ketosis present but no elevated
    BG</p>
</li>
</ul>
<p><img src="../endocrinology/main/output/media/image15.jpeg"
style="width:5.30253in;height:3.57163in"
alt="A picture containing text, receipt Description automatically generated" /></p>
<p>Hypothyroidism – Griffin Bullock</p>
<p>Background</p>
<ul>
<li>Elevated TSH and low FT4 (primary hypothyroidism)</li>
</ul>
<!-- -->

<ul>
<li>Hashimoto’s (autoimmune) thyroiditis, iodine deficiency, drugs
    (amiodarone, dopamine antagonists), adrenal insufficiency, thyroid
    hormone resistance (genetic), non-thyroidal illness (recovery
    phase), post-surgery or ablation for hyperthyroidism</li>
</ul>
<!-- -->

<ul>
<li>
<p>Elevated TSH and normal FT4: subclinical hypothyroidism</p>
</li>
<li>
<p>Low-Normal TSH, low FT4: central hypothyroidism, sick euthyroid</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Often non-specific and vague: fatigue, cold intolerance, weight
    gain, constipation, dry skin, myalgia, edema menstrual
    irregularities, depression, mental dysfunction</p>
</li>
<li>
<p>Goiter, bradycardia, diastolic hypertension, delayed relaxation
    following reflex testing</p>
</li>
<li>
<p>Lab abnormalities: microcytic anemia, hypercholesterolemia,
    hyponatremia, elevated CK</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>TSH: If elevated repeat TSH and obtain T4</p>
</li>
<li>
<p>Lipid panel, CBC, BMP</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Treatment required if ↓ T4, significantly ↑ TSH (>10), or symptoms
    with any lab abnormality</p>
</li>
<li>
<p>Titrate therapy to a normal TSH (unless central hypothyroidism, then
    target free T4 levels)</p>
</li>
<li>
<p>Observation of asymptomatic pts with subclinical hypothyroidism
    (normal T4, mild ↑ TSH)</p>
</li>
<li>
<p>Treatment is with formulation of T4 (full replacement is
    approximately 1.6 mcg/kg/day)</p>
</li>
<li>
<p>Initial Dose:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Young/healthy patients: full anticipated dose</p>
</li>
<li>
<p>Older patients or patients with CAD: 25-50 mcg daily</p>
</li>
</ul>
<!-- -->

<ul>
<li>Increased doses required for: pregnancy, estrogen therapy, weight
    gain, PPI therapy, GI disorders (↓ absorption), ferrous sulfate
    therapy</li>
</ul>
<p>Additional information</p>
<ul>
<li>
<p>Pts should take Levothyroxine alone, 1 hr prior to eating to ensure
    appropriate absorption</p>
</li>
<li>
<p>Of note, missed doses can be taken along with the next dose</p>
</li>
<li>
<p>Symptoms improve in 2-3 weeks. TSH steady state requires 6 weeks</p>
</li>
<li>
<p>Dose can be titrated every 6 weeks based on TSH</p>
</li>
<li>
<p>Pregnancy: Pregnancy causes lab changes due to differing levels
    thyroid binding globulin. Use tables based on trimester to interpret
    values</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>TPO antibody testing should be conducted if abnormal as this affects
    risk of complications</p>
</li>
<li>
<p>Hypothyroid pts are at increased risk for preeclampsia, placental
    abruption, preterm labor/delivery</p>
</li>
<li>
<p>Refer to endocrine for close monitoring and adjustment to avoid
    fetal complications</p>
</li>
</ul>
<p>Thyroid Nodules – Terra Swanson</p>
<p>Background</p>
<ul>
<li>
<p>~50% of adults will have a thyroid nodule on ultrasound</p>
</li>
<li>
<p>Benign: goiter, cyst, inflammatory, Hashimoto’s, follicular adenoma
    (microadenoma)</p>
</li>
<li>
<p>Malignant: follicular, papillary, medullary, anaplastic, metastatic,
    thyroid lymphoma</p>
</li>
<li>
<p>Risk factors for malignancy: age \&lt;30, head or neck radiation,
    family history of thyroid cancer</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Initial work-up after a nodule is found (either clinically or
    incidentally on imaging)</li>
</ul>
<!-- -->

<ul>
<li>TSH, Free T4, Thyroid U/S</li>
</ul>
<p>Management</p>
<ul>
<li>If Low TSH: Likely a hyperfunctioning nodule (benign in 95% of
    cases)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Order Iodine-123 or technetium-99m thyroid scan</p>
<ul>
<li>
<p>If hyperfunctioning → measure T3/free T4 if ↑, treat for
    hyperthyroidism</p>
</li>
<li>
<p>If non-functioning → proceed as if TSH were normal</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Normal or elevated TSH:</li>
</ul>
<!-- -->

<ul>
<li>
<p>FNA indicated based on U/S findings listed below (determined by
    TI-RADS system)</p>
<ul>
<li>
<p>Nodules >1 cm that have high- or intermediate-suspicion pattern</p>
</li>
<li>
<p>Nodules >1.5 cm that have low-suspicion pattern</p>
</li>
<li>
<p>Nodules >2 cm that have very-low-suspicion pattern</p>
</li>
</ul>
</li>
<li>
<p>FNA cytology determines the plan of action:</p>
<ul>
<li>
<p>Benign → periodic US monitoring at 12-24 months, then at
    increasing intervals</p>
</li>
<li>
<p>Indeterminate → repeat FNA in 3-12 months</p>
</li>
<li>
<p>Malignant → surgical referral</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Nodules that do not meet FNA criteria, US findings determine the
    timing for follow-up imaging:</li>
</ul>
<!-- -->

<ul>
<li>
<p>High suspicion: 6-12 months</p>
</li>
<li>
<p>Low to intermediate suspicion: 12-24 months</p>
</li>
<li>
<p>Nodules >1 cm with very ↓ suspicion OR pure cyst: >24 months if at
    all</p>
</li>
</ul>
<!-- -->

<ul>
<li>Nodules \&lt;1 cm with very ↓ suspicion OR pure cyst: no further
    imaging necessary</li>
</ul>
<p>Hyperthyroidism – Griffin Bullock</p>
<p>Background</p>
<ul>
<li>
<p>Low TSH and High T4 and/or T3 (primary): Graves’ disease, Toxic
    goiter, TSH-producing adenoma, hyperemesis gravidarum, subacute
    granulomatous thyroiditis, amiodarone, radiation, excessive
    replacement, struma ovarii</p>
</li>
<li>
<p>Low TSH/Normal T4 and T3: Subclinical hyperthyroidism, central
    hypothyroidism, non-thyroidal illness, recovery from
    hyperthyroidism, pregnancy (physiologic)</p>
</li>
<li>
<p>Subclinical Hyperthyroidism: repeat testing to verify abnormality is
    not transient</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Anxiety, emotional lability, heat intolerance, tremor, palpitations,
    increased appetite, unexplained weight loss, new onset atrial
    fibrillation, myopathy, menstrual disorder, exophthalmos,
    tachycardia, pretibial myxedema, hyperreflexia, lid lag, changes to
    hair or skin</li>
</ul>
<p>Evaluation</p>
<ul>
<li>TSH, free T4, free T3 (only T3 or T4 may be elevated, though both
    often are)</li>
</ul>
<!-- -->

<ul>
<li>Biotin affects assay, causes falsely ↓ TSH and falsely ↑ FT4/FT3</li>
</ul>
<!-- -->

<ul>
<li>CBC: May have a normocytic anemia due to increased plasma volume</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Thyrotropin antibodies (Graves-specific test, not sensitive)</p>
</li>
<li>
<p>Radioiodine uptake scan if thyrotropin antibodies negative</p>
</li>
<li>
<p>Treatment: methimazole, PTU, beta blockers, radioiodine ablation,
    surgery</p>
</li>
<li>
<p>Pts should be referred to endocrinology for treatment plan based on
    work up</p>
</li>
</ul>
<p>Thyroid Storm – Gaby Schroeder</p>
<p>Background</p>
<ul>
<li>
<p>Diagnosis is based on recognition of exaggerated signs/symptoms of
    thyrotoxicosis leading to multi-organ dysfunction in the setting of
    precipitating event</p>
</li>
<li>
<p>Common Precipitants: Grave’s Disease, surgery, trauma, pregnancy,
    stress, infection, MI/PE, medication non-compliance, iodine loads</p>
</li>
<li>
<p>Use Burch-Wartofsky Point Scale (BWPS); available on MD Calc</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>>45 highly suggestive</p>
</li>
<li>
<p>25-44 impending storm</p>
</li>
<li>
<p>\&lt;25 unlikely to represent storm</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>ENDOCRINE EMERGENCY - if suspected consult Endocrine ASAP</p>
</li>
<li>
<p>Therapies directed towards thyroid gland</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>PTU: Preferred, 500-1000mg loading dose, followed by 250mg q4 -6
    hours (PO, rectal)</p>
</li>
<li>
<p>Methimazole: q4-6 hours, dose varies (PO, rectal, IV)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Therapies directed toward decreasing T4 to T3 conversion</li>
</ul>
<!-- -->

<ul>
<li>
<p>Propranolol (60-80mg PO q4)</p>
</li>
<li>
<p>Hydrocortisone (300mg x1, 100mg q8) - treats high incidence of
    co-existing adrenal insufficiency</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cholestyramine 4g QID can be considered to reduce enteric
    recirculation</p>
</li>
<li>
<p>Refractory Storm: plasmapheresis and plasma exchange</p>
</li>
<li>
<p>Close hemodynamic monitoring, may need vasopressors (consider
    transfer to ICU)</p>
</li>
</ul>
<p>Adrenal Insufficiency – Griffin Bullock</p>
<p>Background</p>
<ul>
<li>Differential: Primary (Adrenals) vs Secondary (Pituitary):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Exogenous steroid use (>10 mg for >3wks) undergoing severe
    physiologic stress or sudden discontinuation of steroid</p>
</li>
<li>
<p>Autoimmune adrenal insufficiency</p>
</li>
<li>
<p>Infection/Infiltration: tuberculosis, sarcoidosis, malignancy</p>
</li>
<li>
<p>Hemorrhage (Waterhouse-Friderichsen syndrome)</p>
</li>
<li>
<p>Pituitary mass/tumor, infarct, infiltration, surgery</p>
</li>
<li>
<p>Trauma</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Generalized weakness, lightheaded, abdominal pain, nausea, weight
    loss, fatigue</p>
</li>
<li>
<p>Lab Abnormalities: hyponatremia, hyperkalemia, hypoglycemia</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Inpatient Setting</li>
</ul>
<!-- -->

<ul>
<li>
<p>Draw AM cortisol and ACTH (ideally 8am) 0.25mg cosyntropin cortisol
    1 hour after</p>
<ul>
<li>Cortisol level ≥18-20 rules out primary adrenal insufficiency
    (and most secondary)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Outpatient Setting</li>
</ul>
<!-- -->

<ul>
<li>
<p>Draw AM cortisol level for screening (>15 rules typically rules out
    adrenal insufficiency)</p>
</li>
<li>
<p>ACTH stimulation for confirmation</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Consult endocrine if ACTH stimulation test is abnormal</p>
</li>
<li>
<p>Adrenal crisis (if concerned, treat first, test later)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>BMP, glucose monitoring, ACTH level, serum cortisol</p>
</li>
<li>
<p>Fluid resuscitation: NS or D5NS. Do not use hypotonic saline.</p>
</li>
<li>
<p>Hydrocortisone 100mg x1 followed by 50mg q8h</p>
</li>
</ul>
<p>Stress Dose Steroids – Griffin Bullock</p>
<p>Primary Options</p>
<ul>
<li>
<p>Dexamethasone 4 mg IV: does not affect cortisol assays, ideal if
    diagnosis uncertain</p>
</li>
<li>
<p>Hydrocortisone 100 mg IV bolus then 50 mg q8h until stable: greater
    mineralocorticoid activity. Ideal if adrenal insufficiency
    known/confirmed or if hyperkalemic (K>6.0)</p>
</li>
</ul>
<p>When to Use</p>
<ul>
<li>
<p>Concern for adrenal crisis</p>
</li>
<li>
<p>Patients with known adrenal insufficiency:</p>
</li>
</ul>
<!-- -->

<ul>
<li>Minor Illness: ↑ dose x3 for 3 d or until clinically improved &amp;
    acute stress resolved</li>
</ul>
<!-- -->

<ul>
<li>Surgery: dependent on severity of operation</li>
</ul>
<!-- -->

<ul>
<li>
<p>Minor (e.g. hernia repair): hydrocortisone 25 mg for 1 day</p>
</li>
<li>
<p>Moderate (e.g. cholecystectomy): 50-75 mg day of surgery and post-op
    day 1</p>
</li>
<li>
<p>Major (e.g. CABG): 100-150 mg daily 2-3 days (would consult
    endocrine in this setting)</p>
</li>
<li>
<p>Trauma, critical illness, or unclear give stress dose</p>
</li>
</ul>
<p>Steroid Conversion Chart – Neil Phillips</p>
<table>
<colgroup>
<col style="width: 29%" />
<col style="width: 20%" />
<col style="width: 33%" />
<col style="width: 16%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug Name</th>
<th>Equivalent doses (mg)</th>
<th>Anti-inflammatory activity relative to hydrocortisone</th>
<th><p>Duration of</p>
<p>action (hrs)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Hydrocortisone (cortisol)</td>
<td>20</td>
<td>1</td>
<td>8 to 12</td>
</tr>
<tr class="even">
<td>Cortisone acetate</td>
<td>25</td>
<td>0.8</td>
<td>8 to 12</td>
</tr>
<tr class="odd">
<td>Prednisone</td>
<td>5</td>
<td>4</td>
<td>12 to 36</td>
</tr>
<tr class="even">
<td>Prednisolone</td>
<td>5</td>
<td>4</td>
<td>12 to 36</td>
</tr>
<tr class="odd">
<td>Methylprednisolone</td>
<td>4</td>
<td>5</td>
<td>12 to 36</td>
</tr>
<tr class="even">
<td>Triamcinolone</td>
<td>4</td>
<td>5</td>
<td>12 to 36</td>
</tr>
<tr class="odd">
<td>Dexamethasone</td>
<td>0.75</td>
<td>30</td>
<td>36 to 72</td>
</tr>
<tr class="even">
<td>Betamethasone</td>
<td>0.6</td>
<td>30</td>
<td>36 to 72</td>
</tr>
</tbody>
</table>

<p>Severe Hypertriglyceridemia (HTG) – Chloe de Crecy</p>
<p>Background</p>
<ul>
<li>Elevated triglycerides (TG) on a <u>fasting</u> lipid panel</li>
</ul>
<!-- -->

<ul>
<li>
<p>Normal: \&lt;150 mg/dL</p>
</li>
<li>
<p>Moderate HTG: 150-499 mg/dL</p>
</li>
<li>
<p>Moderate to severe HTG: 500-999 mg/dL</p>
</li>
<li>
<p>Severe HTG: >1000 mg/dL</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nearly all patients with severe HTG have a genetic predisposition
    and an additional factor known to raise serum TGs (e.g. diabetes,
    alcohol abuse, oral estrogen therapy, hypothyroidism, nephrotic
    syndrome, propofol, ART)</p>
</li>
<li>
<p>Risks of hypertriglyceridemia: pancreatitis (requires serum TG >500
    mg/dL), ASCVD</p>
</li>
<li>
<p>Signs: xanthomas, hepatosplenomegaly, lipemia retinalis, milky
    appearance of plasma</p>
</li>
<li>
<p>Symptoms: short-term memory loss, abdominal pain, flushing with
    alcohol</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Order lipid panel for: usual outpatient screening, acute
    pancreatitis, cutaneous xanthomas, family members with familial HTG,
    monitoring HTG treatment</p>
</li>
<li>
<p>Note: Sodium, glucose, amylase, LDL readings can be affected by HTG</p>
</li>
<li>
<p>Consider sending A1c, Cr, TSH</p>
</li>
<li>
<p>Assess medication list for secondary causes</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>HTG induced pancreatitis</li>
</ul>
<!-- -->

<ul>
<li>
<p>If pt has hypocalcemia, lactic acidosis, or multi-organ dysfunction</p>
<ul>
<li>
<p>Initiate plasmapheresis and monitor serum TG after each cycle
    until \&lt;500</p>
</li>
<li>
<p>Severe dietary fat restriction (\&lt;5%) until TG \&lt;1000</p>
</li>
</ul>
</li>
<li>
<p>If none of the above and pt is hyperglycemic</p>
<ul>
<li>
<p>Start insulin gtt, IVF, monitor q1h BG and q12h TG</p>
</li>
<li>
<p>Discontinue insulin when serum TG \&lt;500</p>
</li>
<li>
<p>Severe dietary fat restriction (\&lt;5%) until TG \&lt;1000</p>
</li>
</ul>
</li>
<li>
<p>If none of the above and patient is euglycemic</p>
<ul>
<li>
<p>Monitor q12h TG until \&lt;500</p>
</li>
<li>
<p>Severe dietary fat restriction (\&lt;5%) until TG \&lt;1000</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Long-term Management (once TG \&lt;1000, otherwise decreased efficacy)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pharmacologic: fibrates (most commonly fenofibrate), statins,
    niacin, omega-3 fatty acids</p>
</li>
<li>
<p>Nonpharmacologic: discontinue alcohol use, dietary fat and sugar
    restriction (target fat intake at \&lt;10% of calorie intake), exercise</p>
</li>
</ul>
<p>Adrenal Incidentalomas – Matthew Gonzalez</p>
<p>Background</p>
<ul>
<li>
<p>Adrenal mass >1cm, discovered by chance on radiographic imaging</p>
</li>
<li>
<p>Less than 1% are malignant</p>
</li>
<li>
<p>Supportive of benign: \&lt;4 cm in size, smooth borders, homogenous
    appearance, \&lt;10 HU (Hounsfield units), rapid contrast washout (on
    "adrenal phase" imaging)</p>
</li>
<li>
<p>Supportive of malignancy: >4 cm in size, irregular borders, > 20
    HU on unenhanced CT, delayed contrast washout, tumor calcifications,
    increase in size over time, presence in young pts and hx cancer</p>
<p>Evaluation</p>
</li>
<li>
<p>All incidentalomas should be screened for pheochromocytoma (~3%
    incidence) before operative intervention (24-hour urine fractionated
    metanephrines, catecholamines, plasma fractionated metanephrines)</p>
</li>
<li>
<p>Cortisol secreting adenoma (~6% incidence) causing Cushing's
    syndrome: baseline serum DHEAS, low dose (1mg) overnight
    dexamethasone suppression test</p>
</li>
<li>
<p>Aldosterone secreting adenoma (\&lt;1% incidence) causing
    hyperaldosteronism: if hypertensive (HTN) or hypokalemic order
    plasma aldosterone and renin, confirmatory testing with sodium
    loading (oral vs IV) and 24-hour urine aldosterone, sodium, and
    creatinine</p>
<p>Management</p>
</li>
<li>
<p>If benign appearing and not hormone producing: interval imaging in
    ~1 year, and repeat hormone work up</p>
</li>
<li>
<p>Unilateral adrenal incidentaloma</p>
</li>
</ul>
<!-- -->

<ul>
<li>If progression free (stable size, and not hormone producing) can
    consider monitoring cessation after 4 years</li>
</ul>
<!-- -->

<ul>
<li>Pheochromocytomas should undergo surgical evaluation for removal</li>
</ul>
<!-- -->

<ul>
<li>Alpha blockade (phenoxybenzamine) + propranolol prior to resection
    to avoid HTN crisis</li>
</ul>
<!-- -->

<ul>
<li>
<p>Aldosteronoma: should undergo surgical evaluation for definitive
    treatment; if unable to undergo surgery can use mineralocorticoid
    antagonist (e.g. spironolactone)</p>
</li>
<li>
<p>Cortisoloma: if clinically significant should undergo surgical
    removal, will need perioperative glucocorticoid administration to
    avoid iatrogenic adrenal insufficiency</p>
</li>
<li>
<p>Macroadenomas (masses >4 cm) are usually malignant and should be
    considered for surgical resection due to higher risk of carcinoma</p>
</li>
<li>
<p>Bilateral adrenal incidentalomas</p>
</li>
</ul>
<!-- -->

<ul>
<li>Surgical evaluation + will need adrenal venous sampling to confirm
    laterality in hormone producing tumors.</li>
</ul>
<p>Additional information</p>
<ul>
<li>
<p>Not all hyperaldosterone states will have both HTN and hypokalemia</p>
</li>
<li>
<p>Subclinical Cushing's syndrome may be present based on initial
    dexamethasone suppression test, perform additional testing to
    determine if clinically significant</p>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Endocrinology</h1>
                        <h1 class='nav-section-title' id='section-gastroenterology'>
                            Gastroenterology <a class='headerlink' href='#section-gastroenterology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="gastroenterology-gastroenterology-acute-abdominal-pain"><h1 id="gastroenterology-gastroenterology-acute-abdominal-pain-acute-abdominal-pain">Acute Abdominal Pain<a class="headerlink" href="#gastroenterology-gastroenterology-acute-abdominal-pain-acute-abdominal-pain" title="Permanent link">&para;</a></h1>
<p>Alex Mamunes</p>
<hr />
<h2 id="gastroenterology-gastroenterology-acute-abdominal-pain-general-approach">General Approach<a class="headerlink" href="#gastroenterology-gastroenterology-acute-abdominal-pain-general-approach" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Rule out life threatening causes: Obstruction, Perforation,
    Dissection, AAA rupture, Inferior MI, Ectopic Pregnancy</p>
</li>
<li>
<p>History: pain quality/timing/location/severity, aggravating and
    alleviating factors (eating, bowel movements, position),
    nausea/emesis, bowel changes, flatus &amp; prior episodes</p>
</li>
<li>
<p>Initial labs: CBC, BMP, LFTs, INR, lactate, lipase, U/A, urine hCG</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 15%" />
<col style="width: 25%" />
<col style="width: 34%" />
<col style="width: 24%" />
</colgroup>
<thead>
<tr class="header">
<th>System</th>
<th>Causes</th>
<th>Common features</th>
<th>Workup</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Esophagus</td>
<td>Esophagitis – GERD, EOE, candida, HSV, CMV, pill, functional</td>
<td>Epigastric pain, nocturnal reflux, odynophagia, dysphagia, thrush,
immunocompromised</td>
<td>Trial PPI, nystatin swish and swallow, consider EGD</td>
</tr>
<tr class="even">
<td rowspan="3">Stomach</td>
<td>Dyspepsia</td>
<td>Epigastric pain, indigestion, bloating</td>
<td>H. pylori testing, Trial PPI, ± EGD</td>
</tr>
<tr class="odd">
<td>Peptic ulcer disease</td>
<td>NSAID use, better or worse w/ food, ± melena</td>
<td>CBC, H. pylori testing, EGD</td>
</tr>
<tr class="even">
<td>Gastritis</td>
<td>NSAID use, ETOH abuse, burning epigastric pain</td>
<td></td>
</tr>
<tr class="odd">
<td>Liver</td>
<td>Hepatitis: Ischemic, Viral, ETOH, trauma, toxins, autoimmune,
congestive</td>
<td><p>RUQ pain ± jaundice</p>
<p>EtOH, Tylenol or IVDU</p></td>
<td>LFTs, INR, ETOH, Tylenol lvl, viral panel, RUQ U/S + dopplers;
CT</td>
</tr>
<tr class="even">
<td>Spleen</td>
<td>Splenomegaly: increased size, infarct, abscess</td>
<td>LUQ pain</td>
<td>Physical exam, CT</td>
</tr>
<tr class="odd">
<td rowspan="4">Biliary</td>
<td>Biliary colic</td>
<td><p>Overweight, ♀, 40’s, lasts hrs, worse with food,</p>
<p>RUQ pain scapula</p></td>
<td>LFTs, RUQ U/S</td>
</tr>
<tr class="even">
<td>Cholecystitis</td>
<td>RUQ pain (Murphy’s sign), nausea, emesis with fever</td>
<td></td>
</tr>
<tr class="odd">
<td>Choledocholithiasis</td>
<td>RUQ pain, N/V with jaundice</td>
<td>CBC, LFTs, RUQ U/S, blood cx</td>
</tr>
<tr class="even">
<td>Ascending cholangitis</td>
<td>RUQ pain, N/V, jaundice, fever; hypotension, AMS</td>
<td></td>
</tr>
<tr class="odd">
<td>Pancreas</td>
<td>Acute or chronic Pancreatitis; Complications (fluid, collection,
necrosis, pseudocyst)</td>
<td><p>ETOH use, gallstones, epigastric pain back, N/V</p>
<p>Chronic pancreatitis: calcifications on CT</p></td>
<td>Lipase, CT A/P (rarely necessary within 24-48 hrs), RUQ U/S for
gallstones</td>
</tr>
<tr class="even">
<td rowspan="12">Intestines</td>
<td>Gastroenteritis</td>
<td>N/V, sick contact, undercooked food, travel</td>
<td>Supportive care</td>
</tr>
<tr class="odd">
<td>Diverticulitis</td>
<td>Older, h/o diverticulosis, LLQ pain with fever</td>
<td><p>CBC (leukocytosis)</p>
<p>CT A/P w contrast</p></td>
</tr>
<tr class="even">
<td>Constipation</td>
<td>h/o IBS, narcotic use, unable to pass stool, straining</td>
<td>KUB</td>
</tr>
<tr class="odd">
<td>Bowel Obstruction/Ileus</td>
<td>Prior hernia, abd surgery or malignancy, pain, nausea, emesis,
distention inability to pass stool or flatus</td>
<td><p>KUB (air fluid levels)</p>
<p>CT is more sensitive</p>
<p>If concerned, page EGS and consider NGT to suction</p></td>
</tr>
<tr class="even">
<td>Acute Small Bowel Mesenteric Ischemia</td>
<td>Vascular disease, A-Fib, dissection, thrombosis, rapid onset,
severe, periumbilical with N/V, recent hypotensive episode,
post-prandial</td>
<td><p>CBC (leukocytosis)</p>
<p>BMP (metabolic acidosis), Lactate</p>
<p>CT A/P w contrast (CTA if suspicion)</p></td>
</tr>
<tr class="odd">
<td>Colonic non-occlusive Mesenteric Ischemia: ischemic colitis</td>
<td>Cramping pain, laterally (most often left), urge to defecate +
hematochezia</td>
<td><p>CBC, BMP, Lactate</p>
<p>CT A/P w contrast</p>
<p>+/- colonoscopy</p></td>
</tr>
<tr class="even">
<td>Appendicitis</td>
<td>Periumbilical to RLQ with N/V, later fever</td>
<td>CBC, Lactate, CT A/P w/contrast</td>
</tr>
<tr class="odd">
<td>IBD Flare</td>
<td>H/o Crohn’s or UC, Abd pain, fever, diarrhea, hematochezia</td>
<td>CBC, Lactate, CTE, ESR, CRP, C-diff, GIPP</td>
</tr>
<tr class="even">
<td>C. diff colitis</td>
<td>Antibiotic exposure, diarrhea, abdominal cramping</td>
<td><p>C-diff PCR, CBC (leukocytosis)</p>
<p>KUB (megacolon)</p></td>
</tr>
<tr class="odd">
<td>Ogilvie’s syndrome</td>
<td>Pseudo-obstruction in elderly pt, signs of obstruction w/o
mechanical cause</td>
<td>CBC, lactate, CT A/P w contrast</td>
</tr>
<tr class="even">
<td>Volvulus</td>
<td>Progressive abdominal pain, nausea, distention, constipation,
vomiting</td>
<td><p>CBC, lactate</p>
<p>CT A/P w contrast</p></td>
</tr>
<tr class="odd">
<td>Typhlitis</td>
<td>Neutropenia, abdominal pain (often RLQ), fever</td>
<td><p>CBC with diff, CT A/P w/ contrast, blood cx, C-diff;</p>
<p>empiric abx</p></td>
</tr>
<tr class="even">
<td rowspan="3">OBGYN</td>
<td>Ectopic pregnancy</td>
<td>Sexually active, 6-7 wks after LMP, RLQ or LLQ pain + vaginal
bleeding</td>
<td>Urine hCG, pelvic US, CBC, T&amp;S</td>
</tr>
<tr class="odd">
<td><p>Pelvic inflammatory disease, endometritis,</p>
<p>Tubo-ovarian abscess</p></td>
<td>Sexually active, h/o STI, purulent discharge, cervical motion
tenderness, ± fever</td>
<td>Pelvic exam w/ culture, GC probe, pelvic US</td>
</tr>
<tr class="even">
<td>Ovarian torsion</td>
<td>Young, sudden onset &amp; severe, often with N/V</td>
<td>Pelvic US w/ doppler</td>
</tr>
<tr class="odd">
<td rowspan="5">Kidney</td>
<td>Nephrolithiasis</td>
<td>h/o kidney stones, Crohn’s disease, sharp flank pain, paroxysms, ±
hematuria</td>
<td>U/A, CT A/P without contrast</td>
</tr>
<tr class="even">
<td>UTI</td>
<td>Suprapubic pain, dysuria, cloudy urine, new odor</td>
<td>U/A with culture</td>
</tr>
<tr class="odd">
<td>Pyelonephritis</td>
<td>Flank pain, fever/chills, CVA tenderness, usually UTI symptoms</td>
<td><p>U/A with culture, BMP</p>
<p>CT A/P w/contrast</p></td>
</tr>
<tr class="even">
<td>Urinary Retention</td>
<td>Older pt, male with BPH, anticholinergics</td>
<td>Post-void residual</td>
</tr>
<tr class="odd">
<td>Renal infarct</td>
<td>h/o vascular disease or A-fib, acute flank pain with N/V, +/- fever,
HTN</td>
<td><p>CBC, BMP, UA, ECG (r/o a-fib)</p>
<p>CT A/P w contrast</p></td>
</tr>
<tr class="even">
<td rowspan="3">Vascular</td>
<td>Myocardial infarction</td>
<td>CAD risk factors, DoE, epigastric, diaphoresis</td>
<td>ECG, troponin</td>
</tr>
<tr class="odd">
<td>Aortic Dissection</td>
<td>Vascular Risk factors, sudden onset, tearing pain back</td>
<td>CT dissection rule out</td>
</tr>
<tr class="even">
<td>AAA rupture</td>
<td>Vascular risk factors, sudden onset back, hypotensive, pulsatile
abdominal mass</td>
<td>CT A/P w contrast, consult vascular surgery</td>
</tr>
<tr class="odd">
<td rowspan="3">MSK/skin</td>
<td>Herpes zoster</td>
<td>Immunocompromised, dermatomal rash, burning pain</td>
<td><p>Physical exam</p>
<p>Vesicle PCR for zoster</p></td>
</tr>
<tr class="even">
<td>Muscle strain</td>
<td>h/o trauma, overuse, heavy exercise, worse with twisting or
bending</td>
<td>Physical exam; rest, NSAIDs</td>
</tr>
<tr class="odd">
<td>Hernia</td>
<td>Bulge, worse w/valsalva</td>
<td>CT A/P non con</td>
</tr>
<tr class="even">
<td rowspan="2">Pulmonary</td>
<td>Pneumonia</td>
<td>Productive cough, fever</td>
<td>CXR, CBC, sputum cx</td>
</tr>
<tr class="odd">
<td>Pulmonary embolus</td>
<td>Tachycardia, tachypnea, hypoxemia</td>
<td><p>ECG, trop, BNP</p>
<p>CTA chest</p></td>
</tr>
<tr class="even">
<td>Functional</td>
<td>IBS, depression, dyspepsia, anxiety abdominal migraine,
functional</td>
<td><p>Imaging negative</p>
<p>Otherwise negative workup</p></td>
<td>Above workup</td>
</tr>
<tr class="odd">
<td rowspan="5">Other</td>
<td>Adrenal crisis</td>
<td>Hypotension, fatigue, lethargy, N/V, weight loss,
hyperpigmentation</td>
<td>BMP (↓Na, ↑K, ↓ Glu) Cort. stim</td>
</tr>
<tr class="even">
<td>Intra-abdominal abscess</td>
<td>Prior intra-abdominal disease or surgery, fever</td>
<td><p>CBC, blood cx</p>
<p>CT A/P w/ contrast</p></td>
</tr>
<tr class="odd">
<td>DKA</td>
<td>Nausea, emesis, general abdominal pain</td>
<td><p>CBC, BMP, U/A</p>
<p>β–hydroxy butyrate</p></td>
</tr>
<tr class="even">
<td>Hypercalcemia</td>
<td><p>N/V, constipation,</p>
<p>↑ thirst, ↑ urination, bone pain, muscle weakness, confusion,
fatigue</p></td>
<td>BMP, ionized calcium, PTH, Vit D, PTHrp</td>
</tr>
<tr class="odd">
<td>Acute intermittent porphyria</td>
<td>Severe, poorly localized with motor/sensory neuropathy, red urine,
tachycardia</td>
<td>Urinary PBG</td>
</tr>
</tbody>
</table></section><section class="print-page" id="gastroenterology-gastroenterology-acute-diverticulitis"><h1 id="gastroenterology-gastroenterology-acute-diverticulitis-acute-diverticulitis">Acute Diverticulitis<a class="headerlink" href="#gastroenterology-gastroenterology-acute-diverticulitis-acute-diverticulitis" title="Permanent link">&para;</a></h1>
<p>Michael Koenig</p>
<hr />
<h2 id="gastroenterology-gastroenterology-acute-diverticulitis-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-acute-diverticulitis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Inflammation and/or infection of a diverticulum, a small
    out-pouching along wall of colon</li>
<li>Presence of colonic flora on urine culture or pneumaturia suggests
    colovesical fistula</li>
<li>Most pts with uncomplicated diverticulitis have significant
    improvement 2-3 days after antibiotics</li>
</ul>
<h2 id="gastroenterology-gastroenterology-acute-diverticulitis-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-acute-diverticulitis-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Lower abdominal pain (85% LLQ), tenderness to palpation on exam,
    N/V, low-grade fever, change in bowel habits (constipation or
    diarrhea)</li>
</ul>
<h2 id="gastroenterology-gastroenterology-acute-diverticulitis-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-acute-diverticulitis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>CBC w/diff, CMP, Lipase, U/A, β - hCG</li>
<li>Imaging: CT abdomen/pelvis with oral and IV contrast</li>
<li>CT findings: localized bowel wall thickening (>4mm), paracolic fat
    stranding, presence of colonic diverticula</li>
</ul>
<h2 id="gastroenterology-gastroenterology-acute-diverticulitis-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-acute-diverticulitis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Bowel rest vs. clear liquids (advance diet as tolerated)</li>
<li>PO or IV antibiotics: should cover GNRs and anaerobic organisms</li>
<li>Zosyn, cefepime + metronidazole, or meropenem (if high risk for
    organisms w/ESBL)</li>
<li>Cipro/flagyl if PO</li>
<li>If low risk and mild disease, may not need antibiotics</li>
<li>Continue IV abx until abdominal pain/tenderness is resolved (usually
    3-5 days), then transition to oral: cipro + metronidazole or
    Augmentin to complete 10-14 d course</li>
<li>Colonoscopy after complete resolution of symptoms (6 – 8 weeks) to
    definitively rule out presence of underlying colorectal cancer
    (unless performed in last year)</li>
</ul>
<h2 id="gastroenterology-gastroenterology-acute-diverticulitis-complications">Complications<a class="headerlink" href="#gastroenterology-gastroenterology-acute-diverticulitis-complications" title="Permanent link">&para;</a></h2>
<ul>
<li>Pts who fail to improve or deteriorate require repeat imaging</li>
<li>Abscess continue antibiotics &amp; percutaneous drainage (if possible)
    for abscesses &gt; 4 cm</li>
<li>Surgery if no improvement 2-3 days after drainage</li>
<li>Obstruction: radiographic differentiation between acute
    diverticulitis and colon cancer is difficult; thus surgical
    resection of bowel is needed to relieve obstruction and rule out
    cancer</li>
<li>Fistula: Rarely heal spontaneously, require surgical correction</li>
<li>Perforation:<ul>
<li>Microperforation (contained perforation):</li>
<li>Presence of small amount of air bubbles, but no oral contrast
    outside of colon on CT</li>
<li>Most treated with IV abx and bowel rest like uncomplicated
    diverticulitis</li>
<li>Frank perforation:<ul>
<li>Intraabdominal free air, diffuse peritonitis requires emergency
    surgery</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-acute-pancreatitis"><h1 id="gastroenterology-gastroenterology-acute-pancreatitis-acute-pancreatitis">Acute Pancreatitis<a class="headerlink" href="#gastroenterology-gastroenterology-acute-pancreatitis-acute-pancreatitis" title="Permanent link">&para;</a></h1>
<p>Alex Wiles</p>
<hr />
<h2 id="gastroenterology-gastroenterology-acute-pancreatitis-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-acute-pancreatitis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Common causes: Gallstones (40%), EtOH (30%)</li>
<li>Other causes: post-ERCP, pancreatic cancer/obstruction, blunt
    abdominal trauma, hypertriglyceridemia (TG &gt;1000), hypercalcemia,
    drugs (thiazides, protease inhibitors, azathioprine, 6MP), mumps,
    Coxsackie, vasculitis, pregnancy, genetic (PRSS1, SPINK1, CFTR),
    autoimmune (IgG4), scorpion venom</li>
<li>Several scoring systems:<ul>
<li>BISAP (BUN &gt;25, Impaired mental status, SIRS, Age &gt;60, Pleural
effusion)<ul>
<li>0–2 Mortality &lt;2%; 3-5 Mortality &gt;15%</li>
</ul>
</li>
<li>APACHE II (MD Calc, several factors)<ul>
<li>0–8 Mortality &lt;4%; &gt; 8 Mortality 11–18%</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-acute-pancreatitis-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-acute-pancreatitis-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Must have 2 out of the three:<ul>
<li>Pain characteristic of pancreatitis (sharp, epigastric, radiating to
back)</li>
<li>Imaging characteristic of pancreatitis (US, CT, MRI)</li>
<li>Enzymes (lipase or amylase) >3x ULN (use lipase, much more
specific)</li>
<li>*If pain is characteristic and lipase &gt; 3x ULN, no need for CT A/P</li>
</ul>
</li>
<li>Grading Severity:<ul>
<li>Mild: no organ failure or systemic complications</li>
<li>Moderate: transient organ failure (&lt;48 hours)</li>
<li>Severe: persistent organ failure (&gt;48 hours)</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-acute-pancreatitis-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-acute-pancreatitis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Lipase, CBC, CMP, lipid panel, lactate, direct bilirubin</li>
<li>Obtain RUQ U/S for all pts, evaluates for gallstones</li>
<li>CT A/P w/ IV contrast if indicated<ul>
<li>Reserved for patients not improving at 48-72 hour to assess for
complications</li>
<li>If performed at onset, underestimates severity (necrosis takes 72
hours from onset)</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-acute-pancreatitis-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-acute-pancreatitis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Fluids, Fluids, Fluids:<ul>
<li>First 12-24 hrs: IVF at 200 to 500 cc/hr, or 5-10 cc/kg / hr (2.5 –<blockquote>
<p>4 L within first 24 hrs)</p>
</blockquote>
</li>
<li>Follow HCT and BUN as markers for successful fluid resuscitation</li>
<li>Aggressive IVF in first 24 hours reduces both morbidity and
mortality</li>
<li>Persistent hemoconcentration at 24 hr is associated with necrotizing
pancreatitis</li>
</ul>
</li>
<li>Pain Control:<ul>
<li>Common starting narcotic regimen is oxycodone 10 mg q6h PRN and
hydromorphone 0.5 mg q4h for breakthrough</li>
</ul>
</li>
<li>Nutrition:<ul>
<li>NPO but start PO diet as soon as patient can tolerate (even within
24 hours)</li>
<li>Clear liquid diet or mechanical soft and advance as tolerated</li>
<li>Low fat diet (Fatty acids → CCK → trypsinogen to trypsin)</li>
<li>If NPO &gt; 72 hours, attempt PO and if fail, place Dobhoff for
enteral nutrition at latest by day five… outcomes with NG/NJ &gt;&gt;&gt;
TPN</li>
</ul>
</li>
<li>Antibiotics:<ul>
<li>Fever, leukocytosis common, not an indication for ABX as the
necrosis is sterile</li>
<li>Infection of the necrosis should be suspected with failure to
improve 7 days after onset</li>
<li>Cefepime + Flagyl or carbapenem</li>
</ul>
</li>
<li>EUS or IR guided drain for aspirate: can be done on immature
    collections for diagnostic purposes but typically only done if
    collection is walled-off—at least 4 weeks</li>
<li>Endoscopic Intervention (cystogastrostomy) has emerged as first-line
    therapy for symptomatic pseudocysts or walled-off pancreatic
    necrosis , with step-up therapy to video assisted retroperitoneal
    debridement (VARD) or surgery when needed</li>
</ul>
<h2 id="gastroenterology-gastroenterology-acute-pancreatitis-additional-information">Additional Information<a class="headerlink" href="#gastroenterology-gastroenterology-acute-pancreatitis-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>If choledocholithiasis on Imaging urgent ERCP for patients with
    cholangitis or obstructive jaundice, otherwise elective ERCP</li>
<li>If Intermediate probability for choledocholithiasis MRCP or EUS or
    (for patients requiring cholecystectomy Intraoperative cholangiogram</li>
<li>If biliary sludge but no stones on U/S, still consider
    cholecystectomy (likely microlithiasis)</li>
<li>Complications:<ul>
<li>ARDS, abdominal compartment syndrome, AKI, DIC</li>
<li>&lt; 4 weeks after pancreatitis: Peripancreatic fluid collection,
acute necrotic collection</li>
<li>
<blockquote>
<p>6 weeks after pancreatitis: Pancreatic pseudocyst, walled-off
necrosis (WON)</p>
</blockquote>
</li>
</ul>
</li>
<li>Most fluid collections should be followed over time as acute
    collections can resolve and are unable to be sampled safely with EUS</li>
<li>Gallstone pancreatitis:<ul>
<li>All pts should have cholecystectomy once recovered (recurrence is
25-30%) with EGS</li>
<li>Performed during initial admission in cases of mild acute
pancreatitis</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-biliary-disease"><h1 id="gastroenterology-gastroenterology-biliary-disease-biliary-disease">Biliary Disease<a class="headerlink" href="#gastroenterology-gastroenterology-biliary-disease-biliary-disease" title="Permanent link">&para;</a></h1>
<p>Alex Wiles, Anton de Witte</p>
<hr />
<h2 id="gastroenterology-gastroenterology-biliary-disease-pearls">Pearls<a class="headerlink" href="#gastroenterology-gastroenterology-biliary-disease-pearls" title="Permanent link">&para;</a></h2>
<ul>
<li>ERCP is not available at VA: requires fee-basis consult to VUMC,
    contact GI to arrange</li>
<li>Prior cholecystectomy CBD normally dilates to 10 mm, not pathologic</li>
<li>Pneumobilia generally indicates performance of prior biliary
    sphincterotomy and/or biliary stent</li>
<li>CBD dilation classically > 6mm, but CBD dilates with age: 70 yo
    7mm, 80 yo 8mm; opiates can also cause biliary dilatation</li>
</ul>
<h2 id="gastroenterology-gastroenterology-biliary-disease-biliary-colic">Biliary Colic<a class="headerlink" href="#gastroenterology-gastroenterology-biliary-disease-biliary-colic" title="Permanent link">&para;</a></h2>
<ul>
<li>Transient biliary obstruction typically at the GB neck without GB
    inflammation (no fever)</li>
<li>Presentation: Constant (not colicky) intense, dull RUQ pain and N/V
    for 30 minutes to 6 hours, then resolves, provoked by fatty foods
    (CCK), absent Murphy’s sign</li>
<li>Biliary colic generally consists of discrete episodes separated by
    weeks to months, and not daily pain</li>
<li>Evaluation: Normal (CBC, LFTs, Lipase, Lactate)</li>
<li>Imaging: RUQ U/S: cholelithiasis (stones in GB)</li>
<li>Management: Elective cholecystectomy as outpatient</li>
</ul>
<h2 id="gastroenterology-gastroenterology-biliary-disease-acute-calculous-cholecystitis">Acute Calculous Cholecystitis<a class="headerlink" href="#gastroenterology-gastroenterology-biliary-disease-acute-calculous-cholecystitis" title="Permanent link">&para;</a></h2>
<ul>
<li>Inflammation of the GB from an obstructing stone in the GB neck or
    cystic duct</li>
<li>Ddx: PUD, pancreatitis, choledocholithiasis, ascending cholangitis,
    IBD, Fitz-Hugh Curtis</li>
<li>Presentation: Severe constant RUQ pain, fever/chills, N/V, + Murphy
    sign</li>
<li>Evaluation: CBC (leukocytosis), CMP (mild AST/ALT ↑), Lipase,
    Lactate, BCx x2</li>
<li>Imaging: RUQ U/S: gallstones + GB wall thickening or pericholecystic
    edema<ul>
<li>If U/S non-diagnostic (no stones or GB inflammation) HIDA Scan (lack
of GB filling)</li>
</ul>
</li>
<li>Management<ul>
<li>NPO, IVF, IV Abx until resolved or surgical removal</li>
<li>Urgent Cholecystectomy (&lt;72H) with EGS;</li>
<li>If poor surgical candidate: Cholecystostomy with IR; endoscopic
drainage options for selected patients (i.e. poor surgical
candidates also with ascites)</li>
</ul>
</li>
<li>Complications: gangrenous cholecystitis, perforation, emphysematous
    cholecystitis, chole-cysto-enteric fistula, gallstone ileus</li>
</ul>
<h2 id="gastroenterology-gastroenterology-biliary-disease-acute-acalculous-cholecystitis">Acute Acalculous Cholecystitis<a class="headerlink" href="#gastroenterology-gastroenterology-biliary-disease-acute-acalculous-cholecystitis" title="Permanent link">&para;</a></h2>
<ul>
<li>Inflammation of the GB without obstructing stone (due to stasis and
    ischemia)</li>
<li>Presentation: Seen in critically ill/ICU pts; similar history as
    above; may present as unexplained fever or RUQ mass (rarely
    jaundice)</li>
<li>Ddx: calculous cholecystitis, pancreatitis, hepatic abscess</li>
<li>Evaluation: Same as acute calculous cholecystitis</li>
<li>Imaging: GB wall thickening, pericholecystic edema, intramural gas,
    GB distention</li>
<li>Management<ul>
<li>Supportive care, antibiotics, GB drainage</li>
<li>IVF, correct electrolyte abnormalities, NPO</li>
<li>Broad spectrum antibiotic coverage</li>
<li>Place CT-guided procedure consult for cholecystostomy placement vs
Endoscopic drainage (transpapillary cystic duct stent via ERCP or
cholecystoduodenostomy by EUS)</li>
<li>Consult EGS if necrosis, perforation, or emphysematous changes
present</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-biliary-disease-choledocholithiasis">Choledocholithiasis<a class="headerlink" href="#gastroenterology-gastroenterology-biliary-disease-choledocholithiasis" title="Permanent link">&para;</a></h2>
<ul>
<li>Obstruction of biliary outflow by CBD stone without inflammation (no
    fever)</li>
<li>Impacted cystic duct stone (cholecystitis) with compression of the
    CBD (Mirizzi syndrome)</li>
<li>Presentation: RUQ pain (can be painless), N/V and jaundice</li>
<li>Evaluation:<ul>
<li>CMP and D-bili (Bili/ALP/ GGT ↑↑↑, AST/ALT mild ↑), CBC
(Leukocytosis suggests cholangitis), Lipase</li>
<li>Imaging: RUQ U/S: dilated CBD (ULN is 6mm) MRCP/EUS vs ERCP (see
below)<ul>
<li>MRCP preferred given non-invasive but has lower sensitivity for
smaller stones (consider EUS if still have suspicion despite
negative MRCP or if patient contraindication to/intolerance of MRI)</li>
</ul>
</li>
</ul>
</li>
<li>Management:<ul>
<li>NPO &amp; IVF, pain control PRN</li>
<li>Stratify risk to determine whether to pursue MRCP (noninvasive,
diagnostic) vs ERCP</li>
<li>If any one of the following, patient is HIGH risk consult GI for<blockquote>
<p>ERCP + EGS to consider cholecystectomy</p>
</blockquote>
<ul>
<li>CBD stone on imaging</li>
<li>Acute cholangitis</li>
<li>Tbili &gt; 4 AND dilated CBD (&gt;6mm with GB, &gt; 8mm without GB)</li>
</ul>
</li>
<li>If any one of the following, patient is INTERMEDIATE risk consider
    MRCP (or EUS or cholecystectomy with intraoperative cholangiogram)<ul>
<li>Abnormal liver enzymes</li>
<li>Age &gt; 55</li>
<li>Dilated CBD on U/S with Tbili &lt; 4</li>
<li>If CBD stone seen on MRCP or EUS ERCP,</li>
<li>If no CBD stone but patient has GB sludge or cholelithiasis EGS
    consult for cholecystectomy + intraoperative cholangiogram</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-biliary-disease-acute-cholangitis">Acute Cholangitis<a class="headerlink" href="#gastroenterology-gastroenterology-biliary-disease-acute-cholangitis" title="Permanent link">&para;</a></h2>
<ul>
<li>Bacterial infection of biliary tract 2/2 obstruction (typically
    stones) or prior instrumentation (ERCP)</li>
<li>Pts with malignant obstruction typically do not develop cholangitis</li>
<li>Presentation: Charcot triad (RUQ pain, fever, jaundice); Reynolds’
    Pentad (AMS, Hypotension)</li>
<li>Evaluation<ul>
<li>CBC, CMP (D bili, ALP ↑↑↑) Blood Cultures, Lipase,
Lactate</li>
<li>CRP, AST/ALT can be ↑↑ as well</li>
<li>Imaging: RUQ U/S: dilated CBD (ULN is 6mm), no need for MRCP/EUS</li>
<li>Consider MRCP overnight if ERCP is not being done emergently</li>
</ul>
</li>
<li>Management<ul>
<li>NPO, IVF</li>
<li>Consult GI for urgent/emergent ERCP (generally within 24 hr)</li>
<li>If ERCP not feasible or fails to establish biliary drainage, can
consider EUS-guided biliary drainage, percutaneous transhepatic
cholangiography, or surgical decompression</li>
<li>Antibiotics for Biliary Disease (IDSA Guidelines):<ul>
<li>Mild to moderate acute cholecystitis (stable):</li>
<li>Ceftriaxone 2g daily, Cefazolin 1-2g q8H</li>
</ul>
</li>
<li>Cholangitis or Severe acute cholecystitis (unstable or
immunocompromised):<ul>
<li>Zosyn 3.375g q8H, Meropenem 1g q8H or Cipro 500 q12H and Flagyl
500 q8H</li>
</ul>
</li>
<li>Healthcare-associated Biliary infections: consider Vancomycin
    (order w/ PK consult)</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-c-diff"><h1 id="gastroenterology-gastroenterology-c-diff-clostridioides-difficile-infections">Clostridioides Difficile Infections<a class="headerlink" href="#gastroenterology-gastroenterology-c-diff-clostridioides-difficile-infections" title="Permanent link">&para;</a></h1>
<p>Anton de Witte</p>
<hr />
<h2 id="gastroenterology-gastroenterology-c-diff-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-c-diff-background" title="Permanent link">&para;</a></h2>
<ul>
<li><em>Clostridioides difficile</em> is the causative bacteria for
    antibiotic-associated colitis</li>
<li>Always consider C. diff in a hospitalized patient with unexplained
    leukocytosis</li>
<li>Microbiology: Anaerobic gram-positive, spore-forming,
    toxin-producing bacillus</li>
<li>Outside colon, exists in spore form – resistant to heat, acid, and
    antibiotics (why we must wash our hands)</li>
<li>Spores are transferred from environment to person, once in intestine
    convert to functional vegetative, toxin-producing forms susceptible
    to antibiotics</li>
<li>To be pathogenic, must release toxin (A+B) to cause colitis and
    diarrhea</li>
<li>Risk Factors: Antibiotic use (during use or typically up to 1 month
    after use), age >65, hospitalization, enteral feeding, obesity,
    stem cell transplant, chemo, IBD, cirrhosis, &plusmn; PPI use (no clear
    causal relationship)</li>
</ul>
<h2 id="gastroenterology-gastroenterology-c-diff-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-c-diff-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Spectrum from asymptomatic carrier to fulminant colitis with toxic
    megacolon</li>
<li>Asymptomatic carrier: 20% of hospitalized patients (50% of adults in
    long term care facilities)</li>
<li>Non-severe disease: watery diarrhea (&gt;3 unformed stools in 24
    hours), lower abdominal pain, nausea, ± fever, leukocytosis (WBC
    &gt;15,000)</li>
<li>Severe disease: diarrhea, diffuse abdominal pain, abdominal
    distention, fever, lactic acidosis, AKI (Cr &gt; 1.5), marked
    leukocytosis (sometimes &gt;40,000)</li>
<li>Fulminant disease: Severe criteria + hypotension/shock, ileus
    (rare), or megacolon (&gt;7cm colon diameter and/or &gt;12cm cecum
    diameter)</li>
<li>Recurrent disease (relapse &gt; reinfection): resolution of symptoms
    on therapy followed by reappearance of symptoms within 2-8 weeks
    after stopping therapy; (Up to 25% of patients have recurrence)</li>
<li>If symptoms never resolve, consider refractory C. diff or
    alternative diagnosis</li>
</ul>
<h2 id="gastroenterology-gastroenterology-c-diff-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-c-diff-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Stool PCR for toxigenic strains (very sensitive, can detect
    asymptomatic carriers w/o toxin production); with reflex EIA (enzyme
    immunoassay) for toxins A and B (specificity of 99%)<ul>
<li>PCR (+)/Toxin (-) = carrier</li>
<li>PCR (+)/Toxin (+) = treat</li>
<li>PCR (-) = no treatment</li>
</ul>
</li>
<li>Imaging<ul>
<li>Nonsevere disease: no imaging necessary</li>
<li>Severe or fulminant disease: CT a/p with oral and IV contrast</li>
</ul>
</li>
<li>Endoscopy: Typically used when alternative diagnosis is suspected;
    not warranted for classical symptoms, positive laboratory tests, or
    clinical response to treatment</li>
</ul>
<h2 id="gastroenterology-gastroenterology-c-diff-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-c-diff-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Contact precautions until at least 48 hours after diarrhea resolves</li>
<li>Classify patient disease severity to guide treatment algorithm</li>
<li>Do not repeat stool testing – 50% remain positive after treatment up
    to 6 weeks later</li>
</ul>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 74%" />
</colgroup>
<thead>
<tr class="header">
<th>Clinical Condition</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td colspan="2"><strong>Non-fulminant disease</strong></td>
</tr>
<tr class="even">
<td>Initial episode (non-severe or severe)</td>
<td><p>-<u>First line</u>: PO Vancomycin 125mg QID x 10 days OR PO
Fidaxomicin 200mg BID x 10 days</p>
<p>-<u>Second line</u>: (only for non-severe disease in low-risk
patients): PO Metronidazole 500mg TID x 10-14 days</p></td>
</tr>
<tr class="odd">
<td>Recurrent episode</td>
<td><p>Consult GI</p>
<p>First Recurrence:</p>
<p>-<u>First line</u>: PO Fidaxomicin 200mg BID x 10 days</p>
<p>-<u>Second line</u>: Vancomycin Taper (PO 125mg QID x 14 days PO
125mg BID x 7 days PO 125mg QD x 7 days PO 125mg q72h x 2-8 weeks)</p>
<p>-<u>Adjunctive therapy</u>: IV Bezlotoxumab 10mg/kg x1</p>
<p>Second or Further Recurrence:</p>
<p>-Same as above</p>
<p>-Consider Fecal Microbiota Transplantation (FMT)</p></td>
</tr>
<tr class="even">
<td colspan="2"><strong>Fulminant disease</strong></td>
</tr>
<tr class="odd">
<td>Fulminant disease</td>
<td><p>Consult GI and EGS</p>
<p>Ileus Absent:</p>
<p>-PO Vancomycin 500mg QID + IV Metronidazole 500mg TID</p>
<p>Ileus Present</p>
<p>-Same as above + consider Vancomycin enemas 500mg q6h</p>
<p>Consider colectomy or FMT</p></td>
</tr>
</tbody>
</table></section><section class="print-page" id="gastroenterology-gastroenterology-chronic-pancreatitis"><h1 id="gastroenterology-gastroenterology-chronic-pancreatitis-chronic-pancreatitis">Chronic Pancreatitis<a class="headerlink" href="#gastroenterology-gastroenterology-chronic-pancreatitis-chronic-pancreatitis" title="Permanent link">&para;</a></h1>
<p>AJ De Witte</p>
<hr />
<h2 id="gastroenterology-gastroenterology-chronic-pancreatitis-definition">Definition<a class="headerlink" href="#gastroenterology-gastroenterology-chronic-pancreatitis-definition" title="Permanent link">&para;</a></h2>
<p>A syndrome characterized by irreversible chronic progressive
pancreatic inflammation, fibrosis, and scarring, resulting in damage to
and loss of exocrine (acinar), endocrine (islet cells), and ductal cells</p>
<h2 id="gastroenterology-gastroenterology-chronic-pancreatitis-etiology">Etiology<a class="headerlink" href="#gastroenterology-gastroenterology-chronic-pancreatitis-etiology" title="Permanent link">&para;</a></h2>
<p>TIGAR-O mnemonic</p>
<ul>
<li><u>T</u>oxic Metabolic: EtOH, tobacco use, hyperCa (Ca > 12), HLD
    (fasting TG > 300, nonfasting > 500), CKD 5, medications, toxins</li>
<li><u>I</u>diopathic: early onset (age \&lt; 35), late onset (age > 35)</li>
<li><u>G</u>enetic: Autosomal dominant (PRSS1 gene), recessive (CFTR,
    SPINK1, etc.)</li>
<li><u>A</u>utoimmune: IgG4-related (AIP type 1), AIP type 2</li>
<li><u>R</u>ecurrent, severe acute pancreatitis</li>
<li><u>O</u>bstructive: pancreas divisum, ampullary stenosis, main duct
    pancreatic stones or strictures, widespread calcifications, mass
    causing duct obstruction</li>
</ul>
<h2 id="gastroenterology-gastroenterology-chronic-pancreatitis-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-chronic-pancreatitis-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Abdominal pain (most common)</li>
<li>Exocrine insufficiency: diarrhea, steatorrhea, weight loss<ul>
<li>Typically occurs later in disease process</li>
</ul>
</li>
<li>Endocrine insufficiency: diabetes</li>
<li>Occasionally asymptomatic</li>
</ul>
<h1 id="gastroenterology-gastroenterology-chronic-pancreatitis-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-chronic-pancreatitis-evaluation" title="Permanent link">&para;</a></h1>
<ul>
<li>Imaging: CT or MRI (may be negative early in course of disease)<ul>
<li>If CT or MRI negative but suspicion for CP remains high,
    consider EUS &plusmn; biopsy or secretin-enhanced MRCP</li>
</ul>
</li>
<li>Labs:<ul>
<li>BMP, LFTs, lipid panel, PeTH</li>
<li>Consider genetic testing, especially in younger patients and/or
    patients without clear etiology</li>
<li>Pancreatic function testing diagnoses exocrine insufficiency but
    is not necessary for diagnosis of CP<ul>
<li>Gold standard = 72-hour fecal fat (&gt; 7g of fat per 100g
    stool per day) - rarely done</li>
<li>More practical = fecal elastase (&lt;100 = diagnostic, 100-200
    = indeterminate)<ul>
<li>Must be performed on formed stool, can be false positive
    If watery specimen</li>
<li>Do not have to stop pancreatic enzymes to measure</li>
</ul>
</li>
</ul>
</li>
<li>Lipase and amylase levels can be elevated, but are usually
    normal due to pancreatic scarring and fibrosis</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-chronic-pancreatitis-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-chronic-pancreatitis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Tobacco and EtOH cessation</li>
<li>Pancreatic enzyme replacement therapy if evidence/diagnosis of
    exocrine insufficiency<ul>
<li>Usual dose: 50,000 units/meal + 25,000 units with snacks</li>
<li>Should take with first bite of a meal and consider adding extra
    enzymes or splitting up dose throughout meal if lasting longer
    than 15 mins</li>
<li>If lack of response: try increasing dose, confirm compliance,
    add PPI, split up dose throughout meal, look for concurrent GI
    disorders</li>
</ul>
</li>
<li>Pain: Tylenol + NSAIDs &gt; Opioids (Tramadol), consider SSRI/SNRI/TCA
    or gabapentin<ul>
<li>For refractory pain, other options include celiac plexus
    blockade or total pancreatectomy with islet auto transplant</li>
</ul>
</li>
<li>Vitamin supplementation + Vit D + Ca</li>
<li>Consider antioxidants (selenium, ascorbic acid, β-carotene, and
    methionine, vitamin E) – mixed evidence but some studies have shown
    improved pain control</li>
<li>Routine testing for osteoporosis and fat-soluble vitamin
    deficiencies</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-constipation"><h1 id="gastroenterology-gastroenterology-constipation-constipation">Constipation<a class="headerlink" href="#gastroenterology-gastroenterology-constipation-constipation" title="Permanent link">&para;</a></h1>
<p>Chelsie Sievers</p>
<hr />
<h2 id="gastroenterology-gastroenterology-constipation-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-constipation-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Definition: presence of lumpy/hard stools, straining, use of digital
    maneuvers, sensation of incomplete evacuation, frequency \&lt;3 BM per
    week.</li>
<li>Common etiologies: opioid-induced, medications (anti-depressants,
    iron, anticholinergics) hypothyroidism, hypokalemia, pregnancy, IBS,
    neurogenic (trauma, MS, Parkinson disease, diabetes, autonomic
    dysregulation).</li>
<li>Always think about risk of obstruction (prior abdominal surgeries,
    oncology history or risk for GI/GU malignancies, history of
    IBD/Crohn’s).</li>
</ul>
<h2 id="gastroenterology-gastroenterology-constipation-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-constipation-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Evaluate etiologies plus lifestyle factors (low fiber intake, low
    fluid intake, reduced mobility, acute illness)</li>
<li>Clinical diagnosis, no need for imaging unless concerned for
    obstruction → KUB/ CT</li>
<li>BMP + Mg to evaluate electrolytes, consider TSH if chronic</li>
<li>Rectal exam to exclude rectal mass or fecal impaction
    (constipation + diarrhea doesn’t exclude impaction/obstruction.
    Overflow around mass = encoparesis)</li>
</ul>
<h2 id="gastroenterology-gastroenterology-constipation-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-constipation-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Stop or minimize offending medications if possible</li>
<li>Optimize lifestyle factors: out of bed, walking hallways, increase
    fluid intake, + cup of coffee if appropriate.</li>
<li>Escalating pathway: ensure meds are scheduled not PRN<ul>
<li>MiraLAX (PEG) 17g BID (can give TID) + Senna nightly (can
    &gt; increase to BID and/or 2 tabs) → Bisacodyl suppository → enema
    &gt; (tap water or SMOG) → stronger osmotic laxative (lactulose
    &gt; 20mg once, Mag-citrate, Golytely) → escalate lactulose dosing
    &gt; 20 – 30 mg q2hrs</li>
</ul>
</li>
<li>Other considerations:<ul>
<li>Avoid Fleet enemas (sodium-phosphate) in CKD and geriatric
    &gt; populations</li>
<li>“The hand that writes for opioids also writes a bowel regimen”<ul>
<li>Generally, start with scheduled MiraLAX (PEG) 17g daily +
  senna nightly</li>
<li>If severe and unrelieved by escalating therapies, can try
  methylnaltrexone</li>
</ul>
</li>
<li>Lactulose can cause severe bloating and cramping</li>
<li>In patients unable to take PO: place DHT to deliver meds or
    rectal lactulose (important for patients with cirrhosis with
    AMS/HE).</li>
<li>In patients with CF (at risk for distal intestinal obstruction
    syndrome): ensure have pancreatic enzymes ordered, managed
    more like constipation than true obstruction: PO/ NGT MiraLAX
    QID or Golytely.</li>
<li>Acute colonic pseudo-obstruction (Ogilvie's syndrome): >12cm
    cecal diameter = severe dilation, risk of perforation. Treated
    with neostigmine, 2mg IV over 3 to 5 minutes. Monitor for
    bradycardia, hypotension, and dysrhythmias (relative
    contraindications: recent MI, asthma, PUD, epilepsy).
    Decompression with colonoscopy used in some cases.</li>
<li>Consider pelvic floor dysfunction, pelvic floor PT may be
    helpful</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>Laxatives</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism</td>
<td>Examples</td>
<td>Effects</td>
</tr>
<tr>
<td>Bulking-agent</td>
<td>Psyllium seed (Metamucil), methylcellulose (Citrucel)</td>
<td>Absorb water and increase fecal bulk</td>
</tr>
<tr>
<td>Osmotic Laxatives</td>
<td>Polyethylene glycol (PEG = MiraLAX and Golytely), lactulose, mag-citrate</td>
<td>Hyperosmotic substances, pull fluid into GI tract</td>
</tr>
<tr>
<td>Stimulant Laxative</td>
<td>Senna, Bisacodyl (Dulcolax)</td>
<td>Stimulates peristalsis</td>
</tr>
<tr>
<td>Stool Softener</td>
<td>Docusate (Colace)</td>
<td>Generally ineffective</td>
</tr>
<tr>
<td>Opioid antagonist</td>
<td>Methylnaltrexone (Reslistor)</td>
<td>Peripheral acting opioid antagonist, inhibits opioid-induced decreased gastrointestinal motility</td>
</tr>
<tr>
<td>cGMP Agonist</td>
<td>Linaclotide (Linzess), Plecanatide (Trulance)</td>
<td>Stimulates intestinal secretion of Cl-/HCO3-</td>
</tr>
<tr>
<td>Prostaglandin derivative</td>
<td>Lubiprostone (Amitiza)</td>
<td>Increases intestinal chloride-rich fluid secretion</td>
</tr>
</tbody>
</table></section><section class="print-page" id="gastroenterology-gastroenterology-diarrhea"><h1 id="gastroenterology-gastroenterology-diarrhea-diarrhea">Diarrhea<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-diarrhea" title="Permanent link">&para;</a></h1>
<p>Charles Oertli</p>
<hr />
<h2 id="gastroenterology-gastroenterology-diarrhea-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<blockquote>
<p>3 BM/day OR abnormally loose stool</p>
</blockquote>
</li>
<li>Acute (&lt;2 weeks), persistent (2-4 weeks), or chronic (>4 weeks)</li>
<li>95% of acute diarrhea is self-limited &amp; no additional treatment
    needed</li>
<li>Most cases of acute diarrhea are due to infections</li>
<li>Non-infectious etiologies become more common with increasing
    duration</li>
<li>Voluminous watery diarrhea more likely disorder of small bowel</li>
<li>Small volume frequent diarrhea more likely disorder of colon</li>
<li>Nocturnal diarrhea suggests an inflammatory or secretory etiology</li>
</ul>
<h2 id="gastroenterology-gastroenterology-diarrhea-acute-diarrhea">Acute Diarrhea<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-acute-diarrhea" title="Permanent link">&para;</a></h2>
<h3 id="gastroenterology-gastroenterology-diarrhea-etiology">Etiology<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-etiology" title="Permanent link">&para;</a></h3>
<ul>
<li>Watery diarrhea: viral gastroenteritis (norovirus, rotavirus,
    enteric adenovirus), C. diff, C. perfringens, S. Aureus, Bacillus
    cereus, enterotoxigenic E. coli, Cryptosporidium, Listeria,
    Cyclospora, vibrio cholerae, (Giardia is typically more chronic),
    Tropheryma whipplei, COVID</li>
<li>Inflammatory diarrhea: Salmonella, Campylobacter, Shigella, EHEC,
    Yersinia, E histolytica, invasive viruses (CMV, HSV), Non-cholera
    vibrio. Look for red flag symptoms (see below).</li>
<li>Medications, specifically antibiotics</li>
</ul>
<h3 id="gastroenterology-gastroenterology-diarrhea-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-presentation" title="Permanent link">&para;</a></h3>
<ul>
<li>Evaluate for red flags (BATS are Vulnerable vampires)<ul>
<li><u>B</u>loody stools,</li>
<li><u>A</u>ntibiotics/Recent hospitalization<ul>
<li>Any antibiotic can cause C. diff; the longer the treatment, the
  more likely</li>
<li>Most common to cause C. diff: Clindamycin &gt;&gt;
  Penicillins/Cephalosporins/Fluoroquinolones</li>
</ul>
</li>
<li><u>T</u>oo many stools: >6 unformed stools/day</li>
<li><u>S</u>epsis (Fever) or <u>S</u>evere abdominal pain</li>
<li><u>V</u>ulnerable (Age >70 yr, immunocompromised, IVDU, IBD,
pregnant, travel)</li>
</ul>
</li>
</ul>
<h3 id="gastroenterology-gastroenterology-diarrhea-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-evaluation" title="Permanent link">&para;</a></h3>
<ul>
<li>All patients: CBC w/ diff and BMP to eval for leukocytosis (C.diff),
    AKI, electrolyte abnormalities, thrombocytopenia/anemia (HUS),
    eosinophilia (parasites)</li>
<li>If red flag symptoms or diarrhea > 7d: ESR/CRP, C.diff, GIPP</li>
<li>If immunocompromised: consider CMV, MAC, microsporidia</li>
<li>If abdominal pain: consider CT A/P with IV contrast</li>
<li>If concern for IBD or hx of IBD: CT Enterography with PO and IV
    contrast</li>
<li>Blood Cultures if febrile/septic</li>
</ul>
<h3 id="gastroenterology-gastroenterology-diarrhea-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-management" title="Permanent link">&para;</a></h3>
<ul>
<li>All patients: supportive care with PO or IVF, electrolyte repletion</li>
<li>If C.diff negative or treatment for C.diff started, ok for
    symptomatic treatment with Loperamide<ul>
<li>Start with Loperamide 4mg x1 then transition to 2mg QID (AC+HS)
    (maximum 16mg/day)</li>
<li>If fever or inflammatory symptoms and C.diff not back, ok for
    Bismuth subsalicylate (Pepto-Bismol) 30mL or 2 tablets q30min x8</li>
</ul>
</li>
<li>Indications for antibiotics:<ul>
<li>GIPP negative for Shigella, 0157:H7 (can precipitate HUS) and
salmonella (can prolong carrier state)</li>
<li>Empiric antibiotic therapy ONLY if toxic appearance or high concern
for progressive illness/decompensation</li>
<li>Ciprofloxacin 500 mg BID or levofloxacin 500 mg daily x 3-5 days</li>
<li>Azithromycin 500 mg daily x 3 days</li>
<li>Ampicillin + gentamicin used for pregnant women to cover for
    Listeria</li>
<li>C. diff positive (see section below)</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-diarrhea-approach-to-chronic-diarrhea">Approach to Chronic Diarrhea<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-approach-to-chronic-diarrhea" title="Permanent link">&para;</a></h2>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Causes of Watery Diarrhea</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Secretory</td>
<td>Motility</td>
<td>Osmotic</td>
</tr>
<tr class="even">
<td><p>Microscopic colitis</p>
<p>Bile acid malabsorption</p>
<p>Carcinoid</p>
<p>Crohn’s disease</p>
<p>Gastrinoma</p>
<p>VIPoma</p>
<p>Mastocytosis</p>
<p>Addison’s disease</p></td>
<td><p>Hyperthyroidism</p>
<p>Diabetes</p>
<p>Amyloidosis</p>
<p>Systemic scleroderma</p></td>
<td><p>Lactose intolerance</p>
<p>Bile salt diarrhea</p>
<p>Sugar alcohols: sorbitol, mannitol, xylitol</p></td>
</tr>
<tr class="odd">
<td>Meds: antibiotics, caffeine, colchicine, NSAIDs, antineoplastics,
antiarrhythmics (digoxin), metformin, carbamazepine</td>
<td>Meds: macrolides, metoclopramide, bisacodyl, senna,
pyridostigmine</td>
<td>Meds: citrates, lactulose, magnesium-containing antacids,
mycophenolate, antibiotics, propranolol, hydralazine, procainamide</td>
</tr>
<tr class="even">
<td colspan="3">Functional: IBS</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="2">Causes of Fatty Diarrhea (Steatorrhea)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Malabsorption</td>
<td>Inflammatory</td>
</tr>
<tr class="even">
<td><p>Celiac disease</p>
<p>Gastric bypass</p>
<p>Short bowel syndrome</p>
<p>Tropical Sprue</p>
<p>Whipple disease</p>
<p>Small intestinal bacterial overgrowth (SIBO)</p>
<p>Post-infectious malabsorptive diarrhea</p>
<p>Maldigestion</p>
<p>Pancreatic insufficiency</p>
<p>Hepatobiliary disorders</p></td>
<td><p>Diverticulitis</p>
<p>Ischemic colitis</p>
<p>Neoplasia</p>
<p>Radiation colitis</p>
<p>Arsenic poisoning</p>
<p>Microscopic colitis</p>
<p>Invasive infections: bacterial (tuberculosis, yersinosis), viral
(CMV, HSV),</p>
<p>Parasites (amebiasis, strongyloidiasis)</p>
<p>Inflammatory bowel disease</p></td>
</tr>
</tbody>
</table>

<h3 id="gastroenterology-gastroenterology-diarrhea-evaluation_1">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-evaluation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Labs: CBC w/ diff, CMP, ESR/CRP, TSH, celiac serologies if high
    suspicion (anti-TTG)</li>
<li>Spot fecal elastase Steatorrhea (greasy, malodorous stools that
    float)</li>
<li>Colonoscopy indicated if alarm symptoms are present ( >45 yrs and
    hasn’t had one, or \&lt;45 yrs and concern for IBD, CMV, ischemic
    colitis or microscopic colitis)</li>
<li>If concern for IBS: Rome IV criteria (see section on “IBS” below)</li>
</ul>
<h3 id="gastroenterology-gastroenterology-diarrhea-management_1">Management<a class="headerlink" href="#gastroenterology-gastroenterology-diarrhea-management_1" title="Permanent link">&para;</a></h3>
<ul>
<li>IBS: trial elimination diet/low FODMAP, antidiarrheals</li>
<li>Pancreatic insufficiency: enzyme replacement (Creon), consult
    nutrition for assistance</li>
<li>Celiac: eliminate gluten, will need outpatient nutrition follow-up</li>
<li>Bile acid malabsorption: can try cholestyramine (can affect
    absorption of other meds)</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-esophageal-disorders"><h1 id="gastroenterology-gastroenterology-esophageal-disorders-esophageal-disorders">Esophageal Disorders<a class="headerlink" href="#gastroenterology-gastroenterology-esophageal-disorders-esophageal-disorders" title="Permanent link">&para;</a></h1>
<p>Caroline Barrett</p>
<hr />
<h2 id="gastroenterology-gastroenterology-esophageal-disorders-dysphagias">Dysphagias<a class="headerlink" href="#gastroenterology-gastroenterology-esophageal-disorders-dysphagias" title="Permanent link">&para;</a></h2>
<ul>
<li>Oropharyngeal dysphagia = difficulty initiating a swallow</li>
<li>Associated with coughing, choking, nasopharyngeal regurgitation, and
    aspiration</li>
<li>Causes: Structural (Zenker’s diverticula, malignancy, goiter,
    stricture, radiation injury, infection), Neuromuscular (stroke,
    Parkinson disease, dementia, ALS, MS)</li>
<li>Esophageal dysphagia: Difficulty swallowing several seconds after
    initiation; associated w/sensation of food getting stuck in
    esophagus</li>
<li>Dysphagia to solids = mechanical obstruction<ul>
<li>Foreign body: Inability to swallow solids and/or liquids,
    including oral secretions<ul>
<li>Most common foreign body = food in esophagus</li>
</ul>
</li>
<li>Progressive: esophageal stricture, peptic stricture, esophageal,
    cancer</li>
<li>Intermittent: esophageal ring/web, eosinophilic esophagitis
    (particularly in young pts)</li>
</ul>
</li>
<li>Dysphagia to solids and liquids = motility disorder<ul>
<li>Causes: achalasia, scleroderma, distal esophageal spasm (DES),
    hypercontractile (nutcracker) esophagus</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-esophageal-disorders-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-esophageal-disorders-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>If oropharyngeal dysphagia: videofluoroscopic modified barium
    swallow and fiberoptic endoscopic evaluation of swallowing (FEES)</li>
<li>When to order barium esophogram:<ul>
<li>Pre-endoscopy if clinical history suspicious for proximal esophageal
    lesion (i.e. Zenker’s) or known complex stricture (post-caustic
    injury or radiation)<ul>
<li>Don’t order if a food impaction is suspected or if imminent
    endoscopy</li>
</ul>
</li>
<li>Post-endoscopy if mechanical obstruction is still suspected (EGD can
    miss lower esophageal rings or extrinsic esophageal compression)</li>
</ul>
</li>
<li>EGD if concerns for mechanical obstruction</li>
<li>Manometry for motility disorders</li>
</ul>
<h2 id="gastroenterology-gastroenterology-esophageal-disorders-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-esophageal-disorders-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Food impaction: IV glucagon to relax lower esophageal sphincter to
    allow food passage</li>
<li>Otherwise, requires urgent upper endoscopy for removal</li>
<li>Additional management is specific to the final diagnosis</li>
</ul>
<h3 id="gastroenterology-gastroenterology-esophageal-disorders-odynophagia">Odynophagia<a class="headerlink" href="#gastroenterology-gastroenterology-esophageal-disorders-odynophagia" title="Permanent link">&para;</a></h3>
<ul>
<li>Pain with swallowing</li>
<li>Associated with esophagitis</li>
</ul>
<p>PIECE mnemonic for esophagitis:</p>
<ul>
<li>Pill-induced: NSAIDs, ART, KCl, doxycycline, bisphosphonates<ul>
<li>Discontinue culprit med or substitute with liquid formulation;
prevent by taking culprit meds w/ 8oz water and sit upright for 30
mins after</li>
</ul>
</li>
<li>Infectious: usually in immunosuppressed pts</li>
<li>Candida Esophagitis: most common in HIV or heme malignancies, pts on
    antibiotics and steroid use<ul>
<li>Can exist without OP thrush</li>
<li>Diagnosis: white mucosal plaque-like lesions on EGD biopsy and
    culture</li>
</ul>
</li>
<li>HSV Esophagitis. Occurs most commonly in solid organ, BMT transplant
    recipients, and immunosuppressed patients<ul>
<li>Diagnosis: well-circumscribed ulcers on EGD, biopsy or brushings
    of ulcer edge</li>
<li>Rx: acyclovir 400mg PO five times daily for 14-21 days
    (immunocompromised) or acyclovir 5mg/kg IV q8h for 7-14 days if
    unable to tolerate PO; 200mg PO five times daily or 400mg PO
    three times daily for 7-10 days (immunocompetent)</li>
</ul>
</li>
<li>CMV Esophagitis: suspect in HIV pts w/ CD4\&lt;50<ul>
<li>Diagnosis: linear/longitudinal ulcers on EGD, biopsy</li>
<li>Rx: ganciclovir 5mg/kg IV q12h for 21-42 days; change to PO once
    pt able to tolerate; If contraindication to ganciclovir
    (leukopenia, thrombocytopenia) can use Foscarnet. PO
    valganciclovir can be used in patients who can tolerate and
    absorb oral medications. Treatment duration is 3-6 weeks based
    on expert opinion and response to disease</li>
</ul>
</li>
<li>Eosinophilic Esophagitis (see below)</li>
<li>Caustic: alkali-induced injury, acid-induced injury, acute period
    (several days) following esophageal radiofrequency ablation for
    Barrett’s.</li>
<li>GERD (see below)</li>
</ul>
<h3 id="gastroenterology-gastroenterology-esophageal-disorders-gerd">GERD<a class="headerlink" href="#gastroenterology-gastroenterology-esophageal-disorders-gerd" title="Permanent link">&para;</a></h3>
<p>Background</p>
<ul>
<li>Condition that develops when reflux of stomach contents causes
    symptoms and/or complications</li>
<li>Classified base on appearance of esophageal mucosa on EGD</li>
<li>Erosive esophagitis: endoscopically visible breaks in distal
    esophageal mucosa + GERD</li>
<li>Nonerosive reflux disease: presence of symptoms of GERD without
    esophageal mucosal injury</li>
</ul>
<p>Presentation</p>
<ul>
<li>Esophageal symptoms: heartburn, regurgitation, chest pain,
    dysphagia, globus sensation, odynophagia</li>
<li>Extra-esophageal symptoms: chronic cough, hoarseness</li>
<li>Complications: Esophageal stricture, Barrett’s esophagus, esophageal
    adenocarcinoma</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Dx can often be made clinically in pts with classic heartburn and/or
    regurgitation</li>
<li>If dx uncertain, can perform ambulatory pH monitoring + impedance</li>
<li>EGD indicated for the following:</li>
<li>Presence of alarm features (dysphagia, persistent vomiting, GI
    cancer in 1º relative, odynophagia, GI bleeding, weight loss, iron
    deficiency anemia, ≥age > 60 y/o with new-onset GERD symptoms)</li>
<li>Risk factors for Barrett’s esophagus (duration of GERD at least 5-10
    years [must be present], >50 yo, male, white, hiatal hernia,
    obesity, nocturnal reflux, tobacco use, first-degree relative w/
    Barrett’s and/or adenocarcinoma)</li>
<li>Abnormal UGI tract imaging (i.e. luminal abnormalities).</li>
<li>Continued symptoms despite adequate PPI therapy</li>
</ul>
<p>Management</p>
<ul>
<li>Lifestyle and dietary modifications in all pts (weight loss; elevate
    HOB; avoid precipitants such as fatty foods, caffeine, alcohol,
    spicy foods, large meals, late night meals)</li>
<li>Mild/intermittent symptoms (\&lt;2 episodes/wk) and no erosive
    esophagitis step-up therapy q4-8 wks until symptoms are controlled,
    then continue for at least 8 wks:</li>
<li>Low-dose H2RA prn standard dose H2RA BID (min 2 wks) discontinue
    H2RA and start daily low dose PPI standard dose PPI</li>
<li>Frequent symptoms (>2 episodes/wk, and/or severe symptoms that
    impair QOL) step-down therapy in order to optimize symptom relief</li>
<li>Standard-dose PPI daily (8 wks) low-dose PPI daily H2RA (if
    mild/intermittent symptoms) stop if asymptomatic<ul>
<li>PPIs should be prescribed at lowest dose and for shortest
    duration appropriate</li>
<li>Instruct patients on optimal PPI use: most effective at gastric
    acid suppression when taken 30-60 minutes before a meal</li>
<li>Taper if taking for >6 months and plan to discontinue</li>
</ul>
</li>
<li>Medications:<ul>
<li>Low dose H2RA: famotidine 10mg BID</li>
<li>Standard dose H2RA: famotidine 20mg BID</li>
<li>Low dose PPI: omeprazole 10 mg daily</li>
<li>Standard dose PPI: omeprazole 20 mg daily</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Erosive esophagitis and Barrett’s esophagus:<ul>
<li>Require maintenance acid suppression with a standard dose PPI daily
    given likelihood of recurrent symptoms and complications if stopped</li>
</ul>
</li>
<li>Recurrent Symptoms (&#8532; of pts with nonerosive reflux disease
    relapse when acid suppression is discontinued):<ul>
<li>If ≥3 months after discontinuing repeat 8-week course</li>
<li>If &lt;3 months of discontinuing, EGD (if not already performed) to
    rule out other etiologies or complications</li>
</ul>
</li>
</ul>
<h3 id="gastroenterology-gastroenterology-esophageal-disorders-eosinophilic-esophagitis">Eosinophilic Esophagitis<a class="headerlink" href="#gastroenterology-gastroenterology-esophageal-disorders-eosinophilic-esophagitis" title="Permanent link">&para;</a></h3>
<p>Background</p>
<ul>
<li>Pt usually with a history of asthma/allergies/eczema</li>
<li>Dysphagia (most commonly to solid foods), food impaction, central
    chest pain, GERD/refractory heartburn, upper abdominal pain</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Diagnostic criteria</li>
<li>Symptoms related to esophageal dysfunction</li>
<li>EGD with &gt;15 eos/hpf on biopsy and exclusion of other causes</li>
<li>50-60% pts will have elevated serum IgE lvl; peripheral eosinophilia
    can be seen but is generally mild.</li>
</ul>
<p>Management</p>
<ul>
<li>Standard dose PPI for 8 weeks &plusmn; elimination diet if still
    symptomatic after 4 weeks, increase PPI to BID if responsive,
    continue PPI at lowest dose possible for symptom control</li>
<li>Alternative treatment is swallowed budesonide or fluticasone</li>
<li>Intermittent dilation of strictures to relieve dysphagia, but no
    effect on underlying inflammation</li>
<li>Should undergo evaluation by allergist, given strong association
    with allergies</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-gastroparesis"><h1 id="gastroenterology-gastroenterology-gastroparesis-gastroparesis">Gastroparesis<a class="headerlink" href="#gastroenterology-gastroenterology-gastroparesis-gastroparesis" title="Permanent link">&para;</a></h1>
<p>Hashim Hayat</p>
<hr />
<h2 id="gastroenterology-gastroenterology-gastroparesis-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-gastroparesis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Syndrome of objectively delayed gastric emptying in absence of
    mechanical obstruction</li>
<li>Etiology: Diabetes (most common), post-surgical (gastric or
    bariatric surgery), thyroid dysfunction, autoimmune or neurologic
    disorders, medication-induced (GLP-1 agonists, narcotics,
    anticholinergic agents</li>
</ul>
<h2 id="gastroenterology-gastroenterology-gastroparesis-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-gastroparesis-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Nausea, vomiting (may contain food eaten several hours prior),
    abdominal pain (dull, crampy; rarely a predominant symptom), early
    satiety, postprandial fullness, bloating, weight loss in severe
    cases</li>
</ul>
<h2 id="gastroenterology-gastroenterology-gastroparesis-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-gastroparesis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Exclude mechanical obstruction and mucosal disease with CTE and EGD</li>
<li>Scintigraphic gastric emptying study = gold standard for diagnosis
    (measures gastric retention of solids at 4h)</li>
<li>Stop medications that may affect gastric emptying 48 hrs prior to
    testing</li>
<li>Must have blood sugar \&lt; 275 (Hyperglycemia delays gastric emptying)</li>
</ul>
<h2 id="gastroenterology-gastroenterology-gastroparesis-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-gastroparesis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Support with IVF and electrolytes – PO intake preferred</li>
<li>Glycemic control in diabetics</li>
<li>Stop offending medications</li>
<li>Nutrition consult for teaching on frequent small volume meals that
    are low in fat and soluble fiber</li>
<li>If continued symptoms after above, try prokinetics and antiemetics</li>
<li>Prokinetics<ul>
<li>Liquid formulations preferred for better absorption</li>
<li>Give 15min before meals and at bedtime.</li>
<li>First line is Reglan. If no response, try Domperidone and
    subsequently erythromycin (not good for long term, pts develop
    tachyphylaxis)</li>
</ul>
</li>
<li>Antiemetics: helps symptoms but do not improve gastric emptying</li>
<li>In severe cases patients may require enteral feeding (post pyloric
    preferred) or venting g-tube</li>
<li>Emerging endoscopic treatment options: G-POEM (gastric peroral
    endoscopic myotomy)</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-gi-bleeding"><h1 id="gastroenterology-gastroenterology-gi-bleeding-gi-bleeding">GI Bleeding<a class="headerlink" href="#gastroenterology-gastroenterology-gi-bleeding-gi-bleeding" title="Permanent link">&para;</a></h1>
<p>Matthew Meyers</p>
<hr />
<h2 id="gastroenterology-gastroenterology-gi-bleeding-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-gi-bleeding-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Intraluminal blood loss anywhere from the nasopharynx/oral cavity to
    the anus</li>
<li>Don’t forget epistaxis or oropharyngeal bleeding as possible source
    of melena</li>
<li>IV PPI prior to endoscopy may ↓ need for endoscopic therapy but does
    not impact transfusion requirement, rebleeding risk, need for
    surgical intervention, or mortality</li>
<li>Classification: relative location to the Ligament of Treitz (LoT)</li>
<li>Upper = proximal to LoT<ul>
<li>PUD, gastritis (alcohol, stress, NSAIDs, ASA), esophagitis,
    variceal bleed, Mallory-Weiss tear, AVM, Dieulafoy’s lesion,
    aorto-enteric fistula, gastric antral vascular ectasias,
    malignancy</li>
</ul>
</li>
<li>Lower = distal to LoT<ul>
<li>Diverticular bleed, ischemic/infectious/IBD/radiation colitis,
    malignancy, angiodysplasia, anorectal (hemorrhoids, anal
    fissure), Meckel’s diverticulum, post-polypectomy bleed</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-gi-bleeding-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-gi-bleeding-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Hematemesis (very specific for upper GI bleed), hematochezia
    (usually lower although brisk upper possible), melena (usually
    upper), coffee-ground emesis, epigastric/abdominal pain, acute or
    chronic, hx of GI bleed and prior endoscopies, NSAID use, alcohol
    use, anticoagulant use, hx of cirrhosis</li>
<li>Exam: VITALS – assess stability to determine resuscitation needs,
    MICU vs. floor; orthostatic vs, rectal exam every time (smear stool
    on white tissue paper to look for melena), look for signs of
    cirrhosis (jaundice, palmar erythema, ascites, spider angiomata)</li>
</ul>
<h2 id="gastroenterology-gastroenterology-gi-bleeding-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-gi-bleeding-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>CBC, PT/INR, CMP, Lactic Acid, Blood Gas</li>
<li>EGD: usually best</li>
<li>Difficulty localizing GIB: pill-capsule, balloon enteroscopy
    Meckel’s scan, tagged RBC scan</li>
<li>Massive lower GI bleeds will require arteriography</li>
</ul>
<h2 id="gastroenterology-gastroenterology-gi-bleeding-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-gi-bleeding-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Secure airway (intubation) if comatose, extremely combative, or
    massive hematemesis</li>
<li>At least 2 large bore IV’s (&gt; 18 gauge) – ask nurses directly to
    ensure these are placed</li>
<li>Maintain active type and screen</li>
<li>Bolus IVF to maintain MAP &gt;65H/H monitoring q6-q12 hours;
    transfusions as indicated</li>
<li>IV PPI (pantoprazole) 40 mg BID if thought to be upper/possible
    ulcer</li>
<li>If cirrhotic, Ceftriaxone 1g daily for empiric SBP prophylaxis</li>
<li>If possibility of variceal bleed: Octreotide IV 50 mcg x1 then 50
    mcg/hr drip x 3-5 days</li>
<li>NPO if unstable vs. clear liquids (no reds or purples) until morning
    for EGD</li>
<li>Never give prep to a patient for colonoscopy (GoLytely) without
    discussing with GI fellow</li>
<li>Consult gastroenterology to facilitate endoscopy</li>
<li>If endoscopy is unable to stop bleeding IR is next who can embolize</li>
<li>If embolization fails EGS for source removal</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-gi-covid"><h1 id="gastroenterology-gastroenterology-gi-covid-gi-manifestations-of-covid">GI Manifestations of COVID<a class="headerlink" href="#gastroenterology-gastroenterology-gi-covid-gi-manifestations-of-covid" title="Permanent link">&para;</a></h1>
<p>Taylor Riggs</p>
<hr />
<h2 id="gastroenterology-gastroenterology-gi-covid-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-gi-covid-background" title="Permanent link">&para;</a></h2>
<ul>
<li>GI manifestations are reported up to 60% of patients with COVID</li>
<li>GI symptoms may be the only symptom or precede other symptoms</li>
<li>GI manifestations are felt to be due to expression of ACE2 receptor
    throughout the GI tract</li>
</ul>
<h2 id="gastroenterology-gastroenterology-gi-covid-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-gi-covid-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Diarrhea – more common in severe disease</li>
<li>~20% have diarrhea as first symptom of COVID; on average, lasts
    about 5 days</li>
<li>Nausea and vomiting – associated with more severe disease</li>
<li>Mesenteric ischemia – likely due to intestinal microvascular injury</li>
<li>Elevated liver enzymes – likely due to inflammatory response and
    direct virus-related toxicity</li>
<li>Hepatocellular pattern of injury most common; elevated bilirubin
    seen in severe disease</li>
<li>Usually self-limited</li>
<li>Pancreatitis has been reported in several cases, but no causal link
    has been established</li>
</ul>
<h2 id="gastroenterology-gastroenterology-gi-covid-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-gi-covid-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Largely supportive care</li>
<li>Monitor LFTs, coags, consider checking lipase if abdominal pain</li>
<li>If LFTs not improving after several days or underlying chronic liver
    disease, obtain RUQ U/S, consider hepatitis serologies</li>
<li>Consider medications/antiviral medications as culprit and
    discontinue as indicated</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-ibs"><h1 id="gastroenterology-gastroenterology-ibs-irritable-bowel-syndrome">Irritable Bowel Syndrome<a class="headerlink" href="#gastroenterology-gastroenterology-ibs-irritable-bowel-syndrome" title="Permanent link">&para;</a></h1>
<p>Hashim Hayat</p>
<hr />
<h2 id="gastroenterology-gastroenterology-ibs-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-ibs-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Diagnose by the Rome IV criteria, no longer a diagnosis of exclusion</li>
<li>Recurrent abdominal pain on average at least 1 day/week in the last
    3 months with an onset at least 6 months prior, associated
    with <strong>two or more</strong> of the following criteria<ul>
<li>Pain related to defecation</li>
<li>Change in frequency of stool</li>
<li>Change in form (appearance) of stool</li>
</ul>
</li>
<li>Patient has none of the following warning signs: >50yrs, evidence
    of GIB, nocturnal pain or BMs, unintentional weight loss, family hx
    of colorectal cancer or IBD, palpable abdominal mass or LAD, IDA,
    +FOBT</li>
<li>Classified based on predominant bowel habits<ul>
<li>Diarrhea: &gt;25% BMs with Bristol stool types 6 or 7</li>
<li>Constipation: &gt;25% BMs with Bristol stool types 1 or 2</li>
<li>Mixed: both of above</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-ibs-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-ibs-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Thorough H&amp;P for alarm symptoms as above</li>
<li>Consider limited testing with CBC, CMP, CRP, celiac serology, fecal
    calprotectin</li>
</ul>
<h2 id="gastroenterology-gastroenterology-ibs-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-ibs-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Treatment involves lifestyle and dietary modifications, psychosocial
    treatment, and pharmacologic treatment</li>
<li>Pain:<ul>
<li>Peppermint oil (smooth muscle relaxant) – IBGuard, Iberogast</li>
<li>Antispasmodics: Hyosciamine acts faster than Dicyclomine</li>
<li>TCAs: Amitriptyline or nortriptyline (causes less constipation so
better in IBS-C)</li>
</ul>
</li>
<li>Bloating:<ul>
<li>Low FODMAP diet</li>
<li>Rifaximin as empiric treatment for SIBO</li>
<li>No evidence for probiotics (can potentially worsen bloating 2/2
SIBO)</li>
</ul>
</li>
<li>Bowel regulation:<ul>
<li>IBS-D: Start with Loperamide (up to 16g daily), consider Lomotil if
refractory</li>
<li>IBS-C: Miralax, fiber supplement (Ispaghula husk orange), Linzess
(first line but can be expensive), Trulance, or Amitiza</li>
</ul>
</li>
<li>Other<ul>
<li>Psychotherapy, CBT</li>
<li>SSRIs, SNRIs for concomitant mood disorders</li>
<li>Gabapentin, lyrica</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-inflammatory-bowel-disease"><h1 id="gastroenterology-gastroenterology-inflammatory-bowel-disease-inflammatory-bowel-disease">Inflammatory Bowel Disease<a class="headerlink" href="#gastroenterology-gastroenterology-inflammatory-bowel-disease-inflammatory-bowel-disease" title="Permanent link">&para;</a></h1>
<p>Francesca Raffa</p>
<hr />
<h2 id="gastroenterology-gastroenterology-inflammatory-bowel-disease-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-inflammatory-bowel-disease-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Ulcerative colitis (UC): colon only (can have backwash ileitis);
    contiguous lesions; mucosal inflammation</li>
<li>Crohn’s disease (CD): any part of the GI tract; “skip lesions”;
    transmural inflammation</li>
<li>Important historical considerations to include in your documentation
    and presentation:<ul>
<li>Location of disease (CD: LB/SB, LB only, SB only; UC: proctitis,
left-sided or pancolitis)</li>
<li>Complications: Fistulizing, strictures, perianal, prior surgeries,
current IBD treatment</li>
<li>Include last endoscopies and imaging findings; current and prior IBD
treatment and reason for transition (SEs, failure), primary IBD
provider</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-inflammatory-bowel-disease-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-inflammatory-bowel-disease-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>UC: frequent diarrhea (often bloody), tenesmus, urgency, abdominal
    pain; may have fever, malaise, and weight loss<ul>
<li>Complications: severe bleeding/anemia, fulminant colitis, toxic
megacolon</li>
</ul>
</li>
<li>CD: abdominal pain, nausea/vomiting, fever, malaise, weight loss;
    May also have diarrhea (± bloody depending on CD location)<ul>
<li>Complications: fistulas (entero-enteric, entero-vesicular,
entero-cutaneous, rectovaginal, perianal, retroperitoneal),
abscesses, strictures, obstruction</li>
</ul>
</li>
<li>Extra-intestinal (EI): arthritis, sacro-iliitis, uveitis,
    episcleritis, aphthous ulcers, erythema nodosum, pyoderma
    gangrenosum, PSC (esp. UC), nephrolithiasis, thromboembolism</li>
</ul>
<h2 id="gastroenterology-gastroenterology-inflammatory-bowel-disease-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-inflammatory-bowel-disease-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>CBC w/diff, CMP, CRP, ESR, ± blood cultures</li>
<li>If diarrhea: GI Pathogen panel and C. diff</li>
<li>If anemic: obtain iron studies and type &amp; screen</li>
<li>If weight loss or concern for malnutrition: albumin, pre-albumin,
    Vitamin D, B12, folate</li>
<li>Imaging:<ul>
<li>CT Enterography (oral contrast) preferred in CD, for
luminal/extra-luminal complications</li>
<li>How to order CTE: “CT abdomen pelvis enterography”, order barium
(Volumen) 0.1% oral suspension x2, 1<sup>st</sup> dose to be given by nurse 60
min before study, 2<sup>nd</sup> study to be given 30 min before (nurse should
be in contact with CT tech)</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-inflammatory-bowel-disease-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-inflammatory-bowel-disease-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute Flare</li>
<li>Pain control: usually a major component of hospital course<ul>
<li>Avoid NSAIDs, oral pain medications are preferred</li>
<li>If pain is difficult to control, consider Acute Pain Service
    consult</li>
<li>Narcotics and Imodium are contraindicated in toxic megacolon</li>
</ul>
</li>
<li>Antibiotics: appropriately treat infections (intra-abdominal or
    perianal abscess) with antibiotics (consider prior culture data,
    often use cipro/flagyl)</li>
<li>VTE Prophylaxis: All IBD patients, even if having blood in stool
    (unless requiring transfusion) as they are at much higher risk of
    VTE</li>
<li>Nutrition: Nutrition consult for all IBD patients; For severe
    malnutrition or if prolonged bowel rest is needed, TPN is sometimes
    initiated</li>
<li>Anemia: Ferritin \&lt;100 or iron sat \&lt;20 with ferritin \&lt;300,
    consider iron infusions (if no bacteremia) or transfuse for severe
    anemia</li>
<li>Smoking Cessation (esp. with CD): discuss smoking cessation &amp;
    consult tobacco cessation</li>
<li>Consult Colorectal Surgery (not EGS): SBO, toxic megacolon, bowel
    perforation, peritonitis</li>
<li>Immunosuppression: (Infections must be ruled out and/or treated
    before starting)</li>
<li>Steroids:<ul>
<li>Methylprednisolone (Solumedrol); often 20 mg BID for three days</li>
<li>Transition to oral (40 mg prednisone daily) once clinically
    improved/tolerating PO; typically prescribe a prolonged taper on
    discharge (often down by 5 mg every week)</li>
<li>If severe proctitis: consider rectal steroids (hydrocortisone
    enema/foam)</li>
</ul>
</li>
<li>If lack of response to steroids: additional medical therapy
    (biologics), bowel rest with TPN, or surgical intervention<ul>
<li>Infliximab (Inflectra) is available at VUMC</li>
<li>If patient fails to respond to steroids, should consider
    possibility of CMV colitis (usually evaluated by biopsy on flex
    sig or colonoscopy)</li>
<li>Prior to initiating a biologic, all patients must have the
    following negative studies within the last year: Quantiferon
    Gold and CXR, Hepatitis B serologies, HIV, urine histoplasma Ag
    (some providers)</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-intestinal-ischemia"><h1 id="gastroenterology-gastroenterology-intestinal-ischemia-intestinal-ischemia">Intestinal Ischemia<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-intestinal-ischemia" title="Permanent link">&para;</a></h1>
<p>Michael Koenig</p>
<hr />
<h2 id="gastroenterology-gastroenterology-intestinal-ischemia-acute-mesenteric-ischemia">Acute Mesenteric Ischemia<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-acute-mesenteric-ischemia" title="Permanent link">&para;</a></h2>
<ul>
<li>Sudden onset ↓ or absence of blood flow to the small intestines</li>
<li>Mesenteric Arterial Occlusion:<ul>
<li>Arterial Embolism: Associated with cardiac arrhythmias (atrial
fibrillation), valvular disease, endocarditis, ventricular aneurysm,
aortic atherosclerosis, and aortic aneurysm</li>
<li>Arterial thrombosis: Most commonly from atherosclerotic disease; can
also be 2/2 abdominal trauma, infection, or dissection</li>
</ul>
</li>
<li>Venous thrombosis:<ul>
<li>Associated w/ hypercoagulable states, malignancy, prior abdominal
surgery, abdominal mass venous compression, intra-abdominal
inflammatory processes</li>
</ul>
</li>
<li>Non occlusive mesenteric ischemia:<ul>
<li>Intestinal hypoperfusion and vasoconstriction; associated with
decreased cardiac output, sepsis, vasopressor use</li>
</ul>
</li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-presentation" title="Permanent link">&para;</a></h3>
<ul>
<li>Early: Abdominal pain is most common symptom, abdominal distension</li>
<li>Abdominal tenderness is not prominent early (“pain out of proportion
    to the exam”)</li>
<li>Arterial occlusion: Sudden onset, severe periumbilical pain, nausea,
    and emesis</li>
<li>Venous thrombosis: More insidious onset abdominal pain, waxing and
    waning</li>
<li>Nonocclusive mesenteric ischemia: variable location and severity of
    abdominal pain; often overshadowed by a precipitating disorder</li>
<li>Late: As transmural bowel infarction develops, abdomen becomes
    distended, bowel sounds become absent, and peritoneal signs develop </li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-evaluation" title="Permanent link">&para;</a></h3>
<ul>
<li>Type and Screen, Lactic acid, BMP, CBC</li>
<li>Imaging: KUB: Normal in > 25% of cases</li>
<li>Ileus w/ distended bowel loops, bowel wall thickening, ± pneumatosis
    intestinalis</li>
<li>Free intraperitoneal air immediate abdominal exploration</li>
<li>CT Angiography: no oral contrast, obscures mesenteric vessels, ↓
    bowel wall enhancement</li>
<li>Focal or segmental bowel wall thickening, intestinal pneumatosis,
    portal vein gas, porto-mesenteric thrombosis, mesenteric arterial
    calcification, mesenteric artery occlusion</li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-management" title="Permanent link">&para;</a></h3>
<ul>
<li>General: IVFs, NPO, hemodynamic monitoring and support (try to avoid
    vasoconstricting agents), anticoagulation, broad-spectrum
    antibiotics, pain control</li>
<li>If develops peritonitis or evidence of perforation on CT EGS consult
    for surgery</li>
<li>Mesenteric arterial embolism: Embolectomy vs. local infusion of
    thrombolytic agent</li>
<li>Mesenteric arterial thrombosis: Surgical revascularization vs.
    thrombolysis with endovascular angioplasty and stenting</li>
<li>Venous thrombosis: Anticoagulation; possible thrombolysis if
    persistent symptoms</li>
<li>Nonocclusive occlusion: Treat underlying cause, stop
    vasoconstriction meds, consider intra-arterial vasodilator infusion</li>
</ul>
<h2 id="gastroenterology-gastroenterology-intestinal-ischemia-chronic-mesenteric-ischemia">Chronic Mesenteric Ischemia<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-chronic-mesenteric-ischemia" title="Permanent link">&para;</a></h2>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-background" title="Permanent link">&para;</a></h3>
<ul>
<li>↓ blood flow to intestines, typically caused by atherosclerosis of
    mesenteric vessel</li>
<li>High-grade mesenteric vascular stenoses in at least two major
    vessels (celiac, SMA, or IMA) must be established</li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-presentation_1">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-presentation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Recurrent dull, crampy, postprandial abdominal pain</li>
<li>Pts develop food aversion and often have associated weight loss</li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-evaluation_1">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-evaluation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>CTA abdomen/pelvis is preferred (>90% sensitivity and specificity)</li>
<li>Can also consider duplex U/S and gastric tonometry</li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-management_1">Management<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-management_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Conservative management if asymptomatic: smoking cessation and
    secondary prevention to limit progression of atherosclerotic disease</li>
<li>Nutritional evaluation</li>
<li>Revascularization (open vs. endovascular) is indicated if symptoms
    are present</li>
<li>Mesenteric angioplasty and stenting is first-line therapy</li>
<li>Goal is to prevent future bowel infarction</li>
</ul>
<h2 id="gastroenterology-gastroenterology-intestinal-ischemia-ischemic-colitis">Ischemic Colitis<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-ischemic-colitis" title="Permanent link">&para;</a></h2>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-background_1">Background<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Sudden, transient reduction in blood flow to colon</li>
<li>Typically at “watershed” areas, such as the splenic flexure and
    rectosigmoid junction</li>
<li>Most often nonocclusive (95% of cases) and affects older adults</li>
<li>Risk factors: ACS, hemodialysis, shock, aortoiliac instrumentation,
    cardiopulmonary bypass, extreme exercise (marathon running)</li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-presentation_2">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-presentation_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Rapid onset, mild cramping abdominal pain, associated with urge to
    defecate, hematochezia</li>
<li>Tenderness present (typically over left side)</li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-evaluation_2">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-evaluation_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Lactic acid (nonspecific but elevated), LDH, CPK, CBC
    (leukocytosis), BMP (metabolic acidosis)</li>
<li>KUB; if peritonitis or signs of severe ischemia → surgery </li>
<li>CT A/P with IV contrast (and oral contrast if patient can tolerate)</li>
<li>Consider CTA A/P if suspicion for vascular occlusion</li>
<li>Colonoscopy confirms diagnosis. </li>
<li>Edematous, friable mucosa; erythema; and interspersed pale areas;
    bluish hemorrhagic nodules representing submucosal bleeding</li>
<li>Segmental distribution, abrupt transition between injured and
    non-injured mucosa</li>
</ul>
<h3 id="gastroenterology-gastroenterology-intestinal-ischemia-management_2">Management<a class="headerlink" href="#gastroenterology-gastroenterology-intestinal-ischemia-management_2" title="Permanent link">&para;</a></h3>
<p>General: IVFs, bowel rest, antibiotics (Zosyn vs CTX/flagyl)</p>
<table>
<colgroup>
<col style="width: 13%" />
<col style="width: 38%" />
<col style="width: 47%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Ischemic Colitis Management</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td></td>
<td><strong>Classification</strong></td>
<td><strong>Management</strong></td>
</tr>
<tr class="even">
<td><strong>Mild</strong></td>
<td>No risk factors (see below)</td>
<td><p>Supportive care and observation</p>
<p>Antibiotics can be stopped if no ulceration</p></td>
</tr>
<tr class="odd">
<td><strong>Moderate</strong></td>
<td>1-3 risk factors</td>
<td><p>Same as mild ischemia if no vascular occlusion</p>
<p>Systemic anticoagulation +/- vascular intervention if mesenteric
occlusion</p></td>
</tr>
<tr class="even">
<td><strong>Severe</strong></td>
<td>&gt; 3 risk factors, peritoneal signs, pneumatosis,
pneumoperitoneum, gangrene or pancolonic ischemia on colonoscopy</td>
<td>Consult EGS for abdominal exploration and segmental resection</td>
</tr>
<tr class="odd">
<td colspan="3"><em><strong>Risk factors:</strong> male, SBP &lt;90, HR
&gt;100, WBC&gt;15k, Hgb &lt;12, Na &lt;136, BUN &gt;20, LDH &gt;350,
isolated right-sided colonic involvement, abdominal pain with rectal
bleeding</em></td>
</tr>
</tbody>
</table></section><section class="print-page" id="gastroenterology-gastroenterology-nausea-vomiting"><h1 id="gastroenterology-gastroenterology-nausea-vomiting-nausea-vomiting">Nausea &amp; Vomiting<a class="headerlink" href="#gastroenterology-gastroenterology-nausea-vomiting-nausea-vomiting" title="Permanent link">&para;</a></h1>
<p>Taylor Riggs</p>
<hr />
<h2 id="gastroenterology-gastroenterology-nausea-vomiting-etiology">Etiology<a class="headerlink" href="#gastroenterology-gastroenterology-nausea-vomiting-etiology" title="Permanent link">&para;</a></h2>
<p>VOMMIIT mnemonic</p>
<ul>
<li>
<p><u>V</u>estibular: Labyrinthitis, vestibular neuritis, meniere’s
    disease, cerebellar stroke</p>
</li>
<li>
<p><u>O</u>bstruction: adhesions, hernia, volvulus, constipation, gastric
    outlet obstruction</p>
</li>
<li>
<p><u>M</u>otility: gastroparesis, GERD, autonomic dysfunction</p>
</li>
<li>
<p><u>M</u>edications: antibiotics, SSRI, opioids, cannabinoid
    hyperemesis</p>
</li>
<li>
<p><u>I</u>nfection: gastroenteritis, hepatitis, pyelonephritis,
    cholecystitis</p>
</li>
<li>
<p><u>I</u>nflammation: PUD, pancreatitis</p>
</li>
<li>
<p><u>T</u>oxins: uremia, ketoacidosis, hypercalcemia, chemotherapy</p>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-nausea-vomiting-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-nausea-vomiting-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>All patients: CBC (leukocytosis, Hgb), BMP (AG, Ca, lytes, AKI),
    LFTs, lipase, lactate, UA</p>
</li>
<li>
<p>If risk factors: consider TSH, AM cortisol, troponin, β hCG, UDS</p>
</li>
<li>
<p>EKG to eval for ischemia and baseline QTc</p>
</li>
<li>
<p>Imaging:</p>
<ul>
<li>If concern for obstruction (abd distention, decreased BMs) KUB,
consider CT A/P</li>
<li>If concern for biliary pathology (RUQ pain, abnl LFTs) RUQ U/S</li>
<li>If vestibular/concern for CNS pathology CTH vs MRI brain</li>
</ul>
</li>
</ul>
<h1 id="gastroenterology-gastroenterology-nausea-vomiting-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-nausea-vomiting-management" title="Permanent link">&para;</a></h1>
<p>Address underlying cause and stop medications as appropriate</p>
<ul>
<li>Many antiemetics prolong QTc, however in patients without underlying
    cardiac conduction abnormality, electrolyte abnormality, or organ
    failure the risk of QTc prolongation leading to significant
    arrhythmia is low.</li>
<li>Obtain screening EKG in patients with underlying heart disease,
    electrolyte abnormalities, organ failure or on other QTc prolonging
    meds (antiarrhythmics, antipsychotics, antibiotics)</li>
<li>4-8 mg of IV Zofran is estimated to prolong QTc by ~6ms</li>
<li>Try to pick a medication that will address the underlying etiology
    of nausea</li>
<li>If patient does not respond to a medication in a certain class, try
    a medication from a different class (see below)</li>
</ul>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 27%" />
<col style="width: 32%" />
<col style="width: 17%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="4">Anti-Emetics</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Med (by class)</td>
<td>Typical Dose</td>
<td>Side Effects</td>
<td>Prolongs QT?</td>
</tr>
<tr class="even">
<td colspan="4"><strong>Serotonin antagonists</strong></td>
</tr>
<tr class="odd">
<td>Ondansetron (Zofran)</td>
<td>4-8mg PO/IV q6h</td>
<td>Constipation, headache, arrhythmia, serotonin syndrome</td>
<td>Yes</td>
</tr>
<tr class="even">
<td><p>Granisetron</p>
<p>(Kytril)1</p></td>
<td>1 mg PO BID, 2mg pre-chemo, OR 10mcg/kg IV pre-chemo</td>
<td>‘’</td>
<td>Yes</td>
</tr>
<tr class="odd">
<td colspan="4"><strong>Dopamine Antagonists</strong></td>
</tr>
<tr class="even">
<td>Prochlorperazine (Compazine)</td>
<td>5-10 mg PO/IV q6h, 25 mg PR q6h</td>
<td>EPS, less sedation than H-blockers (e.g. Phenergan)</td>
<td>Yes</td>
</tr>
<tr class="odd">
<td><p>Haloperidol</p>
<p>(Haldol)</p></td>
<td>0.5-1 mg PO/IV q6h</td>
<td>EPS, arrhythmia</td>
<td>Yes</td>
</tr>
<tr class="even">
<td>Zyprexa (Olanzapine)</td>
<td>5 -10mg PO qdaily</td>
<td>EPS, constipation, anticholinergic</td>
<td>Mild ^</td>
</tr>
<tr class="odd">
<td colspan="4"><strong>Dopamine and Serotonin Antagonists</strong></td>
</tr>
<tr class="even">
<td>Metoclopramide (Reglan)</td>
<td>10 mg PO/IV q6h</td>
<td>EPS/dystonia, arrhythmias, drowsiness/dizziness, diarrhea</td>
<td>Yes</td>
</tr>
<tr class="odd">
<td colspan="4"><strong>GABA-A Agonist</strong></td>
</tr>
<tr class="even">
<td><p>Lorazepam</p>
<p>(Ativan)</p></td>
<td>0.5-1mg PO/IV q6h PRN</td>
<td>Sedation, delirium, amnesia, respiratory depression</td>
<td>No</td>
</tr>
<tr class="odd">
<td colspan="4"><strong>H1 Antagonists</strong></td>
</tr>
<tr class="even">
<td>Promethazine (Phenergan)</td>
<td>12.5 - 25mg PO /PR /IV q6h (avoid IV use if possible)</td>
<td>Sedation, EPS (D2 antagonist also), arrhythmias, blurry vision</td>
<td>Yes</td>
</tr>
<tr class="odd">
<td>Diphenhydramine (Benadryl)</td>
<td>25-50mg PO/IV q6h</td>
<td>Sedation, delirium, urinary retention, ileus</td>
<td>Yes</td>
</tr>
<tr class="even">
<td><p>Meclizine</p>
<p>(Antivert)</p></td>
<td>12.5-25mg PO q6h</td>
<td>Sedation, dizziness, falls, blurry vision</td>
<td>Yes</td>
</tr>
<tr class="odd">
<td colspan="4"><strong>Anticholinergics</strong></td>
</tr>
<tr class="even">
<td>Scopolamine</td>
<td>1 mg patch q3day</td>
<td>Dry mouth, blurry vision, drowsiness</td>
<td>No</td>
</tr>
<tr class="odd">
<td colspan="4"><strong>Glucocorticoids</strong></td>
</tr>
<tr class="even">
<td>Dexamethasone</td>
<td>4-8mg PO/IV prior to chemo or XRT, typically use with other
agents</td>
<td>Hyperglycemia, fluid retention, delirium</td>
<td>No</td>
</tr>
<tr class="odd">
<td colspan="4"><strong>NK1 Antagonists</strong></td>
</tr>
<tr class="even">
<td>Aprepitant</td>
<td>Given prior to/with chemo</td>
<td>Fatigue, neutropenia</td>
<td>No</td>
</tr>
<tr class="odd">
<td colspan="4"><strong>CBD Agonists</strong></td>
</tr>
<tr class="even">
<td>Dronabinol</td>
<td>2.5-5mg BID</td>
<td>Dizziness, increased appetite, Tachycardia, hypotension</td>
<td>No</td>
</tr>
</tbody>
</table></section><section class="print-page" id="gastroenterology-gastroenterology-peptic-ulcer-disease"><h1 id="gastroenterology-gastroenterology-peptic-ulcer-disease-peptic-ulcer-disease">Peptic Ulcer Disease<a class="headerlink" href="#gastroenterology-gastroenterology-peptic-ulcer-disease-peptic-ulcer-disease" title="Permanent link">&para;</a></h1>
<p>Michelle Izmaylov</p>
<hr />
<h2 id="gastroenterology-gastroenterology-peptic-ulcer-disease-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-peptic-ulcer-disease-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Ulceration in the GI tract wall extending through the muscularis
    mucosa into deeper layers</li>
<li>Most common in the stomach and proximal duodenum</li>
<li>Less common in the lower esophagus, the distal duodenum, or the
    jejunum<ul>
<li>↑ suspicion for unopposed hypersecretory states, like
    Zollinger-Ellison syndrome</li>
</ul>
</li>
<li>Causes: NSAID use and Helicobacter pylori >> steroids, malignancy,
    and acute stress</li>
</ul>
<h2 id="gastroenterology-gastroenterology-peptic-ulcer-disease-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-peptic-ulcer-disease-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Episodic gnawing or burning epigastric pain, 2 - 5 hr after meals,
    nausea, vomiting, heartburn, bloating, postprandial belching, and
    loss of appetite</li>
<li>Nocturnal pain: acid is secreted in absence of a food buffer</li>
<li>Classic teaching for ulcers: Gastric (pain worse w/eating); Duodenal
    (pain better w/eating)</li>
<li>May be asymptomatic until complications such as hemorrhage or
    perforation</li>
<li>Alarm features: unintentional weight loss, persistent vomiting,
    melena, progressive dysphagia, early satiety, recurrent vomiting,
    palpable abdominal mass, lymphadenopathy, family history of upper
    gastrointestinal cancer, and iron deficiency anemia</li>
</ul>
<h2 id="gastroenterology-gastroenterology-peptic-ulcer-disease-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-peptic-ulcer-disease-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>CBC and H Pylori testing if no strong NSAID use history</li>
<li>Urea breath or stool antigen (pt needs to stop PPI for 1-2 weeks, to
    avoid false - for both)</li>
<li>EGD: if alarm features or patient is older than 55</li>
</ul>
<h2 id="gastroenterology-gastroenterology-peptic-ulcer-disease-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-peptic-ulcer-disease-management" title="Permanent link">&para;</a></h2>
<ul>
<li>General: treat underlying cause (i.e. H. pylori, stop NSAIDs, etc),
    encourage smoking cessation, and limit alcohol intake to 1
    drink/day.</li>
<li>If complicated peptic ulcer (i.e. bleeding, perforation, or gastric
    outlet obstruction):<ul>
<li>EGD to determine etiology and for possible treatment</li>
<li>IV PPI (if bleeding IV PPI for 72 hrs after endoscopic treatment
oral PPI)</li>
</ul>
</li>
<li>If uncomplicated peptic ulcer (not caused by H. pylori):<ul>
<li>Antisecretory therapy with oral PPI (i.e. omeprazole 20 to 40 mg
daily):<ul>
<li>If caused by NSAIDs: Duration: \&lt;1 cm ulcer 4-6 wks; ≥1 cm ulcer
6-8 wks</li>
</ul>
</li>
<li>If not caused by NSAIDs, Duration:<ul>
<li>Duodenal ulcer: 4 weeks</li>
<li>Gastric ulcer: 8 weeks</li>
</ul>
</li>
</ul>
</li>
<li>If ulcer caused by H. pylori:<ul>
<li>Treat with PPI BID for 14 days with an appropriate combination
antibiotic regimen.</li>
<li>Confirm H. pylori eradication (via stool antigen test, urease breath
test, or EGD >4 weeks after completion of therapy). If not
eradicated, retreat</li>
</ul>
</li>
</ul>
<h2 id="gastroenterology-gastroenterology-peptic-ulcer-disease-additional-information">Additional Information<a class="headerlink" href="#gastroenterology-gastroenterology-peptic-ulcer-disease-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>Continue maintenance PPI therapy (omeprazole 20 mg daily) for the
    following:<ul>
<li>Peptic ulcer >2 cm and age >50 or multiple co-morbidities</li>
<li>Frequently recurrent peptic ulcers (>2 in one year)</li>
<li>H. pylori-negative, NSAID-negative ulcer disease</li>
<li>Failure to eradicate H. pylori (including salvage therapy)</li>
<li>Condition requiring long term aspirin/NSAID use</li>
<li>Persistent ulcer on repeat EGD (if performed)</li>
</ul>
</li>
<li>Indications for repeat EGD (8-12 weeks):<ul>
<li>Persistent/recurrent symptoms despite medical therapy</li>
<li>Complicated ulcer (bleeding), with evidence of ongoing bleeding</li>
<li>Giant gastric ulcer (>2 cm) or features of malignancy at index
endoscopy</li>
<li>Gastric ulcer that was not biopsied or inadequately sampled on
initial EGD</li>
<li>Gastric ulcer in pt w/risk factors for gastric cancer (&gt;50 yo, H.
pylori, immigrant from high prevalence area [Japan, Korea, Taiwan,
Costa Rica], FHx, presence of gastric atrophy, adenoma, dysplasia,
intestinal metaplasia)</li>
</ul>
</li>
</ul></section><section class="print-page" id="gastroenterology-gastroenterology-small-bowel-obstruction"><h1 id="gastroenterology-gastroenterology-small-bowel-obstruction-small-bowel-obstruction-sbo">Small Bowel Obstruction (SBO)<a class="headerlink" href="#gastroenterology-gastroenterology-small-bowel-obstruction-small-bowel-obstruction-sbo" title="Permanent link">&para;</a></h1>
<p>Alex Wiles</p>
<hr />
<h2 id="gastroenterology-gastroenterology-small-bowel-obstruction-background">Background<a class="headerlink" href="#gastroenterology-gastroenterology-small-bowel-obstruction-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Risk Factors: prior abdominal surgeries (adhesions), malignancy,
    hernia, intestinal inflammation (IBD)/stricture, radiation, abscess,
    foreign bodies</li>
<li>Indicators for bowel ischemia: fever, leukocytosis, tachycardia,
    peritonitis</li>
<li>Ddx: early appendicitis, large bowel obstruction, Ogilvie’s, DKA,
    Pancreatitis, IBD, Gastric outlet obstruction</li>
</ul>
<h2 id="gastroenterology-gastroenterology-small-bowel-obstruction-presentation">Presentation<a class="headerlink" href="#gastroenterology-gastroenterology-small-bowel-obstruction-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Nausea, emesis, intermittent colic, bloating, constipation</li>
<li>Obstipation if completely obstructed, loss of flatulence</li>
<li>Exam: classically with “tinkling” bowel sounds, tympanic abdomen,
    distended abdomen</li>
</ul>
<h2 id="gastroenterology-gastroenterology-small-bowel-obstruction-evaluation">Evaluation<a class="headerlink" href="#gastroenterology-gastroenterology-small-bowel-obstruction-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>CBC, BMP, lipase, hepatic function panel, lactate (sensitive, not
    specific for ischemia)</li>
<li>Start with KUB to rule out perforation but typically will require CT
    (x-ray only ~80% sensitive)</li>
<li>CT abdomen/pelvis with IV contrast is optimal study if adequate
    renal function<ul>
<li>No oral contrast (American College of Radiology (ACR)
Appropriateness Criteria) as it will not aid diagnosis and can lead
to aspiration; IV helps evaluate ischemia</li>
</ul>
</li>
<li>Key word: transition point</li>
<li>Non-specific signs of bowel inflammation: bowel wall thickening,
    submucosal edema</li>
</ul>
<h2 id="gastroenterology-gastroenterology-small-bowel-obstruction-management">Management<a class="headerlink" href="#gastroenterology-gastroenterology-small-bowel-obstruction-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Consult EGS: if any concern for SBO, evaluate need for urgent
    surgery</li>
<li>Surgical indications complete obstruction, CT with ischemia,
    perforation</li>
<li>Gastric decompression: place NGT (prevent aspiration)</li>
<li>NPO until obstruction relieved and NGT removed</li>
<li>Fluids: two large bore IVs (nursing communication); LR bolus +
    maintenance while NPO</li>
<li>If no resolution of partial obstruction at 48 hours:</li>
<li>Fluoroscopy Upper GI small bowel ft (follow through)<ul>
<li>In comments, write “Gastrografin contrast” (water-soluble
    contrast) which osmotically reduces bowel wall edema and aids
    peristalsis</li>
<li>If gastrografin reaches the colon within 24 hours, it predicts
    clinical resolution of SBO without surgery</li>
<li>Note: this can also be therapeutic for pSBO and get bowels moving</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Gastroenterology</h1>
                        <h1 class='nav-section-title' id='section-geriatrics'>
                            Geriatrics <a class='headerlink' href='#section-geriatrics' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="geriatrics-geriatrics-dementia"><h1 id="geriatrics-geriatrics-dementia-dementia">Dementia<a class="headerlink" href="#geriatrics-geriatrics-dementia-dementia" title="Permanent link">&para;</a></h1>
<p>Thomas Horton</p>
<hr />
<h2 id="geriatrics-geriatrics-dementia-background">Background<a class="headerlink" href="#geriatrics-geriatrics-dementia-background" title="Permanent link">&para;</a></h2>
<ul>
<li><strong>Alzheimer’s Disease (AD)</strong>: short-term memory deficits prominent</li>
<li><strong>Vascular Dementia</strong>: “Stepwise decline” in memory and functional
    status</li>
<li><strong>Lewy Body Dementia</strong>: hallucinations, memory difficulties with
    atypical Parkinsonism early</li>
<li><strong>Frontotemporal Dementia</strong>: behavioral (aggressive or
    disinhibited), language (primary progressive aphasias) or memory
    (Alzheimer’s/FTD overlap) variants</li>
<li><strong>Posterior Cortical Atrophy</strong>: visual difficulties and ocular
    apraxia preceding memory problems</li>
<li><strong>Creutzfeldt-Jakob Disease (CJD)</strong>: manifests with subacute
    cognitive decline, seizures, vision loss, personality changes. Can
    develop startle myoclonus</li>
<li><strong>Corticobasal degeneration</strong>: focal neurologic changes with
    parkinsonism</li>
<li><strong>Neurosyphilis</strong>: rare, but treatable, present with a range of
    cognitive changes. Develop meningovascular encephalitis. Pts can
    develop an arteritis, headache, and hydrocephalus.</li>
<li><strong>Normal Pressure Hydrocephalus (NPH)</strong>: “wet, wacky and wobbly”
    meaning incontinence, gait apraxia and cognitive changes (usually
    frontal symptoms)</li>
<li><strong>Autoimmune Dementias</strong>: includes limbic encephalitis (like NMDA)
    where there are memory and personality changes, autonomic changes,
    hallucinations, and seizures</li>
</ul>
<table style="width:100%;">
<colgroup>
<col style="width: 27%" />
<col style="width: 27%" />
<col style="width: 44%" />
</colgroup>
<thead>
<tr class="header">
<th>Normal Aging</th>
<th>Mild Cognitive Impairment</th>
<th><p>Alzheimer’s Dementia</p>
<p>(DSM V Diagnostic Crit.)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Mild decline in working memory</p>
<p>More effort/time needed to recall new info</p>
<p>New learning slowed but well compensated by lists, calendars,
etc.</p>
<p>+</p>
<p>No impairment in social &amp; occupation functioning</p></td>
<td><p>Subjective complaint of cognitive decline in at least one
domain</p>
<p>+</p>
<p>Cognitive decline is noticeable and measurable</p>
<p>+</p>
<p>No impairment in social &amp; occupation functioning</p></td>
<td><p>Evidence of significant cognitive decline from a <em>previous
level of performance in one or more cognitive domains</em></p>
<p>+</p>
<p>Causes significant impairment in social &amp; occupation
functioning</p>
<p>+</p>
<p>Other medical &amp; psychiatric conditions, including delirium, have
been excluded</p>
<p>+</p>
<p>Insidious onset and gradual progression of impairment in at least two
cognitive domains</p></td>
</tr>
<tr class="even">
<td colspan="3"><strong>Cognitive domains</strong><em>:</em>
learning/memory, language, executive function, complex attention,
perceptual motor, social cognition</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 17%" />
<col style="width: 18%" />
<col style="width: 19%" />
<col style="width: 27%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Alzheimer’s Disease</th>
<th>Vascular Dementia</th>
<th>Lewy Body Dementia</th>
<th>Frontotemporal Dementia</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Onset</strong></td>
<td>Gradual</td>
<td>Sudden or stepwise</td>
<td>Gradual</td>
<td>Gradual (age &lt; 60)</td>
</tr>
<tr class="even">
<td><strong>Cognitive Domains &amp; Symptoms</strong></td>
<td>Memory, language, visuospatial</td>
<td>Depends on location of ischemia</td>
<td>Memory, visuospatial</td>
<td>Executive dysfunction, personality changes, disinhibition, language,
+/- memory</td>
</tr>
<tr class="odd">
<td><strong>Motor Symptoms</strong></td>
<td><p>Rare early</p>
<p>Apraxia later</p></td>
<td>Correlates with ischemia</td>
<td>Parkinsonism</td>
<td>None</td>
</tr>
<tr class="even">
<td><strong>Progression</strong></td>
<td>Gradual (over 8-10 years)</td>
<td>Gradual or stepwise with further ischemia</td>
<td>Gradual, but faster than Alzheimer’s disease</td>
<td>Gradual, but faster than Alzheimer’s disease</td>
</tr>
<tr class="odd">
<td><strong>Imaging</strong></td>
<td>Possible global atrophy</td>
<td>Cortical or subcortical on MRI</td>
<td>Possible global atrophy</td>
<td>Atrophy in frontal &amp; temporal lobes</td>
</tr>
</tbody>
</table>

<h2 id="geriatrics-geriatrics-dementia-evaluation">Evaluation<a class="headerlink" href="#geriatrics-geriatrics-dementia-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>MINI-COG: Screening test for cognitive impairment (highly sensitive)<ul>
<li>Ask pt to remember three words (banana, sunrise, chair). Ask pt to
repeat immediately</li>
<li>Ask pt to draw clock. After numbers are on the face, ask pt to “set
hands to 10 past 11”<ul>
<li>Correct is all numbers in right position AND hands pointing to
the 11 and the 2</li>
</ul>
</li>
</ul>
</li>
<li>Ask pt to recall the three words</li>
</ul>
<!--
<img src="../geriatrics/geriatrics-dementia/output/media/image16.png"
style="width:2.41484in;height:1.09028in"
alt="Diagram Description automatically generated" />
-->

<ul>
<li>
<p>MOCA: Montreal Cognitive Assessment</p>
<ul>
<li>Lengthier test of cognition (but highly specific for cognitive
impairment)</li>
<li>Useful for detecting subtle deficits as in Mild Cognitive Impairment
(MCI)</li>
<li>Scores:<ul>
<li>18-25: Mild cognitive impairment</li>
<li>10-17: Moderate cognitive impairment</li>
<li>&lt;10: Severe cognitive impairment</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Rule out reversible causes of dementia-like symptoms: <strong>DEMENTIA</strong></p>
<ul>
<li>Drugs</li>
<li>Emotional (depression)</li>
<li>Metabolic (CHF, COPD, CKD, OSA)</li>
<li>Endocrine (hypothyroidism, hyperparathyroidism, hyponatremia)</li>
<li>Nutrition (B12 deficiency)</li>
<li>Trauma (chronic SDH)</li>
<li>Infection</li>
<li>Arterial (vascular)</li>
</ul>
</li>
<li>B12, thyroid studies</li>
<li>RPR, HIV testing in at-risk patient groups</li>
<li>Neuropsych testing can be done for more clear patterns of
    dysfunction</li>
<li>MRI brain with contrast if concerned for inflammatory or infectious
    causes<ul>
<li>CJD: cortical ribboning on DWI with T2 hyperintensity in the
thalamus and basal ganglia</li>
<li>Sulcal crowding and bowing of the corpus callosum can be seen in NPH
on imaging</li>
</ul>
</li>
</ul>
<h2 id="geriatrics-geriatrics-dementia-management">Management<a class="headerlink" href="#geriatrics-geriatrics-dementia-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Targeting Cognitive Impairment<ul>
<li>Cholinesterase Inhibitors: Donepezil, rivastigmine<ul>
<li>Indicated for any stage (except FTD)</li>
<li>SE: GI (nausea, diarrhea), bradycardia, orthostasis</li>
</ul>
</li>
<li>NMDA antagonists: Memantine<ul>
<li>Indicated in moderate to severe AD in combination with
    cholinesterase inhibitors</li>
<li>Fewer SE than cholinergic medications</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Vitamin supplementation (i.e. Vitamin E)</p>
<ul>
<li>Unclear benefit in delaying progression of dementia</li>
</ul>
</li>
<li>
<p>Targeting Behaviors</p>
<ul>
<li>Non-pharmacologic management has the best evidence of effectiveness</li>
<li>Depression: Treat with antidepressants (SSRI’s)</li>
<li>Sleep Disturbance: Mirtazapine (7.5 mg nightly) or Trazodone (25 mg
    nightly)</li>
<li>Agitation: Try SSRI (citalopram, sertraline)<ul>
<li>Consider antipsychotics (black box warning increased risk of
    death in elderly)</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-falls"><h1 id="geriatrics-geriatrics-falls-falls">Falls<a class="headerlink" href="#geriatrics-geriatrics-falls-falls" title="Permanent link">&para;</a></h1>
<p>Thomas Horton</p>
<hr />
<h2 id="geriatrics-geriatrics-falls-background">Background<a class="headerlink" href="#geriatrics-geriatrics-falls-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Screen annually for falls in the past year</li>
<li>History of fall is a strong risk factor for future falls</li>
<li>Recommended History Screening Tool: CDC STEADI Algorithm</li>
<li>Physical Exam Screening Tools:</li>
<li>If potentially unstable injuries (new spine fracture or lower
    extremity fracture): Ask ortho to clear the patient for mobility</li>
<li>If no potentially unstable injuries, attempt to get the patient out
    of bed<ul>
<li>If lying down, have them lift each leg off the bed</li>
<li>If they can do this, ask them to sit up on side of bed</li>
<li>If they can do this, ask them to stand</li>
<li>If they can do this without assistance, then observe them walk</li>
</ul>
</li>
<li>The Timed “up and Go” Test (TUG) tool for fall risk<ul>
<li>Have the patient rise from sitting in a chair, walk 10 feet
    forward, turn around, walk back to chair, and sit down</li>
<li>Patients who require &gt; 10 seconds are at increased risk for
    falls</li>
</ul>
</li>
<li>Med Rec:<ul>
<li>Antipsychotics, antidepressants, anticholinergics, anxiolytics,
sedatives/hypnotics, anti-hypertensives, antiarrhythmics, steroids,
statins all can increase risk of falls</li>
</ul>
</li>
</ul>
<h2 id="geriatrics-geriatrics-falls-management">Management<a class="headerlink" href="#geriatrics-geriatrics-falls-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Rule out other causes: Cardiac, Neurologic, Infectious</li>
<li>Check Vitamin D levels (goal > 30) and supplement (800-1000 IU
    daily) if at increased fall risk</li>
<li>Assess visual acuity (e.g. expedite cataract surgery)</li>
<li>Hearing assessment (audiology screen)</li>
<li>Consult Inpatient PT/OT and refer for HH PT/OT for home safety
    evaluation at discharge</li>
<li>Recommend non-skid shoes with a backing (sneaker)</li>
<li>Modify extrinsic risk factors for falls: removal of fall hazards,
    placement of handrails</li>
<li>Referral to Exercise programs: At VUMC = Dayani Center “Ambulatory
    Referral to Medical Fitness” outpatient order</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-frailty"><h1 id="geriatrics-geriatrics-frailty-frailty">Frailty<a class="headerlink" href="#geriatrics-geriatrics-frailty-frailty" title="Permanent link">&para;</a></h1>
<p>Thomas Horton</p>
<hr />
<h2 id="geriatrics-geriatrics-frailty-background">Background<a class="headerlink" href="#geriatrics-geriatrics-frailty-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Syndrome of physiological decline in late life, characterized by
    marked vulnerability to adverse health outcomes</li>
</ul>
<h2 id="geriatrics-geriatrics-frailty-evaluation">Evaluation<a class="headerlink" href="#geriatrics-geriatrics-frailty-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>FRAIL Scale Identifies frailty in community dwelling elders (1 -2 =
    prefrail; > 3 = frail)<ul>
<li>Fatigue: are you Fatigued more often than not?</li>
<li>Resistance: are you able to climb a flight of stairs?</li>
<li>Aerobic: are you bale to walk a block?</li>
<li>Illness: Do you have more than five illnesses?</li>
<li>Loss: Have you lost more than 5% of weight in 6 months?</li>
</ul>
</li>
<li>Order Vitamin D and B-12 Levels.</li>
</ul>
<h2 id="geriatrics-geriatrics-frailty-management">Management<a class="headerlink" href="#geriatrics-geriatrics-frailty-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Adapt interventions to the individual, incorporating patient
    preferences and stage on the spectrum of frailty</li>
<li>Exercise programs with additional physical and occupational therapy
    input if indicated.</li>
<li>Optimize nutrition via supplementation (Vit D, B12)</li>
<li>Comprehensive Geriatric Assessment; Outpatient PACE</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-functional-status"><h1 id="geriatrics-geriatrics-functional-status-functional-status">Functional Status<a class="headerlink" href="#geriatrics-geriatrics-functional-status-functional-status" title="Permanent link">&para;</a></h1>
<p>Thomas Horton</p>
<hr />
<h2 id="geriatrics-geriatrics-functional-status-background">Background<a class="headerlink" href="#geriatrics-geriatrics-functional-status-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Functional status: Ability to perform activities necessary in daily
    life (ADL)</li>
</ul>
<table>
<colgroup>
<col style="width: 29%" />
<col style="width: 35%" />
<col style="width: 34%" />
</colgroup>
<thead>
<tr class="header">
<th>Basic ADL’s</th>
<th>Instrumental ADL’s</th>
<th>Advanced ADL’s</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p><u>D</u>ressing</p>
<p><u>E</u>ating</p>
<p><u>A</u>mbulating/transfer</p>
<p><u>T</u>oileting/continence</p>
<p><u>H</u>ygiene (bathing)</p></td>
<td><p><u>S</u>hopping</p>
<p><u>H</u>ousekeeping &amp; laundry</p>
<p><u>H</u>andling medications</p>
<p><u>A</u>ccounting (finances)</p>
<p><u>F</u>ood preparation</p>
<p><u>T</u>elephone</p>
<p><u>T</u>ransportation (driving)</p></td>
<td><p>Fulfill societal, community and family roles</p>
<p>Participate in recreational tasks</p></td>
</tr>
</tbody>
</table>

<h2 id="geriatrics-geriatrics-functional-status-evaluation">Evaluation<a class="headerlink" href="#geriatrics-geriatrics-functional-status-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Katz ADL scale, Lawton-Brody IADL scale, Get up and Go test, MMSE,
    Geriatric depression scale.</li>
<li>Vulnerable Elders Scale-13: Identifies community dwelling pts at
    risk for decline over 5 yrs</li>
<li>Functional decline is not normal with aging and warrants detailed
    physical, cognitive, and psychosocial evaluations</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-malnutrition"><h1 id="geriatrics-geriatrics-malnutrition-malnutrition">Malnutrition<a class="headerlink" href="#geriatrics-geriatrics-malnutrition-malnutrition" title="Permanent link">&para;</a></h1>
<p>Thomas Horton</p>
<hr />
<h2 id="geriatrics-geriatrics-malnutrition-background">Background<a class="headerlink" href="#geriatrics-geriatrics-malnutrition-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Needs to meet two or more of following criteria:<ul>
<li>Insufficient calorie intake</li>
<li>Weight loss</li>
<li>Loss of muscle mass</li>
<li>Loss of subcutaneous fat</li>
<li>Localized fluid accumulation that may mask weight loss</li>
<li>Diminished functional status as measured in handgrip strength</li>
</ul>
</li>
<li>Reversible causes of malnutrition:<ul>
<li>Food security (poverty), dental status (dentition, gum health),
dietary restrictions, food-related functional status (shop, prepare
meals, feed self), depression, dementia, alcoholism, swallowing
ability</li>
</ul>
</li>
</ul>
<h2 id="geriatrics-geriatrics-malnutrition-evaluation">Evaluation<a class="headerlink" href="#geriatrics-geriatrics-malnutrition-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Assess for depression</li>
<li>Screening with Mini Nutritional Assessment (good sensitivity and
    specificity)</li>
<li>Order: CBC, CMP, TSH</li>
<li>Nutritional deficiencies: B12, folate, vitamin D</li>
<li>Consider CT C/A/P depending on history</li>
<li>Refeeding: K, Phos, Mg BID until stable and no longer having to
    replete</li>
</ul>
<h2 id="geriatrics-geriatrics-malnutrition-management">Management<a class="headerlink" href="#geriatrics-geriatrics-malnutrition-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Manage reversible causes of malnutrition as above</li>
<li>Medications: consider Remeron (7.5 mg nightly). Avoid Megace (NNH =
    23 for death)</li>
<li>Liberalize dietary restrictions</li>
<li>Nutritional Supplementation: Oral enteral supplements (i.e.
    nutritional shakes)</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-medication-management"><h1 id="geriatrics-geriatrics-medication-management-medication-management">Medication Management<a class="headerlink" href="#geriatrics-geriatrics-medication-management-medication-management" title="Permanent link">&para;</a></h1>
<p>Thomas Horton</p>
<hr />
<ul>
<li>Medication Reconciliation Upon Admission</li>
<li>Evaluating for Polypharmacy – Beer’s Criteria</li>
<li>Pharmacologic changes in the elderly<ul>
<li>Pharmacokinetic (PK): Decreased hepatic and renal clearance.
Reduction in first pass metabolism. Drug distribution changes due to
decreased TBW and lean body mass resulting in relative increase in
fat.</li>
<li>Pharmacodynamic (PD): Exaggerated responses to pharmacologic therapy
(therapeutic and adverse effects).</li>
</ul>
</li>
<li>Avoid Prescribing Defaults:<ul>
<li>NSAIDs can lead to gastritis, which can lead to prescription of PPI</li>
<li>Diuretics can lead to urinary incontinence, which can lead to
prescription of oxybutynin</li>
<li>HCTZ can lead to hyperuricemia which can lead to prescription of
allopurinol</li>
</ul>
</li>
<li>Discharge Tips for med adherence: provide pillboxes &amp; arrange
    blister packs for meds</li>
<li>Recommended Tools: deprescribing.org (App available); medstopper.com</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-overview"><h1 id="geriatrics-geriatrics-overview-geriatrics-overview">Geriatrics Overview<a class="headerlink" href="#geriatrics-geriatrics-overview-geriatrics-overview" title="Permanent link">&para;</a></h1>
<p>Thomas Horton</p>
<hr />
<h2 id="geriatrics-geriatrics-overview-4-ms-of-age-friendly-care">4 M’s of Age-Friendly Care<a class="headerlink" href="#geriatrics-geriatrics-overview-4-ms-of-age-friendly-care" title="Permanent link">&para;</a></h2>
<p>Endorsed by the IHI to provide best evidence-based care to older
patients across all settings of care:</p>
<ul>
<li>What **M**atters Most: Understand each patients specific healthcare
    goals in the short and long term. Ask “what matters most” and align
    the care plan with what matters.</li>
<li>**M**edication: Aim to reduce adverse drug events in the elderly by
    thorough med rec and avoiding potentially inappropriate medications
    (e.g. Beers Criteria) when possible</li>
<li>**M**entation: Identify, treat, and manage dementia, depression, and
    delirium across various settings of care.</li>
<li>**M**obility: Assess and optimize mobility</li>
</ul>
<p>Vanderbilt’s FACETS Inpatient Geriatrics Curriculum: <a href="https://sites.google.com/view/facetscourse">https://sites.google.com/view/facetscourse</a></p>
<h2 id="geriatrics-geriatrics-overview-physiological-changes-with-aging">Physiological Changes with Aging<a class="headerlink" href="#geriatrics-geriatrics-overview-physiological-changes-with-aging" title="Permanent link">&para;</a></h2>
<ul>
<li><strong>Cardiovascular</strong>: Decreased vascular compliance and increased
    stiffness (intimal thickening). Decreased cardiac output. Maximum
    achievable HR decreases. Increase in systolic BP with decrease in
    diastolic BP (wider PP).</li>
<li><strong>Endocrine/Immune:</strong> Impairment of glucose tolerance (insulin
    resistance). Decreased sympathetic response to stress. Impairment of
    T-cell immunity and increased susceptibility to infection.</li>
<li><strong>Gastrointestinal:</strong> Decreased GI absorption, gastric emptying,
    motility, acid secretion, and hepatic blood flow. Reduced appetite
    and alterations of taste and smell.</li>
<li><strong>Musculoskeletal:</strong> Decreased bone density, muscle mass and
    strength. Increased fracture risk.</li>
<li><strong>Neurologic:</strong> Reduced cortical volume. Blunted vision, auditory
    function, and vibrotactile sensation. Decreased autonomic neural
    response. Slowed cognition and reflexes.</li>
<li><strong>Pulmonary:</strong> Increased chest wall rigidity. Decreased respiratory
    muscle strength. Decreased FEV1; FVC. Diminished ventilatory
    response to hypercapnia and hypoxia.</li>
<li><strong>Renal:</strong> Increased glomerulosclerosis. Decreased GFR and renal
    clearance of drugs/metabolites (↓ 1mL/min per year after age 40; Cr
    may stay the same due to reduced muscle mass). Reduced tubular
    function.</li>
</ul></section><section class="print-page" id="geriatrics-geriatrics-urinary-incontinence-and-foley-catheter"><h1 id="geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-urinary-incontinence-and-foley-catheters">Urinary Incontinence and Foley Catheters<a class="headerlink" href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-urinary-incontinence-and-foley-catheters" title="Permanent link">&para;</a></h1>
<p>Thomas Horton</p>
<hr />
<h2 id="geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-background">Background<a class="headerlink" href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-background" title="Permanent link">&para;</a></h2>
<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 42%" />
<col style="width: 39%" />
</colgroup>
<thead>
<tr class="header">
<th>Types of UI</th>
<th>Mechanism</th>
<th>Associated Symptoms</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Stress</td>
<td><p>Incompetent urethral sphincter</p>
<p>(post-prostatectomy)</p></td>
<td><p>UI with physical exertion</p>
<p>(cough, laughter, sneeze)</p></td>
</tr>
<tr class="even">
<td>Urge</td>
<td><p>↑ bladder contraction from detrusor instability</p>
<p>(infection, stone, T2DM, caffeine, meds, BPH</p></td>
<td>Frequency, nocturia, sudden urge</td>
</tr>
<tr class="odd">
<td>Overflow</td>
<td>↓ contractility/outlet obstruction (BPH, anticholinergic
medications, T2DM, pelvic trauma, spinal cord disease, MS, polio)</td>
<td>Hesitancy, weak stream, sense of incomplete emptying</td>
</tr>
<tr class="even">
<td>Functional</td>
<td>Physical, emotional, or cognitive disability</td>
<td>Depression, pain, evidence of physical, sensory, or cognitive
impairment</td>
</tr>
</tbody>
</table>

<h2 id="geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-evaluation">Evaluation<a class="headerlink" href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Medication Reconciliation:<ul>
<li>Alcohol, α-Adrenergic agonists, α-Adrenergic blockers, ACE
inhibitors, Anticholinergics, Antipsychotics, Calcium channel
blockers, oral estrogen, GABAergic agents, NSAID’s, narcotics</li>
</ul>
</li>
<li>Order Hemoglobin A1C, Electrolytes (particularly calcium), UA</li>
<li>Rule out retention using PVR</li>
<li>Rectal exam to rule out fecal impaction</li>
</ul>
<h2 id="geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-management">Management<a class="headerlink" href="#geriatrics-geriatrics-urinary-incontinence-and-foley-catheter-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Skin care for urinary incontinence:</li>
<li>Barrier creams: Venelex, petroleum, zinc oxide</li>
<li>Diapers only when up out of bed</li>
<li>Chucks while in bed (don’t hold moisture up close to the skin like
    diapers do)</li>
<li>Offer toileting Q1-2hours</li>
<li>Indications for a foley:<ul>
<li>Inability to void</li>
<li>Need for accurate UOP monitoring when patient unable to comply</li>
<li>Urinary Incontinence AND open sacral or perineal wound</li>
<li>Perioperative Use</li>
<li>Comfort care at end of life</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Geriatrics</h1>
                        <h1 class='nav-section-title' id='section-hematology-oncology'>
                            Hematology oncology <a class='headerlink' href='#section-hematology-oncology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="hematology-oncology-hematologyoncology-anemia"><h1 id="hematology-oncology-hematologyoncology-anemia-anemia">Anemia<a class="headerlink" href="#hematology-oncology-hematologyoncology-anemia-anemia" title="Permanent link">&para;</a></h1>
<p>Anemia – Margaret Wheless</p>
<p>General Approach to Diagnosis</p>
<ul>
<li>First evaluate RI (decreased production) vs ↑RI (loss vs hemolysis)<ul>
<li>Reticulocyte
    index &gt; 2%: see below</li>
<li>RI \&lt; 2%:  hypoproliferative
    
    stratify based on RBC size<ul>
<li>Microcytic
    vs. Normocytic vs. Macrocytic</li>
<li>Exception to ↓RI is thalassemia where RI can be slightly ↑</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Symptoms: fatigue/malaise, DOE, angina (if CAD)</li>
<li>Hx of systemic illness, ETOH abuse, Family History</li>
<li>Signs:<ul>
<li>Pallor
    , tachycardia, orthostatic hypotension, purpura, glossitis,
    koilonychia (IDA)</li>
<li>Jaundice (2/2 hemolysis)</li>
<li>Splenomegaly: suggests ex
    tramedullary hematopoiesis or sequestration</li>
<li>Neurologic
    symptoms:
    suggests
    B12 deficiency</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC w/diff, reticulocyte count, peripheral blood smear, Iron studies
    (TIBC, Ferritin)</li>
<li>Hemolysis labs: Bilirubin, LDH, haptoglobin</li>
<li>Nutritional studies: B12, folate</li>
</ul>
<p>Reticulocyte Index > 2%</p>
<p>Background</p>
<ul>
<li>Consumption vs Blood loss</li>
<li>Loss: acute bleed vs iatrogenic from labs</li>
<li>Hemolysis:
    Microangiopathic hemolytic anemia (MAHA), autoimmune hemolytic
    anemia, intrinsic RBC defects</li>
</ul>
<p>Evaluation</p>
<ul>
<li>LDH, ↑indirect bilirubin, ↓haptoglobin, PT/PTT</li>
<li>Peripheral
    blood smear: looking for schistocytes</li>
<li>Consider
    direct antiglobulin test (DAT) if suspicion for autoimmune cause</li>
</ul>
<p>Extrinsic RBC causes:</p>
<ul>
<li>If
    schistocytes
    ± thrombocytopenia = MAHA: TTP, DIC, HUS, HELLP,
    mechanical valves, malignant HTN, cocaine, scleroderma renal crisis<ul>
<li>Check Cr and Plt count to evaluate for TTP</li>
<li>mechanical valves, malignant HTN, cocaine, scleroderma renal
    crisis</li>
</ul>
</li>
<li>If
    DAT
    positive = AIHA</li>
<li>Order
    cold agglutinin titer</li>
</ul>
<p>Intrinsic RBC causes:</p>
<ul>
<li>Sickle
    cell disease: chronic hemolysis + splenic sequestration crisis where
    RI is
    ↑
    vs aplastic crisis where RI is
    ↓
    (see sickle cell section)</li>
<li>Hereditary
    spherocytosis</li>
<li>Hereditary
    elliptocytosis</li>
<li>PNH
    (generally see pancytopenia, RI is lower than expected for severity
    of anemia)</li>
<li>G6PD
    : bite cells, Heinz bodies on PBS
    : Usually
    precipitated by drugs: nitrofurantoin,
    dapsone
    , sulfonamides, rasburicase, primaquine</li>
</ul>
<p>Management</p>
<ul>
<li>MAHA: Caused by DIC, TTP, HUS<ul>
<li>DIC: sepsis, malignancy, pregnancy<ul>
<li>Treat underlying cause</li>
<li>If active bleeding: FFP, cryoprecipitate (to keep
    fibrinogen&gt;100) and platelets</li>
</ul>
</li>
<li>TTP: Order ADAMTS13<ul>
<li>Will need PLEX</li>
</ul>
</li>
<li>If concern for TTP you should immediately consult Heme and
    NephrologyHUS: + shiga toxin, AKI, diarrhea</li>
<li>Other: mechanical valves, malignant HTN, cocaine, scleroderma
    renal crisis<ul>
<li>Treat underlying cause</li>
</ul>
</li>
</ul>
</li>
<li>Autoimmune
    hemolytic anemia (AIHA):<ul>
<li>Cold
    : IgM binds at temp \&lt;37<ul>
<li>Caused
    by lymphoproliferative disorder (Waldenstrom
    ’
    s), mycoplasma, EBV, HIV</li>
<li>Consult heme. Treat underlying
    . Consider rituximab (steroids don
    ’
    t work)</li>
</ul>
</li>
<li>Warm
    : IgG<ul>
<li>Idiopathic
    or associated with lymphoma, SLE, drugs, babesiosis, HIV</li>
<li>Can use steroids, IVIG, ritux</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>RBC Size Framework</p>
<p>Normocytic Anemia: MCV 80-100</p>
<ul>
<li>Look for pancytopenia (eg. something else may be happening in the
    BM, splenic
    sequestration
    , PNH, etc)</li>
<li>Anemia
    of chronic disease may also be microcytic</li>
<li>Mixed
    macrocytic/microcytic disease: look for ↑RDW</li>
<li>CKD: low Erythropoietin (EPO) levels</li>
<li>Endocrine disease: ↓metabolic demand/O2 requirement</li>
<li>Pure red cell aplasia: associated with destructive Ab (CLL, thymoma,
    parvovirus, autoimmune)</li>
<li>Bone marrow biopsy may be indicated if normocytic with low RI
    without an identifiable cause or anemia associated with other
    cytopenia’s</li>
</ul>
<p>Microcytic anemia: MCV \&lt;80</p>
<p>(Mnemonic: SALTI)</p>
<ul>
<li>Sideroblastic, anemia of chronic disease, lead poisoning,
    thalassemia and iron-deficiency</li>
<li>See Table</li>
</ul>
<table>
<thead>
<tr>
<th>Disease</th>
<th>Etiology</th>
<th>Evaluation</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sideroblastic</td>
<td>MDS Idiopathic ETOH, Lead, Isoniazid, Cu deficiency</td>
<td>Social hx, work, TB, consider Lead level Fe:↑↑ ferritin:↑nl or ↑ TIBC: nl Smear: basophilic stippling BMbx: ringed sideroblasts</td>
<td>NaN</td>
</tr>
<tr>
<td>Anemia of chronic disease</td>
<td>Chronic inflammation, malignancy, HIV autoimmune dz, Inflammation (IL6, TNF α)↓</td>
<td>Fe/TIBC >18% Fe: ↓↓ ferritin:↑↑ TIBC:↓↓</td>
<td>Tx: underlying dz EPO if Hgb \&lt;10 and serum EPO \&lt;500 Replete Fe if ferritin \&lt;100 or TIBC \&lt;20%</td>
</tr>
<tr>
<td>Thalassemia</td>
<td>↓ synthesis of α or β chains leads to ↓ erythropoiesis and ↑ hemolysis</td>
<td>Family Hx of anemia Mentzer’s index: MCV/RBC \&lt;13 = thalassemia Normal Fe studies; can mimic microcytic anemia and Fe overload from transfusions Diagnosis: Hb electrophoresis</td>
<td>α thal more common in Asian/African descent β thal common in Mediterranean descent Tx: transfusions, folate, Fe chelator depending on severity</td>
</tr>
<tr>
<td>Iron (Fe) deficiency</td>
<td>Chronic bleeding: colon cancer heavy menstrual periods, cirrhosis (portal gastropathy) Supply: malnutrition, Crohn’s dz, celiac dz, subtotal gastrectomy Demand: pregnancy</td>
<td>Fe/TIBC \&lt;18% Fe:↓↓ TIBC:↑ nl to ↑ ferritin: \&lt; 15, \&lt;41 w/co-morb. Mentzer’s index: >13 Consider celiac testing based on clinical suspicion Investigate for GIB or sources of blood loss</td>
<td>Oral Fe: 6wks to correct anemia, 6mo to replete stores; dose every other day ( ↑ absorption w/ ↓ GI side effects); add Vit C for ↑ absorption If can’t tolerate PO consider IV Fe (Avoid when bacteremic HFrEF: IV Fe if ferritin \&lt;100 OR 100-300 w/ Fe sat \&lt;20%</td>
</tr>
</tbody>
</table>
<p>Macrocytic Anemia: MCV >100</p>
<ul>
<li>Non-megaloblastic:<ul>
<li>ETOH:
    BM suppression, macrocytosis independent from cirrhosis or
    vitamin deficiency</li>
<li>Liver disease</li>
<li>Hypothyroidism</li>
<li>MDS</li>
<li>Medications that impair DNA synthesis: zidovudine, 5-FU,
    hydroxyurea, ara-C, AZT</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Megaloblastic<ul>
<li>B12 deficiency<ul>
<li>Total body stores last 2-3 yr; absorbed in terminal ileum,
    requires IF</li>
<li>Can have neurologic changes (subacute combined
    degeneration); paresthesias, ataxia, dementia (reversible
    with early treatment)</li>
<li>Etiology: malnutrition (alcoholics, vegan), pernicious
    anemia, gastrectomy, Crohn’s disease, chronic pancreatitis,
    celiac disease (8-41% of pt)</li>
<li>Dx:
    ↓
    B12,
    ↑
    MMA,
    ↑
    homocysteine</li>
<li>If B12 low normal but have neuro sx, can get MMA to help
    confirm dx<ul>
<li>Tx: either monthly IM or sublingual B12 (oral not
    absorbed if no IF)</li>
</ul>
</li>
</ul>
</li>
<li>Folate deficiency<ul>
<li>Total body stores last 2-3 mo; absorbed mostly in jejunum</li>
<li>Etiology: malnutrition, decreased absorption (celiac disease
    2/2 damaged jejunum), impaired metabolism (MTX, TMP),
    ↑requirement (hemolysis, malignancy, dialysis)</li>
<li>Dx: ↓folate, ↑homocysteine but wnl MMA</li>
<li>Tx: PO folate 1-4 mg daily</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-anticoagulation"><h1 id="hematology-oncology-hematologyoncology-anticoagulation-anticoagulation">Anticoagulation<a class="headerlink" href="#hematology-oncology-hematologyoncology-anticoagulation-anticoagulation" title="Permanent link">&para;</a></h1>
<p>Anticoagulation – Madeleine Turcotte</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agent</td>
<td>Dose</td>
<td>Renal Dose</td>
<td>Prophylaxis</td>
<td>Monitoring</td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>80 U/kg bolus, then 18 U/kg/hr</td>
<td>No change necessary</td>
<td>5000 U q8 hr</td>
<td>PTT (automatic in order set)</td>
</tr>
<tr>
<td>Enoxaparin (Lovenox)</td>
<td>1 mg/kg q 12 hr</td>
<td>1 mg/kg daily</td>
<td>40 mg daily or 30 mg BID</td>
<td>LMWH level (anti-Xa level) Best checked 4 hr after 4<sup>th</sup> dose</td>
</tr>
<tr>
<td>Warfarin (Coumadin)</td>
<td>Start 2-5mg daily and monitor INR Can consult Pharmacy</td>
<td>No change necessary</td>
<td>NaN</td>
<td>PT/INR Use Chromogenic Factor X assay if pt has APLS</td>
</tr>
<tr>
<td>Dabigatran (Pradaxa)</td>
<td>After 5 days of a parenteral AC, 150 mg BID</td>
<td>Avoid use</td>
<td>NaN</td>
<td>Can test drug level if concerned (Any DOAC)</td>
</tr>
<tr>
<td>Rivaroxaban (Xarelto)</td>
<td>15 mg BID x21 d then 20 mg daily</td>
<td>Avoid use in CrCl\&lt;30</td>
<td>10mg QD</td>
<td>NaN</td>
</tr>
<tr>
<td>Apixaban (Eliquis)</td>
<td>10mg BID x7d, then 5mg BID</td>
<td>VTE: No adjustment</td>
<td>2.5 mg BID</td>
<td>A Fib: 2.5mg BID, if 2 of the following: Cr 1.5, Age > 80 Weight \&lt; 60kg</td>
</tr>
<tr>
<td>Edoxaban (Savaysa)</td>
<td>After 5 days of a parenteral AC, 60 mg daily</td>
<td>30 mg for CrCl 15-50 Avoid if CrCl > 95</td>
<td>NaN</td>
<td>Best studied option in renal dysfunction</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAC/DOAC</td>
<td>Warfarin</td>
</tr>
<tr>
<td>Quick onset/offset, fixed dosing</td>
<td>Antidote/reversal agent available</td>
</tr>
<tr>
<td>Reduced incidence of hemorrhagic stroke</td>
<td>Measurable levels of anticoagulation effect</td>
</tr>
<tr>
<td>Fewer drug interactions, no food interaction</td>
<td>Strongest evidence in patients with ESRD</td>
</tr>
<tr>
<td>No need for routine monitoring</td>
<td>Lower risk of GI bleeding (varies)</td>
</tr>
<tr>
<td>Monthly cost $350-450 but discounts available</td>
<td>Monthly cost: $4</td>
</tr>
</tbody>
</table>
<p>Additional Information</p>
<ul>
<li>VA favors dabigatran among DOACs<ul>
<li>Dabigatran cannot be stored in a pill box</li>
<li>PADR for apixaban citing “patient uses a pillbox and cannot use
    dabigatran”</li>
</ul>
</li>
<li>Concomitant Malignancy: favor LMWH, can also use apixaban</li>
<li>Renal dysfunction: favor warfarin, apixaban or edoxaban</li>
<li>Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have
    higher risk of GI bleed)</li>
<li>Pregnancy: LMWH (other agents may cross the placenta)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>Agent / Duration</td>
<td>Other Notes</td>
</tr>
<tr>
<td>VTE</td>
<td>Any agent Duration: See VTE section</td>
<td>See Deciding between Agents</td>
</tr>
<tr>
<td>Atrial Fib (non-valvular)</td>
<td>Apixaban or dabigatran Duration: Indefinite CHADSVASc > 2, Consider if score of 1</td>
<td>All DOACs: ↓ rates of ICH Apixaban &amp; dabigatran: superior to warfarin in preventing stroke</td>
</tr>
<tr>
<td>Artificial Heart Valves</td>
<td>Warfarin Target INR depends on type of valve If the pt has concurrent Afib, may need higher INR goal Duration: Mechanical, Indefinite Surgically placed bioprosthetic, 3-6 months</td>
<td>DOACs contraindicated with mechanical valves! Bioprosthetic valves: DOACs okay if coexisting indication No AC after TAVR unless patient has other indication</td>
</tr>
<tr>
<td>ACS</td>
<td>PCI: Heparin or LMWH until PCI Fibrinolytic: 2-8 days after fibrinolysis</td>
<td>If other indication for AC, assess bleeding/thrombosis risks to determine AC/Antiplatelet combination</td>
</tr>
<tr>
<td>ACS</td>
<td>No PCI: rivaroxaban 2.5 mg BID for 1 year, then reassess risk/benefit</td>
<td>If other indication for AC, assess bleeding/thrombosis risks to determine AC/Antiplatelet combination</td>
</tr>
<tr>
<td>LV Thrombus</td>
<td>Warfarin superior Duration: At least 3 months</td>
<td>AC can also be considered in patients with MI who are at high risk for LV thrombus: LVEF \&lt;30% w/ antero-apical wall motion abnormalities</td>
</tr>
<tr>
<td>Portal Vein Thrombus</td>
<td>Any agent DOAC preferred In cirrhosis (INR may not reflect level of anticoagulation) Duration: 3-6 months, or indefinitely if pt has permanent thrombotic risk factors</td>
<td>Consider bleeding risk: large esophageal varices</td>
</tr>
<tr>
<td>Thrombophilia</td>
<td>Any agent (DOACs less effective in APS) Duration: 6 months after any thrombosis Lifelong if recurrent, life-threatening, or unprovoked</td>
<td>Antiphospholipid antibody syndrome: lifelong warfarin for any thrombosis that is otherwise unprovoked</td>
</tr>
</tbody>
</table>
<p>Transitioning Between Anticoagulants with DOACs</p>
<ul>
<li>LMWH
    to Warfarin<ul>
<li>Warfarin and LMWH given simultaneously until INR is therapeutic
    for 24 hours</li>
</ul>
</li>
<li>Warfarin
    to DOAC<ul>
<li>Start
    DOAC when INR \&lt; 2.0</li>
</ul>
</li>
<li>DOAC
    to Warfarin<ul>
<li>High Risk DVT/PE – start LMWH or UFH, then start Warfarin</li>
<li>Low to Moderate Risk DVT/PE – Start warfarin while patient on
    DOAC, Stop DOAC on Day 3 of warfarin therapy, Check INR on day 4</li>
</ul>
</li>
<li>LMWH
    to DOAC<ul>
<li>Stop LMWH and start DOAC when due for next dose of LMWH (within
    2 hrs)</li>
</ul>
</li>
<li>DOAC
    to LMWH<ul>
<li>Stop
    DOAC and start LMWH when due for next DOAC dose</li>
</ul>
</li>
<li>UFH
    to DOAC<ul>
<li>Start
    DOAC when IV stopped (30 min prior to cessation if high risk for
    thrombosis)</li>
<li>DOAC
    to UFH</li>
<li>Start IV heparin with bolus when next DOAC dose is due</li>
</ul>
</li>
</ul>
<p>Peri-Procedural Management of Anticoagulation</p>
<ul>
<li>Temporary IVC filter indicated in pts with very recent acute VTE
    (within 3-4 weeks) if the procedure requires AC delay &gt;12 hours</li>
<li>For those at high risk of thromboembolism:<ul>
<li>Consider continuing AC for low-bleeding-risk procedures, i.e.
    dental procedures, cutaneous biopsy/excision, ICD placement,
    endovascular procedures.</li>
<li>Can bridge with LMWH or heparin drip</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Stop before procedure</td>
<td>Restart after procedure</td>
</tr>
<tr>
<td>Warfarin</td>
<td>5 days prior, check INR day of</td>
<td>12 to 24 hours after</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
<td>1 day after (2 days if high bleeding risk)</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
<td>1 day after (2 days if high bleeding risk)</td>
</tr>
<tr>
<td>Apixaban</td>
<td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
<td>1 day after (2 days if high bleeding risk)</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>One day prior (2 days if CrCl 30-50 or procedure is high bleeding risk)</td>
<td>1 day after (2 days if high bleeding risk)</td>
</tr>
<tr>
<td>Heparin</td>
<td>Stop infusion 4-5 hours prior</td>
<td>24 hours after</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>24 hours prior (hold evening dose if BID dosing, give half of AM dose if daily dosing)</td>
<td>24 hours after, (48-72 hours if high bleeding risk)</td>
</tr>
</tbody>
</table>
<p>Strategies for Reversal of Anticoagulation</p>
<p>Warfarin</p>
<ul>
<li>Vitamin
    K: onset at 12 hours but takes 24-48 hrs for full effect<ul>
<li>Life Threatening Bleeding: Give IV Vitamin K 10 mg over 30
    minutes</li>
<li>Intracranial
    bleed, bleed with hemodynamic instability, emergent procedure
    Non-life threatening<ul>
<li>INR \&lt;5: Vitamin K not recommended</li>
<li>INR 5-10: Vitamin K 1-5 mg IV or PO</li>
<li>INR &gt;10: Vitamin K 5mg PO or 5 mg IV</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>Prior to surgery
        -   Rapid reversal INR &gt; 5: 5mg Vit K IV (24 hours prior to
            procedure)</li>
<li>FFP<ul>
<li>15 ml/kg (i.e. 4 units/70 kg person) if need reversal \&lt;24
    hrs, plus give Vitamin K</li>
</ul>
</li>
<li>KCentra ($$$): Contains Factors II, VII, IX, and X with Protein
    C, Protein S, and heparin<ul>
<li>Given instead of plasma when insufficient time for
    plasma/Vit K to work</li>
<li>Avoid giving this in HIT</li>
<li>Administer with Vitamin K</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Dabigatran</p>
<ul>
<li>Idarucizumab
    ($$$) will reverse if prolonged thrombin time – Consult Hematology</li>
</ul>
<p>Xa</p>
<p>drugs</p>
<p>(Rivaroxaban, apixaban, edoxaban)</p>
<ul>
<li>FEIBA
    (Factor VIII inhibitor bypassing activity) – can promote coagulation
    but is not a reversal agent; limited data to support use</li>
<li>Consult Hematology before using; andexanet alfa is not yet available
    here</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-bone-marrow-transplant"><h1 id="hematology-oncology-hematologyoncology-bone-marrow-transplant-bone-marrow-transplant">Bone Marrow Transplant<a class="headerlink" href="#hematology-oncology-hematologyoncology-bone-marrow-transplant-bone-marrow-transplant" title="Permanent link">&para;</a></h1>
<p>Bone Marrow Transplant – Michael LaPelusa</p>
<p>Background</p>
<ul>
<li>Donor selection<ul>
<li>Autologous: self, no matching required</li>
<li>Allogeneic: non-self, matching based on HLA (more matching -&gt;
    less GVHD risk)<ul>
<li>Matched-related donor (MRD): fully matched sibling</li>
<li>Matched-unrelated donor (MUD): From NMDP database</li>
<li>Haploidentical: Half matched sibling or parent</li>
</ul>
</li>
</ul>
</li>
<li>Source of stem cells:<ul>
<li>Peripheral blood stem cells (PBSCs) vs bone marrow-derived cells
    vs umbilical cord</li>
<li>Timeline for transplant:T -14 d: cell mobilization and
    collection (G-CSF used to help mobilize stem cells)</li>
<li>T -8 d to T-3d: conditioning regimen, initiation of GVHD ppx,
    TLS ppx and sinusoidal obstruction syndrome ppx</li>
<li>T = 0 d: transplant</li>
<li>T +7 d to T +30 d: engraftment</li>
</ul>
</li>
</ul>
<p>Complications/Adverse Effects:</p>
<ul>
<li>Infectious
    : Neutropenic fever, typhlitis, GNR, HSV, respiratory/enteral
    viruses (adenovirus, RSV, parainfluenza), Aspergillus, Candida</li>
<li>Non
    -infectious<ul>
<li>Nausea, vomiting, mucositis</li>
<li>Cytopenia’s: Transfuse as needed (plt &gt;10, hematocrit &gt;21)</li>
<li>Hepatic
    veno-occlusive disease/sinusoidal obstructive syndrome:<ul>
<li>2/2 cytotoxic venule damage from chemo resulting in thrombi
    formation</li>
<li>Diagnosis: T Bili &gt;2, hepatomegaly/RUQ pain, weight gain &gt;
    2-5%</li>
<li>Evaluation: RUQ US with doppler</li>
<li>Treatment: Per heme attending; Consider defibrotide</li>
</ul>
</li>
<li>Graft failure – primary (persistent neutropenia without
    engraftment) or secondary (delayed pancytopenia 2/2 immune
    phenomena or infection after engraftment)</li>
<li>Engraftment
    syndrome:<ul>
<li>Pathophys: PMN recovery -&gt; cytokine storm -&gt; vascular leak</li>
<li>Symptoms: fever, tachycardia, hypotension, SOB, pulmonary
    edema, rash, weight gain, bone pain, confusion</li>
<li>Diagnosis: clinical; Workup specific symptoms</li>
<li>Treatment: high-dose IV steroids</li>
</ul>
</li>
<li>Acute GVHD:<ul>
<li>Only in allogenic; Increased risk with more HLA mismatch</li>
<li>Pathophys: donor T cells attack recipient (Th1-mediated)</li>
<li>Symptoms: skin rash, cholestatic liver injury, diarrhea</li>
<li>Treatment: IV steroids (methylprednisolone 1-2mg/kg x 5d)<ul>
<li>If refractory: mycophenolate, etanercept, ruxolitinib,
    antithymocyte globulin</li>
</ul>
</li>
</ul>
</li>
<li>Chronic GVHD (typically after T+100d s/p allo)<ul>
<li>Can involve all organs but typically see a scleroderma-like
    picture (xerophthalmia, xerostomia dysphagia, arthritis,
    skin changes, malar rash, obliterative bronchiolitis,
    cholestatic liver injury, cytopenia’s)</li>
<li>Treatment: steroids (also photophoresis for skin), consider
    trials of ruxolitinib, ibrutinib, rituximab if refractory</li>
</ul>
</li>
<li>PTLD</li>
</ul>
</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-chemotherapy-toxicity"><h1 id="hematology-oncology-hematologyoncology-chemotherapy-toxicity-chemotherapy-toxicity">Chemotherapy Toxicity<a class="headerlink" href="#hematology-oncology-hematologyoncology-chemotherapy-toxicity-chemotherapy-toxicity" title="Permanent link">&para;</a></h1>
<p>Chemotherapy Toxicities - Beau Hilton</p>
<ul>
<li>The role of Intern/Resident on the Hematology/Oncology services is
    largely to work with the fellow to monitor and manage adverse
    effects of chemotherapy</li>
<li>Concerns about specific immune-related adverse event: refer to
    “Toxicities associated with checkpoint inhibitor immunotherapy,” on
    UpToDate</li>
<li>Treatment of immune checkpoint inhibitor toxicities: “Management of
    Immunotherapy-Related Toxicities” in the NCCN Guidelines for
    Supportive Care section</li>
</ul>
<p>Neutropenia:</p>
<ul>
<li>Chemotherapy-associated: usually 5-18 days after treatment</li>
<li>Cancer infiltrate of bone marrow</li>
<li>New occult infection: especially EBV, CMV</li>
<li>Patients can be safely discharged with ANC &gt; 500</li>
</ul>
<p>Mucositis:</p>
<ul>
<li>Worst in pts receiving concurrent radiation to head and neck,
    rectum, prostate</li>
<li>Begins shortly after chemo dose, usually peaks on day 7</li>
<li>High risk: bleomycin, cytarabine, anthracyclines, etoposide, 5-FU,
    methotrexate</li>
<li>Treatment: “Salt and soda” rinses (1 tsp salt, 1 tsp baking sode in
    1-quart water, swish and spit 5 times per day), viscous lidocaine,
    capsaicin candy, Magic Mouthwash</li>
</ul>
<p>Immune Checkpoint Inhibitor Toxicities:</p>
<p>Treatment: low-dose glucocorticoids (prednisone, 0.5 mg/kg) for mild
adverse events, high dose glucocorticoids (prednisone, 1-2 mg/kg) for
severe adverse events</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Event Type</td>
<td>Incidence with anti-CTLA-4 (ipilimumab)</td>
<td>Incidence with anti‐PD1/PD‐L1 (nivolumab, pembrolizumab)</td>
</tr>
<tr>
<td>Skin (pruritus, acne, TEN)</td>
<td>30%</td>
<td>30%</td>
</tr>
<tr>
<td>Colitis</td>
<td>25%</td>
<td>5%</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>20%</td>
<td>20%</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>10%</td>
<td>1%</td>
</tr>
<tr>
<td>Hypophysitis</td>
<td>10%</td>
<td>rare</td>
</tr>
<tr>
<td>Pneumonitis</td>
<td>2-5%</td>
<td>2-5%</td>
</tr>
<tr>
<td>Myocarditis (fatality&gt;25%)</td>
<td>\&lt;1%</td>
<td>\&lt;1%</td>
</tr>
<tr>
<td>Neurotoxicity (GBS, myasthenia gravis, encephalitis)</td>
<td>\&lt;1%</td>
<td>\&lt;1%</td>
</tr>
</tbody>
</table>
<p>Chemotherapeutic Agent</p>
<p>Toxicities</p>
<table>
<thead>
<tr>
<th>Organ System</th>
<th>Agent</th>
<th>Side Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating Agents</td>
<td>Busulfan</td>
<td>Pulmonary fibrosis or diffuse alveolar hemorrhage (8%)</td>
</tr>
<tr>
<td>Alkylating Agents</td>
<td>Cyclophosphamide</td>
<td>Myopericarditis. Hemorrhagic cystitis (prevention: hydration; monitoring: daily UA, Tx: Mesna</td>
</tr>
<tr>
<td>Alkylating Agents</td>
<td>Ifosfamide</td>
<td>Encephalopathy (tx: methylene blue)</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>5- Fluorouracil (5-FU)/ Capecitabine (metabolized to FU)</td>
<td>Coronary vasospasm (ppx: CCB); palmar-plantar erythrodysesthesia</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Cladribine, pentostatin</td>
<td>Dose reduced for CrCl</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Cytarabine (Ara-C)</td>
<td>Irreversible cerebellar ataxia (if high dose, neuro checks required). Conjunctivitis (prevent with prophylactic steroid eye drops)</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Gemcitabine</td>
<td>Transient transaminitis. Decrease dose only if hyperbilirubinemia.</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Methotrexate</td>
<td>Hepatotoxicity, renal failure, high dose requires leucovorin</td>
</tr>
<tr>
<td>Antitumor antibiotics</td>
<td>Anthracyclines (doxorubicin, duanorubicin, idarubicin)</td>
<td>HFrEF (need TTE prior). Most notable with doxorubicin.</td>
</tr>
<tr>
<td>Antitumor antibiotics</td>
<td>Bleomycin</td>
<td>Pulmonary fibrosis (10%). Potentiated with G-CSF</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Alemtuzumab</td>
<td>Severe and prolonged cytopenias</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Bevacizumab</td>
<td>HFrEF, HTN, hyperglycemia, hypomag, DVT, pulm hemorrhage</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Rituximab</td>
<td>Hypophos, hepatotoxicity, HBV reactivation (screen all patients), peripheral neuropathy</td>
</tr>
<tr>
<td>Platinum Agents</td>
<td>Cisplatin, oxaliplatin, carboplatin</td>
<td>Nephrotoxicity, worst with cisplatin. Rental tubular acidosis. Neurotoxicity- >85% oxaliplatin (parasthesias, cold sensitivity, cramps), neuropathy, ototoxicity</td>
</tr>
<tr>
<td>Taxanes</td>
<td>Docetaxel, paclitaxel</td>
<td>Hypersensivitivy reaction. Often require premedication with steroids and H1/H2 blockers.</td>
</tr>
<tr>
<td>Topoisomerase Inhibitors</td>
<td>Irinotecan, topotecan, etoposide</td>
<td>Irinotecan- acute diarrhea can be treated with atropine</td>
</tr>
<tr>
<td>Tyrosine Kinase Inhibitors</td>
<td>Imatinib, Dasatinib, Nilotinib, Bosutinib</td>
<td>Qtc prolongation, pulmonary effusion, hepatotoxicity</td>
</tr>
<tr>
<td>Vinca alkaloid</td>
<td>Vincristine</td>
<td>Peripheral neuropathy and ototoxicity (vestibular system lost first)</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hematology-oncology-hematologyoncology-coagulopathies"><h1 id="hematology-oncology-hematologyoncology-coagulopathies-coagulopathies">Coagulopathies<a class="headerlink" href="#hematology-oncology-hematologyoncology-coagulopathies-coagulopathies" title="Permanent link">&para;</a></h1>
<p>Coagulopathies – Jason Jones</p>
<ul>
<li>If you have a pt with pathological bleeding, first determine
    <strong>platelet vs coagulation</strong> disorder</li>
<li>Platelet Disorders: Skin/Mucous membrane bleeding; Petechiae; Often
    mild bleeding following surgery and tends to immediately follow
    surgery</li>
<li>Coagulation defect: Bleeding deep in soft tissues (muscles/joints);
    hemarthroses, hematomas; Tend to have delayed bleeding after surgery
    that can be severe<ul>
<li>Coagulopathies can be divided into <strong>Hereditary</strong> vs
    <strong>Acquired</strong> causes</li>
</ul>
</li>
</ul>
<p>Hereditary</p>
<p>Hemophilia A (Factor VIII Deficiency) and Hemophilia B (Factor IX
Deficiency)</p>
<ul>
<li>Inherited in X-linked Recessive pattern</li>
<li>Diagnosis: Isolated prolonged PTT with normalization upon mixing
    study</li>
<li>Management
    : purified/recombinant Factor VIII or IX. Desmopressin for mild
    disease</li>
<li>If you have patient with hemophilia who needs a procedure/surgery or
    is acutely ill, this requires consult to benign hematology</li>
</ul>
<p>von Willebrand Disease (vWD)</p>
<ul>
<li>Can be hereditary (common) or acquired</li>
<li>Abnormal quantity or function of von Willebrand Factor (vWF) needed
    for platelet function</li>
<li>Type 1 (most common): Quantitative defect. Low quantity, normal
    function of vWF</li>
<li>Type 2: Qualitative defect. Normal quantity, abnormal function of
    vWF. In Type 2A, large multimer formation is impaired</li>
<li>Type 3 (rarest): Complete absence of vWF
    
    phenotypically similar to hemophilia A</li>
<li>Order in Epic: vW Profile = vWF Ag, Factor VIII Activity, Ristocetin
    Cofactor Activity</li>
<li>Management
    : Desmopressin (DDAVP) can be useful as prophylaxis or treatment</li>
</ul>
<p>Acquired</p>
<p>Coagulation Factor Inhibitors</p>
<ul>
<li>Associated with autoimmune disease (paraneoplastic vs. autoantibody)</li>
<li>Seen in hemophilia due to frequent treatments with recombinant
    factors (alloantibody)</li>
<li>Diagnosis: Elevated PTT that does not normalize with mixing study</li>
<li>Management
    : Immunosuppression with steroids; cyclophosphamide &plusmn; rituximab<ul>
<li>Consult
    Hematology early (rare disorder with major bleeding
    complications)</li>
</ul>
</li>
</ul>
<p>Vitamin K Deficiency</p>
<ul>
<li>Caused by malnutrition, liver disease, or iatrogenic with warfarin</li>
<li>Causes deficiency of Vit K dependent coagulation factors (Factors
    II, VII, IX, X)</li>
<li>Diagnosis: elevated PT, if severe may have prolonged PTT as well</li>
<li>Vitamin K deficiency will correct in the lab in a mixing study</li>
<li>Management
    : Replace vitamin K, see "Transfusion" section for more details</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-dic"><h1 id="hematology-oncology-hematologyoncology-dic-dic">DIC<a class="headerlink" href="#hematology-oncology-hematologyoncology-dic-dic" title="Permanent link">&para;</a></h1>
<p>Disseminated <span id="DIC"></span> Intravascular Coagulation (DIC) -
Eric Singhi</p>
<p>Background</p>
<ul>
<li>Concurrent activation of the coagulation pathway and fibrinolytic
    pathway</li>
<li>Widespread endothelial injury + exposure to circulating
    procoagulants
    
    activation of coagulation cascade
    
    thrombin production in small and medium-sized vessels</li>
<li>Consumption of platelets, fibrin, and coagulation factors -&gt;
    fibrinolysis -&gt; end organ damage and hemolysis</li>
<li>Etiologies:<ul>
<li>Infection/Sepsis, Liver disease, Pancreatitis, Trauma</li>
<li>Malignancies: mucin-secreting pancreatic/gastric adenocarcinoma,
    brain tumors, prostate cancer, all acute leukemias, acute
    promyelocytic leukemia</li>
<li>Obstetric complications (i.e. preeclampsia/eclampsia, placental
    abruption)</li>
<li>Acute hemolytic transfusion reaction (i.e. ABO incompatible
    transfusion)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Exam:  petechiae, bleeding (mucosal, IV site, surgical wound site,
    hematuria), ecchymoses, thrombosis (i.e. cold, pulseless
    extremities)</li>
<li>CBC,  PT/INR, aPTT, Fibrinogen, D-Dimer, Peripheral Blood Smear</li>
<li>“DIC labs” = q6h fibrinogen, PT/INR, aPTT (space out when lower
    risk)</li>
<li>Findings suggestive of DIC: thrombocytopenia, prolonged aPTT and
    PT/INR, hypofibrinogenemia, elevated D-dimer, fibrin degradation
    products, schistocytes</li>
</ul>
<p>Management</p>
<ul>
<li>Treat the underlying cause!</li>
<li>Hemodynamic support (i.e. hypotension): Intravenous fluid
    resuscitation</li>
<li>Vitamin K for INR &gt; 1.7 or bleeding</li>
<li>If bleeding consider FFP, Vitamin K to correct coagulopathy</li>
<li>Hypofibrinogenemia treatment: Cryoprecipitate 5-10 units if
    fibrinogen \&lt; 100</li>
<li>Thrombocytopenia treatment: plt transfusion as normally indicated</li>
<li>DVT ppx if not bleeding and plt &gt; 50</li>
<li>VTE: anticoagulation if plt &gt; 50 and no massive bleeding</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-dvts"><h1 id="hematology-oncology-hematologyoncology-dvts-dvts">DVTs<a class="headerlink" href="#hematology-oncology-hematologyoncology-dvts-dvts" title="Permanent link">&para;</a></h1>
<p>Deep Vein Thromboses – Trey Richardson</p>
<ul>
<li>Background:
    Incidence of 1-2 per 1,000 people per year</li>
<li>Depending on the study and population, associated with a 15%
    mortality rate</li>
<li>70% of patients with PE have a detectable DVT</li>
<li>List of deep veins<ul>
<li>Distal Lower Ext.: Posterior tibial, Anterior tibial, Peroneal,
    Gastrocnemius, Soleus veins</li>
<li>Proximal Lower Ext.: External, Internal, and Common iliac;
    Common, superficial, and deep femoral veins; Popliteal vein</li>
<li>Upper extremity: Radial, ulnar, brachial, axillary, and
    subclavian veins</li>
</ul>
</li>
<li>Risk Factors for Provoked DVT/PE – Known Event<ul>
<li>Major risk factors: major surgery &gt;30 minutes, hospitalization &gt;
    3 days, C-section</li>
<li>Minor Risk Factors: Surgery \&lt;30 minutes, Hospitalization \&lt;3
    days, pregnancy, estrogen therapy, reduced mobility &gt;3 days,
    infection in past 3 months</li>
</ul>
</li>
<li>Persistent risk factors: Malignancy (active), inflammatory bowel
    disease, hereditary thrombophilia, CHF</li>
<li>Active cancer (LR of 2.6) recent trauma/surgery or immobilization
    (LR of 1.6 each) are the clinical scenarios when suspicion should be
    the highest</li>
</ul>
<p>Presentation</p>
<ul>
<li>Asymmetric calf swelling of &gt; 2cm sensitivity/specificity for DVT of
    60-70% and a likelihood ratio (LR) of 2.1</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Wells’ Criteria for DVT can help guide diagnostic testing<ul>
<li>If a patient has a low pre-test probability, a negative D-dimer
    can rule out DVT</li>
<li>In a high pre-test probability patient a negative D-dimer is
    less helpful</li>
</ul>
</li>
<li>Whole-leg (common femoral to deep calf veins) ultrasounds with
    doppler</li>
</ul>
<p>Management</p>
<ul>
<li>Prophylaxis<ul>
<li>Padua score: Score &gt; 4 high risk; A score \&lt;4 low risk for
    thrombosis</li>
</ul>
</li>
<li>Choice of anticoagulation for treatment: (See anticoagulation
    section)</li>
<li>Duration of treatment<ul>
<li>Provoked: 3-6 mos or until provoking factor (trauma, surgery,
    malignancy) is removed<ul>
<li>Pts w/high risk cancers require more tailored therapy since
    the provoking factor is the malignancy itself. GI
    malignancies tend to be the highest risk.</li>
</ul>
</li>
<li>Unprovoked: Requires life-long anticoagulation along with
    assistance from hematology</li>
<li>Recurrent: Even if they have all ben provoked, requires
    life-long treatment<ul>
<li>Close follow-up with hematology</li>
</ul>
</li>
<li>Distal:  Limited data, but can treat for 3 months or monitor for
    resolution with serial US</li>
<li>Upper Extremity: Treat as DVT for at least 3 months</li>
<li>Superficial vein : treat for 3 mo, if within 2 cm of junction w/
    deep vein (high risk of propagation)</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Decision to screen for hyper-coagulable disorders based on age
    (\&lt;45), history of prior DVTs, family hx of clotting disorders, and
    hx of thrombi in atypical locations (arterial)</li>
<li>If no contraindications (acute bleeding, planned procedure,
    thrombocytopenia etc.) then most patients will tolerate prophylaxis</li>
<li>Follow up ultrasound<ul>
<li>Limited data regarding utility of follow up ultrasound but may
    be warranted if patient at high risk for post-thrombotic
    complications or has persistent symptoms</li>
</ul>
</li>
<li>What about IVC filters?<ul>
<li>In patients at high risk for DVT and in whom anti-coagulation is
    contraindicated (thrombocytopenia, recent intra-cranial bleed,
    recent GI bleed) placement of a retrievable IVC filter should be
    discussed with IR</li>
</ul>
</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-hypercoagulable-states"><h1 id="hematology-oncology-hematologyoncology-hypercoagulable-states-hypercoagulable-states">Hypercoagulable States<a class="headerlink" href="#hematology-oncology-hematologyoncology-hypercoagulable-states-hypercoagulable-states" title="Permanent link">&para;</a></h1>
<p>Hypercoagulable States – Chris Cann</p>
<p>Background</p>
<ul>
<li>Virchow’s triad: 1. Hypercoagulability 2. Blood flow stasis 3.
    Endothelial injury</li>
<li>Diagnostic thrombophilia testing indications:<ul>
<li>Idiopathic or recurrent VTE</li>
<li>First VTE at \&lt;40 years old</li>
<li>VTE in the setting of strong family history</li>
<li>VTE in unusual vascular site (cerebral, renal, mesenteric)</li>
<li>Recurrent pregnancy loss</li>
</ul>
</li>
<li>Separated into Acquired and Hereditary factors:<ul>
<li>Hereditary: Factor V Leiden, Prothrombin mutation, Protein C/S
    deficiency, Antithrombin deficiency</li>
<li>Acquired
    :<ul>
<li>APLS</li>
<li>HIT</li>
<li>Major surgery/trauma</li>
<li>Nephrotic Syndrome</li>
<li>Smoking</li>
<li>Pregnancy</li>
<li>Oral Contraceptives</li>
<li>Immobilization (bedridden, hip/knee replacement) Infection
    in past 3 months</li>
<li>Active malignancy</li>
<li>Estrogen replacement therapy</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Testing: all specific testing for hereditary disorders and APS
    should be performed at least 4-6 weeks after an acute thrombotic
    event or discontinuation of anticoagulant/thrombolytic therapies to
    avoid interference</li>
</ul>
<p>Antiphospholipid antibody syndrome (APLS):</p>
<p>Background</p>
<ul>
<li>Most
    common acquired factor (anti-phospholipid antibodies present in 3-5%
    population)</li>
<li>Recurrent
    pregnancy loss, provoked DVT in young, unprovoked VTE and arterial
    thrombosis in young, thrombosis unusual sites, thrombosis in
    autoimmune disease</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Positive for at least 1 lab criterion on at least 2 occasions, at
    least 12 weeks apart:<ul>
<li>Lupus
    anticoagulant: can occur in relation to drugs or infection;
    transient are associated with thrombotic risk</li>
<li>Anticardiolipin
    antibodies</li>
<li>B2GP1
    (anti-beta2-glycoprotein) antibodies</li>
</ul>
</li>
<li>Must also meet at least 1 of the following clinical criteria:<ul>
<li>Vascular
    thrombosis: DVT, arterial thrombosis, or small vessel thrombosis
    of any organ</li>
<li>Pregnancy
    loss: there are specific criteria for this – consult UpToDate or
    other resource</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Aspirin for primary prevention; warfarin for treatment (INR 2-3)</li>
<li>Do NOT use DOACs for APLS (see TRAPS trial: rivaroxaban inferior to
    warfarin)</li>
<li>Rituximab for recurrent thrombosis despite anticoagulation
    (controversial)</li>
</ul>
<p>Heparin-induced thrombocytopenia (HIT)</p>
<p>Type</p>
<p>1: Mild and self-limited (not immune-mediated)</p>
<ul>
<li>Occurs within the first 2 days of first-time exposure</li>
<li>Platelet count normalizes with continued heparin therapy</li>
</ul>
<p>Type 2 (what we typically refer to as HIT): Immune mediated</p>
<ul>
<li>Fall in plt 30% to over 50% (even if plt count &gt;150) and/or
    thrombotic event has occurred</li>
<li>4-10 days after new exposure to heparin derivative OR≤</li>
<li>1 day after restarting heparin derivative that had been used 30-100
    days prior<ul>
<li>If exposed to heparin within 100 days, will have platelet drop
    within 24 hr</li>
</ul>
</li>
<li>Frequency: unfractionated heparin &gt; LMWH;  Surgical wards &gt;  medical
    wards</li>
<li>50% will have thrombotic event in 30 days if HIT is untreated, with
    20% mortality</li>
<li>Arterial thrombi are common in HIT</li>
<li>HIT results from antibodies to complexes of platelet factor 4 (PF4)
    and heparin, further activating platelets (the activated platelets
    aggregate causing thrombocytopenia)</li>
</ul>
<p>Evaluation</p>
<ul>
<li><span id="FourT"></span>
    4T score (0-8 points):<ul>
<li>Thrombocytopenia (0-2 pts): degree and nadir of platelet count
    drop</li>
<li>Timing (0-2 pts): timing of fall after initial or recurrent
    heparin exposure</li>
<li>Thrombosis (0-2 pts): thrombosis, skin necrosis, non-necrotizing
    lesions, acute systemic reaction to heparin</li>
<li>Other causes of thrombocytopenia (0-2 pts): more points if no
    alternate cause</li>
</ul>
</li>
<li>Solid-phase ELISA for heparin-PF4 antibodies: ​​​​​​​<ul>
<li>0.2-0.4 is indeterminate</li>
<li>> 0.4 is positive</li>
<li>> 1.4 HIT is likely</li>
<li>> 2 confirms HIT ​​​​​​​</li>
<li>The lab at VUMC will perform functional SRA reflexively for all
    values &gt;0.2</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>0-3 points: Low concern for HIT; can restart heparin</li>
<li>4-5 points: Intermediate probability (~10%) - hold heparin, <strong>start
    non-heparin anticoagulant</strong></li>
<li>6 points: High probability (~50%) - hold heparin, <strong>start
    non-heparin anticoagulant</strong></li>
<li>Argatroban (direct thrombin inhibitor) for prophylaxis and treatment
    of thrombosis<ul>
<li>Avoid platelet transfusions as can increase thrombogenic effect</li>
<li>Avoid warfarin until complete platelet recovery as may cause
    microthrombosis</li>
</ul>
</li>
<li>Hematology consult for all confirmed HIT</li>
</ul>
<p>Factor V Leiden mutation</p>
<p>Evaluation</p>
<ul>
<li>Activated protein C resistance assay<ul>
<li>APC ratio in patient vs normal</li>
<li>normal &gt;2.0, heterozygotes 1.5-2.0, homozygotes \&lt;1.5</li>
</ul>
</li>
<li>FVL mutation is then determined via PCR</li>
<li>Screen with APC assay rather than PCR initially; cost effective</li>
</ul>
<p>Management</p>
<ul>
<li>VTE treatment same as general population<ul>
<li>VTE 4-8x risk in heterozygotes; 80x risk in homozygotes</li>
</ul>
</li>
<li>Avoid OCPs: increased risk for VTE</li>
</ul>
<p>Prothrombin gene mutation</p>
<p>Evaluation: PCR of G20210A mutation (2-4% Europeans carry mutation)</p>
<p>Management: VTE treatment same as general population &amp; Avoid OCPs</p>
<p>Protein C &amp; S Deficiency</p>
<p>Background</p>
<ul>
<li>Autosomal dominant; first event occurs between 10-50 years of age</li>
<li>Synthesized in liver and Vit K dependent, therefore low levels in
    hepatic dysfunction and warfarin use/vitamin K deficiency</li>
<li>Protein C: low in settings of thrombosis, DIC, nephrotic syndrome,
    intra/post-op</li>
<li>Protein S : low in infectious (HIV) and autoimmune processes (IBD)</li>
<li>Protein S decreases during pregnancy (decreased free Protein S,
    normal total Protein S)<ul>
<li>Do not misdiagnose a pregnant patient with PS deficiency</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Functional Protein C &amp; S assays<ul>
<li>Used for screening prior to use of immunologic methods to
    measure free protein levels</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>VTE treatment same as general population</li>
<li>Avoid OCPs</li>
<li>High risk patients may require protein C concentrate prior to
    surgery</li>
<li>Increased risk of warfarin-induced skin necrosis</li>
</ul>
<p>Antithrombin deficiency</p>
<p>Background</p>
<ul>
<li>Autosomal dominant, does not skip generations</li>
<li>VTE in unusual sites (cerebral sinuses, renal veins)</li>
<li>Present \&lt; 50 y/o, but rarely in first two decades</li>
<li>Decreased in liver disease, nephrotic syndrome, protein losing
    enteropathy, burn, trauma, bypass surgery, metastatic tumors,
    premenopausal, OCP use, pregnancy</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Functional antithrombin activity (AT-heparin cofactor assay)</li>
<li>Then perform antigen quantity testing</li>
</ul>
<p>Management</p>
<ul>
<li>Can use Argatroban as does not require antithrombin function</li>
<li>Warfarin preferred in VTE (titrate up based on expression of
    antithrombin deficiency)</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-leukemia"><h1 id="hematology-oncology-hematologyoncology-leukemia-leukemia">Leukemia<a class="headerlink" href="#hematology-oncology-hematologyoncology-leukemia-leukemia" title="Permanent link">&para;</a></h1>
<p>Acute Leukemia - Robert Corty</p>
<p>Background</p>
<ul>
<li>Unchecked proliferation of WBC precursors causes marrow failure</li>
<li>Can be fatal in days to months</li>
<li>Pt’s with suspected acute leukemia require hospitalization for
    urgent diagnosis &amp; treatment</li>
<li>APL has both the highest in-hospital mortality &amp; highest cure rate</li>
<li>Types:<ul>
<li>AML
    = Acute Myeloid Leukemia – most common</li>
<li>APL
    = acute promyelocytic leukemia
    
    translocation (15;17)</li>
<li>ALL
    = acute lymphocytic leukemia</li>
</ul>
</li>
<li>Risk Factors:<ul>
<li>ionizing radiation</li>
<li>chemical exposures(e.g benzene)</li>
<li>HIV</li>
<li>immunosuppression</li>
<li>myeloproliferative disorders</li>
<li>aplastic anemia</li>
<li>chemotherapy, specifically, alkylating agents and topoisomerase
    inhibitors</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Leukocytosis, often blastocytosis: leukemia cutis, gingival
    hypertrophy, leukostasis</li>
<li>Functional Leukopenia, often neutropenia: recurrent infections</li>
<li>Anemia: fatigue, pallor, dyspnea</li>
<li>Thrombocytopenia: gingival bleeding, epistaxis, petechiae,
    ecchymoses, menorrhagia</li>
<li>Extramedullary hematopoiesis: splenomegaly, hepatomegaly,
    lymphadenopathy</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Diagnosis of acute leukemia requires one of the following:<ul>
<li>20% blasts in peripheral blood</li>
<li>> 20% blasts in bone marrow biopsy</li>
<li>Any pathognomonic cytogenetic abnormality of t(8;21), inv(16),
    t(15;17)</li>
</ul>
</li>
<li>Check for the presence of these time-sensitive conditions.<ul>
<li>DIC – check fibrinogen, PT, PTT, platelets</li>
<li>TLS – check uric acid, phosphate, LDH, K+</li>
<li>Neutropenic fever – check temp, neutrophil count</li>
<li>Leukostasis  (see below)</li>
<li>Presumptive APL – promyelocytes on diff, DIC or Auer rods on
    smear</li>
</ul>
</li>
<li>Confirm if peripheral flow cytometry ordered/in process</li>
</ul>
<!-- -->

<ul>
<li>Use hematology admission order set<ul>
<li>Set RBC and Plt transfusion thresholds</li>
<li>Order nurse-driven electrolyte repletion</li>
<li>ECG and TTE to establish pre-chemotherapy cardiac function</li>
<li>Daily labs: CBC, TLS, DIC</li>
<li>TLS prophylaxis</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Page heme fellow<ul>
<li>Discuss chemo plan and order double lumen PICC for reliable
    access</li>
<li>If findings suggest APL discuss starting ATRA</li>
<li>Subspecialized lab tests: bone marrow biopsy, cytogenetics, FISH</li>
</ul>
</li>
<li>Monitor for Common Complications/Emergencies: (see individual
    sections)<ul>
<li>TLS, DIC, Febrile Neutropenia, Leukostasis</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Obtain blood product consent on admission</li>
<li>APL Specific findings: promyelocytes on differential or Auer rods on
    smear</li>
<li>Differentiation syndrome: promyelocytes differentiate<ul>
<li>Symptoms and signs: fever, SOB, Hypotn, peripheral edema,
    pleural effusion, AKI</li>
<li>Diagnosis: No defined criteria.  If suspicious, discuss with
    hematology fellow</li>
<li>Management: <strong>steroids</strong> .  If critically ill, <strong>hold</strong> <strong>ATRA</strong>
    <strong>and</strong> <strong>ATO</strong> and consider <strong>hydroxyurea</strong></li>
</ul>
</li>
</ul>
<p>Leukemia Treatment Overview</p>
<ul>
<li>General strategy is to use “induction” chemo to try to induce
    clinicopathologic (as opposed to molecular) “remission”</li>
<li>Defined as absence of symptoms, normal CBC, and \&lt; 5% blasts in bone
    marrow (on day 28)</li>
<li>Then waiting in hospital until neutrophil count &gt; 500 (typically ~3
    weeks)</li>
<li>From there, bone marrow transplant (for high risk disease) or
    “consolidation” chemo for normal-risk or low-risk disease</li>
</ul>
<p>AML</p>
<p>Induction</p>
<ul>
<li>Typical is “7+3” i.e. idrarubicin on days 1-3 and cytarabine on days
    1-7</li>
<li>If therapy-related AML, MDS-related AML, or AML with cytogenetics
    similar to MDS, use “Vyxeos” which is liposomal daunorubicin and
    cytarabine on days 1, 3, and 5</li>
<li>If low-risk dz (t(8;21) or inv(16)), use cytarabine on days 1-7, and
    3 days of low-dose daunorubicin + gemtuzumab-ozogamicin</li>
<li>There are other induction regimens that can be used depending on
    specific cytogenetics and patient frailty, which is beyond beyond
    the scope of the handbook</li>
</ul>
<p>Consolidation</p>
<ul>
<li>Typically  “HiDAC”(high-dose Ara-C – brand name for cytarabine)<ul>
<li>Generally too toxic for pts with age &gt; 60, so a dose reduction
    is used</li>
</ul>
</li>
<li>In the case of relapse, typical treatment is a different high-dose
    chemo and BMT if possible</li>
</ul>
<p>ALL</p>
<ul>
<li>Typical induction is “HyperCVAD” (hyper-fractionated
    cyclophosphamide, vincristine, doxorubicin (“A” due to trade name
    Adriamycin), and dexamethasone</li>
<li>If t(9;22) (known as Philadelphia chromosome), use tyrosine kinase
    inhibitor (TKI)</li>
<li>If CD20+, use rituximab (requires CNS prophylaxis)</li>
</ul>
<p>Common Chemotherapy Regimens for Leukemia Encountered as Inpatient</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regimen</td>
<td>Components</td>
<td>Use</td>
</tr>
<tr>
<td>7+3</td>
<td>Cytarabine (Ara-C) x 7 d &amp; Anthracycline (e.g. idarubicin x3 d)</td>
<td>AML induction</td>
</tr>
<tr>
<td>Vyxeos</td>
<td>Cytarabine + liposomal daunorubicin</td>
<td>AML-MRC or t-AML</td>
</tr>
<tr>
<td>CLAG-M</td>
<td>Cladribine, cytarabine (Ara-C), Filgrastim (G-CSF), mitoxantrone</td>
<td>AML induction (relapsed/refractory)</td>
</tr>
<tr>
<td>HIDAC</td>
<td>High-dose cytarabine</td>
<td>AML consolidation</td>
</tr>
<tr>
<td>ATRA</td>
<td>All-trans retinoic acid given with arsenic trioxide (ATO)</td>
<td>APL (APML)</td>
</tr>
<tr>
<td>HyperCVAD/MA</td>
<td>CVAD = Cyclophosphamide, vincristine, doxorubicin, dexamethasone MA = methotrexate/cytarabine (Given as alternating cycles)</td>
<td>ALL</td>
</tr>
<tr>
<td>R-CHOP</td>
<td>Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone</td>
<td>NHL</td>
</tr>
<tr>
<td>R-EPOCH</td>
<td>Etoposide plus the drugs above (dosing is different)</td>
<td>NHL</td>
</tr>
<tr>
<td>ABVD</td>
<td>Doxorubicin, bleomycin, vinblastine, dacarbazine</td>
<td>HL</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hematology-oncology-hematologyoncology-lymphoma"><h1 id="hematology-oncology-hematologyoncology-lymphoma-lymphoma">Lymphoma<a class="headerlink" href="#hematology-oncology-hematologyoncology-lymphoma-lymphoma" title="Permanent link">&para;</a></h1>
<p>Lymphoma - Margaret Wheless</p>
<p>Background</p>
<ul>
<li>Malignancy of lymphoid cells comprising multiple different cancers
    of the immune system depending on the subtype and stage of
    development of cell/tissue involved</li>
<li>Characterized by lymphadenopathy &amp; constitutional “B” symptoms:<ul>
<li>Fevers, drenching night sweats and weight loss</li>
</ul>
</li>
<li>Branch point of diagnosis:<ul>
<li>Hodgkin: 10% - superficial, nodal disease with orderly spread</li>
<li>Non
    -Hodgkin: 90% - diffuse, nodal and extranodal disease with
    noncontiguous spread</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>B symptoms; pruritus (10-15% of pt with HL); history of radiation</li>
<li>Lymphadenopathy: painless, firm, fixed, &gt;1cm</li>
<li>Exam: head &amp; neck, tonsils, axilla, testes, liver, spleen</li>
<li>CBC, CMP, LDH, Uric Acid</li>
<li>HBV, HCV,  HIV, EBV, Quant gold, Treponemal Ab, ANA</li>
<li>Imaging: CXR
    
    most will eventually need PET-CT; MRI brain if neuro symptoms</li>
<li>Diagnosis requires tissue<ul>
<li>Excisional
    Lymph node biopsy (surg onc. Consult)</li>
<li>Core biopsy (CT guided procedure consult)</li>
</ul>
</li>
<li>Ann Arbor Staging System: I. 1 LN region<ul>
<li>II. &gt;2 LN regions, same side of diaphragm</li>
<li>III. LN regions on both sides of diaphragm</li>
<li>IV. Dissem dz w/ 1+ extralymphatic organ</li>
</ul>
</li>
</ul>
<p>Non-Hodgkin Lymphoma (NHL)</p>
<p>Background</p>
<ul>
<li>65 y/o, M&gt;F, 85-90% B-cell</li>
<li>Associated with immunodeficiency (HIV, post-transplant), autoimmune
    disease (both the disease and immunosuppression), infection (EBV,
    HTLV-1, H pylori,  HCV, Borrelia, C</li>
<li>psittacosis, Coxiella)</li>
<li>Stratify into:<ul>
<li>Good prognosis
    :
    waxing/waning LAD, cytopenias, hepatomegaly or splenomegaly</li>
<li>Poor
    prognosis
    : Aggressive presentation: fever, night sweats, weight loss, TLS</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good Prognosis</td>
<td>Good Prognosis</td>
<td>Good Prognosis</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Key Features</td>
<td>Workup/Treatment</td>
</tr>
<tr>
<td>Follicular Lymphoma</td>
<td>20-30% of NHL T (14; 18) bcl-2 over expression; CD19+, 20+, 10+, CD5-, CD23- Grading based on # large cells 1: \&lt;25%, 2: 25-50%, 3. >50% (grade 3= closer to DLBCL)</td>
<td>Watchful waiting Treatment: bulky LAD symptomatic disease End-organ damage Cytopenia’s Excision or radiation (stage I) Bendamustine-R (B-R) or RCHOP (&gt; I)</td>
</tr>
<tr>
<td>Marginal Zone Lymphoma</td>
<td>Usually located in the GI, thyroid, orbit, lung, breast, salivary glands</td>
<td>Treatment: Treat H pylori if MALT Treat HCV if splenic Extranodal MALT: B-R, rituximab x 4 doses</td>
</tr>
<tr>
<td>Mycosis Fungoides Sezary syndrome</td>
<td>Skin plaques with atypical CD4+ cells May progress to Sezary syndrome aka T cell leukemia</td>
<td>Workup: Skin biopsy Treatment: Light therapy, topical steroids, superficial radiation</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Aggressive/Poor Prognosis</td>
<td>NaN</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Key Features</td>
<td>Workup/Treatment</td>
</tr>
<tr>
<td>DLBCL</td>
<td>~25% of NHL; CD20+, CD45+ CD5+ confers the worst prognosis Can arise as transformation from low- grade lymphoma (Richter’s transformation) 60% present with advanced disease Risk factors for CNS disease: involvement of testicle, paranasal sinus, epidural space, bone marrow or >1 extra nodal sites + ↑LDH CNS disease needs IT and systemic MTX</td>
<td>If PET/CT reveals BM disease then no need for biopsy Tx: RCHOP vs DA-R-EPOCH (double hit) Use IPI prognostic scoring</td>
</tr>
<tr>
<td>Mantle Cell Lymphoma</td>
<td>7% NHL; CD20+, CD200+ T(11;14) =↑Cyclin D1 M&gt;F; avg age ~50-60s Most present with diffuse disease Blastoid variant more often involves CNS</td>
<td>Dx: pathology from bx Use MIPI prognostic tool Treatment: Aggressive: R-hyperCVAD-M/ara-C Poor PS: BR &amp; Rituximab</td>
</tr>
<tr>
<td>Double or Triple Hit Lymphoma</td>
<td>Similar to DLBCL with combination of bcl-2, bcl-6, or myc aberrations conveying double or triple hits Very aggressive needs intrathecal ppx even if no evidence of CNS disease</td>
<td>PET/CT for staging; if no evidence of BM involvement on PET, will need biopsy Tx: Da-R-EPOCH vs R hyperCVAD/MA vs R-CODOX-M/ IVAC</td>
</tr>
<tr>
<td>Burkitt Lymphoma</td>
<td>MYC translocation - most commonly t (8;14) with path showing classic “starry-sky” Rapidly growing tumors HIV: CNS relapse is 30-50% if no CNS ppx 1. Endemic (African jaw); often EBV/CD21+ 2. Sporadic (in the US): median age 30 at dx; present w/ abdominal masses &amp; metastasis 3. Immunodeficiency-related (often seen with CD4 counts >200); more often involve LN, CNS, and BM</td>
<td>R-EPOCH vs R-CODOX-M/IVAC Everyone gets CNS prophylaxis TLS prophylaxis for all pts Everyone will need TTE before anthracycline-based chemo</td>
</tr>
<tr>
<td>Lymphoblastic Lymphoma</td>
<td>Express TdT+ (cyclin D1 -) Aggressive; often present with mediastinal mass and CNS involvement Consider empiric allopurinol before starting chemotherapy</td>
<td>Treated like acute leukemias Will need LP with IT chemo</td>
</tr>
<tr>
<td>Anaplastic Large Cell Lymphoma (ALCL)</td>
<td>\&lt; 2% of NHL Primary cutaneous variant can arise from existing mycosis fungoides Worse outcome predictor includes increased β-2 microglobulin >3 and age >40</td>
<td>Use IPI prognostic tool Treatment: check CD30 &plusmn; status - CD30+: BV(brentuximab)+ CHP (cyclophosphamide, doxorubicin, prednisone) CD30-: CHOP + etoposide</td>
</tr>
</tbody>
</table>
<p>Hodgkin Lymphoma (HL)</p>
<p>Background</p>
<ul>
<li>Bimodal Distritbution: 15-35 y/o and &gt;50; M&gt;F</li>
<li>CD15+, CD30+ (Reed Sternberg cells “owl eyes”)</li>
<li>Associated with EBV in immunocompromised pt</li>
<li>4 classical types<ul>
<li>Nodular sclerosing (60-80%): young adult, F&gt;M, low stage,
    mediastinal LAD, collagen bands</li>
<li>Lymphocyte rich (5%): best prog</li>
<li>Lymphocyte depleted (\&lt;1%): worst prognosis, older, M&gt;F,
    disseminated, HIV+, diffuse positive and RS cells</li>
<li>Mixed (15-30%): older, M&gt;F, intermediate prognosis</li>
</ul>
</li>
<li>1 nonclassical (5%): nodular lymphocyte predominant, peripheral LN</li>
</ul>
<p>Presentation</p>
<ul>
<li>Lymphadenopathy (usually contiguous), generalized pruritus,
    Incidental mediastinal mass</li>
<li>B-Symptoms: fevers, night sweats, weight loss</li>
</ul>
<p>Evaluation</p>
<ul>
<li>IPS negative prognostic calculator: albumin \&lt;4, hemoglobin \&lt;10.5,
    male, stage IV by Ann Arbor, age&gt;45, WBC count&gt; 15K, lymphocyte \&lt;8%</li>
</ul>
<p>Management</p>
<ul>
<li>Stage I-II: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
    ± RT</li>
<li>Stages III-IV: ABVD x6 or escalated BEACOPP (bleo, etop, doxo,
    cyclophos, vinc, procarbazine, prednisone)</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Pts will need TTE prior to chemo given the use of anthracycline</li>
<li>Increased risk of secondary cancers (~25% of pt with 40% increased
    risk over next 40 years)</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-medical-oncology-resources"><h1 id="hematology-oncology-hematologyoncology-medical-oncology-resources-medical-oncology-resources">Medical Oncology Resources<a class="headerlink" href="#hematology-oncology-hematologyoncology-medical-oncology-resources-medical-oncology-resources" title="Permanent link">&para;</a></h1>
<p>Medical Oncology Resources – Eric Lander</p>
<p>VUMC Oncology Rotation Tips:</p>
<p>The inpatient oncology rotation involves complex decisions often
resulting from advancing diseases. The question “What do you want?” is
too simple. Rather, it should be “Given your current circumstance, and
given our choices, which path would you prefer to take?” Patients want
advice from their outpatient doctors who have been caring for them for
years. Therefore, treatment and goals discussions often must pass
through the inpatient attending to the outpatient attending. Be sure to
define how communication with this primary oncologist will be handled.</p>
<p>Oncology summary sentence in presentation:</p>
<ol>
<li>Cancer type and stage (at diagnosis – *stage never changes even if
    progressed*)</li>
<li>Pertinent tumor genetic information</li>
<li>Any relevant surgeries (e.g. resections)</li>
<li>Most recent treatment</li>
<li>Trajectory of disease (e.g. progressive, improving, or stable)</li>
<li>Patient’s primary oncologist</li>
</ol>
<p>Ex: Ms. X is a 64 y/o female w/ stage IIIa adenocarcinoma of the lung
post resection now with metastases to the spine (patient of Dr. Y)
admitted w/intractable back pain and leg weakness. Full NGS at diagnosis
with no actionable mutations, and was 40% positive for PDL1. No previous
chemo.</p>
<p>NCCN:</p>
<p>National Comprehensive Cancer Center Network: (</p>
<p><a href="https://www.nccn.org/">https://www.nccn.org/</a></p>
<p>): consensus based treatment guidelines for most hematopoietic and solid
tumors.  Free for house staff.</p></section><section class="print-page" id="hematology-oncology-hematologyoncology-myelodysplastic-syndromes"><h1 id="hematology-oncology-hematologyoncology-myelodysplastic-syndromes-myelodysplastic-syndromes">Myelodysplastic Syndromes<a class="headerlink" href="#hematology-oncology-hematologyoncology-myelodysplastic-syndromes-myelodysplastic-syndromes" title="Permanent link">&para;</a></h1>
<p>Myelodysplastic Syndromes – Peter Hanna</p>
<p>Background</p>
<ul>
<li>MDS is a <strong>malignant</strong> clonal myeloid disorder resulting in
    ineffective hematopoiesis leading to peripheral cytopenia’s and a
    risk of transformation to acute myeloid leukemia (AML)</li>
<li>The bone marrow is <strong>hypercellular and dysplastic</strong> usually</li>
<li>20% of cases have hypocellular marrow and look like aplastic anemia</li>
<li>Usually idiopathic, a disease of the elderly (median onset at
    age 70)</li>
<li>The WHO has several classification schemes for MDS</li>
<li>Most important for classification is the percent of blasts in the
    bone marrow</li>
<li>Note &gt;20% blasts in marrow = AML. Thus MDS &amp; AML are on a continuum</li>
</ul>
<p>Presentation</p>
<ul>
<li>50% asymptomatic; Symptoms can include nonspecific but gradual
    fatigue, weakness</li>
<li>Dysplastic cells do not work properly
    
    infections and bleeding are more likely</li>
<li>B symptoms like fever or weight loss
    
    more consistent with myeloproliferative disorder</li>
<li>Macrocytic anemia is most common finding; followed by bicytopenia or
    pancytopenia<ul>
<li>Isolated neutropenia or thrombocytopenia are unusual</li>
</ul>
</li>
<li>Ask about secondary causes:<ul>
<li>Exposure to chemicals (benzene, crude oil/gasoline industry,
    cigarette smoke), chemotherapy, radiation</li>
<li>Medications, alcohol use, chronic infections (HIV)
    
    marrow toxicity/dysplasia</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Goal
    is to rule out reversible causes of dysplasia and cytopenias</li>
<li>CBC w/differential, Peripheral Smear, B12, Folate, HIV<ul>
<li>May consider Copper &amp; Zinc (send out labs, are expensive and
    rare)</li>
</ul>
</li>
<li>Dysplastic changes on peripheral smear: hypogranulated/hyposegmented
    neutrophils, hypogranulated platelets and macrocytosis of RBCs<ul>
<li>Circulating myeloblasts can be seen</li>
</ul>
</li>
<li>Final diagnosis made by Bone marrow Biopsy</li>
</ul>
<p>Management</p>
<ul>
<li>Molecular characteristics define the “risk” of the disease
    
    dictates treatments</li>
<li>Prognostic scoring tools: revised international prognostic staging
    system (R-IPSS)</li>
<li>Management general paradigm:<ul>
<li>Asymptomatic: with
    low-risk disease = monitoring</li>
<li>Low-risk disease
    + symptoms due to anemia only
    
    transfusions, erythrocyte stimulating agents, and treatment with
    Luspatercept</li>
<li>MDS with isolated del(5q):
    treated with lenalidomide</li>
<li>High-risk patients
    :  treated with hypomethylating agents</li>
<li>Only curative intervention = hematopoietic stem cell transplant
    (HSCT)</li>
</ul>
</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-myeloproliferative-neoplasms"><h1 id="hematology-oncology-hematologyoncology-myeloproliferative-neoplasms-myeloproliferative-neoplasms">Myeloproliferative Neoplasms<a class="headerlink" href="#hematology-oncology-hematologyoncology-myeloproliferative-neoplasms-myeloproliferative-neoplasms" title="Permanent link">&para;</a></h1>
<p>Myeloproliferative Neoplasms (MPNs)—Christina Snider</p>
<p>Background</p>
<ul>
<li>MPNs = chronic myeloid disorders caused by abnormal proliferation of
    mature bone marrow cell lineages (granulocytes, erythrocytes, or
    megakaryocytes)</li>
<li>MPNs differ from myelodysplastic syndrome (MDS)—cells in MPNs are
    normally developed (i.e. not dysplastic)</li>
<li>Four “classic” MPNs: polycythemia vera, essential thrombocythemia,
    primary myelofibrosis and chronic myeloid leukemia (CML)</li>
</ul>
<p>Polycythemia Vera (PV)</p>
<ul>
<li>Polycythemia is a general term: Men = Hb/Hct &gt; 16.5/49%;  Women =
    Hb/Hct &gt; 16/48%</li>
<li>Relative polycythemia
    = Concentrated H/H due to decreased plasma volume<ul>
<li>Diuretic use, vomiting, diarrhea;  H/H should normalize with
    fluid resuscitation</li>
</ul>
</li>
<li>Absolute polycythemia
    = Increased RBC mass<ul>
<li>Primary
    polycythemia: 2/2 Inherited/acquired mutation in RBC progenitor</li>
<li>Secondary polycythemia: Increase in RBC mass due to elevated
    serum EPO<ul>
<li>Hypoxia/cardiopulmonary associated (chronic pulmonary
    disease, R-to-L cardiac shunts, sleep apnea, obesity
    hypoventilation syndrome, chronic carbon monoxide poisoning,
    including heavy smoking)</li>
<li>Kidney associated causes (following renal transplant, renal
    artery stenosis, hydronephrosis)</li>
<li>Autonomous EPO production from an EPO-producing tumors
    (rare)</li>
<li>Steroid Use</li>
</ul>
</li>
</ul>
</li>
<li>Epidemiology: Median age of diagnosis is 60 years; 25% cases present
    at age \&lt;50 years.</li>
<li>>95% PV pts have <em>JAK2</em> V617F mutation, but <em>JAK2</em> V617F mutation
    is not specific to PV and can be seen in other MPNs</li>
</ul>
<p>Presentation</p>
<ul>
<li>Incidentally elevated H/H</li>
<li>Splenomegaly, generalized pruritus (post-warm bath/shower), unusual
    thrombosis</li>
<li>Erythromelalgia: intermittent occurrence of red, hot, painful
    extremities</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC with differential and peripheral smear</li>
<li>EPO level</li>
<li>Rule out secondary causes: Sleep Study, Carboxyhemoglobin, steroids</li>
<li>Peripheral blood screen for <em>JAK2</em> V617F mutation</li>
</ul>
<p>Management</p>
<ul>
<li>PV treatment aims to prevent thrombosis and bleeding events.</li>
<li>Phlebotomy: maintain Hct \&lt;45% (One unit 500 mL decreases Hct by 3%)</li>
<li>ASA 81 mg for thrombosis prevention and symptom control</li>
<li>Hydroxyurea: indicated for high-risk patients (&gt;60 years old or with
    history of thrombosis)</li>
<li>Interferon-alfa, busulfan, or ruxolitinib: indicated in select
    high-risk patients</li>
</ul>
<p>Essential thrombocythemia (ET)</p>
<p>Background</p>
<ul>
<li>Clonal stem cell disorder w/ increased platelet counts (&gt;450k/uL)</li>
<li>Risks of thrombosis and hemorrhage</li>
<li>Median age of diagnosis: 60 years; Twice as common in females.</li>
</ul>
<p>Presentation</p>
<ul>
<li>Incidental thrombocytosis on CBC</li>
<li>Splenomegaly, unusual thrombosis, and erythromelalgia</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Screen for conditions that cause reactive thrombocytosis: Chronic
    inflammatory diseases, infections, bleeding/hemolysis, iron
    deficiency, post splenectomy</li>
<li>CBC with smear (platelet anisocytosis) ranging from very small to
    giant platelets</li>
<li>CMP, LDH, Uric Acid, iron studies</li>
<li>BCR ABL1 testing may be sent to exclude CML</li>
<li>Bone marrow biopsy with staining, cytogenetics, and molecular
    testing for JAK2 mutations</li>
</ul>
<p>Management</p>
<ul>
<li>Avoid ASA 81 in patients with platelet counts &gt;1 million/uL microL
    complicated by acquired von Willebrand syndrome due to increased
    risk of bleeding</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of ET</td>
<td>Treatment of ET</td>
<td>Treatment of ET</td>
</tr>
<tr>
<td>Risk Score (IPSET-thrombosis)</td>
<td>Features</td>
<td>Treatment</td>
</tr>
<tr>
<td>High</td>
<td>Hx of thrombosis and/or >age 60 with JAK2 V617F mutation</td>
<td>Cytoreduction (target plt 100-400k) w/ hydroxyurea, systemic anticoagulation &plusmn;antiplatelet agent</td>
</tr>
<tr>
<td>Intermediate</td>
<td>Age >60, no JAK2 V617F mutation, no history of thrombosis</td>
<td>Cytoreduction (target plt 100-400k) w/ hydroxyurea, systemic anticoagulation &plusmn;antiplatelet agent</td>
</tr>
<tr>
<td>Low</td>
<td>Age =\&lt;60 w/ JAK2 V617F mutation and no history of thrombosis</td>
<td>Observation vs. daily ASA 81</td>
</tr>
<tr>
<td>Very Low</td>
<td>Age =\&lt;60, no JAK2 V617F mutation, no history of thrombosis</td>
<td>Observation vs. daily ASA 81</td>
</tr>
</tbody>
</table>
<p>Primary Myelofibrosis (PMF)</p>
<p>Background</p>
<ul>
<li>Clonal proliferation of myeloid cells with variable morphologic
    maturity resulting in reactive marrow fibrosis and extramedullary
    hematopoiesis</li>
<li>Least favorable prognosis out of MPN</li>
</ul>
<p>Presentation</p>
<ul>
<li>Fatigue, weight loss, low grade fever, bone pain, and night sweats</li>
<li>Marked splenomegaly &plusmn;hepatomegaly (due to extramedullary
    hematopoiesis)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>smear: teardrop shaped RBCs (dacrocytes)</li>
<li>Bone marrow biopsy: “dry tap” due to extensive reticulin and/or
    collagen fibrosis</li>
<li>mutually exclusive mutations in JAK2, MPL, or CALR</li>
</ul>
<p>Management</p>
<ul>
<li>Low risk patients: Observe if asymptomatic</li>
<li>Cure by allogenic HCT transplantation in young, high risk patients</li>
<li>Complex treatment options, consult Hematology</li>
<li>Treatment of anemias include transfusion support</li>
<li>Surgical splenectomy if abdominal pain or transfusion dependent
    anemia</li>
</ul>
<p>Chronic Myelogenous Leukemia (CML)</p>
<p>Background</p>
<ul>
<li>Definition: MPN overproduction of myeloid stem cells that can
    differentiate</li>
<li>Chronic phase: 85% of pts<ul>
<li>Fatigue, weight loss, bleeding</li>
<li>Abdominal fullness and early satiety due to splenomegaly</li>
<li>WBC on CBC is typically &gt;100k, and smear shows neutrophilic
    cells in all stages of maturation with \&lt;2% blasts</li>
</ul>
</li>
<li>Accelerated phase: Refractory leukocytosis, 10-19% blasts in
    peripheral blood or bone marrow, worsening peripheral basophilia,
    thrombocytopenia</li>
<li>Blast phase = acute leukemia. &gt;20% blasts in peripheral blood or
    bone marrow, extramedullary proliferation of blasts</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Typical findings in blood and bone marrow and confirmation of
    Philadelphia chromosome ( <em>BCR-ABL1</em> fusion gene) via conventional
    cytogenetics, FISH, or rt-PCR</li>
</ul>
<p>Management</p>
<ul>
<li>Hydroxyurea can be used to reduce WBC while awaiting confirmation</li>
<li>Oral tyrosine kinase inhibitors (TKIS): Imatinib, dasatinib,
    nilotinib, and ponatinib</li>
<li>Allogenic hematopoietic cell transplantation: Curative option for
    pts in accelerated and blast phase, as well as young pts w/chronic
    phase CML who do not respond to TKI therapy</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever"><h1 id="hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever-neutropenia-and-neutropenic-fever">Neutropenia and Neutropenic Fever<a class="headerlink" href="#hematology-oncology-hematologyoncology-neutropenia-and-neutropenic-fever-neutropenia-and-neutropenic-fever" title="Permanent link">&para;</a></h1>
<p>Neutropenia &amp; Neutropenic Fever – Jennifer Marvin-Peek</p>
<p>Background</p>
<ul>
<li>Neutrope
    nia: absolute neutrophil count (ANC) \&lt; 1500<ul>
<li>Severe neutropenia: absolute neutrophil count (ANC) \&lt;500 [Use
    manual count if available]</li>
<li>Typically
    requires immediate evaluation and often hospitalization</li>
<li>>500 is threshold for allowing pt’s to return home after
    chemo-induced neutropenia</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism</td>
<td>Causes</td>
<td>Example(s)</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Drug-associated</td>
<td>Cytotoxic or immunosuppressive agents Methimazole, PTU, Colchicine Macrolides, Bactrim, Dapsone, Vancomycin Amphotericin, Acyclovir, Ganciclovir TCAs, Clozapine, Carbamazepine, Valproate ACEI, Digoxin, Propranolol, Procainamide</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Radiation exposure</td>
<td>NaN</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Malignancies</td>
<td>Leukemias, MDS</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Infection</td>
<td>Hepatitis, HIV, EBV, CMV Rickettsia, Tularemia, Typhoid, TB</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Nutritional deficiency</td>
<td>Vitamin B12, Folate, Copper</td>
</tr>
<tr>
<td>Neutrophil Production</td>
<td>Other</td>
<td>Aplastic anemia Benign ethnic neutropenia</td>
</tr>
<tr>
<td>Redistribution</td>
<td>Splenomegaly</td>
<td>Margination &amp; sequestration</td>
</tr>
<tr>
<td>Congenital</td>
<td>Genetics</td>
<td>Benign ethnic neutropenia, familial neutropenia</td>
</tr>
<tr>
<td>Immune destruction</td>
<td>Autoimmune disorders</td>
<td>RA, SLE</td>
</tr>
<tr>
<td>Immune destruction</td>
<td>Other</td>
<td>Autoimmune neutropenia</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>ANC \&lt;500<ul>
<li>Check all lines/IVs for erythema and induration daily</li>
<li>Check mouth for mucositis, mouth care after meals and before bed</li>
<li>Assess for Neutropenic Fever &amp; Complications – see below</li>
<li>Evaluate for indications for prophylaxis – see below</li>
<li>Provide Neutropenic Precautions:<ul>
<li>Neutropenic
    diet: low microbial diet</li>
<li>Idea
    is to prevent food-borne illness, however has not been shown
    to decrease infection risk in meta-analyses</li>
<li>No raw, or undercooked foods</li>
<li>No deli meats, seafood, salad bars, unpasteurized products
    or raw sprouts</li>
<li>No digital rectal exams or enemas/suppositories (risk of
    bacterial translocation)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Neutropenic Fever</p>
<ul>
<li>ANC \&lt;500 and T&gt; 100.4 °F or 38.0 °C</li>
<li>Neutropenic pts are unable to mount an adequate immune response and
    can become critically ill very quickly</li>
<li>Do not wait for a temp re-check, you need to start antibiotics
    immediately</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Chest X-ray</li>
<li>Two sets of blood cultures (one from PICC/port if present)</li>
<li>Urinalysis AND urine culture (not the reflex order set)</li>
<li>If diarrhea, get C. diff PCR</li>
<li>If abdominal pain, get CT A/P with IV contrast</li>
</ul>
<p>Management</p>
<ul>
<li>Empirically treat with Cefepime</li>
<li>Indications for Vancomycin:<ul>
<li>Hemodynamically unstable</li>
<li>Severe mucositis</li>
<li>Focal consolidation on CXR</li>
<li>Erythema/induration around line</li>
<li>Concern for skin/soft tissue infection</li>
<li>GPCs in blood</li>
<li>Fever continues &gt;24h on cefepime</li>
</ul>
</li>
<li>Additional Coverage:<ul>
<li>If abdominal pain/diarrhea: Flagyl 500mg q8h</li>
<li>Concern for C-diff: PO Vancomycin 125mg q6h</li>
<li>Still fevering on Cefepime at 72 hrs (differs by attending)
    
    Meropenem</li>
</ul>
</li>
<li>Fungal coverage: Consider if risk factors (TPN) or persistent fevers
    (&gt;72hrs)<ul>
<li>Micafungin 100 mg IV daily or Voriconazole 200mg PO BID</li>
</ul>
</li>
</ul>
<p>Neutropenic Complications</p>
<p>Mucositis</p>
<ul>
<li>Can
    range from mouth soreness to severe erosions preventing
    eating/drinking</li>
<li>Can
    become secondarily infected with Candida, HSV<ul>
<li>Management
    :<ul>
<li>Routine oral care with a soft toothbrush to remove plaque</li>
<li>Oral rinses with saline and/or sodium bicarbonate</li>
<li>Magic mouthwash for symptomatic relief (or viscous lidocaine
    at the VA)</li>
<li>Typically recovers quickly when ANC &gt; 500</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Neutropenic</p>
<p>enterocolitis (Typhlitis)</p>
<ul>
<li>Life
    -threatening bacterial translocation due to breakdown of gut-mucosal
    barrier</li>
<li>Presentation
    :
    Abdominal pain + fever<ul>
<li>&plusmn; abdominal distension, nausea, vomiting, watery and/or bloody
    diarrhea</li>
</ul>
</li>
<li>Diagnosis
    :
    CT
    A/P with contrast, consider C. diff PCR if diarrhea</li>
<li>Treatment
    :<ul>
<li>Cefepime/Flagyl OR Zosyn</li>
<li>If no perforation/abscess on CT scan, typically continue until
    14 days after ANC recovers &gt;500 and abdominal pain resolves</li>
<li>Can change to cipro/flagyl once ANC &gt;500</li>
<li>If perforation/abscess: will need imaging to confirm resolution,
    and longer duration of abx</li>
</ul>
</li>
</ul>
<p>Neutropenic Prophylaxis</p>
<ul>
<li>Used
    if ANC is expected to be \&lt; 500 for &gt; 7 days</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Most Common Regimen</td>
<td>Alternatives</td>
</tr>
<tr>
<td>Bacterial</td>
<td>Levofloxacin 500mg PO daily</td>
<td>Cefdinir 300mg PO BID</td>
</tr>
<tr>
<td>Viral</td>
<td>Valacyclovir 500mg PO BID</td>
<td>Acyclovir 400mg PO BID (adjust for renal dysfunction)</td>
</tr>
<tr>
<td>Fungal</td>
<td>Fluconazole 400mg PO daily</td>
<td>Posaconazole 300 PO BID x2 days 300 daily (AML induction for aspergillus) Micafungin 50mg IV daily</td>
</tr>
<tr>
<td>PJP (if steroids)</td>
<td>Inhaled pentamidine 300 mg monthly</td>
<td>Dapsone (check G6PD) Avoid Bactrim (risk of myelosuppression)</td>
</tr>
</tbody>
</table>
<p>Filgrastim (G-CSF – Neupogen/Zarxio)</p>
<ul>
<li>Induces bone marrow production of Neutrophils</li>
<li>Can be given for chemo-induced neutropenia in non-AML malignancies</li>
<li>Sometimes given in AML in certain regimens like CLAG-M</li>
<li>Dose: either 300mcg or 480mcg (rounded from 5 mcg/kg/day)</li>
<li>Common side effects: fatigue, nausea</li>
<li>PEG-filgrastim (Neulasta): long-acting version that is only given as
    an outpatient</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-oncologic-emergencies"><h1 id="hematology-oncology-hematologyoncology-oncologic-emergencies-oncologic-emergencies">Oncologic Emergencies<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-oncologic-emergencies" title="Permanent link">&para;</a></h1>
<p>Madeleine Turcotte</p>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-leukostasis">Leukostasis<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-leukostasis" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-presentation">Presentation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-presentation" title="Permanent link">&para;</a></h3>
<ul>
<li>Respiratory: dyspnea, hypoxia (note CXR may be normal)<ul>
<li>PaO2 by ABG often falsely low dt WBC consuming O2 <em>in vitro</em> .
    Trust SpO2.</li>
</ul>
</li>
<li>CNS: headache, AMS, vision changes, dizziness, tinnitus, gait
    instability, neuro deficit</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation" title="Permanent link">&para;</a></h3>
<ul>
<li>CBC with diff and peripheral blood smear</li>
<li>Imaging: CT head to evaluate neuro deficit and to check for ICH</li>
<li>Chest X-Ray vs CT chest to evaluate dyspnea</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management" title="Permanent link">&para;</a></h3>
<ul>
<li>Page hematology fellow for guidance if you feel this dx is likely</li>
<li>Hydrea (discuss with fellow) Hydrea 50 – 100 mg/kg/day divided
    between bid dosing</li>
<li>Emergent cytoreduction<ul>
<li>Leukapheresis: page nephrology and place dialysis catheter</li>
</ul>
</li>
<li>Chemotherapy per hematology fellow</li>
<li>Transfer/admit to ICU</li>
</ul>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-tumor-lysis-syndrome-bradley-christensen">Tumor Lysis Syndrome - Bradley Christensen<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-tumor-lysis-syndrome-bradley-christensen" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-background">Background<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Lysis of malignant cells either spontaneously or in response to
    chemotherapy causing release of K, Phos, nucleic acids, and
    cytokines</li>
<li>Consequences:<ul>
<li>Hyperkalemia- most urgent and immediately life threatening</li>
<li>Hyperphosphatemia- binds Ca2+ and leads to CaP crystal
    deposition-&gt; AKI, HypoCa</li>
<li>Hyperuricemia (from breakdown of DNA)-&gt;precipitation in renal
    tubules-&gt;AKI</li>
<li>Hypotension, AKI from cytokine release</li>
</ul>
</li>
<li>Laboratory TLS (at least
    two within 2d before or 7d after start of chemotherapy):<ul>
<li>Uric acid ≥ 8 mg/dL, Ca2+ ≤ 7 mg, K+ ≥ 6 mEq/L, or PO43- ≥ 4.5
    mg/dL /dL</li>
<li>OR &gt; 25% change from baseline in these values</li>
</ul>
</li>
<li>Clinical TLS: laboratory TLS + AKI, arrhythmia, seizure, tetany,
    death</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_1">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Risk Stratification:<ul>
<li>Highest risk <strong>after</strong> tarting chemotherapy, but can occur spontaneously</li>
</ul>
</li>
<li>Tumor characteristics which confer a <strong>higher risk</strong> of developing
    TLS:<ul>
<li>High (&gt;5% risk): ALL (WBC&gt; 100K or LDH 2x ULN), AML (WBC&gt; 100K),
    Burkitt’s (III/IV or LDH≥2xULN, DLBCL with bulky disease,
    intermediate risk + AKI/CKD</li>
<li>Intermediate: ALL (WBC\&lt;100K, LDH \&lt;2x ULN), AML (WBC 25-100K),
    Burkitt’s LDH\&lt;2x ULN), DLBCL (non-bulky, LDH&gt;ULN), CLL (if tx
    with fludarabine, rituximab, lenalidomide, or venetoclax +LN
    5-10 cm or ALC≥25K), plasma cell leukemia, rare chemo-sensitive
    solid tumors (small cell)</li>
<li>Low: all others</li>
</ul>
</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management_1">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management_1" title="Permanent link">&para;</a></h3>
<p>Prevention:</p>
<ul>
<li>High risk:  q8h TLS labs, IVF (±loop diuretic if volume overload),
    allopurinol, ± rasburicase</li>
<li>Intermediate – q8h TLS labs, IVF, allopurinol</li>
<li>Low – daily TLS labs, IVF<ul>
<li>Significant hydration: goal to maintain UOP 80-100 mL/hr</li>
<li>Allopurinol: 300 mg PO BID for CrCl &gt; 20 mL/min, UpToDate renal
    dosing if lower</li>
<li>Rasburicase ($$$): contraindicated in G6PD (send G6PD if not
    urgent and AA, Asian or Jewish descent)<ul>
<li>Given if uric acid &gt; 8 mg/dL: get fellow approval before ordering</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Treatment: (Can use as night/cross cover handoff)</p>
<ul>
<li>K <sup>+</sup> <u>></u> 5.5:  STAT EKG. Kayexalate 30g orally or
    60g per rectum (unless contraindicated) x1<ul>
<li>Give 10 U insulin/1 amp D50</li>
<li>If EKG changes, then calcium gluconate and D5W at 100 mL/hr with
    repeat BG in 1 hr</li>
</ul>
</li>
<li>Uric acid <u>></u> 8 with 25% change from baseline: page hematology
    fellow to discuss rasburicase</li>
<li>PO4 <u>></u> 4.5 with 25% change from baseline: start/↑ phos binder (sevelamer)<ul>
<li>Dialysis may be necessary in patients with poor renal function.</li>
</ul>
</li>
<li>IV calcium: do not administer unless symptomatic AND
    hyperphosphatemia is corrected<ul>
<li>With high phos, IV calcium can lead to calcium deposition and
    renal failure</li>
</ul>
</li>
<li>Hemodialysis: pt with anuria, refractory hyperkalemia, and
    symptomatic hypocalcemia</li>
<li>Consequence of WBC’s plugging up microvasculature</li>
<li>Most common in AML with hyperleukocytosis (defined as WBC &gt; 100K/µL) If cell not sticky (CLL) generally not going to cause despite high
    WBC count.</li>
</ul>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-superior-vena-cava-svc-syndrome">Superior Vena Cava (SVC) Syndrome<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-superior-vena-cava-svc-syndrome" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-background_1">Background<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Commonly Associated Malignancies: Lung Cancer, Non-Hodgkin or Hodgkin
    Lymphoma, Mediastinal Germ Cell Tumors, Thymic Malignancies</li>
<li>Partial or complete obstruction of the SVC impedes blood return from
    the upper extremities, head, neck, and brain resulting in upstream
    congestion</li>
<li>Can be 2/2 a mass in the mediastinum or thrombosis (foreign body i.e. catheter)</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_1">Presentation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Facial or neck swelling without generalized edema</li>
<li>Sense of head fullness, exacerbated by leaning forward or lying
    down, which may indicate cerebral edema</li>
<li>Pulmonary symptoms including dyspnea, stridor, hoarseness, cough -
    due to edema narrowing the nasal passages and larynx or mechanical
    airway obstruction</li>
<li>Physical Exam: facial and neck edema particularly of the eye lids in
    the morning, distended neck and chest veins; can also sometimes see
    upper extremity swelling, papilledema, plethora. Look for associated
    lymph node enlargement anywhere particularly including
    supraclavicular, cervical and axillary region</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_2">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_2" title="Permanent link">&para;</a></h3>
<ul>
<li>AFP, β-hCG if no tissue Dx</li>
<li>CXR: may show mass, perihilar or mediastinal disease</li>
<li>Contrasted CT scan ± CT Venography:  Phased to get a view of clot
    contribution to obstruction  guides decision regarding anticoagulation or stenting<ul>
<li>Radiology attending can coordinate with techs (requires verbal direct
    request)</li>
</ul>
</li>
<li>MRI/MRV may provide additional information (often not possible due
    to pt too sick)</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management_2">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Assess airway and prepare for intubation if needed</li>
<li>Keep head of bed elevated</li>
<li>Thrombosis:<ul>
<li>Removal of lines/catheters associated with thrombus</li>
<li>Consideration of anticoagulation (risks vs benefits patient
    dependent)</li>
</ul>
</li>
<li>Tumor compression: the type of tumor guides treatment (tissue biopsy
    is key)</li>
<li>Stat/urgent consultations:<ul>
<li>Interventional radiology for possible stenting/dilatation</li>
<li>Radiation oncology- for radiation therapy</li>
<li>Interventional pulmonology – for help with tissue dx</li>
<li>Medical oncology – for help with diagnosis and chemotherapy</li>
</ul>
</li>
</ul>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-spinal-cord-compression">Spinal Cord Compression<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-spinal-cord-compression" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-background_2">Background<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-background_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Malignancies where cord compression is most common:</li>
<li>Multiple Myeloma, Lymphoma (both Hodgkin and NHL), Lung, Breast,
    Prostate Cancer</li>
<li>Tumor mass &amp; compressed and often displaced bone  impinges thecal sac or nerve roots spinal cord or any spinal nerves including the cauda equina</li>
<li>Impingement causes pain and can lead to neurologic dysfunction</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_2">Presentation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Back pain, motor or sensory deficits</li>
<li>Cauda Equina syndrome  bowel or bladder incontinence, ataxia</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_3">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Neurologic exam with sensation testing seeking level below an
    identified dermatome</li>
<li>Lab testing: If no known malignancy check CBC, CMP, SPEP, and (in
    males) PSA</li>
<li>Bladder US if suspicion or retention with or without overflow
    incontinence</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management_3">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management_3" title="Permanent link">&para;</a></h3>
<ul>
<li>If suspected, MRI without and with contrast best for diagnosis; if
    patient unable to have MRI, CT myelography may be considered</li>
<li>Immediate high dose steroids (dosing is controversial with
    recommendations ranging from 4 to 100 mg of <strong>dexamethasone</strong> q6h -
    choice of dexamethasone is to minimize mineralocorticoid effects.
    Most common dosing is 10mg IV x1 followed by 4mg IV q6h)</li>
<li>Consider stat/urgent consultation with:<ul>
<li>Neurosurgery for diagnostic/therapeutic intervention</li>
<li>Radiation oncology- for radiation therapy</li>
<li>Medical oncology – for help with diagnosis and chemotherapy</li>
</ul>
</li>
<li>Ensure regular neuro-vascular checks and close monitoring.</li>
<li>Early PT if LE weakness</li>
</ul>
<h2 id="hematology-oncology-hematologyoncology-oncologic-emergencies-brain-metastases">Brain Metastases<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-brain-metastases" title="Permanent link">&para;</a></h2>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-background_3">Background<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-background_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Common Malignancies: Lung (NSCLC), breast, kidney, colorectal
    carcinomas &amp; melanomas</li>
<li>Significantly more common than primary brain tumors</li>
<li>Occur in 10 - 30% of adults w/systemic malignancies</li>
<li>80% of brain mets occur in the cerebrum at grey/white matter
    junction</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_3">Presentation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-presentation_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Highly variable: so consider brain mets any cancer pt w/ neurologic
    or behavioral changes</li>
<li>Headache: worse in the mornings, with bending over or with valsalva</li>
<li>Nausea/vomiting</li>
<li>Cognitive dysfunction: changes in memory, mood or personality</li>
<li>Focal neurologic deficits</li>
<li>Signs of elevated ICP: papilledema, vision changes, drowsiness,
    presyncope<ul>
<li>Seizures</li>
<li>Stroke (particularly in melanoma, choriocarcinoma, thyroid &amp;
    renal carcinomas)</li>
</ul>
</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_4">Evaluation<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-evaluation_4" title="Permanent link">&para;</a></h3>
<ul>
<li>STAT CT if concerned for stroke or elevated ICP</li>
<li>MRI with contras: most sensitive, can differentiate b/w metastases
    vs. other lesions<ul>
<li>Suggestive
    features: multiple lesions, location, circumscribed margins,
    vasogenic edema</li>
</ul>
</li>
<li>If pt has no known primary tumor: consider CT C/A/P &plusmn; PET to
    identify primary</li>
<li>Biopsy with histopathology &amp; IHC: if diagnosis in doubt or if only a
    single lesion is present</li>
</ul>
<h3 id="hematology-oncology-hematologyoncology-oncologic-emergencies-management_4">Management<a class="headerlink" href="#hematology-oncology-hematologyoncology-oncologic-emergencies-management_4" title="Permanent link">&para;</a></h3>
<ul>
<li>If severe HA, N/V, focal deficits: systemic glucocorticoids<ul>
<li>Dexamethasone 10mg IV x1 followed by 4mg IV q6h (can be PO if
    tolerated)</li>
</ul>
</li>
<li>Stat/urgent consults:<ul>
<li>Neurosurgery
    – for diagnostic/therapeutic intervention</li>
<li>Radiation
    oncology – for radiation therapy</li>
<li>Medical
    oncology – for help with diagnosis and chemotherapy</li>
</ul>
</li>
<li>Ensure regular neuro-vascular checks and close monitoring</li>
<li>Do not perform LP without input from neurology</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-paraneoplastic-syndromes"><h1 id="hematology-oncology-hematologyoncology-paraneoplastic-syndromes-paraneoplastic-syndromes">Paraneoplastic Syndromes<a class="headerlink" href="#hematology-oncology-hematologyoncology-paraneoplastic-syndromes-paraneoplastic-syndromes" title="Permanent link">&para;</a></h1>
<p>Paraneoplastic Syndromes – Justin Lo</p>
<p><span id="Paraneoplastic"></span></p>
<p>Hypercalcemia of malignancy</p>
<p>Background</p>
<ul>
<li>Caused
    by PTHrP production, osteolytic lesions, and/or rarely exogenous Vit
    D</li>
<li>PTHrP
    
    Breast cancer, NSCLC (squamous)</li>
<li>Osteolysis
    
    Multiple Myeloma, Breast Cancer;</li>
<li>Exogenous Vit D
    
    Lymphoma</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Correct [Ca <sup>+2</sup> ] for hypoalbuminemia: add 0.8 x (4.0 –
    albumin)</li>
<li>Send basic hyperCa <sup>+2</sup> work-up – PTH, Vit D, etc (see
    hypercalcemia section)</li>
<li>PTHrP is called “Parathyroid Hormone-related Peptide-ARUP” in Epic</li>
</ul>
<p>Management</p>
<ul>
<li>First-line: IVF without calcium such as Normosol
    
    goal urinary output of 150-200 mL/hr<ul>
<li>Strict I/Os; Cautious IV fluids if pt w/cardiac or renal
    dysfunction</li>
<li>Add Furosemide if hypervolemic (do not empirically start)</li>
</ul>
</li>
<li>Second-line: Zoledronic acid 4mg IV (takes 24-48 hours to see
    effect)</li>
<li>AMS or severe hypercalcemia (&gt;14mg/dL): calcitonin 4 IU/kg (req.
    attending approval)</li>
<li>Monitor creatinine, calcium and potassium</li>
<li>Begin treatment for underlying malignancy ASAP</li>
</ul>
<p>SIADH</p>
<p>Background</p>
<ul>
<li>Euvolemic hypotonic hyponatremia with urine sodium &gt;20 and typically
    urine Osm &gt;100</li>
<li>Associated with: SCLC (most common), head/neck cancers, breast
    cancer</li>
<li>See "Nephrology" for additional information</li>
</ul>
<p>Management</p>
<ul>
<li>Free water restriction to 800mL/day</li>
<li>Refractory: salt supplementation (e.g. salt tabs) &plusmn; loop diuretic</li>
</ul>
<p>Carcinoid Syndrome</p>
<p>Background</p>
<ul>
<li>Episodic
    flushing, diarrhea, wheezing/SOB due to secretion of histamine &amp;
    serotonin</li>
<li>Most common: Neuroendocrine tumors – GI (often with mets to liver
    and lung)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Urine: UR 5-HIAA (ARUP)</li>
<li>Imaging to identify tumor(s) (CT chest/abdomen/pelvis)</li>
</ul>
<p>Management</p>
<ul>
<li>Short-term treatment: subQ or IV octreotide (see UpToDate for
    dosing)</li>
<li>Antidiarrheals (Imodium, Lomotil, etc.) to slow transit</li>
<li>Long-term treatment: depot (IM) forms of octreotide and lanreotide</li>
</ul>
<p>Autoimmune encephalitis, encephalomyelitis, and myelitis</p>
<p>Background</p>
<ul>
<li>Encephalopathy (limbic or brainstem), &plusmn; myelitis (limb ataxia,
    sensory deficits)</li>
<li>Associated with small cell lung cancer and checkpoint inhibitor
    therapy</li>
</ul>
<p>Evaluation</p>
<ul>
<li>LP: make sure to order CSF oligoclonal bands &amp; CSF IgG index</li>
<li>“Paraneoplastic AutoAb Eval-MAYO” (add "CSF" to the front of the
    order name if for LP)</li>
<li>NMDA-R can be ordered as a standalone test</li>
<li>CT head</li>
<li>EEG if concern for subclinical seizures</li>
</ul>
<p>Management:</p>
<p>Consult Neurology, for possible immunosuppressive therapy (steroids,
IVIG)</p>
<p>Lambert-Eaton myasthenic syndrome (LEMS)</p>
<p>Background</p>
<ul>
<li>Muscle
    weakness due to autoantibody against calcium channels resulting in
    ↓
    ACh release</li>
<li>Associated
    with SCLC (most common) &amp; lymphoma</li>
</ul>
<p>Presentation: Proximal muscle weakness, diminished DTRs</p>
<p>Evaluation</p>
<ul>
<li>Nerve conduction studies: EMG w/ NCV</li>
<li>Serum “Paraneoplastic AutoAb Eval-MAYO”</li>
</ul>
<p>Management:</p>
<p>Consult Neurology</p></section><section class="print-page" id="hematology-oncology-hematologyoncology-plasma-cell-dyscrasias"><h1 id="hematology-oncology-hematologyoncology-plasma-cell-dyscrasias-plasma-cell-dyscrasias">Plasma Cell Dyscrasias<a class="headerlink" href="#hematology-oncology-hematologyoncology-plasma-cell-dyscrasias-plasma-cell-dyscrasias" title="Permanent link">&para;</a></h1>
<p>Plasma Cell Dyscrasias – Jennifer Marvin-Peek</p>
<p>Background</p>
<ul>
<li>A heterogenous group of benign, premalignant, and malignant
    conditions characterized by clonal proliferation of plasma cells</li>
<li>Results in production of monoclonal immunoglobulins or polypeptides
    (i.e. monoclonal proteins, or M-protein) in serum and/or urine</li>
<li>Includes monoclonal gammopathy of undetermined significance (MGUS),
    smoldering myeloma (SMM), multiple myeloma (MM), Waldenstrom’s
    macroglobulinemia (WM), extra-medullary plasmacytoma, AL
    amyloidosis, POEMS syndrome, Castleman’s disease</li>
<li>Complications: Increased infectious risk, renal failure,
    hyperviscosity syndrome, malignant hypercalcemia, pain crisis from
    bony disease</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Signs</td>
</tr>
<tr>
<td>Fatigue, weakness, weight loss Bone pain Paresthesias, neuropathy, radiculopathy Visual disturbances (if hyperviscosity present) Lymphadenopathy (uncommon) Fever (uncommon)</td>
<td>Anemia (Hgb \&lt;10) Renal insufficiency (Cr > 2) Hypercalcemia (Ca > 11.5) Elevated protein gap (Total protein - Alb > 4) Osteolytic bone lesions (typically central) Unexplained heavy proteinuria Rouleux formation on blood smear</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>CBC
    w/ diff, BMP (for Ca, Cr)</li>
<li>SPEP with immunofixation, UPEP (24 hour urine) with immunofixation,
    urinalysis, serum free light chains (FLC)</li>
<li>Quantitative immunoglobulins (IgA, IgM, IgG, IgD, IgE)</li>
<li>If  Hgb \&lt;10, Cr &gt;2, Ca &gt;11.5, M-protein &gt;1.5, non-IgG M-spike,
    abnormal FLC ratio:<ul>
<li>Bone marrow biopsy + cytogenetics, peripheral blood smear review</li>
<li>LDH, albumin, CRP,
    β
    2-microglobulin, serum viscosity</li>
<li>Skeletal survey</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional Tips for Lab Interpretation</td>
<td>Additional Tips for Lab Interpretation</td>
<td>Additional Tips for Lab Interpretation</td>
</tr>
<tr>
<td>SPEP/UPEP</td>
<td>Free light chains (FLC)</td>
<td>Urinalysis</td>
</tr>
<tr>
<td>Immunofixation determines clonality (e.g. mono or polyclonal) Monoclonal spike >1.5 is indicative of underlying dyscrasia Polyclonal spike suggests infectious, inflammatory, or reactive etiology</td>
<td>Ratio of kappa/lambda >3 highly suggestive of plasma cell dyscrasia -Ratio 1.65 to 3 can be due to infectious process or renal insufficiency Helpful in pts that only produce bence jones protein (FLC w/o heavy chain) which isn’t seen on SPEP</td>
<td>Detects albumin, not light chains In myeloma cast nephropathy, get negative dipstick since proteinuria is from FLC (i.e. Bence Jones proteinuria) In AL amyloid, dipstick will be positive 2/2 albumin loss from nephrotic syndrome</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Monoclonal Gammopathy of Unknown Significance (MGUS)</td>
<td>Smoldering Multiple Myeloma (SMM)</td>
<td>Multiple Myeloma (MM)</td>
</tr>
<tr>
<td>% Plasma Cells in BM</td>
<td>\&lt;10%</td>
<td>10-60%</td>
<td>≥ 10% (typically >30%)</td>
</tr>
<tr>
<td>Monoclonal Protein</td>
<td>IgG, IgA, IgM: 1.5 -3</td>
<td>IgG or IgA >3</td>
<td>IgG or IgA >3</td>
</tr>
<tr>
<td>Laboratory studies</td>
<td>Normal Hgb, Ca, Cr</td>
<td>Normal Hgb, Ca, Cr</td>
<td>↓Hgb, ↑Ca, ↑Cr</td>
</tr>
<tr>
<td>Symptoms</td>
<td>None</td>
<td>None</td>
<td>Lytic bone lesions, fatigue</td>
</tr>
<tr>
<td>Prognosis</td>
<td>1% / year progression to MM</td>
<td>10% / year progression to MM</td>
<td>R-ISS staging (see below)</td>
</tr>
<tr>
<td>Monitoring and/or Treatment</td>
<td>Monitoring only Yearly: Symptom check SPEP, FLC, CBC, BMP</td>
<td>Monitoring only In 2-3 months, repeat SPEP, FLC, CBC, BMP Yearly skeletal survey</td>
<td>Chemotherapy, plus SCT for eligible patients</td>
</tr>
</tbody>
</table>
<p>Multiple Myeloma</p>
<p>Evaluation</p>
<ul>
<li>Diagnosis requires:<ul>
<li>One of:<ul>
<li>Clonal
    bone marrow plasma cells &gt;10%</li>
</ul>
</li>
<li>Biopsy
    proven extramedullary plasmacytoma (tumor of plasma cells) AND
    ≥1 myeloma-defining event:<ul>
<li>One or more of the CRAB criteria</li>
<li>Clonal
    bone m
    arrow plasma cells ≥ 60%</li>
<li>Serum
    FLC ratio ≥ 100 or ≤0.01</li>
<li>>1
    focal
    lesion larger than 5mm on MRI</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Active disease: induction includes a proteasome inhibitor
    (bortezomib or carfilzomib)</li>
<li>Consolidation therapy includes SCT for eligible patients \&lt;65-70
    years old</li>
<li>Maintenance therapy is often given indefinitely, typically
    lenalidomide and/or bortezomib</li>
<li>VTE prophylaxis if on an immunomodulatory agent with 2 VTE risk
    factors<ul>
<li>If only 0-1
    VTE
    risk factors
    
    aspirin</li>
</ul>
</li>
<li>Supportive Care: EPO for anemia, analgesia ± radiotherapy for bone
    pain, vaccinations</li>
<li>Bisphosphonate (ideally zoledronic acid)</li>
<li>(Val)Acyclovir ppx if on bortezomib</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Prognosis<ul>
<li>Revised Multiple Myeloma International Staging System (R-ISS)
    (available on MD Calc)<ul>
<li>Serum
    β
    2-microglobulin (indicator of plasma cell turnover)</li>
<li>Serum albumin</li>
<li>Serum LDH</li>
</ul>
</li>
<li>Cytogenetic markers from biopsy</li>
</ul>
</li>
</ul>
<p>Lymphoplasmacytic Lymphoma</p>
<p>Waldenstrom’s Macroglobulinemia (IgM)</p>
<p>Presentation</p>
<ul>
<li>Hyper-viscosity syndrome
    : blurred vision, dizziness, diplopia, ataxia, vertigo stroke, coma</li>
<li>Peripheral neuropathy</li>
<li>Retinal changes: dilated veins, hemorrhages, papilledema</li>
<li>Cryoglobulinemia: large IgM complexes precipitate out in the cold,
    causing Raynaud's, urticaria, purpura, acral cyanosis, tissue
    necrosis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Requires: IgM monoclonal gammopathy on SPEP,  BM biopsy w/≥10%
    plasma cells, and MYD88 mutation detected</li>
<li>CBC, coagulation studies, cryoglobulins, IgM,
    β
    2-microglobulin</li>
<li>Serum viscosity (If \&lt;4 symptoms are rare, If &gt;6 typically
    symptomatic)</li>
</ul>
<p>Management</p>
<ul>
<li>Only treated if symptomatic</li>
<li>If Hyper-viscosity syndrome treatment in Plasma Exchange</li>
<li>Induction: may include bendamustine &plusmn; rituximab if IgM level is
    \&lt;4000 (Rituximab can temporarily
    ↑
    IgM and
    ↑
    risk of hyperviscosity syndrome)</li>
<li>Monitor response with: IgM levels, monoclonal IgM on SPEP</li>
</ul>
<p>Other Plasma Cell Dyscrasias</p>
<p>Light Chain (AL) Amyloidosis</p>
<ul>
<li>Extracellular deposition of misfolded light chains</li>
<li>Most commonly kidney &amp; heart</li>
<li>Features:
    ​​​​​​​<ul>
<li>Nephrotic syndrome</li>
<li>Restrictive CM</li>
<li>Peripheral neuropathy</li>
<li>Hepatomegaly</li>
<li>Macroglossia</li>
<li>Easy bruising/bleeding</li>
<li>Orthostasis</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Diagnosis:<ul>
<li>Need
    ALL
    4:
    ​​​​​​​<ul>
<li>Amyloid related systemic syndrome</li>
<li>Positive congo red staining on any tissue</li>
<li>Evidence that amyloid is light chain related</li>
<li>Evidence of monoclonal plasma cell disorder ​​​​​​​</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>POEMS Syndrome</p>
<ul>
<li>Unknown, possibly chronic overproduction of pro-inflammatory
    cytokines such as <strong>VEGF</strong></li>
<li>Features:
    P
    olyneuropathy, <strong>O</strong> rganomegaly, <strong>E</strong> ndocrinopathy, <strong>M</strong>
    onoclonal protein (usually
    λ
    light chain), <strong>S</strong> kin changes</li>
<li>Diagnosis:<ul>
<li>Mandatory Criteria
    ​​​​​​​<ul>
<li>Peripheral neuropathy</li>
<li>Monoclonal plasma cell disorder ​​​​​​​</li>
</ul>
</li>
<li>Major Criteria (need &#8531;)<ul>
<li>Osteosclerotic lesions, VEGF, Castleman disease</li>
</ul>
</li>
<li>​​​​​​​
    Minor Criteria (need &#8537;)<ul>
<li>​​​​​​​
    Organomegaly</li>
<li>Volume overload</li>
<li>Endocrinopathy</li>
<li>Skin changes</li>
<li>Papilledema</li>
<li>Thrombocytosis or polycythemia</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Castleman Disease</p>
<ul>
<li>Angiofollicular lymph node hyperplasia</li>
<li>Antibodies to HHV-8 implicated in &gt;50% of cases</li>
<li>Features
    : <strong>Lymphadenopathy</strong> , Fever, night sweats, fatigue, Fluid
    accumulation</li>
<li>Skin findings: violaceous Lymph node biopsy w/characteristic
    hematopathology papules</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-sickle-cell-crisis"><h1 id="hematology-oncology-hematologyoncology-sickle-cell-crisis-sickle-cell-crisis">Sickle Cell Crisis<a class="headerlink" href="#hematology-oncology-hematologyoncology-sickle-cell-crisis-sickle-cell-crisis" title="Permanent link">&para;</a></h1>
<p>S <span id="Sickle_cell"></span> ickle Cell Crisis – Michael J. Neuss</p>
<p>Background</p>
<ul>
<li>Present with severe pain in bone, joints, chest, abdomen</li>
<li>Causes: (
    HIDISC) <strong>H</strong> ypoxia, <strong>I</strong> schemia, <strong>D</strong> ehydration, <strong>I</strong>
    nfection, <strong>S</strong> tress, <strong>C</strong> old</li>
<li>Cant Miss:<ul>
<li>Acute
    chest: hypoxia + fever + chest pain + new infiltrate on CXR</li>
<li>PE (ACS less likely in these patients); avascular necrosis of
    hip, priapism, stroke</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Labs: LDH (high), Hgb/Hct (low; check vs baseline), retic, smear,
    WBC</li>
<li>If febrile: UA + Blood cultures</li>
<li>Send Hgb S level, and compare to baseline w/ other hospital
    admissions</li>
<li>Imaging: CXR, MRI for hip pain, Abdominal U/S or CT abdomen</li>
<li>Maintain active type and <em>cross</em> given probability of antibodies</li>
</ul>
<p>Management</p>
<p>General:</p>
<ul>
<li>Look for a care coordination yellow note in the Summary Tab<ul>
<li>Heme clinic will have specific management preferences for
    individual patients</li>
</ul>
</li>
<li>Maintain hydration, IVF at 150-200 cc/hr (if no contraindication)</li>
<li>Oxygen:
    goal sat ~95% (higher O2 goal will help to prevent further
    sickling!)</li>
<li>Continue folic acid 1 mg qDay</li>
<li>Continue hydroxyurea if uncomplicated pain crisis<ul>
<li>Hold if counts suppressed or concern for infection</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>If in the MICU: consider discussion for plasma exchange (if Hgb SS
    or SC or S-Thal)</li>
<li>Transfuse: Simple transfusion if Hgb lower than baseline and/or
    complications<ul>
<li>Avoid transfusions when able, given risk of antibody formation</li>
</ul>
</li>
</ul>
<p>Pain:</p>
<ul>
<li>Will
    generally require opiates, likely initiation of PCA</li>
<li>All
    SS patients should have <strong>pain plans</strong> ; inpatient pain plans are in
    the <strong>problem list under sickle cell disease</strong> or in the <strong>care
    coordination</strong> section of Epic</li>
<li>Outpatient
    plans (to which you will transition pts back prior to discharge) are
    not standardized in location, but can be under Media (with a pain
    contract) or found in notes</li>
</ul>
<p>Acute</p>
<p>chest:</p>
<ul>
<li>Consult Hematology at time of admission</li>
<li>D5 &frac12; NS @ 150-250 cc/hr</li>
<li>Transfuse hgb to &gt;10</li>
<li>PCA w/ dilaudid</li>
<li>Abx for CAP (vs HAP if risk factors) ± bronchodilators</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-thrombocytopenia"><h1 id="hematology-oncology-hematologyoncology-thrombocytopenia-thrombocytopenia">Thrombocytopenia<a class="headerlink" href="#hematology-oncology-hematologyoncology-thrombocytopenia-thrombocytopenia" title="Permanent link">&para;</a></h1>
<p>Thrombocytopenia – Robert Dunn</p>
<p>Background</p>
<ul>
<li>Platelet
    count \&lt;150 k/µL (mild), 50-100 k/µL (moderate), \&lt;50 k/µL (severe)</li>
<li>Framework for differential: Platelet
    Consumption, sequestration, or destruction</li>
<li>Causes
    to consider:<ul>
<li>Can’t Miss Diagnoses: TTP, HUS, HELLP, DIC, HIT</li>
<li>Splenomegaly can represent: Plt sequestration, cirrhosis, portal
    hypertension</li>
<li>Drug-induced: (
    Antibiotics, heparin, chemo, GpIIb/IIIa antagonists,
    H2-antagonists)</li>
<li>Rheumatologic cause – SLE and sarcoidosis</li>
<li>Sepsis, independent of DIC</li>
<li>Immune thrombocytopenia (ITP) is a diagnosis of exclusion</li>
<li>Massive physiologic consumption: large hematoma, active
    hemorrhage</li>
<li>Cirrhosis – results in low thrombopoietin (TPO)</li>
<li>Chronic alcohol use – direct marrow suppression</li>
<li>Infections: HIV, HCV, EBV, Parvovirus, Rickettsia, H. pylori</li>
<li>Bone marrow failure: aplastic anemia, MDS, leukemia,
    chemotherapy</li>
<li>Dilutional: fluid resuscitation and massive transfusion</li>
<li>Platelet clumping (lab artifact)</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Petechiae
    (lower legs typical site; in mouth = wet purpura)</li>
<li>Overt bleeding,
    mucosal bleeding, epistaxis (seen when \&lt;20 k/µL ),
    Splenomegaly</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CMP, CBC w/diff, peripheral smear, citrated platelet count, immature
    patelet fraction (IPF)</li>
<li>LDH, Fibrinogen, PT/aPTT</li>
<li>Determine timing of decline<ul>
<li>Look
    at other cell lines - never normal to have two cytopenia’s</li>
<li>Review
    recent initiation of drugs: (heparin, antibiotics, and
    chemotherapy)</li>
</ul>
</li>
<li>Consider abdominal ultrasound to look for splenomegaly and liver
    pathology</li>
<li>Infectious work up (HIV, HCV)</li>
<li>Calculate 4T Score and consider your pretest probability for HIT
    testing<ul>
<li>HIT
    Ab: ELISA is first test – only run once/day at VUMC so order
    early if considering</li>
<li>Reflex Serotonin release assay (SRA) for confirmation</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Plt
    \&lt;50k<ul>
<li>Discontinue pharmacologic DVT prophylaxis</li>
<li>If on anticoagulation
    : consider risk/benefits of continued anticoagulation<ul>
<li>Can
    transfuse plt’s if AC is mandatory</li>
</ul>
</li>
</ul>
</li>
<li>Plt
    \&lt;10k<ul>
<li>Transfuse
    platelets given risk of spontaneous intracranial hemorrhage</li>
<li>In pt’s with HIT or TTP, there is theoretical concern that
    transfusing plt can “fuel the fire”
    and lead to more thrombosis<ul>
<li>Therefore,
    bleeding with HIT or TTP, discuss with Hematology before
    transfusion</li>
</ul>
</li>
</ul>
</li>
<li>HIT<ul>
<li>If pretest probability is high or HIT is confirmed</li>
<li>Stop Unfractionated and low molecular weight heparin products</li>
<li>Start Argatroban gtt</li>
</ul>
</li>
<li>If schistocytes present on peripheral smear = TTP<ul>
<li>Contact Nephrology and Hematology for PLEX</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Clumping on lab draws:<ul>
<li>Obtain Citrated platelet (“blue top” tube – CPRS refers to it as
    a blue top platelet count)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>If
    no
    resolution, obtain a "Gold top" LAB 301 in Epic (Named: Plt count)</li>
</ul></section><section class="print-page" id="hematology-oncology-hematologyoncology-transfusion-medicine"><h1 id="hematology-oncology-hematologyoncology-transfusion-medicine-transfusion-medicine">Transfusion Medicine<a class="headerlink" href="#hematology-oncology-hematologyoncology-transfusion-medicine-transfusion-medicine" title="Permanent link">&para;</a></h1>
<p>Transfusion Medicine – R. Dixon Dorand</p>
<p>VUMC: search “Blood” and select General Blood Administration – follow
prompts</p>
<p>For emergent transfusions, call the blood bank (615-322-2233)</p>
<ul>
<li>RNs on 10T and 11N can follow transfusion protocols for pRBCs and
    Plts – enter as a Nursing Communication or as part of the
    Hematology/Oncology Admission Order set.</li>
<li>Nurses will NOT check post-transfusion levels unless you specify to
    do so; this is only needed in specific scenarios (e.g. “platelet
    refractoriness”)</li>
<li>At VUMC, all special processing of blood products (such as
    irradiation) will be decided by blood bank based on special
    considerations listed in order set. Examples include: stem cell
    transplant, hematologic malignancy, or thalassemia</li>
<li>Patients with
    frequent transfusions (e.g. sickle cell hemoglobinopathy) should
    have an RBC Extended Phenotype ordered (once) for minor RBC antigens
    to avoid immunization and antibody development to these proteins</li>
<li>You may ask the VUMC hematology lab to email you pictures of the
    peripheral smear</li>
</ul>
<p>VA: Orders Tab – Blood Bank Orders – follow prompts to select
appropriate product. Must order both the blood product AND the
transfusion order (“Transfuse blood”)</p>
<ul>
<li>You need to specify all special processing such as irradiation</li>
<li>To order a Type &amp; Screen as a lab, you must go to Blood Bank Orders</li>
<li>Type &amp; Screen and Transfusion results are under the Blood tab in
    Results</li>
</ul>
<p>Remember:</p>
<ul>
<li>You must send Type and Screen &amp; consent the patient</li>
<li>To consent at VUMC, use Medex. To consent at the VA, use iMedConsent</li>
<li>On Brittingham or BMT, all blood products must be irradiated. This
    will happen at VUMC if you
    select the right indication for blood; at the VA you must still
    specify this.</li>
</ul>
<p>Red Blood Cell Transfusion</p>
<ul>
<li>Volume
    200-300 mL per unit prbc</li>
<li>In general, 1 unit of packed RBCs increases Hgb by 1g/dL and hct by
    ~3%</li>
<li>Assessment
    of the post-transfusion Hgb can be performed 15 min following
    transfusion, but ideally 1 hour after completion</li>
</ul>
<p>Indications:</p>
<ul>
<li>Hgb \&lt;9-10 g/dL – Acute coronary syndrome</li>
<li>Hgb \&lt;8 g/dL or Hct \&lt;25 – Bone marrow failure or receiving
    antineoplastic therapy<ul>
<li>Also
    sometimes
    used in pts with pre-existing CAD</li>
</ul>
</li>
<li>Hgb \&lt;7 g/
    dL or Hct \&lt;21 – ICU, GI Bleeding, Oncology patient on Treatment</li>
</ul>
<p>Indications for Platelets</p>
<ul>
<li>\&lt;11 k/µL – all patients, reduce risk of spontaneous hemorrhage (use
    on BMT, Brittingham)</li>
<li>\&lt;20 k/µL – patients receiving induction chemotherapy with a fever</li>
<li>\&lt;50 k/µL – active bleeding, scheduled to undergo select invasive
    procedure</li>
<li>\&lt;100 k/µL – CNS hemorrhage, intrathecal catheter<ul>
<li>This is also the threshold used for most Neurosurgical
    procedures</li>
</ul>
</li>
</ul>
<p>Fresh Frozen Plasma (FFP) &amp; Cryoprecipitate (Cryo)</p>
<p>Cryoprecipitate: FFP enriched for von Willebrand factor, factor VIII,
factor XIII, and fibrinogen</p>
<p>FFP:</p>
<ul>
<li>Once thawed, must be used in 24 hrs (due to decline in labile
    coagulation factors)</li>
<li>Must be ABO compatible but not crossmatched or Rh typing</li>
<li>Only administer FFP if INR ≥1.7 (FFP will not fix an INR \&lt; 1.7)</li>
</ul>
<p>Indications for transfusion:</p>
<p>- Bleeding:</p>
<ul>
<li>FFP If INR &gt;1.7</li>
<li>Cryoprecipitate if fibrinogen \&lt;100.</li>
</ul>
<p>- DIC:</p>
<ul>
<li>Fibrinogen \&lt;100: Transfuse 5 – 10 units cryoprecipitate and repeat
    fibrinogen. If bleeding, consider raising transfusion threshold of
    cryoprecipitate to fibrinogen \&lt;150</li>
<li>For
    elevated INR, consider FFP transfusion. Thresholds for doing this
    vary by attending</li>
</ul>
<p>- Cirrhosis <strong>:</strong></p>
<ul>
<li>General concept: PT/INR, aPTT are unreliable markers for bleeding.
    Fibrinogen ≤100 – 120 or thromboelastography are better surrogates
    for bleeding risk</li>
<li>Transfuse fibrinogen ≤100 – 120 if the patient is actively bleeding
    or about to undergo a procedure or surgery other than paracentesis</li>
<li>Transfuse FFP based on hepatology team preference (generally few
    indications for FFP)</li>
</ul>
<p>Transfusion Premedication &amp; Reactions</p>
<ul>
<li>If you are concerned about a serious transfusion reaction, pause the
    transfusion and contact the blood bank asap</li>
<li>Order the transfusion reaction blood testing in Epic. You will send
    a CBC, the bag of blood products, and the completed form to the
    blood bank for analysis</li>
</ul>
<p>Premedication:</p>
<ul>
<li>Only
    if history of severe reaction<ul>
<li>Diphenhydramine 25-50mg IV</li>
<li>Acetaminophen 650 mg PO</li>
<li>Meperidine
    25-50 mg IV (optional for chills)</li>
<li>Hydrocortisone 50 mg IV (optional, for severe reactions or
    reactions despite acetaminophen and diphenhydramine)</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reaction</td>
<td>Signs &amp; Symptoms</td>
<td>Etiology</td>
<td>Clinical Action</td>
</tr>
<tr>
<td>Allergic (mild)</td>
<td>Pruritus, hives limited to small area</td>
<td>Antibodies to transfused plasma proteins</td>
<td>Pause transfusion. Administer antihistamines. Resume transfusion if improved; NO samples necessary. If no improvement in 30 min treat as moderate to severe.</td>
</tr>
<tr>
<td>Allergic (moderate to severe)</td>
<td>Generalized hives (&gt;&#8532; body surface), bronchospasm &amp; dyspnea, abdominal pain, hypotension, nausea, anaphylaxis</td>
<td>Antibodies to transfused plasma proteins usually IgE but can also be IgA, Possible allergen in blood product</td>
<td>Administer antihistamines, epinephrine, vasopressors and corticosteroids as needed. Send product to blood bank.</td>
</tr>
<tr>
<td>Febrile Non-Hemolytic</td>
<td>Rise of temp >1°C, chills, rigors, anxiety.</td>
<td>Cytokines released from residual white blood cells in the blood product</td>
<td>Mild: administer antipyretics as needed</td>
</tr>
<tr>
<td>Acute Hemolytic</td>
<td>Hemoglobinemia / uria, fever, chills, anxiety, shock, flank pain, chest pain, unexplained bleeding, cardiac arrest</td>
<td>Intravascular hemolysis usually due to ABO incompatibility; Recheck for patient ID or clinical error. This is an emergency.</td>
<td>Treat shock w/vasopressors; maintain airway; administer fluids and maintain brisk diuresis; monitor for AKI. If DIC present, consider heparin. Administer blood products as needed after etiology is clear.</td>
</tr>
<tr>
<td>Septic</td>
<td>Rise of temp > 2°C, sudden hypotension or hypertension, shock</td>
<td>Micro-organism (i.e. bacteria) in donor bag (Greater risk in apheresis vs. RBC)</td>
<td>Send bag/tubing to transfusion medicine. Order BCx. Broad spectrum abx Pressor support if necessary.</td>
</tr>
<tr>
<td>TRALI – Transfusion Related Acute Lung Injury</td>
<td>Acute respiratory distress usually within 1-2 hours of transfusion. Non-cardiogenic pulmonary edema unresponsive to diuretics; Dx of exclusion.</td>
<td>Usually donor HLA antibodies from transfused plasma. Recipient has corresponding antigens; causes neutrophil activation that results in extravasation of fluid into air spaces</td>
<td>Respiratory support! Most will resolve within 24-96 hours. Steroids, diuretics: no known benefit.</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hematology-oncology-main"><p>Anemia – Margaret Wheless</p>
<p>Presentation</p>
<ul>
<li>Symptoms:</li>
</ul>
<!-- -->

<ul>
<li>Fatigue/malaise, dyspnea on exertion, angina (if history of CAD)</li>
</ul>
<!-- -->

<ul>
<li>Signs:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pallor, tachycardia, orthostatic hypotension, purpura, glossitis,
    koilonychia (in IDA)</p>
</li>
<li>
<p>Jaundice (if hemolysis)</p>
</li>
<li>
<p>Splenomegaly: suggests extramedullary hematopoiesis or sequestration</p>
</li>
<li>
<p>Neurologic symptoms: suggests B12 deficiency</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>CBC w/diff, reticulocyte count, peripheral blood smear, Iron studies
    (TIBC, Ferritin)</li>
</ul>
<!-- -->

<ul>
<li>
<p>RI > 2%: blood loss vs hemolysis; see below</p>
<ul>
<li>Hemolysis labs: Bilirubin, LDH, haptoglobin</li>
</ul>
</li>
<li>
<p>RI \&lt; 2%: hypoproliferative stratify based on RBC size</p>
<ul>
<li>Microcytic (\&lt;80) vs. Normocytic (80-100) vs. Macrocytic (>100)</li>
</ul>
</li>
</ul>
<p>Reticulocyte Index > 2%</p>
<p>Background</p>
<ul>
<li>Etiology: Consumption vs Blood loss</li>
</ul>
<!-- -->

<ul>
<li>
<p>Loss: acute bleed vs iatrogenic from labs</p>
</li>
<li>
<p>Hemolysis: Microangiopathic hemolytic anemia (MAHA), autoimmune
    hemolytic anemia (AIHA), intrinsic RBC defects</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>LDH, ↑indirect bilirubin, ↓haptoglobin, PT/PTT</p>
</li>
<li>
<p>Peripheral blood smear: evaluated for schistocytes, bite cells, spur
    cells, spherocytes, etc.</p>
</li>
<li>
<p>Direct antiglobulin test (DAT) to evaluate for autoimmune hemolytic
    anemia</p>
</li>
</ul>
<p>Extrinsic RBC causes:</p>
<ul>
<li>
<p>If schistocytes ± thrombocytopenia = MAHA: TTP, DIC, HUS, HELLP,
    mechanical valves, malignant HTN, cocaine, scleroderma renal crisis</p>
</li>
<li>
<p>If DAT positive = AIHA</p>
</li>
</ul>
<p>Intrinsic RBC causes:</p>
<ul>
<li>
<p>Sickle cell disease: chronic hemolysis + splenic sequestration
    crisis where RI is↑ vs aplastic crisis where RI is↓ (see sickle cell
    section)</p>
</li>
<li>
<p>Hereditary spherocytosis</p>
</li>
<li>
<p>Hereditary elliptocytosis</p>
</li>
<li>
<p>PNH</p>
</li>
<li>
<p>G6PD: bite cells, Heinz bodies</p>
</li>
</ul>
<!-- -->

<ul>
<li>Usually precipitated by drugs: nitrofurantoin, dapsone,
    sulfonamides, rasburicase, primaquine</li>
</ul>
<p>Management</p>
<ul>
<li>MAHA</li>
</ul>
<!-- -->

<ul>
<li>
<p>DIC: sepsis, malignancy, pregnancy</p>
<ul>
<li>
<p>Treat underlying cause</p>
</li>
<li>
<p>If active bleeding: FFP, cryoprecipitate (to keep
    fibrinogen>100) and platelets</p>
</li>
</ul>
</li>
<li>
<p>TTP: Order ADAMTS13 (prior to plasma transfusion or exchange)</p>
<ul>
<li>If concern for TTP you should immediately consult Heme and
    Nephrology</li>
</ul>
</li>
<li>
<p>HUS: + shiga toxin, AKI, diarrhea</p>
</li>
</ul>
<!-- -->

<ul>
<li>AIHA:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cold (rare): IgM binds at temp \&lt;37</p>
<ul>
<li>
<p>Caused by lymphoproliferative disorder (Waldenström
    Macroglobulinemia), mycoplasma, EBV, HIV</p>
</li>
<li>
<p>Consult heme. Treat underlying. Consider rituximab (steroids
    ineffective)</p>
</li>
</ul>
</li>
<li>
<p>Warm: IgG</p>
<ul>
<li>
<p>Idiopathic or associated with lymphoma, SLE, drugs, babesiosis,
    HIV</p>
</li>
<li>
<p>Can use steroids, IVIG, rituximab</p>
</li>
</ul>
</li>
</ul>
<p>RBC Size Framework</p>
<p>Normocytic Anemia: MCV 80-100</p>
<ul>
<li>Etiologies:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Anemia of inflammation: (may also be microcytic)</p>
</li>
<li>
<p>Anemia of CKD: low Erythropoietin (EPO) levels</p>
</li>
<li>
<p>Endocrine disease (hypothyroidism, adrenal insufficiency):
    ↓metabolic demand/O2 requirement</p>
</li>
<li>
<p>Mixed macrocytic/microcytic disease may have a normal MCV: look for
    ↑RDW</p>
</li>
<li>
<p>Pure red cell aplasia: associated with destructive Ab (CLL, thymoma,
    parvovirus, autoimmune)</p>
</li>
<li>
<p>Paroxysmal nocturnal hemoglobinuria (PNH)</p>
</li>
<li>
<p>Splenic sequestration</p>
</li>
<li>
<p>Bone marrow failure or infiltration (typically will see
    pancytopenia)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Bone marrow biopsy may be indicated if no identifiable cause or
    anemia is associated with other cytopenia’s</li>
</ul>
<p>Microcytic anemia: MCV \&lt;80 (mnemonic: SALTI)</p>
<ul>
<li>Sideroblastic, Anemia of chronic disease, Lead poisoning,
    Thalassemia and Iron-deficiency</li>
</ul>
<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 26%" />
<col style="width: 25%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th>Disease</th>
<th>Etiology</th>
<th>Evaluation</th>
<th>Considerations</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Sideroblastic</td>
<td><p>MDS</p>
<p>Idiopathic</p>
<p>EtOH, Lead, Isoniazid</p>
<p>Cu deficiency</p></td>
<td><p>Social hx, TB, consider Lead level</p>
<p>Fe: ↑↑</p>
<p>Ferritin: ↑ to nL</p>
<p>TIBC: nL</p>
<p>Smear: basophilic stippling</p>
<p>BMBx: ringed sideroblasts</p></td>
<td>In clinical practice this is usually acquired; either due to alcohol
(can resolved with cessation) or primary bone marrow disorder (e.g.
MDS-RARS)</td>
</tr>
<tr class="even">
<td>Anemia of Inflammation (formerly chronic disease)</td>
<td>Chronic inflammation, malignancy, HIV, autoimmune dz, heart failure,
etc.</td>
<td><p>Fe/TIBC &gt;18%</p>
<p>Fe: ↓↓</p>
<p>Ferritin: ↑↑</p>
<p>TIBC: ↓↓</p></td>
<td><p>Treat underlying disease</p>
<p>Replete Fe if ferritin &lt;100 or TIBC &lt;20%</p>
<p>EPO if Hgb &lt;10 and serum EPO &lt;10</p></td>
</tr>
<tr class="odd">
<td>Thalassemia</td>
<td><p>↓ synthesis of α or β chains leads to ↓ erythropoiesis and ↑
hemolysis</p>
<p>Family Hx of anemia</p></td>
<td><p>Mentzer’s index: MCV/RBC &lt;13 = thalassemia</p>
<p>Normal Fe studies; can mimic microcytic anemia and Fe overload from
transfusions</p>
<p>Diagnosis: Hb electrophoresis (α will be normal)</p></td>
<td><p>α-thal more common in Asian/African descent</p>
<p>β thal common in Mediterranean descent</p>
<p>Tx: transfusions, folate, Fe chelator depending on severity</p></td>
</tr>
<tr class="even">
<td>Iron (Fe) deficiency</td>
<td><p>Chronic bleeding: colon cancer, heavy menstrual periods,
cirrhosis (portal gastropathy)</p>
<p>Supply: malnutrition, Crohn’s dz, Celiac dz, subtotal gastrectomy</p>
<p>Demand: pregnancy</p></td>
<td><p>Fe/TIBC &lt;18%</p>
<p>Fe:↓↓ TIBC:↑ nl to ↑</p>
<p>Ferritin: &lt; 100</p>
<p>Mentzer’s index: &gt;13</p>
<p>Consider celiac testing based on clinical suspicion</p>
<p>Investigate for GIB or source of blood loss</p></td>
<td><p>Oral Fe: 6wks to correct anemia, 6mo to replete stores; dose
every other day (↑ absorption w/ ↓ GI side effects); add Vit C for ↑
absorption</p>
<p>If can’t tolerate PO consider IV Fe (Avoid when bacteremic)</p>
<p>HFrEF: IV Fe if ferritin &lt;100 OR 100-300 w/ Fe sat
&lt;20%</p></td>
</tr>
</tbody>
</table>

<p>Macrocytic Anemia: MCV >100</p>
<ul>
<li>Non-megaloblastic:</li>
</ul>
<!-- -->

<ul>
<li>
<p>ETOH, liver disease, hypothyroidism, MDS</p>
</li>
<li>
<p>Medications that impair DNA synthesis: zidovudine, 5-FU,
    hydroxyurea, ara-C, AZT, MTX</p>
</li>
</ul>
<!-- -->

<ul>
<li>Megaloblastic</li>
</ul>
<!-- -->

<ul>
<li>
<p>B12 deficiency</p>
<ul>
<li>
<p>Presentation: neurologic changes (subacute combined
    degeneration), paresthesia, ataxia, dementia (reversible with
    early treatment)</p>
</li>
<li>
<p>Etiology: malnutrition (alcoholics, vegan), pernicious anemia,
    gastrectomy, Crohn’s disease, chronic pancreatitis, celiac
    disease</p>
</li>
<li>
<p>Diagnosis: ↓B12, ↑MMA, ↑homocysteine</p>
</li>
<li>
<p>Treatment: either monthly IM or sublingual B12 (oral not
    absorbed if no IF)</p>
</li>
</ul>
</li>
<li>
<p>Folate deficiency</p>
<ul>
<li>
<p>Etiology: malnutrition, decreased absorption (e.g. Celiac
    disease), impaired metabolism (MTX, TMP), ↑requirement
    (hemolysis, malignancy, dialysis)</p>
</li>
<li>
<p>Diagnosis: ↓folate, ↑homocysteine, MMA will be normal</p>
</li>
<li>
<p>Treatment: PO folate 1-4 mg daily</p>
</li>
</ul>
</li>
</ul>
<p>Neutropenia &amp; Neutropenic Fever – Jennifer Marvin-Peek</p>
<p>Background</p>
<ul>
<li>Neutropenia: absolute neutrophil count (ANC) \&lt; 1500</li>
</ul>
<!-- -->

<ul>
<li>Severe neutropenia: absolute neutrophil count (ANC) \&lt;500 (Use
    manual count if available)</li>
</ul>
<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 26%" />
<col style="width: 55%" />
</colgroup>
<thead>
<tr class="header">
<th>Mechanism</th>
<th>Causes</th>
<th>Example (s)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td rowspan="6">Neutrophil production</td>
<td>Drug associated</td>
<td><p>Cytotoxic or immunosuppressive agents</p>
<p>Methimazole, PTU, Colchicine</p>
<p>Macrolides, Bactrim, Dapsone, Vancomycin</p>
<p>Amphotericin, Acyclovir, Ganciclovir</p>
<p>TCAs, Clozapine, Carbamazepine, Valproate</p>
<p>ACEI, Digoxin, Propranolol, Procainamide</p></td>
</tr>
<tr class="even">
<td>Radiation exposure</td>
<td></td>
</tr>
<tr class="odd">
<td>Malignancies</td>
<td>Leukemias, MDS</td>
</tr>
<tr class="even">
<td>Infection</td>
<td><p>Hepatitis, HIV, EBV, CMV</p>
<p>Rickettsia, Tularemia, Typhoid, TB</p></td>
</tr>
<tr class="odd">
<td>Nutritional deficiency</td>
<td>Vitamin B12, Folate, Copper</td>
</tr>
<tr class="even">
<td>Other</td>
<td>Aplastic anemia, Benign ethnic neutropenia</td>
</tr>
<tr class="odd">
<td>Redistribution</td>
<td>Splenomegaly</td>
<td>Margination and sequestration</td>
</tr>
<tr class="even">
<td>Congenital</td>
<td>Genetics</td>
<td>Benign ethnic neutropenia, familial neutropenia</td>
</tr>
<tr class="odd">
<td rowspan="2">Immune destruction</td>
<td>Autoimmune disorders</td>
<td>RA, SLE</td>
</tr>
<tr class="even">
<td>Other</td>
<td>Autoimmune neutropenia</td>
</tr>
</tbody>
</table>

<p>Management</p>
<ul>
<li>If ANC \&lt;500</li>
</ul>
<!-- -->

<ul>
<li>
<p>Check all lines/IVs for erythema and induration daily</p>
</li>
<li>
<p>Check mouth for mucositis, mouth care after meals and before bed</p>
</li>
<li>
<p>Assess for Neutropenic Fever &amp; Complications – see below</p>
</li>
<li>
<p>Evaluate for indications for prophylaxis – see below</p>
</li>
<li>
<p>No evidence to support use of neutropenic diet</p>
</li>
<li>
<p>No digital rectal exams or enemas/suppositories (risk of bacterial
    translocation)</p>
</li>
</ul>
<p>Neutropenic Fever</p>
<ul>
<li>
<p>ANC \&lt;500 and T> 100.4 °F or 38.0 °C</p>
</li>
<li>
<p>Neutropenic pts are unable to mount an adequate immune response and
    can become critically ill very quickly</p>
</li>
<li>
<p>Do not wait for a temp re-check, you need to start antibiotics
    immediately</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Chest X-ray</p>
</li>
<li>
<p>Two sets of blood cultures (one from PICC/port if present)</p>
</li>
<li>
<p>Urinalysis AND urine culture (not the reflex order set)</p>
</li>
<li>
<p>If diarrhea, get C. diff PCR</p>
</li>
<li>
<p>If abdominal pain, get CT A/P with IV contrast</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Empirically treat with Cefepime</p>
</li>
<li>
<p>Indications for Vancomycin:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hemodynamically unstable</p>
</li>
<li>
<p>Severe mucositis</p>
</li>
<li>
<p>Focal consolidation on CXR</p>
</li>
<li>
<p>Erythema/induration around line</p>
</li>
<li>
<p>Concern for skin/soft tissue infection</p>
</li>
<li>
<p>GPCs in blood</p>
</li>
<li>
<p>Fever continues >24h on cefepime</p>
</li>
</ul>
<!-- -->

<ul>
<li>Additional Coverage:</li>
</ul>
<!-- -->

<ul>
<li>
<p>If abdominal pain/diarrhea: Flagyl 500mg q8h</p>
</li>
<li>
<p>Concern for C-diff: PO Vancomycin 125mg q6h</p>
</li>
<li>
<p>Still fevering on Cefepime at 72 hrs (differs by attending)
    Meropenem</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Fungal coverage: Consider if risk factors (TPN) or persistent fevers
    (>72hrs)</p>
<ul>
<li>Micafungin 100 mg IV daily or Voriconazole 200mg PO BID</li>
</ul>
</li>
</ul>
<p>Neutropenic Complications</p>
<p>Mucositis</p>
<ul>
<li>
<p>Can range from mouth soreness to severe erosions preventing
    eating/drinking</p>
</li>
<li>
<p>Can become secondarily infected with Candida, HSV</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Management:</p>
<ul>
<li>
<p>Routine oral care with a soft toothbrush to remove plaque</p>
</li>
<li>
<p>Oral rinses with saline and/or sodium bicarbonate</p>
</li>
<li>
<p>Magic mouthwash for symptomatic relief (or viscous lidocaine at
    the VA)</p>
</li>
<li>
<p>Typically recovers quickly when ANC > 500</p>
</li>
</ul>
</li>
</ul>
<p>Neutropenic enterocolitis (Typhlitis)</p>
<ul>
<li>
<p>Life-threatening bacterial translocation due to breakdown of
    gut-mucosal barrier</p>
</li>
<li>
<p>Presentation: Abdominal pain + fever</p>
</li>
</ul>
<!-- -->

<ul>
<li>&plusmn; abdominal distension, nausea, vomiting, watery and/or bloody
    diarrhea</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diagnosis: CT A/P with contrast, consider C. diff PCR if diarrhea</p>
</li>
<li>
<p>Treatment:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cefepime/Flagyl OR Zosyn</p>
</li>
<li>
<p>If no perforation/abscess on CT scan, typically continue until 14
    days after ANC recovers >500 and abdominal pain resolves</p>
</li>
<li>
<p>Can change to cipro/flagyl once ANC >500</p>
</li>
<li>
<p>If perforation/abscess: will need imaging to confirm resolution, and
    longer duration of abx</p>
</li>
</ul>
<p>Neutropenic Prophylaxis</p>
<ul>
<li>Used if ANC is expected to be \&lt; 500 for > 7 days</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 33%" />
<col style="width: 46%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Most Common Regimens</th>
<th>Alternatives</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Bacterial</td>
<td>Levofloxacin 500mg daily (renally dosed)</td>
<td>Cefdinir 300mg BID</td>
</tr>
<tr class="even">
<td>Viral</td>
<td>Valacyclovir 500mg BID</td>
<td>Acyclovir 400mg BID (renally dosed)</td>
</tr>
<tr class="odd">
<td>Fungal</td>
<td>Fluconazole 400mg daily</td>
<td><p>Posaconazole 300mg BID x2 days 300mg daily (AML induction for
aspergillus)</p>
<p>Micafungin 50mg IV daily</p></td>
</tr>
<tr class="even">
<td>PJP (if steroids)</td>
<td>Inhaled pentamidine 300mg qmonthly</td>
<td><p>Dapsone (check G6PD)</p>
<p>Avoid Bactrim (risk of myelosuppression)</p></td>
</tr>
</tbody>
</table>

<p>Filgrastim (G-CSF – Neupogen/Zarxio /Granix)</p>
<ul>
<li>
<p>Induces bone marrow production of neutrophils</p>
</li>
<li>
<p>Dose: either 300mcg or 480mcg (rounded from 5 mcg/kg/day)</p>
</li>
<li>
<p>Common side effects: fatigue, nausea</p>
</li>
<li>
<p>PEG-filgrastim (Neulasta): long-acting version that is only given as
    an outpatient</p>
</li>
</ul>
<p>Thrombocytopenia – Robert Dunn</p>
<p>Background</p>
<ul>
<li>
<p>Platelet count \&lt;150k (mild), 50-100k (moderate), \&lt;50k (severe)</p>
</li>
<li>
<p>Framework for differential: consumption, sequestration, destruction,
    production</p>
</li>
<li>
<p>Causes to consider:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Can’t Miss Diagnoses: TTP, HUS, HELLP, DIC, HIT</p>
</li>
<li>
<p>Platelet clumping (lab artifact - pseudothrombocytopenia)</p>
</li>
<li>
<p>Splenomegaly can represent: Plt sequestration, cirrhosis, portal
    hypertension</p>
</li>
<li>
<p>Drug-induced: (Antibiotics, heparin, chemo, GpIIb/IIIa antagonists,
    H2-antagonists)</p>
</li>
<li>
<p>Rheumatologic cause – SLE, sarcoidosis, scleroderma renal crisis</p>
</li>
<li>
<p>Sepsis, independent of DIC</p>
</li>
<li>
<p>Immune thrombocytopenia (ITP) is a diagnosis of exclusion</p>
</li>
<li>
<p>Massive physiologic consumption: large hematoma, active hemorrhage</p>
</li>
<li>
<p>Cirrhosis – results in low thrombopoietin (TPO) and increased
    clearance</p>
</li>
<li>
<p>Chronic alcohol use – direct marrow suppression</p>
</li>
<li>
<p>Infections: HIV, HCV, EBV, Parvovirus, Rickettsia, H. pylori, CMV</p>
</li>
<li>
<p>Bone marrow failure: aplastic anemia, MDS, leukemia, chemotherapy</p>
</li>
<li>
<p>Dilutional: fluid resuscitation and massive transfusion</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Petechiae – typically begins distally on lower legs (in mouth = wet
    purpura), seen when \&lt;10-20k</p>
</li>
<li>
<p>Overt bleeding, mucosal bleeding, epistaxis (seen when \&lt;20k)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>CMP, CBC w/diff, peripheral smear, citrated platelet count, immature
    platelet fraction (IPF)</p>
</li>
<li>
<p>LDH, Fibrinogen, d-dimer, PT/aPTT</p>
</li>
<li>
<p>Determine timing of decline as well as prior values</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Look at other cell lines - never normal to have two cytopenia’s</p>
</li>
<li>
<p>Review recent initiation of drugs: (heparin, antibiotics, and
    chemotherapy)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider abdominal ultrasound to look for splenomegaly and liver
    pathology</p>
</li>
<li>
<p>Infectious work up (HIV, HCV)</p>
</li>
<li>
<p>Calculate 4T Score and consider your pretest probability for HIT
    testing</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>HIT Ab: ELISA is first test – only run once/day at VUMC so order
    early if considering</p>
</li>
<li>
<p>Reflex Serotonin release assay (SRA) for confirmation (VUMC performs
    reflexive testing)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Plt \&lt;50k</li>
</ul>
<!-- -->

<ul>
<li>
<p>Discontinue pharmacologic DVT prophylaxis (unless HIT)</p>
</li>
<li>
<p>If on anticoagulation: consider risk/benefits of continued
    anticoagulation</p>
<ul>
<li>Can transfuse plt’s if AC is mandatory</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Plt \&lt;10k</li>
</ul>
<!-- -->

<ul>
<li>
<p>Transfuse platelets given risk of spontaneous intracranial
    hemorrhage</p>
</li>
<li>
<p>In pt’s with HIT or TTP, there is theoretical concern that
    transfusing plt can “fuel the fire” and lead to more thrombosis, but
    if there is active bleeding then consider platelets</p>
<ul>
<li>Therefore, bleeding with HIT or TTP, discuss with Hematology
    before transfusion</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>HIT</li>
</ul>
<!-- -->

<ul>
<li>
<p>If pretest probability is high or HIT is confirmed</p>
</li>
<li>
<p>Stop Unfractionated and low molecular weight heparin products</p>
</li>
<li>
<p>Start Argatroban gtt</p>
</li>
</ul>
<!-- -->

<ul>
<li>If schistocytes present on peripheral smear = concern for TTP</li>
</ul>
<!-- -->

<ul>
<li>
<p>Draw ADAMTS13</p>
</li>
<li>
<p>Contact Nephrology and Hematology for PLEX</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Clumping on lab draws:</li>
</ul>
<!-- -->

<ul>
<li>Obtain Citrated platelet (“blue top” tube – CPRS refers to it as a
    blue top platelet count)</li>
</ul>
<!-- -->

<ul>
<li>If no resolution, obtain a "Gold top" LAB 301 in Epic (Named: Plt
    count) (ACD tube)</li>
</ul>
<p>Pancytopenia – Thomas Gracie</p>
<p>Background</p>
<ul>
<li>Framework for differential:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Impaired production (aplastic anemia, marrow infiltration, marrow
    suppression, vitamin/nutritional deficiencies, sepsis, cirrhosis)</p>
</li>
<li>
<p>Peripheral destruction (autoimmune hemolytic, hypersplenism)</p>
</li>
<li>
<p>Combined process (PNH, SLE, leukemia, HLH, infections)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Medications: NSAIDs, AEDs, steroids, chemotherapy, antivirals,
    immunosuppression</p>
</li>
<li>
<p>PMHx: autoimmune disease (SLE, RA), radiation, gastric surgery,
    malabsorption, liver disease, hematologic malignancy</p>
</li>
<li>
<p>Social Hx: EtOH use, malnutrition, occupational exposures, exposures
    to TB or leishmaniasis</p>
</li>
<li>
<p>Exam: lymphadenopathy, hepatosplenomegaly, neuropathy, petechiae,
    stigmata of liver disease, cachexia</p>
</li>
<li>
<p>Diagnostic studies: CBC w/ diff, CMP, reticulocyte count, peripheral
    smear, viral studies (hepatitis A/B/C, EBV, CMV, HIV, parvovirus
    B19), vitamin levels (B12, folate, copper, zinc), iron studies,
    hemolysis labs (LDH, haptoglobin, Coombs), flow cytometry, bone
    marrow biopsy, cytogenetics and FISH</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>For pancytopenia that is acute (hospital onset) often observation is
    the best approach</p>
</li>
<li>
<p>When pancytopenia is slow, progressive over time, or acute without
    any other precipitating factors then would consult hematology for
    consideration of a bone marrow syndromes</p>
</li>
</ul>
<p>Leukocytosis – Kenna Koehler</p>
<p>Background</p>
<ul>
<li>
<p>Common progenitor cells (stem cells) are located in the bone marrow
    and give rise to erythrocytes, myeloblasts, megakaryoblasts</p>
</li>
<li>
<p>Normal WBC can vary by age and pregnancy, for the purpose of this
    section will assume this is for an average, non-pregnant adult</p>
</li>
<li>
<p>Chronic mild neutrophilic leukocytosis (10-20k) is common with
    tobacco use and obesity, both due to mechanisms related to chronic
    inflammation</p>
</li>
<li>
<p>Reactive (typically 11k-30k) - surgery, exercise, trauma, burns,
    emotional stress</p>
</li>
<li>
<p>Leukemoid reaction (typically 50k-100k) - severe infections
    (fulminant <em>C difficile</em>), organ rejection</p>
</li>
<li>
<p>If greater than 100k, think leukemia or myeloproliferative disorder</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Neutrophilia (neutrophil count >7k)</li>
</ul>
<!-- -->

<ul>
<li>Bacterial infection, pregnancy, rheumatologic disease, steroids,
    beta agonists, lithium, colony-stimulating factors, splenectomy or
    functional asplenia, congenital (hereditary/chronic idiopathic
    neutrophilia), Down syndrome, leukocyte adhesion deficiency,
    malignancy, smoking, obesity</li>
</ul>
<!-- -->

<ul>
<li>Lymphocytosis (>40% of WBC count or >4,500k/mm<sup>3</sup>)</li>
</ul>
<!-- -->

<ul>
<li>Infections (pertussis, syphilis, CMV, EBV, hepatitis A/B/C, toxo),
    hypersensitivity reactions, thyrotoxicosis, Addison's disease,
    hematologic malignancies, “reactive”</li>
</ul>
<!-- -->

<ul>
<li>Monocytosis (>8% of WBC count or >880/mm<sup>3</sup>)</li>
</ul>
<!-- -->

<ul>
<li>Infections (TB, fungal disease, protozoa, tick-borne), autoimmune
    disease, malignancy (CMML)</li>
</ul>
<!-- -->

<ul>
<li>Eosinophilia (>500/mm<sup>3</sup>)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hypersensitivity (asthma, urticaria, atopic dermatitis, eosinophilic
    esophagitis), drug reactions, malignancies, connective tissue
    disease, idiopathic hypereosinophilic syndrome, infections
    (helminths, Scarlet fever, Hansen's disease), sarcoidosis, SLE</p>
</li>
<li>
<p>Hypereosinophilia if AEC>1500, typically merits heme evaluation</p>
</li>
<li>
<p>Hypereosinophilic syndrome: AEC>1500 and organ dysfunction from
    eosinophils</p>
</li>
</ul>
<!-- -->

<ul>
<li>Basophilia (>100/mm<sup>3</sup>)</li>
</ul>
<!-- -->

<ul>
<li>CML, thyroid disease, IBC, chronic dermatitis, infections
    (varicella)</li>
</ul>
<p>Venous Thromboembolism – Kenna Koehler</p>
<p>Background</p>
<ul>
<li>
<p>Includes both deep vein thrombosis (DVTs) and pulmonary embolism
    (PE). See “Pulmonary Embolism” section in cardiology for more
    information on PEs</p>
</li>
<li>
<p>Risk Factors for Provoked DVT/PE</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Major risk factors: major surgery >30 minutes, hospitalization > 3
    days, C-section</p>
</li>
<li>
<p>Minor Risk Factors: Surgery \&lt;30 minutes, Hospitalization \&lt;3 days,
    pregnancy, estrogen therapy, reduced mobility >3 days</p>
</li>
</ul>
<!-- -->

<ul>
<li>Non-transient risk factors: Malignancy (active), IBD, liver disease,
    hereditary thrombophilia</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Asymmetric calf swelling of >2cm sensitivity and specificity for
    DVT of 60-70%</p>
</li>
<li>
<p>Wells’ Criteria for DVT can help guide diagnostic testing</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If a patient has a low pre-test probability, a negative D-dimer can
    rule out DVT</p>
</li>
<li>
<p>In a high pre-test probability patient a negative D-dimer is less
    helpful</p>
</li>
</ul>
<!-- -->

<ul>
<li>Whole-leg ultrasounds with doppler</li>
</ul>
<p>Management</p>
<ul>
<li>Prophylaxis: Padua score</li>
</ul>
<!-- -->

<ul>
<li>
<p>Score > 4 high risk, recommend pharmacologic prophylaxis</p>
<ul>
<li>Subcutaneous Low Molecular Weight Heparin (LMWH) or Subcutaneous
    Heparin</li>
</ul>
</li>
<li>
<p>Score \&lt;4 is low risk; recommend ambulation and SCDs</p>
</li>
</ul>
<!-- -->

<ul>
<li>Treatment (see anticoagulation section)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Subcutaneous low molecular weight heparin (LMWH)</p>
</li>
<li>
<p>Oral factor Xa inhibitors (rivaroxaban, apixaban)</p>
</li>
<li>
<p>Intravenous unfractionated heparin</p>
</li>
<li>
<p>Warfarin (with bridge therapy)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Duration of treatment</li>
</ul>
<!-- -->

<ul>
<li>
<p>Provoked: 3 months or until provoking factor (trauma, surgery,
    malignancy) is removed</p>
</li>
<li>
<p>Unprovoked: Typically requires life-long anticoagulation along with
    assistance from hematology</p>
</li>
</ul>
<!-- -->

<ul>
<li>Anticoagulation in malignancy:</li>
</ul>
<!-- -->

<ul>
<li>
<p>LMWH or DOAC (most evidence for apixaban and rivaroxaban) while
    malignancy still active</p>
</li>
<li>
<p>Avoid rivaroxaban and edoxaban in GI malignancies (increased rates
    of bleeding)</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Should we get a follow up ultrasound?</li>
</ul>
<!-- -->

<ul>
<li>A follow up ultrasound at the CONCLUSION of anticoagulation can help
    establish a post-treatment baseline and provide a baseline study for
    future comparison that can be critical for the diagnosis of
    recurrent/new DVT (which is very difficult to determine
    radiographically without a comparison imaging study)</li>
</ul>
<!-- -->

<ul>
<li>What about IVC filters?</li>
</ul>
<!-- -->

<ul>
<li>Select circumstances for these: In patients with acute DVT or PE and
    in whom anti-coagulation is absolutely contraindicated
    (thrombocytopenia, recent intra-cranial bleed, recent GI bleed)
    placement of a retrievable IVC filter should be discussed with
    Hematology and IR</li>
</ul>
<p>Anticoagulation – Madeleine Turcotte</p>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 18%" />
<col style="width: 18%" />
<col style="width: 18%" />
<col style="width: 21%" />
</colgroup>
<thead>
<tr class="header">
<th>Agent</th>
<th>Treatment Dose</th>
<th>Renal Dose</th>
<th>Prophylaxis</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Unfractionated heparin</td>
<td>80 U/kg bolus, then 18 U/kg/hr</td>
<td>No change necessary</td>
<td>5000 U q8h</td>
<td>PTT (automatic in order set)</td>
</tr>
<tr class="even">
<td><p>Enoxaparin</p>
<p>(Lovenox)</p></td>
<td>1 mg/kg q12h</td>
<td>1 mg/kg daily</td>
<td><p>40 mg daily</p>
<p>      or</p>
<p>30 mg BID</p></td>
<td><p>LMWH level (anti-Xa level)</p>
<p>Best checked 4 h after 4th dose</p>
<p> </p></td>
</tr>
<tr class="odd">
<td>Warfarin (Coumadin)</td>
<td><p>Start 2-5mg daily and monitor INR</p>
<p>Can consult Pharmacy</p>
<p> </p></td>
<td><p>No change</p>
<p>necessary</p></td>
<td>N/A</td>
<td><p>PT/INR</p>
<p>Use Chromogenic Factor X assay if pt has APLS</p></td>
</tr>
<tr class="even">
<td>Dabigatran (Pradaxa)</td>
<td><p>After 5 days of a parenteral AC,</p>
<p>150 mg BID</p></td>
<td>Avoid use</td>
<td>N/A</td>
<td><p>Can test drug level if concerned</p>
<p>(Any DOAC)</p></td>
</tr>
<tr class="odd">
<td>Rivaroxaban (Xarelto)</td>
<td>15 mg BID x21 d then 20 mg daily</td>
<td>Avoid use in CrCl&lt;30</td>
<td>10mg QD</td>
<td> </td>
</tr>
<tr class="even">
<td>Apixaban (Eliquis)</td>
<td>10mg BID x7d, then 5mg BID</td>
<td>VTE: No adjustment</td>
<td>2.5 mg BID</td>
<td><p>A Fib:</p>
<p>2.5mg BID, if 2 of the following:</p>
<p>Cr 1.5, Age &gt; 80</p>
<p>Weight &lt; 60kg</p></td>
</tr>
<tr class="odd">
<td>Edoxaban (Savaysa)</td>
<td><p>After 5 days of a parenteral AC,</p>
<p>60 mg daily</p></td>
<td><p>30 mg for</p>
<p>CrCl 15-50</p>
<p>Avoid if CrCl &gt; 95</p></td>
<td> </td>
<td>Best studied option in renal dysfunction</td>
</tr>
</tbody>
</table>

<p>Additional Information</p>
<ul>
<li>VA is starting to move towards rivaroxaban and apixaban for extended
    secondary thromboprophylaxis</li>
</ul>
<!-- -->

<ul>
<li>Write in your PADR for apixaban citing “patient uses a pillbox and
    cannot use dabigatran”</li>
</ul>
<!-- -->

<ul>
<li>
<p>Renal dysfunction: favor warfarin, apixaban or edoxaban</p>
</li>
<li>
<p>Hx of GI bleed: avoid dabigatran, rivaroxaban, edoxaban (may have
    higher risk of GI bleed)</p>
</li>
<li>
<p>Pregnancy: UFH/LMWH (other agents may cross the placenta)</p>
</li>
</ul>
<p>Transitioning Between Anticoagulants with DOACs</p>
<ul>
<li>LMWH to Warfarin</li>
</ul>
<!-- -->

<ul>
<li>Warfarin and LMWH given simultaneously until INR is therapeutic for
    24 hours</li>
</ul>
<!-- -->

<ul>
<li>Warfarin to DOAC</li>
</ul>
<!-- -->

<ul>
<li>Start DOAC when INR \&lt; 2.0</li>
</ul>
<!-- -->

<ul>
<li>DOAC to Warfarin</li>
</ul>
<!-- -->

<ul>
<li>
<p>High Risk DVT/PE – start LMWH or UFH, then start Warfarin</p>
</li>
<li>
<p>Low to Moderate Risk DVT/PE – Start warfarin while patient on DOAC,
    Stop DOAC on Day 3 of warfarin therapy, Check INR on day 4</p>
</li>
</ul>
<!-- -->

<ul>
<li>LMWH to DOAC</li>
</ul>
<!-- -->

<ul>
<li>Stop LMWH and start DOAC when due for next dose of LMWH (within 2
    hrs)</li>
</ul>
<!-- -->

<ul>
<li>DOAC to LMWH</li>
</ul>
<!-- -->

<ul>
<li>Stop DOAC and start LMWH when due for next DOAC dose</li>
</ul>
<!-- -->

<ul>
<li>UFH to DOAC</li>
</ul>
<!-- -->

<ul>
<li>
<p>Start DOAC when IV stopped (30 min prior to cessation if high risk
    for thrombosis)</p>
</li>
<li>
<p>DOAC to UFH</p>
</li>
<li>
<p>Start IV heparin with bolus when next DOAC dose is due</p>
</li>
</ul>
<p>Peri-Procedural Management of Anticoagulation</p>
<ul>
<li>
<p>Temporary IVC filter indicated in pts with very recent acute VTE
    (within 3-4 weeks) if the procedure requires AC delay >12 hours</p>
</li>
<li>
<p>For those at high risk of thromboembolism:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider continuing AC for low-bleeding-risk procedures, i.e. dental
    procedures, cutaneous biopsy/excision, ICD placement, endovascular
    procedures.</p>
</li>
<li>
<p>Can bridge with LMWH or heparin drip</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 43%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Stop before procedure</th>
<th>Restart after procedure</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Warfarin</td>
<td>5 days prior, check INR day of</td>
<td>12 to 24 hours after</td>
</tr>
<tr class="even">
<td>Dabigatran</td>
<td rowspan="4"><p>48 hours prior</p>
<p>(longer if CrCl 30-50 or procedure is high bleeding risk)</p></td>
<td rowspan="4"><p>1 day after</p>
<p>(2 days if high bleeding risk)</p></td>
</tr>
<tr class="odd">
<td>Rivaroxaban</td>
</tr>
<tr class="even">
<td>Apixaban</td>
</tr>
<tr class="odd">
<td>Edoxaban</td>
</tr>
<tr class="even">
<td>Heparin</td>
<td>Stop infusion 4-5 hours prior</td>
<td>24 hours after</td>
</tr>
<tr class="odd">
<td>Enoxaparin</td>
<td>12 - 24 hours prior</td>
<td>24 hours after, (48-72 hours if high bleeding risk)</td>
</tr>
</tbody>
</table>

<p>Strategies for Reversal of Anticoagulation</p>
<p>Warfarin</p>
<ul>
<li>Vitamin K: onset within a few hours but takes 24-48 hrs for full
    effect</li>
</ul>
<!-- -->

<ul>
<li>
<p>Life Threatening Bleeding: Give IV Vitamin K 10 mg over 30 minutes</p>
</li>
<li>
<p>Intracranial bleed, bleed with hemodynamic instability, emergent
    procedure non-life threatening</p>
<ul>
<li>
<p>INR \&lt;5: Vitamin K not recommended</p>
</li>
<li>
<p>INR 5-10: Vitamin K 1-5 mg IV or PO</p>
</li>
<li>
<p>INR >10: Vitamin K 5mg PO or 5 mg IV</p>
</li>
</ul>
</li>
<li>
<p>Prior to surgery</p>
<ul>
<li>Rapid reversal INR > 5: 5mg Vit K IV (24 hours prior to
    procedure)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>FFP</li>
</ul>
<!-- -->

<ul>
<li>15 ml/kg (i.e. 4 units/70 kg person) if need reversal \&lt;24 hrs, plus
    give Vitamin K</li>
</ul>
<!-- -->

<ul>
<li>KCentra ($$$): Contains Factors II, VII, IX, and X with Protein C,
    Protein S, and heparin</li>
</ul>
<!-- -->

<ul>
<li>
<p>Given instead of plasma when insufficient time for plasma/Vit K to
    work (i.e. for life threatening hemorrhage)</p>
</li>
<li>
<p>Avoid giving this in HIT</p>
</li>
<li>
<p>Administer with Vitamin K</p>
</li>
</ul>
<p>Dabigatran</p>
<ul>
<li>Idarucizumab ($$$) will reverse if prolonged thrombin time (remember
    to check!) – Consult Hematology</li>
</ul>
<p>Factor Xa Inhibitors (rivaroxaban, apixaban, edoxaban)</p>
<ul>
<li>
<p>FEIBA (Factor VIII inhibitor bypassing activity) – can promote
    coagulation but is <u>not a reversal agent</u>; limited data to
    support use</p>
</li>
<li>
<p>Consult Hematology before using; andexanet alfa (FDA approved) is
    not on VUMC formulary but is on the VA formulary</p>
</li>
</ul>
<p>Hypercoagulable States – Chris Cann</p>
<p>Background</p>
<ul>
<li>
<p>Virchow’s triad: 1. Hypercoagulability 2. Stasis 3. Endothelial
    injury</p>
</li>
<li>
<p>Diagnostic thrombophilia testing indications:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Idiopathic or recurrent VTE</p>
</li>
<li>
<p>First VTE at \&lt;40 years old</p>
</li>
<li>
<p>VTE in the setting of strong family history</p>
</li>
<li>
<p>VTE in unusual vascular site (cerebral, renal, mesenteric)</p>
</li>
<li>
<p>Recurrent pregnancy loss</p>
</li>
</ul>
<!-- -->

<ul>
<li>Must consider if thrombophilia testing will change clinical
    management</li>
</ul>
<!-- -->

<ul>
<li>
<p>If the unprovoked VTE warrants indefinite anticoagulation then
    testing may not be helpful</p>
</li>
<li>
<p>However, if VTE provoked by minor risk factor (OCPs) with an
    underlying thrombophilia might change the decision, then testing may
    be informative</p>
</li>
</ul>
<!-- -->

<ul>
<li>Separated into Acquired and Hereditary conditions:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hereditary: Factor V Leiden mutation, Prothrombin mutation, Protein
    C or S deficiency, Antithrombin deficiency</p>
</li>
<li>
<p>Acquired:</p>
<ul>
<li>
<p>Antiphospholipid Syndrome (APLS)</p>
</li>
<li>
<p>Heparin induced thrombocytopenia (HIT)</p>
</li>
<li>
<p>Major surgery/trauma</p>
</li>
<li>
<p>Nephrotic Syndrome</p>
</li>
<li>
<p>Smoking</p>
</li>
<li>
<p>Pregnancy</p>
</li>
<li>
<p>Oral Contraceptives</p>
</li>
<li>
<p>Immobilization (bedridden, hip/knee replacement)</p>
</li>
<li>
<p>Active malignancy</p>
</li>
<li>
<p>Estrogen replacement therapy</p>
</li>
<li>
<p>Note: Travel (plane, train, automobile) is NOT on this list and
    this is NOT considered a provoking risk factor</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Testing: all specific testing for hereditary disorders and APS
    should be performed at least 4-6 weeks after an acute thrombotic
    event or discontinuation of anticoagulant/thrombolytic therapies to
    avoid interference</li>
</ul>
<p>Antiphospholipid antibody syndrome (APLS)</p>
<p>Background</p>
<ul>
<li>
<p>Most common acquired disorder (anti-phospholipid antibodies present
    in 3-5% population)</p>
</li>
<li>
<p>Recurrent pregnancy loss, provoked DVT in young, unprovoked VTE and
    arterial thrombosis in young, thrombosis unusual sites, thrombosis
    in autoimmune disease</p>
</li>
<li>
<p>This is a clinicopathologic diagnosis (need both clinical and
    laboratory criteria)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Positive for at least 1 lab criterion on at least 2 occasions, at
    least 12 weeks apart:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Lupus anticoagulant: can occur in relation to drugs or infection;
    transient are associated with thrombotic risk</p>
</li>
<li>
<p>Anticardiolipin antibodies</p>
</li>
<li>
<p>B2GP1 (anti-beta2-glycoprotein) antibodies</p>
</li>
</ul>
<!-- -->

<ul>
<li>Must also meet at least 1 of the following clinical criteria:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Vascular thrombosis: DVT, arterial thrombosis, or small vessel
    thrombosis of any organ</p>
</li>
<li>
<p>Pregnancy loss: there are specific criteria for this – consult
    UpToDate or other resource</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Aspirin for primary prevention; warfarin for treatment (INR 2-3)</p>
</li>
<li>
<p>Do NOT use DOACs for triple positive APLS (see TRAPS trial:
    rivaroxaban inferior to warfarin)</p>
</li>
<li>
<p>Rituximab for recurrent thrombosis despite anticoagulation
    (controversial) – call hematology</p>
</li>
</ul>
<p>Heparin-induced thrombocytopenia (HIT)</p>
<p>Type 1: Mild and self-limited (not immune-mediated)</p>
<ul>
<li>
<p>Occurs within the first 2 days of first-time exposure</p>
</li>
<li>
<p>Platelet count normalizes with continued heparin therapy</p>
</li>
</ul>
<p>Type 2 (what we typically refer to as HIT): Immune mediated</p>
<ul>
<li>Fall in plt 30% to over 50% (even if plt count >150) and/or
    thrombotic event has occurred</li>
</ul>
<!-- -->

<ul>
<li>
<p>4-10 days after new exposure to heparin derivative OR≤</p>
</li>
<li>
<p>1 day after restarting heparin derivative that had been used 30-100
    days prior</p>
<ul>
<li>If exposed to heparin within 100 days, will have platelet drop
    within 24 hr</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Frequency: unfractionated heparin > LMWH; Surgical wards > medical
    wards</p>
</li>
<li>
<p>50% will have thrombotic event in 30 days if HIT is untreated, with
    20% mortality</p>
</li>
<li>
<p>Arterial thrombi are common in HIT</p>
</li>
<li>
<p>HIT results from antibodies to complexes of platelet factor 4 (PF4)
    and heparin, further activating platelets (the activated platelets
    aggregate causing thrombocytopenia)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>4T score (0-8 points):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Thrombocytopenia (0-2 pts): degree and nadir of platelet count drop</p>
</li>
<li>
<p>Timing (0-2 pts): timing of fall after initial or recurrent heparin
    exposure</p>
</li>
<li>
<p>Thrombosis (0-2 pts): thrombosis, skin necrosis, non-necrotizing
    lesions, acute systemic reaction to heparin</p>
</li>
<li>
<p>Other causes of thrombocytopenia (0-2 pts): more points if no
    alternate cause</p>
</li>
</ul>
<!-- -->

<ul>
<li>Solid-phase ELISA for heparin-PF4 antibodies:</li>
</ul>
<!-- -->

<ul>
<li>
<p>0.2-0.4 is indeterminate</p>
</li>
<li>
<p>> 0.4 is positive</p>
</li>
<li>
<p>> 1.4 HIT is likely</p>
</li>
<li>
<p>> 2 confirms HIT</p>
</li>
<li>
<p>The lab at VUMC will perform functional SRA reflexively for all
    values >0.2</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>0-3 points: Low concern for HIT; can restart heparin</p>
</li>
<li>
<p>4-5 points: Intermediate probability (~10%) - hold heparin, start
    non-heparin anticoagulant</p>
</li>
<li>
<p>6 points: High probability (~50%) - hold heparin, start non-heparin
    anticoagulant</p>
</li>
<li>
<p>Argatroban (direct thrombin inhibitor) for prophylaxis and treatment
    of thrombosis</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Avoid platelet transfusions as can increase thrombogenic effect</p>
</li>
<li>
<p>Avoid warfarin until complete platelet recovery as may cause
    microthrombosis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Hematology consult for all confirmed HIT</li>
</ul>
<p>Factor V Leiden mutation</p>
<p>Evaluation</p>
<ul>
<li>Activated protein C resistance assay</li>
</ul>
<!-- -->

<ul>
<li>
<p>APC ratio in patient vs normal</p>
</li>
<li>
<p>normal >2.0, heterozygotes 1.5-2.0, homozygotes \&lt;1.5</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>FVL mutation is then determined via PCR</p>
</li>
<li>
<p>Screen with APC assay rather than PCR initially; cost effective</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>VTE treatment same as general population</li>
</ul>
<!-- -->

<ul>
<li>VTE 4-8x risk in heterozygotes; 80x risk in homozygotes</li>
</ul>
<!-- -->

<ul>
<li>Avoid OCPs: increased risk for VTE</li>
</ul>
<p>Prothrombin gene mutation</p>
<p>Evaluation:</p>
<ul>
<li>PCR of G20210A mutation (2-4% prevalence)</li>
</ul>
<p>Management:</p>
<ul>
<li>VTE treatment same as general population &amp; avoid OCPs</li>
</ul>
<p>Protein C &amp; S Deficiency</p>
<p>Background</p>
<ul>
<li>
<p>Autosomal dominant; first event occurs between 10-50 years of age</p>
</li>
<li>
<p>Synthesized in liver and Vit K dependent, therefore low levels in
    hepatic dysfunction and warfarin use/vitamin K deficiency</p>
</li>
<li>
<p>Protein C: low in settings of thrombosis, DIC, nephrotic syndrome,
    intra/post-op</p>
</li>
<li>
<p>Protein S: low in infectious (HIV) and autoimmune processes (IBD)</p>
</li>
<li>
<p>Protein S decreases during pregnancy (decreased free Protein S,
    normal total Protein S)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Do not misdiagnose a pregnant patient with PS deficiency</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Functional Protein C &amp; S assays</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>VTE treatment same as general population</p>
</li>
<li>
<p>Avoid OCPs</p>
</li>
<li>
<p>High risk patients may require protein C concentrate prior to
    surgery</p>
</li>
<li>
<p>Increased risk of warfarin-induced skin necrosis</p>
</li>
</ul>
<p>Antithrombin deficiency</p>
<p>Background</p>
<ul>
<li>
<p>Autosomal dominant, does not skip generations</p>
</li>
<li>
<p>VTE in unusual sites (cerebral sinuses, renal veins)</p>
</li>
<li>
<p>Present \&lt; 50 y/o, but rarely in first two decades</p>
</li>
<li>
<p>Decreased in liver disease, nephrotic syndrome, protein losing
    enteropathy, burn, trauma, bypass surgery, metastatic tumors,
    premenopausal, OCP use, pregnancy</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Functional antithrombin activity (AT-heparin cofactor assay)</p>
</li>
<li>
<p>Then perform antigen quantity testing</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Can use Argatroban as does not require antithrombin function</p>
</li>
<li>
<p>Warfarin preferred in VTE (titrate up based on expression of
    antithrombin deficiency)</p>
</li>
</ul>
<p>Coagulopathies – Jason Jones</p>
<ul>
<li>
<p>Step one: determine if platelet vs coagulation disorder</p>
</li>
<li>
<p>Platelet Disorders: Skin/mucous membrane bleeding; Petechiae; Often
    mild bleeding following surgery and tends to immediately follow
    surgery</p>
</li>
<li>
<p>Coagulation defect: Bleeding deep in soft tissues (muscles/joints);
    hemarthroses, hematomas; tendency to have delayed bleeding after
    surgery that can be severe</p>
</li>
<li>
<p>Coagulopathies can be divided into Hereditary vs Acquired causes</p>
</li>
</ul>
<p>Hereditary</p>
<p>Hemophilia A (Factor VIII Deficiency) and Hemophilia B (Factor IX
Deficiency)</p>
<ul>
<li>
<p>Inherited in X-linked Recessive pattern</p>
</li>
<li>
<p>Diagnosis: Isolated prolonged PTT with normalization upon mixing
    study</p>
</li>
<li>
<p>Management: purified/recombinant Factor VIII or IX. Desmopressin for
    mild disease</p>
</li>
<li>
<p>Consult benign hematology every time these patients are admitted</p>
</li>
</ul>
<p>von Willebrand Disease (vWD)</p>
<ul>
<li>
<p>Can be hereditary (common) or acquired</p>
</li>
<li>
<p>Abnormal quantity or function of von Willebrand Factor (vWF) needed
    for platelet function</p>
</li>
<li>
<p>Type 1 (most common): Quantitative defect. Low quantity, normal
    function of vWF</p>
</li>
<li>
<p>Type 2: Qualitative defect. Normal quantity, abnormal function of
    vWF.</p>
</li>
<li>
<p>Type 3 (rare): Complete absence of vWF, phenotypically similar to
    hemophilia A</p>
</li>
<li>
<p>Order in Epic: vW Profile = vWF Ag, Factor VIII Activity, Ristocetin
    Cofactor Activity</p>
</li>
<li>
<p>Management: Desmopressin (DDAVP) can be useful as prophylaxis or
    treatment; most patients are treated with factor concentrate
    replacements</p>
</li>
</ul>
<p>Acquired</p>
<p>Coagulation Factor Inhibitors</p>
<ul>
<li>
<p>Associated with autoimmune disease (paraneoplastic vs. autoantibody)</p>
</li>
<li>
<p>Seen in hemophilia due to frequent treatments with recombinant
    factors (alloantibody)</p>
</li>
<li>
<p>Diagnosis: Elevated PTT that does not normalize with mixing study</p>
</li>
<li>
<p>Management: Immunosuppression with steroids; cyclophosphamide &plusmn;
    rituximab</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consult Hematology always (rare disorder with major bleeding
    complications)</li>
</ul>
<p>Vitamin K Deficiency</p>
<ul>
<li>
<p>Caused by malnutrition, liver disease, or iatrogenic with warfarin</p>
</li>
<li>
<p>Diagnosis: elevated PT, if severe may have prolonged PTT as well</p>
</li>
<li>
<p>Management: Replace vitamin K</p>
</li>
</ul>
<p>Disseminated Intravascular Coagulation (DIC) - Eric Singhi</p>
<p>Background</p>
<ul>
<li>Concurrent activation of the coagulation pathway and fibrinolytic
    pathway</li>
</ul>
<!-- -->

<ul>
<li>Consumption of platelets, fibrin, and coagulation factors
    fibrinolysis end organ damage and hemolysis</li>
</ul>
<!-- -->

<ul>
<li>Etiologies:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Infection/Sepsis, Liver disease, Pancreatitis, Trauma</p>
</li>
<li>
<p>Malignancies: mucin-secreting pancreatic/gastric adenocarcinoma,
    brain tumors, prostate cancer, all acute leukemias, acute
    promyelocytic leukemia</p>
</li>
<li>
<p>Obstetric complications (i.e. preeclampsia/eclampsia, placental
    abruption)</p>
</li>
<li>
<p>Acute hemolytic transfusion reaction (i.e. ABO incompatible
    transfusion)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Exam: petechiae, bleeding (mucosal, IV site, surgical wound site,
    hematuria), ecchymoses, thrombosis (i.e. cold, pulseless
    extremities)</p>
</li>
<li>
<p>CBC, PT/INR, aPTT, Fibrinogen, D-Dimer, Peripheral Blood Smear</p>
</li>
<li>
<p>“DIC labs” = q6h fibrinogen, PT/INR, aPTT (space out when lower
    risk)</p>
</li>
<li>
<p>Findings suggestive of DIC: thrombocytopenia, prolonged aPTT and
    PT/INR, hypofibrinogenemia, elevated D-dimer, fibrin degradation
    products, schistocytes</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Treat the underlying cause!</p>
</li>
<li>
<p>Vitamin K for INR > 1.7 or bleeding</p>
</li>
<li>
<p>Hypofibrinogenemia treatment: Cryoprecipitate 5-10 units if
    fibrinogen \&lt; 100</p>
</li>
<li>
<p>Thrombocytopenia treatment: plt transfusion as normally indicated</p>
</li>
<li>
<p>DVT ppx if not bleeding and plt > 50</p>
</li>
<li>
<p>VTE: anticoagulation if plt > 50 and no massive bleeding</p>
</li>
</ul>
<p>Transfusion Medicine – R. Dixon Dorand</p>
<p>For emergent transfusions, call the blood bank (615-322-2233)</p>
<ul>
<li>
<p>RNs on 10T and 11N can follow transfusion protocols for pRBCs and
    Plts – enter as a Nursing Communication or as part of the
    Hematology/Oncology Admission Order set.</p>
</li>
<li>
<p>At VUMC, all special processing of blood products (such as
    irradiation) will be decided by blood bank based on special
    considerations listed in order set. Examples include: stem cell
    transplant, hematologic malignancy, or thalassemia</p>
</li>
<li>
<p>Patients with frequent transfusions (e.g. sickle cell
    hemoglobinopathy) should have an RBC Extended Phenotype ordered
    (once) for minor RBC antigens to avoid immunization and antibody
    development to these proteins</p>
</li>
<li>
<p>You may ask the VUMC hematology lab to email you pictures of the
    peripheral smear</p>
</li>
</ul>
<p>VA: Orders Tab – Blood Bank Orders – follow prompts to select
appropriate product. Must order both the blood product AND the
transfusion order (“Transfuse blood”)</p>
<ul>
<li>
<p>You need to specify all special processing such as irradiation</p>
</li>
<li>
<p>To order a Type &amp; Screen as a lab, you must go to Blood Bank Orders</p>
</li>
<li>
<p>Type &amp; Screen and Transfusion results are under the Blood tab in
    Results</p>
</li>
</ul>
<p>Red Blood Cell Transfusion</p>
<ul>
<li>
<p>Volume 200-300 mL per unit prbc</p>
</li>
<li>
<p>In general, 1 unit of packed RBCs increases Hgb by 1g/dL and HCT by
    ~3%</p>
</li>
<li>
<p>Assessment of the post-transfusion Hgb can be performed 15 min
    following transfusion, but ideally 1 hour after completion</p>
</li>
</ul>
<p>Indications:</p>
<ul>
<li>
<p>Hgb \&lt;9-10 g/dL – Acute coronary syndrome</p>
</li>
<li>
<p>Hgb \&lt;8 g/dL or Hct \&lt;25 – Bone marrow failure or receiving
    antineoplastic therapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>Also sometimes used in pts with pre-existing CAD</li>
</ul>
<!-- -->

<ul>
<li>Hgb \&lt;7 g/dL or Hct \&lt;21 – ICU, GI Bleeding, Oncology patient on
    Treatment</li>
</ul>
<p>Indications for Platelets</p>
<ul>
<li>
<p>\&lt;11 k/µL – all patients, reduce risk of spontaneous hemorrhage (use
    on BMT, Brittingham)</p>
</li>
<li>
<p>\&lt;50 k/µL – active bleeding, scheduled to undergo select invasive
    procedure</p>
</li>
<li>
<p>\&lt;100 k/µL – CNS hemorrhage, intrathecal catheter</p>
</li>
</ul>
<!-- -->

<ul>
<li>This is also the threshold used for most Neurosurgical procedures</li>
</ul>
<p>Fresh Frozen Plasma (FFP) &amp; Cryoprecipitate (Cryo)</p>
<p>Cryoprecipitate</p>
<ul>
<li>FFP enriched for von Willebrand factor, factor VIII, factor XIII,
    and fibrinogen</li>
</ul>
<p>FFP</p>
<ul>
<li>
<p>Once thawed, must be used in 24 hrs (due to decline in labile
    coagulation factors)</p>
</li>
<li>
<p>Must be ABO compatible but not crossmatched or Rh typing</p>
</li>
<li>
<p>Only administer FFP if INR ≥1.7 (FFP will not fix an INR \&lt; 1.7)</p>
</li>
</ul>
<p>Indications for transfusion</p>
<ul>
<li>Bleeding:</li>
</ul>
<!-- -->

<ul>
<li>
<p>FFP If INR >1.7</p>
</li>
<li>
<p>Cryoprecipitate if fibrinogen \&lt;100.</p>
</li>
</ul>
<!-- -->

<ul>
<li>DIC:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Fibrinogen \&lt;100: Transfuse 5 – 10 units cryoprecipitate and repeat
    fibrinogen. If bleeding, consider raising transfusion threshold of
    cryoprecipitate to fibrinogen \&lt;150</p>
</li>
<li>
<p>For elevated INR, consider FFP transfusion. Thresholds for doing
    this vary by attending</p>
</li>
</ul>
<!-- -->

<ul>
<li>Cirrhosis:</li>
</ul>
<!-- -->

<ul>
<li>
<p>General concept: PT/INR, aPTT are unreliable markers for bleeding.
    Fibrinogen ≤100 – 120 or thromboelastography are better surrogates
    for bleeding risk</p>
</li>
<li>
<p>Transfuse fibrinogen ≤100 – 120 if the patient is actively bleeding
    or about to undergo a procedure or surgery other than paracentesis</p>
</li>
<li>
<p>Transfuse FFP based on hepatology team preference (generally few
    indications for FFP)</p>
</li>
</ul>
<p>Transfusion Premedication &amp; Reactions</p>
<ul>
<li>
<p>If you are concerned about a serious transfusion reaction, pause the
    transfusion and contact the blood bank asap</p>
</li>
<li>
<p>Order the transfusion reaction blood testing in Epic. You will send
    a CBC, the bag of blood products, and the completed form to the
    blood bank for analysis</p>
</li>
</ul>
<p>Premedication:</p>
<ul>
<li>Only if history of severe reaction</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diphenhydramine 25-50mg IV</p>
</li>
<li>
<p>Acetaminophen 650 mg PO</p>
</li>
<li>
<p>Meperidine 25-50 mg IV (optional for chills)</p>
</li>
<li>
<p>Hydrocortisone 50 mg IV (optional, for severe reactions or reactions
    despite acetaminophen and diphenhydramine)</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 26%" />
<col style="width: 27%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr class="header">
<th>Reaction</th>
<th>Signs &amp; Symptoms</th>
<th>Etiology</th>
<th>Clinical Action</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Allergic (mild)</td>
<td>Pruritus, hives limited to small area</td>
<td>Antibodies to transfused plasma proteins</td>
<td>Pause transfusion. Administer antihistamines. Resume transfusion if
improved; NO samples necessary. If no improvement in 30 min treat as
moderate to severe.</td>
</tr>
<tr class="even">
<td>Allergic<br />
(moderate<br />
to severe)</td>
<td>Generalized hives<br />
(&gt;2/3 body surface),<br />
bronchospasm &amp; dyspnea, abdominal pain, hypotension,<br />
nausea, anaphylaxis</td>
<td>Antibodies to<br />
transfused plasma<br />
proteins usually IgE but can also be IgA, Possible allergen in blood
product</td>
<td>Administer antihistamines, epinephrine, vasopressors and
corticosteroids as needed. Send product to blood bank.</td>
</tr>
<tr class="odd">
<td>Febrile Non-Hemolytic</td>
<td>Rise of temp &gt;1°C, chills, rigors, anxiety.</td>
<td>Cytokines released from residual white blood cells in the blood
product</td>
<td>Mild: administer antipyretics as needed</td>
</tr>
<tr class="even">
<td>Acute<br />
Hemolytic</td>
<td>Hemoglobinemia /<br />
uria, fever, chills,<br />
anxiety, shock,<br />
flank pain, chest<br />
pain, unexplained<br />
bleeding, cardiac<br />
arrest</td>
<td><p>Intravascular hemolysis usually due to ABO incompatibility;
Recheck for patient ID or clinical error.</p>
<p>This is an emergency.</p></td>
<td>Treat shock w/vasopressors; maintain airway; administer fluids and
maintain brisk diuresis; monitor for AKI.. Administer blood products as
needed after etiology is clear.</td>
</tr>
<tr class="odd">
<td>Septic</td>
<td>Rise of temp &gt; 2°C, sudden hypotension or hypertension,<br />
shock</td>
<td>Micro-organism (i.e. bacteria) in donor bag (Greater risk in
apheresis vs. RBC)</td>
<td>Send bag/tubing to transfusion medicine. Order BCx. Broad spectrum
abx  Pressor support if necessary.</td>
</tr>
<tr class="even">
<td>TRALI –<br />
Transfusion<br />
Related<br />
Acute Lung<br />
Injury</td>
<td>Acute respiratory<br />
distress usually<br />
within 1-2 hours<br />
of transfusion.<br />
Non-cardiogenic<br />
pulmonary edema<br />
unresponsive to<br />
diuretics; Dx of exclusion.</td>
<td>Usually donor HLA<br />
antibodies from<br />
transfused plasma. Recipient has corresponding<br />
antigens; causes neutrophil<br />
activation that<br />
results in<br />
extravasation of<br />
fluid into air<br />
spaces</td>
<td>Respiratory support! Most will resolve within 24-96 hours. Steroids,
diuretics: no known benefit.</td>
</tr>
</tbody>
</table>

<p>Sickle Cell Crisis – Michael J. Neuss</p>
<p>Background</p>
<ul>
<li>
<p>Present with severe pain in bone, joints, chest, abdomen</p>
</li>
<li>
<p>Causes: (HIDISC) Hypoxia, Ischemia, Dehydration, Infection, Stress,
    Cold</p>
</li>
<li>
<p>Can’t Miss:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Acute chest: hypoxia + fever + chest pain + new infiltrate on CXR
    (consult benign hematology immediately, do not wait until the next
    day)</p>
</li>
<li>
<p>PE (ACS less likely in these patients); avascular necrosis of hip,
    priapism, stroke</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Labs: LDH (high), Hgb/Hct (low; check vs baseline), retic, smear,
    WBC</p>
</li>
<li>
<p>If febrile: UA + Blood cultures</p>
</li>
<li>
<p>Send Hgb S level, and compare to baseline w/ other hospital
    admissions</p>
</li>
<li>
<p>Imaging: CXR, MRI for hip pain, Abdominal U/S or CT abdomen</p>
</li>
<li>
<p>Maintain active type and cross given probability of antibodies</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>General:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Look for a care coordination yellow note in the Summary Tab</p>
<ul>
<li>Heme clinic will have specific management preferences for
    individual patients</li>
</ul>
</li>
<li>
<p>Maintain hydration, IVF at 150-200 cc/hr (if no contraindication)</p>
</li>
<li>
<p>Oxygen: goal sat ~95% (higher O2 goal will help to prevent further
    sickling!)</p>
</li>
<li>
<p>Continue folic acid 1 mg qDay</p>
</li>
<li>
<p>Continue hydroxyurea if uncomplicated pain crisis</p>
<ul>
<li>Hold if counts suppressed or concern for infection</li>
</ul>
</li>
<li>
<p>If in the MICU: consider discussion for plasma exchange (if Hgb SS
    or SC or S-Thal)</p>
</li>
<li>
<p>Transfuse: Simple transfusion if Hgb lower than baseline and/or
    complications</p>
<ul>
<li>Avoid transfusions when able, given risk of antibody formation</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Pain:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Will generally require opiates, likely initiation of PCA</p>
</li>
<li>
<p>All SS patients should have pain plans; inpatient pain plans are in
    the problem list under sickle cell disease or in the care
    coordination section of Epic</p>
</li>
<li>
<p>Outpatient plans (to which you will transition pts back prior to
    discharge) are not standardized in location, but can be under Media
    (with a pain contract) or found in notes</p>
</li>
</ul>
<!-- -->

<ul>
<li>Acute chest:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consult Hematology at time of admission</p>
</li>
<li>
<p>D5 &frac12; NS @ 150-250 cc/hr</p>
</li>
<li>
<p>Transfuse hgb to >10</p>
</li>
<li>
<p>PCA w/ dilaudid</p>
</li>
<li>
<p>Abx for CAP (vs HAP if risk factors) ± bronchodilators</p>
</li>
</ul>
<p>Lymphoma – Danielle Fishman</p>
<p>Background</p>
<ul>
<li>
<p>Classically characterized by lymphadenopathy &amp; constitutional “B”
    symptoms: fevers, drenching night sweats and weight loss</p>
</li>
<li>
<p><strong>Hodgkin:</strong> 10% - superficial, nodal disease with orderly spread</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Bimodal Distribution: 15-35 years and >50 years; M>F</p>
</li>
<li>
<p>CD15+, CD30+ (Reed Sternberg cells “owl eyes”)</p>
</li>
<li>
<p>Associated with EBV in immunocompromised patient</p>
</li>
</ul>
<!-- -->

<ul>
<li><strong>Non-Hodgkin:</strong> 90% - diffuse, nodal and extranodal disease with
    noncontiguous spread</li>
</ul>
<!-- -->

<ul>
<li>
<p>Average 65 years, M>F, 85-90% B-cell</p>
</li>
<li>
<p>Associated with immunodeficiency (HIV, post-transplant), autoimmune
    disease, infection (EBV, HTLV-1, H pylori, HCV, Borrelia, C
    psittacosis, Coxiella)</p>
</li>
</ul>
<p>General Evaluation</p>
<ul>
<li>History</li>
</ul>
<!-- -->

<ul>
<li>B symptoms; pruritus (10-15% of pt with HL); history of radiation</li>
</ul>
<!-- -->

<ul>
<li>Physical Exam</li>
</ul>
<!-- -->

<ul>
<li>
<p>Head &amp; neck, tonsils, axilla, testes, liver, spleen</p>
</li>
<li>
<p>Lymphadenopathy: painless, firm, fixed, >1cm</p>
</li>
</ul>
<!-- -->

<ul>
<li>Lab tests:</li>
</ul>
<!-- -->

<ul>
<li>
<p>CBC, CMP, LDH, Uric Acid, Phosphorus</p>
</li>
<li>
<p>Consider HBV, HCV, HIV, EBV, Quant gold, Treponemal Ab, ANA</p>
</li>
</ul>
<!-- -->

<ul>
<li>Imaging:</li>
</ul>
<!-- -->

<ul>
<li>
<p>CT chest, abdomen, pelvis</p>
</li>
<li>
<p>Most will eventually need PET-CT; MRI brain if neuro symptoms</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consider LP for NHL with high risk of CNS involvement or presence of
    neurological symptoms</li>
</ul>
<!-- -->

<ul>
<li>
<p>Risk factors: Burkitt, Lymphoblastic, testicular involvement,
    double/triple hit</p>
</li>
<li>
<p>Multiple LPs may be required to diagnose CNS lymphoma</p>
</li>
</ul>
<!-- -->

<ul>
<li>Diagnosis requires tissue</li>
</ul>
<!-- -->

<ul>
<li>
<p>Excisional Lymph node biopsy (Surg Onc Consult)</p>
</li>
<li>
<p>Core biopsy (CT guided procedure consult)</p>
</li>
<li>
<p>Of note, steroids may impact value of biopsy results</p>
</li>
</ul>
<!-- -->

<ul>
<li>Lugano Classification: staging of lymphoma</li>
</ul>
<!-- -->

<ul>
<li>
<p>I. 1 LN region or single extra lymphatic organ/site without nodal
    involvement</p>
</li>
<li>
<p>II. >2 LN regions, same side of diaphragm</p>
</li>
<li>
<p>III. LN regions on both sides of diaphragm</p>
</li>
<li>
<p>IV. Disseminated disease w/ 1+ extralymphatic organ</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p><strong>Hodgkin:</strong></p>
<ul>
<li>IPS negative prognostic calculator: albumin \&lt;4, hemoglobin
    &gt; \&lt;10.5, male, stage IV disease, age>45, WBC count> 15K,
    &gt; lymphocyte \&lt;8% of WBC count</li>
</ul>
</li>
<li>
<p><strong>Non-Hodgkin:</strong></p>
<ul>
<li>
<p><strong>Good prognosis:</strong> Follicular, Marginal Zone, Mycosis
    &gt; Fungoides/Sezary Syndrome</p>
</li>
<li>
<p><strong>Poor prognosis:</strong> DLBCL – can arise from low grade lymphoma
    &gt; (Richter transformation), Double**/**Triple Hit: bcl-2, bcl-6,
    &gt; or myc aberrations, Mantle Cell, Burkitt, Lymphoblastic
    &gt; Lymphoma, and Anaplastic Large Cell Lymphoma</p>
</li>
</ul>
</li>
</ul>
<p>General Management:</p>
<ul>
<li>
<p>ECG and TTE to establish pre-chemotherapy cardiac function – many
    chemo regimens with anthracyclines</p>
</li>
<li>
<p>Daily labs: CBC, TLS, LDH</p>
</li>
<li>
<p>TLS prophylaxis: mIVF, allopurinol</p>
</li>
</ul>
<p>Common Chemotherapy Regimens for Lymphoma</p>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 50%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th>Regimen</th>
<th>Components</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>R-CHOP</td>
<td>Rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone</td>
<td>NHL</td>
</tr>
<tr class="even">
<td>R-EPOCH</td>
<td><p>Etoposide plus the drugs above</p>
<p>(dosing is different)</p></td>
<td><p>NHL</p>
<p>(Double/Triple hit)</p></td>
</tr>
<tr class="odd">
<td>Hyper-CVAD</td>
<td>Cyclophosphamide, vincristine, doxorubicin, and dexamethasone</td>
<td>NHL</td>
</tr>
<tr class="even">
<td>HD-MTX + R</td>
<td>High Dose methotrexate + Rituxumab</td>
<td>Primary CNS Lymphoma</td>
</tr>
<tr class="odd">
<td>ABVD</td>
<td>Doxorubicin, bleomycin, vinblastine, dacarbazine</td>
<td>HL</td>
</tr>
</tbody>
</table>

<p>Myelodysplastic Syndromes – Peter Hanna</p>
<p>Background</p>
<ul>
<li>
<p>MDS is a malignant clonal myeloid disorder resulting in ineffective
    (dysplastic) hematopoiesis leading to peripheral cytopenia’s and a
    risk of transformation to acute myeloid leukemia (AML)</p>
</li>
<li>
<p>Usually idiopathic, a disease of the elderly (median onset at age
    70)</p>
</li>
<li>
<p>The WHO has several classification schemes for MDS</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Most important for classification is the percent of blasts in the
    bone marrow</p>
</li>
<li>
<p>Note >20% blasts in marrow = AML. Thus MDS &amp; AML are on a continuum</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>50% asymptomatic; Symptoms can include nonspecific but gradual
    fatigue, weakness</p>
</li>
<li>
<p>Dysplastic cells do not work properly infections and bleeding are
    more likely</p>
</li>
<li>
<p>Macrocytic anemia is most common finding; followed by bicytopenia or
    pancytopenia</p>
</li>
<li>
<p>Isolated neutropenia or thrombocytopenia are unusual but possible</p>
</li>
<li>
<p>Ask about secondary causes:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Exposure to chemicals (benzene, crude oil/gasoline industry,
    cigarette smoke), chemotherapy, radiation</p>
</li>
<li>
<p>Medications, alcohol use, chronic infections (HIV)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Goal is to rule out reversible causes of dysplasia and cytopenias</p>
</li>
<li>
<p>CBC w/differential, Peripheral Smear, B12, Folate, HIV</p>
</li>
</ul>
<!-- -->

<ul>
<li>May consider Copper &amp; Zinc (send out labs, are expensive and rare
    but check when MDS is being considered)</li>
</ul>
<!-- -->

<ul>
<li>Dysplastic changes on peripheral smear: hypogranulated/hyposegmented
    neutrophils, hypogranulated platelets and macrocytosis of RBCs</li>
</ul>
<!-- -->

<ul>
<li>Circulating myeloblasts can be seen</li>
</ul>
<!-- -->

<ul>
<li>Final diagnosis made by Bone marrow Biopsy</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Molecular characteristics define the “risk” of the disease and
    dictates treatments</p>
</li>
<li>
<p>Prognostic scoring tools: revised international prognostic staging
    system (R-IPSS)</p>
</li>
<li>
<p>Management general paradigm:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Asymptomatic: with low-risk disease = monitoring</p>
</li>
<li>
<p>Low-risk disease + symptoms due to anemia only: transfusions,
    erythrocyte stimulating agents, and treatment with Luspatercept</p>
</li>
<li>
<p>MDS with isolated del(5q): treated with lenalidomide</p>
</li>
<li>
<p>High-risk patients: treated with hypomethylating agents</p>
</li>
<li>
<p>Only curative intervention = hematopoietic stem cell transplant
    (HSCT)</p>
</li>
</ul>
<p>Acute Leukemia – Robert Corty</p>
<p>Background</p>
<ul>
<li>
<p>Hematology malignant caused by unchecked proliferation of WBC
    precursors in the bone marrow</p>
</li>
<li>
<p>Pt’s with suspected acute leukemia require hospitalization for
    urgent diagnosis &amp; treatment</p>
</li>
<li>
<p>Types:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>AML = Acute Myeloid Leukemia</p>
<ul>
<li>APL = Acute Promyelocytic Leukemia defined by translocation
    (15;17) PML-RARA</li>
</ul>
</li>
<li>
<p>ALL = Acute Lymphocytic Leukemia</p>
</li>
</ul>
<!-- -->

<ul>
<li>Risk Factors:</li>
</ul>
<!-- -->

<ul>
<li>
<p>radiation, chemical exposures (e.g benzene), chemotherapy (esp
    alkylating agents)</p>
</li>
<li>
<p>HIV, immunosuppression, smoking</p>
</li>
<li>
<p>myeloproliferative disorders, aplastic anemia</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Leukocytosis, leukemia cutis, gingival hypertrophy, leukostasis</p>
</li>
<li>
<p>Functional Leukopenia, often neutropenia: recurrent infections</p>
</li>
<li>
<p>Anemia: fatigue, pallor, dyspnea</p>
</li>
<li>
<p>Thrombocytopenia: gingival bleeding, epistaxis, petechiae,
    ecchymoses, menorrhagia</p>
</li>
<li>
<p>Extramedullary hematopoiesis: splenomegaly, hepatomegaly,
    lymphadenopathy</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Diagnosis of acute leukemia requires one of the following:</li>
</ul>
<!-- -->

<ul>
<li>
<p>20% blasts in peripheral blood</p>
</li>
<li>
<p>> 20% blasts in bone marrow biopsy</p>
</li>
<li>
<p>Any pathognomonic cytogenetic abnormality of t(8;21), inv(16),
    t(15;17)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Check for the presence of these time-sensitive conditions.</li>
</ul>
<!-- -->

<ul>
<li>
<p>DIC – check fibrinogen, PT, PTT, platelets</p>
</li>
<li>
<p>TLS – check uric acid, phosphate, K+</p>
</li>
<li>
<p>Neutropenic fever – check temp, neutrophil count</p>
</li>
<li>
<p>Leukostasis (see below)</p>
</li>
<li>
<p>Presumptive APL – promyelocytes on diff, DIC or Auer rods on smear</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Confirm if peripheral flow cytometry ordered/in process</p>
</li>
<li>
<p>Use hematology admission order set</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Set RBC and Plt transfusion thresholds</p>
</li>
<li>
<p>Order nurse-driven electrolyte repletion</p>
</li>
<li>
<p>ECG and TTE to establish pre-chemotherapy cardiac function</p>
</li>
<li>
<p>Daily labs: CBC, TLS, DIC</p>
</li>
<li>
<p>TLS prophylaxis</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Consult hematology</li>
</ul>
<!-- -->

<ul>
<li>
<p>Discuss chemo plan and order double lumen PICC for reliable access</p>
</li>
<li>
<p>If findings suggest APL start ATRA</p>
</li>
<li>
<p>Subspecialized lab tests: bone marrow biopsy, cytogenetics, FISH</p>
</li>
</ul>
<!-- -->

<ul>
<li>Monitor for Common Complications/Emergencies: (see individual
    sections)</li>
</ul>
<!-- -->

<ul>
<li>TLS, DIC, Febrile Neutropenia, Leukostasis</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>Obtain blood product consent on admission</p>
</li>
<li>
<p>APL Specific findings: promyelocytes on differential or Auer rods on
    smear</p>
</li>
<li>
<p>Differentiation syndrome: promyelocytes differentiate</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Symptoms and signs: fever, SOB, Hypotn, peripheral edema, pleural
    effusion, AKI</p>
</li>
<li>
<p>Diagnosis: No defined criteria. If suspicious, discuss with
    hematology fellow</p>
</li>
<li>
<p>Management: steroids. If critically ill, hold ATRA and ATO and
    consider hydroxyurea</p>
</li>
</ul>
<p>Leukemia Treatment Overview</p>
<ul>
<li>
<p>General strategy is to use “induction” chemo to try to induce
    clinicopathologic (as opposed to molecular) “remission”</p>
</li>
<li>
<p>Defined as absence of symptoms, normal CBC, and \&lt; 5% blasts in bone
    marrow (on day 28)</p>
</li>
<li>
<p>Then waiting in hospital until neutrophil count > 500 (typically
    ~3 weeks)</p>
</li>
<li>
<p>From there, bone marrow transplant (for high-risk disease) or
    “consolidation” chemo for normal-risk or low-risk disease</p>
</li>
</ul>
<p>AML</p>
<ul>
<li>Induction</li>
</ul>
<!-- -->

<ul>
<li>
<p>Typical is “7+3” i.e. idrarubicin on days 1-3 and cytarabine on days
    1-7</p>
</li>
<li>
<p>If therapy-related AML, MDS-related AML, or AML with cytogenetics
    similar to MDS, use “Vyxeos” which is liposomal daunorubicin and
    cytarabine on days 1, 3, and 5</p>
</li>
<li>
<p>If low-risk dz (t(8;21) or inv(16)), use cytarabine on days 1-7, and
    3 days of low-dose daunorubicin + gemtuzumab-ozogamicin</p>
</li>
<li>
<p>There are other induction regimens that can be used depending on
    specific cytogenetics and patient frailty, which is beyond the scope
    of the handbook</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consolidation</li>
</ul>
<!-- -->

<ul>
<li>
<p>Typically “HiDAC”(high-dose Ara-C i.e. cytarabine)</p>
<ul>
<li>Generally too toxic for pts with age > 60, so a dose reduction
    is used</li>
</ul>
</li>
<li>
<p>In the case of relapse, typical treatment is a different high-dose
    chemo and BMT if possible</p>
</li>
</ul>
<p>ALL</p>
<ul>
<li>
<p>Typical induction is “HyperCVAD” (hyper-fractionated
    cyclophosphamide, vincristine, doxorubicin (“A” due to trade name
    Adriamycin), and dexamethasone</p>
</li>
<li>
<p>If t(9;22) (known as Philadelphia chromosome), use tyrosine kinase
    inhibitor (TKI)</p>
</li>
<li>
<p>If CD20+, use rituximab</p>
</li>
</ul>
<p>Common Chemotherapy Regimens for Leukemia Encountered as Inpatient</p>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 48%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th>Regimen</th>
<th>Components</th>
<th>Use</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>7+3</p>
<p> </p></td>
<td>Cytarabine (Ara-C) x 7 d &amp; Anthracycline  (e.g. idarubicin x3
d)</td>
<td>AML induction</td>
</tr>
<tr class="even">
<td>Vyxeos</td>
<td>Cytarabine + liposomal daunorubicin</td>
<td>AML-MRC or t-AML</td>
</tr>
<tr class="odd">
<td>CLAG-M</td>
<td>Cladribine, cytarabine (Ara-C), Filgrastim (G-CSF),
mitoxantrone</td>
<td>AML induction (relapsed/refractory)</td>
</tr>
<tr class="even">
<td>HIDAC</td>
<td>High-dose cytarabine</td>
<td>AML consolidation</td>
</tr>
<tr class="odd">
<td>ATRA</td>
<td><p>All-trans retinoic acid</p>
<p>given with arsenic trioxide (ATO)</p></td>
<td>APL (APML)</td>
</tr>
<tr class="even">
<td>HyperCVAD/MA</td>
<td><p>CVAD = Cyclophosphamide, vincristine, doxorubicin,
dexamethasone</p>
<p>MA = methotrexate/cytarabine </p>
<p>(Given as alternating cycles)</p></td>
<td>ALL</td>
</tr>
<tr class="odd">
<td>R-CHOP</td>
<td>Rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone</td>
<td>NHL</td>
</tr>
<tr class="even">
<td>R-EPOCH</td>
<td><p>Etoposide plus the drugs above</p>
<p>(dosing is different)</p></td>
<td>NHL</td>
</tr>
<tr class="odd">
<td>ABVD</td>
<td>Doxorubicin, bleomycin, vinblastine, dacarbazine</td>
<td>HL</td>
</tr>
</tbody>
</table>

<p>Plasma Cell Dyscrasias – Rahul Shah, Jennifer Marvin-Peek</p>
<p>Background</p>
<ul>
<li>
<p>A heterogenous group of benign, premalignant, and malignant
    conditions characterized by clonal proliferation of plasma cells</p>
</li>
<li>
<p>Results in over-production of monoclonal immunoglobulins or
    polypeptides (i.e., M-protein) that can be detected in serum and/or
    urine</p>
</li>
<li>
<p>Includes monoclonal gammopathy of undetermined significance (MGUS),
    smoldering myeloma (SMM), multiple myeloma (MM), Waldenström
    Macroglobulinemia (WM), extra-medullary plasmacytoma, AL
    amyloidosis, POEMS syndrome</p>
</li>
<li>
<p>Spectrum of MGUS, SMM, and MM represents natural progression of same
    disease process</p>
</li>
<li>
<p>Complications: Increased infectious risk, cytopenias, renal failure,
    hyperviscosity syndrome, malignant hypercalcemia, pain crisis from
    bony disease</p>
</li>
<li>
<p>Elevated gamma/protein gap (serum total protein minus albumin >4)
    often prompts work-up for an underlying plasma cell dyscrasia (high
    specificity but low sensitivity)</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 48%" />
<col style="width: 51%" />
</colgroup>
<thead>
<tr class="header">
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Fatigue, weakness, weight loss</p>
<p>Bone pain</p>
<p>Paresthesias, neuropathy, radiculopathy</p>
<p>Visual disturbances</p>
<p>(if hyperviscosity present)</p>
<p>Lymphadenopathy (uncommon)</p>
<p>Fever (uncommon)</p></td>
<td><p>Anemia (Hgb &lt;10)</p>
<p>Renal insufficiency (Cr &gt; 2)</p>
<p>Hypercalcemia (Ca &gt; 11.5)</p>
<p>Elevated protein gap (Total protein - Alb &gt; 4)</p>
<p>Osteolytic bone lesions (typically central)</p>
<p>Unexplained heavy proteinuria</p>
<p>Rouleaux formation on blood smear</p></td>
</tr>
</tbody>
</table>

<p>Evaluation</p>
<ul>
<li>
<p>CBC w/ diff, peripheral blood smear, CMP (for Ca, Cr, albumin), LDH,
    CRP, urinalysis</p>
</li>
<li>
<p>SPEP with immunofixation, UPEP (24-hour urine) with immunofixation,
    serum free light chains (FLC)</p>
</li>
<li>
<p>Quantitative immunoglobulins (IgA, IgM, IgG, IgD, IgE)</p>
</li>
<li>
<p>If Hgb \&lt;10, Cr >2, Ca >11.5, M-protein >1.5, non-IgG M-spike,
    abnormal FLC ratio:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Bone marrow biopsy + cytogenetics</p>
</li>
<li>
<p>β2-microglobulin, serum viscosity (in WM)</p>
</li>
<li>
<p>Skeletal imaging to identify bone lesions: skeletal survey (x-ray)
    often done initially, then more sensitive CT/PET-CT/MRI if biopsy
    shows SMM/MM</p>
</li>
<li>
<p>If considering amyloidosis: abdominal wall fat pad biopsy with Congo
    red staining typically sufficient vs direct biopsy of
    amyloid-involved tissue</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 32%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Additional Tips for Lab Interpretation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>SPEP/UPEP</td>
<td>Free light chains (FLC)</td>
<td>Urinalysis</td>
</tr>
<tr class="even">
<td><p>Initial screening test to look and quantify M-protein</p>
<p>Serum immunofixation determines clonality</p>
<p>(e.g. mono or polyclonal)</p>
<p> </p>
<p>Monoclonal spike &gt;1.5 is indicative of underlying dyscrasia</p>
<p> </p>
<p>Polyclonal spike suggests infectious, inflammatory, or reactive
etiology</p></td>
<td><p>Ratio of kappa/lambda &gt;3 highly suggestive of plasma cell
dyscrasia or amyloidosis</p>
<p> </p>
<p>Ratio 1.65 to 3 can be due to infectious process or renal
insufficiency</p>
<p> </p>
<p>Helpful in pts that only produce Bence-Jones protein (FLC w/o heavy
chain) which isn't seen on SPEP</p></td>
<td><p>Detects albumin, not light chains</p>
<p> </p>
<p>In myeloma cast nephropathy, dipstick will be negative since
proteinuria is from FLC (i.e. Bence-Jones proteinuria)</p>
<p> </p>
<p>In AL amyloid, dipstick will be positive 2/2 albumin loss from
nephrotic syndrome</p></td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 25%" />
<col style="width: 22%" />
<col style="width: 27%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><p>Monoclonal Gammopathy of Unknown Significance</p>
<p>(MGUS)</p></th>
<th><p>Smoldering Multiple Myeloma</p>
<p>(SMM)</p></th>
<th><p>Multiple Myeloma</p>
<p>(MM)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>% Plasma Cells in BM</td>
<td>&lt;10%</td>
<td>10-60%</td>
<td>≥ 10% (typically &gt;30%)</td>
</tr>
<tr class="even">
<td>Monoclonal Protein</td>
<td>IgG, IgA, IgM: 1.5 -3</td>
<td>IgG or IgA &gt;3</td>
<td>IgG or IgA &gt;3</td>
</tr>
<tr class="odd">
<td>Laboratory studies</td>
<td>Normal Hgb, Ca, Cr</td>
<td>Normal Hgb, Ca, Cr</td>
<td>↓Hgb, ↑Ca, ↑Cr</td>
</tr>
<tr class="even">
<td>Symptoms</td>
<td>None</td>
<td>None</td>
<td>Lytic bone lesions, fatigue</td>
</tr>
<tr class="odd">
<td>Prognosis</td>
<td>1% / year progression to MM</td>
<td>10% / year progression to MM</td>
<td>R-ISS staging (see below)</td>
</tr>
<tr class="even">
<td>Monitoring and/or Treatment</td>
<td><p>Monitoring only</p>
<p>Yearly:</p>
<p>Symptom check</p>
<p>SPEP, FLC, CBC, BMP</p></td>
<td><p>Monitoring only</p>
<p>In 2-3 months, repeat SPEP, FLC, CBC, BMP</p>
<p>Yearly skeletal survey</p></td>
<td>Chemotherapy, plus SCT for eligible patients</td>
</tr>
</tbody>
</table>

<p>Multiple Myeloma</p>
<p>Evaluation</p>
<ul>
<li>
<p>Diagnosis requires clonal bone marrow plasma cells ≥10% or
    bony/extramedullary plasmacytoma AND one or more end-organ event
    (CRAB criteria) or biomarker of myeloma</p>
</li>
<li>
<p>CRAB criteria</p>
<ul>
<li>Hypercalcemia, renal impairment, anemia, bone osteolytic lesions</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Biomarkers of multiple myeloma</p>
<ul>
<li>
<p>Clonal bone marrow plasma cells ≥ 60%</p>
</li>
<li>
<p>Serum FLC ratio ≥ 100 or ≤ 0.01</p>
</li>
<li>
<p>>1 focal lesion ≥ 5mm on MRI</p>
</li>
</ul>
</li>
<li>
<p>Skeletal imaging: Whole-body PET-CT or CT preferred, MRI, bone
    survey (x-ray)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>First-line induction therapy typically is RVd: immunomodulatory
    agent (lenalidomide [<u>R</u>evlimid]), proteasome inhibitor
    (bortezomib [<u>V</u>elcade]) and <u>d</u>examethasone</p>
</li>
<li>
<p>Consolidation therapy includes autologous SCT for transplant
    eligible patients</p>
</li>
<li>
<p>Maintenance therapy is often given indefinitely, typically
    lenalidomide or bortezomib</p>
</li>
<li>
<p>Relapsed disease is often treated with anti-CD38 monoclonal Ab
    (daratumumab) with a steroid and either immunomodulatory drug or
    proteosome inhibitor; CAR-T also recently approved for relapsed MM</p>
</li>
<li>
<p>Supportive Care</p>
</li>
</ul>
<!-- -->

<ul>
<li>VTE prophylaxis with DOAC or LMWH if on an immunomodulatory agent
    &gt; with 2 VTE risk factors; if only 0-1 VTE risk factors aspirin</li>
</ul>
<!-- -->

<ul>
<li>
<p>EPO and G-CSF for treatment-related anemia and neutropenia</p>
</li>
<li>
<p>Bisphosphonate (ideally zoledronic acid) to reduce risk of
    &gt; fractures; analgesia ± radiotherapy for bone pain and palliation</p>
</li>
<li>
<p>(Val)acyclovir if on bortezomib for VZV prophylaxis</p>
</li>
</ul>
<p>Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia (IgM)</p>
<p>Presentation</p>
<ul>
<li>
<p>Hyperviscosity syndrome: blurred vision, dizziness, diplopia,
    hypoxia, ataxia, vertigo, stroke, coma</p>
</li>
<li>
<p>Peripheral neuropathy</p>
</li>
<li>
<p>Retinal changes: dilated veins, hemorrhages, papilledema</p>
</li>
<li>
<p>Cryoglobulinemia: large IgM complexes precipitate out in the cold,
    causing Raynaud's, urticaria, purpura, acral cyanosis, tissue
    necrosis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Requires: IgM monoclonal gammopathy on SPEP, BM biopsy w/≥10%
    lymphocytes with plasmacytoid differentiation (late stage B-cell
    differentiation), and MYD88 mutation detected</p>
</li>
<li>
<p>CBC, coagulation studies, cryoglobulins, IgM, β2-microglobulin</p>
</li>
<li>
<p>Serum viscosity (If \&lt;4 symptoms are rare, If >6 typically
    symptomatic)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Asymptomatic patients managed with close observation</p>
</li>
<li>
<p>Symptomatic hyperviscosity is treated with plasmapheresis</p>
</li>
<li>
<p>Induction: may include bendamustine &plusmn; rituximab if IgM level is
    \&lt;4000 (Rituximab can temporarily ↑ IgM and ↑ risk of hyperviscosity
    syndrome)</p>
</li>
<li>
<p>Monitor response with: IgM levels, monoclonal IgM on SPEP</p>
</li>
</ul>
<p>Other Plasma Cell Dyscrasias</p>
<p>Light Chain (AL) Amyloidosis</p>
<ul>
<li>Extracellular deposition of misfolded light chains (most commonly
    kidney &amp; heart)</li>
</ul>
<!-- -->

<ul>
<li>Features: nephrotic syndrome, restrictive CM, peripheral neuropathy,
    &gt; HSM, macroglossia, easy bruising/bleeding,
    &gt; dysautonomia/orthostasis</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diagnosis:</p>
<ul>
<li>Need ALL 4: amyloid related systemic syndrome, positive congo
    &gt; red staining on any tissue, evidence that amyloid is light
    &gt; chain related, evidence of monoclonal plasma cell disorder</li>
</ul>
</li>
</ul>
<p>POEMS Syndrome</p>
<ul>
<li>
<p>Cause unknown, possibly chronic overproduction of pro-inflammatory
    cytokines such as VEGF</p>
</li>
<li>
<p>Features: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal
    protein (usually λ light chain), Skin changes</p>
</li>
<li>
<p>Diagnosis:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mandatory Criteria: peripheral neuropathy, monoclonal plasma cell
    disorder</p>
</li>
<li>
<p>Major Criteria (need &#8531;): osteosclerotic lesions, VEGF, Castleman
    disease</p>
</li>
<li>
<p>Minor Criteria (need &#8537;): organomegaly, volume overload,
    endocrinopathy, skin changes, papilledema, thrombocytosis or
    polycythemia</p>
</li>
</ul>
<p>Castleman Disease</p>
<ul>
<li>
<p>Angiofollicular lymph node hyperplasia</p>
</li>
<li>
<p>Antibodies to HHV-8 implicated in >50% of cases</p>
</li>
<li>
<p>Features: Lymphadenopathy, fever, night sweats, fatigue, fluid
    accumulation, violaceous lymph node biopsy w/characteristic
    hematopathology papules</p>
</li>
</ul>
<p>Myeloproliferative Neoplasms (MPNs) – Christina Snider</p>
<p>Background</p>
<ul>
<li>
<p>MPNs = chronic myeloid disorders caused by abnormal proliferation of
    mature bone marrow cell lineages (granulocytes, erythrocytes, or
    megakaryocytes)</p>
</li>
<li>
<p>MPNs differ from myelodysplastic syndrome (MDS); cells in MPNs are
    normally developed (i.e. not dysplastic)</p>
</li>
<li>
<p>Four “classic” MPNs: polycythemia vera, essential thrombocythemia,
    primary myelofibrosis and chronic myeloid leukemia (CML)</p>
</li>
</ul>
<p>Polycythemia Vera (PV)</p>
<p>Background</p>
<ul>
<li>
<p>Polycythemia is a general term: Men = Hb/Hct > 16.5/49%; Women =
    Hb/Hct > 16/48%</p>
</li>
<li>
<p>Relative polycythemia = Concentrated H/H due to decreased plasma
    volume</p>
</li>
</ul>
<!-- -->

<ul>
<li>Diuretic use, vomiting, diarrhea; H/H should normalize with fluid
    resuscitation</li>
</ul>
<!-- -->

<ul>
<li>Absolute polycythemia = Increased RBC mass</li>
</ul>
<!-- -->

<ul>
<li>
<p>Primary polycythemia: 2/2 Inherited/acquired mutation in RBC
    progenitor</p>
</li>
<li>
<p>Secondary polycythemia: Increase in RBC mass due to elevated serum
    EPO</p>
<ul>
<li>
<p>Hypoxia/cardiopulmonary associated (chronic pulmonary disease,
    R-to-L cardiac shunts, sleep apnea, obesity hypoventilation
    syndrome, chronic carbon monoxide poisoning, including heavy
    smoking)</p>
</li>
<li>
<p>Kidney associated causes (following renal transplant, renal
    artery stenosis, hydronephrosis)</p>
</li>
<li>
<p>Autonomous EPO production from an EPO-producing tumors (rare)</p>
</li>
<li>
<p>Steroid Use</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Epidemiology: Median age of diagnosis is 60 years; 25% cases present
    at age \&lt;50 years.</p>
</li>
<li>
<p>>95% PV pts have JAK2 V617F mutation, but JAK2 V617F mutation is
    not specific to PV and can be seen in other MPNs</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Incidentally elevated H/H</p>
</li>
<li>
<p>Splenomegaly, generalized pruritus (post-warm bath/shower), unusual
    thrombosis</p>
</li>
<li>
<p>Erythromelalgia: intermittent occurrence of red, hot, painful
    extremities</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>CBC with differential and peripheral smear</p>
</li>
<li>
<p>EPO level</p>
</li>
<li>
<p>Rule out secondary causes: Sleep Study, Carboxyhemoglobin, steroids</p>
</li>
<li>
<p>Peripheral blood screen for JAK2 V617F mutation</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>PV treatment aims to prevent thrombosis and bleeding events.</p>
</li>
<li>
<p>Phlebotomy: maintain Hct \&lt;45% (One unit 500 mL decreases Hct by 3%)</p>
</li>
<li>
<p>ASA 81 mg for thrombosis prevention and symptom control</p>
</li>
<li>
<p>Hydroxyurea: indicated for high-risk patients (>60 years old or
    with history of thrombosis)</p>
</li>
<li>
<p>Interferon-alfa, busulfan, or ruxolitinib: indicated in select
    high-risk patients</p>
</li>
</ul>
<p>Essential thrombocythemia (ET)</p>
<p>Background</p>
<ul>
<li>
<p>Clonal stem cell disorder w/ increased platelet counts (>450k/uL)</p>
</li>
<li>
<p>Risks of thrombosis and hemorrhage</p>
</li>
<li>
<p>Median age of diagnosis: 60 years; Twice as common in females.</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Incidental thrombocytosis on CBC</p>
</li>
<li>
<p>Splenomegaly, unusual thrombosis, and erythromelalgia</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Screen for conditions that cause reactive thrombocytosis: Chronic
    inflammatory diseases, infections, bleeding/hemolysis, iron
    deficiency, post splenectomy</p>
</li>
<li>
<p>CBC with smear (platelet anisocytosis) ranging from very small to
    giant platelets</p>
</li>
<li>
<p>CMP, LDH, Uric Acid, iron studies</p>
</li>
<li>
<p>BCR ABL1 testing should be sent to exclude CML</p>
</li>
<li>
<p>Bone marrow biopsy with staining, cytogenetics, and molecular
    testing for JAK2, CALR, MPL mutations</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Avoid ASA 81 in patients with platelet counts >1 million
    complicated by acquired von Willebrand syndrome due to increased
    risk of bleeding</li>
</ul>
<table>
<colgroup>
<col style="width: 35%" />
<col style="width: 29%" />
<col style="width: 35%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Treatment of ET</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p><strong> Risk Score</strong></p>
<p><strong>(IPSET-thrombosis)</strong></p></td>
<td><strong>Features</strong></td>
<td><strong>Treatment</strong></td>
</tr>
<tr class="even">
<td>High</td>
<td>Hx of thrombosis and/or &gt;age 60 with JAK2 V617F mutation</td>
<td rowspan="2">Cytoreduction (target plt 100-400k) w/ hydroxyurea,
systemic anticoagulation +/-antiplatelet agent</td>
</tr>
<tr class="odd">
<td>Intermediate</td>
<td>Age &gt;60, no JAK2 V617F mutation, no history of thrombosis</td>
</tr>
<tr class="even">
<td>Low</td>
<td>Age =&lt;60 w/ JAK2 V617F mutation and no history of thrombosis</td>
<td rowspan="2"><p>Observation vs. daily ASA 81</p>
<p> </p></td>
</tr>
<tr class="odd">
<td>Very Low</td>
<td>Age =&lt;60, no JAK2 V617F mutation, no history of thrombosis</td>
</tr>
</tbody>
</table>

<p>Primary Myelofibrosis (PMF)</p>
<p>Background</p>
<ul>
<li>
<p>Clonal proliferation of myeloid cells with variable morphologic
    maturity resulting in reactive marrow fibrosis and extramedullary
    hematopoiesis</p>
</li>
<li>
<p>Least favorable prognosis out of MPN</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Fatigue, weight loss, low grade fever, bone pain, and night sweats</p>
</li>
<li>
<p>Marked splenomegaly &plusmn;hepatomegaly (due to extramedullary
    hematopoiesis)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>smear: teardrop shaped RBCs (dacrocytes)</p>
</li>
<li>
<p>Bone marrow biopsy: “dry tap” due to extensive reticulin and/or
    collagen fibrosis mutually exclusive mutations in JAK2, MPL, or CALR</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Low risk patients: Observe if asymptomatic</p>
</li>
<li>
<p>Cure by allogenic HCT transplantation in young, high-risk patients</p>
</li>
<li>
<p>Treatment of anemias include transfusion support</p>
</li>
<li>
<p>Surgical splenectomy if abdominal pain or transfusion dependent
    anemia (used very infrequently)</p>
</li>
</ul>
<p>Chronic Myelogenous Leukemia (CML)</p>
<p>Background</p>
<ul>
<li>
<p>Definition: MPN characterized by the overproduction of myeloid stem
    cells that can differentiate</p>
</li>
<li>
<p>Chronic phase:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Fatigue, weight loss, bleeding</p>
</li>
<li>
<p>Abdominal fullness and early satiety due to splenomegaly</p>
</li>
<li>
<p>WBC on CBC is typically >100k, and smear shows neutrophilic cells
    in all stages of maturation with \&lt;2% blasts</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Accelerated phase: Refractory leukocytosis, 10-19% blasts in
    peripheral blood or bone marrow, worsening peripheral basophilia,
    thrombocytopenia</p>
</li>
<li>
<p>Blast phase = acute leukemia. >20% blasts in peripheral blood or
    bone marrow, extramedullary proliferation of blasts</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Typical findings in blood and bone marrow and confirmation of
    Philadelphia chromosome (BCR-ABL1 fusion gene) via conventional
    cytogenetics, FISH, or rt-PCR</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Hydroxyurea can be used to reduce WBC while awaiting confirmation</p>
</li>
<li>
<p>Oral tyrosine kinase inhibitors (TKIS): Imatinib, dasatinib,
    nilotinib, and ponatinib</p>
</li>
<li>
<p>Allogenic hematopoietic cell transplantation: Curative option for
    pts in accelerated and blast phase, as well as young pts w/chronic
    phase CML who do not respond to TKI therapy</p>
</li>
</ul>
<p>Bone Marrow Transplant – Chelsie Sievers</p>
<p>Background</p>
<ul>
<li>Donor selection</li>
</ul>
<!-- -->

<ul>
<li>
<p>Autologous: self, no matching required (no GVHD risk, but also no
    graft-vs-tumor effect)</p>
</li>
<li>
<p>Allogeneic: non-self, matching based on HLA (more matched = less
    GVHD risk)</p>
<ul>
<li>
<p>Matched-related donor (MRD): fully matched sibling</p>
</li>
<li>
<p>Matched-unrelated donor (MUD): From NMDP database</p>
</li>
<li>
<p>Haploidentical: Half matched sibling or parent</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Source of stem cells:</li>
</ul>
<!-- -->

<ul>
<li>Peripheral blood stem cells (PBSCs) vs bone marrow-derived cells vs
    umbilical cord</li>
</ul>
<!-- -->

<ul>
<li>Conditioning regimens:</li>
</ul>
<!-- -->

<ul>
<li>Myeloablative vs Reduced-intensity conditioning (RIC)</li>
</ul>
<!-- -->

<ul>
<li>GVHD prophylaxis (for allo-SCT):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Regimen varies, can include tacrolimus, MMF, MTX, or thymo and
    alemtuzumab during conditioning</p>
<p>Complications/Adverse Effects:</p>
</li>
</ul>
<!-- -->

<ul>
<li>Infectious</li>
</ul>
<!-- -->

<ul>
<li>
<p>Neutropenic fever, neutropenic enterocolitis (typhlitis)</p>
</li>
<li>
<p>Bacterial infections</p>
</li>
<li>
<p>Viral infections</p>
<ul>
<li>
<p>CMV: check weekly PCR levels post-allo-SCT</p>
<ul>
<li>All CMV+ recipients are treated with letermovir
    prophylactically regardless of donor status</li>
</ul>
</li>
<li>
<p>EBV: check weekly PCR levels post allo-SCT. If EBV VL >1000 on
    two occasions, can treat with pre-emptive rituximab to reduce
    the risk of PTLD</p>
</li>
</ul>
</li>
<li>
<p>Invasive fungal infections (e.g. aspergillus, candida)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Non-infectious</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nausea, vomiting, diarrhea, mucositis, cytopenias</p>
</li>
<li>
<p>Hepatic veno-occlusive disease (VOD)/sinusoidal obstructive syndrome
    (SOS)</p>
<ul>
<li>
<p>Pathophysiology: sinusoidal endothelial cell damage from
    conditioning chemo post-sinusoidal portal HTN cytokine release
    multiorgan failure and death</p>
</li>
<li>
<p>Diagnosis: T Bili >2, hepatomegaly/RUQ pain, weight gain >
    2-5%</p>
</li>
<li>
<p>Evaluation: RUQ US with doppler</p>
</li>
<li>
<p>Treatment: Per heme attending; generally supportive, consider
    defibrotide</p>
</li>
</ul>
</li>
<li>
<p>Graft failure:</p>
<ul>
<li>
<p>Primary (persistent neutropenia without engraftment)</p>
</li>
<li>
<p>Secondary (delayed pancytopenia 2/2 immune phenomena or
    infection after engraftment)</p>
</li>
</ul>
</li>
<li>
<p>Engraftment syndrome:</p>
<ul>
<li>
<p>Pathophysiology: PMN recovery cytokine storm vascular leak</p>
</li>
<li>
<p>Symptoms: fever, tachycardia, hypotension, SOB, pulmonary edema,
    rash, weight gain, bone pain, confusion</p>
</li>
<li>
<p>Diagnosis: Clinical</p>
</li>
<li>
<p>Treatment: high-dose IV steroids</p>
</li>
</ul>
</li>
<li>
<p>Acute GVHD:</p>
<ul>
<li>
<p>Only in allogenic; Increased risk with more HLA mismatch</p>
</li>
<li>
<p>Pathophysiology: donor T cells attack recipient (Th1-mediated)</p>
</li>
<li>
<p>Symptoms: skin rash, cholestatic liver injury, diarrhea</p>
</li>
<li>
<p>Treatment: IV steroids (methylprednisolone 1-2mg/kg x 5d)</p>
<ul>
<li>If refractory: mycophenolate, etanercept, ruxolitinib,
    antithymocyte globulin</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Chronic GVHD (typically after T+100)</p>
<ul>
<li>
<p>Can involve all organs but typically see a scleroderma-like
    picture (xerophthalmia, xerostomia dysphagia, arthritis, skin
    changes, malar rash, obliterative bronchiolitis, cholestatic
    liver injury, cytopenias)</p>
</li>
<li>
<p>Treatment: steroids (also photophoresis for skin), consider
    trials of ruxolitinib, ibrutinib, rituximab if refractory</p>
</li>
</ul>
</li>
<li>
<p>PTLD (post-transplant lymphoproliferative disorders)</p>
<ul>
<li>
<p>Pathophysiology: B-cell proliferative disease typically 2/2
    &gt; latent EBV</p>
</li>
<li>
<p>Symptoms: fever, weight loss, fatigue, lymphadenopathy,
    &gt; extra-nodal masses, ↑ EBV PCR</p>
</li>
</ul>
</li>
</ul>
<p>CAR T-cell Therapy – Chelsie Sievers</p>
<p>Background</p>
<ul>
<li>
<p>Chimeric antigen receptor T cells (CAR-T) are a type of autologous
    T-cell therapy collected from the patient and genetically modified
    to contain an extracellular tumor-specific antigen target linked to
    the internal component of the T-cell receptor.</p>
</li>
<li>
<p>Goal: patient's own T-cells can specifically target the tumor cell
    population.</p>
</li>
<li>
<p>FDA approved therapies: Kymriah (CD19), Abecema (BCMA), Breyanzi
    (CD19), Tecartus (CD19), Yescarta (CD19)</p>
</li>
</ul>
<p>Complications:</p>
<ul>
<li>
<p>Cytokine Release Syndrome</p>
<ul>
<li>
<p>Pathophysiology: Supraphysiologic immune cell response with
    release of inflammatory cytokines.</p>
<ul>
<li>
<p>Grade 1: fever ≥ 100.4, no hypotension, no hypoxia</p>
</li>
<li>
<p>Grade 2: fever ≥ 100.4, hypotension not requiring
    vasopressors and/or hypoxia requiring \&lt; 6L</p>
</li>
<li>
<p>Grade 3: fever ≥ 100.4, hypotension requiring a vasopressor,
    hypoxia requiring > 6L or non-rebreather</p>
</li>
<li>
<p>Grade 4: fever ≥ 100.4, hypotension requiring multiple
    vasopressors, hypoxia requiring positive pressure</p>
</li>
</ul>
</li>
<li>
<p>Work-up: blood and urine cultures (IV abx if needed)</p>
</li>
<li>
<p>Treatment: acetaminophen for fever, ICU transfer (grade 1 okay
    for floor), Tocilizumab 8 mg/kg IV (max 800mg; up to 3 doses in
    24 hours, 8 hours apart), Dexamethasone 10 mg IV q 6 hours
    (grade 3-4).</p>
</li>
</ul>
</li>
<li>
<p>ICANS: Immune Effector Cell-Associated Neurotoxicity Syndrome</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pathophysiology: high systemic inflammation leaky blood brain
    barrier encephalopathy &plusmn; cerebral edema.</p>
<ul>
<li>
<p>Based on ICE score: Orientation: orientation to year, month,
    city, hospital: 4 points; Naming: ability to name 3 objects (eg,
    point to clock, pen, button): 3 points; Following commands:
    ability to follow simple commands (eg, “Show me 2 fingers” or
    “Close your eyes and stick out your tongue”): 1 point; Writing:
    ability to write a standard sentence (eg, “Our national bird is
    the bald eagle”): 1 point; Attention: ability to count backwards
    from 100 by 10: 1 point.</p>
</li>
<li>
<p>Grade 1: ICE score: 7-9</p>
</li>
<li>
<p>Grade 2: ICE score: 3-6</p>
</li>
<li>
<p>Grade 3: ICE score 0-2</p>
</li>
<li>
<p>Grade 4: ICE score 0</p>
</li>
</ul>
</li>
<li>
<p>Work-up: neuro consult, fundoscopic exam for papilledema, consider
    MRI brain w/&amp;w/o contrast, consider EEG, consider non-con CT head if
    headache/lethargy.</p>
</li>
<li>
<p>Treatment: q4hr neuro checks (q1hr if grade > 2 → ICU transfer),
    Keep Na 135-145 with hypertonic saline if necessary (Na 145-150 if
    grade 4), consider thiamine supplementation 500mg q8hrs,
    Dexamethasone 10 mg q 6 hours (if seizure give 20mg x 1, then 10mg
    q6hrs) (grade 2-3), Methylprednisolone 1000 mg IV q 24 x 3 days
    (grade 4).</p>
</li>
</ul>
<p>Oncologic Emergencies – Madeleine Turcotte</p>
<p>Leukostasis</p>
<p>Presentation</p>
<ul>
<li>
<p>Primarily occurs with acute myeloid leukemia and acute lymphoblastic
    leukemia. This is not common with CLL or CML with high leukocyte
    counts in the absence of a significant increased portion of
    peripheral blasts</p>
</li>
<li>
<p>Respiratory: dyspnea, hypoxia (note CXR may be normal)</p>
</li>
</ul>
<!-- -->

<ul>
<li>PaO2 by ABG often falsely low from WBC consuming O2 in vitro. Trust
    SpO2.</li>
</ul>
<!-- -->

<ul>
<li>CNS: headache, AMS, vision changes, dizziness, tinnitus, gait
    instability, neuro deficit</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>CBC with diff and peripheral blood smear</p>
</li>
<li>
<p>Imaging: CT head to evaluate neuro deficit and to check for ICH</p>
</li>
<li>
<p>Chest X-Ray vs CT chest to evaluate dyspnea and air space
    abnormalities</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Call hematology</p>
</li>
<li>
<p>Emergent cytoreduction</p>
</li>
</ul>
<!-- -->

<ul>
<li>Leukapheresis: page nephrology and place dialysis catheter</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hydroxyurea and chemotherapy per hematology fellow</p>
</li>
<li>
<p>Transfer/admit to ICU</p>
</li>
</ul>
<p>Tumor Lysis Syndrome – Bradley Christensen</p>
<p>Background</p>
<ul>
<li>
<p>Lysis of malignant cells either spontaneously or in response to
    chemotherapy causing release of K, Phos, nucleic acids, and
    cytokines</p>
</li>
<li>
<p>Consequences:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hyperkalemia: most urgent and immediately life threatening</p>
</li>
<li>
<p>Hyperphosphatemia: binds Ca and leads to CaPhos crystal deposition
    AKI, HypoCa</p>
</li>
<li>
<p>Hyperuricemia (from breakdown of DNA) precipitation in renal tubules
    AKI</p>
</li>
<li>
<p>Hypotension, AKI from cytokine release</p>
</li>
</ul>
<!-- -->

<ul>
<li>Laboratory TLS</li>
</ul>
<!-- -->

<ul>
<li>
<p>Uric acid ≥ 8, Ca2+ ≤ 7, K+, or PO43- ≥ 4.5</p>
</li>
<li>
<p>OR > 25% change from baseline in these values</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Risk Stratification:</li>
</ul>
<!-- -->

<ul>
<li>Highest risk after starting chemotherapy, but can occur
    spontaneously</li>
</ul>
<!-- -->

<ul>
<li>Tumor characteristics which confer a higher risk of developing TLS:</li>
</ul>
<!-- -->

<ul>
<li>
<p>High (>5% risk): ALL (WBC> 100K or LDH 2x ULN), AML (WBC> 100K),
    Burkitt’s (III/IV or LDH≥2xULN, DLBCL with bulky disease,
    intermediate risk + AKI/CKD</p>
</li>
<li>
<p>Intermediate: ALL (WBC\&lt;100K, LDH \&lt;2x ULN), AML (WBC 25-100K),
    Burkitt’s LDH\&lt;2x ULN), DLBCL (non-bulky, LDH>ULN), CLL (if tx with
    fludarabine, rituximab, lenalidomide, or venetoclax +LN 5-10 cm or
    ALC≥25K), plasma cell leukemia, rare chemo-sensitive solid tumors
    (small cell)</p>
</li>
<li>
<p>Low: all others</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Prevention:</li>
</ul>
<!-- -->

<ul>
<li>
<p>High risk: q6-8h TLS labs, IVF (±loop diuretic if volume overload),
    allopurinol, ± rasburicase</p>
</li>
<li>
<p>Intermediate – q8h TLS labs, IVF, allopurinol</p>
</li>
<li>
<p>Low – daily TLS labs, IVF</p>
<ul>
<li>
<p>Significant hydration: goal to maintain UOP 80-100 mL/hr</p>
</li>
<li>
<p>Allopurinol: 300 mg PO BID for CrCl > 20 mL/min, UpToDate renal
    dosing if lower</p>
</li>
<li>
<p>Rasburicase ($$$): contraindicated in G6PD (send G6PD if not
    urgent and AA, Asian or Jewish descent)</p>
<ul>
<li>Given if uric acid > 8 mg/dL: get fellow approval before
    ordering</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Treatment: (Can use as night/cross cover handoff)</li>
</ul>
<!-- -->

<ul>
<li>
<p>K+ > 5.5: STAT EKG. Kayexalate 30g orally or 60g per rectum (unless
    contraindicated) x1</p>
<ul>
<li>
<p>Give 10 U insulin/1 amp D50</p>
</li>
<li>
<p>If EKG changes, then calcium gluconate and D5W at 100 mL/hr with
    repeat BG in 1 hr</p>
</li>
</ul>
</li>
<li>
<p>Uric acid > 8 with 25% change from baseline: page hematology fellow
    to discuss rasburicase</p>
</li>
<li>
<p>PO4 > 4.5 with 25% change from baseline: start/↑ phos binder
    (sevelamer)</p>
</li>
<li>
<p>Dialysis may be necessary in patients with poor renal function.</p>
</li>
<li>
<p>IV calcium: do not administer unless symptomatic AND
    hyperphosphatemia is corrected</p>
<ul>
<li>With high phos, IV calcium can lead to calcium deposition and
    renal failure</li>
</ul>
</li>
<li>
<p>Hemodialysis: pt with anuria, refractory hyperkalemia, and
    symptomatic hypocalcemia</p>
</li>
</ul>
<p>Superior Vena Cava (SVC) Syndrome</p>
<p>Background</p>
<ul>
<li>
<p>Commonly Associated Malignancies: Lung Cancer, Non-Hodgkin or
    Hodgkin Lymphoma, Mediastinal Germ Cell Tumors, Thymic Malignancies</p>
</li>
<li>
<p>Partial or complete obstruction of the SVC impedes blood return from
    the upper extremities, head, neck, and brain resulting in upstream
    congestion</p>
</li>
<li>
<p>Can be 2/2 a mass in the mediastinum or thrombosis (foreign body
    i.e. catheter)</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Facial or neck swelling without generalized edema</p>
</li>
<li>
<p>Sense of head fullness, exacerbated by leaning forward or lying down</p>
</li>
<li>
<p>Pulmonary symptoms including dyspnea, stridor, hoarseness, cough -
    due to edema narrowing the nasal passages and larynx or mechanical
    airway obstruction</p>
</li>
<li>
<p>Physical Exam: facial and neck edema particularly of the eye lids in
    the morning, distended neck and chest veins; can also sometimes see
    upper extremity swelling, papilledema, plethora. Look for associated
    lymph node enlargement anywhere particularly including
    supraclavicular, cervical, and axillary region</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>CXR: may show mass, perihilar or mediastinal disease</p>
</li>
<li>
<p>Contrasted CT scan ± CT Venography: Phased to get a view of clot
    contribution to obstruction guides decision regarding
    anticoagulation or stenting</p>
</li>
</ul>
<!-- -->

<ul>
<li>Radiology attending can coordinate with techs (requires verbal
    direct request)</li>
</ul>
<!-- -->

<ul>
<li>MRI/MRV may provide additional information (often not possible due
    to pt too sick)</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Assess airway and prepare for intubation if needed</p>
</li>
<li>
<p>Keep head of bed elevated</p>
</li>
<li>
<p>Thrombosis:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Removal of lines/catheters associated with thrombus</p>
</li>
<li>
<p>Consideration of anticoagulation</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Tumor compression: the type of tumor guides treatment (tissue biopsy
    is key)</p>
</li>
<li>
<p>Stat/urgent consultations:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Interventional radiology for possible stenting/dilatation</p>
</li>
<li>
<p>Radiation oncology- for radiation therapy</p>
</li>
<li>
<p>Interventional pulmonology – for help with tissue dx</p>
</li>
<li>
<p>Medical oncology – for help with diagnosis and chemotherapy</p>
</li>
</ul>
<p>Spinal Cord Compression</p>
<p>Background</p>
<ul>
<li>Malignancies where cord compression is most common:</li>
</ul>
<!-- -->

<ul>
<li>Multiple Myeloma, Lymphoma (both Hodgkin and NHL), Lung, Breast,
    Prostate Cancer</li>
</ul>
<!-- -->

<ul>
<li>Tumor mass &amp; compressed and often displaced bone impinges thecal sac
    or nerve roots spinal cord or any spinal nerves including the cauda
    equina</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Back pain, motor, or sensory deficits</p>
</li>
<li>
<p>Cauda Equina syndrome bowel or bladder incontinence, ataxia</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Neurologic exam with sensation testing seeking level below an
    identified dermatome</p>
</li>
<li>
<p>Lab testing: If no known malignancy check CBC, CMP, SPEP, and (in
    males) PSA</p>
</li>
<li>
<p>Bladder US if suspicion or retention with or without overflow
    incontinence</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>If suspected, order MRI without and with contrast; if patient unable
    to have MRI, CT myelography may be considered</p>
</li>
<li>
<p>Immediate high dose steroids (dosing is controversial with
    recommendations ranging from 4 to 100 mg of dexamethasone q6h -
    choice of dexamethasone is to minimize mineralocorticoid effects.
    Most common dosing is 10mg IV x1 followed by 4mg IV q6h)</p>
</li>
<li>
<p>Consider stat/urgent consultation with:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Neurosurgery for diagnostic/therapeutic intervention</p>
</li>
<li>
<p>Radiation oncology- for radiation therapy</p>
</li>
<li>
<p>Medical oncology – for help with diagnosis and chemotherapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>Ensure regular neuro-vascular checks and close monitoring.</li>
</ul>
<p>Brain Metastases</p>
<p>Background</p>
<ul>
<li>
<p>Common malignancies: Lung (NSCLC), breast, kidney, colorectal
    carcinomas &amp; melanomas</p>
</li>
<li>
<p>Significantly more common than primary brain tumors</p>
</li>
<li>
<p>80% of brain metastasis occur in the cerebrum at grey/white matter
    junction</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Highly variable: consider brain mets in any cancer pt w/ neurologic
    or behavioral changes</p>
</li>
<li>
<p>Headache: worse in the mornings, with bending over or with valsalva</p>
</li>
<li>
<p>Nausea/vomiting</p>
</li>
<li>
<p>Cognitive dysfunction: changes in memory, mood or personality</p>
</li>
<li>
<p>Focal neurologic deficits</p>
</li>
<li>
<p>Signs of elevated ICP: papilledema, vision changes, drowsiness,
    presyncope</p>
</li>
<li>
<p>Seizures</p>
</li>
<li>
<p>Stroke (particularly in melanoma, choriocarcinoma, thyroid &amp; renal
    carcinomas)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>STAT CT if concerned for stroke or elevated ICP</p>
</li>
<li>
<p>MRI with contrast: most sensitive, can differentiate between
    metastases vs. other lesions</p>
</li>
</ul>
<!-- -->

<ul>
<li>Suggestive features: multiple lesions, location, circumscribed
    margins, vasogenic edema</li>
</ul>
<!-- -->

<ul>
<li>
<p>If pt has no known primary tumor: consider CT C/A/P &plusmn; PET to
    identify primary</p>
</li>
<li>
<p>Biopsy with histopathology &amp; IHC: if diagnosis in doubt or if only a
    single lesion is present</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>If severe HA, N/V, focal deficits: systemic glucocorticoids</li>
</ul>
<!-- -->

<ul>
<li>Dexamethasone 10mg IV x1 followed by 4mg IV q6h (can be PO if
    tolerated)</li>
</ul>
<!-- -->

<ul>
<li>Stat/urgent consults:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Neurosurgery – for diagnostic/therapeutic intervention</p>
</li>
<li>
<p>Radiation oncology – for radiation therapy</p>
</li>
<li>
<p>Medical oncology – for help with diagnosis and chemotherapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ensure regular neuro-vascular checks and close monitoring</p>
</li>
<li>
<p>Do not perform LP without input from neurology</p>
</li>
</ul>
<p>Paraneoplastic Syndromes – Justin Lo</p>
<p>Hypercalcemia of malignancy</p>
<p>Background</p>
<ul>
<li>Caused by PTHrP production, osteolytic lesions, and/or rarely
    exogenous Vit D</li>
</ul>
<!-- -->

<ul>
<li>
<p>PTHrP: Breast cancer, NSCLC (squamous)</p>
</li>
<li>
<p>Osteolysis: Multiple Myeloma, Breast Cancer;</p>
</li>
<li>
<p>Exogenous Vit D: Lymphoma</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Correct [Ca+2] for hypoalbuminemia: add 0.8 x (4.0 – albumin)</p>
</li>
<li>
<p>Send basic hyperCa+2 work-up – PTH, Vit D, etc. (see hypercalcemia
    section)</p>
</li>
<li>
<p>PTHrP is called “Parathyroid Hormone-related Peptide-ARUP” in Epic</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>First-line: IVF without calcium such as Normosol; goal urinary
    output of 150-200 mL/hr</li>
</ul>
<!-- -->

<ul>
<li>
<p>Strict I/Os; Cautious IV fluids if pt w/cardiac or renal dysfunction</p>
</li>
<li>
<p>Add Furosemide if hypervolemic (do not empirically start)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Second-line: Zoledronic acid 4mg IV (takes 24-48 hours to see
    effect)</p>
</li>
<li>
<p>AMS or severe hypercalcemia (>14mg/dL): calcitonin 4 IU/kg (req.
    attending approval)</p>
</li>
</ul>
<p>SIADH</p>
<p>Background</p>
<ul>
<li>
<p>Euvolemic hypotonic hyponatremia with urine sodium >20 and
    typically urine Osm >100</p>
</li>
<li>
<p>Associated with: SCLC (most common), head/neck cancers, breast
    cancer</p>
</li>
<li>
<p>See "Nephrology" for additional information</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Free water restriction to 800mL/day</p>
</li>
<li>
<p>Refractory: salt supplementation (e.g. salt tabs) &plusmn; loop diuretic</p>
</li>
</ul>
<p>Carcinoid Syndrome</p>
<p>Background</p>
<ul>
<li>
<p>Episodic flushing, diarrhea, wheezing/SOB due to secretion of
    histamine &amp; serotonin</p>
</li>
<li>
<p>Most common: Neuroendocrine tumors – GI (often with mets to liver
    and lung)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Urine: UR 5-HIAA (ARUP)</p>
</li>
<li>
<p>Imaging to identify tumor(s) (CT chest/abdomen/pelvis)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Short-term treatment: subQ or IV octreotide (see UpToDate for
    dosing)</p>
</li>
<li>
<p>Antidiarrheals (Imodium, Lomotil, etc.) to slow transit</p>
</li>
<li>
<p>Long-term treatment: depot (IM) forms of octreotide and lanreotide</p>
</li>
</ul>
<p>Autoimmune encephalitis, encephalomyelitis, and myelitis</p>
<p>Background</p>
<ul>
<li>
<p>Encephalopathy (limbic or brainstem), &plusmn; myelitis (limb ataxia,
    sensory deficits)</p>
</li>
<li>
<p>Associated with small cell lung cancer and checkpoint inhibitor
    therapy</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>LP: make sure to order CSF oligoclonal bands &amp; CSF IgG index</p>
</li>
<li>
<p>“Paraneoplastic AutoAb Eval-MAYO” (add "CSF" to the front of the
    order name if for LP)</p>
</li>
<li>
<p>NMDA-R can be ordered as a standalone test</p>
</li>
<li>
<p>CT head</p>
</li>
<li>
<p>EEG if concern for subclinical seizures</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Consult Neurology, for possible immunosuppressive therapy (steroids,
    IVIG)</li>
</ul>
<p>Lambert-Eaton myasthenic syndrome (LEMS)</p>
<p>Background</p>
<ul>
<li>
<p>Muscle weakness due to autoantibody against calcium channels
    resulting in ↓ ACh release</p>
</li>
<li>
<p>Associated with SCLC (most common) &amp; lymphoma</p>
</li>
</ul>
<p>Presentation:</p>
<ul>
<li>Proximal muscle weakness, diminished DTRs</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Nerve conduction studies: EMG w/ NCV</p>
</li>
<li>
<p>Serum “Paraneoplastic AutoAb Eval-MAYO”</p>
</li>
</ul>
<p>Management</p>
<p>Consult Neurology</p>
<p>Therapy Toxicities – Rahul Shah</p>
<p>Immune Checkpoint Inhibitor Toxicities:</p>
<ul>
<li>
<p>Immune checkpoint inhibitors augment the endogenous immune response
    against tumors, which may lead to autoimmune-like toxicities, known
    as immune-related adverse events (irAEs)</p>
</li>
<li>
<p>Treatment: low-dose glucocorticoids (prednisone, 0.5 mg/kg) for mild
    adverse events, high dose glucocorticoids (prednisone, 1-2 mg/kg)
    for severe adverse events</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 31%" />
<col style="width: 32%" />
<col style="width: 36%" />
</colgroup>
<thead>
<tr class="header">
<th>Adverse Event Type</th>
<th><p>Incidence with anti-CTLA-4</p>
<p>(e.g. ipilimumab)</p></th>
<th><p>Incidence with anti‐PD1/PD‐L1</p>
<p>(e.g. nivolumab, pembrolizumab)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Skin (rash, pruritus, TEN)</td>
<td>30%</td>
<td>30%</td>
</tr>
<tr class="even">
<td>Colitis</td>
<td>25%</td>
<td>5%</td>
</tr>
<tr class="odd">
<td>Hypothyroidism</td>
<td>20%</td>
<td>20%</td>
</tr>
<tr class="even">
<td>Hepatitis</td>
<td>10%</td>
<td>1%</td>
</tr>
<tr class="odd">
<td>Hypophysitis</td>
<td>10%</td>
<td>rare</td>
</tr>
<tr class="even">
<td>Pneumonitis</td>
<td>2-5%</td>
<td>2-5%</td>
</tr>
<tr class="odd">
<td>Myocarditis</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr class="even">
<td>Neurotoxicity (GBS, myasthenia gravis, encephalitis)</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
</tbody>
</table>

<p>Cytotoxic Agent Toxicities</p>
<table>
<thead>
<tr>
<th>Class</th>
<th>Agent</th>
<th> Side Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alkylating Agents</td>
<td>Busulfan</td>
<td>Pulmonary fibrosis or diffuse alveolar hemorrhage</td>
</tr>
<tr>
<td></td>
<td>Cyclophosphamide</td>
<td>Myopericarditis, hemorrhagic cystitis (prevention: hydration; monitoring: daily UA, tx: mesna)</td>
</tr>
<tr>
<td></td>
<td>Ifosfamide</td>
<td>Encephalopathy (tx: methylene blue), nephrotoxicity, hemorrhagic cystitis</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>5- Fluorouracil (5-FU)/ Capecitabine (metabolized to FU)</td>
<td>Myelosuppression, coronary vasospasm, palmar-plantar erythrodysesthesia, mucositis</td>
</tr>
<tr>
<td></td>
<td>Cladribine, pentostatin</td>
<td>Dose reduced for CrCl</td>
</tr>
<tr>
<td></td>
<td>Cytarabine (Ara-C)</td>
<td>Irreversible cerebellar ataxia (if high dose, neuro checks required), conjunctivitis (prevent with prophylactic steroid eye drops)</td>
</tr>
<tr>
<td></td>
<td>Gemcitabine</td>
<td>Transient transaminitis, peripheral edema, rash, rarely: pulmonary toxicity, hemolytic uremic syndrome, capillary leak syndrome</td>
</tr>
<tr>
<td></td>
<td>Methotrexate</td>
<td>Stomatitis, hepatotoxicity, renal failure, high dose requires leucovorin</td>
</tr>
<tr>
<td>Antitumor antibiotics</td>
<td>Anthracyclines (doxorubicin, daunorubicin, idarubicin)</td>
<td>HFrEF (need TTE prior). Most notable with doxorubicin.</td>
</tr>
<tr>
<td></td>
<td>Bleomycin</td>
<td>Pulmonary fibrosis. Potentiated with G-CSF</td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Alemtuzumab</td>
<td>Severe and prolonged cytopenias</td>
</tr>
<tr>
<td></td>
<td>Bevacizumab</td>
<td>HFrEF, HTN, hyperglycemia, hypomag, DVT, pulm hemorrhage, GI bleeding/fistulas/perforation, wound healing complications</td>
</tr>
<tr>
<td></td>
<td>Rituximab</td>
<td>Hypophos, hepatotoxicity, HBV reactivation (screen all patients), peripheral neuropathy; transfusion reaction during 1<sup>st</sup> time infusion</td>
</tr>
<tr>
<td>Platinum Agents</td>
<td>Cisplatin, oxaliplatin, carboplatin</td>
<td>Nephrotoxicity, worst with cisplatin. Rental tubular acidosis. Neurotoxicity (parasthesias, cold sensitivity, cramps, peripheral neuropathy), ototoxicity (high frequency hearing loss), constipation, hypomag</td>
</tr>
<tr>
<td>Taxanes</td>
<td>Docetaxel, paclitaxel</td>
<td>Hypersensitivity reaction (often require premedication with steroids and H1/H2 blockers); peripheral neuropathy</td>
</tr>
<tr>
<td>Topoisomerase Inhibitors</td>
<td>Irinotecan, topotecan, etoposide</td>
<td>Irinotecan- acute diarrhea can be treated with atropine; delayed with atropine</td>
</tr>
<tr>
<td>Tyrosine Kinase Inhibitors</td>
<td>Imatinib, Dasatinib, Nilotinib, Bosutinib</td>
<td>QTc prolongation, pulmonary effusion, hepatotoxicity</td>
</tr>
<tr>
<td>Vinca alkaloid</td>
<td>Vincristine</td>
<td>Peripheral neuropathy and ototoxicity (vestibular system lost first)</td>
</tr>
</tbody>
</table></section><h1 class='nav-section-title-end'>Ended: Hematology oncology</h1>
                        <h1 class='nav-section-title' id='section-hepatology'>
                            Hepatology <a class='headerlink' href='#section-hepatology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="hepatology-hepatology-acute-liver-failure"><h1 id="hepatology-hepatology-acute-liver-failure-acute-liver-injury-and-failure">Acute Liver Injury and Failure<a class="headerlink" href="#hepatology-hepatology-acute-liver-failure-acute-liver-injury-and-failure" title="Permanent link">&para;</a></h1>
<p>Hannah Lomzenski, and Lauren Chan</p>
<hr />
<h2 id="hepatology-hepatology-acute-liver-failure-background">Background<a class="headerlink" href="#hepatology-hepatology-acute-liver-failure-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Acute liver injury (ALI): elevated liver enzymes + INR ≥1.5 but NO encephalopathy</p>
</li>
<li>
<p>Acute liver failure (ALF): elevated liver enzymes + encephalopathy/AMS in the absence of pre-existing liver disease*</p>
<ul>
<li>*Chronic autoimmune hepatitis, HBV, Wilson disease, and Budd-Chiari syndrome can have ALF if they develop new AMS, despite the presence of a pre-existing liver disease</li>
</ul>
</li>
<li>
<p>Alcohol-associated hepatitis (AH) is not ALF (see above)</p>
</li>
</ul>
<h2 id="hepatology-hepatology-acute-liver-failure-etiology">Etiology<a class="headerlink" href="#hepatology-hepatology-acute-liver-failure-etiology" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>R-factor (if history, exam, and diagnostic data are inconclusive i.e. R-factor is not a replacement to clinical judgement) = (ALT/uln ALT) / (ALP/uln ALP); See chart below</p>
<ul>
<li>R &gt; 5 = hepatocellular injury; R&lt;2 = cholestatic injury; R 2-5 = mixed injury</li>
</ul>
</li>
<li>
<p>Isolated hyperbilirubinemia: Differentiate direct versus indirect</p>
<ul>
<li>Direct: Refer to cholestatic pattern</li>
<li>Indirect: Gilbert vs hemolysis</li>
</ul>
</li>
<li>
<p>Drugs Associated with liver injury</p>
<ul>
<li>
<p>Hepatocellular pattern: acarbose, Acetaminophen, Allopurinol, Amiodarone, Baclofen, Bupropion, Fluoxetine, HAART (Nevirapine), Kava kava, Isoniazid, Ketoconazole, Lisinopril, Losartan, Methotrexate, NSAIDs, Omeprazole, Oxacillin/Nafcillin, Paroxetine, Pyrazinamide, Propylthiouracil, Rifampin, Risperidone, Sertraline, Statins, Tetracycline, Trazodone, Valproic Acid</p>
</li>
<li>
<p>Mixed pattern: Amitriptyline, Azathioprine, Captopril, Carbamazepine, Clindamycin, Cyproheptadine, Enalapril, Flutemide, Nitrofurantoin, Phenobarbital, Phenytoin, Sulfonamides, Trazodone, Verapamil</p>
</li>
<li>
<p>Cholestatic pattern: Amoxicillin-clavulanic acid, Anabolic steroids, Chlorpromazine, Clopidogrel, Oral contraceptives, Erythromycins, Estrogens, Irbesartan, Mirtazapine, Phenothiazines, Terbinafine, Tricyclics</p>
</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 34%" />
<col style="width: 25%" />
<col style="width: 40%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Hepatocellular Injury: R factor &gt; 5 (Primary
elevation of AST/ALT)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Acetaminophen intoxication<sup>$</sup></td>
<td></td>
<td><p>Acetaminophen lvl</p>
<p>Aspirin lvl</p></td>
</tr>
<tr class="even">
<td>Acute Viral Hepatitis</td>
<td><p>Hep A<sup>$</sup>, B*<sup>$</sup>, C*, D, E</p>
<p>EBV, CMV, HSV, VZV</p></td>
<td>Viral serologies (see below), hx of tattoos, IVDU, piercings, blood
transfusion prior to 1990s, intranasal cocaine use and mass vaccinations
(in 3rd world countries)</td>
</tr>
<tr class="odd">
<td>Autoimmune hepatitis\*</td>
<td>Autoantibodies and high serum globulins</td>
<td>Anti-smooth muscle (f-actin), ANA, ANCA, anti-liver kidney microsome
(anti-LKM-1), anti-soluble liver antigen/liver-pancreas IgG</td>
</tr>
<tr class="even">
<td>Budd-Chiari Syndrome\*</td>
<td>Hepatic vein obstruction</td>
<td>Ultrasound of abdomen w/ doppler, CT w/ contrast</td>
</tr>
<tr class="odd">
<td>DILI – Drug Induced Liver Injury\*<sup>$</sup></td>
<td>Many drugs</td>
<td>See above<br />
\*Query NIH Liver Tox database: <a
href="https://www.livertox.nih.gov">https://www.livertox.nih.gov</a></td>
</tr>
<tr class="even">
<td>HELLP Syndrome, Acute Fatty Liver of Pregnancy</td>
<td>Pregnancy</td>
<td>Requires urgent delivery regardless of gestational age</td>
</tr>
<tr class="odd">
<td>Ischemic Liver Injury (Shock Liver)<sup>$</sup></td>
<td>Shock (can be of any variety)</td>
<td>AST and ALT can be in the thousands, high LDH, history of
hypotension</td>
</tr>
<tr class="even">
<td>Toxins</td>
<td>Ethanol, cocaine, mushroom (Amanita phalloides)</td>
<td>UDS, ethanol level, PEth lvl</td>
</tr>
<tr class="odd">
<td>Wilson’s Disease\*</td>
<td>Copper overload</td>
<td>Ceruloplasmin level (screening), 24h urine copper (confirmation),
quantitative copper on liver biopsy</td>
</tr>
<tr class="even">
<td colspan="3"><em>\*May present with chronic liver injury as well; $May
present with AST/ALT &gt;100</em></td>
</tr>

</tbody>
</table>

<table>
<thead>
<tr>
<th>Cholestatic Injury: R Factor \&lt; 2 (Primarily elevated Alkaline phosphatase)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute biliary obstruction</td>
<td>Gallstones</td>
<td>Abdominal ultrasound, MRCP, ERCP</td>
</tr>
<tr>
<td>DILI – Drug-induced liver injury*<sup>$</sup></td>
<td>Many drugs, consult livertox website</td>
<td>Common: Augmentin, Bactrim, amiodarone, Imuran</td>
</tr>
<tr>
<td>Malignancy*</td>
<td>Pancreas, cholangiocarcinoma</td>
<td>CT abdomen, ERCP</td>
</tr>
<tr>
<td>Primary Biliary Cirrhosis*</td>
<td>Autoimmune</td>
<td>Anti-mitochondrial antibody</td>
</tr>
<tr>
<td>Primary Sclerosing Cholangitis*</td>
<td>Autoimmune, associated with IBD</td>
<td>MRCP, ERCP</td>
</tr>
<tr>
<td>Critical illness or COVID cholangiopathy</td>
<td>Hypotension, COVID</td>
<td>MRCP with biliary stenosis, appropriate history</td>
</tr>
<tr>
<td><em>*May present with chronic liver injury as well; $May present with AST/ALT >100</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<h2 id="hepatology-hepatology-acute-liver-failure-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-acute-liver-failure-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Consult hepatology early! (to assist with workup AND for transplant
    evaluation)</li>
<li>
<p>Labs:</p>
<ul>
<li>CBC w/diff, CMP, Dbili, Mg, Phos, T&amp;S, BCx, UCx, PT/INR, aPTT, fibrinogen</li>
<li>Amylase, lipase </li>
<li>Beta-hCG for females of reproductive age</li>
<li>ABG with arterial lactate, ammonia (arterial &gt;124 predicts mortality and CNS complications e.g. need for intubation, seizures, cerebral edema, &lt;75 very unlikely to develop ICH) </li>
<li>Viral etiologies: Virtal hepatitis serologies (HAV panel, HBV panel, HCV IgG &plusmn; PCR quant, HDV if known HBV (with low or undetectable HBV load as Misc Reference Test, Hepatitis E PCR ent as miscellaneous if pregnant or travel to southeast Asia), HIV p24 Ag and HIV Ab, EBV Qt, CMV Qt, HSV &frac12; Qt, VZV IgM/IgG</li>
<li>Toxins: UDS, ethanol level &plusmn; Peth, acetaminophen level (drawn &gt; 4 hours after last known ingestion), Salicylate level</li>
<li>Autoimmune / genetic: ANA, ASMA, IgG, AMA (if predominantly elevated ALP), ceruloplasmin</li>
</ul>
</li>
<li>
<p>Imaging:</p>
<ul>
<li>RUQ abdominal ultrasound <strong>with doppler</strong> (important to assess
    vasculature!)</li>
<li>Consider CT with contrast in patients with normal renal function
    and high suspicion of Budd-Chiari syndrome or malignancy with
    negative ultrasound  (better for assessing the hepatic veins)
    and helps with transplant evaluation</li>
<li>Consider TTE to rule out cardiac dysfunction; helpful for
    transplant consideration</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-acute-liver-failure-criteria-for-transplantation">Criteria for Transplantation:<a class="headerlink" href="#hepatology-hepatology-acute-liver-failure-criteria-for-transplantation" title="Permanent link">&para;</a></h2>
<ul>
<li>King’s College criteria:
    helps identify patients needing transplant referral/consideration<ul>
<li>ALF due to acetaminophen:<ul>
<li>Arterial pH \&lt;7.3 after resuscitation and &gt;24 hr since
    ingestion, OR</li>
<li>Arterial Lactate &gt;3 after adequate fluid resuscitation, OR</li>
<li>Grade III-IV HE, SCr &gt;3.4, <strong>and</strong> INR &gt;6.5 all within 24h period</li>
</ul>
</li>
</ul>
</li>
<li>ALF not due to acetaminophen: INR &gt; 6.5 OR 3 of the 5 following
    criteria:<ul>
<li>Indeterminate etiology, drug-induced hepatitis</li>
<li>Age \&lt;10 or &gt;40</li>
<li>Interval of jaundice to encephalopathy &gt;7 days</li>
<li>Bilirubin &gt; 17.5 mg/dl (300 micromol/L) </li>
<li>INR &gt;3.5</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-acute-liver-failure-management">Management<a class="headerlink" href="#hepatology-hepatology-acute-liver-failure-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Any pt with concern for ALF should be cared for in MICU (even if mild change in mental status)</li>
<li>Pts with ALF die acutely from hypoglycemia, cerebral edema, and
    infection</li>
<li>ABC’s:<ul>
<li>Intubate for GCS \&lt;8, Grade 3 or 4 HE</li>
<li>IVF resuscitation with isotonic crystalloid (most pts are volume
    deplete; avoid hypotonic fluids due to risk of cerebral edema)</li>
<li>Vasopressive agents for persistent hypotension (norepinephrine
    preferred)</li>
</ul>
</li>
<li>Monitoring:<ul>
<li>Q1-2h neuro checks, Q1-2h glucose checks</li>
<li>Closely monitor CMP, INR q6-8 hrs</li>
</ul>
</li>
<li>Treatment of Primary Injury<ul>
<li>IV N-acetylcysteine - improves transplant-free survival even in
    patients WITHOUT acetaminophen induced acute liver failure<ul>
<li>Initial loading dose = 150mg/kg over 1 hour, then 50mg/kg/hr
    for 4 hours, then 100mg/kg/hr for 16 hours ​​​​​​​</li>
<li>Patients with early stage hepatic encephalopathy (grade
    I/II) have increased transplant free survival, while those
    with grade III/IV do not</li>
</ul>
</li>
<li>See below for etiology-specific treatment; hepatology consult
    for LT eval</li>
<li>Early toxicology consultation if suspected ingestion/overdose<ul>
<li>For acute management contact Poison Control <strong>800-222-1222</strong></li>
</ul>
</li>
</ul>
</li>
<li>Treatment of Secondary Complications<ul>
<li>Infection: abx only if progressing HE, signs of infection, or
    development of SIRS; ppx abx do not reduce mortality</li>
<li>Cerebral edema/increased ICP:  elevated HOB to 30 degrees, quiet
    and dimly lit room, minimize IVF, goal Na 145-155,
    hyperventilation if concern for impending herniation. Consider
    3% saline (500mL) and/or mannitol (1g/kg, 20%) for pt at highest
    risk (serum ammonia &gt;150, grade III/IV HE, ARF, vasopressor
    support</li>
<li>Seizures: phenytoin (no evidence to support seizure ppx)</li>
<li>Renal Failure: early CRRT if persistent Metabolic Acidosis,
    Volume Overload, Hyperammonemia, falling UOP</li>
<li>Coagulopathy: IV Vit K; products for invasive procedures or
    active bleeding only</li>
</ul>
</li>
<li>Additional Supportive Care<ul>
<li>PPI for bleeding ppx</li>
<li>Enteral nutrition within 2-3 days; avoid TPN if possible; avoid
    NG feeds if progressive HE; NG should only be placed w/
    intubation as gagging increases ICP</li>
<li>Prefer propofol for sedation for better neuro exams and may reduce cerebral blood flow</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-acute-liver-failure-specific-management-by-etiology">Specific Management by Etiology:<a class="headerlink" href="#hepatology-hepatology-acute-liver-failure-specific-management-by-etiology" title="Permanent link">&para;</a></h2>
<ul>
<li>Acetaminophen<ul>
<li>Early toxicology consultation if suspected ingestion/overdose</li>
<li>For acute management contact Poison Control 800-222-1222</li>
<li>Activated charcoal within 4 hours of ingestion, most effective within 1 hour</li>
<li>IV N-acetylcysteine per protocol, look up Rumack-Matthew Nomogram and consult with toxicology<ul>
<li>In Epic: search “N-acetylcysteine” and select order set “Acetaminophen overdose”</li>
</ul>
</li>
</ul>
</li>
<li>
<p>AFLP/HELLP – delivery</p>
</li>
<li>
<p>Amanita phalloides – IV fluid resuscitation, PO charcoal, IV penicillin, IV acetylcysteine</p>
</li>
<li>
<p>Autoimmune – IV steroids following approval by hepatology (and typically post biopsy). Azathioprine generally deferred until cholestasis resolved (Mycophenolate can be used instead)</p>
</li>
<li>
<p>Budd-Chiari – anticoagulation, IR-guided endovascular therapy, transplant (must rule out underlying malignancy and evaluate for thrombotic disorders)</p>
</li>
<li>
<p>HAV/HEV – supportive care, consider ribavirin for ALF due to HEV</p>
</li>
<li>
<p>HBV – nucleos(t)ide analogue; orthotopic liver transplant</p>
</li>
<li>
<p>HSV – acyclovir</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-alcoholic-hepatitis"><h1 id="hepatology-hepatology-alcoholic-hepatitis-alcoholic-hepatitis">Alcoholic Hepatitis<a class="headerlink" href="#hepatology-hepatology-alcoholic-hepatitis-alcoholic-hepatitis" title="Permanent link">&para;</a></h1>
<p>Julie Cui, Alex Wiles</p>
<hr />
<h2 id="hepatology-hepatology-alcoholic-hepatitis-background">Background<a class="headerlink" href="#hepatology-hepatology-alcoholic-hepatitis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Acute onset of rapidly progressive jaundice in pt with heavy EtOH intake (&gt;40g in females or &gt;60g in males EtOH/day for &gt;6 mos, or within &lt;60 days of abstinence)<ul>
<li>May present after they have quit drinking due to immunosuppressive effects of alcohol</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-alcoholic-hepatitis-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-alcoholic-hepatitis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>AST &gt;60, AST/ALT &gt;1.5, both values &lt;400 IU/L; TBili &gt;3.0 mg/dL, documentation of heavy EtOH use until 8 weeks prior to presentation</p>
</li>
<li>
<p>Prognostication with Maddrey’s Discriminant Function: 4.6 * (PTpt – PTctrl) + Tbili</p>
<ul>
<li>Maddrey &gt; 32 = poor 30d prognosis &amp; may benefit from steroids (see below)</li>
</ul>
</li>
<li>
<p>RUQ U/S to rule out obstructive cause of jaundice</p>
</li>
<li>
<p>Biopsy is not typically required but will show neutrophilic lobular inflammation, hepatocyte ballooning, steatosis, and pericellular fibrosis.</p>
</li>
<li>
<p>Phosphatidylethanol (PEth) level is a biomarker of ethanol consumption over ~ 4wks; &gt;20 ng/mL can indicate chronic moderate/heavy alcohol intake</p>
<ul>
<li>A single episode consumption can result in detectable Peth for up to 12 days. Can be elevated for months with regular heavy alcohol intake</li>
<li>EtOH levels may be negative unless acutely intoxicated</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-alcoholic-hepatitis-management">Management<a class="headerlink" href="#hepatology-hepatology-alcoholic-hepatitis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Supportive Care is essential! Consult nutrition, start high protein, high calorie diet, high dose Thiamine x 3d, Folate, MVI</p>
</li>
<li>
<p>Full infection workup (CXR, UA, BCx, paracentesis) regardless of symptoms</p>
</li>
<li>
<p>Steroids: STOP-AH Trial (NEJM 2015) showed improved mortality at 28 days but not at 90 days in patients with Maddrey &gt; 32 who received steroids; the decision to treat is very nuanced and should be discussed with hepatology attending.</p>
<ul>
<li>Prednisolone 40mg daily for pts who meet above criteria</li>
<li>Contraindications to steroids include: presence of infection (must rule out first including TB, uncontrolled GI bleeding, AKI w/ Cr &gt;2.5 mg/dL)</li>
<li>The Lille score can be used to guide continuation of steroids after 7 d of therapy</li>
<li>NAC can be considered as adjunctive therapy to steroids and may decrease 30-day mortality, though has not demonstrated longer mortality benefit at 3 or 6 months</li>
</ul>
</li>
<li>
<p>Monitor on CIWA</p>
<ul>
<li>Psychiatry consultation as appropriate, consideration of medical therapy (see “Substance Use Disorders” section in psychiatry)</li>
</ul>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-ascites"><h1 id="hepatology-hepatology-ascites-ascites-and-hepatic-hydrothorax">Ascites and Hepatic Hydrothorax<a class="headerlink" href="#hepatology-hepatology-ascites-ascites-and-hepatic-hydrothorax" title="Permanent link">&para;</a></h1>
<p>Lauren Evers Carlini, Thomas Strobel</p>
<hr />
<h1 id="hepatology-hepatology-ascites-ascites">Ascites<a class="headerlink" href="#hepatology-hepatology-ascites-ascites" title="Permanent link">&para;</a></h1>
<h2 id="hepatology-hepatology-ascites-background">Background<a class="headerlink" href="#hepatology-hepatology-ascites-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Associated with a reduction in 5 year survival from 80% to 30%.</p>
</li>
<li>
<p>Most often due to portal hypertension. Less common causes include peritoneal or metastatic cancer, heart failure, tuberculosis, nephrotic syndrome, Budd-Chiari, sinusoidal obstructive syndrome (S.O.S), or complications from procedures and pancreatitis</p>
</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade</td>
<td>Definition</td>
<td>Treatment</td>
</tr>
<tr>
<td>Grade 1 Ascites</td>
<td>Only seen on imaging</td>
<td>2g Na restriction</td>
</tr>
<tr>
<td>Grade 2 Ascites</td>
<td>Moderate, symmetric abdominal distension</td>
<td>2g Na restriction, diuretics</td>
</tr>
<tr>
<td>Grade 3 Ascites</td>
<td>Marked, tense abdominal distension</td>
<td>LVP + Na restriction, diuretics (unless refractory)</td>
</tr>
</tbody>
</table>
<h2 id="hepatology-hepatology-ascites-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-ascites-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Bedside ultrasound on admission to confirm presence of ascites</p>
</li>
<li>
<p>Diagnostic paracentesis in all pts with ascites on admission mainly to rule out occult SBP</p>
<ul>
<li>Initial paracentesis or when cause of ascites is uncertain: Total Protein, serum and BF Albumin, cell count w/diff, culture</li>
<li>Subsequent/Serial paracenteses: cell count w/diff, culture, protein</li>
<li>Always inoculate culture bottles at bedside (VA does not allow bedside innoculation)</li>
</ul>
</li>
<li>
<p>See Procedure section for guidance on paracentesis. </p>
</li>
<li>
<p>Serum-ascites albumin gradient (SAAG) = serum albumin - ascites albumin.</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Protein Ascites (not serum)</td>
<td>SAAG > 1.1 g/dL (Portal HTN )</td>
<td>SAAG \&lt; 1.1 g/dL (Non-portal HTN )</td>
</tr>
<tr>
<td>\&lt; 2.5 g/dL</td>
<td>Cirrhosis</td>
<td>Nephrotic Syndrome Myxedema</td>
</tr>
<tr>
<td>> 2.5 g/dL</td>
<td>Post-hepatic portal HTN: Cardiac Ascites Budd-Chiari</td>
<td>Malignant Ascites Pancreatic Ascites TB</td>
</tr>
</tbody>
</table>
<ul>
<li>
<p>Calculate PMNs from fluid (see SBP below)</p>
</li>
<li>
<p>Other tests:</p>
<ul>
<li>Triglycerides: if fluid is milky</li>
<li>Cytology: if very concerned for peritoneal carcinomatosis. May need up to 3 separate samples (50ml or more) to be able to detect malignant cells</li>
<li>ADA: if concern for peritoneal TB</li>
<li>Hematocrit: For bloody appearing fluid (not just serosanguinous) to rule out hemoperitoneum. There needs to be a recent serum HCT for comparison.</li>
<li>Amylase: If concerned for pancreatic ascites</li>
<li>Glucose, LDH if concern about secondary peritonitis (see below)</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-ascites-management">Management<a class="headerlink" href="#hepatology-hepatology-ascites-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>2000mg sodium restriction per day for all ascites (Grade 1-3)</p>
</li>
<li>
<p>Diuretics (spironolactone and typically furosemide)</p>
<ul>
<li>Start at 100mg of spironolactone with up titration to 400mg</li>
<li>Furosemide is added if insufficient diuresis or if limited by hyperkalemia. Use more loop diuretics in patients with CKD</li>
<li>If Urine Na:K ratio &lt;1, indicates insufficient natriuresis. Can ↑ doses to a max of 400:160</li>
<li>If poor response can change to torsemide 10mg and ↑ to 40mg max (per single dose)</li>
<li>Fluid restriction usually not necessary unless serum sodium &lt;125 mmol/L</li>
</ul>
</li>
<li>
<p>Large volume paracentesis should be performed for tense ascites or refractory ascites (grade 3), regardless of serum Cr. Pts should be tapped dry with each paracentesis</p>
</li>
<li>
<p>Give 6-8g of albumin per liter of ascites removed, even if &lt; 5L</p>
</li>
<li>
<p>Target weight loss of 0.5 kg/day when diuresing to avoid renal injury</p>
</li>
<li>
<p>Discontinue NSAIDs and ACEI/ARB</p>
</li>
</ul>
<h2 id="hepatology-hepatology-ascites-refractory-ascites">Refractory Ascites:<a class="headerlink" href="#hepatology-hepatology-ascites-refractory-ascites" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Two distinctions:</p>
<ul>
<li>Diuretic-resistant: lack of response to diuretics (max spironolactone 400mg/lasix 160mg), Na restriction and rapid recurrence following paracentesis</li>
<li>Diuretic-intractable: unable to tolerate diuretic therapy 2/2 adverse drug effects (unexplained HE, AKI, K abnormalities, hypoNa, intractable muscle cramps)</li>
</ul>
</li>
<li>
<p>Management aside from liver transplant:</p>
<ul>
<li>Discontinue diuretics once refractory ascites has been established</li>
<li>Consider oral midodrine; can be especially helpful if pt is also hypotensive</li>
<li>Serial paracenteses, generally arranged OP with IR</li>
<li>Consider TIPS (trans jugular intrahepatic portosystemic shunt; has survival benefit). Following TIPS, cessation or decrease in ascites should occur in 4-6 weeks</li>
<li>Consider discontinuing beta blockers in patients with refractory ascites if sBP &lt;90, SCr &gt;1.5, or Na &lt;130</li>
</ul>
</li>
</ul>
<h1 id="hepatology-hepatology-ascites-hepatic-hydrothorax">Hepatic Hydrothorax<a class="headerlink" href="#hepatology-hepatology-ascites-hepatic-hydrothorax" title="Permanent link">&para;</a></h1>
<h2 id="hepatology-hepatology-ascites-background_1">Background<a class="headerlink" href="#hepatology-hepatology-ascites-background_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Transudative effusion, typically unilateral (75% right sided); reflects ascitic fluid that passes through defects in the diaphragm. 10% can develop without clinical ascites.</p>
</li>
<li>
<p>Present in 4-12% of cirrhotics and portends a poor prognosis (75% mortality within 90 days)</p>
</li>
</ul>
<h2 id="hepatology-hepatology-ascites-evaluation_1">Evaluation<a class="headerlink" href="#hepatology-hepatology-ascites-evaluation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Often suspected clinically, though must exclude pleural/cardiopulmonary process</p>
</li>
<li>
<p>Thoracentesis will demonstrate a transudative effusion and should be evaluated with standard pleural fluid lab tests: cell count, protein, albumin, LDH, culture</p>
<ul>
<li>Other considerations: triglycerides, amylase, hematocrit, cytology</li>
</ul>
</li>
<li>
<p>Rule out SBE which is diagnosed the same as SBP (PMN&gt;250)</p>
</li>
</ul>
<h2 id="hepatology-hepatology-ascites-management_1">Management<a class="headerlink" href="#hepatology-hepatology-ascites-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Similar management of ascites as noted above</p>
</li>
<li>
<p>AVOID chest-tube placement. associated with increased morbidity and mortality due to extensive loss of fluid, electrolytes and protein as well as increased infection risk</p>
<ul>
<li>PleurX catheters can be considered for palliation (e.g., hospice patients)</li>
</ul>
</li>
<li>
<p>Refractory Hydrothorax is defined similarly and managed similarly with serial thoracentesis or TIPS. </p>
</li>
<li>
<p>Management of spontaneous bacterial empyema is the same as in SBP (see below)</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-cirrhosis"><h1 id="hepatology-hepatology-cirrhosis-cirrhosis-overview">Cirrhosis Overview<a class="headerlink" href="#hepatology-hepatology-cirrhosis-cirrhosis-overview" title="Permanent link">&para;</a></h1>
<p>Hannah Angle, Lee Richardson </p>
<hr />
<h2 id="hepatology-hepatology-cirrhosis-background">Background<a class="headerlink" href="#hepatology-hepatology-cirrhosis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Standard 1-liner for any patient with cirrhosis:</li>
</ul>
<p><img alt="cirrhosis one-liner" src="../images/cirrhosisoneliner.png" /></p>
<ul>
<li>
<p>Example 1-liner: 65yo M with cirrhosis due to HCV decompensated by ascites and HE (MELD 25) who is listed for transplant and followed by Dr. Izzy</p>
</li>
<li>
<p>Etiology of cirrhosis: HCV&gt;HBV, EtOH, NASH, Wilson’s, hemochromatosis, A1AT deficiency, autoimmune hepatitis, PSC, PBC, congestive hepatopathy (right heart failure), medication-induced</p>
</li>
<li>
<p>Complications that cause decompensation: overt ascites (or hepatic hydrothorax), overt hepatic encephalopathy (HE), esophageal variceal hemorrhage (EVH)</p>
</li>
<li>
<p>Always calculate daily MELD-Na scores (predicts 3 mo survival based on Tbili, Cr, INR, Na)</p>
</li>
</ul>
<h2 id="hepatology-hepatology-cirrhosis-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-cirrhosis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Goals: establish cause of cirrhosis, evaluate for complications and treat accordingly, determine prognosis, and consider transplant evaluation</p>
</li>
<li>
<p>History:</p>
<ul>
<li>Symptoms suggesting decompensation: confusion, sleep disturbances, abdominal swelling, lower extremity edema, scleral icterus/jaundice, pruritus, easy bruising/bleeding (skin, mouth, GI tract), dyspnea</li>
<li>Social history: EtOH and drug use hx, date of last drink, average # of drinks/day, duration of EtOH use, prior rehab, hx of DUI, if there has been continued EtOH use despite knowledge of liver disease; these factors all impact transplant candidacy</li>
<li>Ascites: compliance with diuretics, compliance with salt restriction, frequency of paracentesis (volume removed, date of last para), h/o SBP</li>
<li>HE: compliance with lactulose, # of BMs per day, any potential triggers (see HE section)</li>
<li>GIB/EVH: hematemesis, coffee ground emesis, melena, hematochezia (duration, volume, # of bleeding episodes), last EGD (varices, banding) and colonoscopy, compliance with non-selective BBs</li>
</ul>
</li>
<li>
<p>Physical exam: asterixis, ascites, edema/anasarca, splenomegaly, muscle wasting, gynecomastia, testicular atrophy, palmar erythema, spider angiomata, scleral icterus/jaundice, petechiae/ecchymoses, caput medusa, Terry’s nails</p>
</li>
<li>
<p>Labs</p>
<ul>
<li>Initial Workup: CMP, CBC, coags, UA, HCV/HBV, Fe studies, PEth</li>
<li>Unless requested by hepatology, defer to outpatient: AFP, ANA, IgG, A1AT, ceruloplasmin, AMA (PBC), ASMA (AIH), anti-SLA (AIH), anti-LKM (AIH)</li>
</ul>
</li>
<li>
<p>Imaging:</p>
<ul>
<li>Abdominal US with duplex </li>
<li>For transplant eval, needs triple phase CT A/P (contrasted study, arterial and venous phases) or MRI abdomen with contrast</li>
</ul>
</li>
<li>
<p>Liver biopsy: gold standard for cirrhosis diagnosis but is not always needed if clinical presentation, labs, and imaging consistent with cirrhosis</p>
</li>
</ul>
<h2 id="hepatology-hepatology-cirrhosis-lab-abnormalities">Lab abnormalities<a class="headerlink" href="#hepatology-hepatology-cirrhosis-lab-abnormalities" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Hyponatremia (see hyponatremia section below)</p>
</li>
<li>
<p>Cirrhotic coagulopathy (increased INR): due to ↓ coagulation factor production</p>
</li>
<li>
<p>Thrombocytopenia: due to splenic sequestration, ↓ TPO production</p>
</li>
<li>
<p>Hypoalbuminemia: indications for 25% albumin transfusion – SBP (1.5g/kg on day 1, 1g/kg on day 3), LVP (6-8g/L of ascites), HRS (albumin challenge: 1g/kg/day with max 100 g/day x 2 days), hypoNa &lt;125 and refractory to fluid restriction</p>
</li>
</ul>
<h2 id="hepatology-hepatology-cirrhosis-management">Management<a class="headerlink" href="#hepatology-hepatology-cirrhosis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Nutrition: high protein diet, 2g Na restriction (if ascites present)</p>
<ul>
<li>Mediterranean diet for NASH</li>
<li>Fluid restriction if hyponatremic</li>
</ul>
</li>
<li>
<p>Immunizations: ensure up-to-date with HBV/HAV, PPSV23, Prevnar, Flu, COVID-19 vaccines</p>
</li>
<li>
<p>Consider consulting Addiction Psych and Social Work for pts with EtOH use disorder - can assist with arranging Intensive Outpatient Program (IOP), Alcoholics Anonymous (AA)</p>
</li>
<li>
<p>General screenings include: HCC screening (q6 months), EVH screening (see section below), monitor for other decompensations and treat accordingly, monitor MELD and consider transplant evaluation when &gt;15</p>
</li>
</ul>
<h2 id="hepatology-hepatology-cirrhosis-medication-tips">Medication Tips:<a class="headerlink" href="#hepatology-hepatology-cirrhosis-medication-tips" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Pain: 2g limit Tylenol, No NSAIDs, limit sedating medications especially with HE.</p>
<ul>
<li>Tramadol 25-50mg generally safe to use</li>
</ul>
</li>
<li>
<p>Pruritus: Sarna lotion, can spot dose antihistamines. Can discuss with pharmacist/attending about starting sertraline, cholestyramine (interacts with many medications), or rifampin.</p>
</li>
<li>
<p>Anxiety/insomnia: hydroxyzine, avoid benzodiazepines</p>
</li>
<li>
<p>If needed for EtOH withdrawal, use lorazepam (Ativan) instead of chlordiazepoxide (Librium) or diazepam (Valium) due to its shorter half life</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-coagulopathy"><h1 id="hepatology-hepatology-coagulopathy-coagulopathy-in-cirrhosis">Coagulopathy in Cirrhosis<a class="headerlink" href="#hepatology-hepatology-coagulopathy-coagulopathy-in-cirrhosis" title="Permanent link">&para;</a></h1>
<p>Garren Montgomery, John Laurenzano</p>
<hr />
<h2 id="hepatology-hepatology-coagulopathy-background">Background<a class="headerlink" href="#hepatology-hepatology-coagulopathy-background" title="Permanent link">&para;</a></h2>
<ul>
<li>The liver is responsible for production of both pro- (factor II, V, VII, IV, X, and XI) and anti-coagulants (protein C, S) in hemostasis. Factor VIII is the only one not made by the liver.</li>
<li>Thrombocytopenia is caused by splenic sequestration from portal HTN, failure to produce thrombopoietin (TPO), and bone marrow failure</li>
</ul>
<h2 id="hepatology-hepatology-coagulopathy-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-coagulopathy-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>INR/PT, and PTT are poorly reflective of bleeding risk</p>
</li>
<li>
<p>TEG screens and other measures of comprehensive coagulation in cirrhotics</p>
</li>
</ul>
<h2 id="hepatology-hepatology-coagulopathy-management">Management<a class="headerlink" href="#hepatology-hepatology-coagulopathy-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Even in bleeding, there is no need to intervene on an INR or platelet value</p>
</li>
<li>
<p>Pre-procedural FFP is not recommended, even in the presence of bleeding, but is frequently requested by different proceduralists</p>
</li>
<li>
<p>Low risk procedures (i.e., paracentesis) do not require pre-procedural blood products</p>
</li>
<li>
<p>In bleeding pts, the following are recommended per AASLD and AGA guidelines</p>
<ul>
<li>IV Vitamin K 10mg x 3 days</li>
<li>FFP: Not recommended, unless as part of a balanced transfusion effort to avoid transfusion related coagulopathy, or if a TEG screen suggests potential benefit</li>
<li>Cryoprecipitate: if fibrinogen &lt; 120</li>
<li>Platelets: No specific targets regardless of bleeding. Pre-procedurally, recommend &gt;50</li>
</ul>
</li>
<li>
<p>Appropriate DVT ppx should be given with few exceptions (plts &lt;50k, active hemorrhage)</p>
</li>
<li>
<p>For TEG transfusion recommendations are as follows:</p>
<ul>
<li>10 mg/kg FFP if R-time &gt;10 minutes</li>
<li>1u Plts if maximum amplitude &lt;55 mm</li>
<li>5u cryo if alpha angle &lt;45</li>
</ul>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-hepatic-encephalopathy"><h1 id="hepatology-hepatology-hepatic-encephalopathy-hepatic-encephalopathy-he">Hepatic Encephalopathy (HE)<a class="headerlink" href="#hepatology-hepatology-hepatic-encephalopathy-hepatic-encephalopathy-he" title="Permanent link">&para;</a></h1>
<h2 id="hepatology-hepatology-hepatic-encephalopathy-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-hepatic-encephalopathy-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Asterixis: inability to maintain stable posture; many ways to assess<ul>
<li>Check for clonus</li>
<li>Have pt “hold out hands like you are stopping traffic” (if following commands)</li>
<li>Shine light in pupil (look up video of hippus)</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade</td>
<td>Behavior change</td>
<td>Asterixis</td>
<td>Cerebral Edema in Acute Liver Failure:</td>
</tr>
<tr>
<td>I</td>
<td>Mild confusion, changes in behavior, increased sleep</td>
<td>No Asterixis</td>
<td>No cerebral edema</td>
</tr>
<tr>
<td>II</td>
<td>Moderate confusion, lethargic</td>
<td>Asterixis</td>
<td>Rare cerebral edema</td>
</tr>
<tr>
<td>III</td>
<td>Marked confusion, arousable but falls asleep, incoherent speech</td>
<td>Asterixis</td>
<td>~30% cerebral edema</td>
</tr>
<tr>
<td>IV</td>
<td>Coma</td>
<td>No Asterixis</td>
<td>~75% cerebral edema</td>
</tr>
</tbody>
</table>
<ul>
<li>Identify precipitants<ul>
<li>Infection (rule out SBP in addition to CXR, BCx, UA/Cx
    regardless of sxs),</li>
<li>Medication non-adherence (lactulose)</li>
<li>GI bleed (perform rectal exam and observe hgb trend)</li>
<li>Over-diuresis resulting in dehydration, lyte abnormalities
    (especially hypoK)</li>
<li>Sedatives/benzo/opiate administration (UDS)</li>
<li>Post-TIPS, other large but spontaneous shunt (imaging can be
    useful to determine if there is a shunt, and if an intervention
    is feasible on such a shunt).</li>
</ul>
</li>
<li>Ammonia (NH <sub>3</sub> ) levels do not play a role in the acute
    management of hepatic encephalopathy; if pt has AMS or HE, you will
    treat the HE regardless</li>
<li>Arterial NH <sub>3</sub> is used in acute liver failure for
    <strong>prognostication</strong> (not for management)</li>
</ul>
<h2 id="hepatology-hepatology-hepatic-encephalopathy-management">Management<a class="headerlink" href="#hepatology-hepatology-hepatic-encephalopathy-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Always determine precipitant and treat underlying condition</p>
</li>
<li>
<p>Lactulose 30mL TID initially</p>
<ul>
<li>Titrate dose to at least 4 BMs daily, avoid excessive stool
    output which may exacerbate HE due to dehydration and
    electrolyte abnormalities</li>
<li>Consider lactulose enemas vs DHT placement if pt unable to
    tolerate PO<ul>
<li>DHT are <strong>not</strong> contraindicated in patients with esophageal
    varices, but should be avoided in patients with recent
    hemorrhage or banding</li>
</ul>
</li>
<li>Add Rifaximin after the second episode of HE, or if failure to
    respond to lactulose<ul>
<li>Frequently requires prior auth for OP approval and is
    expensive</li>
</ul>
</li>
</ul>
</li>
<li>Lactulose is generally continued indefinitely after first episode of
    HE, though discontinuation can be considered if predisposing factors
    (recurrent infection, EVH, EtOH use) have resolved</li>
</ul></section><section class="print-page" id="hepatology-hepatology-hepatocellular-carcinoma"><h1 id="hepatology-hepatology-hepatocellular-carcinoma-hepatocellular-carcinoma-hcc">Hepatocellular Carcinoma (HCC)<a class="headerlink" href="#hepatology-hepatology-hepatocellular-carcinoma-hepatocellular-carcinoma-hcc" title="Permanent link">&para;</a></h1>
<p>Julie Cui, Lee Richardson </p>
<hr />
<h2 id="hepatology-hepatology-hepatocellular-carcinoma-background">Background<a class="headerlink" href="#hepatology-hepatology-hepatocellular-carcinoma-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Pts with HCV cirrhosis are at greatest risk (incidence 2-4% per year)</p>
</li>
<li>
<p>In chronic HBV and NASH, pts can develop HCC without having cirrhosis</p>
</li>
</ul>
<h2 id="hepatology-hepatology-hepatocellular-carcinoma-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-hepatocellular-carcinoma-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Regular screening in pts with cirrhosis (or chronic HBV without cirrhosis) for HCC</p>
<ul>
<li>RUQ U/S q6mo (with or without AFP)</li>
<li>Routine screening with CT or MRI is not recommended</li>
</ul>
</li>
<li>
<p>Options If U/S not satisfactory:</p>
<ul>
<li>CT A/P w/contrast, in comments specify triple phase for HCC screening</li>
<li>MRI, specify Gadovist (preferred contrast agent)</li>
<li>Contrast-enhanced ultrasound</li>
</ul>
</li>
<li>
<p>AFP trend is more useful than one value in time, though AFP &gt;20 should prompt multiphase CT or MRI for further evaluation</p>
</li>
<li>
<p>Diagnosis can be made either by imaging (most common) or biopsy (rare)</p>
</li>
<li>Triple phase CT demonstrates strong early uptake in arterial phase, with subsequent wash-out in portal-venous phase</li>
<li>If diagnosis remains unclear: can surveillance imaging or biopsy</li>
<li>LI-RADS system notes risk of malignancy based on imaging characteristics</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>LI-RADS</td>
<td>What does it mean?</td>
<td>What do we do?</td>
</tr>
<tr>
<td>LR-1 to LR-2</td>
<td>Definitely/Probably benign</td>
<td>Routine surveillance, consider diagnostic imaging within 6 mos</td>
</tr>
<tr>
<td>LR-3 to LR-4</td>
<td>Indeterminate/Probably HCC</td>
<td>Repeat or alternative diagnostic imaging in 3-6 mos. Consider Bx for LI-RADS 4</td>
</tr>
<tr>
<td>LR-5</td>
<td>Definitely HCC</td>
<td>Plan treatment as noted below</td>
</tr>
<tr>
<td>LR-M</td>
<td>Cancer but may not be HCC</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<h2 id="hepatology-hepatology-hepatocellular-carcinoma-management">Management<a class="headerlink" href="#hepatology-hepatology-hepatocellular-carcinoma-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Lesions that meet Milan criteria can qualify for MELD exception points and are considered transplant candidates</p>
<ul>
<li>This accounts for pts with minimal synthetic dysfunction (and therefore low MELD)</li>
</ul>
</li>
<li>
<p>Milan criteria:</p>
<ul>
<li>Single tumor with diameter &gt;2cm but &lt;5 cm, no more than 3 tumors, each &lt;3 cm</li>
<li>No signs of extra-hepatic involvement or vascular invasion</li>
</ul>
</li>
<li>
<p>Liver transplant is definitive treatment, although resection can also be curative (favored in pts with early cirrhosis i.e. Child Pugh A)</p>
</li>
<li>Locoregional therapies: Pts with unresectable disease, or who are not surgical candidates</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy</td>
<td>Details</td>
</tr>
<tr>
<td>Radiofrequency ablation</td>
<td>If in a favorable location and size, IR can percutaneously ablate with a large needle that emits microwave frequencies</td>
</tr>
<tr>
<td>Trans-arterial chemoembolization (TACE)</td>
<td>Chemotherapeutic agents injected into the tumor to occlude the feeding blood supply to the area.</td>
</tr>
<tr>
<td>Trans-arterial radioembolization (TARE)</td>
<td>Like TACE, though radioactive compound (i.e. Y-90) used to occlude the feeding blood supply.</td>
</tr>
<tr>
<td>Stereotactic body Radiation Therapy (SBRT)</td>
<td>Radiation therapy: can be used as an alternative to ablation and is generally performed in those meeting Milan criteria</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>For metastatic disease</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hepatology-hepatology-hepatorenal-syndrome"><h1 id="hepatology-hepatology-hepatorenal-syndrome-hepatorenal-syndrome">Hepatorenal Syndrome<a class="headerlink" href="#hepatology-hepatology-hepatorenal-syndrome-hepatorenal-syndrome" title="Permanent link">&para;</a></h1>
<p>Garren Montgomery</p>
<hr />
<h2 id="hepatology-hepatology-hepatorenal-syndrome-background">Background<a class="headerlink" href="#hepatology-hepatology-hepatorenal-syndrome-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Portal HTN causes shear stress on portal vessels -&gt; endothelium release of vasodilators -&gt; splanchnic vasodilation and reduced effective blood volume (decreased MAP) -&gt; RAAS activation -&gt; sodium and water retention and severe renal vasoconstriction</p>
</li>
<li>
<p>Bacterial translocation (as seen in SBP) -&gt; increased circulating pro-inflammatory cytokines -&gt; splanchnic vasodilation</p>
</li>
<li>
<p>Definitions:</p>
<ul>
<li>HRS-AKI (formerly type I HRS): Rise in Cr ≥0.3 within 48h, rise in Cr ≥50% within 7 days, OR UOP &lt;0.5 mL/kg/hr for 6 hours</li>
<li>HRS-NAKI (“non-AKI”) (formerly type II HRS):</li>
<li>HRS-AKD: eGFR&lt;60 for &lt;3 months in absence of other structural causes OR % rise in Cr ≤50% using last available Cr over last 3 months as baseline</li>
<li>HRS-CKD: eGFR&lt;60 for ≥3 months in absence of other structural causes</li>
</ul>
</li>
<li>
<p>Diagnostic Criteria</p>
<ul>
<li>Diagnosis of AKI (see above) without other cause (see below</li>
<li>No response or inadequate response at 48 hrs after volume expansion with albumin and withdrawal of diuretics</li>
<li>Absence of proteinuria (&lt;500 mg/d), absence of hematuria (&lt;50 RBCs per HPF), normal renal ultrasound (exclude if patient has known CKD</li>
<li>Suggestion of renal vasoconstriction with FeNa &lt;0.2, FeUrea &lt;20 (most sensitive diagnostic measure). UNa &lt;20 is suggestive but not diagnostic given baseline sodium avidity in cirrhosis and inability to calculate FeNa</li>
<li>Cut off for ATN in cirrhosis is a FeNa &gt;0.5, rather than 1 in the general population</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-hepatorenal-syndrome-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-hepatorenal-syndrome-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Step 1: Exclude other obvious causes of renal injury such as hypovolemia or ATN</p>
<ul>
<li>Common precipitants of AKI: infection, overdiuresis, GI bleeding, recent LVP without subsequent volume expansion, nephrotoxic drugs/NSAIDs</li>
<li>Workup: BMP, UA with microscopy, urine electrolytes (FeNa, FeUrea), urine protein/Cr ratio, renal ultrasound (to assess for chronicity), diagnostic para to rule out SBP</li>
</ul>
</li>
<li>
<p>Step 2: Diuretic cessation/albumin challenge</p>
<ul>
<li>STOP all diuretics, beta blockers, NSAIDs, ACE/ARBs, anti-hypertensives, vasodilators, nephrotoxins</li>
<li>START volume expansion with albumin 1g/kg/day (up to a max of 100 g/day) x2 days</li>
</ul>
</li>
<li>
<p>Step 3: Diagnosis of HRS</p>
<ul>
<li>If no other clear cause of AKI is identified and SCr has not improved after 48 hours of diuretic cessation and volume expansion, proceed promptly to vasopressor treatment</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-hepatorenal-syndrome-management">Management<a class="headerlink" href="#hepatology-hepatology-hepatorenal-syndrome-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Pharmacologic therapies (in order of preference):<ul>
<li>Terlipressin + albumin. Most effective combo based on clinical trials, NOW AVAILABLE (ongoing clinical trial at VUMC)</li>
<li>Norepinephrine + albumin (25-50 g/day)<ul>
<li>Most likely to be used at VUMC, requires central access (PICC vs triple lumen) but can be administered on stepdown unit</li>
<li>Guidelines recommend NE to be dosed at 0.5-3 mg/hr. Would ask fellow, attending or pharmacist for baseline. VUMC protocol for ICU and stepdown:<ul>
<li>Start NE gtt at 3mcg/min. If UOP is &lt;200 or MAP &lt;10mm Hg from baseline, increase by 3 mcg/min every 4 hours</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Continue to hold diuretics. LVP is still generally considered safe even in HRS if indicated by tense ascites (account for albumin repletion from LVP and HRS protocol). This can be attending specific and would confirm prior to performing</p>
</li>
<li>
<p>Therapy is generally continued until HRS is reversed or the hepatology attending deems it refractory to medical treatment</p>
</li>
<li>
<p>Patients with HRS-NAKI (formerly type II HRS) may respond to the above therapies, but recurrence of renal dysfunction after withdrawal of vasoconstrictors is the norm and thus current guidelines do not recommend them for this scenario</p>
</li>
<li>
<p>RRT: Dialysis can be considered for those who fail to respond to pharmacologic therapy, particularly ONLY as a bridge to liver transplant. Decision to initiate should be individualized</p>
</li>
<li>
<p>Liver transplant: The best and most definitive treatment regardless of response to pharmacologic therapy</p>
</li>
</ul>
<h2 id="hepatology-hepatology-hepatorenal-syndrome-simultaneous-liver-kidney-transplant">Simultaneous liver-kidney transplant:<a class="headerlink" href="#hepatology-hepatology-hepatorenal-syndrome-simultaneous-liver-kidney-transplant" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>HRS often resolves with LT alone. Indications for kidney transplant are usually for patients with severe chronic renal dysfunction or on RRT. Must consult transplant nephrology.</p>
</li>
<li>
<p>Criteria for SLKT:</p>
<ul>
<li>eGFR &lt;60 for &gt;30 days AND latest eGFR &lt;30</li>
<li>eGFR &lt;25 for &gt;6 consecutive weeks with a documented eGFR q7 days</li>
<li>Metabolic syndromes and polycystic disease</li>
</ul>
</li>
<li>
<p>Can qualify for safety net kidney transplant after liver transplant if eGFR &lt;20 2-12 months post-operatively (would be at higher priority than the rest of the kidney transplant list)</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-hyponatremia-cirrhosis"><h1 id="hepatology-hepatology-hyponatremia-cirrhosis-hyponatremia-in-cirrhosis">Hyponatremia in Cirrhosis<a class="headerlink" href="#hepatology-hepatology-hyponatremia-cirrhosis-hyponatremia-in-cirrhosis" title="Permanent link">&para;</a></h1>
<p>John Laurenzano</p>
<hr />
<h2 id="hepatology-hepatology-hyponatremia-cirrhosis-background">Background<a class="headerlink" href="#hepatology-hepatology-hyponatremia-cirrhosis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Most commonly is hypervolemic hyponatremia, driven by release of ADH from decreased effective arterial blood volume (EABV) in the setting of portal hypertension</p>
</li>
<li>
<p>Hyponatremia in cirrhosis is a marker of advanced disease and is associated with higher rates of SBP, HE, HRS, and mortality. </p>
</li>
</ul>
<h2 id="hepatology-hepatology-hyponatremia-cirrhosis-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-hyponatremia-cirrhosis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Standard evaluation of hyponatremia, including Uosm, Sosm, UNa to rule out competing processes (e.g. beer potomania) </li>
</ul>
<h2 id="hepatology-hepatology-hyponatremia-cirrhosis-management">Management<a class="headerlink" href="#hepatology-hepatology-hyponatremia-cirrhosis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Discontinue anti-hypertensives (including beta blockers) in patients with ascites and hyponatremia. Hold diuretics when Na &lt;125 </p>
</li>
<li>
<p>Fluid restriction is recommended only in patients with Na &lt;125. Restriction is generally effective at 1-1.5L and must be less than daily urine output to increase free water excretion </p>
</li>
<li>
<p>Replete potassium to 4.0, as potassium is as osmotically active and results in shifts in extra and intracellular fluids which lead to a net increase in serum sodium. </p>
</li>
<li>
<p>25% albumin infusion (1g/kg split into BID dosing), has been shown to increase serum sodium and have higher rates of hyponatremia resolution at 30 days </p>
</li>
<li>
<p>Other treatment considerations include vasopressors, vaptans, urea tabs</p>
</li>
<li>
<p>Salt tabs should not be used to raise serum Na due to worsening hypervolemia</p>
</li>
<li>
<p>Nephrology should be consulted if not improved after 48 hours</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-liver-transplantation"><h1 id="hepatology-hepatology-liver-transplantation-liver-transplant-lt-workup">Liver Transplant (LT) Workup<a class="headerlink" href="#hepatology-hepatology-liver-transplantation-liver-transplant-lt-workup" title="Permanent link">&para;</a></h1>
<p>Lauren Evers Carlini</p>
<hr />
<h2 id="hepatology-hepatology-liver-transplantation-background">Background<a class="headerlink" href="#hepatology-hepatology-liver-transplantation-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Model for End-stage Liver Disease (MELD-Na) score: initially developed to predict survival following TIPS placement, though is now used to objectively rank patients in terms of priority for liver transplant (LT)<ul>
<li>Factors in total bilirubin, creatinine, and INR. An updated version,
the MELD-Na score, factors in the serum Na as well.</li>
<li>Exception points given for complications like HCC and
    hepatopulmonary syndrome (HPS), leading to score in mid to high
    20’s even if biologic MELD is low</li>
</ul>
</li>
<li>Listing a patient for LT is determined by a multidisciplinary transplant
    committee<ul>
<li>Acute liver failure pts take precedence over decompensated
    cirrhosis pts for LT</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications</td>
<td>Contraindications*</td>
</tr>
<tr>
<td>Cirrhosis with MELD ≥ 15 or evidence of decompensation (ascites, variceal bleed, HE, HPS, portopulmonary HTN)</td>
<td>Ongoing substance abuse (must have documented abstinence ≥ 3 mos); some special considerations for pts who did not know of EtOH hepatitis or EtOH use d/o but highly variable</td>
</tr>
<tr>
<td>Acute Liver Failure</td>
<td>Untreated or recurrent malignancy</td>
</tr>
<tr>
<td>HCC that meets Milan criteria</td>
<td>Active Infection, AIDS</td>
</tr>
<tr>
<td>Pts with early hilar cholangio-carcinoma that meets specific criteria</td>
<td>Documented history of medical noncompliance</td>
</tr>
<tr>
<td>Other rare dz (e.g., familial amyloid polyneuropathy or hyperoxaluria)</td>
<td>Lack of Adequate social support</td>
</tr>
<tr>
<td></td>
<td>Anatomic Contraindications; Chronic cardiac/pulmonary conditions that significantly increase perioperative risk (e.g., severe pulm HTN)</td>
</tr>
<tr>
<td>* Advanced age (&gt;70) is not in itself a contraindication but candidates > 70 should be almost free of comorbidities to be considered for LT*</td>
<td></td>
</tr>
</tbody>
</table>
<h2 id="hepatology-hepatology-liver-transplantation-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-liver-transplantation-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Abdominal CT (triple phase) or MRI (multiphase with contrast) to
    evaluate for hepatic malignancy and vascular anatomy</p>
</li>
<li>
<p>Infectious workup: TB testing, HIV, RPR, VZV, CMV, EBV, and
    Hepatitis A, B, and C.</p>
</li>
<li>
<p>Cardiac evaluation: EKG and TTE with bubble are required. Functional testing: CT coronaries with fractional flow, invasive angiography and intervention may be necessary depending on pre-test probability. </p>
</li>
<li>
<p>PFT’s, carotid ultrasound, panorex, etc. </p>
</li>
<li>
<p>Appropriate cancer screenings (colonoscopy, pap smear, mammogram, and PSA
    if applicable)</p>
</li>
<li>
<p>DEXA scan</p>
</li>
<li>
<p>Certification of completion of intensive outpatient program (IOP)
    for substance abuse</p>
</li>
<li>
<p>Evaluation by hepatobiliary surgical team after obtaining cross
    sectional imaging</p>
</li>
<li>
<p>Psychosocial evaluation (consult Psychiatry, social work)</p>
</li>
<li>
<p>Current VUMC policy: pts should be abstinent from alcohol no less than 3-6 months, although exceptions may be m ade for early liver transplant based on a very strict protocol. Discuss exception criteria iwth attending if suspect patient unlikely to survive hospitalization without transplant </p>
</li>
<li>
<p>Both living and deceased donor transplant are offered at VUMC. Donor
    evaluation, however, cannot be started before the potential
    recipient is deemed a candidate</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-medication-pearls"><h1 id="hepatology-hepatology-medication-pearls-medication-pearls">Medication Pearls<a class="headerlink" href="#hepatology-hepatology-medication-pearls-medication-pearls" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross Cover Pearls – Garren Montgomery</td>
</tr>
</tbody>
</table>
<p>Pain:</p>
<ul>
<li>General rule is to avoid opioids in cirrhosis as they are largely
    metabolized by the liver and can cause confusion, which may be
    mistakenly attributed to HE</li>
<li>Alternative options:<ul>
<li>Tylenol (up to 2g/day)</li>
<li>Tramadol 50mg BID or 25 mg q8h generally safe if not responsive
    to Tylenol</li>
<li>Increased risk of seizures and serotonin syndrome (avoid if on
    SSRI/SNRI)</li>
<li>Lidocaine patches for localized pain</li>
<li>Gabapentin, with added benefit of treating alcohol use d/o (up
    to 1200mg daily)</li>
<li>Pregabalin 50mg BID</li>
<li>Nortriptyline 10 mg qHS</li>
</ul>
</li>
</ul>
<p>Anxiety:</p>
<ul>
<li>Benzo’s should generally be avoided due to their risk for causing
    confusion<ul>
<li>If needed for EtOH withdrawal, use lorazepam (Ativan) instead of
    chlordiazepoxide (librium) or diazepam (valium) due to its
    shorter half life</li>
</ul>
</li>
<li>Antihistamines such as Hydroxyzine (Atarax) are preferred for prn</li>
</ul>
<p>Pruritis:</p>
<ul>
<li>Cholestyramine 4g/day titrated up to 4 times daily = 16g/day max<ul>
<li>SE: poor taste, bloating, constipation, GI distress</li>
<li>very important NOT to dose around other medications given
    potential for interaction/blocking absorption</li>
</ul>
</li>
<li>Sertraline: 50-100 mg/day</li>
<li>Antihistamines: Benadryl, doxepin 10 mg qHS</li>
<li>Topicals such as sarna lotion</li>
<li>Rifampin 150-300 mg/day; second-line agent<ul>
<li>Side effects: N/V/D, HA, flushing, thrombocytopenia, turns body
    fluids orange</li>
<li>Be VERY mindful of potential drug/drug interactions with
    Rifampin (there are many); would talk to hepatology
    attending/pharmacist before initiating</li>
</ul>
</li>
</ul>
<p>Insomnia:</p>
<ul>
<li>Melatonin preferred; Hydroxyzine (12.5mg-25mg); Trazodone (100mg);
    <strong>avoid benzo's</strong></li>
</ul></section><section class="print-page" id="hepatology-hepatology-nash-and-nafld"><h1 id="hepatology-hepatology-nash-and-nafld-nash-and-nafld">NASH and NAFLD<a class="headerlink" href="#hepatology-hepatology-nash-and-nafld-nash-and-nafld" title="Permanent link">&para;</a></h1>
<p>John Laurenzano</p>
<hr />
<h2 id="hepatology-hepatology-nash-and-nafld-background">Background<a class="headerlink" href="#hepatology-hepatology-nash-and-nafld-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Non-alcoholic fatty liver disease (NAFLD): presence of hepatic steatosis in the absence of secondary causes (e.g, EtOH)</p>
</li>
<li>
<p>Non-alcoholic steatohepatitis (NASH): evidence of active inflammation in conjunction with steatosis (elevated liver enzymes or evidence on bx)</p>
</li>
<li>
<p>Strong association with metabolic syndrome, T2DM, HTN, obesity, prior cholecystectomy</p>
</li>
<li>
<p>Generally asymptomatic</p>
</li>
<li>
<p>Considered to be a common cause of cryptogenic cirrhosis</p>
</li>
</ul>
<h2 id="hepatology-hepatology-nash-and-nafld-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-nash-and-nafld-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>NASH manifests with elevated liver enzymes, typically 2-5x the ULN, in a roughly 1:1 ratio (as opposed to alcoholic steatohepatitis), though ALT may be higher than AST</p>
</li>
<li>
<p>NAFLD is asymptomatic and frequently found incidentally via imaging</p>
</li>
<li>
<p>Exclusion of alternative causes and comorbid liver conditions: HCV, HBV, EtOH</p>
</li>
<li>
<p>Note: Ferritin is frequently elevated, though not to the extent of hemochromatosis. Low level auto-antibodies are also frequently present</p>
</li>
<li>
<p>Can be diagnosed based on imaging alone (and frequently is)</p>
<ul>
<li>
<p>Ultrasound is used most frequently, though MRI and CT also are acceptable; use risk scores to determine the risk of advanced fibrosis and identify those who would benefit from biopsy</p>
<ul>
<li>Fibrosis-4 (FIB 4) score</li>
<li>NAFLD fibrosis score</li>
</ul>
</li>
<li>
<p>More accurate, non-invasive fibrosis assessments can be done using elastography which can be vibration based (fibroscan), ultrasound based (sheer-wave), or MR-based</p>
<ul>
<li>Available at VUMC and can be ordered by anyone. Insurance will not cover MRE if BMI &lt;35</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-nash-and-nafld-management">Management<a class="headerlink" href="#hepatology-hepatology-nash-and-nafld-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Aggressive risk factor modification and management of comorbidities (HLD, HTN, T2DM)</p>
</li>
<li>
<p>Weight loss: Mediterranean diet&gt;low fat diet (dose dependent improvement)</p>
</li>
<li>
<p>No specific medications are FDA approved currently</p>
<ul>
<li>Pioglitazone has shown benefit in pts with T2DM and NASH</li>
<li>Vitamin E has shown benefit in pts without T2DM and proven NASH</li>
<li>Ongoing studies for SGLT-2i and GLP-1ra; some promise indicated for the latter</li>
</ul>
</li>
<li>
<p>While bariatric surgery is not a specific indication for NASH/NAFLD, increasing evidence demonstrates resolution of NASH and fibrosis in pts with clinically significant weight loss</p>
</li>
<li>
<p>Referral to the surgical weight loss clinic should be considered in any patient who meets obesity guidelines for bariatric surgery (BMI &gt;40, or &gt;35 with metabolic comorbidities)</p>
</li>
</ul>
<h2 id="hepatology-hepatology-nash-and-nafld-additional-information">Additional Information<a class="headerlink" href="#hepatology-hepatology-nash-and-nafld-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Statins: should be used for HLD in pts with NASH, NAFLD and NASH cirrhosis</p>
</li>
<li>
<p>Statin use in decompensated NASH cirrhosis is controversial, and they are less likely to derive benefit given overall poor prognosis. There is an increased risk of rhabdomyolysis in pts with acute on chronic liver failure and are considered contraindicated</p>
</li>
<li>
<p>Metformin is safe and may have a survival benefit in patients with diabetes and cirrhosis. Discontinue only in those who have increased risk for lactic acidosis (renal impairment and significant EtOH). Sulfonylureas are generally avoided.</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-portal-vein-thrombosis"><h1 id="hepatology-hepatology-portal-vein-thrombosis-portal-vein-thrombosis-pvt">Portal Vein Thrombosis (PVT)<a class="headerlink" href="#hepatology-hepatology-portal-vein-thrombosis-portal-vein-thrombosis-pvt" title="Permanent link">&para;</a></h1>
<p>John Laurenzano</p>
<hr />
<h2 id="hepatology-hepatology-portal-vein-thrombosis-background">Background<a class="headerlink" href="#hepatology-hepatology-portal-vein-thrombosis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Portal Vein Thrombosis (PVT) can worsen decompensation (i.e. variceal hemorrhage), however, worsening portal HTN -&gt; more sluggish flow -&gt; increased risk PVT</li>
</ul>
<h2 id="hepatology-hepatology-portal-vein-thrombosis-presentation">Presentation<a class="headerlink" href="#hepatology-hepatology-portal-vein-thrombosis-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Often identified asymptomatically on U/S, but can be identified by new or worsening decompensation of portal HTN</li>
<li>Variceal hemorrhage is the most common decompensating event associated with PVT</li>
<li>Intestinal ischemia (abdominal pain, hematochezia) from PVT is exceedingly rare but associated with significant morbidity and mortality</li>
</ul>
<h2 id="hepatology-hepatology-portal-vein-thrombosis-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-portal-vein-thrombosis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>RUQ U/S with doppler<ul>
<li>Once identified, should be further assessed with triple phase CT or MRI with Gadovist contrast to exclude HCC with tumor thrombus</li>
</ul>
</li>
<li>
<p>Pts with newly identified PVT should undergo EGD to evaluate for high-risk varices, both for diagnostic and therapeutic considerations</p>
</li>
<li>
<p>PVT in pts without cirrhosis should prompt evaluation for hypercoagulable disorders</p>
</li>
</ul>
<h2 id="hepatology-hepatology-portal-vein-thrombosis-management">Management<a class="headerlink" href="#hepatology-hepatology-portal-vein-thrombosis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Start anticoagulation if acute thrombus occludes &gt;50% of main portal vein, &lt;50% but extends into SMV, thrombus is symptomatic, or patient is a transplant candidate (irrespective of size). Requires discussion with attending/transplant team.</p>
<ul>
<li>Anticoagulation options: warfarin, LMWH, or DOAC</li>
<li>DOAC’s are safe in Childs Class A, can be used with caution in Childs B, and are contraindicated in Childs C</li>
</ul>
</li>
<li>
<p>Pts with chronic occlusive PVT (&gt;6 mos) or with cavernous transformation with collaterals do not generally benefit from anticoagulation</p>
</li>
<li>
<p>Pts with high-risk varices should undergo endoscopic management or be on NSBB for prophylaxis for variceal hemorrhage, as noted above</p>
</li>
<li>
<p>TIPS with portal vein recanalization has recently emerged as a therapeutic modality for PVT</p>
</li>
<li>
<p>Pts should undergo follow up intermittently with ultrasound to assess for recanalization. AC may be stopped if there is failure to recanalize.</p>
</li>
<li>
<p>If pts are not candidates for AC, they'll simply be treated for complications of portal HTN</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-post-liver-transplant-management"><h1 id="hepatology-hepatology-post-liver-transplant-management-post-liver-transplant-management">Post-Liver Transplant Management<a class="headerlink" href="#hepatology-hepatology-post-liver-transplant-management-post-liver-transplant-management" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post Liver Transplant Management – Lauren Evers Carlini, Gabe Sandoval</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Immunosuppression (IS): pts typically start out on 2-3
    immunosuppression medications, including a calcineurin inhibitor
    (CNI, tacrolimus or cyclosporine), a glucocorticoid (prednisone),
    and potentially another agent (i.e., mycophenolate mofetil).
    Decreased over time, as long as there is no evidence of rejection</li>
<li>ID ppx:  PJP (trimethoprim-sulfamethoxazole), CMV if at risk for
    reactivation (valganciclovir or ganciclovir; highest risk is D+/R-;
    typically 3-6 months based on when ppx is stopped), and candida
    (fluconazole) for weeks to months after LT.</li>
<li>Screening for malignancy: post-transplant pts are at increased risk
    of malignancy due to IS. Pts must follow all standard cancer
    screening guidelines, as well as annual dermatology evaluation for
    skin cancers (high incidence of SCC).</li>
<li>Avoid live vaccines after transplantation; pts are given a list and
    in general admitted pts are not given vaccinations in house.</li>
<li>When admitted, LT recipients should have home IS meds continued
    (unless otherwise advised by attending or transplant pharmacist),
    with daily trough levels. See below.</li>
<li>Hepatology should always be consulted for these pts</li>
</ul>
<p>Transplant medications</p>
<p>Tacrolimus:</p>
<ul>
<li>Mainstay of post-transplant IS</li>
<li>Doses should be timed for 0600/1800 while admitted, regardless of
    home schedule</li>
<li>Pts need tacro levels QAM at 0500 while hospitalized(specific order
    in Epic);</li>
<li>Goal levels (generally):<ul>
<li>0-3 months post-transplant: 8-10 ng/mL</li>
<li>3-12 months: 6-8 ng/mL</li>
<li>>12 months: 3-6 ng/mL</li>
</ul>
</li>
<li>Side effects: Nephrotoxicity, neurotoxicity (HA, confusion, seizure,
    paresthesia’s, tremor; more common w/tacrolimus vs cyclosporine),
    N/V/D, hyperkalemia, hypomagnesemia, hyperglycemia, hyperuricemia,
    alopecia, HTN, HLD</li>
<li>Note: transplant pharmacists (on weekdays) are your go-to resource
    for adjusting dosage and goal levels; you will not be making these
    decisions independently</li>
</ul>
<p>Cyclosporine:</p>
<ul>
<li>Used in pts transplanted before tacrolimus was available, pts unable
    to tolerate tacrolimus, or those with a contraindication to
    tacrolimus</li>
<li>Doses should be timed for 0600/1800 while admitted, regardless of
    home schedule</li>
<li>Pts need cyclosporine levels QAM at 0500 while hospitalized
    (specific order in Epic)</li>
<li>Goal levels (generally):<ul>
<li>0-3 months post-transplant: 150-200 ng/mL</li>
<li>3-6 months: 150 ng/mL</li>
<li>6-12 months: 100 ng/mL</li>
<li>>12 months: 60-100 ng/mL</li>
</ul>
</li>
<li>Side effects: Nephrotoxicity, hypomagnesemia, hyperglycemia,
    neurotoxicity (HA, tremors, paresthesia, seizure), gingival
    hyperplasia, hirsutism, malignancy (lymphoma), HTN, HLD</li>
</ul></section><section class="print-page" id="hepatology-hepatology-sbp"><h1 id="hepatology-hepatology-sbp-spontaneous-bacterial-peritonitis-sbp">Spontaneous Bacterial Peritonitis (SBP)<a class="headerlink" href="#hepatology-hepatology-sbp-spontaneous-bacterial-peritonitis-sbp" title="Permanent link">&para;</a></h1>
<p>Patricia Checinski</p>
<hr />
<h1 id="hepatology-hepatology-sbp-background">Background<a class="headerlink" href="#hepatology-hepatology-sbp-background" title="Permanent link">&para;</a></h1>
<ul>
<li>
<p>Infection of ascitic fluid without evidence of a surgical intra-abdominal source</p>
</li>
<li>
<p>Presentation: fever, abdominal pain, encephalopathy, renal failure, acidosis, and/or leukocytosis</p>
</li>
</ul>
<h1 id="hepatology-hepatology-sbp-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-sbp-evaluation" title="Permanent link">&para;</a></h1>
<ul>
<li>
<p>Any pt with cirrhosis and ascites who is admitted should have diagnostic paracentesis to rule out SBP. Delaying paracentesis &gt; 12 hours is associated with a 2.7-fold increase in mortality.</p>
</li>
<li>
<p>Obtain cell count with diff.</p>
<ul>
<li>Calculate the PMNs: total nucleated cells x % neutrophils.</li>
<li>PMNs &gt; 250 cells is diagnostic of SBP. If there are greater than 100k RBCs, you should correct for them: for every 250 RBCs, subtract 1 PMN</li>
</ul>
</li>
<li>
<p>A positive ascitic bacterial culture with PMN &lt;250 is called bacterascites and asymptomatic patients should NOT receive antibiotics. You will also frequently see culture-negative SBP (neutrocytic ascites) which SHOULD be treated (see below).</p>
</li>
</ul>
<h2 id="hepatology-hepatology-sbp-management">Management<a class="headerlink" href="#hepatology-hepatology-sbp-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Immediately start empiric antibiotics</p>
</li>
<li>
<p>Guidelines recommend cefotaxime IV 2gm q8 hours x 5 days, but we commonly use ceftriaxone IV 2g q24h for 5-7 days at VUMC and Nashville VA.</p>
<ul>
<li>Most common culprits (E. coli, Klebsiella, streptococcal species, staphylococcal species)</li>
<li>If SBP developed with recent hospital admission (90 days), recent exposure to BSA, diagnosed &gt;48 hours of admission, or with sepsis, consider zosyn or meropenem to cover MDROs</li>
</ul>
</li>
<li>
<p>IV albumin 1.5 g/kg on day 1 and 1g/kg on day 3</p>
</li>
<li>
<p>Discontinue beta-blockers once SBP develops and do not restart until SBP is completely treated, Na &gt;130, and no AKI</p>
</li>
<li>
<p>PPI’s ↑ risk for SBP in pts with cirrhosis, and should be reviewed for appropriateness</p>
</li>
<li>
<p>Repeat diagnostic paracentesis two days after antibiotics initiated</p>
<ul>
<li>If &lt;25% decrease in PMNs, antibiotics should be broadened and consider secondary bacterial peritonitis</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-sbp-prophylaxis">Prophylaxis<a class="headerlink" href="#hepatology-hepatology-sbp-prophylaxis" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>GI bleed: ceftriaxone 1g daily ciprofloxacin 500mg BID (preferred) or Bactrim one DS tablet BID x 5-7 days</p>
</li>
<li>
<p>Outpatient lifelong ppx, indications:</p>
<ul>
<li>Prior SBP</li>
<li>Ascitic protein &lt;1.5 AND<ul>
<li>Child Pugh &gt;9 and bilirubin &gt;3 OR</li>
<li>Renal dysfunction (Cr &gt;1.2, Na &lt;130, or BUN &gt;25)</li>
</ul>
</li>
<li>Preferred: Bactrim DS tab daily or ciprofloxacin 500mg daily</li>
<li>Alternatives: cefdinir 300mg daily, Augmentin 875/125 daily</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-sbp-if-suspicion-is-high-for-secondary-bacterial-peritonitis">If suspicion is high for secondary bacterial peritonitis:<a class="headerlink" href="#hepatology-hepatology-sbp-if-suspicion-is-high-for-secondary-bacterial-peritonitis" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Examine serum-ascites albumin gradient (SAAG). SBP develops in pts with portal hypertension, defined by SAAG &gt; 1.1 g/dL. SBP is unlikely if SAAG is &lt; 1.1 g/dL.</p>
</li>
<li>
<p>While not particularly sensitive, an ascitic leukocyte count of 5-10k should prompt consideration of secondary peritonitis</p>
</li>
<li>
<p>Amylase from fluid can also be helpful to point towards pancreatic ascites, while bilirubin can indicate gallbladder perforation. Peritoneal fluid CEA and alkaline phosphatase can additionally help identify hollow viscus injury.</p>
</li>
<li>
<p>Evaluate with cross-sectional imaging and surgical consultation as appropriate</p>
</li>
<li>
<p>Runyon’s Criteria to distinguish, requires &#8532; criteria below (protein, glucose, LDH)</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Spontaneous</td>
<td>Secondary</td>
</tr>
<tr>
<td>Protein (g/dL)</td>
<td>\&lt; 1</td>
<td>> 1</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>≥50</td>
<td>\&lt; 50</td>
</tr>
<tr>
<td>LDH (U)</td>
<td>Elevated, but \&lt; 225</td>
<td>> 225</td>
</tr>
<tr>
<td>Organisms</td>
<td>0-1</td>
<td>Polymicrobial</td>
</tr>
</tbody>
</table></section><section class="print-page" id="hepatology-hepatology-tips"><h1 id="hepatology-hepatology-tips-transjugular-intrahepatic-portosystemic-shunt-tips">Transjugular Intrahepatic Portosystemic Shunt (TIPS)<a class="headerlink" href="#hepatology-hepatology-tips-transjugular-intrahepatic-portosystemic-shunt-tips" title="Permanent link">&para;</a></h1>
<hr />
<p>Pakinam Mekki</p>
<h2 id="hepatology-hepatology-tips-background">Background<a class="headerlink" href="#hepatology-hepatology-tips-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>A Transjugular Intrahepatic Portosystemic Shunt or TIPS procedure is done by interventional radiology to manage sequelae of portal hypertension (specifically variceal bleeding and ascites)</p>
</li>
<li>
<p>A low-resistance shunt is created between an intrahepatic branch of the portal vein and the hepatic vein, allowing blood to bypass the high-resistance vessels within the fibrotic liver</p>
</li>
</ul>
<h2 id="hepatology-hepatology-tips-evaluation">Evaluation<a class="headerlink" href="#hepatology-hepatology-tips-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Indications for TIPS</p>
<ul>
<li>Variceal hemorrhage (esophageal, gastric, etc.)</li>
<li>Early “preemptive” TIPS is an urgent TIPS placement within 72 hrs (preferably within 24 hours) of initial endoscopic hemostasis in pts at high risk for rebleeding (Child-Pugh Class B with active bleeding upon insertion of endoscope or Child-Pugh Class C with recent bleeding</li>
<li>“Rescue” TIPS is placed in pts with active, uncontrolled variceal bleeding or if bleeding recurs despite maximal endoscopic and pharmacologic therapy</li>
<li>Refractory ascites (prolongs survival)</li>
<li>Other: portal hypertensive gastropathy, PVT recanalization, Budd-Chiari syndrome, hepatic hydrothorax</li>
</ul>
</li>
<li>
<p>Contraindications to TIPS</p>
<ul>
<li>Absolute contraindications<ul>
<li>Primary prevention of variceal bleeding, congestive heart failure, severe tricuspid regurgitation, severe pulmonary hypertension, multiple hepatic cysts or masses, Sepsis, unrelieved biliary obstruction</li>
</ul>
</li>
<li>Relative contraindications<ul>
<li>Hepatic encephalopathy, hepatic tumors (especially if centrally located), thrombocytopenia, moderate pulmonary hypertension</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Pre-procedure preparation</p>
<ul>
<li>Labs: CBC, CMP, INR</li>
<li>Liver imaging to assess portal system patency and exclude liver masses<ul>
<li>Ideally triple phase CT with contrast</li>
<li>In pts with renal impairment or active variceal bleeding, RUQ U/S with doppler is acceptable</li>
</ul>
</li>
<li>TTE to evaluate for evidence of congestive heart failure, pulmonary hypertension, or valvular disease.</li>
<li>Antibiotic ppx with ceftriaxone 1g IV once at the time of TIPS insertion as enteric bacteria within the static portal system can enter systemic circulation</li>
<li>Patients with HE should receive rifaximin prophylaxis starting 2 weeks before procedure</li>
</ul>
</li>
</ul>
<h2 id="hepatology-hepatology-tips-management-post-tips">Management Post-TIPS<a class="headerlink" href="#hepatology-hepatology-tips-management-post-tips" title="Permanent link">&para;</a></h2>
<ul>
<li>Immediately following TIPS, pts are observed in the hospital overnight for complications<ul>
<li>Monitor CBC and vitals closely. If hemodynamically unstable, STAT CBC and low threshold to obtain CTA A/P to evaluate for a bleeding source</li>
</ul>
</li>
<li>
<p>TIPS causes a substantial increase in venous return to the heart, which can unmask cardiac dysfunction that was previously compensated for</p>
</li>
<li>
<p>Obtain RUQ U/S with Doppler to assess shunt patency 1 month of TIPS placement, or if ascites and/or variceal hemorrhage reoccur</p>
</li>
<li>
<p>If patient with a TIPS develops refractory HE, can consider TIPS revision to lessen HE symptoms</p>
</li>
</ul></section><section class="print-page" id="hepatology-hepatology-upper-gi-bleed-cirrhosis"><h1 id="hepatology-hepatology-upper-gi-bleed-cirrhosis-gastroesophageal-varices-and-hemorrhage">Gastroesophageal Varices and Hemorrhage<a class="headerlink" href="#hepatology-hepatology-upper-gi-bleed-cirrhosis-gastroesophageal-varices-and-hemorrhage" title="Permanent link">&para;</a></h1>
<p>Patricia Checinski</p>
<hr />
<h2 id="hepatology-hepatology-upper-gi-bleed-cirrhosis-background">Background<a class="headerlink" href="#hepatology-hepatology-upper-gi-bleed-cirrhosis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Varices form due to portosystemic collaterals in the setting of portal HTN</p>
</li>
<li>
<p>The risk of mortality with each episode of esophageal variceal hemorrhage (EVH) is 15-25%</p>
</li>
<li>
<p>Recurrence occurs in 60% of patients within 1-2 years of the index event</p>
</li>
</ul>
<h2 id="hepatology-hepatology-upper-gi-bleed-cirrhosis-variceal-screening">Variceal Screening<a class="headerlink" href="#hepatology-hepatology-upper-gi-bleed-cirrhosis-variceal-screening" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Not all pts with cirrhosis require screening. Can be omitted without clinically significant portal hypertension (e.g. low liver stiffness (on elastography) and platelets &gt;150) or if pt already on non-selective beta blocker (NSBB) with HR 55-60</p>
</li>
<li>
<p>Compensated cirrhosis without varices: EGD q3yr, unless active liver injury (obesity, EtOH use, ongoing viral infxn), then q2yr</p>
</li>
<li>
<p>Compensated cirrhosis with small varices: EGD q2yr unless active liver injury, then q1yr</p>
</li>
<li>
<p>Decompensated cirrhosis with no or small nonbleeding varices: EGD q1yr, and at initial time of decompensation</p>
</li>
</ul>
<h2 id="hepatology-hepatology-upper-gi-bleed-cirrhosis-management-non-bleeding-varices">Management (Non-Bleeding Varices)<a class="headerlink" href="#hepatology-hepatology-upper-gi-bleed-cirrhosis-management-non-bleeding-varices" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Primary ppx with either NSBB (preferred) or endoscopic band ligation (EBL)</p>
<ul>
<li>Nadolol (given nightly as portal pressures are highest at night) or propranolol (BID)</li>
<li>Carvedilol has greater portal pressures and may be preferred if tolerated (goal 6.25mg BID)</li>
<li>For 2 º ppx, initiate ~72hr after acute bleed has resolved and octreotide discontinued</li>
<li>Discontinue if: hypotension (sBP &lt;90), AKI, SBP or hyponatremia with refractory ascites</li>
</ul>
</li>
<li>
<p>Secondary ppx with both NSBB and EBL.</p>
</li>
<li>NSBB are associated with reduced mortality, while EBL is not</li>
</ul>
<h2 id="hepatology-hepatology-upper-gi-bleed-cirrhosis-management-bleeding-varices">Management (Bleeding Varices)<a class="headerlink" href="#hepatology-hepatology-upper-gi-bleed-cirrhosis-management-bleeding-varices" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Place two large-bore IVs (18G or larger), resuscitate with blood products and albumin. Activate massive transfusion protocol if needed.</p>
</li>
<li>
<p>Consider intubation if need for emergent EGD, change in mental status, ongoing hematemesis, concern of ability to protect airway</p>
</li>
<li>
<p>Start octreotide 50 mcg IV bolus followed by continuous infusion of 50 mcg/h, to be continued for at least 2 days should EVH be confirmed on endoscopy</p>
</li>
<li>
<p>Ceftriaxone 1g IV q24h for SBP prophylaxis (reduced mortality), then transition to PO ciprofloxacin for total 7-day course</p>
</li>
<li>
<p>Consult GI for upper endoscopy. Endoscopic therapies performed include variceal band ligation and sclerotherapy.</p>
</li>
<li>
<p>Consider balloon tamponade with Blakemore as temporizing measure before definitive management. Patient must be intubated before placement, and preferably GI should be made aware prior to placement.</p>
</li>
<li>
<p>No role for the correction of INR, even in the presence of bleeding as excessive blood products and FFP can increase portal pressures and cause worsening bleeding</p>
<ul>
<li>Vitamin K can be given w/ ↑ INR, though is unlikely to help in the acute setting</li>
<li>Check TEG and fibrinogen and transfuse based on results</li>
<li>AASLD does not recommend specific platelet targets during variceal hemorrhage</li>
<li>Administer blood products in balanced ratio to avoid transfusion related coagulopathy (VUMC MTP is 6:4:1 of RBC:FFP:PLT)</li>
</ul>
</li>
</ul></section><section class="print-page" id="hepatology-main"><p>Cirrhosis Overview – Lee Richardson, Hannah Angle</p>
<p>Background</p>
<ul>
<li>Standard 1-liner for any patient with cirrhosis:</li>
</ul>
<!-- -->

<ul>
<li>Example 1-liner: 65yo M with cirrhosis due to HCV decompensated by
    ascites and HE (MELD 25) who is listed for transplant and followed
    by Dr. Izzy</li>
</ul>
<!-- -->

<ul>
<li>
<p>Etiology of cirrhosis: HCV>HBV, EtOH, NASH, Wilson’s,
    hemochromatosis, A1AT deficiency, autoimmune hepatitis, PSC, PBC,
    congestive hepatopathy (right heart failure), medication-induced</p>
</li>
<li>
<p>Complications that cause decompensation: overt ascites (or hepatic
    hydrothorax), overt hepatic encephalopathy (HE), esophageal variceal
    hemorrhage (EVH)</p>
</li>
<li>
<p>Always calculate daily MELD-Na scores (predicts 3 mo survival based
    on Tbili, Cr, INR, Na)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Goals: establish cause of cirrhosis, evaluate for complications and
    treat accordingly, determine prognosis, and consider transplant
    evaluation</li>
</ul>
<!-- -->

<ul>
<li>History:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Symptoms suggesting decompensation: confusion, sleep disturbances,
    abdominal swelling, lower extremity edema, scleral icterus/jaundice,
    pruritus, easy bruising/bleeding (skin, mouth, GI tract), dyspnea</p>
</li>
<li>
<p>Social history: EtOH and drug use hx, date of last drink, average #
    of drinks/day, duration of EtOH use, prior rehab, hx of DUI, if
    there has been continued EtOH use despite knowledge of liver
    disease; these factors all impact transplant candidacy</p>
</li>
<li>
<p>Ascites: compliance with diuretics, compliance with salt
    restriction, frequency of paracentesis (volume removed, date of last
    para), h/o SBP</p>
</li>
<li>
<p>HE: compliance with lactulose, # of BMs per day, any potential
    triggers (see HE section)</p>
</li>
<li>
<p>GIB/EVH: hematemesis, coffee ground emesis, melena, hematochezia
    (duration, volume, # of bleeding episodes), last EGD (varices,
    banding) and colonoscopy, compliance with non-selective BBs</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Physical exam: asterixis, ascites, edema/anasarca, splenomegaly,
    muscle wasting, gynecomastia, testicular atrophy, palmar erythema,
    spider angiomata, scleral icterus/jaundice, petechiae/ecchymoses,
    caput medusa, Terry’s nails</p>
</li>
<li>
<p>Labs</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Initial Workup: CMP, CBC, coags, UA, HCV/HBV, Fe studies, PEth</p>
</li>
<li>
<p>Unless requested by hepatology, defer to outpatient: AFP, ANA, IgG,
    A1AT, ceruloplasmin, AMA (PBC), ASMA (AIH), anti-SLA (AIH), anti-LKM
    (AIH)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Imaging:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Abdominal US with duplex unless done in past 6 months or indication
    for repeating sooner (concern for new portal vein thrombosis)</p>
</li>
<li>
<p>For transplant eval, needs triple phase CT A/P (contrasted study,
    arterial and venous phases) or MRI abdomen with contrast</p>
</li>
</ul>
<!-- -->

<ul>
<li>Liver biopsy: gold standard for cirrhosis diagnosis but is not
    always needed if clinical presentation, labs, and imaging consistent
    with cirrhosis</li>
</ul>
<p>Lab abnormalities</p>
<ul>
<li>
<p>Hyponatremia (see hyponatremia section below)</p>
</li>
<li>
<p>Cirrhotic coagulopathy (increased INR): due to ↓ coagulation factor
    production</p>
</li>
<li>
<p>Thrombocytopenia: due to splenic sequestration, ↓ TPO production</p>
</li>
<li>
<p>Hypoalbuminemia: indications for 25% albumin transfusion – SBP
    (1.5g/kg on day 1, 1g/kg on day 3), LVP (6-8g/L of ascites), HRS
    (albumin challenge: 1g/kg/day with max 100 g/day x 2 days), hypoNa
    \&lt;125 and refractory to fluid restriction</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Nutrition: high protein diet, 2g Na restriction (if ascites
    present),</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider MVI, folate, thiamine (particularly in pts with EtOH use
    disorder)</p>
</li>
<li>
<p>Mediterranean diet for NASH</p>
</li>
<li>
<p>Fluid restriction if hyponatremic</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Immunizations: ensure up-to-date with HBV/HAV, PPSV23, Prevnar, Flu,
    COVID-19 vaccines</p>
</li>
<li>
<p>Consider consulting Addiction Psych and Social Work for pts with
    EtOH use disorder - can assist with arranging Intensive Outpatient
    Program (IOP), Alcoholics Anonymous (AA)</p>
</li>
<li>
<p>General screenings include: HCC screening (q6 months), EVH screening
    (see section below), monitor for other decompensations and treat
    accordingly, monitor MELD and consider transplant evaluation when
    >15</p>
</li>
<li>
<p>Refer to hepatology outpatient</p>
</li>
</ul>
<p>Medication Tips:</p>
<ul>
<li>Pain: 2g limit Tylenol, No NSAIDs, limit sedating medications
    especially with HE.</li>
</ul>
<!-- -->

<ul>
<li>Tramadol 25-50mg generally safe to use</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pruritus: Sarna lotion, can spot dose antihistamines. Can discuss
    with pharmacist/attending about starting sertraline, cholestyramine
    (interacts with many medications), or rifampin.</p>
</li>
<li>
<p>Anxiety/insomnia: hydroxyzine, avoid benzodiazepines</p>
</li>
<li>
<p>If needed for EtOH withdrawal, use lorazepam (Ativan) instead of
    chlordiazepoxide (Librium) or diazepam (Valium) due to its shorter
    half life</p>
</li>
</ul>
<p>Liver Transplant (LT) Workup – Lauren Evers Carlini</p>
<p>Background</p>
<ul>
<li>Model for End-stage Liver Disease (MELD-Na) score: initially
    developed to predict survival following TIPS placement, though is
    now used to objectively rank patients in terms of priority for liver
    transplant (LT)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Factors in total bilirubin, creatinine, INR, and Na.</p>
</li>
<li>
<p>Exception points given for complications like HCC and
    hepatopulmonary syndrome (HPS), leading to score in mid to high 20’s
    even if biologic MELD is low</p>
</li>
<li>
<p>Highest score lasts for 7 days</p>
</li>
</ul>
<!-- -->

<ul>
<li>Listing a pt for LT is determined by a multidisciplinary transplant
    committee</li>
</ul>
<!-- -->

<ul>
<li>Acute liver failure pts take precedence over decompensated cirrhosis
    pts for LT</li>
</ul>
<table>
<thead>
<tr>
<th>Indications</th>
<th>Contraindications*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis with MELD ≥ 15 or evidence of decompensation (ascites, variceal bleed, HE, HPS, portopulmonary HTN)</td>
<td>Ongoing substance abuse (must have documented abstinence ≥ 3 mos) – refer to exception policy in Alcoholic Hepatitis section</td>
</tr>
<tr>
<td>Acute liver failure</td>
<td>Untreated or recurrent malignancy</td>
</tr>
<tr>
<td>HCC that meets Milan criteria</td>
<td>Active infection, AIDS</td>
</tr>
<tr>
<td>Pts with early hilar cholangio-carcinoma that meets specific criteria</td>
<td>Documented history of medical noncompliance</td>
</tr>
<tr>
<td>Other rare diseases (e.g., familial amyloid polyneuropathy or hyperoxaluria)</td>
<td>Lack of adequate social support</td>
</tr>
<tr>
<td></td>
<td>Anatomic contraindications: chronic cardiac/pulmonary conditions that significantly increase perioperative risk (e.g., severe pulm HTN)</td>
</tr>
<tr>
<td><em>* Advanced age (>70) is not itself a contraindication but candidates >70 should be almost free of comorbidities to be considered</em></td>
<td></td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>
<p>Abdominal CT (triple phase) or MRI (multiphase with contrast) to
    evaluate for hepatic malignancy and vascular anatomy</p>
</li>
<li>
<p>Infectious workup: TB testing, HIV, RPR, VZV, CMV, EBV, and
    Hepatitis A, B, and C</p>
</li>
<li>
<p>Cardiac evaluation: EKG and TTE with bubble are required. Functional
    testing: CT coronaries with fractional flow, invasive angiography
    and intervention may be necessary depending on pre-test probability.</p>
</li>
<li>
<p>PFT’s, carotid ultrasound, panorex, etc.</p>
</li>
<li>
<p>Appropriate cancer screenings (colonoscopy, pap smear, mammogram,
    and PSA if applicable)</p>
</li>
<li>
<p>DEXA scan</p>
</li>
<li>
<p>Certification of completion of intensive outpatient program (IOP)
    for substance abuse</p>
</li>
<li>
<p>Evaluation by hepatobiliary surgical team after obtaining cross
    sectional imaging</p>
</li>
<li>
<p>Psychosocial evaluation (consult Psychiatry, social work)</p>
</li>
<li>
<p>Current VUMC policy: pts should be abstinent from alcohol for no
    less than 3-6 months, although exceptions may be made for early
    liver transplant based on a very strict protocol. Discuss exception
    criteria with attending if suspect patient unlikely to survive
    hospitalization without transplant</p>
</li>
</ul>
<p>Both living and deceased donor transplant are offered at VUMC. Donor
evaluation, however, cannot be started before the potential recipient is
deemed a candidate.</p>
<p>Ascites and Hepatic Hydrothorax – Lauren Evers Carlini, Thomas Strobel</p>
<p>Ascites</p>
<p>Background</p>
<ul>
<li>
<p>Associated with a reduction in 5 year survival from 80% to 30%.</p>
</li>
<li>
<p>Most often due to portal hypertension. Less common causes include
    peritoneal or metastatic cancer, heart failure, tuberculosis,
    nephrotic syndrome, Budd-Chiari, sinusoidal obstructive syndrome
    (S.O.S), or complications from procedures and pancreatitis</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1 Ascites</td>
<td>Only seen on imaging</td>
<td>2g Na restriction</td>
</tr>
<tr>
<td>Grade 2 Ascites</td>
<td>Moderate, symmetric abdominal distension</td>
<td>2g Na restriction, diuretics</td>
</tr>
<tr>
<td>Grade 3 Ascites</td>
<td>Marked, tense abdominal distension</td>
<td>LVP + Na restriction, diuretics (unless refractory)</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>
<p>Bedside ultrasound on admission to confirm presence of ascites</p>
</li>
<li>
<p>Diagnostic paracentesis in all pts with ascites on admission mainly
    to rule out occult SBP</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Initial paracentesis or when cause of ascites is uncertain: Total
    Protein, serum and BF Albumin, cell count w/diff, culture</p>
</li>
<li>
<p>Subsequent/Serial paracenteses: cell count w/diff, culture, protein</p>
</li>
<li>
<p>Always inoculate culture bottles at bedside</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>There is no guideline for INR cutoff for paracentesis, although our
    procedure team often looks for INR \&lt; 3.5 (IR usually doesn’t care
    about INR)</p>
</li>
<li>
<p>Serum-ascites albumin gradient (SAAG) = serum albumin - ascites
    albumin.</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 29%" />
<col style="width: 34%" />
<col style="width: 35%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Total Protein Ascites</p>
<p>(not serum)</p></th>
<th><p>SAAG &gt; 1.1 g/dL</p>
<p>(Portal HTN)</p></th>
<th><p>SAAG &lt; 1.1 g/dL</p>
<p>(Non-portal HTN)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>&lt; 2.5 g/dL</td>
<td>Cirrhosis</td>
<td><p>Nephrotic Syndrome</p>
<p>Myxedema</p></td>
</tr>
<tr class="even">
<td>&gt; 2.5 g/dL</td>
<td><p>Post-hepatic portal HTN:</p>
<p>Cardiac Ascites</p>
<p>Budd-Chiari</p></td>
<td><p>Malignant Ascites</p>
<p>Pancreatic Ascites</p>
<p>TB</p></td>
</tr>
</tbody>
</table>

<ul>
<li>
<p>Calculate PMNs from fluid (see SBP below)</p>
</li>
<li>
<p>Other tests:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Triglycerides: if fluid is milky</p>
</li>
<li>
<p>Cytology: if very concerned for peritoneal carcinomatosis. May need
    up to 3 separate samples (50ml or more) to be able to detect
    malignant cells</p>
</li>
<li>
<p>ADA: if concern for peritoneal TB</p>
</li>
<li>
<p>Hematocrit: For bloody appearing fluid (not just serosanguinous) to
    rule out hemoperitoneum. There needs to be a recent serum HCT for
    comparison.</p>
</li>
<li>
<p>Amylase: If concerned for pancreatic ascites</p>
</li>
<li>
<p>Glucose, LDH if concern about secondary peritonitis (see below)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>2000mg sodium restriction per day for all ascites (Grade 1-3)</p>
</li>
<li>
<p>Diuretics (spironolactone and typically furosemide)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Start at 100mg of spironolactone with up titration to 400mg</p>
</li>
<li>
<p>Furosemide is added if insufficient diuresis or if limited by
    hyperkalemia. Use more loop diuretics in patients with CKD.</p>
</li>
<li>
<p>If Urine Na:K ratio \&lt;1, indicates insufficient natriuresis. Can ↑
    doses to a max of 400:160</p>
</li>
<li>
<p>If poor response can change to torsemide 10mg and ↑ to 40mg max (per
    single dose)</p>
</li>
<li>
<p>Fluid restriction usually not necessary unless serum sodium \&lt;125
    mmol/L</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Large volume paracentesis should be performed for tense ascites or
    refractory ascites (grade 3), regardless of serum Cr. Pts should be
    tapped dry with each paracentesis</p>
</li>
<li>
<p>Give 6-8g of albumin per liter of ascites removed, even if \&lt; 5L</p>
</li>
<li>
<p>Target weight loss of 0.5 kg/day when diuresing to avoid renal
    injury</p>
</li>
<li>
<p>Discontinue NSAIDs and ACEI/ARB</p>
</li>
</ul>
<p>Refractory Ascites:</p>
<ul>
<li>Two distinctions:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diuretic-resistant: lack of response to diuretics (max
    spironolactone 400mg/lasix 160mg), Na restriction and rapid
    recurrence following paracentesis</p>
</li>
<li>
<p>Diuretic-intractable: unable to tolerate diuretic therapy 2/2
    adverse drug effects (unexplained HE, AKI, K abnormalities, hypoNa,
    intractable muscle cramps)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Management aside from liver transplant:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Discontinue diuretics once refractory ascites has been established</p>
</li>
<li>
<p>Consider oral midodrine; can be especially helpful if pt is also
    hypotensive</p>
</li>
<li>
<p>Serial paracenteses, generally arranged OP with IR</p>
</li>
<li>
<p>Consider TIPS (trans jugular intrahepatic portosystemic shunt; has
    survival benefit). Following TIPS, cessation or decrease in ascites
    should occur in 4-6 weeks</p>
</li>
<li>
<p>Consider discontinuing beta blockers in patients with refractory
    ascites if sBP \&lt;90, SCr >1.5, or Na \&lt;130</p>
</li>
</ul>
<p>Hepatic Hydrothorax</p>
<p>Background</p>
<ul>
<li>
<p>Transudative effusion, typically unilateral (75% right sided);
    reflects ascitic fluid that passes through defects in the diaphragm.
    10% can develop without clinical ascites.</p>
</li>
<li>
<p>Present in 4-12% of cirrhotics and portends a poor prognosis (75%
    mortality within 90 days)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Often suspected clinically, though must exclude
    pleural/cardiopulmonary process</p>
</li>
<li>
<p>Thoracentesis will demonstrate a transudative effusion and should be
    evaluated with standard pleural fluid lab tests: cell count,
    protein, albumin, LDH, culture</p>
</li>
</ul>
<!-- -->

<ul>
<li>Other considerations: triglycerides, amylase, hematocrit, cytology</li>
</ul>
<!-- -->

<ul>
<li>Rule out SBE which is diagnosed the same as SBP (PMN>250)</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Similar management of ascites as noted above</p>
</li>
<li>
<p>AVOID chest-tube placement. Associated with increased morbidity and
    mortality due to extensive loss of fluid, electrolytes and protein
    as well as increased infection risk</p>
</li>
</ul>
<!-- -->

<ul>
<li>PleurX catheters can be considered for palliation (e.g., hospice
    patients)</li>
</ul>
<!-- -->

<ul>
<li>Refractory Hydrothorax is defined similarly and managed similarly
    with serial thoracentesis or TIPS. For those who are not candidates,
    consider:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Chemical pleurodesis (not commonly performed at VUMC due to
    complications)</p>
</li>
<li>
<p>Thoracoscopic mesh repair in pts with clear diaphragmatic deficits
    (not common practice at VUMC )</p>
</li>
</ul>
<!-- -->

<ul>
<li>Management of spontaneous bacterial empyema is the same as in SBP
    (see below)</li>
</ul>
<p>Spontaneous Bacterial Peritonitis (SBP) – Patricia Checinski</p>
<p>Background</p>
<ul>
<li>
<p>Infection of ascitic fluid without evidence of a surgical
    intra-abdominal source</p>
</li>
<li>
<p>Presentation: fever, abdominal pain, encephalopathy, renal failure,
    acidosis, and/or leukocytosis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Any pt with cirrhosis and ascites who is admitted should have
    diagnostic paracentesis to rule out SBP. Delaying paracentesis > 12
    hours is associated with a 2.7-fold increase in mortality.</p>
</li>
<li>
<p>Obtain cell count with diff.</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Calculate the PMNs: total nucleated cells x % neutrophils.</p>
</li>
<li>
<p>PMNs > 250 cells is diagnostic of SBP. If there are greater than
    100k RBCs, you should correct for them: for every 250 RBCs, subtract
    1 PMN</p>
</li>
</ul>
<!-- -->

<ul>
<li>A positive ascitic bacterial culture with PMN \&lt;250 is called
    bacterascites and asymptomatic patients should NOT receive
    antibiotics. You will also frequently see culture-negative SBP
    (neutrocytic ascites) which SHOULD be treated (see below).</li>
</ul>
<p>Management</p>
<ul>
<li>Immediately start empiric antibiotics</li>
</ul>
<!-- -->

<ul>
<li>
<p>Guidelines recommend cefotaxime IV 2gm q8 hours x 5 days, but we
    commonly use ceftriaxone IV 2g q24h for 5-7 days at VUMC and
    Nashville VA.</p>
<ul>
<li>
<p>Most common culprits (E. coli, Klebsiella, streptococcal
    species, staphylococcal species)</p>
</li>
<li>
<p>If SBP developed with recent hospital admission (90 days),
    recent exposure to BSA, diagnosed >48 hours of admission, or
    with sepsis, consider zosyn or meropenem to cover MDROs</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>IV albumin 1.5 g/kg on day 1 and 1g/kg on day 3</p>
</li>
<li>
<p>Discontinue beta-blockers once SBP develops and do not restart until
    SBP is completely treated, Na >130, and no AKI</p>
</li>
<li>
<p>PPI’s ↑ risk for SBP in pts with cirrhosis, and should be reviewed
    for appropriateness</p>
</li>
<li>
<p>Repeat diagnostic paracentesis two days after antibiotics initiated</p>
</li>
</ul>
<!-- -->

<ul>
<li>If \&lt;25% decrease in PMNs, antibiotics should be broadened. Consider
    secondary bacterial peritonitis</li>
</ul>
<p>Prophylaxis</p>
<ul>
<li>
<p>GI bleed: ceftriaxone 1g daily ciprofloxacin 500mg BID (preferred)
    or Bactrim one DS tablet BID x 5-7 days</p>
</li>
<li>
<p>Outpatient lifelong ppx:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Indicated for:</p>
<ul>
<li>
<p>Prior SBP</p>
</li>
<li>
<p>Ascitic protein \&lt;1.5 AND</p>
<ul>
<li>
<p>Child Pugh >9 and bilirubin >3 OR</p>
</li>
<li>
<p>Renal dysfunction (Cr >1.2, Na \&lt;130, or BUN >25)</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Preferred: Bactrim DS tab daily or ciprofloxacin 500mg daily</p>
</li>
<li>
<p>Alternatives: cefdinir 300mg daily, Augmentin 875/125 daily</p>
</li>
</ul>
<p>If suspicion is high for secondary bacterial peritonitis:</p>
<ul>
<li>
<p>Examine serum-ascites albumin gradient (SAAG). SBP develops in pts
    with portal hypertension, defined by SAAG > 1.1 g/dL. SBP is
    unlikely if SAAG is \&lt; 1.1 g/dL.</p>
</li>
<li>
<p>While not particularly sensitive, an ascitic leukocyte count of
    5-10k should prompt consideration of secondary peritonitis</p>
</li>
<li>
<p>Amylase from fluid can also be helpful to point towards pancreatic
    ascites, while bilirubin can indicate gallbladder perforation.
    Peritoneal fluid CEA and alkaline phosphatase can additionally help
    identify hollow viscus injury.</p>
</li>
<li>
<p>Evaluate with cross-sectional imaging and surgical consultation as
    appropriate</p>
</li>
<li>
<p>Runyon’s Criteria to distinguish, requires &#8532; criteria below
    (protein, glucose, LDH)</p>
</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th>Spontaneous</th>
<th>Secondary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein (g/dL)</td>
<td>\&lt; 1</td>
<td>> 1</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>≥50</td>
<td>\&lt; 50</td>
</tr>
<tr>
<td>LDH (U)</td>
<td>Elevated, but \&lt; 225</td>
<td>> 225</td>
</tr>
<tr>
<td>Organisms</td>
<td>0-1</td>
<td>Polymicrobial</td>
</tr>
</tbody>
</table>
<p>Gastroesophageal Varices and Hemorrhage – Patricia Checinski</p>
<p>Background</p>
<ul>
<li>
<p>Varices form due to portosystemic collaterals in the setting of
    portal HTN</p>
</li>
<li>
<p>The risk of mortality with each episode of esophageal variceal
    hemorrhage (EVH) is 15-25%</p>
</li>
<li>
<p>Recurrence occurs in 60% of patients within 1-2 years of the index
    event</p>
</li>
</ul>
<p>Variceal Screening</p>
<ul>
<li>
<p>Not all pts with cirrhosis require screening. Can be omitted without
    clinically significant portal hypertension (e.g. low liver stiffness
    (on elastography) and platelets >150) or if pt already on
    non-selective beta blocker (NSBB) with HR 55-60</p>
</li>
<li>
<p>Compensated cirrhosis without varices: EGD q3yr, unless active liver
    injury (obesity, EtOH use, ongoing viral infxn), then q2yr</p>
</li>
<li>
<p>Compensated cirrhosis with small varices: EGD q2yr unless active
    liver injury, then q1yr</p>
</li>
<li>
<p>Decompensated cirrhosis with no or small nonbleeding varices: EGD
    q1yr, and at initial time of decompensation</p>
</li>
</ul>
<p>Management (Non-Bleeding Varices)</p>
<ul>
<li>Primary ppx with either NSBB (preferred) or endoscopic band ligation
    (EBL)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nadolol (given nightly as portal pressures are highest at night) or
    propranolol (BID)</p>
</li>
<li>
<p>Carvedilol has greater portal pressures and may be preferred if
    tolerated (goal 6.25mg BID)</p>
</li>
<li>
<p>For 2 º ppx, initiate ~72hr after acute bleed has resolved and
    octreotide discontinued</p>
</li>
<li>
<p>Discontinue if: hypotension (sBP \&lt;90), AKI, SBP or hyponatremia
    with refractory ascites</p>
</li>
</ul>
<!-- -->

<ul>
<li>Secondary ppx with both NSBB and EBL.</li>
</ul>
<!-- -->

<ul>
<li>NSBB are associated with reduced mortality, while EBL is not</li>
</ul>
<p>Management (Bleeding Varices)</p>
<ul>
<li>
<p>Place two large-bore IVs (18G or larger), resuscitate with blood
    products and albumin. Activate massive transfusion protocol if
    needed.</p>
</li>
<li>
<p>Consider intubation if need for emergent EGD, change in mental
    status, ongoing hematemesis, concern of ability to protect airway</p>
</li>
<li>
<p>Start octreotide 50 mcg IV bolus followed by continuous infusion of
    50 mcg/h, to be continued for at least 2 days should EVH be
    confirmed on endoscopy</p>
</li>
<li>
<p>Ceftriaxone 1g IV q24h for SBP prophylaxis (reduced mortality), then
    transition to PO ciprofloxacin for total 7-day course</p>
</li>
<li>
<p>Consult GI for upper endoscopy. Endoscopic therapies performed
    include variceal band ligation and sclerotherapy.</p>
</li>
<li>
<p>Consider balloon tamponade with Blakemore as temporizing measure
    before definitive management. Patient must be intubated before
    placement, and preferably GI should be made aware prior to
    placement.</p>
</li>
<li>
<p>No role for the correction of INR, even in the presence of bleeding
    as excessive blood products and FFP can increase portal pressures
    and cause worsening bleeding</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Vitamin K can be given w/ ↑ INR, though is unlikely to help in the
    acute setting</p>
</li>
<li>
<p>Check TEG and fibrinogen and transfuse based on results</p>
</li>
<li>
<p>AASLD does not recommend specific platelet targets during variceal
    hemorrhage</p>
</li>
<li>
<p>Administer blood products in balanced ratio to avoid transfusion
    related coagulopathy (VUMC MTP is 6:4:1 of RBC:FFP:PLT)</p>
</li>
</ul>
<p>Hepatic Encephalopathy (HE)</p>
<p>Evaluation</p>
<ul>
<li>Asterixis: inability to maintain stable posture; many ways to assess</li>
</ul>
<!-- -->

<ul>
<li>
<p>Check for clonus</p>
</li>
<li>
<p>Have pt “hold out hands like you are stopping traffic” (if following
    commands)</p>
</li>
<li>
<p>Shine light in pupil (look up video of hippus)</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>Grade</th>
<th>Behavior Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Mild confusion, changes in behavior, increased sleep, no asterixis, cannot be confirmed without neuropsych testing</td>
</tr>
<tr>
<td>II</td>
<td>Moderate confusion, lethargic, AAOx2, +asterixis</td>
</tr>
<tr>
<td>III</td>
<td>Marked confusion, arousable but falls asleep, incoherent speech, AAOx1, +asterixis</td>
</tr>
<tr>
<td>IV</td>
<td>Coma</td>
</tr>
</tbody>
</table>
<ul>
<li>Identify precipitants</li>
</ul>
<!-- -->

<ul>
<li>
<p>Infection (rule out SBP in addition to CXR, BCx, UA/Cx),</p>
</li>
<li>
<p>Medication non-adherence (lactulose)</p>
</li>
<li>
<p>GI bleed (perform rectal exam and observe Hgb trend)</p>
</li>
<li>
<p>Over-diuresis resulting in dehydration, electrolyte abnormalities
    (especially hypoK)</p>
</li>
<li>
<p>Sedatives/benzo/opiate administration (UDS)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ammonia (NH3) levels do not play a role in the acute management of
    HE</p>
</li>
<li>
<p>Arterial NH3 is used in acute liver failure for prognostication (not
    for management)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Always determine precipitant and treat underlying condition</p>
</li>
<li>
<p>Lactulose 30mL TID initially</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Titrate dose to at least 4 BMs daily, avoid excessive stool output
    which may exacerbate HE due to dehydration and electrolyte
    abnormalities</p>
</li>
<li>
<p>Consider lactulose enemas vs DHT placement if pt unable to tolerate
    PO</p>
<ul>
<li>DHT are not contraindicated in patients with esophageal varices,
    but should be avoided in patients with recent hemorrhage or
    banding</li>
</ul>
</li>
<li>
<p>Add Rifaximin after the second episode of HE, or if failure to
    respond to lactulose</p>
<ul>
<li>Frequently requires prior authorization for outpatient approval
    and is expensive</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Lactulose is generally continued indefinitely after first episode of
    HE, though discontinuation can be considered if predisposing factors
    (recurrent infection, EVH, EtOH use) have resolved</li>
</ul>
<p>AKI &amp; Hepatorenal Syndrome (HRS) – Garren Montgomery</p>
<p>Background</p>
<ul>
<li>
<p>Portal HTN causes shear stress on portal vessels endothelium release
    of vasodilators splanchnic vasodilation and reduced effective blood
    volume (decreased MAP) RAAS activation sodium and water retention
    and severe renal vasoconstriction</p>
</li>
<li>
<p>Bacterial translocation (as seen in SBP) increased circulating
    pro-inflammatory cytokines splanchnic vasodilation</p>
</li>
<li>
<p>Definitions:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>HRS-AKI (formerly type I HRS): Rise in Cr ≥0.3 within 48h, rise in
    Cr ≥50% within 7 days, OR UOP \&lt;0.5 mL/kg/hr for 6 hours</p>
</li>
<li>
<p>HRS-NAKI (“non-AKI”) (formerly type II HRS):</p>
<ul>
<li>
<p>HRS-AKD: eGFR\&lt;60 for \&lt;3 months in absence of other structural
    causes OR % rise in Cr ≤50% using last available Cr over last 3
    months as baseline</p>
</li>
<li>
<p>HRS-CKD: eGFR\&lt;60 for ≥3 months in absence of other structural
    causes</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Diagnostic Criteria</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diagnosis of AKI (see above) without other cause (see below)</p>
</li>
<li>
<p>No response or inadequate response at 48 hrs after volume expansion
    with albumin and withdrawal of diuretics</p>
</li>
<li>
<p>Absence of proteinuria (\&lt;500 mg/d), absence of hematuria (\&lt;50 RBCs
    per HPF), normal renal ultrasound (exclude if patient has known CKD)</p>
</li>
<li>
<p>Suggestion of renal vasoconstriction with FeNa \&lt;0.2, FeUrea \&lt;20
    (most sensitive diagnostic measure). UNa \&lt;20 is suggestive but not
    diagnostic given baseline sodium avidity in cirrhosis and inability
    to calculate FeNa</p>
</li>
<li>
<p>Cut off for ATN in cirrhosis is a FeNa >0.5, rather than 1 in the
    general population</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Step 1: Exclude other obvious causes of renal injury such as
    hypovolemia or ATN</li>
</ul>
<!-- -->

<ul>
<li>
<p>Common precipitants of AKI: infection, overdiuresis, GI bleeding,
    recent LVP without subsequent volume expansion, nephrotoxic
    drugs/NSAIDs</p>
</li>
<li>
<p>Workup: BMP, UA with microscopy, urine electrolytes (FeNa, FeUrea),
    urine protein/Cr ratio, renal ultrasound (to assess for chronicity),
    diagnostic para to rule out SBP</p>
</li>
</ul>
<!-- -->

<ul>
<li>Step 2: Diuretic cessation/albumin challenge</li>
</ul>
<!-- -->

<ul>
<li>
<p>STOP all diuretics, beta blockers, NSAIDs, ACE/ARBs,
    anti-hypertensives, vasodilators, nephrotoxins</p>
</li>
<li>
<p>START volume expansion with albumin 1g/kg/day (up to a max of 100
    g/day) x2 days</p>
</li>
</ul>
<!-- -->

<ul>
<li>Step 3: Diagnosis of HRS</li>
</ul>
<!-- -->

<ul>
<li>If no other clear cause of AKI is identified and SCr has not
    improved after 48 hours of diuretic cessation and volume expansion,
    proceed promptly to vasopressor treatment</li>
</ul>
<p>Management</p>
<ul>
<li>Pharmacologic therapies (in order of preference):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Terlipressin + albumin. Most effective combo based on clinical
    trials, NOW AVAILABLE (ongoing clinical trial at VUMC)</p>
</li>
<li>
<p>Norepinephrine + albumin (25-50 g/day)</p>
<ul>
<li>
<p>Most likely to be used at VUMC, requires central access (PICC vs
    triple lumen) but can be administered on stepdown unit</p>
</li>
<li>
<p>Guidelines recommend NE to be dosed at 0.5-3 mg/hr. Would ask
    fellow, attending or pharmacist for baseline. VUMC protocol for
    ICU and stepdown:</p>
<ul>
<li>Start NE gtt at 3mcg/min. If UOP is \&lt;200 or MAP \&lt;10mm Hg
    from baseline, increase by 3 mcg/min every 4 hours</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Continue to hold diuretics. LVP is still generally considered safe
    even in HRS if indicated by tense ascites (account for albumin
    repletion from LVP and HRS protocol). This can be attending specific
    and would confirm prior to performing</p>
</li>
<li>
<p>Therapy is generally continued until HRS is reversed or the
    hepatology attending deems it refractory to medical treatment</p>
</li>
<li>
<p>Patients with HRS-NAKI (formerly type II HRS) may respond to the
    above therapies, but recurrence of renal dysfunction after
    withdrawal of vasoconstrictors is the norm and thus current
    guidelines do not recommend them for this scenario</p>
</li>
<li>
<p>RRT: Dialysis can be considered for those who fail to respond to
    pharmacologic therapy, particularly ONLY as a bridge to liver
    transplant. Decision to initiate should be individualized</p>
</li>
<li>
<p>Liver transplant: The best and most definitive treatment regardless
    of response to pharmacologic therapy</p>
<p>Simultaneous liver-kidney transplant:</p>
</li>
<li>
<p>HRS often resolves with LT alone. Indications for kidney transplant
    are usually for patients with severe chronic renal dysfunction or on
    RRT. Must consult transplant nephrology.</p>
</li>
<li>
<p>Criteria for SLKT:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>eGFR \&lt;60 for >30 days AND latest eGFR \&lt;30</p>
</li>
<li>
<p>eGFR \&lt;25 for >6 consecutive weeks with a documented eGFR q7 days</p>
</li>
<li>
<p>Metabolic syndromes and polycystic disease</p>
</li>
</ul>
<!-- -->

<ul>
<li>Can qualify for safety net kidney transplant after liver transplant
    if eGFR \&lt;20 2-12 months post-operatively (would be at higher
    priority than the rest of the kidney transplant list)</li>
</ul>
<p>Hyponatremia in Cirrhosis – John Laurenzano</p>
<p>Background </p>
<ul>
<li>
<p>Most commonly is hypervolemic hyponatremia, driven by release of ADH
    from decreased effective arterial blood volume (EABV) in the setting
    of portal hypertension</p>
</li>
<li>
<p>Hyponatremia in cirrhosis is a marker of advanced disease and is
    associated with higher rates of SBP, HE, HRS, and mortality. </p>
</li>
</ul>
<p>Evaluation </p>
<ul>
<li>Standard evaluation of hyponatremia, including Uosm, Sosm, UNa to
    rule out competing processes (e.g. beer potomania) </li>
</ul>
<p>Management </p>
<ul>
<li>
<p>Discontinue anti-hypertensives (including beta blockers) in patients
    with ascites and hyponatremia. Hold diuretics when Na \&lt;125 </p>
</li>
<li>
<p>Fluid restriction is recommended only in patients with Na \&lt;125.
    Restriction is generally effective at 1-1.5L and must be less than
    daily urine output to increase free water excretion </p>
</li>
<li>
<p>Replete potassium to 4.0, as potassium is as osmotically active and
    results in shifts in extra and intracellular fluids which lead to a
    net increase in serum sodium. </p>
</li>
<li>
<p>25% albumin infusion (1g/kg split into BID dosing), has been shown
    to increase serum sodium and have higher rates of hyponatremia
    resolution at 30 days </p>
</li>
<li>
<p>Other treatment considerations include vasopressors, vaptans, urea
    tabs</p>
</li>
<li>
<p>Salt tabs should not be used to raise serum Na due to worsening
    hypervolemia</p>
</li>
<li>
<p>Nephrology should be consulted if not improved after 48 hours</p>
</li>
</ul>
<p>Transjugular Intrahepatic Portosystemic Shunt (TIPS) – Pakinam Mekki</p>
<p>Background</p>
<ul>
<li>
<p>A Transjugular Intrahepatic Portosystemic Shunt or TIPS procedure is
    done by interventional radiology to manage sequelae of portal
    hypertension (specifically variceal bleeding and ascites)</p>
</li>
<li>
<p>A low-resistance shunt is created between an intrahepatic branch of
    the portal vein and the hepatic vein, allowing blood to bypass the
    high-resistance vessels within the fibrotic liver</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Indications for TIPS</li>
</ul>
<!-- -->

<ul>
<li>
<p>Variceal hemorrhage (esophageal, gastric, etc.)</p>
<ul>
<li>
<p>Early “preemptive” TIPS is an urgent TIPS placement within 72
    hrs (preferably within 24 hours) of initial endoscopic
    hemostasis in pts at high risk for rebleeding (Child-Pugh Class
    B with active bleeding upon insertion of endoscope or Child-Pugh
    Class C with recent bleeding</p>
</li>
<li>
<p>“Rescue” TIPS is placed in pts with active, uncontrolled
    variceal bleeding or if bleeding recurs despite maximal
    endoscopic and pharmacologic therapy</p>
</li>
</ul>
</li>
<li>
<p>Refractory ascites (prolongs survival)</p>
</li>
<li>
<p>Other: portal hypertensive gastropathy, PVT recanalization,
    Budd-Chiari syndrome, hepatic hydrothorax</p>
</li>
</ul>
<!-- -->

<ul>
<li>Contraindications to TIPS</li>
</ul>
<!-- -->

<ul>
<li>
<p>Absolute contraindications</p>
<ul>
<li>Primary prevention of variceal bleeding, congestive heart
    failure, severe tricuspid regurgitation, severe pulmonary
    hypertension, multiple hepatic cysts or masses, Sepsis,
    unrelieved biliary obstruction</li>
</ul>
</li>
<li>
<p>Relative contraindications</p>
<ul>
<li>Hepatic encephalopathy, hepatic tumors (especially if centrally
    located), thrombocytopenia, moderate pulmonary hypertension</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Pre-procedure preparation</li>
</ul>
<!-- -->

<ul>
<li>
<p>Labs: CBC, CMP, INR</p>
</li>
<li>
<p>Liver imaging to assess portal system patency and exclude liver
    masses</p>
<ul>
<li>
<p>Ideally triple phase CT with contrast</p>
</li>
<li>
<p>In pts with renal impairment or active variceal bleeding, RUQ
    U/S with doppler is acceptable</p>
</li>
</ul>
</li>
<li>
<p>TTE to evaluate for evidence of congestive heart failure, pulmonary
    hypertension, or valvular disease.</p>
</li>
<li>
<p>Antibiotic ppx with ceftriaxone 1g IV once at the time of TIPS
    insertion as enteric bacteria within the static portal system can
    enter systemic circulation</p>
</li>
<li>
<p>Patients with HE should receive rifaximin prophylaxis starting 2
    weeks before procedure</p>
</li>
</ul>
<p>Management Post-TIPS</p>
<ul>
<li>Immediately following TIPS, pts are observed in the hospital
    overnight for complications</li>
</ul>
<!-- -->

<ul>
<li>Monitor CBC and vitals closely. If hemodynamically unstable, STAT
    CBC and low threshold to obtain CTA A/P to evaluate for a bleeding
    source</li>
</ul>
<!-- -->

<ul>
<li>
<p>TIPS causes a substantial increase in venous return to the heart,
    which can unmask cardiac dysfunction that was previously compensated
    for</p>
</li>
<li>
<p>Obtain RUQ U/S with Doppler to assess shunt patency 1 month of TIPS
    placement, or if ascites and/or variceal hemorrhage reoccur</p>
</li>
<li>
<p>If patient with a TIPS develops refractory HE, can consider TIPS
    revision to lessen HE symptoms</p>
</li>
</ul>
<p>Hepatocellular Carcinoma (HCC) – Lee Richardson, Julie Cui</p>
<p>Background</p>
<ul>
<li>
<p>Pts with HCV cirrhosis are at greatest risk (incidence 2-4% per
    year)</p>
</li>
<li>
<p>In chronic HBV and NASH, pts can develop HCC without having
    cirrhosis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Regular screening in pts with cirrhosis (or chronic HBV without
    cirrhosis) for HCC</li>
</ul>
<!-- -->

<ul>
<li>
<p>RUQ U/S q6mo (with or without AFP)</p>
</li>
<li>
<p>Routine screening with CT or MRI is not recommended</p>
</li>
</ul>
<!-- -->

<ul>
<li>Options If U/S not satisfactory:</li>
</ul>
<!-- -->

<ul>
<li>
<p>CT A/P w/contrast, in comments specify triple phase for HCC
    screening</p>
</li>
<li>
<p>MRI, specify Gadovist (preferred contrast agent)</p>
</li>
<li>
<p>Contrast-enhanced ultrasound</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>AFP trend is more useful than one value in time, though AFP >20
    should prompt multiphase CT or MRI for further evaluation</p>
</li>
<li>
<p>Diagnosis can be made either by imaging (most common) or biopsy
    (rare)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Triple phase CT demonstrates strong early uptake in arterial phase,
    with subsequent wash-out in portal-venous phase</p>
</li>
<li>
<p>If diagnosis remains unclear: can surveillance imaging or biopsy</p>
</li>
<li>
<p>LI-RADS system notes risk of malignancy based on imaging
    characteristics</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>LI-RADS</th>
<th>What does it mean?</th>
<th>What do we do?</th>
</tr>
</thead>
<tbody>
<tr>
<td>LR-1 to LR-2</td>
<td>Definitely/probably benign</td>
<td>Routine surveillance, consider diagnostic imaging within 6 mos</td>
</tr>
<tr>
<td>LR-3 to LR-4</td>
<td>Indeterminate/probably HCC</td>
<td>Repeat or alternative diagnostic imaging in 3-6 mos. Consider Bx for LI-RADS 4</td>
</tr>
<tr>
<td>LR-5</td>
<td>Definitely HCC</td>
<td>Plan treatment as noted below</td>
</tr>
<tr>
<td>LR-M</td>
<td>Cancer, but may not be HCC</td>
<td></td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>Lesions that meet Milan criteria can qualify for MELD exception
    points and are considered transplant candidates</li>
</ul>
<!-- -->

<ul>
<li>This accounts for pts with minimal synthetic dysfunction (and
    therefore low MELD)</li>
</ul>
<!-- -->

<ul>
<li>Milan criteria:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Single tumor with diameter >2cm but \&lt;5 cm, no more than 3 tumors,
    each \&lt;3 cm</p>
</li>
<li>
<p>No signs of extra-hepatic involvement or vascular invasion</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Liver transplant is definitive treatment, although resection can
    also be curative (favored in pts with early cirrhosis i.e. Child
    Pugh A)</p>
</li>
<li>
<p>Locoregional therapies: Pts with unresectable disease, or who are
    not surgical candidates</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>Therapy</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiofrequency ablation</td>
<td>If in a favorable location and size, IR can percutaneously ablate with a large needle that emits microwave frequencies</td>
</tr>
<tr>
<td>Trans-arterial chemoembolization (TACE)</td>
<td>Chemotherapeutic agents injected into the tumor to occlude the feeding blood supply to the area.</td>
</tr>
<tr>
<td>Trans-arterial radioembolization (TARE)</td>
<td>Like TACE, though radioactive compound (i.e. Y-90) used to occlude the feeding blood supply.</td>
</tr>
<tr>
<td>Stereotactic body Radiation Therapy (SBRT)</td>
<td>Radiation therapy: can be used as an alternative to ablation or trans-arterial therapy</td>
</tr>
<tr>
<td>Systemic Chemotherapy</td>
<td>For metastatic disease</td>
</tr>
</tbody>
</table>
<p>Coagulopathy in Cirrhosis – Garren Montgomery, John Laurenzano</p>
<p>Background</p>
<ul>
<li>
<p>The liver is responsible for production of both pro- (factor II, V,
    VII, IV, X, and XI) and anti-coagulants (protein C, S) in
    hemostasis. Factor VIII is the only one not made by the liver.</p>
</li>
<li>
<p>Thrombocytopenia is caused by splenic sequestration from portal HTN,
    failure to produce thrombopoietin (TPO), and bone marrow failure</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>INR/PT, and PTT are poorly reflective of bleeding risk</p>
</li>
<li>
<p>TEG screens and other measures of comprehensive coagulation in
    cirrhotics</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Even in bleeding, there is no need to intervene on an INR or
    platelet value</p>
</li>
<li>
<p>Pre-procedural FFP is not recommended, even in the presence of
    bleeding, but is frequently requested by different proceduralists</p>
</li>
<li>
<p>Low risk procedures (i.e., paracentesis) do not require
    pre-procedural blood products</p>
</li>
<li>
<p>In bleeding pts, the following are recommended per AASLD and AGA
    guidelines</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>IV Vitamin K 10mg x 3 days</p>
</li>
<li>
<p>FFP: Not recommended, unless as part of a balanced transfusion
    effort to avoid transfusion related coagulopathy, or if a TEG screen
    suggests potential benefit</p>
</li>
<li>
<p>Cryoprecipitate: if fibrinogen \&lt; 120</p>
</li>
<li>
<p>Platelets: No specific targets regardless of bleeding.
    Pre-procedurally, recommend >50</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Appropriate DVT ppx should be given with few exceptions (plts \&lt;50k,
    active hemorrhage)</p>
</li>
<li>
<p>For TEG transfusion recommendations are as follows:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>10 mg/kg FFP if R-time >10 minutes</p>
</li>
<li>
<p>1u Plts if maximum amplitude \&lt;55 mm</p>
</li>
<li>
<p>5u cryo if alpha angle \&lt;45</p>
</li>
</ul>
<p>Portal Vein Thrombosis (PVT) – John Laurenzano</p>
<p>Background</p>
<ul>
<li>Portal Vein Thrombosis (PVT) can worsen decompensation (i.e.
    variceal hemorrhage), however, worsening portal HTN more sluggish
    flow increased risk PVT</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Often identified asymptomatically on U/S, but can be identified by
    new or worsening decompensation of portal HTN</p>
</li>
<li>
<p>Variceal hemorrhage is the most common decompensating event
    associated with PVT</p>
</li>
<li>
<p>Intestinal ischemia (abdominal pain, hematochezia) from PVT is
    exceedingly rare but associated with significant morbidity and
    mortality</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>RUQ U/S with doppler</li>
</ul>
<!-- -->

<ul>
<li>Once identified, should be further assessed with triple phase CT or
    MRI with Gadovist contrast to exclude HCC with tumor thrombus</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pts with newly identified PVT should undergo EGD to evaluate for
    high-risk varices, both for diagnostic and therapeutic
    considerations</p>
</li>
<li>
<p>PVT in pts without cirrhosis should prompt evaluation for
    hypercoagulable disorders</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Start anticoagulation if acute thrombus occludes >50% of main
    portal vein, \&lt;50% but extends into SMV, thrombus is symptomatic, or
    patient is a transplant candidate (irrespective of size). Requires
    discussion with attending/transplant team.</li>
</ul>
<!-- -->

<ul>
<li>
<p>Anticoagulation options: warfarin, LMWH, or DOAC</p>
</li>
<li>
<p>DOAC’s are safe in Childs Class A, can be used with caution in
    Childs B, and are contraindicated in Childs C</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pts with chronic occlusive PVT (>6 mos) or with cavernous
    transformation with collaterals do not generally benefit from
    anticoagulation</p>
</li>
<li>
<p>Pts with high-risk varices should undergo endoscopic management or
    be on NSBB for prophylaxis for variceal hemorrhage, as noted above</p>
</li>
<li>
<p>TIPS with portal vein recanalization has recently emerged as a
    therapeutic modality for PVT</p>
</li>
<li>
<p>Pts should undergo follow up intermittently with ultrasound to
    assess for recanalization. AC may be stopped if there is failure to
    recanalize.</p>
</li>
<li>
<p>If pts are not candidates for AC, they'll simply be treated for
    complications of portal HTN</p>
</li>
</ul>
<p>Alcoholic Hepatitis – Alex Wiles, Julie Cui</p>
<p>Background</p>
<ul>
<li>Acute onset of rapidly progressive jaundice in pt with heavy EtOH
    intake (>40g in females or >60g in males EtOH/day for >6 mos, or
    within \&lt;60 days of abstinence)</li>
</ul>
<!-- -->

<ul>
<li>May present after they have quit drinking due to immunosuppressive
    effects of alcohol</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>AST >60, AST/ALT >1.5, both values \&lt;400 IU/L; TBili >3.0 mg/dL,
    documentation of heavy EtOH use until 8 weeks prior to presentation</p>
</li>
<li>
<p>Prognostication with Maddrey’s Discriminant Function: 4.6 * (PTpt –
    PTctrl) + Tbili</p>
</li>
</ul>
<!-- -->

<ul>
<li>Maddrey > 32 = poor 30d prognosis &amp; may benefit from steroids (see
    below)</li>
</ul>
<!-- -->

<ul>
<li>
<p>RUQ U/S to rule out obstructive cause of jaundice</p>
</li>
<li>
<p>Biopsy is not typically required but will show neutrophilic lobular
    inflammation, hepatocyte ballooning, steatosis, and pericellular
    fibrosis.</p>
</li>
<li>
<p>Phosphatidylethanol (PEth) level is a biomarker of ethanol
    consumption over ~ 4wks; >20 ng/mL can indicate chronic
    moderate/heavy alcohol intake</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>A single episode consumption can result in detectable Peth for up to
    12 days. Can be elevated for months with regular heavy alcohol
    intake</p>
</li>
<li>
<p>EtOH levels may be negative unless acutely intoxicated</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Supportive Care is essential! Consult nutrition, start high protein,
    high calorie diet, high dose Thiamine x 3d, Folate, MVI</p>
</li>
<li>
<p>Full infection workup (CXR, UA, BCx, paracentesis) regardless of
    symptoms</p>
</li>
<li>
<p>Steroids: STOP-AH Trial (NEJM 2015) showed improved mortality at 28
    days but not at 90 days in patients with Maddrey > 32 who received
    steroids; the decision to treat is very nuanced and should be
    discussed with hepatology attending.</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Prednisolone 40mg daily for pts who meet above criteria</p>
<ul>
<li>Contraindications to steroids include: presence of infection
    (must rule out first including TB, uncontrolled GI bleeding, AKI
    w/ Cr >2.5 mg/dL)</li>
</ul>
</li>
<li>
<p>The Lille score can be used to guide continuation of steroids after
    7 d of therapy</p>
</li>
<li>
<p>NAC can be considered as adjunctive therapy to steroids and may
    decrease 30-day mortality, though has not demonstrated longer
    mortality benefit at 3 or 6 months</p>
</li>
</ul>
<!-- -->

<ul>
<li>Monitor on CIWA</li>
</ul>
<!-- -->

<ul>
<li>Psychiatry consultation as appropriate, consideration of medical
    therapy (see “Substance Use Disorders” section in psychiatry)</li>
</ul>
<p>NASH and NAFLD – John Laurenzano</p>
<p>Background</p>
<ul>
<li>
<p>Non-alcoholic fatty liver disease (NAFLD): presence of hepatic
    steatosis in the absence of secondary causes (e.g, EtOH)</p>
</li>
<li>
<p>Non-alcoholic steatohepatitis (NASH): evidence of active
    inflammation in conjunction with steatosis (elevated liver enzymes
    or evidence on bx)</p>
</li>
<li>
<p>Strong association with metabolic syndrome, T2DM, HTN, obesity,
    prior cholecystectomy</p>
</li>
<li>
<p>Generally asymptomatic</p>
</li>
<li>
<p>Considered to be a common cause of cryptogenic cirrhosis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>NASH manifests with elevated liver enzymes, typically 2-5x the ULN,
    in a roughly 1:1 ratio (as opposed to alcoholic steatohepatitis),
    though ALT may be higher than AST</p>
</li>
<li>
<p>NAFLD is asymptomatic and frequently found incidentally via imaging</p>
</li>
<li>
<p>Exclusion of alternative causes and comorbid liver conditions: HCV,
    HBV, EtOH</p>
</li>
<li>
<p>Note: Ferritin is frequently elevated, though not to the extent of
    hemochromatosis. Low level auto-antibodies are also frequently
    present</p>
</li>
<li>
<p>Can be diagnosed based on imaging alone (and frequently is)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ultrasound is used most frequently, though MRI and CT also are
    acceptable; use risk scores to determine the risk of advanced
    fibrosis and identify those who would benefit from biopsy</p>
<ul>
<li>
<p>Fibrosis-4 (FIB 4) score</p>
</li>
<li>
<p>NAFLD fibrosis score</p>
</li>
</ul>
</li>
<li>
<p>More accurate, non-invasive fibrosis assessments can be done using
    elastography which can be vibration based (fibroscan), ultrasound
    based (sheer-wave), or MR-based</p>
<ul>
<li>Available at VUMC and can be ordered by anyone. Insurance will
    not cover MRE if BMI \&lt;35</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Aggressive risk factor modification and management of comorbidities
    (HLD, HTN, T2DM)</p>
</li>
<li>
<p>Weight loss: Mediterranean diet>low fat diet (dose dependent
    improvement)</p>
</li>
<li>
<p>No specific medications are FDA approved currently</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pioglitazone has shown benefit in pts with T2DM and NASH</p>
</li>
<li>
<p>Vitamin E has shown benefit in pts without T2DM and proven NASH</p>
</li>
<li>
<p>Ongoing studies for SGLT-2i and GLP-1ra; some promise indicated for
    the latter</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>While bariatric surgery is not a specific indication for NASH/NAFLD,
    increasing evidence demonstrates resolution of NASH and fibrosis in
    pts with clinically significant weight loss</p>
</li>
<li>
<p>Referral to the surgical weight loss clinic should be considered in
    any patient who meets obesity guidelines for bariatric surgery (BMI
    >40, or >35 with metabolic comorbidities)</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>Statins: should be used for HLD in pts with NASH, NAFLD and NASH
    cirrhosis</p>
</li>
<li>
<p>Statin use in decompensated NASH cirrhosis is controversial, and
    they are less likely to derive benefit given overall poor prognosis.
    There is an increased risk of rhabdomyolysis in pts with acute on
    chronic liver failure and are considered contraindicated</p>
</li>
<li>
<p>Metformin is safe and may have a survival benefit in patients with
    diabetes and cirrhosis. Discontinue only in those who have increased
    risk for lactic acidosis (renal impairment and significant EtOH).
    Sulfonylureas are generally avoided.</p>
</li>
</ul>
<p>Acute Liver Injury and Failure – Jacob Parnell, Judd Heideman, Hannah
Lomzenski, and Lauren Chan</p>
<p>Background</p>
<ul>
<li>
<p>Acute liver injury (ALI): elevated liver enzymes + INR ≥1.5 but NO
    encephalopathy</p>
</li>
<li>
<p>Acute liver failure (ALF): elevated liver enzymes +
    encephalopathy/AMS in the absence of pre-existing liver disease*</p>
</li>
</ul>
<!-- -->

<ul>
<li>*Chronic autoimmune hepatitis, HBV, Wilson disease, and Budd-Chiari
    syndrome can have ALF if they develop new AMS, despite the presence
    of a pre-existing liver disease</li>
</ul>
<!-- -->

<ul>
<li>Alcohol-associated hepatitis (AH) is not ALF (see above)</li>
</ul>
<p>Etiology</p>
<ul>
<li>R-factor (if history, exam, and diagnostic data are inconclusive
    i.e. R-factor is not a replacement to clinical judgement) = (ALT/uln
    ALT) / (ALP/uln ALP); See chart below</li>
</ul>
<!-- -->

<ul>
<li>R > 5 = hepatocellular injury; R\&lt;2 = cholestatic injury; R 2-5 =
    mixed injury</li>
</ul>
<!-- -->

<ul>
<li>Isolated hyperbilirubinemia: Differentiate direct versus indirect</li>
</ul>
<!-- -->

<ul>
<li>
<p>Direct: Refer to cholestatic pattern</p>
</li>
<li>
<p>Indirect: Gilbert vs hemolysis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Drugs Associated with liver injury</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hepatocellular pattern: acarbose, Acetaminophen, Allopurinol,
    Amiodarone, Baclofen, Bupropion, Fluoxetine, HAART (Nevirapine),
    Kava kava, Isoniazid, Ketoconazole, Lisinopril, Losartan,
    Methotrexate, NSAIDs, Omeprazole, Oxacillin/Nafcillin, Paroxetine,
    Pyrazinamide, Propylthiouracil, Rifampin, Risperidone, Sertraline,
    Statins, Tetracycline, Trazodone, Valproic Acid</p>
</li>
<li>
<p>Mixed pattern: Amitriptyline, Azathioprine, Captopril,
    Carbamazepine, Clindamycin, Cyproheptadine, Enalapril, Flutemide,
    Nitrofurantoin, Phenobarbital, Phenytoin, Sulfonamides, Trazodone,
    Verapamil</p>
</li>
<li>
<p>Cholestatic pattern: Amoxicillin-clavulanic acid, Anabolic steroids,
    Chlorpromazine, Clopidogrel, Oral contraceptives, Erythromycins,
    Estrogens, Irbesartan, Mirtazapine, Phenothiazines, Terbinafine,
    Tricyclics</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 34%" />
<col style="width: 25%" />
<col style="width: 40%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3">Hepatocellular Injury: R factor &gt; 5 (Primary
elevation of AST/ALT)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Acetaminophen intoxication<sup>$</sup></td>
<td></td>
<td><p>Acetaminophen lvl</p>
<p>Aspirin lvl</p></td>
</tr>
<tr class="even">
<td>Acute Viral Hepatitis</td>
<td><p>Hep A<sup>$</sup>, B*<sup>$</sup>, C*, D, E</p>
<p>EBV, CMV, HSV, VZV</p></td>
<td>Viral serologies (see below), hx of tattoos, IVDU, piercings, blood
transfusion prior to 1990s, intranasal cocaine use and mass vaccinations
(in 3rd world countries)</td>
</tr>
<tr class="odd">
<td>Autoimmune hepatitis\*</td>
<td>Autoantibodies and high serum globulins</td>
<td>Anti-smooth muscle (f-actin), ANA, ANCA, anti-liver kidney microsome
(anti-LKM-1), anti-soluble liver antigen/liver-pancreas IgG</td>
</tr>
<tr class="even">
<td>Budd-Chiari Syndrome\*</td>
<td>Hepatic vein obstruction</td>
<td>Ultrasound of abdomen w/ doppler, CT w/ contrast</td>
</tr>
<tr class="odd">
<td>DILI – Drug Induced Liver Injury\*<sup>$</sup></td>
<td>Many drugs</td>
<td>See above<br />
\*Query NIH Liver Tox database: <a
href="https://www.livertox.nih.gov">https://www.livertox.nih.gov</a></td>
</tr>
<tr class="even">
<td>HELLP Syndrome, Acute Fatty Liver of Pregnancy</td>
<td>Pregnancy</td>
<td>Requires urgent delivery regardless of gestational age</td>
</tr>
<tr class="odd">
<td>Ischemic Liver Injury (Shock Liver)<sup>$</sup></td>
<td>Shock (can be of any variety)</td>
<td>AST and ALT can be in the thousands, high LDH, history of
hypotension</td>
</tr>
<tr class="even">
<td>Toxins</td>
<td>Ethanol, cocaine, mushroom (Amanita phalloides)</td>
<td>UDS, ethanol level, PEth lvl</td>
</tr>
<tr class="odd">
<td>Wilson’s Disease\*</td>
<td>Copper overload</td>
<td>Ceruloplasmin level (screening), 24h urine copper (confirmation),
quantitative copper on liver biopsy</td>
</tr>
<tr class="even">
<td colspan="3"><em>\*May present with chronic liver injury as well; $May
present with AST/ALT &gt;100</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cholestatic Injury: R Factor \&lt; 2 (Primarily elevated Alkaline phosphatase)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute biliary obstruction</td>
<td>Gallstones</td>
<td>Abdominal ultrasound, MRCP, ERCP</td>
</tr>
<tr>
<td>DILI – Drug-induced liver injury*<sup>$</sup></td>
<td>Many drugs, consult livertox website</td>
<td>Common: Augmentin, Bactrim, amiodarone, Imuran</td>
</tr>
<tr>
<td>Malignancy*</td>
<td>Pancreas, cholangiocarcinoma</td>
<td>CT abdomen, ERCP</td>
</tr>
<tr>
<td>Primary Biliary Cirrhosis*</td>
<td>Autoimmune</td>
<td>Anti-mitochondrial antibody</td>
</tr>
<tr>
<td>Primary Sclerosing Cholangitis*</td>
<td>Autoimmune, associated with IBD</td>
<td>MRCP, ERCP</td>
</tr>
<tr>
<td>Critical illness or COVID cholangiopathy</td>
<td>Hypotension, COVID</td>
<td>MRCP with biliary stenosis, appropriate history</td>
</tr>
<tr>
<td><em>*May present with chronic liver injury as well; $May present with AST/ALT >100</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>
<p>Consult hepatology early! (to assist with workup AND for transplant
    evaluation)</p>
</li>
<li>
<p>Labs:</p>
</li>
<li>
<p>CBC w/diff, CMP, Dbili, Mg, Phos, T&amp;S, BCx, UCx, PT/INR, aPTT,
    fibrinogen</p>
</li>
<li>
<p>Amylase, lipase</p>
</li>
<li>
<p>Beta-hCG for females of childbearing age</p>
</li>
<li>
<p>ABG with arterial lactate, ammonia (arterial >124 predicts
    mortality and CNS complications e.g., need for intubation, seizures,
    cerebral edema, \&lt;75 very unlikely to develop ICH)</p>
</li>
<li>
<p>Viral etiologies: Viral hepatitis serologies (HAV panel, HBV panel,
    HCV IgG &plusmn; PCR quant, HDV if known HBV (with low or undetectable
    HBV load) as Misc Reference Test, Hepatitis E PCR sent as
    miscellaneous if pregnant or travel to southeast Asia), HIV p24 Ag
    and HIV Ab, EBV Qt, CMV Qt, HSV &frac12;, Qt, VZV IgM/IgG</p>
</li>
<li>
<p>Toxins: UDS, ethanol level &plusmn; Peth, acetaminophen level (drawn ≥4
    hours after last known ingestion), salicylate level</p>
</li>
<li>
<p>Autoimmune/genetic: ANA, ASMA, IgG, AMA (if predominantly elevated
    ALP), ceruloplasmin</p>
</li>
</ul>
<!-- -->

<ul>
<li>Imaging:</li>
</ul>
<!-- -->

<ul>
<li>
<p>RUQ U/S with doppler</p>
</li>
<li>
<p>Consider CT with contrast in patients with normal renal function and
    high suspicion of Budd-Chiari syndrome or malignancy with negative
    ultrasound (better for assessing the hepatic veins) and helps with
    transplant evaluation</p>
</li>
<li>
<p>Consider ERCP/MRCP for cholestatic etiologies</p>
</li>
</ul>
<p>Criteria for Transplantation:</p>
<ul>
<li>King’s College criteria: helps identify patients needing transplant
    referral/consideration for acetaminophen overdose</li>
</ul>
<!-- -->

<ul>
<li>
<p>Arterial pH \&lt;7.3 after resuscitation and >24 hr since ingestion,
    OR</p>
</li>
<li>
<p>Arterial lactate >3 after adequate fluid resuscitation, OR</p>
</li>
<li>
<p>Grade III- IV HE, SCr >3.4, and INR >6.5 all within 24h period</p>
</li>
</ul>
<!-- -->

<ul>
<li>ALF not due to acetaminophen: INR > 6.5 OR 3 of the 5 following
    criteria:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Indeterminate non HAV, non HBV etiology, drug-induced hepatitis</p>
</li>
<li>
<p>Age \&lt;10 or >40</p>
</li>
<li>
<p>Interval of jaundice to onset of encephalopathy >7 days</p>
</li>
<li>
<p>Bilirubin > 17.5mg/dl (300μmol/L)</p>
</li>
<li>
<p>INR >3.5</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Any pt with concern for ALF should be cared for in MICU (even if
    mild change in mental status)</p>
</li>
<li>
<p>Pts with ALF may die acutely from hypoglycemia, cerebral edema, and
    infection</p>
</li>
<li>
<p>ABC’s:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Intubate for GCS \&lt;8, Grade 3 or 4 HE</p>
</li>
<li>
<p>IVF resuscitation with isotonic crystalloid (most pts are volume
    deplete; avoid hypotonic fluids due to risk of cerebral edema)</p>
</li>
<li>
<p>Vasopressive agents for persistent hypotension (guidelines outline
    the choice of pressors and should be here)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Monitoring:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Q1-2h neuro checks, Q1-2h glucose checks</p>
</li>
<li>
<p>Closely monitor CMP, INR q6-8 hrs</p>
</li>
</ul>
<!-- -->

<ul>
<li>Treatment of Primary Injury</li>
</ul>
<!-- -->

<ul>
<li>
<p>IV N-acetylcysteine: Must be given when acetaminophen toxicity is
    known or suspected. It may be considered in other etiologies of ALF
    as it may improve transplant-free survival especially those with ALF
    due to non acetaminophen DILI.</p>
<ul>
<li>
<p>Initial loading dose = 150mg/kg over 1 hour, then 50mg/kg/hr for
    4 hours, then 100mg/kg/hr for 16 hours</p>
</li>
<li>
<p>Patients with early-stage hepatic encephalopathy (grade I/II)
    have increased transplant free survival, while those with grade
    III/IV do not</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Treatment of Secondary Complications</li>
</ul>
<!-- -->

<ul>
<li>
<p>Infection: Rule out infection with CXR, Blood cultures, UA for every
    ALF. Antibiotics only if progressing HE, signs of infection, or
    development of SIRS</p>
</li>
<li>
<p>Cerebral edema/increased ICP:</p>
<ul>
<li>
<p>Grade I-II hepatic encephalopathy: lactulose but should not be
    administered to the point of diarrhea, and may interfere with
    the surgical field by increasing bowel distention during liver
    transplantation</p>
</li>
<li>
<p>Grade III-IV hepatic encephalopathy: elevated HOB to 30 degrees,
    quiet and dimly lit room, should be intubated, and ICP monitor
    are recommended (if not feasible, hourly neuro checks can be an
    alternative). If ICP becomes elevated:</p>
<ul>
<li>
<p>Mannitol (0.5-1g/kg) is first line</p>
</li>
<li>
<p>If high ICP is refractory to osmotic agents, consider
    phenobarbital, indomethacin, and/or cooling to 33-34 degrees
    Celsius if awaiting LT</p>
</li>
<li>
<p>Hyperventilation may be considered for impending ventilation</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Seizures: phenytoin (no evidence to support seizure ppx), short
    acting benzodiazepines if refractory</p>
</li>
<li>
<p>Renal Failure: early CRRT if persistent metabolic acidosis, volume
    overload, falling UOP</p>
</li>
<li>
<p>Coagulopathy: IV Vit K (at least one dose) routinely to rule out Vit
    K deficiency, products for invasive procedures or active bleeding
    only</p>
</li>
<li>
<p>Metabolic: Correction of hypoglycemia and electrolyte abnormalities</p>
</li>
<li>
<p>Circulatory dysfunction/shock: Goal MAP >75 mmHg. Ensure
    intravascularly replete, add norepinephrine first line, vasopressin
    can be used second line but may increase ICP. Consider stress dose
    steroids for refractory shock.</p>
</li>
</ul>
<!-- -->

<ul>
<li>Additional Supportive Care</li>
</ul>
<!-- -->

<ul>
<li>
<p>PPI for bleeding ppx</p>
</li>
<li>
<p>Enteral nutrition EARLY; avoid TPN if possible</p>
</li>
<li>
<p>Prefer propofol for sedation for better neuro exams and may reduce
    cerebral blood flow</p>
</li>
</ul>
<p>Specific Management by Etiology:</p>
<ul>
<li>Acetaminophen</li>
</ul>
<!-- -->

<ul>
<li>
<p>Early toxicology consultation if suspected ingestion/overdose</p>
</li>
<li>
<p>For acute management contact Poison Control 800-222-1222</p>
</li>
<li>
<p>Activated charcoal within 4 hours of ingestion, most effective
    within 1 hour</p>
</li>
<li>
<p>IV N-acetylcysteine per protocol, look up Rumack-Matthew Nomogram
    and consult with toxicology</p>
<ul>
<li>In Epic: search “N-acetylcysteine” and select order set
    “Acetaminophen overdose”</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>AFLP/HELLP – delivery</p>
</li>
<li>
<p>Amanita phalloides – IV fluid resuscitation, PO charcoal, IV
    penicillin, IV acetylcysteine</p>
</li>
<li>
<p>Autoimmune – IV steroids following approval by hepatology (and
    typically post biopsy). Azathioprine generally deferred until
    cholestasis resolved (Mycophenolate can be used instead)</p>
</li>
<li>
<p>Budd-Chiari – anticoagulation, IR-guided endovascular therapy,
    transplant (must rule out underlying malignancy and evaluate for
    thrombotic disorders)</p>
</li>
<li>
<p>HAV/HEV – supportive care, consider ribavirin for ALF due to HEV</p>
</li>
<li>
<p>HBV – nucleos(t)ide analogue; orthotopic liver transplant</p>
</li>
<li>
<p>HSV – acyclovir</p>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Hepatology</h1>
                        <h1 class='nav-section-title' id='section-hospital-medicine'>
                            Hospital medicine <a class='headerlink' href='#section-hospital-medicine' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="hospital-medicine-hospital-medicine-enteral-nutrition"><h1 id="hospital-medicine-hospital-medicine-enteral-nutrition-enteral-nutrition">Enteral Nutrition<a class="headerlink" href="#hospital-medicine-hospital-medicine-enteral-nutrition-enteral-nutrition" title="Permanent link">&para;</a></h1>
<p>Soibhan Kelley</p>
<hr />
<h2 id="hospital-medicine-hospital-medicine-enteral-nutrition-indications-for-enteral-feeding">Indications for enteral feeding<a class="headerlink" href="#hospital-medicine-hospital-medicine-enteral-nutrition-indications-for-enteral-feeding" title="Permanent link">&para;</a></h2>
<ul>
<li>Patients with high nutritional risk who are unable to maintain their own intake<ul>
<li>Guidelines recommend calculating nutritional risk based on validated scoring tool (ex: Malnutrition Screening Tool). This is usually completed by the nutrition team</li>
<li>Recognize who would benefit from nutrition consult to assist with risk determination<ul>
<li>Patients with &gt;5% weight loss in past 1-3 months or decreased oral intake coupled with increased metabolic demands due to medical illness or surgery</li>
</ul>
</li>
</ul>
</li>
<li>Patients with low nutritional risk may not need enteral feeding if it is anticipated they will resume intake in 5-7 days</li>
<li>Critically ill patients: goal is early initiation of tube feeding (within 48 hours)</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-enteral-nutrition-contraindications-to-enteral-nutrition">Contraindications to enteral nutrition<a class="headerlink" href="#hospital-medicine-hospital-medicine-enteral-nutrition-contraindications-to-enteral-nutrition" title="Permanent link">&para;</a></h2>
<ul>
<li>Bowel obstruction or severe ileus</li>
<li>Ischemic bowel</li>
<li>Acute peritonitis</li>
<li>Major gastrointestinal bleeding</li>
<li>Intractable vomiting</li>
<li>Significant hemodynamic instability<ul>
<li>Patients who are not adequately volume resuscitated and have significant hemodynamic instability (i.e., have high pressor requirements) are thought to be at increased risk for bowel ischemia<ul>
<li>Pressors in general are not a contraindication to tube feeds. Ok to start once pressors are down-trending or at a stable level</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-enteral-nutrition-initiating-tube-feeds">Initiating tube feeds<a class="headerlink" href="#hospital-medicine-hospital-medicine-enteral-nutrition-initiating-tube-feeds" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Enteral access</p>
<ul>
<li>Nasogastric or orogastric feeding tube in acute setting. See procedures section for tips on placement</li>
<li>For most patients, enteral feeding is safe with gastric tube placement<ul>
<li>Consider post-pyloric placement for patients with high aspiration risk, impaired gastric motility, or patients who have demonstrated intolerance with gastric feeding</li>
</ul>
</li>
<li>Consider percutaneous endoscopic gastrostomy (PEG) tube placement if anticipate enteral nutrition &gt;4 weeks</li>
</ul>
</li>
<li>
<p>Choice of formula and rate</p>
<ul>
<li>Place nutrition consult. RD will calculation caloric and protein needs to determine goal rate and formulation</li>
<li>
<p>OK to start tube feeds prior to recommendations and adjust later, especially if recommendations will be delayed. It only takes a simple calculation to make a reasonable tube feeding plan</p>
<ul>
<li>Use weight-based dosing for calorie requirements<ul>
<li>Use 25-30 cal/kg (use ideal body weight for most patients, use actual weight for underweight patient) to estimate daily needs</li>
</ul>
</li>
<li>Most common formula used at VUMC is Nutren 1.5 (1.5 cal/ml) or Novasource renal if significant renal impairment (2 cal/ml)</li>
<li>Patients may need additional free water (most tube feed formulas are comprised of 80-85% water but varies with type). Typically dose as bolus of free water every 4-6 hours.<ul>
<li>May empirically try 250cc free water every 4 hours and monitor Na trends. May need more if already with a large fluid deficit (ex: hypernatremia) or if high volume losses</li>
<li>May use clinical calculators as below</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Calculate hourly rate based on daily calorie need and formula calorie density</p>
<ul>
<li>Ex: Patient with IBW of 70Kg will need estimated 1,750 calories per day (70 x 25 cal/kg)</li>
<li>If using Nutren 1.5, this will equal 1,167 ml per day (1,750 divided by 1.5 calories per ml). This would equal a goal rate of about 50ml per hour (rounded up) of Nutren 1.5</li>
<li>Resources for quick calculations:<ul>
<li>Search for “tube feed cheat sheet” on google and will find reference tables on EMCrit.org that gives you rate per hour for different weights and formula types</li>
<li>Clincalc.com also has a useful enteral nutrition calculator</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Start initially at a low rate (such as 10 mL/hr) to assess tolerability and advance to goal</p>
<ul>
<li>Advance quickly if no concern for refeeding syndrome (ex: increase by 10cc/hr q6h)</li>
<li>If risk for refeeding syndrome or other issues with tolerability, typically advance more slowly over several days</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-enteral-nutrition-potential-complications">Potential Complications<a class="headerlink" href="#hospital-medicine-hospital-medicine-enteral-nutrition-potential-complications" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Aspiration</p>
<ul>
<li>Recommendation to keep head of bed elevated at 30 to 45 degrees (low quality, mixed evidence). Consider risks of this positioning (ex: formation of pressure ulcers)</li>
<li>Consider post-pyloric placement if issues with aspiration (low quality, mixed evidence)</li>
</ul>
</li>
<li>
<p>Diarrhea or constipation</p>
<ul>
<li>Consider wheat dextrin fiber supplement (low quality evidence) but discontinue if not associated with clinical improvement. Avoid less soluble fibers such as psyllium due to risk of clogging tube. Avoid in patients with reduced GI motility due to rare risk of bezoar formation</li>
</ul>
</li>
<li>
<p>Hyperglycemia</p>
<ul>
<li>See endocrine section for management</li>
</ul>
</li>
<li>
<p>Refeeding syndrome</p>
<ul>
<li>Monitor q8 hour Mg, phos, K in high-risk patients (underweight, recent weight loss, prolonged poor intake) and advance to goal slowly</li>
</ul>
</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients"><h1 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-guidelines-for-pregnant-patients">Guidelines for Pregnant Patients<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-guidelines-for-pregnant-patients" title="Permanent link">&para;</a></h1>
<p>Ahmad Dbouk and Samuel Lazaroff</p>
<hr />
<h2 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-acute-cystitis">Acute Cystitis:<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-acute-cystitis" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Significantly increased prevalence in pregnancy</p>
</li>
<li>
<p>Symptoms: dysuria (urgency/frequency common in pregnancy)</p>
</li>
<li>
<p>Diagnosis: evidence of pyuria and &gt;103 cfu/ml (note, if neg would test for g/c)</p>
</li>
<li>
<p>Treatment: Empiric with cephalexin, cefpodoxime, amoxicillin-clavulanate, fosfomycin. Nitrofurantoin ok in second or third trimester. Avoid Bactrim in first trimester and near term. Tailor based on culture results.</p>
</li>
<li>
<p>Note that asymptomatic bacteriuria is treated in pregnancy (in contrast with general public). Same antibiotic choices as above</p>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-pyelonephritis">Pyelonephritis:<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-pyelonephritis" title="Permanent link">&para;</a></h2>
<ul>
<li>Symptoms: fever, flank pain, and nausea/vomiting, dysuria</li>
<li>Diagnosis: clinical suspicion + pyuria and bacteriuria</li>
<li>Treatment: IV antibiotics for 1 <sup>st</sup> 24-48hrs; beta-lactams
    preferred</li>
<li>Mild to moderate: ceftriaxone or cefepime</li>
<li>Moderate to severe: piperacillin-tazobactam or meropenem</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-hyperemesis-gravidarum">Hyperemesis Gravidarum:<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-hyperemesis-gravidarum" title="Permanent link">&para;</a></h2>
<ul>
<li>Presentation: Hormone mediated nausea/vomiting typically starting
    before 9wks GA</li>
<li>Differential: gastroenteritis, hepatitis, biliary tract disease,
    obstruction, pancreatitis, pyelonephritis, nephrolithiasis, ovarian
    torsion, DKA, hyperparathyroidism, migraines, preeclampsia</li>
<li>Workup: BMP, mg, phos, LFTs, lipase (may be mildly elevated in HG),
    UA,</li>
<li>Treatment:<ul>
<li>
<ul>
<li>First Line: Ginger, doxylamine (25mg PO q6), pyridoxine
        (20mg PO q6)</li>
<li>Second Line: metoclopramide (10mg q6), Promethazine (12.5mg
    q6)</li>
<li>Third Line: ondansetron (8mg q12hrs, after 1<sup>st</sup> trimester)</li>
<li>Hydration: 1L LR on admission + banana bag q24hrs</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-hypertension">Hypertension:<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-hypertension" title="Permanent link">&para;</a></h2>
<ul>
<li>Both gestational HTN and preeclampsia/HELLP are typically
    diagnosed &gt;20w GA</li>
<li>Tx options: nifedipine, labetalol, methyldopa, hydral (2
    <sup>nd</sup> line), clonidine (2 <sup>nd</sup> line)</li>
<li>Avoid: ACEs, ARBs, MRAs, Nitroprusside</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-diabetes">Diabetes:<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-diabetes" title="Permanent link">&para;</a></h2>
<ul>
<li>Due to hormonal changes associated with pregnancy, pregnant patients
    are at higher risk for poor control and DKA</li>
<li>Oral regimens are generally transitioned to insulin-based regimens.</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-gerd">GERD:<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-gerd" title="Permanent link">&para;</a></h2>
<ul>
<li>1<sup>st</sup> Line: Can use antacids; avoid sodium bicarbonate and magnesium
    trisilicate</li>
<li>2<sup>nd</sup> Line: Sucralfate 1g PO TID</li>
<li>3<sup>rd</sup> Line: Cimetidine 200mg (30min prior to eating)</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-guidelines-pregnant-patients-asthma">Asthma:<a class="headerlink" href="#hospital-medicine-hospital-medicine-guidelines-pregnant-patients-asthma" title="Permanent link">&para;</a></h2>
<ul>
<li>Similar rescue and controller medications as in non-pregnant patient</li>
<li>Would favor using LABA over leukotriene receptor antagonists or
    theophylline for additional therapy</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-lines-and-catheters"><h1 id="hospital-medicine-hospital-medicine-lines-and-catheters-lines-and-catheters">Lines and Catheters<a class="headerlink" href="#hospital-medicine-hospital-medicine-lines-and-catheters-lines-and-catheters" title="Permanent link">&para;</a></h1>
<p>Ahman Dbouk and Samuel Lazaroff</p>
<hr />
<h2 id="hospital-medicine-hospital-medicine-lines-and-catheters-foley-catheter">Foley Catheter<a class="headerlink" href="#hospital-medicine-hospital-medicine-lines-and-catheters-foley-catheter" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Indications: urinary retention, close urine output monitoring in critical illness or renal failure, need for strict I&amp;Os (ex: diuresis) and unable to be achieved without catheter, surgery, open sacral/perineal wounds with incontinence, patient comfort at end of life</p>
<ul>
<li>Urinary incontinence alone is not an indication for foley catheter</li>
</ul>
</li>
<li>
<p>Duration of use is biggest risk factor for CAUTI</p>
<ul>
<li>Best way to prevent CAUTI is to avoid inappropriate placement</li>
<li>Assess daily whether foley can be removed</li>
</ul>
</li>
<li>
<p>Chronic Foleys generally should be exchanged at time of admission</p>
</li>
<li>
<p>Any concern for catheter obstruction (particularly with blood clots) should prompt urgent urology consult for irrigation/intervention (typically after RN has attempted)</p>
</li>
<li>
<p>Difficult foley placement</p>
<ul>
<li>Make sure an attempt has been made with a Coudé catheter. This catheter has a curved tip that can be useful in patients with BPH</li>
</ul>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-lines-and-catheters-picc">PICC<a class="headerlink" href="#hospital-medicine-hospital-medicine-lines-and-catheters-picc" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Single lumen: long term Abx, stable IV access with intermittent draws</p>
</li>
<li>
<p>Double lumen: special populations (ICU or chemo), TPN w/ lipids (incompatible with many IV medications)</p>
</li>
<li>
<p>Risk factors for CLABSI/VTE: ↑↑duration, ↑↑number of lumens, left arm, lower extremity</p>
</li>
<li>
<p>A note on midlines:</p>
<ul>
<li>A midline is just a long PIV inserted into the deep veins in the arm, typically 6-15cm<ul>
<li>For reference, when you place an US-guided IV, the “long” 18G needles at VUMC are 2.5 inches (~6.4cm)</li>
<li>Not much benefit compared to US-guided IV. Useful for stable IV access for meds and fluids. Not a stable route for blood draws</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-lines-and-catheters-g-tube">G-Tube<a class="headerlink" href="#hospital-medicine-hospital-medicine-lines-and-catheters-g-tube" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Troubleshooting: EGS consult for malposition/not functioning, wound consult for skin breakdown</p>
</li>
<li>
<p>G-tube study: 30mL Gastrograffin via tube [resident often must push], and order KUB</p>
</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-mobility-and-hospital-therapy"><h1 id="hospital-medicine-hospital-medicine-mobility-and-hospital-therapy-mobility-and-in-hospital-therapy">Mobility and In-Hospital Therapy<a class="headerlink" href="#hospital-medicine-hospital-medicine-mobility-and-hospital-therapy-mobility-and-in-hospital-therapy" title="Permanent link">&para;</a></h1>
<p>Add columns for “PT DC Recs” and “OT DC Recs” to see dispo plans on your
EPIC list, and consult PT/OT early in hospitalization!</p>
<ul>
<li>How to reach PT/OT/SLP in hospital:<ul>
<li>Check “Care Team” in Patient Summary tab for pts’ specific
    provider and page their associated pager</li>
<li>If provider is not listed:<ul>
<li>For PT/OT page Inpatient Rehab pager 835-1147</li>
<li>For SLP: see last note and page number at the bottom</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Physical Therapy: specifically targets mobility and activity to overcome
physical impairment. (Think: lower extremity and gait).</p>
<p>Occupational Therapy: aims to improve pt’s ability to participate in
daily activities, often involving use of the hands. Skills are tailored
to pt’s cognitive abilities. (Think: head and upper extremity).</p>
<p>Speech Language Pathology</p>
<ul>
<li>Perform fluoro-guided video swallow studies and provide guidance for
    mechanically altered solid and liquid diets</li>
<li>Can perform cognitive assessment on patients, helping in assessment
    of competency</li>
</ul>
<p>Ordering Home Health</p>
<ul>
<li>VU: CM typically coordinates this for you. If not, place ambulatory
    referral to home health in discharge orders. Select needed services
    on dropdown menu</li>
<li>VA: Orders
    à
    Consult Menu
    à
    “Services NOT offered by TVHS” (under Community Care on bottom
    right)
    à
    options for PT and OT under Skilled Home Health in rightmost column</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-telemetry"><h1 id="hospital-medicine-hospital-medicine-telemetry-telemetry">Telemetry<a class="headerlink" href="#hospital-medicine-hospital-medicine-telemetry-telemetry" title="Permanent link">&para;</a></h1>
<p>Ahmad Dbouk and Samuel Lazaroff</p>
<hr />
<h2 id="hospital-medicine-hospital-medicine-telemetry-background">Background<a class="headerlink" href="#hospital-medicine-hospital-medicine-telemetry-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Many monitored pts do not have a true indication</p>
<ul>
<li>Leads to alarm fatigue, unnecessary workups, and is expensive</li>
</ul>
</li>
<li>
<p>Telemetry is not a substitute for more frequent vital signs</p>
</li>
<li>
<p>Discuss frequently on rounds: always reassess need and indication</p>
</li>
<li>
<p>Stable patients without troponin elevation or new arrythmias are typically appropriate for transfers without telemetry</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Scenario</td>
<td>Duration</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Cardiac</td>
</tr>
<tr>
<td>ACS Post-MI</td>
<td>24-48h 48h after revascularization</td>
</tr>
<tr>
<td>Vasospastic angina</td>
<td>Until symptoms resolve</td>
</tr>
<tr>
<td>Any event requiring ICD shocks</td>
<td>Remainder of hospitalization</td>
</tr>
<tr>
<td>New/unstable atrial tachyarrhythmias</td>
<td>Until stable on medical therapies</td>
</tr>
<tr>
<td>Chronic AF w/ recurrence of RVR</td>
<td>Clinical judgement</td>
</tr>
<tr>
<td>Ventricular tachyarrhythmias</td>
<td>Until definitive therapy</td>
</tr>
<tr>
<td>Symptomatic bradycardia</td>
<td>Until definitive therapy</td>
</tr>
<tr>
<td>Decompensated CHF</td>
<td>Until underlying cause treated</td>
</tr>
<tr>
<td>Procedural</td>
<td>Procedural</td>
</tr>
<tr>
<td>Ablation (regardless of co-morbidities)</td>
<td>12-24h after procedure</td>
</tr>
<tr>
<td>Cardiac surgery</td>
<td>48-72h, or until discharge if high risk for decompensation</td>
</tr>
<tr>
<td>Non-cardiac major surgery in patient with AF risk factors</td>
<td>Until discharge from step-down or ICU</td>
</tr>
<tr>
<td>Conscious sedation</td>
<td>Until patient awake, alert, HDS</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>Miscellaneous</td>
</tr>
<tr>
<td>Endocarditis</td>
<td>Until clinically stable</td>
</tr>
<tr>
<td>CVA</td>
<td>24-48h</td>
</tr>
<tr>
<td>Electrolyte derangement (K, Mg)</td>
<td>Until normalization</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>Clinical judgement</td>
</tr>
<tr>
<td>Drug overdose</td>
<td>Until free of influence of substance</td>
</tr>
</tbody>
</table>
<p>Notable non-indications:</p>
<ul>
<li>PCI for non-ACS indication (i.e. pre-transplant), non-cardiac chest
    pain, Pt with AICD admitted for non-cardiac cause, non-cardiac
    surgery, chronic AF and clinically stable</li>
<li>Contraindicated in hospice/comfort care</li>
<li>Nearly all noncardiac conditions (i.e.,
    undifferentiated sepsis, stable GI bleed, alcohol withdrawal) upon
    transfer out of ICU</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-transitions-of-care"><h1 id="hospital-medicine-hospital-medicine-transitions-of-care-transitions-of-care-tips-for-safe-discharges">Transitions of Care: Tips for Safe Discharges<a class="headerlink" href="#hospital-medicine-hospital-medicine-transitions-of-care-transitions-of-care-tips-for-safe-discharges" title="Permanent link">&para;</a></h1>
<p>Soibhan Kelley</p>
<hr />
<ul>
<li>
<p>Discharge from hospital represents a period of vulnerability for patients. Medical errors (especially medication errors) following discharge are exceedingly common and can lead to adverse events</p>
</li>
<li>
<p>At VUMC we are fortunate to have the Discharge Care Center</p>
<ul>
<li>Multidisciplinary team including nurses, social workers, care coordinators, and pharmacists</li>
<li>Phone number is included on discharge paperwork and patients can contact them 24/7. The DCC also reaches out to patients through an automated system</li>
</ul>
</li>
<li>
<p>How residents can promote safe discharges:</p>
<ul>
<li><em>Communicate with patient’s outpatient team (i.e. PCP)</em><ul>
<li>Typically achieved through the discharge summary<ul>
<li>Include a list of specific, actionable follow-up tasks and assign a responsible party.</li>
<li>Place in easy-to-view spot at the top of the summary<ul>
<li>Ex: Instead of writing “follow-up BMP after initiation of furosemide,” write “PCP to check BMP in 2 weeks after initiation of furosemide”</li>
<li>Include any pending studies and appointments from hospital admission</li>
</ul>
</li>
<li>All relevant parties should receive a copy of the discharge summary (see appendices section for mechanics of discharge process)<ul>
<li>It is useful to send patient with a printed copy of the discharge summary if they will follow-up outside VUMC</li>
<li>For high-risk discharges (patients with poor health literacy, hx of being lost to follow-up, patients following up outside VUMC) consider calling PCP’s office to set follow-up</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><em>Complete an accurate and thorough medication reconciliation</em></p>
<ul>
<li>An accurate discharge medication list depends on having a complete admission medication reconciliation (utilize pharmacy consult!)<ul>
<li>Three steps to medication reconciliation:<ul>
<li>Verification: Performing a Best Possible Medication History</li>
<li>Clarification: Checking that medications and doses are appropriate</li>
<li>Reconciliation: Record all medication changes</li>
</ul>
</li>
<li>Seek to use at least two sources of information</li>
<li>Keep a list of any held or changed medications in your hospital course. Medication changes can be lost when not communicated during team transitions</li>
<li>Review medication changes on rounds and with pharmacist on day of discharge (bonus points for day prior to discharge)</li>
</ul>
</li>
<li>Highlight any significant medication changes on discharge summary<ul>
<li>Can include as follow-up tasks if pertinent (ex: PCP to follow-up BP in 2 weeks. Losartan held on d/c due to AKI but anticipate need to reinitiate once Cr normalizes)</li>
</ul>
</li>
<li>Be sure to communicate any changes with the patient and/or caregiver</li>
</ul>
</li>
<li>
<p><em>Ensure that appropriate resources and follow-up appointments have been requested</em> (PT/OT, skilled or non-skilled nursing HH, PCP follow-up, etc.)</p>
</li>
<li>
<p><em>Effectively communicate discharge plan to patient</em></p>
<ul>
<li>Discuss medication changes, tasks for patient to complete, follow-up appointments<ul>
<li>Key points should also be written in the patient instructions box</li>
<li>Useful to include educational sheets in the AVS (searchable in discharge navigator)</li>
<li>Utilize the teach-back method to ensure your instructions were effectively communicated</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="hospital-medicine-hospital-medicine-wounds"><h1 id="hospital-medicine-hospital-medicine-wounds-wounds-adapted-from-dr-duggans-geriatrics-guide">Wounds − Adapted from Dr. Duggan’s Geriatrics Guide<a class="headerlink" href="#hospital-medicine-hospital-medicine-wounds-wounds-adapted-from-dr-duggans-geriatrics-guide" title="Permanent link">&para;</a></h1>
<hr />
<ul>
<li>
<p>To do when admitting a patient with wounds:</p>
<ul>
<li>Document ALL wounds that are present on admission. This affects reimbursement</li>
</ul>
</li>
<li>
<p>Use the Haiku app on your cell phone to document images of wounds in chart</p>
</li>
<li>
<p>Wound Service hours are Monday through Friday, 6 AM - 2 PM</p>
<ul>
<li>
<p>If there is an urgent/emergent wound need (i.e. needs surgical eval or management), consult the appropriate surgical service</p>
</li>
<li>
<p>While awaiting consultation, initiate topical wound care orders (detailed below)</p>
</li>
</ul>
</li>
<li>
<p>Consider contributing factors: nutritional, pressure-offloading equipment, wound supplies, PT/OT, home health nursing</p>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-wounds-types-of-wounds">Types of wounds<a class="headerlink" href="#hospital-medicine-hospital-medicine-wounds-types-of-wounds" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Arterial wound - Calciphylaxis</p>
</li>
<li>
<p>Venous leg wound - Fistula</p>
</li>
<li>
<p>Diabetic foot wound - Abscess</p>
</li>
<li>
<p>Vasculitis - Skin tear</p>
</li>
<li>
<p>Pyoderma gangrenosum - Pressure injury</p>
</li>
<li>
<p>Fungating lesion - Ischemic ulcers / gangrene</p>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-wounds-vascular-wound-etiologies">Vascular Wound Etiologies<a class="headerlink" href="#hospital-medicine-hospital-medicine-wounds-vascular-wound-etiologies" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Arterial: located on distal ends of digits, shallow, well-defined borders, pale/necrotic wound bed, minimal exudate due to poor blood flow, cramping pain or a constant deep ache</p>
</li>
<li>
<p>Diabetic: plantar surface of foot, callused wound margins; usually painless due to neuropathy</p>
</li>
<li>
<p>Venous: located on medial malleolus or gravity dependent areas, irregular edges, ruddy red with yellow slough and copious exudate</p>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-wounds-pressure-injury-staging">Pressure Injury Staging<a class="headerlink" href="#hospital-medicine-hospital-medicine-wounds-pressure-injury-staging" title="Permanent link">&para;</a></h2>
<p><img alt="stages of pressure sores" src="../images/image17.png" /></p>
<table style="width:100%;">
<colgroup>
<col style="width: 17%" />
<col style="width: 17%" />
<col style="width: 15%" />
<col style="width: 15%" />
<col style="width: 14%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr class="header">
<th>Feature</th>
<th>Deep Tissue Injury</th>
<th>Stage 1</th>
<th>Stage 2</th>
<th>Stage 3</th>
<th>Stage 4</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Skin Consistency</td>
<td>Boggy</td>
<td>Boggy</td>
<td>Variable</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr class="even">
<td>Skin color/nature of lesion</td>
<td>Non-blanching purple or maroon, may appear as blood-filled
blister</td>
<td>Non-blanching erythema</td>
<td>Abrasion, blister, or shallow crater</td>
<td>Variable</td>
<td><p>Variable.</p>
<p>If eschar, must be removed in order to stage, or is
unstageable</p></td>
</tr>
<tr class="odd">
<td>Depth</td>
<td>Epidermis intact</td>
<td>Epidermis intact</td>
<td>Through surface of epidermis and outer dermis</td>
<td>SQ tissue to, but not through, fascia</td>
<td>Full-thickness loss w/ destruction, necrosis, or damage to muscle,
bone, supporting structures</td>
</tr>
</tbody>
</table>

<h2 id="hospital-medicine-hospital-medicine-wounds-non-acute-wound-consult-guidelines">Non-Acute Wound Consult Guidelines<a class="headerlink" href="#hospital-medicine-hospital-medicine-wounds-non-acute-wound-consult-guidelines" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Order “Inpatient Consult to Adult Wound" for these wound types: diabetic foot wounds*, venous, arterial, pressure injuries (consult required for DTI, stage 3, 4, and unstageable), IV infiltrate, skin tears, moisture-associated dermatitis, calciphylaxis, vasculitis, pyoderma gangrenosum, fungating lesion, abscess*, surgical wounds*, or wound VAC</p>
</li>
<li>
<p>*Diabetic foot wounds: if pt being followed by podiatry, order "Inpatient Consult to Podiatry"</p>
</li>
<li>
<p>*Abscess: if chronic due to IBD, consult colorectal surgery</p>
</li>
<li>
<p>*Surgical wounds: if pt has VUMC surgeon, consult the respective surgical service</p>
</li>
<li>
<p>Order "Inpatient Consult to Adult Ostomy / Fistula / Tube" for ostomy, trach, PEG, associated needs or complications (etc)</p>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-wounds-acute-wound-consult-guidelines">Acute Wound Consult Guidelines<a class="headerlink" href="#hospital-medicine-hospital-medicine-wounds-acute-wound-consult-guidelines" title="Permanent link">&para;</a></h2>
<ul>
<li>Abscess, hematoma, or osteomyelitis with overlying wound – whom to consult for drainage/debridement:<ul>
<li>Face – Face</li>
<li>Chest/Sternum – CT surgery</li>
<li>Breast – General surgery</li>
<li>Spine – Spine</li>
<li>Arm (hand to elbow) – Hand</li>
<li>Lower leg (foot to knee) – Ortho</li>
<li>Labial – OB/GYN</li>
<li>Scrotal – Urology</li>
<li>Buttock, thigh (knee to hip), arm (elbow to shoulder) – EGS consult</li>
<li>Perirectal/Rectal <em>acute</em> abscess – EGS; (<em>chronic</em> due to IBD – Colorectal Surgery)</li>
</ul>
</li>
<li>Necrotizing Fasciitis – whom to consult for URGENT/EMERGENT surgical eval:<ul>
<li>Genitalia – Urology</li>
<li>Buttocks, perineum, abdomen – EGS</li>
<li>Upper extremity (shoulder to hand) – Hand</li>
<li>Lower extremity (hip to toes) – Ortho</li>
</ul>
</li>
</ul>
<h2 id="hospital-medicine-hospital-medicine-wounds-wound-care-order-while-awaiting-consultant-recs">Wound Care (order while awaiting consultant recs)<a class="headerlink" href="#hospital-medicine-hospital-medicine-wounds-wound-care-order-while-awaiting-consultant-recs" title="Permanent link">&para;</a></h2>
<ul>
<li>Superficial wounds<ul>
<li>Stage 1 or 2 pressure injuries, moisture-associated skin damage, or skin tears<ul>
<li>Order “Adult Skin Care Guidelines” and use the order set to guide you</li>
</ul>
</li>
</ul>
</li>
<li>Shallow Stage 3 pressure injuries (i.e., &lt;1cm deep) or diabetic foot ulcers<ul>
<li>Order “Wound Care”: Frequency 2x weekly and prn; Cleanse with NS; protect periwound with Mepilex foam (type in comments)</li>
</ul>
</li>
<li>
<p>Painful superficial wounds with no infection (i.e. vasculitis, PG, calciphylaxis)</p>
<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS; Apply Vaseline; Protect periwound with Xeroform and dry gauze (type in comments)<ul>
<li>If wound is on the hand, arm, foot, or lower leg consider wrapping in Kerlix</li>
<li>If wound is on the trunk (i.e., abdomen or buttocks), consider covering with an ABD pad and secure with medipore tape</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Infected superficial wounds</p>
<ul>
<li>Odor alone does NOT indicate infection; wounds with necrotic tissue may have odor</li>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS, Apply Silvadene; Protect periwound with Xeroform and dry gauze (type in comments)<ul>
<li>If wound is on hand, arm, foot, or lower leg consider wrapping in a Kerlix</li>
<li>If wound is on the trunk (i.e., abdomen or buttocks), consider covering with an ABD pad and secure with medipore tape</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Medication order required: Silvadene q12h; in Admin Inst put “per wound care orders”</p>
</li>
<li>
<p>Deep wounds (i.e., stage 3, 4, or deep diabetic foot wound (all &gt;1cm deep))</p>
<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS, pack with Dakin’s 0.025% (1/20 strength) soaked continuous Kerlix roll; Protect periwound with ABD pad &amp; medipore tape (type in comments)</li>
<li>If wound care is painful, consider changing to daily dressing changes</li>
<li>Medication order required: Dakin’s 0.025% solution q12h; in Admin Inst put “per wound care orders”</li>
</ul>
</li>
<li>
<p>Deep tissue injury</p>
<ul>
<li>Medication order required: Venelex (balsam peru-castor oil) ointment q4h; in admin instructions put location to apply ointment and put “no dressing”</li>
</ul>
</li>
<li>
<p>Fungating mass</p>
<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with baby shampoo and water, NS, Metrogel (type in comments); Protect with Xeroform, ABD pad, medipore tape</li>
<li>Medication order required: metrogel q12h; in Admin Inst put “per wound care orders”</li>
</ul>
</li>
<li>
<p>Wound VAC</p>
<ul>
<li>Vanderbilt surgeon – consult Vanderbilt provider to provide care<ul>
<li>Ensure connected to VUMC wound VAC. Pt shouldn't use home unit while admitted</li>
<li>Order “nursing communication” to “Obtain wound VAC hospital machine and canister from service center to connect pt to hospital machine.”</li>
<li>Wound VAC should not be left without suction for more than 2 hours</li>
<li>Settings: 125 mmHg continuous</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Non VUMC surgeon (i.e., gets wound care at outside hospital/wound care center)</p>
<ul>
<li>Discontinue wound VAC as soon as possible</li>
<li>Remove all of the clear plastic drape just like you would remove tape</li>
<li>Remove all of the sponge just like you would remove gauze packing</li>
<li>Examine the wound to ensure no residual sponge by gently probing site</li>
<li>Rinse with saline, initiate care based wound type as above</li>
</ul>
</li>
<li>
<p>Leg wrap</p>
<ul>
<li>Ex: Unna's boot, ACE and 2, 3, or 4 layer compression</li>
<li>Remove by cutting the wrap off</li>
<li>Assess the wound and order dressing based on type of wound as above</li>
<li>Order ACE bandage wrapped toe-to-knee. Remove q12h to assess skin</li>
</ul>
</li>
</ul></section><section class="print-page" id="hospital-medicine-main"><p>Telemetry – Ahmad Dbouk and Samuel Lazaroff</p>
<p>Background</p>
<ul>
<li>Many monitored pts do not have a true indication</li>
</ul>
<!-- -->

<ul>
<li>Leads to alarm fatigue, unnecessary workups, and is expensive</li>
</ul>
<!-- -->

<ul>
<li>
<p>Telemetry is not a substitute for more frequent vital signs</p>
</li>
<li>
<p>Discuss frequently on rounds: always reassess need and indication</p>
</li>
<li>
<p>Stable patients without troponin elevation or new arrythmias are
    typically appropriate for transfers without telemetry</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 50%" />
<col style="width: 50%" />
</colgroup>
<thead>
<tr class="header">
<th>Clinical Scenario</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td colspan="2"><strong>Cardiac</strong></td>
</tr>
<tr class="even">
<td><p>ACS</p>
<p>Post-MI</p></td>
<td><p>24-48h</p>
<p>48h after revascularization</p></td>
</tr>
<tr class="odd">
<td>Vasospastic angina</td>
<td>Until symptoms resolve</td>
</tr>
<tr class="even">
<td>Any event requiring ICD shocks</td>
<td>Remainder of hospitalization</td>
</tr>
<tr class="odd">
<td>New/unstable atrial tachyarrhythmias</td>
<td>Until stable on medical therapies</td>
</tr>
<tr class="even">
<td>Chronic AFib w/ recurrence of RVR</td>
<td>Clinical judgement</td>
</tr>
<tr class="odd">
<td>Ventricular tachyarrhythmias</td>
<td>Until definitive therapy</td>
</tr>
<tr class="even">
<td>Symptomatic bradycardia</td>
<td>Until definitive therapy</td>
</tr>
<tr class="odd">
<td>Decompensated CHF</td>
<td>Until underlying cause treated</td>
</tr>
<tr class="even">
<td colspan="2"><strong>Procedural</strong></td>
</tr>
<tr class="odd">
<td>Ablation (regardless of co-morbidities)</td>
<td>12-24h after procedure</td>
</tr>
<tr class="even">
<td>Cardiac surgery</td>
<td>48-72h or until discharge if high risk for decompensation</td>
</tr>
<tr class="odd">
<td>Non-cardiac major surgery in patient with AFib risk factors</td>
<td>Until discharge from step-down or ICU</td>
</tr>
<tr class="even">
<td>Conscious sedation</td>
<td>Until patient awake, alert, HDS</td>
</tr>
<tr class="odd">
<td colspan="2"><strong>Miscellaneous</strong></td>
</tr>
<tr class="even">
<td>Endocarditis</td>
<td>Until clinically stable</td>
</tr>
<tr class="odd">
<td>CVA</td>
<td>24-48h</td>
</tr>
<tr class="even">
<td>Electrolyte derangement (K, Mg)</td>
<td>Until normalization</td>
</tr>
<tr class="odd">
<td>Hemodialysis</td>
<td>Clinical judgement</td>
</tr>
<tr class="even">
<td>Drug overdose</td>
<td>Until free of influence of substance</td>
</tr>
</tbody>
</table>

<p>Notable non-indications:</p>
<ul>
<li>
<p>PCI for non-ACS indication (i.e. pre-transplant), non-cardiac chest
    pain, pt with AICD admitted for non-cardiac condition, non-cardiac
    surgery, chronic rate-controlled AFib</p>
</li>
<li>
<p>Contraindicated in hospice/comfort care</p>
</li>
<li>
<p>Nearly all noncardiac conditions (i.e., undifferentiated sepsis,
    stable GI bleed, alcohol withdrawal) upon transfer out of ICU</p>
</li>
</ul>
<p>Lines and Catheters – Ahmad Dbouk and Samuel Lazaroff</p>
<p>Foley Catheter</p>
<ul>
<li>Indications: urinary retention, close urine output monitoring in
    critical illness or renal failure, need for strict I&amp;Os (ex:
    diuresis) and unable to be achieved without catheter, surgery, open
    sacral/perineal wounds with incontinence, patient comfort at end of
    life</li>
</ul>
<!-- -->

<ul>
<li>Urinary incontinence alone is not an indication for foley catheter</li>
</ul>
<!-- -->

<ul>
<li>Duration of use is biggest risk factor for CAUTI</li>
</ul>
<!-- -->

<ul>
<li>
<p>Best way to prevent CAUTI is to avoid inappropriate placement</p>
</li>
<li>
<p>Assess daily whether foley can be removed</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Chronic Foleys generally should be exchanged at time of admission</p>
</li>
<li>
<p>Any concern for catheter obstruction (particularly with blood clots)
    should prompt urgent urology consult for irrigation/intervention
    (typically after RN has attempted)</p>
</li>
<li>
<p>Difficult foley placement</p>
</li>
</ul>
<!-- -->

<ul>
<li>Make sure an attempt has been made with a Coudé catheter. This
    catheter has a curved tip that can be useful in patients with BPH</li>
</ul>
<p>PICC</p>
<ul>
<li>
<p>Single lumen: long term Abx, stable IV access with intermittent
    draws</p>
</li>
<li>
<p>Double lumen: special populations (ICU or chemo), TPN w/ lipids
    (incompatible with many IV medications)</p>
</li>
<li>
<p>Risk factors for CLABSI/VTE: ↑↑duration, ↑↑number of lumens, left
    arm, lower extremity</p>
</li>
<li>
<p>A note on midlines:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>A midline is just a long PIV inserted into the deep veins in the
    arm, typically 6-15cm</p>
<ul>
<li>
<p>For reference, when you place an US-guided IV, the “long” 18G
    needles at VUMC are 2.5 inches (~6.4cm)</p>
</li>
<li>
<p>Not much benefit compared to US-guided IV. Useful for stable IV
    access for meds and fluids. Not a stable route for blood draws</p>
</li>
</ul>
</li>
</ul>
<p>G-Tube</p>
<ul>
<li>
<p>Troubleshooting: EGS consult for malposition/not functioning, wound
    consult for skin breakdown</p>
</li>
<li>
<p>G-tube study: 30mL Gastrograffin via tube [resident often must
    push], and order KUB</p>
</li>
</ul>
<p>Transitions of Care: Tips for Safe Discharges – Soibhan Kelley</p>
<p>Discharge from hospital represents a period of vulnerability for
patients. Medical errors (especially medication errors) following
discharge are exceedingly common and can lead to adverse events</p>
<p>At VUMC we are fortunate to have the Discharge Care Center</p>
<ul>
<li>
<p>Multidisciplinary team including nurses, social workers, care
    coordinators, and pharmacists</p>
</li>
<li>
<p>Phone number is included on discharge paperwork and patients can
    contact them 24/7. The DCC also reaches out to patients through an
    automated system</p>
</li>
</ul>
<p>How residents can promote safe discharges:</p>
<ul>
<li><strong>Communicate with patient’s outpatient team (i.e. PCP)</strong></li>
</ul>
<!-- -->

<ul>
<li>
<p>Typically achieved through the discharge summary</p>
<ul>
<li>
<p>Include a list of specific, actionable follow-up tasks and
    assign a responsible party. Place in easy-to-view spot at the
    top of the summary</p>
<ul>
<li>
<p>Ex: Instead of writing “follow-up BMP after initiation of
    furosemide,” write “PCP to check BMP in 2 weeks after
    initiation of furosemide”</p>
</li>
<li>
<p>Include any pending studies and appointments from hospital
    admission</p>
</li>
</ul>
</li>
<li>
<p>All relevant parties should receive a copy of the discharge
    summary (see appendices</p>
<p>section for mechanics of discharge process)</p>
<ul>
<li>It is useful to send patient with a printed copy of the
    discharge summary if they will follow-up outside VUMC</li>
</ul>
</li>
</ul>
</li>
<li>
<p>For high-risk discharges (patients with poor health literacy, hx of
    being lost to follow-up, patients following up outside VUMC)
    consider calling PCP’s office to set follow-up</p>
</li>
</ul>
<!-- -->

<ul>
<li><strong>Complete an accurate and thorough medication reconciliation</strong></li>
</ul>
<!-- -->

<ul>
<li>
<p>An accurate discharge medication list depends on having a complete
    admission medication reconciliation (utilize pharmacy consult!)</p>
<ul>
<li>
<p>Three steps to medication reconciliation:</p>
<ul>
<li>
<p>Verification: Performing a Best Possible Medication History</p>
</li>
<li>
<p>Clarification: Checking that medications and doses are
    appropriate</p>
</li>
<li>
<p>Reconciliation: Record all medication changes</p>
</li>
</ul>
</li>
<li>
<p>Seek to use at least two sources of information</p>
</li>
<li>
<p>Keep a list of any held or changed medications in your hospital
    course. Medication changes can be lost when not communicated
    during team transitions</p>
</li>
<li>
<p>Review medication changes on rounds and with pharmacist on day
    of discharge (bonus points for day prior to discharge)</p>
</li>
</ul>
</li>
<li>
<p>Highlight any significant medication changes on discharge summary</p>
<ul>
<li>Can include as follow-up tasks if pertinent (ex: PCP to
    follow-up BP in 2 weeks. Losartan held on d/c due to AKI but
    anticipate need to reinitiate once Cr normalizes)</li>
</ul>
</li>
<li>
<p>Be sure to communicate any changes with the patient and/or caregiver</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p><strong>Ensure that appropriate resources and follow-up appointments have
    been requested</strong> (PT/OT, skilled or non-skilled nursing HH, PCP
    follow-up, etc.)</p>
</li>
<li>
<p><strong>Effectively communicate discharge plan to patient</strong></p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Discuss medication changes, tasks for patient to complete, follow-up
    appointments</p>
<ul>
<li>
<p>Key points should also be written in the patient instructions
    box</p>
</li>
<li>
<p>Useful to include educational sheets in the AVS (searchable in
    discharge navigator)</p>
</li>
<li>
<p>Utilize the teach-back method to ensure your instructions were
    effectively communicated</p>
</li>
</ul>
</li>
</ul>
<p>Enteral Nutrition – Soibhan Kelley</p>
<p>Indications for enteral feeding</p>
<ul>
<li>Patients with high nutritional risk who are unable to maintain their
    own intake</li>
</ul>
<!-- -->

<ul>
<li>
<p>Guidelines recommend calculating nutritional risk based on validated
    scoring tool (ex: Malnutrition Screening Tool). This is usually
    completed by the nutrition team</p>
</li>
<li>
<p>Recognize who would benefit from nutrition consult to assist with
    risk determination</p>
<ul>
<li>Patients with >5% weight loss in past 1-3 months or decreased
    oral intake coupled with increased metabolic demands due to
    medical illness or surgery</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Patients with low nutritional risk may not need enteral feeding if
    it is anticipated they will resume intake in 5-7 days</p>
</li>
<li>
<p>Critically ill patients: goal is early initiation of tube feeding
    (within 48 hours)</p>
</li>
</ul>
<p>Contraindications to enteral nutrition</p>
<ul>
<li>
<p>Bowel obstruction or severe ileus</p>
</li>
<li>
<p>Ischemic bowel</p>
</li>
<li>
<p>Acute peritonitis</p>
</li>
<li>
<p>Major gastrointestinal bleeding</p>
</li>
<li>
<p>Intractable vomiting</p>
</li>
<li>
<p>Significant hemodynamic instability</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Patients who are not adequately volume resuscitated and have
    significant hemodynamic instability (i.e., have high pressor
    requirements) are thought to be at increased risk for bowel ischemia</p>
<ul>
<li>Pressors in general are not a contraindication to tube feeds. Ok
    to start once pressors are down-trending or at a stable level</li>
</ul>
</li>
</ul>
<p>Initiating tube feeds</p>
<ul>
<li>Enteral access</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nasogastric or orogastric feeding tube in acute setting. See
    procedures section for tips on placement</p>
</li>
<li>
<p>For most patients, enteral feeding is safe with gastric tube
    placement</p>
<ul>
<li>Consider post-pyloric placement for patients with high
    aspiration risk, impaired gastric motility, or patients who have
    demonstrated intolerance with gastric feeding</li>
</ul>
</li>
<li>
<p>Consider percutaneous endoscopic gastrostomy (PEG) tube placement if
    anticipate enteral nutrition >4 weeks</p>
</li>
</ul>
<!-- -->

<ul>
<li>Choice of formula and rate</li>
</ul>
<!-- -->

<ul>
<li>
<p>Place nutrition consult. RD will calculation caloric and protein
    needs to determine goal rate and formulation</p>
</li>
<li>
<p>OK to start tube feeds prior to recommendations and adjust later,
    especially if recommendations will be delayed. It only takes a
    simple calculation to make a reasonable tube feeding plan</p>
<ul>
<li>
<p>Use weight-based dosing for calorie requirements</p>
<ul>
<li>Use 25-30 cal/kg (use ideal body weight for most patients,
    use actual weight for underweight patient) to estimate daily
    needs</li>
</ul>
</li>
<li>
<p>Most common formula used at VUMC is Nutren 1.5 (1.5 cal/ml) or
    Novasource renal if significant renal impairment (2 cal/ml)</p>
</li>
<li>
<p>Patients may need additional free water (most tube feed formulas
    are comprised of 80-85% water but varies with type). Typically
    dose as bolus of free water every 4-6 hours.</p>
<ul>
<li>
<p>May empirically try 250cc free water every 4 hours and
    monitor Na trends. May need more if already with a large
    fluid deficit (ex: hypernatremia) or if high volume losses</p>
</li>
<li>
<p>May use clinical calculators as below</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Calculate hourly rate based on daily calorie need and formula
    calorie density</p>
<ul>
<li>
<p>Ex: Patient with IBW of 70Kg will need estimated 1,750 calories
    per day (70 x 25 cal/kg)</p>
</li>
<li>
<p>If using Nutren 1.5, this will equal 1,167 ml per day (1,750
    divided by 1.5 calories per ml). This would equal a goal rate of
    about 50ml per hour (rounded up) of Nutren 1.5</p>
</li>
<li>
<p>Resources for quick calculations:</p>
<ul>
<li>
<p>Search for “tube feed cheat sheet” on google and will find
    reference tables on EMCrit.org that gives you rate per hour
    for different weights and formula types</p>
</li>
<li>
<p>Clincalc.com also has a useful enteral nutrition calculator</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Start initially at a low rate (such as 10 mL/hr) to assess
    tolerability and advance to goal</p>
<ul>
<li>
<p>Advance quickly if no concern for refeeding syndrome (ex:
    increase by 10cc/hr q6h)</p>
</li>
<li>
<p>If risk for refeeding syndrome or other issues with
    tolerability, typically advance more slowly over several days</p>
</li>
</ul>
</li>
</ul>
<p>Potential Complications</p>
<ul>
<li>Aspiration</li>
</ul>
<!-- -->

<ul>
<li>
<p>Recommendation to keep head of bed elevated at 30 to 45 degrees (low
    quality, mixed evidence). Consider risks of this positioning (ex:
    formation of pressure ulcers)</p>
</li>
<li>
<p>Consider post-pyloric placement if issues with aspiration (low
    quality, mixed evidence)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Diarrhea or constipation</li>
</ul>
<!-- -->

<ul>
<li>Consider wheat dextrin fiber supplement (low quality evidence) but
    discontinue if not associated with clinical improvement. Avoid less
    soluble fibers such as psyllium due to risk of clogging tube. Avoid
    in patients with reduced GI motility due to rare risk of bezoar
    formation</li>
</ul>
<!-- -->

<ul>
<li>Hyperglycemia</li>
</ul>
<!-- -->

<ul>
<li>See endocrine section for management</li>
</ul>
<!-- -->

<ul>
<li>
<p>Refeeding syndrome</p>
<p>Monitor q8 hour Mg, phos, K in high-risk patients (underweight,
recent weight loss, prolonged poor intake) and advance to goal
slowly</p>
</li>
</ul>
<p>Guidelines for Pregnant Patients – Ahmad Dbouk and Samuel Lazaroff</p>
<p>Acute Cystitis</p>
<ul>
<li>
<p>Significantly increased prevalence in pregnancy</p>
</li>
<li>
<p>Symptoms: dysuria (urgency/frequency common in pregnancy)</p>
</li>
<li>
<p>Diagnosis: evidence of pyuria and >103 cfu/ml (note, if neg would
    test for g/c)</p>
</li>
<li>
<p>Treatment: Empiric with cephalexin, cefpodoxime,
    amoxicillin-clavulanate, fosfomycin. Nitrofurantoin ok in second or
    third trimester. Avoid Bactrim in first trimester and near term.
    Tailor based on culture results.</p>
</li>
<li>
<p>Note that asymptomatic bacteriuria is treated in pregnancy (in
    contrast with general public). Same antibiotic choices as above</p>
</li>
</ul>
<p>Pyelonephritis</p>
<ul>
<li>
<p>Symptoms: fever, flank pain, and nausea/vomiting, dysuria</p>
</li>
<li>
<p>Diagnosis: clinical suspicion + pyuria and bacteriuria</p>
</li>
<li>
<p>Treatment: IV antibiotics for 1<sup>st</sup> 24-48hrs; beta-lactams preferred</p>
</li>
<li>
<p>Mild to moderate: ceftriaxone or cefepime</p>
</li>
<li>
<p>Moderate to severe: piperacillin-tazobactam or meropenem</p>
</li>
</ul>
<p>Hyperemesis Gravidarum</p>
<ul>
<li>
<p>Presentation: Hormone mediated nausea/vomiting typically starting
    before 9wks GA</p>
</li>
<li>
<p>Differential: gastroenteritis, hepatitis, biliary tract disease,
    obstruction, pancreatitis, pyelonephritis, nephrolithiasis, ovarian
    torsion, DKA, hyperparathyroidism, migraines, preeclampsia</p>
</li>
<li>
<p>Workup: BMP, mg, phos, LFTs, lipase (may be mildly elevated in HG),
    UA,</p>
</li>
<li>
<p>Treatment:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>First Line: Ginger, doxylamine (25mg PO q6), pyridoxine (20mg PO q6)</p>
</li>
<li>
<p>Second Line: metoclopramide (10mg q6), Promethazine (12.5mg q6)</p>
</li>
<li>
<p>Third Line: ondansetron (8mg q12hrs, after 1<sup>st</sup> trimester)</p>
</li>
<li>
<p>Hydration: 1L LR on admission + banana bag q24hrs</p>
</li>
</ul>
<p>Hypertension:</p>
<ul>
<li>
<p>Both gestational HTN and preeclampsia/HELLP are typically diagnosed
    >20w GA</p>
</li>
<li>
<p>Tx options: nifedipine, labetalol, methyldopa, hydral (2<sup>nd</sup> line),
    clonidine (2<sup>nd</sup> line)</p>
</li>
<li>
<p>Avoid: ACEs, ARBs, MRAs, Nitroprusside</p>
</li>
</ul>
<p>Diabetes</p>
<ul>
<li>
<p>Due to hormonal changes associated with pregnancy, pregnant patients
    are at higher risk for poor control and DKA</p>
</li>
<li>
<p>Oral regimens are generally transitioned to insulin-based regimens.</p>
</li>
</ul>
<p>GERD:</p>
<ul>
<li>
<p>1<sup>st</sup> Line: Can use antacids; avoid sodium bicarbonate and magnesium
    trisilicate</p>
</li>
<li>
<p>2<sup>nd</sup> Line: Sucralfate 1g PO TID</p>
</li>
<li>
<p>3<sup>rd</sup> Line: Cimetidine 200mg (30min prior to eating)</p>
</li>
</ul>
<p>Asthma</p>
<ul>
<li>
<p>Similar rescue and controller medications as in non-pregnant patient</p>
</li>
<li>
<p>Would favor using LABA > leukotriene receptor antagonists for
    additional therapy</p>
</li>
</ul>
<p>Wounds − Adapted from Dr. Duggan’s Geriatrics Guide</p>
<p>To do when admitting a patient with wounds:</p>
<ul>
<li>
<p>Document ALL wounds that are present on admission. This affects
    reimbursement</p>
</li>
<li>
<p>Use the Haiku app on your cell phone to document images of wounds in
    chart</p>
</li>
<li>
<p>Wound Service hours are Monday through Friday, 6 AM - 2 PM</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If there is an urgent/emergent wound need (i.e. needs surgical
    eval or management), consult the appropriate surgical service</p>
</li>
<li>
<p>While awaiting consultation, initiate topical wound care orders
    (detailed below)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consider contributing factors: nutritional, pressure-offloading
    equipment, wound supplies, PT/OT, home health nursing</li>
</ul>
<p>Types of wounds</p>
<ul>
<li>
<p>Arterial wound - Calciphylaxis</p>
</li>
<li>
<p>Venous leg wound - Fistula</p>
</li>
<li>
<p>Diabetic foot wound - Abscess</p>
</li>
<li>
<p>Vasculitis - Skin tear</p>
</li>
<li>
<p>Pyoderma gangrenosum - Pressure injury</p>
</li>
<li>
<p>Fungating lesion - Ischemic ulcers / gangrene</p>
</li>
</ul>
<p>Vascular Wound Etiologies</p>
<ul>
<li>
<p>Arterial: located on distal ends of digits, shallow, well-defined
    borders, pale/necrotic wound bed, minimal exudate due to poor blood
    flow, cramping pain or a constant deep ache</p>
</li>
<li>
<p>Diabetic: plantar surface of foot, callused wound margins; usually
    painless due to neuropathy</p>
</li>
<li>
<p>Venous: located on medial malleolus or gravity dependent areas,
    irregular edges, ruddy red with yellow slough and copious exudate</p>
</li>
</ul>
<p>Pressure Injury Staging</p>
<p><img src="../hospital-medicine/main/output/media/image17.png"
style="width:3.42149in;height:1.11309in"
alt="A picture containing text Description automatically generated" /></p>
<table style="width:100%;">
<colgroup>
<col style="width: 17%" />
<col style="width: 17%" />
<col style="width: 15%" />
<col style="width: 15%" />
<col style="width: 14%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr class="header">
<th>Feature</th>
<th>Deep Tissue Injury</th>
<th>Stage 1</th>
<th>Stage 2</th>
<th>Stage 3</th>
<th>Stage 4</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Skin Consistency</td>
<td>Boggy</td>
<td>Boggy</td>
<td>Variable</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr class="even">
<td>Skin color/nature of lesion</td>
<td>Non-blanching purple or maroon, may appear as blood-filled
blister</td>
<td>Non-blanching erythema</td>
<td>Abrasion, blister, or shallow crater</td>
<td>Variable</td>
<td><p>Variable.</p>
<p>If eschar, must be removed in order to stage, or is
unstageable</p></td>
</tr>
<tr class="odd">
<td>Depth</td>
<td>Epidermis intact</td>
<td>Epidermis intact</td>
<td>Through surface of epidermis and outer dermis</td>
<td>SQ tissue to, but not through, fascia</td>
<td>Full-thickness loss w/ destruction, necrosis, or damage to muscle,
bone, supporting structures</td>
</tr>
</tbody>
</table>

<p>Non-Acute Wound Consult Guidelines</p>
<ul>
<li>
<p>Order “Inpatient Consult to Adult Wound" for these wound types:
    diabetic foot wounds*, venous, arterial, pressure injuries (consult
    required for DTI, stage 3, 4, and unstageable), IV infiltrate, skin
    tears, moisture-associated dermatitis, calciphylaxis, vasculitis,
    pyoderma gangrenosum, fungating lesion, abscess*, surgical
    wounds*, or wound VAC</p>
</li>
<li>
<p>*Diabetic foot wounds: if pt being followed by podiatry, order
    "Inpatient Consult to Podiatry"</p>
</li>
<li>
<p>*Abscess: if chronic due to IBD, consult colorectal surgery</p>
</li>
<li>
<p>*Surgical wounds: if pt has VUMC surgeon, consult the respective
    surgical service</p>
</li>
<li>
<p>Order "Inpatient Consult to Adult Ostomy / Fistula / Tube" for
    ostomy, trach, PEG, associated needs or complications (etc)</p>
</li>
</ul>
<p>Acute Wound Consult Guidelines</p>
<ul>
<li>Abscess, hematoma, or osteomyelitis with overlying wound – whom to
    consult for drainage/debridement:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Face – Face</p>
</li>
<li>
<p>Chest/Sternum – CT surgery</p>
</li>
<li>
<p>Breast – General surgery</p>
</li>
<li>
<p>Spine – Spine</p>
</li>
<li>
<p>Arm (hand to elbow) – Hand</p>
</li>
<li>
<p>Lower leg (foot to knee) – Ortho</p>
</li>
<li>
<p>Labial – OB/GYN</p>
</li>
<li>
<p>Scrotal – Urology</p>
</li>
<li>
<p>Buttock, thigh (knee to hip), arm (elbow to shoulder) – EGS consult</p>
</li>
<li>
<p>Perirectal/Rectal <em>acute</em> abscess – EGS; (<em>chronic</em> due to IBD –
    Colorectal Surgery)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Necrotizing Fasciitis – whom to consult for URGENT/EMERGENT surgical
    eval:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Genitalia – Urology</p>
</li>
<li>
<p>Buttocks, perineum, abdomen – EGS</p>
</li>
<li>
<p>Upper extremity (shoulder to hand) – Hand</p>
</li>
<li>
<p>Lower extremity (hip to toes) – Ortho</p>
</li>
</ul>
<p>Wound Care (order while awaiting consultant recs)</p>
<ul>
<li>Superficial wounds</li>
</ul>
<!-- -->

<ul>
<li>
<p>Stage 1 or 2 pressure injuries, moisture-associated skin damage, or
    skin tears</p>
<ul>
<li>Order “Adult Skin Care Guidelines” and use the order set to
    guide you</li>
</ul>
</li>
<li>
<p>Shallow Stage 3 pressure injuries (i.e., \&lt;1cm deep) or diabetic
    foot ulcers</p>
<ul>
<li>Order “Wound Care”: Frequency 2x weekly and prn; Cleanse with
    NS; protect periwound with Mepilex foam (type in comments)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Painful superficial wounds with no infection (i.e. vasculitis, PG,
    calciphylaxis)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS; Apply
    Vaseline; Protect periwound with Xeroform and dry gauze (type in
    comments)</p>
<ul>
<li>
<p>If wound is on the hand, arm, foot, or lower leg consider
    wrapping in Kerlix</p>
</li>
<li>
<p>If wound is on the trunk (i.e., abdomen or buttocks), consider
    covering with an ABD pad and secure with medipore tape</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Infected superficial wounds</li>
</ul>
<!-- -->

<ul>
<li>
<p>Odor alone does NOT indicate infection; wounds with necrotic tissue
    may have odor</p>
</li>
<li>
<p>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS, Apply
    Silvadene; Protect periwound with Xeroform and dry gauze (type in
    comments)</p>
<ul>
<li>
<p>If wound is on hand, arm, foot, or lower leg consider wrapping
    in a Kerlix</p>
</li>
<li>
<p>If wound is on the trunk (i.e., abdomen or buttocks), consider
    covering with an ABD pad and secure with medipore tape</p>
</li>
</ul>
</li>
<li>
<p>Medication order required: Silvadene q12h; in Admin Inst put “per
    wound care orders”</p>
</li>
</ul>
<!-- -->

<ul>
<li>Deep wounds (i.e., stage 3, 4, or deep diabetic foot wound (all
    >1cm deep))</li>
</ul>
<!-- -->

<ul>
<li>
<p>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS, pack
    with Dakin’s 0.025% (1/20 strength) soaked continuous Kerlix roll;
    Protect periwound with ABD pad &amp; medipore tape (type in comments)</p>
</li>
<li>
<p>If wound care is painful, consider changing to daily dressing
    changes</p>
</li>
<li>
<p>Medication order required: Dakin’s 0.025% solution q12h; in Admin
    Inst put “per wound care orders”</p>
</li>
</ul>
<!-- -->

<ul>
<li>Deep tissue injury</li>
</ul>
<!-- -->

<ul>
<li>Medication order required: Venelex (balsam peru-castor oil)
    ointment q4h; in admin instructions put location to apply ointment
    and put “no dressing”</li>
</ul>
<!-- -->

<ul>
<li>Fungating mass</li>
</ul>
<!-- -->

<ul>
<li>
<p>Order “Wound Care”: Frequency 2 times daily; Cleanse with baby
    shampoo and water, NS, Metrogel (type in comments); Protect with
    Xeroform, ABD pad, medipore tape</p>
</li>
<li>
<p>Medication order required: metrogel q12h; in Admin Inst put “per
    wound care orders”</p>
</li>
</ul>
<!-- -->

<ul>
<li>Wound VAC</li>
</ul>
<!-- -->

<ul>
<li>
<p>Vanderbilt surgeon – consult Vanderbilt provider to provide care</p>
<ul>
<li>
<p>Ensure connected to VUMC wound VAC. Pt shouldn't use home unit
    while admitted</p>
</li>
<li>
<p>Order “nursing communication” to “Obtain wound VAC hospital
    machine and canister from service center to connect pt to
    hospital machine.”</p>
</li>
<li>
<p>Wound VAC should not be left without suction for more than 2
    hours</p>
</li>
<li>
<p>Settings: 125 mmHg continuous</p>
</li>
</ul>
</li>
<li>
<p>Non VUMC surgeon (i.e., gets wound care at outside hospital/wound
    care center)</p>
<ul>
<li>
<p>Discontinue wound VAC as soon as possible</p>
</li>
<li>
<p>Remove all of the clear plastic drape just like you would remove
    tape</p>
</li>
<li>
<p>Remove all of the sponge just like you would remove gauze
    packing</p>
</li>
<li>
<p>Examine the wound to ensure no residual sponge by gently probing
    site</p>
</li>
<li>
<p>Rinse with saline, initiate care based wound type as above</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Leg wrap</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ex: Unna's boot, ACE and 2, 3, or 4 layer compression</p>
</li>
<li>
<p>Remove by cutting the wrap off</p>
</li>
<li>
<p>Assess the wound and order dressing based on type of wound as above</p>
</li>
<li>
<p>Order ACE bandage wrapped toe-to-knee. Remove q12h to assess skin</p>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Hospital medicine</h1>
                        <h1 class='nav-section-title' id='section-infectious-diseases'>
                            Infectious diseases <a class='headerlink' href='#section-infectious-diseases' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="infectious-diseases-infectious-disease-sexually-transmitted-diseases"><h1 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-sexually-transmitted-infections">Sexually Transmitted Infections<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-sexually-transmitted-infections" title="Permanent link">&para;</a></h1>
<p>Ashley Zeoli</p>
<hr />
<h1 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-gonorrhea">Gonorrhea<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-gonorrhea" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-background">Background<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Cause: gram-negative coccus <em>Neisseria gonorrhoeae</em></li>
<li>Gonorrhea causes a spectrum of disease including urethritis, cervicitis, epididymitis, proctitis, pharyngeal infections, conjunctivitis, PID, and disseminated gonococcal infection</li>
</ul>
<h2 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Microbial diagnosis is required to diagnose gonorrhea, rather than clinical diagnosis alone</li>
<li>Test of choice: NAAT of the first-catch urine in men; NAAT of vaginal swab in women<ul>
<li>Also perform co-testing for chlamydia</li>
</ul>
</li>
<li>NAAT of pharyngeal or rectal swab should also be performed in patients with reported symptoms and recent sexual exposure. Note this is also routine testing in patients on PREP.</li>
<li>Routine screening should be offered to sexually active patients, as many are asymptomatic</li>
</ul>
<h2 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-management">Management<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Ceftriaxone is the only current antibiotic that meets the strict treatment efficacy goals with single-dose therapy. CTX also has a low rate of drug resistance, which is becoming an increasing issue in the treatment of gonorrhea.</p>
<ul>
<li><b>High dose IM ceftriaxone</b> (&lt;150kg 500mg IM; &gt;150mg 1g IM)<ul>
<li>Same for pharyngitis or conjunctivitis</li>
</ul>
</li>
<li>CTX allergies: Azithromycin (2g PO x1) + Gentamicin (240mg IM x1) or Gemifloxacin</li>
</ul>
</li>
<li>
<p>Treatment of chlamydia must also be accompanied with gonorrhea treatment when it has not been excluded with molecular testing.</p>
<ul>
<li>Doxycycline 100mg BID for 7 days</li>
</ul>
</li>
<li>
<p>Patients who have persistent symptoms despite treatment should be suspected of having resistant gonorrhea. Test with culture and antimicrobial susceptibility testing (with or without NAAT).</p>
</li>
<li>
<p>Patients with recurrent symptoms after period of resolution should be re-evaluated for gonorrhea and other STIs</p>
</li>
</ul>
<h1 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-chlamydia">Chlamydia<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-chlamydia" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-background_1">Background<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-background_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Cause: gram negative bacteria <em>Chlamydia trachomatis</em></p>
</li>
<li>
<p>Most individuals are asymptomatic though causes a wide array of infections: urethritis, cervicitis -&gt; PID, conjunctivitis, perihepatitis (Fitz-Hugh-Curtis syndrome), pneumonia, proctitis, epididymitis, reactive arthritis, pharyngitis, lymphogranuloma venereum (LGV), endemic trachoma</p>
</li>
<li>
<p>Differential diagnosis: <em>Neisseria gonorrhoeae</em>, <em>Trichomonas vaginalis</em>, <em>Mycoplasma genitalium</em></p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-evaluation_1">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-evaluation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Test of choice: NAAT of vaginal swab in females (first catch urine also adequate); NAAT of first catch urine in males.</p>
</li>
<li>
<p>NAATs can detect both LGV and non-LGV chlamydia trachomatis, but cannot distinguish between them</p>
</li>
<li>
<p>Any patient with signs and symptoms concerning for chlamydia should be tested. Testing should also routinely be offered to sexually active individuals since most patients are asymptomatic. Note this is also routine testing in patients on PREP.</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-management_1">Management<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p><b>Doxycycline 100mg BID x 7 days</b> is the preferred treatment in non-pregnant patients (azithromycin is NOT preferred)
Alternative treatment options (for allergies/severe contraindications): azithromycin (1g PO x 1), levofloxacin (500mg PO daily x7 days), and ofloxacin (300mg BID PO x7 days)
Patients with recent potential or confirmed exposure within the last 1-2 weeks should be treated empirically</p>
</li>
<li>
<p>Patients with persistent symptoms, confirmed infection, and who already underwent appropriate treatment, likely have a re-infection, rather than treatment failure. Test again.</p>
</li>
<li>
<p>Patients with recurrent symptoms after resolution should be re-tested for chlamydia with a NAAT and other STIs (gonorrhea, BV, etc).</p>
</li>
<li>
<p>Empiric therapy for gonorrhea should be given to patients unless NAAT is negative</p>
</li>
</ul>
<h1 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-syphilis">Syphilis<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-syphilis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-background_2">Background<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-background_2" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Caused by the spirochete, <em>Treponema pallidum</em>, which is visualized by dark field microscopy</p>
</li>
<li>
<p>High rate of HIV co-infection among MSM with syphilis (~42%)</p>
</li>
<li>
<p>Transmitted by direct contact with an infectious lesion during sex. Infection can occur anywhere inoculation occurs (i.e. contact with infected secretions can result in a lesion on any tissue site)</p>
</li>
<li>
<p>Can readily cross the placenta -&gt; fetal infection</p>
</li>
<li>
<p>Patients can present with a variety of symptoms, depending on their place in the disease course</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-disease-sexually-transmitted-diseases-evaluation_2">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-disease-sexually-transmitted-diseases-evaluation_2" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Test all patients with signs and symptoms, as well as patients who are at increased risk for acquiring infection (patients with sexual partner with early syphilis, MSM, people living with HIV, high risk sexual behaviors, and history of commercial sex work or incarceration)</p>
</li>
<li>
<p>HIV testing should be offered to all patients who test positive</p>
</li>
<li>
<p>Pregnant patients should be screened for syphilis</p>
</li>
<li>
<p>There are two types of serologic tests: treponemal-specific tests (FTA-ABS, MHA-TP, TPPA, TP-EIA, CIA) and nontreponemal tests (RPR, VDRL, TRUST). Either can be used as initial screening, but confirmatory testing with the other is needed due to false positives.</p>
<ul>
<li>Treponemal specific are usually used as confirmatory tests when nontreponemal tests are reactive. They are reported as reactive or non-reactive. Once positive, usually positive for life.</li>
<li>Nontreponemal quantifies amount of antibody present and can be used to detect titers to assess for treatment. Titers should decline after a patient has been treated. A rise in titers in a previously treated patient should be concerning for new infection.<ul>
<li>Requires a humoral response, so can be false negatives if immunocompromised</li>
<li>False positives: autoimmune diseases, pregnancy, other infections</li>
</ul>
</li>
</ul>
</li>
<li>
<p>At VUMC, a positive treponemal IgG reflexes to a RPR titer.</p>
</li>
<li>
<p>Neurosyphilis can occur at any time after infection. All newly diagnosed patients with syphilis should have a full neurologic exam and if any abnormalities should have an LP sent for CSF-VDRL.</p>
</li>
<li>
<p>Any patients with syphilis and vision changes should undergo ophthalmology evaluation.</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 41%" />
<col style="width: 39%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>+ Treponemal</p>
</blockquote></th>
<th>- Treponemal</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>+ Non-treponemal</strong></td>
<td>Diagnostic of syphilis (completely new, or potentially
re-infected)</td>
<td>Likely false positive</td>
</tr>
<tr class="even">
<td><strong>- Non-treponemal</strong></td>
<td>Likely history of successfully treated syphilis</td>
<td>Likely not syphilis, or false negative (due to prozone\* effect)</td>
</tr>
<tr class="odd">
<td colspan="3"><em>\*Prozone effect:</em> when there is an overabundance
of antibodies and they interfere with clumping/formation of
antigen-antibody complex so agglutination cannot be visualized</td>
</tr>
</tbody>
</table>

<p>Management</p>
<ul>
<li>To assess treatment efficacy, we want to see a fourfold decrease in
    titer after treatment</li>
</ul>
<table>
<colgroup>
<col style="width: 15%" />
<col style="width: 34%" />
<col style="width: 23%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Symptoms</th>
<th>Treatment</th>
<th>Treatment Alternatives</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Primary</td>
<td>Painless chancre at inoculation site with regional
lymphadenopathy</td>
<td rowspan="3">PCN G benzathine 2.4 million units IM x1</td>
<td rowspan="3"><p>Doxycycline 100mg PO BID x 14 days</p>
<p>OR</p>
<p>Ceftriaxone 1-2g daily IM or IV x 10-14 days</p>
<p>OR</p>
<p>Tetracycline 500mg PO QID x 14 days</p>
<p>OR</p>
<p>Amoxicillin 3g BID and probenecid 500mg BID x 14 days</p></td>
</tr>
<tr class="even">
<td>Secondary</td>
<td>Systemic illness with rash (palms, soles), fever, malaise, alopecia,
hepatitis, mucous patches, condyloma, pharyngitis</td>
</tr>
<tr class="odd">
<td>Early Latent</td>
<td>Infected, but no symptoms. Occurs within one year of initial
infection.</td>
</tr>
<tr class="even">
<td>Tertiary</td>
<td>Symptomatic late syphilis (CV system, gummatous disease)</td>
<td rowspan="2">PCN G benzathine 2.4 million units IM weekly x3
weeks</td>
<td rowspan="2"><p>Doxycycline 100mg PO BID x 4 weeks</p>
<p>OR</p>
<p>Ceftriaxone 2g daily IM or IV x 10-14 days</p></td>
</tr>
<tr class="odd">
<td>Late Latent</td>
<td><p>Infected, but no symptoms. Occurs &gt;1 year after initial
infection.</p>
<p>Assume late latent with date of infection unknown</p></td>
</tr>
<tr class="even">
<td><p>Neuro</p>
<p>syphilis</p></td>
<td><p>Can occur at any time.</p>
<p>Early: asymptomatic or symptomatic meningitis, vision loss, hearing
loss</p>
<p>Late: brain and spinal cord manifestations (dementia, tabes
dorsalis)</p>
<p>Treat ocular syphilis like neurosyphilis</p></td>
<td><p>Aqueous PCN G 3-4 million units IV q4h x 10-14 days</p>
<p>OR</p>
<p>PCN G procaine 2.4 million units IM daily and probenecid 500mg PO QID
x 10-14 days</p></td>
<td><p>If PCN allergic, desensitize</p>
<p>Ceftriaxone 2g daily IM or IV x 10-14 days</p></td>
</tr>
</tbody>
</table></section><section class="print-page" id="infectious-diseases-infectious-diseases-aids-defining-conditions"><h1 id="infectious-diseases-infectious-diseases-aids-defining-conditions-aids-defining-conditions">AIDS Defining Conditions<a class="headerlink" href="#infectious-diseases-infectious-diseases-aids-defining-conditions-aids-defining-conditions" title="Permanent link">&para;</a></h1>
<p>AIDS Defining Clinical Conditions – Rebecca Choudhury</p>
<p>AIDS is defined by HIV infection with concurrent absolute CD4 count
\&lt;200, CD4 percentage \&lt;14%, or one of the following conditions,
predominately opportunistic infections and HIV associated malignancies</p>
<p>Neurologic</p>
<p>/Ophthalmologic</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>CNS</p>
<p>toxoplasmosis</p>
<ul>
<li>Presentation: Variable, depending on disease burden/location, may
    include AMS, headache, seizure, ataxia, and focal neurologic
    deficits, &plusmn; fever and flu-like symptoms</li>
<li>Evaluation: MRI w/Ring-enhancing lesions on brain imaging ( <em>Note</em> :
    can appear similar to CNS lymphoma), serum Toxoplasma IgG/IgM and
    (ideally) CSF Toxoplasma PCR. Brain biopsy may be indicated if
    diagnostic uncertainty.</li>
<li>Management: Pyrimethamine, sulfadiazine, and leucovorin is the
    preferred regimen, discuss dosing with pharmacy. Alternative
    regimens: clindamycin, Bactrim, atovaquone, and/or azithromycin.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Progressive multifocal leukoencephalopathy (PML)</p>
<ul>
<li>Presentation: chronic (weeks to months), progressive neurologic
    dysfunction, particularly incoordination
    and other motor dysfunction, aphasia, sometimes cognitive impairment
    and personality changes</li>
<li>Evaluation:  MRI brain w/patchy areas of demyelination in the
    subcortical white matter; location is variable, but p
    arietal, occipital, and cerebellar involvement are common. JC virus
    PCR from CSF. Brain biopsy (uncommonly done)</li>
<li>Management: Initiation of ART may slow/stop progression. Fatal if
    HIV goes untreated.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>HIV-related encephalopathy</p>
<ul>
<li>Presentation: Similar to other progressive dementias, with short
    term memory loss followed by
    worsening global cognitive dysfunction, motor deficits, sometimes
    seizures in late stages</li>
<li>Evaluation: MRI w/diffuse cerebral atrophy and/or demyelinating
    lesions similar to PML. CSF w/elevated protein &plusmn; lymphocytic
    pleocytosis, with no alternative cause. Send HIV RNA from the CSF,
    usually + in HIV encephalopathy</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Cryptococcal meningitis</p>
<ul>
<li>Presentation: Subacute to chronically worsening HA and fevers;
    meningismus and photophobia may be present but are often absent;
    rarely, focal neurologic deficits</li>
<li>Evaluation: LP to check opening pressure and can send serum and CSF
    Cryptococcus Ag. Brain imaging may be non-diagnostic</li>
<li>Treatment: Induction therapy with amphotericin and flucytosine x14
    days (at least), with repeat LP close to end of
    induction to confirm CSF inflammation is improving and fungal
    culture is negative.
    Maintenance therapy consists of high dose fluconazole for at least 8
    weeks. Pts may require serial LP to manage ICP</li>
<li>Delay ART for several weeks after start of treatment to avoid risk
    of IRIS.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>CMV retinitis (with vision loss)</p>
<ul>
<li>Presentation: Blurry vision, focal blind spots, visual field
    deficits, or scotomas and floaters. Typically begins unilateral,
    though often progresses to bilateral involvement.</li>
<li>Evaluation: Always consult ophtho if you suspect it! Hemorrhagic
    retinitis, “tomato soup and milk” appearance on dilated exam. May
    cause complete retinal detachment. Check CMV pcr serum (or vitreous)</li>
<li>Management:  PO valgancyclovir (+intravitreous ganciclovir or
    foscarnet in severe disease). If not on ART, must delay ART for at
    least 2 weeks after start of CMV retinitis treatment to prevent
    immune recovery uveitis</li>
</ul>
<p>Pulmonary</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Pneumocystis jirovecii pneumonia (PJP)</p>
<ul>
<li>Presentation: fever, shortness of breath, cough (usually
    non-productive), sometimes night sweats and weight loss. Hypoxia out
    of proportion to exam.</li>
<li>Evaluation: CT chest appearance usually bilateral and diffuse with
    GGOs and cystic lesions of varying size. Large cysts can rupture,
    causing pneumothorax.<ul>
<li>Induced sputum (or bronchoscopy sample) with cytology and GMS
    stain.</li>
<li>Send serum LDH and 1,3-BD-glucan:  should be elevated, but are
    nonspecific.</li>
</ul>
</li>
<li>Management: Bactrim is the preferred treatment; PO is preferable as
    Bactrim is 100% bioavailable. **If patient is hypoxic, need to
    consider of adding steroids, can measure A-a gradient. Alternative
    regimens may include primaquine + clindamycin or IV (NOT inhaled)
    pentamidine.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Pulmonary tuberculosis</p>
<ul>
<li>Presentation: With low CD4, can have upper lobe cavities but also
    atypical radiographic pattern, including a normal-appearing CXR.
    Have a high degree of suspicion in any patient with advanced HIV and
    respiratory complaints.</li>
<li>Evaluation: TB skin tests and IGRAs have a high false negative rate
    in advanced HIV. At VUMC, any pt with HIV and respiratory complaints
    must be placed on airborne until TB ruleout- 3 sputum mycobacterial
    cultures collected at least 8 hours apart. If concentrated smear is
    negative x3, TB is unlikely (though have to follow up final culture
    to be sure).</li>
<li>Management: RIPE therapy is the standard initial treatment, with
    adjustment if needed for drug resistance or contraindications</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Herpes simplex tracheobronchitis and/or pneumonitis/pneumonia</p>
<ul>
<li>Evaluation: bronchoscopy with positive HSV PCR from BAL &plusmn; lung
    biopsy. (Usually associated with HSV-1)</li>
<li>Management:  agent and duration not well defined for
    bronchopulmonary disease; depending on severity of presentation,
    likely IV acyclovir to start followed by transition to PO antiviral
    once evidence of clinical improvement, for a total of 10-14 days.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Recurrent pneumonia NOS</p>
<p>Histoplasmosis, cryptococcosis, coccidiomycosis, and non-TB
mycobacterial infections (including MAC) limited to the pulmonary system
are not AIDs defining illnesses, though pts with advanced HIV and other
severely immunosuppressed states are at higher risk.</p>
<p>Gastrointestinal</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Esophageal candidiasis</p>
<ul>
<li>Presentation: Dysphagia, odynophagia or both. Concurrent
    oropharyngeal candidiasis (“thrush’) is common but not universal.</li>
<li>Evaluation: Typically presumptive. Treatment is the test; start
    fluconazole and consider EGD if symptoms do not improve after
    several days (in which case candidiasis may be severe, or it might
    not be the cause)</li>
<li>Management: Fluconazole; nystatin is ineffective, especially in the
    severely immunocompromised</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Herpes simplex esophagitis</p>
<ul>
<li>Evaluation: EGD shows diffuse ulcerations throughout the esophagus;
    in severe disease ulcers may coalesce into dark patches, “black
    esophagus.” Esophageal biopsy is definitive, but can infer based on
    EGD appearance and serum studies.</li>
<li>Management: Similar to other mucocutaneous infections, consider IV
    acyclovir at first and transition to PO once clinically improved</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>CMV esophagitis/enteritis/colitis</p>
<ul>
<li>Presentation: GI bleeding (colitis) or dysphagia and odynophagia
    (esophagitis)</li>
<li>Evaluation: serum CMV PCR, consult GI for consideration of
    EGD/colonoscopy</li>
<li>Management: (val)ganciclovir, foscarnet if ganciclovir resistance or
    contraindication</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Chronic (&gt;1 mo) intestinal isosporiasis</p>
<ul>
<li>Evaluation: Stool ova/parasite can capture Iospora belli (new name
    Cystoisospora belli), may need serial analysis due to intermittent
    shedding. Oocysts may also be seen on duodenal biopsy.</li>
<li>Management: Bactrim; pyrimethamine + leucovorin if Bactrim is
    contraindicated
    -</li>
</ul>
<p>Chronic intestinal cryptosporidiosis</p>
<ul>
<li>Presentation: Diarrhea; may infect respiratory tract, causing
    nonproductive cough</li>
<li>Evaluation: on GiPP or Cryptosporidium Ag</li>
<li>Management: Early initiation or optimization of ART; Monotherapy
    with nitazoxanide is preferred; raising CD4 count &gt;100 is necessary
    to cure infection</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Recurrent salmonella septicemia</p>
<ul>
<li>Generally sensitive to fluoroquinolones, but if not clinically
    improving as expected you can request sensitivities from the
    microbiology lab.</li>
</ul>
<p>Neoplastic</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Non-Hodgkin’s lymphoma - Burkitt’s, immunoblastic (subset of DLBCL), and
1º CNS</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Kaposi’s sarcoma</p>
<ul>
<li>Presentation: Distinctive mucocutaneous lesions, usually raised,
    papular, violaceous or darkly colored, non-tender and non-pruritic.
    Can also involve the visceral organs (esp lungs and GI tract) and
    deep lymphatic system.</li>
<li>Evaluation: clinical, tissue biopsy for staging, HHV-8 serum PCR.</li>
<li>Management: Limited mucocutaneous disease may resolve with
    initiation/optimization of ART, but widespread or resistant disease
    may require additional local therapies (ex radiation) or systemic
    chemo</li>
<li>Bacillary angiomatosis (caused by Bartonella) may present similarly,
    but can be distinguished from KS on biopsy. It is neither a cancer
    nor an AIDS defining clinical condition, and is usually treated with
    doxycycline.</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Cervical cancer</p>
<ul>
<li>Presentation, diagnosis, and treatment are essentially the same as
    in HIV-negative patients, but incidence is higher and disease
    progression is often more rapid</li>
</ul>
<p>Multisystem/Miscellaneous</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Extrapulmonary or disseminated Mycobacterial infection (TB and non-TB)</p>
<ul>
<li>TB can go everywhere; some notable extrapulmonary sites include
    lymph nodes (e.g., scrofula), bones and joints (e.g., Pott’s disease
    of the spine), pleura and pericardium, GU tract, and CNS. Dx can
    come from tissue culture and sometimes MTB PCR for more rapid
    detection (needs ID approval).</li>
<li>TB-IRIS may be severe (esp with high infection burden) and hard to
    distinguish from TB treatment failure; can also be seen in
    adequately treated TB (provoked by the presence of dead bacteria)
    and undiagnosed latent TB.</li>
<li>Disseminated MAC is usually diagnosed with AFB blood culture (only 1
    positive needed). Think about it in patients with uncontrolled HIV
    and severe immunosuppression (esp CD4 \&lt;50), with unintentional
    weight loss, chronic diarrhea and/or dyspnea, and evidence of GI
    malabsorption or with bone marrow suppression</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Extrapulmonary or disseminated Histoplasmosis, Cryptococcocosis, and
Coccidiodomycosis</p>
<ul>
<li>Can be difficult to distinguish based on clinical presentation and
    imaging alone. Diagnosed by culture and/or antigen testing depending
    on the organism and site of infection, and diagnosis may be
    supported by serologic studies.</li>
<li>Initial treatment of choice: liposomal amphotericin B in almost all
    cases</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Chronic mucocutaneous HSV</p>
<ul>
<li>Defined as mucocutaneous lesions present for &gt;1 month, can be
    present at any site</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-antimicrobial-prophylaxis"><h1 id="infectious-diseases-infectious-diseases-antimicrobial-prophylaxis-antimicrobial-prophylaxis">Antimicrobial prophylaxis<a class="headerlink" href="#infectious-diseases-infectious-diseases-antimicrobial-prophylaxis-antimicrobial-prophylaxis" title="Permanent link">&para;</a></h1>
<p>Antimicrobial Prophylaxis per CD4 Counts – Rachael Pellegrino</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 counts</td>
<td>Opportunistic Infection</td>
<td>Indication for Prophylaxis</td>
<td>Medication</td>
<td>Special Notes</td>
</tr>
<tr>
<td>\&lt;200 cells/mm3</td>
<td>Pneumocystis Pneumonia (PJP)</td>
<td>CD4 \&lt; 200, or CD4 \&lt; 14%, or CD4 200-250 w/ delayed init. ART &amp; poor f/u</td>
<td>TMP-SMX: 1 DS daily (qd), or TMP-SMX: 1SS qd TMP-SMX: 1 DS TIW</td>
<td>If intolerant of TMP-SMX: dapsone*, or pentamidine, or atovaquone</td>
</tr>
<tr>
<td>\&lt;200 cells/mm3</td>
<td>Toxoplasma gondii encephalitis</td>
<td>Toxoplasma IgG + and CD4 \&lt; 100</td>
<td>TMP-SMX 1 DS tab daily</td>
<td>Alternative regimens: Dapsone, or Atovaquone (all regimens effect. for PJP )</td>
</tr>
<tr>
<td>\&lt;200 cells/mm3</td>
<td>Mycobacterium avium- intracellulare (MAC, MAI)</td>
<td>Only if not on fully suppressive ART and active disseminated MAC is ruled out</td>
<td>- Azithromycin 1200 mg weekly, or -Clarithromycin 500 mg BID, or - Rifabutin 300 mg daily</td>
<td>NOT indicated for those initiating ART</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>Infection</th>
<th>Screening Indication</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis A Virus (HAV)</td>
<td>Non-immune w/ ↑ risk for HAV infection (MSM, IVDU) or chronic liver disease</td>
<td>HAV vaccine</td>
</tr>
<tr>
<td>Hepatitis B Virus (HBV)</td>
<td>Pts w/o chronic HBV or non-immune</td>
<td>HBV vaccine. Ideally admin. before CD4 \&lt; 350</td>
</tr>
<tr>
<td>Human Papilloma virus (HPV)</td>
<td>Age 13-45</td>
<td>HPV vaccine series</td>
</tr>
<tr>
<td>Influenza A and B Virus</td>
<td>All patients</td>
<td>Yearly inactivated influenza vaccine</td>
</tr>
<tr>
<td>Latent Mycobacterium tuberculosis infection (LTBI)</td>
<td>-Pts with positive screening test for LTBI w/ no evidence of active disease. -Pts w/ known exposure</td>
<td>(INH 300mg + pyridoxine 25-50mg) PO daily for 9 months</td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td>All patients</td>
<td>PCV13 and PPV23 (order and timing depends on previous vaccination history and CD4)</td>
</tr>
<tr>
<td>Syphilis</td>
<td>All pts exposed to sex partner with syphilis diagnosis</td>
<td>Screening for syphilis and gonorrhea/chlamydia with treatment if indicated.</td>
</tr>
<tr>
<td>Varicella Zoster Virus (VZV)</td>
<td>Pre-exposure: CD4&gt;200, no previous vaccine.Shingrix (recombinant vaccine) is not live virus, only Zostavax (live virus) is contraindicated for CD4 \&lt;200). Post-exposure: Close contact, particularly if CD4 \&lt;200</td>
<td>Pre-exposure: Consider vaccination Post-exposure: Varicella-zoster immune globulin</td>
</tr>
</tbody>
</table></section><section class="print-page" id="infectious-diseases-infectious-diseases-bacteremia"><h1 id="infectious-diseases-infectious-diseases-bacteremia-bacteremia-interpreting-genmark-eplex-results-vasp">Bacteremia: Interpreting GenMark ePlex® Results – VASP<a class="headerlink" href="#infectious-diseases-infectious-diseases-bacteremia-bacteremia-interpreting-genmark-eplex-results-vasp" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-bacteremia-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-bacteremia-background" title="Permanent link">&para;</a></h2>
<ul>
<li>When BCx turn positive, the lab reports Gram stain and GenMark
    ePlex® results to help guide empiric therapy, while awaiting further
    species identification and susceptibilities.</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-bacteremia-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-bacteremia-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Start empiric antibiotic therapy (based on clinical picture and
    table below)</p>
</li>
<li>
<p>Consider ordering repeat BCx x2 based on organism to document
    clearance</p>
<ul>
<li>Repeat for: <em>Staph</em> (MRSA or MSSA), <em>Strep lugdunensis</em></li>
<li>If source control &amp; no endovascular infxn, no need to repeat (most
other strep and GNR’s)</li>
</ul>
</li>
<li>
<p><a href="https://www.vumc.org/antimicrobial-stewardship-program/antibiograms">VUMC
    antibiograms</a>
    can be used to reference typical resistance patterns and most common
    organisms in blood cultures.</p>
</li>
<li>
<p><em>Candida</em> in a blood culture is NEVER considered a contaminant</p>
</li>
</ul>
<p>GRAM POSITIVE COCCI </p>
<table>
<colgroup>
<col style="width: 37%" />
<col style="width: 28%" />
<col style="width: 34%" />
</colgroup>
<thead>
<tr class="header">
<th><blockquote>
<p>Organism</p>
</blockquote></th>
<th><blockquote>
<p>Resistance Marker</p>
</blockquote></th>
<th><blockquote>
<p>Preliminary Recommendation</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td rowspan="2"><p><em>Staphylococcus aureus</em></p>
<blockquote>
<p>or</p>
</blockquote>
<p><em>Staphylococcus lugdunensis</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>mecA detected</td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td>No mecA detected</td>
<td><p>Start nafcillin or cefazolin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Staphylococcus epidermidis</em></p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start therapy if uncertain</p></td>
<td>mecA detected</td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td>No mecA detected</td>
<td><p>Start nafcillin or cefazolin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td><p>Other coagulase negative <em>Staph</em></p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start abx if uncertain</p></td>
<td></td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td><em>Streptococcus: agalactiae, pyogenes, anginosus</em></td>
<td></td>
<td><p>Start penicillin IV or CTX IV</p>
<p>Stop empiric vancomycin</p></td>
</tr>
<tr class="odd">
<td><em>Streptococcus pneumoniae</em></td>
<td></td>
<td><p>Start ceftriaxone</p>
<p>Stop empiric vancomycin</p>
<p>Await PCN sensitivity data</p></td>
</tr>
<tr class="even">
<td><p>Other <em>Streptococcus</em></p>
<p>-May be contaminant</p></td>
<td></td>
<td><p>Start ceftriaxone</p>
<p>Stop empiric vancomycin</p>
<p>Await PCN sensitivity data</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Enterococcus faecalis</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>vanA or vanB detected</td>
<td><p>Start daptomycin 8-10mg/kg/day IV</p>
<p>Don’t treat w vancomycin IV</p>
<p>Contact precautions</p></td>
</tr>
<tr class="even">
<td>No vanA or vanB</td>
<td><p>Start ampicillin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Enterococcus faecium</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>vanA or vanB detected</td>
<td><p>Start daptomycin 8-10mg/kg/day IV</p>
<p>Don’t treat w vancomycin IV</p>
<p>Contact precautions</p></td>
</tr>
<tr class="even">
<td>No vanA or vanB</td>
<td><p>Start vancomycin IV</p>
<p>Follow-up ampicillin sensitivities</p></td>
</tr>
<tr class="odd">
<td colspan="2"><p><em>Micrococcus</em></p>
<p>-Often if in a single blood culture is skin contaminant</p></td>
<td><p>Repeat BCx</p>
<p>Start vancomycin IV if uncertain</p></td>
</tr>
</tbody>
</table>

<p>GRAM POSITIVE RODS</p>
<table>
<colgroup>
<col style="width: 46%" />
<col style="width: 53%" />
</colgroup>
<thead>
<tr class="header">
<th><blockquote>
<p>Organism</p>
</blockquote></th>
<th><blockquote>
<p>Preliminary Recommendation</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><em>Listeria monocytogenes</em></td>
<td><p>Start ampicillin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="even">
<td><p>Other Gram positive rod (e.g. <em>Bacillus cereus, Corynebacterium,
Cutibacterium acnes, Lactobacillus</em>)</p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start therapy if uncertain</p></td>
<td><p>Start vancomycin IV</p>
<p>Follow-up sensitivities; some GPRs are resistant to
vancomycin</p></td>
</tr>
</tbody>
</table>

<p>GRAM NEGATIVE RODS *Consult ID if carbapenem resistance detected*</p>
<table>
<colgroup>
<col style="width: 29%" />
<col style="width: 70%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Organism</strong></th>
<th><strong>Preliminary Recommendation</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><em>Acinetobacter baumannii</em></td>
<td>Start ampicillin/sulbactam</td>
</tr>
<tr class="even">
<td><em>Bacteroides fragilis</em></td>
<td><p>Start metronidazole</p>
<p>If polymicrobial infection, piperacillin/tazobactam,
ampicillin/sulbactam, or meropenem based on other organisms</p>
<p>Do NOT double cover anaerobes</p></td>
</tr>
<tr class="odd">
<td><em>Citrobacter spp.</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Cronobacter sakazakii</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Enterobacter (non-cloacae complex)</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Enterobacter cloacae complex</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Escherichia coli</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><p><em>Fusobacterium nucleatum</em></p>
<p><em>Fusobacterium necrophorum</em></p></td>
<td>Start ampicillin/sulbactam or start/continue metronidazole</td>
</tr>
<tr class="odd">
<td><em>Haemophilus influenzae</em></td>
<td>Start/continue ceftriaxone</td>
</tr>
<tr class="even">
<td><em>Klebsiella oxytoca</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="odd">
<td><em>Klebsiella pneumoniae group</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><em>Morganella morganii</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Neisseria meningitidis</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><p><em>Proteus spp.</em></p>
<p><em>Proteus mirabilis</em></p></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="odd">
<td><em>Pseudomonas aeruginosa</em></td>
<td>Start/continue cefepime or piperacillin-tazobactam</td>
</tr>
<tr class="even">
<td><em>Salmonella spp</em></td>
<td>Start/continue ceftriaxone</td>
</tr>
<tr class="odd">
<td><p><em>Serratia spp.</em></p>
<p><em>Serratia marcescens</em></p></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Stenotrophomonas maltophilia</em></td>
<td>Start trimethoprim-sulfamethoxazole (15-20mg/kg/day divided q8h for
normal renal function)</td>
</tr>
<tr class="odd">
<td colspan="2">Gram-Negative Resistance Genes</td>
</tr>
<tr class="even">
<td>CTX-M Positive (ESBL)</td>
<td><p>Start meropenem</p>
<p>Consider an Infectious Diseases consult</p>
<p>Contact precautions (see Infection Prevention website)</p></td>
</tr>
<tr class="odd">
<td><p>IMP Positive</p>
<p>KPC Positive</p>
<p>NDM Positive</p>
<p>OXA (OXA-23 and OXA-48) Positive</p>
<p>VIM Positive</p></td>
<td><p>Carbapenemase-producing organism</p>
<p>Obtain Infectious Disease consultation</p>
<p>Contact precautions (see Infection Prevention website)</p></td>
</tr>
</tbody>
</table></section><section class="print-page" id="infectious-diseases-infectious-diseases-brief-overview-art"><h1 id="infectious-diseases-infectious-diseases-brief-overview-art-brief-overview-of-art">Brief Overview of ART<a class="headerlink" href="#infectious-diseases-infectious-diseases-brief-overview-art-brief-overview-of-art" title="Permanent link">&para;</a></h1>
<p>Overview of Antiretroviral Therapy – Joseph Quintana</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed Dose Combination regimens</td>
<td>Fixed Dose Combination regimens</td>
<td>Renal Dose Adj.</td>
<td>Specific Considerations</td>
</tr>
<tr>
<td>Biktarvy®</td>
<td>Bictegravir/ Emtricitabine/ Tenofovir (Alafenamide)</td>
<td>d/c if CrCl \&lt; 30; ok w/HD</td>
<td>↑ Metformin levels Contraindicated w/: rifampin, dofetilide, rifabutin Avoid close admin. w/: laxatives, sucralfate, iron, calcium</td>
</tr>
<tr>
<td>Triumeq®</td>
<td>Abacavir/ Dolutegravir/ Lamivudine</td>
<td>Dose adj individual components \&lt;50 mg/min</td>
<td>Dolutegravir can ↑ metformin &amp; dofetilide levels; dose adj needed w/rifampin use Same absorption issues with polyvalent cation administration (as below with bictegravir) also apply to dolutegravir</td>
</tr>
<tr>
<td>Genvoya®</td>
<td>Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir (Alafenamide)</td>
<td>d/c if CrCl \&lt; 30; ok in HD</td>
<td>Many DDI with Genvoya (and other regimens with pharmacologic booster [cobicistat] due to CYP 3A4 inhibition</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuceloside RTI</td>
<td>Dose adj</td>
<td>Specific SE</td>
<td>Major DDI</td>
<td>Special Points</td>
</tr>
<tr>
<td>Abacavir (ABC)</td>
<td>Hepatic dysfunction</td>
<td>↑ LDL/TG ↑ risk MI</td>
<td>Tenofovir (df)</td>
<td>Requires testing for HLA B5701; Avoid if previous hyper-sensitivity</td>
</tr>
<tr>
<td>Emtricitabine (FTC)</td>
<td>Renal (adj by CrCl)</td>
<td>Rash, Insomnia, Rhabdomyolysis, Hyperpigmentation in palms/soles</td>
<td>Lamivudine</td>
<td>Active against HBV</td>
</tr>
<tr>
<td>Lamivudine (3TC)</td>
<td>Renal (adj by CrCl)</td>
<td>Nausea, HA, peripheral neuropathy, neutropenia, rash</td>
<td>Emtritabine</td>
<td>Active against HBV</td>
</tr>
<tr>
<td>Tenofovir Alafenamide (TAF)</td>
<td>D/c for CrCl \&lt; 15</td>
<td>↑ lipids in TAF vs TDF</td>
<td>AED’s may $ levels</td>
<td>Tx of choice for HBV; ↑ lipids</td>
</tr>
<tr>
<td>Tenofovir Disoproxil (TDF)</td>
<td>Renal (adj by CrCl)</td>
<td>N/V, # LFT, asymptomatic # CK</td>
<td>--</td>
<td>Active against HBV</td>
</tr>
</tbody>
</table>
<p>NRTI Additional Information</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Tenofovir
    alone is indicated for HBV, in which case you should be mindful of
    renal clearance when dosing. In HIV, it is only indicated in
    combination with emtricitabine and fixed-dose combination
    formulations, in which it is contraindicated if CrCl\&lt;30</p>
</li>
<li>
<p>Class-wide Side Effect: Lactic acidosis, steatosis and lipoatrophy</p>
</li>
<li>
<p>Resistance: M184V confers high resistance to emtricitabine and
    lamivudine, mid-level resistance to abacavir</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrase Inhibitor</td>
<td>Dose Adj.</td>
<td>Specific SE</td>
<td>Major DDI</td>
<td>Special Points</td>
</tr>
<tr>
<td>Raltegravir (RAL)</td>
<td>--</td>
<td>--</td>
<td>Rifampin, AED’s</td>
<td>--</td>
</tr>
<tr>
<td>Dolutegravir (DTG)</td>
<td>*see special points*</td>
<td>Hyperglycemia Weight gain</td>
<td>Rifampin, Efavirenz ↑metformin lvls</td>
<td>Avoid close admin w/ laxatives, sucralfate,  iron, calcium May ↑Cr, w/o effect on renal fxn</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>NNRTIs</td>
<td>Hepatic Adj</td>
<td>Specific SE</td>
<td>Major DDI</td>
<td>Special Points</td>
</tr>
<tr>
<td>Efavirenz</td>
<td>D/c if Child Pugh B/C</td>
<td>Psychosis, vivid dreams, SI, mania, seizures; ↑ Lipids &amp; glucose</td>
<td>Plavix, Azole, antifungals, some statins * clarithromycin, Buprenorphine</td>
<td>Give before meals; d/c if rash develops</td>
</tr>
<tr>
<td>Etravirine (ETR)</td>
<td>NaN</td>
<td>Hypersensitivity  ↑ Lipids &amp; glucose</td>
<td>Plavix, clarithromycin</td>
<td>NaN</td>
</tr>
<tr>
<td>Nevirapine (NVP)</td>
<td>D/c if Child Pugh B/C</td>
<td>Steven Johnson Syndrome</td>
<td>Azoles, OCP’s, statins, clarithro-mycin</td>
<td>Don’t start if CD4 >250 in women, CD4 >400 in men; Don’t admin w/antacids</td>
</tr>
<tr>
<td>Rilpivirine (RPV)</td>
<td>NaN</td>
<td>Depression</td>
<td>AED’s, PPI’s, dexamethasone</td>
<td>Must be taken w/ full meal; Don’t use if HIV RNA >100k + CD4 \&lt; 200; Don’t admin w/antacids</td>
</tr>
<tr>
<td>Doravirine</td>
<td>NaN</td>
<td>Nightmares</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>NNRTI Additional Information</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Class-wide Side Effect: hepatitis, rashes</p>
</li>
<li>
<p>Resistance: K103N resistance to efavirenz and nevirapine</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protease inhibitors</td>
<td>Hepatic Dose adj</td>
<td>Specific SE</td>
<td>Major DDI</td>
<td>Special Points</td>
</tr>
<tr>
<td>Atazanavir (ATV)</td>
<td>Based on Childs Pugh</td>
<td>Jaundice, Kidney stones AV block, Pancreatitis Rhabdomyolysis</td>
<td>CYP3A4 Inhibitors PPI and H2 blockers</td>
<td>Admin w/ meals</td>
</tr>
<tr>
<td>Darunavir (DRV)</td>
<td>NaN</td>
<td>Rashes Pancreatitis</td>
<td>CYP3A4 Inhibitors Azoles can be used cautiously with drug level monitoring</td>
<td>Must d/c if rash</td>
</tr>
<tr>
<td>Lopinavir (LPV)</td>
<td>NaN</td>
<td>AV block, QT changes Pancreatitis Hepatitis</td>
<td>CYP3A4 Inhibitors</td>
<td>Admin w/ meals</td>
</tr>
</tbody>
</table>
<p>Protease Inhibitor Additional Information</p>
<ul>
<li>
<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>All protease inhibitors must be boosted:</p>
<ul>
<li>Ritonavir: can cause MSK pain, rhabdomyolysis, not expected at
    usual doses</li>
<li>Cobicistat: may increase Cr without effect on renal function</li>
</ul>
</li>
<li>
<p>Class-wide Side Effects: hepatitis, hypersensitivity reactions,
    #
    cholesterol/TG, hyperglycemia, GI upset, lipodystrophy</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-cns-infection"><h1 id="infectious-diseases-infectious-diseases-cns-infection-central-nervous-system-infection-vasp">Central Nervous System Infection – VASP<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-central-nervous-system-infection-vasp" title="Permanent link">&para;</a></h1>
<h1 id="infectious-diseases-infectious-diseases-cns-infection-bacterial-meningitis">Bacterial Meningitis<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-bacterial-meningitis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-cns-infection-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Blood cultures prior to antibiotics if possible</p>
</li>
<li>
<p>Head CT pre-LP, only if: Immunocompromised, hx of CNS diseases
    (shunts, trauma, tumors), papilledema on exam or FND, AMS, or new
    onset seizure.</p>
</li>
<li>
<p>If there is a delay in obtaining head CT or LP, DO NOT delay
    antibiotics.</p>
</li>
<li>
<p>Lumbar puncture (See Procedures Section):</p>
<ul>
<li>
<p>Obtain: Opening pressure, cell count + differential, glucose,
protein, bacterial culture</p>
</li>
<li>
<p>Send an extra tube or two of CSF to the lab, if possible, to be
frozen in case extra testing is needed (Order ‘Miscellaneous test’
and for test name put “Please freeze CSF in virology;” reference
lab: VUMC, specimen type: CSF)</p>
</li>
<li>
<p>Additional studies to consider in select pts: HSV 1, 2 PCR (NOT
antibodies), VZV PCR, VDRL, Crypto Ag, fungal and/or AFB cultures,
MTB PCR, West Nile Virus Ab, Enterovirus PCR, Histoplasma Ag, or
Biofire Meningitis/Encephalitis Panel. These should not be performed
routinely on all patients and consult ID where management questions
exist.</p>
</li>
<li>
<p>If Biofire Meningitis/Encephalitis Panel is performed, double check
what is included to avoid sending duplicate individual tests (ie
HSV, VZV, enterovirus, etc.) A negative cryptococcus on Biofire does
not exclude disease (CSF Crypto Ag is more sensitive)</p>
</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-cns-infection-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>ANTIBIOTICS AS SOON AS POSSIBLE:</p>
<ul>
<li>
<p>Ceftriaxone 2g IV q12h + Vancomycin, adjusted for renal function</p>
</li>
<li>
<p>Piperacillin-tazobactam cannot be used due to poor CNS penetration</p>
</li>
<li>
<p>IV ampicillin 2g q4h for optional coverage of Listeria for
immunocompromised patients, pregnant women, or age >50 (adjust
based on renal function)</p>
</li>
<li>
<p>IV acyclovir 10 mg/kg (based on adjusted body weight) q8h, if
suspected HSV or VZV meningitis, make sure to run with adequate
pre-hydration with NS</p>
</li>
<li>
<p>Consider empiric PO/IV doxycycline 100mg BID if tick-borne illness
is suspected</p>
</li>
</ul>
</li>
<li>
<p>Steroids: Based on IDSA guidelines, steroids (dexamethasone 0.15
    mg/kg q6h) should be given about 10-20 minutes before the first dose
    of antibiotics, or at the same time, in patients with suspected
    bacterial meningitis. IF pneumococcus is isolated, continue IV
    steroids for 2-4 days; otherwise, can discontinue</p>
</li>
<li>
<p>ID consultation: Duration should be guided by ID and varies based on
    organism recovered</p>
</li>
</ul>
<h1 id="infectious-diseases-infectious-diseases-cns-infection-encephalitis">Encephalitis<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-encephalitis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-cns-infection-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-background" title="Permanent link">&para;</a></h2>
<ul>
<li>The presence or absence of normal brain function/cognition is the
    important distinguishing clinical feature between encephalitis and
    meningitis</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-cns-infection-evaluation_1">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-evaluation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>MRI more sensitive that CT, although imaging may or may not
    demonstrate abnormal radiographic findings in patients with
    encephalitis</p>
</li>
<li>
<p>LP – similar studies as for meningitis (see above) + BioFire MEP for
    ALL pts</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-cns-infection-management_1">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Acyclovir 10mg/kg IV q8hr, consideration of antibacterial therapy if
    unable to conclusively exclude a bacterial meningitis, consideration
    of doxycycline if tick-borne infection is on the differential, and
    further treatment as guided by ID</p>
</li>
<li>
<p>ID consult is strongly encouraged for all patients with suspected
    encephalitis</p>
</li>
</ul>
<h1 id="infectious-diseases-infectious-diseases-cns-infection-brain-abscess">Brain Abscess<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-brain-abscess" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-cns-infection-evaluationmanagement">Evaluation/Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-evaluationmanagement" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Consult: Neurosurgery and ID</p>
</li>
<li>
<p>Blood Cultures, HIV testing in any patient with a brain lesion</p>
</li>
<li>
<p>Empiric antibiotics:</p>
<ul>
<li>
<p>IV Vancomycin (target trough 15 - 20 mcg/mL) + ceftriaxone 2g IV
q12h + metronidazole 500mg IV/PO q6h</p>
</li>
<li>
<p>If concern for extension from otitis externa, use an antipseudomonal
cephalosporin (cefepime 2g IV Q8h) instead of ceftriaxone</p>
</li>
<li>
<p>Brain abscesses generally polymicrobial, thus broad-spectrum
antibiotics indicated</p>
</li>
</ul>
</li>
<li>
<p>Aminoglycosides, macrolides, tetracyclines (e.g. doxycycline),
    clindamycin, beta-lactam/beta-lactamase combinations (e.g., Zosyn)
    and 1<sup>st</sup>-generation cephalosporins (e.g., cefazolin) should NOT be
    used as they do not cross BBB at high concentration.</p>
</li>
<li>
<p>Antibiotic Duration: Based on surgical drainage and Infectious
    Diseases guidance</p>
</li>
</ul>
<h1 id="infectious-diseases-infectious-diseases-cns-infection-epidural-abscess">Epidural Abscess<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-epidural-abscess" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-cns-infection-management_2">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-cns-infection-management_2" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>If spinal lesion, consult ‘Spine surgery’ and it will be directed to
    Ortho-Spine or Neurosurgery, depending on who is on call.</p>
</li>
<li>
<p>Antibiotics should be started as soon as the diagnosis of epidural
    abscess is suspected, immediately following the collection of two
    sets of blood cultures</p>
<ul>
<li>
<p>Vancomycin 15-20mg/kg IV q8-12h (adjusted for renal function) +
ceftriaxone 2g IV q24h (or q12hr if there is secondary meningitis)</p>
</li>
<li>
<p>Use cefepime 2g IV q8h instead of ceftriaxone if concern for
<em>Pseudomonas</em></p>
</li>
</ul>
</li>
<li>
<p>ID consult is strongly encouraged and they will guide duration</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-community-acquired-pneumonia"><h1 id="infectious-diseases-infectious-diseases-community-acquired-pneumonia-community-acquired-pneumonia-cap">Community Acquired Pneumonia (CAP)<a class="headerlink" href="#infectious-diseases-infectious-diseases-community-acquired-pneumonia-community-acquired-pneumonia-cap" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-community-acquired-pneumonia-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-community-acquired-pneumonia-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>All PNA that does not otherwise meet criteria for Hospital Acquired
    Pneumonia (PNA that develops ≥48 hours after hospital admission),
    Ventilator Associated Pneumonia (PNA that develops ≥48-72 hours
    after endotracheal intubation), or aspiration PNA</p>
</li>
<li>
<p>Healthcare-associated pneumonia is no longer a clinical entity per
    2016 IDSA guidelines</p>
</li>
<li>
<p>MRSA Risk Factors: recent history, cavitary lesion, post-influenza
    bacterial PNA, pts with IDU, severe hypoxemia requiring intubation</p>
</li>
<li>
<p><em>Pseudomonas</em>: Double coverage is not indicated in general
    population; LVQ has 82% sensitivity so not recommended unless
    isolate proven susceptible</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-community-acquired-pneumonia-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-community-acquired-pneumonia-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Sputum cultures prior to abx, consider BCx in select groups (severe
    pneumonia, ICU admission, cavitary disease, immunosuppression).</p>
</li>
<li>
<p>Rule out flu if the right season, COVID-19, consider RVP if it will
    change management</p>
</li>
<li>
<p>CURB-65 or PSI can aid in decision between outpatient vs inpatient
    therapy</p>
<ul>
<li>CURB65: Confusion, Uremia (BUN >=19 mg/dL), RR (>30/min),
BP(\&lt;90/60 mmHg), Age ≥ 65 If ≥ 2, hospitalization is recommended.</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider urine pneumococcal Ag, urine Legionella Ag in severe CAP
    and in certain pts (e.g., neutropenia, asplenia, obstructive lung
    disease, hyponatremia, diarrhea, or heavy alcohol use); these are
    performed at reference labs and will take several days to return.</p>
</li>
<li>
<p>CRP, ESR, and pro-calcitonin have not been shown to reliably improve
    outcomes; however, pro-calcitonin \&lt; 0.25 suggests against bacterial
    respiratory infection and antibiotic discontinuation is encouraged</p>
</li>
<li>
<p>PA/ lateral CXR to evaluate for and localize infiltrate. If
    immunocompromised, consider CT chest w/o contrast (does not improve
    outcomes)</p>
<ul>
<li>Lobar Consolidation - likely bacterial</li>
<li>Interstitial Infiltrate - likely atypical vs. viral vs.
non-infectious</li>
<li>Cavitation - concerning for fungal vs. necrotizing vs. mycobacterial</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-community-acquired-pneumonia-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-community-acquired-pneumonia-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Antibiotic Duration: 5-7 days (at least 5 days and improvement with
    clinical stability)</li>
</ul>
<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 36%" />
<col style="width: 0%" />
<col style="width: 41%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th colspan="2"><blockquote>
<p>Outpatient</p>
</blockquote></th>
<th><blockquote>
<p>Inpatient (Non- ICU &amp; ICU)</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>No MRSA or Pseudomonas suspected</td>
<td><p>Low Risk\*:</p>
<p>-Amoxicillin 1g TID</p>
<p>High Risk:</p>
<p>-Amoxicillin-clavulanate 875/125 BID + Macrolide</p>
<p>-Cefdinir 300 BID + Macrolide</p>
<p>-Amoxicillin 1g TID + Macrolide</p>
<p>-Levofloxacin 750 daily</p></td>
<td colspan="2">CTX 2g q24 + Azithromycin 500 daily OR Levofloxacin 750
daily</td>
</tr>
<tr class="even">
<td>MRSA or Pseudomonas suspected</td>
<td></td>
<td colspan="2"><p>MRSA: Vancomycin OR Linezolid</p>
<blockquote>
<p>(if no bacteremia)</p>
</blockquote>
<p>Pseudomonas: Cefepime 2g q8h</p></td>
</tr>
</tbody>
</table>

<p>*No chronic heart, lung, liver, renal disease, DM, alcoholism,
immunocompromise</p>
<h2 id="infectious-diseases-infectious-diseases-community-acquired-pneumonia-additional-information">Additional Information<a class="headerlink" href="#infectious-diseases-infectious-diseases-community-acquired-pneumonia-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>MRSA nasal swab has reported negative predictive value for MRSA
    pneumonia ranging 95% to >99%; consider sending and if negative,
    discontinue MRSA agent</p>
</li>
<li>
<p>CTX is generally adequate coverage for aspiration PNA without
    evidence of abscess, empyema, or cavitary lesion on imaging</p>
</li>
<li>
<p>Aspiration pneumonia can be confused for aspiration pneumonitis
    which does not need to be treated with antibiotics. Rapid resolution
    of leukocytosis and stabilization of vitals suggest aspiration
    pneumonitis and consideration of stopping antibiotics.</p>
</li>
<li>
<p>There is low sensitivity of S. pneumoniae to azithromycin (42%) and
    doxycycline (72%), so these should not be used as monotherapy</p>
</li>
<li>
<p>Check for drug interactions with linezolid (e.g., SSRI, methadone,
    methamphetamine use)</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-diabetic-foot-infection"><h1 id="infectious-diseases-infectious-diseases-diabetic-foot-infection-diabetic-foot-infection-vasp">Diabetic Foot Infection – VASP<a class="headerlink" href="#infectious-diseases-infectious-diseases-diabetic-foot-infection-diabetic-foot-infection-vasp" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-diabetic-foot-infection-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-diabetic-foot-infection-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Plain radiograph for all pts; MRI w/contrast if abscess/osteo
    suspected</p>
</li>
<li>
<p>BCx (prior to antibiotics) if systemic signs of infection, or severe
    infection</p>
<ul>
<li>Do not culture swabs of lesions, as these generally only grow
colonizing organisms.</li>
</ul>
</li>
<li>
<p>Consult podiatry if osteomyelitis present for bone specimen culture
    and pathology (either from debridement specimen or bone biopsy)
    prior to starting antibiotics.</p>
</li>
<li>
<p>Consult surgery if concern for abscess, gas in tissue, joint
    involvement</p>
</li>
<li>
<p>Assess peripheral vasculature, consider arterial flow
    studies/vascular surgery consult</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-diabetic-foot-infection-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-diabetic-foot-infection-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Assess Severity:</p>
<ul>
<li>
<p>Mild: Local infxn, skin/subQ tissue only, erythema >0.5 cm but ≤2cm
from ulcer</p>
</li>
<li>
<p>Moderate: Local infxn w/erythema > 2 cm from ulcer or deeper
structures included without SIRS</p>
</li>
<li>
<p>Severe: Local infxn with systemic inflammation as evidenced by >2
SIRS criteria</p>
<ul>
<li>
<p>Consider anti-pseudomonal coverage if at risk for <em>Pseudomonas</em>
infection (e.g. wet; failure of prior antibiotic therapy;
chronic wound).</p>
</li>
<li>
<p>Consider anaerobic coverage with metronidazole if foul-smelling
and/or necrotic.</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 14%" />
<col style="width: 36%" />
<col style="width: 49%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>Non-purulent, no MRSA risk factors</p>
</blockquote></th>
<th><blockquote>
<p>Purulent, MRSA risk factors</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Mild</td>
<td><p>Cephalexin 500 QID OR</p>
<p>Amoxicillin-clavulanate 875/125 BID</p></td>
<td><p>TMP-SMX DS 1-2 tabs BID OR</p>
<p>Doxycycline 100 BID</p></td>
</tr>
<tr class="even">
<td>Moderate</td>
<td><p>Amoxicillin-clavulanate 875/125 BID OR</p>
<p>Ampicillin-sulbactam 3g q6h OR</p>
<p>Piperacillin-tazobactam 3.375g q8h ext infusion OR</p>
<p>Levofloxacin 500 daily</p></td>
<td><p>TMP-SMX DS 1-2 tabs BID + cephalexin 500 QID OR
Amoxicillin-clavulanate 875/125 BID</p>
<p>Vancomycin 15-20mg/kg q8-12h + ampicillin-sulbactam 3g q6h
(anaerobic, but NO Pseudomonas cvg) OR cefepime 2g q8h (Pseudomonas cvg)
+ metronidazole 500 q8h (anaerobic cvg)</p></td>
</tr>
<tr class="odd">
<td>Severe</td>
<td colspan="2">Vancomycin 15-20 mg/kg q8-12h + cefepime 2g q8h +
metronidazole 500 q8h</td>
</tr>
</tbody>
</table>

<h2 id="infectious-diseases-infectious-diseases-diabetic-foot-infection-additional-information">Additional Information<a class="headerlink" href="#infectious-diseases-infectious-diseases-diabetic-foot-infection-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>If pt HDS, hold abx until deep tissue/operative cultures obtained.</p>
</li>
<li>
<p>Most diabetic foot infections are polymicrobial in nature.</p>
</li>
<li>
<p>Culture results may guide therapy, but all pathogens identified may
    not require treatment.</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-endocarditis"><h1 id="infectious-diseases-infectious-diseases-endocarditis-endocarditis">Endocarditis<a class="headerlink" href="#infectious-diseases-infectious-diseases-endocarditis-endocarditis" title="Permanent link">&para;</a></h1>
<p>Justin Smith</p>
<hr />
<h2 id="infectious-diseases-infectious-diseases-endocarditis-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-endocarditis-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Multiple etiologies of endocarditis:<ul>
<li>Typical Bacterial<ul>
<li><em>S. aureus</em>, <em>Enterococcus spp</em> (<em>E. faecalis</em> most commonly),
    viridans group <em>streptococci</em>, <em>Strep gallolyticus</em> (formerly <em>S.
    bovis</em>)</li>
<li>HACEK
    : <em>Haemophilus</em>, <em>Aggregatibacter</em>, <em>Cardiobacterium</em>, <em>Eikenella</em>,
    <em>Kingella</em></li>
</ul>
</li>
<li>Other infectious<ul>
<li>Culture negative: often recent antimicrobial exposure, slow
    growing organism</li>
<li><em>Coxiella</em>, <em>Brucella</em>, <em>Bartonella</em>, <em>Chlamydia</em>, <em>Legionella</em>,
    <em>Mycoplasma</em>, <em>Tropheryma whipplei</em>, <em>Propionibacterium acnes</em></li>
<li>Fungal: <em>Candida</em> and <em>aspergillus</em> most common</li>
</ul>
</li>
<li>Non-infectious: a.k.a., marantic endocarditis, Libbman-Sacks
    Endocarditis<ul>
<li>Rare, most common in advanced malignancy, SLE, inflammatory
    conditions</li>
<li>Higher risk for embolization compared to IE</li>
<li>Risk factors: IV drug use, congenital heart disease, valve
    abnormalities, intracardiac devices, recent cardiac surgery</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-endocarditis-presentation">Presentation<a class="headerlink" href="#infectious-diseases-infectious-diseases-endocarditis-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Fever (90%), Murmur (85%), Other: splenomegaly, splinter
    hemorrhages, Janeway lesions, Osler Nodes, Roth Spots</p>
</li>
<li>
<p>Persistent bacteremia despite appropriate treatment, new onset
    cardiac dysfunction, new onset valve abnormalities, stroke, other
    thromboembolic events, metastatic infections/abscesses, splenic
    abscess, septic pulmonary emboli</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-endocarditis-duke-criteria">Duke Criteria:<a class="headerlink" href="#infectious-diseases-infectious-diseases-endocarditis-duke-criteria" title="Permanent link">&para;</a></h2>
<ul>
<li>Pathologic Criteria<ul>
<li>Microorganisms: culture or histology proven: vegetation,
    embolus, or intracardiac abscess</li>
<li>Pathologic vegetations: vegetation of abscess with histology
    proven endocarditis</li>
</ul>
</li>
<li>Clinical Criteria<ul>
<li>Major:<ul>
<li>2x positive blood cultures from a typical organism</li>
<li>Evidence of endocardial involvement</li>
</ul>
</li>
</ul>
</li>
<li>Minor<ul>
<li>Predisposing heart condition/IVDU</li>
<li>Fever</li>
<li>Vascular phenomena (Glomerulonephritis)</li>
<li>Immunologic phenomena (Osler Nodes, Roth Spots, +Rheumatoid
    factor, GN)</li>
<li>Micro (Cultures that don’t fit the above, or serologic evidence
    of acute infection)<ul>
<li>
<ul>
<li>
<ul>
<li>-</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Definite: 2 Major, 1 major and 3 minor, or 5 minor</li>
<li>Possible: 1 major and 1 minor, or 3 minor</li>
<li>Rejected: firm alternate diagnosis, resolution of evidence with \&lt;4
    days of antibiotics, or absence of pathologic evidence with \&lt;4days
    of antibiotics</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-endocarditis-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-endocarditis-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Physical exam: murmur, decreased peripheral perfusion, evidence of
    heart failure, petechiae, splinter hemorrhages, Janeway
    lesions/Osler nodes, organomegaly</li>
<li>Blood cultures: at least three sets from different sites over a span
    of several hours</li>
<li>Echo (TTE vs TEE)<ul>
<li>It can be reasonable to start with TEE if pretest probability is
    high enough, if patient has known valvular abnormalities, or TTE
    will be technically difficult
-</li>
</ul>
</li>
<li>EKG: new heart block or prolonged PR raises concern for
    endocardial/perivalvular abscess. Endocarditis patients should be on
    telemetry, monitored closely by team</li>
<li>CXR: infiltrates suggestive of septic pulmonary emboli, pulmonary
    edema, cardiomegaly</li>
<li>Imaging of distant affected site if concerned for septic emboli</li>
<li>Other advanced imaging in select scenario: cardiac CTA, cardiac MRI,
    FDG-PET/CT</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-endocarditis-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-endocarditis-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Empiric antibiotics:<ul>
<li>If bacteria isolated from blood, reference bacteremia section
    for abx choice</li>
<li>If awaiting cultures<ul>
<li>Native valve: Vancomycin</li>
<li>Prosthetic valve: Vancomycin and cefepime, consider
    gentamicin</li>
</ul>
</li>
</ul>
</li>
<li>Duration: determined by ID, often 4-6 weeks</li>
<li>Surgical consult, if valve dysfunction, perivalvular abscess, large
    (&gt;20mm) vegetations</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-endocarditis-additional-information">Additional Information:<a class="headerlink" href="#infectious-diseases-infectious-diseases-endocarditis-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Complications: </p>
<ul>
<li>
<p>Cardiac:</p>
<ul>
<li>Heart failure:  usually secondary to valve dysfunction. Most
    common when aortic valve involved, risk also depends on
    organism (worst is <em>Staph aureus</em> )</li>
<li>Perivalvular abscess: suspect when there are conduction
    abnormalities on EKG; most likely when aortic valve
    involved, less likely with mitral valve.</li>
<li>Pericarditis: can be suppurative or non-suppurative</li>
<li>Intracardiac Fistula</li>
</ul>
</li>
<li>
<p>Septic emboli and metastatic abscesses</p>
</li>
<li>Mycotic aneurysm: usually occurs at vessel branch points</li>
</ul>
</li>
<li>
<p>Follow Up</p>
<ul>
<li>Repeat TTE at completion of treatment to establish new baseline</li>
<li>Followed for valvular dysfunction with frequency determined by
    nature of the dysfunction. (MR caused by IE should be followed
    on a timeline like other MR)</li>
<li>Regular dental care, Prior IE is an indication for SBE
    prophylaxis with dental work.</li>
</ul>
</li>
<li>
<p>Episode of IE is an indication for PDA or VSD closure</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-febrile-neutropenia"><h1 id="infectious-diseases-infectious-diseases-febrile-neutropenia-febrile-neutropenia">Febrile Neutropenia<a class="headerlink" href="#infectious-diseases-infectious-diseases-febrile-neutropenia-febrile-neutropenia" title="Permanent link">&para;</a></h1>
<p><img src="/sites/default/files/inline-images/FN%20Algorithm%208_18-2.jpg" data-entity-type="file" data-entity-uuid="caec4a22-0ae5-4554-9e25-953d435ef2f4" alt="Febrile Neutropenia" /></p></section><section class="print-page" id="infectious-diseases-infectious-diseases-fungal-infections"><h1 id="infectious-diseases-infectious-diseases-fungal-infections-fungal-infections">Fungal Infections<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-fungal-infections" title="Permanent link">&para;</a></h1>
<p>Justin Smith</p>
<hr />
<h1 id="infectious-diseases-infectious-diseases-fungal-infections-histoplasmosis">Histoplasmosis<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-histoplasmosis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Endemic to Ohio and Mississippi river valley</p>
</li>
<li>
<p>Pulmonary infiltrate with hilar or mediastinal LAD, pulmonary
    nodule/cavitary lesion, pulmonary syndrome with erythema nodosum</p>
</li>
<li>
<p>DDx: TB, malignancy, sarcoidosis (if considering sarcoidosis, rule
    out histoplasmosis as sarcoidosis treatment can induce disseminated
    histoplasmosis)</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Antigen (requires attending approval): For acute pulmonary
    histoplasmosis, 65% urine sensitivity, 69% serum sensitivity, and
    83% sensitivity when co-tested. Thus, both serum and urine Ag are
    usually sent together</p>
<ul>
<li>Lower rates of positivity when disease is localized, versus diffuse
throughout the lungs or disseminated.</li>
<li>There are relatively high rates of cross-reactivity, where
histoplasma antigen will be positive with blastomycosis; therefore,
do not order blasto Ag if ordering histo Ag in MOST cases</li>
</ul>
</li>
<li>
<p>Serology: Consider Histoplasma Ab if evaluating for pulmonary
    disease</p>
</li>
<li>
<p>Culture: most useful in chronic infections, sensitivity is low in
    acute/localized and may take >6 weeks to grow.</p>
</li>
<li>
<p>Bronchoscopy: If clinical suspicion is high and work up negative,
    consider interventional pulmonology consult for consideration of
    bronchoscopy</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Outpatient/Mild disease:</p>
<ul>
<li>Tx not required if symptoms \&lt;4 weeks, initiate if symptomatic
beyond 4 weeks</li>
<li>Itraconazole: 200mg TID x3 days loading, then BID (adjusted by
levels which are drawn 2 weeks post-start) for 6-12 weeks minimum</li>
<li>Can use oral formulation or capsules (capsules require high acidity,
give with food consumption or OJ or coke; do not use capsules if
patient is on H2 blockers/PPI)</li>
<li>Voriconazole, Posaconazole: used if not tolerating itraconazole or
as salvage therapy</li>
</ul>
</li>
<li>
<p>Inpatient/Moderate to Severe Disease:</p>
<ul>
<li>
<p>Amphotericin: 1-2 weeks induction, followed by PO itraconazole for
12 weeks (total)</p>
</li>
<li>
<p>Methylprednisolone: help to prevent ARDS with significant lung
involvement</p>
</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-additional-information">Additional Information<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Complications: Pericarditis, arthritis/arthralgias with erythema
    nodosum, chronic cavitary lesions, fibrosing mediastinitis,
    broncholithiasis</p>
</li>
<li>
<p>Disseminated Histoplasmosis:</p>
<ul>
<li>Typically found in immunocompromised populations</li>
<li>Clinical presentations: FUO, weight loss, disseminated LAD,
cutaneous manifestations, bone marrow suppression/pancytopenia,
liver enzymes elevation, various solid organ involvement on imaging
(liver, spleen, adrenals, nodes)</li>
<li>Management<ul>
<li>Mild: itraconazole</li>
<li>Moderate to Severe: amphotericin induction followed by
itraconazole</li>
<li>CNS involvement: amphotericin for 4-6 weeks as induction</li>
</ul>
</li>
</ul>
</li>
</ul>
<h1 id="infectious-diseases-infectious-diseases-fungal-infections-blastomycosis">Blastomycosis<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-blastomycosis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-background_1">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-background_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Endemic to Mississippi/Ohio river valley, southern and midwestern
    US, great lakes</p>
</li>
<li>
<p>Pulmonary syndrome: cough, fever, hemoptysis, chest pain, dyspnea</p>
<ul>
<li>Can result in both an acute or chronic pneumonia, as well as ARDS</li>
</ul>
</li>
<li>
<p>Cutaneous: raised verrucous lesion, varying in color, with irregular
    borders</p>
</li>
<li>
<p>MSK: osteolytic lesion, draining sinus, soft tissue swelling</p>
</li>
<li>
<p>Multi-system: up to 20-40% of cases, most typically lung/skin
    involvement.</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-evaluation_1">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-evaluation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Culture: typically takes 1-4 weeks</p>
</li>
<li>
<p>Ag: urine >serum. ~90% sensitive, but only 80% specific because of
    cross-reactivity</p>
</li>
<li>
<p>Serology: available, but not very useful because of high degree of
    cross-reactivity</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-management_1">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Mild: PO itraconazole for 6-12 months with loading, check level at 2
    weeks</p>
</li>
<li>
<p>Moderate to Severe: induction with Amphotericin, followed by 6-12
    months of PO itraconazole</p>
</li>
</ul>
<h1 id="infectious-diseases-infectious-diseases-fungal-infections-candida">Candida<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-candida" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-background_2">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-background_2" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Oropharyngeal: white plaques in mouth, change in taste, erythema
    without plaques</p>
<ul>
<li>Usually seen in infants, older adults, immunocompromised host (HIV
or chemotherapy), inhaled steroid users</li>
</ul>
</li>
<li>
<p>Esophageal: odynophagia, especially retrosternal pain (AIDS defining
    illness)</p>
</li>
<li>
<p>Vulvovaginitis: itching, burning, vaginal discharge, vulvar
    erythema, vulvar edema, dyspareunia, dysuria</p>
</li>
<li>
<p>Balanitis: painful white plaques with burning and itching on the
    glans penis</p>
</li>
<li>
<p>Mastitis: erythema, tenderness in breast feeding woman.</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-management_2">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-management_2" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Depends on specifics, but typically nystatin or fluconazole EXCEPT
    <em>C. glabrata</em> (proof of fluconazole susceptibility needed) and <em>C.
    krusei</em> (intrinsically resistant to fluconazole)</p>
</li>
<li>
<p>Cx generally not indicated unless complicated pt with extensive tx
    history for Candida</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-fungal-infections-additional-information_1">Additional Information<a class="headerlink" href="#infectious-diseases-infectious-diseases-fungal-infections-additional-information_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Disseminated disease<ul>
<li>Presentation: Primarily immunocompromised populations (hematologic
malignancies, solid organ transplant recipients, receiving
chemotherapy, TPN, steroid use, broad spectrum antibiotics) and ICU
settings (especially, burn, trauma, and neonatal)</li>
<li>Diagnosis: <em>Candida</em> in a bacterial blood culture (NEVER
contaminant)</li>
<li>Start micafungin 100mg IV and consult ID for candidemia or if
concerned for disseminated disease</li>
</ul>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-general-tips"><h1 id="infectious-diseases-infectious-diseases-general-tips-general-tips">General Tips<a class="headerlink" href="#infectious-diseases-infectious-diseases-general-tips-general-tips" title="Permanent link">&para;</a></h1>
<ul>
<li>
<p>Vanderbilt Antibiotics Stewardship Program (VASP) has a
    <a href="https://www.vumc.org/antimicrobial-stewardship-program/">website</a>
    with much of the below guidance as well as Vanderbilt antibiograms, with
    our resistance patterns</p>
</li>
<li>
<p>Does your pt need to be on precautions?
    Check the <a href="https://www.vumc.org/infectioncontrol/12177">Infection Prevention Website</a>
    under ‘isolation’ tab or page the infection control pager in E-star
    paging for additional questions</p>
</li>
<li>
<p>Page 317-4376 for approval of restricted antimicrobials at VUMC
    (page the VA ID fellow at the VA)</p>
</li>
<li>
<p>The lab will automatically update the Tennessee health department
    with reportable diseases</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-gu-infection"><h1 id="infectious-diseases-infectious-diseases-gu-infection-genitourinary-infection-vasp">Genitourinary Infection – VASP<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-genitourinary-infection-vasp" title="Permanent link">&para;</a></h1>
<h1 id="infectious-diseases-infectious-diseases-gu-infection-asymptomatic-bacteriuria">Asymptomatic Bacteriuria<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-asymptomatic-bacteriuria" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Isolation of bacteria in an appropriately collected urine specimen from an
    individual without symptoms or signs of urinary tract infection.
    Bacteriuria, foul odor, urine appearance, pyuria and/or bacteriuria
    alone are not indicative of infection.</li>
<li>Anuric ESRD patients may have bacteriuria from colonization due to
    lack of flushing of bladder, avoid sending UA/Ucx unless patient is
    symptomatic</li>
<li>Treatment
    only required for specific populations:<ul>
<li>Pregnant women (screening performed at 12 – 16 weeks)</li>
<li>Anticipated urologic intervention</li>
<li>Some
    renal transplant recipients, depending on time since transplant</li>
</ul>
</li>
</ul>
<h1 id="infectious-diseases-infectious-diseases-gu-infection-uncomplicated-urinary-tract-infection-uti">Uncomplicated Urinary Tract Infection (UTI)<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-uncomplicated-urinary-tract-infection-uti" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-background_1">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-background_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Clinical symptoms of UTI (dysuria/urgency/frequency/ hematuria) in
    non-pregnant, immunocompetent, neurologically-intact pts with normal
    urologic anatomy and no indwelling urinary catheters</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Empiric therapy<ul>
<li>Nitrofurantoin monohydrate: 100 mg PO BID x 5 days (avoid if any
    concern for pyelonephritis or if creatinine clearance \&lt;60)</li>
<li>Cephalexin
    250-500mg q6h x5-7 days</li>
</ul>
</li>
<li>Alternative
    therapies<ul>
<li>Fosfomycin: 3 grams of powder mixed in water as a single PO dose
    (avoid if any concern for ascending UTI or pyelonephritis).
    Susceptibility test results must be requested of micro lab and
    are only possible for E. coli and E. Faecalis.</li>
<li>Amoxicillin-clavulanate: 875-125mg PO BID x5 days</li>
<li>Ciprofloxacin: 250mg PO BID x3 days<ul>
<li>FQ’s should be reserved for more serious infections than
    uncomplicated cystitis, and only after susceptibility
    results are confirmed given high rates of resistance from
    overuse (~25% of <em>E. coli</em> are resistant to ciprofloxacin
    at VUMC)</li>
<li>Adverse effect profile &gt;> beta-lactams (i.e.
    QT-prolongation, tendinopathies)</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-additional-information">Additional Information<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-additional-information" title="Permanent link">&para;</a></h2>
<ul>
<li>MDR cystitis: ESBL isolates are increasingly common due to antibiotic overuse<ul>
<li>Before treating, decide if this is a TRUE UTI</li>
<li>If true, consider Fosfomycin (if <em>E. coli</em> ) or nitrofurantoin (if
susceptibility is confirmed – <em>K. pneumoniae</em> and <em>Enterobacter</em> spp
are usually resistant), gentamicin or tobramycin 5-7mg/kg IV once, or ID consultation</li>
<li>Ask the lab to check susceptibility results to these antibiotics, for the future reference</li>
</ul>
</li>
</ul>
<h1 id="infectious-diseases-infectious-diseases-gu-infection-complicated-uti-and-pyelonephritis">Complicated UTI and Pyelonephritis<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-complicated-uti-and-pyelonephritis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-background_2">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-background_2" title="Permanent link">&para;</a></h2>
<ul>
<li>Fever, pyuria, and costovertebral angle tenderness suggest
    pyelonephritis. </li>
<li>Consider it a complicated UTI if any of the following are present: <ul>
<li>Renal calculi or other obstructive disease, immunosuppressed
    host, abnormal urological anatomy or physiology (including stents), presence of a
    urinary catheter</li>
<li>Malse sex alone does NOT qualify as complicated </li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>UA with reflex urine culture</p>
</li>
<li>
<p>BCx and UCx prior to antibiotics</p>
</li>
<li>
<p>If there is no pyuria, consider an alternative diagnosis, or
    proximal ureteral obstruction</p>
<ul>
<li>Pyuria is common in the presence of a urinary catheter, kidney stones,
    urostomy, ileal conduit and other invasive devices, and may not
    indicate infection</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-management_1">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Duration: 7-14 days, depending on antibiotic choice</li>
<li>Tailor therapy once/if cultures are available. If no improvement in
    48h, consider imaging to rule out complications (e.g., perinephric
    abscess)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>First Line</td>
<td>Alternative</td>
</tr>
<tr>
<td>Outpatient</td>
<td>Ciprofloxacin 750 BID (or 500 BID if bacteremia r/o)  x 7d</td>
<td>NaN</td>
</tr>
<tr>
<td>Inpatient</td>
<td>- CTX 2g q24h - Cefepime 2g q8h - Meropenem 2g q8h (if h/o or confirmed ESBL w/in last 90 d)</td>
<td>- Ertapenem 1g q24 instead of Meropenem if no Pseudomonas - Ciprofloxacin 750 PO BID (500 PO BID if bacteremia ruled out) OR 400 IV BID (if suscept confirmed)*</td>
</tr>
</tbody>
</table>
<p>*FQ’s have same bioavailability if given PO or IV so oral is preferred</p>
<h1 id="infectious-diseases-infectious-diseases-gu-infection-catheter-associated-urinary-tract-infection-cauti">Catheter Associated Urinary Tract Infection (CAUTI)<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-catheter-associated-urinary-tract-infection-cauti" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-background_3">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-background_3" title="Permanent link">&para;</a></h2>
<ul>
<li>Culture growth of &gt; 10 <sup>3</sup> cfu/mL of uropathogenic
    bacteria + signs or symptoms consistent with infection (without
    another identified etiology) + indwelling urethral/suprapubic
    catheter or intermittent catheterization.<ul>
<li>This includes pts with catheters in place during the preceding
    48 hours</li>
</ul>
</li>
<li>Duration = greatest risk factor (Increases 3-10% per day of
    catheterization)<ul>
<li>Other risks: female sex, diabetes, elderly, colonization of
    catheter bag, poor care</li>
</ul>
</li>
<li>Bacteriuria, foul odor, pyuria, urine appearance and/or bacteriuria
    alone are not indicative of infection in patients who are otherwise
    asymptomatic.</li>
<li>Ensure clean sample collected<ul>
<li>Ideally, catheter is removed and midstream sample obtained</li>
<li>If catheterization required; removal of old catheter and sample
    taken from new</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-gu-infection-management_2">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-gu-infection-management_2" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Distinguish uncomplicated vs complicated UTI (see above)</p>
</li>
<li>
<p>Antimicrobial management:</p>
<ul>
<li>Guided by cultures and susceptibilities</li>
<li>Empiric guidance as per management of uncomplicated/complicated
    UTI and per prior culture data/susceptibilities when available</li>
<li>Duration: 7 – 14 days depending on antibiotic, clinical response
    and whether infection constitutes complicated vs uncomplicated
    UTI</li>
<li>Special note regarding <strong>Candida</strong> UTI management: Candida Is
    generally not pathogenic</li>
<li>Presence
    in urine does not indicate infection (unless perinephric
    abscess, renal transplant, or complex fistulous disease)</li>
<li>Fluconazole
    achieves excellent urinary penetration</li>
<li>Echinocandins do not, and other azoles are not well studied in
    UTIs</li>
<li>If
    fluconazole
    resistant Candida cultured or suspected, consult ID</li>
<li>Susceptibilities are not routinely run on Candida from urine
    cultures and would need to be requested if concern for true
    infection.</li>
</ul>
</li>
<li>
<p>Catheter management</p>
<ul>
<li>At the least, catheters should be replaced at the time of
    antibiotic initiation (preferably removed) </li>
<li>Preferably, catheters should be removed</li>
<li>If catheterization is necessary, intermittent catheterization is
    preferred over continuous use. Condom catheters and pure wicks also 
    preferred over foley catheter</li>
</ul>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-hap-and-vap"><h1 id="infectious-diseases-infectious-diseases-hap-and-vap-hospital-acquired-pneumonia-hap-and-ventilator-associated-pneumonia-vap">Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP)<a class="headerlink" href="#infectious-diseases-infectious-diseases-hap-and-vap-hospital-acquired-pneumonia-hap-and-ventilator-associated-pneumonia-vap" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-hap-and-vap-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-hap-and-vap-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>HAP: Pneumonia that develops >48 hours after admission</p>
</li>
<li>
<p>VAP: Pneumonia that develops >48 hours after endotracheal
    intubation</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-hap-and-vap-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-hap-and-vap-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Cultures of blood, sputum, endotracheal aspirate and/or bronchoscopy
    specimen</p>
</li>
<li>
<p>Consider MRSA nares to help with de-escalation</p>
</li>
<li>
<p>If there is concern for respiratory viruses: send influenza, COVID,
    RVP</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-hap-and-vap-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-hap-and-vap-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Initially cover for MRSA and <em>Pseudomonas</em></p>
</li>
<li>
<p>Antibiotic Duration: 7 days in uncomplicated cases, although
    specific pathogens (e.g., <em>Pseudomonas</em>) may require longer duration
    and ID guidance</p>
</li>
<li>
<p>Consider ID consultation if the patient is not clinically improving
    on empiric therapy or if an MDR pathogen grows from culture</p>
</li>
<li>
<p>If no MRSA isolated and pt is improving, consider stopping
    vancomycin ASAP</p>
</li>
<li>
<p>There is concern for nephrotoxicity with combination Vancomycin and
    piperacillin-tazobactam, but data controversial</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 34%" />
<col style="width: 49%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>MRSA Coverage</p>
</blockquote></th>
<th><blockquote>
<p>Pseudomonas Coverage</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>First Line</td>
<td>Vancomycin (Pharmacy dosing)</td>
<td>Cefepime 2g q8h OR Piperacillin-tazobactam 3.375 q8h extended
infusion OR Ceftazidime 2g q8h</td>
</tr>
<tr class="even">
<td>Alternative</td>
<td>Vancomycin allergy: Linezolid 600 mg PO q12h</td>
<td>True PCN allergy: Aztreonam 2g q8h</td>
</tr>
</tbody>
</table></section><section class="print-page" id="infectious-diseases-infectious-diseases-hiv-art-general-concepts"><h1 id="infectious-diseases-infectious-diseases-hiv-art-general-concepts-hivaids-and-art">HIV/AIDS and ART<a class="headerlink" href="#infectious-diseases-infectious-diseases-hiv-art-general-concepts-hivaids-and-art" title="Permanent link">&para;</a></h1>
<p>Kathryn Snyder and Quinton Taylor</p>
<h2 id="infectious-diseases-infectious-diseases-hiv-art-general-concepts-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-hiv-art-general-concepts-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Why is ART important?</p>
<ul>
<li>Clear morbidity and mortality benefits across all CD4 counts</li>
<li>Decreases subsequent infections (both common and opportunistic)</li>
<li>Decreased HIV related comorbid conditions, viral reservoirs, and
transmission</li>
</ul>
</li>
<li>
<p>New HIV Diagnosis</p>
<ul>
<li>ID consult if patient is not on Rogers ID service (important for
initiation, follow up [CCC], social work assistance)</li>
<li>ART is indicated for all HIV+ patients, regardless of CD4; however,
starting ART requires appropriate outpatient follow up</li>
<li>
<p>Lab evaluation:</p>
<ul>
<li>
<p>HIV viral load, genotype, and resistance testing</p>
</li>
<li>
<p>T cell subsets (CD4 Count), CBC with differential, CMP, UA</p>
</li>
<li>
<p>HLA*B5701 testing before using abacavir containing regimen</p>
</li>
<li>
<p>QuantiFERON Gold</p>
</li>
<li>
<p>Pregnancy testing</p>
</li>
<li>
<p>Viral hepatitis serologies</p>
</li>
<li>
<p>Toxoplasma serologies</p>
</li>
<li>
<p>Other STI screening (Syphilis, Gonorrhea/Chlamydia)</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Timing of ART initiation</p>
<ul>
<li>Factors affecting timing of initiation<ul>
<li>Drug toxicity and interactions, risks for resistance, adherence barriers</li>
<li>Treatment of opportunistic infections may delay initiation of ART given associated risk of immune reconstitution inflammatory syndrome (IRIS)<ul>
<li>Delay ART for several weeks after initiation of therapy for cryptococcal meningitis, tuberculosis, and CMV retinitis</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>ART plan for overnight admits: okay to continue home ART, special
    consideration for:</p>
<ul>
<li>Patients with hepatic or renal dysfunction may need dose adjustment</li>
<li>Interactions with other newly initiated medications</li>
<li>If there is concern for non-adherence, can hold morning dose</li>
<li>Combination pills may need to be ordered as separate components</li>
</ul>
</li>
<li>
<p>Common key regimens for initiation</p>
<ul>
<li>Most regimens consist of an NRTI backbone (2 agents) plus a 3<sup>rd</sup> agent</li>
<li>Some dual therapy regimens (such as Dovato@) are non-inferior to
standard 3-drug therapy</li>
<li>Many patients are started on combination pill regimens, including
Integrase Inhibitor based regimens: Biktarvy®, Dovato®, Triumeq®,
Genvoya®, dolutegravir + Descovy®</li>
</ul>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-inpatient-covid19"><h1 id="infectious-diseases-infectious-diseases-inpatient-covid19-inpatient-covid-19-management">Inpatient COVID-19 Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-inpatient-covid19-inpatient-covid-19-management" title="Permanent link">&para;</a></h1>
<p>Kathryn Snyder</p>
<hr />
<h1 id="infectious-diseases-infectious-diseases-inpatient-covid19-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-inpatient-covid19-background" title="Permanent link">&para;</a></h1>
<ul>
<li>COVID-19 is the novel coronavirus responsible for the ongoing
    pandemic that started in late 2019. The virus has ongoing mutations
    resulting in new dominant strains.</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-inpatient-covid19-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-inpatient-covid19-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Please see the most updated VUMC and VA guidance due to frequently
    evolving recommendations.</p>
</li>
<li>
<p>Please refer to the hospital’s current maximum oxygen requirement
    allowed on the floor to ensure patient is appropriately triaged.</p>
</li>
<li>
<p>Basic admission workup for symptomatic, confirmed COVID-19</p>
<ul>
<li>
<p>Labs: CBC with diff, CMP, d-dimer, ferritin, CRP, ESR, PT/INR, PTT,
procalcitonin, RPP</p>
</li>
<li>
<p>Imaging: portable CXR</p>
</li>
<li>
<p>Nursing: Strict I/O</p>
</li>
<li>
<p>Enhanced precautions (contact, airborne, eye protection)</p>
</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-inpatient-covid19-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-inpatient-covid19-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Fluid balance goal slightly net negative to even</p>
</li>
<li>
<p>Anticoagulation/DVT prophylaxis:</p>
<ul>
<li>Please see latest VUMC or VA guidance based on clinical status
(supplemental O2 requirements, ICU vs floor, etc.)</li>
</ul>
</li>
<li>
<p>Pharmacologic therapies</p>
<ul>
<li>Note: Therapies, indications, and contraindications are frequently
changing, please see latest VUMC/VA guidelines for specific
indications for these medications or others</li>
</ul>
</li>
<li>
<p>Remdesivir</p>
<ul>
<li>
<p>Loading dose 200mg IV x1 then 100mg daily x 4 days</p>
</li>
<li>
<p>For use in patients hospitalized for COVID within 7 days of
    symptom onset</p>
</li>
<li>
<p>Contraindications: known hypersensitivity, ALT >/= 10x ULN,
    high-flow NC, PPV, intubated, or on ECMO</p>
</li>
<li>
<p>Monitoring: baseline CBC, INR, q48h CMP</p>
</li>
</ul>
</li>
<li>
<p>Dexamethasone</p>
<ul>
<li>
<p>6mg PO/IV x 10 days; consideration of longer taper if no
    clinical improvement or persistently elevated CRP</p>
</li>
<li>
<p>Contraindications: no hard contraindications, use clinical
    judgement if concomitant serious bacterial/fungal infection</p>
</li>
</ul>
</li>
<li>
<p>Antibiotics:</p>
<ul>
<li>
<p>The incidence of superimposed bacterial infection in the setting
    of COVID-19 is low</p>
</li>
<li>
<p>The majority of patients do not need additional coverage for
    bacterial pneumonia</p>
</li>
<li>
<p>You can use procalcitonin to guide decision</p>
</li>
</ul>
</li>
<li>
<p>Other pharmacologic therapies include baricitinib (JAK inhibitor),
    tocilizumab (IL-6 inhibitor) and monoclonal antibodies</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>Complications and special considerations for COVID-19 patients</p>
<ul>
<li>
<p>High PE/DVT risk</p>
</li>
<li>
<p>Superimposed bacterial PNA</p>
</li>
<li>
<p>AKI</p>
</li>
<li>
<p>GI symptoms/abnormalities (see GI section on COVID-19)</p>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-orthopedic-infection"><h1 id="infectious-diseases-infectious-diseases-orthopedic-infection-joint-infections-and-osteomyelitis-vasp">Joint Infections and Osteomyelitis – VASP<a class="headerlink" href="#infectious-diseases-infectious-diseases-orthopedic-infection-joint-infections-and-osteomyelitis-vasp" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-orthopedic-infection-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-orthopedic-infection-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Blood cultures prior to antibiotics</p>
</li>
<li>
<p>MRI is the most sensitive and specific imaging modality for
    osteomyelitis.</p>
</li>
<li>
<p>Ortho consult for joint fluid aspirate or bone bx; send for culture
    and send fluid for cell count/differential.</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-orthopedic-infection-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-orthopedic-infection-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Hold antibiotics until culture obtained, if patient is clinically
    stable</p>
</li>
<li>
<p>Osteomyelitis is a 6-week treatment course, can consider early
    transition (at 2-3 weeks) to oral if good bioavailability and
    susceptibility.</p>
</li>
<li>
<p>For prosthetic joint infection, procedure/retention of hardware
    determines duration</p>
</li>
<li>
<p>First line empiric: Vancomycin + ciprofloxacin 750mg BID</p>
</li>
<li>
<p>Antimicrobial therapy will ultimately be guided by culture data, ID
    consult recommended for joint infection treatment due to need for
    prolonged antibiotic therapy</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-pulmonary-infections"><h1 id="infectious-diseases-infectious-diseases-pulmonary-infections-pulmonary-infections">Pulmonary Infections<a class="headerlink" href="#infectious-diseases-infectious-diseases-pulmonary-infections-pulmonary-infections" title="Permanent link">&para;</a></h1>
<p>VASP, Evan Schwartz</p>
<hr />
<h1 id="infectious-diseases-infectious-diseases-pulmonary-infections-acute-bronchitis">Acute Bronchitis<a class="headerlink" href="#infectious-diseases-infectious-diseases-pulmonary-infections-acute-bronchitis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-pulmonary-infections-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-pulmonary-infections-background" title="Permanent link">&para;</a></h2>
<ul>
<li>1-3 wks productive cough, often preceded by URI, may have wheezing/rhonchi</li>
<li>Distinct from chronic bronchitis (&gt;3 mos of consecutive cough x 2 consecutive yrs)</li>
<li>Distinct from PNA (parenchymal consolidation, fever &gt;100.4F, hypoxia, tachypnea)</li>
<li>DDx: COVID-19, post-nasal drip, GERD, undertreated/new asthma, ACE-i induced bradykinin cough, undertreated CHF, acute PE, or new lung cancer</li>
<li>Clinical dx; CXR/labs not necessary unless PNA suspected</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-pulmonary-infections-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-pulmonary-infections-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Supportive: lozenges, cough suppressants (guaifenesin or dextromethorphan), smoking cessation. Consider albuterol inhaler for wheezing</li>
<li>No indication for antibiotics</li>
</ul>
<h1 id="infectious-diseases-infectious-diseases-pulmonary-infections-influenza">Influenza<a class="headerlink" href="#infectious-diseases-infectious-diseases-pulmonary-infections-influenza" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-pulmonary-infections-background_1">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-pulmonary-infections-background_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Dx often clinical w/cough, sore throat, #sputum/nasal discharge, HA, fever, myalgias, and malaise; ± N/V/D. Exam with increased flushing, rarely with lower respiratory symptoms</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-pulmonary-infections-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-pulmonary-infections-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>During flu season: Obtain COVID/RPP or dedicated influenza PCR; testing is more accurate if obtained within 96 hour of symptom onset</p>
</li>
<li>
<p>CXR if concerned for bacterial superinfection</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-pulmonary-infections-management_1">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-pulmonary-infections-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Antivirals most effective when given &lt;48 hours from symptom onset; however, recommended to be given if symptomatic despite duration and to all hospitalized patients</p>
</li>
<li>
<p>Oseltamivir 75mg BID x 5 days, peramivir 600mg IV x 1 (needs renal adjustment), or baloxavir (age ≥12) 40mg once (use 80 mg if &gt;80kg)</p>
</li>
<li>
<p>Amantadine and rimantadine are no longer used due to emerging resistance</p>
</li>
</ul></section><section class="print-page" id="infectious-diseases-infectious-diseases-ssti"><h1 id="infectious-diseases-infectious-diseases-ssti-skin-and-soft-tissue-infection-ssti-vasp">Skin and Soft Tissue Infection (SSTI) - VASP<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-skin-and-soft-tissue-infection-ssti-vasp" title="Permanent link">&para;</a></h1>
<h1 id="infectious-diseases-infectious-diseases-ssti-cellulitis">Cellulitis<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-cellulitis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-ssti-background">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-background" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>DDx: erysipelas, pyomyositis, necrotizing fasciitis, osteomyelitis,
    venous stasis, shingles, gout</p>
</li>
<li>
<p>Pathogens: Streptococcus species: Group A (most common), B, C, G,
    Staphylococcus aureus (including MSSA and MRSA)</p>
<ul>
<li>Non-purulent, lymphangitis, or erysipelas? Think <em>Streptococcus</em></li>
<li>
<ul>
<li>Purulence (abscess or boil)? Think <em>Staphylococcus</em></li>
</ul>
</li>
</ul>
</li>
<li>
<p>Unique clinical scenarios and associated organisms/organisms to
    consider:</p>
<ul>
<li>
<p>Dog/cat bite: <em>Pasteurella multicoda, Capnocytophaga canimorsus</em></p>
</li>
<li>
<p>Human bite: <em>Eikenella corrodens</em>, oral anaerobes, <em>S. aureus</em></p>
</li>
<li>
<p>Fresh water exposure: <em>Aeromonas hydropholia, Plesiomonas
shigelloides</em></p>
</li>
<li>
<p>Saltwater exposure: <em>Vibrio vulnificus</em></p>
</li>
<li>
<p>Neutropenia, presence of ecthyma: Gram negatives (<em>Pseudomonas
aeruginosa</em>)</p>
</li>
<li>
<p>Immunocompromised: Fungal (<em>Candida</em> spp, <em>Cryptococcus</em>),
<em>Nocardia</em>, non-tubercular mycobacteria)</p>
</li>
<li>
<p>Burn patients: <em>Pseudomonas, Acinetobacter, Fusarium</em></p>
</li>
</ul>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-ssti-evaluation">Evaluation<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Outline border of erythema and obtain urgent surgery consultation if
    rapid spread of infection, crepitus, air in tissues or pain
    dramatically out of proportion to exam</p>
</li>
<li>
<p>Blood cultures (BCx): ONLY needed if systemic signs/symptoms of
    infection or immunocompromised (most pts will not need BCx or
    imaging)</p>
</li>
<li>
<p>Ultrasound for underlying abscess</p>
</li>
<li>
<p>CT/MRI w/contrast: if necrotizing fasciitis, pyomyositis or
    osteomyelitis suspected</p>
</li>
<li>
<p>Bilateral lower extremity cellulitis is RARE and warrants further
    consideration of other non-infectious etiologies</p>
</li>
<li>
<p>Elevation test: if erythema improves after elevating leg above the
    level of the heart for 1-2 minutes, less likely to be infectious
    cellulitis</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-ssti-management">Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-management" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Antibiotics for 5 days for uncomplicated; can extend to 10-14 days
    if little to no improvement, more extensive/serious infection, or if
    immunosuppressed</p>
</li>
<li>
<p>Typically improvement is not seen until >48 hours of antibiotics,
    usually longer</p>
</li>
<li>
<p>Provide anti-<em>Staphylococcal</em> antibiotics for purulent cellulitis in
    addition to I&amp;D, if abscess present</p>
</li>
<li>
<p>Clinical appearance may often appear to worsen initially despite
    adequate therapy</p>
</li>
<li>
<p>Always elevate the extremity for more rapid clinical improvement!</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 28%" />
<col style="width: 23%" />
<col style="width: 22%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>No Staphylococcus suspected</p>
</blockquote></th>
<th><blockquote>
<p>MSSA</p>
</blockquote></th>
<th><blockquote>
<p>MRSA</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Mild/Moderate</p>
<p>(Outpatient)</p></td>
<td><p>Cephalexin 500 QID</p>
<p>Amoxicillin 500 TID</p>
<p>Cefadroxil 1g BID</p></td>
<td><p>Cephalexin 500 QID</p>
<p>Cefadroxil 1g BID</p>
<p>Dicloxacillin 500 QID</p>
<p>\*Clindamycin 300-450 q6</p></td>
<td><p>TMP/SMX 1-2 DS tabs BID</p>
<p>Doxycycline 100 BID</p></td>
</tr>
<tr class="even">
<td>Severe (Inpatient)</td>
<td><p>Cefazolin 2g q8h</p>
<p>CTX 2g q24h</p></td>
<td><p>Cefazolin 2g q8h</p>
<p>Nafcillin 2g q4h</p></td>
<td>Vancomycin</td>
</tr>
<tr class="odd">
<td colspan="4">\*<em>Consider for PCN allergy; check antibiogram (VUMC
vs VA) for Staph sensitivities; clindamycin should NOT be used for strep
coverage</em></td>
</tr>
</tbody>
</table>

<h1 id="infectious-diseases-infectious-diseases-ssti-necrotizing-fasciitis">Necrotizing Fasciitis<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-necrotizing-fasciitis" title="Permanent link">&para;</a></h1>
<h2 id="infectious-diseases-infectious-diseases-ssti-background_1">Background<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-background_1" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>Infection of the deeper soft tissues that causes necrosis along the muscle fascia and overlying subcutaneous fat that is rapidly progressive and lethal if not addressed</p>
</li>
<li>
<p>Clinical cues include rapid spread, pain out of proportion to exam, crepitus and hemorrhagic bullae</p>
</li>
</ul>
<h2 id="infectious-diseases-infectious-diseases-ssti-evaluationmanagement">Evaluation/Management<a class="headerlink" href="#infectious-diseases-infectious-diseases-ssti-evaluationmanagement" title="Permanent link">&para;</a></h2>
<ul>
<li>
<p>SURGICAL EMERGENCY!</p>
<ul>
<li>STAT consult to surgical service for emergent debridement (generally EGS vs ortho)</li>
<li>Imaging does NOT rule out necrotizing fasciitis and should not delay these consultations</li>
</ul>
</li>
<li>
<p>ID consult</p>
<ul>
<li>Blood cultures, but this should not delay antibiotic administration</li>
<li>Contact and droplet precautions x first 24h of abx therapy; after this, contact precautions only if draining or contained wounds</li>
<li>Vancomycin + either piperacillin-tazobactam 3.375g IV q8h extended infusion OR cefepime 2gm IV q8h + clindamycin 600mg-900mg IV q8h (for antitoxin effects)</li>
</ul>
</li>
</ul></section><section class="print-page" id="infectious-diseases-main"><p>General Tips</p>
<ul>
<li>
<p>Vanderbilt Antibiotics Stewardship Program (VASP) has a
    <a href="https://www.vumc.org/antimicrobial-stewardship-program/">website</a>
    with much of the below guidance as well as Vanderbilt antibiograms, with
    our resistance patterns</p>
</li>
<li>
<p>Does your pt need to be on precautions?
    Check the <a href="https://www.vumc.org/infectioncontrol/12177">Infection Prevention Website</a>
    under ‘isolation’ tab or page the infection control pager in E-star
    paging for additional questions</p>
</li>
<li>
<p>Page 317-4376 for approval of restricted antimicrobials at VUMC
    (page the VA ID fellow at the VA)</p>
</li>
<li>
<p>The lab will automatically update the Tennessee health department
    with reportable diseases</p>
</li>
</ul>
<p>Skin and Soft Tissue Infection (SSTI) – VASP</p>
<p>Cellulitis</p>
<p>Background</p>
<ul>
<li>
<p>DDx: erysipelas, pyomyositis, necrotizing fasciitis, osteomyelitis,
    venous stasis, shingles, gout</p>
</li>
<li>
<p>Pathogens: Streptococcus species: Group A (most common), B, C, G,
    Staphylococcus aureus (including MSSA and MRSA)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Non-purulent, lymphangitis, or erysipelas? Think <em>Streptococcus</em></p>
</li>
<li>
<p>Purulence (abscess or boil)? Think <em>Staphylococcus</em></p>
</li>
</ul>
<!-- -->

<ul>
<li>Unique clinical scenarios and associated organisms/organisms to
    consider:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Dog/cat bite: <em>Pasteurella multicoda, Capnocytophaga canimorsus</em></p>
</li>
<li>
<p>Human bite: <em>Eikenella corrodens</em>, oral anaerobes, <em>S. aureus</em></p>
</li>
<li>
<p>Fresh water exposure: <em>Aeromonas hydropholia, Plesiomonas
    shigelloides</em></p>
</li>
<li>
<p>Saltwater exposure: <em>Vibrio vulnificus</em></p>
</li>
<li>
<p>Neutropenia, presence of ecthyma: Gram negatives (<em>Pseudomonas
    aeruginosa</em>)</p>
</li>
<li>
<p>Immunocompromised: Fungal (<em>Candida</em> spp, <em>Cryptococcus</em>),
    <em>Nocardia</em>, non-tubercular mycobacteria)</p>
</li>
<li>
<p>Burn patients: <em>Pseudomonas, Acinetobacter, Fusarium</em></p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Outline border of erythema and obtain urgent surgery consultation if
    rapid spread of infection, crepitus, air in tissues or pain
    dramatically out of proportion to exam</p>
</li>
<li>
<p>Blood cultures (BCx): ONLY needed if systemic signs/symptoms of
    infection or immunocompromised (most pts will not need BCx or
    imaging)</p>
</li>
<li>
<p>Ultrasound for underlying abscess</p>
</li>
<li>
<p>CT/MRI w/contrast: if necrotizing fasciitis, pyomyositis or
    osteomyelitis suspected</p>
</li>
<li>
<p>Bilateral lower extremity cellulitis is RARE and warrants further
    consideration of other non-infectious etiologies</p>
</li>
<li>
<p>Elevation test: if erythema improves after elevating leg above the
    level of the heart for 1-2 minutes, less likely to be infectious
    cellulitis</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Antibiotics for 5 days for uncomplicated; can extend to 10-14 days
    if little to no improvement, more extensive/serious infection, or if
    immunosuppressed</p>
</li>
<li>
<p>Typically improvement is not seen until >48 hours of antibiotics,
    usually longer</p>
</li>
<li>
<p>Provide anti-<em>Staphylococcal</em> antibiotics for purulent cellulitis in
    addition to I&amp;D, if abscess present</p>
</li>
<li>
<p>Clinical appearance may often appear to worsen initially despite
    adequate therapy</p>
</li>
<li>
<p>Always elevate the extremity for more rapid clinical improvement!</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 25%" />
<col style="width: 28%" />
<col style="width: 23%" />
<col style="width: 22%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>No Staphylococcus suspected</p>
</blockquote></th>
<th><blockquote>
<p>MSSA</p>
</blockquote></th>
<th><blockquote>
<p>MRSA</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Mild/Moderate</p>
<p>(Outpatient)</p></td>
<td><p>Cephalexin 500 QID</p>
<p>Amoxicillin 500 TID</p>
<p>Cefadroxil 1g BID</p></td>
<td><p>Cephalexin 500 QID</p>
<p>Cefadroxil 1g BID</p>
<p>Dicloxacillin 500 QID</p>
<p>\*Clindamycin 300-450 q6</p></td>
<td><p>TMP/SMX 1-2 DS tabs BID</p>
<p>Doxycycline 100 BID</p></td>
</tr>
<tr class="even">
<td>Severe (Inpatient)</td>
<td><p>Cefazolin 2g q8h</p>
<p>CTX 2g q24h</p></td>
<td><p>Cefazolin 2g q8h</p>
<p>Nafcillin 2g q4h</p></td>
<td>Vancomycin</td>
</tr>
<tr class="odd">
<td colspan="4">\*<em>Consider for PCN allergy; check antibiogram (VUMC
vs VA) for Staph sensitivities; clindamycin should NOT be used for strep
coverage</em></td>
</tr>
</tbody>
</table>

<p>Necrotizing Fasciitis</p>
<p>Background</p>
<ul>
<li>
<p>Infection of the deeper soft tissues that causes necrosis along the
    muscle fascia and overlying subcutaneous fat that is rapidly
    progressive and lethal if not addressed</p>
</li>
<li>
<p>Clinical cues include rapid spread, pain out of proportion to exam,
    crepitus and hemorrhagic bullae</p>
</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>SURGICAL EMERGENCY!</li>
</ul>
<!-- -->

<ul>
<li>
<p>STAT consult to surgical service for emergent debridement (generally
    EGS vs ortho)</p>
</li>
<li>
<p>Imaging does NOT rule out necrotizing fasciitis and should not delay
    these consultations</p>
</li>
</ul>
<!-- -->

<ul>
<li>ID consult</li>
</ul>
<!-- -->

<ul>
<li>
<p>Blood cultures, but this should not delay antibiotic administration</p>
</li>
<li>
<p>Contact and droplet precautions x first 24h of abx therapy; after
    this, contact precautions only if draining or contained wounds</p>
</li>
<li>
<p>Vancomycin + either piperacillin-tazobactam 3.375g IV q8h extended
    infusion OR cefepime 2gm IV q8h + clindamycin 600mg-900mg IV q8h
    (for antitoxin effects)</p>
</li>
</ul>
<p>Genitourinary Infection – VASP</p>
<p>Asymptomatic Bacteriuria</p>
<p>Background</p>
<ul>
<li>
<p>Isolation of bacteria in an appropriately collected urine specimen
    from an individual without symptoms or signs of urinary tract
    infection. Bacteriuria, foul odor, urine appearance, pyuria, falls
    and/or confusion alone are not indicative of infection.</p>
</li>
<li>
<p>Oliguric ESRD patients may have bacteriuria from colonization due to
    lack of flushing of bladder; avoid sending UA/UCx unless patient is
    symptomatic</p>
</li>
<li>
<p>Treatment only required for specific populations:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pregnant women (screening performed at 12 – 16 weeks)</p>
</li>
<li>
<p>Anticipated urologic intervention - when requesting, be sure to ask
    for Micro help in identifying potential pathogens needing treatment
    vs. likely contaminants</p>
</li>
<li>
<p>Some renal transplant recipients, depending on time since transplant</p>
</li>
</ul>
<p>Uncomplicated Urinary Tract Infection (UTI)</p>
<p>Background</p>
<ul>
<li>Clinical symptoms of UTI (dysuria/urgency/frequency/ hematuria) in
    non-pregnant, immunocompetent, neurologically intact pt with normal
    urologic anatomy and no indwelling urinary catheters</li>
</ul>
<p>Management</p>
<ul>
<li>Empiric therapy</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nitrofurantoin monohydrate: 100 mg PO BID x 5 days (avoid if any
    concern for pyelonephritis or if creatinine clearance \&lt;60)</p>
</li>
<li>
<p>Cephalexin 250-500mg q6h x5-7 days</p>
</li>
</ul>
<!-- -->

<ul>
<li>Alternative therapies</li>
</ul>
<!-- -->

<ul>
<li>
<p>Fosfomycin: 3 grams of powder mixed in water as a single PO dose
    (avoid if any concern for ascending UTI or pyelonephritis).
    Susceptibility test results must be requested of micro lab and are
    only possible for E. coli and E. Faecalis.</p>
</li>
<li>
<p>Amoxicillin-clavulanate: 875-125mg PO BID x5 days</p>
</li>
<li>
<p>Ciprofloxacin: 250mg PO BID x3 days</p>
<ul>
<li>
<p>FQ’s should be reserved for more serious infections than
    uncomplicated cystitis, and only after susceptibility results
    are confirmed given high rates of resistance</p>
</li>
<li>
<p>Adverse effect profile >> beta-lactams (i.e. QT-prolongation,
    tendinopathies)</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Avoid amoxicillin, ampicillin, and Trimethoprim-sulfamethoxazole
    (TMP-SMX) due to increasing resistance unless culture data with
    confirmed susceptibility</li>
</ul>
<p>Additional Information</p>
<ul>
<li>MDR cystitis: ESBL isolates are increasingly common due to
    antibiotic overuse</li>
</ul>
<!-- -->

<ul>
<li>
<p>Before treating, decide if this is a TRUE UTI</p>
</li>
<li>
<p>If true, consider Fosfomycin (if <em>E. coli</em>) or nitrofurantoin (if
    susceptibility is confirmed – <em>K. pneumoniae</em> and <em>Enterobacter</em> spp
    are usually resistant), gentamicin or tobramycin 5-7mg/kg IV once,
    or ID consultation</p>
</li>
<li>
<p>Ask the lab to check susceptibility results to these antibiotics for
    future reference</p>
</li>
</ul>
<p>Complicated UTI and Pyelonephritis</p>
<p>Background</p>
<ul>
<li>
<p>Fever, pyuria, and costovertebral angle tenderness suggest
    pyelonephritis.</p>
</li>
<li>
<p>Consider it a complicated UTI if any of the following are present:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Renal calculi or other obstructive disease, immunosuppressed host,
    abnormal urological anatomy or physiology (including stents),
    presence of a urinary catheter</p>
</li>
<li>
<p>Male sex alone does NOT qualify as complicated</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>UA with reflex urine culture</p>
</li>
<li>
<p>BCx and UCx prior to antibiotics</p>
</li>
<li>
<p>If there is no pyuria, consider an alternative diagnosis, or
    proximal ureteral obstruction</p>
</li>
</ul>
<!-- -->

<ul>
<li>Pyuria is common in the presence of a urinary catheter, kidney
    stones, urostomy, ileal conduit and other invasive devices, and may
    not indicate infection</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Antibiotic Duration: 7-14 days, depending on antibiotic choice</p>
</li>
<li>
<p>Tailor therapy once/if cultures are available. If no improvement in
    48h, consider imaging to rule out complications (e.g., perinephric
    abscess)</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 14%" />
<col style="width: 37%" />
<col style="width: 47%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>First Line</p>
</blockquote></th>
<th><blockquote>
<p>Alternative</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Outpatient</td>
<td>Amoxicillin-clavulanic acid 875-125mg BID x14 days</td>
<td><p>Ciprofloxacin 750mg BID</p>
<p>(or 500 BID if bacteremia ruled out) x 7 days</p></td>
</tr>
<tr class="even">
<td>Inpatient</td>
<td><p>CTX 2g q24h<br />
Cefepime 2g q8h</p>
<p>Pip/tazo (3.375g q6h or extended infusion of 3.375g q8h infused over
4h) IV</p>
<p>Meropenem 1g q8h (if h/o or confirmed ESBL within the last 90
days)</p></td>
<td><p>Ertapenem 1g q24 instead of Meropenem if no
<em>Pseudomonas</em></p>
<p>Ciprofloxacin 750mg PO BID (500 mg PO BID if bacteremia ruled out) OR
400mg IV BID (if susceptibility confirmed)\*</p></td>
</tr>
</tbody>
</table>

<p>*FQ’s have same bioavailability if given PO or IV so oral is preferred</p>
<p>Catheter Associated Urinary Tract Infection (CAUTI)</p>
<p>Background</p>
<ul>
<li>Culture growth of > 10<sup>3</sup> cfu/mL of uropathogenic
    bacteria + signs or symptoms consistent with infection (without
    another identified etiology) + indwelling urethral/suprapubic
    catheter or intermittent catheterization.</li>
</ul>
<!-- -->

<ul>
<li>This includes pts with catheters in place during the preceding 48
    hours</li>
</ul>
<!-- -->

<ul>
<li>Duration = greatest risk factor (Increases 3-10% per day of
    catheterization)</li>
</ul>
<!-- -->

<ul>
<li>Other risks: female sex, diabetes, elderly, colonization of catheter
    bag, poor care</li>
</ul>
<!-- -->

<ul>
<li>
<p>Bacteriuria, foul odor, pyuria, urine appearance falls and/or
    confusion alone are not indicative of infection in patients who are
    otherwise asymptomatic.</p>
</li>
<li>
<p>Ensure clean sample collected</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ideally, catheter is removed and midstream sample obtained</p>
</li>
<li>
<p>If catheterization required; removal of old catheter and sample
    taken from new catheter</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Distinguish uncomplicated vs complicated UTI (see above)</p>
</li>
<li>
<p>Antimicrobial management:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Guided by cultures and susceptibilities</p>
</li>
<li>
<p>Empiric guidance as per management of uncomplicated/complicated UTI
    and per prior culture data/susceptibilities when available.</p>
</li>
<li>
<p>Duration: 7 – 14 days depending on antibiotic, clinical response and
    whether infection constitutes complicated vs uncomplicated UTI</p>
</li>
<li>
<p>Special note regarding <em>Candida</em> UTI management: <em>Candida</em> is
    generally not pathogenic</p>
<ul>
<li>
<p>Presence in urine does not indicate infection (unless
    perinephric abscess, renal transplant, or complex fistulous
    disease)</p>
</li>
<li>
<p>Fluconazole achieves excellent urinary penetration</p>
</li>
<li>
<p>If fluconazole-resistant <em>Candida</em> is cultured or suspected,
    consult ID</p>
</li>
<li>
<p>Susceptibilities are not routinely run-on <em>Candida</em> from urine
    cultures and would need to be requested if concern for true
    infection.</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Catheter management</li>
</ul>
<!-- -->

<ul>
<li>
<p>At the least, catheters should be replaced at the time of antibiotic
    initiation (preferably removed)</p>
</li>
<li>
<p>If catheterization is necessary, intermittent catheterization is
    preferred over continuous use with patient educations on
    cleaning/hygiene prior to catheterization. Condom catheters and pure
    wicks also preferred over foley catheter</p>
</li>
</ul>
<p>Sexually Transmitted Infections – Ashley Zeoli</p>
<p>Gonorrhea</p>
<p>Background</p>
<ul>
<li>
<p>Cause: gram-negative coccus <em>Neisseria gonorrhoeae</em></p>
</li>
<li>
<p>Gonorrhea causes a spectrum of disease including urethritis,
    cervicitis, epididymitis, proctitis, pharyngeal infections,
    conjunctivitis, PID, and disseminated gonococcal infection</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Microbial diagnosis is required to diagnose gonorrhea, rather than
    clinical diagnosis alone</p>
</li>
<li>
<p>Test of choice: NAAT of the first-catch urine in men; NAAT of
    vaginal swab in women</p>
</li>
</ul>
<!-- -->

<ul>
<li>Also perform co-testing for chlamydia</li>
</ul>
<!-- -->

<ul>
<li>
<p>NAAT of pharyngeal or rectal swab should also be performed in
    patients with reported symptoms and recent sexual exposure. Note
    this is also routine testing in patients on PREP.</p>
</li>
<li>
<p>Routine screening should be offered to sexually active patients, as
    many are asymptomatic</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Ceftriaxone is the only current antibiotic that meets the strict
    treatment efficacy goals with single-dose therapy. CTX also has a
    low rate of drug resistance, which is becoming an increasing issue
    in the treatment of gonorrhea.</li>
</ul>
<!-- -->

<ul>
<li>
<p><strong>High dose IM ceftriaxone</strong> (\&lt;150kg 500mg IM; >150mg 1g IM)</p>
<ul>
<li>Same for pharyngitis or conjunctivitis</li>
</ul>
</li>
<li>
<p>CTX allergies: Azithromycin (2g PO x1) + Gentamicin (240mg IM x1) or
    Gemifloxacin</p>
</li>
</ul>
<!-- -->

<ul>
<li>Treatment of chlamydia must also be accompanied with gonorrhea
    treatment when it has not been excluded with molecular testing.</li>
</ul>
<!-- -->

<ul>
<li>Doxycycline 100mg BID for 7 days</li>
</ul>
<!-- -->

<ul>
<li>
<p>Patients who have persistent symptoms despite treatment should be
    suspected of having resistant gonorrhea. Test with culture and
    antimicrobial susceptibility testing (with or without NAAT).</p>
</li>
<li>
<p>Patients with recurrent symptoms after period of resolution should
    be re-evaluated for gonorrhea and other STIs</p>
</li>
</ul>
<p>Chlamydia</p>
<p>Background</p>
<ul>
<li>
<p>Cause: gram negative bacteria <em>Chlamydia trachomatis</em></p>
</li>
<li>
<p>Most individuals are asymptomatic though causes a wide array of
    infections: urethritis, cervicitis PID, conjunctivitis,
    perihepatitis (Fitz-Hugh-Curtis syndrome), pneumonia, proctitis,
    epididymitis, reactive arthritis, pharyngitis, lymphogranuloma
    venereum (LGV), endemic trachoma</p>
</li>
<li>
<p>Differential diagnosis: Neisseria gonorrhoeae, Trichomonas
    vaginalis, Mycoplasma genitalium</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Test of choice: NAAT of vaginal swab in females (first catch urine
    also adequate); NAAT of first catch urine in males.</p>
</li>
<li>
<p>NAATs can detect both LGV and non-LGV chlamydia trachomatis, but
    cannot distinguish between them</p>
</li>
<li>
<p>Any patient with signs and symptoms concerning for chlamydia should
    be tested. Testing should also routinely be offered to sexually
    active individuals since most patients are asymptomatic. Note this
    is also routine testing in patients on PREP.</p>
</li>
</ul>
<p>Management</p>
<ul>
<li><strong>Doxycycline</strong> <strong>100mg BID x 7 days</strong> is the preferred treatment in
    non-pregnant patients (azithromycin is NOT preferred)</li>
</ul>
<!-- -->

<ul>
<li>Alternative treatment options (for allergies/severe
    contraindications): azithromycin (1g PO x 1), levofloxacin (500mg PO
    daily x7 days), and ofloxacin (300mg BID PO x7 days)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Patients with recent potential or confirmed exposure within the last
    1-2 weeks should be treated empirically</p>
</li>
<li>
<p>Patients with persistent symptoms, confirmed infection, and who
    already underwent appropriate treatment, likely have a re-infection,
    rather than treatment failure. Test again.</p>
</li>
<li>
<p>Patients with recurrent symptoms after resolution should be
    re-tested for chlamydia with a NAAT and other STIs (gonorrhea, BV,
    etc).</p>
</li>
<li>
<p>Empiric therapy for gonorrhea should be given to patients unless
    NAAT is negative</p>
</li>
</ul>
<p>Syphilis</p>
<p>Background</p>
<ul>
<li>
<p>Caused by the spirochete, <em>Treponema pallidum,</em> which is visualized
    by dark field microscopy</p>
</li>
<li>
<p>High rate of HIV co-infection among MSM with syphilis (~42%)</p>
</li>
<li>
<p>Transmitted by direct contact with an infectious lesion during sex.
    Infection can occur anywhere inoculation occurs (i.e. contact with
    infected secretions can result in a lesion on any tissue site)</p>
</li>
<li>
<p>Can readily cross the placenta fetal infection</p>
</li>
<li>
<p>Patients can present with a variety of symptoms, depending on their
    place in the disease course</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Test all patients with signs and symptoms, as well as patients who
    are at increased risk for acquiring infection (patients with sexual
    partner with early syphilis, MSM, people living with HIV, high risk
    sexual behaviors, and history of commercial sex work or
    incarceration)</p>
</li>
<li>
<p>HIV testing should be offered to all patients who test positive</p>
</li>
<li>
<p>Pregnant patients should be screened for syphilis</p>
</li>
<li>
<p>There are two types of serologic tests: treponemal-specific tests
    (FTA-ABS, MHA-TP, TPPA, TP-EIA, CIA) and nontreponemal tests (RPR,
    VDRL, TRUST). Either can be used as initial screening, but
    confirmatory testing with the other is needed due to false
    positives.</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Treponemal specific are usually used as confirmatory tests when
    nontreponemal tests are reactive. They are reported as reactive or
    non-reactive. Once positive, usually positive for life.</p>
</li>
<li>
<p>Nontreponemal quantifies amount of antibody present and can be used
    to detect titers to assess for treatment. Titers should decline
    after a patient has been treated. A rise in titers in a previously
    treated patient should be concerning for new infection.</p>
<ul>
<li>
<p>Requires a humoral response, so can be false negatives if
    immunocompromised</p>
</li>
<li>
<p>False positives: autoimmune diseases, pregnancy, other
    infections</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>At VUMC, a positive treponemal IgG reflexes to a RPR titer.</p>
</li>
<li>
<p>Neurosyphilis can occur at any time after infection. All newly
    diagnosed patients with syphilis should have a full neurologic exam
    and if any abnormalities should have an LP sent for CSF-VDRL.</p>
</li>
<li>
<p>Any patients with syphilis and vision changes should get an
    ophthalmology evaluation.</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 41%" />
<col style="width: 39%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>+ Treponemal</p>
</blockquote></th>
<th>- Treponemal</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>+ Non-treponemal</strong></td>
<td>Diagnostic of syphilis (completely new, or potentially
re-infected)</td>
<td>Likely false positive</td>
</tr>
<tr class="even">
<td><strong>- Non-treponemal</strong></td>
<td>Likely history of successfully treated syphilis</td>
<td>Likely not syphilis, or false negative (due to prozone\* effect)</td>
</tr>
<tr class="odd">
<td colspan="3"><em>\*Prozone effect:</em> when there is an overabundance
of antibodies and they interfere with clumping/formation of
antigen-antibody complex so agglutination cannot be visualized</td>
</tr>
</tbody>
</table>

<p>Management</p>
<ul>
<li>To assess treatment efficacy, we want to see a fourfold decrease in
    titer after treatment</li>
</ul>
<table>
<colgroup>
<col style="width: 15%" />
<col style="width: 34%" />
<col style="width: 23%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Symptoms</th>
<th>Treatment</th>
<th>Treatment Alternatives</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Primary</td>
<td>Painless chancre at inoculation site with regional
lymphadenopathy</td>
<td rowspan="3">PCN G benzathine 2.4 million units IM x1</td>
<td rowspan="3"><p>Doxycycline 100mg PO BID x 14 days</p>
<p>OR</p>
<p>Ceftriaxone 1-2g daily IM or IV x 10-14 days</p>
<p>OR</p>
<p>Tetracycline 500mg PO QID x 14 days</p>
<p>OR</p>
<p>Amoxicillin 3g BID and probenecid 500mg BID x 14 days</p></td>
</tr>
<tr class="even">
<td>Secondary</td>
<td>Systemic illness with rash (palms, soles), fever, malaise, alopecia,
hepatitis, mucous patches, condyloma, pharyngitis</td>
</tr>
<tr class="odd">
<td>Early Latent</td>
<td>Infected, but no symptoms. Occurs within one year of initial
infection.</td>
</tr>
<tr class="even">
<td>Tertiary</td>
<td>Symptomatic late syphilis (CV system, gummatous disease)</td>
<td rowspan="2">PCN G benzathine 2.4 million units IM weekly x3
weeks</td>
<td rowspan="2"><p>Doxycycline 100mg PO BID x 4 weeks</p>
<p>OR</p>
<p>Ceftriaxone 2g daily IM or IV x 10-14 days</p></td>
</tr>
<tr class="odd">
<td>Late Latent</td>
<td><p>Infected, but no symptoms. Occurs &gt;1 year after initial
infection.</p>
<p>Assume late latent with date of infection unknown</p></td>
</tr>
<tr class="even">
<td><p>Neuro</p>
<p>syphilis</p></td>
<td><p>Can occur at any time.</p>
<p>Early: asymptomatic or symptomatic meningitis, vision loss, hearing
loss</p>
<p>Late: brain and spinal cord manifestations (dementia, tabes
dorsalis)</p>
<p>Treat ocular syphilis like neurosyphilis</p></td>
<td><p>Aqueous PCN G 3-4 million units IV q4h x 10-14 days</p>
<p>OR</p>
<p>PCN G procaine 2.4 million units IM daily and probenecid 500mg PO QID
x 10-14 days</p></td>
<td><p>If PCN allergic, desensitize</p>
<p>Ceftriaxone 2g daily IM or IV x 10-14 days</p></td>
</tr>
</tbody>
</table>

<p>Pulmonary Infections – VASP, Evan Schwartz</p>
<p>Acute Bronchitis</p>
<p>Background</p>
<ul>
<li>
<p>1-3 wks productive cough, often preceded by URI, may have
    wheezing/rhonchi</p>
</li>
<li>
<p>Distinct from chronic bronchitis (>3 mos of consecutive cough x 2
    consecutive yrs)</p>
</li>
<li>
<p>Distinct from PNA (parenchymal consolidation, fever >100.4F,
    hypoxia, tachypnea)</p>
</li>
<li>
<p>DDx: COVID-19, post-nasal drip, GERD, undertreated/new asthma, ACE-i
    induced bradykinin cough, undertreated CHF, acute PE, or new lung
    cancer</p>
</li>
<li>
<p>Typically a clinical dx; CXR/labs not necessary unless PNA suspected</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Supportive: lozenges, cough suppressants (guaifenesin or
    dextromethorphan), smoking cessation. Consider albuterol inhaler for
    wheezing</p>
</li>
<li>
<p>No indication for antibiotics</p>
</li>
</ul>
<p>Influenza</p>
<p>Background</p>
<ul>
<li>Dx often clinical w/cough, sore throat, #sputum/nasal discharge,
    HA, fever, myalgias, and malaise; ± N/V/D. Exam with increased
    flushing, rarely with lower respiratory symptoms</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>During flu season: Obtain COVID/RPP or dedicated influenza PCR;
    testing is more accurate if obtained within 96 hour of symptom onset</p>
</li>
<li>
<p>CXR if concerned for bacterial superinfection</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Antivirals most effective when given \&lt;48 hours from symptom onset;
    however, recommended to be given if symptomatic despite duration and
    to all hospitalized patients</p>
</li>
<li>
<p>Oseltamivir 75mg BID x 5 days, peramivir 600mg IV x 1 (needs renal
    adjustment), or baloxavir (age ≥12) 40mg once (use 80 mg if >80kg)</p>
</li>
<li>
<p>Amantadine and rimantadine are no longer used due to emerging
    resistance</p>
</li>
</ul>
<p>Inpatient COVID-19 Management – Kathryn Snyder</p>
<p>Background</p>
<ul>
<li>COVID-19 is the novel coronavirus responsible for the ongoing
    pandemic that started in late 2019. The virus has ongoing mutations
    resulting in new dominant strains.</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Please see the most updated VUMC and VA guidance due to frequently
    evolving recommendations.</p>
</li>
<li>
<p>Please refer to the hospital’s current maximum oxygen requirement
    allowed on the floor to ensure patient is appropriately triaged.</p>
</li>
<li>
<p>Basic admission workup for symptomatic, confirmed COVID-19</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Labs: CBC with diff, CMP, d-dimer, ferritin, CRP, ESR, PT/INR, PTT,
    procalcitonin, RPP</p>
</li>
<li>
<p>Imaging: portable CXR</p>
</li>
<li>
<p>Nursing: Strict I/O</p>
</li>
<li>
<p>Enhanced precautions (contact, airborne, eye protection)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Fluid balance goal slightly net negative to even</p>
</li>
<li>
<p>Anticoagulation/DVT prophylaxis:</p>
</li>
</ul>
<!-- -->

<ul>
<li>Please see latest VUMC or VA guidance based on clinical status
    (supplemental O2 requirements, ICU vs floor, etc.)</li>
</ul>
<!-- -->

<ul>
<li>Pharmacologic therapies</li>
</ul>
<!-- -->

<ul>
<li>
<p>Note: Therapies, indications, and contraindications are frequently
    changing, please see latest VUMC/VA guidelines for specific
    indications for these medications or others</p>
</li>
<li>
<p>Remdesivir</p>
<ul>
<li>
<p>Loading dose 200mg IV x1 then 100mg daily x 4 days</p>
</li>
<li>
<p>For use in patients hospitalized for COVID within 7 days of
    symptom onset</p>
</li>
<li>
<p>Contraindications: known hypersensitivity, ALT >/= 10x ULN,
    high-flow NC, PPV, intubated, or on ECMO</p>
</li>
<li>
<p>Monitoring: baseline CBC, INR, q48h CMP</p>
</li>
</ul>
</li>
<li>
<p>Dexamethasone</p>
<ul>
<li>
<p>6mg PO/IV x 10 days; consideration of longer taper if no
    clinical improvement or persistently elevated CRP</p>
</li>
<li>
<p>Contraindications: no hard contraindications, use clinical
    judgement if concomitant serious bacterial/fungal infection</p>
</li>
</ul>
</li>
<li>
<p>Antibiotics:</p>
<ul>
<li>
<p>The incidence of superimposed bacterial infection in the setting
    of COVID-19 is low</p>
</li>
<li>
<p>The majority of patients do not need additional coverage for
    bacterial pneumonia</p>
</li>
<li>
<p>You can use procalcitonin to guide decision</p>
</li>
</ul>
</li>
<li>
<p>Other pharmacologic therapies include baricitinib (JAK inhibitor),
    tocilizumab (IL-6 inhibitor) and monoclonal antibodies</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Complications and special considerations for COVID-19 patients</li>
</ul>
<!-- -->

<ul>
<li>
<p>High PE/DVT risk</p>
</li>
<li>
<p>Superimposed bacterial PNA</p>
</li>
<li>
<p>AKI</p>
</li>
<li>
<p>GI symptoms/abnormalities (see GI section on COVID-19)</p>
</li>
</ul>
<p>Community Acquired Pneumonia (CAP)</p>
<p>Background</p>
<ul>
<li>
<p>All PNA that does not otherwise meet criteria for Hospital Acquired
    Pneumonia (PNA that develops ≥48 hours after hospital admission),
    Ventilator Associated Pneumonia (PNA that develops ≥48-72 hours
    after endotracheal intubation), or aspiration PNA</p>
</li>
<li>
<p>Healthcare-associated pneumonia is no longer a clinical entity per
    2016 IDSA guidelines</p>
</li>
<li>
<p>MRSA Risk Factors: recent history, cavitary lesion, post-influenza
    bacterial PNA, pts with IDU, severe hypoxemia requiring intubation</p>
</li>
<li>
<p><em>Pseudomonas</em>: Double coverage is not indicated in general
    population; LVQ has 82% sensitivity so not recommended unless
    isolate proven susceptible</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Sputum cultures prior to abx, consider BCx in select groups (severe
    pneumonia, ICU admission, cavitary disease, immunosuppression).</p>
</li>
<li>
<p>Rule out flu if the right season, COVID-19, consider RVP if it will
    change management</p>
</li>
<li>
<p>CURB-65 or PSI can aid in decision between outpatient vs inpatient
    therapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>CURB65: Confusion, Uremia (BUN >=19 mg/dL), RR (>30/min),
    BP(\&lt;90/60 mmHg), Age ≥ 65 If ≥ 2, hospitalization is recommended.</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider urine pneumococcal Ag, urine Legionella Ag in severe CAP
    and in certain pts (e.g., neutropenia, asplenia, obstructive lung
    disease, hyponatremia, diarrhea, or heavy alcohol use); these are
    performed at reference labs and will take several days to return.</p>
</li>
<li>
<p>CRP, ESR, and pro-calcitonin have not been shown to reliably improve
    outcomes; however, pro-calcitonin \&lt; 0.25 suggests against bacterial
    respiratory infection and antibiotic discontinuation is encouraged</p>
</li>
<li>
<p>PA/ lateral CXR to evaluate for and localize infiltrate. If
    immunocompromised, consider CT chest w/o contrast (does not improve
    outcomes)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Lobar Consolidation - likely bacterial</p>
</li>
<li>
<p>Interstitial Infiltrate - likely atypical vs. viral vs.
    non-infectious</p>
</li>
<li>
<p>Cavitation - concerning for fungal vs. necrotizing vs. mycobacterial</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Antibiotic Duration: 5-7 days (at least 5 days and improvement with
    clinical stability)</li>
</ul>
<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 36%" />
<col style="width: 0%" />
<col style="width: 41%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th colspan="2"><blockquote>
<p>Outpatient</p>
</blockquote></th>
<th><blockquote>
<p>Inpatient (Non- ICU &amp; ICU)</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>No MRSA or Pseudomonas suspected</td>
<td><p>Low Risk\*:</p>
<p>-Amoxicillin 1g TID</p>
<p>High Risk:</p>
<p>-Amoxicillin-clavulanate 875/125 BID + Macrolide</p>
<p>-Cefdinir 300 BID + Macrolide</p>
<p>-Amoxicillin 1g TID + Macrolide</p>
<p>-Levofloxacin 750 daily</p></td>
<td colspan="2">CTX 2g q24 + Azithromycin 500 daily OR Levofloxacin 750
daily</td>
</tr>
<tr class="even">
<td>MRSA or Pseudomonas suspected</td>
<td></td>
<td colspan="2"><p>MRSA: Vancomycin OR Linezolid</p>
<blockquote>
<p>(if no bacteremia)</p>
</blockquote>
<p>Pseudomonas: Cefepime 2g q8h</p></td>
</tr>
</tbody>
</table>

<p>*No chronic heart, lung, liver, renal disease, DM, alcoholism,
immunocompromise</p>
<p>Additional Information</p>
<ul>
<li>
<p>MRSA nasal swab has reported negative predictive value for MRSA
    pneumonia ranging 95% to >99%; consider sending and if negative,
    discontinue MRSA agent</p>
</li>
<li>
<p>CTX is generally adequate coverage for aspiration PNA without
    evidence of abscess, empyema, or cavitary lesion on imaging</p>
</li>
<li>
<p>Aspiration pneumonia can be confused for aspiration pneumonitis
    which does not need to be treated with antibiotics. Rapid resolution
    of leukocytosis and stabilization of vitals suggest aspiration
    pneumonitis and consideration of stopping antibiotics.</p>
</li>
<li>
<p>There is low sensitivity of S. pneumoniae to azithromycin (42%) and
    doxycycline (72%), so these should not be used as monotherapy</p>
</li>
<li>
<p>Check for drug interactions with linezolid (e.g., SSRI, methadone,
    methamphetamine use)</p>
</li>
</ul>
<p>Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia
(VAP)</p>
<p>Background</p>
<ul>
<li>
<p>HAP: Pneumonia that develops >48 hours after admission</p>
</li>
<li>
<p>VAP: Pneumonia that develops >48 hours after endotracheal
    intubation</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Cultures of blood, sputum, endotracheal aspirate and/or bronchoscopy
    specimen</p>
</li>
<li>
<p>Consider MRSA nares to help with de-escalation</p>
</li>
<li>
<p>If there is concern for respiratory viruses: send influenza, COVID,
    RVP</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Initially cover for MRSA and <em>Pseudomonas</em></p>
</li>
<li>
<p>Antibiotic Duration: 7 days in uncomplicated cases, although
    specific pathogens (e.g., <em>Pseudomonas</em>) may require longer duration
    and ID guidance</p>
</li>
<li>
<p>Consider ID consultation if the patient is not clinically improving
    on empiric therapy or if an MDR pathogen grows from culture</p>
</li>
<li>
<p>If no MRSA isolated and pt is improving, consider stopping
    vancomycin ASAP</p>
</li>
<li>
<p>There is concern for nephrotoxicity with combination Vancomycin and
    piperacillin-tazobactam, but data controversial</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 34%" />
<col style="width: 49%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>MRSA Coverage</p>
</blockquote></th>
<th><blockquote>
<p>Pseudomonas Coverage</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>First Line</td>
<td>Vancomycin (Pharmacy dosing)</td>
<td>Cefepime 2g q8h OR Piperacillin-tazobactam 3.375 q8h extended
infusion OR Ceftazidime 2g q8h</td>
</tr>
<tr class="even">
<td>Alternative</td>
<td>Vancomycin allergy: Linezolid 600 mg PO q12h</td>
<td>True PCN allergy: Aztreonam 2g q8h</td>
</tr>
</tbody>
</table>

<p>Diabetic Foot Infection – VASP</p>
<p>Evaluation</p>
<ul>
<li>
<p>Plain radiograph for all pts; MRI w/contrast if abscess/osteo
    suspected</p>
</li>
<li>
<p>BCx (prior to antibiotics) if systemic signs of infection, or severe
    infection</p>
</li>
</ul>
<!-- -->

<ul>
<li>Do not culture swabs of lesions, as these generally only grow
    colonizing organisms.</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consult podiatry if osteomyelitis present for bone specimen culture
    and pathology (either from debridement specimen or bone biopsy)
    prior to starting antibiotics.</p>
</li>
<li>
<p>Consult surgery if concern for abscess, gas in tissue, joint
    involvement</p>
</li>
<li>
<p>Assess peripheral vasculature, consider arterial flow
    studies/vascular surgery consult</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Assess Severity:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mild: Local infxn, skin/subQ tissue only, erythema >0.5 cm but ≤2cm
    from ulcer</p>
</li>
<li>
<p>Moderate: Local infxn w/erythema > 2 cm from ulcer or deeper
    structures included without SIRS</p>
</li>
<li>
<p>Severe: Local infxn with systemic inflammation as evidenced by >2
    SIRS criteria</p>
<ul>
<li>
<p>Consider anti-pseudomonal coverage if at risk for <em>Pseudomonas</em>
    infection (e.g. wet; failure of prior antibiotic therapy;
    chronic wound).</p>
</li>
<li>
<p>Consider anaerobic coverage with metronidazole if foul-smelling
    and/or necrotic.</p>
</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 14%" />
<col style="width: 36%" />
<col style="width: 49%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th><blockquote>
<p>Non-purulent, no MRSA risk factors</p>
</blockquote></th>
<th><blockquote>
<p>Purulent, MRSA risk factors</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Mild</td>
<td><p>Cephalexin 500 QID OR</p>
<p>Amoxicillin-clavulanate 875/125 BID</p></td>
<td><p>TMP-SMX DS 1-2 tabs BID OR</p>
<p>Doxycycline 100 BID</p></td>
</tr>
<tr class="even">
<td>Moderate</td>
<td><p>Amoxicillin-clavulanate 875/125 BID OR</p>
<p>Ampicillin-sulbactam 3g q6h OR</p>
<p>Piperacillin-tazobactam 3.375g q8h ext infusion OR</p>
<p>Levofloxacin 500 daily</p></td>
<td><p>TMP-SMX DS 1-2 tabs BID + cephalexin 500 QID OR
Amoxicillin-clavulanate 875/125 BID</p>
<p>Vancomycin 15-20mg/kg q8-12h + ampicillin-sulbactam 3g q6h
(anaerobic, but NO Pseudomonas cvg) OR cefepime 2g q8h (Pseudomonas cvg)
+ metronidazole 500 q8h (anaerobic cvg)</p></td>
</tr>
<tr class="odd">
<td>Severe</td>
<td colspan="2">Vancomycin 15-20 mg/kg q8-12h + cefepime 2g q8h +
metronidazole 500 q8h</td>
</tr>
</tbody>
</table>

<p>Additional Information</p>
<ul>
<li>
<p>If pt HDS, hold abx until deep tissue/operative cultures obtained.</p>
</li>
<li>
<p>Most diabetic foot infections are polymicrobial in nature.</p>
</li>
<li>
<p>Culture results may guide therapy, but all pathogens identified may
    not require treatment.</p>
</li>
</ul>
<p>Joint Infections and Osteomyelitis – VASP</p>
<p>Evaluation</p>
<ul>
<li>
<p>Blood cultures prior to antibiotics</p>
</li>
<li>
<p>MRI is the most sensitive and specific imaging modality for
    osteomyelitis.</p>
</li>
<li>
<p>Ortho consult for joint fluid aspirate or bone bx; send for culture
    and send fluid for cell count/differential.</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Hold antibiotics until culture obtained, if patient is clinically
    stable</p>
</li>
<li>
<p>Osteomyelitis is a 6-week treatment course, can consider early
    transition (at 2-3 weeks) to oral if good bioavailability and
    susceptibility.</p>
</li>
<li>
<p>For prosthetic joint infection, procedure/retention of hardware
    determines duration</p>
</li>
<li>
<p>First line empiric: Vancomycin + ciprofloxacin 750mg BID</p>
</li>
<li>
<p>Antimicrobial therapy will ultimately be guided by culture data, ID
    consult recommended for joint infection treatment due to need for
    prolonged antibiotic therapy</p>
</li>
</ul>
<p>Bacteremia: Interpreting GenMark ePlex® Results – VASP</p>
<p>Background</p>
<ul>
<li>When BCx turn positive, the lab reports Gram stain and GenMark
    ePlex® results to help guide empiric therapy, while awaiting further
    species identification and susceptibilities.</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Start empiric antibiotic therapy (based on clinical picture and
    table below)</p>
</li>
<li>
<p>Consider ordering repeat BCx x2 based on organism to document
    clearance</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Repeat for: <em>Staph</em> (MRSA or MSSA), <em>Strep lugdunensis</em></p>
</li>
<li>
<p>If source control &amp; no endovascular infxn, no need to repeat (most
    other strep and GNR’s)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p><a href="https://www.vumc.org/antimicrobial-stewardship-program/antibiograms">VUMC
    antibiograms</a>
    can be used to reference typical resistance patterns and most common
    organisms in blood cultures.</p>
</li>
<li>
<p><em>Candida</em> in a blood culture is NEVER considered a contaminant</p>
</li>
</ul>
<p>GRAM POSITIVE COCCI </p>
<table>
<colgroup>
<col style="width: 37%" />
<col style="width: 28%" />
<col style="width: 34%" />
</colgroup>
<thead>
<tr class="header">
<th><blockquote>
<p>Organism</p>
</blockquote></th>
<th><blockquote>
<p>Resistance Marker</p>
</blockquote></th>
<th><blockquote>
<p>Preliminary Recommendation</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td rowspan="2"><p><em>Staphylococcus aureus</em></p>
<blockquote>
<p>or</p>
</blockquote>
<p><em>Staphylococcus lugdunensis</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>mecA detected</td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td>No mecA detected</td>
<td><p>Start nafcillin or cefazolin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Staphylococcus epidermidis</em></p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start therapy if uncertain</p></td>
<td>mecA detected</td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td>No mecA detected</td>
<td><p>Start nafcillin or cefazolin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td><p>Other coagulase negative <em>Staph</em></p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start abx if uncertain</p></td>
<td></td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td><em>Streptococcus: agalactiae, pyogenes, anginosus</em></td>
<td></td>
<td><p>Start penicillin IV or CTX IV</p>
<p>Stop empiric vancomycin</p></td>
</tr>
<tr class="odd">
<td><em>Streptococcus pneumoniae</em></td>
<td></td>
<td><p>Start ceftriaxone</p>
<p>Stop empiric vancomycin</p>
<p>Await PCN sensitivity data</p></td>
</tr>
<tr class="even">
<td><p>Other <em>Streptococcus</em></p>
<p>-May be contaminant</p></td>
<td></td>
<td><p>Start ceftriaxone</p>
<p>Stop empiric vancomycin</p>
<p>Await PCN sensitivity data</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Enterococcus faecalis</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>vanA or vanB detected</td>
<td><p>Start daptomycin 8-10mg/kg/day IV</p>
<p>Don’t treat w vancomycin IV</p>
<p>Contact precautions</p></td>
</tr>
<tr class="even">
<td>No vanA or vanB</td>
<td><p>Start ampicillin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Enterococcus faecium</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>vanA or vanB detected</td>
<td><p>Start daptomycin 8-10mg/kg/day IV</p>
<p>Don’t treat w vancomycin IV</p>
<p>Contact precautions</p></td>
</tr>
<tr class="even">
<td>No vanA or vanB</td>
<td><p>Start vancomycin IV</p>
<p>Follow-up ampicillin sensitivities</p></td>
</tr>
<tr class="odd">
<td colspan="2"><p><em>Micrococcus</em></p>
<p>-Often if in a single blood culture is skin contaminant</p></td>
<td><p>Repeat BCx</p>
<p>Start vancomycin IV if uncertain</p></td>
</tr>
</tbody>
</table>

<p>GRAM POSITIVE RODS</p>
<table>
<colgroup>
<col style="width: 46%" />
<col style="width: 53%" />
</colgroup>
<thead>
<tr class="header">
<th><blockquote>
<p>Organism</p>
</blockquote></th>
<th><blockquote>
<p>Preliminary Recommendation</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><em>Listeria monocytogenes</em></td>
<td><p>Start ampicillin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="even">
<td><p>Other Gram positive rod (e.g. <em>Bacillus cereus, Corynebacterium,
Cutibacterium acnes, Lactobacillus</em>)</p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start therapy if uncertain</p></td>
<td><p>Start vancomycin IV</p>
<p>Follow-up sensitivities; some GPRs are resistant to
vancomycin</p></td>
</tr>
</tbody>
</table>

<p>GRAM NEGATIVE RODS *Consult ID if carbapenem resistance detected*</p>
<table>
<colgroup>
<col style="width: 29%" />
<col style="width: 70%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Organism</strong></th>
<th><strong>Preliminary Recommendation</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><em>Acinetobacter baumannii</em></td>
<td>Start ampicillin/sulbactam</td>
</tr>
<tr class="even">
<td><em>Bacteroides fragilis</em></td>
<td><p>Start metronidazole</p>
<p>If polymicrobial infection, piperacillin/tazobactam,
ampicillin/sulbactam, or meropenem based on other organisms</p>
<p>Do NOT double cover anaerobes</p></td>
</tr>
<tr class="odd">
<td><em>Citrobacter spp.</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Cronobacter sakazakii</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Enterobacter (non-cloacae complex)</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Enterobacter cloacae complex</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Escherichia coli</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><p><em>Fusobacterium nucleatum</em></p>
<p><em>Fusobacterium necrophorum</em></p></td>
<td>Start ampicillin/sulbactam or start/continue metronidazole</td>
</tr>
<tr class="odd">
<td><em>Haemophilus influenzae</em></td>
<td>Start/continue ceftriaxone</td>
</tr>
<tr class="even">
<td><em>Klebsiella oxytoca</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="odd">
<td><em>Klebsiella pneumoniae group</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><em>Morganella morganii</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Neisseria meningitidis</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><p><em>Proteus spp.</em></p>
<p><em>Proteus mirabilis</em></p></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="odd">
<td><em>Pseudomonas aeruginosa</em></td>
<td>Start/continue cefepime or piperacillin-tazobactam</td>
</tr>
<tr class="even">
<td><em>Salmonella spp</em></td>
<td>Start/continue ceftriaxone</td>
</tr>
<tr class="odd">
<td><p><em>Serratia spp.</em></p>
<p><em>Serratia marcescens</em></p></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Stenotrophomonas maltophilia</em></td>
<td>Start trimethoprim-sulfamethoxazole (15-20mg/kg/day divided q8h for
normal renal function)</td>
</tr>
<tr class="odd">
<td colspan="2">Gram-Negative Resistance Genes</td>
</tr>
<tr class="even">
<td>CTX-M Positive (ESBL)</td>
<td><p>Start meropenem</p>
<p>Consider an Infectious Diseases consult</p>
<p>Contact precautions (see Infection Prevention website)</p></td>
</tr>
<tr class="odd">
<td><p>IMP Positive</p>
<p>KPC Positive</p>
<p>NDM Positive</p>
<p>OXA (OXA-23 and OXA-48) Positive</p>
<p>VIM Positive</p></td>
<td><p>Carbapenemase-producing organism</p>
<p>Obtain Infectious Disease consultation</p>
<p>Contact precautions (see Infection Prevention website)</p></td>
</tr>
</tbody>
</table>

<p>Endocarditis – Justin Smith</p>
<p>Background</p>
<ul>
<li>Multiple etiologies of endocarditis:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Typical Bacterial</p>
<ul>
<li>
<p><em>S. aureus, Enterococcus</em> spp (<em>E. faecalis</em> most commonly),
    viridans group <em>streptococci</em>, <em>Strep gallolyticus</em> (formerly
    <em>S. bovis</em>)</p>
</li>
<li>
<p>HACEK: <em>Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella</em></p>
</li>
</ul>
</li>
<li>
<p>Other infectious</p>
<ul>
<li>Culture negative: often recent antimicrobial exposure, slow
    growing organism</li>
<li><em>Coxiella</em>, <em>Brucella</em>, <em>Bartonella</em>, <em>Chlamydia</em>, <em>Legionella</em>,
    <em>Mycoplasma</em>, <em>Tropheryma whipplei</em>, <em>Cutibacterium acnes</em> (formerly <em>P. acnes</em>)</li>
<li>Fungal: <em>Candida</em> and <em>aspergillus</em> most common</li>
</ul>
</li>
<li>
<p>Non-infectious: a.k.a., marantic endocarditis, Libbman-Sacks
    Endocarditis</p>
<ul>
<li>Rare, most common in advanced malignancy, SLE, inflammatory
    conditions</li>
<li>Higher risk for embolization compared to IE</li>
<li>Risk factors: IV drug use, congenital heart disease, valve
    abnormalities, intracardiac devices, recent cardiac surgery</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Fever (90%), murmur (85%), other: splenomegaly, splinter
    hemorrhages, Janeway lesions, Osler nodes, Roth spots</p>
</li>
<li>
<p>Persistent bacteremia despite appropriate treatment, new onset
    cardiac dysfunction, new onset valve abnormalities, stroke, other
    thromboembolic events, metastatic infections/abscesses, splenic
    abscess, septic pulmonary emboli</p>
</li>
</ul>
<p>Duke Criteria:</p>
<ul>
<li>Pathologic Criteria</li>
</ul>
<!-- -->

<ul>
<li>
<p>Microorganisms: culture or histology proven: vegetation, embolus, or
    intracardiac abscess</p>
</li>
<li>
<p>Pathologic vegetations: vegetation of abscess with histology proven
    endocarditis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Clinical Criteria</li>
</ul>
<!-- -->

<ul>
<li>
<p>Definite: 2 Major, 1 major and 3 minor, or 5 minor</p>
</li>
<li>
<p>Possible: 1 major and 1 minor, or 3 minor</p>
</li>
<li>
<p>Rejected: firm alternate diagnosis, resolution of evidence with \&lt;4
    days of antibiotics, or absence of pathologic evidence with \&lt;4days
    of antibiotics</p>
</li>
</ul>
<table>
<thead>
<tr>
<th><strong>Major Criteria</strong></th>
<th><strong>Minor Criteria</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>2x positive blood cultures from a typical organism</td>
<td>Predisposing heart condition/IDU</td>
</tr>
<tr>
<td>Evidence of endocardial involvement</td>
<td>Fever</td>
</tr>
<tr>
<td></td>
<td>Vascular phenomena (glomerulonephritis)</td>
</tr>
<tr>
<td></td>
<td>Immunologic phenomena (Osler nodes, Roth spots, +rheumatoid factor, GN)</td>
</tr>
<tr>
<td></td>
<td>Micro (cultures that don’t fit the above, or serologic evidence of acute infection)</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>
<p>Physical exam: murmur, decreased peripheral perfusion, evidence of
    heart failure, petechiae, splinter hemorrhages, Janeway
    lesions/Osler nodes, organomegaly</p>
</li>
<li>
<p>Blood cultures: at least three sets from different sites over a span
    of several hours</p>
</li>
<li>
<p>Echo (TTE vs TEE)</p>
</li>
</ul>
<!-- -->

<ul>
<li>It can be reasonable to start with TEE if pretest probability is
    high enough, if patient already has known valvular abnormalities, or
    TTE will be technically difficult</li>
</ul>
<!-- -->

<ul>
<li>
<p>EKG: new heart block or prolonged PR raises concern for
    endocardial/perivalvular abscess. Endocarditis patients should be on
    telemetry, monitored closely by team.</p>
</li>
<li>
<p>CXR: infiltrates suggestive of septic pulmonary emboli, pulmonary
    edema, cardiomegaly</p>
</li>
<li>
<p>Imaging of distant affected site if concerned for septic emboli</p>
</li>
<li>
<p>Other advanced imaging in select scenario: cardiac CTA, cardiac MRI,
    FDG-PET/CT</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Empiric antibiotics:</li>
</ul>
<!-- -->

<ul>
<li>
<p>If bacteria isolated from blood, reference bacteremia section for
    abx choice</p>
</li>
<li>
<p>If awaiting cultures</p>
<ul>
<li>
<p>Native valve: Vancomycin &plusmn; GNR coverage (depending on clinical
    stability, risk factors, etc.)</p>
</li>
<li>
<p>Prosthetic valve: Vancomycin and cefepime, consider gentamicin</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Antibiotic Duration: determined by ID, often 4-6 weeks</p>
</li>
<li>
<p>Cardiac surgery consult: if valve dysfunction, perivalvular abscess,
    large (>20mm) vegetations, heart block, ongoing embolization on
    abx, delayed Cx clearance (>1 week on abx)</p>
</li>
</ul>
<p>Additional Information:</p>
<ul>
<li>Complications:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cardiac:</p>
<ul>
<li>
<p>Heart failure: usually secondary to valve dysfunction. Most
    common when aortic valve involved, risk also depends on organism
    (worst is <em>Staph aureus</em>)</p>
</li>
<li>
<p>Perivalvular abscess: suspect when there are conduction
    abnormalities on EKG.</p>
</li>
<li>
<p>Pericarditis: can be suppurative or non-suppurative</p>
</li>
<li>
<p>Intracardiac Fistula</p>
</li>
</ul>
</li>
<li>
<p>Septic emboli and metastatic abscesses</p>
</li>
<li>
<p>Mycotic aneurysm: usually occurs at vessel branch points</p>
</li>
</ul>
<!-- -->

<ul>
<li>Follow Up</li>
</ul>
<!-- -->

<ul>
<li>
<p>Repeat TTE at completion of treatment to establish new baseline</p>
</li>
<li>
<p>Followed for valvular dysfunction with frequency determined by
    nature of the dysfunction</p>
</li>
<li>
<p>Regular dental care; prior IE is an indication for SBE prophylaxis
    with dental work.</p>
</li>
</ul>
<!-- -->

<ul>
<li>Episode of IE is an indication for PDA or VSD closure</li>
</ul>
<p>Central Nervous System Infection – VASP</p>
<p>Bacterial Meningitis</p>
<p>Evaluation</p>
<ul>
<li>
<p>Blood cultures prior to antibiotics if possible</p>
</li>
<li>
<p>Head CT pre-LP, only if: Immunocompromised, hx of CNS diseases
    (shunts, trauma, tumors), papilledema on exam or FND, AMS, or new
    onset seizure.</p>
</li>
<li>
<p>If there is a delay in obtaining head CT or LP, DO NOT delay
    antibiotics.</p>
</li>
<li>
<p>Lumbar puncture (See Procedures Section):</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Obtain: Opening pressure, cell count + differential, glucose,
    protein, bacterial culture</p>
</li>
<li>
<p>Send an extra tube or two of CSF to the lab, if possible, to be
    frozen in case extra testing is needed (Order ‘Miscellaneous test’
    and for test name put “Please freeze CSF in virology;” reference
    lab: VUMC, specimen type: CSF)</p>
</li>
<li>
<p>Additional studies to consider in select pts: HSV 1, 2 PCR (NOT
    antibodies), VZV PCR, VDRL, Crypto Ag, fungal and/or AFB cultures,
    MTB PCR, West Nile Virus Ab, Enterovirus PCR, Histoplasma Ag, or
    Biofire Meningitis/Encephalitis Panel. These should not be performed
    routinely on all patients and consult ID where management questions
    exist.</p>
</li>
<li>
<p>If Biofire Meningitis/Encephalitis Panel is performed, double check
    what is included to avoid sending duplicate individual tests (ie
    HSV, VZV, enterovirus, etc.) A negative cryptococcus on Biofire does
    not exclude disease (CSF Crypto Ag is more sensitive)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>ANTIBIOTICS AS SOON AS POSSIBLE:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ceftriaxone 2g IV q12h + Vancomycin, adjusted for renal function</p>
</li>
<li>
<p>Piperacillin-tazobactam cannot be used due to poor CNS penetration</p>
</li>
<li>
<p>IV ampicillin 2g q4h for optional coverage of Listeria for
    immunocompromised patients, pregnant women, or age >50 (adjust
    based on renal function)</p>
</li>
<li>
<p>IV acyclovir 10 mg/kg (based on adjusted body weight) q8h, if
    suspected HSV or VZV meningitis, make sure to run with adequate
    pre-hydration with NS</p>
</li>
<li>
<p>Consider empiric PO/IV doxycycline 100mg BID if tick-borne illness
    is suspected</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Steroids: Based on IDSA guidelines, steroids (dexamethasone 0.15
    mg/kg q6h) should be given about 10-20 minutes before the first dose
    of antibiotics, or at the same time, in patients with suspected
    bacterial meningitis. IF pneumococcus is isolated, continue IV
    steroids for 2-4 days; otherwise, can discontinue</p>
</li>
<li>
<p>ID consultation: Duration should be guided by ID and varies based on
    organism recovered</p>
</li>
</ul>
<p>Encephalitis</p>
<p>Background</p>
<ul>
<li>The presence or absence of normal brain function/cognition is the
    important distinguishing clinical feature between encephalitis and
    meningitis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>MRI more sensitive that CT, although imaging may or may not
    demonstrate abnormal radiographic findings in patients with
    encephalitis</p>
</li>
<li>
<p>LP – similar studies as for meningitis (see above) + BioFire MEP for
    ALL pts</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Acyclovir 10mg/kg IV q8hr, consideration of antibacterial therapy if
    unable to conclusively exclude a bacterial meningitis, consideration
    of doxycycline if tick-borne infection is on the differential, and
    further treatment as guided by ID</p>
</li>
<li>
<p>ID consult is strongly encouraged for all patients with suspected
    encephalitis</p>
</li>
</ul>
<p>Brain Abscess</p>
<p>Evaluation/Management</p>
<ul>
<li>
<p>Consult: Neurosurgery and ID</p>
</li>
<li>
<p>Blood Cultures, HIV testing in any patient with a brain lesion</p>
</li>
<li>
<p>Empiric antibiotics:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>IV Vancomycin (target trough 15 - 20 mcg/mL) + ceftriaxone 2g IV
    q12h + metronidazole 500mg IV/PO q6h</p>
</li>
<li>
<p>If concern for extension from otitis externa, use an antipseudomonal
    cephalosporin (cefepime 2g IV Q8h) instead of ceftriaxone</p>
</li>
<li>
<p>Brain abscesses generally polymicrobial, thus broad-spectrum
    antibiotics indicated</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Aminoglycosides, macrolides, tetracyclines (e.g. doxycycline),
    clindamycin, beta-lactam/beta-lactamase combinations (e.g., Zosyn)
    and 1<sup>st</sup>-generation cephalosporins (e.g., cefazolin) should NOT be
    used as they do not cross BBB at high concentration.</p>
</li>
<li>
<p>Antibiotic Duration: Based on surgical drainage and Infectious
    Diseases guidance</p>
</li>
</ul>
<p>Epidural Abscess</p>
<p>Management</p>
<ul>
<li>
<p>If spinal lesion, consult ‘Spine surgery’ and it will be directed to
    Ortho-Spine or Neurosurgery, depending on who is on call.</p>
</li>
<li>
<p>Antibiotics should be started as soon as the diagnosis of epidural
    abscess is suspected, immediately following the collection of two
    sets of blood cultures</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Vancomycin 15-20mg/kg IV q8-12h (adjusted for renal function) +
    ceftriaxone 2g IV q24h (or q12hr if there is secondary meningitis)</p>
</li>
<li>
<p>Use cefepime 2g IV q8h instead of ceftriaxone if concern for
    <em>Pseudomonas</em></p>
</li>
</ul>
<!-- -->

<ul>
<li>ID consult is strongly encouraged and they will guide duration</li>
</ul>
<p>Fungal Infections – Justin Smith</p>
<p>Histoplasmosis</p>
<p>Background</p>
<ul>
<li>
<p>Endemic to Ohio and Mississippi river valley</p>
</li>
<li>
<p>Pulmonary infiltrate with hilar or mediastinal LAD, pulmonary
    nodule/cavitary lesion, pulmonary syndrome with erythema nodosum</p>
</li>
<li>
<p>DDx: TB, malignancy, sarcoidosis (if considering sarcoidosis, rule
    out histoplasmosis as sarcoidosis treatment can induce disseminated
    histoplasmosis)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Antigen (requires attending approval): For acute pulmonary
    histoplasmosis, 65% urine sensitivity, 69% serum sensitivity, and
    83% sensitivity when co-tested. Thus, both serum and urine Ag are
    usually sent together</li>
</ul>
<!-- -->

<ul>
<li>
<p>Lower rates of positivity when disease is localized, versus diffuse
    throughout the lungs or disseminated.</p>
</li>
<li>
<p>There are relatively high rates of cross-reactivity, where
    histoplasma antigen will be positive with blastomycosis; therefore,
    do not order blasto Ag if ordering histo Ag in MOST cases</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Serology: Consider Histoplasma Ab if evaluating for pulmonary
    disease</p>
</li>
<li>
<p>Culture: most useful in chronic infections, sensitivity is low in
    acute/localized and may take >6 weeks to grow.</p>
</li>
<li>
<p>Bronchoscopy: If clinical suspicion is high and work up negative,
    consider interventional pulmonology consult for consideration of
    bronchoscopy</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Outpatient/Mild disease:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Tx not required if symptoms \&lt;4 weeks, initiate if symptomatic
    beyond 4 weeks</p>
</li>
<li>
<p>Itraconazole: 200mg TID x3 days loading, then BID (adjusted by
    levels which are drawn 2 weeks post-start) for 6-12 weeks minimum</p>
</li>
<li>
<p>Can use oral formulation or capsules (capsules require high acidity,
    give with food consumption or OJ or coke; do not use capsules if
    patient is on H2 blockers/PPI)</p>
</li>
<li>
<p>Voriconazole, Posaconazole: used if not tolerating itraconazole or
    as salvage therapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>Inpatient/Moderate to Severe Disease:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Amphotericin: 1-2 weeks induction, followed by PO itraconazole for
    12 weeks (total)</p>
</li>
<li>
<p>Methylprednisolone: help to prevent ARDS with significant lung
    involvement</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>Complications: Pericarditis, arthritis/arthralgias with erythema
    nodosum, chronic cavitary lesions, fibrosing mediastinitis,
    broncholithiasis</p>
</li>
<li>
<p>Disseminated Histoplasmosis:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Typically found in immunocompromised populations</p>
</li>
<li>
<p>Clinical presentations: FUO, weight loss, disseminated LAD,
    cutaneous manifestations, bone marrow suppression/pancytopenia,
    liver enzymes elevation, various solid organ involvement on imaging
    (liver, spleen, adrenals, nodes)</p>
</li>
<li>
<p>Management</p>
<ul>
<li>
<p>Mild: itraconazole</p>
</li>
<li>
<p>Moderate to Severe: amphotericin induction followed by
    itraconazole</p>
</li>
<li>
<p>CNS involvement: amphotericin for 4-6 weeks as induction</p>
</li>
</ul>
</li>
</ul>
<p>Blastomycosis</p>
<p>Background</p>
<ul>
<li>
<p>Endemic to Mississippi/Ohio river valley, southern and midwestern
    US, great lakes</p>
</li>
<li>
<p>Pulmonary syndrome: cough, fever, hemoptysis, chest pain, dyspnea</p>
</li>
</ul>
<!-- -->

<ul>
<li>Can result in both an acute or chronic pneumonia, as well as ARDS</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cutaneous: raised verrucous lesion, varying in color, with irregular
    borders</p>
</li>
<li>
<p>MSK: osteolytic lesion, draining sinus, soft tissue swelling</p>
</li>
<li>
<p>Multi-system: up to 20-40% of cases, most typically lung/skin
    involvement.</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Culture: typically takes 1-4 weeks</p>
</li>
<li>
<p>Ag: urine >serum. ~90% sensitive, but only 80% specific because of
    cross-reactivity</p>
</li>
<li>
<p>Serology: available, but not very useful because of high degree of
    cross-reactivity</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Mild: PO itraconazole for 6-12 months with loading, check level at 2
    weeks</p>
</li>
<li>
<p>Moderate to Severe: induction with Amphotericin, followed by 6-12
    months of PO itraconazole</p>
</li>
</ul>
<p>Candida</p>
<p>Background</p>
<ul>
<li>Oropharyngeal: white plaques in mouth, change in taste, erythema
    without plaques</li>
</ul>
<!-- -->

<ul>
<li>Usually seen in infants, older adults, immunocompromised host (HIV
    or chemotherapy), inhaled steroid users</li>
</ul>
<!-- -->

<ul>
<li>
<p>Esophageal: odynophagia, especially retrosternal pain (AIDS defining
    illness)</p>
</li>
<li>
<p>Vulvovaginitis: itching, burning, vaginal discharge, vulvar
    erythema, vulvar edema, dyspareunia, dysuria</p>
</li>
<li>
<p>Balanitis: painful white plaques with burning and itching on the
    glans penis</p>
</li>
<li>
<p>Mastitis: erythema, tenderness in breast feeding woman.</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Depends on specifics, but typically nystatin or fluconazole EXCEPT
    <em>C. glabrata</em> (proof of fluconazole susceptibility needed) and <em>C.
    krusei</em> (intrinsically resistant to fluconazole)</p>
</li>
<li>
<p>Cx generally not indicated unless complicated pt with extensive tx
    history for Candida</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Disseminated disease</li>
</ul>
<!-- -->

<ul>
<li>
<p>Presentation: Primarily immunocompromised populations (hematologic
    malignancies, solid organ transplant recipients, receiving
    chemotherapy, TPN, steroid use, broad spectrum antibiotics) and ICU
    settings (especially, burn, trauma, and neonatal)</p>
</li>
<li>
<p>Diagnosis: <em>Candida</em> in a bacterial blood culture (NEVER
    contaminant)</p>
</li>
<li>
<p>Start micafungin 100mg IV and consult ID for candidemia or if
    concerned for disseminated disease</p>
</li>
</ul>
<p>HIV/AIDS and ART – Kathryn Snyder and Quinton Taylor</p>
<p>Background</p>
<ul>
<li>Why is ART important?</li>
</ul>
<!-- -->

<ul>
<li>
<p>Clear morbidity and mortality benefits across all CD4 counts</p>
</li>
<li>
<p>Decreases subsequent infections (both common and opportunistic)</p>
</li>
<li>
<p>Decreased HIV related comorbid conditions, viral reservoirs, and
    transmission</p>
</li>
</ul>
<!-- -->

<ul>
<li>New HIV Diagnosis</li>
</ul>
<!-- -->

<ul>
<li>
<p>ID consult if patient is not on Rogers ID service (important for
    initiation, follow up [CCC], social work assistance)</p>
</li>
<li>
<p>ART is indicated for all HIV+ patients, regardless of CD4; however,
    starting ART requires appropriate outpatient follow up</p>
</li>
<li>
<p>Lab evaluation:</p>
<ul>
<li>
<p>HIV viral load, genotype, and resistance testing</p>
</li>
<li>
<p>T cell subsets (CD4 Count), CBC with differential, CMP, UA</p>
</li>
<li>
<p>HLA*B5701 testing before using abacavir containing regimen</p>
</li>
<li>
<p>QuantiFERON Gold</p>
</li>
<li>
<p>Pregnancy testing</p>
</li>
<li>
<p>Viral hepatitis serologies</p>
</li>
<li>
<p>Toxoplasma serologies</p>
</li>
<li>
<p>Other STI screening (Syphilis, Gonorrhea/Chlamydia)</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Timing of ART initiation</li>
</ul>
<!-- -->

<ul>
<li>
<p>Factors affecting timing of initiation</p>
<ul>
<li>
<p>Drug toxicity and interactions, risks for resistance, adherence
    barriers</p>
</li>
<li>
<p>Treatment of opportunistic infections may delay initiation of
    ART given associated risk of immune reconstitution inflammatory
    syndrome (IRIS)</p>
<ul>
<li>Delay ART for several weeks after initiation of therapy for
    cryptococcal meningitis, tuberculosis, and CMV retinitis</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>ART plan for overnight admits: okay to continue home ART, special
    consideration for:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Patients with hepatic or renal dysfunction may need dose adjustment</p>
</li>
<li>
<p>Interactions with other newly initiated medications</p>
</li>
<li>
<p>If there is concern for non-adherence, can hold morning dose</p>
</li>
<li>
<p>Combination pills may need to be ordered as separate components</p>
</li>
</ul>
<!-- -->

<ul>
<li>Common key regimens for initiation</li>
</ul>
<!-- -->

<ul>
<li>
<p>Most regimens consist of an NRTI backbone (2 agents) plus a
    3<sup>rd</sup> agent</p>
</li>
<li>
<p>Some dual therapy regimens (such as Dovato@) are non-inferior to
    standard 3-drug therapy</p>
</li>
<li>
<p>Many patients are started on combination pill regimens, including
    Integrase Inhibitor based regimens: Biktarvy®, Dovato®, Triumeq®,
    Genvoya®, dolutegravir + Descovy®</p>
</li>
</ul>
<p>AIDS Defining Clinical Conditions – Rebecca Choudhury</p>
<p>AIDS is defined by HIV infection with concurrent absolute CD4 count
\&lt;200, CD4 percentage \&lt;14%, or one of the following conditions
(predominately opportunistic infections and HIV associated
malignancies):</p>
<p>Neurologic/Ophthalmologic</p>
<p>CNS toxoplasmosis</p>
<ul>
<li>
<p>Presentation: Variable, depending on disease burden/location, may
    include AMS, headache, seizure, ataxia, and focal neurologic
    deficits, &plusmn; fever and flu-like symptoms</p>
</li>
<li>
<p>Evaluation: MRI w/ring-enhancing lesions on brain imaging, serum
    Toxoplasma IgG/IgM and (ideally) CSF Toxoplasma PCR (though CSF
    Toxoplasma PCR has a low sensitivity). Response to empiric therapy
    (~90% will have radiographic improvement after 14 days) can also be
    diagnostic. Brain biopsy may be indicated if diagnostic uncertainty.</p>
</li>
<li>
<p>Management: Pyrimethamine, sulfadiazine, and leucovorin is the
    preferred regimen, discuss dosing with pharmacy. Alternative
    regimens: clindamycin, Bactrim, atovaquone</p>
</li>
</ul>
<p>Progressive multifocal leukoencephalopathy (PML)</p>
<ul>
<li>
<p>Presentation: chronic (weeks to months), progressive neurologic
    dysfunction, particularly incoordination and other motor
    dysfunction, aphasia, sometimes cognitive impairment and personality
    changes</p>
</li>
<li>
<p>Evaluation: MRI brain w/patchy areas of demyelination in the
    subcortical white matter; location is variable, but parietal,
    occipital, and cerebellar involvement are common. JC virus PCR from
    CSF. Brain biopsy.</p>
</li>
<li>
<p>Management: Initiation of ART (there is no specific JC
    virus-directed therapy), IRIS may occur in which case clinical
    worsening before improvement may be seen. Fatal if HIV goes
    untreated.</p>
</li>
</ul>
<p>HIV-related encephalopathy</p>
<ul>
<li>
<p>Presentation: Similar to other progressive dementias, with short
    term memory loss followed by worsening global cognitive dysfunction,
    motor deficits, sometimes seizures in late stages</p>
</li>
<li>
<p>Evaluation: MRI w/diffuse cerebral atrophy and/or demyelinating
    lesions similar to PML. CSF w/elevated protein &plusmn; lymphocytic
    pleocytosis, with no alternative cause. Send HIV RNA from the CSF,
    usually + in HIV encephalopathy</p>
</li>
</ul>
<p>Cryptococcal meningitis</p>
<ul>
<li>
<p>Presentation: Subacute to chronically worsening HA and fevers;
    meningismus and photophobia may be present but are often absent;
    rarely, focal neurologic deficits</p>
</li>
<li>
<p>Evaluation: LP to check opening pressure and can send serum and CSF
    Cryptococcus Ag. Brain imaging may be non-diagnostic</p>
</li>
<li>
<p>Treatment: Induction therapy with amphotericin and flucytosine x14
    days (at least), with repeat LP close to end of induction to confirm
    CSF inflammation is improving and fungal culture is negative.
    Consolidation therapy consists of high dose fluconazole for at least
    8 weeks, followed by maintenance therapy with fluconazole for one
    year. Pts may require serial LP or VP shunt to manage ICP.</p>
</li>
</ul>
<!-- -->

<ul>
<li>Delay ART for several weeks after start of treatment to avoid risk
    of IRIS.</li>
</ul>
<p>CMV retinitis (with vision loss)</p>
<ul>
<li>
<p>Presentation: Blurry vision, focal blind spots, visual field
    deficits, or scotomas and floaters. Typically begins unilateral,
    though often progresses to bilateral involvement.</p>
</li>
<li>
<p>Evaluation: Always consult ophtho if you suspect it! May cause
    complete retinal detachment. Check serum CMV PCR (or vitreous if
    able)</p>
</li>
<li>
<p>Management: PO valgancyclovir (+intravitreous ganciclovir or
    foscarnet in severe disease). If not on ART, must delay ART for at
    least 2 weeks after start of CMV retinitis treatment to prevent
    immune recovery uveitis</p>
</li>
</ul>
<p>Pulmonary</p>
<p><em>Pneumocystis jirovecii</em> pneumonia (PJP)</p>
<ul>
<li>
<p>Presentation: fever, shortness of breath, cough (usually
    non-productive), sometimes night sweats and weight loss. Hypoxia out
    of proportion to exam.</p>
</li>
<li>
<p>Evaluation: CT chest appearance usually bilateral and diffuse with
    GGOs and cystic lesions of varying size. Large cysts can rupture,
    causing pneumothorax.</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Transbronchial biopsy, BAL, or induced sputum with cytology and GMS
    stain.</p>
</li>
<li>
<p>Sputum Pneumocystis PCR can be done, but this is a send-out with
    long turn-around-time</p>
</li>
<li>
<p>Consider serum LDH and 1,3-BD-glucan: should be elevated, but are
    nonspecific.</p>
</li>
</ul>
<!-- -->

<ul>
<li>Management: Bactrim is the preferred treatment; PO is preferable as
    Bactrim is 100% bioavailable. Check ABG on ROOM AIR to consider of
    adding adjunctive steroids (If A-a gradient >/=35mmHg and/or PaO2
    \&lt;70mmHg). Alternative regimens may include primaquine + clindamycin
    or IV (NOT inhaled) pentamidine.</li>
</ul>
<p>Pulmonary tuberculosis</p>
<ul>
<li>
<p>Presentation: With low CD4, can have upper lobe cavities but also
    atypical radiographic pattern, including a normal-appearing CXR.
    Have a high degree of suspicion in any patient with advanced HIV and
    respiratory complaints.</p>
</li>
<li>
<p>Evaluation: TB skin tests and IGRAs have a high false negative rate
    in advanced HIV. At VUMC, any pt with HIV and respiratory complaints
    must be placed on airborne until TB ruleout- 3 sputum mycobacterial
    cultures collected at least 8 hours apart. If concentrated smear is
    negative x3, TB is unlikely (though have to follow up final culture
    to be sure).</p>
</li>
<li>
<p>Management: RIPE therapy is the standard initial treatment, with
    adjustment if needed for drug resistance or contraindications</p>
</li>
</ul>
<p><em>Herpes simplex</em> tracheobronchitis and/or pneumonitis/pneumonia</p>
<ul>
<li>
<p>Evaluation: bronchoscopy with positive HSV PCR from BAL &plusmn; lung
    biopsy. (Usually associated with HSV-1)</p>
</li>
<li>
<p>Management: agent and duration not well defined for bronchopulmonary
    disease; depending on severity of presentation, likely IV acyclovir
    to start followed by transition to PO antiviral once evidence of
    clinical improvement, for a total of 10-14 days.</p>
</li>
</ul>
<p>Gastrointestinal</p>
<p>Esophageal candidiasis</p>
<ul>
<li>
<p>Presentation: Dysphagia, odynophagia or both. Concurrent
    oropharyngeal candidiasis (“thrush’) is common but not universal.</p>
</li>
<li>
<p>Evaluation: Typically presumptive. Treatment is the test; start
    fluconazole and consider EGD if symptoms do not improve after
    several days (in which case candidiasis may be severe, or it might
    not be the cause)</p>
</li>
<li>
<p>Management: Fluconazole; nystatin is ineffective, especially in the
    severely immunocompromised</p>
</li>
</ul>
<p><em>Herpes simplex</em> esophagitis</p>
<ul>
<li>
<p>Evaluation: EGD shows diffuse ulcerations throughout the esophagus;
    in severe disease ulcers may coalesce into dark patches, “black
    esophagus.” Esophageal biopsy is definitive, but can infer based on
    EGD appearance and serum studies.</p>
</li>
<li>
<p>Management: Similar to other mucocutaneous infections, consider IV
    acyclovir at first and transition to PO once clinically improved</p>
</li>
</ul>
<p>CMV esophagitis/enteritis/colitis</p>
<ul>
<li>
<p>Presentation: GI bleeding (colitis) or dysphagia and odynophagia
    (esophagitis)</p>
</li>
<li>
<p>Evaluation: serum CMV PCR, consult GI for consideration of
    EGD/colonoscopy</p>
</li>
<li>
<p>Management: (val)ganciclovir, foscarnet if ganciclovir resistance or
    contraindication</p>
</li>
</ul>
<p>Chronic (>1 mo) intestinal isosporiasis</p>
<ul>
<li>
<p>Evaluation: Stool ova/parasite can capture Iospora belli (new name
    Cystoisospora belli), may need serial analysis due to intermittent
    shedding. Oocysts may also be seen on duodenal biopsy.</p>
</li>
<li>
<p>Management: Bactrim; pyrimethamine + leucovorin if Bactrim is
    contraindicated</p>
</li>
</ul>
<p>Chronic intestinal cryptosporidiosis</p>
<ul>
<li>
<p>Presentation: Diarrhea; may infect respiratory tract, causing
    nonproductive cough</p>
</li>
<li>
<p>Evaluation: on GiPP or Cryptosporidium Ag</p>
</li>
<li>
<p>Management: Early initiation or optimization of ART; Monotherapy
    with nitazoxanide is preferred; raising CD4 count >100 is necessary
    to cure infection</p>
</li>
</ul>
<p>Recurrent <em>Salmonella</em> septicemia</p>
<ul>
<li>Generally sensitive to fluoroquinolones, but if not clinically
    improving as expected you can request sensitivities from the
    microbiology lab.</li>
</ul>
<p>Neoplastic</p>
<p>Non-Hodgkin’s lymphoma</p>
<ul>
<li>DLBCL, Burkitt’s, immunoblastic (subset of DLBCL), primary effusion
    lymphoma, and 1º CNS</li>
</ul>
<p>Kaposi’s sarcoma</p>
<ul>
<li>
<p>Presentation: Distinctive mucocutaneous lesions, usually raised,
    papular, violaceous or darkly colored, non-tender and non-pruritic.
    Can also involve the visceral organs (esp lungs and GI tract) and
    deep lymphatic system.</p>
</li>
<li>
<p>Evaluation: clinical, tissue biopsy for staging, HHV-8 serum PCR.</p>
</li>
<li>
<p>Management: Limited mucocutaneous disease may resolve with
    initiation/optimization of ART, but widespread or resistant disease
    may require additional local therapies (eg: radiation) or systemic
    chemo</p>
</li>
<li>
<p>Bacillary angiomatosis (caused by Bartonella) may present similarly,
    but can be distinguished from KS on biopsy. It is neither a cancer
    nor an AIDS defining clinical condition, and is usually treated with
    doxycycline.</p>
</li>
</ul>
<p>Cervical cancer</p>
<ul>
<li>Presentation, diagnosis, and treatment are essentially the same as
    in HIV-negative patients, but incidence is higher and disease
    progression is often more rapid</li>
</ul>
<p>Multisystem/Miscellaneous</p>
<p>Extrapulmonary or disseminated Mycobacterial infection (TB and non-TB)</p>
<ul>
<li>
<p>TB can go everywhere; some notable extrapulmonary sites include
    lymph nodes (e.g., scrofula), bones and joints (e.g., Pott’s disease
    of the spine), pleura and pericardium, GU tract, and CNS. Dx can
    come from tissue culture and sometimes MTB PCR for more rapid
    detection (needs ID approval).</p>
</li>
<li>
<p>TB-IRIS may be severe (esp with high infection burden) and hard to
    distinguish from TB treatment failure; can also be seen in
    adequately treated TB (provoked by the presence of dead bacteria)
    and undiagnosed latent TB.</p>
</li>
<li>
<p>Disseminated MAC is usually diagnosed with AFB blood culture (only 1
    positive needed). Think about it in patients with uncontrolled HIV
    and severe immunosuppression (esp CD4 \&lt;50), with unintentional
    weight loss, chronic diarrhea and/or dyspnea, and evidence of GI
    malabsorption or with bone marrow suppression</p>
</li>
</ul>
<p>Extrapulmonary or disseminated Histoplasmosis, Cryptococcocosis, and
Coccidiodomycosis</p>
<ul>
<li>
<p>Can be difficult to distinguish based on clinical presentation and
    imaging alone. Diagnosed by culture and/or antigen testing depending
    on the organism and site of infection, and diagnosis may be
    supported by serologic studies.</p>
</li>
<li>
<p>Initial treatment of choice: liposomal amphotericin B in almost all
    cases</p>
</li>
</ul>
<p>Chronic mucocutaneous HSV</p>
<ul>
<li>
<p>Defined as mucocutaneous lesions present for >1 month, can be
    present at any site</p>
<p>Multicentric Castleman’s Disease</p>
</li>
<li>
<p>See “Plasma Cell Dyscrasias” section in Hematology/Oncology for more
    details</p>
</li>
</ul>
<p>Overview of Antiretroviral Therapy – Kathryn Snyder and Quinton Taylor</p>
<table>
<colgroup>
<col style="width: 14%" />
<col style="width: 18%" />
<col style="width: 25%" />
<col style="width: 41%" />
</colgroup>
<tbody>
<tr class="odd">
<td colspan="2"><strong>Fixed Dose Combination regimens</strong></td>
<td><strong>Renal Dosing</strong></td>
<td><strong>Specific Considerations</strong></td>
</tr>
<tr class="even">
<td>Biktarvy®</td>
<td>Bictegravir/ Emtricitabine/ Tenofovir (Alafenamide)</td>
<td>Discontinue if CrCl &lt; 30; ok w/HD</td>
<td><p>↑ Metformin levels</p>
<p>Contraindicated with: rifampin, dofetilide, rifabutin</p>
<p>Avoid close admin. with: laxatives, sucralfate, polyvalent cations
(iron, calcium, etc.)</p></td>
</tr>
<tr class="odd">
<td>Dovato®</td>
<td><p>Doltegravir/</p>
<p>Lamivudine</p></td>
<td><p>CrCl 30-50: monitor for hematologic toxicities with
lamivudine</p>
<p>CrCl&lt;30: do not use combo pill; dose-adjust individual
components</p></td>
<td><p>↑ Metformin levels</p>
<p>Dose adjustment needed with rifampin use</p>
<p>Contraindicated w/dofetilide and multiple antiepileptic drugs</p>
<p>Avoid close admin. with polyvalent cations (iron, calcium, etc.)</p>
<p>Test all patients for HBV prior to initiation</p></td>
</tr>
<tr class="even">
<td>Symtuza®</td>
<td><p>Tenofavir alafenamide/</p>
<p>Emtricitabin/</p>
<p>Darunavir/</p>
<p>Cobistat</p></td>
<td>Discontinue if CrCl&lt;30; ok w/HD but dose after HD on dialysis
days</td>
<td><p>Contraindicated w/rifampin, rifabutin, simvastatin, multiple
antiepileptic drugs</p>
<p>Note that cobistat can increase serum creatinine without affecting
glomerular filtration so cautiously interpret serum creatinine
levels</p></td>
</tr>
<tr class="odd">
<td>Triumeq®</td>
<td>Abacavir/ Dolutegravir/ Lamivudine</td>
<td><p>CrCL 30-50: monitor for hematologic toxicities with
lamivudine</p>
<p>CrCl&lt; 30; do not use combo pill; dose-adjust individual
components</p></td>
<td><p>↑ Metformin levels</p>
<p>Dose adjustment needed with rifampin use</p>
<p>Contraindicated w/dofetilide and multiple antiepileptic drugs</p>
<p>Avoid close admin. with polyvalent cations (iron, calcium, etc.)</p>
<p>Test all patients for HBV prior to initiation</p></td>
</tr>
<tr class="even">
<td>Genvoya®</td>
<td><p>Elvitegravir/ Cobicistat/ Emtricitabin/</p>
<p>Tenofovir (Alafenamide)</p></td>
<td>Discontinue if CrCl &lt; 30; ok w/HD</td>
<td>Many drug-drug interactions due to CYP 3A4 inhibition with
cobicistat</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 20%" />
<col style="width: 26%" />
<col style="width: 17%" />
<col style="width: 16%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Nucleoside RTI</strong></td>
<td><strong>Dose adj</strong></td>
<td><strong>Specific Side Effects</strong></td>
<td><strong>Major DDI</strong></td>
<td><strong>Special Points</strong></td>
</tr>
<tr class="even">
<td>Abacavir (ABC)</td>
<td>Hepatic dysfunction</td>
<td><p>↑ LDL/TG</p>
<p>↑ risk MI</p></td>
<td>Tenofovir</td>
<td>Requires testing for HLA B5701</td>
</tr>
<tr class="odd">
<td><p>Emtricitabine</p>
<p>(FTC)</p></td>
<td>Renal</td>
<td>Rash, insomnia, rhabdomyolysis, hyperpigmentation in
palms/soles</td>
<td>Lamivudine</td>
<td>Active against HBV</td>
</tr>
<tr class="even">
<td><p>Lamivudine</p>
<p>(3TC)</p></td>
<td>Renal</td>
<td>Nausea, HA, peripheral neuropathy, neutropenia, rash</td>
<td>Emtricitabine</td>
<td>Active against HBV</td>
</tr>
<tr class="odd">
<td>Tenofovir Alafenamide (TAF)</td>
<td>Discontinue if CrCl &lt; 15</td>
<td>↑ lipids</td>
<td>AED’s may ↑ levels</td>
<td>Tx of choice for HBV</td>
</tr>
<tr class="even">
<td>Tenofovir Disoproxil (TDF)</td>
<td>Renal</td>
<td>N/V, ↑ LFTs, asymptomatic ↑CK, renal dysfunction, bone mineral
density loss</td>
<td><blockquote>
<p>--</p>
</blockquote></td>
<td>Active against HBV</td>
</tr>
</tbody>
</table>

<p>NRTI Additional Information</p>
<ul>
<li>
<p>Tenofovir alone is indicated for HBV, in which case you should be
    mindful of renal clearance when dosing. In HIV, it is only used in
    combination with emtricitabine and third agent. Contraindicated if
    CrCl\&lt;30</p>
</li>
<li>
<p>Class-wide side effect: Lactic acidosis, steatosis and lipoatrophy
    (though very rare with contemporary NRTIs)</p>
</li>
<li>
<p>Resistance: M184V confers high resistance to emtricitabine and
    lamivudine, mid-level resistance to abacavir, hypersusceptibility to
    tenofovir</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 14%" />
<col style="width: 20%" />
<col style="width: 16%" />
<col style="width: 29%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Integrase Inhibitor</strong></td>
<td><strong>Dose Adj.</strong></td>
<td><strong>Specific Side Effects</strong></td>
<td><strong>Major DDI</strong></td>
<td><strong>Special Points</strong></td>
</tr>
<tr class="even">
<td>Raltegravir (RAL)</td>
<td><blockquote>
<p>--</p>
</blockquote></td>
<td><blockquote>
<p>--</p>
</blockquote></td>
<td>Rifampin, AED’s</td>
<td><blockquote>
<p>--</p>
</blockquote></td>
</tr>
<tr class="odd">
<td>Dolutegravir (DTG)</td>
<td>*see special points*</td>
<td><p>Hyperglycemia</p>
<p>Weight gain</p></td>
<td><p>Rifampin, Efavirenz</p>
<p>↑Metformin</p></td>
<td><p>Avoid close admin with laxatives, sucralfate, iron, calcium</p>
<p>May ↑Cr, without effect on renal function</p></td>
</tr>
</tbody>
</table>

<table style="width:100%;">
<colgroup>
<col style="width: 15%" />
<col style="width: 13%" />
<col style="width: 24%" />
<col style="width: 23%" />
<col style="width: 22%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>NNRTIs</strong></td>
<td><strong>Hepatic Adj</strong></td>
<td><strong>Specific Side Effects</strong></td>
<td><strong>Major DDI</strong></td>
<td><strong>Special Points</strong></td>
</tr>
<tr class="even">
<td>Efavirenz</td>
<td>Stop if Child Pugh B/C</td>
<td><p>Psychosis, vivid dreams, SI, mania, seizures;</p>
<p>↑ Lipids &amp; glucose</p></td>
<td>Azoles, antifungals, clopidogrel, some statins, clarithromycin,
Buprenorphine</td>
<td>Give before meals; discontinue if rash develops</td>
</tr>
<tr class="odd">
<td>Etravirine (ETR)</td>
<td></td>
<td><p>Hypersensitivity</p>
<p>↑ Lipids &amp; glucose</p></td>
<td>Clopidogrel, clarithromycin</td>
<td></td>
</tr>
<tr class="even">
<td>Nevirapine (NVP)</td>
<td>Stop if Child Pugh B/C</td>
<td>Steven Johnson Syndrome</td>
<td>Azoles, OCP’s, statins, clarithromycin</td>
<td><p>Don’t start if CD4 &gt;250 in women, CD4 &gt;400 in men;</p>
<p>Don’t admin with antacids</p></td>
</tr>
<tr class="odd">
<td>Rilpivirine (RPV)</td>
<td></td>
<td>None</td>
<td>AED’s, PPI’s, dexamethasone</td>
<td><p>Must be taken with full meal; Don’t use if HIV RNA &gt;100k + CD4
&lt; 200;</p>
<p>Don’t admin with antacids</p></td>
</tr>
</tbody>
</table>

<p>NNRTI Additional Information</p>
<ul>
<li>
<p>Class-wide side effect: hepatitis, rashes</p>
</li>
<li>
<p>Resistance: K103N resistance to efavirenz and nevirapine</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 14%" />
<col style="width: 30%" />
<col style="width: 24%" />
<col style="width: 14%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Protease inhibitors</strong></td>
<td><strong>Hepatic Dose adj</strong></td>
<td><strong>Specific Side Effects</strong></td>
<td><strong>Major DDI</strong></td>
<td><strong>Special Points</strong></td>
</tr>
<tr class="even">
<td>Atazanavir (ATV)</td>
<td>Based on Childs Pugh</td>
<td>Jaundice, Kidney stones, AV block, Pancreatitis, Rhabdomyolysis</td>
<td><p>CYP3A4 Inhibitors</p>
<p>PPI and H2 blockers</p></td>
<td>Admin with meals</td>
</tr>
<tr class="odd">
<td>Darunavir (DRV)</td>
<td></td>
<td><p>Rashes</p>
<p>Pancreatitis</p></td>
<td><p>CYP3A4 Inhibitors</p>
<p>Azoles can be used cautiously with drug level monitoring</p></td>
<td>Must stop if rash</td>
</tr>
<tr class="even">
<td>Lopinavir (LPV)</td>
<td></td>
<td><p>AV block, QT changes</p>
<p>Pancreatitis</p>
<p>Hepatitis</p></td>
<td>CYP3A4 Inhibitors</td>
<td>Admin with meals</td>
</tr>
</tbody>
</table>

<p>Protease Inhibitor Additional Information</p>
<ul>
<li>All protease inhibitors must be boosted:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ritonavir: can cause MSK pain, rhabdomyolysis, although not expected
    at usual doses</p>
</li>
<li>
<p>Cobicistat: may increase Cr without effect on renal function</p>
</li>
</ul>
<!-- -->

<ul>
<li>Class-wide side effects: hepatitis, hypersensitivity reactions,
    increased cholesterol/TG, hyperglycemia, GI upset, lipodystrophy</li>
</ul>
<p>Antimicrobial Prophylaxis per CD4 Counts – Rachael Pellegrino</p>
<table>
<colgroup>
<col style="width: 14%" />
<col style="width: 19%" />
<col style="width: 21%" />
<col style="width: 22%" />
<col style="width: 21%" />
</colgroup>
<thead>
<tr class="header">
<th>CD4 counts</th>
<th>Opportunistic Infection</th>
<th>Indication for Prophylaxis</th>
<th>Medication</th>
<th>Special Notes</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>&lt;200 cells/mm3</td>
<td>Pneumocystis Pneumonia (PJP)</td>
<td>CD4 &lt; 200, or CD4 &lt; 14%, may consider discontinuation if CD4
100-200 in setting of viral suppression</td>
<td>TMP-SMX: 1 DS daily (qd), or TMP-SMX: 1SS qd TMP-SMX: 1 DS TIW</td>
<td>If intolerant of TMP-SMX: dapsone\*, or inhaled pentamidine, or
atovaquone</td>
</tr>
<tr class="even">
<td>&lt;200 cells/mm3</td>
<td>Toxoplasma gondii encephalitis</td>
<td>Toxoplasma IgG + and CD4 &lt; 100</td>
<td>TMP-SMX 1 DS tab daily</td>
<td><p>Alternative regimens: dapsone + pyramethamine + leucovorin, or
atovaquone (all regimens also</p>
<p>effective for PJP )</p></td>
</tr>
<tr class="odd">
<td>&lt;50 cells/mm3</td>
<td>Mycobacterium avium- intracellulare (MAC, MAI)</td>
<td>Only if not on fully suppressive ART and active disseminated MAC is
ruled out</td>
<td>Azithromycin 1200 mg weekly, or Clarithromycin 500 mg BID, or
Rifabutin 300 mg daily</td>
<td>NOT indicated for those initiating ART</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 23%" />
<col style="width: 32%" />
<col style="width: 43%" />
</colgroup>
<thead>
<tr class="header">
<th><blockquote>
<p>Infection</p>
</blockquote></th>
<th><blockquote>
<p>Screening Indication</p>
</blockquote></th>
<th><blockquote>
<p>Intervention</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Hepatitis A Virus (HAV)</td>
<td>Non-immune with ↑ risk for HAV infection (MSM, IVDU) or chronic
liver disease</td>
<td>HAV vaccine series</td>
</tr>
<tr class="even">
<td>Hepatitis B Virus (HBV)</td>
<td>Pts without chronic HBV or non-immune</td>
<td>HBV vaccine series</td>
</tr>
<tr class="odd">
<td>Human Papilloma virus (HPV)</td>
<td>Age 13-45</td>
<td>HPV vaccine series</td>
</tr>
<tr class="even">
<td>Influenza A and B Virus</td>
<td>All patients</td>
<td>Yearly inactivated influenza vaccine</td>
</tr>
<tr class="odd">
<td>Latent Mycobacterium tuberculosis infection (LTBI)</td>
<td><p>Pts with positive screening test for LTBI with no evidence of
active disease.</p>
<p>Pts with known exposure</p></td>
<td>(INH 300mg + pyridoxine 25-50mg) PO daily for 9 months</td>
</tr>
<tr class="even">
<td>Streptococcus pneumoniae</td>
<td>All patients</td>
<td><p>Patients without any previous pneumococcal vaccines: Give PCV15
or PCV20. If PCV15 is used, also give PPSV23 in 1 year.</p>
<p>Patients who have already received PPSV23: Give PCV15 or PCV20 one
year after most recent PPSV23 vaccine</p>
<p>Patients who have already received PCV13: Give PPSV23</p></td>
</tr>
<tr class="odd">
<td>Syphilis</td>
<td>All sexually active pts</td>
<td>Screening for syphilis and gonorrhea/chlamydia with treatment if
indicated.</td>
</tr>
<tr class="even">
<td>Herpes zoster (shingles)</td>
<td>Patients &gt; age 50</td>
<td>Shingrix (recombinant zoster) vaccine series</td>
</tr>
</tbody>
</table></section><h1 class='nav-section-title-end'>Ended: Infectious diseases</h1>
                        <h1 class='nav-section-title' id='section-nephrology'>
                            Nephrology <a class='headerlink' href='#section-nephrology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="nephrology-main"><p>Acute Kidney Injury (AKI) – Terra Swanson</p>
<p>Background:</p>
<ul>
<li>Definition based on 2012 KDIGO Guidelines: </li>
</ul>
<!-- -->

<ul>
<li>
<p>Rise in serum creatinine (sCr) > 0.3 mg/dL within 48 hours, or
    increase > 1.5 x baseline in 7 days  </p>
</li>
<li>
<p>Urine volume \&lt;0.5 cc/Kg/H for at least 6 H</p>
</li>
</ul>
<p>Framework for AKI </p>
<ul>
<li>Pre-renal/hemodynamic AKI:  </li>
</ul>
<!-- -->

<ul>
<li>
<p>Volume depletion: GI losses, hemorrhage, burns, critical illness
    increased insensible losses </p>
</li>
<li>
<p>Decreased effective circulating volume: cardiorenal, hepatorenal,
    hemodynamic effects of ACEi/ARB </p>
</li>
<li>
<p>Afferent arteriole constriction [NSAIDs, Iodinated contrast] </p>
</li>
<li>
<p>Renal vein thrombus </p>
</li>
</ul>
<!-- -->

<ul>
<li>Intra-renal: Glomerular, tubular, or interstitial diseases</li>
</ul>
<!-- -->

<ul>
<li>
<p>ATN = Most common form of intrinsic AKI. Can be Ischemic or toxic</p>
<ul>
<li>Toxins can be broken down further into endogenous (e.g. rhabdo)
    and exogenous (e.g. drugs)</li>
</ul>
</li>
<li>
<p>Acute Interstitial Nephritis (AIN): Usually drug induced (NSAIDs,
    PPIs, beta lactam abx)  </p>
</li>
<li>
<p>Glomerulonephritis</p>
</li>
<li>
<p>Other causes:  </p>
<ul>
<li>
<p>Crystalline nephropathy: IV acyclovir, tumor lysis, ethylene
    glycol </p>
</li>
<li>
<p>Small vessel disease: MAHA, TTP, HUS</p>
</li>
<li>
<p>Large vessel disease: Aortic dissection, renal artery stenosis  </p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Post-renal: Can occur at any level of the GU system </li>
</ul>
<!-- -->

<ul>
<li>
<p>Ureteral: stones, external compression (malignancy, LAD, abscess) </p>
</li>
<li>
<p>Bladder: neurogenic bladder, malignancy, obstructing blood clot </p>
</li>
<li>
<p>Urethra: BPH, prostate cancer, prostatitis  </p>
</li>
</ul>
<!-- -->

<ul>
<li>Pre-renal azotemia and acute tubular necrosis comprise the majority
    of inpatient acute kidney injuries</li>
</ul>
<p>Evaluation </p>
<ul>
<li>
<p>History and volume exam</p>
</li>
<li>
<p>Labs: CMP, urinalysis, protein/Cr ratio</p>
</li>
<li>
<p>500cc-1L IV fluid challenge: If sCr improves to baseline in \&lt;48H
    then the insult was likely pre-renal. If not, then look for other
    etiologies</p>
</li>
<li>
<p>Evaluate for obstruction: I/O cath, Foley, Post Void Residual >250
    cc</p>
</li>
<li>
<p>Who needs a renal ultrasound? </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>No obvious cause of AKI</p>
</li>
<li>
<p>Abrupt oliguria or anuria (think renal vein thrombus or obstruction)</p>
</li>
<li>
<p>High suspicion for bladder outlet obstruction (PVRs might give you
    same data) </p>
</li>
<li>
<p>Add doppler to evaluate for renal artery stenosis (or if working up
    resistant hypertension) </p>
</li>
</ul>
<!-- -->

<ul>
<li>Urine Electrolytes </li>
</ul>
<!-- -->

<ul>
<li>
<p>FENa \&lt;1% or FEUrea \&lt;33% (if on diuretics) suggest pre-renal
    physiology</p>
<ul>
<li>
<p>Caveat, only validated in <em>oliguric</em> patients and more difficult
    to interpret after fluids, diuretics, etc</p>
</li>
<li>
<p>Not needed in the initial work-up of all patients with AKI. If
    high suspicion for pre-renal etiology, trial fluid challenge and
    assess response first</p>
</li>
</ul>
</li>
<li>
<p>Urine sodium can be used to assess Na avidity: UNa > 40 suggests
    ATN and UNa \&lt; 20 suggests pre-renal</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>All causes</li>
</ul>
<!-- -->

<ul>
<li>
<p>Minimize fluctuations in blood pressure</p>
</li>
<li>
<p>Consider holding anti-hypertensive medications, especially ACEi/ARB
    (remember to determine plan to resume at/after discharge)</p>
</li>
<li>
<p>Avoid unnecessary nephrotoxins</p>
</li>
<li>
<p>Dose-adjust medications for changing renal function</p>
</li>
</ul>
<!-- -->

<ul>
<li>Pre-Renal</li>
</ul>
<!-- -->

<ul>
<li>
<p>True volume depletion- Intravenous volume expansion</p>
</li>
<li>
<p>Cardiorenal syndrome- Decongestion/diuresis</p>
</li>
<li>
<p>Hepatorenal syndrome- See Hepatology section for more information</p>
</li>
</ul>
<!-- -->

<ul>
<li>Post-renal</li>
</ul>
<!-- -->

<ul>
<li>
<p>Relieve Obstruction: I/O cath, foley, Urostomy (Urology),
    percutaneous nephrostomy (IR)</p>
</li>
<li>
<p>Monitor for post-obstructive diuresis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Intra-renal</li>
</ul>
<!-- -->

<ul>
<li>
<p>ATN- supportive care, monitor for post-ATN diuresis. If delayed
    recovery, may need outpatient dialysis</p>
</li>
<li>
<p>Glomerulonephritis- Consult AKI service for assistance with biopsy
    and selecting immunosuppressive agents if needed</p>
</li>
<li>
<p>AIN- Review meds, consult nephrology for possible biopsy and
    recommendations for steroids</p>
</li>
</ul>
<!-- -->

<ul>
<li>Monitor for renal recovery </li>
</ul>
<!-- -->

<ul>
<li>Suspect concomitant ATN if sCr declines with volume expansion,
    diuresis, or relief of obstruction but remains a few points above
    baseline</li>
</ul>
<!-- -->

<ul>
<li>When to consult Nephrology</li>
</ul>
<!-- -->

<ul>
<li>
<p>Urgent indication for dialysis (see “Renal Replacement Therapy”)</p>
</li>
<li>
<p>Abrupt anuria</p>
</li>
<li>
<p>Cr worsening or urine output inadequate w/o clear cause</p>
</li>
<li>
<p>Need for kidney biopsy  </p>
</li>
</ul>
<p>Additional Information </p>
<ul>
<li>Rhabdomyolysis: UA positive for blood but no RBCs on microscopy</li>
</ul>
<!-- -->

<ul>
<li>
<p>Toxic damage due to myoglobin</p>
</li>
<li>
<p>Serologic markers of muscle injury: elevated CK, AST>AST with
    normal ALK Phos </p>
</li>
<li>
<p>Fluids adjusted to urine output goal of 200-300 mL/hr until CK
    declines</p>
<ul>
<li>Consider isotonic bicarb for initial 1-2L of IVF urine
    alkalinization to reduce precipitation</li>
</ul>
</li>
<li>
<p>Avoid calcium repletion for hypocalcemia unless symptomatic </p>
</li>
</ul>
<!-- -->

<ul>
<li>Post-obstructive diuresis </li>
</ul>
<!-- -->

<ul>
<li>
<p>Necessary process to clear accumulated uremic toxins</p>
</li>
<li>
<p>Replace ~50% of urine output to prevent pre-renal azotemia</p>
</li>
<li>
<p>Monitor calcium, phosphorus, and magnesium in severe
    post-obstructive diuresis</p>
</li>
</ul>
<p>Contrast Induced AKI (CI-AKI) – Trey Richardson</p>
<p>Background</p>
<ul>
<li>
<p>When someone develops an AKI do your due diligence and evaluate for
    the usual causes of AKI, regardless of when they were given contrast</p>
</li>
<li>
<p>Mechanism of injury: direct toxic effect leading to tubular necrosis
    and arteriolar vasoconstriction leading to medullary ischemia</p>
</li>
</ul>
<p>KDIGO Criteria for CI-AKI:</p>
<ul>
<li>sCr increase by 0.5mg/dl or 25% increase in sCr from baseline 48 H
    after radiologic procedure where intravenous contrast was
    administered</li>
</ul>
<p>Who is at risk for CI-AKI?</p>
<ul>
<li>
<p>Normal kidney function: incidence of CI-AKI is 1-3%</p>
</li>
<li>
<p>Pre-existing CKD: Incidence of CI-AKI may be as high as 20% in
    patients with CKD 4-5</p>
</li>
<li>
<p>Other risk factors include: diabetes, heart failure, and advanced
    age</p>
</li>
<li>
<p>No real sCr or eGFR threshold below which iodinated contrast is
    contraindicated, especially in patients for whom imaging will alter
    management (e.g. acute stroke, PE, STEMI)</p>
</li>
</ul>
<p>Risk reduction strategies</p>
<ul>
<li>Volume expansion with isotonic crystalloid (PRESERVE Trial) in
    patients with AKI or eGFR \&lt;30 ml/min/1.73m^2 who are clinically
    hypo or euvolemic</li>
</ul>
<!-- -->

<ul>
<li>1cc/kg/hr for 6-12 hours before/during and 6-12 hours after the
    procedure in patients at high risk for CI-AKI. This rate can be
    decreased based on the risk for hypervolemia</li>
</ul>
<!-- -->

<ul>
<li>
<p>If the patient is volume overloaded, they probably should not
    receive volume expansion prior to a contrasted study</p>
</li>
<li>
<p>Never delay a necessary procedure out of concern for worsening renal
    function. If in doubt, talk to nephrology</p>
</li>
</ul>
<p>Iodinated contrast in CKD-5/ESRD patients</p>
<ul>
<li>
<p>Iodinated contrast does not need to be dialyzed immediately</p>
</li>
<li>
<p>Avoid giving if you are trying to preserve residual kidney function
    in ESRD on PD</p>
</li>
</ul>
<p>Gadolinium contrast for MRI</p>
<ul>
<li>Contraindicated in any AKI or if GFR \&lt;30 in CKD given risk of
    nephrogenic systemic fibrosis.</li>
</ul>
<p>Approach to Chronic Kidney Disease – Terra Swanson</p>
<p>Definition of CKD</p>
<ul>
<li>
<p>Decreased kidney function or one or more markers of kidney damage
    for 3 or more months</p>
</li>
<li>
<p>History of kidney transplant</p>
</li>
<li>
<p>GFR \&lt; 60; Staging helps risk-stratify pts likely to progress or
    develop complications of CKD</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>CKD IIIa: eGFR 45-60</p>
</li>
<li>
<p>CKD IIIb: eGFR 30-44</p>
</li>
<li>
<p>CKD IV: eGFR 15-30</p>
</li>
<li>
<p>CKD V: eGFR \&lt; 15</p>
</li>
</ul>
<!-- -->

<ul>
<li>Markers of kidney damage</li>
</ul>
<!-- -->

<ul>
<li>
<p>Albumin/Cr ratio</p>
<ul>
<li>
<p>Mild: 0-30 mg/g</p>
</li>
<li>
<p>Moderate: 30-300 mg/g</p>
</li>
<li>
<p>Severe: >300 mg/g</p>
</li>
</ul>
</li>
<li>
<p>Urine sediment: RBC casts, WBC casts, oval fat bodies or fatty
    casts, granular casts</p>
</li>
<li>
<p>Electrolyte derangements</p>
</li>
<li>
<p>Abnormalities on histology</p>
</li>
<li>
<p>Structural abnormalities: (cysts, hydronephrosis, scarring, masses,
    renal artery stenosis)</p>
</li>
</ul>
<p>When to refer to nephrology clinic</p>
<ul>
<li>
<p>eGFR \&lt; 45</p>
</li>
<li>
<p>Persistent urine albumin/creatinine ratio > 300 mg/g</p>
</li>
<li>
<p>Urine protein/creatinine ratio greater than 500 mg/g</p>
</li>
<li>
<p>Rapid loss of kidney function (> 30% decline over 4 months)</p>
</li>
<li>
<p>Hematuria not 2/2 urologic condition or if there are RBC casts on UA</p>
</li>
<li>
<p>Inability to identify presumed cause of renal dysfunction</p>
</li>
<li>
<p>Difficult to manage complications (hyperkalemia, anemia,
    bone-mineral disease, HTN)</p>
</li>
<li>
<p>Confirmed or presumed hereditary kidney disease (PCKD suspected)</p>
</li>
</ul>
<p>Complications of CKD</p>
<p>Imbalance of water homeostasis</p>
<ul>
<li>
<p>As renal mass declines the ability to both concentrate and dilute
    the urine is impaired</p>
</li>
<li>
<p>This manifests as hyponatremia (no end-organ to respond to ADH) and
    edema</p>
</li>
<li>
<p>Treat this with water restriction, diuretics or, eventually,
    ultrafiltration</p>
</li>
</ul>
<p>Metabolic acidosis</p>
<ul>
<li>
<p>Correcting serum bicarbonate to a goal of 23-30 meq/L slows decline
    in renal function and protects against bone-mineral complications of
    chronic metabolic acidosis</p>
</li>
<li>
<p>Can calculate bicarbonate deficit to estimate dose of bicarbonate</p>
</li>
<li>
<p>If bicarb \&lt; 22, consider:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Sodium bicarb 650 mg TID (8mEq bicarb per 650mg tablet) up to
    5850mg/day (70 mEq or 3 tabs TID)</p>
</li>
<li>
<p>Sodium citrate (Bicitra): 1mL = 1 mEq * Careful in cirrhosis since
    citrate cannot be metabolized</p>
</li>
<li>
<p>Baking soda (sodium bicarbonate): 1 teaspoon = 59 mEq HCO3 (careful
    of Na load)</p>
</li>
</ul>
<p>HTN in CKD</p>
<ul>
<li>
<p>Goal BP \&lt; 120/80 (Class 2B recommendation) based on SPRINT trial,
    ACC/AHA 2017, and KDIGO 2021 guidelines</p>
</li>
<li>
<p>All comers: Diet (e.g. DASH) and lifestyle modifications</p>
</li>
<li>
<p>CKD without albuminuria or DM:</p>
</li>
</ul>
<!-- -->

<ul>
<li>Start pharmacotherapy based on ASCVD risk as well as risk for other
    target organ damage</li>
</ul>
<!-- -->

<ul>
<li>CKD with moderate to severe albuminuria w/ or w/out DM</li>
</ul>
<!-- -->

<ul>
<li>
<p>ACEi or ARB titrated to maximally tolerated dose (Class 1B
    recommendation)</p>
</li>
<li>
<p>Thiazide-like diuretics (see CLICK trial for chlorthalidone in
    advanced CKD)</p>
</li>
<li>
<p>Loop diuretics can assist with volume driven HTN in patients with
    CKD 4-5</p>
</li>
</ul>
<!-- -->

<ul>
<li>HTN in kidney transplant</li>
</ul>
<!-- -->

<ul>
<li>CCBs or ARBs are first line (Class 1C recommendation)</li>
</ul>
<!-- -->

<ul>
<li>Consider stopping ACE-i/ARB if:</li>
</ul>
<!-- -->

<ul>
<li>
<p>GFR declines >30% over 4 months. Consider evaluation for renal
    artery stenosis</p>
</li>
<li>
<p>K > 5.5 despite low K diet, optimizing dose of diuretics, or adding
    K-binders</p>
</li>
</ul>
<p>Anemia in CKD</p>
<ul>
<li>
<p>Multifactorial: decreased EPO production, impaired iron absorption,
    uremic toxins suppressing bone marrow, loss of blood in dialysis
    circuit, and from GI AVMs</p>
</li>
<li>
<p>Indications for iron supplementation in non-dialysis patients:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>ALL patients with TSAT \&lt;20% and ferritin \&lt;100 ng/mL</p>
</li>
<li>
<p>Patients with Hb \&lt;13 and TSAT \&lt;30% and ferritin \&lt;500 ng/mL</p>
<ul>
<li>Can start with PO supplementation (see Anemia section). Reassess
    iron levels in 1-3 mos; if not appropriately ↑, consider IV iron
    repletion</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Dialysis patients:</li>
</ul>
<!-- -->

<ul>
<li>
<p>IV Iron preferred method of repletion for HD patients with</p>
<ul>
<li>
<p>TSAT \&lt; 20% and ferritin \&lt; 200</p>
</li>
<li>
<p>TSAT \&lt;30% and ferritin \&lt;500 AND with Hb \&lt; 10 OR are on EPO</p>
</li>
</ul>
</li>
<li>
<p>Dosing: usually administered at HD sessions</p>
<ul>
<li>
<p>125 mg ferric gluconate at consecutive HD sessions x 8 doses</p>
</li>
<li>
<p>100 mg iron sucrose at consecutive HD sessions x 10 doses</p>
</li>
<li>
<p>Ferumoxytol 510mg at the end of two HD sessions 1-4 weeks apart</p>
</li>
</ul>
</li>
<li>
<p>Indications for EPO</p>
<ul>
<li>Pts w/ Hb \&lt;10 who are not iron deficient (ferritin >500) or
    who’s anemia persists despite adequate iron repletion</li>
</ul>
</li>
</ul>
<p>Hyperkalemia (Goal K \&lt; 5.5)</p>
<ul>
<li>
<p>Patients with diabetic nephropathy (T4 RTA) and CKD 5-ESRD are at
    the highest risk</p>
</li>
<li>
<p>Strategies to mitigate hyperK</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Low K diet (\&lt; 40-70 mEq/day or 1500-2700 mg/day)</p>
</li>
<li>
<p>Loop diuretics</p>
</li>
<li>
<p>GI cation exchangers</p>
<ul>
<li>
<p>Patiromer (Veltassa): binds K in colon in exchange for calcium</p>
</li>
<li>
<p>Sodium zirconium cyclosilicate (Lokelma): binds K throughout
    intestine in exchange for sodium and H+</p>
</li>
<li>
<p>Do not use Kayexelate as chronic therapy</p>
</li>
</ul>
</li>
<li>
<p>Treat metabolic acidosis</p>
</li>
</ul>
<p>Mineral bone disease in ESRD</p>
<ul>
<li>
<p>Avoid calcium supplementation in mild or asymptomatic hypocalcemia</p>
</li>
<li>
<p>Replace vitamin D to >20 (weak evidence)</p>
</li>
<li>
<p>Phos goal \&lt; 5.5</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Sevelamer: use lowest dose effective to achieve Phos \&lt; 5.5</p>
<ul>
<li>
<p>Phos 5.5-7.5: initial dose 800 TID with meals</p>
</li>
<li>
<p>Phos 7.5-9.0: initial dose 1200-1600 TID with meals</p>
</li>
<li>
<p>Phos > 9: initial dose 1600 TID</p>
</li>
<li>
<p>Can titrate dosing by 400 to 800 mg per meal at 2-week intervals</p>
</li>
</ul>
</li>
<li>
<p>Restrict dietary phos to 900 mg/day</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>PTH goal in CKD3: 2x ULN</p>
</li>
<li>
<p>PTH Goal in ESRD: 2-10x ULN</p>
</li>
</ul>
<p>Diabetes in CKD</p>
<ul>
<li>
<p>Individualize A1C goals. Both the ADA and VA-DOD have guidelines for
    selecting A1C targets</p>
</li>
<li>
<p>Treatment:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Metformin remains first-line but should be dose-reduced based on
    eGFR</p>
<ul>
<li>
<p>eGFR > 45: Maximum daily dose of 2000mg/day (1000mg bid)</p>
</li>
<li>
<p>eGFR \&lt; 45: Reduce max daily dose to 1000mg/day (500mg bid)</p>
</li>
<li>
<p>eGFR \&lt; 30: Discontinue if high risk for volume mediated
    AKI/chronically ill</p>
</li>
</ul>
</li>
<li>
<p>SGLT-2 inhibitors for patients with eGFR > 30 reduces progression
    to ESRD and death from renal or cardiovascular causes (Evidence:
    DAPA-CKD, CREEDENCE)</p>
</li>
<li>
<p>Finerenone (non-steroidal MRA)- would ask nephrology for help if
    considering this option since relatively new and increased risk for
    hyperkalemia. (Evidence: FIDELIO)</p>
</li>
</ul>
<p>Dialysis initiation</p>
<ul>
<li>
<p>Early (CKD3a or 3b) referral to nephrology has better outcomes</p>
</li>
<li>
<p>Uremic symptoms: fatigue, sleep disturbance, N/V, decreased
    appetite, dysgeusia, itching, hiccupping</p>
</li>
<li>
<p>Refractory hyper K</p>
</li>
<li>
<p>Refractory hypertension</p>
</li>
<li>
<p>Plot your patient’s eGFR using the graph function in EPIC or CPRS to
    determine trajectory (normal age-related decline after age 60 is ~
    1ml/min/m2)</p>
</li>
</ul>
<p>Renal Replacement Therapy (RRT) Basics – Daniel Motta</p>
<p>Background/Terminology</p>
<ul>
<li>
<p><strong>Dialysis</strong> (diffusive clearance)- solutes diffuse down
    concentration gradients through a semipermeable membrane separating
    blood and dialysate</p>
</li>
<li>
<p><strong>Dialysate</strong> (dialysis bath)- electrolyte solution used to create
    concentration gradient for dialysis. Customizable to treat specific
    electrolyte and acid-base derangements</p>
</li>
<li>
<p><strong>Effluent</strong>- Fluid removed during dialysis or ultrafiltration</p>
</li>
<li>
<p><strong>Ultrafiltration-</strong> Hydrostatic pressure “pushing” water through a
    membrane. There is no dialysate solution used during
    ultrafiltration. Solutes are removed through the process of solvent
    drag. The effluent in this case is isotonic to plasma</p>
</li>
<li>
<p><strong>Total ultrafiltration (UF)</strong> - overall ultrafiltration volume
    produced during treatment</p>
</li>
<li>
<p><strong>UF net</strong> - net ultrafiltrate volume removed from the patient by
    the machine. The overall volume can be completely replaced (net
    even), partially replaced, or not replaced at all. UF net is the
    difference between UF and the volume replaced in the circuit</p>
</li>
<li>
<p><strong>Timing of dialysis</strong>- There are several studies in this space
    (IDEAL, IDEAL-ICU, AKIKI, STARRT, ELAINE). In both the outpatient
    and the inpatient setting, there is no compelling evidence that
    early start dialysis improves mortality compared to later starts</p>
</li>
</ul>
<p>Outpatient Modalities</p>
<ul>
<li>
<p>Intermittent hemodialysis (iHD)</p>
</li>
<li>
<p>In home hemodialysis</p>
</li>
<li>
<p>Peritoneal dialysis</p>
</li>
</ul>
<p>If someone with ESRD is admitted:</p>
<ul>
<li>
<p>Urgent ESRD consult if acute need, otherwise can consult them
    routinely</p>
</li>
<li>
<p>Routine orders include MWF phos checks and a renal diet</p>
</li>
<li>
<p>For peritoneal dialysis pts, their diet can be more liberal and
    include low phos only or even regular diet (Can just ask what diet
    he/she follows at home)</p>
</li>
</ul>
<p>Acute Setting</p>
<ul>
<li>Indications: AKI leading to life-threatening changes in fluid,
    electrolyte, and acid-base balance or toxic ingestion [AEIOU]</li>
</ul>
<!-- -->

<ul>
<li>
<p>Acidosis: Severe metabolic acidosis (serum pH\&lt;7.1) refractory to
    correcting volume status or other electrolyte derangements</p>
</li>
<li>
<p>Electrolytes: Severe hyperkalemia >6.5 despite medical management
    (e.g. loop diuretics, IV fluids, GI cation exchangers, correcting
    acidemia, etc.)</p>
</li>
<li>
<p>Intoxication: Dialyzable toxins and medications</p>
<ul>
<li>
<p>Alcohols: ethylene glycol, methanol, isopropyl alcohol,
    diethylene glycol, and propylene glycol</p>
</li>
<li>
<p>Medications: lithium, salicylates, valproic acid, phenytoin,
    barbiturates, carbamazepine, vancomycin, aminoglycosides, etc.</p>
</li>
</ul>
</li>
<li>
<p>Overload: Severe fluid overload (e.g., pulmonary edema) refractory
    to diuretics</p>
</li>
<li>
<p>Uremia: Uremic complications: encephalopathy, pericarditis, platelet
    dysfunction</p>
</li>
</ul>
<!-- -->

<ul>
<li>Can perform furosemide stress test to help predict who is likely to
    recover their kidney function</li>
</ul>
<!-- -->

<ul>
<li>
<p>If Lasix naïve, administer 1mg/kg as a bolus. If on a loop diuretic,
    administer 1.5 mg/kg as a bolus</p>
</li>
<li>
<p>If within the hour they have made 200 cc of urine, then they are
    likely to regain kidney function</p>
</li>
</ul>
<!-- -->

<ul>
<li>Modalities</li>
</ul>
<!-- -->

<ul>
<li>
<p>iHD: Ideal for removal of toxins (e.g. alcohols, dialyzable meds).
    Use with caution in hypotensive patients</p>
</li>
<li>
<p>CRRT: Set a rate of volume removal (typically 0-200 cc/hr) less
    rapid fluid/electrolytes shifts better tolerated in patients with
    hemodynamic instability</p>
<ul>
<li>
<p>Anti-coagulation options- to prevent clotting of circuit</p>
<ul>
<li>
<p>None</p>
</li>
<li>
<p>Heparin (preferred). Can be either within the circuit or
    systemic if indicated for another reason (e.g. DVT/PE).</p>
</li>
<li>
<p>Citrate (need to monitor calcium frequently)</p>
</li>
</ul>
</li>
<li>
<p>Complications of CRRT: Infections, hypophosphatemia</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Access</li>
</ul>
<!-- -->

<ul>
<li>
<p>Dialysis catheter (aka: Vascath)</p>
<ul>
<li>
<p>Non-tunneled catheter (Trialysis) used for acute dialysis</p>
</li>
<li>
<p>Different lengths depending on site (see procedures section)</p>
</li>
</ul>
</li>
<li>
<p>Tunneled dialysis catheter (ex: Permcath)</p>
<ul>
<li>
<p>Typically used as a bridge to fistula/graft placement</p>
</li>
<li>
<p>Placed by IR</p>
</li>
</ul>
</li>
</ul>
<p>Peritoneal Dialysis Peritonitis</p>
<p>Background</p>
<ul>
<li>
<p>Typically occurs due to contamination with pathogenic skin bacteria
    during exchanges or due to exit-site/tunnel infection</p>
</li>
<li>
<p>Usually presents with cloudy effluent fluid and abdominal pain. Can
    also be asymptomatic</p>
</li>
<li>
<p>Important history to obtain: recent contamination, accidental
    disconnection, endoscopic or gynecologic procedure, as well as the
    presence of constipation or diarrhea</p>
</li>
<li>
<p>Definitive diagnosis requires 2 of the following:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Clinical features consistent with peritonitis</p>
</li>
<li>
<p>Positive dialysis effluent culture</p>
</li>
<li>
<p>Dialysis effluent with WBC > 100 with PMN > 50%</p>
<ul>
<li>Even if WBC count \&lt; 100, presence of > 50% PMNs is still
    strong evidence of peritonitis in pts with rapid cycle PD</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Examine catheter exit site</p>
</li>
<li>
<p>Culture peritoneal fluid (requires specific technique, done by
    nephrology)</p>
</li>
<li>
<p>Peritoneal cell count with diff, gram stain and culture</p>
</li>
<li>
<p>Obtain peripheral blood cultures if there is concern for sepsis</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>All PD orders, intraperitoneal antibiotics, and prescription
    adjustments should be directed by ESRD consult service (page them
    overnight if concerns)</p>
</li>
<li>
<p>Treatment with intraperitoneal antibiotics should be started
    immediately after specimens have been obtained if there is high
    clinical suspicion</p>
</li>
<li>
<p>Empiric antibiotics regimen should cover both gram-positive and
    gram-negative organisms, typically with vancomycin and third
    generation Cephalosporin</p>
</li>
<li>
<p>Systemic antibiotics are generally not necessary unless pts have
    systemic signs of sepsis</p>
</li>
<li>
<p>Pts with relapsing, recurrent or repeat peritonitis will likely need
    catheter removal</p>
</li>
</ul>
<p>Secondary prevention</p>
<ul>
<li>Treatment with intraperitoneal OR IV antibiotics (for any infection
    requiring > 1 dose of antibiotics) requires prophylaxis for fungal
    peritonitis with either:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nystatin 400,000 to 500,000 units orally TID</p>
</li>
<li>
<p>Fluconazole 200 mg every other day or 100 mg qdaily</p>
</li>
</ul>
<!-- -->

<ul>
<li>Dialysate should be drained the day of endoscopies or gynecological
    procedures</li>
</ul>
<p>Intravenous Fluids – Chandler Montgomery</p>
<p>Indications for intravenous fluid</p>
<ul>
<li>
<p>Restoration or maintenance of tissue perfusion</p>
</li>
<li>
<p>Correction of electrolyte abnormalities</p>
</li>
<li>
<p>Nutritional supplementation in those without reliable enteric access</p>
</li>
</ul>
<p>Categorized into crystalloids and colloids</p>
<ul>
<li>
<p>Crystalloid = water + electrolytes</p>
</li>
<li>
<p>Colloid = water + proteins/large molecules</p>
</li>
</ul>
<p>Terms</p>
<ul>
<li>
<p>Osmolarity: osmoles of solute per L of solution</p>
</li>
<li>
<p>Tonicity: ability to induce movement of water across a membrane</p>
</li>
<li>
<p>Buffer: anions such as lactate, acetate, gluconate which are
    metabolized to bicarbonate in vivo with the goal of sustaining
    normal plasma pH</p>
</li>
</ul>
<p>Crystalloids</p>
<ul>
<li>Isotonic fluids used for volume resuscitation</li>
</ul>
<!-- -->

<ul>
<li>After ~ 30 mins, redistribute such that only 25% remains w/in
    intravascular space</li>
</ul>
<!-- -->

<ul>
<li>Balanced solutions (ex: Lactated Ringer’s, Plasma-Lyte)= have
    electrolytes concentrations similar to plasma</li>
</ul>
<!-- -->

<ul>
<li>
<p>NS may lead to renal vasoconstriction, AKI, hemodynamic instability,
    increased mortality</p>
<ul>
<li>SMART and SALT-ED: balanced solutions had lower rates of death,
    new renal replacement therapy, or persistent renal dysfunction
    compared to NS</li>
</ul>
</li>
<li>
<p>Situations where NS may be preferred:</p>
<ul>
<li>
<p>Cerebral edema/traumatic brain injury</p>
</li>
<li>
<p>Hypovolemic hyponatremia</p>
</li>
<li>
<p>Pre-existing hypochloremic metabolic alkalosis (e.g. after
    vomiting or over diuresis)</p>
</li>
</ul>
</li>
<li>
<p>Notes on LR</p>
<ul>
<li>
<p>The small amount of K in LR (~4 mEq/L) is unlikely to
    significantly exacerbate hyperkalemia</p>
</li>
<li>
<p>Lactate in LR is sodium lactate. No hydrogen ions are being
    added to plasma</p>
</li>
</ul>
</li>
</ul>
<p><strong>Common crystalloid solutions:</strong></p>
<table style="width:100%;">
<colgroup>
<col style="width: 11%" />
<col style="width: 8%" />
<col style="width: 8%" />
<col style="width: 6%" />
<col style="width: 8%" />
<col style="width: 6%" />
<col style="width: 10%" />
<col style="width: 11%" />
<col style="width: 12%" />
<col style="width: 14%" />
</colgroup>
<thead>
<tr class="header">
<th>Fluid</th>
<th>Na</th>
<th>Cl</th>
<th>K</th>
<th>Ca</th>
<th>Mg</th>
<th>Glucose</th>
<th>Buffer</th>
<th>Osmolarity</th>
<th>Tonicity</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Plasma</td>
<td>~140</td>
<td>~100</td>
<td>~4</td>
<td>~2.4</td>
<td>1.0</td>
<td>~0.85</td>
<td>Bicarb ~24</td>
<td>~290</td>
<td>NA</td>
</tr>
<tr class="even">
<td>Normal 0.9% saline</td>
<td>154</td>
<td>154</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>308</td>
<td>Isotonic</td>
</tr>
<tr class="odd">
<td>Lactated Ringer’s</td>
<td>130</td>
<td>109</td>
<td>4.0</td>
<td>2.7</td>
<td>0</td>
<td>0</td>
<td>Lactate 28</td>
<td>273</td>
<td>Isotonic</td>
</tr>
<tr class="even">
<td><p>Plasma-Lyte/</p>
<p>Normosol</p></td>
<td>140</td>
<td>98</td>
<td>5.0</td>
<td>0</td>
<td>3.0</td>
<td>0</td>
<td><p>Gluconate 23</p>
<p>Acetate 27</p></td>
<td>295</td>
<td>Isotonic</td>
</tr>
<tr class="odd">
<td>D5W + 150 mEq HCO3-</td>
<td>150</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>50</td>
<td>Bicarb 150</td>
<td>300</td>
<td>Isotonic</td>
</tr>
<tr class="even">
<td>3% Saline</td>
<td>513</td>
<td>513</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1026</td>
<td>Hypertonic</td>
</tr>
<tr class="odd">
<td>D5W</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>50</td>
<td>0</td>
<td>252</td>
<td>Hypotonic</td>
</tr>
</tbody>
</table>

<p>Colloids</p>
<ul>
<li>Albumin: extracted from human plasma</li>
</ul>
<!-- -->

<ul>
<li>
<p>5% - Used after plasma exchange</p>
</li>
<li>
<p>25% - raises oncotic pressure and restore intravascular volume</p>
<ul>
<li>
<p>Uses: Post-LVP, diagnosis and treatment of hepatorenal syndrome,
    SBP (see Hepatology)</p>
</li>
<li>
<p>Evidence base for use outside of above indications is poor (SAFE
    trial)</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Blood Products: Packed RBCs, FFP, cryoprecipitate, etc</li>
</ul>
<p>Acid-Base – Ned Hardison and Trey Richardson</p>
<p>Background</p>
<ul>
<li>
<p>Abnormal serum H+ concentrations lead to impaired cellular function
    (cardiac arrest, vasodilation, decreased response to
    catecholamines), electrolyte abnormalities (e.g. hypo- and
    hyperkalemia, hypo- and hypercalcemia), impaired glucose metabolism,
    impaired drug metabolism, and a whole host of other complications
    that translate to increased morbidity and mortality</p>
</li>
<li>
<p>ABG/VBG reference ranges:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>pH = 7.36-7.44 (~7.32-7.40)</p>
</li>
<li>
<p>PCO2 = 36-44 mmHg</p>
</li>
<li>
<p>pO2: 60-100 mmHg</p>
</li>
<li>
<p>HCO3 = 22-26 mEq/L</p>
</li>
</ul>
<!-- -->

<ul>
<li>Useful formulas</li>
</ul>
<!-- -->

<ul>
<li>
<p>pH on ABG = VBG pH + 0.035</p>
</li>
<li>
<p>Anion Gap= Na-(Cl+Bicarb)</p>
</li>
<li>
<p>Normal Anion Gap= 12-14</p>
</li>
<li>
<p>Calculated Osmolarity= 2[Na]+ ([Glucose]/18) + ([BUN]/2.8)</p>
</li>
<li>
<p>Osmolar gap= Measured osmolarity – Calculated osmolarity</p>
</li>
<li>
<p>Winter’s formula for respiratory compensation for AGMA: expected
    pCO2 = 1.5 (serum bicarb) +8 &plusmn; 2</p>
<ul>
<li>Shortcut: Expected
    <em>p**C**O</em><sub>2</sub> ≈ <em>l**a**s**t</em> <em>t**w**o</em> <em>d**i**g**i**t**s</em> <em>o**f</em> <em>p**H</em></li>
</ul>
</li>
</ul>
<p>General Approach to Acid-Base Derangements</p>
<ul>
<li>
<p>Step 1: Determine if the patient is acidemic or alkalemic (look at
    the pH)</p>
</li>
<li>
<p>Step 2: Determine the primary disorder (metabolic or respiratory)</p>
</li>
<li>
<p>Step 3: Calculate anion gap (see section below)</p>
</li>
<li>
<p>Step 4: Is there appropriate compensation?</p>
</li>
<li>
<p>Step 5: Evaluate for secondary disorders</p>
</li>
</ul>
<p>Anion Gap Metabolic Acidosis</p>
<p>Background</p>
<ul>
<li>Na+ is the predominant cation in normal plasma. Cl- and HCO3- are
    the predominant anions. There are anions that are not directly
    measured (e.g. most binding globulins, immunoglobulins, clotting
    factors, and other proteins). These unmeasured anions are
    responsible for the normal anion gap of ~12 meq/L. When there are
    extra unmeasured anions within the plasma, the anion gap increases</li>
</ul>
<p>Differential</p>
<ul>
<li>
<p>GOLDMARK: Glycols, oxyproline (acetaminophen metabolite), L-lactate,
    D-lactate, methanol, ASA, renal failure/uremia, ketoacids</p>
<p>Evaluate for secondary disorders</p>
</li>
<li>
<p>Corrected bicarbonate</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Corrected <em>H**C**O</em><sub>3</sub> = patient’s <em>H**C**O</em><sub>3</sub> +
    (patient’s anion gap - 12)</p>
<ul>
<li>
<p>Corrected <em>H**C**O</em><sub>3</sub> > 26, coexisting metabolic
    alkalosis,</p>
</li>
<li>
<p>Corrected HCO3 \&lt;22 coexisting non-AG metabolic acidosis</p>
</li>
</ul>
</li>
</ul>
<p>Osmolar Gap</p>
<ul>
<li>If there is an anion gap, it is worthwhile to always calculate an
    osmolar gap. You will be surprised the number of toxic ingestions
    you catch this way</li>
</ul>
<p>Non-anion gap metabolic acidosis (NAGMA)</p>
<ul>
<li>There are two places from which people can waste bicarbonate- the
    kidneys and the gut</li>
</ul>
<!-- -->

<ul>
<li>
<p>The urine anion-gap, which corresponds to unmeasured urinary NH4+
    (primary means of renal acid excretion), can differentiate between
    the two</p>
</li>
<li>
<p>Urine anion gap = Unmeasured cations (NH4+) – unmeasured anions =
    U­Na + UK – UCl</p>
<ul>
<li>
<p>Positive value-> low NH4+-> renal losses</p>
<ul>
<li>
<p>RTA</p>
</li>
<li>
<p>Carbonic anhydrase inhibition: acetazolamide, topiramate</p>
</li>
<li>
<p>Adrenal insufficiency</p>
</li>
<li>
<p>Normal saline infusion</p>
</li>
</ul>
</li>
<li>
<p>Ne-<strong><em>GUT</em></strong>-ive value->high NH4+->kidneys working
    appropriately-> GI losses</p>
<ul>
<li>
<p>Diarrhea</p>
</li>
<li>
<p>Pancreatic fistula</p>
</li>
<li>
<p>Ureterosigmoidostomy</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Caveat: Proximal RTA has a normal distal urine acidification and has
    a negative urine AG</li>
</ul>
<p>Managing Metabolic Acidosis</p>
<ul>
<li>
<p>Lactic acidosis is the most common cause of anion gap metabolic
    acidosis that we encounter</p>
</li>
<li>
<p>In general, avoid use of bicarbonate to treat lactic acidosis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Remember: H<sup>+</sup> + HCO3<sup>-</sup> \&lt;-> H2CO3 \&lt;-> H2O +
    CO2. While administering bicarbonate will transiently improve pH,
    carbonic acid will eventually form and ultimately worsen acidemia</li>
</ul>
<!-- -->

<ul>
<li>In acute NAGMA, reasonable to give bicarbonate when bicarb \&lt;12 or
    pH \&lt;7.1-7.2</li>
</ul>
<!-- -->

<ul>
<li>Pay close attention to other electrolyte levels, especially
    potassium as it shifts back into cells</li>
</ul>
<p>Metabolic Alkalosis</p>
<p>Background</p>
<ul>
<li>
<p>Metabolic alkalosis occurs as a primary disorder or as compensation
    for respiratory acidosis. A thorough history and exam can usually
    clarify which of these two scenarios is occurring</p>
</li>
<li>
<p>In order for metabolic alkalosis to occur, there has to be both an
    inciting phase (e.g. volume depletion) and a maintenance phase (e.g.
    hypochloremia or hypokalemia)</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Most symptoms of metabolic alkalosis (confusion, nausea, vomiting,
    tremors) occur as a result of other electrolyte abnormalities
    (hypocalcemia, hypokalemia)</p>
</li>
<li>
<p>Serum pH of >7.55 is likely the threshold where symptoms will
    develop</p>
</li>
</ul>
<p>Causes</p>
<ul>
<li>Saline responsive (e.g. hypochloremia)</li>
</ul>
<!-- -->

<ul>
<li>
<p>True volume depletion</p>
</li>
<li>
<p>NG suction/Nausea/vomiting</p>
</li>
<li>
<p>Diuretic use</p>
</li>
</ul>
<!-- -->

<ul>
<li>Saline refractory</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hypokalemia</p>
</li>
<li>
<p>Milk-Alkali syndrome</p>
</li>
<li>
<p>Mineralocorticoid excess states</p>
</li>
<li>
<p>Bartters Syndrome</p>
</li>
<li>
<p>Gitelman’s Syndrome</p>
</li>
</ul>
<p>Treatment</p>
<ul>
<li>Saline Responsive/Hypochloremia</li>
</ul>
<!-- -->

<ul>
<li>
<p>If volume deplete, then normal saline is treatment of choice</p>
</li>
<li>
<p>If alkalosis develops in setting of diuresis, then make sure
    replacing KCl and consider acetazolamide</p>
</li>
</ul>
<!-- -->

<ul>
<li>Saline refractory</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hypokalemia- replenish potassium stores</p>
</li>
<li>
<p>Hyperaldosteronism- covered in more detail in the endocrinology
    section</p>
</li>
<li>
<p>Bartter syndrome and Gitelman syndrome - replace electrolytes and
    refer to nephrology</p>
</li>
</ul>
<p>Electrolytes</p>
<p>Hypercalcemia – Rebecca Choudhry and Trevor Stevens</p>
<p>Background</p>
<ul>
<li>
<p>Total serum Calcium >10.5</p>
</li>
<li>
<p>Most (99%) Ca+2 is anhydrous and stored in bone. The remaining 1% is
    60% bound (mostly to albumin), and 40% ionized and able to exert a
    physiologic effect</p>
</li>
<li>
<p>Remember, there is an inverse relationship between pH and Ca2+. As
    pH declines, serum Ca increases due to H+ binding to albumin and
    releasing Ca2+</p>
</li>
<li>
<p>Don’t forget to correct calcium level if hypoalbuminemia (or check
    ionized calcium level),</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Corrected Ca2+ = ((Normal albumin – Patient’s albumin) x 0.8)) +
    Patient’s Ca2+</p>
<ul>
<li>This equation Is less reliable at very low albumin</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Ca+2 > 12 can cause shortened QT interval, 2<sup>nd</sup> and 3<sup>rd</sup> degree heart
    block, ventricular arrhythmias, and ST elevations mimicking MI</p>
</li>
<li>
<p>Severe manifestations uncommon at Ca+2 \&lt;14</p>
</li>
<li>
<p>“Stones, bones, thrones, belly groans, and psychiatric overtones”</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Bone pain</p>
</li>
<li>
<p>Polydipsia/polyuria- due to nephrogenic DI</p>
</li>
<li>
<p>Nausea/constipation</p>
</li>
<li>
<p>Depressed mood/cognitive impairment</p>
</li>
<li>
<p>Decreased level of consciousness</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Measure PTH</li>
</ul>
<!-- -->

<ul>
<li>
<p>Normal or ↑ PTH</p>
<ul>
<li>
<p>Primary hyperparathyroidism: ↑ Ca+2 and ↓ PO4-3</p>
</li>
<li>
<p>Tertiary hyperparathyroidism (autologous secretion of PTH in
    CKD/ESRD)</p>
</li>
<li>
<p>Familial hypercalciuric hypercalcemia (often asymptomatic, no
    treatment required).</p>
</li>
<li>
<p>Li toxicity</p>
</li>
</ul>
</li>
<li>
<p>↓ PTH</p>
<ul>
<li>
<p>Humoral hypercalcemia of malignancy (PTHrP)</p>
</li>
<li>
<p>Malignancy (boney metastases)</p>
</li>
<li>
<p>Excess vitamin D intake</p>
</li>
<li>
<p>Granulomatous disease: 1,25 dihydroxy vitamin D, 25
    hydroxyvitamin D, or ACE level</p>
</li>
<li>
<p>Milk-alkali syndrome</p>
</li>
<li>
<p>Medications (classically HCTZ)</p>
</li>
<li>
<p>Thyrotoxicosis</p>
</li>
<li>
<p>Adrenal insufficiency</p>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>If Ca+2 \&lt; 12 and asymptomatic</li>
</ul>
<!-- -->

<ul>
<li>
<p>Encourage PO hydration</p>
</li>
<li>
<p>Normal saline if hypovolemic</p>
</li>
<li>
<p>Evaluate for underlying cause</p>
</li>
</ul>
<!-- -->

<ul>
<li>If Ca+2 > 12 with symptoms or Ca > 14</li>
</ul>
<!-- -->

<ul>
<li>
<p>Trend Ca q8 hrs, EKG, monitor on telemetry; strict I/Os &plusmn; foley
    catheter</p>
</li>
<li>
<p>Volume expansion w/ NS bolus followed by continuous infusion at ~
    200cc/hr</p>
<ul>
<li>Goal UOP 100-150cc/hr</li>
</ul>
</li>
<li>
<p>Add loop diuretic (Lasix) once patient is volume expanded</p>
</li>
<li>
<p>Bisphosphonates</p>
<ul>
<li>Zoledronic acid 4mg IV (EGFR >60), Pamidronate 90mg IV (EGFR
    15-60)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If Ca+2 >14 or neurologic symptoms, consider subq (not intranasal)
    calcitonin</p>
<ul>
<li>
<p>VUMC: requires approval from an oncology or endocrine attending</p>
</li>
<li>
<p>Tachyphylaxis after ~48H</p>
</li>
</ul>
</li>
<li>
<p>Additional Information</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>In CHF pt, consider early addition of a loop diuretic, especially if
    volume overloaded</p>
</li>
<li>
<p>In ESRD pt with hypercalcemia (rare), patient with oliguric AKI not
    responsive to IVF, or pt with severely elevated Ca 16-18, consult
    endocrine and nephrology early</p>
</li>
<li>
<p>In pts with sarcoidosis or lymphoma, consider glucocorticoids</p>
</li>
</ul>
<p>Hypocalcemia – Trey Richardson</p>
<p>Background</p>
<ul>
<li>Can be divided into low parathyroid hormone and high parathyroid
    hormone states</li>
</ul>
<!-- -->

<ul>
<li>
<p>Low PTH</p>
<ul>
<li>
<p>Magnesium deficiency</p>
</li>
<li>
<p>Post-operative for parathyroidectomy</p>
</li>
<li>
<p>DiGeorge syndrome</p>
</li>
<li>
<p>Medications: Bisphosphonates, denosumab, aminoglycosides,
    gadolinium</p>
</li>
<li>
<p>Acidemia (Serum Ca is inversely proportional to pH)</p>
</li>
<li>
<p>Infiltrative disease: sarcoid, hemochromatosis, malignancies</p>
</li>
<li>
<p>Autoimmune hypoparathyroidism</p>
</li>
<li>
<p>CRRT (if using regional citrate anticoagulation)</p>
</li>
</ul>
</li>
<li>
<p>High PTH</p>
<ul>
<li>
<p>Late-stage CKD</p>
</li>
<li>
<p>Hyperphosphatemia</p>
</li>
<li>
<p>Vitamin D deficiency</p>
</li>
<li>
<p>Pseudohypoparathyroidism/Parathyroid resistance</p>
</li>
<li>
<p>Consumption/deposition: Pancreatitis, rhabdomyolysis, some
    osteoblastic metastases</p>
</li>
<li>
<p>Sepsis or critical illness</p>
</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Chvostek and Trousseau’s signs , laryngospasm, seizures, widened QRS
    and arrhythmias</p>
</li>
<li>
<p>Hemodynamic instability</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Check PTH, albumin, iCal, VBG, Vitamin D</p>
</li>
<li>
<p>Review medications for possible offenders</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Under most circumstances there is no need to replace calcium.
    Instead, focus on correcting the underlying perturbation (e.g.
    acidemia, hypomagnesemia, treating pancreatitis, etc. )</p>
</li>
<li>
<p>If hemodynamic instability, cardiac electrical instability, seizures
    then aggressive intravenous replacement is warranted.</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Also consider preemptive repletion for patients requiring
    high-volume of blood transfusions (citrate in blood products can
    cause hypocalcemia)</p>
</li>
<li>
<p>1 g of CaCl is equivalent to 3 grams of Ca Gluconate</p>
</li>
</ul>
<!-- -->

<ul>
<li>Avoid treatment in hyperphosphatemia, advanced CKD/ESRD, and
    rhabdomyolysis</li>
</ul>
<p>Hypernatremia – Lauren Chan</p>
<p>Overview of dysnatremias</p>
<ul>
<li>
<p>Fluctuations in serum Na reflect fluctuations in plasma free water</p>
</li>
<li>
<p>Sodium is the major driver of tonicity. The clinical signs and
    symptoms of serum Na fluctuations are related to changes in tonicity
    with most profound effects on cerebral tissue</p>
</li>
<li>
<p>Two major mechanisms maintain plasma osmolarity between 275 and 290:
    Thirst and secretion of ADH. When these mechanisms malfunction,
    dysnatremias occur</p>
</li>
</ul>
<p>Background</p>
<ul>
<li>
<p>Definition: Na+ >145</p>
</li>
<li>
<p>Hypernatremia = decreased free water</p>
</li>
<li>
<p>Almost always due to inadequate free water intake (ICU patients,
    dementia, limited mobility, tube feeding/TPN, impaired
    thirst/adipsia from hypothalamic stroke). Hospital acquired
    hypernatremia is iatrogenic and correlates with poor outcomes</p>
</li>
<li>
<p>Can also occur from: Na+ overload (salt poisoning, iatrogenic from
    NS infusion, over correction), osmotic diuresis (hyperglycemia,
    SGLT-2 inhibitors, urea, mannitol), diabetes insipidus</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Lethargy, irritability, confusion</p>
</li>
<li>
<p>Seizures, coma, hemorrhagic stroke, or subarachnoid hemorrhage (from
    the effects of hypertonic serum on cerebral vasculature)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Step 1: Treat underlying cause (vomiting, hyperglycemia,
    medications)</p>
</li>
<li>
<p>Step 2: Determine volume status: If severely hypovolemic, the
    patient will need IV crystalloid to restore volume in addition to
    free water</p>
</li>
<li>
<p>Step 3: Estimate and replace free water deficit (FWD):</p>
</li>
</ul>
<!-- -->

<ul>
<li>FWD = TBW x [(serum Na/140) - 1]</li>
</ul>
<!-- -->

<ul>
<li>Step 4: Account for ongoing insensible losses and electrolyte free
    water clearance</li>
</ul>
<!-- -->

<ul>
<li>
<p>Rule of thumb for accounting for electrolyte free water clearance.
    <em>This is in addition to replacing free water deficit</em></p>
<ul>
<li>
<p>0-1 Liter of urine output: Ignore, no need to replace</p>
</li>
<li>
<p>1-3 Liters of urine output: Replace half of the losses</p>
</li>
<li>
<p>>3 liters of urine output: Replace all urine losses</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>No evidence that overcorrecting hypernatremia is harmful. In fact,
    there is increased mortality with overly cautious correction or
    under correction</p>
</li>
<li>
<p>If able, replace free water enterally. Otherwise, administer D5W
    intravenously</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>Pts w/ suspected DI: Consult Nephrology (may require desmopressin or
    may receive desmopressin once stabilized to differentiate between
    central and nephrogenic DI)</p>
</li>
<li>
<p>Pts with hypokalemia: giving K decreases total amount of free water
    you are giving the pt</p>
</li>
</ul>
<p>Hyponatremia – Lauren Chan</p>
<p>Background</p>
<ul>
<li>Definition:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mild: Na+ 130-134</p>
</li>
<li>
<p>Moderate: Na+ 125-129</p>
</li>
<li>
<p>Severe: Na+ \&lt;125</p>
</li>
</ul>
<!-- -->

<ul>
<li>Hyponatremia occurs when free water reabsorption (i.e. ADH is on) or
    intake exceeds free water excretion</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Mild to moderate symptoms: lethargy, N/V, dizziness, confusion,
    fatigue, cramping</p>
</li>
<li>
<p>Severe symptoms: obtundation, coma, respiratory arrest, seizure</p>
</li>
</ul>
<p>Evaluation and Management</p>
<ul>
<li>Step 1: Serum osm </li>
</ul>
<!-- -->

<ul>
<li>
<p>>295: Hyper-osmolar, presence of other molecules that contribute to
    serum osmolarity </p>
<ul>
<li>
<p>Glucose, mannitol, iodinated contrast</p>
</li>
<li>
<p>If hyperglycemic, corrected serum Na+ = measured Na+ +
    1.6*[(glucose – 100)/100]  </p>
<ul>
<li>
<p>If corrected Na+ is normal, treat hyperglycemia; not a water
    balance problem </p>
</li>
<li>
<p>If corrected Na+ is low, there is hypotonic hyponatremia +
    coexisting hyperglycemia </p>
</li>
</ul>
</li>
<li>
<p>Renal failure (urea) and ethanol: Ineffective osmoles that can
    freely diffuse across cells and do NOT lead to hyponatremia</p>
</li>
</ul>
</li>
<li>
<p>275-295: Iso-osmolar </p>
<ul>
<li>Pseudohyponatremia 2/2 hypertriglyceridemia, paraproteinemia, or
    lipoprotein X: Serum Na not actually low, due to how the lab is
    calculated </li>
</ul>
</li>
<li>
<p>\&lt;275: Hypo-osmolar à Step 2 </p>
</li>
</ul>
<!-- -->

<ul>
<li>Step 2: Urine Osm</li>
</ul>
<!-- -->

<ul>
<li>
<p>Surrogate for ADH activity</p>
</li>
<li>
<p>Uosm \&lt;100 or Uosm \&lt; Sosm correlates with low ADH</p>
<ul>
<li>
<p>Primary polydipsia: Free water intake>output  </p>
</li>
<li>
<p>Tea and toast: Lack solute to effectively concentrate urine </p>
</li>
<li>
<p>Beer drinkers’ potomania: Mixture of the two above</p>
</li>
</ul>
</li>
<li>
<p>Uosm >100 or Uosm > Sosm correlates with high ADH Step 3 </p>
</li>
</ul>
<!-- -->

<ul>
<li>Step 3: Urine Na</li>
</ul>
<!-- -->

<ul>
<li>
<p>Is ADH on in the setting of decreased effective arterial bloodvolume
    (EABV) or decreased mean arterial pressure (i.e. appropriate ADH)?</p>
</li>
<li>
<p>UNa \&lt;20: Low EABV à RAAS upregulation w/ Na avidity-> appropriate
    ADH release</p>
<ul>
<li>
<p>If true volume depletion, then trial 500cc-1L NS bolus and
    monitor serum Na. IVF bolus->Increase EABV à ↓ ADH release à ↑
    free water excretion</p>
</li>
<li>
<p>If edematous state (e.g. heart failure or cirrhosis), then
    decongestion with diuretics may improve serum Na</p>
</li>
</ul>
</li>
<li>
<p>UNa >40: Euvolemic with no stimulus for ADH-> SIADH</p>
<ul>
<li>
<p>SIADH from: n/v, malignancy, meds, surgery, pulmonary disease,
    hormones, pain, bladder distension: ↑ ADH out of proportion to
    stimulus  </p>
<ul>
<li>
<p>Treat with water restriction. Can add NaCl or urea tabs if
    fluid restriction is severe </p>
</li>
<li>
<p>Water restriction (L/day) = 600 / uosm (600 mEq Na in
    American diet/day)</p>
</li>
<li>
<p>Salt wasting: diuretics, cerebral salt wasting (aka
    hypovolemic SIADH), SSRIs</p>
</li>
<li>
<p>Other: Hypothyroidism, adrenal insufficiency </p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>If still stumped, can check a FeNa and measure a serum uric acid</li>
</ul>
<!-- -->

<ul>
<li>
<p>FeNa \&lt;0.5 % suggests appropriate ADH activity.</p>
</li>
<li>
<p>High uric acid suggests some degree of volume depletion and
    appropriate ADH activity.</p>
</li>
</ul>
<p>Rate of correction</p>
<ul>
<li>Acute (\&lt;48 hrs)</li>
</ul>
<!-- -->

<ul>
<li>
<p>If symptomatic, give 150 cc bolus 3% NaCl up to two times.</p>
</li>
<li>
<p>Monitor Na+ q1-2 hr</p>
</li>
<li>
<p>Goal is an initial rapid 4-6 mEq/L correction and then hold</p>
<ul>
<li>May require Hypertonic Saline infusion with DDAVP clamp if at
    risk of over-correcting</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Chronic (>48 hrs or unknown, higher risk for osmotic demyelination
    if corrected too quickly):</li>
</ul>
<!-- -->

<ul>
<li>Goal Na+ correction rate 4-6 mEq/L over 24 hrs (Max 8mEq/L)</li>
</ul>
<p>When to call Nephrology</p>
<ul>
<li>If you are worried about rapid over-correction:</li>
</ul>
<!-- -->

<ul>
<li>
<p>High risk patients are those with rapidly reversible causes</p>
<ul>
<li>
<p>Low solute states (Beer drinker’s potomania, psychogenic
    polydipsia, tea-toast)- as soon as they decrease their excess
    free water intake, they will rapidly clear free water</p>
</li>
<li>
<p>Volume depletion- as volume is replaced and the stimulus for ADH
    release is switched off, then they will rapidly clear the excess
    free water if they have normal underlying kidney function</p>
</li>
</ul>
</li>
<li>
<p>High risk for ODS includes: chronic liver disease, Na \&lt;105 meq/dL,
    alcoholism, and malnutrition.</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consideration of DDAVP clamp</li>
</ul>
<p>Hyperkalemia – Mengyao Tang and Amanda Morrison</p>
<p>Background</p>
<ul>
<li>Causes:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cellular shifts: Acidemia, Rhabdomyolysis, TLS, beta blockade</p>
</li>
<li>
<p>Aldosterone deficient states: T4 RTA, Primary adrenal insufficiency</p>
</li>
<li>
<p>Decreased distal tubular delivery: Volume depletion</p>
</li>
<li>
<p>Decreased clearance: AKI, CKD, ESRD</p>
</li>
<li>
<p>Excessive intake</p>
</li>
<li>
<p>Medication-related: ACEi, ARB, MRA, NSAIDs, TMP/SMX, digoxin,
    heparin</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pseudo-Hyperkalemia: hemolysis, severe leukocytosis</p>
</li>
<li>
<p>Symptoms are rare, but usually manifest as cardiac dysrhythmias</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Confirm hyperkalemia with repeat BMP</p>
</li>
<li>
<p>Check EKG for hyperkalemic changes (sensitivity for EKG findings in
    hyper K is poor)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>K+ 5.5-6.5: peaked T waves, prolonged PR interval</p>
</li>
<li>
<p>K+ 6.5-8: prolonged QRS, loss of P wave, ST elevation, ectopic beats</p>
</li>
<li>
<p>K+ >8: sine wave pattern, asystole, PEA, VF</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>If EKG changes or signs of instability</li>
</ul>
<!-- -->

<ul>
<li>
<p>Calcium gluconate 1g IV (effective within 3-5 min)</p>
<ul>
<li>
<p>Stabilizes cardiac membrane for ~60mins</p>
</li>
<li>
<p>SHOULD BE REPEATED HOURLY while hyperkalemic</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Shift K+ (temporizing measures)</li>
</ul>
<!-- -->

<ul>
<li>
<p>D50 w/ regular insulin 10 units (can order using Adult Hyperkalemia
    order set in epic)</p>
<ul>
<li>
<p>Use 5 units if there is renal impairment</p>
</li>
<li>
<p>Lasts for 4-6hrs (can be longer in renal impairment)</p>
</li>
</ul>
</li>
<li>
<p>Correct acidosis- Consider using isotonic bicarb</p>
</li>
<li>
<p>Beta Agonists (e.g. high-dose albuterol nebulizer); lasts 2-4 hrs</p>
<ul>
<li>Note that typical albuterol nebulizer is 2.5mg, need 10-20mg to
    have an effect</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Increase K+ Excretion</li>
</ul>
<!-- -->

<ul>
<li>
<p>Loop diuretic- if the kidneys work, use them</p>
<ul>
<li>If there is AKI or a volume deficit can administer with IVF</li>
</ul>
</li>
<li>
<p>Volume expansion with IVF: Increases distal Na delivery and K
    excretion. NS and LR are likely equally effective.</p>
</li>
<li>
<p>GI cation exchangers</p>
<ul>
<li>
<p>Kayexalate (Polystyrene sulfonate)- only effective if having
    BMs. 60g PO q2h until bowel movement (If using oral, ensure
    patient is having bowel movements and is not obstructed, could
    cause bowel injury/ necrosis). PO can take up to 6hrs to work.
    Consider per rectal administration for faster action but DO NOT
    GIVE WITH SORBITOL per rectum</p>
</li>
<li>
<p>Lokelma (Sodium-zirconium-cyclosilicate) 10 g PO TID for 48 H.
    Actively exchanges K for other cations within the small bowel
    and works within 2 hours. Remember to stop once the K is normal
    since can cause hypokalemia. Also keep in mind the high Na
    content of Lokelma (400mg/5g dose of lokelma)</p>
<ul>
<li>Needs approval from nephrology</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Hemodialysis: Consult nephrology early if severe hyper K+</p>
</li>
</ul>
<p>Hypokalemia – Peter Thorne and Patrick Steadman</p>
<p>Background</p>
<ul>
<li>
<p>Potassium (K+) \&lt; 3.5 mEq/L</p>
</li>
<li>
<p>98% of total body K+ is intracellular (majority in muscle cells)</p>
</li>
<li>
<p>Goal: prevent life threatening complication (e.g. arrhythmia),
    replace deficit, elucidate cause</p>
</li>
<li>
<p>Insulin and catecholamines (Beta adrenoreceptors) are key drivers of
    transcellular shifts</p>
</li>
<li>
<p>H+ and K+ will trade places to maintain electroneutrality</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Malaise, weakness, myalgias, decreased gastrointestinal motility</p>
</li>
<li>
<p>EKG changes:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mild: ST segment depression, decreased T wave amplitude</p>
</li>
<li>
<p>Severe: U-waves (most commonly seen in precordial leads V2 and V3)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Severe hypokalemia can lead to rhabdomyolysis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>History: decreased K+ intake, increased entry into cells (ex:
    elevated beta-adrenergic activity, hypothermia), GI losses, urinary
    losses (diuretics, hypomagnesemia, RTA, tubular defects,
    hyperaldosteronism)</p>
</li>
<li>
<p>If concomitant metabolic alkalosis: Normal/low BP suggests diuretic
    use, vomiting or Gitelman/Bartter syndromes</p>
</li>
<li>
<p>Hypertension suggests renovascular disease or primary
    mineralocorticoid excess</p>
</li>
<li>
<p>Labs: BMP, CBC, VBG, urine electrolytes, magnesium, POC glucose, CK.
    Possibly aldosterone, renin, cortisol pending clinical context</p>
</li>
<li>
<p>Imaging: Renal US, CT AP</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Check Mg+2, replete to 2; Give empirically while waiting for serum
    Mg+2</p>
</li>
<li>
<p>K+ preparation (route); replete to 4</p>
</li>
<li>
<p>Choice of agent:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>KCl is used for repletion in the hospital</p>
<ul>
<li>
<p>PO tablets for mild asymptomatic hypokalemia</p>
</li>
<li>
<p>IV can be given through peripheral (rate is 10mEq/hr, may have
    burning sensation) or central access</p>
</li>
</ul>
</li>
<li>
<p>K+ bicarbonate can be dissolved and put through G tube</p>
<ul>
<li>Useful in pts with hypokalemia and metabolic acidosis</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Dose:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Normal renal function: 10 mEq K+ is expected to raise serum [K+]
    by 0.1 mEq/L</p>
</li>
<li>
<p>Significant CKD or AKI: at risk of overcorrection</p>
<ul>
<li>
<p>Shortcut: multiply the mEq by the Cr = how much K+ expected to
    rise</p>
</li>
<li>
<p>Once K+ higher than 5.5, K+ increases much faster and rules
    above do not apply</p>
</li>
</ul>
</li>
</ul>
<p>Hyperphosphatemia – Peter Thorne and Amanda Morrison</p>
<p>Background</p>
<ul>
<li>
<p>Phosphate (PO4-3) >4.5mg/dL</p>
</li>
<li>
<p>Etiologies:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cellular shifts: Cellular lysis (TLS, Rhabdomyolysis), Acidemia</p>
</li>
<li>
<p>Increased intake/absorption or iatrogenic hyperphosphatemia (Over
    repletion, Vitamin D toxicity, use of Fleet’s enemas, etc.)</p>
</li>
<li>
<p>Decreased phosphate clearance (Acute or chronic renal disease,
    hypoparathyroidism, pseudohypoparathyroidism)</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Symptoms are usually secondary to coexistent hypocalcemia
    (psychosis, seizure, perioral paresthesia’s, muscle weakness)</p>
</li>
<li>
<p>Can cause acute phosphate nephropathy with phosphate containing
    laxatives</p>
</li>
<li>
<p>Calciphylaxis if concurrent hypercalcemia (high Ca+2 x PO4-3product)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Labs: BMP (calcium, creatinine), VBG, Vit D, PTH, PTHrP, lactate</li>
</ul>
<p>Management</p>
<ul>
<li>Acute</li>
</ul>
<!-- -->

<ul>
<li>
<p>If renal function normal, can often treat with IVF (promote PO4-3
    excretion)</p>
</li>
<li>
<p>Consider need for calcium supplementation (see hypocalcemia section)</p>
</li>
<li>
<p>If renal function impaired and severe hypocalcemia present =
    consider hemodialysis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Chronic</li>
</ul>
<!-- -->

<ul>
<li>
<p>Usually secondary to chronic renal failure, goal PO4-3 3.5-5.5 in
    CKD patients</p>
</li>
<li>
<p>Renal diet (low PO4-3)</p>
</li>
<li>
<p>PO4-3 binders: Ca+2 containing (calcium carbonate and calcium
    acetate) and non Ca+2 containing (sevelamer, lanthanum, and iron
    based such as ferric citrate)</p>
<ul>
<li>
<p>Sevelamer is significantly more expensive than calcium
    containing binders</p>
<ul>
<li>
<p>Given 3 times daily with meals, started at 800mg (Can be ↑
    to 1,600mg TID)</p>
</li>
<li>
<p>Should not be given if pt is not eating</p>
</li>
</ul>
</li>
<li>
<p>Calcium acetate: started at 1334mg TID with meals</p>
</li>
</ul>
</li>
<li>
<p>Limit dose changes to chronic binders upon discharge</p>
</li>
<li>
<p>Need to avoid calcium containing binders in patients with
    calciphylaxis</p>
</li>
</ul>
<p>Hypophosphatemia – Peter Thorne</p>
<p>Background</p>
<ul>
<li>
<p>Required for metabolic pathways (ATP production!)</p>
</li>
<li>
<p>Most renal reabsorption occurs in proximal tubule via
    sodium-phosphate cotransporter</p>
</li>
<li>
<p>Common causes</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Internal redistribution, reduced intestinal absorption</p>
</li>
<li>
<p>Refeeding syndrome</p>
</li>
<li>
<p>Alkalemia</p>
</li>
<li>
<p>Phos binders on purpose or inadvertently (calcium, aluminum,
    magnesium antacids)</p>
</li>
<li>
<p>Excessive loss (diarrhea, CRRT, increased urinary excretion)</p>
</li>
<li>
<p>Proximal tubular dysfunction such as in Fanconi Syndrome</p>
</li>
<li>
<p>Hyperparathyroidism causes renal phos wasting</p>
</li>
<li>
<p>Post-parathyroidectomy leading to hungry bone syndrome</p>
</li>
<li>
<p>Vitamin D deficiency or resistance</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Mild Hypophosphatemia (serum >2.0) rarely symptomatic</p>
</li>
<li>
<p>PO4-3\&lt; 2.0: Muscle weakness</p>
</li>
<li>
<p>PO4-3\&lt; 1.0: Heart failure, respiratory failure, rhabdomyolysis,
    seizures</p>
</li>
<li>
<p>Failure to wean from ventilator</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Urine PO4-3 level if cause not readily apparent</p>
</li>
<li>
<p>Calculate Fe PO4-3 ([U PO4-3 x PCr x 100]/[P PO4-3x UCr])</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Fe PO4-3 \&lt; 5% = normal renal response to hypophos: redistribution
    or ↓ absorption</p>
</li>
<li>
<p>Fe PO4-3 > 5% = renal phos wasting</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Caution replacing in pts with impaired renal function: start with
    half suggested dose</p>
</li>
<li>
<p>If K+ > 4 and patient requires IV repletion, may need to use sodium
    PO4-3 in place of K+ PO4-3 IV; po preferred unless severe or
    symptomatic, or patient cannot take po</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>K-Phos neutral: oral, each 250mg tablet has 8 mmol of PO4-3 and
    1.1mEq of K+</p>
</li>
<li>
<p>K+ PO4-3: IV, each mL has 3mmol PO4-3, 4.4 meq K+</p>
</li>
<li>
<p>Na+ PO4-3: IV, each mL has 3mmol PO4-3</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>PO4-3>1.5: PO: 40 – 80 mmol K+Phos neutral (aim for 1 mmol/kg)
    divided into 3-4 doses/day</p>
</li>
<li>
<p>PO4-3 1.25 - 1.5: oral 100 mmol K+ PO4-3neutral in 3-4 divided doses
    if asymptomatic</p>
</li>
</ul>
<!-- -->

<ul>
<li>IV: 30 mmol K+ PO4-3over 6 hours (aim for 0.4mmol/kg) if symptomatic</li>
</ul>
<!-- -->

<ul>
<li>PO4-3\&lt;1.25: IV: 80mmol K+Phos over approximately 12 hours (aim for
    0.5mmol/kg)</li>
</ul>
<!-- -->

<ul>
<li>Check serum PO4-3 2-12 hrs after last dose of PO4-3 to determine if
    additional needs</li>
</ul>
<p>Hypomagnesemia – Mike Tozier</p>
<p>Background</p>
<ul>
<li>
<p>Definition: Mg2+ \&lt; 1.8 mg/dL, most pts asymptomatic until \&lt;1.2
    mg/dL. Severe [Mg+2] \&lt; 1 mg/dL</p>
</li>
<li>
<p>Causes:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>GI losses: Diarrhea, malabsorption, acute pancreatitis, EtOH use,
    TPN, vomiting, NG suction, GI fistulas, anorexia, short gut
    syndrome, small bowel bypass</p>
</li>
<li>
<p>Drugs: PPIs, loop diuretics, thiazides, digoxin, amphotericin,
    aminoglycosides, foscarnet, cisplatin, calcineurin inhibitors,
    laxatives, pentamidine</p>
</li>
<li>
<p>Kidney losses: post-ATN diuresis, Bartter syndrome and Gitelman
    syndrome</p>
</li>
<li>
<p>Cellular shifts: DKA treatment/recovery, refeeding, hungry bone
    syndrome, correction of metabolic acidosis, pancreatitis, EtOH
    withdrawal</p>
</li>
<li>
<p>Other: DM, hyper Ca, hyperthyroid, hyperaldosteronism, burns,
    lactation, Vit D deficiency, heat, prolonged exercise, mitral valve
    prolapse, pseudohypomagnesemia 2/2 EDTA tube, lactation</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Refractory hypocalcemia or hypokalemia, arrhythmias, muscle weakness</p>
</li>
<li>
<p>Severe symptoms: seizures, drowsiness, confusion, coma, arrhythmias</p>
</li>
<li>
<p>Vertical nystagmus, tetany (Chvostek sign, Trousseau), tremors,
    fasciculations</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>EKG: Initially wide QRS, peaked Ts. Progresses to wide PR,
    diminished T, arrhythmias</p>
</li>
<li>
<p>Labs: Ca+2, K+, can use FEMg (order urine Mg+2 and Cr, serum Cr and
    Mg) or 24-hour urine for Mg to distinguish renal vs GI etiology
    (FEMg>2% renal, \&lt;2% GI)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Correct underlying cause, replete based on severity (Dosing below
    for normal GFR)</p>
</li>
<li>
<p>Oral: asymptomatic pts, can cause GI symptoms, not well absorbed</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Sustained release (Mg Chloride or Mg L-lactate) better tolerated and
    absorbed, though standard preparations (Mg oxide) are faster acting</p>
</li>
<li>
<p>Mg chloride: 3-4 tabs BID (total 30 to 56 meq [15 to 28 mmol]) for
    severe hypo Mg</p>
</li>
<li>
<p>2-4 tabs daily (total 10 to 28 meq [5 to 14 mmol]) for mild hypo
    Mg</p>
</li>
<li>
<p>Mg oxide: 400-800 mg BID (20 to 40 mmol [40 to 80 meq]) for
    mod-severe hypo Mg</p>
</li>
</ul>
<!-- -->

<ul>
<li>Intravenous: for symptomatic patients or if GI intolerance to oral</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mg \&lt;1 mg/dL: 4 to 8g of MgSO4 (32 to 64 meq [16 to 32 mmol]) over
    12 to 24 hrs</p>
</li>
<li>
<p>Mg 1 to 1.5 mg/dL: 4 g MgSO4 (16 to 32 meq [8 to 16 mmol]) over 4
    to 12 hrs</p>
</li>
<li>
<p>Mg 1.6 to 1.9 give 1 to 2 grams MgSO4 (8 to 16 meq [4 to 8 mmol])
    1-2 hrs</p>
<ul>
<li>VUMC only has 4g bags of IV mag so would need to ask nurses to
    only infuse &frac12; bag</li>
</ul>
</li>
<li>
<p>Infusion rate should not exceed 2 g/hr to minimize urinary excretion</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>Renal impairment: replete with caution, reduce dose by 50-75% and
    monitor closely</p>
</li>
<li>
<p>If persistent hypo Mg in pts requiring diuresis, try K-sparing
    diuretic (e.g. Amiloride)</p>
</li>
<li>
<p>Treat concomitant hypokalemia, hypocalcemia or hypophosphatemia</p>
</li>
<li>
<p>In pts with concomitant hypophos and hypocalcemia, IV Mg alone ->
    worse hypophos</p>
</li>
</ul>
<p>Approach to Urinalysis – Laura Binari, Patrick Steadman</p>
<p>Background</p>
<ul>
<li>
<p>3 components: Gross Evaluation, Dipstick Analysis, Microscopic Exam</p>
</li>
<li>
<p>Indications: dysuria, gross hematuria, fever + GU symptoms, AKI,
    volume overload</p>
</li>
<li>
<p>If Foley, obtain sample from catheter, not the urine bag</p>
</li>
<li>
<p>Spinning Urine</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>At VUMC, take sample to lab on 4<sup>th</sup> floor to centrifuge the sample at
    1500 rpm for 5 minutes, remove supernatant and then resuspend
    sediment, place drops of urine on the slide, examine with microscope</p>
</li>
<li>
<p>At the VA, there is a microscopy room where you can spin urine as
    well</p>
</li>
<li>
<p>Ideally, the specimen should be a fresh catch (\&lt;2-4 hours old);
    Beware: casts like to migrate to the edges of the coverslip!</p>
</li>
</ul>
<p>Gross Evaluation</p>
<ul>
<li>
<p>Turbid: Infection, precipitated crystals, or chyluria</p>
</li>
<li>
<p>Color: Red Urine (broad DDx, see Hematuria section, includes certain
    meds such as rifampin/phenytoin), White (polyuria, phosphate
    crystals), Green (methylene blue), Pink (uric acid crystals,
    post-propofol infusion), Black (hemoglobinuria/myoglobinuria)</p>
</li>
</ul>
<p>Dipstick Analysis</p>
<ul>
<li>Quality of sample: should have zero squamous epithelial cells</li>
</ul>
<!-- -->

<ul>
<li>
<p>Specific gravity: normal = 1.010</p>
</li>
<li>
<p>Surrogate for urine osmolality &amp; hydration: can have falsely high
    specific gravity if large particles (contrast, glucose) present</p>
</li>
<li>
<p>Trick: Last 2 digits of S.G. x 30 = Uosm. For example: S.G. is
    1.013; 13 x 30 = 390 mOsm/L</p>
</li>
</ul>
<!-- -->

<ul>
<li>Urinary pH: normal pH is 5.5-6.5</li>
</ul>
<!-- -->

<ul>
<li>
<p>Alkaline pH: bicarb suppl, vegan diet, urease producing organisms
    (staghorn calculi)</p>
</li>
<li>
<p>Acidic pH: uric acid stones, appropriate response to acidemia</p>
</li>
</ul>
<!-- -->

<ul>
<li>Proteinuria: dipstick detects albumin ONLY (not paraproteins)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mild albuminuria (30-300 mg/day) not detected by standard dipsticks</p>
</li>
<li>
<p>F/u with spot protein to Cr ratio or 24 hr urine collection
    (nephrotic range >3.5 g/day)</p>
</li>
<li>
<p>Transient: due to volume depletion, CHF, fever, postural,
    exercise-induced</p>
</li>
<li>
<p>Ddx: primary glomerular dx, secondary glomerular dx (DM, amyloid,
    infxn, sickle cell, etc.) vs tubular vs overflow (multiple myeloma)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Heme (see hematuria section): False(+) if semen, false(-) w/
    ascorbic acid</p>
</li>
<li>
<p>WBC:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>False(+) 2/2 contamination with squamous cells. If bacteria ->
    consider UTI/pyelo w/hematuria -> inflammation; May have sterile
    pyuria</p>
</li>
<li>
<p>Ddx includes chlamydia, ureaplasma, TB, malignancy, viral infxn,
    kidney stones, GN, urethritis, steroid, cyclophosphamide use</p>
</li>
</ul>
<!-- -->

<ul>
<li>Ketones:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Never normal in urine; only detects acetic acid</p>
</li>
<li>
<p>Ddx: DKA, starvation ketoacidosis, pregnancy, keto diet</p>
</li>
</ul>
<!-- -->

<ul>
<li>Glucose: max threshold at proximal tubule exceeded (~serum glucose
    180 mg/dL)</li>
</ul>
<!-- -->

<ul>
<li>DM, Cushing’s, liver/pancreatic dx, SGLT2i use; or a primary defect
    of proximal reabsorption (w/phosphaturia, uricosuria, amino aciduria
    think Fanconi syndrome)</li>
</ul>
<!-- -->

<ul>
<li>Leukocyte esterase: enzyme released by lysed neutrophils,
    macrophages</li>
</ul>
<!-- -->

<ul>
<li>Associated with pyuria and infections; false(-) from hematuria or
    glucosuria</li>
</ul>
<!-- -->

<ul>
<li>Nitrites: reduction of urinary nitrates by nitrate reductase</li>
</ul>
<!-- -->

<ul>
<li>Certain bacteria (e.g. Enterobacteriaceae) express, others (e.g.
    Enterococci) do not</li>
</ul>
<!-- -->

<ul>
<li>Bilirubin: conjugated = water soluble (passes through glomerulus),
    unlike unconjugated</li>
</ul>
<!-- -->

<ul>
<li>Liver dysfunction and biliary obstruction</li>
</ul>
<!-- -->

<ul>
<li>Urobilinogen: end product of conjugated bilirubin, normally
    ~1.0mg/dL is normal</li>
</ul>
<!-- -->

<ul>
<li>Can be elevated due to hepatocellular dx or hemolysis</li>
</ul>
<p>Microscopic Examination of the Urine Sediment</p>
<ul>
<li>Cells:</li>
</ul>
<!-- -->

<ul>
<li>Dysmorphic RBCs (sign of GN), squamous epithelial cells
    (contamination), tubular cells (abnormal, indicates renal dx),
    neutrophils (UTI, AIN, TB, sterile pyuria), eosinophils (think AIN,
    not sensitive thus cannot exclude diagnosis)</li>
</ul>
<!-- -->

<ul>
<li>Casts:</li>
</ul>
<!-- -->

<ul>
<li>Hyaline (pyelo; CKD, normal subjects), RBC (GN), WBC (GN, pyelo,
    interstitial dx, inflammation), epithelial - renal tubular cells
    (ATN, interstitial nephritis, nephritic sx, heavy metal ingestion),
    granular or waxy (presence of kidney disease, but nonspecific),
    muddy brown casts (ATN); fatty (nephrotic syndrome)</li>
</ul>
<!-- -->

<ul>
<li>Crystals:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ca++ oxalate (envelope/dumbbell shape), uric acid (rhombic/rosette
    shaped, classically formed in acidic urine), cystine (hexagonal,
    found in cystinuria), Mg ++ ammonium phosphate (aka struvite stones,
    from increased ammonia production, in setting of urease producing
    bacteria such as Proteus or Klebsiella UTIs)</p>
</li>
<li>
<p>Calcium oxalate crystals + AKI, consider ethylene glycol
    intoxication</p>
</li>
<li>
<p>Uric Acid crystals + AKI, consider tumor lysis syndrome</p>
</li>
</ul>
<p>Hematuria – Laura Binari/Patrick Steadman</p>
<p>Background</p>
<ul>
<li>
<p>Definition: 3 urinalyses with three or more RBC/hpf; 1 urinalysis
    with 100 RBC/hpf or gross hematuria (1 cc blood/L urine can induce
    color change)</p>
</li>
<li>
<p>Causes:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Can be transient (exercise-induced, menses, trauma)</p>
</li>
<li>
<p>Concurrent pyuria/dysuria: consider urinary tract infection or
    bladder malignancy</p>
<ul>
<li>Malignancy risk factors: male sex, age > 50, smoking Hx,
    exposures to benzene/aromatic amine, cyclophosphamide,
    indwelling foreign body, pelvis irradiation, chronic UTIs, heavy
    NSAID use, urologic disorders (nephrolithiasis, BPH)</li>
</ul>
</li>
<li>
<p>Recent URI: think infection related glomerulonephritis, IgA,
    vasculitis, anti-GBM</p>
</li>
<li>
<p>Positive Family Hx of Hematuria: consider PKD, Sickle Cell Disease</p>
</li>
<li>
<p>Bleeding from other sites: think inherited/acquired bleeding
    disorder, anticoagulation</p>
</li>
<li>
<p>Unilateral Flank Pain: Ureteral calculus, renal malignancy, IgA
    Nephropathy</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 31%" />
<col style="width: 16%" />
<col style="width: 23%" />
<col style="width: 14%" />
<col style="width: 14%" />
</colgroup>
<thead>
<tr class="header">
<th rowspan="2">Glomerular</th>
<th colspan="4">Extraglomerular (Non-Glomerular Source)</th>
</tr>
<tr class="odd">
<th><strong>Kidney</strong></th>
<th><p><strong>Ureter/</strong></p>
<p><strong>Bladder</strong></p></th>
<th><p><strong>Prostate/</strong></p>
<p><strong>Urethra</strong></p></th>
<th><strong>Other</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>IgA Nephropathy</p>
<p>IgA Vasculitis</p></td>
<td>Pyelo</td>
<td>Cystitis</td>
<td>BPH</td>
<td>Exercise-Induced</td>
</tr>
<tr class="even">
<td>Lupus Nephritis</td>
<td>Renal Cell Carcinoma</td>
<td>Urothelial Malignancy</td>
<td>Prostate Cancer</td>
<td>Bleeding Diathesis</td>
</tr>
<tr class="odd">
<td>Infection-related glomerulonephritis</td>
<td>PKD</td>
<td>Nephrolithiasis</td>
<td>TURP</td>
<td>Meds (AC)</td>
</tr>
<tr class="even">
<td>Anti-GBM Disease (Goodpasture’s)</td>
<td><p>Sickle Cell</p>
<p>Papillary Necrosis</p></td>
<td>Ureteral Stricture</td>
<td>Urethritis (STI)</td>
<td>Menses</td>
</tr>
<tr class="odd">
<td>ANCA-associated</td>
<td>Malignant HTN</td>
<td>Hemorrhagic Cystitis (chemo/rads)</td>
<td></td>
<td><p>TB</p>
<p>Schistoso-miasis</p></td>
</tr>
<tr class="even">
<td>Genetic (Thin Basement Membrane Nephropathy/Alport Syndrome)</td>
<td><p>Arterial embolism</p>
<p>Vein thrombus</p></td>
<td>Traumatic Foley/procedure</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>Evaluation</p>
<ul>
<li>Step 1: Confirm the presence of hematuria</li>
</ul>
<!-- -->

<ul>
<li>
<p>Dipstick positive heme: urinary RBCs (hematuria), free myoglobin or
    free hemoglobin</p>
</li>
<li>
<p>Centrifuge the urine</p>
<ul>
<li>
<p>Red sediment -> true hematuria (urinary RBCs)</p>
</li>
<li>
<p>Red supernatant +</p>
<ul>
<li>
<p>Positive dipstick: myoglobulin or hemoglobin</p>
</li>
<li>
<p>Negative dipstick porphyria, Pyridium, beets, rhubarb, or
    ingestion of food dyes</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th>Glomerular</th>
<th>Extraglomerular</th>
</tr>
</thead>
<tbody>
<tr>
<td>Color (if gross hematuria)</td>
<td>Red, Cola, Smoky</td>
<td>Red/Pink</td>
</tr>
<tr>
<td>Clots</td>
<td>Absent</td>
<td>Present/Absent</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>May be >500 mg/day</td>
<td>\&lt;500 mg/day</td>
</tr>
<tr>
<td>RBC morphology</td>
<td>Dysmorphic RBCs present</td>
<td>Normal (isomorphic)</td>
</tr>
<tr>
<td>RBC casts</td>
<td>May be present</td>
<td>Absent</td>
</tr>
</tbody>
</table>
<ul>
<li>Step 2: Determine if there is a GLOMERULAR or NON-GLOMERULAR source
    of bleeding</li>
</ul>
<!-- -->

<ul>
<li>
<p>Glomerular Bleeding:</p>
<ul>
<li>
<p>Isolated Hematuria: Differential includes IgA Nephropathy, thin
    BM dx, Alport’s</p>
</li>
<li>
<p>Nephritic syndrome (new proteinuria, pyuria, HTN, edema, rise in
    Cr): post-infectious GN, MPGN, ANCA vasculitis, Goodpasture’s,
    lupus nephritis</p>
</li>
<li>
<p>Workup: anti-GMB, anti-DNase/ASO, ANA, ANCA, C3, C4, cryo, Hep B
    &amp; C, HIV</p>
</li>
<li>
<p>Indications for Renal Biopsy: glomerular bleeding + risk factors
    for progressive disease, including albuminuria > 30 mg/day, new
    hypertension > 140/90 or significant elevation over baseline
    BP, rise in serum creatinine</p>
</li>
</ul>
</li>
<li>
<p>Extraglomerular Bleeding (Imaging Section)</p>
<ul>
<li>
<p>If historical clues suggest nephrolithiasis, start with non-con
    CT A/P</p>
</li>
<li>
<p>Gross Hematuria otherwise should be evaluated with CT A/P w/ and
    w/o contrast (CT urography); consult urology for cystoscopy
    (often done as outpatient referral)</p>
</li>
<li>
<p>If clots are passed, more likely to be secondary to lower
    urinary source, and if a high burden of clots poses a risk of
    obstruction (urologic emergency)</p>
</li>
<li>
<p>If extraglomerular bleeding with clots: hematuria catheter needs
    to be placed ASAP (2 valve catheter, 20-24 Fr (!); page urology
    if nursing unable to obtain)</p>
</li>
</ul>
</li>
<li>
<p>CT Urography is more sensitive than IV pyelogram for renal masses
    and stones.</p>
</li>
<li>
<p>Prefer Renal and Bladder Ultrasound in pregnant patients</p>
</li>
<li>
<p>All pts w/gross hematuria that is non-glomerular in source, in whom
    infection has been ruled out, warrant cystoscopy. Additionally, all
    patients with clots need cystoscopy</p>
</li>
</ul>
<p>Kidney Transplant Medicine – Trey Richardson</p>
<p>Introduction</p>
<ul>
<li>The goal of this section is to serve as a guide for tackling the
    most common transplant complications as well as offer a few tips for
    managing immunosuppression while kidney transplant patients are
    admitted to the hospital</li>
</ul>
<p>Alphabet soup</p>
<ul>
<li>
<p>PRA: panel reactive antibodies</p>
</li>
<li>
<p>DSA: donor specific antibodies</p>
</li>
<li>
<p>CMV (-/+): indicates the CMV status of both the recipient and the
    donor</p>
</li>
<li>
<p>FK506 or FK: another name for tacrolimus</p>
</li>
<li>
<p>KDPI: Kidney donor profile index used to “grade” the quality of the
    donated organ</p>
</li>
<li>
<p>X/6 MM: indicates the number of HLA subtypes that are mismatched
    between donor and recipient</p>
</li>
</ul>
<p>Infections in Kidney Transplant Recipients</p>
<p>Background</p>
<ul>
<li>Infections in a kidney transplant recipient can be divided into 3
    phases:</li>
</ul>
<!-- -->

<ul>
<li>
<p>\&lt;1-month post-transplant</p>
<ul>
<li>Surgical site infections, nosocomial infections (e.g. C. Diff,
    CAUTIs, and CLABSIs), and donor-derived infections/reactivation
    of latent recipient infections predominate</li>
</ul>
</li>
<li>
<p>1-6 months post-transplant</p>
<ul>
<li>Depleted immune-system regenerates increased risk for
    disseminated fungal (e.g. PJP, histo/blasto) and viral
    infections (HSV, adenovirus)</li>
</ul>
</li>
<li>
<p>>6 months post-transplant</p>
<ul>
<li>Risk for atypical infections persists, but common community
    acquired syndromes should still be on the differential</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>This section will focus on the most common infection in kidney
    transplant recipients- infections of the urinary tract</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>UA with culture </p>
</li>
<li>
<p>Examine the native kidneys (CVA tenderness) AND the allograft
    (almost always in RLQ, denervated so the graft itself will not be
    tender, but the surrounding soft-tissue may)</p>
</li>
<li>
<p>Renal U/S (of both allograft and native kidneys) or CT AP if:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Early post-op (1 month)</p>
</li>
<li>
<p>Recurrent (2+ episodes in year)</p>
</li>
<li>
<p>History of nephrolithiasis or if sepsis/bacteremia</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Blood cultures if systemic signs/symptoms</p>
</li>
<li>
<p>Consider testing for C. urealyticum, and sending fungal and AFB
    urine cultures if UA is recurrently positive but culture negative</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Remove or replace indwelling catheters</p>
</li>
<li>
<p>Review prior culture susceptibilities (if available)</p>
</li>
<li>
<p>Empiric antibiotic regimens:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Asymptomatic bacteriuria: treat with FQ or beta lactam for 5-7 days
    if \&lt;3 mos post-transplant</p>
</li>
<li>
<p>Simple cystitis: Fluoroquinolones (ciprofloxacin 250 BID or Levaquin
    500 mg daily), Augmentin (500 mg BID), 3<sup>rd</sup> gen cephalosporin
    (cefpodoxime 100 mg BID or cefixime 400 mg daily) or nitrofurantoin
    100 mg BID (if GFR>30, only treats cystitis since drug only
    concentrates in the urine)</p>
<ul>
<li>
<p>\&lt; 6 mos post-transplant: treat for 10-14 days</p>
</li>
<li>
<p>>6 mos post-transplant: treat for 5-7 days</p>
</li>
</ul>
</li>
<li>
<p>Complicated UTI/Pyelonephritis (cover Pseudomonas, gram negatives
    and Enterococcus): Ceftriaxone 2g daily (preferred), Cefepime 2g
    q8hrs (add Vancomycin when using cephalosporin if suspicious for
    enterococcus) or Pip-tazo 3.75g q6hrs, can also use meropenem 1g q8h
    (need ID approval)</p>
<ul>
<li>
<p>Treat for 14-21 days</p>
</li>
<li>
<p>For stable pts with mild complicated UTI, can consider giving
    more narrow empiric antibiotics: Augmentin 875 mg BID or
    ciprofloxacin 500 mg q12h</p>
</li>
</ul>
</li>
<li>
<p>MDR UTI: Consult transplant ID</p>
<ul>
<li>Options: meropenem-vaborbactam, ceftolozone-tazobactam,
    ceftazidime-avibactam</li>
</ul>
</li>
<li>
<p>In pts w/PCKD, include lipophilic antibiotic (such as ciprofloxacin)
    to penetrate cysts</p>
</li>
</ul>
<p>Prevention</p>
<ul>
<li>
<p>Bactrim used for PJP prophylaxis during first 6 mos post-transplant
    also prevents UTIs</p>
</li>
<li>
<p>Basic infection prevention measures for all comers (e.g. hydration,
    frequent voiding, wiping front to back, voiding after sexual
    intercourse)</p>
</li>
</ul>
<p>Acute Kidney Injury of Kidney Transplant</p>
<p>Background</p>
<ul>
<li>Most patients admitted to medicine services with kidney transplants
    are >3 months post-op. Therefore, we are typically not managing
    perioperative complications such as delayed graft function, or
    hyper-acute rejection. Below are the most common causes of acute
    kidney injury in kidney transplant recipients.</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Signs and symptoms of UTI?</p>
</li>
<li>
<p>Assess volume status</p>
</li>
<li>
<p>Review meds for recent medication changes</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Common offenders: NSAIDs, ACE, diuretics, azole antifungals</p>
</li>
<li>
<p>Medication non-adherence</p>
</li>
</ul>
<!-- -->

<ul>
<li>Tacrolimus (FK) or cyclosporine (CsA) level</li>
</ul>
<!-- -->

<ul>
<li>
<p>FK levels increase with n/v, diarrhea due to alterations in
    p-glycoprotein expression within inflamed GI tract</p>
</li>
<li>
<p>FK toxicity also causes diarrhea and volume depletion</p>
</li>
</ul>
<!-- -->

<ul>
<li>Proteinuria:</li>
</ul>
<!-- -->

<ul>
<li>Transplant patients with 1 g/day proteinuria usually get biopsies</li>
</ul>
<!-- -->

<ul>
<li>
<p>Review donor characteristics (CMV status, PRA, % HLA antibodies
    present, DSAs)</p>
</li>
<li>
<p>BK PCR: consider only if unclear source of AKI and no recent titers</p>
</li>
</ul>
<!-- -->

<ul>
<li>Serum PCR is test of choice</li>
</ul>
<!-- -->

<ul>
<li>Renal transplant U/S (costly and not always warranted)</li>
</ul>
<!-- -->

<ul>
<li>
<p>\&lt; 1 week post-transplant: If acute graft dysfunction, look for
    thrombosis, urine/ureter leak</p>
</li>
<li>
<p>> 1 week post-transplant:</p>
<ul>
<li>
<p>Cr does not respond to 48 hours of current management</p>
</li>
<li>
<p>Lack of clear, reversible causes</p>
</li>
<li>
<p>Hydronephrosis (can occur after stent removal 4-6 wks after
    transplant or due to perinephric fluid collection)</p>
</li>
<li>
<p>Arterial stenosis (↑ velocities in renal artery -- very
    concerning when velocity >300), tardus parvus waveforms)</p>
</li>
<li>
<p>Perinephric abscess with recurrent UTI/pyelonephritis</p>
</li>
<li>
<p>Urinoma (usually first 2-3 weeks), hematoma (after a biopsy)</p>
</li>
</ul>
</li>
<li>
<p>Unique findings:</p>
<ul>
<li>Resistive indices: reflect central renal vascular compliance.
    High indices in transplant patients signify parenchymal problem
    (rejection, infection, ATN)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Biopsy</li>
</ul>
<!-- -->

<ul>
<li>
<p>To differentiate ATN vs rejection vs BK nephropathy vs recurrent
    disease (FSGS, lupus, etc.)</p>
</li>
<li>
<p>Post Biopsy Care:</p>
<ul>
<li>
<p>Watch for bleeding and HTN</p>
</li>
<li>
<p>Blood can get into collecting system, then the capsule, and into
    the perinephric space causing Page Kidney (aka Pressure
    Tamponade)</p>
<ul>
<li>Compressed renal vessels-> RAAS surge --> rapid, severe
    HTN (STAT page the renal fellow)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Kidney Transplant Rejection</p>
<p>Background</p>
<ul>
<li>Rejection is divided into acute vs chronic and T-cell mediated or
    antibody mediated</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pathologists can determine the type of rejection and the chronicity
    by observing the structures that are acutely involved (e.g.
    tubulitis, glomerulitis, arteritis, and capillaritis) as well as the
    time course of involvement (e.g. presence of fibrosis)</p>
</li>
<li>
<p>Structures exhibiting fibrosis represent chronic rejection that is
    unlikely to respond to treatment, whereas acute inflammation may be
    amenable to acute therapies</p>
</li>
<li>
<p>This section will focus on acute rejection since this is the
    clinical entity we will most likely manage while on the wards</p>
</li>
</ul>
<p>Acute Rejection</p>
<ul>
<li>Acute T cell mediated rejection</li>
</ul>
<!-- -->

<ul>
<li>
<p>Infiltration of the graft by lymphocytes and inflammatory cells
    characterized by tubulitis, interstitial inflammation, and arteritis
    (on occasion)</p>
</li>
<li>
<p>Treatment:</p>
<ul>
<li>
<p>High dose glucocorticoids (methyl prednisolone) is first line
    (~ 5 days)</p>
</li>
<li>
<p>Thymoglobulin (polyclonal Ig anti-T cell)</p>
<ul>
<li>
<p>Use depends on severity of rejection</p>
</li>
<li>
<p>Indicated if Cr fails to improve after steroids</p>
</li>
<li>
<p>T cell subsets are measured during treatment until depleted</p>
</li>
</ul>
</li>
<li>
<p>Tacro target levels are reset to ~8-10 if treated for acute T
    cell mediated rejection</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Acute antibody mediated rejection (ABMR)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Donor specific antibody mediated rejection characterized by
    glomerulitis, peri-tubular capillaritis (microcirculation
    inflammation), complement deposition (C4d staining), and presence of
    DSA</p>
</li>
<li>
<p>Treatment = B-cell depletion therapy</p>
<ul>
<li>
<p>IV methyl prednisone 500 mg IV x 3-5 days</p>
</li>
<li>
<p>Plasmapheresis (If with high titers of DSA)</p>
</li>
<li>
<p>IVIG 2 g/kg (max 140 g)</p>
</li>
<li>
<p>Rituximab 375 mg/m2</p>
</li>
</ul>
</li>
</ul>
<p>Kidney Transplant Immunosuppression</p>
<p>Background</p>
<ul>
<li>
<p>Most patients with kidney transplants are on triple therapy with an
    anti-metabolite (azathioprine or mycophenolate compound) or mTOR
    inhibitor + calcineurin inhibitor + prednisone</p>
</li>
<li>
<p>You may also come across patients who are on monthly infusions with
    belatacept, a selective T-cell co-stimulation blocker</p>
</li>
</ul>
<p>Calcineurin inhibitors</p>
<ul>
<li>Tacrolimus (FK), cyclosporine (CsA)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Envarsus XR is a once a day long acting formulation of tacrolimus</p>
</li>
<li>
<p>Common side-effects</p>
<ul>
<li>
<p>Worsening kidney function: mediated by vasoconstriction to the
    afferent arterioles</p>
</li>
<li>
<p>Hypertension- treat with CCBs</p>
</li>
<li>
<p>Diabetes</p>
</li>
<li>
<p>Hand tremors, headache, nausea</p>
</li>
<li>
<p>Thrombotic microangiopathy</p>
</li>
<li>
<p>T4 RTA- hyperkalemia</p>
</li>
<li>
<p>Gingival hyperplasia</p>
</li>
</ul>
</li>
</ul>
<p>mTOR Inhibitors</p>
<ul>
<li>Sirolimus, everolimus</li>
</ul>
<!-- -->

<ul>
<li>Major side effects: Poor wound healing, rarely pneumonitis</li>
</ul>
<p>Anti-metabolites</p>
<ul>
<li>
<p>Azathioprine</p>
</li>
<li>
<p>Mycophenolate preparations: Mycophenolate mofetil (Cellcept, MMF),
    Mycophenolic acid (Myfortic)</p>
</li>
<li>
<p>Side effects: Bone marrow suppression- hold for lymphopenia; GI
    upset- hold for diarrhea</p>
</li>
</ul>
<p>Additional Information for Overnight Admits:</p>
<ul>
<li>Do not change immunosuppression</li>
</ul>
<!-- -->

<ul>
<li>Exception: If pt has severe diarrhea, can hold night tacro dose and
    inform the day team</li>
</ul>
<!-- -->

<ul>
<li>Daily tacrolimus or cyclosporine level (order qam at 5:00). Always
    order tacrolimus or cyclosporine dose at 6:00 am and 6:00 pm
    (regardless of what time patient takes at home, lab can only run am
    tacro levels at a certain time in batches)</li>
</ul>
<!-- -->

<ul>
<li>EXCEPTION: If late afternoon admission, consider paging the fellow
    (since its early) and ask if they want the evening dose held until
    the am level comes back</li>
</ul>
<!-- -->

<ul>
<li>Transplant patients with normal kidney function can have regular
    diet</li>
</ul></section><section class="print-page" id="nephrology-nephrology-acute-rejection"><h1 id="nephrology-nephrology-acute-rejection-acute-rejection">Acute Rejection<a class="headerlink" href="#nephrology-nephrology-acute-rejection-acute-rejection" title="Permanent link">&para;</a></h1>
<p>Acute Rejection</p>
<ul>
<li>T cell mediated (Cellular Rejection)<ul>
<li>Infiltration of the graft by <strong>lymphocytes</strong> and inflammatory
    cells</li>
<li>Treatment: high dose steroids (methyl pred) is first line (~ 5
    days <u>+)</u><ul>
<li>Thymoglobulin (polyclonal Ig anti-T cell)</li>
<li>Use depends on severity of rejection</li>
<li>Indicated if Cr fails to improve after steroids</li>
<li>T cell subsets are measured before and during treatment
    until depleted</li>
<li>Tacro target levels are <strong>reset to ~8</strong> if treated for
    acute T cell mediated rejection</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Antibody Mediated Rejection (ABMR)<ul>
<li>Acute tissue injury with circulating donor-specific antibodies
    (DSAs); requires evidence of <strong>antibody-mediated damage</strong><ul>
<li>Ig’s deposit and activate complement: key is C4d staining in
    the graft will be strongly positive</li>
</ul>
</li>
<li>Treatment:<ul>
<li>IV methyl prednisone (3-5 days)</li>
<li>Plasmapheresis</li>
<li>+
    IVIG<ul>
<li>Followed often by Rituxan before d/c</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-aki"><h1 id="nephrology-nephrology-aki-aki">AKI<a class="headerlink" href="#nephrology-nephrology-aki-aki" title="Permanent link">&para;</a></h1>
<p>Acute Kidney Injury (AKI) – Joseph Quintana, Mengyao Tang</p>
<p>Background</p>
<ul>
<li>Rise
    in Creatinine (Cr) <strong><u>></u> 0.3 mg/dL</strong> within 48 hours, or
    increase <strong><u>></u> 1.5 x baseline</strong> in 7 days<ul>
<li>Oliguria = \&lt; 0.3 mL/kg/hr or \&lt; 500 mL/day</li>
<li>Anuria = \&lt; 50 mL/day</li>
</ul>
</li>
<li>ACE
    -i’s and ARB’s alter the renal autoregulation and exacerbate
    pre-renal AKI</li>
<li>Acute
    Tubular Necrosis (ATN)
    and pre-renal disease comprise 66% of inpatient AKI<ul>
<li>Pre-
    renal:<ul>
<li>Fluid losses: GI, blood, Respiratory or metabolic losses
    [fevers, tachypnea, sepsis]</li>
<li>Decreased
    effective intravascular volume [HFrEF, Hepatorenal]</li>
<li>Afferent
    arteriole constriction [NSAIDs, Iodinated contrast]</li>
</ul>
</li>
<li>Intra-renal (Tubular and interstitial disease)
    :<ul>
<li>ATN =
    Most
    common
    ;
    Ischemia or nephrotoxin</li>
<li>ACE-i + NSAIDs, ACE-i + contrast, prerenal + ACE-i,
    prerenal + NSAIDs</li>
<li>Acute
    Interstitial
    Nephritis (AIN) usually drug-induced</li>
<li>Other
    causes
    :<ul>
<li>Crystalline nephropathy: IV acyclovir, tumor lysis</li>
<li>Small vessel disease: MAHA, TTP, HUS</li>
<li>Large vessel problems: Aortic dissection, renal artery
    stenosis</li>
<li>Glomerular disease: Nephritic pattern</li>
</ul>
</li>
</ul>
</li>
<li>Post-renal (Obstruction):<ul>
<li>Ureteral: obstructing stones (B/L or one with single
    kidney), external compression</li>
<li>Bladder: neurogenic bladder, malignancy, obstructing blood
    clot</li>
<li>Urethra: BPH</li>
<li>Misplaced Foley catheter</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Urinalysis
    , Strict I/O’s</li>
<li>Fluid
    challenge:<ul>
<li>Improve
    w/ diuresis
    
    CHF</li>
<li>Improve
    w/ resuscitation
    
    hypovolemia</li>
</ul>
</li>
<li>Protein
    /Cr urine spot ratio
    : quantify tubular vs glomerular range proteinuria</li>
<li>Post
    Void R
    esidual bladder scan, great test, low cost, high reward<ul>
<li>Elevated PVRs = 250 cc plus</li>
</ul>
</li>
<li>Who
    needs imaging (Renal U/S)?<ul>
<li>No obvious cause of AKI, unremarkable history and bland urine</li>
<li>Abrupt oliguria or anuria</li>
<li>High suspicion for bladder outlet obstruction (PVRs might give
    you same data)</li>
<li>Add doppler to evaluate for renal artery stenosis (or if
    treating resistant hypertension)</li>
</ul>
</li>
<li>Urine
    Electrolytes<ul>
<li>FE
    Na
    &amp;
    FE Urea (if on diuretics): Can suggest pre-renal vs ATN<ul>
<li>Faults
    :
    validated in “fresh” <strong>oliguric</strong> patients (interpretation
    becomes more difficult after intervention with fluids,
    diuretics, etc.); 1% cutoff more accurate in severe AKI; Na
    <sup>+</sup> intake affects impression; one measurement may
    be inaccurate</li>
<li>Urine sodium can be used to assess tubular avidity
    (typically urine Na &gt; 40 in ATN and \&lt; 20 in pre-renal; note
    these are not absolute numbers, and there can be overlap)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Hold
    ACE-i/ARB (remember to determine plan to resume at/after discharge)</li>
<li>Avoid unnecessary nephrotoxins: antibiotics, amphotericin,
    tenofovir, chemotherapy</li>
<li>Dose
    -adjust renally cleared medications: gabapentin, cefepime, morphine,
    metformin</li>
<li>Relieve
    Obstruction: I/O cath, foley, Urostomy
    
    Urology,
    Percutaneous nephrostomy
    
    IR</li>
<li>When
    to consider Nephrology – AKI consult:<ul>
<li>Urgent indication for dialysis (see “Renal Replacement Therapy”
    below)</li>
<li>Cr worsening over 48-72 hrs w/o clear cause</li>
<li>Evaluate for need for dialysis in the near future</li>
<li>Concern for acute glomerulonephritis as cause</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Rhabdomyolysis:
    UA positive for blood but no RBCs on microscopy<ul>
<li>Serologic markers of muscle injury:  AST/ALT elevation with
    normal ALK Phos<ul>
<li>
<ul>
<li>Fluids:
        Goal of 6-12 L resuscitation in first 24 hrs if pt can
        tolerate (not well studied)</li>
<li>Traditional thought = Urine goal of 200-300 mL/hr, until
    CK \&lt;5000</li>
<li>Avoid calcium repletion for hypocalcemia unless
    symptomatic</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Post
    -obstructive diuresis<ul>
<li>Monitor pt after relief of obstruction due to possibility of
    severe polyuria (&gt;4-5 L/day)</li>
<li>Replete fluids to prevent volume contraction and hypokalemia</li>
<li>½ NS to replace about 50-75% of urinary losses</li>
<li>If pt develops hypo/hypernatremia, consider an alternative
    resuscitation fluid</li>
<li>Monitor calcium, phosphorus and magnesium in severe
    post-obstructive diuresis</li>
</ul>
</li>
<li>Iodinated
    Contrast
    :<ul>
<li>Does not need to be dialyzed; thought to be due to afferent
    arterial spasm which occurs immediately with contrast</li>
<li>Avoid giving if you are trying to preserve kidney function in
    CKD or AKI pts</li>
<li>No absolute cut-off in CKD, although GFR \&lt;30 is commonly used
    as a strong contraindication and GFR 30-45 as a relative
    contraindication</li>
<li>If there is time pre contrast you can ensure the patient is
    volume replete with isotonic fluid to decrease the risk of
    contrast nephropathy</li>
<li>If it is an emergency, you should not delay the contrasted
    procedure (i.e. STEMI)</li>
</ul>
</li>
<li>Avoid
    gadolinium contrast from MRI in any AKI or if <strong>GFR \&lt;30</strong> in CKD
    given <strong>risk of nephrogenic systemic fibrosis as an absolute
    contraindication</strong> ; GFR &gt;30 is fine</li>
<li>eGFR
    equations are based on stable kidney Fx, acute changes in Cr make it
    unreliable</li>
</ul></section><section class="print-page" id="nephrology-nephrology-approach-ckd"><h1 id="nephrology-nephrology-approach-ckd-approach-to-ckd">Approach to CKD<a class="headerlink" href="#nephrology-nephrology-approach-ckd-approach-to-ckd" title="Permanent link">&para;</a></h1>
<p>Approach to Chronic Kidney Disease – Taylor Riggs</p>
<p>Background</p>
<ul>
<li>Decreased
    kidney function or one or more markers of kidney damage for <strong>3 or
    more months</strong></li>
<li>GFR
    \&lt; 60; Staging helps risk-stratify pts likely to progress or develop
    complications of CKD</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>CKD IIIa: eGFR 45-60</li>
<li>CKD IIIb: eGFR 30-44</li>
<li>CKD IV: eGFR 15-30</li>
<li>CKD V: eGFR \&lt; 15</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Markers
    of kidney damage<ul>
<li>Albuminuria (albumin:creatinine &gt; 300mg/g or urine
    protein:creatinine &gt; 500mg/g)</li>
<li>Urine sediment: RBC cases, WBC casts, oval fat bodies or fatty
    casts, granular casts</li>
<li>Electrolytes or other abnormalities due to tubular disorders</li>
<li>Abnormalities on histology (glomerular, vascular or cystic
    disease, TIN)</li>
<li>Structural abnormalities: (cysts, hydronephrosis, scarring,
    masses, renal artery stenosis)</li>
<li>History of kidney transplant (rejection, drug toxicity 2/2
    calcineurin inhibitors, BK virus nephropathy, recurrent disease
    leading to transplant)</li>
</ul>
</li>
<li>Refer
    to AKI section for a detailed list of etiologies</li>
</ul>
<p>When to refer to nephrology clinic</p>
<ul>
<li>eGFR
    \&lt; 30</li>
<li>Persistent
    urine albumin/creatinine ratio &gt; 300 mg/g</li>
<li>Urine protein/creatinine ratio greater than 500 mg/g</li>
<li>Rapid
    loss of kidney function (&gt; 30% decline over 4 months)</li>
<li>Hematuria not 2/2 urologic condition or RBC casts</li>
<li>Inability
    to identify presumed cause of renal dysfunction</li>
<li>Difficult
    to manage complications (hyperkalemia, anemia, bone-mineral disease,
    HTN)</li>
<li>Confirmed
    or presumed hereditary kidney disease (PCKD suspected)</li>
</ul>
<p>Albuminuria</p>
<ul>
<li>Microalbuminuria
    : 30-300 mg/day</li>
<li>Macroalbuminuria
    : &gt; 300 mg/day (UA typically only detects these pts)<ul>
<li>In patients with albuminuria found on UA, confirm albuminuria
    with 2 repeat tests over 3-6 months. Early morning void sample
    is best. Ensure patient does not have UTI, fever, recent IV
    contrast, hematuria, or alkaline urine.</li>
<li>After confirmation, monitor annually.</li>
<li>For patients with CKD or DM but without albuminuria, monitor
    annually for development of albuminuria</li>
</ul>
</li>
<li>Treatment
    : reducing proteinuria can slow the progression of renal disease<ul>
<li>ACEi/ARBs: reduce intraglomerular pressure, thereby reducing
    proteinuria</li>
<li>Work over weeks to months. Not as rapid as anti-HTN effect.</li>
<li>Goal is to titrate ACEi/ARB to BP \&lt; 130/90</li>
<li>Most effective when used in conjunction with low Na diet
    (\&lt;2g/d) &plusmn; diuretics</li>
</ul>
</li>
<li>Can
    add other anti-hypertensives to achieve goal BP if ACEi/ARB alone
    not able to be tolerated due to side effects (e.g. hyperkalemia)</li>
</ul>
<p>Metabolic acidosis</p>
<ul>
<li>Goal
    bicarbonate: 23-30</li>
<li>Can
    calculate bicarbonate deficit (MDcalc has calculator) and use that
    to estimate dose</li>
<li>If
    bicarb
    \&lt; 22, consider starting:<ul>
<li>Sodium bicarb 650 mg TID (8mEq bicarb per 650mg tablet). Can
    titrate up to 5850mg/day (70 mEq or 3 tabs TID)</li>
<li>Sodium citrate (bicitra): 1mL = 1 mEq</li>
<li>Baking soda: 1 teaspoon = 59 mEq HCO3 (often well-tolerated by
    patient compared to bicitra in terms of taste)</li>
</ul>
</li>
</ul>
<p>HTN in CKD</p>
<ul>
<li>Goal
    BP \&lt; 130/80</li>
<li>CKD
    stage 1 or 2 without albuminuria or DM:<ul>
<li>Usual first line BP medications (ACEi/ARB, CCB, or HCTZ)</li>
</ul>
</li>
<li>CKD
    stage 3 or greater<ul>
<li>ACEi or ARB is first line</li>
<li>Can add diuretics to ACEi/ARB for adjunctive therapy in CKD 4-5</li>
<li>HCTZ not effective with eGFR \&lt; 30</li>
<li>Low sodium diet effective in volume and BP control</li>
</ul>
</li>
<li>Consider
    stopping ACEi/ARB if:<ul>
<li>GFR declines &gt;30% over 4 months and consider evaluation for
    renal artery stenosis with Duplex Doppler renal u/s vs CTA or
    MRA as initial screening</li>
<li>K &gt; 5.5 despite efforts to decrease potassium (i.e. low K diet,
    optimizing dose of diuretics, adding K-binders)</li>
<li>If patient has an AKI on CKD, especially if pre-renal</li>
</ul>
</li>
</ul>
<p>Anemia in CKD</p>
<ul>
<li>Etiology
    : reduced EPO, chronic inflammation, uremic platelets/platelet
    dysfunction, loss of blood in dialysis circuit</li>
<li>Indications
    for iron supplementation in non-dialysis patients:<ul>
<li>ALL patients with TSAT \&lt;20% and ferritin \&lt;100 ng/mL</li>
<li>Patients with Hb \&lt;13 and TSAT \&lt;30% and ferritin \&lt;500 ng/mL</li>
<li>Can consider oral iron supplementation unless severe anemia or
    iron deficiency</li>
<li>PO Iron dosing: New evidence shows that every other day oral
    iron leads to increased absorption and efficacy and decreased
    side effects<ul>
<li>
<ul>
<li>Ferrous sulfate 325mg (65mg elemental iron) every other
        day</li>
<li>Reassess iron levels in 1-3 mos; if not appropriately
    ↑
    , consider IV iron repletion</li>
</ul>
</li>
</ul>
</li>
<li>IV Fe dosing: 1000 mg IV, either via 1 dose or multiple doses
    depending on formulation<ul>
<li>
<ul>
<li>Ferric gluconate: max dose 250 mg over 1 hr, dosed
        weekly for 3-4 doses</li>
<li>Iron dextran: 1000
    mg in a single dose, infused over one hour (less
    preferred due to
    higher risk of allergic reactions; requires te
    s
    t dose 5 min prior)</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Dialysis
    patients:<ul>
<li>IV Iron preferred method of repletion for HD patients with<ul>
<li>
<ul>
<li>TSAT \&lt; 20% and ferritin \&lt; 200</li>
<li>TSAT \&lt;30
    % and ferritin \&lt;500 AND with Hb \&lt; 10 OR are on EPO</li>
</ul>
</li>
</ul>
</li>
<li>Dosing: usually administered at HD sessions<ul>
<li>
<ul>
<li>125 mg ferric gluconate at consecutive HD sessions x 8
        doses</li>
<li>100 mg iron sucrose at consecutive HD sessions x 10
    doses</li>
<li>Ferumoxytol 510mg at the end of two HD sessions 1-4
    weeks apart</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Indications
    for EPO<ul>
<li>Pts w/ Hb \&lt;10 who are not iron deficient or who’s anemia
    persists despite adequate iron repletion</li>
</ul>
</li>
</ul>
<p>Hyperkalemia (Goal K \&lt; 5.5)</p>
<ul>
<li>Generally
    , only develops in patients who are oliguric or with other problems,
    such as high K diet or hypoaldosteronism (due to ACEi/ARB)<ul>
<li>Low K diet (\&lt; 40-70 mEq/day or 1500-2700 mg/day)</li>
<li>Add loop diuretics if hypertensive or hypervolemic; Can use
    thiazide if GFR &gt; 30</li>
<li>GI cation exchangers: work within hours<ul>
<li>
<ul>
<li>Patiromer (Veltassa): binds K in colon in exchange for
        calcium</li>
<li>Sodium zirconium cyclosilicate (Lokelma): binds K
    throughout intestine in exchange for sodium and H
    <sup>+</sup></li>
<li>Need nephrology
    attending approval for Lokelma</li>
</ul>
</li>
</ul>
</li>
<li>Do not use Kayexelate as chronic therapy</li>
<li>Ensure acidosis is treated due to resulting extracellular K
    <sup>+</sup> shift (see next section)</li>
<li>Consider discontinuing ACEi/ARB if K persistently &gt; 5.5</li>
</ul>
</li>
</ul>
<p>Mineral bone disease in ESRD</p>
<ul>
<li>Ca goal: \&lt; 9.5. Avoid supplementation in mild or asymptomatic
    hypocalcemia</li>
<li>Vit D25 goal: &gt; 20. Replete as in normal population</li>
<li>Phos
    goal: \&lt; 5.5. Start phosphate binders (sevelamer or noncalcium-based
    binders typically preferred) with goal Phos 3.5-5.5<ul>
<li>Sevelamer: use lowest dose effective to achieve Phos \&lt; 5.5<ul>
<li>
<ul>
<li>Phos 5.5-7.5: initial dose 800 TID with meals</li>
<li>Phos 7.5-9.0: initial dose 1200-1600 TID with meals</li>
<li>Phos &gt; 9: initial dose 1600 TID</li>
<li>Can titrate
    dosing by 400 to 800 mg per meal at 2 week intervals</li>
</ul>
</li>
</ul>
</li>
<li>Restrict dietary phos to 900 mg/day</li>
</ul>
</li>
<li>PTH
    goal: 2-9 x ULN, although exact goal unknown in assessing renal bone
    disease. Treatment involves calcimemetics, calcitriol, and synthetic
    vitamin D analogues.</li>
</ul>
<p>Diabetes in CKD</p>
<ul>
<li>A1c
    goal:<ul>
<li>\&lt; 7% in patients with long lifespan, few comorbidities, and
    minimal hypoglycemia</li>
<li>\&lt; 8% in patients with multiple comorbidities and frequent/high
    risk for hypoglycemia</li>
</ul>
</li>
<li>Treatment
    :<ul>
<li>Metformin remains first-line but should be dose-reduced based on
    eGFR<ul>
<li>
<ul>
<li>eGFR &gt; 45: Maximum daily dose of 2000mg/day (1000mg bid)</li>
<li>eGFR \&lt; 45: Reduce max daily dose to 1000mg/day (500mg
    bid)</li>
<li>eGFR \&lt; 30: Discontinue</li>
</ul>
</li>
</ul>
</li>
<li>SGLT-2 inhibitors for patients with eGFR &gt; 30 reduces
    progression to ESRD and death from renal or cardiovascular
    causes</li>
</ul>
</li>
</ul>
<p>Dialysis initiation</p>
<ul>
<li>Dialysis
    education is usually started once patients are in CKD IV with eGFR
    15-30, so earlier referral to nephrology may be helpful in patients
    with eGFR 30-45 who you think may be heading towards eGFR \&lt;30</li>
<li>Late
    referral to a nephrologist (ie, less than three months before the
    start of dialysis therapy) is associated with higher mortality after
    the initiation of dialysis</li>
</ul></section><section class="print-page" id="nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants"><h1 id="nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants-common-side-effects-of-renal-transplant-immune-suppresants">Common Side Effects of Renal Transplant Immune Suppresants<a class="headerlink" href="#nephrology-nephrology-common-side-effects-renal-transplant-immune-suppresants-common-side-effects-of-renal-transplant-immune-suppresants" title="Permanent link">&para;</a></h1>
<p>Common Side Effects of Renal Transplant Immune Suppressants</p>
<p>Tacrolimus</p>
<ul>
<li>Toxicity
    mediated by vasoconstriction to the afferent arterioles</li>
<li>Symptoms
    /signs: Hand tremors, headache, nausea, thrombotic microangiopathy,
    hyperkalemia</li>
<li>Calcium
    channel blockers can prevent the
    ↑
    renal vasoconstriction thus most transplant patients with HTN are on
    dihydropyridine CCBs</li>
</ul>
<p>Mycophenolate</p>
<ul>
<li>Symptoms
    /signs: diarrhea, abdominal pain, nausea, leukopenia, anemia,
    thrombocytopenia, tremor</li>
<li>Can cause microscopic colitis</li>
</ul>
<p>Diarrhea</p>
<ul>
<li>Common
    SE in patients on Mycophenolate and Tacro [common regimen]<ul>
<li>Diarrhea [usually severe] can precede Tacro toxicity<ul>
<li>Diarrhea causes increased Tacro levels due to
    ↑
    absorption and
    ↓
    intraluminal metabolism</li>
</ul>
</li>
<li>Mechanism<ul>
<li>↓
    enzymatic activity of the CYP3A system + P-glycopeptide in
    enterocytes damaged by inflammation and infection lead to
    decreased intraluminal tacro metabolism</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information for Overnight Admits:</p>
<ul>
<li>Transplant
    teams do not want the night team to change transplant medications
    overnight</li>
<li>Exception
    : If pt has severe diarrhea, can hold night tacro dose and inform
    the day team</li>
<li>Ensure the pt gets a daily tacrolimus level (order q am at 5:00).
    Always order tacrolimus dose at 6:00 am and 6:00 pm (regardless of
    what time patient takes at home, lab can only run am tacro levels at
    a certain time in batches)</li>
<li>EXCEPTION
    : If late afternoon admission, consider paging the fellow (since its
    early) and ask if they want the evening dose held until the am level
    comes back</li>
<li>Transplant patients with normal kidney function can have regular
    diet</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hematuria"><h1 id="nephrology-nephrology-hematuria-hematuria">Hematuria<a class="headerlink" href="#nephrology-nephrology-hematuria-hematuria" title="Permanent link">&para;</a></h1>
<p>Hematuria – Laura Binari/Patrick Steadman</p>
<p>Background</p>
<ul>
<li>Definition
    :
    3 urinalyses with three or more RBC/hpf; 1 urinalysis with 100
    RBC/hpf or g
    ross hematuria (1 cc blood/L urine can induce color change)</li>
<li>Can be transient (exercise-induced, menses, trauma)</li>
<li>Hemoglobinuria: Hgb should be found only in intact RBCs, presence in
    urine suggests intravascular hemolysis AND fully saturated
    haptoglobin sites in serum</li>
<li>Myoglobinuria: should be found only in intact muscle, presence in
    urine suggests myonecrosis (serum haptoglobin has LOW affinity for
    myoglobin)</li>
<li>Concurrent pyuria/dysuria: consider urinary tract infection or
    bladder malignancy</li>
<li>Recent URI: think infection related glomerulonephritis, IgA,
    vasculitis, anti-GBM</li>
<li>Positive Family Hx of Hematuria: consider PKD, Sickle Cell Disease</li>
<li>Bleeding from other sites: think inherited/acquired bleeding
    disorder, anticoagulation</li>
<li>Unilateral Flank Pain: Ureteral calculus, renal malignancy, IgA
    Nephropathy</li>
<li>Microscopic hematuria
    – should be considered for CT Urography and cystoscopy</li>
<li>Malignancy Risk Factors: male sex, age &gt; 35, smoking Hx, exposures
    to benzene/aromatic amine, cyclophosphamide, indwelling foreign
    body, pelvis irradiation, chronic UTIs, h/o heavy NSAID use, h/o
    urologic disorders/disease (nephrolithiasis, BPH)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glomerular</td>
<td>Extraglomerular (Non-Glomerular Source)</td>
<td>Extraglomerular (Non-Glomerular Source)</td>
<td>Extraglomerular (Non-Glomerular Source)</td>
<td>Extraglomerular (Non-Glomerular Source)</td>
</tr>
<tr>
<td>Glomerular</td>
<td>Kidney</td>
<td>Ureter/ Bladder</td>
<td>Prostate/ Urethra</td>
<td>Other</td>
</tr>
<tr>
<td>IgA Nephropathy IgA Vasculitis</td>
<td>Pyelo</td>
<td>Cystitis</td>
<td>BPH</td>
<td>Exercise-Induced</td>
</tr>
<tr>
<td>Lupus Nephritis</td>
<td>Renal Cell Carcinoma</td>
<td>Urothelial Malignancy</td>
<td>Prostate Cancer</td>
<td>Bleeding Diathesis</td>
</tr>
<tr>
<td>Infection-related glomerulonephritis</td>
<td>PKD</td>
<td>Nephrolithiasis</td>
<td>TURP</td>
<td>Meds (AC)</td>
</tr>
<tr>
<td>Anti-GBM Disease (Goodpasture’s)</td>
<td>Sickle Cell Papillary Necrosis</td>
<td>Ureteral Stricture</td>
<td>Urethritis (STI)</td>
<td>Menses</td>
</tr>
<tr>
<td>ANCA-associated</td>
<td>Malignant HTN</td>
<td>Hemorrhagic Cystitis (chemo/rads)</td>
<td>NaN</td>
<td>TB Schistoso-miasis</td>
</tr>
<tr>
<td>Genetic (Thin Basement Membrane Nephropathy/Alport Syndrome)</td>
<td>Arterial embolism Vein thrombus</td>
<td>Traumatic Foley/procedure</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Step 1: Confirm the presence of hematuria<ul>
<li>Dipstick positive heme: urinary RBCs (hematuria), free myoglobin
    or free hemoglobin</li>
<li>Centrifuge the urine<ul>
<li>
<ul>
<li>Red sediment -&gt; true hematuria (urinary RBCs)</li>
<li>Red supernatant +</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>Positive dipstick: myoglobulin or hemoglobin</li>
<li>Negative dipstick porphyria, Pyridium, beets, rhubarb, or
    ingestion of food dyes</li>
</ul>
</li>
<li>
<p>Step 2: Determine if there is a GLOMERULAR or NON-GLOMERULAR source
    of bleeding</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Glomerular</td>
<td>Extraglomerular</td>
</tr>
<tr>
<td>Color (if gross hematuria)</td>
<td>Red, Cola, Smoky</td>
<td>Red/Pink</td>
</tr>
<tr>
<td>Clots</td>
<td>Absent</td>
<td>Present/Absent</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>May be > 500 mg/day</td>
<td>\&lt; 500 mg/day</td>
</tr>
<tr>
<td>RBC Morphology</td>
<td>Dysmorphic RBCs present</td>
<td>Normal (isomorphic)</td>
</tr>
<tr>
<td>RBC Casts</td>
<td>May be Present</td>
<td>Absent</td>
</tr>
</tbody>
</table>
<ul>
<li>
<ul>
<li>Glomerular Bleeding:
        -   -   Isolated Hematuria: Differential includes IgA
                Nephropathy, thin BM dx, Alport’s
            -   Nephritic syndrome (new proteinuria, pyuria, HTN, edema,
                rise in Cr): post-infectious GN, MPGN, ANCA vasculitis,
                Goodpasture’s, lupus nephritis
            -   Workup: anti-GMB, anti-DNase/ASO, ANA, ANCA, C3, C4,
                cryo, Hep B &amp; C, HIV
            -   Indications for Renal Biopsy: glomerular bleeding + risk
                factors for progressive disease, including albuminuria &gt;
                30 mg/day, new hypertension &gt; 140/90 or significant
                elevation over baseline BP, rise in serum creatinine</li>
<li>Extraglomerular Bleeding (Imaging Section)<ul>
<li>
<ul>
<li>If historical clues suggest nephrolithiasis, start with
        non-con CT A/P</li>
<li>Gross Hematuria otherwise should be evaluated with CT
    A/P w/ and w/o contrast (CT urography); consult urology
    for cystoscopy (often done as outpatient referral)</li>
<li>If clots are passed, more likely to be secondary to
    lower urinary source, and if a high burden of clots
    poses a risk of obstruction (urologic emergency)</li>
<li>If extraglomerular bleeding with clots: hematuria
    catheter needs to be placed ASAP (2 valve catheter,
    20-24 Fr (!); page urology if nursing unable to obtain)</li>
</ul>
</li>
</ul>
</li>
<li>CT Urography is more sensitive than IV pyelogram for renal
    masses and stones.</li>
<li>Prefer Renal and Bladder Ultrasound in pregnant patients</li>
<li>All pts w/gross hematuria that is non-glomerular in source, in
    whom infection has been ruled out, warrant cystoscopy
    . Additionally, all patients with clots need cystoscopy</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypercalcemia"><h1 id="nephrology-nephrology-hypercalcemia-hypercalcemia">Hypercalcemia<a class="headerlink" href="#nephrology-nephrology-hypercalcemia-hypercalcemia" title="Permanent link">&para;</a></h1>
<p>Hypercalcemia – Rebecca Choudhry, Trevor Stevens</p>
<p>Background</p>
<ul>
<li>Definition
    : Total serum Calcium (Ca <sup>+2</sup> ) &gt;10.5</li>
<li>REMEMBER
    : Most Ca <sup>+2</sup> in the serum is bound primarily to albumin</li>
<li>In a hypoalbuminemic pt, you can correct the total Ca <sup>+2</sup>
    level with the formula:
    -<ul>
<li>0.8 x (4 – albumin level) + uncorrected Ca <sup>+2</sup> =
    corrected Ca <sup>+2</sup></li>
</ul>
</li>
<li>Ca <sup>+2</sup>
    > 12 can cause shortened QT interval;
    Ca <sup>+2</sup>
    at high levels can cause 2
    nd
    and 3 <sup>rd</sup> degree heart block, ventricular arrhythmias, and
    ST elevations mimicking MI</li>
<li>Pts with
    Ca <sup>+2</sup>
    \&lt;12 or chronic moderate hypercalcemia are often asymptomatic</li>
<li>Severe
    manifestations uncommon at
    Ca <sup>+2</sup>
    \&lt;14</li>
</ul>
<p>Presentation</p>
<ul>
<li>“
    Stones
    , bones, thrones
    , belly groans, and psychiatric overtones”<ul>
<li>Bone pain</li>
<li>Polydipsia/polyuria</li>
<li>Nausea/constipation</li>
<li>Depressed mood/cognitive impairment</li>
<li>Decreased level of consciousness</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Step
    1: Stop any contributing medications: Ca <sup>+2</sup> supplements,
    vitamin D, HCTZ</li>
<li>Step
    2: Check PTH! Then check magnesium, phosphorus, total vitamin D.</li>
<li>Step
    3: Determine if PTH is low or normal/high<ul>
<li>
<ul>
<li>Normal or ↑
        PTH
        -   Primary hyperparathyroidism:
            ↑
            Ca <sup>+2</sup>
            and
            ↓
            PO <sub>4</sub> <sup>-3</sup>
        -   Tertiary hyperparathyroidism (autologous secretion of
            PTH in CKD/ESRD)
            -   PTH often &gt; 800 with
                ↑
                Ca <sup>+2</sup>
                and
                ↑
                PO <sub>4</sub> <sup>-3</sup>
        -   Familial
            hypercalciuric hypercalcemia (often asymptomatic, no
            treatment required)
        -   24-hour urine
            Ca <sup>+2</sup>
            \&lt; 200</li>
<li>↓
    PTH<ul>
<li>Humoral hypercalcemia of malignancy: PTHrP</li>
<li>Malignancy: Bone survey for blastic lesions, skeletal
    survey for lytic lesions</li>
<li>Excess vitamin D intake: 25 hydroxyvitamin D</li>
<li>Granulomatous disease: 1,25 dihydroxy vitamin D, 25
    hydroxyvitamin D, nl or ACE</li>
<li>Milk-alkali syndrome</li>
<li>Immobilization</li>
<li>Medications (HCTZ)</li>
<li>Thyrotoxicosis: TSH</li>
<li>Adrenal insufficiency: AM cortisol</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Step 4: Determine if
    Ca <sup>+2</sup>
    > 14 (corrected for albumin) or symptomatic and treat accordingly<ul>
<li>
<ul>
<li>If
        Ca <sup>+2</sup>
        \&lt; 14 and asymptomatic
        -   Encourage PO hydration
        -   Replete volume with IV normal saline if hypovolemic
        -   Address underlying cause as above</li>
<li>If
    Ca <sup>+2</sup>
    > 12 with symptoms or Ca &gt; 14<ul>
<li>Trend Ca q8 hrs, EKG, monitor on telemetry; strict I/Os
    <u>+</u>
    foley catheter</li>
<li>Replete volume w/ IV NS boluses then start maintenance
    IVF at ~ 200cc/hr<ul>
<li>Goal UOP is 100-150cc/hr</li>
</ul>
</li>
<li>Add loop diuretic (Lasix) only AFTER patient is volume
    replete</li>
<li>Bisphosphonate:<ul>
<li>Zoledronic acid 4mg IV (EGFR &gt;60), Pamidronate 90mg
    IV (EGFR 15-60)</li>
</ul>
</li>
</ul>
</li>
<li>If
    Ca <sup>+2</sup>
    >14 or neurologic symptoms, consider sub q (NOT
    intranasal!) calcitonin<ul>
<li>VUMC: requires approval from an oncology or endocrine
    attending<ul>
<li>Page VU/VA endocrine consult fellow to get approval</li>
<li>If cancer pt, page malignant heme or solid tumor
    fellow ​​​​​​​</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>­</p>
<p>Additional Information</p>
<ul>
<li>In
    CHF pt, consider early addition of a loop diuretic, especially if
    volume overloaded</li>
<li>In ESRD pt with hypercalcemia (rare), patient with oliguric AKI not
    responsive to IVF, or pt with severely elevated Ca 16-18, consult
    endocrine and nephrology early</li>
<li>In pts with sarcoid or lymphoma, consider high dose steroids (e.g.
    prednisone 60 mg daily although typically only need 15-25 mg/day)</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hyperkalemia"><h1 id="nephrology-nephrology-hyperkalemia-hyperkalemia">Hyperkalemia<a class="headerlink" href="#nephrology-nephrology-hyperkalemia-hyperkalemia" title="Permanent link">&para;</a></h1>
<p>Hyperkalemia – Mengyao Tang, Amanda Morrison</p>
<p>Background</p>
<ul>
<li>Causes: excessive intake (iatrogenic, supplementation), insufficient
    loss (CKD, AKI, type IV RTA, adrenal insufficiency, intracellular
    release or shifts (rhabdo, TLS, acidosis)</li>
<li>Medication-related: ACEi, ARB, MRA, NSAIDs, TMP/SMX, digoxin,
    heparin</li>
<li>“Pseudo”: hemolysis, severe leukocytosis, hand exercises w/
    tourniquet on during labdraw</li>
<li>Can be asymptomatic, or develop parasthesias, hyporeflexia, muscle
    weakness, GI upset</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Confirm it is real: check for hemolysis, repeat BMP</li>
<li>Check EKG for hyperkalemic changes<ul>
<li>
<ul>
<li>K <sup>+</sup> 5.5-6.5:  peaked T waves, prolonged PR
        interval</li>
<li>K <sup>+</sup> 6.5-8: prolonged QRS, loss of P wave, ST
    elevation, ectopic beats</li>
<li>K <sup>+</sup> &gt;8: sine wave pattern, asystole, PEA, VF</li>
</ul>
</li>
</ul>
</li>
<li>To establish cause once confirmed:<ul>
<li>
<ul>
<li>Labs: CBC with diff, UA, urine electrolytes, Mg, VBG
        -   Also consider LDH, haptoglobin, uric acid, CK</li>
<li>Imaging: bladder scan, renal ultrasound</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>If there are EKG changes<ul>
<li>
<ul>
<li>Calcium gluconate 1g IV (effective within 3-5 min)
        -   Stabilizes cardiac membrane for ~60mins
        -   SHOULD BE REPEATED HOURLY while Hyperkalemic</li>
</ul>
</li>
</ul>
</li>
<li>Correct acidosis: Can use NaHCO3 dosed based on bicarb deficit</li>
<li>Shift
    K <sup>+</sup>
    Intracellularly<ul>
<li>
<ul>
<li>D50 w/ regular insulin 10 units (can order using Adult
        Hyperkalemia order set in epic)
        -   Consider using 5 units if there is renal impairment
        -   Lasts for 4-6hrs (can be longer in renal impairment)</li>
<li>Beta Agonists (e.g. high-dose albuterol nebulizer); lasts
    2-4 hrs</li>
</ul>
</li>
</ul>
</li>
<li>Increase
    K <sup>+</sup>
    Excretion<ul>
<li>
<ul>
<li>Loop diuretic (e.g. lasix)
        -   If there is AKI or a volume deficit can administer with
            IVF (Don’t dry out an already dry patient! Sometimes a
            dry patient only needs fluids to start kaliuresis)
        -   Kayexalate 60g PO q2h until bowel movement (If using
            oral, ensure patient is having bowel movements and is
            not obstructed, could cause bowel injury/ necrosis)
            -   PO can take up to 2hrs to work
            -   Strongly consider per rectal administration for
                quicker onset of action or if unable to tolerate PO
                -   DO NOT GIVE WITH SORBITOL per rectum</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Hemodialysis<ul>
<li>
<ul>
<li>Can correct K <sup>+</sup> rapidly but will take time to set
        up, especially if pt does not have access</li>
<li>Consult nephrology early if severe hyper K <sup>+</sup> or
    concerned that pt will not respond</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypernatremia"><h1 id="nephrology-nephrology-hypernatremia-hypernatremia">Hypernatremia<a class="headerlink" href="#nephrology-nephrology-hypernatremia-hypernatremia" title="Permanent link">&para;</a></h1>
<p>Hypernatremia – Rebecca Choudhury, Trevor Stevens</p>
<p>Background</p>
<ul>
<li>Definition
    = Na <sup>+</sup> &gt;145;
    Hypernatremia is a lack of free water</li>
<li>Dehydration is both hypernatremia AND hypovolemia</li>
<li>New studies suggest there is no evidence that overcorrection of
    hypernatremia leads to adverse outcomes! Do not undertreat!</li>
<li>Common
    causes:
    Inadequate free water intake relative to solute intake (dementia,
    limited mobility, tube feeding/TPN (ICU), impaired thirst/adipsia
    from hypothalamic stroke)</li>
<li>Less common causes: Increased insensible losses, Upper GI losses,
    Na <sup>+</sup>
    overload (salt poisoning, iatrogenic from NS infusion,
    overcorrection)<ul>
<li>Renal losses: osmotic diuresis (hyperglycemia, SGLT-2
    inhibitors, urea, mannitol), central or nephrogenic diabetes
    insipidus</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Lethargy, irritability, confusion, esp. if chronic</li>
<li>Seizures, coma, hemorrhagic stroke, or subarachnoid hemorrhage in
    severe acute hypernatremia (typically &gt;158)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>If
    Na <sup>+</sup>
    145-150 and free water deficit \&lt; 3L, trial free water first, and if
    no improvement perform workup as below:</li>
<li>If
    Na <sup>+</sup>
    > 150, check serum osm, UA, urine
    Na <sup>+</sup>
    and urine osm if etiology is unclear<ul>
<li>
<ul>
<li>UOsm &gt;600, U
        Na <sup>+</sup>
        low (typically \&lt;25): volume depletion</li>
<li>UOsm &gt;600, U
    Na <sup>+</sup>
    high (typically &gt;100):
    Na <sup>+</sup>
    overload</li>
<li>UOsm \&lt; SOsm (typically \&lt;300): DI</li>
<li>UOsm 300-600: osmotic diuresis and/or partial DI</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Step 1: Treat any underlying cause (vomiting, hyperglycemia,
    medications)</li>
<li>Step 2: Determine volume status: If severely volume deplete (i.e.
    hypotensive) the patient will need lactated ringers to restore
    volume first and then D5W to restore free water</li>
<li>Step 3: Estimate free water deficit (FWD) and replete as below:<ul>
<li>Online calculators available (MDCalc)
    : FWD = TBW x [(serum Na/140) - 1]</li>
</ul>
</li>
<li>Step 4: determine if chronic or acute</li>
</ul>
<p>Acute Hypernatremia</p>
<ul>
<li>Correction for severe
    hypernatremia (\&lt;48 in duration, Na &gt;158), Na <sup>+</sup> \&lt;145
    within 24h</li>
<li>Requires
    ICU level care:
    Trend
    Na <sup>+</sup>
    q 2-3 hrs (plus glucose, if using D5W)<ul>
<li>Once
    Na <sup>+</sup>
    \&lt;145, can space to q6-8hrs</li>
</ul>
</li>
<li>Start D5W at 3-6 cc/kg/hr ( <sup>1/</sup> <sub>2</sub> NS if pt is
    severely hyperglycemic), titrate to desired correction rate</li>
</ul>
<p>Chronic Hypernatremia</p>
<ul>
<li>Correction
    (&gt;48h, most common scenario), aim for slow correction of
    10 mEq/L per day</li>
<li>Use the free water deficit to guide your plan and total free water
    needs</li>
<li>Trend Na q8-12hrs until stable at desired correction rate, then can
    space to q12-24h</li>
<li>Start D5W and give based on free water deficit; for starting rate
    and length you can also use “Stone’s formula”: 2 x body weight in kg
    = rate [mL/hr], and 2 x change in
    Na <sup>+</sup>
    desired = length [hrs] (e.g. if you want to drop
    Na <sup>+</sup>
    by 6 then run for 12 hrs)</li>
<li>If severely hyperglycemic: Use &frac12;NS at 1.35 mL/hr x patient’s
    weight in kg if pt</li>
<li>If mild and pt neurologically intact, may be done with oral or
    enteral (if feeding tube) water</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Pts w/
    suspected DI: <strong>Consult Nephrology</strong> (may require desmopressin or
    may receive desmopressin once stabilized to differentiate between
    central and nephrogenic DI)</li>
<li>Consider Urine volume an ongoing loss of free water, and add it to
    the D5W replacement</li>
<li>Pts with hypokalemia: giving K decreases total amount of free water
    you are giving the pt</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hyperphosphatemia"><h1 id="nephrology-nephrology-hyperphosphatemia-hyperphosphatemia">Hyperphosphatemia<a class="headerlink" href="#nephrology-nephrology-hyperphosphatemia-hyperphosphatemia" title="Permanent link">&para;</a></h1>
<p>Hyperphosphatemia – Peter Thorne, Amanda Morrison</p>
<p>Background</p>
<ul>
<li>Phosphate (
    PO <sub>4</sub> <sup>-3</sup>
    ) &gt;4.5mg/dL</li>
<li>Etiologies:<ul>
<li>Cellular lysis (TLS, Rhabdomyolysis)</li>
<li>Increased intake/absorption or iatrogenic hyperphosphatemia
    (Over repletion, Vitamin D toxicity, use of Fleet’s enemas,
    etc.)</li>
<li>Decreased phosphate clearance (Acute or chronic renal disease,
    hypoparathyroidism, pseudohypoparathyroidism)</li>
<li>Acute extracellular shifts of phosphate (DKA, severe Lactic
    acidosis)</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Symptoms are usually secondary to coexistent hypocalcemia
    (psychosis, seizure, perioral paresthesia’s, muscle weakness)</li>
<li>Can cause Acute phosphate nephropathy with phosphate containing
    laxatives</li>
<li>Calciphylaxis if concurrent hypercalcemia (high Ca <sup>+2</sup> x
    PO <sub>4</sub> <sup>-3</sup>
    product)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Labs: BMP (calcium, creatinine), Vit D, PTH, PTHrP, lactate</li>
</ul>
<p>Management</p>
<p>Acute</p>
<ul>
<li>If renal function normal, can often treat with IVF (promote
    PO <sub>4</sub> <sup>-3</sup>
    excretion)</li>
<li>Consider need for calcium supplementation (see hypocalcemia section)</li>
<li>If renal function impaired and severe hypocalcemia present =
    consider hemodialysis</li>
</ul>
<p>Chronic</p>
<ul>
<li>Usually secondary to chronic renal failure, goal
    PO <sub>4</sub> <sup>-3</sup>
    3.5-5.5 in CKD patients</li>
<li>Renal diet (low
    PO <sub>4</sub> <sup>-3</sup>
    )</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    binders: Ca <sup>+2</sup> containing (calcium carbonate and calcium
    acetate) and non Ca <sup>+2</sup> containing (sevelamer, lanthanum,
    and iron based such as ferric citrate)<ul>
<li>
<ul>
<li>Sevelamer is significantly more expensive than calcium
        containing binders
        -   Given 3 times daily with meals, started at 800mg (Can be
            ↑
            to 1,600mg TID)
        -   Should not be given if pt is not eating</li>
<li>Calcium acetate: started at 1334mg TID with meals</li>
</ul>
</li>
</ul>
</li>
<li>Limit dose changes to chronic binders upon discharge</li>
<li>Need to avoid calcium containing binders in patients with
    calciphylaxis</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypokalemia"><h1 id="nephrology-nephrology-hypokalemia-hypokalemia">Hypokalemia<a class="headerlink" href="#nephrology-nephrology-hypokalemia-hypokalemia" title="Permanent link">&para;</a></h1>
<p>Hypokalemia – Peter Thorne/Patrick Steadman</p>
<p>Background</p>
<ul>
<li>Potassium (K <sup>+</sup> ) \&lt; 3.5 mEq/L</li>
<li>98% of total body K <sup>+</sup> is intracellular (majority in
    muscle cells)</li>
<li>Goal: prevent life threatening complication (e.g. arrhythmia),
    replace deficit, elucidate cause</li>
<li>Insulin and catecholamines (Beta adrenoreceptors) are key drivers of
    transcellular shifts</li>
<li>H+ and K <sup>+</sup> will trade places to maintain
    electroneutrality</li>
</ul>
<p>Presentation</p>
<ul>
<li>Malaise, weakness, myalgias, decreased gastrointestinal motility</li>
<li>EKG changes:<ul>
<li>Mild: ST segment depression, decreased T wave amplitude</li>
<li>Severe: U-waves (most commonly seen in precordial leads V2 and
    V3)</li>
</ul>
</li>
<li>Severe hypokalemia can lead to rhabdomyolysis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>History: Consider decreased
    K <sup>+</sup>
    intake, increased entry into cells (ex: Increased cell production,
    elevated beta-adrenergic activity, hypothermia), GI losses, urinary
    losses (diuretics, hypomagnesemia, RTA, tubular defects,
    hyperaldosteronism)</li>
<li>If concomitant metabolic alkalosis: Normal/low BP suggests diuretic
    use, vomiting or Gitelman/Bartter syndromes</li>
<li>Hypertension suggests renovascular disease or primary
    mineralocorticoid excess</li>
<li>Labs: BMP, CBC, VBG, urine electrolytes, magnesium, POC glucose, CK</li>
<li>Imaging: Renal US, CT A/P</li>
<li>Other: aldosterone, renin, cortisol</li>
</ul>
<p>Management</p>
<ul>
<li>Check Mg <sup>+2</sup> , replete to 2; Give empirically while
    waiting for serum Mg <sup>+2</sup></li>
<li>K <sup>+</sup>
    preparation (route); replete to 4</li>
<li>Choice of agent:<ul>
<li>KCl is used for repletion in the hospital<ul>
<li>
<ul>
<li>PO tablets for mild asymptomatic hypokalemia</li>
<li>IV can be given through peripheral (
    rate is 10mEq/hr)
    or central access</li>
</ul>
</li>
</ul>
</li>
<li>K <sup>+</sup> bicarbonate can be dissolved and put through G
    tube<ul>
<li>
<ul>
<li>Useful in pts with hypokalemia and metabolic acidosis</li>
</ul>
</li>
</ul>
</li>
<li>K <sup>+</sup> acetate is given IV, rarely used (often additive
    to TPN)</li>
</ul>
</li>
<li>Dose:<ul>
<li>Normal renal function: 10 mEq K <sup>+</sup> is expected to
    raise serum [K <sup>+</sup> ] by 0.1 mEq/L</li>
<li>Significant CKD or AKI: at risk of overcorrection<ul>
<li>
<ul>
<li>Shortcut: multiply the mEq by the Cr = how much
        K <sup>+</sup>
        expected to rise</li>
</ul>
</li>
</ul>
</li>
<li>Once
    K <sup>+</sup>
    higher than 5.5,
    K <sup>+</sup>
    increases much faster and rules above do not apply</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypomagnesemia"><h1 id="nephrology-nephrology-hypomagnesemia-hypomagnesemia">Hypomagnesemia<a class="headerlink" href="#nephrology-nephrology-hypomagnesemia-hypomagnesemia" title="Permanent link">&para;</a></h1>
<p>Hypomagnesemia – Mike Tozier</p>
<p>Background</p>
<ul>
<li>Serum Magnesium (Mg <sup>+2</sup> ) \&lt; 1.8 mg/dL, most pts
    asymptomatic until \&lt;1.2 mg/dL<ul>
<li>
<ul>
<li>Severe [
        Mg <sup>+2</sup> ] \&lt; 1 mg/dL</li>
</ul>
</li>
</ul>
</li>
<li>Causes<ul>
<li>
<ul>
<li>GI: Diarrhea, malabsorption, acute pancreatitis, EtOH use,
        terminal cancer, TPN, vomiting, NG suction, GI fistulas,
        anorexia, short gut syndrome, small bowel bypass</li>
<li>Drugs: PPIs, loop diuretics, thiazides, digoxin,
    amphotericin, aminoglycosides, foscarnet, cisplatin,
    cetuximab, CNIs, laxatives, pentamidine</li>
<li>Renal: ATN recovery, transplant, others genetic or drugs as
    listed elsewhere</li>
<li>Extracellular-&gt;Intracellular shift: DKA treatment/recovery,
    refeeding, hungry bone syndrome, correction of metabolic
    acidosis, pancreatitis, EtOH withdrawal</li>
<li>Genetic: Gittleman, Bartter, multiple other rare conditions</li>
<li>Other: DM, hyperCa, hyperthyroid, hyperaldosteronism, burns,
    lactation, Vit D deficiency, heat, prolonged exercise,
    mitral valve prolapse, pseudohypomagnesemia 2/2 EDTA tube,
    lactation</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Consider in ICU pts, refractory hypocalcemia or hypokalemia, heart
    failure, any arrhythmia, chronic diarrhea/GI losses, refeeding, pts
    on PPIs or diuretics</li>
<li>Initial symptoms: nausea, vomiting, appetite loss, fatigue,
    weakness, paresthesia’s, contractions, cramps, depression,
    agitation, psychosis, dysphagia</li>
<li>Severe symptoms: seizures, drowsiness, confusion, coma, arrhythmias</li>
<li>Vertical nystagmus, tetany (Chvostek sign, Trousseau), tremors,
    fasciculations, seizures</li>
<li>EKG: Initially wide QRS, peaked Ts. Progresses to wide PR,
    diminished T, arrhythmias</li>
<li>Other labs: Ca <sup>+2</sup> , K <sup>+</sup> , can use FE
    Mg <sup>+2</sup>
    (order urine
    Mg <sup>+2</sup>
    and Cr, serum Cr and
    Mg <sup>+2</sup>
    ) or 24-hour urine for
    Mg <sup>+2</sup>
    to distinguish renal vs GI etiology (FE
    Mg <sup>+2</sup>
    >2% renal, \&lt;2% GI)</li>
<li>Urine studies need to be done when pt at steady state, if checked
    shortly after IV magnesium given you will see elevated magnesium
    excretion no matter the cause</li>
</ul>
<p>Management</p>
<ul>
<li>Correct
    underlying cause, replete based on severity (Dosing below for normal
    GFR)</li>
<li>Oral
    : asymptomatic pts, can cause GI symptoms, not well absorbed<ul>
<li>
<ul>
<li>Sustained release (
        Mg <sup>+2</sup>
        Chloride or
        Mg <sup>+2</sup>
        L-lactate) better tolerated and absorbed, though standard
        preparations (
        Mg <sup>+2</sup>
        oxide) are faster acting</li>
<li>Mg <sup>+2</sup>
    chloride: 3-4 tabs BID (total 30 to 56 meq [15 to 28
    mmol]) for severe hypo
    Mg <sup>+2</sup></li>
<li>2-4 tabs daily (total 10 to 28 meq [5 to 14 mmol]) for
    mild hypo
    Mg <sup>+2</sup></li>
<li>Mg <sup>+2</sup>
    oxide: 400-800 mg BID (20 to 40 mmol [40 to 80 meq]) for
    mod-severe hypo
    Mg <sup>+2</sup></li>
</ul>
</li>
</ul>
</li>
<li>Intravenous
    : for symptomatic patients or if GI intolerance to oral<ul>
<li>
<ul>
<li>Mg <sup>+2</sup>
        \&lt;1 mg/dL: 4 to 8g of MgSO4 (32 to 64 meq [16 to 32 mmol])
        over 12 to 24 hrs</li>
<li>Mg <sup>+2</sup>
    1 to 1.5 mg/dL: 4 g MgSO4 (16 to 32 meq [8 to 16 mmol])
    over 4 to 12 hrs</li>
<li>Mg <sup>+2</sup>
    1.6 to 1.9 give 1 to 2 grams MgSO4 (8 to 16 meq [4 to 8
    mmol]) 1-2 hrs</li>
<li>VUMC only has 4g bags of IV mag so would need to ask nurses
    to only infuse &frac12; bag</li>
<li>Infusion rate should not exceed 2 g/hr to minimize urinary
    excretion</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Renal impairment: replete with caution, reduce dose by 50-75% and
    monitor closely</li>
<li>If persistent hypo
    Mg <sup>+2</sup>
    in pts requiring diuresis, try K-sparing diuretic (e.g. Amiloride)</li>
<li>Treat concomitant hypokalemia, hypocalcemia or hypophosphatemia</li>
<li>In pts with concomitant hypophos and hypocalcemia, IV
    Mg <sup>+2</sup>
    alone -&gt; worse hypophos</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hyponatremia"><h1 id="nephrology-nephrology-hyponatremia-hyponatremia">Hyponatremia<a class="headerlink" href="#nephrology-nephrology-hyponatremia-hyponatremia" title="Permanent link">&para;</a></h1>
<p>Hyponatremia – Kaitlyn Reasoner</p>
<p>Background</p>
<ul>
<li>Definition: Serum Na <sup>+</sup> \&lt;135 mEq/L. A problem of excess
    free water.</li>
<li>Can
    be due to
    ↑
    water intake or
    ↑
    ADH release</li>
<li>ADH
    is released in response to
    ↑
    serum osm or
    ↓
    volume (low cardiac output can also look like low volume to the
    body, e.g. heart failure exacerbation)</li>
<li>The
    body will protect volume over preserving a normal osmolarity and ADH
    will be released for low
    volume/low CO despite a low osm</li>
<li>Herniation almost exclusively occurs in acute settings including
    large volume H2O ingestion (ecstasy usage, runners, psychogenic),
    post-op, intracranial pathology</li>
<li>Severity:<ul>
<li>Mild
    :
    Na <sup>+</sup>
    130-134</li>
<li>Moderate
    :
    Na <sup>+</sup>
    125-129</li>
<li>Severe
    :
    Na <sup>+</sup>
    \&lt;125</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Mild to moderate symptoms include lethargy, N/V, dizziness,
    confusion, fatigue, cramping</li>
<li>Severe
    symptoms
    include obtundation, coma, respiratory arrest, seizure.</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>Rule
    out pseudohyponatremia, review meds and infusions (often hypotonic)<ul>
<li>If pt also has hypokalemia, correcting the K <sup>+</sup> will
    also increase the
    Na <sup>+</sup>
    and this must
    be taken into account when calculating the amount of
    Na <sup>+</sup>
    needed</li>
</ul>
</li>
<li>Step 1:
    Rule out pseudohyponatremia<ul>
<li>Causes of pseudohyponatremia include hyperglycemia (most
    common), sorbitol, mannitol, sucrose, elevated lipids, TSH, or
    protein</li>
<li>Check glucose, TSH, lipids, and protein level</li>
<li>If hyperglycemic
    , corrected serum
    Na <sup>+</sup>
    = measured
    Na <sup>+</sup>
    + 1.6*[(glucose – 100)/100]<ul>
<li>
<ul>
<li>If corrected
        Na <sup>+</sup>
        is normal, treat hyperglycemia; there is not a water
        balance problem</li>
<li>If corrected
    Na <sup>+</sup>
    is low, there is hypotonic hyponatremia + coexisting
    hyperglycemia</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Step 2:
    Determine if ADH is high or low and treat accordingly<ul>
<li>Send urine osm and urine
    Na <sup>+</sup>
    at the same time you send serum osm</li>
<li>High ADH
    =
    ↑
    urine osm or urine osm&gt;serum osm</li>
<li>Low ADH
    , high free water intake =
    ↓
    urine osm or urine osm\&lt; serum osm<ul>
<li>
<ul>
<li>Causes: primary polydipsia, beer potomania, tea &amp; toast</li>
<li>Treatment <strong>:</strong> restrict free water</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Step 3:
    If ADH is high, determine if it is <strong>appropriate</strong> versus
    <strong>inappropriate</strong> elevation<ul>
<li>Appropriate
    ADH is due to
    ↓
    actual/perceived
    circulatory volume or
    ↓
    cardiac output<ul>
<li>
<ul>
<li>Causes:  hypovolemia, cirrhosis, heart failure/
        ↓
        CO, nephrotic syndrome, salt wasting (HCTZ, cerebral,
        SSRIs, etc.)</li>
<li>Urine
    Na <sup>+</sup>
    usually \&lt;30 mmol</li>
<li>Treatment: Stop offending medications &amp; Correct volume
    perturbation</li>
</ul>
</li>
</ul>
</li>
<li>Inappropriate
    ADH
    ↑
    , euvolemic or
    ↑
    ADH out of proportion to stimulus, urine
    Na <sup>+</sup>
    >30<ul>
<li>
<ul>
<li>Causes: SIADH (malignancy, meds, surgery, pulmonary
        disease, hormones, pain, or bladder distension)</li>
<li>Treatment: water restriction, can add NaCl tabs or urea
    if fluid restriction is severe</li>
<li>Calculate Water
    restriction for SIADH (L per day) = 600 / Urine osm<ul>
<li>600 is the
    average salt meq in an American diet per day</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<p>Consider nephrology consult if:</p>
<ul>
<li>Considering ddAVP clamp for overcorrection, or suspect this will
    happen, PO urea (a non-sodium osmole), Lasix if appropriate,
    vaptans, salt tablets</li>
<li>ICU care for pts with serum
    Na <sup>+</sup>
    \&lt;120</li>
<li>Pts at high risk for osmotic demyelination: chronic liver disease,
    chronic alcohol use, concurrent
    hypokalemia, malnourishment, serum sodium \&lt;105</li>
</ul>
<p>Acute (\&lt;48 hrs)</p>
<ul>
<li>If severe or symptomatic + not autocorrecting, give 50 cc bolus 3%
    NaCl (HTS)</li>
<li>Monitor
    Na <sup>+</sup>
    q1-2 hr</li>
<li>Goal is an initial rapid 4-6 mEq/L correction and then hold<ul>
<li>May
    require Hypertonic Saline
    infusion</li>
</ul>
</li>
</ul>
<p>Chronic (&gt;48 hrs or unknown, higher risk for osmotic demyelination if
corrected too quickly):</p>
<ul>
<li>Goal
    Na <sup>+</sup>
    correction rate 4-6 mEq/L over 24 hrs (Max 8mEq/L)<ul>
<li>8 mEq/L per 24 hrs thereafter</li>
</ul>
</li>
<li>If severe, proceed
    as under acute above</li>
</ul></section><section class="print-page" id="nephrology-nephrology-hypophosphatemia"><h1 id="nephrology-nephrology-hypophosphatemia-hypophosphatemia">Hypophosphatemia<a class="headerlink" href="#nephrology-nephrology-hypophosphatemia-hypophosphatemia" title="Permanent link">&para;</a></h1>
<p>Hypophosphatemia – Peter Thorne</p>
<p>Background</p>
<ul>
<li>PO <sub>4</sub>
    -3
    \&lt; 2.3mg/dL</li>
<li>Common Causes<ul>
<li>
<ul>
<li>Internal redistribution, reduced intestinal absorption</li>
<li>Malnourished pts: refeeding syndrome and intracellular
    movement/use of phos</li>
<li>Insulin moves phos intracellular as does respiratory
    alkalosis</li>
<li>Phos binders on purpose or inadvertently (calcium, aluminum,
    magnesium antacids)</li>
<li>Excessive loss (diarrhea, CRRT, increased urinary excretion)</li>
<li>Proximal tubular dysfunction such as in Fanconi Syndrome</li>
<li>Hyperparathyroidism causes renal phos wasting</li>
<li>Post-parathyroidectomy leading to hungry bone syndrome</li>
<li>Vitamin D deficiency or resistance</li>
</ul>
</li>
</ul>
</li>
<li>PO <sub>4</sub>
    -3
    is primarily found in bone and intracellular space</li>
<li>Required for metabolic pathways (ATP production!)</li>
<li>Most renal reabsorption occurs in proximal tubule via
    sodium-phosphate cotransporter</li>
</ul>
<p>Presentation</p>
<ul>
<li>Mild Hypophosphatemia (serum &gt;2.0) rarely symptomatic</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    \&lt; 2.0: Muscle weakness</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    \&lt; 1.0: Heart failure, respiratory failure, rhabdomyolysis, seizures</li>
<li>Failure to wean from ventilator</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Urine
    PO <sub>4</sub> <sup>-3</sup>
    level if cause not readily apparent</li>
<li>Calculate
    Fe
    PO <sub>4</sub> <sup>-3</sup>
    ([U
    PO <sub>4</sub> <sup>-3</sup>
    x PCr x 100]/[P
    PO <sub>4</sub> <sup>-3</sup>
    x UCr]).<ul>
<li>
<ul>
<li>Fe
        PO <sub>4</sub> <sup>-3</sup>
        \&lt; 5% = normal renal response to hypophos: redistribution or
        ↓
        absorption</li>
<li>Fe
    PO <sub>4</sub> <sup>-3</sup>
    > 5% = renal phos wasting</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Caution repleting pts with impaired renal function: start with half
    suggested dose</li>
<li>If K <sup>+</sup> &gt; 4 and patient requires IV repletion, may need to
    use sodium
    PO <sub>4</sub> <sup>-3</sup>
    in place of K <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    IV; po preferred unless severe or symptomatic, or patient cannot
    take po</li>
<li>K-
    Phos
    neutral: oral, each 250mg tablet has 8 mmol of
    PO <sub>4</sub> <sup>-3</sup>
    and 1.1mEq of K <sup>+</sup></li>
<li>K <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    : IV, each mL has 3mmol
    PO <sub>4</sub> <sup>-3</sup>
    , 4.4 meq K <sup>+</sup></li>
<li>Na <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    : IV, each mL has 3mmol
    PO <sub>4</sub> <sup>-3</sup></li>
<li>IV
    repletion
    is diluted in 250mL NS or D5W and infused over 4-6 hrs</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    >1.5: PO: 40 – 80 mmol
    K <sup>+</sup>
    Phos neutral (aim for 1 mmol/kg) divided into 3-4 doses/day</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    1.25 - 1.5: oral 100 mmol
    K <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    neutral in 3-4 divided doses if asymptomatic</li>
<li>IV: 30 mmol K <sup>+</sup>
    PO <sub>4</sub> <sup>-3</sup>
    over 6 hours
    (aim for 0.4mmol/kg)
    if symptomatic</li>
<li>PO <sub>4</sub> <sup>-3</sup>
    \&lt;1.25: IV: 80mmol
    K <sup>+</sup>
    Phos over approximately 12 hours (aim for 0.5mmol/kg)<ul>
<li>
<ul>
<li>Check serum
        PO <sub>4</sub> <sup>-3</sup>
        2-12 hrs after last dose of
        PO <sub>4</sub> <sup>-3</sup>
        to determine if additional needs</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-metabolic-acidosis"><h1 id="nephrology-nephrology-metabolic-acidosis-metabolic-acidosis">Metabolic acidosis<a class="headerlink" href="#nephrology-nephrology-metabolic-acidosis-metabolic-acidosis" title="Permanent link">&para;</a></h1>
<p>Approach to Metabolic Acidosis – Ned Hardison</p>
<p>ABG (VBG) reference ranges:</p>
<ul>
<li>pH
    = 7.36-7.44 (~7.32-7.40)</li>
<li>PCO2
    = 36-44 mmHg</li>
<li>HCO3
    = 22-26 mEq/L</li>
<li>VBG
    can be used to screen for hypercarbia, but not to assess degree of
    hypercarbia</li>
<li>pH
    between ABG and VBG correlates well with mean difference 0.035 pH
    units</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Disorder</td>
<td>pH</td>
<td>PaCO2</td>
<td>HCO3</td>
</tr>
<tr>
<td>Metabolic acidosis</td>
<td>↓</td>
<td>↓</td>
<td>↓↓</td>
</tr>
<tr>
<td>Metabolic alkalosis</td>
<td>↑</td>
<td>↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>Respiratory acidosis</td>
<td>↓</td>
<td>↑↑</td>
<td>↑</td>
</tr>
<tr>
<td>Respiratory alkalosis</td>
<td>↑</td>
<td>↓↓</td>
<td>↓</td>
</tr>
</tbody>
</table>
<p><img src="/sites/default/files/inline-images/Equations.png" data-entity-type="file" data-entity-uuid="a98df158-2416-441f-8fd3-0f2e195b5b56" alt="Equations" /></p>
<p>Non-anion gap metabolic acidosis (NAGMA)</p>
<ul>
<li>In
    practice
    , there are two sources of bicarb deficit – kidneys or gut<ul>
<li>
<ul>
<li>Urine anion-gap can differentiate between the two</li>
<li>It corresponds to unmeasured NH4+ which kidneys should
    excrete to remove acid excess if they are functioning
    appropriately</li>
</ul>
</li>
</ul>
</li>
<li>Urine
    anion gap = Unmeasured cations (NH4+) – unmeasured anions = U­Na +
    UK – UCl<ul>
<li>
<ul>
<li>Positive
        value, low NH4+, kidneys not working appropriately, = renal
        etiology</li>
<li>Ne-GUT-ive
    value, high NH4+, kidneys working appropriately = gut loss</li>
</ul>
</li>
</ul>
</li>
<li>Caveat
    : Proximal RTA has a normal distal urine acidification and has a
    negative urine AG</li>
</ul>
<p>Managing Metabolic Acidosis</p>
<ul>
<li>Metabolic acidosis is evidence of an underlying metabolic
    derangement</li>
<li>Severe
    metabolic acidosis due to shock and hypoperfusion can lead to poor
    response to vasopressors, arrhythmias, and cerebral edema<ul>
<li>
<ul>
<li>1 ampule NaHCO3 = 50 mEq NaHCO3, can give 1-3 amps</li>
<li>NaHCO3 solution alone is hypertonic; Administer in &frac12; NS or
    D5W to avoid hypernatremia but NS usually avoided b/c of
    risk of worsening acidosis</li>
<li>Or a bicarb gtt, order 3 amps of NaHCO3 in 1L of D5W</li>
</ul>
</li>
</ul>
</li>
<li>Evidence
    for use of bicarbonate is mixed: No proven benefit in lactic
    acidosis or DKA, but some experts suggest use in DKA when pH\&lt;7.1<ul>
<li>
<ul>
<li>In acute NAGMA, reasonable to give bicarbonate when bicarb
        \&lt;12 or pH \&lt;7.1-7.2</li>
</ul>
</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Anion Gap</td>
<td>Non-anion gap</td>
</tr>
<tr>
<td>Etiologies</td>
<td>Glycols (ethylene, diethylene, propylene) Oxoproline (d/t APAP overdose) L-lactate (std. measured lactate) D-lactate (d/t short bowel syndrome) Methanol (and other alcohols) Aspirin Renal failure (uremia, PO4, SO4) Ketoacidosis (DM, EtOH, starvation)</td>
<td>Gut Losses: Diarrhea Renal Losses: - AKI, CKD - Renal tubular acidosis - Crystalloid infusion - Carbonic anhydrase inhibitors</td>
</tr>
<tr>
<td>Further Workup</td>
<td>For all cases: BMP, consider ABG, UA, &plusmn; EKG</td>
<td>For all cases: BMP, consider ABG, UA, &plusmn; EKG</td>
</tr>
<tr>
<td>Further Workup</td>
<td>- Elevated osmolar gap (&gt;10) can suggest ingestion (G or M, above) - Calculate ∆∆ , interpret as above - Consider UA (ketonuria), LFTs, lactate, Utox, β-OH-butyrate, APAP/ASA/EtOH levels - Evaluate medication list for causes(e.g. Metformin, Linezolid)</td>
<td>- Urine anion gap - &plusmn; further w/u of AKI/RTA</td>
</tr>
</tbody>
</table></section><section class="print-page" id="nephrology-nephrology-peritonitis-patients-pd"><h1 id="nephrology-nephrology-peritonitis-patients-pd-peritonitis-in-patients-on-pd">Peritonitis in patients on PD<a class="headerlink" href="#nephrology-nephrology-peritonitis-patients-pd-peritonitis-in-patients-on-pd" title="Permanent link">&para;</a></h1>
<p>Peritonitis in patients on PD</p>
<p>Background</p>
<ul>
<li>Etiology
    likely 2/2 contamination with pathogenic skin bacteria during
    exchanges or due to exit-site or tunnel infection</li>
<li>Usually present with cloudy effluent fluid and abdominal pain but
    can be present even in the absence of one of these</li>
<li>Important
    history to obtain: recent contamination, accidental disconnection,
    endoscopic or gynecologic procedure, as well as the presence of
    constipation or diarrhea</li>
<li>Definitive
    diagnosis requires 2 of the following:<ul>
<li>Clinical features consistent with peritonitis</li>
<li>Positive dialysis effluent culture</li>
<li>Dialysis effluent with WBC &gt; 100 with PMN &gt; 50%<ul>
<li>
<ul>
<li>Even
        if WBC count \&lt; 100, presence of &gt; 50% PMNs is still
        strong evidence of peritonitis in pts with rapid cycle
        PD</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Culture
    peritoneal fluid (requires training and equipment, performed by
    Nephrology)</li>
<li>Peritoneal
    cell count with diff, gram stain and culture</li>
<li>Obtain
    peripheral blood cultures if there is concern for sepsis</li>
</ul>
<p>Management</p>
<ul>
<li>All
    PD orders, intraperitoneal antibiotics, and prescription adjustments
    should be directed by ESRD consult service (page them overnight if
    concerns)</li>
<li>Treatment
    with intraperitoneal antibiotics should be started immediately after
    specimens have been obtained if there is high clinical suspicion</li>
<li>Empiric
    antibiotics regimen should cover both gram positive and gram
    negative organisms, typically with Vanc and third generation
    Cephalosporin</li>
<li>Systemic
    antibiotics are generally not necessary unless pts have systemic
    signs of sepsis</li>
<li>Pts
    with relapsing, recurrent or repeat peritonitis will likely need
    catheter removal</li>
</ul>
<p>Secondary prevention</p>
<ul>
<li>Treatment
    with intraperitoneal OR IV antibiotics (for any infection
    requiring &gt; 1 dose of antibiotics) requires prophylaxis for fungal
    peritonitis with either:<ul>
<li>Nystatin 400,000 to 500,000 units orally TID</li>
<li>Fluconazole 200 mg every other day or 100 mg qdaily</li>
</ul>
</li>
<li>Dialysate
    should be drained the day of endoscopies or gynecological procedures</li>
</ul></section><section class="print-page" id="nephrology-nephrology-renal-replacement-therapy"><h1 id="nephrology-nephrology-renal-replacement-therapy-renal-replacement-therapy">Renal Replacement Therapy<a class="headerlink" href="#nephrology-nephrology-renal-replacement-therapy-renal-replacement-therapy" title="Permanent link">&para;</a></h1>
<p>Renal Replacement Therapy – Joseph Quintana, David Li, Taylor Riggs</p>
<p>Indications</p>
<p>for Acute Renal Replacement Therapy [</p>
<p>AEIOU</p>
<p>]</p>
<ul>
<li>Acidosis
    : intractable severe pH \&lt;7.1 <u>and</u> hypervolemia<ul>
<li>Unless
    acidemia quickly reversible like DKA</li>
</ul>
</li>
<li>Electrolytes:
    K, Na, Ca, Phos, Uric acid which are unable to correct by
    noninvasive or temporizing measures<ul>
<li>Hyperkalemia
    : &gt;6.5 mEq/L, cardiac changes, warrant urgent dialysis;
    Temporize them until dialysis (insulin D5/D50, IV calcium,
    albuterol, potassium binders)</li>
</ul>
</li>
<li>Intoxication
    : methanol, ethylene glycol, Lithium, ASA</li>
<li>Overload
    : fluid overload, particularly hypervolemia and pulmonary edema, and
    particularly with renal failure (AKI or ESRD)<ul>
<li>Try IV Lasix challenge 240 mg IV (if &gt;200 mL in 2 hrs urine,
    then no need for dialysis);<ul>
<li>Can discuss sequential nephron blockade with nephrology</li>
</ul>
</li>
<li>If anuric w/o pulmonary edema: nephrology will give things 24
    hours to settle out</li>
</ul>
</li>
<li>Uremia
    : pericarditis, seizure, functional platelet dysfunction in advance
    of a pending procedure, or decline in mental status</li>
</ul>
<p>ESRD Admits</p>
<ul>
<li>Consult
    ESRD in the morning for routine dialysis unless more urgently needed</li>
<li>Routine
    orders include MWF phos checks and Renal diet</li>
<li>For
    peritoneal dialysis pts, their diet can be more liberal and include
    low phos only or even regular diet (Can just ask what diet he/she
    follows at home)</li>
</ul></section><section class="print-page" id="nephrology-nephrology-transplant-aki"><h1 id="nephrology-nephrology-transplant-aki-transplant-aki">Transplant AKI<a class="headerlink" href="#nephrology-nephrology-transplant-aki-transplant-aki" title="Permanent link">&para;</a></h1>
<p>Transplant</p>
<p>AKI</p>
<p>Background</p>
<ul>
<li>Allograft
    dysfunction<ul>
<li>Increase in serum <strong>Cr <u>></u> 25 %</strong> from baseline in 1-3
    months</li>
<li>Failure of creatine to decrease post-transplant</li>
<li>Proteinuria &gt;1g/day</li>
</ul>
</li>
<li>How
    to think of transplant AKI?  Categorize dysfunction relative to
    transplant date<ul>
<li>Don’t forget about: Pre-, intra- and post- renal</li>
</ul>
</li>
<li>Dysfunction
    by time course:<ul>
<li>\&lt; 1-week
    post-transplant: [usually managed within transplant
    hospitalization]<ul>
<li>Often delayed graft function, can require dialysis in week 1
    until graft function</li>
<li>Vascular thrombosis of graft vessels, ATN (common in
    deceased donors)</li>
</ul>
</li>
<li><strong>> 1-week</strong> post-transplant (
    HIGH YIELD)<ul>
<li>Pyelonephritis/complicated UTI: Fever, abdominal pain, graft
    tenderness</li>
<li>Medication changes: hold new medications if possible<ul>
<li>Common offenders: NSAIDs, ACE, diuretics, azole
    antifungals</li>
<li>Medication non-compliance: Tacro and cyclosporine
    (rejection)</li>
</ul>
</li>
<li>Tacrolimus (FK) or cyclosporine (CsA) level:
    supra-therapeutic CNI causes arteriolar constriction and
    decreased GFR<ul>
<li>FK levels increase with n/v, diarrhea. FK toxicity also
    causes n/v, diarrhea (chicken vs egg argument)</li>
<li>FK or CsA should be dosed at 6 AM and 6 PM. FK levels
    must be drawn at 5 am (12-hour trough level) to be
    reliable for dosing adjustments</li>
</ul>
</li>
<li>Hypovolemia: fluids</li>
<li>Proteinuria: Transplant patients with 1 g/day proteinuria
    usually get biopsies<ul>
<li>Pts are commonly admitted for proteinuria found during
    chronic monitoring</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Check
    <strong>Cr nadir</strong> post-transplant</li>
<li>Obtain donor characteristics (CMV status, PRA, % HLA antibodies
    present)</li>
<li>Urinalysis
    , Protein/Cr spot ratio</li>
<li>Always
    schedule Tacro and cyclosporine level lab draws</li>
<li>Check
    prev. labs for <strong>donor-specific antibodies</strong> (DSAs)</li>
<li>BK &amp; CMV PCR: consider only if unclear source of AKI and no recent
    titers<ul>
<li>Avoid
    Ig assays, if evaluating for disease PCRs are test of choice</li>
</ul>
</li>
<li>Renal
    transplant U/S
    ($$)
    ? Are you answering a question?<ul>
<li>\&lt; 1 week:
    If acute graft dysfunction, look for thrombosis or urine/ureter
    leak</li>
<li>> 1 week
    :<ul>
<li>Cr does not respond to 48 hours of current management</li>
<li>Lack of clear, reversible causes</li>
<li>Hydronephrosis (can occur after stent removal 4-6 wks after
    transplant or due to perinephric fluid collection)</li>
<li>Arterial stenosis (
    ↑
    velocities in renal artery, tardus parvus waveforms)</li>
<li>Perinephric abscess with recurrent UTI/pyelonephritis</li>
<li>Urinoma (usually first 2-3 weeks), hematoma (after a biopsy)</li>
</ul>
</li>
<li>Unique findings:<ul>
<li>Resistive indices
    : reflect central renal vascular compliance</li>
<li>High indices in transplant patients signify parenchymal
    problem (rejection, infection, ATN)</li>
</ul>
</li>
</ul>
</li>
<li>Still
    Stumped?<ul>
<li>Viral infections: BK, CMV: check PCRs</li>
<li>Adenovirus associated with hemorrhagic cystitis, hepatitis, and
    nephritis in transplant patients. Check PCRs (Nasopharynx,
    blood, GI pathogen panel) positivity may suggest</li>
<li>Post-transplant lymphoproliferative disease (PTLD): lymphoid
    proliferations in transplants due to immunosuppression<ul>
<li>Serious and potentially fatal; Majority occur in the
    presence of EBV</li>
</ul>
</li>
<li>Biopsy: if renal u/s unremarkable likely warrant biopsy to guide
    therapy<ul>
<li>ATN vs rejection vs Adenovirus vs recurrent disease (FSGS,
    lupus, etc.)</li>
</ul>
</li>
</ul>
</li>
<li>Post
    Biopsy Care:
    -<ul>
<li>Watch for bleeding and HTN<ul>
<li>Blood can get into collecting system, then the capsule, and
    into the perinephric space</li>
<li>Page Kidney aka Pressure Tamponade: blood in the capsule
    compresses renal vessels</li>
<li>RAAS surge &rarr; <strong>rapid, severe HTN</strong> (STAT page the renal
    fellow)</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-ua"><h1 id="nephrology-nephrology-ua-ua">UA<a class="headerlink" href="#nephrology-nephrology-ua-ua" title="Permanent link">&para;</a></h1>
<p>Approach to Urinalysis – Laura Binari, Patrick Steadman</p>
<p>Background</p>
<ul>
<li>3
    components
    : Gross Evaluation, Dipstick Analysis, Microscopic Exam</li>
<li>Indications: dysuria, gross hematuria, fever, encephalopathy, AKI,
    volume overload</li>
<li>Technique: collect in clear, dry container; Pts instructed to clean
    external genitalia, provide midstream specimen; If Foley, obtain
    sample from catheter, not the urine bag</li>
<li>Spinning
    Urine<ul>
<li>
<ul>
<li>At VUMC, take sample to lab on 4 <sup>th</sup> floor to
        centrifuge the sample at 1500 rpm for 5 minutes, remove
        supernatant and then resuspend sediment, place drops of
        urine on the slide (there are slides with several discs),
        examine with microscope</li>
<li>At the VA, there is a microscopy room where you can spin
    urine as well- the renal fellow should be happy to help]
    Ideally, the specimen should be a fresh catch (\&lt;2-4 hours
    old); Beware: casts like to migrate to the edges of the
    coverslip!</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Gross Evaluation</p>
<ul>
<li>Turbid: DDx Is infection, precipitated crystals, chyluria</li>
<li>Color: Red Urine (broad DDx, see Hematuria section, includes certain
    meds such as rifampin/phenytoin), White (polyuria, phosphate
    crystals), Green (methylene blue), Pink (uric acid crystals,
    post-propofol infusion), Black (hemoglobinuria/myoglobinuria)</li>
</ul>
<p>Dipstick Analysis</p>
<ul>
<li>Quality of sample: should have zero squamous epithelial cells</li>
<li>Specific gravity
    : normal = 1.010<ul>
<li>
<ul>
<li>Surrogate for urine osmolality &amp; hydration status: can have
        falsely high specific gravity if large particles (contrast,
        glucose) present</li>
<li>Trick: Last 2 digits of S.G. x 30 = Uosm. For example; S.G.
    is 1.013; 13 x 30 = 390 mOsm/L</li>
</ul>
</li>
</ul>
</li>
<li>Urinary pH
    : normal pH is 5.5-6.5<ul>
<li>
<ul>
<li>Alkaline pH: bicarb suppl., vegan diet, urease producing
        organisms (staghorn calculi)</li>
<li>Acidic pH: uric acid stones, appropriate response to
    acidemia</li>
</ul>
</li>
</ul>
</li>
<li>Proteinuria
    : dipstick detects albumin ONLY (not paraproteins)<ul>
<li>
<ul>
<li>Mild albuminuria (30-300 mg/day) not detected by standard
        dipsticks</li>
<li>F/u with spot protein to Cr ratio or 24 hr urine collection
    (nephrotic range &gt;3.5 g/day); consider UPEP/SPEP based on
    clinical presentation.</li>
<li>Transient: due to volume depletion, CHF, fever, postural,
    exercise-induced</li>
<li>Ddx: primary glomerular dx, secondary glomerular dx (DM,
    amyloid, infxn, sickle cell, etc.) vs tubular vs overflow
    (multiple myeloma)</li>
</ul>
</li>
</ul>
</li>
<li>Heme
    (see hematuria section): False(+) if semen, false(-) w/ ascorbic
    acid</li>
<li>WBC
    :<ul>
<li>
<ul>
<li>False(+) 2/2 contamination with squamous cells. If bacteria
        -&gt; consider UTI/pyelo w/hematuria -&gt; inflammation; May have
        sterile pyuria</li>
<li>Ddx includes chlamydia, ureaplasma, TB, malignancy, viral
    infxn, kidney stones, GN, urethritis, steroid,
    cyclophosphamide use</li>
</ul>
</li>
</ul>
</li>
<li>Ketones
    : detects acetic acid (not beta-hydroxybutyrate)<ul>
<li>
<ul>
<li>Never normal in urine; only detects acetic acid</li>
<li>Ddx: DKA, starvation ketoacidosis, pregnancy, keto diet</li>
</ul>
</li>
</ul>
</li>
<li>Glucose
    : max threshold at proximal tubule exceeded (~serum glucose 180
    mg/dL)<ul>
<li>
<ul>
<li>DM, Cushing’s, liver/pancreatic dx, SGLT2i use; or a primary
        defect of proximal reabsorption (w/phosphaturia, uricosuria,
        amino aciduria think Fanconi syndrome)</li>
</ul>
</li>
</ul>
</li>
<li>Leukocyte
    <strong>esterase</strong> : enzyme released by lysed neutrophils, macrophages<ul>
<li>
<ul>
<li>Associated with pyuria and infections; false(-) from
        hematuria or glucosuria</li>
</ul>
</li>
</ul>
</li>
<li>Nitrites
    : reduction of urinary nitrates by nitrate reductase<ul>
<li>
<ul>
<li>Certain bacteria (e.g. Enterobacteriaceae) express, others
        (e.g. Enterococci) do not</li>
<li>Specific but not sensitive for UTI</li>
</ul>
</li>
</ul>
</li>
<li>Bilirubin
    : conjugated = water soluble (passes through glomerulus), unlike
    unconjugated<ul>
<li>
<ul>
<li>Liver dysfunction and biliary obstruction</li>
</ul>
</li>
</ul>
</li>
<li>Urobilinogen
    : end product of conjugated bilirubin, normally ~1.0mg/dL is normal<ul>
<li>
<ul>
<li>Can be elevated due to hepatocellular dx or hemolysis</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Microscopic Examination of the Urine Sediment</p>
<ul>
<li>Purpose
    : confirm/quantify dipstick findings + additional information in
    form of cells, casts, or crystals; Casts are cylindrical structures
    formed in tubule lumen</li>
<li>Cells
    :<ul>
<li>
<ul>
<li>Dysmorphic RBCs (sign of GN), squamous epithelial cells
        (contamination), tubular cells (abnormal, indicates renal
        dx), neutrophils (UTI, AIN, TB, sterile pyuria), eosinophils
        (think AIN, not sensitive thus cannot exclude diagnosis)</li>
</ul>
</li>
</ul>
</li>
<li>Casts
    :<ul>
<li>
<ul>
<li>Hyaline (pyelo; CKD, normal subjects), RBC (GN), WBC (GN,
        pyelo, interstitial dx, inflammation), epithelial - renal
        tubular cells (ATN, interstitial nephritis, nephritic sx,
        heavy metal ingestion), granular or waxy (presence of kidney
        disease, but nonspecific), muddy brown casts (ATN); fatty
        (nephrotic syndrome)</li>
</ul>
</li>
</ul>
</li>
<li>Crystals
    :<ul>
<li>
<ul>
<li>Ca++ oxalate (envelope/dumbbell shape), uric acid
        (rhombic/rosette shaped, classically formed in acidic
        urine), cystine (hexagonal, found in cystinuria), Mg ++
        ammonium phosphate (aka struvite stones, from increased
        ammonia production, in setting of urease producing bacteria
        such as Proteus or Klebsiella UTIs)</li>
<li>Calcium oxalate crystals + AKI, consider ethylene glycol
    intoxication</li>
<li>Uric Acid crystals + AKI, consider tumor lysis syndrome</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="nephrology-nephrology-uti-renal-transplant"><h1 id="nephrology-nephrology-uti-renal-transplant-uti-in-renal-transplant">UTI in Renal Transplant<a class="headerlink" href="#nephrology-nephrology-uti-renal-transplant-uti-in-renal-transplant" title="Permanent link">&para;</a></h1>
<p>UTI in Renal Transplant</p>
<p>Background</p>
<ul>
<li>Most
    common post-renal transplant infection</li>
<li>Associated
    with increased risk of rejection, allograft dysfunction and
    morbidity/mortality</li>
<li>Risk
    Factors
    /Unique Considerations for Transplant Patients:<ul>
<li>Vesicoureteral
    reflex is common in transplant patients due to short transplant
    ureter and no valve at vesicoureteral junction</li>
<li>Native
    kidneys/ureteral stumps (particularly if history of PKD), renal
    calculi, urinary tract abnormalities such as vesicoureteral
    reflex</li>
<li>Catheterization or indwelling urinary stents, defunctionalized
    bladder (related to prior oliguria/prolonged dialysis), deceased
    donor transplant, delayed graft function, transplant
    immunosuppression and/or systemic illness on steroids and
    immunosuppression (may mask symptoms of sepsis)</li>
</ul>
</li>
<li>Common
    organisms:<ul>
<li>GNRs: E. Coli most common, Pseudomonas, Enterococcus, Klebsiella</li>
<li>Increasing resistance to ciprofloxacin and Bactrim due to
    frequent use for prophylaxis</li>
</ul>
</li>
<li>Prevention
    :<ul>
<li>Prophylactic antibiotics: Bactrim DS daily, often used 6
    months-1year after transplant<ul>
<li>
<ul>
<li>If unable to tolerate Bactrim, consider cephalosporins
        or nitrofurantoin (if GFR&gt;60 and typically for 1 month
        only) in effort to prevent fluoroquinolone resistance</li>
</ul>
</li>
</ul>
</li>
<li>Basic infection prevention measures: hydration, frequent
    voiding, wiping front to back, voiding after sexual intercourse</li>
<li>Removal of indwelling devices/catheters as able</li>
<li>Consider post-coital antibiotics for women with recurrent UTI
    after sexual intercourse</li>
<li>Estrogen cream for peri/postmenopausal women (restores
    epithelial barrier)</li>
<li>Inconclusive data on cranberry juice</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Simple cystitis:
    dysuria, frequency/urgency, hematuria, suprapubic tenderness. No
    systemic symptoms and no indwelling catheters/stents/tubes.</li>
<li>Acute pyelonephritis/complicated UTI:
    above symptoms + fever/chills, malaise, nausea or allograft pain,
    leukocytosis<ul>
<li>Also includes urinary tract anomalies and/or indwelling
    catheters/stents/tubes</li>
</ul>
</li>
<li>The transplanted kidney is denervated, and pts may be not have upper
    urinary symptoms</li>
</ul>
<p>Evaluation</p>
<ul>
<li>UA
    with culture (midstream collection or “clean catch”)</li>
<li>Examine
    the native kidneys (CVA tenderness) AND the allograft (RLQ or LLQ)</li>
<li>Renal
    U/S (of both allograft and native kidneys) if: early post-op (1
    month), recurrent (2+ episodes in year), history of nephrolithiasis
    or if sepsis/bacteremia</li>
<li>Blood cultures if signs/symptoms of complicated UTI (systemic
    symptoms) OR if urine culture are consistent w/ hematogenous spread
    to the bladder (such as Staph aureus)</li>
<li>Consider
    testing for C. urealyticum if UA positive but culture negative</li>
</ul>
<p>Management</p>
<ul>
<li>Always
    get UA with culture (midstream collection)</li>
<li>Remove
    or replace indwelling catheters</li>
<li>Review
    prior culture susceptibilities (if available)</li>
<li>Empiric
    antibiotic regimens:<ul>
<li>
<ul>
<li>Simple cystitis
        : Fluoroquinolones (ciprofloxacin 250 BID or Levaquin 500 mg
        daily), Augmentin (500 mg BID), 3 <sup>rd</sup> gen
        cephalosporin (cefpodoxime 100 mg BID or cefixime 400 mg
        daily) or nitrofurantoin 100 mg BID (if GFR&gt;30)</li>
<li>Complicated UTI/Pyelonephritis
    (cover <em>Pseudomonas,</em> gram negatives and <em>Enterococcus</em> ):
    Rocephin 2g daily (preferred), Cefepime 2g q8hrs or Zosyn
    3.75g q6hrs, can also use meropenem 1g q8h (need ID
    approval)<ul>
<li>Note, Dr. Langone does not like Rocephin, but prefers:
    Cefepime if LE+, nitrite +, Zosyn if LE+ and nitrite –
    (covers enterococcus), or LVQ</li>
</ul>
</li>
<li>For stable pts with mild complicated UTI, can consider
    giving more narrow empiric antibiotics: Augmentin 875 mg BID
    or ciprofloxacin 500 mg q12h</li>
<li>MDR UTI: Consult transplant ID<ul>
<li>Options: meropenem-vaborbactam, ceftolozone-tazobactam,
    ceftazidime-avibactam</li>
</ul>
</li>
<li>If pts w/PCKD, include lipophilic antibiotic (such as
    ciprofloxacin) to penetrate cysts</li>
</ul>
</li>
</ul>
</li>
<li>Duration
    :<ul>
<li>
<ul>
<li>Simple cystitis: \&lt;6 months post-transplant: 10-14 d; &gt;6
        months post-transplant: 5-7 d</li>
<li>Complicated UTI: 14-21 d</li>
<li>Transition to oral if susceptible to Levaquin or Cipro
    (bioavailable in urinary tract)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Asymptomatic
    bacteriuria: no consensus; recommend getting 2 <sup>nd</sup> culture
    to confirm prior to treating<ul>
<li>
<ul>
<li>Often treated if \&lt;1-3 months since transplant. &gt; 3 months
        post-transplant likely do not require UA screenings and/or
        treatment for asymptomatic bacteriuria</li>
</ul>
</li>
</ul>
</li>
<li>Positive
    Blood Cultures Related to UTI<ul>
<li>
<ul>
<li>Repeat blood cultures are NOT typically indicated for
        uncomplicated gram negative bacteremia or for bacteremia
        from a localized source (such as pyelonephritis)</li>
<li>Consider repeating cultures when: concern for endovascular
    involvement, MDR gram negative bacilli, persistence of
    fever/leukocytosis &gt;72 hours after initiation of appropriate
    antibiotic
    regimen, new sepsis, concern for abscess or no source
    control</li>
</ul>
</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Nephrology</h1>
                        <h1 class='nav-section-title' id='section-neurology'>
                            Neurology <a class='headerlink' href='#section-neurology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="neurology-main"><p>Neurology</p>
<!-- these sections don't have specific authors listed - are they all by Hunter? -->

<p>Editor: Hunter Hewitt, MD</p>
<p>Reviewed by Christopher Lee, MD</p>
<p>Neurologic Emergencies</p>
<p>Stroke</p>
<p>Background</p>
<ul>
<li>
<p>Preferred term: Stroke (CVA is like saying heart attack instead of
    STEMI)</p>
</li>
<li>
<p>Sudden onset, focal (usually one-sided) neurologic deficits:
    weakness, sensory loss, vision loss, ataxia/unsteadiness, vertigo,
    double vision, facial droop, dysarthria, aphasia</p>
</li>
<li>
<p>Differential:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>stroke (ischemic or hemorrhagic)</p>
</li>
<li>
<p>seizure or post-ictal paralysis</p>
</li>
<li>
<p>headache phenomena (complex migraine)</p>
</li>
<li>
<p>cervical spinal cord lesions, though these more commonly cause
    bilateral symptoms</p>
</li>
</ul>
<!-- -->

<ul>
<li>Stroke-like symptoms can also develop as recrudescence – previous
    stroke or brain lesion symptoms worsening with systemic
    toxic/metabolic/infectious processes or hypotension</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Critical decision-making information: last known normal (LKN), time
    symptoms first observed, anticoagulation status, recent surgeries,
    history of bleeding (severe GIB or ICH), recent medications,
    platelet count, and baseline neuro exam</p>
</li>
<li>
<p>If symptoms developed with LKN within 24 hours -> stroke alert!</p>
</li>
<li>
<p><strong>If > 24 hours, can request Neuroalert Instead</strong></p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>VUMC: call 11111 and tell the operator stroke alert and current
    patient location</p>
</li>
<li>
<p>NAVA: call an RRT and stat page 835-5137, include in the page 911 at
    the end of the call back number to signal it is a stroke alert</p>
</li>
</ul>
<!-- -->

<ul>
<li>Stat head CTP (order CTH/CTA) for consideration of tPA or
    endovascular therapy</li>
</ul>
<!-- -->

<ul>
<li>
<p>If renal function is abnormal, discuss with neurology</p>
</li>
<li>
<p>Generally, go for CTA if the patient is a thrombectomy candidate
    <strong>(within 24 hrs of onset)</strong></p>
</li>
<li>
<p>MRI/MRA is an option but takes longer (MRAs are also better with
    Gadolinium)</p>
</li>
<li>
<p>Neurology service should be leading this portion</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Blood pressure goals</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ischemic stroke:</p>
<ul>
<li>
<p>In general aim for SBP \&lt;220</p>
</li>
<li>
<p>Patients with intracranial atherosclerosis may require higher BP
    to maintain perfusion</p>
</li>
</ul>
</li>
<li>
<p>Hemorrhagic stroke:</p>
<ul>
<li>
<p>SBP \&lt; 140 (BP management is key)</p>
</li>
<li>
<p>These pts are managed in Neuro ICU</p>
</li>
<li>
<p>Reverse coagulopathies and keep platelets >100,000</p>
</li>
</ul>
</li>
</ul>
<p>Status Epilepticus</p>
<p>Background</p>
<ul>
<li>
<p>Either a single seizure >5 minutes or ≥2 seizures occurring without
    a return to baseline in between</p>
</li>
<li>
<p>Differentiating convulsive seizures from non-epileptic events
    (“pseudoseizure”):</p>
</li>
</ul>
<!-- -->

<ul>
<li>Features that suggest non-epileptic/psychogenic event include
    moaning or talking throughout the event, “no-no” head shake,
    repetitive movements of opposing muscle groups, very arrhythmic or
    purposeful-looking movements, or seizures that have been ongoing for
    “hours”</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Fingerstick glucose, BMP/CBC, and UDS</p>
</li>
<li>
<p>Consult Neurology</p>
</li>
<li>
<p>EEG (start with 2hr) to determine if it is seizure or not and for
    titration of medications</p>
</li>
<li>
<p>Consider a non-contrasted head CT; MRI cannot be obtained while EEG
    is attached</p>
</li>
<li>
<p>Up to half of pts presenting in status epilepticus have no history
    of seizure, so they need urgent head imaging, consideration for
    lumbar puncture, infectious and toxic workup, tox screen, and
    sometimes rheumatologic or paraneoplastic workup</p>
</li>
<li>
<p>If Hx of seizure or on Antiseizure meds (ASMs) please order trough
    levels</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>ABCs! Start with benzos:</li>
</ul>
<!-- -->

<ul>
<li>
<p>2 mg lorazepam IV then repeat q1-3 minutes up to 0.1 mg/kg OR</p>
</li>
<li>
<p>5 mg of diazepam IV every minute (takes longer to give diazepam so
    would give concurrent ASM)</p>
</li>
<li>
<p>10 mg IM midazolam if no IV access</p>
</li>
</ul>
<!-- -->

<ul>
<li>After 2 rounds of benzos, would shift to antiepileptics if still in
    status (neurology should be contacted here if not already):</li>
</ul>
<!-- -->

<ul>
<li>
<p>IV fosphenytoin 20 mg/kg</p>
</li>
<li>
<p>IV levetiracetam 30-60 mg/kg <strong>(generally 3g, up to 4.5g max)</strong></p>
</li>
<li>
<p>IV valproic acid 30 mg/kg</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If still seizing at this point, the patient will likely need
    intubation</p>
</li>
<li>
<p>These pts MUST be placed on EEG if they get paralyzed or sedated
    because convulsive status often continues as nonconvulsive status,
    which still damages the brain!</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If still seizing, patients should be on midazolam, propofol or
    barbiturate infusions</p>
</li>
<li>
<p>Focal seizures, such as arm or face twitching with retained
    awareness do not always need to be treated to the point of
    initiating coma</p>
</li>
</ul>
<p>Myasthenia Gravis (MG) and Lambert-Eaton Myasthenic Syndrome (LEMS)</p>
<p>Background</p>
<ul>
<li>
<p>Disorders of the neuromuscular junction</p>
</li>
<li>
<p>MG affects the post-synaptic cleft at the acetylcholine receptor</p>
</li>
<li>
<p>LEMS affects the pre-synaptic cleft at the calcium channels</p>
</li>
</ul>
<!-- -->

<ul>
<li>Many cases are paraneoplastic (classically small cell lung
    carcinoma)</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Double vision, ptosis, dysarthria, dysphagia</p>
</li>
<li>
<p>Dyspnea looks different than in other conditions: air hunger,
    usually also with dysphagia</p>
</li>
<li>
<p>Initially, the patient may not look sick or distressed, but may have
    a short inspiratory time or difficulty speaking in complete
    sentences due to shallow breathing</p>
</li>
<li>
<p>Most pts have a known history of myasthenia, but up to 20% present
    initially with crisis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Exam</li>
</ul>
<!-- -->

<ul>
<li>
<p>Look closely for ptosis, nasal speech, weak neck flexion/extension
    (same nerve roots as diaphragm), interrupted speech to take extra
    breaths</p>
</li>
<li>
<p>These patients do not exhibit “huffing and puffing” like in
    COPD/asthma exacerbations</p>
<ul>
<li>Patients with NMJ disease can go from talking to intubated
    within several hours!</li>
</ul>
</li>
<li>
<p>LEMS: less ocular weakness, but do have extremity weakness and
    absent reflexes.</p>
</li>
<li>
<p>Pulmonary compromise is very rare in LEMS</p>
</li>
</ul>
<!-- -->

<ul>
<li>EMG/NCS</li>
</ul>
<!-- -->

<ul>
<li>
<p>MG: decremental response to repetitive stimulation</p>
</li>
<li>
<p>LEMS: increased amplitude in response to repetitive stimulation</p>
</li>
</ul>
<!-- -->

<ul>
<li>Labs</li>
</ul>
<!-- -->

<ul>
<li>Myasthenia antibody panels (send prior to IVIG/PLEX being given)</li>
</ul>
<!-- -->

<ul>
<li>Imaging</li>
</ul>
<!-- -->

<ul>
<li>Consider chest CT to look for thymic hyperplasia</li>
</ul>
<p>Management</p>
<ul>
<li>Monitor NIF (negative inspiratory force) at baseline and q4h</li>
</ul>
<!-- -->

<ul>
<li>
<p>Measure of diaphragmatic strength</p>
</li>
<li>
<p>Normal is \&lt;-60</p>
</li>
<li>
<p>If below -30, consider elective intubation</p>
</li>
<li>
<p>Note that patient effort will affect NIF values</p>
</li>
</ul>
<!-- -->

<ul>
<li>IVIG or PLEX</li>
</ul>
<!-- -->

<ul>
<li>
<p>Both have similar supportive evidence; IVIG is usually easier to do</p>
</li>
<li>
<p>PLEX has the risks you would expect with dialysis (e.g. fluid
    shifts) and coagulopathy</p>
</li>
<li>
<p>IVIG -> check IgA levels. Can increase risk of DVT, has risk of
    aseptic meningitis and provides significant fluid load so not ideal
    for pts with CHF</p>
</li>
</ul>
<!-- -->

<ul>
<li>Steroids</li>
</ul>
<!-- -->

<ul>
<li>
<p>Usually up-titrated SLOWLY (by 10-20 mg prednisone daily)</p>
</li>
<li>
<p>Rapid increases in steroids can worsen patients with MG**, so talk
    to neuro before adjusting**</p>
</li>
</ul>
<!-- -->

<ul>
<li>Pyridostigmine</li>
</ul>
<!-- -->

<ul>
<li>
<p>Typically continue at their home dose</p>
</li>
<li>
<p>Too much pyridostigmine can make patients worse (more secretions),
    so for those doing poorly on >90 mg per dose, consider lowering the
    dose</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Treat underlying causes of exacerbations: usually infections or
    other toxic/metabolic insults</p>
</li>
<li>
<p>Remove/avoid exacerbating medications: fluoroquinolones,
    aminoglycosides, beta blockers, and magnesium</p>
</li>
<li>
<p>LEMS specific management:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>3,4-diaminopyridine</p>
</li>
<li>
<p>Can respond to IVIG or pyridostigmine</p>
</li>
<li>
<p><strong>Workup for underlying neoplasm</strong></p>
</li>
</ul>
<p>Acute Inflammatory Demyelinating Polyneuropathy (AIDP)</p>
<p>Background</p>
<ul>
<li>
<p>Rapid onset polyneuropathy that manifests most often with ascending
    weakness and numbness that can involve the respiratory and facial
    musculature</p>
</li>
<li>
<p>Usually preceded by infectious illness a few weeks prior</p>
</li>
<li>
<p><strong>Patients are much more likely to get AIDP from an infection than
    any vaccine, weak vaccine links to AIDP are an addition 1-2 cases
    per million flu vaccines.</strong></p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Acute, progressive extremity weakness, weak or absent reflexes, and
    potentially subjective sensatory changes, especially back pain</li>
</ul>
<!-- -->

<ul>
<li>
<p>There are a TON of variants of AIDP, with some having cranial nerve
    weakness early, proximal weakness, sensory ataxia, primarily sensory
    loss, or rapid muscle weakness; do not use lack of classic ascending
    weakness to dismiss the idea of AIDP</p>
</li>
<li>
<p>Sensory loss is common in an ascending pattern too</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>LP – albuminocytologic dissociation = high protein with normal cell
    count</li>
</ul>
<!-- -->

<ul>
<li>One exception is HIV, which can cause AIDP but also have a high cell
    count and high protein count</li>
</ul>
<!-- -->

<ul>
<li>EMG/NCS</li>
</ul>
<!-- -->

<ul>
<li>
<p>Demyelinating pattern (temporal dispersion and decreased conduction
    velocities).</p>
</li>
<li>
<p><strong>This can be normal in the first few days, and is most useful 2+
    weeks out if the diagnosis is still unclear</strong></p>
</li>
</ul>
<!-- -->

<ul>
<li>Differential diagnosis: spinal cord lesions, LEMS, MG, acute HIV or
    HCV, viral myelitis (entero/West Nile)</li>
</ul>
<p>Management</p>
<ul>
<li>ABCs! NIF at baseline then Q4-6 hours</li>
</ul>
<!-- -->

<ul>
<li>NIF \&lt; -30 with good effort generally warrants ICU monitoring</li>
</ul>
<!-- -->

<ul>
<li>
<p>IVIG or PLEX</p>
</li>
<li>
<p>Can get worse with steroids</p>
</li>
</ul>
<p>Elevated Intracranial Pressure (ICP) and Hydrocephalus</p>
<p>Background</p>
<ul>
<li>Communicating hydrocephalus (i.e. non-obstructive)</li>
</ul>
<!-- -->

<ul>
<li>Causes: subarachnoid granule scarring after subarachnoid hemorrhage
    or meningitis, ependymoma producing excess CSF, venous sinus
    thrombosis</li>
</ul>
<!-- -->

<ul>
<li>Non-communicating hydrocephalus (i.e. obstructive)</li>
</ul>
<!-- -->

<ul>
<li>Causes: tumor, abscess, or hematoma in the midline ventricular
    structures</li>
</ul>
<!-- -->

<ul>
<li>Eventually, elevated ICP will cause brain herniation</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Headache, blurred vision, visual field reduction, enlarged blind
    spot, nausea, vomiting, syncope, coma</p>
</li>
<li>
<p>Sixth nerve palsies are common</p>
</li>
<li>
<p>Third nerve palsies <strong>(blown pupil)</strong> are classically associated
    with uncal herniation</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Good visual exam: visual fields, enlarged blind spot, papilledema
    (may not be present if very rapid ICP increase, even with vision
    loss), and 6<sup>th</sup> nerve palsies</p>
</li>
<li>
<p>Stat head CT to look for obstructions, mass lesions</p>
</li>
</ul>
<!-- -->

<ul>
<li>NSGY evaluation if obstructive lesion (removal vs ventricular drain)</li>
</ul>
<!-- -->

<ul>
<li>CTV or MRV to look for venous sinus thrombosis</li>
</ul>
<!-- -->

<ul>
<li>Venous sinus thrombosis needs AC, even if there is some degree of
    hemorrhagic infarction</li>
</ul>
<!-- -->

<ul>
<li>If no obstructive lesion LP with opening pressure</li>
</ul>
<!-- -->

<ul>
<li>If workup is otherwise normal, except for elevated opening pressure
    diagnosis = IIH</li>
</ul>
<p>Management</p>
<ul>
<li>Idiopathic intracranial hypertension (IIH)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diamox and/or topiramate</p>
</li>
<li>
<p>Ophthalmology evaluation emergently for consideration of nerve
    sheath fenestrations or urgent VPS placement if severe disc edema</p>
</li>
<li>
<p>If there is clinical concern for herniation:</p>
<ul>
<li>
<p>Mannitol: 50g IV, can be given peripherally. Has risks of renal
    injury</p>
</li>
<li>
<p>Hypertonic saline: 3%, 7% or 23% saline can be given, needs
    central access</p>
</li>
<li>
<p>Maintain head of bed at least 30° and loosen neck obstructions
    (c-collars) as able</p>
</li>
<li>
<p>NSGY consult for shunt consideration</p>
</li>
</ul>
</li>
<li>
<p>Hyperventilation can be done with goal PaCO2 30-34 mm Hg or ETCO2
    20-30 mmHg but is only a temporizing measure <strong>and risks rebound
    edema</strong></p>
<ul>
<li>After 4-6 hrs, compensatory pH changes in the blood prevent
    vasoconstrictive affects</li>
</ul>
</li>
</ul>
<p>Common Neurologic Problems</p>
<p>Altered Mental Status (AMS)</p>
<p>Background</p>
<ul>
<li>Definition: Change in a patient’s baseline cognition</li>
</ul>
<!-- -->

<ul>
<li>Can be hypoactive (lethargic) or hyperactive (agitated)</li>
</ul>
<!-- -->

<ul>
<li>Risk factors: Functional impairment, age > 75, dementia,
    depression, ETOH/substance use disorder, sensory impairment, recent
    surgery</li>
</ul>
<p>Etiologies: Consider MOVE STUPID mnemonic</p>
<ul>
<li>
<p>Metabolic (Hypo/hypernatremia, Hypercalcemia)</p>
</li>
<li>
<p>Oxygen (Hypoxia)</p>
</li>
<li>
<p>Vascular (CVA, Bleed, MI, CHF)</p>
</li>
<li>
<p>Endocrine (Hypoglycemia, Thyroid, Adrenal)</p>
</li>
<li>
<p>Seizure (postictal state)</p>
</li>
<li>
<p>Trauma</p>
</li>
<li>
<p>Uremia</p>
</li>
<li>
<p>Psychiatric</p>
</li>
<li>
<p>Infection</p>
</li>
<li>
<p>Drugs – intoxication, withdrawal, or medications</p>
</li>
<li>
<p>Delirium – see “Delirium” section in psychiatry</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Consider broad toxic, metabolic, and infectious workup as
    appropriate</li>
</ul>
<!-- -->

<ul>
<li>TSH, Vitamin B12, CBC, CMP, UA, CXR, VBG, blood Cx, glucose, UDS</li>
</ul>
<!-- -->

<ul>
<li>Review of medications</li>
</ul>
<!-- -->

<ul>
<li>Sedatives, anticholinergics, benzos/EtOH toxicity or withdrawal</li>
</ul>
<!-- -->

<ul>
<li>Head imaging in the setting of focal neurologic findings</li>
</ul>
<!-- -->

<ul>
<li>
<p>Start with head CT – note strokes take up to 24 hours to show up on
    CT</p>
</li>
<li>
<p>Consider MRI if high concern for stroke, inflammatory changes or
    infection</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>LP should be performed if there is any concern for meningitis</p>
</li>
<li>
<p>EEG is reasonable with fluctuating mental status or seizure-like
    activity</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>First line: nonpharmacologic interventions: HOMMEEESS</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hydration/nutrition: ensure patient fed, rule out constipation and
    urinary retention</p>
</li>
<li>
<p>Orientation</p>
</li>
<li>
<p>Mobilize out of bed 3x/daily as able</p>
</li>
<li>
<p>Manage pain</p>
</li>
<li>
<p>Eliminate unnecessary devices (restraints, catheters, tele, lines)
    and meds</p>
</li>
<li>
<p>Environmental modification: minimize devices, lights on/windows open
    during day</p>
</li>
<li>
<p>Engage family</p>
</li>
<li>
<p>Sensory restoration: use eyeglasses and hearing aids and reorient</p>
</li>
<li>
<p>Sleep protocol: minimize nighttime vitals, earplugs, sleep mask and
    no TV at night</p>
</li>
</ul>
<!-- -->

<ul>
<li>Second line: Pharmacologic approaches, see "Delirium" in section in
    psychiatry</li>
</ul>
<p>Seizure without Status Epilepticus</p>
<p>Background</p>
<ul>
<li>
<p>Risk factors: birth trauma, prematurity, TBI with loss of awareness
    > 1 hours or penetrating wound, strokes/tumors/abscesses, history
    of meningitis/encephalitis</p>
</li>
<li>
<p>Key for seizures: stereotyped event with sudden onset/offset</p>
</li>
</ul>
<!-- -->

<ul>
<li>Generally, if full body systems are involved (e.g., jerking or tonic
    activity), then there will also be loss of awareness</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>A clear description or recording of seizure semiology is helpful</p>
</li>
<li>
<p>Provoked seizures can develop with medications, hypo/hyperglycemia,
    significant electrolyte abnormalities (e.g. hyponatremia), and CNS
    infections</p>
</li>
<li>
<p>EEG is necessary for spell capture</p>
</li>
<li>
<p>MRI brain with and without contrast once stable</p>
</li>
</ul>
<p>Management</p>
<table>
<colgroup>
<col style="width: 44%" />
<col style="width: 55%" />
</colgroup>
<thead>
<tr class="header">
<th>AED</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Levetiracetam (Keppra) (PO/IV)</td>
<td><p>Sedation and agitation, worsening of underlying mood
disorders.</p>
<p>Can trial B6 supplementation to help with mood effects</p></td>
</tr>
<tr class="even">
<td>Valproic acid (Depakote) (PO/IV)</td>
<td>Sedation, hirsutism, PCOS, P450 inhibitor, nausea, liver injury,
hyperammonemia</td>
</tr>
<tr class="odd">
<td>Phenytoin (Dilantin) (PO/Fosphenytoin IV)</td>
<td>Sedation, gingival hyperplasia</td>
</tr>
<tr class="even">
<td>Lacosamide (Vimpat) (PO/IV)</td>
<td>Heart block, dizziness, ataxia</td>
</tr>
<tr class="odd">
<td>Topiramate (Topamax) (PO)</td>
<td>Kidney stones, metabolic acidosis, paresthesias, weight loss,
cognitive slowing</td>
</tr>
<tr class="even">
<td>Carbamazepine (Tegretol) (PO)</td>
<td>Hyponatremia, SJS (in Han Chinese check HLA), bone marrow
suppression (rare)</td>
</tr>
<tr class="odd">
<td>Oxcarbazepine (Trileptal) (PO)</td>
<td>Similar to carbamazepine</td>
</tr>
<tr class="even">
<td>Lamotrigine (Lamictal) (PO)</td>
<td>SJS/TEN, nausea. Least sedating</td>
</tr>
<tr class="odd">
<td>Zonisamide (Zonegran) (PO)</td>
<td>Sedation, ataxia, nausea, confusion</td>
</tr>
</tbody>
</table>

<p>Non-Epileptic Spells (aka PNES, psychogenic non-epileptic spells)</p>
<ul>
<li>
<p>Can be very difficult to distinguish from epileptic seizures</p>
</li>
<li>
<p>Features more common in PNES</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Retained awareness with bilateral extremity “seizing”</p>
</li>
<li>
<p>Opisthotonus (arching the back)</p>
</li>
<li>
<p>Talking during a spell</p>
</li>
<li>
<p>Excessively long spells (e.g. lasts hour or days)</p>
</li>
<li>
<p>Forced eye closure</p>
</li>
<li>
<p>Coachability during a spell or reacting to external stimuli</p>
</li>
<li>
<p>Heavy breathing during a spell with lots of rigorous movement</p>
</li>
<li>
<p>Immediately returning to normal after a spell</p>
</li>
</ul>
<!-- -->

<ul>
<li>Features more common in epileptic seizures:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Seizures arising out of sleep</p>
</li>
<li>
<p>Highly stereotyped</p>
</li>
<li>
<p>Incontinence</p>
</li>
<li>
<p>Severe injuries (e.g. burns)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Management</li>
</ul>
<!-- -->

<ul>
<li>
<p>Try to avoid excessive BZD use</p>
</li>
<li>
<p>This requires good clinical judgement as you wouldn't want to
    withhold Ativan and discover that the pt was having true atypical
    seizures. The compromise would be: do not repeatedly administer BZDs
    when there is suspicion for PNES as well as no evidence of response
    to prior BZD administration.</p>
</li>
</ul>
<p>Syncopal Convulsions</p>
<ul>
<li>Very common, can present with posturing and tonic-clonic movements
    happening for a few moments after syncope</li>
</ul>
<!-- -->

<ul>
<li>
<p>Should not last for more than 30 seconds</p>
</li>
<li>
<p>These are just related to syncope and do not typically require
    seizure medications</p>
</li>
<li>
<p>Workup:</p>
<ul>
<li>
<p>Two-hour EEG and MRI (with and without contrast)</p>
</li>
<li>
<p>Infectious workup, BMP, CBC, blood glucose, toxicology/drug
    screen</p>
</li>
<li>
<p>If there is concern for convulsive syncope, (carefully) check
    orthostatic vitals</p>
</li>
</ul>
</li>
</ul>
<p>Inpatient Headache (HA)</p>
<p>Background</p>
<ul>
<li>
<p>Important to distinguish primary and secondary headache</p>
</li>
<li>
<p>Red flags for secondary headaches (SNOOPP): Systemic symptoms,
    Neurologic symptoms, Onset that is sudden (thunderclap), Older age
    (new headache >40), Progression or evolution in previous headaches,
    Postural component</p>
</li>
<li>
<p>Other red flags: preceding trauma, headache awakening patient from
    sleep, no headache-free intervals, thunderclap headache (maximal
    intensity develops within 11 minutes or less)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Get a good description of where the pain is, when, associated
    symptoms, and assess for “red flag” features listed above</p>
</li>
<li>
<p>If there are any red flag features imaging and workup are necessary</p>
</li>
<li>
<p>Imaging depends on highest suspicions, but CTA head/neck is
    appropriate to evaluate for aneurysm (including neck to consider
    dissection). If any focal signs, MRI is generally preferred; venous
    imaging can be beneficial in headaches with features of elevated ICP</p>
</li>
<li>
<p>If no red flag features, then workup is not necessary, and focus is
    on treatment</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>NSAIDs and Tylenol for infrequent headaches, but consistent use
    (>2-3 a week) runs the risk of rebound headaches</p>
</li>
<li>
<p>Triptans for migraine, but contraindicated in patients with CAD,
    uncontrolled HTN, previous stroke. They must be used within 6 hour
    of onset</p>
</li>
</ul>
<!-- -->

<ul>
<li>There are theoretical concerns of serotonin syndrome when used with
    SSRI/SNRIs</li>
</ul>
<!-- -->

<ul>
<li>Migraines:</li>
</ul>
<!-- -->

<ul>
<li>
<p>“Migraine cocktail”: 1L fluid bolus, 4g Mg, IV Compazine(10mg) OR
    Phenergan(20mg) with Benadryl (25mg)</p>
</li>
<li>
<p>2<sup>nd</sup> line: Depakote 1000 mg IV, decadron 10mg IV , &plusmn;
    toradol 30mg IV, flexeril 10mg PO</p>
</li>
</ul>
<!-- -->

<ul>
<li>Cluster headache:</li>
</ul>
<!-- -->

<ul>
<li>Triptans, high flow O2 (>10 L), sometimes intranasal lidocaine if
    no arrhythmia history</li>
</ul>
<p>Outpatient Headache</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 41%" />
<col style="width: 38%" />
</colgroup>
<thead>
<tr class="header">
<th>Type</th>
<th>Presentation</th>
<th>First line meds</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Tension type (most common)</td>
<td>Generally bilateral, pressure/tightness, mild/moderate pain, no
significant photophobia, phonophobia, or nausea</td>
<td>Acetaminophen, TCAs, SNRIs</td>
</tr>
<tr class="even">
<td>Migraine</td>
<td><p>Unilateral, pulsating, moderate-to-severe pain, lasts 4-72hr,
worse with activity and improves with sleep</p>
<p>Associated with nausea, photophobia or phonophobia</p>
<p>± Aura</p></td>
<td><p>Acute: triptans</p>
<p>Preventive: TCAs, propranolol, topiramate, VPA</p></td>
</tr>
<tr class="odd">
<td>Cluster</td>
<td>Severe, often extreme unilateral orbital/supra-orbital/temporal
pain, often with lacrimation, rhinorrhea, sweating, swelling of face,
visual changes</td>
<td>Acute: 100% FiO2 at 12L/min for at least 15 mins, triptans,
Indomethacin</td>
</tr>
<tr class="even">
<td>Medication Overuse</td>
<td>HA at least ½ the days of the month, w/medication intake at least ½
the days of the month; often presents as worsening HA despite increased
intake of medication. Often seen with meds that include caffeine
(Excedrin, fioricet)</td>
<td>\*STOP offending medication, typically via taper. HA will worsen
before it gets better, start concurrent daily prophylactic headache
medication</td>
</tr>
</tbody>
</table>

<p>Medication Overview:</p>
<ul>
<li>Abortive</li>
</ul>
<!-- -->

<ul>
<li>
<p>Triptans (e.g. sumatriptan or rizatriptan)</p>
<ul>
<li>
<p>Cannot be used more than 10 days/month</p>
</li>
<li>
<p>Avoid in pts with hypertension/CAD</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Preventative</li>
</ul>
<!-- -->

<ul>
<li>
<p>Amitriptyline: indicated for both migraine and tension-type. Helps
    with sleep and comorbid depression. Most common side effects (SE) =
    dry mouth, sedation</p>
</li>
<li>
<p>Topiramate: has the best evidence among migraine meds. Can
    theoretically help with weight loss. Most common SE = sodas taste
    bad, sedation, parasthesias</p>
</li>
<li>
<p>Propranolol: useful for relative lack of interactions. Mild
    cardiac/blood pressure effects compared to other beta-blockers. Most
    common SE = drowsiness</p>
</li>
<li>
<p>Magnesium oxide: reduces headache frequency with almost no SE. Start
    400mg daily, can go up to 800mg BID. Patients can increase dose
    until they get diarrhea.</p>
</li>
<li>
<p>Riboflavin (vitamin B2): mild effect but effectively has no side
    effects. 400mg daily.</p>
</li>
<li>
<p>Gabapentin: can be useful if HAs have stabbing/electric quality.
    Main SE = sedation</p>
</li>
<li>
<p>Venlafaxine: useful for migraines with significant vestibular
    symptoms (dizziness). SE = hypertension/tachycardia.</p>
</li>
<li>
<p>Verapamil: can be used for migraine and cluster headaches. Can use
    ER formulation</p>
</li>
<li>
<p>Botox: can be administered every 3 months. Can be very effective,
    but pts generally will have had to fail multiple medications for
    insurance to approve refer to neuro resident clinic</p>
</li>
<li>
<p>CGRP receptor modulators (mostly injections) such as Rimegepant are
    newer options</p>
</li>
</ul>
<p>Parkinson’s Disease</p>
<p>Clinical Presentation</p>
<ul>
<li>
<p>Resting tremor is typically a very early symptom, often worse on one
    side</p>
</li>
<li>
<p>Cogwheel rigidity; can be confused for paratonia, which is seen in
    demented or encephalopathic patients who have involuntary variable
    resistance movements during passive ROM assessment</p>
</li>
<li>
<p>Speech changes (low volume), hand-writing changes (slow small
    movements)</p>
</li>
<li>
<p>Gait changes</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Festination – slow start with movements that gradually build up
    speed</p>
</li>
<li>
<p>En bloc turning – taking multiple steps to turn around</p>
</li>
</ul>
<!-- -->

<ul>
<li>Anosmia and REM behavior sleep disorders are very common</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Clinical diagnosis; there are some supportive imaging studies like
    DaTscan that looks for activity of substantia nigra (usually not
    necessary)</p>
</li>
<li>
<p>Clinical response to dopamine replacement is so typical that if a
    patient does not respond, it is important to consider a Parkinson
    plus syndrome (see below)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Dopamine replacement – carbidopa/levodopa; dosed at regular
    intervals several times a day. These generally do not need to be
    held on admission.</li>
</ul>
<!-- -->

<ul>
<li>If pt is altered, can hold anticholinergics, MAO-B inhibitors or
    COMT inhibitors</li>
</ul>
<!-- -->

<ul>
<li>
<p>Dopamine agonists – can cause confusion, hallucinations, dyskinesias</p>
</li>
<li>
<p>MAO-B inhibitors (MAOIs): can cause confusion, hallucinations,
    insomnia and dyskinesias</p>
</li>
<li>
<p>COMT inhibitors – can cause confusion, hallucinations, insomnia, and
    dyskinesias</p>
</li>
<li>
<p>Anticholinergics – useful for tremor when there is not much
    bradykinesia or gait disturbances. In older pts cognitive changes
    are a bigger concern along with hallucinations</p>
</li>
<li>
<p>PD medications are rarely titrated in the hospital because acute
    medical illness makes PD symptoms worse and everything will need to
    be re-adjusted as an outpatient</p>
</li>
<li>
<p>Be cautious with PRN anti-emetics in patients with PD. Many work via
    dopamine antagonism. Zofran is generally the safest option.</p>
</li>
<li>
<p>Similarly, many antipsychotics have dopamine antagonism. Safest
    option is seroquel</p>
</li>
</ul>
<p>Parkinson Plus Syndromes</p>
<p>Evaluation</p>
<ul>
<li>Consider if atypical features such as bilateral symmetric onset,
    early cognitive/personality changes, cerebellar findings, or
    prominent autonomic dysfunction early</li>
</ul>
<p>Types</p>
<ul>
<li>Progressive Supranuclear Palsy</li>
</ul>
<!-- -->

<ul>
<li>
<p>PD symptoms with early falls and minimal tremor</p>
</li>
<li>
<p>Vertical eye movement abnormalities</p>
</li>
</ul>
<!-- -->

<ul>
<li>Multisystem Atrophy</li>
</ul>
<!-- -->

<ul>
<li>
<p>Profound orthostatic hypotension without any increase in HR</p>
</li>
<li>
<p>Three types:</p>
<ul>
<li>
<p>MSA-A – autonomic features prominent (previously Shy-Drager
    Syndrome)</p>
</li>
<li>
<p>MSA-P – prominent atypical Parkinsonism features</p>
</li>
<li>
<p>MSA-C – prominent cerebellar dysfunction</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Lewy Body Dementia</li>
</ul>
<!-- -->

<ul>
<li>Parkinsonism with prominent early cognitive impairment and
    hallucinations</li>
</ul>
<p>Brain Masses</p>
<p>Background</p>
<ul>
<li>Neoplasm is the biggest concern</li>
</ul>
<!-- -->

<ul>
<li>
<p>90% of malignant brain masses are metastatic</p>
<ul>
<li>
<p>Most commonly: lung, RCC, breast, melanoma</p>
</li>
<li>
<p>Highest bleeding risk: melanoma, thyroid, choriocarcinoma, RCC</p>
</li>
</ul>
</li>
<li>
<p>Primary brain tumors</p>
<ul>
<li>
<p>Gliomas: WHO Grade I-IV</p>
<ul>
<li>
<p>Glioblastoma multiforme (GBM) – WHO Grade IV; large
    heterogenous masses with edema; heterogenous contrast
    enhancement; can cross the corpus callosum</p>
</li>
<li>
<p>Lower grade gliomas – include oligodendrogliomas and
    astrocytomas</p>
</li>
</ul>
</li>
<li>
<p>Meningioma: usually low grade</p>
<ul>
<li>
<p>Can be left alone and monitored with yearly MRI</p>
</li>
<li>
<p>If symptomatic, may need resection/radiation</p>
</li>
</ul>
</li>
<li>
<p>Ependymoma: uncommon. Can cause CSF outflow obstruction</p>
</li>
<li>
<p>CNS lymphoma – diffuse WM involvement, with mass effect,
    restricts diffusion on MRI with prominent contrast enhancement.
    Can also cross the corpus callosum</p>
<ul>
<li>Usually B-cell, initially responds significantly to steroids</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>A significant number of brain lesions are detected incidentally</p>
</li>
<li>
<p>If a patient has a first-time seizure, brain mass needs to be ruled
    out</p>
</li>
<li>
<p>HA (usually constant, severe), seizure, and focal neurologic
    deficits</p>
</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>Imaging: MRI w/ and w/o contrast provides the most information</li>
</ul>
<!-- -->

<ul>
<li>Findings suggesting malignant lesions: marked edema, multifocal
    lesions, or presence at gray-white junctions</li>
</ul>
<!-- -->

<ul>
<li>
<p>LP may be indicated if herniation risk is low, particularly if
    concerned for infection</p>
</li>
<li>
<p>Biopsy will ultimately be needed in most cases, which is done by
    NSGY</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Work up for primary malignancy, CT C/A/P + PET</p>
</li>
<li>
<p>Steroids are generally indicated for treatment of edema</p>
</li>
</ul>
<!-- -->

<ul>
<li>Decadron 10 mg IV to start; then transition to 4mg IV q6h with SSI</li>
</ul>
<!-- -->

<ul>
<li>Symptomatic tumors need eval by NSGY for resection consideration and
    radiation oncology</li>
</ul>
<p>Amyotrophic Lateral Sclerosis (ALS)</p>
<p>Background</p>
<ul>
<li>
<p>Progressive weakness, often asymmetric and profound with no sensory
    loss</p>
</li>
<li>
<p>Combination of LMN and UMN findings</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>LMN findings: weakness, flaccidity, absent/decreased reflexes,
    fasciculations</p>
</li>
<li>
<p>UMN findings: weakness, spasticity, hyperreflexia, pathologic
    reflexes (e.g. extensor plantar response), slow movements</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pts with bulbar symptoms may complain of difficulty swallowing,
    changes in their voice, or increased saliva production (they just
    aren’t swallowing it)</p>
</li>
<li>
<p>Tongue fasciculations are fairly uncommon in other disorders and is
    a good clue for ALS if present (these can be hard to be certain of –
    tongue movements that are symmetric are typically not
    fasciculations)</p>
</li>
<li>
<p>Pseudobulbar affect – inappropriate laughing or crying; relatively
    common in ALS</p>
</li>
<li>
<p>FVC is an important marker for function</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>EMG/NCS is gold standard; El Escorial Criteria looks for evidence of
    UMN and LMN findings at cranial, cervical, thoracic and lumbosacral
    levels to determine if ALS or not</p>
</li>
<li>
<p>Exclude mimicking lesions, which may be treatable (see below)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Patients with ALS are ideally treated with a multidisciplinary team
    of Neurologists, Pulmonologists, Speech therapists, PT, OT and
    mobility</p>
</li>
<li>
<p>Two medications have been shown to add a few months to survival:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Riluzole - PO med; have to track CBC/LFTs. Side effects: GI and
    general weakness</p>
</li>
<li>
<p>Edaravone (Radicava) – IV, given daily for 2 weeks every month. SE =
    HA, bruising</p>
</li>
</ul>
<p>Mimics of ALS</p>
<ul>
<li>
<p>High cervical spine lesions –UMN changes in upper extremity with LMN
    pattern in LE</p>
</li>
<li>
<p>Primary Lateral Sclerosis – UMN-only disease, much less common with
    much slower progression. Many transition to ALS in the first 1-2
    years, which then is likely a spectrum of the same disease</p>
</li>
<li>
<p>Multifocal Motor Neuropathy – rare autoimmune disorder that looks
    like ALS with LMN signs only, responds to IVIG. Can have anti-GM1 Ab
    in blood. EMG/NCS pattern is different with conduction block</p>
</li>
<li>
<p>Kennedy Disease – X-linked genetic disorder with progressive LMN
    pattern of weakness and endocrine disorders w/androgen resistance
    profile (gynecomastia, defective spermatogenesis)</p>
</li>
<li>
<p>Inclusion Body Myositis – can be asymmetric with grip weakness and
    quadriceps weakness. Biopsy and atrophy pattern usually
    distinguishes it. CPK 500-800.</p>
</li>
<li>
<p>Polymyositis/dermatomyositis – proximal weakness in arms/legs, CPK
    > 1000, usually younger onset (30-40s), no UMN signs</p>
</li>
</ul>
<p>Multiple Sclerosis</p>
<p>Background</p>
<ul>
<li>
<p>Progressive inflammatory disorder primarily manifesting with
    demyelination of the central white matter</p>
</li>
<li>
<p>Optic neuritis and transverse myelitis (spinal cord lesion) are
    common presentations</p>
</li>
<li>
<p>Generally develop over a few days; very uncommon to happen suddenly
    (e.g., patients will complain about a dark spot appearing in their
    vision that expands over several days)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>MRI w/ and w/o contrast can identify plaques and determine if they
    are more acute</li>
</ul>
<!-- -->

<ul>
<li>“Active” MS plaque will enhance, and continues to for weeks (even
    after treatment)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Modified MacDonald Criteria: ≥3 characteristic demyelinating lesions
    (>1 cm, periventricular, infratentorial (brainstem/cerebellum/cord)
    or juxtacortical in location) with evidence of separation in time
    (active and chronic)</p>
</li>
<li>
<p>LP with studies for oligoclonal bands, IgG index, cell count and
    protein, anti-mog, anti-aqp4</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Treat flares and optic neuritis with steroids</li>
</ul>
<!-- -->

<ul>
<li>
<p>Speeds up recovery, but does not improve the degree of recovery</p>
</li>
<li>
<p>Often dosing starts with methylpred 1g</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If a patient with known MS has worsening symptoms that are not new,
    then recrudescence is the likely cause infectious/toxic/metabolic
    workup and imaging is needed</p>
</li>
<li>
<p>There are several long-term medications; common side effects listed
    below:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Interferon (SQ injections) – flu-like symptoms, injection site
    reactions</p>
</li>
<li>
<p>Glatiramer acetate (SQ) – injection site reactions</p>
</li>
<li>
<p>Fingolimod (PO) – macular edema, liver injury, increased risk of
    skin cancer</p>
</li>
<li>
<p>Teriflunomide (PO) – liver injury, hair loss, immunosuppression,
    teratogenic</p>
</li>
<li>
<p>Dimethyl fumarate (PO) – GI side effects, lymphocytopenia, liver
    injury</p>
</li>
<li>
<p>Natalizumab (IV) – PML concern, immunosuppression</p>
</li>
<li>
<p>Ocrelizumab (IV) – contraindicated in active HBV infection, cannot
    give live vaccines</p>
</li>
<li>
<p>Alemtuzumab (IV) – autoimmune disease, rash, headache</p>
</li>
</ul>
<p>Neuromyelitis Optica and Spectrum Disorder</p>
<ul>
<li>
<p>Demyelinating disease due to Ab against aquaporin-4 (on
    oligodendrocytes)</p>
</li>
<li>
<p>Classically causes optic neuritis and longitudinally extensive
    transverse myelitis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Can be more aggressive than MS</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diagnose with NMO antibodies and MS workup as above</p>
</li>
<li>
<p>Treated with steroids, but in severe or refractory cases may require
    PLEX</p>
</li>
</ul>
<p>Vertigo</p>
<p>Background</p>
<ul>
<li>Clinical Presentation</li>
</ul>
<!-- -->

<ul>
<li>
<p>Sensation of the room spinning or moving, or themselves spinning or
    moving</p>
</li>
<li>
<p>Must distinguish from orthostasis/presyncope via history</p>
</li>
</ul>
<!-- -->

<ul>
<li>Causes: most easily differentiated based on chronicity and triggers
    rather than description of symptoms</li>
</ul>
<!-- -->

<ul>
<li>
<p>BPPV - short duration, very positional, classically nystagmus is
    horizontal and torsional with the posterior canal being most
    commonly involved</p>
</li>
<li>
<p>Vestibular neuronitis/labyrinthitis – typically follows URI or ear
    infections; often self-limited, but can be severe/prolonged, in
    which case it is treated with steroids</p>
</li>
<li>
<p>Menière’s Disease – tinnitus and low range frequency hearing loss,
    generally progressive and treated with diuretics, meclizine and
    sometimes surgeries or intratympanic injections</p>
</li>
<li>
<p>Endolymphatic Leak – usually following trauma or concussive blasts,
    requires ENT eval and management. Classically a loud sound will
    cause vertigo and nystagmus</p>
</li>
<li>
<p>vertiginous migraine: usual migraine triggers, may have aura.
    Episodic nature and often positive family hx of migraine or even
    vertiginous migraine.</p>
</li>
<li>
<p>Stroke – sudden onset, ask about vascular risk factors, rare cause
    of isolated vertigo</p>
</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>Careful exam of vertigo will be more helpful than random scans, but
    pt has to be symptomatic for exam to mean anything:</li>
</ul>
<!-- -->

<ul>
<li>
<p>HINTS Battery – Head Impulse test, Nystagmus pattern, Test of skew</p>
<ul>
<li>
<p>Central pattern – no corrective saccade, multidirectional
    nystagmus, skew present</p>
</li>
<li>
<p>Peripheral pattern – corrective saccade, unidirectional
    nystagmus, no skew present</p>
</li>
</ul>
</li>
<li>
<p>Dix-Hallpike Test</p>
</li>
<li>
<p>Cerebellar testing: FNF, HKS, mirroring, gait</p>
</li>
<li>
<p>Outpatient Vestibular function testing with ENT</p>
</li>
</ul>
<!-- -->

<ul>
<li>Central patterns will need head and vessel imaging (looking for
    vertebral dissection or basilar clots)</li>
</ul>
<!-- -->

<ul>
<li>Often, central vertigo is due to centrally acting medications</li>
</ul>
<!-- -->

<ul>
<li>
<p>Peripheral causes are varied and often require eval by ENT as an
    outpatient</p>
</li>
<li>
<p>Treatment with anticholinergics like meclizine or scopolamine is
    often helpful</p>
</li>
<li>
<p>Vestibular therapy with OT is also very beneficial</p>
</li>
</ul></section><section class="print-page" id="neurology-neurology-aidp"><h1 id="neurology-neurology-aidp-aidp">AIDP<a class="headerlink" href="#neurology-neurology-aidp-aidp" title="Permanent link">&para;</a></h1>
<p>Acute Inflammatory Demyelinating Polyneuropathy (AIDP)</p>
<p>Background</p>
<ul>
<li>Rapid onset polyneuropathy that manifests most often with ascending
    weakness and numbness that can involve the respiratory and facial
    musculature also</li>
<li>Usually
    preceded by infectious illness a few weeks prior, some flu
    vaccination associations</li>
</ul>
<p>Presentation</p>
<ul>
<li>Acute
    , progressive extremity weakness, weak or absent reflexes, and
    potentially subjective sensatory changes</li>
<li>Often, infectious symptoms precede AIDP symptoms by a few weeks<ul>
<li>There are a TON of variants of AIDP, with some having cranial
    nerve weakness early, proximal weakness, sensory ataxia,
    primarily sensory loss, or rapid muscle weakness; <strong>do not use</strong>
    lack of classic ascending weakness to dismiss the idea of AIDP</li>
<li>Sensory loss is common in an ascending pattern too</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>LP
    – albuminocytologic dissociation = high protein &amp; normal cell count<ul>
<li>One exception is HIV, which can cause AIDP but also have a high
    cell count and high protein count</li>
</ul>
</li>
<li>EMG/NCS
    – shows a demyelinating pattern (temporal dispersion and decreased
    conduction velocities). This can be normal in the first few days and
    may need to be repeated 2 weeks after if the diagnosis is not clear</li>
<li>Differential diagnosis <strong>:</strong> spinal cord lesions can mimic GBS
    including with areflexia, LEMS, sometimes MG, acute HIV or HCV,
    viral myelitis (entero/West Nile)</li>
</ul>
<p>Management</p>
<ul>
<li>ABCs! NIF at baseline then Q4-6 hours<ul>
<li>NIF \&lt; -30 with good effort generally warrants ICU monitoring</li>
</ul>
</li>
<li>IVIG
    or PLEX (PLEX requires central line)</li>
<li>Can get worse if you give them steroids</li>
</ul></section><section class="print-page" id="neurology-neurology-als"><h1 id="neurology-neurology-als-als">ALS<a class="headerlink" href="#neurology-neurology-als-als" title="Permanent link">&para;</a></h1>
<p>Amyotrophic Lateral Sclerosis (ALS)</p>
<p>Background</p>
<ul>
<li>Progressive weakness, often asymmetric and profound with no sensory
    loss</li>
<li>Combination of LMN and UMN findings<ul>
<li>LMN findings: weakness, flaccidity, absent/decreased reflexes,
    fasciculations</li>
<li>UMN findings: weakness, spasticity, hyperreflexia, pathologic
    reflexes (e.g. extensor plantar response), slow movements</li>
</ul>
</li>
<li>Pts with bulbar symptoms may complain of difficulty swallowing,
    changes in their voice, or increased saliva production (they just
    aren’t swallowing it)</li>
<li>Tongue fasciculations are fairly uncommon in other disorders and is
    a good clue for ALS if present (these can be hard to be certain of –
    tongue movements that are symmetric are typically not
    fasciculations)</li>
<li>Pseudobulbar affect – inappropriate laughing or crying; relatively
    common in ALS</li>
<li>FVC is an important marker for function</li>
</ul>
<p>Evaluation</p>
<ul>
<li>EMG/NCS is gold standard; El Escorial Criteria looks for evidence of
    UMN and LMN findings at cranial, cervical, thoracic and lumbosacral
    levels to determine if ALS or not</li>
<li>Exclude mimicking lesions, which may be treatable (see below)</li>
</ul>
<p>Management</p>
<ul>
<li>Patients with ALS are ideally treated with a multidisciplinary team
    of Neurologists, Pulmonologists, Speech therapists, PT, OT and
    mobility</li>
<li>Two medications have been shown to add a few months to survival:<ul>
<li>Riluzole - PO med; have to track CBC/LFTs. Side effects: GI and
    general weakness</li>
<li>Edaravone (Radicava) – IV, given daily for 2 weeks every month.
    SE = HA, bruising</li>
</ul>
</li>
</ul>
<p>Mimics of ALS</p>
<ul>
<li>High cervical spine lesions –UMN changes in upper extremity with LMN
    pattern in LE</li>
<li>Primary Lateral Sclerosis – UMN-only disease, much less common with
    much slower progression. Many transition to ALS in the first 1-2
    years, which then is likely a spectrum of the same disease</li>
<li>Multifocal Motor Neuropathy – rare autoimmune disorder that looks
    like ALS with LMN signs only, responds to IVIG. Can have anti-GM1 Ab
    in blood. EMG/NCS pattern is different with conduction block</li>
<li>Kennedy Disease – X-linked genetic disorder with progressive LMN
    pattern of weakness and endocrine disorders w/androgen resistance
    profile (gynecomastia, defective spermatogenesis)</li>
<li>Inclusion Body Myositis – can be asymmetric with grip weakness and
    quadriceps weakness. Biopsy and atrophy pattern usually
    distinguishes it. CPK 500-800.</li>
<li>Polymyositis/dermatomyositis – proximal weakness in arms/legs, CPK &gt;
    1000, usually younger onset (30-40s), no UMN signs</li>
</ul></section><section class="print-page" id="neurology-neurology-ams"><h1 id="neurology-neurology-ams-ams">AMS<a class="headerlink" href="#neurology-neurology-ams-ams" title="Permanent link">&para;</a></h1>
<p>Delirium &amp; Altered Mental Status (AMS)</p>
<p>Background</p>
<ul>
<li>Why delirium matters:<ul>
<li>Increased morbidity</li>
<li>Hospital complications, falls, infection, prolonged mechanical
    ventilation</li>
<li>ADL dependence and long-term functional impairment</li>
<li>Long-term cognitive impairment</li>
<li>Psychiatric (depression 4x more common than PTSD) and impaired
    Quality of Life</li>
</ul>
</li>
<li>Departure
    from pt’s baseline cognition: hypoactive (lethargic) or hyperactive
    (agitated)</li>
<li>Risk factors:<ul>
<li>Functional impairment</li>
<li>Age &gt; 75</li>
<li>Dementia</li>
<li>Depression</li>
<li>ETOH use disorder</li>
<li>Sensory impairment</li>
<li>Surgery (repair of aortic aneurysm, trauma, NSGY, thoracic
    surgery)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Consider MOVE STUPID mnemonic:<ul>
<li>Metabolic
    (Hypo/hypernatremia, Hypercalcemia)</li>
<li>Oxygen
    (Hypoxia)</li>
<li>Vascular
    (CVA, Bleed, MI, CHF)</li>
<li>Endocrine
    (Hypoglycemia, Thyroid)</li>
<li>Seizure
    (postictal state)</li>
<li>Trauma (concussion)</li>
<li>Uremia</li>
<li>Psychogenic</li>
<li>Infection</li>
<li>Drugs
    - intoxication or withdrawal</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Screening
    Tools:<ul>
<li>Wards
    : bCAM: Brief-Confusion Assessment Method</li>
<li>ICU: CAM-ICU: Confusion Assessment Method for ICU</li>
</ul>
</li>
<li>Broad toxic/metabolic/infectious workup<ul>
<li>TSH, Vitamin B12, CMP, UA, chest X-ray, seasonal infection
    testing</li>
</ul>
</li>
<li>Review
    of medications-&gt; sedatives, anticholinergics, central alpha
    agonists/antagonists, benzos/EtOH toxicity or withdrawal (check home
    med list to ensure something like chronic benzos weren’t held on
    admission)</li>
<li>Head imaging in the setting of focal neurologic findings<ul>
<li>CT helps to identify hemorrhage and large structural lesions;
    strokes take up to 24 hours to show up on CT<ul>
<li>Some strokes can cause AMS without other obvious focal signs</li>
</ul>
</li>
<li>MRI: stroke, inflammatory changes or infectious changes more
    clearly w/ contrast</li>
</ul>
</li>
<li>LP should be performed if there is any concern for meningitis<ul>
<li>For meningitis, empirically treat with acyclovir/vanc/CTX at
    minimum, + ampicillin if old or young for Listeria coverage</li>
</ul>
</li>
<li>EEG is reasonable with fluctuating mental status or seizure-like
    activity</li>
<li>Catatonia (Bush-Francis scale is a 24-point scale that covers
    features of catatonia)</li>
</ul>
<p>Management</p>
<ul>
<li>First line, Nonpharmacologic interventions: <strong>HOMMEEESS</strong><ul>
<li>H
    ydration/nutrition:<ul>
<li>Ensure patient fed, hold diuretics if poor PO intake, rule
    out constipation and urinary retention</li>
</ul>
</li>
<li>O
    rientation</li>
<li>M
    obilize out of bed 3x/daily as able, PT/OT</li>
<li>M
    anage pain</li>
<li>E
    liminate unnecessary devices (restraints, catheters, tele,
    lines) and meds</li>
<li>E
    nvironmental modification<ul>
<li>Minimize devices, lights on/windows open during day</li>
</ul>
</li>
<li>E
    ngage family</li>
<li>S
    ensory restoration: use eyeglasses and hearing aids and reorient</li>
<li>S
    leep protocol<ul>
<li>Minimize nighttime vitals, earplugs, sleep mask and no TV at
    nigh</li>
</ul>
</li>
</ul>
</li>
<li>​​​​​​​​​​​​​​
    Second line, Pharmacologic approaches, see "Management of Agitation"</li>
</ul></section><section class="print-page" id="neurology-neurology-basic-seizures"><h1 id="neurology-neurology-basic-seizures-seizures">Seizures<a class="headerlink" href="#neurology-neurology-basic-seizures-seizures" title="Permanent link">&para;</a></h1>
<p>Seizure without Status Epilepticus</p>
<p>Background</p>
<ul>
<li>Risk factors: birth trauma, prematurity, TBI with loss of
    awareness &gt; 1 hour, strokes/tumors/abscesses, history of
    meningitis/encephalitis</li>
<li>Key for seizures: stereotyped event with sudden onset/offset<ul>
<li>Generally, if full body systems are involved (e.g., jerking or
    tonic activity, then there will also be loss of awareness)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>A clear description or recording of seizure semiology is helpful</li>
<li>Provoked seizures can develop with medications, hypo/hyperglycemia,
    significant electrolyte abnormalities (e.g. hyponatremia), and CNS
    infections</li>
<li>EEG is necessary for spell capture</li>
<li>MRI brain with and without contrast</li>
</ul>
<p>Management</p>
<ul>
<li>Common AEDs with indications and typical side effects (SE):<ul>
<li>Levetiracetam/Keppra (PO/IV): general or focal sz. SE: sedation
    and agitation, can worsen underlying mood disorders</li>
<li>Valproic acid/Depakote (PO/IV): general or focal sz. SE:
    sedation, hirsutism, PCOS like symptoms, P450 inhibitor, nausea,
    liver injury, hyperammonemia</li>
<li>Phenytoin/Dilantin (PO/fosphenytoin is IV): focal or general sz.
    SE: sedation, unsteadiness, gingival hyperplasia</li>
<li>Lacosamide/Vimpat (PO/IV): focal or general. SE: heart block
    (don’t use if pt has pre-existing blocks), dizziness, ataxia</li>
<li>Topiramate/Topamax (PO) –general or focal sz. SE: kidney stones,
    metabolic acidosis, paresthesia’s, weight loss, cognitive
    slowing</li>
<li>Carbamazepine/Tegretol (PO) –focal and general sz. SE: hypoNa,
    in Han Chinese HLA testing is recommended due to risk of SJS,
    rare reports of bone marrow suppression</li>
<li>Oxcarbazepine/Trileptal (PO) –focal and general sz. SE similar
    to carbamazepine, hypoNa</li>
<li>Lamotrigine/Lamictal (PO) –general or focal sz. Benefit of mood
    stabilization. SE: SJS/TEN, nausea. One of the least sedating
    AEDs</li>
<li>Zonisamide/Zonegran (PO) –general and focal. SE: somnolence,
    ataxia, nausea, confusion</li>
</ul>
</li>
</ul>
<p>Non-Epileptic Spells (aka PNES, psychogenic non-epileptic spells)</p>
<ul>
<li>Can be very difficult to distinguish from epileptic seizures</li>
<li>Retained awareness with bilateral extremities “seizing” is very
    unusual for epileptic sz’s</li>
<li>Other red flags: opisthotonus (arching the back), talking during a
    spell, excessively long spells (if historically patient has
    “seizures lasting for hours or days” at home), forced eye closure,
    coachability during a spell or reacting to external stimuli, very
    heavy breathing during a spell with lots of rigorous movement,
    immediately returning to normal after a spell</li>
<li>Things that are hard to be non-epileptic: seizures arising out of
    sleep, highly stereotyped, incontinence, severe injuries (e.g.
    burns)</li>
<li>If high concern for PNES, try to avoid excessive BZD use. This
    requires good clinical judgement as you wouldn't want to withhold
    Ativan and discover that the pt was having true atypical seizures.
    The compromise would be: do not repeatedly administer BZDs when
    there is suspicion for PNES as well as no evidence of response to
    prior BZD administration.</li>
<li>Notably, <strong>syncopal convulsions</strong> are very common, with posturing
    and tonic-clonic movements happening for a few moments after syncope<ul>
<li>Should not last for more than 10-15 seconds</li>
<li>These are just related to syncope and do not typically require
    seizure medications</li>
<li>Workup:<ul>
<li>
<ul>
<li>Two-hour EEG and MRI (with and without contrast)</li>
<li>Infectious workup, BMP, CBC, blood glucose,
    toxicology/drug screen</li>
<li>If there is concern for convulsive syncope, (carefully)
    check orthostatic vitals</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-brain-masses"><h1 id="neurology-neurology-brain-masses-brain-masses">Brain Masses<a class="headerlink" href="#neurology-neurology-brain-masses-brain-masses" title="Permanent link">&para;</a></h1>
<p>Brain Masses</p>
<p>Background</p>
<ul>
<li>Neoplasm is the biggest concern: ~ 90% of malignant brain masses
    are metastatic</li>
<li>Other etiologies: abscess, tumefactive demyelinating lesions,
    vascular malformations, sometimes other causes of edema (e.g.
    paraneoplastic)</li>
<li>Most common metastatic brain tumors: lung, RCC, breast, and melanoma</li>
<li>Tumors with high bleeding risk: melanoma, thyroid, choriocarcinoma,
    and RCC</li>
<li>Gliomas: WHO Grade I-IV, with IV being glioblastoma multiforme (GBM)<ul>
<li>GBM appears as large heterogeneous masses with edema;
    heterogenous contrast enhancement; can cross the corpus callosum</li>
<li>Lower grade gliomas, which includes oligodendrogliomas and
    astroytomas</li>
</ul>
</li>
<li>Meningioma – usually low grade and either left alone and monitored,
    but can be symptomatic in which they are resected/radiated</li>
<li>Ependymoma – uncommon, usually lower grade can cause CSF outflow
    obstruction</li>
<li>CNS lymphoma – diffuse WM involvement, with mass effect, restricts
    diffusion on MRI with prominent contrast enhancement. Can also cross
    the corpus callosum<ul>
<li>Usually B-cell, initially responds significantly to steroids</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>A significant number of brain lesions are detected incidentally</li>
<li>If a pt has a first-time seizure, brain mass needs to be ruled out</li>
<li>HA (usually constant, severe), seizure and focal neurologic deficits</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>Imaging: MRI w/ and w/o contrast provides the most information<ul>
<li>Findings suggesting malignant lesions: marked edema, multifocal
    lesions, or presence at gray-white junctions</li>
</ul>
</li>
<li>LP may be indicated if herniation risk is low, particularly if
    concerned for infection</li>
<li>Biopsy will ultimately be needed in most cases, which is done
    through NSGY</li>
</ul>
<p>Management</p>
<ul>
<li>Work up for primary malignancy, CT C/A/P <u><sub>+</sub></u> PET</li>
<li>Steroids are generally indicated for treatment of edema<ul>
<li>Decadron 10 mg IV to start; then transition to 4mg IV q6h with
    SSI</li>
</ul>
</li>
<li>If seizure develops would treat as outlined in seizure section</li>
<li>Symptomatic tumors need eval by NSGY for resection consideration</li>
<li>Other options include radiation, which does happen as inpatient but
    it is rare</li>
</ul></section><section class="print-page" id="neurology-neurology-elevated-icp-and-hydrocephalus"><h1 id="neurology-neurology-elevated-icp-and-hydrocephalus-elevated-icp-and-hydrocephalus">Elevated ICP and Hydrocephalus<a class="headerlink" href="#neurology-neurology-elevated-icp-and-hydrocephalus-elevated-icp-and-hydrocephalus" title="Permanent link">&para;</a></h1>
<p>Elevated Intracranial Pressure and Hydrocephalus</p>
<p>Background</p>
<ul>
<li>Communicating hydrocephalus: can be 2/2 subarachnoid granule
    scarring after subarachnoid hemorrhage or meningitis, ependymoma
    producing excess CSF, venous sinus thrombosis</li>
<li>Non
    -communicating hydrocephalus (i.e. obstructive) - usually due to a
    mass lesion such as a tumor, abscess, or hematoma in the midline
    ventricular structures</li>
<li>Eventually, elevated intracranial pressures will cause herniation of
    brain</li>
</ul>
<p>Presentation</p>
<ul>
<li>Headache
    , blurred vision, visual field reduction, enlarged blind spot, may
    pass out, develop nausea or vomiting followed by coma</li>
<li>Sixth nerve palsies are common with elevated ICP</li>
<li>Compressive 3 <sup>rd</sup> nerve palsies are classically associated
    with uncal herniation</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Need a good visual exam: look for restricted visual fields, enlarged
    blind spot, papilledema (may not be present if very rapid ICP
    increase, even with vision loss), and 6 <sup>th</sup> nerve palsies</li>
<li>Stat head CT to look for obstructions, mass lesions</li>
<li>Venous imaging is also usually necessary: CTV or MRV to look for
    venous sinus thrombosis<ul>
<li>Venous sinus thrombosis needs AC, even if there is some degree
    of hemorrhagic infarction</li>
</ul>
</li>
<li>Obstructive lesions require NSGY eval for either removal of the
    lesion or a ventricular drain</li>
<li>If
    no
    obstructive lesion, then LP will be needed for opening pressure</li>
<li>If workup is normal, except for elevated opening pressure, it is IIH</li>
</ul>
<p>Management</p>
<ul>
<li>Idiopathic intracranial hypertension (IIH) is treated with diamox
    and/or topiramate<ul>
<li>Patients with IIH will need ophthalmology evaluation emergently,
    if there is severe disc edema then nerve sheath fenestrations or
    urgent VPS placement may be needed.</li>
<li>If there is clinical concern for herniation:<ul>
<li>Mannitol – 50 grams IV, can be given peripherally. Has risks
    of renal injury</li>
<li>Hypertonic saline – 3%, 7% or 23% saline can be given, needs
    central access</li>
<li>Maintain
    head of bed at least 30° and loosen neck obstructions
    (c-collars) as able</li>
<li>NSGY consult for shunt consideration</li>
</ul>
</li>
<li>Hyperventilation is controversial but can be done with goal
    PaCO2 30-34 mm Hg or ETCO2 20-30 mmHg<ul>
<li>If lower, there is concern for cerebral ischemia</li>
<li>After 4-6 hrs, compensatory pH changes in the blood prevent
    vasoconstrictive affects</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-inpatient-headache"><h1 id="neurology-neurology-inpatient-headache-inpatient-headache">Inpatient Headache<a class="headerlink" href="#neurology-neurology-inpatient-headache-inpatient-headache" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inpatient Headache (HA)</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Important to distinguish 1º° and 2º° headache</li>
<li>Red flags for
    2º° <strong>headaches (SNOOP):</strong> <strong>S</strong> ystemic symptoms, <strong>N</strong> eurologic
    symptoms, <strong>O</strong> nset that is sudden (thunderclap), <strong>O</strong> lder age
    (new headache &gt;40), <strong>P</strong> rogression or evolution in previous
    headaches [the ‘P’ is also used for <strong>P</strong> ositional component]<ul>
<li>Other red flags: preceding trauma, HA awakening pt from sleep,
    no HA-free intervals</li>
<li>Thunderclap suggests that maximal HA intensity develops within
    10 seconds</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Get a good description of where the pain is, when, associated
    symptoms, and assess for “red flag” features listed above</li>
<li>If there are any red flag features imaging and workup are necessary</li>
<li>Imaging depends on highest suspicions, but CTA head/neck is
    appropriate to evaluate for aneurysm (including neck to consider
    dissection). If any focal signs, MRI is generally preferred; venous
    imaging can be beneficial in headaches with features of elevated ICP</li>
<li>If no red flag features, then workup is not necessary, and focus is
    on treatment</li>
</ul>
<p>Management</p>
<ul>
<li>NSAIDs and Tylenol for infrequent headaches, but consistent use
    (&gt;2-3 a week) runs the risk of rebound headaches</li>
<li>Triptans for migraine, but contraindicated in patients with CAD,
    uncontrolled HTN, previous stroke<ul>
<li>There are theoretical concerns of serotonin syndrome when used
    with SSRI/SNRIs</li>
</ul>
</li>
<li>Acute migraine in hospital: “migraine cocktail” -&gt; 1 L fluid bolus,
    2-4 grams of magnesium sulfate, IV Compazine
    (10mg)/Phenergan(20mg)/Reglan (20mg) with Benadryl (25mg)<ul>
<li>If that does not work: Depakote 1000 mg IV, decadron 10mg IV ,
    &plusmn; toradol 30mg IV, flexeril 10mg PO</li>
</ul>
</li>
<li>Cluster headache – also responds to triptans, high flow O2 (&gt;10 L),
    sometimes intranasal lidocaine if no arrhythmia history</li>
</ul></section><section class="print-page" id="neurology-neurology-ms"><h1 id="neurology-neurology-ms-ms">MS<a class="headerlink" href="#neurology-neurology-ms-ms" title="Permanent link">&para;</a></h1>
<p>Multiple Sclerosis</p>
<p>Background</p>
<ul>
<li>Progressive inflammatory disorder primarily manifesting with
    demyelination of the central white matter</li>
<li>Optic neuritis and transverse myelitis (spinal cord lesion) are
    common presentations</li>
<li>Generally develop over a few days; very uncommon to happen suddenly
    ( e.g., patients will complain about a dark spot appearing in their
    vision that expands over several days)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>MRI w/ and w/o contrast can identify plaques and determine if they
    are more acute<ul>
<li>“Active” MS plaque will enhance, and continues to for weeks
    (even after treatment)</li>
</ul>
</li>
<li>Modified MacDonald Criteria:
    ≥
    3 characteristic demyelinating lesions (&gt;1 cm, periventricular,
    infratentorial (brainstem/cerebellum/cord) or juxtacortical in
    location) with evidence of separation in time (active and chronic)</li>
<li>LP can be done to look for oligoclonal bands, IgG index, cell count
    and protein</li>
</ul>
<p>Management</p>
<ul>
<li>Treat flares with steroids: speeds up recovery but does not improve
    the degree of recovery<ul>
<li>Would confirm with Neurology (as primary or consulting team)
    preferred dose, which is often methylpred 1g to start</li>
<li>Current guidelines are for optic neuritis to be treated with IV
    steroids, but recent data challenges this</li>
</ul>
</li>
<li>If a patient with known MS has worsening symptoms that are not new,
    then recrudescence is the likely cause -&gt; infectious/toxic/metabolic
    workup and imaging is needed</li>
<li>Several long-term medications, with common side effects listed
    below:<ul>
<li>Interferon (SQ injections) – flu-like symptoms, injection site
    reactions</li>
<li>Glatiramer acetate (SQ) – injection site reactions</li>
<li>Fingolimod (PO) – macular edema, liver injury, increased risk of
    skin cancer</li>
<li>Teriflunomide (PO) – liver injury, hair loss, immunosuppression,
    teratogenic</li>
<li>Dimethyl fumarate (PO) – GI side effects, lymphocytopenia, liver
    injury</li>
<li>Natalizumab (IV) – PML concern, immunosuppression</li>
<li>Ocrelizumab (IV) – contraindicated in active HBV infection,
    cannot give live vaccines</li>
<li>Alemtuzumab (IV) – autoimmune disease, rash, headache</li>
</ul>
</li>
</ul>
<p>Neuromyelitis Optica and Spectrum Disorder:</p>
<ul>
<li>Demyelinating disease due to Ab against aquaporin-4 (on
    oligodendrocytes)</li>
<li>Classically causes optic neuritis and longitudinally extensive
    transverse myelitis</li>
<li>Can be more aggressive than MS and needs steroids but in severe or
    refractory cases PLEX</li>
<li>NMO antibodies and MS workup as above is done</li>
</ul></section><section class="print-page" id="neurology-neurology-myasthenia-etc"><h1 id="neurology-neurology-myasthenia-etc-myasthenia-etc">Myasthenia etc<a class="headerlink" href="#neurology-neurology-myasthenia-etc-myasthenia-etc" title="Permanent link">&para;</a></h1>
<p>Myasthenia Gravis (MG) and Lambert-Eaton Myasthenic Syndrome (LEMS)</p>
<p>Background</p>
<ul>
<li>Both are disorders at the neuromuscular junction</li>
<li>MG
    affects
    the post-synaptic cleft at the acetylcholine receptor</li>
<li>LEMS
    affects
    the pre-synaptic cleft at the calcium channels</li>
</ul>
<p>Presentation</p>
<ul>
<li>Double
    vision, ptosis, dysarthria, dysphagia</li>
<li>Dyspnea looks different than in other conditions: air hunger,
    usually also with dysphagia</li>
<li>Initially
    , the patient may not look sick or distressed, but may have a short
    inspiratory time or difficulty speaking in complete sentences due to
    shallow breathing</li>
<li>Most pts have a known history of myasthenia, but up to 20% present
    initially with crisis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Exam: Look closely for ptosis, nasal speech, weak neck
    flexion/extension (same nerve roots as diaphragm), interrupted
    speech to take extra breaths</li>
<li>These patients do not exhibit “huffing and puffing” work of
    breathing in the way that pts with COPD/asthma exacerbations or post
    exercise may look<ul>
<li>Patients with NMJ disease can go from talking to intubated
    within several hours!</li>
<li>LEMS: less ocular weakness, but do have extremity weakness and
    absent reflexes. Many cases are paraneoplastic (classically
    small cell carcinoma of the lung)</li>
<li>Pulmonary compromise is very rare in LEMS</li>
</ul>
</li>
<li>EMG
    /NCS - MG will show decremental response to rapid stim, and single
    fiber EMG (gold standard) can be done. SFEMG cannot be done in ICU
    settings due to electrical artifact</li>
<li>Myasthenia
    antibody panels can be ordered (send prior to IVIG/PLEX being given)</li>
<li>Chest CT -&gt; looking for thymic hyperplasia</li>
</ul>
<p>Management</p>
<ul>
<li>NIF (negative inspiratory force, a measurement of diaphragmatic
    strength; normal is \&lt; -60) at baseline on arrival and then Q4-6H<ul>
<li>If getting below -30 consider elective intubation, certainly ICU</li>
<li>Can see NIF under flowsheets on Epic</li>
<li>Some pts’ effort can be impaired resulting in poor NIF values</li>
</ul>
</li>
<li>IVIG or PLEX -&gt; both have similar supportive evidence; IVIG is
    usually easier to do<ul>
<li>PLEX
    has the risks you would expect with dialysis (e.g. fluid shifts)
    and coagulopathy</li>
<li>IVIG
    -&gt; have to check IgA levels (deficiency is a rare cause of
    anaphylaxis) and can increase risk of DVT, has risk of aseptic
    meningitis and provides and significant fluid load so not ideal
    for pts with CHF</li>
</ul>
</li>
<li>Steroids are also usually up-titrated SLOWLY (by 10-20 mg prednisone
    daily, not much more of an increase) and pyridostigmine is continued</li>
<li>Rapid increases in steroids can worsen patients with MG</li>
<li>Too much pyridostigmine can make patients worse, so for those doing
    poorly on &gt;90 mg per dose, consider lowering the dose</li>
<li>Treat underlying causes of exacerbations: usually infections or
    other toxic/metabolic insults</li>
<li>Remove/avoid exacerbating medications: fluoroquinolones,
    aminoglycosides, beta blockers, and magnesium</li>
<li>LEMS
    : 3,4-diaminopyridine and can respond to IVIG or pyridostigmine</li>
</ul></section><section class="print-page" id="neurology-neurology-outpatient-headache"><h1 id="neurology-neurology-outpatient-headache-outpatient-headache">Outpatient Headache<a class="headerlink" href="#neurology-neurology-outpatient-headache-outpatient-headache" title="Permanent link">&para;</a></h1>
<p>Outpatient Headache</p>
<p>Background</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type</td>
<td>Presentation</td>
<td>First line meds</td>
</tr>
<tr>
<td>Tension type (most common)</td>
<td>Generally bilateral, pressure/tightness, mild/moderate pain, no significant photophobia/phonophobia, nausea</td>
<td>Acetaminophen, TCA’s, SNRI’s, anticonvulsants</td>
</tr>
<tr>
<td>Migraine</td>
<td>Unilateral/pulsating, moderate/severe pain, lasting 4-72hr, associated nausea, photophobia or phonophobia; ± aura, worse with physical activity, often improves with sleep</td>
<td>Acute: triptans Preventive: TCAs, propranolol, topiramate, VPA</td>
</tr>
<tr>
<td>Cluster</td>
<td>Severe, often extreme unilateral orbital/supra-orbital/temporal pain, often with lacrimation, rhinorrhea, sweating/swelling of face, visual change</td>
<td>Acute: 100% FiO2 at 12L/min for at least 15 mins, triptans Preventive: verapamil; some data for nightly melatonin to regulate circadian rhythms</td>
</tr>
<tr>
<td>Medication Overuse</td>
<td>HA at least ½ the days of the month, w/medication intake at least ½ the days of the month; often presents as worsening HA despite increased intake of medication. Often seen with meds that include caffeine (excedrine, fioricet)</td>
<td>Acute: 100% FiO2 at 12L/min for at least 15 mins, triptans Preventive: Verapamil *STOP offending medication, typically via taper. HA will worsen before it gets better (can be alleviated with naproxen taper and/or steroid dose pack)</td>
</tr>
</tbody>
</table>
<p>Medication Overview:</p>
<ul>
<li>Abortive<ul>
<li>Sumatriptan or rizatriptan are generally first choices. Cannot
    be used more than 10 days/month. Avoid in pts with
    hypertension/CAD</li>
</ul>
</li>
<li>Preventative – generally start low and increase dose every few weeks<ul>
<li>Amitriptyline: indicated for both migraine and tension-type.
    Helps with sleep and comorbid depression. Most common side
    effects (SE) = dry mouth, sedation</li>
<li>Topiramate: has the best evidence among migraine meds. Can
    theoretically help with weight loss. Most common SE = sodas
    taste bad, sedation</li>
<li>Propranolol: useful for relative lack of interactions. Mild
    cardiac/blood pressure effects compared to other beta-blockers.
    Most common SE = drowsiness</li>
<li>Magnesium oxide: reduces headache frequency with almost no SE.
    Start 400mg daily, can go up to 800mg BID. Patients can increase
    dose until they get diarrhea.</li>
<li>Riboflavin (vitamin B2): mild effect but effectively has no side
    effects. 400mg daily.</li>
<li>Gabapentin: can be useful if HAs have stabbing/electric quality.
    Main SE = sedation</li>
<li>Venlafaxine: useful for migraines with significant vestibular
    symptoms (dizziness)
    -<ul>
<li>Major
    SE = insomnia, hypertension/tachycardia</li>
</ul>
</li>
<li>Verapamil: can be used for migraine and cluster headaches. Can
    use ER formulation</li>
<li>Botox: can be administered every 3 months. Can be very
    effective, but pts generally will have had to fail multiple
    medications for insurance to approve</li>
<li>CGRP receptor modulators (mostly injections) such as Rimegepant
    are newer options</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-parkinson"><h1 id="neurology-neurology-parkinson-parkinson">Parkinson<a class="headerlink" href="#neurology-neurology-parkinson-parkinson" title="Permanent link">&para;</a></h1>
<p>Parkinson’s Disease</p>
<p>Background</p>
<ul>
<li>Tremor is typically a very early symptom, and worse on one side</li>
<li>Cogwheel rigidity can be confused for paratonia, which is seen in
    demented or encephalopathic patients who have involuntary variable
    resistance movements during passive ROM assessment</li>
<li>Gait, speech changes (low volume), hand-writing changes of slow
    small movements</li>
<li>Festination – slow start with movements that gradually build up
    speed</li>
<li>En bloc turning – taking multiple steps to turn around</li>
<li>Anosmia and REM behavior sleep disorders are very common</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Clinical diagnosis; there are some supportive imaging studies like
    DaTscan that looks for activity of substantia nigra (usually not
    necessary)</li>
<li>Clinical response to dopamine replacement is so typical that if a
    patient does not respond, it is important to consider a Parkinson
    plus syndrome (see below)</li>
</ul>
<p>Management</p>
<ul>
<li>Dopamine replacement – carbidopa/levodopa; dosed at regular
    intervals several times a day. These generally do not need to be
    held on admission.<ul>
<li>If pt is altered, can hold anticholinergics, MAO-B inhibitors or
    COMT inhibitors</li>
</ul>
</li>
<li>Dopamine agonists – can cause confusion, hallucinations, dyskinesias</li>
<li>MAO-B inhibitors (MAOIs): can cause confusion, hallucinations,
    insomnia and dyskinesias<ul>
<li>Theoretical risk of Serotonin Syndrome (usually need both MAO-A
    and MAO-B for serotonin syndrome risk)</li>
</ul>
</li>
<li>COMT inhibitors – can cause confusion, hallucinations, insomnia, and
    dyskinesias</li>
<li>Anticholinergics – useful for tremor when there is not much
    bradykinesia or gait disturbances. In older pts cognitive changes
    are a bigger concern along with hallucinations</li>
<li>PD medications are rarely titrated in the hospital because acute
    medical illness makes PD symptoms worse and everything will need to
    be re-adjusted as an outpatient</li>
<li>Be cautious with PRN anti-emetics in patients with PD
    . Many work via dopamine antagonism. Zofran is generally the safest
    option.</li>
<li>Similarly, many antipsychotics have dopamine antagonism. Safest
    options include seroquel, nuplazid (less effective in acute setting)
    and clozapine.</li>
</ul>
<p>Parkinson Plus Syndromes</p>
<ul>
<li>Atypical features such as bilateral symmetric onset, early
    cognitive/personality changes, cerebellar findings, or prominent
    autonomic dysfunction early</li>
<li>Progressive Supranuclear Palsy – PD symptoms with early falls and
    minimal tremor, vertical eye movement abnormalities</li>
<li>Multisystem Atrophy (there are three types)<ul>
<li>Each typically has profound orthostatic hypotension without any
    increase in HR</li>
<li>MSA-A – autonomic features prominent (previously Shy-Drager
    Syndrome)</li>
<li>MSA-P – prominent atypical Parkinsonism features</li>
<li>MSA-C – prominent cerebellar dysfunction</li>
</ul>
</li>
<li>Lewy Body Dementia – Parkinsonism with prominent early cognitive
    impairment and hallucinations</li>
</ul></section><section class="print-page" id="neurology-neurology-status-epilepticus"><h1 id="neurology-neurology-status-epilepticus-status-epilepticus">Status Epilepticus<a class="headerlink" href="#neurology-neurology-status-epilepticus-status-epilepticus" title="Permanent link">&para;</a></h1>
<p>Status Epilepticus</p>
<p>Background</p>
<ul>
<li>Either a single seizure &gt;5 minutes or
    ≥
    2 seizures occurring without a return to baseline in between
    [previous guidelines used 30 minutes as a marker, but this has been
    updated]</li>
<li>Differentiating convulsive seizures from non-epileptic events
    (“pseudoseizure”):<ul>
<li>Features that suggest non-epileptic/psychogenic event include
    moaning or talking throughout the event, “no-no” head shake,
    repetitive movements of opposing muscle groups, very arrhythmic
    or purposeful-looking movements, or seizures that have been
    ongoing for “hours”</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Fingerstick
    glucose, BMP/CBC, and UDS</li>
<li>Consult Neurology</li>
<li>EEG (start with 2hr) to determine if it is seizure or not and for
    titration of medications</li>
<li>Consider a non-contrasted head CT; MRI cannot be obtained while EEG
    is attached</li>
<li>Up to half of pts presenting in status epilepticus have no history
    of seizure, so they need urgent head imaging, consideration for
    lumbar puncture, infectious and toxic workup, tox screen, and
    sometimes rheumatologic or paraneoplastic workup</li>
</ul>
<p>Management</p>
<ul>
<li>ABCs
    !
    Start with <strong>benzos</strong> : 2 mg lorazepam IV every minute or 5 mg of
    diazepam IV every minute (they do take a few minutes to work,
    though) up to 0.1 mg/kg of lorazepam</li>
<li>After
    2 rounds of benzos, would shift to antiepileptics if pt is still in
    status (neurology should be contacted here if not already):<ul>
<li>IV fosphenytoin 20 mg/kg</li>
<li>IV levetiracetam 30-60 mg/kg (generally 3 grams is good)</li>
<li>IV valproic acid 30 mg/kg</li>
</ul>
</li>
<li>If
    still seizing at this point, the pt will likely need be intubated</li>
<li>These pts MUST be placed on EEG if they get paralyzed or sedated
    because <strong>convulsive status often continues as nonconvulsive status,
    which still damages the brain!</strong><ul>
<li>If still seizing, pts should be on midazolam, propofol or
    barbiturate infusions for burst suppression</li>
<li>Focal seizures, such as arm or face twitching with <strong>retained</strong>
    awareness do not always need to be treated to the point of
    initiating coma</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-stroke-0"><h1 id="neurology-neurology-stroke-0-stroke">Stroke<a class="headerlink" href="#neurology-neurology-stroke-0-stroke" title="Permanent link">&para;</a></h1>
<p>Background</p>
<ul>
<li>Former, nonpreferred term: <strong>cerebrovascular accident</strong></li>
<li>Sudden onset, focal (usually one-sided) neurologic deficits:
    weakness, sensory loss, vision loss, ataxia/unsteadiness, vertigo,
    double vision, facial droop, dysarthria, aphasia</li>
<li>Differential:<ul>
<li>stroke (ischemic or hemorrhagic)</li>
<li>seizure or post-ictal paralysis</li>
<li>headache phenomena</li>
<li>cervical spinal cord lesions, though these more commonly cause
    bilateral symptoms</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Stroke-like symptoms can also develop as recrudescence – previous
    stroke or brain lesion symptoms worsening with systemic
    toxic/metabolic/infectious processes (or hypotension)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Critical
    decision-making information: last known normal (LKN), time symptoms
    first observed, anticoagulation status, why pt is admitted, recent
    surgeries, history of bleeding (severe GIB or ICH), recent
    medications, last platelet count, and baseline neuro exam</li>
<li>If symptoms developed with LKN within 24 hours -&gt; stroke alert!<ul>
<li>VUMC: call 11111 and tell the operator stroke alert and current
    pt location</li>
</ul>
</li>
<li>NAVA: call an RRT and stat page <strong>835-5137</strong> , include in the page
    <strong>911</strong> at the end of the call back number to signal it is a stroke
    alert</li>
<li>Stat head CTP (order CTH/CTA) for consideration of tPA or
    endovascular therapy<ul>
<li>If renal fx is abnormal, discuss with neurology</li>
<li>Generally, go for CTA if the pt is a thrombectomy candidate</li>
<li>MRI/MRA is an option but takes longer (MRAs are also better with
    Gadolinium)</li>
<li>Neurology service should be leading this portion</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Blood pressure goals<ul>
<li>Ischemic stroke: in general SBP \&lt;220</li>
<li>Pts with intracranial atherosclerosis may require higher BP to
    maintain perfusion, which may necessitate discontinuing BP meds</li>
<li>Hemorrhagic strokes (which will be obvious on CTH): SBP \&lt; 140
    (BP management is key)<ul>
<li>These pts are managed in Neuro ICU</li>
<li>Reverse coagulopathies and keep platelets &gt;100,000</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="neurology-neurology-vertigo"><h1 id="neurology-neurology-vertigo-vertigo">Vertigo<a class="headerlink" href="#neurology-neurology-vertigo-vertigo" title="Permanent link">&para;</a></h1>
<p>Vertigo</p>
<p>Background</p>
<ul>
<li>Sensation of the room spinning or moving, or themselves spinning or
    moving</li>
<li>Distinguishing between vertigo and orthostasis/presyncope via
    history is important<ul>
<li>Ask about triggers, exacerbating factors, duration, if it has
    happened before</li>
<li>Ask about vascular risk factors, as stroke is an uncommon cause
    of isolated vertigo</li>
<li>Presentation based on Cause:<ul>
<li>BPPV – short duration, very positional, classically
    nystagmus is horizontal and torsional with the posterior
    canal being most commonly involved</li>
<li>Vestibular Neuronitis/labyrinthitis – typically follows URI
    or ear infections; often self-limited, but can be
    severe/prolonged, in which case it is treated with steroids</li>
<li>Menière’s Disease – tinnitus and low range frequency hearing
    loss, generally progressive and treated with diuretics,
    meclizine and sometimes surgeries or intratympanic
    injections</li>
<li>Endolymphatic Leak – usually following trauma or concussive
    blasts, requires ENT eval and management. Classically a loud
    sound will cause vertigo and nystagmus</li>
<li>Vertigo may also be caused by migraines, possibly without
    associated headache</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Evaluation/Management</p>
<ul>
<li>Careful exam of vertigo will be more helpful than random scans, but
    pt has to be symptomatic for exam to mean anything:<ul>
<li>HINTS Battery
    – head impulse test, nystagmus pattern, test of skew<ul>
<li>Central pattern – no corrective saccade, multidirectional
    nystagmus, skew present</li>
<li>Peripheral pattern –
    corrective saccade, unidirectional nystagmus, no skew
    present</li>
</ul>
</li>
<li>Dix-Hallpike Test</li>
<li>Cerebellar testing: FNF, HKS, mirroring, gait</li>
</ul>
</li>
<li>Central patterns will need head imaging with vessel imaging (looking
    for vertebral dissection or basilar clots)<ul>
<li>Often, central vertigo is due to centrally acting medications</li>
</ul>
</li>
<li>Peripheral causes are varied and often require eval by ENT as an
    outpatient</li>
<li>Treatment with anticholinergics like meclizine or scopolamine is
    often helpful</li>
<li>Vestibular therapy with OT is also very beneficial</li>
<li>Example of HINTS test</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Neurology</h1>
                        <h1 class='nav-section-title' id='section-ophthalmology'>
                            Ophthalmology <a class='headerlink' href='#section-ophthalmology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="ophthalmology-main"><p>Basic Eye Anatomy</p>
<ul>
<li>
<p><u>Sclera</u> - White wall of the eye</p>
</li>
<li>
<p><u>Conjunctiva</u> - Translucent, vascularized tissue that covers
    the anterior sclera (bulbar conjunctiva) and lines the inner aspect
    of the eyelids (palpebral conjunctiva). When the eyes get “red,” it
    is usually the conjunctiva, and not the sclera, that is irritated
    (conjunctival vessels dilate).</p>
</li>
<li>
<p><u>Cornea</u> - Transparent, bubble-like structure in front of the
    eye.</p>
</li>
<li>
<p><u>Iris</u> - “colored” part of the eye that dilates and constricts
    the pupil to let in more or less light</p>
</li>
<li>
<p><u>Pupil</u> - the central hole in the iris</p>
</li>
<li>
<p><u>Anterior Chamber (AC)</u> - the space between the cornea and the
    iris</p>
</li>
<li>
<p><u>Aqueous Humor</u> - clear fluid that fills the anterior and
    posterior chambers, produced by the ciliary body. Nourishes the
    cornea. The balance of aqueous production and drainage dictates the
    intraocular pressure (IOP).</p>
</li>
<li>
<p><u>Iridocorneal angle (or just, the Angle)</u> - angle between the
    iris and the cornea and site of the Trabecular Meshwork, which
    drains aqueous humor from the anterior chamber into the ocular
    venous system.</p>
</li>
<li>
<p><u>Lens</u> - transparent structure located behind the iris that
    helps focus light onto the retina; also responsible for
    accommodation (focusing at near). Located behind the iris. A
    cataract is an opacification of the lens.</p>
</li>
<li>
<p><u>Ciliary body</u> - ring structure that sits behind the iris.
    Produces aqueous humor and suspends the Lens via filaments called
    Zonules.</p>
</li>
<li>
<p><u>Posterior chamber</u> - the space between the iris and the lens</p>
</li>
<li>
<p><u>Vitreous chamber</u> - the space between the lens and the retina</p>
</li>
<li>
<p><u>Vitreous humor</u> - thick, jelly-like transparent substance that
    fills the vitreous chamber</p>
</li>
<li>
<p><u>Retina</u> - tissue that lines the inner back wall of the eye,
    contains photoreceptors and interneurons that absorb light and
    convert it into visual electrochemical signals</p>
</li>
<li>
<p><u>Macula</u> - area of the retina responsible for central vision.
    The fovea is the center of the macula.</p>
</li>
<li>
<p><u>Choroid</u> - highly vascularized layer of tissue posterior to
    the retina</p>
</li>
<li>
<p><u>Optic disc</u> - head of the optic nerve; the optic nerve is
    composed of the axons of the retinal ganglion neurons, transmitting
    visual electrochemical signals from the retina to the brain.</p>
</li>
<li>
<p><u>Uvea</u> - iris + ciliary body + choroid. These 3 tissues are
    actually connected and collectively make up the vascular layer of
    the eye.</p>
</li>
<li>
<p><u>The Anterior segment</u> - all structures that make up the
    “front” of the eye, i.e., anterior to the vitreous chamber (cornea,
    iris, iridocorneal angle, lens, ciliary body, aqueous humor)</p>
</li>
<li>
<p><u>The Posterior segment</u> - all structures that make up the
    “back” of the eye, i.e., the vitreous chamber and all structures
    contained within it (vitreous humor, retina, choroid, optic nerve)</p>
</li>
</ul>
<p>Common Abbreviations in Ophthalmology</p>
<ul>
<li>
<p>OD = Right eye | OS = Left eye | OU = Both eyes</p>
</li>
<li>
<p>VA = Visual Acuity | VAcc = with correction [glasses or contact
    lenses] | VAsc = without correction</p>
</li>
<li>
<p>PH = Pinhole acuity</p>
</li>
<li>
<p>PHNI = No Improvement of vision with a pinhole</p>
</li>
<li>
<p>Gtt = drop</p>
</li>
<li>
<p>Ung = ointment</p>
</li>
<li>
<p>EOM = Extraocular Muscles</p>
</li>
<li>
<p>IOP = Intraocular Pressure</p>
</li>
<li>
<p>CVF = Confrontational Visual Fields</p>
</li>
<li>
<p>CF = Count Fingers</p>
</li>
<li>
<p>HM = Hand Motion</p>
</li>
<li>
<p>DFE = Dilated Fundus Exam | SLE = Slit Lamp Exam | PLE = Pen Light
    Exam</p>
</li>
<li>
<p>RAPD = Relative Afferent Pupillary Defect</p>
</li>
<li>
<p>KED = corneal epithelial defect (i.e., abrasion)</p>
</li>
<li>
<p>PEE / SPK = corneal punctate epithelial erosions / superficial
    punctate keratopathy</p>
</li>
<li>
<p>FBS = Foreign body sensation</p>
</li>
<li>
<p>PFATs = Preservative-Free Artificial Tears</p>
</li>
<li>
<p>SCH = Subconjunctival hemorrhage</p>
</li>
<li>
<p>DD = Disc Diameters in size</p>
</li>
<li>
<p>W&amp;q = Conjunctiva is white and quiet (normal)</p>
</li>
<li>
<p>D&amp;q = Anterior chamber is deep and quiet (normal, without
    inflammation)</p>
</li>
<li>
<p>AC = Anterior Chamber</p>
</li>
<li>
<p>ON = Optic Nerve | ONH = Optic Nerve Head</p>
</li>
<li>
<p>RD = Retinal Detachment</p>
</li>
<li>
<p>PVD = Posterior Vitreous Detachment</p>
</li>
<li>
<p>DR = Diabetic Retinopathy | NPDR: Nonproliferative DR | PDR:
    Proliferative DR</p>
</li>
<li>
<p>CNV = Choroidal Neovascularization</p>
</li>
<li>
<p>NVI = Neovascularization of the Iris | NVA = Neovascularization of
    the Angle | NVD = Neovascularization of the optic Disc | NVE =
    Neovascularization elsewhere (usually peripheral retina)</p>
</li>
<li>
<p>CE/IOL = Cataract Extraction with IntraOcular Lens insertion (i.e.,
    cataract surgery)</p>
</li>
<li>
<p>IV = Intravitreal (as usually in “IV injection”)</p>
</li>
</ul>
<p>Taking a Good Ocular History</p>
<p>History of Present Illness:</p>
<ul>
<li>
<p>Duration/Onset/Timing of visual or eye symptoms</p>
</li>
<li>
<p>Eye pain? Quality/Severity?</p>
</li>
<li>
<p>Symptoms constant or intermittent?</p>
</li>
<li>
<p>Has this happened to you before?</p>
</li>
<li>
<p>Any flashes/floaters/curtains/veils coming down in your field of
    vision? Timing of these?</p>
</li>
<li>
<p>Any associated systemic symptoms (nausea/vomiting, fever/chills,
    headaches, neurologic deficits)</p>
</li>
</ul>
<p>Past Ocular History:</p>
<ul>
<li>
<p>Do you wear glasses? For distance or reading or both? Contact
    lenses?</p>
</li>
<li>
<p>When was the last time you saw an eye doctor?</p>
</li>
<li>
<p>History of eye surgeries?</p>
</li>
<li>
<p>History of any other eye conditions? Cataracts, glaucoma, macular
    degeneration, diabetic retinopathy?</p>
</li>
</ul>
<p>Family History:</p>
<ul>
<li>Family history of any eye diseases? Glaucoma, macular degeneration,
    diabetic retinopathy?</li>
</ul>
<p>Social History:</p>
<ul>
<li>Use of tobacco, alcohol, illicit drugs?</li>
</ul>
<p>Approach to Blurry Vision</p>
<p><img src="../ophthalmology/main/output/media/image18.png"
style="width:3.63889in;height:2.69212in"
alt="A picture containing text Description automatically generated" />
Key Points:</p>
<ul>
<li>
<p>This flowchart is meant to serve as a guide. Bear in mind that there
    are always exceptions.</p>
</li>
<li>
<p>Many ocular problems are not urgent and can be dealt with
    outpatient. Assessing the acuity of onset is the first step.</p>
</li>
<li>
<p>In general, the top differential for blurry vision is Dry Eye,
    Cataract, or Uncorrected refractive error.</p>
</li>
<li>
<p>If the symptoms are acute and just in one eye, it is more likely to
    be ocular and warrants further investigation (likely ophthalmology
    consult).</p>
</li>
</ul>
<p>Approach to Double Vision (Diplopia)</p>
<p><img src="../ophthalmology/main/output/media/image19.jpeg"
style="width:3.75in;height:1.18885in"
alt="Diagram Description automatically generated" /></p>
<p>Key Points</p>
<ul>
<li>
<p>This flowchart is meant to serve as a guide. Bear in mind that there
    are always exceptions.</p>
</li>
<li>
<p>Most important question to ask with any patient complaining of
    double vision is whether it goes away when covering one eye. If it
    does, then it is an ocular misalignment issue (= true binocular
    diplopia).</p>
</li>
<li>
<p>If the diplopia is acute and constant, this requires more urgent
    evaluation than if intermittent.</p>
</li>
<li>
<p>Look at the pupil and eye movements:</p>
</li>
</ul>
<!-- -->

<ul>
<li>If the eye is dilated (“blown pupil”), abducted and infraducted
    (“down and out position”), and ptotic, this is classic for a
    complete CN3 palsy and requires immediate neuroimaging (e.g. CTA
    head) to rule out an enlarging aneurysm.</li>
</ul>
<p>Approach to Flashes, Floaters, Spots</p>
<p><img src="../ophthalmology/main/output/media/image20.jpeg"
style="width:3.74868in;height:1.86066in"
alt="Diagram Description automatically generated" />Key Points</p>
<ul>
<li>
<p>This flowchart is meant to serve as a guide. Bear in mind that there
    are always exceptions.</p>
</li>
<li>
<p>Scintillating or colorful lights/spots, especially if bilateral, are
    likely migrainous in nature.</p>
</li>
<li>
<p>A patient may say they see a visual disturbance in the left eye,
    when in reality it is in the left visual field of both eyes
    (indicating that it is a neurological issue, e.g., migraine). Ask if
    the patient has tried closing one eye to see if the visual
    phenomenon is actually in one eye.</p>
</li>
<li>
<p>Rapid onset of floaters, often preceded by a peripheral
    crescent-shaped light flash, is classic for posterior vitreous
    detachment. A black curtain or veil that comes down in the vision is
    classic for retinal detachment.</p>
</li>
</ul>
<p>Approach to a Red Eye</p>
<p>When the conjunctiva is vasodilated, or “injected,” the eye looks red.
The more inflamed the conjunctiva, the angrier-looking the eye.</p>
<p>Differential for Red Eye:</p>
<ul>
<li>Dry Eye</li>
</ul>
<!-- -->

<ul>
<li>Trace diffuse injection, blurry vision that fluctuates, gritty
    sensation, clears with blinking</li>
</ul>
<!-- -->

<ul>
<li>Corneal abrasion / ulceration / exposure keratopathy</li>
</ul>
<!-- -->

<ul>
<li>Unilateral, moderate to severe injection, may be diffuse or
    sectoral, pain, blurry vision, mucus discharge, history of poor
    blink rate, intubated/sedated status.</li>
</ul>
<!-- -->

<ul>
<li>Subconjunctival hemorrhage</li>
</ul>
<!-- -->

<ul>
<li>Patch of bright red, often with sharp borders. Due to rupture of
    conjunctival vessel. Whole conjunctiva can be involved and may be
    bright red. Looks scarier than it is. Common in patients on
    anticoagulation or after a Valsalva event (e.g., coughing). Will
    resolve spontaneously.</li>
</ul>
<!-- -->

<ul>
<li>Allergic conjunctivitis</li>
</ul>
<!-- -->

<ul>
<li>Chemosis, mild to moderate injection, blurry vision, very itchy,
    watery discharge, hx of allergies/atopy</li>
</ul>
<!-- -->

<ul>
<li>Viral or Bacterial conjunctivitis</li>
</ul>
<!-- -->

<ul>
<li>Moderate to severe injection, scattered subconjunctival hemorrhages
    or petechiae, itchy or burning/painful eyes. If viral, look for
    preauricular adenopathy or recent URI.</li>
</ul>
<!-- -->

<ul>
<li>Acute angle closure glaucoma</li>
</ul>
<!-- -->

<ul>
<li>Severe eye pain with nausea/vomiting, rock-hard eye, mid-dilated and
    fixed pupil, blurry vision</li>
</ul>
<!-- -->

<ul>
<li>Uveitis/Episcleritis/Scleritis</li>
</ul>
<!-- -->

<ul>
<li>Eye pain, perilimbal injection (“ciliary flush”), blurry vision, may
    have history of autoimmune disease. Episcleritis vs Scleritis can be
    difficult to discern. Scleritis may have a deeper, violaceous hue.</li>
</ul>
<!-- -->

<ul>
<li>Endophthalmitis</li>
</ul>
<!-- -->

<ul>
<li>Eye pain, history of trauma or eye surgery, severe vision loss,
    history of immunocompromise and systemic infection (if endogenous)</li>
</ul>
<!-- -->

<ul>
<li>Carotid-cavernous fistula</li>
</ul>
<!-- -->

<ul>
<li>Engorged and tortuous conjunctival vessels, recent history of
    trauma, resistance to retropulsion (pushing the globe back in)</li>
</ul>
<p>Anisocoria</p>
<p>Background</p>
<ul>
<li>
<p>Anisocoria = unequal pupil size</p>
</li>
<li>
<p>Constriction of the pupil is driven by parasympathetic innervation;
    Dilation by sympathetic innervation</p>
</li>
<li>
<p>Physiological anisocoria = pupil sizes differ by \&lt;1mm. Normal.</p>
</li>
</ul>
<p>Conditions that can cause anisocoria:</p>
<ul>
<li>Benign episodic mydriasis</li>
</ul>
<!-- -->

<ul>
<li>Intermittent episodes of pupillary dilation and possible association
    with migraine. No other significant neurologic or ocular symptoms
    present. Important to exclude other causes of mydriasis prior to
    this diagnosis.</li>
</ul>
<!-- -->

<ul>
<li>Horner’s syndrome</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pupillary miosis + ipsilateral upper lid ptosis</p>
</li>
<li>
<p>May be congenital or acquired</p>
</li>
<li>
<p>Acquired causes include: trauma involving sympathetic pathway,
    carotid dissection, cavernous sinus pathology, stroke, neck or
    thoracic surgery, or Pancoast / mediastinal tumor (rare).</p>
</li>
<li>
<p>If suspect new onset Horner’s, consider Neurology and Ophthalmology
    consult.</p>
</li>
</ul>
<!-- -->

<ul>
<li>CN3 Palsy</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pupillary mydriasis (“blown pupil”) + adduction, supraduction,
    infraduction deficit, “down and out position”, upper lid ptosis.
    Must rule out a compressive lesion on CN3.</p>
</li>
<li>
<p>If new onset, consider head imaging and Neurology and Ophthalmology
    consult</p>
</li>
</ul>
<!-- -->

<ul>
<li>Medications (especially anticholinergics)</li>
</ul>
<!-- -->

<ul>
<li>Commonly seen in young patients with scopolamine patches who forget
    to wash hands after handling the patch; dilation can last one day to
    a couple weeks.</li>
</ul>
<!-- -->

<ul>
<li>Trauma</li>
</ul>
<!-- -->

<ul>
<li>Damage to the iris sphincter after eye trauma can cause a dilated
    pupil that is poorly reactive to light.</li>
</ul>
<!-- -->

<ul>
<li>Eye surgery</li>
</ul>
<!-- -->

<ul>
<li>Patients who have undergone intraocular surgery (like cataract
    surgery) may have an irregularly shaped, less reactive, and slightly
    dilated pupil as compared to the other eye due to damage or
    stretching of the iris during the operation.</li>
</ul>
<!-- -->

<ul>
<li>Infections</li>
</ul>
<!-- -->

<ul>
<li>
<p>Viral infections and syphilis can cause parasympathetic denervation,
    resulting in a relatively mydriatic pupil that is poorly reactive to
    light. However, the accommodative pupillary response (i.e.,
    constriction at focusing on an object at near) may be intact.</p>
</li>
<li>
<p>“Adie’s Tonic Pupil” = Idiopathic cause of parasympathetic
    denervation presenting similarly as above. However, viruses (HSV)
    are sometimes thought to be behind idiopathic cases.</p>
</li>
</ul>
<!-- -->

<ul>
<li>Acute angle closure glaucoma</li>
</ul>
<!-- -->

<ul>
<li>During an acute attack, the pupil may be mid-dilated and sluggish to
    light. However, patients will also have symptoms of acute angle
    closure (e.g., headaches, nausea/vomiting, eye pain, etc. See
    Glaucoma section for more info).</li>
</ul>
<p>Conjunctivitis</p>
<p>Background and Presentation</p>
<ul>
<li>
<p>Allergic, viral, or bacterial cause</p>
</li>
<li>
<p>All forms present with red and irritated conjunctiva</p>
</li>
<li>
<p>In practice it can be difficult to distinguish between the types of
    conjunctivitis. However, these are rough guidelines:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Allergic: hx of allergies/atopy, bilateral, chemosis, watery/mucoid
    discharge, itchiness predominant symptom</p>
</li>
<li>
<p>Viral: hx of recent URI or exposure, unilateral first then
    bilateral, itchy/burning, subconjunctival hemorrhages or petechiae,
    watery/mucoid discharge, tender preauricular lymph nodes</p>
</li>
<li>
<p>Bacterial: itching less prominent, burning/aching/stabbing
    discomfort predominates, unilateral first then bilateral,
    mucoid/purulent discharge (and more copious)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Blurry vision is common, but loss of vision should not occur if
    disease limited to conjunctiva.</li>
</ul>
<p>Management:</p>
<ul>
<li>
<p>Allergic: eliminate allergen, artificial tears,
    antihistamine/mast-cell stabilizer drops (olopatadine, ketotifen),
    oral antihistamine (diphenhydramine, loratadine)</p>
</li>
<li>
<p>Viral: 4-8x/day artificial tears, cold compresses, isolation
    precautions.</p>
</li>
<li>
<p>Bacterial: culture/swab the ocular discharge, isolation precautions,
    moxifloxacin drops (Vigamox) QID or trimethoprim/polymyxin B
    drops/ointment for 5-7 days</p>
</li>
<li>
<p>Consult ophthalmology if concern for worsening</p>
</li>
</ul>
<p>Corneal Abrasion, Exposure Keratopathy, Ulceration</p>
<p>Background</p>
<ul>
<li>
<p>Corneal abrasion = corneal epithelial defect (KED): an area of
    missing corneal epithelium. This is akin to a scratch on the skin.
    Most common causes include trauma, excessive surface dryness,
    infection, and neurotrophic disease</p>
</li>
<li>
<p>Exposure keratopathy = development of corneal epithelial defects
    secondary to incomplete closure of the eyelids (i.e., prolonged
    exposure of the cornea to air). Most often occurs in patients who
    are intubated/sedated, have poor orbicularis tone/paralysis (Bell
    palsy), or have abnormal blink rate (e.g., Parkinson’s).</p>
</li>
<li>
<p>Corneal ulceration = the injury extends past the corneal epithelium
    and ‘ulcerates’ into the underlying stroma. Ulcerations are often
    infectious and develop after untreated abrasions (abrasions are
    essentially open wounds). In rare cases ulcerations can also be
    sterile (autoimmune/inflammatory).</p>
</li>
</ul>
<p>Presentation and Evaluation</p>
<ul>
<li>
<p>Abrasions and ulcerations are often extremely painful. May be
    exacerbated by blinking.</p>
</li>
<li>
<p>Conjunctival injection; but sometimes the eye can appear normal, or
    only have trace redness, and the pain may seem out of proportion to
    external appearance.</p>
</li>
<li>
<p>Mucus discharge /crusting</p>
</li>
<li>
<p>Photophobia and tearing</p>
</li>
<li>
<p>Blurry vision</p>
</li>
<li>
<p>Ulcerations will present with the above, but also have a whitish
    infiltrate in the cornea. The conjunctival injection and discharge
    will often be a lot worse.</p>
</li>
<li>
<p>1 drop of Proparacaine 0.5% will improve pain</p>
</li>
</ul>
<!-- -->

<ul>
<li>Note: Proparacaine is used only for diagnostic, and not therapeutic,
    purposes. Do not administer proparacaine on a scheduled or PRN basis
    for pain. The duration of action is only 15 minutes, and repeated
    chronic use can lead to corneal melt/ulceration.</li>
</ul>
<!-- -->

<ul>
<li>1 drop of Fluorescein followed by shining a blue light (or Wood’s
    lamp) will reveal the KED.</li>
</ul>
<p>Management</p>
<ul>
<li>VUMC Perioperative Corneal Abrasion Protocol</li>
</ul>
<!-- -->

<ul>
<li>
<p>If patient is recently postop, or underwent recent extubation, and
    presents with eye pain/burning, blurry vision, redness, photophobia,
    VUMC has a periop corneal abrasion protocol (do not place
    ophthalmology consult):</p>
<ul>
<li>
<p>Erythromycin ophthalmic ointment TID into the lower fornix of
    eye x5 days</p>
</li>
<li>
<p>If the pain and redness do not improve within 48 hours, then
    consult ophthalmology</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Corneal Abrasion</li>
</ul>
<!-- -->

<ul>
<li>
<p>If patient’s signs and symptoms are consistent with a corneal
    abrasion, try erythromycin ophthalmic ointment TID as above.</p>
</li>
<li>
<p>If the pain and redness do not improve within 48 hours, or have
    other concerns, consult ophthalmology</p>
</li>
</ul>
<!-- -->

<ul>
<li>Exposure Keratopathy</li>
</ul>
<!-- -->

<ul>
<li>
<p>If patient is intubated and sedated, or cannot otherwise fully close
    his/her eyes, take the following measures to prevent development of
    corneal abrasion or ulceration:</p>
<ul>
<li>
<p>Moisture chambers (aka bubble shields) to eyes at all times</p>
</li>
<li>
<p>Copious amount of lubricating ophthalmic ointment (e.g.,
    Lubrifresh) in eyes TID</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Corneal Ulceration</li>
</ul>
<!-- -->

<ul>
<li>If you see whitish material in the cornea itself, this is likely a
    corneal ulceration and warrants an ophthalmology consult.</li>
</ul>
<p>Cataracts</p>
<p>Background</p>
<ul>
<li>
<p>Opacification of the eye’s natural lens</p>
</li>
<li>
<p>Primary cause is normal aging, occurs bilaterally and symmetrically</p>
</li>
<li>
<p>Other causes include congenital, trauma, and medications (esp
    chronic / long-term steroid use</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Most common symptoms include progressive decreased vision over
    years, increased glare, increased difficulty with night vision</li>
</ul>
<p>Evaluation and Management</p>
<ul>
<li>
<p>Unless the cataracts are dense enough, it is difficult to appreciate
    without a slit lamp exam</p>
</li>
<li>
<p>Please place an outpatient referral.</p>
</li>
</ul>
<p>Dry Eye</p>
<p>Background</p>
<ul>
<li>
<p>Most common ocular complaint, especially amongst patients admitted
    to the hospital!</p>
</li>
<li>
<p>Due to insufficient tear production and/or imbalance in the
    components that make up the tear film</p>
</li>
<li>
<p>Etiology is vast and can include aging, eye strain/overuse, contact
    lens use, systemic and topical medications, post eye surgery,
    nutritional deficiencies, autoimmune disease, or concomitant with
    other ocular conditions.</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Blurry vision bilaterally that comes and goes (very common–if the
    patient complains of fluctuating blurriness, Dry Eye should be at
    the top of your differential!)</p>
</li>
<li>
<p>Excessive tearing /watery eyes</p>
</li>
<li>
<p>Stinging, burning, soreness, discomfort, gritty/foreign body
    sensation</p>
</li>
<li>
<p>Discomfort with eye movements</p>
</li>
<li>
<p>Trace/mild conjunctival injection</p>
</li>
</ul>
<p>Evaluation and Management</p>
<ul>
<li>If a patient's symptoms sound like Dry Eye, order some
    preservative-free (PF) artificial tears at least 4x/day and
    lubricating eye ointment at bedtime to see if the patient's symptoms
    improve.</li>
</ul>
<!-- -->

<ul>
<li>
<p>Polyvinyl alcohol-povidone PF (Refresh Classic)</p>
</li>
<li>
<p>Lubricating ophthalmic ointment (Lubrifresh)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Order them SCHEDULED. Do not order these eye drops PRN (patients
    will not ask for them).</p>
</li>
<li>
<p>If a patient's symptoms fail to improve or worsen on artificial
    tears, consider paging ophthalmology for additional assistance. If
    there is no apparent imminent threat to vision, you can place an
    ophthalmology outpatient referral upon discharge.</p>
</li>
</ul>
<p>Fungemia and Intraocular Involvement</p>
<p>The American Academy of Ophthalmology currently does NOT recommend
routine Ophthalmology consults for visually asymptomatic patients with
systemic candidemia. The incidence of candidemia-related endophthalmitis
detected from routine screenings is \&lt;1%.</p>
<p>By contrast, if the patient has visual symptoms, an Ophthalmology
consult is warranted.</p>
<ul>
<li>Breazzano MP et al. American Academy of Ophthalmology
    Recommendations on Screening for Endogenous Candida Endophthalmitis.
    Ophthalmology. 2022 Jan;129(1):73-76.</li>
</ul>
<p>Giant Cell Arteritis: Role of Ophthalmology</p>
<p>If a patient has systemic symptoms suspect of GCA (see “Rheumatology
section”), when is it appropriate to consult Ophthalmology?</p>
<ul>
<li>
<p>If patient HAS visual symptoms (acute vision loss, new onset
    diplopia), consult ophthalmology.</p>
</li>
<li>
<p>If patient DOES NOT have visual symptoms, DO NOT consult
    ophthalmology (e.g., to rule out “retinal vasculitis.”)</p>
</li>
<li>
<p>It is extremely unlikely that Ophthalmology will find a pertinent
    ocular finding in the absence of visual symptoms to support a
    diagnosis of GCA.</p>
</li>
<li>
<p>Bottom line: If you suspect GCA given the other systemic symptoms
    (regardless of visual status), treat promptly with high dose
    steroids!</p>
</li>
<li>
<p>Temporal Artery biopsies are typically performed by Vascular
    Surgery.</p>
</li>
</ul>
<p>Glaucoma</p>
<p>Background</p>
<ul>
<li>
<p>Glaucoma is a disease of the optic nerve that follows a
    characteristic pattern of optic nerve fiber degeneration.</p>
</li>
<li>
<p>High intraocular pressure (IOP) is believed to be the main etiology
    of the disease.</p>
</li>
<li>
<p>While the “normal” IOP range is between 11 and 21 mmHg, there are
    individuals who have a pressure above 21 that do NOT develop
    glaucoma. Conversely, there are individuals who have a pressure in
    the normal range that DO develop glaucoma (= Normal Tension
    Glaucoma).</p>
</li>
<li>
<p>Aqueous humor fills the anterior chamber and drains through a
    sieve-like structure called the trabecular meshwork (TM), located in
    the angle between the iris and the cornea. After passing through TM,
    aqueous drains into the eye’s venous system. Impediment to aqueous
    flow will cause elevated IOP.</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>All glaucomas generally cause progressive peripheral visual field
    loss that ultimately encroaches on central fixation and leads to
    irreversible blindness if left untreated.</p>
</li>
<li>
<p>A glaucomatous optic nerve is often described as “cupped”</p>
</li>
<li>
<p>Presents in an acute or chronic fashion:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Acute Angle-Closure Glaucoma</p>
<ul>
<li>
<p>The iridocorneal angle rapidly closes, blocking aqueous drainage
    and causing a sudden rise in IOP (usually >40mmHg).</p>
</li>
<li>
<p>Symptoms and Signs: intense eye or orbital pain, headache,
    nausea/vomiting, blurred vision, halos around lights, fixed and
    mid-dilated pupil, rock-hard eye, conjunctival redness, cloudy
    cornea.</p>
</li>
<li>
<p>Usually unilateral, but occasionally can be bilateral.</p>
</li>
<li>
<p>Classic trigger is a pupil-dilating factor (e.g., dark
    environment or anticholinergic medications) in a person with
    anatomically narrow angles.</p>
</li>
<li>
<p>If IOP is not lowered within hours, permanent optic nerve damage
    and vision loss will likely occur.</p>
</li>
</ul>
</li>
<li>
<p>Primary Open Angle Glaucoma (POAG)</p>
<ul>
<li>
<p>The iridocorneal angle is open, but due to inadequately
    functioning TM (or other mechanism) aqueous does not drain
    properly and IOP is chronically elevated.</p>
</li>
<li>
<p>POAG is often painless and without noticeable vision changes in
    the early stage of disease. Individuals can go undiagnosed for
    years, sitting at an IOP of say 30mmHg, without being aware they
    are losing vision until the vision loss is severe.</p>
</li>
<li>
<p>POAG is the most common glaucoma in the US. When a patient says
    they have a history of glaucoma, they probably have POAG.</p>
</li>
</ul>
</li>
</ul>
<p>Evaluation and Management</p>
<ul>
<li>Primary Open Angle:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Continue the patient’s home glaucoma drops; caution if they develop
    a medical condition that results in a contraindication (See table
    below)</p>
</li>
<li>
<p>No need to officially place an Ophthalmology consult to order a
    patient’s home glaucoma drops; feel free to page Ophthalmology if
    you have questions.</p>
</li>
<li>
<p>Pro tip: Often patients will remember the cap color of the drops
    they take but not the names!</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 10%" />
<col style="width: 16%" />
<col style="width: 10%" />
<col style="width: 18%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th>Name (brand)</th>
<th>Cap color</th>
<th>Class</th>
<th>Dosing</th>
<th>Possible side effects</th>
<th>Relative contraindications</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Timolol (Timoptic)</td>
<td>Yellow</td>
<td>Nonselective beta-blocker</td>
<td>BID</td>
<td>Bradycardia, bronchospasm, hypotension</td>
<td>Heart conditions (CHF, heart block), asthma/COPD</td>
</tr>
<tr class="even">
<td><p>Latanoprost</p>
<p>(Xalatan)</p></td>
<td>Teal</td>
<td>Prostaglandin analogue</td>
<td>QHS</td>
<td>Flulike symptoms, joint pains</td>
<td>Pregnancy (category C), uveitis</td>
</tr>
<tr class="odd">
<td><p>Brimonidine</p>
<p>(Alphagan)</p></td>
<td>Purple</td>
<td>Alpha-2 agonist</td>
<td>BID-TID</td>
<td>Allergic conjunctivitis, CNS depression, bradycardia</td>
<td>Infants and young children</td>
</tr>
<tr class="even">
<td><p>Dorzolamide</p>
<p>(Trusopt)</p></td>
<td>Orange</td>
<td>Carbonic anhydrase inhibitor</td>
<td>BID</td>
<td>Acidosis, hypokalemia, malaise, GI upset, metallic taste</td>
<td>Renal insufficiency, Hepatic cirrhosis, Sickle cell disease, caution
when using with other K-wasting drugs</td>
</tr>
<tr class="odd">
<td><p>Acetazolamide</p>
<p>(Diamox) PO</p></td>
<td>PO tablet</td>
<td>Carbonic anhydrase inhibitor</td>
<td><p>250mg</p>
<p>BID-QID</p></td>
<td>Same as dorzolamide, but side effects more likely to occur given
PO</td>
<td>Same as dorzolamide, but side effects more likely to occur given
PO</td>
</tr>
</tbody>
</table>

<p><em>Cosopt (Blue cap) = dorzolamide + timolol</em></p>
<p><em>Combigan (Purple cap) = brimonidine + timolol</em></p>
<ul>
<li>Acute Angle Closure:</li>
</ul>
<!-- -->

<ul>
<li>
<p>If suspect acute angle closure given the signs described above,
    consult Ophthalmology ASAP.</p>
</li>
<li>
<p>The goal is to lower the IOP ASAP. Target is \&lt;30mmHg.</p>
</li>
<li>
<p>Administer frequent rotating rounds of all the IOP-lowering drops: 1
    drop of Cosopt (then wait 5 minutes), followed by Brimonidine (then
    wait 5 minutes), followed by Latanoprost (then wait 5 minutes)--then
    keep repeating the cycle until the IOP goes down.</p>
</li>
<li>
<p>Concurrently, administer one dose of IV Diamox 500mg if not
    contraindicated (e.g., renal insufficiency or hepatic cirrhosis).
    Ophthalmology will recheck the IOP every hour or so to ensure that
    the IOP is responding (usually it does).</p>
</li>
<li>
<p>If the IOP does not respond, patient will need a bedside AC tap to
    offload aqueous and lower the pressure.</p>
</li>
<li>
<p>Patient should ultimately get a Laser Peripheral Iridotomy (LPI) to
    avoid future angle-closure attacks, which is typically performed as
    an outpatient procedure.</p>
</li>
</ul>
<p>Orbital vs Preseptal Cellulitis</p>
<p>Background</p>
<ul>
<li>
<p>The septum is a fibrous, membranous structure that divides the
    anterior from the posterior orbit.</p>
</li>
<li>
<p>Preseptal cellulitis = infection is bound anterior to the septum</p>
</li>
<li>
<p>Orbital cellulitis (AKA postseptal cellulitis) = infection extends
    posterior to the septum</p>
</li>
<li>
<p>Common risk factors/etiologies: URI, acute or chronic sinusitis,
    trauma, tooth abscess, stye or other local/adjacent skin
    infection/condition, local/adjacent bug bite, immunocompromised
    state, underlying systemic infection</p>
</li>
<li>
<p>Often bacterial cause (gram positive Staph or Strep species, and/or
    gram negative anaerobic species like Peptococcus or Bacteroides).
    Consider fungal infection (Aspergillus, Mucor) in immunocompromised
    or diabetic patients.</p>
</li>
</ul>
<p>Presentation</p>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 33%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr class="header">
<th>Preseptal Cellulitis</th>
<th>Can be Present in Either</th>
<th>Orbital Cellulitis</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>-Patient less toxic appearing</p>
<p>No visual compromise</p>
<p>-Mild conjunctival injection, no to minimal chemosis</p>
<p>-No or minimal limitation of eye movements</p>
<p>-No or minimal proptosis</p>
<p>-Symptoms improving with PO antibiotics</p></td>
<td><p>-Erythema and Edema of eyelids (upper and/or lower) and
periorbital skin</p>
<p>-Fever (although more likely in Orbital cellulitis)</p>
<p>-Difficulty opening the eye d/t swelling</p>
<p>-Blurry vision</p>
<p>-Tearing/ocular discharge</p></td>
<td><p>-Patient more toxic appearing</p>
<p>-Pain with eye movements</p>
<p>-Limitation of eye movements +/- diplopia</p>
<p>-Proptosis</p>
<p>-Severe conjunctival injection + chemosis</p>
<p>-Vision may be compromised</p>
<p>-Symptoms not improving after course of PO antibiotics</p></td>
</tr>
</tbody>
</table>

<p>Evaluation</p>
<ul>
<li>
<p>Vital signs</p>
</li>
<li>
<p>Labs: CBC, CMP, ESR, CRP, blood cultures, wound culture if any open
    draining areas</p>
</li>
<li>
<p>Imaging: CT orbits with and without contrast</p>
</li>
<li>
<p>Daily or BID photographs to track progression</p>
</li>
<li>
<p>You can use the LRINEC scale to help assess whether the infection is
    necrotizing:</p>
</li>
<li>
<p><a href="https://www.mdcalc.com/lrinec-score-necrotizing-soft-tissue-infection">https://www.mdcalc.com/lrinec-score-necrotizing-soft-tissue-infection</a>.
    Necrotizing soft tissue infections should be addressed immediately
    and undergo surgical debridement ASAP.</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Preseptal cellulitis can usually be managed on an outpatient basis
    with PO antibiotics (e.g. augmentin) with close followup.</p>
</li>
<li>
<p>However, if condition is worsening, if there is failure to improve
    on PO antibiotics, or if concerned for postseptal extension (i.e.,
    that the preseptal cellulitis has evolved into an orbital
    cellulitis), management generally includes:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>IV broad spectrum antibiotics (usually Unasyn + Vancomycin to start
    if no intracranial extension; could also do Vancomycin +
    Ceftriaxone + Flagyl)</p>
</li>
<li>
<p>Ophthalmology Consult</p>
</li>
<li>
<p>Consider ID consult</p>
</li>
<li>
<p>Consider ENT consult if concomitant sinus disease (most of the time
    there is)</p>
</li>
<li>
<p>Consider OMFS consult if suspect etiology is odontogenic</p>
</li>
<li>
<p>Tobradex eye drops QID to affected eye</p>
</li>
<li>
<p>Nasal toilet (afrin, flonase, nasal saline)--usually dictated by ENT</p>
</li>
<li>
<p>Warm compresses at least QID to affected eye</p>
</li>
<li>
<p>Trend daily CRP</p>
</li>
</ul>
<!-- -->

<ul>
<li>If there is failure to improve on the above regimen, a large orbital
    abscess, optic nerve stretch on CT scan, evidence of necrotizing
    infection, or visual compromise, the patient may need to undergo
    surgical drainage.</li>
</ul>
<p>Optic Neuritis</p>
<p>Background</p>
<ul>
<li>Optic neuritis is inflammation of the optic nerve. Often caused by
    demyelinating disease (e.g., Multiple sclerosis). Less often, can be
    caused by infection (viral etiology, bartonella, Lyme, syphilis, TB,
    toxoplasmosis) or infiltrative process (e.g., sarcoidosis,
    malignancy).</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Symptoms include scotoma, constant blurry vision or blurred spot,
    pain with eye movements, along with other systemic neurologic
    symptoms (if demyelinating process)</p>
</li>
<li>
<p>If patient is of age 20s-40s and female, autoimmune/demyelinating
    disease is at top of the differential</p>
</li>
<li>
<p>If patient is older, consider other causes</p>
</li>
<li>
<p>If patient is immunocompromised, infectious etiology becomes more
    likely</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Consult both Ophthalmology and Neurology if concerned for an optic
    neuritis</p>
</li>
<li>
<p>MRI brain and orbits with and without contrast, thin slices, fat
    suppression</p>
</li>
<li>
<p>If no contraindications to imaging, obtain LP with CSF studies
    (glucose, protein, cell count, Gram stain, bacterial/viral cultures,
    RPR/VDRL, oligos, consider NMO/AQP4)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>High dose IV methylprednisolone</p>
</li>
<li>
<p>If vision continues to worsen and/or presence of other systemic
    neurologic symptoms despite steroid treatment, consider escalation
    to PLEX therapy with assistance of neurology</p>
</li>
</ul>
<p>Papilledema</p>
<p>Background</p>
<ul>
<li>
<p>Papilledema refers to edema of the optic nerve due to increased
    intracranial pressure</p>
</li>
<li>
<p>Ophthalmology is often consulted to rule out papilledema in patients
    who fit the “Idiopathic Intracranial Hypertension (IIH)” profile, or
    with patients with other reasons for high ICP</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Symptoms of increased ICP: headaches that vary with position (often
    worse with bending over), nausea, vomiting, neck
    stiffness/meningismus, pulsatile tinnitus, fevers/chills</p>
</li>
<li>
<p>Visual symptoms of papilledema: transient visual obscurations,
    dimming of vision, blurry vision, loss of color vision/red
    desaturation, loss of peripheral vision, scotoma.</p>
</li>
</ul>
<p>Evaluation and Management</p>
<ul>
<li>
<p>Consult Ophthalmology and Neurology if concerned for papilledema.
    Neurosurgery should be involved if there is concern for shunt
    failure or other neurosurgical problem.</p>
</li>
<li>
<p>Ophthalmology / Neurology will advise on what imaging to order
    (usually MRI / MRV brain with and without contrast, + MRI Orbits
    with and without contrast and fat suppression)</p>
</li>
<li>
<p>If no contraindications after imaging, obtain LP with opening
    pressure, with CSF sent for cells, protein, glucose, and
    infectious/neoplastic workup where appropriate</p>
</li>
<li>
<p>Ophthalmology / Neurology may recommend initiation of PO or IV
    acetazolamide (Diamox). These may be contraindicated or need to be
    renally dosed if the patient has chronic kidney disease.</p>
</li>
</ul>
<p>Retinal Detachment and Posterior Vitreous Detachment</p>
<p>Background</p>
<ul>
<li>
<p>Retinal detachment (RD) = detachment of retinal tissue from the back
    of the eye. Risk factors include trauma, high myopia
    (nearsightedness), older age, history of RD in the other eye, prior
    eye surgery, and family history.</p>
</li>
<li>
<p>Posterior Vitreous Detachment (PVD) = detachment of vitreous (jelly)
    from the retina. PVDs eventually will happen to all adults as the
    vitreous liquefies and shrivels with age. Some are asymptomatic.</p>
</li>
<li>
<p>PVDs can lead to RDs, but not always. As the vitreous peels away
    from the underlying retina, vitreous can pull a piece of retina with
    it, causing a retinal tear. The retinal tear, if not treated, can
    evolve into an RD.</p>
</li>
</ul>
<p>Presentation and Evaluation</p>
<ul>
<li>
<p>Both can present with acute flashes and floaters</p>
</li>
<li>
<p>However, RDs will often present with a black curtain or veil that
    comes down somewhere in the patient’s field of vision. PVDs may
    result in blurriness, but will not present with veils, scotomas, or
    severe loss of vision.</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>If patient presents with acute flashes, floaters, and/or black
    curtains in field of vision in one eye, consult ophthalmology.</p>
</li>
<li>
<p>If not acute, or if symptoms occur in both eyes simultaneously,
    chances are this is not a PVD or an RD. See Approach to Flashes,
    Floaters, Spots.</p>
</li>
</ul>
<p>Uveitis (includes Iritis, Cyclitis, Retinitis, Choroiditis)</p>
<p>Background</p>
<ul>
<li>
<p>”Uvea” = iris + ciliary body + choroid (these 3 tissues are
    connected and make up the vascular layer of the eye)</p>
</li>
<li>
<p>Uveitis = inflammation of either or all of these structures.
    However, “uveitis” is a bit of a misnomer, since it is used to
    denote inflammation of any ocular component</p>
</li>
<li>
<p>Uveitis is usually associated with autoimmune conditions, but
    infections can also cause uveitis.</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 13%" />
<col style="width: 18%" />
<col style="width: 19%" />
<col style="width: 25%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr class="header">
<th></th>
<th>Anterior Uveitis</th>
<th>Intermediate Uveitis</th>
<th>Posterior Uveitis</th>
<th>Panuveitis</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Practical synonyms</td>
<td>Iritis</td>
<td>Pars planitis, Cyclitis</td>
<td>Retinitis, Choroiditis, Chorioretinitis</td>
<td>Diffuse uveitis</td>
</tr>
<tr class="even">
<td>Definition</td>
<td>Inflammation localized to the anterior segment</td>
<td>Inflammation localized to the vitreous cavity and pars plana</td>
<td>Inflammation localized to choroid and retina</td>
<td>Inflammation involving the anterior, intermediate, and posterior
structures</td>
</tr>
<tr class="odd">
<td>Symptoms</td>
<td><p>Vision loss</p>
<p>Usually painful</p>
<p>Perilimbal redness</p></td>
<td><p>Vision loss</p>
<p>Pain varies</p></td>
<td><p>Vision loss</p>
<p>Pain varies</p></td>
<td><p>Vision loss</p>
<p>Pain varies</p></td>
</tr>
<tr class="even">
<td>Common etiologies</td>
<td><p>Idiopathic</p>
<p>HLA-B27</p>
<p>IBD, psoriatic arthritis, ankylosing spondylitis, reactive
arthritis</p></td>
<td><p>Spillover from anterior uveitis</p>
<p>Multiple sclerosis</p>
<p>Lymphoma</p>
<p>Sarcoid</p>
<p>Syphilis</p>
<p>TB</p></td>
<td><p>Immunocompromised (HIV, transplant)</p>
<p>CMV, HSV, VZV</p>
<p>Vasculitis</p>
<p>Sarcoidosis</p>
<p>Toxoplasmosis</p>
<p>Syphilis</p>
<p>TB</p></td>
<td><p>Lymphoma</p>
<p>Behcet’s disease</p>
<p>Sarcoid</p>
<p>Syphilis</p>
<p>TB</p>
<p>Toxoplasmosis</p></td>
</tr>
</tbody>
</table>

<p>Management</p>
<ul>
<li>
<p>If you suspect a patient has uveitis, consult ophthalmology for
    evaluation.</p>
</li>
<li>
<p>Patients with any of the above associated systemic conditions (e.g.,
    IBD) do not need an inpatient Ophthalmology consult unless the
    patient has visual symptoms. Referral to outpatient Ophthalmology is
    appropriate for routine screening.</p>
</li>
</ul>
<p>Wilson’s Disease: Ophthalmic Manifestations</p>
<ul>
<li>
<p>The two classic ophthalmic manifestations of Wilson’s disease are
    the “Kayser-Fleischer ring” (copper deposition around the corneal
    limbus) and the “Sunflower cataract” (copper deposition in the
    lens).</p>
</li>
<li>
<p>Wilson’s disease rarely affects vision (unless the sunflower
    cataract is very advanced).</p>
</li>
<li>
<p>Unless the disease is very advanced/has been present for years, it
    is impossible for one to detect subtle copper deposition in the
    cornea, iridocorneal angle, or lens without an office-based slit
    lamp exam and gonioscopy (only available in the outpatient setting).</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Furthermore, the presence or absence of a Kayser-Fleischer ring does
    not rule in or rule out the disease</p>
</li>
<li>
<p>Testing for decreased ceruloplasmin, urinary copper levels, and
    genetic testing are more effective diagnostic methods.</p>
</li>
</ul>
<!-- -->

<ul>
<li>If concerned about the visual impact of a developing sunflower
    cataract, an outpatient ophthalmology referral is appropriate.</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Ophthalmology</h1>
                        <h1 class='nav-section-title' id='section-outpatient-medicine'>
                            Outpatient medicine <a class='headerlink' href='#section-outpatient-medicine' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="outpatient-medicine-main"><p>Obesity/Nutrition – Mackenzie Samson</p>
<p>Background</p>
<ul>
<li>
<p>BMI = Body Weight (kg) / Height (meters)2</p>
</li>
<li>
<p>Underweight = BMI \&lt;18.5</p>
</li>
<li>
<p>Normal = BMI 18.5-24.9</p>
</li>
<li>
<p>Overweight = BMI 25.0-29.9</p>
</li>
<li>
<p>Obesity:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Class I 30-34.9</p>
</li>
<li>
<p>Class II 35-39.9</p>
</li>
<li>
<p>Class IIIA 40-44.9</p>
</li>
<li>
<p>Class IIIB 45-49.9</p>
</li>
<li>
<p>Class IIIC 50+</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Goals: Target initial weight loss of 5-7% body weight, schedule
    frequent follow up to assess progress. Request pts send 48 hr food
    log. Encourage accountability “buddies.” Consider weight loss apps:
    My Fitness Pal, Lose it, Noom</p>
</li>
<li>
<p>Dietary options:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Calorie restriction > macronutrient composition (e.g., low fat, low
    carb)</p>
</li>
<li>
<p>Mediterranean: high in unsaturated fats, fruit/veg, legumes, grain,
    moderate dairy &amp; EtOH, less meat. Adherence leads to decreased
    overall mortality and CV mortality; may decrease diabetes incidence
    independent of weight loss</p>
</li>
<li>
<p>Dot phrases below for pictoral representation of cultural diets
    adapted to fit Mediterranean guidelines (Asian, African, Latin
    American)</p>
</li>
<li>
<p>DASH: High in fruits/vegetables, moderate dairy, \&lt; 25% caloric
    intake from fat (decreases SBP/DBP)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Exercise: >30 min, 5-7 days per week, ideally a combo of aerobic +
    resistance training.</li>
</ul>
<!-- -->

<ul>
<li>Exercise alone is not sufficient for weight loss</li>
</ul>
<!-- -->

<ul>
<li>
<p>Medications: If BMI ≥30 or BMI ≥27 with ≥1 comorbidity. Significant
    short term weight loss (~ 5-15 lbs), but weight is typically gained
    back when stopped. See table below</p>
</li>
<li>
<p>Referral to medical weight loss: If BMI ≥ 30 or BMI ≥27 with
    comorbid conditions (fatty liver disease, diabetes mellitus, HTN,
    OSA)</p>
</li>
<li>
<p>Referral to surgical weight loss: If BMI ≥40 or BMI ≥35 with
    comorbid conditions</p>
</li>
<li>
<p>VA: consider referral to MOVE program (in person/telehealth options)</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 27%" />
<col style="width: 34%" />
<col style="width: 37%" />
</colgroup>
<thead>
<tr class="header">
<th>Medication</th>
<th>Mechanism</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Orlistat (Xenical)</td>
<td>Reduces fat adsorption</td>
<td>Diarrhea, gas, leakage of oily stools, stomach pain</td>
</tr>
<tr class="even">
<td>Phentermine-topiramate (Qsymia)</td>
<td>Phentermine: appetite suppression<br />
<br />
Topiramate (anticonvulsant, migraine txt): ?appetite suppression,
?altered satiety perception</td>
<td>Constipation, dizziness, dry mouth, taste changes, tingling of hands
and feet, insomnia</td>
</tr>
<tr class="odd">
<td>Naltrexone-bupropion (Contrave)</td>
<td>Naltrexone (partial opioid antagonist; used for alcohol dependence):
?altered satiety perception<br />
<br />
Bupropion (antidepressant): ?altered satiety perception</td>
<td>Constipation, diarrhea, dizziness, dry mouth, headache, BP,
tachycardia, insomnia, liver damage, nausea/vomiting</td>
</tr>
<tr class="even">
<td>Liraglutide (Saxenda)</td>
<td>Appetite suppression; quickens satiety<br />
<br />
(Victoza: lower dose formulation, FDA-approved for T2DM)</td>
<td>Nausea, diarrhea, constipation, abdominal pain, headache,
tachycardia</td>
</tr>
<tr class="odd">
<td>Phentermine (Ionamin)</td>
<td>Reduces appetite<br />
Note: FDA-approved only for short-term use—up to 12 weeks</td>
<td>Dry mouth, constipation, insomnia, dizziness, nervousness/
restlessness headache, HTN, tachycardia</td>
</tr>
<tr class="even">
<td>Semaglutide (Ozempic/Rybelsus)</td>
<td>Glucagon-like peptide-1 receptor agonist; reduces appetite</td>
<td>Nausea, vomiting, diarrhea, abdominal pain, constipation</td>
</tr>
</tbody>
</table>

<p>Additional Information</p>
<ul>
<li>EPIC Dot phrases:</li>
</ul>
<!-- -->

<ul>
<li>
<p>.NHFOODINSECURITY </p>
</li>
<li>
<p>.NHFOODASIANDIET </p>
</li>
<li>
<p>.NHFOODLATINDIET </p>
</li>
<li>
<p>.NHFOODAFRICANDIET </p>
</li>
<li>
<p>.NHFOODHEALTHYPLATE </p>
</li>
<li>
<p>.NHOBESITYYMCA </p>
</li>
</ul>
<p>Lipids – Brittany Saldivar</p>
<p>Background</p>
<ul>
<li>
<p>1º Prevention: pts at increased risk who have not yet had a vascular
    event</p>
</li>
<li>
<p>2º Prevention: pts with pre-existing occlusive vascular disease or
    ASCVD (e.g., stroke, TIA, CAD + angina, ACS, coronary or arterial
    revascularization, PAD)</p>
</li>
<li>
<p>Screening: USPSTF 2016 Guidelines: q5years for adults 40-75yrs</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>ACC/AHA 2019 Guideline: adults 20-39 q 4-6yrs; \&lt;21yrs if strong fam
    hx; 40-75 “routinely” assess CV risk and calculate 10 yr ASCVD risk
    (lipid pnl q3-12 months)</p>
</li>
<li>
<p>Dot phrase: .ASCVD2013</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Fasting vs Non-Fasting Lipid Panel</li>
</ul>
<!-- -->

<ul>
<li>Triglycerides are most impacted by non-fasting testing which can
    artificially lower LDL-C depending on how the laboratory
    measures/calculates LDL. Consider fasting lipid panels when
    triglyceride levels are high</li>
</ul>
<!-- -->

<ul>
<li>Consider 2º causes of HLD in initial workup: hypothyroidism, DM,
    EtOH use, smoking, liver disease, nephrotic syndrome, CKD, meds
    (e.g., thiazide, glucocorticoids)</li>
</ul>
<p>Management</p>
<ul>
<li>Lifestyle changes:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Heart Healthy Diet: ↓ trans/saturated fats, choose skim milk,
    low-fat dairy products</p>
</li>
<li>
<p>Emphasizes fruits, vegetables, whole grains, poultry, fish, nuts and
    olive oil, while limiting red and processed meats, sodium and
    sugar-sweetened foods and beverages</p>
</li>
<li>
<p>Promote a healthy weight, regular exercise, smoking cessation, limit
    EtOH</p>
</li>
</ul>
<p>Statin Therapy</p>
<ul>
<li>
<p>Initiate as outlined in the following algorithms</p>
</li>
<li>
<p>Check AST/ALT prior to initiation</p>
</li>
<li>
<p>Note that PCE used to estimate ASCVD risk is best validated for
    non-Hispanic whites and blacks. Consider use of additional risk
    prediction tools/factors in other patient populations</p>
</li>
</ul>
<p><img src="../outpatient-medicine/main/output/media/image21.jpg"
style="width:3.41538in;height:2.37961in"
alt="Diagram Description automatically generated" /></p>
<p>Figure from 2019 ACC/AHA Guideline on Primary Prevention of
Cardiovascular Disease</p>
<p><img src="../outpatient-medicine/main/output/media/image22.jpeg"
style="width:2.99231in;height:2.02062in"
alt="Diagram Description automatically generated" /></p>
<p>Figure from 2018 ACC/AHA Guideline on Management of Blood Cholesterol</p>
<table>
<colgroup>
<col style="width: 34%" />
<col style="width: 35%" />
<col style="width: 30%" />
</colgroup>
<thead>
<tr class="header">
<th>High Intensity<br />
(Decr LDL-C by &gt; 50%)</th>
<th>Moderate Intensity<br />
(Decr LDL-C by 30% - 49%)</th>
<th>Low Intensity<br />
(Decr LDL-C by &lt;30%)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Atorvastatin (40mg) 80mg\*</p>
<p>Rosuvastatin 20mg (40mg)</p></td>
<td><p><strong>Atorvastatin 10mg</strong> (20mg)</p>
<p><strong>Rosuvastatin</strong> (5mg) <strong>10mg</strong></p>
<p><strong>Simvastatin 20 - 40mg</strong></p></td>
<td>Simvastatin 10mg</td>
</tr>
<tr class="even">
<td></td>
<td><p><strong>Pravastatin 40mg</strong> (80mg)</p>
<p><strong>Lovastatin 40mg</strong> (80mg)</p>
<p>Fluvastatin XL 80mg</p>
<p><strong>Fluvastatin 40mg BID</strong></p>
<p>Pitavastatin 1-4mg</p></td>
<td><p><strong>Pravastatin 10-20mg</strong></p>
<p><strong>Lovastatin 20 mg</strong></p>
<p>Fluvastatin 20-40mg</p></td>
</tr>
<tr class="odd">
<td colspan="3"><em>*Bold denotes dosing with RCT proven LDL lowering
benefit</em></td>
</tr>
</tbody>
</table>

<p>Statin Options</p>
<p>Statin Side effects:</p>
<ul>
<li>Spectrum of statin associated muscle symptoms (SAMS) include
    myalgias, myopathy, rhabdomyolysis, autoimmune myopathy</li>
</ul>
<!-- -->

<ul>
<li>
<p>Myalgias: bilateral involving large muscle groups, onset within
    weeks of initiation of therapy and should resolve within weeks of
    cessation; CK should be normal</p>
</li>
<li>
<p>Consider evaluation with CK, BMP, TSH, and vitamin D</p>
</li>
<li>
<p>ACC has a “Statin Intolerance Calculator” to help assess etiology of
    symptoms</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>If patient is not tolerating a statin, consider:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Holding statin until symptoms resolve and trialing lower dose or
    alternative statin (Pravastatin and Fluvastatin may have lower risks
    of myopathy)</p>
</li>
<li>
<p>Every other day dosing with atorvastatin and rosuvastatin (longer
    half-lives)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If repeated failed attempts, consider alternative agents: Ezetimibe,
    PCSK9 inhibitor</p>
</li>
<li>
<p>PCSK9 inhibitor requires referral to Lipid Clinic</p>
</li>
</ul>
<p>Hypertriglyceridemia:</p>
<ul>
<li>
<p>Moderate: TG 175-499 mg/dL; Moderate-severe 500 - 999; Severe: TG >
    1000</p>
</li>
<li>
<p>Focus on addressing lifestyle factors and stopping medication that
    increase TG’s (HCTZ, some BB’s, estrogens, some ART, antipsychotics)</p>
</li>
<li>
<p>Consider medical therapy when TG> 500mg/dL (increased risk of
    pancreatitis):</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Omega-3-fatty acids (icosapent ethyl) 4gms daily or Vascepa 4gm
    daily</p>
</li>
<li>
<p>Fibrates: Fenofibrate 120 mg daily (avoid in CKD), Gemfibrozil 600mg
    bid (increased risk of myopathy with concomitant statin)</p>
</li>
</ul>
<p>VA- Specific Guidelines</p>
<ul>
<li>
<p><a href="https://www.healthquality.va.gov/guidelines/cd/lipids/index.asp">https://www.healthquality.va.gov/guidelines/cd/lipids/index.asp</a></p>
</li>
<li>
<p>Lowest LDL goal recognized for VA Criteria for Use is 100</p>
</li>
<li>
<p>Preferred statins: Atorvastatin, Simvastatin, Lovastatin</p>
</li>
<li>
<p>Statins that require PADR: Pravastatin, Rosuvastatin (2<sup>nd</sup> line high
    intensity statin)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Must have documented intolerances or drug-drug interaction to all
    preferred statins</li>
</ul>
<!-- -->

<ul>
<li>Other agents that require PADR:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ezetimibe</p>
<ul>
<li>
<p>Pt has tried and failed or not tolerated all statins (allergy,
    AE, etc.)</p>
</li>
<li>
<p>Pt not meeting goal on max dose of statin PLUS bile acid
    sequestrants or niacin</p>
</li>
</ul>
</li>
<li>
<p>Fenofibrate</p>
<ul>
<li>
<p>Pt has tried all formulary alternatives or has contraindication
    to use of formulary alternatives (statin, niacin, gemfibrozil,
    cholestyramine, fish oil)</p>
</li>
<li>
<p>If TG > 500 mg/dL, fenofibrate should be approved</p>
</li>
</ul>
</li>
</ul>
<p>Hypertension (HTN) – Daniel Motta-Calderon</p>
<p>Background</p>
<ul>
<li>
<p>Elevated systolic blood pressure and diastolic blood pressure are
    associated with increased cardiovascular disease (CVD) risk</p>
</li>
<li>
<p>HTN is the most prevalent modifiable risk factor for premature CVD</p>
</li>
</ul>
<p>Definitions</p>
<ul>
<li>
<p>ACC/AHA definition of HTN: taking antihypertensive medication or
    having a systolic pressure ≥130 mmHg and/or a diastolic pressure ≥80
    mmHg</p>
</li>
<li>
<p>Resistant HTN**:** Uncontrolled BP despite taking 3 antihypertensive
    medications including a diuretic OR 4 total medications</p>
</li>
<li>
<p>Whitecoat HTN: Mean BPs lower than threshold of HTN based on
    out-of-office measurements (falsely elevated measurements during
    visits). If SBP > 130 but \&lt; 160, consider screening for white coat
    HTN with home monitoring</p>
</li>
<li>
<p>Masked HTN: Mean BP at/above threshold for hypertension based upon
    out-of-office measurements (falsely decreased measurements during
    visits). If office SBPs consistently 120-129, consider screening for
    masked HTN with home monitoring</p>
<p>Screening</p>
</li>
<li>
<p>Grade A USPTF rec: Screen all adults >18. Screen adults at least
    semiannually if have risk factors for HTN (obesity, AA), or if
    previously measured SBP 120-129</p>
</li>
</ul>
<p>Diagnosis</p>
<ul>
<li>
<p>Proper BP measurement:  legs uncrossed, supported arm at level of
    heart, after 5 minutes of rest and with empty bladder; avoid
    caffeine or tobacco 30 minutes prior</p>
</li>
<li>
<p>Ideally, primary detection in clinical setting (BP ≥130/80) followed
    by confirmation with ambulatory blood pressure monitoring (ABPM): </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>24hrs mean of systolic ≥125 or diastolic ≥75mmHg </p>
</li>
<li>
<p>Daytime mean systolic ≥130mmHg or diastolic ≥80mmHg  </p>
</li>
<li>
<p>Nighttime mean systolic ≥110 mmHg or ≥65 diastolic mmHg </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If ABPM not possible, 2-3 outpatient measurements at 1-4 week
    intervals are required to confirm diagnosis  </p>
</li>
<li>
<p>BP >160/100mmHg in the outpatient setting with evidence of
    end-organ damage (ischemic CMP, CVA, hypertensive retinopathy, LV
    hypertrophy, CKD) </p>
</li>
<li>
<p>Any patient presenting with hypertensive emergency or severe
    asymptomatic hypertension (>180/120mmHg) </p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Assess target organ damage as pertinent: CVA, retinopathy, LV
    hypertrophy/dysfunction, HF, CAD, CKD, PAD.  </li>
</ul>
<!-- -->

<ul>
<li>
<p>BMP, CBC, lipid panel, UA, TSH, EKG. Consider additional testing
    including TTE, urine Alb:Cr ratio, or uric acid, ABI </p>
</li>
<li>
<p>Calculate ACSVD 10y risk</p>
</li>
</ul>
<!-- -->

<ul>
<li>Distinguish between primary (90% incidence) and secondary HTN
    (10%): </li>
</ul>
<!-- -->

<ul>
<li>
<p>Suspect 1º if gradual onset, family hx, associated with weight gain
    &amp; lifestyle factors </p>
</li>
<li>
<p>Suspect 2º if drug-resistant, abrupt onset, onset \&lt;30yo,
    exacerbation of previously controlled HTN, onset of diastolic
    hypertension in older adults >65yo, unprovoked or excessive
    hypokalemia</p>
</li>
</ul>
<table>
<thead>
<tr>
<th><strong>Common 2<sup>o</sup> Causes</strong></th>
<th><strong>Suggestive Features</strong></th>
<th><strong>Diagnostic Testing</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Kidney Disease</td>
<td>Hypervolemia, ↑ Cr, abnormal UA, family history of PKD</td>
<td>UA, Urine Alb:Cr ratio, Renal US</td>
</tr>
<tr>
<td>Renovascular disease (RAS or FMD)</td>
<td>Renal bruit, ↑ Cr after ACE-I or ARB, young age</td>
<td>Doppler renal US</td>
</tr>
<tr>
<td>OSA</td>
<td>Apneic events, somnolence, obesity</td>
<td>Polysomnography</td>
</tr>
<tr>
<td>Primary Hyperaldosteronism</td>
<td>Hypokalemia, metabolic alkalosis, resistant HTN, etc.</td>
<td>Start with plasma aldosterone/renin levels</td>
</tr>
<tr>
<td>Drug or Alcohol Induced</td>
<td>H/o substance use (cocaine, caffeine, nicotine, medications)</td>
<td>UDS, BP improvement after withdrawal of suspected agent</td>
</tr>
<tr>
<td>Uncommon 2<sup>o</sup> causes: Pheochromocytoma, Cushing’s syndrome, thyroid dysfunction, aortic coarctation, primary hyperparathyroidism, acromegaly, congenital adrenal hyperplasia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>Management</p>
<table>
<thead>
<tr>
<th>ACA-AHA guidelines (2017) (based on SPRINT trial)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevated BP</td>
<td>systolic 120-129 mmHg AND diastolic \&lt;80 mmHg</td>
<td>Non-pharmacological interventions and reassess in 3-6 months</td>
</tr>
<tr>
<td>Stage 1</td>
<td>systolic 130-139 mmHg OR diastolic 80-89 mmHg</td>
<td>If 10-y CVD risk ≥10%, non-pharm intervention + BP-lowering medication. Reassess monthly until BP goal met, then every 3-6 months</td>
</tr>
<tr>
<td>Stage 2</td>
<td>systolic ≥140 mmHg OR diastolic ≥90 mmHg</td>
<td>Non-pharmacological intervention + BP lowering medication. Reassess monthly until BP goal met, then every 3-6 months</td>
</tr>
</tbody>
</table>
<p>Non-pharmacological interventions: regardless of stage  </p>
<ul>
<li>
<p>8-14 mmHg ↓: DASH diet (fresh produce, whole grains, low-fat dairy) </p>
</li>
<li>
<p>5-10 mmHg ↓: Weight loss (10 kg or 22 lbs), expect 1mm Hg for every
    1kg reduction in body weight </p>
</li>
<li>
<p>3-9 mmHg ↓: Na+ restriction (1.5 g / day), aerobic exercise for
    90-150 min/week, increased intake of K+ rich foods </p>
</li>
<li>
<p>2-4 mmHg ↓: Moderate EtOH (2 drinks/day for men; 1 drink/day for
    women) </p>
</li>
<li>
<p>Consider deprescribing or switching amphetamines, antidepressants
    (MAOi, SNRIs, TCAs), atypical antipsychotics (clozapine,
    olanzapine), caffeine, decongestants (phenylephrine,
    pseudoephedrine), cyclosporine, oral contraceptives, NSAIDs,
    steroids</p>
</li>
</ul>
<p>Pharmacologic therapy </p>
<ul>
<li>
<p>Three main classes of drugs use for initial monotherapy for primary
    hypertension include: ACE-Is/ARBs, CCBs (most frequently a
    dihydropyridine), and thiazide diuretics</p>
</li>
<li>
<p>Note that there is wide variability among patients as some will
    respond to one antihypertensive drug but not another</p>
</li>
<li>
<p>Black patients often respond best to CCBs or thiazides</p>
</li>
<li>
<p>Individualize therapy depending on comorbidities</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 40%" />
<col style="width: 40%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Drug Class</strong> </th>
<th><strong>Common Drugs</strong> </th>
<th><strong>Side effects/ comments</strong> </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Thiazide diuretics</strong> </td>
<td>HCTZ 12.5-50 mg  <br />
Chlorthalidone 12.5-25 mg: preferred agent based on RCT evidence though
inc risk electrolyte abnormalities</td>
<td><p>HypoNa, HypoMg, HypoK, increased uric acid, hypovolemia, </p>
<p>Orthostatic hypotension </p></td>
</tr>
<tr class="even">
<td><strong>ACE-I</strong> </td>
<td><p>Lisinopril, benazepril, fosinopril, quinapril (all 5-40 mg
daily)</p>
<p>Ramipril, 2.5-20 mg in 1-2 doses </p></td>
<td>Angioedema (more common in AA) AKI, hyperkalemia, cough </td>
</tr>
<tr class="odd">
<td><strong>ARBs</strong> </td>
<td><p>Losartan 25-100 mg in 1-2 doses </p>
<p>Candesartan 8-32 mg in 1-2 doses </p>
<p>Irbesartan 150-300 mg <br />
Valsartan 80-320 mg </p></td>
<td>AKI, hyperkalemia <br />
Angioedema (less frequent than ACE-I) </td>
</tr>
<tr class="even">
<td><strong>CCB</strong> </td>
<td><p>Dihydropyridine: <br />
Amlodipine 2.5-10 mg 1-2 doses Nifedipine 30-120 mg in 1-2 doses </p>
<p>Nondihydropyridine: </p>
<p>Diltiazem ER 120-480 mg Verapamil ER 100-480 mg </p></td>
<td><p>Dihydropyridine:  <br />
Peripheral edema  <br />
Worsening proteinuria </p>
<p> Nondihydropyridine:  <br />
Constipation <br />
Heart block if used with BB  <br />
Contraindicated in HFrEF </p></td>
</tr>
<tr class="odd">
<td><strong>Aldosterone receptor antagonists</strong> </td>
<td>Spironolactone 12.5-50 mg  <br />
Eplerenone 25-50 mg </td>
<td><p>Good choice for resistant HTN </p>
<p>AKI, hyperkalemia <br />
Spironolactone—gynecomastia &amp; sexual side effects </p></td>
</tr>
<tr class="even">
<td><strong>BB</strong> </td>
<td>Carvedilol 6.25-25 mg bid  <br />
Metoprolol succinate 25-200 mg qd <br />
Nebivolol 5-10 mg <br />
Labetalol 100-300 bid </td>
<td>Reserve for CHF/CAD  <br />
Hyperglycemia, fatigue, ↓ HR <br />
β 1-selective may be safer in pts with COPD, asthma, diabetes </td>
</tr>
<tr class="odd">
<td><strong>Vasodilators</strong> </td>
<td>Hydralazine 25-100 mg bid or tid Minoxidil 5-10 mg </td>
<td>Reflex tachycardia, fluid retention </td>
</tr>
<tr class="even">
<td><strong>Centrally- acting agents (alpha 2 agonists)</strong> </td>
<td><p>Clonidine 0.1-0.2 qd, (Weekly transdermal patch is preferred to
avoid non- compliance and subsequent reflex HTN) </p>
<p>Methyldopa 250-500 mg qd </p></td>
<td>Rebound hypertension, withdrawal -Reserved for resistant
hypertension due to unfavorable side effect profile </td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>**Conditions **</th>
<th>**Drug Class **</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure </td>
<td>ACE-I/ARB or ARNI + BB + spironolactone + diuretics  </td>
</tr>
<tr>
<td>CAD </td>
<td>ACE-I or BB </td>
</tr>
<tr>
<td>Diabetes </td>
<td>All first line agents, ACE-I/ARB if presence of albuminuria  </td>
</tr>
<tr>
<td>CKD </td>
<td>ACE-I/ARB </td>
</tr>
<tr>
<td>Recurrent stroke prevention </td>
<td>ACE-I, thiazide diuretic  </td>
</tr>
</tbody>
</table>
<p>If not meeting goals, combination therapy > doubling single agent (more
effective, less side effects) </p>
<ul>
<li>Preferred combinations </li>
</ul>
<!-- -->

<ul>
<li>
<p>ACEi/ARB + CCB </p>
</li>
<li>
<p>ACEi/ARB + CCB + thiazide. </p>
</li>
<li>
<p>ACEi/ARB + CCB + MRA </p>
</li>
<li>
<p>Do not combine beta-blockers with non-dihydropyridines. </p>
</li>
</ul>
<p>Therapy goals </p>
<ul>
<li>
<p>General population: \&lt;130/80mmHg </p>
</li>
<li>
<p>Frail patients with orthostatic hypotension, limited life
    expectancy: consider less aggressive goal \&lt;140/90 </p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>
<p>VA Specific Guidance:
    <a href="https://www.healthquality.va.gov/guidelines/CD/htn/">https://www.healthquality.va.gov/guidelines/CD/htn/</a></p>
</li>
<li>
<p>Agents that require PADR:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>ACEIs - Quinapril</p>
</li>
<li>
<p>ARBs – Candesartan, Irbesartan, Olmesartan, Telmisartan</p>
</li>
<li>
<p>Beta blockers – Labetalol, Nebivolol</p>
</li>
<li>
<p>DHP – Nifedipine SA</p>
</li>
<li>
<p>Aldosterone Receptor Antagonist – Eplerenone</p>
</li>
<li>
<p>Alpha2 Agonist – Clonidine patch</p>
</li>
</ul>
<!-- -->

<ul>
<li>How to get BP cuff at the VA</li>
</ul>
<!-- -->

<ul>
<li>Prosthetics consult BP Cuff TVHS. *Must answer all questions in the
    consult, including blood pressure cuff size</li>
</ul>
<p>Low-cost options</p>
<ul>
<li>
<p>Publix: Free (amlodipine, lisinopril), $7.50 x 90 days (losartan,
    metoprolol tartrate, HCTZ)</p>
</li>
<li>
<p>Walmart: $4/month (amlodipine, carvedilol, enalapril, hydralazine,
    HCTZ, irbesartan, lisinopril, losartan, ramipril)</p>
</li>
</ul>
<p>Asthma – Jared Freitas</p>
<p>Background</p>
<ul>
<li>
<p>Typically diagnosed in childhood, but occupational asthma,
    aspirin-induced asthma and eosinophilic asthma are more commonly
    diagnosed in adults</p>
</li>
<li>
<p>Three most common symptoms: wheezing after trigger, nighttime cough,
    and associated dyspnea</p>
</li>
<li>
<p>COPD-asthma overlap syndromes: newer entity that typically involves
    intermittent symptoms</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Obstruction is present but does not fully resolve with
    bronchodilator</p>
</li>
<li>
<p>Consider this diagnosis in a pt w/significant smoking history who is
    dx’d with asthma at age >40yo</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Ask about triggers: cold, exercise, URIs, allergens, inhaled
    irritants</p>
</li>
<li>
<p>Ask about family history or personal history of atopy, eczema,
    allergic rhinitis</p>
</li>
<li>
<p>Exam: wheezing, prolonged expiratory phase; nasal polyps, rhinitis,
    eczema</p>
</li>
<li>
<p>Spirometry (PFT’s) with reversible obstruction</p>
</li>
</ul>
<!-- -->

<ul>
<li>FEV1/FVC \&lt;0.7; # FEV1 12% and 200 mL after bronchodilator</li>
</ul>
<!-- -->

<ul>
<li>“All That Wheezes Is Not Asthma”. Must rule out alternative
    diagnoses:</li>
</ul>
<!-- -->

<ul>
<li>Panic attacks, upper airway obstruction, foreign body, vocal cord
    dysfunction, CHF (cardiac asthma), COPD, ILD</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider CBC w/diff to screen for significant anemia and
    eosinophilia (associated w/allergic asthma or eosinophilic
    pneumonia)</p>
</li>
<li>
<p>If concerned for allergic asthma or allergic bronchopulmonary
    aspergillosis, consider measuring total serum IgE levels</p>
</li>
</ul>
<p>Classify Severity and Assess for Symptom Control with the RULE OF 2s:</p>
<ul>
<li>
<p>Does the patient have symptoms or require rescue inhaler ≥2 times
    per week?</p>
</li>
<li>
<p>Does the patient endorse nighttime symptoms ≥ 2 times per month?</p>
</li>
<li>
<p>Does the patient have to refill rescue inhaler ≥ 2 times per year?</p>
</li>
<li>
<p>Does the patient ever have to limit activity due to asthma symptoms?</p>
</li>
</ul>
<p>Initial Assessment of Severity:</p>
<ul>
<li>
<p>Intermittent: No to all of the above and FEV1> 80% predicted. Start
    at step 1</p>
</li>
<li>
<p>Persistent: Yes to any question above. Start at Step 2</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mild: Less than daily symptoms, less than weekly nighttime symptoms,
    minor limitation to activities. FEV >80% predicted</p>
</li>
<li>
<p>Moderate: Daily symptoms, weekly nighttime symptoms, some limitation
    to activities. FEV 60-80% predicted</p>
</li>
<li>
<p>Severe: More severe symptoms than above, FEV1 \&lt;60% predicted</p>
<ul>
<li>Consider referral to pulmonary</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Aim to use the lowest possible step to maintain symptom control.
    Also consider stepping down therapy if pt has been well-controlled
    for >3 months</p>
</li>
<li>
<p>Prior to escalating therapy, consider:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Adherence to therapy (including inhaler technique), uncontrolled
    comorbidities (allergies, GERD, OSA, etc), and alternative diagnoses</p>
</li>
<li>
<p>Ensure patients receive MDI and spacer teaching for full effect</p>
</li>
</ul>
<!-- -->

<ul>
<li>Updated Guidelines: prn ICS - LABA > prn SABA Step 1 (mild
    intermittent) and Step 2 (mild persistent)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Reduces exacerbations, easier to schedule does in future if needed</p>
</li>
<li>
<p>SYGMA Trial showed rescue/prn Budesonide-formoterol (ICS - LABA)
    non-inferior to daily ICS-LABA + prn SABA in preventing
    exacerbations</p>
</li>
</ul>
<!-- -->

<ul>
<li>Follow-up</li>
</ul>
<!-- -->

<ul>
<li>
<p>Repeat PFTs q3-6 mos after beginning therapy and q1-2 yrs thereafter</p>
</li>
<li>
<p>Regular follow up at least q6 mos for all patients with asthma</p>
</li>
</ul>
<p>VA specific guidance: </p>
<ul>
<li>
<p>Mometasone is the formulary ICS and Wixela (fluticasone-salmeterol)
    is the formulary ICS/LABA</p>
</li>
<li>
<p>Ordering PFTs: Refer to Pulm section on PFTs for VUMC and VA
    specifics</p>
<p><img src="../outpatient-medicine/main/output/media/image23.gif"
style="width:3.75in;height:3.45417in"
alt="Table Description automatically generated" /></p>
<p>Image by National Heart, Blood, and Lung Institute. Distributed
under a CC BY 2.5 license</p>
<p>Please see above text for updated guidance on using prn ICS – LABA
for step 1/step 2</p>
</li>
</ul>
<p>Preventive Medicine/Screening: (USPSTF) – Christina Snider</p>
<ul>
<li>
<p>Refer to US Preventative Services Task Force for complete list of
    Grade A &amp; B recommendations:
    <a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-and-b-recommendations">https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-and-b-recommendations</a></p>
</li>
<li>
<p>Recommend downloading the “CDC Vaccine Schedules” App on your phone
    to easily filter by medical condition or look at contraindications</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 26%" />
<col style="width: 49%" />
<col style="width: 24%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3"><strong>Preventative Measures for ALL
patients</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Cholesterol screening</td>
<td><p>Men &gt;35 or 20-35 with CV risk</p>
<p>Women &gt;45 or 20-45 with CV risk</p></td>
<td>UpToDate: Grade 2C</td>
</tr>
<tr class="even">
<td>Colorectal cancer</td>
<td><p>All adults age 45-75</p>
<p>FOBT annually</p>
<p>FIT annually</p>
<p>FIT-DNA (Cologuard) q1-3 years</p>
<p>Colonoscopy q 10 years</p>
<p>Flexible sigmoidoscopy q 5 years</p>
<p>Screen earlier if: family hx of CRC or adenomatous polyps at age &lt;
60, hx of IBD, a confirmed or suspected hereditary CRC syndrome, or a hx
abdominal/pelvic radiation</p></td>
<td>Grade A for ages 50-75; Grade B for ages 45-50</td>
</tr>
<tr class="odd">
<td>Depression</td>
<td>Screen for depression in general adult populations. If screening,
must ensure systems are in place for accurate diagnosis, effective
treatment, and appropriate follow up</td>
<td>Grade B</td>
</tr>
<tr class="even">
<td>Diabetes screening</td>
<td>Adults age 35-70 who are overweight or obese</td>
<td>Grade B</td>
</tr>
<tr class="odd">
<td>Falls</td>
<td>Provide exercise interventions to prevent falls in
community-dwelling adults &gt;65 years old who are at increased risk for
falls</td>
<td>Grade B</td>
</tr>
<tr class="even">
<td rowspan="3">Cardiovascular health</td>
<td>Blood pressure screening annually adults &gt;18</td>
<td>Grade A</td>
</tr>
<tr class="odd">
<td>Aspirin 81 mg in age 50-59 with ASCVD risk &gt;10% in 10 years, are
not at increased risk for bleeding, have a life expectancy of at least
10 years, and are willing to take low-dose aspirin daily for at least 10
years.</td>
<td>Grade B</td>
</tr>
<tr class="even">
<td>Statin: See section on Lipids</td>
<td>Grade B</td>
</tr>
<tr class="odd">
<td>Hepatitis C</td>
<td>Adults aged 18 to 79 years (one time screening)</td>
<td>Grade B</td>
</tr>
<tr class="even">
<td>HIV</td>
<td><p>All adolescents and adults 15-65</p>
<p>(one time screening)</p></td>
<td>Grade A</td>
</tr>
<tr class="odd">
<td>Lung cancer</td>
<td><p>Low-dose CT adults 50-80 w/20 pack year smoking history and
currently smoke or quit within the past 15 years</p>
<p>Should discuss risk vs benefits, particularly in pts with serious
co-morbidities who may not tolerate/desire surgery or aggressive
treatment.</p></td>
<td>Grade B</td>
</tr>
<tr class="even">
<td>Obesity</td>
<td>BMI annually in all adults</td>
<td>Grade A</td>
</tr>
</tbody>
</table>

<table style="width:100%;">
<colgroup>
<col style="width: 25%" />
<col style="width: 53%" />
<col style="width: 20%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="3"><strong>Preventative Measures for WOMEN:</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Cervical cancer</td>
<td><p>Ages 21-29: q 3 yrs with cervical cytology alone.</p>
<p>Ages 30-65: q 3 yrs with cervical cytology alone, every 5 years w/
high-risk human papillomavirus (hrHPV) testing alone</p>
<p>or q 5 yrs with hrHPV testing in</p>
<p>combination with cytology (co-testing)</p>
<p>***ACS 2020 guideline change –Age 25-65: preferred HPV test alone q 5
years (or HPV/Pap co-test every 5 years or a Pap every 3
years)***</p></td>
<td>Grade A</td>
</tr>
<tr class="even">
<td>Breast cancer</td>
<td><p>Women 50-74: q2 years</p>
<p>ACS recommends beginning at age 40, Yearly</p>
<p>If family or personal history of breast, ovarian, tubal, or
peritoneal cancer or who have an ancestry associated BRCA1/2 gene
mutations - should assess risk and refer to genetic counseling.</p></td>
<td>Grade B</td>
</tr>
<tr class="odd">
<td>Folic acid</td>
<td>All women who are planning or capable of pregnancy should take daily
folic acid supplement (0.4 – 0.8 mg daily)</td>
<td>Grade A</td>
</tr>
<tr class="even">
<td><p>Chlamydia</p>
<p>Gonorrhea</p></td>
<td>All sexually active women &lt; 24, older women with increased
risk</td>
<td>Grade B</td>
</tr>
<tr class="odd">
<td>Osteoporosis (DEXA)</td>
<td>Women &gt;65, postmenopausal women &lt;65 with increased
osteoporosis risk (can use FRAX tool)</td>
<td>Grade B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Preventive Measures for MEN</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal aortic aneurysm (AAA) screening</td>
<td>Men Ages 65-75 who ever smoked (at least 100 cigarettes total): one-time screening by ultrasonography</td>
<td>Grade B</td>
</tr>
</tbody>
</table>
<p>Approach to Outpatient Anxiety/Depression – Kunal Patel</p>
<p>Background</p>
<ul>
<li>Anxiety disorders: generalized anxiety disorder (GAD), panic
    disorder (PD), agoraphobia, social anxiety disorder (SAD), specific
    phobia</li>
</ul>
<!-- -->

<ul>
<li>
<p>Some of the most prevalent psychiatric disorders</p>
</li>
<li>
<p>Age of onset varies: SAD (~teens), PD (~20s), GAD (broad range,
    incl. >50)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Depression: can refer to a mood state, syndrome, or mental disorder</li>
</ul>
<!-- -->

<ul>
<li>
<p>1-year prevalence of 10%; lifetime prevalence of 21%</p>
</li>
<li>
<p>USPTF recommends screening for depression in the general adult
    population</p>
</li>
<li>
<p>Average age of onset 30 years</p>
</li>
<li>
<p>More common in females (2:1), younger adults, lower income patients,
    and those who are divorced, separated, or widowed</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Anxiety disorders</li>
</ul>
<!-- -->

<ul>
<li>
<p>See table for features to elicit in history</p>
</li>
<li>
<p>Labs (not all may be necessary): CBC, BMP, TSH, UA, EKG, UDS</p>
</li>
</ul>
<!-- -->

<ul>
<li>Major depressive disorder (MDD)</li>
</ul>
<!-- -->

<ul>
<li>
<p>See table for features to elicit in history</p>
</li>
<li>
<p>Labs (not all may be necessary): CBC, BMP, TSH, RPR, hCG, UDS, B12,
    Folate, EKG</p>
</li>
<li>
<p>Determine severity: mild, moderate, severe</p>
<ul>
<li>Degree of functional impairment and disability</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 39%" />
<col style="width: 37%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Disorder</p>
<p><em>(Symptom scales)</em></p></th>
<th>DSM-5 Criteria</th>
<th>Symptoms/features</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Generalized Anxiety Disorder</p>
<p><em>(GAD-7, Hamilton Anxiety Scale)</em></p></td>
<td><p>Excessive anxiety/worry with <strong>≥3 of 6 sx</strong>
occurring most days for <strong>&gt;6 months</strong></p>
<p>Difficult to control worry</p>
<p>Causes clinically significant distress</p>
<p>Not attributable to something else</p></td>
<td><p>Restlessness</p>
<p>Fatigued</p>
<p>Difficulty concentrating</p>
<p>Irritability</p>
<p>Muscle tension</p>
<p>Sleep disturbance</p></td>
</tr>
<tr class="even">
<td>Panic Disorder</td>
<td>Recurrent panic attacks with 1 or more attacks followed by
<strong>&gt;1 month</strong> of fear of another panic attack <strong>(≥4
sx)</strong> or maladaptive behavior</td>
<td><p>Palpitations</p>
<p>Sweating</p>
<p>Trembling</p>
<p>SOB</p>
<p>Feeling of choking</p>
<p>Chest pain</p>
<p>Nausea</p>
<p>Dizziness, lightheaded</p>
<p>Chills/heat sensation</p>
<p>Paresthesias</p>
<p>Derealization/depersonalization</p>
<p>Fear of losing control</p>
<p>Fear of dying</p></td>
</tr>
<tr class="odd">
<td>Social Anxiety Disorder</td>
<td>Fear of social or performance situations to the point where there is
impairment in function</td>
<td><p>Avoidance behavior</p>
<p>Anxiety out of proportion</p>
<p>Anxiety interfering with living</p>
<p>Fear of scrutiny, embarrassment</p>
<p>Fear not better explained by other medical condition</p></td>
</tr>
<tr class="even">
<td><p>Major Depressive Disorder</p>
<p><em>(PHQ-9, HAM-D, MDI, Montgomery-Asberg Depression Rating
Scale)</em></p></td>
<td><p><strong>≥5 sx</strong> during same <strong>2 week</strong>
period; depressed mood and/or loss of interest/pleasure must be present;
exclude sx clearly due to other medical condition</p>
<p>+</p>
<p>Sx cause significant distress, not attributable to other medical
condition or substance, not better explained by other psychotic
disorders, no history of manic or hypomanic episode</p></td>
<td><p>Depressed mood</p>
<p>Loss of interest/pleasure</p>
<p>Weight gain/loss</p>
<p>Insomnia/hypersomnia</p>
<p>Psychomotor agitation/retardation</p>
<p>Fatigue</p>
<p>Feeling worthless/guilt</p>
<p>Decreased concentration</p>
<p>Thoughts of suicide/death</p></td>
</tr>
</tbody>
</table>

<p>Management</p>
<ul>
<li>Anxiety</li>
</ul>
<!-- -->

<ul>
<li>Psychotherapy and/or pharmacotherapy</li>
</ul>
<!-- -->

<ul>
<li>Depression</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mild: psychotherapy and symptom monitoring</p>
</li>
<li>
<p>Moderate: psychotherapy and pharmacotherapy</p>
</li>
<li>
<p>Severe: psych consult, psychotherapy, pharmacotherapy</p>
</li>
</ul>
<p>Psychotherapy</p>
<ul>
<li>
<p>Cognitive behavioral therapy: identifying and modifying negative
    thoughts</p>
</li>
<li>
<p>Behavioral activation: scheduling positive activities and increasing
    positive interactions</p>
</li>
<li>
<p>Interpersonal psychotherapy: addressing interpersonal issues in
    structured manner</p>
</li>
<li>
<p>Find with psychotherapists through VUMC behavioral health referral
    or psychologytoday.com</p>
</li>
<li>
<p>VA specific: First refer to PCMHI (teams for same day assessment,
    otherwise consult) and then if needed to BHIP</p>
</li>
</ul>
<p>Pharmacotherapy</p>
<ul>
<li>
<p>Good starting agents are SSRIs/SNRIs</p>
</li>
<li>
<p>Choose based on patient’s specific symptoms, age, adverse effects,
    co-morbidities, and any potential drug-drug interactions</p>
</li>
<li>
<p>Typically, start at low doses and titrate up every 2 weeks as needed
    until maximum dose reached</p>
</li>
<li>
<p>Full effects not seen until 8-12 weeks, should wait this time before
    switching</p>
</li>
<li>
<p>If no response, switch to another SSRI/SNRI</p>
</li>
<li>
<p>If partial response, augment</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Anxiety disorders: buspirone or gabapentin/pregabalin</p>
</li>
<li>
<p>MDD: Addition of second agent from different class (e.g. bupropion)</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 23%" />
<col style="width: 23%" />
<col style="width: 33%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Daily dose</th>
<th>Adverse effects</th>
<th>Other considerations</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>SSRIs</td>
<td></td>
<td>GI, sexual dysfunction, weight gain</td>
<td></td>
</tr>
<tr class="even">
<td>Citalopram</td>
<td><p>Initial: 20 mg</p>
<p>Target: 20-40 mg</p></td>
<td><p>QTc++ (Most QT prolonging)</p>
<p>Sedation</p></td>
<td>Preferred in older adults due to safety profile Black-box for doses
&gt;40 for QT prolongation</td>
</tr>
<tr class="odd">
<td>Escitalopram</td>
<td><p>Initial: 10 mg</p>
<p>Target: 10-20 mg</p></td>
<td>QTc+</td>
<td>Preferred in older adults due to safety profile the only true
serotonin selective so least off target effects, less drug-drug
interactions</td>
</tr>
<tr class="even">
<td>Fluoxetine</td>
<td><p>Initial: 20 mg</p>
<p>Target: 20-80mg</p></td>
<td><p>The only weight neutral SSRI</p>
<p>Activating</p>
<p>QTc+</p></td>
<td>Long half-life (low withdrawal risk), 1 wk wash-out when
switching</td>
</tr>
<tr class="odd">
<td>Fluvoxamine</td>
<td><p>Initial: 50 mg</p>
<p>Target: 50-200 mg</p></td>
<td>QTc+</td>
<td>Low SD, good for GAD + MDD but many drug-drug interactions, higher
doses require BID schedule</td>
</tr>
<tr class="even">
<td>Paroxetine (IR)</td>
<td><p>Initial: 20 mg</p>
<p>Target: 20-50 mg</p></td>
<td><p>Anticholinergic sedating</p>
<p>Worst SD</p>
<p>Least QTc</p></td>
<td>Short half-life (high risk of withdrawal). Not recommended in older
adults due to anticholinergic effects.</td>
</tr>
<tr class="odd">
<td>Sertraline</td>
<td><p>Initial: 50 mg</p>
<p>Target: 50-200 mg</p></td>
<td><p>QTc+, high SD</p>
<p>Activating</p></td>
<td>Preferred in older adults due to safety profile</td>
</tr>
<tr class="even">
<td>SNRIs</td>
<td></td>
<td><strong>GI, sexual dysfunction, activating</strong></td>
<td></td>
</tr>
<tr class="odd">
<td>Duloxetine</td>
<td><p>Initial: 30-60 mg</p>
<p>Target: 60-120 mg</p></td>
<td>Some weight gain</td>
<td>Good for attention and low energy, good for pain</td>
</tr>
<tr class="even">
<td>Venlafaxine</td>
<td><p>Initial: 37.5-75 mg</p>
<p>Target: 150-375 mg</p></td>
<td><p>QTc+</p>
<p>Worst SD</p>
<p>Some weight gain</p>
<p>Diastolic HTN</p></td>
<td>Risk of withdrawal, good for attention and low energy</td>
</tr>
<tr class="odd">
<td>Desvenlafaxine</td>
<td><p>Initial: 25-50 mg</p>
<p>Target: 50-100 mg</p></td>
<td>Diastolic HTN</td>
<td>Risk of withdrawal, good for attention and low energy</td>
</tr>
<tr class="even">
<td>TCAs</td>
<td></td>
<td>Anticholinergic+++, drowsiness+++, SD+++, weight gain+++</td>
<td></td>
</tr>
<tr class="odd">
<td>Amitriptyline</td>
<td><p>Initial: 25 mg</p>
<p>Target: 150-300 mg</p></td>
<td>QTc+</td>
<td>Greater risk profile than others; not first-line.</td>
</tr>
<tr class="even">
<td>Clomipramine</td>
<td><p>Initial: 25 mg</p>
<p>Target: 75-250 mg</p></td>
<td>QTc++</td>
<td>Greater risk profile than others; not first-line.</td>
</tr>
<tr class="odd">
<td>Others</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>Buspirone</td>
<td><p>Initial: 10-15 mg</p>
<p>Target: 15-60 mg</p></td>
<td>Dizziness, HA, nervousness, drowsiness, activating</td>
<td><p>Anxiety disorders,</p>
<p>add-on for MDD (off-label)</p></td>
</tr>
<tr class="odd">
<td>Mirtazapine</td>
<td><p>Initial: 7.5-15 mg</p>
<p>Target: 15-45 mg</p></td>
<td>Drowsiness+++, anticholinergic, weight gain, dizziness, QTc</td>
<td>Good add-on with SSRI/SNRI for MDD; good for sleep, nightly
dosing</td>
</tr>
<tr class="even">
<td>Trazodone</td>
<td><p>Initial: 100 mg</p>
<p>Target: 200-400 mg</p></td>
<td>Drowsiness+++, dizziness, blurred vision, constipation, priapism,
QTc++</td>
<td>Good for sleep- typically used at lower doses for insomnia</td>
</tr>
<tr class="odd">
<td>Bupropion</td>
<td><p>Initial: 150 mg</p>
<p>Target: 150 mg BID</p></td>
<td>Dry mouth, nausea, activating, dizziness, sweating, QTc, lowers
seizure threshold</td>
<td>Good add-on with SSRI/SNRI for MDD</td>
</tr>
<tr class="even">
<td>Pregabalin</td>
<td><p>Initial: 150 mg/day</p>
<p>Target: 150-600 mg divided BID or TID</p></td>
<td>Dizziness, drowsiness, resp depression, falls, edema, SJS/rash,
DRESS</td>
<td>Anxiety disorders as adjunct (off-label), consider if another
indication (neuropathic pain)</td>
</tr>
<tr class="odd">
<td>Gabapentin</td>
<td><p>Initial: 100-300 mg/day</p>
<p>Target: 2.4g/day divided BID or TID</p></td>
<td>Dizziness, drowsiness, resp depression, falls, edema, SJS/rash,
DRESS</td>
<td>Anxiety disorders as adjunct (off-label), consider if another
indication (neuropathic pain)</td>
</tr>
</tbody>
</table>

<p>Fatigue – Thomas Horton</p>
<p>Background</p>
<ul>
<li>
<p>21-33% of primary care patients describe fatigue as an important
    problem (even if not CC)</p>
</li>
<li>
<p>Obtain a thorough history and validate the patient's concerns</p>
</li>
</ul>
<!-- -->

<ul>
<li>Assess impact on daily life and accommodations the patient has made
    to cope</li>
</ul>
<!-- -->

<ul>
<li>
<p>Description of fatigue: mental vs. physical; sleepiness/tiredness
    vs. "low energy"</p>
</li>
<li>
<p>Assess Chronicity: Acute \&lt;1 month; subacute 1-6 months; Chronic >6
    months</p>
</li>
<li>
<p>Review medication list, age -elated cancer screening, prior lab
    values, imaging findings if applicable</p>
</li>
<li>
<p>Brief Fatigue Inventory or Fatigue Assessment Scale can be used for
    quantification</p>
</li>
</ul>
<p>Common Etiologies</p>
<table>
<thead>
<tr>
<th>System</th>
<th>Differential</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiopulmonary</td>
<td>CHF, CAD/Angina, PVD, Obstructive lung disease, OSA, other sleep-related disorders</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Diabetes, hypothyroidism, adrenal insufficiency, electrolyte abnormalities</td>
</tr>
<tr>
<td>Hematologic/Neoplastic</td>
<td>Anemia, occult malignancy</td>
</tr>
<tr>
<td>Infectious Disease</td>
<td>HIV, Mononucleosis, Hepatitis, other viral, TB, fungal, parasitic</td>
</tr>
<tr>
<td>Medication Use</td>
<td>Opioids, benzodiazepines, antihistamines, muscle relaxants, anti-depressants, beta-blockers, GABA analogues, substance use (ETOH, THC, Cocaine)</td>
</tr>
<tr>
<td>Psychological</td>
<td>Depression, anxiety, somatization disorder, dysthymia</td>
</tr>
<tr>
<td>Rheumatologic</td>
<td>Fibromyalgia, PMR, SLE, RA, Sjögren's</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>
<p>Complete physical exam</p>
</li>
<li>
<p>Lab tests to order if >1 month duration: CMP, CBC w/ diff, HIV,
    Hepatitis B/C, TSH</p>
</li>
</ul>
<!-- -->

<ul>
<li>Autoimmune, inflammatory, pregnancy, CK, PPD tests <em>based on
    clinical context</em></li>
</ul>
<!-- -->

<ul>
<li>
<p>Assess for mood disorder (PHQ-9; GAD7)</p>
</li>
<li>
<p>Assess for sleep disturbance (STOP-BANG, Epworth Sleepiness Scale)</p>
</li>
<li>
<p>Age appropriate cancer screening if applicable</p>
</li>
<li>
<p>Diagnostic imaging studies based on history and physical exam
    findings</p>
</li>
<li>
<p>Screen for domestic violence, housing insecurity, substance use</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Treatment is largely specific to underlying etiology of fatigue (if
    found)</p>
</li>
<li>
<p>Etiology may never be identified</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consider diagnosis of myalgic encephalomyelitis/chronic fatigue
    syndrome (ME/CFS) if other causes have been ruled out</li>
</ul>
<!-- -->

<ul>
<li>
<p>Continue a supportive relationship with patient</p>
</li>
<li>
<p>Consider empiric trial of antidepressant therapy in those with
    residual/idiopathic fatigue with depressed mood even if patient does
    not meet MDD criteria</p>
</li>
</ul>
<p>Chronic Rhinosinusitis – Jared Freitas</p>
<p>Background</p>
<ul>
<li>
<p>Inflammatory syndrome of the paranasal sinuses, with objective
    evidence of inflammation for > 12 weeks, typically in young to
    middle aged adults</p>
</li>
<li>
<p>Symptoms: typically need two of the following:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Anterior/posterior mucopurulent nasal drainage</p>
</li>
<li>
<p>Presence of nasal fullness/congestion</p>
</li>
<li>
<p>Facial pain/pressure, sometimes accompanied by headache (most
    prevalent but least specific)</p>
</li>
<li>
<p>Reduction in sense of smell</p>
</li>
</ul>
<!-- -->

<ul>
<li>Red flag symptoms that require more emergent evaluation by ENT or
    NSGY</li>
</ul>
<!-- -->

<ul>
<li>
<p>Double vision</p>
</li>
<li>
<p>Proptosis</p>
</li>
<li>
<p>Ophthalmoplegia</p>
</li>
<li>
<p>Severe headache</p>
</li>
<li>
<p>Any focal neurologic deficits</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>In addition to clinical history, patients need objective evaluation
    with nasal endoscopy or non-contrasted CT of sinuses (gold standard
    imaging modality) to confirm presence of inflammation and presence
    of nasal polyps</p>
</li>
<li>
<p>Other conditions to consider on differential:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Rhinitis without sinusitis (vasomotor, gustatory, allergic,
    idiopathic)</p>
</li>
<li>
<p>Headache and facial pain syndromes</p>
</li>
<li>
<p>Laryngopharyngeal reflux syndrome</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Daily sinus rinses with saline can clear sinuses of secretions,
    irritants and allergens</p>
</li>
<li>
<p>Utilizing daily intranasal corticosteroid sprays improve symptoms,
    better control when used in conjunction with sprays</p>
</li>
<li>
<p>Short courses of macrolide antibiotics less than 3 weeks duration
    along with short course oral corticosteroids for acute exacerbations</p>
</li>
<li>
<p>When to refer to specialist:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>ENT: Refractory symptoms necessitating rhinoscopy to look for nasal
    polyps, anatomical source of obstruction, ability to get direct
    culture from sinuses, or for sinus surgery as treatment</p>
</li>
<li>
<p>Allergy/immunology: treatment of causal allergen or associated
    immunodeficiency that contributes to recurrent infections</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>10-14 days of oral corticosteroids can also help in patients with
    nasal polyps shrink inflamed tissue and decrease obstructive
    symptoms but require ongoing nasal steroids to prevent recurrence</p>
</li>
<li>
<p>Daily antileukotriene agents and antihistamines can provide benefit
    in patients with an allergic component</p>
<p>Smoking cessation can lead to symptom relief in CRS pts with and w/o
nasal polyps</p>
</li>
</ul></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-asthma"><h1 id="outpatient-medicine-outpatient-medicine-asthma-asthma">Asthma<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-asthma-asthma" title="Permanent link">&para;</a></h1>
<p>Asthma – Trent Goodin, Stacy Blank</p>
<p>Background</p>
<ul>
<li>Ask about triggers: cold, exercise, URIs, allergens, inhaled
    irritants</li>
<li>Ask about family history or personal history of atopy, eczema,
    allergic rhinitis</li>
<li>Exam: wheezing, prolonged expiratory phase; nasal polyps, rhinitis,
    eczema</li>
<li>Evidence of reversible airflow obstruction (i.e. improvement of
    obstruction post-bronchodilator) or airway hyper-reactivity
    (methacholine challenge)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Spirometry (PFT’s) with reversible obstruction<ul>
<li>FEV1/FVC \&lt;0.7;
    #
    FEV1 12% and 200 mL after bronchodilator</li>
</ul>
</li>
<li>“All That Wheezes Is Not Asthma” rule out alternative diagnoses:<ul>
<li>Panic attacks, upper airway obstruction, foreign body, vocal
    cord dysfunction, CHF (cardiac asthma), COPD, ILD</li>
</ul>
</li>
</ul>
<p>Classify Severity and Assess for Symptom Control with the RULE OF 2s:</p>
<ul>
<li>Does the patient have symptoms or require rescue inhaler
    ≥
    2 times per week?</li>
<li>Does the patient endorse nighttime symptoms
    ≥
    2 times per month?</li>
<li>Does the patient have to refill rescue inhaler
    ≥
    2 times per year?</li>
<li>Does the patient ever have to limit activity due to asthma symptoms?</li>
</ul>
<p>Initial Assessment of Severity:</p>
<ul>
<li>Intermittent: No to all of the above and FEV1&gt; 80% predicted. Start
    at step 1</li>
<li>Persistent: Yes to any question above. Start at Step 2</li>
<li>Mild
    :  Less than daily symptoms, less than weekly nighttime symptoms,
    minor limitation to activities<ul>
<li>FEV
    >80% predicted</li>
</ul>
</li>
<li>Moderate:  Daily symptoms, weekly nighttime symptoms, some
    limitation to activities<ul>
<li>FEV
    60-80% predicted</li>
</ul>
</li>
<li>Severe: More severe symptoms than above, FEV1 \&lt;60% predicted<ul>
<li>Consider
    referral to pulmonary</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Aim to use the lowest possible step to maintain symptom control.
    Also consider stepping down therapy if pt has been well-controlled
    for &gt;3 months</li>
<li>Prior to escalating therapy, consider:<ul>
<li>Adherence to therapy (including inhaler technique), uncontrolled
    comorbidities (allergies, GERD, OSA, etc), and alternative
    diagnoses</li>
<li>Ensure patients receive MDI and spacer teaching for full effect.</li>
</ul>
</li>
<li>Updated Guidelines: prn ICS - LABA &gt; prn SABA Step 1 (mild
    intermittent) and Step 2 (mild persistent)<ul>
<li>Reduces exacerbations, easier to schedule does in future if
    needed</li>
<li>SYGMA Trial showed rescue/prn Budesonide-formoterol (ICS - LABA)
    non-inferior to daily ICS-LABA + prn SABA in preventing
    exacerbations</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Follow-up<ul>
<li>Repeat
    PFTs q3-6 mosafter beginning therapy and q1-2 yrs thereafter</li>
<li>Regular follow up at least q6 mos for all patients with asthma</li>
</ul>
</li>
<li>VA specific guidance:<ul>
<li>Mometasone
    is the formulary ICS and Symbicort (budesonide-formoterol) is
    the formulary ICS/LABA</li>
<li>Ordering
    PFTs: Refer to Pulm section on PFTs for VUMC and VA specifics</li>
</ul>
</li>
</ul>
<p><img src="/sites/default/files/inline-images/Asthma.png" data-entity-type="file" data-entity-uuid="f657a07a-26a7-49a4-8f74-4b4bac5b73a7" alt="Asthma" /></p></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-coding-and-informatics"><h1 id="outpatient-medicine-outpatient-medicine-coding-and-informatics-coding-and-informatics">Coding and Informatics<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-coding-and-informatics-coding-and-informatics" title="Permanent link">&para;</a></h1>
<p>Coding and Informatics – Babatunde Carew, Elizabeth Ann Yakes</p>
<p>Background</p>
<ul>
<li>ICD 10 Codes: International Classification of Disease Codes, 10<sup>th</sup>
    Revision. Used to categorize all diseases and symptoms.</li>
<li>CPT Codes: Current Procedural Terminology Codes: Numeric codes
    assigned to every task and service a physician may provide to a
    patient including medical, surgical, and diagnostic services. They
    are used by insurers to determine the amount of reimbursement that a
    practitioner will receive.</li>
<li>E&amp;M Codes: Evaluation and Management Codes. These are a category of
    CPT codes and are the most frequently used. There are different
    levels of E&amp;M codes, which are determined by the complexity of a
    patient visit and documentation requirements. Example: 99204 (new
    patient, level 4) or 99213 (established patient, level 3).</li>
<li>Preventive Service Codes: A category of CPT codes used for annual
    wellness exams. Example: 99395 (established patient, age 18-40).</li>
</ul>
<p>Problem Oriented Visits</p>
<ul>
<li>Return and new patients for which you are mainly addressing one or
    more acute or chronic problems should be filed under an E&amp;M code.</li>
<li>Documentation for these visits only need to include what you as a
    physician think is medically appropriate.</li>
<li>The correct E&amp;M code for the visit will depend on three
    categories: (1) medical complexity, (2) level of risk with
    testing/treatment, and (3) the amount/complexity of data reviewed.
    To meet criteria for a given code, the visit must meet the criteria
    in at least 2 of the 3 aforementioned categories.</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code 99213 (Established) or 99203 (New) - you will sometimes have a level 3 visit when addressing only one problem or providing no prescriptions</td>
<td>Code 99213 (Established) or 99203 (New) - you will sometimes have a level 3 visit when addressing only one problem or providing no prescriptions</td>
<td>Code 99213 (Established) or 99203 (New) - you will sometimes have a level 3 visit when addressing only one problem or providing no prescriptions</td>
</tr>
<tr>
<td>Low Problem Complexity</td>
<td>Low Risk of Diagnostic Testing/Treatment</td>
<td>Limited Data (1 Subcategory Required)</td>
</tr>
<tr>
<td>Two or more self-limited or minor problems OR One stable or chronic illness OR One acute of uncomplicated injury</td>
<td>Low risk of morbidity from additional diagnostic testing/treatment</td>
<td>Subcategory 1 (any 2 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test Subcategory 2 You obtained additional history from someone other than the patient</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>Code 99214 (Establish) or 99204 (New) - most of your visits will fall into this category</td>
<td>NaN</td>
</tr>
<tr>
<td>Moderate Problem Complexity</td>
<td>Moderate Risk of Diagnostic Testing/Treatment</td>
<td>Moderate Risk of Diagnostic Testing/Treatment</td>
<td>Moderate Data (1 Subcategory Required)</td>
<td>Moderate Data (1 Subcategory Required)</td>
<td>NaN</td>
</tr>
<tr>
<td>Two or more stable chronic illnesses OR One or more chronic illnesses with exacerbation, progression, or side effect of treatment OR One undiagnosed new problem with uncertain diagnosis OR One acute illness with systemic symptoms OR One acute complicated injury</td>
<td>Moderate risk of morbidity from additional diagnostic testing/treatment Examples: You are managing prescription drugs Decision regarding minor surgery with identified patient or procedure risk factors Decision regarding major elective surgery without identified patient or procedure risk factors Diagnosis or treatment significantly limited by social determinants of health</td>
<td>Moderate risk of morbidity from additional diagnostic testing/treatment Examples: You are managing prescription drugs Decision regarding minor surgery with identified patient or procedure risk factors Decision regarding major elective surgery without identified patient or procedure risk factors Diagnosis or treatment significantly limited by social determinants of health</td>
<td>Subcategory 1 (any 3 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test You obtained additional history from someone other than the patient Subcategory 2 You interpreted a test independently of the official interpretation which is planned to be performed by someone else Subcategory 3 You discussed management or test interpretation with another physician or qualified health personnel</td>
<td>Subcategory 1 (any 3 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test You obtained additional history from someone other than the patient Subcategory 2 You interpreted a test independently of the official interpretation which is planned to be performed by someone else Subcategory 3 You discussed management or test interpretation with another physician or qualified health personnel</td>
<td>NaN</td>
</tr>
<tr>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
<td>Code 99215 (Established) or 99205 (New) - you will rarely have a level 5 visit due to the severity of the presentation required to meet criteria</td>
</tr>
<tr>
<td>High Problem Complexity</td>
<td>High Problem Complexity</td>
<td>High Risk of Diagnostic Testing/Treatment</td>
<td>High Risk of Diagnostic Testing/Treatment</td>
<td>Extensive Data (2 Subcategories Required)</td>
<td>Extensive Data (2 Subcategories Required)</td>
</tr>
<tr>
<td>One or more chronic illnesses with severe exacerbation, progression, or side effects of treatment OR One acute or chronic illness or injury that poses a threat to life or bodily function</td>
<td>One or more chronic illnesses with severe exacerbation, progression, or side effects of treatment OR One acute or chronic illness or injury that poses a threat to life or bodily function</td>
<td>High risk of morbidity from additional diagnostic testing/treatment Examples: Drug therapy requiring intensive monitoring for toxicity Decision regarding hospitalization Decision regarding elective major surgery with identified patient or procedure risk factors Decision regarding emergency major surgery Decision to make DNR or deescalate care due to poor prognosis</td>
<td>High risk of morbidity from additional diagnostic testing/treatment Examples: Drug therapy requiring intensive monitoring for toxicity Decision regarding hospitalization Decision regarding elective major surgery with identified patient or procedure risk factors Decision regarding emergency major surgery Decision to make DNR or deescalate care due to poor prognosis</td>
<td>Subcategory 1 (any 3 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test You obtained additional history from someone other than the patient Subcategory 2 You interpreted a test independently of the official interpretation which is planned to be performed by someone else Subcategory 3 You discussed management or test interpretation with another physician or qualified health personnel</td>
<td>Subcategory 1 (any 3 elements) You reviewed and summarized a note from an external source You reviewed a test result You ordered a test You obtained additional history from someone other than the patient Subcategory 2 You interpreted a test independently of the official interpretation which is planned to be performed by someone else Subcategory 3 You discussed management or test interpretation with another physician or qualified health personnel</td>
</tr>
<tr>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>Annual Wellness Visits (Not Medicare)</p>
<ul>
<li>Return and new patients you are seeing for a preventive annual exam
    should be filed under a preventive service code.</li>
<li>Documentation for this visit MUST include a comprehensive update of
    PMH, Surgical Hx, Meds/Allergies, Social Hx and Family Hx, a
    14-point ROS (i.e. your note must say something along the lines of
    “14 systems were reviewed and pertinent positives are noted in the
    HPI), and anticipatory guidance/risk factor reduction.</li>
<li>The correct preventive service code will depend on patient age and
    the ICD-10 code should be Z00.00</li>
<li>This visit can only be coded for once every 365 days (although some
    insurances may allow you to code an annual each calendar year, every
    365 days is a safe bet)</li>
<li>CPT Codes:<ul>
<li>Code 99395 (established) or 99385 (new): Preventive Annual Exam,
    age 18-40.</li>
<li>Code 99396 (established) or 99386 (new):Preventive Annual Exam,
    age 40-65.</li>
<li>Code 99397 (established) or 99387 (new): Preventive Annual Exam,
    age 65+ (NOT Medicare patients).</li>
</ul>
</li>
</ul>
<p>Annual Wellness Visits (Medicare)</p>
<ul>
<li>Return and new Medicare patients (not Medicare managed plans like
    Cigna Medicare, etc) you are seeing for a preventive annual exam
    should be filed under a Medicare specific preventive service code.</li>
<li>Patient must complete a health assessment form.</li>
<li>Documentation must include: (1) age specific screening questions
    (cognition, depression, and function, (2) family and social
    history, (3) medication reconciliation (include DME).</li>
<li>Personalized prevention plan services (PPPS) information
    (recommendations for screening/prevention) must be included in the
    after-visit summary (AVS).</li>
<li>Much of this can be completed by the nurse during intake.</li>
<li>Talk to your preceptor before seeing the pt if you need help with
    the logistics!!</li>
<li>G Codes:<ul>
<li>Code G0402: Welcome to Medicare Visit, a one-time benefit visit
    only available within the first 12 months of Medicare Part B.</li>
<li>Code G0439 (established) or G0438 (new): Medicare Preventive
    Annual Exam. Does NOT include a physical exam. PPPS must be
    included in AVS. Ask your fellow residents or attending to share
    a PPPS dot phrase which may be inserted into patient
    instructions.</li>
</ul>
</li>
</ul>
<p>Modifiers</p>
<ul>
<li>Modifiers are numbers/letters that are attached to CPT code for
    billing purposes<ul>
<li>25 Modifier: Alerts the payer that a significant, separately
    identifiable E&amp;M service was provided by the same physician on
    the same day of the procedure or other service. (annual plus
    problem based visit or E&amp;M visit plus procedure)</li>
<li>GC Modifier: Seen by a resident and attending physician (must
    use for PGY-I during first six months)</li>
<li>GE Modifier: Seen by resident alone. If this modifier is used,
    the highest level billable is a level 3 (Note: due to COVID-19
    restrictions, residents (and interns after January) can “solo”
    bill for Level &#8536; with CR (catastrophic response) modifier.</li>
<li>CR: Catastrophic Response (see above).</li>
<li>GT: Telemedicine encounter</li>
</ul>
</li>
</ul></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-hypertension"><h1 id="outpatient-medicine-outpatient-medicine-hypertension-hypertension">Hypertension<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-hypertension-hypertension" title="Permanent link">&para;</a></h1>
<p>Hypertension (HTN) – Jonathan Davis</p>
<p>Background</p>
<ul>
<li>
<h1 id="outpatient-medicine-outpatient-medicine-hypertension-sbp-20-or-dbp-10-doubles-risk-of-stroke-and-cvd">SBP &gt;20 or #DBP &gt;10 doubles risk of stroke and CVD<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-hypertension-sbp-20-or-dbp-10-doubles-risk-of-stroke-and-cvd" title="Permanent link">&para;</a></h1>
</li>
<li>Prevalence ~45% with new cutoff (≥130/80); control achieved in
    ~50%</li>
<li>Definitions<ul>
<li>Resistant HTN:
    Uncontrolled BP despite taking 3 antihypertensive medications
    including a diuretic, OR 4 total medications</li>
<li>Whitecoat HTN
    :  Mean BPs lower than threshold of HTN based upon out-of-office
    measurements (falsely elevated measurements during visits). If
    SBP &gt; 130 but \&lt; 160, consider screening for white coat HTN with
    home monitoring</li>
<li>Masked HTN
    : Mean BP at/above threshold for hypertension based upon
    out-of-office measurements (falsely decreased measurements
    during visits). If office SBPs consistently 120-129 consider
    screening for masked HTN with home monitoring</li>
</ul>
</li>
<li>Diagnosis<ul>
<li>Requires ≥2 elevated pressures on ≥2 occasions<ul>
<li>Home and ambulatory BP monitoring recommended to confirm
    diagnosis</li>
<li>Ideally, measurements with legs uncrossed, arm at level of
    heart, after 5 minutes of rest and with empty bladder; avoid
    caffeine or tobacco 30 minutes prior</li>
<li>Screening</li>
</ul>
</li>
<li>Grade A USPTF rec: Screen all adults &gt;18. Screen adults at least
    semiannually if have risk factors for HTN (obesity, AA), or if
    previously measured SBP 120-129</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACA-AHA guidelines (2017) (based on SPRINT trial)</td>
<td>ACA-AHA guidelines (2017) (based on SPRINT trial)</td>
</tr>
<tr>
<td>Normal</td>
<td>\&lt;120/80 mmHg</td>
</tr>
<tr>
<td>Elevated BP</td>
<td>systolic 120-129 mmHg AND diastolic \&lt;80 mmHg</td>
</tr>
<tr>
<td>Stage 1</td>
<td>systolic 130-139 mmHg OR diastolic 80-89 mmHg</td>
</tr>
<tr>
<td>Stage 2</td>
<td>systolic ≥140 mmHg OR diastolic ≥90 mmHg</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>BMP, CBC, lipid panel, UA, TSH, EKG. Consider additional testing
    including TTE, urine Alb:Cr ratio, or uric acid.</li>
<li>Distinguish between primary (90% incidence) and secondary HTN (10%):<ul>
<li>Suspect 1º if gradual onset, family hx, associated with weight
    gain &amp; lifestyle factors</li>
<li>Suspect 2º if early onset (\&lt; 30yo), late onset (&gt; 65 y/o),
    abrupt onset, disproportionate end-organ damage, resistant HTN</li>
</ul>
</li>
<li>Uncommon causes: Pheochromocytoma, Cushing’s syndrome, thyroid
    dysfunction, aortic coarctation, primary hyperparathyroidism,
    acromegaly, congenital adrenal hyperplasia</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common 2o Causes</td>
<td>Suggestive Feature</td>
<td>Diagnostic Testing</td>
</tr>
<tr>
<td>Primary Kidney Disease</td>
<td>Hypervolemia, ↑ Cr, abnormal UA, fhx of PKD</td>
<td>UA, Urine Alb:Cr ratio, Renal US</td>
</tr>
<tr>
<td>Renovascular disease (RAS or FMD)</td>
<td>Renal bruit, ↑ Cr after ACE-I or ARB, young age</td>
<td>Doppler renal US</td>
</tr>
<tr>
<td>OSA</td>
<td>Apneic events, somnolence, obesity</td>
<td>Polysomnography</td>
</tr>
<tr>
<td>Primary Hyperaldosteronism</td>
<td>Hypokalemia, metabolic alkalosis, resistant HTN, etc.</td>
<td>Start with plasma aldosterone/renin levels</td>
</tr>
<tr>
<td>Drug or Alcohol Induced</td>
<td>Hx of substance use (cocaine, caffeine, nicotine, medications)</td>
<td>UDS, BP improvement after withdrawal of suspected agent</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>JNC 8 recommends treating to a <strong>goal BP \&lt;140/90</strong> in all pts \&lt; 60</li>
<li>Consider intervenable contributing factors:<ul>
<li>Obesity
    , High Na diet (canned foods, fast foods, processed meats)</li>
<li>Excess
    alcohol intake</li>
<li>Medications (e.g., NSAIDs, decongestants, MAOs, clonidine
    withdrawal, cyclosporine, steroids)</li>
<li>Substance use (e.g., caffeine, cocaine, amphetamines)</li>
</ul>
</li>
<li>Lifestyle interventions (first line for any stage of elevated BP):<ul>
<li>8-14 mmHg
    ↓
    :
    DASH diet (fresh produce, whole grains, low-fat dairy)</li>
<li>5-10 mmHg
    ↓
    :
    Weight loss (10 kg or 22 lbs), expect 1mm Hg for every 1kg
    reduction in body weight</li>
<li>3-9 mmHg
    ↓
    :
    Na+ restriction (1.5 g / day), aerobic exercise for 90-150
    min/week, increased intake of K+ rich foods</li>
<li>2-4 mmHg
    ↓
    :
    Moderate EtOH (2 drinks/day for men; 1 drink/day for women)</li>
</ul>
</li>
<li>Medications (See table below):<ul>
<li>Initiate pharmacological therapy with Hypertension Stage I
    (ACC/AHA guideline) and ASCVD score &gt; 10% or Stage II pts
    (regardless of ASCVD score)</li>
<li>Use
    first
    line agents from the following classes<ul>
<li>ACE-I or ARB</li>
<li>Thiazide
    Diuretics (preferred in AAs)</li>
<li>Dihydropyridines
    CCB (preferred in AAs)</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<p>VA Specific Guidance:</p>
<p><a href="https://www.healthquality.va.gov/guidelines/CD/htn/">https://www.healthquality.va.gov/guidelines/CD/htn/</a></p>
<ul>
<li>Preferred Agents/Agents that <strong>don’t require PADR</strong> :<ul>
<li>Diuretics – Any</li>
<li>ACEIs – Lisinopril, Benazepril, Enalapril, Ramipril, Captopril</li>
<li>ARBs – Losartan, Valsartan</li>
<li>Beta Blockers – Carvedilol, Metoprolol tartrate/succinate,
    atenolol, propranolol</li>
<li>DHP – Amlodipine</li>
<li>Non-DHTs – Verapamil, Diltiazem</li>
<li>Aldosterone
    Receptor Antagonist – Spironolactone</li>
<li>Alpha1 Antagonist – Doxazosin, Prazosin, Terazosin</li>
<li>Direct
    Acting Vasodilators – Minoxidil, Hydralazine</li>
<li>Alpha2 Agonist – Clonidine tablet, methyldopa</li>
</ul>
</li>
<li>Agents
    that <strong>require PADR</strong> :<ul>
<li>ACEIs - Quinapril</li>
<li>ARBs – Candesartan, Irbesartan, Olmesartan, Telmisartan</li>
<li>Beta blockers – Labetalol, Nebivolol</li>
<li>DHP – Nifedipine SA</li>
<li>Aldosterone Receptor Antagonist – Eplerenone</li>
<li>Alpha2 Agonist – Clonidine patch</li>
</ul>
</li>
<li>How
    to get BP cuff at the VA<ul>
<li>Consult
    tab: New Consult
    →
    Select Campus
    →
    Select Inpatient or Outpatient
    →
    Prosthetics Main</li>
<li>Consult Menu
    →
    Select Y/N for requirement of discharge
    →
    BP Cuff TVH</li>
<li>*Must answer all questions in the consult, including blood
    pressure cuff size.</li>
</ul>
</li>
</ul>
<p>Cost:</p>
<ul>
<li>Publix: Free (amlodipine, lisinopril), $7.50 x 90 days (losartan,
    metoprolol tartrate, HCTZ)</li>
<li>Walmart: $4/month (amlodipine, carvedilol, enalapril, hydralazine,
    HCTZ, irbesartan, lisinopril, losartan, ramipril)</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Class</td>
<td>Common Drugs</td>
<td>Side effects/ comments</td>
</tr>
<tr>
<td>Thiazide diuretics</td>
<td>HCTZ 12.5-50 mg Chlorthalidone 12.5-25 mg (Preferred agent based on RCT evidence)</td>
<td>- HypoNa, HypoMg, HypoK, increased uric acid, hypovolemia, orthostatic hypotension Ok to use in pregnancy per ACOG (2019), but considered 2<sup>nd</sup> or 3<sup>rd</sup> line</td>
</tr>
<tr>
<td>ACE-I</td>
<td>Lisinopril, benazepril, fosinopril, quinapril (all 5-40 mg daily) Ramipril, 2.5-20 mg in 1-2 doses</td>
<td>-Angioedema (more common in AA) AKI, hyperkalemia, cough -Don’t use with ARB -Contraindicated in pregnancy</td>
</tr>
<tr>
<td>ARBs</td>
<td>Losartan 25-100 mg in 1-2 doses Candesartan 8-32 mg in 1-2 doses Irbesartan 150-300 mg Valsartan 80-320 mg</td>
<td>-AKI, hyperkalemia -Angioedema (less frequent than ACE-I) -Don’t combine with ACE-I -Contraindicated in pregnancy</td>
</tr>
<tr>
<td>CCB</td>
<td>Dihydropyridine: Amlodipine 2.5-10 mg 1-2 doses Nifedipine 30-120 mg in 1-2 doses Nondihydropyridine: Diltiazem ER 120-480 mg Verapamil ER 100-480 mg</td>
<td>Dihydropyridine: -Peripheral edema -Worsening proteinuria Nondihydropyridine: -Constipation -Heart block if used with BB -Contraindicated in HFrEF</td>
</tr>
<tr>
<td>Aldosterone receptor antagonists</td>
<td>Spironolactone 12.5-50 mg Eplerenone 25-50 mg</td>
<td>-Good choice for resistant HTN -AKI, hyperkalemia -Spironolactone—gynecomastia &amp; sexual side effects -Contraindicated in pregnancy</td>
</tr>
<tr>
<td>BB</td>
<td>Carvedilol 6.25-25 mg bid Metoprolol succinate 25-200 mg qd Nebivolol 5-10 mg Labetalol 100-300 bid</td>
<td>Reserve for CHF/CAD -Hyperglycemia, fatigue, ↓ HR β 1-selective may be safer in pts with COPD, asthma, diabetes</td>
</tr>
<tr>
<td>Vasodilators</td>
<td>Hydralazine 25-100 mg bid or tid Minoxidil 5-10 mg</td>
<td>Reflex tachycardia, fluid retention</td>
</tr>
<tr>
<td>Centrally- acting agents (alpha 2 agonists)</td>
<td>Clonidine 0.1-0.2 qd, (Weekly transdermal patch is preferred to avoid non- compliance and subsequent reflex HTN) Methyldopa 250-500 mg qd</td>
<td>Rebound hypertension, withdrawal Reserved for resistant hypertension due to unfavorable side effect profile</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions</td>
<td>Drug Class</td>
</tr>
<tr>
<td>Heart failure</td>
<td>ACE-I/ARB or ARNI + BB + spironolactone + diuretics</td>
</tr>
<tr>
<td>CAD</td>
<td>ACE-I or BB</td>
</tr>
<tr>
<td>Diabetes</td>
<td>All first line agents, ACE-I/ARB if presence of albuminuria</td>
</tr>
<tr>
<td>CKD</td>
<td>ACE-I/ARB</td>
</tr>
<tr>
<td>Recurrent stroke prevention</td>
<td>ACE-I, thiazide diuretic</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Labetalol (first-line), nifedipine, methyldopa, hydralazine</td>
</tr>
</tbody>
</table></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-lipids"><h1 id="outpatient-medicine-outpatient-medicine-lipids-lipids">Lipids<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-lipids-lipids" title="Permanent link">&para;</a></h1>
<p>Lipids – Jonathan Davis</p>
<p>Background</p>
<ul>
<li>1º Prevention: pts  at increased risk who have not yet had a
    vascular event</li>
<li>2º Prevention: pts  with pre-existing occlusive vascular disease or
    ASCVD (e.g., stroke, TIA, CAD + angina, ACS, coronary or arterial
    revascularization, PAD)</li>
<li>Screening:
    USPSTF 2016 Guidelines: adults 40-75yrs<ul>
<li>ACC/AHA 2018 Guideline: adults 21-75 q 4-6yrs; \&lt;21yrs  if
    strong fam hx</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Fasting vs Non-Fasting Lipid Panel.<ul>
<li>Triglycerides
    are most impacted by non-fasting testing which can artificially
    lower LDL-C depending on how the laboratory measures/calculates
    LDL. Consider fasting lipid panels when triglyceride levels are
    high</li>
</ul>
</li>
<li>Consider 2º causes of HLD in initial workup: hypothyroidism, DM,
    EtOH use, smoking, liver disease, nephrotic syndrome, CKD, meds
    (e.g., thiazide, glucocorticoids)</li>
</ul>
<p>Management</p>
<ul>
<li>Lifestyle changes:<ul>
<li>Heart Healthy Diet:
    ↓
    trans/saturated fats, choose skim milk, low-fat dairy products</li>
<li>Emphasizes fruits, vegetables, whole grains, poultry, fish, nuts
    and olive oil, while limiting
    red
    and processed meats, sodium and sugar-sweetened foods and
    beverages</li>
<li>Promote a healthy weight, regular exercise, smoking cessation,
    limit EtOH</li>
</ul>
</li>
</ul>
<p>Statin Therapy</p>
<ul>
<li>Initiate as outlined in the following algorithms (Note: check
    AST/ALT prior to initiation)</li>
</ul>
<p><img src="/sites/default/files/inline-images/LipidOne.png" data-entity-type="file" data-entity-uuid="cf7f75ad-7e26-48a4-9605-0edc0ced7181" alt="Lipid One" /></p>
<p><img src="/sites/default/files/inline-images/LipidTwo.png" data-entity-type="file" data-entity-uuid="f8a5c2ae-1d7e-4258-97af-0daea5129a13" alt="Lipid Two" /></p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>High Intensity ( $LDL-C by > 50%)</td>
<td>Moderate Intensity ($LDL-C by 30% - 49%)</td>
<td>Low Intensity ($LDL-C by \&lt;30%)</td>
</tr>
<tr>
<td>Atorvastatin (40mg) 80mg* Rosuvastatin 20mg (40mg)</td>
<td>Atorvastatin 10mg (20mg) Rosuvastatin (5mg) 10mg Simvastatin 20 - 40mg</td>
<td>Simvastatin 10mg</td>
</tr>
<tr>
<td>NaN</td>
<td>Pravastatin 40mg (80mg) Lovastatin 40mg (80mg) Fluvastatin XL 80mg Fluvastatin 40mg BID Pitavastatin 1-4mg</td>
<td>Pravastatin 10-20mg Lovastatin 20 mg Fluvastatin 20-40mg</td>
</tr>
</tbody>
</table>
<p>*Bold denotes dosing with RTC proven LDL lowering benefit</p>
<p>Statin Side effects</p>
<p>:</p>
<ul>
<li>Myalgias: bilateral involving large muscle groups, onset within
    weeks of initiation of therapy and should resolve within weeks of
    cessation</li>
<li>Spectrum of statin associated muscle symptoms (SAMS) include
    myalgias, myopathy, rhabdomyolysis, autoimmune myopathy, etc.<ul>
<li>Consider
    evaluation with CK, BMP, TSH, and vitamin D</li>
<li>ACC has a “Statin Intolerance Calculator” to help assess
    etiology of symptoms</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>If patient is not tolerating a statin, consider:<ul>
<li>Holding statin until symptoms resolve and trialing lower dose or
    alternative statin (Pravastatin and Fluvastatin may have lower
    risks of myopathy)</li>
<li>Every other day dosing with atorvastatin and rosuvastatin
    (longer half-lives)</li>
</ul>
</li>
<li>If repeated
    failed attempts, consider <strong>alternative agents</strong> : Ezetimibe
    10mg daily</li>
</ul>
<p>Hypertriglyceridemia</p>
<p>:</p>
<ul>
<li>Moderate: TG 175-499 mg/dL; Severe: TG &gt; 500 mg/dL<ul>
<li>Focus
    on addressing lifestyle factors and stopping medication that
    increase TG’s  (HCTZ, some BB’s, estrogens, some ART,
    antipsychotics)</li>
<li>Consider
    medical therapy when TG&gt; 500mg/dL to $ risk of pancreatitis
    with:<ul>
<li>Omega
    -3-fatty acids: 4gms daily or Vascepa 4gm daily</li>
<li>Fibrates
    : Fenofibrate 120mg daily (avoid in CKD), Gemfibrozil 600mg
    daily (increased risk of myopathy with concomitant statin)</li>
</ul>
</li>
</ul>
</li>
<li>PCSK9
    inhibitor
    requires referral to Lipid Clinic</li>
</ul>
<p>VA-</p>
<p>Specific</p>
<p>Guidelines</p>
<ul>
<li><a href="https://www.healthquality.va.gov/guidelines/cd/lipids/index.asp">https://www.healthquality.va.gov/guidelines/cd/lipids/index.asp</a></li>
<li>Lowest
    LDL goal recognized for VA Criteria for Use is 100</li>
<li>Preferred statins:
    Atorvastatin, Simvastatin, Lovastatin</li>
<li>Statins
    that require PADR:
    Pravastatin, Rosuvastatin (2<sup>nd</sup> line high intensity statin)<ul>
<li>Must
    have documented intolerances or drug-drug interaction to all
    preferred statins</li>
</ul>
</li>
<li>Other agents that require PADR:<ul>
<li>Ezetimibe<ul>
<li>pt has tried and failed or not tolerated all statins
    (allergy, AE, etc.)</li>
<li>pt not meeting goal on max dose of statin PLUS bile acid
    sequestrants or niacin</li>
</ul>
</li>
<li>Fenofibrate<ul>
<li>Pt has tried all formulary alternatives or has
    contraindication to use of formulary alternatives (statin,
    niacin, gemfibrozil, cholestyramine, fish oil)</li>
<li>If TG &gt; 500 mg/dL, fenofibrate should be approved</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-obesitynutrition"><h1 id="outpatient-medicine-outpatient-medicine-obesitynutrition-obesitynutrition">Obesity/Nutrition<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-obesitynutrition-obesitynutrition" title="Permanent link">&para;</a></h1>
<p>Obesity/Nutrition – Nina Hill</p>
<p>Background</p>
<ul>
<li>BMI = Body Weight (kg) + Height (meters) squared</li>
<li>Overweight = BMI 25.0-29.9</li>
<li>Obesity:<ul>
<li>Class I 30-34.9</li>
<li>Class II 35-39.9</li>
<li>Class IIIA 40-44.9</li>
<li>Class IIIB 45-49.9</li>
<li>Class IIIC 50+</li>
</ul>
</li>
</ul>
<p>​​​​​​​​​​​​​​</p>
<p>Management</p>
<ul>
<li>Goals: Target initial weight loss of 5-7% body weight, schedule
    frequent follow up to assess progress. Request pts send 48 hr food
    log. Encourage accountability “buddies.” Consider weight loss apps:
    My Fitness Pal, Lose it</li>
<li>Diet:<ul>
<li>Calorie
    restriction &gt; macronutrient composition (e.g., low fat, low
    carb)</li>
<li>Mediterranean
    : high in unsaturated fats, fruit/veg, legumes, grains; moderate
    dairy &amp; EtOH; less meat (decreased overall mortality and CV
    mortality; may decrease diabetes incidence independent of weight
    loss)</li>
<li>Dot phrases
    below for pictoral representation of cultural diets adapted to
    fit Mediterranean guidelines (Asian, African, Latin American)</li>
</ul>
</li>
<li>DASH
    : High in fruits/vegetables, moderate dairy, \&lt; 25% caloric intake
    from fat (decreases SBP/DBP)</li>
<li>Exercise: &gt;30 min, 5-7 days per week, ideally a combo of aerobic +
    resistance training.<ul>
<li>​​​​​​​
    Exercise alone is not sufficient for weight loss.</li>
<li>Medications: If BMI
    ≥30 or
    BMI ≥27 with
    ≥1 comorbidity. Significant short term weight loss (~ 5-15
    lbs), but weight is typically gained back when stopped</li>
</ul>
</li>
<li>Referral to medical weight loss: If BMI
    ≥ 30
    or BMI
    ≥27
    with comorbid conditions (fatty liver disease, diabetes mellitus,
    HTN, OSA)</li>
<li>Referral to surgical weight loss: If BMI
    ≥40
    or BMI
    ≥35
    with comorbid conditions</li>
</ul>
<p>​​​​​​​</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication</td>
<td>Mechanism</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Orlistat (Xenical)</td>
<td>Reduces fat adsorption</td>
<td>Diarrhea, gas, leakage of oily stools, stomach pain</td>
</tr>
<tr>
<td>Phentermine-topiramate (Qsymia)</td>
<td>Phentermine: appetite suppression Topiramate (anticonvulsant, migraine txt): ?appetite suppression, ?altered satiety perception</td>
<td>Constipation, dizziness, dry mouth, taste changes, tingling of hands and feet, insomnia</td>
</tr>
<tr>
<td>Naltrexone-bupropion (Contrave)</td>
<td>Naltrexone (partial opioid antagonist; used for alcohol dependence): ?altered satiety perception Bupropion (antidepressant): ?altered satiety perception</td>
<td>Constipation, diarrhea, dizziness, dry mouth, headache, BP, tachycardia, insomnia, liver damage, nausea/vomiting</td>
</tr>
<tr>
<td>Liraglutide (Saxenda)</td>
<td>Appetite suppression; quickens satiety (Victoza: lower dose formulation, FDA-approved for T2DM)</td>
<td>Nausea, diarrhea, constipation, abdominal pain, headache, tachycardia</td>
</tr>
<tr>
<td>Phentermine (Ionamin)</td>
<td>Reduces appetite Note: FDA-approved only for short-term use—up to 12 weeks</td>
<td>Dry mouth, constipation, insomnia, dizziness, nervousness/ restlessness headache, HTN, tachycardia</td>
</tr>
<tr>
<td>Semaglutide (Ozempic/Rybelsus)</td>
<td>Glucagon-like peptide-1 receptor agonist; reduces appetite</td>
<td>Nausea, vomiting, diarrhea, abdominal pain, constipation</td>
</tr>
</tbody>
</table></section><section class="print-page" id="outpatient-medicine-outpatient-medicine-preventative-medicine"><h1 id="outpatient-medicine-outpatient-medicine-preventative-medicine-preventative-medicine">Preventative Medicine<a class="headerlink" href="#outpatient-medicine-outpatient-medicine-preventative-medicine-preventative-medicine" title="Permanent link">&para;</a></h1>
<p>Preventive Medicine/Screening: (USPSTF) – Toaa Abuelenen, Emily Camp</p>
<ul>
<li>Recommend
    downloading the “CDC Vaccine Schedules” App on your phone to more
    easily filter by medical condition or look at contraindications</li>
<li><a href="https://www.cdc.gov/vaccines/schedules/index.html">https://www.cdc.gov/vaccines/schedules/index.html</a></li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventative Measures for ALL patients</td>
<td>Preventative Measures for ALL patients</td>
<td>Preventative Measures for ALL patients</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>Men >35 or 20-35 with CV risk Women >45 or 20-45 with CV risk</td>
<td>Grade A UpToDate: Grade 2C</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>All adults age 50-75 - FOBT annually - FIT annually  - FIT-DNA (Cologuard) q 1 or 3 years - Colonoscopy q 10 years - Flexible sigmoidoscopy q 5 years Screen earlier if: family hx of CRC or adenomatous polyps at age \&lt; 60, a personal hx of IBD, a confirmed or suspected hereditary CRC syndrome, or a hx of abdominal or pelvic radiation</td>
<td>Grade A</td>
</tr>
<tr>
<td>Diabetes screening</td>
<td>Adults age 40-70 who are overweight or obese</td>
<td>Grade B</td>
</tr>
<tr>
<td>Cardiovascular health</td>
<td>Blood pressure screening annually adults >18</td>
<td>Grade A</td>
</tr>
<tr>
<td>Cardiovascular health</td>
<td>Aspirin 81 mg in age 50-59 with ASCVD risk >10% in 10 years, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.</td>
<td>Grade B</td>
</tr>
<tr>
<td>Cardiovascular health</td>
<td>Statin: See section on Lipids</td>
<td>Grade B</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>Adults aged 18 to 79 years (one time screening).</td>
<td>Grade B</td>
</tr>
<tr>
<td>HIV</td>
<td>All adolescents and adults 15-65 (one time screening)</td>
<td>Grade A</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>Low-dose CT adults 55-80 w/30 pack year smoking history and currently smoke or quit within the past 15 years Should discuss risk vs benefits, particularly in pts with serious co-morbidities who may not tolerate/desire surgery or aggressive treatment.</td>
<td>Grade B</td>
</tr>
<tr>
<td>Obesity</td>
<td>BMI annually in all adults</td>
<td>Grade A</td>
</tr>
<tr>
<td>Depression</td>
<td>All adults including pregnant and post-partum women</td>
<td>Grade B</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventative Measures for WOMEN:</td>
<td>Preventative Measures for WOMEN:</td>
<td>Preventative Measures for WOMEN:</td>
</tr>
<tr>
<td>Cervical cancer</td>
<td>Ages 21-29: q 3 yrs with cervical cytology alone. Ages 30-65: q 3 yrs with cervical cytology alone, every 5 years w/ high-risk human papillomavirus (hrHPV) testing alone or q 5 yrs with hrHPV testing in combination with cytology (co-testing) ***ACS 2020 guideline change –Age 25-65: preferred HPV test alone q 5 years (or HPV/Pap co-test every 5 years or a Pap every 3 years)***</td>
<td>Grade A</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Women 50-74: q2 years ACS recommends beginning at age 40, Yearly If family or personal history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated BRCA&frac12; gene mutations - should assess risk and refer to genetic counseling.</td>
<td>Grade B</td>
</tr>
<tr>
<td>Chlamydia Gonorrhea</td>
<td>All sexually active women \&lt; 24, older women with increased risk</td>
<td>Grade B</td>
</tr>
<tr>
<td>Osteoporosis (DEXA)</td>
<td>Women >65, postmenopausal women \&lt;65 with increased osteoporosis risk (can use FRAX tool)</td>
<td>Grade B</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventive Measures for MEN</td>
<td>Preventive Measures for MEN</td>
<td>Preventive Measures for MEN</td>
</tr>
<tr>
<td>Abdominal aortic aneurysm (AAA) screening</td>
<td>Men Ages 65-75 who ever smoked (at least 100 cigarettes total): one-time screening by ultrasonography</td>
<td>Grade B</td>
</tr>
</tbody>
</table></section><h1 class='nav-section-title-end'>Ended: Outpatient medicine</h1>
                        <h1 class='nav-section-title' id='section-pain-and-palliative'>
                            Pain and palliative <a class='headerlink' href='#section-pain-and-palliative' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="pain-and-palliative-main"><p>Code Status Discussion – Katie Sunthankar</p>
<ul>
<li>The approach to obtaining someone’s code status should be thoughtful
    and pertinent to their current admission or recent change in
    clinical status</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ask yourself “Why would this patient code? Is resuscitation a
    reversible treatment in this patient’s case? What are the chances
    that this patient will survive to discharge following CPR? Is the
    anticipated outcome in line with the patient’s goals?</p>
</li>
<li>
<p>After you have made your assessment, help patient make an educated
    decision based on both the efficacy of resuscitation and the
    patient’s goals</p>
</li>
</ul>
<!-- -->

<ul>
<li>Below are examples of phrases that can be used in framing code
    status.</li>
</ul>
<!-- -->

<ul>
<li>
<p>NEVER say “Do you want us to do everything?” Most patients will
    respond yes to this even if they do not want CPR</p>
</li>
<li>
<p>It is more helpful to give examples of when these situations would
    arise and make recommendations based on your medical judgment
    factoring in patient's goals</p>
</li>
</ul>
<p>Admitting a patient:</p>
<ul>
<li>
<p><strong>Introduction</strong>: Normalize the conversation by stating “these are
    questions we routinely ask everyone when they come into the
    hospital. This is a way for us to understand your wishes in the
    event you are unable to make your own decisions.”</p>
</li>
<li>
<p><strong>Surrogate</strong>: “If you were unable to make decisions for yourself,
    who would you trust to make your decisions? The person you pick
    should be able to speak to your wishes and make the same choices you
    would make for yourself”</p>
</li>
<li>
<p>-<strong>Intubation</strong>: Always do this first so you can avoid the sticky
    DNI but not DNR situation. Again, normalize the question. “Everyone
    has different opinions on what types of medical care they would want
    if they became sicker. One of the things we like to talk about are
    ventilators or breathing machines. Some tell us to try a breathing
    machine for a trial, but they would not want to be kept alive on a
    ventilator.” Now make a recommendation. “In your case I think if you
    were to need a ventilator, I think it would [work, not work,]”
    Pause and allow them to ask questions. Also remember that if they
    say DNI, then they must be DNR because intubation occurs with ACLS
    (this is not allowed at VUMC. It is technically allowed at the VA if
    the patient specifically requests but would not recommend routinely
    providing this option)</p>
</li>
<li>
<p><strong>CPR</strong>: Prime this question with “The next question I have to ask
    you can be hard to think about, but it is important that we know
    what you would want in an emergency. Specifically, if you had a
    cardiac arrest where your heart stops beating and you die, would you
    want chest compressions to try and restart your heart? We know based
    on the evidence that CPR is not always successful. It really depends
    on the situation. In your case, I think CPR would be (make a
    recommendation here). Knowing this, would you want us to attempt CPR
    to resuscitate you?”</p>
</li>
</ul>
<!-- -->

<ul>
<li>A helpful way to share data about the success of CPR: “Can I share
    some numbers about how often CPR can help?” Sometimes using fingers
    to show these numbers helps. “If you take 10 people in this hospital
    and all of their hearts stop beating, which would mean they have
    died, and we get to them as fast as possible, only 3 of them would
    have their hearts restarted and only 1 of them would ever leave the
    hospital.”</li>
</ul>
<p>What if you do not think performing CPR Is medically appropriate?…</p>
<ul>
<li>
<p>At the end of the day, it is their decision (attendings may change
    the code status out of medical futility in Tennessee)</p>
</li>
<li>
<p>Code status can be revisited throughout the hospital stay,
    especially if the patient was initially overwhelmed or if their
    clinical status evolves. Sometimes patients find it helpful to have
    a family member or friend present</p>
</li>
<li>
<p>Consider framing the discussion differently and offer your
    recommendation: “While you are in the hospital, we will support you
    with interventions and medications that we think are helpful based
    on what you have told us important to you. However, we are worried
    that some of the interventions you are asking for may do more harm
    than good. Many people think that CPR works like it does on TV.
    Unfortunately, we know that most patients who need CPR in the
    hospital do not survive like they do on TV. In your case, we do not
    think it would bring you back to your current state. I worry that
    this is not something that will be helpful to you.”</p>
</li>
<li>
<p>Another phrase that is helpful (and when the discussion occurs with
    surrogates leads to higher rates of changing code status than saying
    DNR): “allow for a natural death”. For example, “I worry that given
    how sick your [loved one] is, that the additional interventions of
    CPR if she were to die, would prevent her from having a natural
    death”</p>
</li>
</ul>
<p>Opioids: General Principles &amp; Conversion – Eli Cohen</p>
<p>Oral Morphine Equivalent (OME) Conversion Table:</p>
<table>
<thead>
<tr>
<th>Drug</th>
<th>PO</th>
<th>IV</th>
<th>APAP</th>
<th>IR</th>
<th>ER</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tramadol </td>
<td>0.1x </td>
<td>- </td>
<td>- </td>
<td>Tramadol </td>
<td>Ultram ER™ </td>
<td>NSAID properties </td>
</tr>
<tr>
<td>Morphine </td>
<td>1x </td>
<td>3x </td>
<td>- </td>
<td>Morphine IR </td>
<td>MS-Contin™ </td>
<td>Renally cleared </td>
</tr>
<tr>
<td>Hydrocodone </td>
<td>1x </td>
<td>NA </td>
<td>Lortab </td>
<td>Hydrocodone </td>
<td>NA </td>
<td> </td>
</tr>
<tr>
<td>Oxycodone </td>
<td>1.5x </td>
<td>- </td>
<td>Percocet </td>
<td>Roxicodone™ </td>
<td>Oxycontin™ </td>
<td> </td>
</tr>
<tr>
<td>Hydromorphone </td>
<td>4x </td>
<td>20x </td>
<td>- </td>
<td>IV, Oral </td>
<td>- </td>
<td>Oral is $ </td>
</tr>
<tr>
<td>Fentanyl </td>
<td>300x </td>
<td>300x </td>
<td>- </td>
<td>IV’ Buccal, Nasal </td>
<td>Patch </td>
<td>Dosed in ug, not mg </td>
</tr>
<tr>
<td><em>Abbreviations: ER = extended release; IR = immediate release; APAP = acetaminophen</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>Conversion:</p>
<ul>
<li>
<p>Transition between opiates is done using oral morphine equivalents
    (OMEs). Each drugs’ potency is compared to oral morphine (see
    table). Ex: 1 mg IV morphine = 3 mg PO morphine</p>
</li>
<li>
<p>When transitioning, doses are traditionally reduced by &frac14; to &#8531;
    due to cross tolerance</p>
</li>
<li>
<p>IR/ER regimens: Consider switching to extended release when
    requiring 3-4 doses of intermediate release (IR) medications in a
    24-hour period regularly. The ER medication should treat the chronic
    pain experienced by a patient. The IR preparation is indicated for
    breakthrough pain. The IR dose should be calculated as 10-20% of the
    total OME dose a patient takes daily. Fentanyl patches should last
    72 hours</p>
</li>
</ul>
<p><img src="../pain-and-palliative/main/output/media/image24.png"
style="width:3.32661in;height:1.16in"
alt="Diagram Description automatically generated" /></p>
<p>Patient Controlled Analgesia (PCAs)</p>
<ul>
<li>Pumps can be programmed to deliver a continuous rate and/or a bolus
    dose</li>
</ul>
<!-- -->

<ul>
<li>
<p>Basal rate = a continuous infusion dosed per hour that cannot be
    adjusted by the patient</p>
</li>
<li>
<p>Demand dose = a patient-directed bolus that is given at a prescribed
    frequency whenever the pt presses the button. Both the dose and
    frequency can be adjusted</p>
</li>
<li>
<p>The general rule of thumb is to calculate the total OME delivered
    through the demand when a pt is in steady state and convert 75% of
    this dose into the total continuous rate.</p>
<p>Calculating initial doses:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Basal dose: check what the patient is actually taking at home (may
    be different than what is prescribed, use OME). Take the total daily
    dose and convert to IV and then divide that by 24 hours to get an
    hourly rate. If moderate pain, increase dose by 25-50%; if severe,
    by 50-100%</p>
</li>
<li>
<p>Demand doses: The bolus dose should be 10-20% of total daily dose.
    The availability is based on half-life of the medication (2hr for
    IV). Adjust the availability based on how frequently you want
    patient to be able to have a demand dose (ex: if q10min divide by 12
    or if q15min divide by 8 for 2 hours)</p>
</li>
<li>
<p>Don’t forget to set lock-outs (maximum dose that can be given over a
    certain period of time) that includes both basal and demand doses</p>
</li>
<li>
<p>Remember that the basal rate will not get to steady state for at
    least 8 hrs; When you admit pts or are transitioning pts to a PCA,
    always initiate the PCA pump with a bolus (or loading) dose</p>
</li>
</ul>
<p>How to Order PCA at VUMC</p>
<ul>
<li>Select Analgesic:</li>
</ul>
<!-- -->

<ul>
<li>
<p>*Hydromorphone (most common): Order “Hydromorphone (DILAUDID) PCA”</p>
</li>
<li>
<p>Fentanyl (if on at home; not a good inpatient PCA): Order “Fentanyl
    PCA”</p>
</li>
<li>
<p>*Morphine: Order “Morphine PCA”</p>
</li>
</ul>
<!-- -->

<ul>
<li>Select “[Analgesic] PCA syringe” and adjust the following to pt
    needs:</li>
</ul>
<!-- -->

<ul>
<li>
<p>PCA Dose (“Demand”): amount the patient gets when s/he presses the
    button</p>
</li>
<li>
<p>Lockout Interval: time between which “demand” doses will not be
    administered if s/he presses the button (i.e., the PCA “locks out”)</p>
</li>
<li>
<p>Continuous Dose (“Basal”): amount the pt gets per hr in continuous
    infusion</p>
</li>
<li>
<p>Max Dose: maximum amount of analgesic (Basal + Demand) pt can get in
    24 hours</p>
</li>
</ul>
<!-- -->

<ul>
<li>Select all “PCA Nursing Orders”</li>
</ul>
<p>How to Order PCA at VA</p>
<ul>
<li>
<p>Under Orders, select “Pain/Sedation Infusions”</p>
</li>
<li>
<p>Under “PCAs,” select Analgesic of choice (Hydromorphone or Morphine)</p>
</li>
<li>
<p>Adjust the following:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Load: amount the pt will receive on initial set up of PCA</p>
</li>
<li>
<p>Basal: amount the pt gets per hour in continuous infusion</p>
</li>
<li>
<p>Demand: amount the pt gets when s/he presses the button</p>
</li>
</ul>
<p>Interrogating PCA (to determine amount of analgesia pt received):</p>
<ul>
<li>
<p>Look at IV pump display and hit “Channel Select” on PCA</p>
</li>
<li>
<p>Select “Options” in bottom left of IV pump</p>
</li>
<li>
<p>Select “Patient History” on the left of the screen. This shows the
    administration history for a certain time period (e.g., 24h, 12h,
    4h, etc.)</p>
</li>
<li>
<p>Hit “Zoom” on bottom of screen to change time period to 24 hours.
    Should show:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Total Drug: total amount of drug received in last 24 hours</p>
</li>
<li>
<p>Total Demands: amount of times the pt has pushed the button for
    demand dose</p>
</li>
<li>
<p>Delivered: amount of times the pt actually received a demand dose</p>
</li>
<li>
<p>The difference between “Total Demands” and “Delivered” is the number
    of times the patient pushed the button without receiving a dose</p>
</li>
</ul>
<p>Opioid Side effects</p>
<ul>
<li>Constipation: dose-dependent and will not develop tolerance. If pt
    has opioids, they need robust bowel regimen (MiraLAX, senna) with
    goal of BM ≥every 3 days</li>
</ul>
<!-- -->

<ul>
<li>For opioid-specific constipation can do SQ Relistor<sup>TM</sup>
    (methylnaltrexone) but this is expensive and can only be given in
    the PCU or oncology floors at VUMC. For patients with chronic
    opioid-induced constipation as an outpatient can trial oral agents
    like Movantik<sup>TM</sup> (naloxgeol). Can also consider PO
    naloxone but it does have small amount of bioavailability so watch
    for systemic reversal</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nausea: occurs with opiate naïve pts. Consider starting an
    anti-emetic concurrently. Most pts will develop tachyphylaxis with
    this over a day, so the antiemetic can be discontinued</p>
</li>
<li>
<p>Urinary retention: Consider role of opioids in pts with new-onset or
    worsening urinary retention. Try to de-escalate opioid dosing if
    possible</p>
</li>
<li>
<p>Overdose: In pts with apneic emergency, IV 0.4 mg Naloxone; however,
    low threshold for multiple doses until response. For pts prescribed
    opioids as outpatient, need naloxone 4 mg intranasal</p>
</li>
</ul>
<!-- -->

<ul>
<li>If a patient with chronic opiate dependence is over sedated but not
    in immediate danger of respiratory failure, one can 1) hold the dose
    of opioid and let them wake up on their own or 2) give a dose of
    naloxone 0.02-0.04mg (1/10 of the usual dose). This latter strategy
    prevents opioid withdrawal and precipitation of pain crisis in
    patients on chronic opioids</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pruritis: due to histamine release from mast cells; can be treated
    with antihistamines. The opioid can also be rotated. Some but not
    all pts will develop tachyphylaxis to this symptom</p>
</li>
<li>
<p>Toxicity: hyperalgesia and neuroexcitatory effects (AMS, myoclonic
    jerking, seizures). Risk factors for neuroexcitatory effects are
    rapid titration, dehydration, and/or renal failure. Treatment is to
    rotate to a higher potency opioid and hydrate when possible</p>
</li>
</ul>
<p>Acute and Chronic Pain – Thomas Horton, Soibhan Kelley</p>
<ul>
<li>
<p>There are physiological AND emotional components to pain.
    Biopsychosocial factors must be addressed. Ex: anxiety/depression,
    physical debility, and poor social support. Many pts will never be
    completely free of pain, so it is important to set realistic
    expectations</p>
</li>
<li>
<p>Central sensitization is a phenomenon where the nervous system
    persists in a state of high reactivity which lowers the threshold
    for pain stimuli. Two characteristics of centralized pain are
    allodynia (pain from non-painful stimuli) and hyperalgesia (painful
    stimuli perceived as more painful)</p>
</li>
</ul>
<p>Pharmacologic Therapy</p>
<p>Acetaminophen: 650mg q6hr or 1g q8h. \&lt;3g/day. (\&lt;2g in liver patients)</p>
<ul>
<li>Avoid if you are worried about masking fevers</li>
</ul>
<p>NSAIDs: A great option for acute pain, especially musculoskeletal, HA,
and nephrolithiasis in eligible patients (ex: IV/po ketorolac,
ibuprofen, naproxen, etc.)</p>
<ul>
<li>Avoid in acute or chronic kidney disease and ↑ risk of bleeding.
    Caution in CAD/PVD</li>
</ul>
<p>Topical Analgesics: Best for localized pain but utilized frequently as
part of a multimodal regimen</p>
<ul>
<li>
<p>Lidocaine ointment, patches (PADR needed at VA for patches. Can get
    by saying contraindication to TCA/gabapentinoids/SNRIs due to
    sedation risk)</p>
</li>
<li>
<p>Menthol salicylate gel</p>
</li>
<li>
<p>Diclofenac Gel</p>
</li>
<li>
<p>Capsaicin gel</p>
</li>
<li>
<p>Morphine gel (typically limited to oncology patients with tumor
    breakdown through skin)</p>
</li>
</ul>
<p>Neuropathic Agents: Best for neuropathic pain but can be tried for other
chronic pain or as part of acute pain regimen. SNRIs and TCAs can
provide additional benefit if a pt has comorbid depression, anxiety, or
insomnia (TCA). Most agents take 6-8 weeks for peak effect.</p>
<ul>
<li>
<p>Gabapentin (Initial: 100 to 300 mg 1 to 3 times daily). Can be used
    for acute pain</p>
</li>
<li>
<p>Pregabalin (Initial: 25 to 150 mg/day in 2 to 3 divided doses). Has
    better bioavailability. May work in patients who did not tolerate or
    did not have success with gabapentin</p>
</li>
<li>
<p>Duloxetine (Initial: 30 mg daily for 1 to 2 weeks, then increase to
    60 mg daily as tolerated)</p>
</li>
<li>
<p>Amitriptyline (Initial: 10 to 25 mg once daily at bedtime)</p>
</li>
</ul>
<p>Muscle Relaxants: Should be used temporarily and intermittently but some
benefit from longer term use. Great for paraplegia, spinal injury,
spasticity.</p>
<ul>
<li>
<p>Methocarbamol (Initial: 1.5 g 3 to 4 times daily for 2 to 3 days
    then decrease dose to ≤4.5 g/day in 3 to 4 divided doses). Preferred
    initial agent as has least SE.</p>
</li>
<li>
<p>Tizanidine (Initial: 2 to 4 mg every 6 to 12 hours as needed and/or
    at bedtime) – important to watch out for withdrawal in patients that
    take frequently at home.</p>
</li>
<li>
<p>Cyclobenzaprine (Initial: 5 to 10 mg once daily before bedtime)</p>
</li>
<li>
<p>Metaxalone (Oral: 800 mg 3 to 4 times daily)</p>
</li>
</ul>
<p>Opioids: Frequently used in hospital for acute pain. Limit use as much
as possible in chronic pain as contributes to long-term central
sensitization. May benefit some patient populations but should always be
used as a component of a comprehensive, multimodal, patient-specific
treatment plan.</p>
<ul>
<li>Refer to section under Opioids: General Principles &amp; Conversions for
    OME equivalents</li>
</ul>
<!-- -->

<ul>
<li>
<p>If >80 OME per day, ensure patient is prescribed naloxone</p>
</li>
<li>
<p>If >120 OME per day, refer to pain clinic</p>
</li>
</ul>
<!-- -->

<ul>
<li>Common choices for acute pain in hospital (always start at low end
    for opioid naïve):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Oxycodone (PO) 5-10mg q4 to 6 hours prn</p>
</li>
<li>
<p>Hydromorphone (IV) 0.25 to 1mg q2 to 3 hours prn</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>For pts on opioids at home, should always continue in hospital to
    avoid withdrawal unless clinically contraindicated. Can always
    titrate dose as needed</p>
</li>
<li>
<p>Tramadol: Has opioid &amp; NSAID properties. Of note, tramadol also
    inhibits serotonin and norepinephrine reuptake. Metabolized by
    CYP3A4 and CYP2D6 so there is variability between patients. Typical
    dose: 25 to 50mg q4 to 6 hours prn</p>
</li>
</ul>
<p>NMDA Antagonists: Usually prescribed by our pain management colleagues
but worthwhile to think about as a potential option if a patient’s pain
continues to be difficult to control.</p>
<ul>
<li>
<p>Ketamine (IV infusion). SE includes AMS/delirium, hallucinations,
    and dissociation.</p>
</li>
<li>
<p>Memantine (PO)</p>
</li>
</ul>
<p>Alpha 2 agonists (central pain): Not commonly utilized in everyday
practice, but helpful in certain patients with chronic pain (off-label).
Guanfacine vs clonidine</p>
<p>Non-pharmacologic therapies</p>
<p>Procedural Intervention: Best utilized when there is a specific,
targetable</p>
<ul>
<li>Referral to chronic/interventional pain management (Nerve blocks or
    Radio-ablative therapy)</li>
</ul>
<p>Adjunct Therapies: Patient’s will have varying opinions and responses on
adjunctive therapies, but these can be as important as any pharmacologic
therapy. CBT, personalized exercise regimen, PT/OT, chiropractor,
acupuncture</p>
<p>Additional Resources for Residents</p>
<ul>
<li>
<p>Pain Management Center at VUMC</p>
</li>
<li>
<p>Pain Clinic at the VA. Would specify whether or not you are OK with
    them initiating opioids.</p>
</li>
<li>
<p>Complementary and Integrative Health consult at VA</p>
</li>
<li>
<p>Osher Center for Integrative Health at Vanderbilt</p>
</li>
</ul>
<p>Acute pain for special populations</p>
<p>Renal dysfunction: Check that meds are renally dosed and start with
non-sedating options. Always avoid NSAIDs, morphine and codeine.</p>
<ul>
<li>
<p>Acetaminophen and topicals</p>
</li>
<li>
<p>Opioids: oxycodone 2.5 to 5 mg, IV hydromorphone 0.25-0.5mg,
    fentanyl IV 25 to 50mcg</p>
</li>
<li>
<p>Gabapentin: start with spot 100mg. Be extremely careful with quick
    up titration in CKD due to sedation risk.</p>
</li>
<li>
<p>Methocarbamol: no specific renal dosing, try 500-750mg initially</p>
</li>
</ul>
<p>Cirrhosis: Always avoid NSAIDs, morphine, codeine, hydromorphone (may be
OK in mild to moderate cirrhosis)</p>
<ul>
<li>
<p>Acetaminophen (2g max/d) &amp; topicals are safe</p>
</li>
<li>
<p>Gabapentin: start with spot 100mg</p>
</li>
<li>
<p>Methocarbamol: no specific hepatic dosing, try 500 mg initially</p>
</li>
<li>
<p>Other options: consider tramadol 25-50 mg vs oxycodone 2.5 mg</p>
</li>
</ul>
<p>History of substance use disorder: Overnight, always review handoff as
day team likely has specific plan in place.</p>
<ul>
<li>
<p>With substance use history, typically rely on multimodal agents as
    above. Patients who are in recovery may prefer to avoid opioids
    themselves</p>
</li>
<li>
<p>However, patients with OUD can and do have acute, severe pain due to
    injury, infections, procedures, etc. NEVER withhold opiates if
    clinically appropriate, regardless of substance use history</p>
</li>
</ul>
<p>Hospice</p>
<p>Background</p>
<ul>
<li>Hospice: aims to provide aggressive palliative care for patients at
    the end of their life, usually when life-prolonging treatment
    options have stopped</li>
</ul>
<!-- -->

<ul>
<li>
<p>Eligibility: less than or equal to 6- month life expectancy</p>
<ul>
<li>Consider: palliative performance scale (PPS) rating of \&lt;50-60%,
    dependence in 3 of 6 ADL’s, alteration in nutritional status, or
    documented deterioration in 4-6 months</li>
</ul>
</li>
<li>
<p>Levels of Care</p>
<ul>
<li>
<p>General inpatient care: Patients must require skilled nursing
    care that could not be provided at home (IV medications,
    suction, high flow O2,) No cost to the patient under this level
    of care.</p>
</li>
<li>
<p>Home hospice-Patients are discharged to their "home”: which
    could be a long term care facility, assisted living facility, or
    their house.</p>
</li>
</ul>
</li>
<li>
<p>What is covered?</p>
<ul>
<li>
<p>Personnel:</p>
<ul>
<li>
<p>Hospice RN visits at least weekly and as needed; crisis
    on-call visits available 24/7</p>
</li>
<li>
<p>SW, Chaplain, Hospice MD oversight</p>
</li>
<li>
<p>CNAs: usually 1 hr, 2-3/wk at most</p>
</li>
</ul>
</li>
<li>
<p>Medicines for comfort</p>
</li>
<li>
<p>Medical equipment for comfort and safety including oxygen</p>
</li>
<li>
<p>Up to 13 months of bereavement for caregivers after the death</p>
</li>
<li>
<p>Respite care for 5 days, usually in a nursing home</p>
</li>
<li>
<p>Inpatient hospice at hospice facility or at certain hospitals
    for symptom control for up to 7 days</p>
</li>
</ul>
</li>
<li>
<p>Hospice can be offered to patients without insurance</p>
</li>
</ul>
<p>VA Specifics for Hospice:</p>
<ul>
<li>Main difference compared to VUMC is pt is allowed concurrent care</li>
</ul>
<!-- -->

<ul>
<li>This means vets can continue to receive some treatments for the
    primary condition (e.g., palliative radiation or chemotherapy) and
    still receive hospice services</li>
</ul>
<!-- -->

<ul>
<li>
<p>Additionally, all veterans that go on hospice should have any needed
    nursing home stay (at a contracted SNF) covered by the VA regardless
    of service connection</p>
</li>
<li>
<p>VA Palliative Care team will help with these referrals</p>
</li>
<li>
<p>One (1) F Status at the VA</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Designates “treating specialty” as NA-HOSPICE. Reduces costs for
    families, helps quality metrics. Use this if patient qualifies and
    agrees to hospice care</p>
</li>
<li>
<p>Write Delayed Transfer Orders: Admit to NA-HOSPICE and Specialty as
    “Hospice for Acute Care”</p>
</li>
<li>
<p>Write a nursing text order to “Change Patient to 1-F Status”</p>
</li>
</ul>
<p>Medications for Imminently Dying Patients</p>
<p>General recommendations</p>
<ul>
<li>
<p>At VUMC, there is a very helpful order set titled “Comfort Care
    Orders (Trauma, MICU, SICU, NEURO ICU, Palliative Care”</p>
</li>
<li>
<p>Make sure to remove unnecessary medications, labs, telemetry,
    nursing text orders, etc.</p>
</li>
</ul>
<p>Pain</p>
<ul>
<li>
<p>Morphine 2mg IV or SQ q1h PRN (avoid if renal failure)</p>
</li>
<li>
<p>Hydromorphone 0.25 – 0.5mg IV or SQ q1h PRN</p>
</li>
<li>
<p>Write as PRN, as needed for pain > 2/10 or for air hunger</p>
</li>
<li>
<p>If ineffective after 1 hours, increase by 50-100%</p>
</li>
<li>
<p>If given every hour for 3-4 hours, consider an infusion (given PRN
    dose as hourly rate)</p>
</li>
<li>
<p>Fentanyl is not a great option in ICU unless it is a continuous
    drip. Bolus lasts only 15 mins</p>
</li>
</ul>
<p>Dyspnea/Tachypnea</p>
<ul>
<li>
<p>Assess for volume overload, considering decrease or stopping IVFs or
    tube feeds</p>
</li>
<li>
<p>Opioids are the treatment of choice for dyspnea</p>
</li>
<li>
<p>Consider Benzodiazepines for air hunger not controlled by opiates</p>
</li>
<li>
<p>Supplemental oxygen for comfort (do not base on O2 sat). Consider
    use of cool air or fan</p>
</li>
</ul>
<p>Restlessness/agitation/anxiety</p>
<ul>
<li>
<p>Assess for urinary retention, constipation, pain, other modifiable
    factors</p>
</li>
<li>
<p>Lorazepam (Ativan) 0.5 – 1 mg PO or IV q4h PRN (tablet can be made
    into slurry if patient is experiencing dysphagia)</p>
</li>
</ul>
<p>Nausea</p>
<ul>
<li>
<p>Ondansetron (Zofran) 4mg IV q4h or 8mg q8h PRN</p>
</li>
<li>
<p>Promethazine (Phenergan) 25mg PO or PR q6h PRN; caution can be very
    sedating</p>
</li>
<li>
<p>Prochlorperazine (Compazine) 10mg PO or IV q4h PRN</p>
</li>
<li>
<p>Haloperidol (Haldol)</p>
</li>
<li>
<p>If felt to be obstructive in etiology, try Dexamethasone 4mg IV or
    SQ q8-12h with Octreotide 100-400mcg IV or SQ q8h</p>
</li>
<li>
<p>If felt to be related to anxiety, try Lorazepam; see dosing above</p>
</li>
<li>
<p>Scopolamine is highly anti-cholinergic and takes time to be
    effective, so would NOT use in imminently dying patients</p>
</li>
</ul>
<p>Secretions</p>
<ul>
<li>
<p>Remember: the patient is NOT bothered by their own secretions, and
    it is often the family and caregivers who are likely disturbed, so
    avoid deep suctioning</p>
</li>
<li>
<p>Glycopyrrolate (Robinul) 0.2 – 0.4 mg SQ or IV q6h PRN</p>
</li>
<li>
<p>Atropine 1% Ophthalmic Solution 2 drops sublingual 2-4h PRN</p>
</li>
</ul>
<p>Video Examples for Navigating Difficult Conversations – Mohana Karlekar</p>
<p>Navigating difficult conversations with patients can be daunting
especially if you have never seen someone do one well before.
Conversations should follow a logical and sequential approach. much like
any procedure we perform in medicine. Like all procedures, practice
makes us better</p>
<p>Scan the QR Code to View Video Examples or Search The Learning Exchange
“Navigating Difficult Conversations With Patients”</p>
<p><img src="../pain-and-palliative/main/output/media/image25.png"
style="width:0.85894in;height:0.84768in"
alt="Qr code Description automatically generated" /></p>
<p>Here are some suggestions for “Navigating Difficult Conversations”</p>
<ul>
<li>
<p>Step 1. Determine your message-keep it simple and short</p>
</li>
<li>
<p>Step 2. Identify what type of news you are communicating: breaking
    bad news, assessing understanding of information, communicating
    prognosis, or navigating goals of care</p>
</li>
<li>
<p>Step 3. Pick the video that best suits your purpose</p>
</li>
</ul>
<p><img src="../pain-and-palliative/main/output/media/image26.png"
style="width:2.41722in;height:1.77294in"
alt="Table Description automatically generated" /></p>
<p>The Death Pronouncement – Michael J. Neuss</p>
<p>This scenario arises in a variety of contexts, including the units,
wards, and cross-cover. You might know the patient and family well, but
particularly when cross covering, that may not be the case</p>
<ul>
<li>This approach to the death pronouncement is based in part on the
    AAFP’s “Death Pronouncement: Survival Tips for Residents” (Am Fam
    Physician. 1998 Jul 1;58(1):284-285.)</li>
</ul>
<p>Before Entering:</p>
<ul>
<li>
<p>Familiarize yourself with the most important points of the patient’s
    hospitalization and recent events. Be aware of the circumstances of
    the patient’s death, particularly whether death was expected or
    sudden.</p>
</li>
<li>
<p>Inquire as to which family is present including whether the POA is
    currently at bedside</p>
</li>
<li>
<p>In general, it is best to enter accompanied, ideally with the
    patient’s nurse. It is rare for the chaplain to be present but that
    might also be a consideration.</p>
</li>
</ul>
<p>In The Room:</p>
<ul>
<li>
<p>Especially when cross-covering, make sure to introduce yourself to
    family, and allow them time to introduce themselves to you</p>
</li>
<li>
<p>Less is more when it comes to what you say: it can be good to be
    empathetic (consider only short statements such as “I am sorry for
    your loss”) but focus mainly on the task at hand, allowing time for
    families to be present with their loved one</p>
</li>
<li>
<p>Explain that you have been called to examine the patient to confirm
    that they have passed. Allow a brief time for questions; it is rare
    (but not impossible) that someone may wish to excuse themselves for
    the pronouncement</p>
</li>
<li>
<p>Note the location of a working clock when you enter; your watch is
    ok too but do make sure to avoid looking at your smartphone to check
    the time of death</p>
</li>
</ul>
<p>The Exam and Pronouncement</p>
<ul>
<li>
<p>Identify the patient by wrist band</p>
</li>
<li>
<p>Confirm that the patient does not respond to stimuli; one discreet
    way to confirm a lack of response to tactile stimuli is to hold the
    hand, and apply pressure to a nailbed, appearing to hold the hand
    while looking at/visually inspecting the face or other part of the
    body</p>
</li>
<li>
<p>Confirm the absence of spontaneous respirations and absence of heart
    sounds. Listen for a full minute as some patients have extended
    periods of apnea</p>
</li>
<li>
<p>Examine the pupils and note the absence of pupillary light reflex</p>
</li>
<li>
<p>Note the time at which your examination is completed. This is the
    time of death</p>
</li>
<li>
<p>Make sure to ask if the family would like an autopsy to be
    performed. This is often overlooked, and as awkward as it might feel
    to ask for this, it is a requirement</p>
</li>
<li>
<p>Make sure you have notified the attending of record</p>
</li>
</ul>
<p>*Please see further VA- and VUMC-specific guidance below</p>
<p>Death Process at VUMC</p>
<ul>
<li>
<p>The key thing is to ensure that all components are completed in the
    “Discharge as Deceased” tab under the Transfer-Discharge screen</p>
</li>
<li>
<p>EACH AND EVERY component of this tab must be completed before
    Decedent Affairs will accept the body</p>
</li>
</ul>
<p>Required steps:</p>
<ul>
<li>
<p>Cardiopulmonary Death Charting -> Select “New Reading” and
    complete.</p>
</li>
<li>
<p>Cardiopulmonary Death ->Select “+Create Note”</p>
</li>
<li>
<p>Medical Examiner Criteria -> Select “+New Reading”; Criteria
    requiring notification of ME is listed in a drop down menu in the
    navigator. Includes accidental deaths, threats to public health,
    suspicion for foul play, etc. The Vanderbilt Operator can assist
    with connecting you to the ME; alternatively, you can call
    615-743-1800 during business hours (M-F 8am – 4:30pm) or the
    after-hours pager at 800-216-0107.</p>
</li>
</ul>
<!-- -->

<ul>
<li>All patients diagnosed with Covid are automatic ME cases</li>
</ul>
<!-- -->

<ul>
<li>
<p>Autopsy Criteria -> Select “+New Reading”</p>
</li>
<li>
<p>Preliminary Cause of Death and Date/Time of Death ->. Rather than
    list “Cardiopulmonary arrest,” be specific (e.g., Pulmonary
    Embolism, Myocardial Infarction, Metastatic Colon Cancer, etc.)</p>
</li>
<li>
<p>Deceased’s Info – Report of Death</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>If you need to leave this and return later after collecting
    information, you can access your partially complete entries by
    clicking on the date/time text that appears under the ribbon. This
    is not intuitive because the numbers listing the date/time do not at
    all appear as though they act like a hyperlink (but they do).</p>
</li>
<li>
<p>Be specific; TDS will want you to have listed the name of the family
    you notified, the TDS Case Number (which the RN typically enters),
    and your attending physician’s name (to sign the death certificate;
    give their pager number in this subsection).</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Report of Death Note -> Select “+New Reading” and complete.</p>
</li>
<li>
<p>Complete Synopsis + Hospital Course and then at the very bottom
    under Summary of Death select “+Create Note.”</p>
</li>
<li>
<p>Once all of this paperwork is finished, be sure to touch base with
    the patient’s nurse, usually contact Decedent Affairs and assist in
    making sure the body is moved</p>
</li>
</ul>
<p>Death Process at the VA</p>
<p><img src="../pain-and-palliative/main/output/media/image27.png"
style="width:3.75in;height:4.42569in"
alt="A picture containing timeline Description automatically generated" /></p></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-acute-and-chronic-pain"><h1 id="pain-and-palliative-pain-and-palliative-acute-and-chronic-pain-acute-and-chronic-pain">Acute and Chronic Pain<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-acute-and-chronic-pain-acute-and-chronic-pain" title="Permanent link">&para;</a></h1>
<p>Acute and Chronic Pain – Thomas Horton, Soibhan Kelley</p>
<ul>
<li>There are physiological AND emotional components to pain.
    Biopsychosocial factors must be addressed. Examples include
    anxiety/depression, physical debility, and poor social support. 
    Many pts will not be completely free of pain, so it is important to
    set realistic boundaries and goals along with each individual.</li>
<li>Central sensitization is a phenomenon where the nervous system
    persists in a state of high reactivity which lowers the threshold
    for pain stimuli.  Two characteristics of centralized pain are
    allodynia (pain from non-painful stimuli) and hyperalgesia (painful
    stimuli perceived as more painful).</li>
<li>You must ask “why does this particular patient have pain?” Cancer
    patient vs degenerative disc disease will have different therapeutic
    plans.</li>
</ul>
<p>Pharmacologic Therapy</p>
<p>Acetaminophen</p>
<p>:  650mg q6hr or 1g q8h. \&lt;3g/day. (\&lt;2g in liver patients)</p>
<ul>
<li>Avoid if you are worried about masking fevers.</li>
</ul>
<p>NSAIDs</p>
<p>:  A great option for acute pain, especially musculoskeletal, HA, and
nephrolithiasis in eligible patients (ex: IV/po ketorolac, ibuprofen,
naproxen, etc)</p>
<ul>
<li>Avoid in acute or chronic kidney disease and
    ↑
    risk of bleeding. Caution in CAD/PVD</li>
</ul>
<p>Topical</p>
<dl>
<dt>Analgesics</dt>
<dd>
<p>Best for localized pain but utilized frequently as part of a
multimodal regimen</p>
</dd>
</dl>
<ul>
<li>Lidocaine ointment, patches (PADR needed at VA for patches. Can get
    by saying contraindication to TCA/gabapentinoids/SNRIs due to
    sedation risk)</li>
<li>Menthol
    salicylate gel</li>
<li>Diclofenac Gel (PADR needed at VA)</li>
<li>Capsaicin gel</li>
<li>Morphine gel (typically limited to oncology patients with tumor
    breakdown through skin)</li>
</ul>
<p>Neuropathic Agents</p>
<p>:</p>
<p>Best for neuropathic pain but can be tried for other chronic pain or as
part of acute pain regimen. SNRIs and TCAs can provide additional
benefit if a pt has comorbid depression, anxiety or insomnia (TCA). 
Most agents take 6-8 weeks for peak effect.</p>
<ul>
<li>Gabapentin
    (Initial: 100 to 300 mg 1 to 3 times daily). Can be used for acute
    pain.</li>
<li>Pregabalin
    (Initial: 25 to 150 mg/day in 2 to 3 divided doses). Has better
    bioavailability. May work in patients who did not tolerate or did
    not have success with gabapentin.</li>
<li>Duloxetine
    (
    Initial: 30 mg daily for 1 to 2 weeks, then increase to 60 mg daily
    as tolerated)</li>
<li>Amitriptyline (
    Initial: 10 to 25 mg once daily at bedtime)</li>
</ul>
<p>Muscle Relaxants</p>
<p>:</p>
<p>Should be used temporarily and intermittently but some benefit from
longer term use. Great for paraplegia, spinal injury, spasticity.</p>
<ul>
<li>Methocarbamol (Initial: 1.5 g 3 to 4 times daily for 2 to 3 days
    then decrease dose to ≤4.5 g/day in 3 to 4 divided doses). Preferred
    initial agent as has least SE.</li>
<li>Tizanidine (
    Initial: 2 to 4 mg every 6 to 12 hours as needed and/or at bedtime )
    – important to watch out for withdrawal in patients that take
    frequently at home.</li>
<li>Cyclobenzaprine
    (Initial: 5 to 10 mg once daily before bedtime)</li>
<li>Metaxalone (Oral: 800 mg 3 to 4 times daily)</li>
</ul>
<p>Opioids:</p>
<p>Frequently used in hospital for acute pain. Limit use as much as
possible in chronic pain as contributes to long-term central
sensitization.  May benefit some patient populations but should always
be used as a</p>
<p>component of a comprehensive, multimodal, patient-specific treatment
plan.</p>
<ul>
<li>Refer to section under Opioids: General Principles &amp; Conversions for
    OME equivalents<ul>
<li>If &gt;
    80
    OME per day, ensure patient is prescribed naloxone</li>
<li>If &gt;120 OME per day, refer to pain clinic</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Common choices for acute pain in hospital (always start at low end
    for opioid naïve):<ul>
<li>Oxycodone (PO) 5-10mg q4 to 6 hours prn</li>
<li>Hydromorphone (IV) 0.25 to 1mg q2 to 3 hours prn</li>
</ul>
</li>
<li>For pts on opioids at home, should always continue in hospital to
    avoid withdrawal unless clinically contraindicated (e.g.,
    respiratory depression). Can always titrate dose as needed</li>
<li>Tramadol
    : Has opioid &amp; NSAID properties. Of note, tramadol also inhibits
    serotonin and norepinephrine reuptake. Metabolized by
    CYP3A4 and CYP2D6 so there is variability between patients. Typical
    dose: 25 to 50mg q4 to 6 hours prn.</li>
</ul>
<dl>
<dt>NMDA Antagonists</dt>
<dd>
<p>Usually prescribed by our pain management colleagues but worthwhile to
think about as a potential option if a patient’s pain continues to be
difficult to control.</p>
</dd>
</dl>
<ul>
<li>Ketamine (IV infusion). SE includes AMS/delirium, hallucinations,
    and dissociation.</li>
<li>Memantine (PO)</li>
</ul>
<dl>
<dt>Alpha 2 agonists (central pain)</dt>
<dd>
<p>Not commonly utilized in everyday practice, but helpful in certain
patients with chronic pain (off-label). Guanfacine vs clonidine</p>
</dd>
</dl>
<p>Non-pharmacologic therapies</p>
<dl>
<dt>Procedural Intervention</dt>
<dd>
<p>Best utilized when there is a specific, targetable</p>
</dd>
</dl>
<ul>
<li>Referral
    to chronic/interventional pain management (Nerve blocks or
    Radio-ablative therapy)</li>
</ul>
<dl>
<dt>Adjunct Therapies</dt>
<dd>
<p>Patient’s will have varying opinions and responses on adjunctive
therapies, but these can be as important as any pharmacologic therapy.
CBT, personalized exercise regimen, PT/OT, chiropractor, acupuncture</p>
</dd>
</dl>
<p>Additional Resources for Residents</p>
<ul>
<li>Pain Management Center at VUMC</li>
<li>Pain Clinic at the VA. Would specify whether or not you are OK with
    them initiating opioids.</li>
<li>Osher Center for Integrative Health at Vanderbilt. (VA pts may
    utilize this service if they have private insurance)</li>
</ul>
<p>Acute pain for special populations</p>
<dl>
<dt>Renal dysfunction</dt>
<dd>
<p>Check meds are renally dosed and start with non-sedating options.
Always avoid NSAIDs, morphine and codeine. Acetaminophen and topicals
are safe.</p>
</dd>
</dl>
<ul>
<li>Opioids: oxycodone 2.5 to 5 mg, IV dilaudid 0.25-0.5mg, fentanyl IV
    25 to 50mcg</li>
<li>Gabapentin: start with spot 100mg. Be extremely careful with quick
    uptitration in CKD due to sedation risk.</li>
<li>Methocarbamol: no specific renal dosing, try 500-750mg initially</li>
</ul>
<p>Cirrhosis:</p>
<p>Always avoid NSAIDs, morphine, codeine, hydromorphone (may be OK in mild
to moderate cirrhosis)</p>
<ul>
<li>Acetaminophen (2g max/d) &amp; topicals are safe</li>
<li>Gabapentin: start with spot 100mg</li>
<li>Methocarbamol: no specific hepatic dosing, try 500 mg initially</li>
<li>Other options: consider tramadol 25-50 mg vs oxycodone 2.5 mg</li>
</ul>
<p>History of substance use disorder:</p>
<p>Overnight, always review handoff as day team likely has specific plan in
place.</p>
<ul>
<li>With substance use history, opioids should be avoided. Rely on
    multimodal agents as above</li>
<li>Patients who are in recovery may prefer to avoid opioids themselves<ul>
<li>Pts <strong>can</strong> <strong>and</strong> <strong>do</strong> have acute, severe pain due to
    injury, infections, procedures, et</li>
<li>NEVER withhold
    opiates if clinically appropriate, regardless of substance use
    history</li>
</ul>
</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-code-status-discussion"><h1 id="pain-and-palliative-pain-and-palliative-code-status-discussion-code-status-discussion">Code Status Discussion<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-code-status-discussion-code-status-discussion" title="Permanent link">&para;</a></h1>
<p>Code Status Discussion – Katie Sunthankar</p>
<ul>
<li>The approach to obtaining someone’s code status should be thoughtful
    and pertinent to their current admission or recent change in
    clinical status. First ask yourself “Why would this pt code?  Is
    resuscitation a reversible treatment in this pt’s case?  What are
    the chances that this pt will survive to discharge following CPR? Is
    the anticipated outcome in line with the pt’s goals? After you have
    made your assessment, then make a recommendation based on both the
    efficacy of resuscitation and the patient’s goals. (90-year-old male
    with an MI may survive CPR but may wish to die a natural death. A
    35-year-old with advanced cancer may be willing to endure CPR even
    if the chance of success is miniscule) Sometimes it is difficult to
    ascertain, and you can ask your attending his/her thoughts. For
    example, a 40 y/o pt admitted with cellulitis should probably be
    full code however an 83 y/o pt with class IV NYHA heart failure,
    CKD4 and significant frailty should probably be DNR/DNI. It is
    important that you are incorporating 1) the pt’s goals with 2) your
    understanding about the efficacy of CPR for that pt and help them
    come to an educated decision.</li>
</ul>
<!-- -->

<ul>
<li>Below are examples of phrases that can be used in framing code
    status. It is important to do this step wise. <strong>NEVER say “Do you
    want us to do everything?”</strong> This is a question very few people are
    okay with saying no to. It is more helpful to give examples of when
    these situations would arise.</li>
</ul>
<p>Admitting a patient:</p>
<ul>
<li>Introduction
    : Normalize the conversation by stating that “these are questions we
    routinely ask everyone when they come into the hospital.  This is a
    way for us to understand your wishes in the event you are unable to
    make your own decisions.” Otherwise, they can be caught off guard
    and not be able to meaningfully participate in the conversation.</li>
<li>Surrogate
    : “If you were unable to make decisions for yourself for whatever
    reason, who would you trust to make your decisions?  The person you
    pick does not have to be family but should be able to speak to your
    wishes and make the same choices you would make for yourself. [In a
    cirrhotic] For example, if you were to get confusion from your
    liver disease?”</li>
<li>Intubation
    : Always do this first so you can avoid the sticky DNI but not DNR
    situation. Again, normalize the question.  “Everyone has different
    opinions on what types of medical care they would want if they
    became sicker. One of the things we like to talk about are
    ventilators or breathing machines. Some tell us to try a breathing
    machine for a trial, but they would not want to be kept alive on a
    ventilator.” Now make a recommendation.  “In your case I think if
    you were to need a ventilator, based on your health I think it would
    [work, not work,]” Pause and allow them to ask questions. Also
    remember that if they say DNI, then they <em>must</em> be DNR because
    intubation occurs with ACLS (this is not allowed at VUMC but is at
    the VA… I don’t recommend getting in this situation).</li>
<li>CPR
    : Prime this question with “The next question I have to ask you can
    be hard to think about, but it is important that we know what you
    would want. In the event you had a cardiac arrest, that is, when
    your heart stops beating, which would mean you died? This is
    different from a heart attack. [pause]. We know based on the
    evidence that CPR is not always successful.  It really depends on
    the situation.  In your case, I think CPR would be (make a
    recommendation here). Knowing this, would you want us to attempt CPR
    or try to resuscitate you?”</li>
</ul>
<p>What if you don’t agree with your patient’s decision…</p>
<ul>
<li>At the end of the day, it is their decision (attendings may change
    the code status out of medical futility in Tennessee).</li>
<li>If you think the pt didn’t understand, or was overwhelmed, or the
    clinical situation has changed, you may want to go back and revisit
    the conversation, perhaps with another family or friend present. 
    Some pts have seen CPR on a loved one and seen it be successful and
    others have only seen it on TV. These experiences greatly influence
    their decision.</li>
<li>Consider framing the discussion differently and offer your
    recommendation: “While you are in the hospital, we will support you
    with interventions and medications that we think are helpful based
    on what you have told us important to you. However, we are worried
    that some of the interventions you are asking for may do more harm
    than good. Many people think that CPR works like it does on TV. 
    Unfortunately, we know that the vast majority of patients who need
    CPR in the hospital do not survive like they do on TV.  In your
    case, we do not think it would bring you back to your current
    state.  I worry that this is not something that will be helpful to
    you.”</li>
<li>Sometimes it can be more of a discussion after a patient says “Yes I
    would want CPR” you can respond “I understand and respect your
    choice… maybe we can talk more about this later, in particular if
    your health changes.”</li>
<li>Worried they may not understand CPR? Note that it is important to
    share at the beginning of the conversation otherwise the patient may
    feel like you are trying to coerce them into a decision. “Can I
    share some numbers about how often CPR can help?” Sometimes using
    fingers to show these numbers helps. “If you take 10 people in this
    hospital and all of their hearts stop beating, which would mean they
    have died, and we get to them as fast as possible, only 3 of them
    would have their hearts restarted and only 1 of them would ever
    leave the hospital.”</li>
<li>Another phrase that is helpful (and when the discussion occurs with
    surrogates leads to higher rates of changing code status than saying
    DNR): “allow for a natural death”. For example, “I worry that given
    how sick your [loved one] is, that the additional interventions of
    CPR if she were to die, would prevent her from having a natural
    death”</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-death-pronouncement"><h1 id="pain-and-palliative-pain-and-palliative-death-pronouncement-the-death-pronouncement">The Death Pronouncement<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-death-pronouncement-the-death-pronouncement" title="Permanent link">&para;</a></h1>
<p>The Death Pronouncement – Michael J. Neuss</p>
<p>This scenario arises in a variety of contexts, including the units,
wards, and cross-cover. You might know the patient and family well, but
particularly when cross covering, that may not be the case</p>
<p>This approach to the death pronouncement is based in part on the AAFP’s
“Death Pronouncement: Survival Tips for Residents” (Am Fam Physician.
1998 Jul 1;58(1):284-285.)</p>
<p>Before Entering:</p>
<ul>
<li>Familiarize yourself with the most important points of the patient’s
    hospitalization; it is ok to take a moment to read about the
    patient’s course and inquire about the day’s events with the
    patient’s nurse or other staff.</li>
<li>Inquire as to which family is present prior to entering, including
    whether the POA is currently at bedside.</li>
<li>Be aware of the circumstances of the patient’s death, particularly
    whether death was expected or sudden.</li>
<li>In general, it is best to enter accompanied, ideally with the
    patient’s nurse. It is rare for the chaplain to be present but that
    might also be a consideration.</li>
<li>Inquire with the nurse if Tennessee Donor Services (TDS) has been
    notified; often, when death is anticipated, the nurse will already
    have done this, although that is not always the case. Remember that
    it is not your position/role to approach the family regarding organ
    donation, but TDS should have been notified and there should be a
    case number, which in Epic you will have to document.</li>
</ul>
<p>In The Room:</p>
<ul>
<li>Especially when cross-covering, make sure to introduce yourself to
    family, and allow them time to introduce themselves to you.</li>
<li>Less is more when it comes to what you say: it can be good to be
    empathetic (consider only short statements such as “I am sorry for
    your loss”) but focus mainly on the task at hand, allowing time for
    families to be present with their loved one.</li>
<li>Explain that you have been called to examine the patient to confirm
    that they have passed. Allow a brief time for questions; it is rare
    (but not impossible) that someone may wish to excuse themselves for
    the pronouncement, and although I do not commonly inquire if family
    would like to be present, this is a consideration.</li>
<li>Note the location of a working clock when you enter; your watch is
    ok too but do make sure to avoid looking at your smartphone to check
    the time of death.</li>
</ul>
<p>The Exam And Pronouncement:</p>
<ul>
<li>Identify the patient by wrist band.</li>
<li>Note general appearance.</li>
<li>Confirm that the patient does not respond to stimuli; one discreet
    way to confirm a lack of response to tactile stimuli is to hold the
    hand, and apply pressure to a nailbed, appearing to hold the hand
    while looking at/visually inspecting the face or other part of the
    body. You should avoid any obvious painful stimuli, out of respect
    for the deceased as well as out of deference to family who may be
    present.</li>
<li>Confirm the absence of spontaneous respirations.</li>
<li>Confirm the absence of heart sounds.</li>
<li>Examine the pupils and note the absence of pupillary light reflex.</li>
<li>Note the time at which your examination is completed. This is the
    time of death. It is ok (although not required; this is merely a
    consideration) to speak the time of death quietly and respectfully,
    for the family’s reference as well as staff’s.</li>
<li>Make sure to ask for an autopsy. This is often overlooked, and as
    awkward as it might feel to ask for this, it is a requirement and
    asking later (if overlooked) feels more awkward.</li>
<li>Often phrased as something that must always be offered to all
    families, but not often requested by families of patients.</li>
<li>Make sure you have notified the attending of record</li>
</ul>
<p>*Please see further VA- and VUMC-specific guidance below.</p>
<p>Death Process at the VA</p>
<p>Nurse will notify physician at time of death for pronouncement.</p>
<p>THEN:</p>
<p>Physician will arrive to pronounce patient’s death within 1 hour of
notification by nursing staff.</p>
<p>THEN:</p>
<p>Physician to examine patient and pronounce death—offering family
chaplain support and informing family of death. Chaplain is notified by
calling the Administrative officer on duty (AOD).  Physician informs
nursing staff of time of death so that they can call TN donor services.</p>
<p>THEN:</p>
<p>Physicians at time of pronouncement will ask family regarding the
request for autopsy. VA pays for the autopsy and this is provided as a
benefit to the family if desired.  Family can decline this benefit. 
Physician should document if the family agreed to or declined the
autopsy benefit.</p>
<p>THEN:</p>
<p>Death note is documented in CPRS by physician pronouncing death using
the template provided to house staff.  Death note documents the time of
death, cause of death, family notified, and autopsy request with family
response to the autopsy request.</p>
<p>THEN:</p>
<p>Physician pronouncing death will complete additional death report
paperwork which includes the cause of death.  This death paperwork is
provided to the physician by the charge nurse or clerk and is available
at the nursing station.  Once completed, this paperwork is returned to
the nursing staff.</p>
<p>THEN:</p>
<p>Nursing staff notifies TN donor services.  Nursing staff contacts the VA
decedent affairs clerk during business hours.  Nursing staff may contact
the AOD instead of the decedent affairs clerk if the death occurs after
hours or on weekends.  The decedent affairs clerk or AOD provides
information to family regarding veteran death and funeral benefits.</p>
<p>THEN:</p>
<p>The body of the patient is removed from the room within 4 hours of death
and taken to the morgue to await transfer to the families’ choice of
funeral homes</p>
<p>Death</p>
<p>Process</p>
<p>in EPIC</p>
<ul>
<li>The key thing is to ensure that all components are completed in the
    “Discharge as Deceased” tab under the Transfer-Discharge screen</li>
<li>EACH AND EVERY
    component of this tab must be completed before Decedent Affairs will
    accept the body</li>
</ul>
<p>Required steps:</p>
<ul>
<li>Cardiopulmonary Death Charting
    
    Select “New Reading” and complete.</li>
<li>Cardiopulmonary Death
    
    Select “+Create Note”</li>
<li>Medical Examiner Criteria
    
    Select “+New Reading”; note that in general deaths that we expect
    and have an established medical cause generally do not need to go to
    the Medical Examiner (ME). If there is any concern for harm, foul
    play, drug overdose, etc, have a low threshold to contact the ME.
    The Vanderbilt Operator can assist with connecting you to the ME;
    alternatively, you can call 615-743-1800 during business hours (M-F
    8am – 4:30pm) or the after-hours pager at 800-216-0107.</li>
<li>Autopsy Criteria
    
    Select “+New Reading”</li>
<li>Preliminary Cause of Death and Date/Time of Death
    
    Select the ribbon at the top of this and enter a cause of death.
    Rather than list “Cardiopulmonary arrest” do try to be specific (eg
    Pulmonary Embolism, Myocardial Infarction, Metastatic Colon Cancer,
    etc) if you know the underlying cause of death.</li>
<li>Deceased’s Info – Report of Death. This will ask many questions.<ul>
<li>If you need to leave this and return later after collecting
    information, you can access your partially complete entries by
    clicking on the date/time text that appears under the ribbon.
    This is not intuitive because the numbers listing the date/time
    do not at all appear as though they act like a hyperlink (but
    they do).</li>
<li>Be specific; TDS will want you to have listed the name of the
    family you notified, the TDS Case Number (which the RN should
    have or can assist in collecting), and your attending
    physician’s name (to sign the death certificate; give their
    pager number in this subsection).</li>
</ul>
</li>
<li>Report of Death Note
    
    Select “+New Reading” and complete.</li>
<li>Complete Synopsis + Hospital Course and then at the very bottom
    under Summary of Death select “+Create Note.”</li>
<li>Once all of this paperwork is finished, be sure to touch base with
    the patient’s nurse, as s/he is often the contact for Decedent
    Affairs and can assist in making sure the body is moved
    expeditiously</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-medications-dying-patients"><h1 id="pain-and-palliative-pain-and-palliative-medications-dying-patients-medications-for-dying-patients">Medications for Dying Patients<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-medications-dying-patients-medications-for-dying-patients" title="Permanent link">&para;</a></h1>
<p>Medications for IMMINENTLY dying patients</p>
<p>General recommendations:</p>
<ul>
<li>At VUMC, there is a very helpful order set titled “Comfort Care
    Orders (Trauma, MICU, SICU, NEURO ICU, Palliative Care”</li>
<li>No order set at VA</li>
<li>Clean up orders: make sure to remove unnecessary medications,
    nursing text orders, etc.</li>
<li>Do make sure to order PRNs in anticipation of their need so that
    they become available to RN, particularly in the unit if you
    anticipate rapid progression of events following extubation, etc.</li>
</ul>
<p>Pain:</p>
<ul>
<li>Morphine 2mg IV or SQ q1h PRN</li>
<li>Hydromorphone 0.25 – 0.5mg IV or SQ q1h PRN</li>
<li>Write as PRN, as needed for pain &gt; 2/10 or for air hunger</li>
<li>Hydromorphone is preferable to morphine in patients with renal
    impairment</li>
<li>If ineffective after 1 hours, increase by 50-100%</li>
<li>If given every hour for 3-4 hours, consider an infusion (given PRN
    dose as hourly rate)</li>
<li>Fentanyl is not a great option in ICU unless it is a continuous
    drip. Bolus lasts only 15 mins</li>
</ul>
<p>Dyspnea/Tachypnea:</p>
<ul>
<li>Assess for volume overload, considering decrease or stopping IVFs or
    tube feeds</li>
<li>Opioids are the treatment of choice for dyspnea</li>
<li>Consider Benzodiazepines for air hunger not controlled by opiates</li>
<li>Supplemental oxygen for comfort (do not base on O2 sat)</li>
<li>Consider use of cool air and/or fan to the face/patient</li>
<li>Diuresis, bronchodilators, steroids, other mgmt as indicated if
    underlying cause identified</li>
</ul>
<p>Restlessness/Agitation:</p>
<ul>
<li>Assess for urinary retention, constipation, pain, other modifiable
    factors before initiating medical therapy</li>
<li>Haloperidol (Haldol) 0.5 – 1 mg PO, IV or SQ q4h PRN</li>
<li>Lorazepam (Ativan) 0.5 – 1 mg PO or IV q4h PRN (tablet can be made
    into slurry if patient is experiencing dysphagia)</li>
<li>CAUTION: Benzos can worsen delirium</li>
</ul>
<p>Nausea:</p>
<ul>
<li>Ondansetron (Zofran) 4mg IV q4h or 8mg q8h PRN</li>
<li>Promethazine (Phenergan) 25mg PO or PR q6h PRN; caution can be very
    sedating</li>
<li>Prochlorperazine (Compazine) 10mg PO or IV q4h PRN</li>
<li>Haloperidol (Haldol); see dosing above</li>
<li>If felt to be obstructive in etiology, try Dexamethasone 4mg IV or
    SQ q8-12h with Octreotide 100-400mcg IV or SQ q8h</li>
<li>If felt to be related to anxiety, try Lorazepam; see dosing above</li>
<li>Scopolamine is highly anti-cholinergic and takes time to be
    effective, so would NOT use in imminently dying patients</li>
</ul>
<p>Secretions:</p>
<ul>
<li>Position for comfort; side lying if possible to move sections</li>
<li>Remember: the patient is NOT bothered by their own secretions, and
    it is often the family and caregivers who are likely disturbed, so
    avoid deep suctioning</li>
<li>Glycopyrrolate (Robinol) 0.2 – 0.4 mg SQ or IV q6h PRN (can
    schedule; but use caution as it does cause confusion or other mental
    status changes like many anti-sialagogues)</li>
<li>Atropine 1% Ophthalmic Solution 2 drops SL 2-4h PRN</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-opiate-principles"><h1 id="pain-and-palliative-pain-and-palliative-opiate-principles-opiate-principles">Opiate Principles<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-opiate-principles-opiate-principles" title="Permanent link">&para;</a></h1>
<p>Opioids: General Principles &amp; Conversion – Brian Grieb</p>
<p>Oral Morphine Equivalent (OME) Conversion Table:</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug</td>
<td>PO</td>
<td>IV</td>
<td>APAP</td>
<td>IR</td>
<td>ER</td>
<td>Notes</td>
</tr>
<tr>
<td>Tramadol</td>
<td>0.1x</td>
<td>-</td>
<td>-</td>
<td>Tramadol</td>
<td>Ultram ER™</td>
<td>NSAID properties</td>
</tr>
<tr>
<td>Morphine</td>
<td>1x</td>
<td>3x</td>
<td>-</td>
<td>Morphine IR</td>
<td>MS-Contin™</td>
<td>Renally cleared</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>1x</td>
<td>NaN</td>
<td>Lortab</td>
<td>Hydrocodone</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>1.5x</td>
<td>-</td>
<td>Percocet</td>
<td>Roxicodone™</td>
<td>Oxycontin™</td>
<td>NaN</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>4x</td>
<td>20x</td>
<td>-</td>
<td>IV, Oral</td>
<td>-</td>
<td>Oral is $</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>300x</td>
<td>300x</td>
<td>-</td>
<td>IV’ Buccal, Nasal</td>
<td>Patch</td>
<td>Dosed in ug, not mg</td>
</tr>
</tbody>
</table>
<p>Abbreviations: ER, extended release; IR, immediate release; IV,
intravenous; PO, oral; APAP, Acetaminophen</p>
<p>Conversion:</p>
<ul>
<li>Transition between opiates is done using oral morphine equivalents
    (OMEs), in which each drugs’ potency is compared to oral morphine
    (see table).  For example, 1 mg of IV morphine is equal to 3 mg of
    oral morphine.</li>
<li>When transitioning, doses are traditionally reduced by &frac14; to &#8531;
    due to cross tolerance. (Oxycodone 5 is a pretty standard dose,
    which converts to 7.5 mg of oral morphine, 2.5 mg of iv morphine,
    and 0.375 of iv hydromorphone.)</li>
</ul>
<p><img src="/sites/default/files/inline-images/Opiate_Conversion.jpg" data-entity-type="file" data-entity-uuid="595c75af-cf20-4122-824d-7cd00bea8472" alt="Opiate Conversions" /></p>
<p>Patient Controlled Analgesia (PCAs) aka Pain Pumps:</p>
<ul>
<li>Pumps
    can be programmed to deliver a continuous rate and/or a bolus dose.
    The basal rate is a continuous infusion dosed per hour that cannot
    be adjusted by the patient. The demand dose is a patient-directed
    bolus that is given at a prescribed frequency (whenever the pt
    presses the button).  Both the actual dose and frequency of bolus
    dose can be adjusted. The general rule of thumb is to calculate the
    total OME delivered through the demand when a pt is in steady state
    and convert 75% of this dose into the total continuous rate or basal
    infusion. Alternatively, if a pt is chronically on a long-acting
    opioid, this total amount of OME (sustained release) can be
    converted into a basal rate of opioid.  The demand dose is 25% of
    the hourly rate given every 15 minutes.</li>
<li>Remember that the basal rate will not get to steady state for at
    least 8 hrs; therefore, when you admit pts or are transitioning pts
    to a PCA, always initiate the PCA pump with a bolus (or loading)
    dose.</li>
</ul>
<p>How to Order PCA at VUMC</p>
<p>:</p>
<ul>
<li>Select Analgesic:<ul>
<li>Hydromorphone
    (most common): Order “Hydromorphone (DILAUDID) PCA”</li>
<li>Fentanyl
    (if on at home; not a good inpatient PCA): Order “Fentanyl PCA”</li>
<li>Morphine
    : Order “Morphine PCA”</li>
</ul>
</li>
<li>
<p>Select “[Analgesic] PCA syringe” and adjust the following to pt
    needs:</p>
<ul>
<li>PCA
    Dose (“Demand”): amount the pt gets when s/he presses the button</li>
<li>Lockout
    Interval: time between which “demand” doses will not be
    administered if s/he presses the button (i.e., the PCA “locks
    out”)</li>
</ul>
</li>
<li>
<ol>
<li>Optional: many palliative care providers may not include this to
        allow patients more liberty to control their pain, depending on
        the situation</li>
</ol>
</li>
<li>
<ul>
<li>Continuous
        Dose (“Basal”): amount the pt gets per hr in continuous infusion</li>
<li>Max
    Dose: maximum amount of analgesic (Basal + Demand) pt can get in
    24 hours</li>
</ul>
</li>
<li>
<p>Select “IV Carrier Fluid Options”&gt; Choose Fluid option</p>
</li>
<li>
<p>Select all “PCA Nursing Orders”</p>
</li>
</ul>
<p>How to Order PCA at VA:</p>
<ul>
<li>Under Orders, select “Pain/Sedation Infusions”</li>
<li>Under “PCAs,” select Analgesic of choice (Hydromorphone or Morphine)</li>
<li>Adjust the following:<ul>
<li>Load
    : amount the pt will receive on initial set up of PCA</li>
<li>Basal
    : amount the pt gets per hour in continuous infusion</li>
<li>Demand
    : amount the pt gets when s/he presses the button</li>
</ul>
</li>
</ul>
<p>Interrogating PCA (to determine amount of analgesia pt received):</p>
<ul>
<li>Look at IV pump display. If it does not display info about PCA, hit
    “Channel Select” on PCA</li>
<li>Select “Options” in bottom left of IV pump</li>
<li>Select “Patient History” on the left of the screen. This shows the
    administration history for a certain time period (e.g., 24h, 12h,
    4h, etc)</li>
<li>Hit “Zoom” on bottom of screen to change time period to 24 hours.
    Should show:<ul>
<li>Total
    Drug: total amount of drug received in last 24 hours</li>
<li>Total
    Demands: amount of times the pt has pushed the button for demand
    dose</li>
<li>Delivered
    : amount of times the pt actually received a demand dose</li>
<li>The
    difference between “Total Demands” and “Delivered” is the number
    of times the patient pushed the button without receiving a dose
    (due to pushing the button during the lockout interval).</li>
</ul>
</li>
<li>If you have questions about interrogating the PCA, ask the nurses!
    They are a great resource!</li>
</ul>
<p>Opioid Side effects</p>
<ul>
<li>Constipation: dose-dependent and will not develop tolerance. If pt
    has opioids, they need robust bowel regimen (miralax, senna) with
    goal of BM
    ≥
    every 3 days. For opioid-specific constipation can do SQ Relistor
    (methylnaltrexone) but this is expensive and can only be given in
    the PCU or oncology floors at VUMC. For patients with chronic
    opioid-induced constipation as an outpatient can trial oral agents
    like Movantik (naloxgeol). Can also consider PO naloxone but it does
    have small amount of bioavailability so watch for systemic reversal.</li>
<li>Nausea: occurs with opiate naïve pts. Consider starting an
    anti-emetic concurrently.  Most pts will develop tachyphylaxis with
    this over a day, so the antiemetic can be discontinued.</li>
<li>Urinary retention: Consider role of opioids in pts with new-onset or
    worsening urinary retention. Try to de-escalate opioid dosing if
    possible.</li>
<li>Overdose: In pts with apneic emergency, IV 0.4 mg Naloxone; however,
    low threshold for multiple doses until response. With respiratory
    depression in chronic opioid pts start with IV 0.02 mg q2-3min to
    avoid profound withdrawal. This helps prevent acute pain crisis. In
    pts taking long-acting opioids, may need to redose q30min and
    consider IV infusion for them. For pts prescribed opioids as
    outpatient, need naloxone 4 mg intransasal.</li>
<li>Pruritis: due to histamine release from mast cells; can be treated
    with antihistamines. The opioid can also be rotated. Some but not
    all pts will develop tachyphylaxis to this symptom.</li>
<li>Toxicity: hyperalgesia and neuroexcitatory effects (AMS, myoclonic
    jerking, seizures). Risk   factors for neuroexcitatory effects are
    rapid titration, dehydration or renal failure.</li>
</ul></section><section class="print-page" id="pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations"><h1 id="pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations-video-examples-for-navigating-difficult-conversations">Video Examples for Navigating Difficult Conversations<a class="headerlink" href="#pain-and-palliative-pain-and-palliative-video-examples-navigating-difficult-conversations-video-examples-for-navigating-difficult-conversations" title="Permanent link">&para;</a></h1>
<p>Video Examples for Navigating Difficult Conversations – Mohana Karlekar</p>
<p>Navigating difficult conversations with patients can be daunting
especially if you have never seen someone do one well before. 
Conversations should follow a logical and sequential approach. much like
any procedure we perform in medicine.  Like all procedures, practice
makes us better</p>
<p>Scan the QR Code To View Video Examples Or Search The Learning Exchange
“Navigating Difficult Conversations With Patients”</p>
<p><img src="/sites/default/files/inline-images/QR_Code.png" data-entity-type="file" data-entity-uuid="2c524db5-5c53-4ef3-b775-3b4829476db2" alt="QR Code" /></p>
<p>Good communicators have both <strong>formulated</strong> their message and
<strong>identified</strong> which communication strategy to use before they initiate
a conversation</p>
<p>Here are some suggestions for “Navigating Difficult Conversations”</p>
<ul>
<li>Step 1. Determine your message-keep it simple and short</li>
<li>Step 2. Identify what type of news you are communicating: breaking
    bad news, assessing understanding of information, communicating
    prognosis or navigating goals of care</li>
<li>Step 3. Pick the video that best suits your purpose</li>
</ul>
<p><img src="/sites/default/files/inline-images/SPIKES.jpg" data-entity-type="file" data-entity-uuid="abfa6510-5644-4853-86bb-786aabd5480f" alt="Spikes" /></p></section><h1 class='nav-section-title-end'>Ended: Pain and palliative</h1>
                        <h1 class='nav-section-title' id='section-physical-medicine-rehabilitation'>
                            Physical medicine rehabilitation <a class='headerlink' href='#section-physical-medicine-rehabilitation' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="physical-medicine-rehabilitation-main"><p>Rehabilitation Options – Evan Berlin, Scott Miller, Adam Epps, Lauren
Massey</p>
<p><strong>Physical medicine and rehabilitation (PM&amp;R)</strong> physicians focus on
restoring function and quality of life to those with physical
impairments or disabilities affecting the brain, spinal cord, nerves,
bones, joints, ligaments, muscles, and tendons</p>
<p><strong>Physiatrists</strong> specialize in determining appropriate rehab options for
hospitalized patients</p>
<p>Acute Inpatient Rehabilitation (IPR) or Inpatient Rehabilitation
facility (IRF):</p>
<ul>
<li>
<p>IPR involves a multidisciplinary team of physicians, physical
    therapists, occupational therapists, speech and language
    pathologists</p>
</li>
<li>
<p>Pts admitted to IPR must be able to tolerate a minimum of 3 hours of
    rehab per day for 5 days a week</p>
</li>
<li>
<p>Pts must have medical complexity warranting medical supervision by a
    physician</p>
</li>
<li>
<p>Physicians are required to evaluate admitted patients at least 3
    times a week</p>
</li>
<li>
<p>Average length of stay (LOS) in acute inpatient rehab is 10-12 days</p>
</li>
</ul>
<p>Skilled Nursing Facility (SNF):</p>
<ul>
<li>
<p>Patients admitted to SNF require skilled needs: Wound care, IV
    therapy, Catheter care, PT, OT, and/or SLP</p>
</li>
<li>
<p>There are no minimal requirements for daily therapy, but patients
    may receive up to 1.5 hours/day, depending on availability at the
    facility (in practice it is often less than this)</p>
</li>
<li>
<p>Physicians are required to evaluate admitted patients at least once
    every 30 days</p>
</li>
<li>
<p>Average length of stay is 26 days</p>
</li>
</ul>
<p>Long-Term Acute Care Hospital (LTACH):</p>
<ul>
<li>
<p>Pts admitted to LTACH require extended hospitalization and include
    pts who will be receiving prolonged mechanical ventilation</p>
</li>
<li>
<p>Pts will be recommended for transfer to an LTACH when no reasonable
    functional or medical improvement can be expected in an acute
    inpatient stay</p>
</li>
<li>
<p>LTACHs can be within a hospital or may be free-standing</p>
</li>
<li>
<p>Average length of stay must be greater than 25 days</p>
</li>
</ul>
<p>Assisted Living:</p>
<ul>
<li>
<p>Pts receive a combination of long-term housing, personal care
    services, and health care</p>
</li>
<li>
<p>Designed for individuals who need assistance with activities of
    daily living</p>
</li>
<li>
<p>Can be provided in freestanding communities, near or integrated with
    SNFs, hospitals or retirement communities</p>
</li>
</ul>
<p>Outpatient Services:</p>
<ul>
<li>
<p>Can be ordered at discharge with or without official PT/OT
    recommendations</p>
</li>
<li>
<p>Home health (HH): wide range of healthcare services provided in
    patients home ranging from wound care to IV antibiotics</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>HH PT/OT: pts can receive therapy at home when unable to attend
    outpatient PT/OT</p>
</li>
<li>
<p>HH nursing services: required for IV antibiotics or PICC line
    maintenance; consider for wound care, other services include
    medication adherence and reconciliation</p>
</li>
<li>
<p>HH non-skilled aide: outside the scope of acute hospitalization, but
    helps with ADLs</p>
</li>
</ul>
<!-- -->

<ul>
<li>Outpatient PT/OT: Consider for those who would benefit from therapy
    but do not meet the qualifications for other dispositions or would
    prefer outpatient therapy</li>
</ul>
<p>PM&amp;R Consultation – Evan Berlin, Scott Miller, Adam Epps, Lauren Massey</p>
<p>Reasons for Consultation/Referral to PM&amp;R:</p>
<ul>
<li>If PT/OT recommends Inpatient Rehabilitation (IPR) for post-acute
    disposition</li>
</ul>
<!-- -->

<ul>
<li>Recommended for pts with: Spinal Cord Injuries, Traumatic Brain
    Injuries, Poly-trauma, CVA, Amputation, Burns, Critical Illness
    /Acute Polyneuropathies or Myopathies, Prolonged Hospitalization</li>
</ul>
<!-- -->

<ul>
<li>Benefits of PM&amp;R Consults include:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Confirms and facilitates post- acute rehab disposition (SNF vs IPR
    refined opinion)</p>
</li>
<li>
<p>Provides comprehensive document for insurance and post-acute
    provider resource</p>
</li>
<li>
<p>Facilitates communication between PM&amp;R consultant, primary team,
    case management, PT/OT, and post-acute rehab provider</p>
</li>
<li>
<p>Provision of bedside MSK ultrasound-guided injections: joint
    injections (small and large), bursa injections, peripheral nerve
    injections (lateral femoral cutaneous, carpal tunnel, cubital
    tunnel) and diagnostic joint aspirations</p>
</li>
<li>
<p>Co-management for acute or chronic spasticity, neurogenic bowel and
    bladder</p>
</li>
<li>
<p>Can be helpful in identifying equipment required for discharge</p>
<ul>
<li>
<p>Gait impairments of uncertain etiology impacting post- acute
    care disposition safety</p>
</li>
<li>
<p>Autonomic dysreflexia</p>
</li>
<li>
<p>Paroxysmal sympathetic hyperactivity associated with brain
    injury</p>
</li>
<li>
<p>Contracture, pressure wound insight or prevention</p>
</li>
</ul>
</li>
</ul>
<p>Spasticity – Doug Bryant and Jake Dovgan</p>
<p>Background</p>
<ul>
<li>
<p>Spasticity is a velocity-dependent increase in resistance to passive
    stretch.</p>
</li>
<li>
<p>It differs from hypertonia in that hypertonia is resistance to
    passive stretch that is not velocity-dependent.</p>
</li>
<li>
<p>Spasticity is believed to result from disruption of descending
    inhibitory modulation of the alpha motor neurons by an upper motor
    lesion, producing hyperexcitability.</p>
</li>
<li>
<p>Grading (by the Modified Ashworth Scale)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>0=no increase in tone</p>
</li>
<li>
<p>1=slight increase in muscle tone, manifested by a catch and release
    or by minimal resistance at the end of ROM when affected part is
    moved in flexion or extension</p>
</li>
<li>
<p>1+=slight increase in muscle tone, manifested by a catch followed by
    minimal resistance through the remainder of ROM (less than half)</p>
</li>
<li>
<p>2=more marked increase in muscle tone through most of ROM, but
    affected part is easily moved.</p>
</li>
<li>
<p>3=considerable increases in muscle tone; passive movement difficult</p>
</li>
<li>
<p>4=affected part is rigid in flexion or extension</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Spasticity can have functional benefits, including improving
    standing and transfers. However, it can also cause weakness, poor
    dexterity, pain, and contractures.</p>
</li>
<li>
<p>If spasticity is having undesirable effects, first line of treatment
    is PT/OT and physical modalities such as stretching.</p>
</li>
<li>
<p>Oral Medications</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>Medication</th>
<th>Mechanism of Action</th>
<th>Side Effects/Important Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baclofen</td>
<td>GABA-B agonist</td>
<td>sedation, fatigue, nausea, centrally acting – risk of withdrawal</td>
</tr>
<tr>
<td>Tizanidine</td>
<td>Alpha-2 agonist</td>
<td>sedation, dizziness, xerostomia, weakness, centrally acting – risk of withdrawal</td>
</tr>
<tr>
<td>Diazepam/ Benzodiazepines</td>
<td>GABA-A agonist</td>
<td>sedation, confusion, hypotension, centrally acting – risk of withdrawal</td>
</tr>
<tr>
<td>Dantrolene</td>
<td>inhibits Ca release from sarcoplasmic reticulum</td>
<td>weakness, sedation, nausea, hepatotoxicity, acts directly on skeletal muscle</td>
</tr>
</tbody>
</table>
<ul>
<li>
<p>Intrathecal baclofen: Reserved for patients who have significant
    side effects with oral anti-spasticity medications or who have
    severe, persistent, and diffuse spasticity despite maximal doses.</p>
</li>
<li>
<p>Injections</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Botulinum toxin: Blocks the presynaptic release of acetylcholine
    from motor endplates of the lower motor neuron at the myoneural
    junction. Effect usually lasts 3-8months</p>
</li>
<li>
<p>Alcohol block: Phenol and ethanol are neurolytic agents that can be
    used to block nerves with motor function.</p>
</li>
</ul>
<!-- -->

<ul>
<li>Surgeries</li>
</ul>
<!-- -->

<ul>
<li>Selective dorsal rhizotomy, osteotomy, muscle tendon lengthening,
    release, or transfer</li>
</ul>
<p>***If a patient experiences worsening of spasticity, it is important
to consider other underlying conditions such as infections, pressure
ulcers, constipation, or bladder distention***</p>
<p>Traumatic Brain Injury (TBI) – Jake Dovgan and Doug Bryant</p>
<p>Background</p>
<ul>
<li>
<p>TBI is categorized as a disruption in brain function leading to
    decreased consciousness, memory deficits, neurological deficits, or
    intracranial lesion.</p>
</li>
<li>
<p>This disruption is a result of an external blow or force.</p>
</li>
<li>
<p>Most common causes of TBI are falls and MVC.</p>
</li>
<li>
<p>Falls are the most common cause of TBI in elderly population.</p>
</li>
</ul>
<p>Assessment</p>
<ul>
<li>
<p>Mechanism of injury</p>
</li>
<li>
<p>Initial GCS</p>
</li>
<li>
<p>Loss of consciousness and duration</p>
</li>
<li>
<p>Other injuries</p>
</li>
<li>
<p>Initial evaluation should include a non-contrasted head CT to rule
    out hemorrhage</p>
</li>
<li>
<p>Full neuro exam including but not limited to cranial nerves,
    strength, cognition (orientation), memory, reflexes, sensation,
    cerebellar testing, range of motion of joints, Babinski, and
    Hoffmann's</p>
</li>
</ul>
<p>Classification</p>
<table>
<thead>
<tr>
<th>Severity</th>
<th>GCS</th>
<th>Post-Traumatic Amnesia</th>
<th>Loss of Consciousness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>13-15</td>
<td>\&lt;1 day</td>
<td>\&lt;30 minutes</td>
</tr>
<tr>
<td>Moderate</td>
<td>9-12</td>
<td>1 day to 7 days</td>
<td>>30 minutes and \&lt;24 hours</td>
</tr>
<tr>
<td>Severe</td>
<td>3-8</td>
<td>>1 week</td>
<td>> 24 hours</td>
</tr>
</tbody>
</table>
<p>Evaluation and Management</p>
<ul>
<li>Secondary complications following TBI:</li>
</ul>
<!-- -->

<ul>
<li>In the acute setting, patients who have had a TBI are at risk for
    seizures, agitation, autonomic problems, bowel/bladder, wounds,
    vertigo, headaches, and cognitive impairment, venous thrombosis, and
    spasticity</li>
</ul>
<!-- -->

<ul>
<li>
<p>If concerned about TBI would consult PM&amp;R and Speech Therapy for
    assistance in management of complications and assessment of
    cognition.</p>
</li>
<li>
<p>If concerned for spasticity refer to “Spasticity section” for
    specific medication recommendations.</p>
</li>
</ul>
<p>Musculoskeletal (MSK) Injuries</p>
<p>Shoulder Pain – Joseph Nowatzke</p>
<p>Background</p>
<ul>
<li>
<p>Bones: Clavicle, Scapula (Acromion and Coracoid process) and
    Proximal Humerus  </p>
</li>
<li>
<p>Rotator Cuff: Supraspinatus, Infraspinatus, Teres minor,
    subscapularis</p>
</li>
<li>
<p>Neurovascular: anterior and posterior circumflex humeral arteries,
    branching off axillary artery; Innervated by axillary,
    suprascapular, subscapular nerve off brachial plexus  </p>
</li>
<li>
<p>Labrum is a cup-shaped rim of cartilage lining and reinforces the
    shoulder joint by surrounding the glenoid fossa, allowing extra
    support to the head of the humerus</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Brachial Plexus Palsies </p>
</li>
<li>
<p>Vascular Pathology (e.g. thoracic outlet syndrome, thrombus,
    atherosclerosis, vasculitis) </p>
</li>
</ul>
<!-- -->

<ul>
<li>Typical symptoms are tightness, heaviness, cramping, or weakness
    in arm </li>
</ul>
<!-- -->

<ul>
<li>Rotator Cuff Injuries:  </li>
</ul>
<!-- -->

<ul>
<li>
<p>Impingement Syndrome: supraspinatus is most susceptible</p>
</li>
<li>
<p>Tendinopathy: develops after repetitive motions; pain worsens with
    active movement</p>
</li>
<li>
<p>Tendon Tear: develop as a progression of tendinopathy; develops
    weakness</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Labral Tear &amp; SLAP (superior labral tear from anterior to
    posterior): develop in repetitive overhead motions (swimming,
    baseball, tennis); often described as a “catching” sensation </p>
</li>
<li>
<p>Adhesive capsulitis: “frozen shoulder” stiffened glenohumeral joint,
    loss of both active and passive RoM. Increased frequency in
    diabetics </p>
</li>
<li>
<p>AC (acromioclavicular) joint pain: joint often affected by OA, RA
    and common cause for anterior shoulder pain shoulder separations
    and osteoarthritis  </p>
</li>
<li>
<p>Glenohumeral OA: degeneration of articular cartilage and subchondral
    bone with narrowing of the glenohumeral joint. Presents in older
    adults with progressively worsening anterior shoulder pain and
    stiffness in both passive and active ROM</p>
</li>
<li>
<p>Biceps Tendinopathy: localized anterior shoulder pain, worsened with
    overhead lifting; when rupture develops, will often have a “lump”
    and acute worsening of symptoms </p>
</li>
<li>
<p>Posterior shoulder pain often related to cervical radiculopathy </p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam: </li>
</ul>
<!-- -->

<ul>
<li>
<p>Inspection: Symmetry, erythema, ecchymosis, swelling, deformity,
    muscle atrophy (deltoid, infraspinatus), scapular winging </p>
</li>
<li>
<p>Palpation: warmth, landmarks, tenderness: SC joint, clavicle, AC
    joint, acromion, spine of scapula, bicipital groove, biceps tendon,
    greater tuberosity of humerus, common myofascial trigger points
    (trapezius, levator scapulae, rhomboids, supraspinatus) </p>
</li>
<li>
<p>Passive ROM: performed by the examiner without patient assistance</p>
<ul>
<li>Helps to distinguish motion limitations caused by a structural
    constraint (adhesive capsulitis) vs. motion limitations caused
    by pain </li>
</ul>
</li>
<li>
<p>Active ROM: performed by the pt on their own. Loss of active motion
    usually indicates weakness due to either muscular (tears) or nerve
    injury </p>
</li>
<li>
<p>C-spine: evaluate the C-spine as the origin of pain that may be
    referred to the shoulder </p>
</li>
<li>
<p>Provocation tests: see Below</p>
</li>
</ul>
<!-- -->

<ul>
<li>Imaging:  </li>
</ul>
<!-- -->

<ul>
<li>
<p>Not as useful as a thorough physical exam, especially if
    non-traumatic pain </p>
</li>
<li>
<p>XR: AP (Internal Rotation, External Rotation), Lateral, Scapular and
    axillary views </p>
</li>
<li>
<p>CT: often reserved for traumatic fracture and artificial joint
    assessment </p>
</li>
<li>
<p>MRI w/out contrast: used to evaluate soft tissues, tendons, muscle
    and bursae</p>
</li>
<li>
<p>Ultrasound: becoming more useful for initial evaluation of rotator
    cuff</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 15%" />
<col style="width: 21%" />
<col style="width: 35%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th>Test</th>
<th>Isolates</th>
<th>Action</th>
<th>Positive if</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Empty Can Test</td>
<td>Supraspinatus</td>
<td>Place arms at 80⁰ abduction, 30⁰ forward flexion and pronate hand
with thumbs down; exert downward force at elbows</td>
<td><p>Pain  tendinopathy</p>
<p>Weakness + pain  tear</p></td>
</tr>
<tr class="even">
<td>Neer sign</td>
<td>Subacromial impingement</td>
<td>Passively flex arm with hand pronated (similar to empty can)</td>
<td>If pain subacromial impingement</td>
</tr>
<tr class="odd">
<td>External Rotation</td>
<td>Infraspinatus, teres minor</td>
<td>Arms at side, flex 90⁰ elbow, exert medial force to
distal forearm</td>
<td>Weakness, pain</td>
</tr>
<tr class="even">
<td>Lag sign &amp; Lift-Off test</td>
<td>Subscapularis</td>
<td>Place dorsum of hand on lumbar area of back and actively and
passively move hand off of back</td>
<td>Pain or failure to perform indicates subscapularis pathology</td>
</tr>
<tr class="odd">
<td>Cross arm test</td>
<td>AC joint</td>
<td>Active abduction of arm across torso</td>
<td>Pain AC joint dysfunction</td>
</tr>
<tr class="even">
<td>Speed’s Test</td>
<td>Biceps Tendon</td>
<td>Have pt extend arm in full supination with the shoulder flexed. Ask
pt to elevate arm while applying downward force</td>
<td><p>Pain in the anterior shoulder</p>
<p> Biceps tendon pathology</p></td>
</tr>
</tbody>
</table>

<p>Management</p>
<ul>
<li>
<p>Fractures: require assessment by orthopedics for reduction and
    surgical intervention</p>
</li>
<li>
<p>Soft Tissue Injuries, Arthritis </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Conservative management: referral to PT for muscle strengthening,
    flexibility, and postural improvement.  </p>
</li>
<li>
<p>Consider short course of NSAIDs, 7-10 days (meloxicam, diclofenac)
    for pain relief</p>
</li>
<li>
<p>Injections can often be diagnostic and therapeutic – refer to ortho </p>
</li>
<li>
<p>Sports Medicine referral for surgical evaluation if pt fails
    conservative therapy</p>
</li>
</ul>
<p>Neck Pain – Samir Khan</p>
<p>Background</p>
<ul>
<li>
<p>Most common cause of neck pain in adults: degenerative changes of
    the cervical spine</p>
</li>
<li>
<p>Most atraumatic neck pain does not require imaging</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Cervical muscle strain:  pain + stiffness with movement 2/2 muscular
    injury</p>
</li>
<li>
<p>Degenerative disc disease/osteoarthritis: pain + stiffness with
    movement from derangement in disc architecture leads to inability to
    distribute pressure in the joint</p>
</li>
<li>
<p>Cervical radiculopathy: neuropathic pain, sensory abnormalities,
    and/or weakness in an upper extremity (often radiating to hand)</p>
</li>
<li>
<p>Cervical myelopathy: spinal cord compression causing neurologic
    dysfunction</p>
</li>
</ul>
<!-- -->

<ul>
<li>Earliest symptom is gait disturbance. Pain is uncommon</li>
</ul>
<!-- -->

<ul>
<li>
<p>Non-cervical conditions: shoulder pathology, migraine/headaches,
    occipital neuralgia, torticollis, thoracic outlet syndrome, angina
    pectoris/MI, bony metastases, vertebral artery or carotid artery
    dissection, fibromyalgia, meningitis, transverse myelitis </p>
</li>
<li>
<p>Posterior neck pain </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Axial only à MSK (sprain vs degenerative disc disease) </p>
</li>
<li>
<p>Axial + Extremity Pain  Radiculopathy </p>
</li>
</ul>
<!-- -->

<ul>
<li>Anterior neck pain </li>
</ul>
<!-- -->

<ul>
<li>
<p>Common sources: esophageal, thyroiditis, carotidynia, lymphadenitis,
    Ludwig’s angina</p>
</li>
<li>
<p>Red flags: recent trauma, lower extremity weakness, gait
    abnormality, bowel/bladder incontinence, fever, weight loss </p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Determine MSK (axial pain) vs Radiculopathy/Myelopathy vs
    Non-spinal </li>
</ul>
<table>
<colgroup>
<col style="width: 23%" />
<col style="width: 19%" />
<col style="width: 33%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="4"> Provocation Tests of the Neck</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr class="even">
<td>Spurling’s test </td>
<td>Cervical radiculopathy </td>
<td>Downward pressure applied to top of head with extended neck and
rotates to affected side </td>
<td><p>Reproducible pain beyond shoulder</p>
<p>Neck pain alone is not specific</p></td>
</tr>
<tr class="odd">
<td><p>Elvey's upper limb </p>
<p>tension test </p></td>
<td>Cervical radiculopathy </td>
<td>Head turn contralaterally, arm is abducted while the
elbow extended  </td>
<td>Reproduction of symptoms </td>
</tr>
<tr class="even">
<td>Hoffman sign </td>
<td>Corticospinal lesion (UMN) </td>
<td>Loosely hold middle finger and flick the fingernail downward,
allowing the middle finger to flick upward reflexively</td>
<td>There is flexion &amp; adduction of thumb/index finger on the same
hand</td>
</tr>
</tbody>
</table>

<ul>
<li>Imaging indications: Neuro deficits, Red flags, persistent
    pain (> 6 weeks) </li>
</ul>
<!-- -->

<ul>
<li>
<p>Cervical Plain films, 2-view (AP and lateral) </p>
</li>
<li>
<p>Cervical MRI: visualizes spinal cord, nerve roots, bone marrow,
    discs and soft tissues</p>
<ul>
<li>Usually w/o contrast; can consider contrast if malignancy or
    infection suspected</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>EMG/Nerve Conduction Studies: not routinely used for neck pain
    evaluation, but can be used to distinguish cervical radicular pain
    from peripheral causes of extremity dysesthesia</li>
</ul>
<p>Management</p>
<ul>
<li>Cervical strain, Cervical radiculopathy: PT</li>
</ul>
<!-- -->

<ul>
<li>
<p>5 d course of oral prednisone 60-80 mg, followed by 7-14 day taper</p>
</li>
<li>
<p>Anti-spasmodic prn: Flexeril or Robaxin</p>
</li>
<li>
<p>If not improving or progressive symptoms refer to Ortho Spine + PM&amp;R</p>
</li>
</ul>
<!-- -->

<ul>
<li>Cervical myelopathy requires urgent surgical evaluation  </li>
</ul>
<p>Acute Back Pain – Christian Roehmer</p>
<p>Background</p>
<ul>
<li>
<p>>90% of back pain is nonspecific and musculoskeletal in nature</p>
</li>
<li>
<p>Can’t Miss: Spinal cord compression, cauda equina, cancer, spinal
    abscess, discitis, or osteomyelitis</p>
</li>
<li>
<p>Extra-axial causes: Pancreatitis, nephrolithiasis, pyelonephritis,
    AAA, zoster</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Lumbar strain: diffuse pain in lumbar muscles, may radiate </p>
</li>
<li>
<p>Degenerative disk or facet process: localized lumbar pain, similar
    to lumbar strain </p>
</li>
<li>
<p>Inflammatory arthritis: morning stiffness, improves with movement,
    systemic symptoms </p>
</li>
<li>
<p>Osteoarthritis: pain with use, improves with rest </p>
</li>
<li>
<p>Herniated disk: radiating pain to legs, often below the knees </p>
</li>
<li>
<p>Compression fracture: older patients, trauma, spine tenderness on
    exam </p>
</li>
<li>
<p>Spinal stenosis: pain improves with flexion, shopping cart sign </p>
</li>
<li>
<p>Spondylolysis: pain with extension </p>
</li>
<li>
<p>Spondylolisthesis: pain with activity, improves with rest, can be
    seen with imaging </p>
</li>
<li>
<p>Scoliosis: abnormal spine curvature, seen on physical exam
    inspection </p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam: </li>
</ul>
<!-- -->

<ul>
<li>
<p>Inspection: Should include posture, Adam’s Forward Bend Test
    (screens for scoliosis), and limb length discrepancy à kyphosis,
    lordosis, or scoliosis </p>
</li>
<li>
<p>Palpation/Percussion: Sensitive for identifying spinal infection,
    metastases, or compression fractures</p>
<ul>
<li>Spinous processes, lumbar “step-offs,” paravertebral muscles and
    SI joint</li>
</ul>
</li>
<li>
<p>Range of Motion: Pain with extension and relieved by flexion
    suggests spinal stenosis  </p>
</li>
<li>
<p>Neurologic Examination:</p>
<ul>
<li>
<p>L2: hip flexion; L3: knee extension; L4: dorsiflexion; L5: great
    toe flexion </p>
</li>
<li>
<p>S1: plantarflexion </p>
</li>
</ul>
</li>
<li>
<p>Waddell’s Signs:  Raise suspicion of non-organic pain  </p>
<ul>
<li>
<p>Superficial tenderness, pain that improves with
    distraction (attention diverted)</p>
</li>
<li>
<p>Pain with sham maneuvers (simulation)</p>
</li>
<li>
<p>Overreaction (disproportionate psychomotor responses)</p>
</li>
<li>
<p>Non-physiologic neurologic deficits</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>ESR/CRP: Can be used if concern for infection or malignancy</li>
</ul>
<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 18%" />
<col style="width: 30%" />
<col style="width: 30%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="4">Provocation Tests of the Lower Back </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Test</strong></td>
<td><strong>Isolates</strong></td>
<td><strong>Action</strong></td>
<td><strong>Positive if</strong></td>
</tr>
<tr class="even">
<td>Straight Leg Raise </td>
<td>Lumbosacral nerve roots </td>
<td>Pt is supine, lift one leg (keep straight) while the other leg is
resting flat</td>
<td>Positive for radiculopathy if pt experiences radiating pain to the
leg being lifted </td>
</tr>
<tr class="odd">
<td>Slump Test </td>
<td>Lumbosacral nerve roots </td>
<td>Pt is sitting, have them slump forward w/chin touching chest. Then
passively extend knee and dorsiflex foot</td>
<td><p>Positive for radiculopathy </p>
<p>if any of the steps reproduces radicular pain <br />
 Use with straight leg raise  </p></td>
</tr>
<tr class="even">
<td>Gaenslen’s Test </td>
<td>Sacroiliac Joint </td>
<td>Pt supine, brings knee of leg of side not being tested to chest and
holds it; examiner extends straight leg being tested over edge
of bed </td>
<td>Reproduction of pain deep in upper buttocks </td>
</tr>
<tr class="odd">
<td>Patrick’s (Fabers) Test </td>
<td>Sacroiliac Joint </td>
<td>Pt supine, passively flex hip to 90º, maximally abduct and
externally rotate at hip </td>
<td>Reproduction of pain deep in upper buttocks </td>
</tr>
<tr class="even">
<td>Sacral Thrust </td>
<td>Sacroiliac Joint </td>
<td>Pt prone, apply anteriorly directed thrust over sacrum </td>
<td>Reproduction of pain deep in upper buttocks </td>
</tr>
<tr class="odd">
<td>Distraction </td>
<td>Sacroiliac Joint </td>
<td>Pt supine, apply pressure directed postero-laterally to both
anterior and superior iliac spine </td>
<td>Reproduction of pain deep in upper buttocks </td>
</tr>
<tr class="even">
<td>Compression </td>
<td>Sacroiliac Joint </td>
<td>Pt supine, apply pressure directed postero-laterally to both
anterior and superior iliac spine </td>
<td>Reproduction of pain deep in upper buttocks </td>
</tr>
</tbody>
</table>

<p>Imaging: </p>
<ul>
<li>AP and lateral plain films; Bilateral oblique films (evaluate for
    spondylolysis)</li>
</ul>
<!-- -->

<ul>
<li>Indications: risk of fracture, red flag symptoms, evaluating for
    ankylosing spondylitis, no improvement in pain after conservative
    therapy after 6-12 weeks</li>
</ul>
<!-- -->

<ul>
<li>Non-contrasted MRI (Preferred)</li>
</ul>
<!-- -->

<ul>
<li>Indications: Suspicion for spinal cord/cauda equina compression,
    severe neurological deficits, concern for infection, unexplained
    inflammatory marker elevation</li>
</ul>
<p>Management</p>
<ul>
<li>First line: conservative therapy for 4 to 6 weeks, avoid bedrest</li>
</ul>
<!-- -->

<ul>
<li>
<p>PT</p>
</li>
<li>
<p>NSAIDs: Ibuprofen 600 – 800 mg q 4-6 hr, Diclofenac (topical) 2 g
    TID-QID (7 days)</p>
</li>
<li>
<p>Heat, massage, acupuncture</p>
</li>
</ul>
<!-- -->

<ul>
<li>Adjuncts for pain:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Robaxin: 750 mg – 1.5 g 3-4 times daily for 2-3 days, then \&lt; 4.5
    g/day over 3-4 doses</p>
</li>
<li>
<p>Flexeril: 5 mg tid, or 5 once qhs with Tylenol or NSAID</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pts with neuro deficits or spinal cord compression warrant urgent
    surgical evaluation</p>
</li>
<li>
<p>Refer to Spine PT program at VUMC</p>
</li>
<li>
<p>Refractory or Severe Pain: Referral to orthopedics or PM&amp;R spine
    specialist</p>
</li>
</ul>
<p>Knee Pain – Samuel Lazaroff</p>
<p>Background</p>
<ul>
<li>Key features of the history include:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Location: have patient point to the area that hurts most</p>
</li>
<li>
<p>Weight bearing, systemic symptoms (e.g. fevers)</p>
</li>
<li>
<p>Trauma and mechanism of injury</p>
<ul>
<li>
<p>High-energy trauma: high risk of bony and/or ligamentous injury</p>
</li>
<li>
<p>Low-Energy Trauma and Atraumatic etiologies organized by
    location (see table)</p>
</li>
</ul>
</li>
<li>
<p>Presence/absence of effusion and swelling</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 35%" />
<col style="width: 46%" />
</colgroup>
<thead>
<tr class="header">
<th>Knee Location</th>
<th>Low-Energy Trauma</th>
<th>Atraumatic</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Anterior </td>
<td><p>Patellar subluxation or dislocation (instability) </p>
<p>Patellar fracture </p>
<p>Patellar tendon rupture </p>
<p>Quadriceps tendon rupture </p></td>
<td><p>Tendinopathy: patellar or quadricep</p>
<p>Hoffa’s fat pad syndrome (inflammation of post-patellar fat) </p>
<p>Bursitis  </p>
<p>OA </p></td>
</tr>
<tr class="even">
<td>Medial </td>
<td><p>MCL tear </p>
<p>Acute medial meniscus tear </p></td>
<td><p>Medial meniscus degenerative tear </p>
<p>Pes anserine bursitis </p>
<p>OA </p></td>
</tr>
<tr class="odd">
<td>Lateral </td>
<td><p>LCL tear </p>
<p>Acute lateral meniscus tear </p></td>
<td><p>IT band syndrome </p>
<p>Lateral meniscus degenerative tear </p>
<p>OA </p></td>
</tr>
<tr class="even">
<td>Posterior </td>
<td><p>PCL tear </p>
<p>Hyperextension </p></td>
<td><p>Baker’s cyst </p>
<p>Popliteal art. aneurysm/entrapment </p></td>
</tr>
<tr class="odd">
<td>Generalized </td>
<td><p>ACL tear </p>
<p>PCL tear </p>
<p>Intra-articular fracture </p></td>
<td><p>Patellofemoral pain syndrome </p>
<p>OA </p>
<p>Patellar stress fracture </p>
<p>Referred from hip or ankle </p></td>
</tr>
</tbody>
</table>

<p>Presentation</p>
<ul>
<li>Traumatic Effusion:</li>
</ul>
<!-- -->

<ul>
<li>DDx: ACL or PCL rupture, meniscus tear, patellar instability
    (dislocation of subluxation), bone bruise, fracture </li>
</ul>
<!-- -->

<ul>
<li>Atraumatic Effusion:  </li>
</ul>
<!-- -->

<ul>
<li>Activity related or pain w/activity: Osteoarthritis, Osteochondral
    injury</li>
</ul>
<!-- -->

<ul>
<li>
<p>Not activity-related: Consider autoimmune causes, crystalline
    arthropathy, Lyme disease, Septic arthropathy (including
    gonococcal) </p>
</li>
<li>
<p>Less common causes: primary bone tumor, viral infection
    (Parvo), hyperparathyroidism, hemochromatosis, syphilis, sarcoid,
    Whipple’s </p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam: </li>
</ul>
<!-- -->

<ul>
<li>
<p>Inspection, palpation, AROM, PROM, strength, check for effusion,
    neurovascular exam (incl. reflexes if applicable), provocation (of
    ligaments), gait</p>
</li>
<li>
<p>Examine the back, hip, and ankle as well</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Aspirate if effusion present</p>
</li>
<li>
<p>Ottawa Knee Rule = Imaging if 1 of following: </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>> 55 y/o </p>
</li>
<li>
<p>Isolated tenderness of patella </p>
</li>
<li>
<p>Tenderness of fibular head </p>
</li>
<li>
<p>Unable to flex 90° º</p>
</li>
<li>
<p>Unable to ambulate 4 steps at time of injury and at time
    of evaluation </p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 16%" />
<col style="width: 38%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="4">Provocation Tests of the Knee </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Test</strong></td>
<td><strong>Isolates</strong></td>
<td><strong>Action</strong></td>
<td><strong>Positive if</strong></td>
</tr>
<tr class="even">
<td>Anterior Drawer</td>
<td>ACL </td>
<td>Hip flexed and knee in 90° of flexion, pull anteriorly
on tibia </td>
<td>Tibia translates forward </td>
</tr>
<tr class="odd">
<td>Pivot Shift</td>
<td>ACL </td>
<td>With knee extended, internally rotate the foot and apply
valgus force </td>
<td><p>Translation of femur</p>
<p>or tibia </p></td>
</tr>
<tr class="even">
<td>Lachman </td>
<td>ACL </td>
<td>With knee flexed 20°, hold thigh down with one hand while pulling
anteriorly on tibia with your other hand (with thumb on tibial joint
line) </td>
<td>Soft end point of tibial translation </td>
</tr>
<tr class="odd">
<td>Posterior drawer </td>
<td>PCL </td>
<td>With hip flexed and knee in 90° of flexion, push posteriorly
on tibia </td>
<td>Tibia translates backwards </td>
</tr>
<tr class="even">
<td>Joint line tenderness  </td>
<td>Meniscus </td>
<td>Palpate </td>
<td>Reproduces pain at site </td>
</tr>
<tr class="odd">
<td>McMurray</td>
<td>Meniscus </td>
<td><p>With hip &amp; knee flexed, apply: </p>
<p>Medial: valgus force and internal rotate foot </p>
<p>Lateral: varus force and externally rotate foot </p></td>
<td>Click, pop, or reproduces pain </td>
</tr>
<tr class="even">
<td>Noble Compression </td>
<td>IT band </td>
<td>Patient lies on unaffected side, flex knee while pressure applied to
distal IT band (lateral epicondyle) </td>
<td>Click, pop, or reproduces pain </td>
</tr>
<tr class="odd">
<td>Patellar compression </td>
<td>Patello-femoral pain </td>
<td>With knee extended and quads relaxed, apply direct pressure to
anterior patella as patient tightens quads </td>
<td>Reproduces pain </td>
</tr>
<tr class="even">
<td>Patellar apprehension</td>
<td>Patello-femoral pain </td>
<td>With knee flexed to 30°, displace patella laterally </td>
<td>Patient grimaces or tries to straighten leg </td>
</tr>
</tbody>
</table>

<p>Imaging</p>
<ul>
<li>
<p>X-ray: b/l AP, unilateral, lateral, b/l sunrise view</p>
</li>
<li>
<p>Obtain X-rays in standing position (or joint space narrowing may not
    be apparent) </p>
</li>
<li>
<p>MSK U/S: allows for dynamic imaging and is ≈100% sensitive
    for effusion </p>
</li>
<li>
<p>Also visualizes ligaments, muscles/tendons, joint space,
    and vasculature </p>
</li>
<li>
<p>MRI:  indicated after failure of conservative management or when
    considering surgical repair </p>
</li>
</ul>
<p>Treatment: </p>
<ul>
<li>
<p>RICE (rest, ice, compression, elevation) for acute injuries </p>
</li>
<li>
<p>Bracing </p>
</li>
<li>
<p>NSAIDs: see prior section for anti-inflammatory dosing</p>
</li>
<li>
<p>PT for 4-6 weeks for ligamentous, muscular, or meniscal injury  </p>
</li>
<li>
<p>Antibiotics may be appropriate for bursitis if infection
    is suspected </p>
</li>
<li>
<p>Referral to orthopedics/sports medicine if no improvement after
    conservative therapy </p>
</li>
</ul>
<!-- -->

<ul>
<li>Surgery reserved for young, athletic people with ligamentous injury </li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain-back-pain">Back Pain<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-back-pain-back-pain" title="Permanent link">&para;</a></h1>
<p>Acute Back Pain – Christian Roehmer</p>
<p>Background</p>
<ul>
<li>Lifetime risk ~ 70% of Americans</li>
<li>RF: age, obesity, smoking, socioeconomic status, and psychological
    factors</li>
<li>>90% of back pain is nonspecific and musculoskeletal in nature</li>
<li>Can’t Miss: Spinal cord compression, cauda equina, cancer, spinal
    abscess, or osteomyelitis</li>
<li>Extra-axial causes: Pancreatitis, nephrolithiasis, pyelonephritis,
    AAA, zoster</li>
</ul>
<p>Presentation</p>
<ul>
<li>Lumbar strain: diffuse pain in lumbar muscles, may radiate</li>
<li>Degenerative disk or facet process: localized lumbar pain, similar
    to lumbar strain</li>
<li>Inflammatory arthritis: morning stiffness, improves with movement,
    systemic symptoms</li>
<li>Osteoarthritis: pain with use, improves with rest</li>
<li>Herniated disk: radiating pain to legs, often below the knees</li>
<li>Compression fracture: older patients, trauma, spine tenderness on
    exam</li>
<li>Spinal stenosis: pain improves with flexion, shopping cart sign</li>
<li>Spondylolysis: pain with extension</li>
<li>Spondylolisthesis: pain with activity, improves with rest, can be
    seen with imaging</li>
<li>Scoliosis: abnormal spine curvature, seen on physical exam
    inspection</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam:<ul>
<li>Inspection: Should include posture, Adam’s Forward Bend Test
    (screens for scoliosis), and limb length discrepancy
    
    kyphosis, lordosis, or scoliosis</li>
<li>Palpation/Percussion: Sensitive for identifying spinal
    infection, metastases, or compression fractures<ul>
<li>Spinous processes, lumbar “step-offs,” paravertebral muscles
    and SI joint</li>
</ul>
</li>
<li>Range of Motion: Pain with extension and relieved by flexion
    suggests spinal stenosis</li>
<li>Neurologic Examination:<ul>
<li>L2: hip flexion; L3: knee extension; L4: dorsiflexion; L5:
    great toe flexion</li>
<li>S1: plantarflexion</li>
</ul>
</li>
<li>Waddell’s Signs:  Raise suspicion of <strong>non-organic pain</strong><ul>
<li>Superficial tenderness, pain that improves with
    distraction (attention diverted)</li>
<li>Pain with sham maneuvers (simulation)</li>
<li>Overreaction (disproportionate psychomotor responses)</li>
<li>Non-physiologic neurologic deficits</li>
</ul>
</li>
</ul>
</li>
<li>ESR/CRP: Can be used if concern for infection or malignancy</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provocation Tests of the Lower Back</td>
<td>Provocation Tests of the Lower Back</td>
<td>Provocation Tests of the Lower Back</td>
<td>Provocation Tests of the Lower Back</td>
</tr>
<tr>
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr>
<td>Straight Leg Raise</td>
<td>Lumbosacral nerve roots</td>
<td>Pt is supine, lift one leg (keep straight) while the other leg is resting flat</td>
<td>Positive for radiculopathy if pt experiences radiating pain to the leg being lifted</td>
</tr>
<tr>
<td>Slump Test</td>
<td>Lumbosacral nerve roots</td>
<td>Pt is sitting, have them slump forward w/chin touching chest. Then passively extend knee and dorsiflex foot</td>
<td>Positive for radiculopathy if any of the steps reproduces radicular pain Use with straight leg raise</td>
</tr>
<tr>
<td>Gaenslen’s Test</td>
<td>Sacroiliac Joint</td>
<td>Pt supine, brings knee of leg of side not being tested to chest and holds it; examiner extends straight leg being tested over edge of bed</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
<tr>
<td>Patrick’s (Fabers) Test</td>
<td>Sacroiliac Joint</td>
<td>Pt supine, passively flex hip to 90º, maximally abduct and externally rotate at hip</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
<tr>
<td>Sacral Thrust</td>
<td>Sacroiliac Joint</td>
<td>Pt prone, apply anteriorly directed thrust over sacrum</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
<tr>
<td>Distraction</td>
<td>Sacroiliac Joint</td>
<td>Pt supine, apply pressure directed postero-laterally to both anterior and superior iliac spine</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
<tr>
<td>Compression</td>
<td>Sacroiliac Joint</td>
<td>Pt supine, apply pressure directed postero-laterally to both anterior and superior iliac spine</td>
<td>Reproduction of pain deep in upper buttocks</td>
</tr>
</tbody>
</table>
<ul>
<li>Imaging:<ul>
<li>AP and lateral plain films; Bilateral oblique films (evaluate
    for spondylolysis)<ul>
<li>Indications: Pts at risk of fracture, Red flag symptoms,
    Evaluate for ankylosing spondylitis, No improvement in pain
    after conservative therapy after 6-12 weeks</li>
</ul>
</li>
<li>Non-contrasted MRI (Preferred)<ul>
<li>Indications: Suspicion for spinal cord/cauda equina
    compression, Severe neurological deficits, concern for
    infection, Unexplained inflammatory marker
    ↑</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>First line: conservative therapy for 4 to 6 weeks, <strong>avoid</strong> bedrest<ul>
<li>Physical therapy</li>
<li>NSAIDs: Ibuprofen 600 – 800 mg q 4-6 hr, Diclofenac (topical) 2
    g TID-QID (7 days)</li>
<li>Heat, massage <u>+</u> acupuncture</li>
</ul>
</li>
<li>Adjuncts for pain:<ul>
<li>Robaxin: 750 mg – 1.5 g 3-4 times daily for 2-3 days, then
    <u>\&lt;</u> 4.5 g/day over 3-4 doses</li>
<li>Flexeril: 5 mg tid, or 5 once qhs with Tylenol or NSAID</li>
</ul>
</li>
<li>Pts with neuro deficits or spinal cord compression warrant urgent
    surgical evaluation</li>
<li>Refer to Spine PT program at VUMC</li>
<li>Refractory or Severe Pain: Referral to orthopedics or PM&amp;R spine
    specialist</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain-knee-pain">Knee Pain<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-knee-pain-knee-pain" title="Permanent link">&para;</a></h1>
<p>Knee Pain – Samuel Lazaroff</p>
<p>Background</p>
<ul>
<li>Key features of the history include location: have patient point to
    the area that hurts most</li>
<li>Septic arthritis can also present indolently, with well-appearing,
    afebrile, patients</li>
<li>History of trauma, swelling, systemic symptoms, weight-bearing</li>
<li>Consider mechanism of injury
    à
    presence/absence of effusion
    à
    location<ul>
<li>High-energy trauma:  high risk of bony and/or ligamentous injury</li>
<li>Low-Energy Trauma and Atraumatic etiologies organized by
    location</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knee Location</td>
<td>Low-Energy Trauma</td>
<td>Atraumatic</td>
</tr>
<tr>
<td>Anterior</td>
<td>Patellar subluxation or dislocation (instability) Patellar fracture Patellar tendon rupture Quadriceps tendon rupture</td>
<td>Tendinopathy: patellar or quadricep Hoffa’s fat pad syndrome (inflammation of post-patellar fat) Bursitis OA</td>
</tr>
<tr>
<td>Medial</td>
<td>MCL tear Acute medial meniscus tear</td>
<td>Medial meniscus degenerative tear Pes anserine bursitis OA</td>
</tr>
<tr>
<td>Lateral</td>
<td>LCL tear Acute lateral meniscus tear</td>
<td>IT band syndrome Lateral meniscus degenerative tear OA</td>
</tr>
<tr>
<td>Posterior</td>
<td>PCL tear Hyperextension</td>
<td>Baker’s cyst Popliteal art. aneurysm/entrapment</td>
</tr>
<tr>
<td>Generalized</td>
<td>ACL tear PCL tear Intra-articular fracture</td>
<td>Patellofemoral pain syndrome OA Patellar stress fracture Referred from hip or ankle</td>
</tr>
</tbody>
</table>
<p>Presentation</p>
<ul>
<li>Traumatic Effusion:<ul>
<li>Differential is ACL or PCL rupture, meniscus tear, patellar
    instability (dislocation of subluxation), bone bruise, fracture</li>
</ul>
</li>
<li>Atraumatic Effusion:<ul>
<li>Activity related or pain w/activity: Osteoarthritis,
    Osteochondral injury</li>
</ul>
</li>
<li>Not activity-related: Consider autoimmune causes, crystalline
    arthropathy, Lyme disease, Septic arthropathy (including gonococcal)</li>
<li>Less common causes: primary bone tumor, viral infection
    (Parvo), hyperparathyroidism, hemochromatosis, syphilis, sarcoid,
    Whipple’s</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam:<ul>
<li>Inspection, palpation, AROM, PROM, strength, check for effusion,
    neurovascular exam (incl. reflexes if applicable), provocation
    (of ligaments), gait</li>
<li>Examine the back, hip, and ankle as well</li>
</ul>
</li>
<li>Aspirate if effusion present</li>
<li>Ottawa Knee Rule = Imaging if 1 of following:<ul>
<li>>
    55 y/o</li>
<li>Isolated tenderness of patella</li>
<li>Tenderness of fibular head</li>
<li>Unable to flex 90° º</li>
<li>Unable to ambulate 4 steps at time of injury and at time
    of evaluation</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provocation Tests of the Knee</td>
<td>Provocation Tests of the Knee</td>
<td>Provocation Tests of the Knee</td>
<td>Provocation Tests of the Knee</td>
</tr>
<tr>
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr>
<td>Anterior Drawer</td>
<td>ACL</td>
<td>Hip flexed and knee in 90° of flexion, pull anteriorly on tibia</td>
<td>Tibia translates forward</td>
</tr>
<tr>
<td>Pivot Shift</td>
<td>ACL</td>
<td>With knee extended, internally rotate the foot and apply valgus force</td>
<td>Translation of femur or tibia</td>
</tr>
<tr>
<td>Lachman</td>
<td>ACL</td>
<td>With knee flexed 20°, hold thigh down with one hand while pulling anteriorly on tibia with your other hand (with thumb on tibial joint line)</td>
<td>Soft end point of tibial translation</td>
</tr>
<tr>
<td>Posterior drawer</td>
<td>PCL</td>
<td>With hip flexed and knee in 90° of flexion, push posteriorly on tibia</td>
<td>Tibia translates backwards</td>
</tr>
<tr>
<td>Joint line tenderness</td>
<td>Meniscus</td>
<td>Palpate</td>
<td>Reproduces pain at site</td>
</tr>
<tr>
<td>McMurray</td>
<td>Meniscus</td>
<td>With hip &amp; knee flexed, apply: Medial: valgus force and internal rotate foot Lateral: varus force and externally rotate foot</td>
<td>Click, pop, or reproduces pain</td>
</tr>
<tr>
<td>Noble Compression</td>
<td>IT band</td>
<td>Patient lies on unaffected side, flex knee while pressure applied to distal IT band (lateral epicondyle)</td>
<td>Click, pop, or reproduces pain</td>
</tr>
<tr>
<td>Patellar compression</td>
<td>Patello-femoral pain</td>
<td>With knee extended and quads relaxed, apply direct pressure to anterior patella as patient tightens quads</td>
<td>Reproduces pain</td>
</tr>
<tr>
<td>Patellar apprehension</td>
<td>Patello-femoral pain</td>
<td>With knee flexed to 30°, displace patella laterally</td>
<td>Patient grimaces or tries to straighten leg</td>
</tr>
</tbody>
</table>
<p>Imaging</p>
<ul>
<li>X-ray: b/l AP, unilateral, lateral, b/l sunrise view</li>
<li>Obtain X-rays in standing position (or joint space narrowing may not
    be apparent)</li>
<li>MSK U/S: allows for dynamic imaging and is ≈100% sensitive
    for effusion</li>
<li>Also visualizes ligaments, muscles/tendons, joint space,
    and vasculature</li>
<li>MRI:  indicated after failure of conservative management or when
    considering surgical repair</li>
</ul>
<p>Treatment:</p>
<ul>
<li>RICE (rest, ice, compression, elevation) for acute injuries</li>
<li>Bracing</li>
<li>NSAIDs: see prior section for anti-inflammatory dosing</li>
<li>Physical therapy for 4-6 weeks for ligamentous, muscular, or
    meniscal injury</li>
<li>Antibiotics may be appropriate for bursitis if infection
    is suspected</li>
<li>Referral to orthopedics/sports medicine if no improvement after
    conservative therapy<ul>
<li>Surgery reserved for young, athletic people with
    ligamentous injury</li>
</ul>
</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain-neck-pain">Neck Pain<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-neck-pain-neck-pain" title="Permanent link">&para;</a></h1>
<p>Neck Pain – Samir Khan</p>
<p>Background</p>
<ul>
<li>Neck pain has a prevalence of 10 to 20 percent in the adult
    population</li>
<li>The most common cause of neck pain in adults: Degenerative changes
    of the cervical spine</li>
<li>Most atraumatic neck pain does not require imaging</li>
</ul>
<p>Presentation</p>
<ul>
<li>Cervical muscle strain:  pain <u>+</u> stiffness with movement 2/2
    muscular injury</li>
<li>Degenerative disc disease/osteoarthritis: pain <u>+</u> stiffness
    with movement from derangement in disc architecture leads to
    inability to distribute pressure in the joint</li>
<li>Cervical Radiculopathy: neuropathic pain, sensory abnormalities,
    and/or weakness in an upper extremity (often radiating to hand)</li>
<li>Cervical myelopathy: spinal cord compression causing neurologic
    dysfunction<ul>
<li>Earliest symptom is gait disturbance. Pain is uncommon</li>
</ul>
</li>
<li>Non-cervical conditions: shoulder pathology, migraine/headaches,
    occipital neuralgia, torticollis, thoracic outlet syndrome, angina
    pectoris/MI, bony metastases, vertebral artery or carotid artery
    dissection, fibromyalgia, meningitis, transverse myelitis</li>
<li>Posterior neck pain<ul>
<li>Axial only
    
    MSK (sprain vs degenerative disc disease)</li>
<li>Axial + Extremity Pain -&gt; Radiculopathy</li>
</ul>
</li>
<li>Anterior neck pain<ul>
<li>Common sources: esophageal, thyroiditis, carotidynia,
    lymphadenitis, Ludwig’s angina</li>
</ul>
</li>
<li>Red flags
    : recent trauma, lower extremity weakness, gait abnormality,
    bowel/bladder incontinence, fever, weight loss</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Determine MSK (axial pain) vs Radiculopathy/Myelopathy) vs
    Non-spinal</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provocation Tests of the Neck</td>
<td>Provocation Tests of the Neck</td>
<td>Provocation Tests of the Neck</td>
<td>Provocation Tests of the Neck</td>
</tr>
<tr>
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr>
<td>Spurling’s test</td>
<td>Cervical radiculopathy</td>
<td>Downward pressure applied to top of head with extended neck and rotates to affected side</td>
<td>Reproducible pain beyond shoulder Neck pain alone is not specific</td>
</tr>
<tr>
<td>Elvey's upper limb tension test</td>
<td>Cervical radiculopathy</td>
<td>Head turn contralaterally, arm is abducted while the elbow extended</td>
<td>Reproduction of symptoms</td>
</tr>
<tr>
<td>Hoffman sign</td>
<td>Corticospinal lesion (UMN)</td>
<td>Loosely hold middle finger and flick the fingernail downward, allowing the middle finger to flick upward reflexively</td>
<td>There is flexion &amp; adduction of thumb/index finger on the same hand</td>
</tr>
</tbody>
</table>
<ul>
<li>Imaging indications: Neuro deficits, Red flags, persistent
    pain (&gt; 6 weeks)</li>
<li>Cervical Plain films, 2-view (AP and lateral)</li>
<li>Cervical MRI: visualizes spinal cord, nerve roots, bone marrow,
    discs and soft tissues<ul>
<li>Usually <strong>w/o contrast</strong> ; can consider contrast if malignancy
    or infection suspected</li>
</ul>
</li>
<li>EMG/Nerve Conduction Studies: not routinely used for neck pain eval,
    but can be used to distinguish cervical radicular pain from
    peripheral causes of extremity dysesthesia</li>
</ul>
<p>Management</p>
<ul>
<li>Cervical strain, Cervical radiculopathy: Physical therapy<ul>
<li>5 d course of oral prednisone 60-80 mg, followed by 7-14 day
    taper</li>
<li>Anti-spasmodic prn: Flexeril or Robaxin</li>
<li>If not improving or progressive symptoms refer to Ortho Spine
    <u>+</u> PM&amp;R</li>
</ul>
</li>
<li>Cervical myelopathy urgent surgical evaluation</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation-pmr-consultation">PM&amp;R Consultation<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-pmr-consultation-pmr-consultation" title="Permanent link">&para;</a></h1>
<p>PM&amp;R Consultation – Evan Berlin, Scott Miller, Adam Epps, Lauren Massey</p>
<p>Reasons for Consultation/Referral to PM&amp;R:</p>
<ul>
<li>If PT/OT recommends Inpatient Rehabilitation (IPR) for post-acute
    disposition<ul>
<li>Recommended for pts with: SCI, TBI, Poly-trauma, CVA,
    Amputation, Burns, Critical Illness /Acute Polyneuropathies or
    Myopathies, Prolonged Hospitalization</li>
</ul>
</li>
<li>Benefits
    of PM&amp;R Consults include:<ul>
<li>Confirms
    and facilitates post- acute rehab disposition (SNF vs IPR
    refined opinion)</li>
<li>Provides
    comprehensive document for Insurance and Post-Acute provider
    resource</li>
<li>Facilitates
    communication avenue between PM&amp;R consultant, Primary Team, TMO</li>
<li>Case
    management, PT/OT, and Post- acute rehab provider</li>
<li>Provision
    of bedside MSK ultrasound-guided injections: joint injections
    (small and large), bursa injections, peripheral nerve injections
    (lateral femoral cutaneous, carpal tunnel, cubital tunnel) and
    diagnostic joint aspirations</li>
<li>Co-management for ac
    ute or chronic spasticity, neurogenic bowel and bladder,</li>
<li>Can
    be helpful in identifying equipment required for discharge<ul>
<li>
<ul>
<li>Gait impairments of uncertain etiology impacting post-
        acute care disposition safety</li>
<li>Autonomic dysreflexia</li>
<li>Paroxysmal sympathetic hyperactivity associated with
    brain injury</li>
<li>Contracture, pressure wound insight or prevention</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options-rehabilitation-options">Rehabilitation Options<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-rehabilitation-options-rehabilitation-options" title="Permanent link">&para;</a></h1>
<p>Rehabilitation Options – Evan Berlin, Scott Miller, Adam Epps, Lauren
Massey</p>
<ul>
<li>Physical
    medicine and rehabilitation (PM&amp;R) physicians focus on restoring
    function and quality of life to those with physical impairments or
    disabilities affecting the brain, spinal cord, nerves, bones,
    joints, ligaments, muscles and tendons</li>
<li>Physiatrists
    specialize in determining appropriate rehab options for hospitalized
    patients</li>
</ul>
<!-- -->

<ul>
<li>Acute Inpatient Rehabilitation (IPR) or Inpatient Rehabilitation
    facility (IRF):<ul>
<li>IPR involves a multidisciplinary team of physicians, physical
    therapists, occupational therapists, speech and language
    pathologists</li>
<li>Pts admitted to IPR must be able to tolerate a minimum of 3 hrs
    of rehab per day for 5 days a week</li>
<li>Pts must have medical complexity warranting medical supervision
    by a physician</li>
<li>Physicians are required to evaluate admitted patients at least 3
    times a week</li>
<li>Average length of stay (LOS) in acute inpatient rehab is 12 days</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Skilled Nursing Facility (SNF):<ul>
<li>Patients admitted to SNF require skilled needs: Wound care, IV
    therapy, Catheter care, PT, OT, and/or SLP</li>
<li>There are no minimal requirements for daily therapy, but
    patients may receive up to 1.5 hrs/day, depending on
    availability at the facility (in practice it is often less than
    this)</li>
<li>Physicians are required to evaluate admitted patients at least
    once every 30 days</li>
<li>Average length of stay is 26 days</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Long-Term Acute Care Hospital (LTACH):<ul>
<li>Pts admitted to LTACH require extended hospitalization and
    include pts who will be receiving prolonged mechanical
    ventilation</li>
<li>Pts will be recommended for transfer to an LTACH when no
    reasonable functional or medical improvement can be expected in
    an acute inpatient stay</li>
<li>LTACHs can be within a hospital or may be free-standing</li>
<li>Average length of stay must be greater than 25 days</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Assisted Living:<ul>
<li>Pts receive a combination of long-term housing, personal care
    services, and health care</li>
<li>Designed for individuals who need assistance with activities of
    daily living</li>
<li>Can be provided in freestanding communities, near or integrated
    with SNFs,  hospitals or retirement communities</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Outpatient Services:<ul>
<li>Can be ordered at discharge with or without official PT/OT
    recommendations</li>
<li>Home health (HH): wide range of healthcare services provided in
    patients home ranging from wound care to IV antibiotics</li>
<li>HH PT/OT: pts can receive therapy at home when unable to attend
    outpatient PT/OT</li>
<li>HH nursing services: required for IV antibiotics or PICC line
    maintenance; consider for wound care, other services include
    medication adherence and reconciliation</li>
<li>HH non-skilled aide: outside the scope of acute hospitalization,
    but helps with ADLs</li>
<li>Outpatient PT/OT: Consider for those who would benefit from
    therapy but do not meet the qualifications for other
    dispositions or would prefer outpatient therapy<ul>
<li>Pt would attend therapy sessions at an outpatient clinic</li>
<li>If a pt is receiving other HH services, they do not qualify
    for outpatient PT/OT</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain"><h1 id="physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain-shoulder-pain">Shoulder Pain<a class="headerlink" href="#physical-medicine-rehabilitation-physical-medicine-rehabilitation-shoulder-pain-shoulder-pain" title="Permanent link">&para;</a></h1>
<p>Shoulder Pain – Joseph Nowatzke</p>
<p>Background</p>
<ul>
<li>Bones:
    Clavicle, Scapula (Acromion and Coracoid process) and Proximal
    Humerus</li>
<li>Rotator Cuff: Supraspinatus, Infraspinatus, Teres minor,
    subscapularis</li>
<li>Neurovascular: anterior and posterior circumflex humeral arteries,
    branching off axillary artery; Innervated by axillary,
    suprascapular, subscapular nerve off
    brachial plexus</li>
<li>Labrum is a cup-shaped rim of cartilage lining and reinforces the
    shoulder joint by surrounding the glenoid fossa, allowing extra
    support to the head of the humerus</li>
</ul>
<p>Presentation</p>
<ul>
<li>Brachial Plexus Palsies</li>
<li>Vascular Pathology (e.g. thoracic outlet syndrome, thrombus,
    atherosclerosis, vasculitis)<ul>
<li>Typical symptoms are tightness, heaviness, cramping, or weakness
    in arm</li>
</ul>
</li>
<li>Rotator Cuff Injuries:<ul>
<li>Impingement Syndrome: supraspinatus is most susceptible</li>
<li>Tendinopathy: develops after repetitive motions; pain worsens
    with active movement</li>
<li>Tendon Tear: develop as a progression of tendinopathy; develops
    weakness</li>
</ul>
</li>
<li>Labral Tear &amp; SLAP (superior labral tear from anterior to
    posterior): develop in repetitive overhead motions (swimming,
    baseball, tennis); often described as a “catching” sensation</li>
<li>Adhesive capsulitis: “frozen shoulder” stiffened glenohumeral joint,
    loss of both active and passive RoM. Increased frequency in
    diabetics</li>
<li>AC (acromioclavicular) joint pain: joint often affected by OA, RA
    and common cause for anterior shoulder pain shoulder separations
    and osteoarthritis</li>
<li>Glenohumeral OA: degeneration of articular cartilage and subchondral
    bone with narrowing of the glenohumeral joint. Presents in older
    adults with progressively worsening anterior shoulder pain and
    stiffness in both passive and active ROM</li>
<li>Biceps Tendinopathy: localized anterior shoulder pain, worsened with
    overhead lifting; when rupture develops, will often have a “lump”
    and acute worsening of symptoms</li>
<li>Posterior shoulder pain often related to cervical radiculopathy</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Physical Exam:<ul>
<li>Inspection: Symmetry, erythema, ecchymosis, swelling, deformity,
    muscle atrophy (deltoid, infraspinatus), scapular winging</li>
<li>Palpation: warmth, landmarks, tenderness: SC joint, clavicle, AC
    joint, acromion, spine of scapula, bicipital groove, biceps
    tendon, greater tuberosity of humerus, common myofascial trigger
    points (trapezius, levator scapulae, rhomboids, supraspinatus)</li>
<li>Passive ROM: performed by the examiner without patient
    assistance<ul>
<li>Helps to distinguish motion limitations caused by a
    structural constraint (adhesive capsulitis) vs. motion
    limitations caused by pain</li>
</ul>
</li>
<li>Active ROM: performed by the pt on their own. Loss of active
    motion usually indicates weakness due to either muscular (tears)
    or nerve injury</li>
<li>C-spine: evaluate the C-spine as the origin of pain that may be
    referred to the shoulder</li>
<li>Provocation tests: see Below</li>
</ul>
</li>
<li>Imaging:<ul>
<li>Not as useful as a thorough physical exam, especially if
    non-traumatic pain</li>
<li>XR: AP (Internal Rotation, External Rotation), Lateral, Scapular
    and axillary views</li>
<li>CT: often reserved for traumatic fracture and artificial joint
    assessment</li>
<li>MRI w/out contrast: used to evaluate soft tissues, tendons,
    muscle and bursae</li>
<li>Ultrasound: becoming more useful for initial evaluation of
    rotator cuff</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test</td>
<td>Isolates</td>
<td>Action</td>
<td>Positive if</td>
</tr>
<tr>
<td>Empty Can Test</td>
<td>Supraspinatus</td>
<td>Place arms at 80⁰ abduction, 30⁰ forward flexion and pronate hand with thumbs down; exert downward force at elbows</td>
<td>Pain -&gt; tendinopathy Weakness + pain -&gt; tear</td>
</tr>
<tr>
<td>Neer sign</td>
<td>Subacromial impingement</td>
<td>Passively flex arm with hand pronated (similar to empty can)</td>
<td>If pain -&gt; subacromial impingement</td>
</tr>
<tr>
<td>External Rotation</td>
<td>Infraspinatus, teres minor</td>
<td>Arms at side, flex 90⁰ elbow, exert medial force to distal forearm</td>
<td>Weakness, pain</td>
</tr>
<tr>
<td>Lag sign &amp; Lift-Off test</td>
<td>Subscapularis</td>
<td>Place dorsum of hand on lumbar area of back and actively and passively move hand off of back</td>
<td>Pain or failure to perform indicates subscapularis pathology</td>
</tr>
<tr>
<td>Cross arm test</td>
<td>AC joint</td>
<td>Active abduction of arm across torso</td>
<td>Pain -&gt; AC joint dysfunction</td>
</tr>
<tr>
<td>Speed’s Test</td>
<td>Biceps Tendon</td>
<td>Have pt extend arm in full supination with the shoulder flexed. Ask pt to elevate arm while applying downward force</td>
<td>Pain in the anterior shoulder  Biceps tendon pathology</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>Fractures: require assessment by orthopedics for reduction and
    surgical intervention</li>
<li>Soft Tissue Injuries, Arthritis</li>
<li>Conservative management: referral to physical therapy for muscle
    strengthening, flexibility, and postural improvement.</li>
<li>Consider short course of NSAIDs, 7-10 days (meloxicam, diclofenac)
    for pain relief</li>
<li>Injections can often be diagnostic and therapeutic – refer to ortho</li>
<li>Sports Medicine referral for surgical evaluation if pt fails
    conservative therapy</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Physical medicine rehabilitation</h1>
                        <h1 class='nav-section-title' id='section-procedures'>
                            Procedures <a class='headerlink' href='#section-procedures' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="procedures-main"><h1 id="procedures-main-about">About<a class="headerlink" href="#procedures-main-about" title="Permanent link">&para;</a></h1>
<p>Adapted from Procedure Service Guidebook by Tyson Heller, MD</p>
<p>Procedure Service Video: <a href="https://www.youtube.com/watch?v=UfYmVX8llZk">https://www.youtube.com/watch?v=UfYmVX8llZk</a></p>
<p>Making an ultrasound note: <a href="https://www.youtube.com/watch?v=jIqHOyze2T4">https://www.youtube.com/watch?v=jIqHOyze2T4</a></p>
<h1 id="procedures-main-consent">Consent<a class="headerlink" href="#procedures-main-consent" title="Permanent link">&para;</a></h1>
<ul>
<li>
<p>When printing consent forms at VUMC, use MedEx (on the virtual
    machine/desktop)</p>
</li>
<li>
<p>Telephone consent requires second physician as witness</p>
</li>
<li>
<p>Use CSN (not the MRN) to locate the patient information for that
    specific admission or office visit – ensure patient current room
    number on MedEx screen</p>
</li>
<li>
<p>When consenting pts at NAVA, use the COW with pen pad and the IMed
    Consent forms</p>
</li>
<li>
<p>Informed consent video guide:
    <a href="https://www.youtube.com/watch?v=6yXOEkFqk2o">https://www.youtube.com/watch?v=6yXOEkFqk2o</a></p>
</li>
<li>
<p>Refer to individual procedure sections for procedure-specific risks
    to discuss in consent</p>
</li>
</ul>
<p>Anticoagulation and Bleeding Risk</p>
<table>
<thead>
<tr>
<th>Anticoagulant</th>
<th>How Long to Hold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heparin gtt</td>
<td>4-8 hours, ensure PTT wnl</td>
</tr>
<tr>
<td>LMWH</td>
<td>12-24 hours</td>
</tr>
<tr>
<td>Dabigatran (Pradaxa)</td>
<td>1-2 days</td>
</tr>
<tr>
<td>Apixaban (Eliquis)</td>
<td>1-2 day</td>
</tr>
<tr>
<td>Rivaroxaban (Xarelto)</td>
<td>1-2 days</td>
</tr>
<tr>
<td>Warfarin (Coumadin)</td>
<td>5-7 days</td>
</tr>
</tbody>
</table>
<p>Platelets, INR: refer to individual procedure sections for
procedure-specific guidelines</p>
<p>Anesthesia and Sedation</p>
<ul>
<li>
<p>May be used when pain or anxiety may impede performance and success</p>
</li>
<li>
<p>Relative Contraindications: old age, dementia, respiratory
    difficulty</p>
</li>
<li>
<p>Aim to use local anesthesia with l% to minimize procedural sedation</p>
</li>
<li>
<p>Creating wheal: clean surface w/ chlorhexidine or alcohol swab; with
    22-25G needle, advance needle nearly parallel to skin and aspirate
    to ensure no blood vessel involved, then inject anesthetic to create
    1-2 cm of raised skin; If deeper subcutaneous anesthesia is needed,
    advance needle perpendicular to skin, aspirate as advancing then
    inject the tract, inject anesthetic as needle is withdrawn</p>
</li>
<li>
<p>Local anesthesia can alter landmarks, always double check anatomy
    after injection</p>
</li>
<li>
<p>Minimal Sedation: 0.25mg-2mg Ativan IV or 1mg-2.5mg Midazolam IV</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Midazolam (Versed): faster on (2-5 min) and faster off (30-60 min)</p>
</li>
<li>
<p>Lorazepam (Ativan): onset 5-10 min; Duration 4-8 hours</p>
</li>
</ul>
<p>Paracentesis</p>
<p>Video Guide</p>
<ul>
<li>VUMC Procedure Service video: <a href="https://www.youtube.com/watch?v=pQSsb9705LE&amp;t=160s">https://www.youtube.com/watch?v=pQSsb9705LE&amp;t=160s</a></li>
<li>NEJM video: <a href="https://www.youtube.com/watch?v=KVpwXK7cvzQ">https://www.youtube.com/watch?v=KVpwXK7cvzQ</a></li>
</ul>
<p>Indications</p>
<ul>
<li>
<p>Diagnostic: Evaluation of new onset ascites or of known ascites with
    concern for SBP</p>
</li>
<li>
<p>Therapeutic: tense ascites, refractory to diuretics, causing pt
    discomfort</p>
</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>Significant bowel distension due to ileus or SBO, hemodynamic
    instability (due to large fluid shifts with LVP), DIC,
    infection/breakdown of skin overlying puncture site</li>
</ul>
<p>Consent</p>
<ul>
<li>Risks: abdominal wall hematoma (1%), hemoperitoneum, organ puncture
    / bowel perforation, infection, ascitic fluid leak</li>
</ul>
<p>Pre-procedural considerations</p>
<ul>
<li>
<p><strong>Bleeding risk guidelines:</strong> Plts > 20k, INR \&lt; 4 * (note that
    cirrhosis complicates INR interpretation)</p>
</li>
<li>
<p>If therapeutic, determine volume pt typically gets drained so you
    have enough bottles (tip: call service center to request bottles be
    sent to RN station if you can't find enough)</p>
</li>
<li>
<p>Labs (order before so nurse can print off labels): cell count
    w/diff, BF culture, BF &amp; serum albumin, total protein; cytology if
    c/f malignancy; BF/serum Hct if bloody</p>
</li>
<li>
<p>Measure skin/subQ depth with US to help choose sufficiently long
    needle for diagnostic paras</p>
</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>
<p>Ultrasound Probe: curvilinear</p>
</li>
<li>
<p>Identify safe pocket (>2 cm deep), with no nearby bowel or
    adhesions</p>
</li>
<li>
<p>Local anesthesia with lidocaine all the way to peritoneum, as this
    is most sensitive part</p>
</li>
<li>
<p>Kit: 6 Fr Safe-T-Centesis Kit; gather cx bottles, cx bottle syringe
    adaptor, specimen cup</p>
</li>
<li>
<p>If only diagnostic, use 18G needle with 20-50cc syringe rather than
    kit</p>
</li>
<li>
<p>If high bleeding risk, use long 18G needle &amp; attach to syringe
    instead of 6 Fr. Catheter</p>
</li>
<li>
<p>Avoid surgical scars out of concern for nearby adhesions and
    superficial veins</p>
</li>
<li>
<p>Attempt as lateral as possible to avoid inferior epigastric vessels</p>
</li>
<li>
<p>Roll patient to left or right side to promote pooling of fluid for
    easier/safer access</p>
</li>
<li>
<p>Inoculate culture bottles at bedside rather than sending fluid
    samples to lab for inoculation to increase yield 50% 80% (Note that
    VA does not allow bedside inoculation.)</p>
</li>
<li>
<p>If hernia present, have patient reduce it while draining fluid to
    prevent incarceration</p>
</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>
<p>Albumin (25%) for large volume (>5L fluid removal): give 8 g per
    liter removed, up to 50 g</p>
</li>
<li>
<p>Ascitic leak: Can try skin glue or place 1 figure-of-eight stitch
    with 4.0 vicryl</p>
</li>
<li>
<p>Bleeding complication: hold pressure with quick-clot and gauze for
    >5-10 mins if persistent bleeding at site; if profuse bleeding or
    concern for organ injury, STAT page EGS and/or IR</p>
</li>
</ul>
<p>Thoracentesis</p>
<p>NEJM Video Guide: <a href="https://www.youtube.com/watch?v=ivTyH09BcHg">https://www.youtube.com/watch?v=ivTyH09BcHg</a></p>
<p>Indications</p>
<ul>
<li>
<p>New pleural effusion that has no obvious explanation (not attributed
    to HF alone) or concern for pleural space infection</p>
</li>
<li>
<p>Any respiratory symptoms that would positively respond to large
    volume thoracentesis (>1L)</p>
</li>
</ul>
<p>Contraindications</p>
<ul>
<li>
<p>Skin infection at needle insertion site</p>
</li>
<li>
<p>Large-volume thoracentesis in hepatic hydrothorax (tends to
    reaccumulate). Suspected unexpandable lung</p>
</li>
</ul>
<p>Consent</p>
<ul>
<li>
<p>Common risks (> 5%): coughing, fainting, PTX</p>
</li>
<li>
<p>Rare risks (\&lt; 1%): hemothorax, re-expansion pulmonary edema,
    liver/spleen puncture</p>
</li>
</ul>
<p>Pre-procedural considerations</p>
<ul>
<li>
<p><strong>Bleeding risk guidelines:</strong> Plts > 50k, INR \&lt; 2 * (risk/benefit
    evaluation outside these)</p>
</li>
<li>
<p>If loculations present on US, high risk, or any question about
    indication, refer to Pulm</p>
</li>
<li>
<p>Labs (order before so nurse can print labels): cell count w/diff; BF
    culture, BF &amp; serum LDH, BF &amp; serum total protein; BF &amp; serum Hct if
    bloody; cytology if c/f malignancy; consider triglycerides if
    concerned for chylothorax</p>
</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>
<p>US Probe: Cardiac (or Linear) to identify safe pocket (>2 cm)
    between lung and diaphragm (ask Interventional Pulm or IR if sample
    is needed of a smaller pocket)</p>
</li>
<li>
<p>Kit: 6Fr Safe-T-Centesis kit</p>
</li>
<li>
<p>Upright position is typically preferred; lateral to mid-scap/mid-ax.
    If patient unable to sit upright, refer to procedure team vs
    pulmonology</p>
</li>
<li>
<p>Effusion size: if unable to tap above 9<sup>th</sup> rib, too small; CXR with
    costophrenic angle blunting should correlate to ~250-500mL</p>
</li>
<li>
<p>Insert needle superior to rib to avoid neurovascular bundle (bundles
    run below)</p>
</li>
<li>
<p>Stop if pt has any new/increased chest discomfort, aggressive
    unremitting cough, frank purulence or air on aspiration,
    lightheadedness, hypotension, or vagal response</p>
</li>
<li>
<p>Stop fluid removal after 1.5 L of chronic pleural effusion to reduce
    re-expansion pulmonary edema</p>
</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>
<p>If needing cytology, send at least 60 – 100cc</p>
</li>
<li>
<p>Bleeding complication: STAT page Thoracic Surgery</p>
</li>
<li>
<p>PTX: if pt stable &amp; asymptomatic, supplemental O2 and repeat CXR in
    4hrs; if unstable/symptomatic STAT page to Thoracic Surgery</p>
</li>
<li>
<p>Re-expansion pulmonary edema: persistent cough, frothy sputum.
    Diffuse GGO on side of thoracentesis. Supportive management (oxygen,
    monitor); most resolve in 24-48 hrs. If respiratory distress
    progresses, may need mechanical ventilation</p>
</li>
<li>
<p>Documentation: Effusion US characteristics (anechoic, layering
    debris, septations), reason for ending procedure (stopped early due
    to chest discomfort, complication vs tapped dry), presence of lung
    sliding, if more than scant residual effusion remains post-procedure</p>
</li>
<li>
<p>A routine chest radiograph after thoracentesis is no longer
    indicated for most asymptomatic, non-ventilated patients. Check lung
    slide with US in 2D and M-mode</p>
</li>
</ul>
<p>Central Line</p>
<p>NEJM video guide: <a href="https://www.youtube.com/watch?v=qeVdRCqy_mo">https://www.youtube.com/watch?v=qeVdRCqy_mo</a></p>
<p>Indications</p>
<ul>
<li>
<p>Extracorporeal therapies: HD, CRRT, Plasma (PLEX) or RBC exchange
    transfusion</p>
</li>
<li>
<p>Venous access for: vasopressors, chemotherapy, parenteral nutrition,
    hemodynamic monitoring (CVP, ScvO2) and cardiac parameters (via PA
    catheter), inadequate peripheral access</p>
</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>Increased bleeding risk, anatomic distortion at site selection,
    indwelling vascular hardware (pacemaker, HD access), vascular injury
    proximal to site, skin infection overlying selected site</li>
</ul>
<p>Consent</p>
<ul>
<li>
<p>Immediate complications: bleeding, malposition, arterial puncture,
    arrhythmia, pneumo- or hemothorax, air embolism, damage to
    surrounding structures (nerves, thoracic duct)</p>
</li>
<li>
<p>Delayed complications: infection, thromboembolism, myocardial
    perforation, venous stenosis</p>
</li>
</ul>
<p>Pre-procedural considerations</p>
<ul>
<li>
<p><strong>Bleeding risk guidelines:</strong> Plts > 20k, INR \&lt; 3</p>
</li>
<li>
<p>All patients need to have telemetry &amp; pulse oximetry monitoring</p>
</li>
<li>
<p>With every pt, consider LENGTH, LOCATION, LUMENS, and LINE TYPE!</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 46%" />
<col style="width: 53%" />
</colgroup>
<thead>
<tr class="header">
<th>Central Line</th>
<th><p>Recommended Length</p>
<p>(for patient height &gt;5’5”)</p></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Right IJ or Subclavian</td>
<td>15 cm</td>
</tr>
<tr class="even">
<td>Left IJ or Subclavian</td>
<td>20 cm</td>
</tr>
<tr class="odd">
<td>Femoral</td>
<td>25 cm</td>
</tr>
<tr class="even">
<td colspan="2"><em>*Confirm length of catheter in your kit before you
open/place the line!</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of Line</th>
<th>Uses</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triple Lumen (7Fr)</td>
<td>Central access for vasopressors, caustic infusions</td>
<td>Consider lumens needs; triple lumen is most versatile but can warrant dual lumen</td>
</tr>
<tr>
<td>MAC or Cordis*</td>
<td>‘Short and fat’ allowing rapid transfusion; MAC has two parts and can float a PA catheter through it</td>
<td>MAC is placed with dilator still in introducer</td>
</tr>
<tr>
<td>Dialysis Catheter (Trialysis, 12 Fr)</td>
<td>Dialysis line with two 12 Ga. Lumens for dialysis with a third 17 Ga. lumen for added access</td>
<td>Two serial dilations</td>
</tr>
<tr>
<td>*Can place triple lumen in MAC for additional ports; lose ability to rapidly transfuse</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>Site</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal Jugular Vein</td>
<td>Minimal risk of PTX; improve target with positioning and use of US; easily compressible if bleeding occurs</td>
<td>Risk of carotid puncture, difficult in obese pt; vein collapsibility with hypovolemia</td>
</tr>
<tr>
<td>Subclavian</td>
<td>More comfortable for pts; landmark driven approach; lowest risk infection</td>
<td>Increased risk of PTX, harder to control bleeding with pressure, technically more difficult</td>
</tr>
<tr>
<td>Femoral</td>
<td>Easiest to access, no risk of PTX, can be placed during CPR and intubation</td>
<td></td>
</tr>
</tbody>
</table>
<p>Procedural considerations</p>
<ul>
<li>
<p>Numb pt right after draping, then set up everything to allow time
    for lidocaine to work</p>
</li>
<li>
<p>Set supplies up in exactly the order of use to ensure all are
    present and functioning</p>
</li>
<li>
<p>Cap side ports with blue claves (not included in Trialysis kit)
    prior to flushing</p>
</li>
<li>
<p>For IJ access, place pt in slight Trendelenburg position to engorge
    vein</p>
</li>
<li>
<p>While advancing needle, ensure constant negative pressure with
    aspiration of plunger and visualization of needle tip with US</p>
</li>
<li>
<p>Designate someone to watch tele while threading guidewire to monitor
    for arrhythmias; limit guidewire insertion depth to no more than 16
    cm to reduce arrhythmia risk</p>
</li>
<li>
<p>Always ensure guidewire is secured while it is inside a vein</p>
</li>
<li>
<p>Always ensure target for venous cannulation is visualized and
    guidewire is placed correctly prior to dilation: 1) Compression of
    target vessel 2) Non-pulsatile dark blood return (unless on
    100%FiO2, may be brighter red) 3) US visualization or needle and
    wire 4) can use pressure tubing and angiocath to confirm CVP or
    obtain venous O2 sat</p>
</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>
<p>Every IJ or subclavian central line needs a confirmation CXR to
    confirm no PTX</p>
</li>
<li>
<p>Ideal placement of distal tip: in SVC just outside the right atrium,
    approximately near/superior to carina and right tracheobronchial
    angle</p>
</li>
<li>
<p>Troubleshooting Complications:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Arterial Access or puncture: immediately remove needle and hold
    pressure for 15 mins to prevent hematoma formation; if uncontrolled
    bleeding or artery was dilated, STAT vascular surgery consult</p>
</li>
<li>
<p>Bleeding: place direct pressure; subclavian access precludes ability
    to compress and confers highest bleeding risk; if uncontrolled, STAT
    vascular surgery consult</p>
</li>
<li>
<p>Pulmonary Complications: if free air aspirated into syringe,
    consider PTX vs poor seal of syringe &amp; needle. Close attention to
    pulmonary complication &amp; STAT CXR to assess PTX. If rapid
    deterioration, needle decompression and chest tube placement
    required</p>
</li>
<li>
<p>Venous Air Embolism: can occur if air introduced to system during
    placement, flushing, or if left open to the atmosphere. Effects are
    variable, but if suspected, place pt in left lateral decubitus
    position to trap air in right apex and place pt on 100% O2 to speed
    resorption</p>
</li>
<li>
<p>Arrhythmia: rationale for telemetry monitoring as guidewire can lead
    to atrial or ventricular arrhythmias; immediately withdraw wire to
    lesser depth; if arrythmia persists, abort procedure and treat
    patient and determine cause</p>
</li>
</ul>
<p>Lumbar Puncture</p>
<p>NEJM video Guide: <a href="https://www.youtube.com/watch?v=xnH9gECy_wU">https://www.youtube.com/watch?v=xnH9gECy_wU</a></p>
<p>Indications</p>
<ul>
<li>Diagnosis of suspected CNS infections, CNS malignancies,
    demyelinating diseases, IIH, NPH, autoimmune encephalitis, suspected
    SAH with negative imaging</li>
</ul>
<p>Absolute Contraindications</p>
<ul>
<li>Increased intracranial pressure with risk of herniation (i.e.
    space-occupying lesions, cerebral edema, obstructive hydrocephalus),
    infection or epidural abscess over puncture site, trauma to lumbar
    vertebrae</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>↑ intracranial pressure, thrombocytopenia, bleeding diatheses</li>
</ul>
<p>Consent</p>
<ul>
<li>
<p>Common risks: back pain (~66%), severe headache</p>
</li>
<li>
<p>Rare risks: spinal hematoma (\&lt;0.001%), weakness, radicular
    pain/numbness, bleeding, brain function problems, CNS infection,
    brain herniation</p>
</li>
</ul>
<p>Pre-procedural considerations:</p>
<ul>
<li>
<p><strong>Bleeding risk guidelines:</strong> Plts > 50k, INR \&lt; 1.6 (stricter
    guidelines d/t spinal hematoma risk)</p>
</li>
<li>
<p>CT head not generally needed prior to LP to rule out mass lesion;
    consider if presence of focal neurologic signs, papilledema, recent
    seizure, or immunocompromise</p>
</li>
<li>
<p>Consider sending to fluoro-guided if: attempts without imaging are
    unsuccessful, obese pts with no palpable anatomy, severe scoliosis,
    prior spine surgery, borderline low plts and multiple sticks might
    be needed, or pt requires heavy sedation</p>
</li>
<li>
<p>Anticoagulation: full dose LMWH must be off 24h, ppx LMWH off 12h,
    ppx heparin off 8h, hep gtt off 4-8hrs with repeat lab demonstrating
    normalized PT, P2Y12 inhibitors should be off 7 days to avoid
    bleeding risks, IR guidelines require Plavix to be off 5 days (ASA
    alone is OK)</p>
</li>
<li>
<p>Labs: cell count w/diff, BF culture, glucose, protein; freeze sample
    for future/additional labs (order in epic); if infectious or
    neurological labs are needed, consider consult first</p>
</li>
<li>
<p>Ensure lateral decubitus position for opening pressure with glass
    pressure manometer</p>
</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>
<p>US Probe: Linear (can use curvilinear in obese pts) in transverse
    axis to establish midline &amp; in sagittal axis to identify spinous
    processes</p>
</li>
<li>
<p>Anesthetic use: Lidocaine 1-2% (likely need more than what is
    provided in kit; consider empiric anesthetization of 2 spaces &plusmn;
    Pain-Ease spray</p>
</li>
<li>
<p>Increased number of attempts = increased success rates</p>
</li>
<li>
<p>Higher rate of success if stylet is removed before entering
    subarachnoid space to better observe flow of CSF once in the
    subarachnoid space. Stylet should be replaced prior to LP needle
    removal</p>
</li>
<li>
<p>Aspiration of CSF = increased risk of bleeding. Don’t aspirate!</p>
</li>
<li>
<p>Volume removal for studies: Basic only 2mL per tube in 1-4. Many
    studies ordered: 3mL per tube (*consider calling lab to confirm).
    Cytology desired: call lab to confirm amount needed (rule of thumb
    2/2/6/2mL); Tube 4 is sent for micro to reduce contamination.
    Therapeutic high volume: 30mL max</p>
</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>
<p>Post-LP headache (~10%): encourage pt to lay flat to reduce the
    intensity of symptoms (but does not prevent it); if prolonged,
    consider blood patch (c/s Anesthesia)</p>
</li>
<li>
<p>Neuro changes OR bleeding complications: STAT non-contrast MRI
    lumbar spine for epidural hematoma, q1 neuro-checks x4hrs then q2
    for 24-48hrs &amp; consult NSGY</p>
</li>
<li>
<p>Sample cannot be tubed; someone must walk fluid to the lab</p>
</li>
<li>
<p>Resuming anticoagulation: 1h UFH, 4h LMWH, 6-8h
    rivaroxaban/apixaban, 6h dabigatran/fondaparinux. Longer periods
    should be considered after traumatic tap, and post-procedure
    monitoring of neurological function is recommended for all pts</p>
</li>
</ul>
<p>Arterial Line</p>
<p>NEJM video Guide: <a href="https://www.youtube.com/watch?v=8hK04ai17-k&amp;list=PLaxEyg3FbHI8x5IQMWD0qtbXEzN5RdIKM&amp;index=3">https://www.youtube.com/watch?v=8hK04ai17-k&amp;list=PLaxEyg3FbHI8x5IQMWD0qtbXEzN5RdIKM&amp;index=3</a></p>
<p>Indications</p>
<ul>
<li>
<p>Continuous, accurate hemodynamic monitoring (pts requiring
    vasopressor titration, pts whose BP accuracy is in question)</p>
</li>
<li>
<p>Need for frequent ABGs</p>
</li>
</ul>
<p>Contraindications</p>
<ul>
<li>Abnormal Allen's test, thrombosis of selected site, distorted
    anatomy at selected site (known prior fistulas, grafts,
    malformations), severe PAD at selected site, Raynaud's of selected
    limb</li>
</ul>
<p>Consent</p>
<ul>
<li>Bruising, pain, damage to adjacent structures, infection, bleeding
    (possible extension to RP bleed with femoral placement), hematoma
    formation, vascular complications (dissection, AV fistula,
    pseudoaneurysm), thrombosis, rarely distal ischemia</li>
</ul>
<p>Pre-procedural considerations</p>
<ul>
<li>
<p><strong>Bleeding risk guidelines:</strong> no definitive guidelines (some suggest
    plts > 50K, INR \&lt; 3, PTT \&lt; 100)</p>
</li>
<li>
<p>Palpate of artery of interest to best understand anatomy and
    surrounding structures</p>
</li>
<li>
<p>Allen Test if placing radial artery access: goal to assess
    collateral ulnar blood flow to avoid ischemia. Compress both radial
    and ulnar artery 10-15 sec to allow blanching of palm, then release
    ulnar artery to assess re-perfusion. If blanching quickly resolves,
    ulnar artery will allow distal perfusion</p>
</li>
<li>
<p>If attempting radial access, ensure wrist is adequately extended;
    use towel roll under wrist and tape hand to bed or table</p>
</li>
<li>
<p>Discuss with fellow prior to brachial a-line placement</p>
</li>
<li>
<p>Ask RN to prepare tubing and waveform monitoring prior to time-out</p>
</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>Types of Kits</li>
</ul>
<!-- -->

<ul>
<li>
<p>Arrow kit: all-in-one device that has arterial catheter over
    introducer needle</p>
</li>
<li>
<p>A-line kit: individual introducer needle, guidewires, and sutures;
    multiple steps</p>
</li>
<li>
<p>Micropuncture kit: atraumatic guidewire, microcatheter and
    introducer sheath</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Reconfirm location with US after lidocaine</p>
</li>
<li>
<p>Ensure arterial access (pulsatile flow of bright red blood)</p>
</li>
</ul>
<p>Post- procedural considerations</p>
<ul>
<li>
<p>Immediately connect pressure tubing to catheter while maintaining
    sterile technique</p>
</li>
<li>
<p>Observe monitor for arterial waveform to verify appropriate
    placement</p>
</li>
<li>
<p>If persistent bleeding, hold pressure for 15 mins</p>
</li>
</ul>
<p>US-Guided PIV</p>
<p>VUMC video Guide: <a href="https://www.youtube.com/watch?v=GQGhciB6TvM">https://www.youtube.com/watch?v=GQGhciB6TvM</a></p>
<p>Indications</p>
<ul>
<li>Vascular access; large bore (16-18G) is optimal for blood
    transfusion and faster than central lines (except MAC/Cordis);
    preserves central access (important for ESRD patients)</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>
<p>Infection over the site, severe bleeding diathesis</p>
</li>
<li>
<p>Avoid EJs unless have been trained due to airway compromise if
    extravasation occurs</p>
</li>
</ul>
<p>Consent</p>
<ul>
<li>Common risks: arterial puncture, nerve irritation/damage, infection,
    infiltration, thrombus formation</li>
</ul>
<p>Pre-procedural considerations</p>
<ul>
<li>
<p><strong>Bleeding risk guidelines:</strong> Plts > 10k, no specific INR
    guidelines</p>
</li>
<li>
<p>Location selection: anuric AKI or ESRD patients – d/w renal, avoid
    limb with HD access proximal</p>
</li>
<li>
<p>Target selection: Confirm venous choice with compressibility and
    lack of doppler flow. Should follow the rule of 2s: vein must be at
    least twice the diameter of the catheter being placed, should be no
    more than 2 inches in depth from the surface of the skin, and should
    have at least 2 inches of straight (non-tortuous) length</p>
</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>
<p>US Probe: Linear</p>
</li>
<li>
<p>Kit: IV start kit; ideally 18G needle</p>
</li>
<li>
<p>Anesthetic use: Consider EMLA</p>
</li>
<li>
<p>1<sup>st</sup> choice: basilic, cephalic veins; 2<sup>nd</sup> choice: brachial vein
    (caution adjacent artery)</p>
</li>
<li>
<p>Use tourniquet</p>
</li>
<li>
<p>Start at 45° angle, use 45-45-90 rule to determine starting location
    (start as far from center of probe as the vessel is deep), flatten
    angle once in the vessel to advance ("walk" your way through the
    vessel by repeatedly identifying needle tip in the lumen and
    advancing)</p>
</li>
<li>
<p>Going too shallow could use up too much catheter leaving nothing to
    put in the vein.</p>
</li>
<li>
<p>Going too steep can cause catheter kinking at the hub where it
    sticks out of the skin</p>
</li>
<li>
<p>Hold probe close to skin, holding probe far from the end allows too
    much movement</p>
</li>
<li>
<p>Center the vessel on the ultrasound probe screen prior to sticking,
    place midline on US screen</p>
</li>
<li>
<p>Use both short axis and long axis views to ensure correct placement</p>
</li>
<li>
<p>Short axis- Vessel looks round like a target, helps to scout out the
    tip, and is best for ensuring the vein is entered as opposed to a
    neighboring artery</p>
</li>
<li>
<p>Long axis- The length of the vessel is viewed. This view is intended
    for the final few millimeters of catheter advancement into the vein
    to ensure both bevel and plastic sheath lumen traverse the
    endothelial layer before threading catheter</p>
</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>
<p>DON’T FORGET TO REMOVE TOURNIQUET!! Remove before flushing to
    prevent blowing vein</p>
</li>
<li>
<p>Bleeding complication: if arterial, remove catheter &amp; hold pressure
    at least 5 mins</p>
</li>
</ul>
<p>Dobhoff Tube</p>
<p>Indications</p>
<ul>
<li>
<p>Enteral feeding and medication administration if unable to swallow</p>
</li>
<li>
<p>DHT v NGT: DHT deliver meds and fluids, NGT provide suction to
    decompress (can also deliver meds/fluids); nurses place NGT,
    residents (and ICU nurses) place DHT qUh5AJ5uIZo</p>
</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>
<p>Esophageal varices or strictures (most hepatologists say this is not
    a contra-indication, but discuss if recent bleed or recent banding)</p>
</li>
<li>
<p>Other altered gastric anatomy that may prevent passage. (i.e.
    gastric bypass, esophageal hernias, tumors or other possible
    obstructions)</p>
</li>
<li>
<p>SBO or ileus (use NGT instead for suction)</p>
</li>
</ul>
<p>Absolute Contraindications for blind approach</p>
<ul>
<li>Facial trauma, basilar skull fracture, pharyngeal or esophageal
    trauma</li>
</ul>
<p>Consent</p>
<ul>
<li>Common risks: malposition (lung -> pneumothorax or pneumonia;
    pyriform sinus; coiling anywhere along tract); perforation anywhere
    along the tract; aspiration, nasal ulceration, esophagitis,
    gastritis, bleeding, vagal response, discomfort</li>
</ul>
<p>Pre-procedural considerations</p>
<ul>
<li>
<p><strong>Bleeding risk guidelines:</strong> Plts > 10k, no specific INR
    guidelines</p>
</li>
<li>
<p>Make sure DHT and bridle sizes correlate</p>
</li>
<li>
<p>Measure expected advancement depth by measuring distance from tip of
    nose, around ear, and to xiphoid process</p>
</li>
<li>
<p>Prior to placement, fasten the stylet in the fully-hubbed position
    to reduce bending and folding over of the weighted tip while
    advancing</p>
</li>
<li>
<p>Apply anesthetic with lidocaine gel (order Lidocaine uro-jet) and
    nasal swab to reduce pt discomfort, reduce gag reflex, and assist
    with clearance of the nasal passages</p>
</li>
<li>
<p>Consider fluoro-guided placement after 3 failed bedside attempts</p>
</li>
<li>
<p>Post-pyloric placement</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider in patients with high pulmonary aspiration risk, severe
    esophageal reflux/esophagitis, recurrent emesis, impaired gastric
    mobility, and pancreatitis</p>
</li>
<li>
<p>Refer for fluoro-guided post-pyloric advancement after 1 failed
    bedside attempt</p>
</li>
</ul>
<p>Procedural Considerations</p>
<ul>
<li>
<p>Have the patient sit upright with their head tilted toward the chest
    to encourage posterior oropharyngeal positioning of the DHT while
    advancing</p>
</li>
<li>
<p>Tip: advance horizontally (nose tip to ear lobe), not angled up</p>
</li>
<li>
<p>If pt can participate safely, have the patient swallow in
    conjunction with advancement; pt can suck on straw (with small sips
    of water if low aspiration risk) to utilize pharyngeal muscles to
    position DHT into esophagus</p>
</li>
<li>
<p>Place bridle and dog-bone tape while at the bedside to reduce
    dislodgement</p>
</li>
<li>
<p>Excessive coughing, difficulty phonating, or resistance may indicate
    tracheal placement; withdraw tube and re-attempt. Consider Duonebs
    to reduce bronchospasms</p>
</li>
<li>
<p>Post-pyloric placement has been shown to be up to 90% successful
    with intermittent insufflation of 10-20cc of air ~every 10cm of
    advancement after 55cm to promote pylorus opening. IV Reglan or
    erythromycin may also help</p>
</li>
<li>
<p>When placing bridle (recommend AFTER xray confirmation), keep
    alignment markers (marked on both probes) together so magnetic tips
    will align once past the nasal septum</p>
</li>
<li>
<p>When placing the bridle, remove the green stylet housed within the
    white probe before retracting back and removing the white probe</p>
</li>
</ul>
<p>Post-procedural Considerations</p>
<ul>
<li>
<p>ALWAYS confirm position radiographically via KUB before medications
    are given!</p>
</li>
<li>
<p>Insufflation of air and auscultation of bowel sounds over the
    gastric area can be reassuring of correct placement of DHT prior to
    taping/bridling and leaving the bedside</p>
</li>
<li>
<p>Most mispositioned/coiled tubes have to be removed and re-attempted,
    but it is ok to advance or withdraw if Stylet is still in place.
    However, once removed, a stylet should not be re-introduced to a
    mispositioned/coiled tube due to risk of GI perforation</p>
</li>
<li>
<p>In case of cranial placement, don’t remove, consult NSGY</p>
</li>
<li>
<p>De-clogging: Clog Zapper Kit (can type this into Epic directly);
    coca cola</p>
</li>
</ul></section><section class="print-page" id="procedures-procedures-anesthesia"><h1 id="procedures-procedures-anesthesia-anesthesia">Anesthesia<a class="headerlink" href="#procedures-procedures-anesthesia-anesthesia" title="Permanent link">&para;</a></h1>
<ul>
<li>May be used in which a pt’s pain or anxiety may impede performance
    and success</li>
<li>Relative Contraindications: old age, dementia, respiratory
    difficulty</li>
<li>Aim to use local anesthesia and minimize procedural sedation</li>
<li>Local Anesthesia: lidocaine 1% or 2% – add Epi if &gt;30 mins of
    analgesia required</li>
<li>Creating wheal: clean surface w/ chlorhexidine or alcohol swab; with
    22-25G needle, advance needle parallel to skin and aspirate to
    ensure no blood vessel involved, then inject anesthetic to create
    1-2 cm of raised skin; If deeper subcutaneous anesthesia is needed,
    advance needle perpendicular to skin, aspirate as advancing then
    inject the tract. Inject anesthetic as needle withdrawn.</li>
<li>Local anesthesia can alter landmarks, always double check anatomy
    after injection</li>
<li>Minimal Sedation: 0.25mg-2mg Ativan IV or 1mg-2.5mg Midazolam IV</li>
<li>Midazolam (Versed): faster on (2-5 min) and faster off (30-60 min)</li>
<li>Lorazepam (Ativan): onset 5-10 min; Duration 4-8 hours</li>
</ul></section><section class="print-page" id="procedures-procedures-anticoagulation-parameters"><h1 id="procedures-procedures-anticoagulation-parameters-anticoagulation-parameters">Anticoagulation Parameters<a class="headerlink" href="#procedures-procedures-anticoagulation-parameters-anticoagulation-parameters" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Procedure</td>
<td>PLT &amp; INR</td>
</tr>
<tr>
<td>Paracentesis</td>
<td>PLT > 20k, INR \&lt; 4 *</td>
</tr>
<tr>
<td>Central Line</td>
<td>PLT > 20k, INR \&lt; 3</td>
</tr>
<tr>
<td>Thoracentesis</td>
<td>PLT > 50k, INR \&lt; 2 *</td>
</tr>
<tr>
<td>Lumbar Puncture</td>
<td>PLT > 50k, INR \&lt; 1.6</td>
</tr>
<tr>
<td>US PIV</td>
<td>PLT > 10k, no INR</td>
</tr>
<tr>
<td>DHT</td>
<td>PLT > 10k, no INR</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticoagulant</td>
<td>When to Hold</td>
</tr>
<tr>
<td>Heparin gtt</td>
<td>4-8 hours, ensure PTT wnl</td>
</tr>
<tr>
<td>LMWH</td>
<td>12-24 hours</td>
</tr>
<tr>
<td>Dabigitran</td>
<td>1-2 days</td>
</tr>
<tr>
<td>Eliquis</td>
<td>1-2 day</td>
</tr>
<tr>
<td>Xarelto</td>
<td>1-2 days</td>
</tr>
<tr>
<td>Warfarin</td>
<td>5-7 days</td>
</tr>
</tbody>
</table></section><section class="print-page" id="procedures-procedures-arterial-line"><h1 id="procedures-procedures-arterial-line-arterial-line">Arterial Line<a class="headerlink" href="#procedures-procedures-arterial-line-arterial-line" title="Permanent link">&para;</a></h1>
<p>Pre-procedure considerations</p>
<ul>
<li>Palpate of artery of interest to best understand anatomy and
    surrounding structures</li>
<li>Allen Test if placing radial artery access: goal to assess
    collateral ulnar blood flow to avoid ischemia. Hold both radial and
    ulnar artery 10-15 sec to allow blanching of palm, then release
    ulnar artery to assess perfusion. If blanching quickly resolve,
    ulnar artery will allow distal perfusion</li>
<li>If attempting radial access, ensure wrist is adequately extended,
    often using towel roll under wrist and taping hand to bed or table</li>
</ul>
<p>Procedure considerations</p>
<ul>
<li>Types of Kits<ul>
<li>Arrow kit: all-in-one device that has arterial catheter over
    introducer needle</li>
<li>A-line kit: individual introducer needle, guidewires, and
    sutures; multiple steps</li>
<li>Micropuncture kit: atraumatic guidewire, microcatheter and
    introducer sheath</li>
</ul>
</li>
<li>Reconfirm location with US after lidocaine</li>
<li>Ensure arterial access (pulsatile flow of bright red blood)</li>
</ul>
<p>Post- procedure considerations</p>
<ul>
<li>Immediately connect pressure tubing to catheter while maintaining
    sterile technique</li>
<li>If persistent bleeding, hold pressure for 15 mins.</li>
<li>Can use for frequent ABG checks</li>
</ul></section><section class="print-page" id="procedures-procedures-central-line"><h1 id="procedures-procedures-central-line-central-line">Central line<a class="headerlink" href="#procedures-procedures-central-line-central-line" title="Permanent link">&para;</a></h1>
<p>Video guide:</p>
<p><a href="https://www.youtube.com/watch?v=qeVdRCqy_mo">https://www.youtube.com/watch?v=qeVdRCqy_mo</a></p>
<p>Indications</p>
<ul>
<li>Extracorporeal therapies: HD, CRRT, Plasma (PLEX) or RBC exchange
    transfusion</li>
<li>Venous access for: Vasopressors, Chemotherapy, Parenteral nutrition,
    Hemodynamic monitoring (CVP, ScvO2), and cardiac parameters (via
    pulmonary artery catheter)</li>
</ul>
<p>Contraindications: No true absolute contraindications</p>
<p>Pre-procedural considerations</p>
<ul>
<li>All patients need to have telemetry &amp; pulse oximetry monitoring</li>
<li>With every pt, consider LENGTH, LOCATION, LUMENS, and LINE TYPE!</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Line</td>
<td>Short Stature (\&lt;5’5”)</td>
</tr>
<tr>
<td>Right IJ, Subclavian</td>
<td>\&lt;15 cm</td>
</tr>
<tr>
<td>Left IJ, Subcalvian</td>
<td>\&lt;20 cm</td>
</tr>
<tr>
<td>Femoral</td>
<td>\&lt;25 cm</td>
</tr>
<tr>
<td>Confirm length of catheter in your kit before you open/place the line!</td>
<td>Confirm length of catheter in your kit before you open/place the line!</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site</td>
<td>Advantages</td>
<td>Disadvantages</td>
</tr>
<tr>
<td>Internal Jugular Vein</td>
<td>Minimal risk of PTX; improve target with positioning and use of US; easily compressible if bleeding occurs</td>
<td>Risk of carotid puncture; difficult in obese pt; vein collapsibility with hypovolemia</td>
</tr>
<tr>
<td>Subclavian</td>
<td>More comfortable for pts; landmark driven approach; lowest risk of infection</td>
<td>Increased risk of PTX, harder to control bleeding with pressure; technically more difficult</td>
</tr>
<tr>
<td>Femoral</td>
<td>Easiest to access; no risk of PTX; can be placed during CPR and intubation</td>
<td>High risk of infection and difficult to sterilize; patient unable to move; higher thrombotic risk</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of Line</td>
<td>Uses</td>
<td>Special Consideration</td>
</tr>
<tr>
<td>Triple Lumen (7Fr)</td>
<td>Most common line placed; used for central access for vasopressors, caustic infusions (chemo)</td>
<td>Consider lumens needs; triple lumen is most versatile but can warrant dual lumen</td>
</tr>
<tr>
<td>MAC or Cordis*</td>
<td>‘Short and fat’ allowing rapid transfusion; MAC has two ports</td>
<td>MAC is placed with dilator still in introducer</td>
</tr>
<tr>
<td>Dialysis Catheter (Trialysis, 12 Fr)</td>
<td>Dialysis line with two 12 Ga. Lumens for dialysis with a third 17 Ga. lumen for added access</td>
<td>Two serial dilations</td>
</tr>
</tbody>
</table>
<p>*Can place triple lumen in MAC for additional ports; lose ability to
rapidly transfuse</p>
<p>Procedural considerations</p>
<ul>
<li>Numb pt right after draping, then set up everything to allow time
    for lidocaine to work</li>
<li>Set supplies up in exactly the order of use to ensure all are
    present and functioning</li>
<li>Cap side ports with blue claves (not included in Trialysis kit)
    prior to flushing</li>
<li>For IJ access, place patient in slight Trendelenburg position to
    engorge vein</li>
<li>While advancing needle, ensure constant negative pressure with
    aspiration of plunger and visualization of needle tip with US</li>
<li>Always ensure guidewire is secured while it is inside a vein</li>
<li>Always ensure target for venous cannulation is visualized and
    guidewire is placed correctly prior to dilation: 1) Compression of
    target vessel 2) Non-pulsatile dark blood return (unless on
    100%FiO2, may be brighter red) 3) US visualization or needle and
    wire 4) can use pressure tubing and angiocath to confirm CVP or
    obtain venous O2 sat</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>Every IJ or subclavian central line needs a confirmation CXR to
    confirm no PTX</li>
<li>Ideal placement of distal tip: in SVC just outside the right atrium.
    Approximately near/superior to carina and right tracheobronchial
    angle</li>
<li>Troubleshooting Complications:<ul>
<li>Arterial Access or puncture: immediately remove needle and place
    non-occlusive pressure for 15 mins to prevent hematoma
    formation; if uncontrolled bleeding or artery was dilated, STAT
    vascular surgery consult</li>
<li>Bleeding: place direct pressure; subclavian access precludes
    ability to compress and confers highest bleeding risk; if
    uncontrolled, STAT vascular surgery consult</li>
<li>Pulmonary Complications: if free air aspirated into syringe,
    consider PTX vs poor seal of syringe &amp; needle. Close attention
    to pulmonary complication &amp; STAT CXR to assess PTX. If rapid
    deterioration, needle decompression and chest tube placement
    required</li>
<li>Venous Air Embolism: can occur if air introduced to system
    during placement, flushing, or if left open to the atmosphere.
    Effects are variable, but if suspected, place pt in left lateral
    decubitus position to trap air in right apex and place pt on
    100% O2 to speed resorption</li>
<li>Arrhythmia: rationale for telemetry monitoring as guidewire
    often leads to atrial or ventricular arrhythmias; Immediately
    withdraw wire to lesser depth. If arrythmia persists, abort
    procedure and treat patient and determine cause</li>
</ul>
</li>
</ul></section><section class="print-page" id="procedures-procedures-consent"><h1 id="procedures-procedures-consent-consent">Consent<a class="headerlink" href="#procedures-procedures-consent-consent" title="Permanent link">&para;</a></h1>
<ul>
<li>When printing Consents at VUMC, use MedEx (on the virtual
    machine/desktop)</li>
<li>Ensure pt’s signature; Telephone consent requires second physician
    as witness</li>
<li>Use CSN (not the MRN) to locate the pt information for that specific
    admission or office visit – ensure patient current room number on
    MedEx screen</li>
<li>When consenting pts at NAVA, use the COW with pen pad and the
    I-Consent program</li>
<li>Video guide:
    <a href="https://www.youtube.com/watch?v=6yXOEkFqk2o">https://www.youtube.com/watch?v=6yXOEkFqk2o</a></li>
</ul>
<p>Lumbar Puncture</p>
<ul>
<li>Common risks: backache (~66%), severe headache</li>
<li>Rare risks: spinal hematoma (\&lt;0.001%), weakness, numbness, brain
    function problems, CNS infection, brain herniation</li>
</ul>
<p>Paracentesis</p>
<ul>
<li>Risks: abdominal wall hematoma (1%), hemoperitoneum, organ puncture,
    infection</li>
</ul>
<p>Thoracentesis</p>
<ul>
<li>Common risks (&gt; 5%): coughing, fainting, PTX</li>
<li>Rare risks (\&lt; 1%): hemothorax, emergency surgery, re-expansion
    pulmonary edema</li>
</ul>
<p>Arthrocentesis</p>
<ul>
<li>Common risks: pain during procedure, repeat needle insertion</li>
<li>Rare: damage to surrounding vessels, nerves; iatrogenic septic
    arthritis: (\&lt;0.1%)</li>
</ul>
<p>Dobhoff Tube Placement</p>
<ul>
<li>Common risks: Malpositioned (lung)/coiled tube; perforation anywhere
    along the tract; cranial placement; aspiration, gastritis, bleeding,
    vagal response, significant discomfort</li>
<li>Contraindications: SBO, ileus; use large bore NGT instead (placed by
    bedside nurse)</li>
</ul>
<p>US-Guided PIV Placement</p>
<ul>
<li>Common risks: arterial puncture, nerve irritation/damage
    during/after procedure, infection, infiltration, thrombus formation</li>
</ul></section><section class="print-page" id="procedures-procedures-dht"><h1 id="procedures-procedures-dht-dht">DHT<a class="headerlink" href="#procedures-procedures-dht-dht" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=qUh5AJ5uIZo">https://www.youtube.com/watch?v=qUh5AJ5uIZo</a></p>
<p>Indications</p>
<ul>
<li>Enteral feeding if unable to swallow; passing meds</li>
<li>DHT deliver meds and fluids, NGT provide suction to decompress (can
    also deliver meds/fluids); nurses place NGT, residents (and ICU
    nurses) place DHT</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>Esophageal varices or strictures (most hepatologists say this is not
    a contra-indication)</li>
<li>Other altered gastric anatomy that may prevent passage. (i.e.
    gastric bypass, esophageal hernias, tumors or other possible
    obstructions).</li>
</ul>
<p>Absolute Contraindications for blind approach</p>
<ul>
<li>Facial (increased risk of intracranial placement), pharyngeal or
    esophageal trauma</li>
</ul>
<p>Procedure considerations</p>
<ul>
<li>Silicone-based, flexible tubing, less than 12fr in size, can be left
    in place for longer periods of time. NGTs are PVC-based, more rigid,
    and larger allowing gastric decompression</li>
<li>Prior to placement, fully fasten the stylet in the fully-hubbed
    position to reduce bending and folding over of the weighted tip
    while advancing</li>
<li>Make sure DHT and bridle sizes correlate</li>
</ul>
<p>Group consensus and recommendations</p>
<ul>
<li>Anesthetic use with lidocaine gel (order Lidocaine uro-jet) and
    nasal swab; reduces pt discomfort, reduces gag reflex, and assists
    with clearance of the nasal passages</li>
<li>Have the patient sit upright with the head tilted toward the chest
    to encourage posterior oropharynx positioning of the DHT while
    advancing.</li>
<li>If pt can participate safely, have the patient swallow before
    advancement; pt can suck on straw to utilize pharyngeal muscles to
    position DHT into esophagus</li>
<li>Excessive coughing, difficulty phonating, or resistance may indicate
    trachea placement. Withdraw tube and re-attempt. Consider Duoneb to
    reduce bronchospasms</li>
<li>3 failed attempts should be made at the bedside before sending for
    fluoro-guidance</li>
<li>When post-pyloric placement is requested, 1 attempt at post-pyloric
    placement with the blind approach at the bedside is acceptable
    before referring to fluoroscopic guidance</li>
</ul>
<p>Placement Tips &amp; Tricks</p>
<ul>
<li>Insufflation of air and auscultation of bowel sounds over the
    gastric area can be reassuring of correct placement of DHT prior to
    bridling and leaving the bedside.  Always obtain KUB for
    radiological confirmation of placement. Leaving the stylet in for
    confirmation can make it easier to see on KUB and can allows
    re-advancement</li>
<li>Place bridle and dog-bone tape while at the bedside to reduce
    dislodgement</li>
<li>When placing bridle, keep alignment markers (as clearly marked on
    both probes) together so magnetic tips will align once past the
    nasal septum</li>
<li>When placing the bridle, remove the green stylet housed within the
    white probe before retracting back and removing the white probe</li>
</ul>
<p>Post-pyloric placement</p>
<ul>
<li>Consider in patients with high pulmonary aspiration risk and severe
    esophageal reflux/esophagitis, recurrent emesis, impaired gastric
    motility, and pancreatitis</li>
<li>Post-pyloric placement has been shown up to 90% successful with
    intermittent insufflation of 10-20cc of air ~every 10cm of
    advancement after 55cm to promote pylorus opening. IV Reglan or
    Erythromycin may also help</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>ALWAYS confirm the position radiographically before medications are
    given!</li>
<li>Most mispositioned/coiled tubes have to be removed and re-attempted,
    but it is ok to advance or withdraw if Stylet is still in place.
    However, once removed, a stylet should not be re-introduced to a
    mispositioned/coiled tube due to risk of GI perforation</li>
<li>Listen to the patient, repeat imaging (Plain film or CT) if concern
    for any perforation, and notify appropriate surgical service.</li>
<li>In case of cranial placement, don’t remove, consult NSGY</li>
<li>De-clogging: Clog Zapper Kit (can type this into Epic directly);
    Coca cola</li>
</ul></section><section class="print-page" id="procedures-procedures-lumbar-puncture"><h1 id="procedures-procedures-lumbar-puncture-lumbar-puncture">Lumbar Puncture<a class="headerlink" href="#procedures-procedures-lumbar-puncture-lumbar-puncture" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=xnH9gECy_wU">https://www.youtube.com/watch?v=xnH9gECy_wU</a></p>
<p>Absolute Contraindications</p>
<ul>
<li>Increased intracranial pressure from space occupying lesions</li>
<li>Infection over puncture side or epidural abscess</li>
<li>Trauma to mass or lumbar vertebrae</li>
</ul>
<p>Relative Contraindications</p>
<ul>
<li>↑
    intracranial pressure, thrombocytopenia, bleeding diatheses,
    anticoagulation</li>
</ul>
<p>Pre-procedure considerations:</p>
<ul>
<li>Consider sending to fluoro-guided if: Attempts without imaging are
    unsuccessful, morbidly obese pts with no palpable anatomy, severe
    scoliosis, prior spine surgery, borderline low Plts and multiple
    sticks might be needed, or pt requires heavy sedation</li>
<li>IR guidelines require Plavix to be off 5 days; ASA alone is OK</li>
<li>Full dose LMWH must be off 24h, ppx LMWH off 12h, ppx heparin off
    8h, hep gtt off 4-8hrs with repeat lab demonstrating normalized PT</li>
<li>P2Y12 inhibitors should be held for 7 days to avoid bleeding risks</li>
<li>Labs: cell count w/diff, BF culture, glucose, protein; if infectious
    or neurological labs are needed, consider consult first Try to
    freeze sample for future labs (order in epic).</li>
<li>Ensure lateral decubitus position for open pressure with glass
    pressure manometer</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>US Probe: Linear (can use curvilinear in obese pts) in transverse
    axis to establish midline &amp; in sagittal axis to identify spinous
    processes</li>
<li>Volume removal for studies: Basic only 2mL per tube in 1-4. Many
    studies ordered: 3mL per tube (*consider calling lab to confirm).
    Cytology desired: call lab to confirm amount needed (rule of thumb
    2/2/6/2mL); Tube 4 is sent for micro to reduce contamination.
    Therapeutic high volume: 30mL max</li>
<li>Anesthetic use: Lidocaine 1-2% (likely need more than what is
    provided in kit; consider empiric anesthetization of 2 spaces &plusmn;
    Pain-Ease spray.</li>
<li>Increased number of attempts = increased success rates</li>
<li>Higher rate of success if stylet is removed before entering
    subarachnoid space to better observe flow of CSF once in the
    subarachnoid space. Stylet should be replaced prior to LP needle
    removal</li>
<li>Aspiration of CSF = increase risk of bleeding. Don
    ’
    t do that!</li>
</ul>
<p>Post-procedural considerations <span id="_Hlk64109621"></span></p>
<ul>
<li>Post-LP headache
    (~10%): encourage pt to lay flat to reduce the intensity of
    symptoms (but does not prevent it); if prolonged, consider blood
    patch (c/s Anesthesia)</li>
<li>Neuro changes OR bleeding complications: STAT non-contrast MRI
    lumbar spine for epidural hematoma, q1 neuro-checks x4hrs then q2
    for 24-48hrs &amp; consult NSGY</li>
<li>Sample cannot be tubed; someone must walk fluid to the lab</li>
<li>Resuming anticoagulation: 1h UFH, 4h LMWH, 4-6h
    rivaroxaban/apixaban, 6h dabigatran/fondaparinux. Longer periods
    should be considered after traumatic tap, and post-procedure
    monitoring of neurological function is recommended for all pts</li>
</ul></section><section class="print-page" id="procedures-procedures-paracentesis"><h1 id="procedures-procedures-paracentesis-paracentesis">Paracentesis<a class="headerlink" href="#procedures-procedures-paracentesis-paracentesis" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=pQSsb9705LE&amp;t=160s">https://www.youtube.com/watch?v=pQSsb9705LE&amp;t=160s</a></p>
<p>Indications</p>
<ul>
<li>Diagnostic: Evaluation of new onset ascites, or known ascites in pts
    with clinical decompensation, fever, abdominal pain/tenderness, HE,
    leukocytosis, AKI</li>
<li>Therapeutic: large volume ascites resistant to diuretics causing pt
    discomfort</li>
</ul>
<p>Pre-Procedural considerations</p>
<ul>
<li>If therapeutic, determine volume pt typically gets drained so you
    have enough bottles</li>
<li>Labs (order before so nurse can print off labels): cell count
    w/diff, BF culture, BF &amp; serum albumin, total protein; cytology if
    c/f malignancy; BF/serum Hct if bloody</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>Ultrasound Probe: curvilinear, to identify safe pocket (~2 cm)</li>
<li>Kit: 6 Fr Safe-T-Centesis Kit</li>
<li>If only diagnostic, use 18G needle with 20-50cc syringe rather than
    kit</li>
<li>If high bleeding risk, use long 18 g. needle &amp; attach to syringe
    instead of 6 Fr. Catheter</li>
<li>Avoid surgical scars out of concern for nearby adhesions and
    superficial veins</li>
<li>Z-track
    method: may reduce post-paracentesis ascitic fluid leakage. Once
    into subcutaneous tissue, move superior/inferior to allow tissue
    overlap.</li>
<li>Attempt as lateral as possible to avoid inferior epigastric vessels</li>
<li>Roll patient to left or right side to promote pooling of fluid for
    easier/safer access</li>
<li>Inoculate culture bottles at bedside rather than sending fluid
    samples to lab for inoculation to increase yield 50%
    
    80% (VA does not allow bedside inoculation.)</li>
<li>If hernia present, have patient reduce it while draining fluid to
    prevent incarceration</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>Albumin for large volume (&gt;5L): give 8 grams per liter removed</li>
<li>Ascitic leak: roll pt on opposite side; place 1 figure-of-eight
    stitch with 4.0 vicryl</li>
<li>Bleeding complication – Hold pressure with quick-clot and gauze
    for &gt;5-10 if persistent bleeding at site; if profuse bleeding or
    concern for organ injury, STAT page EGS</li>
</ul></section><section class="print-page" id="procedures-procedures-thoracentesis"><h1 id="procedures-procedures-thoracentesis-thoracentesis">Thoracentesis<a class="headerlink" href="#procedures-procedures-thoracentesis-thoracentesis" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=ivTyH09BcHg">https://www.youtube.com/watch?v=ivTyH09BcHg</a></p>
<p>Indications</p>
<ul>
<li>New pleural effusion (that has no obvious explanation)</li>
<li>Any respiratory symptoms that would positively respond to large
    volume thoracentesis</li>
</ul>
<p>Pre-procedural considerations</p>
<ul>
<li>If loculations present on US, high risk, or any question about
    indication, refer to Pulm</li>
<li>Labs (order before so nurse can print labels): cell count w/diff; BF
    culture, BF &amp; serum LDH, BF &amp; serum total protein; BF &amp; serum Hct if
    bloody; cytology if c/f malignancy</li>
</ul>
<p>Procedural considerations</p>
<ul>
<li>US Probe: Cardiac (or Linear) to identify safe pocket between lung
    and diaphragm</li>
<li>Kit:  6Fr Safe-T-Centesis kit</li>
<li>Upright position is typically preferred; lateral to mid-scap/mid-ax.
    If patient unable to sit upright, refer to procedure team vs
    pulmonology</li>
<li>Effusion size: if unable to tap above 9 <sup>th</sup> rib, too
    small; CXR with costophrenic angle blunting should correlate to
    ~250-500mL</li>
<li>Keep patient in same position throughout</li>
<li>Superior to rib to avoid nerve bundles and vessels</li>
<li>Stop if pt has any new/increased chest discomfort, aggressive
    unremitting cough, frank purulence or air on aspiration,
    lightheadedness, hypotension, or vagal response.</li>
<li>Stop fluid removal after 1.5 L of chronic pleural effusion to reduce
    re-expansion pulmonary edema. May also reduce PTX. Check U-shaped
    manometry every 400-500 cc to assess intrathoracic pressure; avoid
    pressures more negative than -15-20 cm H2O</li>
</ul>
<p>Post-procedural considerations</p>
<ul>
<li>If needing cytology, send at least 60
    –
    100cc</li>
<li>Bleeding complication: STAT page Thoracic Surgery</li>
<li>PTX: if pt stable &amp; asymptomatic, supplemental O2 and repeat CXR in
    4hrs; if unstable/symptomatic STAT page to Thoracic Surgery</li>
<li>Re-expansion pulmonary edema: persistent cough, frothy sputum.
    Diffuse GGO on side of thoracentesis. Supportive management (oxygen,
    monitor); most resolve in 24-48 hrs. If respiratory distress
    progresses, may need mechanical ventilation.</li>
<li>Documentation:  Effusion US characteristics (anechoic, laying
    debris, septations) Reason for ending procedure (stopped early due
    to chest discomfort/cough, complication vs tapped dry); presence of
    lung sliding/whether more than scant residual effusion remains
    post-procedure by ultrasound</li>
<li>A routine chest radiograph after thoracentesis is no longer
    indicated for most asymptomatic, non-ventilated patients. Check lung
    slide with US in 2D and M-mode</li>
</ul></section><section class="print-page" id="procedures-procedures-ultrasound-guided-peripheral-iv"><h1 id="procedures-procedures-ultrasound-guided-peripheral-iv-ultrasound-guided-peripheral-iv">Ultrasound-Guided Peripheral IV<a class="headerlink" href="#procedures-procedures-ultrasound-guided-peripheral-iv-ultrasound-guided-peripheral-iv" title="Permanent link">&para;</a></h1>
<p>Video Guide:</p>
<p><a href="https://www.youtube.com/watch?v=GQGhciB6TvM">https://www.youtube.com/watch?v=GQGhciB6TvM</a></p>
<p>Relative Contraindications</p>
<ul>
<li>Infection over the site, Hemodialysis in that arm (unless cleared by
    renal), Severe bleeding diathesis</li>
<li>We avoid EJs due to airway compromise if extravasation occurs</li>
</ul>
<p>Pre-procedure considerations</p>
<ul>
<li>Location selection: anuric AKI or ESRD patients – d/w renal</li>
<li>Target selection should follow the rule of 2s. Vein must be at least
    twice the diameter of the catheter being placed, should be no more
    than 2 inches in depth from the surface of the skin, and should have
    at least 2 inches of straight (non-tortuous) length</li>
</ul>
<p>Procedure considerations</p>
<ul>
<li>US Probe: Linear</li>
<li>Kit: IV start kit; ideally 18G needle</li>
<li>Anesthetic use: Consider EMLA</li>
<li>1 <sup>st</sup> choice: basilic vein; 2 <sup>nd</sup> choice:
    brachial vein</li>
<li>Use tourniquet; start at 45
    ° angle</li>
<li>Going too shallow could use up too much catheter leaving nothing to
    put in the vein.</li>
<li>Going too steep can cause catheter kinking at the hub where it
    sticks out of the skin</li>
<li>Hold probe close to skin, holding probe far from the end allows too
    much movement</li>
<li>Center the vessel on the ultrasound probe screen prior to sticking</li>
<li>Use both short axis and long axis views to ensure correct placement</li>
<li>Short axis- Vessel looks round like a target, helps to scout out the
    tip, and is best for ensuring the vein is entered as opposed to a
    neighboring artery</li>
<li>Long axis- The length of the vessel is viewed. This view is intended
    for the final few millimeters of catheter advancement into the vein
    to ensure both bevel and plastic sheath lumen traverse the
    endothelial layer before threading catheter</li>
</ul>
<p>Post-procedure considerations</p>
<ul>
<li>DON’T FORGET TO REMOVE TOURNIQUET!! Remove before flushing to
    prevent blowing vein</li>
<li>Bleeding complication: if arterial, remove catheter &amp; hold pressure
    at least 5 mins</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Procedures</h1>
                        <h1 class='nav-section-title' id='section-psychiatry'>
                            Psychiatry <a class='headerlink' href='#section-psychiatry' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="psychiatry-main"><p>Agitation Management – Jonathan Constant, Jonathan Smith</p>
<p>Background</p>
<ul>
<li>Agitation in the hospital result from discomfort, illness,
    medication effects or frustrations the patient is unable to
    meaningfully communicate</li>
</ul>
<p>Presentation</p>
<ul>
<li>Impulsive aggression: spontaneous, explosive, reactive/reflexive,
    not pre-meditated</li>
</ul>
<!-- -->

<ul>
<li>Delirium, psychosis, cognitive deficits, withdrawal/intoxication,
    pain, post-ictal</li>
</ul>
<!-- -->

<ul>
<li>Instrumental aggression: pre-meditated, controlled, purposeful
    behaviors</li>
</ul>
<!-- -->

<ul>
<li>Personality disorders, secondary gain, delusional thought</li>
</ul>
<!-- -->

<ul>
<li>Differential diagnosis for aggression:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Psychoses: mania, depression, schizophrenia, delusional disorder</p>
</li>
<li>
<p>Personality disorder: antisocial, borderline, paranoid, narcissistic</p>
</li>
<li>
<p>Substance use disorder: alcohol, PCP, stimulants, cocaine,
    synthetics</p>
</li>
<li>
<p>Delirium, dementia</p>
</li>
<li>
<p>Frontal lobe syndromes (TBI, CVA, neoplasm, neurodegenerative
    process)</p>
</li>
<li>
<p>Behavior/Developmental: Intermittent explosive, intellectual
    disability</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Examine (when calm) for source of pain, signs of infection,
    discomfort (ex: urinary retention or constipation), toxidromes</p>
</li>
<li>
<p>Neurological exam for focal deficits, ataxia, nystagmus, tremor,
    rigidity, aphasias</p>
</li>
<li>
<p>Review medication list and perform med reconciliation of home meds</p>
</li>
<li>
<p>UDS + review of CSMD for evaluation of intoxication/withdrawal</p>
</li>
<li>
<p>CBC, CMP, UA</p>
</li>
<li>
<p>CT head + EEG if focal neurologic deficits</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Environment</li>
</ul>
<!-- -->

<ul>
<li>
<p>Periodic room searches; search personal belongings, VUPD presence if
    warranted</p>
</li>
<li>
<p>Virtual or 1:1 sitter placement,</p>
</li>
<li>
<p>Delirium precautions (see delirium section)</p>
</li>
<li>
<p>Disposable trays and utensils (minimize potential weapons in the
    room)</p>
</li>
</ul>
<!-- -->

<ul>
<li>De-escalation: Always first line, although impractical if pt is
    unable to communicate effectively, is explosive or already engaging
    in violent/potentially harmful behavior</li>
</ul>
<!-- -->

<ul>
<li>
<p>Nonverbal:</p>
<ul>
<li>
<p>Maintain safe distance, avoid sudden movements, don't touch the
    pt</p>
</li>
<li>
<p>Maintain neutral posture, neutral, sincere eye contact, same
    height</p>
</li>
</ul>
</li>
<li>
<p>Verbal:</p>
<ul>
<li>
<p>Speak in calm, clear tone, avoid confrontation, and offer to
    solve problem if possible</p>
</li>
<li>
<p>Do not insist on having the last word</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Tactics</li>
</ul>
<!-- -->

<ul>
<li>
<p>Redirection: Acknowledge pt's frustrations; shift focus on how to
    solve the problem</p>
</li>
<li>
<p>Aligning goals: Emphasize common ground and big picture; make small
    concessions</p>
</li>
<li>
<p>Know when to disengage/leave room</p>
</li>
</ul>
<!-- -->

<ul>
<li>Restraints</li>
</ul>
<!-- -->

<ul>
<li>
<p>Should be used only when necessary to protect patient or others from
    harm</p>
<ul>
<li>Mechanically restrained patients cannot be left unmonitored</li>
</ul>
</li>
<li>
<p>De-escalate (4 point to 2 point, etc) and remove restraints as soon
    as possible</p>
</li>
<li>
<p>Documentation of restraint:</p>
<ul>
<li>
<p>Face-to-face assessment has to be completed within an hour of
    violent restraint</p>
</li>
<li>
<p>“Restraint Charting” tab – typically in rarely used tab drop
    down</p>
</li>
</ul>
</li>
<li>
<p>Mechanical Restraints:</p>
<ul>
<li>
<p>Soft restraints – most commonly used</p>
</li>
<li>
<p>Hard restraints – reserved for severe behavioral health (only 2
    sets in house)</p>
</li>
<li>
<p>Mittens</p>
</li>
<li>
<p>Posey Vest – prevents exiting bed, allows limbs to be free</p>
</li>
<li>
<p>Posey Bed – wandering patient (TBI, severe dementia)</p>
</li>
</ul>
</li>
<li>
<p>VUMC Orders: “restraint” --> order set</p>
<ul>
<li>
<p>Non-violent non-self-destructive (order lasts up to 48 hrs)</p>
<ul>
<li>Most pts needing restraint: non-psychiatric, delirium,
    dementia, intubation</li>
</ul>
</li>
<li>
<p>Restraint violent self- destructive adult</p>
<ul>
<li>
<p>Order lasts up to 24hr with assessment every 4 hours</p>
</li>
<li>
<p>Mainly severe psychiatric symptoms</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Pharmacological Management for Agitation</p>
<p>As discussed above, behavioral interventions are first line for
agitation management in the hospital. Pharmacologic treatment should
only be used when needed for patient and/or staff safety when
non-pharmacologic interventions are unsuccessful or impractical</p>
<p>Acute Agitation</p>
<ul>
<li>Antipsychotics</li>
</ul>
<!-- -->

<ul>
<li>
<p>Widely effective for acute agitation, especially in delirium and
    psychotic disorders</p>
</li>
<li>
<p>Monitor EKG if repeated dosing or if used with other QT prolonging
    agents</p>
</li>
<li>
<p>Moderate agitation options:</p>
<ul>
<li>
<p>Olanzapine 2.5 - 5mg po q6h prn. Orally disintegrating tab (ODT)
    available</p>
</li>
<li>
<p>Quetiapine 12.5 - 25mg q6h po prn for patients at higher risk of
    extrapyramidal symptoms (EPS)</p>
</li>
</ul>
</li>
<li>
<p>Severe agitation</p>
<ul>
<li>
<p>Haldol 0.5 - 1mg IV/IM q6h prn for older/frail individuals</p>
</li>
<li>
<p>Haldol 2-3mg IV/IM q6h prn for other patients</p>
</li>
<li>
<p>Titrate up to 5 mg and can increase frequency as warranted</p>
</li>
<li>
<p>When using IV Haldol obtain daily EKG, Mg and K levels</p>
</li>
<li>
<p>Stop IV Haldol if QTc > 500 msec</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Benzodiazepines</li>
</ul>
<!-- -->

<ul>
<li>
<p>Lacks EPS that can occur with antipsychotics but can worsen delirium
    &amp; disinhibit patients with neurocognitive-related agitation</p>
</li>
<li>
<p>Can use alone or in addition to antipsychotic agent</p>
</li>
<li>
<p>Preferred for agitation related to intoxication/withdrawal of
    sedatives</p>
<ul>
<li>
<p>Lorazepam preferentially used due to PO, IV and IM availability</p>
</li>
<li>
<p>Lorazepam 2mg PO/IM/IV q6h prn typical starting dose (1mg if
    older/frail)</p>
<ul>
<li>Can increase frequency if warranted. Monitor for respiratory
    suppression</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>If severe agitation not responsive to above, may require sedation
    with infusion:</li>
</ul>
<!-- -->

<ul>
<li>Dexmedetomidine, Propofol or Midazolam</li>
</ul>
<p>Maintenance medications:</p>
<ul>
<li>Antipsychotics</li>
</ul>
<!-- -->

<ul>
<li>
<p>Reserve antipsychotics for severe aggression that pose significant
    risk and aim to wean as soon as safely possible</p>
</li>
<li>
<p>Adverse effects: metabolic, EPS, increased mortality in dementia</p>
</li>
<li>
<p>Most commonly used: Olanzapine, Quetiapine, Risperidone</p>
</li>
</ul>
<!-- -->

<ul>
<li>Antiepileptic agents</li>
</ul>
<!-- -->

<ul>
<li>
<p>May be effective in reduction of impulsive aggression</p>
</li>
<li>
<p>Most commonly used: Depakote</p>
<ul>
<li>Levetiracetam could worsen aggression/agitation</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Beta Blockers and Alpha Agonists</li>
</ul>
<!-- -->

<ul>
<li>
<p>Noradrenergic over-activity implicated in aggression expression</p>
</li>
<li>
<p>Commonly Used: Propranolol, Clonidine, Guanfacine</p>
</li>
</ul>
<!-- -->

<ul>
<li>Serotonergic agents: SSRI/SNRI/buspirone</li>
</ul>
<!-- -->

<ul>
<li>
<p>Useful if co-occurring depression/anxiety disorders</p>
</li>
<li>
<p>Peak onset of action takes weeks</p>
</li>
</ul>
<p>Medical Decision-Making Capacity – Chelsea Sprick, Neil Phillips,
Jonathan Smith</p>
<p>Background</p>
<ul>
<li>
<p>Capacity is a patient’s ability to make a specific medical decision
    at a specific point in time and can be assessed by any physician</p>
</li>
<li>
<p>Competency: “global decision-making capacity,” a legal determination
    made by a judge</p>
</li>
</ul>
<p>Four key components to assess medical decision-making capacity</p>
<ol>
<li>
<p>Choice: patient must clearly indicate a consistent choice</p>
</li>
<li>
<p>“Have you decided whether to follow the recommendation for the
    treatment?”</p>
</li>
<li>
<p>“Can you tell me what your decision is?”</p>
</li>
<li>
<p>Understand: Patient must grasp the fundamental meaning of the
    &gt; information communicated by the medical team</p>
</li>
<li>
<p>“Please tell me in your own words what you were told about:</p>
<ul>
<li>
<p>The problem with (1) your health now and (2) the recommended
    treatment</p>
</li>
<li>
<p>The risks/benefits of (3) treatment, (4) alternative treatments
    and (5) no treatment”</p>
</li>
</ul>
</li>
<li>
<p>Appreciate: the medical condition and likely consequences of
    &gt; treatment options</p>
</li>
<li>
<p>“What do you believe is wrong with your health now?”</p>
</li>
<li>
<p>“What is treatment likely to do for you?”</p>
</li>
<li>
<p>“What do you believe will happen if you’re not treated”</p>
</li>
<li>
<p>“Why do you think this treatment was recommended?”</p>
</li>
<li>
<p>Reason: patient must rationally manipulate relevant information</p>
</li>
<li>
<p>“What makes the chosen option better than the alternative?”</p>
</li>
<li>
<p>“How did you decide to accept or reject the recommended treatment?”</p>
</li>
</ol>
<p>If the patient does not have medical decision-making capacity:</p>
<ul>
<li>
<p>Identify and remedy cause of impairment if possible (if decision is
    non-urgent)</p>
</li>
<li>
<p>Identify surrogate decision maker</p>
</li>
</ul>
<p>Documenting medical decision-making capacity:</p>
<ul>
<li>Use a dot phrase .Capacity that lists the four components and
    document your thought process citing evidence from your interview</li>
</ul>
<p>Medical Holds – Soibhan Kelley, MD</p>
<p>Background</p>
<ul>
<li>6401 vs. 6404</li>
</ul>
<!-- -->

<ul>
<li>
<p>"6401": process to detain someone who has a high likelihood of
    posing harm to themselves or others <em>due to mental illness</em>. Purpose
    is short-term detention until a prompt psychiatric assessment can be
    performed</p>
<ul>
<li>
<p>One person completes this. Can be law enforcement officers,
    psychologists, physicians</p>
</li>
<li>
<p>Must document justification for why the hold is needed (progress
    note, assessment form, etc)</p>
</li>
</ul>
</li>
<li>
<p>"6404": 6404= Certificate of Need. Legal document used for emergency
    involuntary psychiatric admission</p>
<ul>
<li>
<p>Pt must have mental illness or serious emotional disturbance
    (excluding intellectual/developmental disabilities) and pose an
    immediate substantial likelihood of serious harm because of this
    based on a face-to face assessment by a qualified psychiatric
    professional</p>
<ul>
<li>Treatment must be necessary for symptom reduction and lack
    of treatment would lead to deterioration, with no less
    drastic alternative to inpatient hospitalization</li>
</ul>
</li>
<li>
<p>Two certificates needed: the first to transport a patient to a
    psychiatric facility and the second for an involuntary admission</p>
</li>
<li>
<p>Two different <em>qualified persons</em> must each complete a form</p>
<ul>
<li>Psychiatry residents can write these due to their special
    training licenses</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>No AMA Medical Hold: used when a patient does not have capacity to
    leave the hospital against medical advice <em>due to a medical
    condition</em> and needs to remain in the hospital</li>
</ul>
<!-- -->

<ul>
<li>Can be ordered by any physician Medical Hold Order Set</li>
</ul>
<p>VUH specific procedures</p>
<ul>
<li>A physical copy of the first 6404 is required to accompany the
    patient when they are transported to a psychiatric facility after
    medical discharge. The form is completed by the psychiatry team</li>
</ul>
<p>Inpatient Insomnia – Julian Raffoul, Jose Alberto Arriola Vigo</p>
<p>Background</p>
<ul>
<li>
<p>Sleep disturbances in the hospital are multifactorial</p>
</li>
<li>
<p>Consequences of sleep disturbances include changes in cognition,
    behavior, anxiety, pain perception, respiratory function,
    inflammation, and metabolism</p>
</li>
<li>
<p>Goals while inpatient: optimize sleep environment, minimize
    stimulating or sleep-related side effects of concomitant
    medications, utilize non-pharmacologic strategies</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Non-pharmacologic interventions:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Noise reduction: (ear protection, white noise, etc.)</p>
</li>
<li>
<p>Keeps lights on during the day and off at night</p>
</li>
<li>
<p>Reducing nighttime interruptions: Retime VS checks and lab draws</p>
</li>
<li>
<p>Minimize devices (ex: telemetry) and lines as able</p>
</li>
</ul>
<!-- -->

<ul>
<li>Pharmacotherapy:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Minimize medications such as sedatives/hypnotics, opioids,
    glucocorticoids, beta blockers, and certain antibiotics that disturb
    sleep architecture</p>
</li>
<li>
<p>Melatonin: 1-5 mg PO qhs</p>
<ul>
<li>First-line choice based on mild side-effect profile, low
    potential for drug-drug interactions, and improves circadian
    rhythms; Dose 2-3hrs before bedtime</li>
</ul>
</li>
<li>
<p>Trazodone: 25-50 mg PO qhs (max 200 mg/day)</p>
<ul>
<li>
<p>Side effects: headache, dry mouth, and nausea</p>
</li>
<li>
<p>Monitor for orthostasis and infrequent atrial arrhythmias; use
    lowest effective dose</p>
</li>
</ul>
</li>
<li>
<p>Mirtazapine: 7.5-15 mg PO qHS</p>
<ul>
<li>
<p>A primary alpha-2 antagonist with 5-HT2 and H1 antagonism</p>
</li>
<li>
<p>Consider when insomnia appears to be related to primary
    depression</p>
</li>
<li>
<p>Can increase appetite and cause weight gain</p>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Avoid the following in the inpatient setting:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Benzodiazepines</p>
<ul>
<li>Reduces sleep latency and increases total sleep time but avoided
    due to significant adverse effects: respiratory depression,
    cognitive decline, delirium, daytime sleepiness, and falls,
    particularly in hospitalized older adults</li>
</ul>
</li>
<li>
<p>Non-benzodiazepines benzodiazepine receptor agonists (e.g.,
    zolpidem, eszopiclone/zopiclone, zaleplon)</p>
<ul>
<li>Commonly used in the outpatient setting but associated with
    cognitive dysfunction, delirium, and falls in hospitalized
    patients</li>
</ul>
</li>
<li>
<p>Diphenhydramine</p>
<ul>
<li>
<p>Trials evaluating their effectiveness as sleep aids are limited
    and show mixed results</p>
</li>
<li>
<p>Many potential side effects that are enhanced in the inpatient
    setting: impaired cognition, anticholinergic effects
    (constipation, urinary retention)</p>
</li>
</ul>
</li>
</ul>
<p>Substance Use Disorder (SUD) – Barrington Hwang, Kristopher Kast</p>
<p>Background</p>
<ul>
<li>
<p>SUDs are common, complex, and chronic neuropsychiatric disorders
    with well-described inherited risk, dysregulated neurophysiology,
    and multiple effective treatment modalities</p>
</li>
<li>
<p>Pts w/SUD face significant stigma, prior traumatic experiences in
    healthcare environments</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Using the term “abuse” undermines the disease model of addiction</p>
</li>
<li>
<p>Person-centered, specific terminology: “person with opioid and
    alcohol use disorders”</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Avoid the qualifier “Polysubstance.” Instead, clarify specific
    diagnoses for each substance category</p>
</li>
<li>
<p>DSM 5 Criteria (same for most substance categories): Requires 2+
    criteria met in past year; use must cause clinically significant
    impairment and/or distress:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Loss of control – larger amounts, longer time, ongoing use despite
    consequences, efforts/desire to reduce use</p>
</li>
<li>
<p>Physiologic changes -- tolerance, withdrawal (these 2 alone do not
    necessarily imply a disorder if they result from prescribed
    therapy), craving</p>
</li>
<li>
<p>Consequences – hazardous use, interpersonal problems, medical
    problems, failed role obligations, lost activities</p>
</li>
</ul>
<p>General Management:</p>
<ul>
<li>First priority in the inpatient medical setting is to identify and
    stabilize withdrawal states</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mitigate risks of severe sequelae (seizure, delirium)</p>
</li>
<li>
<p>Avoid unintended iatrogenic harm (ex: opioid abstinence leading to
    lost tolerance and post-discharge overdose)</p>
</li>
<li>
<p>Avoid distress-driven AMA discharge</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider Addiction Psychiatry consultation for management of complex
    withdrawal states, substance use disorders and co-occurring
    psychiatric diagnoses, assistance with risk stratification for
    hospital misuse and/or hospital discharge with PICC lines for
    outpatient antibiotics, and differentiation of pain requiring opioid
    therapy and opioid use disorder</p>
</li>
<li>
<p>If in the emergency room and not admitted, consult PAS</p>
</li>
</ul>
<p>Opioid Use Disorder – Rita Hurd, David Marcovitz</p>
<p>Background</p>
<ul>
<li>
<p>Standard of care is opioid stabilization with buprenorphine or
    methadone (in OUD) or other full agonist opioids (in chronic opioid
    therapy)</p>
</li>
<li>
<p>Methadone and buprenorphine can be ordered by any physician for
    inpatients</p>
</li>
<li>
<p>Maintenance agonist therapy should be offered to every patient, with
    preference for an “opt-out” approach (even for uninsured patients
    through state grant funding)</p>
</li>
</ul>
<p>Presentation (Withdrawal)</p>
<ul>
<li>
<p>Restlessness/psychomotor activation, anxiety, irritability, nausea,
    abdominal cramping, loose stool, diffuse musculoskeletal pain,
    chills, insomnia, yawning</p>
</li>
<li>
<p>Pupillary dilation, piloerection, tearing, nasal congestion,
    diaphoresis, restless legs</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Clinical Opioid Withdrawal Scale (COWS): quantifies severity of
    opioid withdrawal and allows for safer buprenorphine inductions</p>
</li>
<li>
<p>Asking about opioid exposure: “You’re uncomfortable. I work with a
    lot of people in the hospital, and some come with regular exposure
    to opioids from a lot of different places (their doctors, friends),
    should we be treating any withdrawal for you?”</p>
</li>
</ul>
<p>Medications for Opioid Use Disorder (MOUD)</p>
<p>Buprenorphine</p>
<ul>
<li>
<p>Partial agonist at the mu opioid receptor with high binding affinity</p>
</li>
<li>
<p>Long half-life (24-36 hours) allows for daily dosing</p>
</li>
<li>
<p>TID dosing is more effective for acute pain (as the analgesic effect
    is shorter-lived)</p>
</li>
<li>
<p>OK to use in renal failure/HD; may reduce dose in hepatic injury</p>
</li>
<li>
<p>All non-pregnant pts should receive buprenorphine-naloxone (e.g.
    Suboxone) formulations to mitigate risk of diversion/injection</p>
</li>
<li>
<p>Induction:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Hold all opioid medication 12+ hours prior to first buprenorphine
    dose (typically, this opioid-free period is overnight from 9 PM to 9
    AM), with a recorded COWS score >8-10;</p>
</li>
<li>
<p>4 mg is given SL, monitoring for oversedation; additional 4 mg is
    given in 1 hour, and final 4 mg at 4 hours (total of 12 mg in first
    day)</p>
<ul>
<li>Only sedation or hypopnea should prevent a full 12 mg dose</li>
</ul>
</li>
<li>
<p>Typical starting dose: 12-16 mg/day</p>
</li>
</ul>
<!-- -->

<ul>
<li>Maintenance: 4-32 mg daily; 16mg and above to suppress opioid use</li>
</ul>
<!-- -->

<ul>
<li>Requires waivered-provider</li>
</ul>
<!-- -->

<ul>
<li>Acute Pain Management in pts using Buprenorphine:</li>
</ul>
<!-- -->

<ul>
<li>
<p>There is no contraindication to full-agonist opioid analgesia for
    breakthrough pain</p>
<ul>
<li>If the etiology of pts pain would require opioid therapy in a
    non-OUD patient, do not avoid opioids; these may be used safely
    in the hospital</li>
</ul>
</li>
<li>
<p>Peri-operative pain management: continue buprenorphine at reduced
    and split doses (4 mg BID or TID); will prevent withdrawal and
    cravings, but NOT manage new pain</p>
</li>
<li>
<p>Post-operatively: reduce opioid requirements and increase
    buprenorphine to home dose</p>
<ul>
<li>If buprenorphine was discontinued, will require induction
    procedure</li>
</ul>
</li>
</ul>
<p>Methadone</p>
<ul>
<li>
<p>Full mu opioid agonist with additional NMDA-receptor activity</p>
</li>
<li>
<p>Better option for individuals who cannot tolerate the buprenorphine
    induction procedure, with significant chronic or escalating pain</p>
</li>
</ul>
<!-- -->

<ul>
<li>Long t&frac12;: 12-36 hrs; max 10 mg/d q7d, to prevent dose-stacking and
    delayed overdose</li>
</ul>
<!-- -->

<ul>
<li>
<p>Safe in renal failure; dose reduction for hepatic injury</p>
</li>
<li>
<p>Potential for QT prolongation at higher doses, warrants QTc
    monitoring</p>
</li>
<li>
<p>Induction:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>In the hospital, start at 10 mg TID, holding doses for sedation or
    hypopnea; lower doses if concerned for respiratory compromise or
    concurrent CNS depressant therapy</p>
</li>
<li>
<p>Limit 40 mg in first 24 hours; then titrate 5 mg/d q3d while
    admitted</p>
</li>
</ul>
<!-- -->

<ul>
<li>Maintenance:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Must confirm dose with methadone clinic before restarting outpatient
    dose; until then, do not give more than initial doses (30 mg in
    single dose, 40 mg in first 24 hours)</p>
</li>
<li>
<p>After confirming home dose, continue as single daily dose</p>
</li>
</ul>
<p>Naltrexone</p>
<ul>
<li>
<p>Mu opioid antagonist; Half-life oral ~4 hours but clinically active
    ~24 hrs</p>
</li>
<li>
<p>IM maintains clinically effective levels up to 30 days</p>
</li>
<li>
<p>High affinity for mu receptor --> CAN precipitate withdrawal
    requiring 7-10 days opioid abstinence prior to initiation</p>
</li>
<li>
<p>If due for monthly injection while admitted, may substitute oral
    formulation until discharged to outpatient provider to receive
    injection</p>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Psychosocial Interventions that complement MOUD:</li>
</ul>
<!-- -->

<ul>
<li>Consider referral to SUD counseling, mutual help (self-help,
    12-step, AA), intensive outpatient, and short- or long-term
    residential treatment</li>
</ul>
<!-- -->

<ul>
<li>
<p>Use of other drugs NOT a contraindication to MOUD, however should
    encourage abstinence from other drugs during therapy (especially
    benzodiazepines)</p>
</li>
<li>
<p>Prescribe intranasal naloxone for overdose prevention to all OUD
    patients discharging from hospital, regardless of MOUD status</p>
</li>
</ul>
<p>Alcohol Use Disorder – Barrington Hwang, Kristopher Kast</p>
<p>Background</p>
<ul>
<li>
<p>50% of hospitalized pts drink alcohol; at-risk alcohol use is >14
    drinks/week or >5 drinks in a sitting (for men; for women and men
    >65, 7 per week, >4 per sitting)</p>
</li>
<li>
<p>Alcohol withdrawal onset occurs 6-12 hours after last drink, with
    90% having non-severe course; CIWA score \&lt;10 at 24-48 hours
    indicates low risk of worsening symptoms</p>
</li>
<li>
<p>Risk of seizures greatest at 12-24 hrs, occurring in ~3% of pts;
    risk of delirium greatest at 48-72 hrs, occurring in ~5%</p>
</li>
<li>
<p>Risk assessment</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>RF: prior seizures/delirium, co-substance use (especially
    benzodiazepines), no abstinent days in past month, presenting BAL
    >200, dysautonomia</p>
</li>
<li>
<p>CIWA symptom-triggered protocol appropriate for pts at low risk of
    severe withdrawal</p>
</li>
<li>
<p>For non-low risk pts, consider benzodiazepine/barbiturate load and
    standing taper;</p>
</li>
</ul>
<!-- -->

<ul>
<li>Indications for admission: prior severe withdrawal (withdrawal
    seizures or delirium), comorbidities (medical and psychiatric
    illness), pregnancy, significant impairment in social/occupational
    functioning, communication barriers, social barriers</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Acute intoxication: disinhibition, slurred speech, ataxia, nystagmus</p>
</li>
<li>
<p>Acute Withdrawal: nausea, vomiting, anxiety, agitation, audio-visual
    and tactile hallucinations, headache, diaphoresis, fine motor tremor
    while arms and fingers outstretched, autonomic hyperactivity</p>
</li>
<li>
<p>Chronic heavy use: Sequelae of chronic liver disease &amp; malnutrition,
    including thiamine deficiency</p>
</li>
<li>
<p>Caine criteria for Wernicke’s encephalopathy:</p>
</li>
</ul>
<!-- -->

<ul>
<li>2 or more: (1) malnutrition, (2) ataxia, (3) oculomotor
    abnormalities, (4) AMS</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Identify last use, quantity per day/week, other sedative-hypnotic
    use, history of withdrawal, social/occupational dysfunction, other
    toxic forms of alcohol compounds including methanol, ethylene glycol</p>
</li>
<li>
<p>Acute Alcohol Withdrawal</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Labs: Blood alcohol level, urine toxicology (&plusmn; ethyl glucuronide
    to detect use in prior 3 days), BMP, CBC, HFTs (AST:ALT elevation
    2:1), CK and β - hCG</p>
</li>
<li>
<p>CIWA score quantifies severity, though subject to inflation by
    subjective symptoms</p>
</li>
</ul>
<p>Management</p>
<p>Acute Alcohol Withdrawal</p>
<ul>
<li>Most patients are appropriate for diazepam-based protocols:</li>
</ul>
<!-- -->

<ul>
<li>
<p>CIWA-based symptom-triggered for low-risk patients</p>
</li>
<li>
<p>Diazepam load + standing taper for non-low risk patients</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Substitute lorazepam for pts with hepatic impairment (risk of
    long-acting accumulation)</p>
</li>
<li>
<p>Benzodiazepine resistance: likely due to poor cross-tolerance, these
    pts require phenobarbital load ( 8-12 mg/kg (up to 15 mg/kg) divided
    into 3 doses 3 hours apart)</p>
</li>
<li>
<p>Add folate, multivitamin, and electrolyte repletion</p>
</li>
<li>
<p>If >2 Caine criteria, treat empirically for Wernicke’s
    encephalopathy with high-dose IV thiamine (500 mg TID IV x 3-5 days)</p>
</li>
<li>
<p>Consider Addiction Psychiatry consultation for complex presentations</p>
</li>
</ul>
<p>Alcohol Use Disorder</p>
<ul>
<li>
<p>After withdrawal stabilization, engage pt in discussion around use
    and educate on connection between use and presenting medical
    problems</p>
</li>
<li>
<p>All patients with AUD should be initiated on pharmacotherapy (MAUD)
    prior to discharge to mitigate risk of relapse, if consistent with
    patient’s goals</p>
</li>
<li>
<p>Additional psychosocial treatments effective for AUD include 12-step
    groups (AA, SMART Recovery), cognitive behavioral therapy, sober
    living facilities, family therapy, contingency management, and
    IOP/residential facilities</p>
</li>
<li>
<p>If patient does not have abstinence goal, reduced or controlled
    drinking may allow for harm reduction; naltrexone and topiramate
    have evidence for non-abstinence outcomes</p>
</li>
<li>
<p>Pharmacologic Interventions:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Naltrexone (cannot be on opioid agonist):</p>
<ul>
<li>
<p>Need 7-10 days since last opioid before starting</p>
</li>
<li>
<p>25 mg x1 day, then titrate up to 50 mg daily; also available in
    q30d IM</p>
</li>
<li>
<p>Monitor liver enzymes; AST/ALT must be \&lt; 3-5x ULN</p>
</li>
</ul>
</li>
<li>
<p>Acamprosate (cannot be used in severe renal impairment)</p>
<ul>
<li>
<p>Head-to-head, inferior to naltrexone (see COMBINE trial)</p>
</li>
<li>
<p>333 mg TID, titrating to 666 mg TID dosing</p>
</li>
</ul>
</li>
<li>
<p>Disulfiram</p>
<ul>
<li>
<p>Infrequently used outside of extreme motivation (e.g.
    professional under monitoring); would not use outside specialist
    care</p>
</li>
<li>
<p>Must abstain from alcohol ~2 weeks after last dose, given risk
    of disulfiram-ethanol reaction (DER), which can be fatal
    depending upon disulfiram and ethanol doses</p>
</li>
</ul>
</li>
<li>
<p>Topiramate</p>
<ul>
<li>
<p>Not FDA-approved for AUD, but has significant supporting
    evidence</p>
</li>
<li>
<p>Useful for individuals without abstinence goal</p>
</li>
<li>
<p>Titrate slowly over 8 weeks to 200-300 mg/d</p>
</li>
</ul>
</li>
<li>
<p>Gabapentin</p>
<ul>
<li>
<p>Not FDA-approved for AUD, but with some evidence</p>
</li>
<li>
<p>Useful for post-acute withdrawal anxiety, insomnia, or
    co-occurring neuropathy</p>
</li>
<li>
<p>Titrate to 900-1800 mg/d divided into TID dosing, monitoring for
    sedation</p>
</li>
<li>
<p>Risk of sedation/apnea if concomitant alcohol use</p>
</li>
</ul>
</li>
</ul>
<p>Delirium – Julian Raffoul, reviewed by Wesley Ely and Jo Ellen Wilson</p>
<p>Background</p>
<ul>
<li>
<p>Definition: acute fluctuating disturbance of attention and awareness
    due to an underlying medical condition</p>
</li>
<li>
<p>Presentation: deficits in attention, orientation, or memory;
    hallucinations or delusions; sleep-wake disturbances; psychomotor
    changes (hyperactive, hypoactive, or mixed); language impairment;
    and/or emotional lability (agitation)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Think about the ABC’s of Delirium</p>
<ul>
<li>
<p>Affect (anxiety, paranoia, irritability, apathy, mood shifts,
    personality changes)</p>
</li>
<li>
<p>Behavior (hallucinations, restlessness or agitation, psychomotor
    abnormalities, sleep disturbances)</p>
</li>
<li>
<p>Cognition (impaired memory, disorientation, disturbances in
    speech)</p>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Use screening tools to assess for delirium: Brief Confusion
    Assessment Method (bCAM). See critical care section for the ICU
    version, CAM-ICU</p>
<p><img src="../psychiatry/main/output/media/image28.png"
style="width:1.9635in;height:1.9635in"
alt="Diagram Description automatically generated" /></p>
</li>
<li>
<p>Once delirium is diagnosed, evaluate for the underlying cause.
    Delirium has many etiologies and may occur alone or in combination
    (in ~10% of cases, no clear cause is found)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Mnemonic for common causes of delirium:</p>
<ul>
<li>
<p>D- Drugs/toxins (use of benzodiazepines, opiates,
    anticholinergics, steroids, etc., withdrawal from ETOH, benzos,
    etc.)</p>
</li>
<li>
<p>E- Eyes/ears (sensory deficits)</p>
</li>
<li>
<p>L- Low perfusion states (MI, PE, heart failure, sepsis)</p>
</li>
<li>
<p>I- Infection</p>
</li>
<li>
<p>R- Retention (urine, stool)</p>
</li>
<li>
<p>I- Intracranial events (trauma, seizure, stroke, hemorrhage)</p>
</li>
<li>
<p>U- Undernutrition/dehydration</p>
</li>
<li>
<p>M- Metabolic, endocrine (Hypo or hyper Na, hyperCa, uremia,
    thyroid, hypoglycemia)</p>
</li>
</ul>
</li>
<li>
<p>See neurology chapter for approach and work-up to AMS in general</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Treat underlying cause as above</p>
</li>
<li>
<p>See critical care section for prevention in the ICU (ABCDEF bundle)</p>
</li>
<li>
<p>Cognitive impairment or disorientation: provide clock, calendar, and
    appropriate lighting. Regular reorientation. Provide cues from a
    familiar environment (pictures, calls or visits from family members)</p>
</li>
<li>
<p>Encourage mobilization</p>
</li>
<li>
<p>Review medications, eliminate sedatives and anticholinergics as able
    (review agents on Beers Criteria medication list)</p>
</li>
<li>
<p>Remove medical support devices as able (foley catheters, telemetry)</p>
</li>
<li>
<p>Maintain normal sleep-wake cycle. Keep lights on in the day and
    avoid excessive naps</p>
</li>
<li>
<p>Ensure adequate bowel regimen and hydration</p>
</li>
<li>
<p>Assess for pain and treat appropriately</p>
</li>
<li>
<p>Ensure hearing aids, glasses, and dentures are available</p>
</li>
<li>
<p>Note on pharmacologic management: There is no pharmacologic
    intervention known to prevent or treat of delirium. Reserve for
    agitation impairing patient safety when non-pharmacologic
    interventions alone are unsuccessful. See agitation section for
    medication approach</p>
</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-agitation-management"><h1 id="psychiatry-psychiatry-agitation-management-agitation-management">Agitation Management<a class="headerlink" href="#psychiatry-psychiatry-agitation-management-agitation-management" title="Permanent link">&para;</a></h1>
<p>Agitation Management – Jonathan Constant, Jonathan Smith</p>
<p>Background</p>
<ul>
<li>Agitation
    in the hospital result from discomfort, illness, medication effects
    or frustrations the pt is unable to meaningfully communicate</li>
<li>Anticipate issues, monitor (COWS, CIWA) and pre-emptively treat
    withdrawal</li>
</ul>
<p>Presentation</p>
<ul>
<li>Impulsive aggression: spontaneous, explosive, reactive/reflexive,
    not pre-meditated<ul>
<li>Delirium, psychosis, cognitive deficits,
    withdrawal/intoxication, pain, post-ictal</li>
</ul>
</li>
<li>Instrumental aggression: pre-meditated, controlled, purposeful
    behaviors<ul>
<li>Personality disorders, secondary gain, delusional thought</li>
</ul>
</li>
<li>Differential diagnosis for aggression:<ul>
<li>Psychoses: mania, depression, schizophrenia, delusional disorder</li>
<li>Personality disorder: antisocial, borderline, paranoid,
    narcissistic</li>
<li>Substance use disorder: alcohol, PCP, stimulants, cocaine,
    synthetics</li>
<li>Epilepsy, Delirium, Dementia</li>
<li>Frontal lobe syndromes (TBI, CVA, neoplasm, neurodegenerative
    process)</li>
<li>Behavior/Developmental: Intermittent explosive, XYY genotype,
    Intellectual Disability</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Examine
    (when calm) for source of pain, signs of infection, obstructions,
    toxidromes</li>
<li>Neurological exam for focal deficits, ataxia, nystagmus, tremor,
    rigidity, aphasias</li>
<li>Review medication list and perform med reconciliation of home meds</li>
<li>UDS + review of CSMD for evaluation of intoxication/withdrawal</li>
<li>CBC, BMP, hepatic function, UA</li>
<li>CT head <u>+</u> EEG if focal neurologic deficits or acute change in
    clinical status</li>
<li>If suspicion: Blood cultures, RPR,  B12, folate, CK (
    ↑
    w/ restraints &amp; aggression)</li>
</ul>
<p>Management</p>
<ul>
<li>Environment<ul>
<li>Periodic room searches; search personal belongings</li>
<li>Virtual or 1:1 sitter placement, VUPD presence if warranted</li>
<li>Delirium precautions</li>
<li>Disposable trays and utensils (
    minimize
    potential weapons in the room)</li>
</ul>
</li>
<li>De-
    escalation
    : Always first line,
    although impractical if pt is unable to communicate effectively, is
    explosive or already engaging in violent/potentially harmful
    behavior<ul>
<li>Nonverbal:<ul>
<li>Maintain safe distance, avoid sudden movements, don't touch
    the pt<ul>
<li>Maintain neutral posture, neutral, sincere eye contact,
    same height</li>
</ul>
</li>
</ul>
</li>
<li>Verbal:<ul>
<li>Speak in calm, clear tone, avoid confrontation, and offer to
    solve problem if possible</li>
<li>Do not insist on having the last word</li>
</ul>
</li>
</ul>
</li>
<li>Tactics<ul>
<li>Redirection:
    Acknowledge pt's frustrations; shift focus on how to solve the
    problem</li>
<li>Aligning goals:
    Emphasize common ground and big picture; make small concessions</li>
<li>B
    e wary of transference, countertransference and situational
    tension</li>
</ul>
</li>
<li>Know when to disengage/leave room</li>
<li>Restraints<ul>
<li>Should be used only when necessary to protect patient or others
    from harm</li>
<li>Should not be used to coerce patient to accept or remain in
    treatment</li>
</ul>
</li>
<li>Mechanically restrained patients <strong>cannot be left unmonitored</strong><ul>
<li>De-escalate (4 point to 2 point, etc) and remove restraints as
    soon as possible</li>
<li>Documentation
    of restraint:</li>
</ul>
</li>
<li>Face-to-face assessment has to be completed within an hour of
    violent restraint</li>
<li>“Restraint Charting” tab – typically in rarely used tab drop down<ul>
<li>Mechanical Restraints:</li>
</ul>
</li>
<li>Soft restraints – most commonly used</li>
<li>Hard restraints – reserved for severe behavioral health (only 2 sets
    in house)</li>
<li>Mittens</li>
<li>Posey Vest – prevents exiting bed, allows limbs to be free</li>
<li>Posey Bed – wandering patient (TBI, severe dementia
    )<ul>
<li>VUMC Orders: “restraint” &rarr; order set</li>
</ul>
</li>
<li>Non-violent non-self-destructive (order lasts up to 48 hrs)<ul>
<li>Most pts needing restraint: non-psychiatric, delirium, dementia,
    intubation</li>
</ul>
</li>
<li>Restraint violent self- destructive adult<ul>
<li>Order
    lasts up to 24hr with assessment every 4 hours</li>
<li>Mainly
    severe psychiatric symptoms</li>
</ul>
</li>
</ul>
<p>Pharmacological Management for Agitation</p>
<p>Acute Agitation</p>
<ul>
<li>Antipsychotics<ul>
<li>Widely effective for acute agitation, especially in delirium and
    psychotic disorders</li>
<li>Choice of agent depends on patient characteristics (movement
    disorders, QTc)</li>
<li>Moderate agitation options:<ul>
<li>Olanzapine 2.5 - 5mg po q6h prn typical starting dose (ODT
    available</li>
<li>Quetiapine 12.5 - 25mg q6h po prn for patients at higher
    risk of EPS</li>
</ul>
</li>
</ul>
</li>
<li>Severe agitation<ul>
<li>Haldol 0.5 - 1mg IV/IM q6h prn for older/frail individuals</li>
<li>Haldol 2-3mg IV/IM q6h prn for other patients</li>
<li>Titrate up to 5 mg and can increase frequency as warranted</li>
<li>When using IV Haldol obtain daily EKG, Mg and K levels</li>
<li>Stop IV Haldol if QTcF greater than 500 msec (
    QTcB overestimates at HR &gt;60)</li>
</ul>
</li>
<li>Benzodiazepines<ul>
<li>May have fewer adverse effects compared to antipsychotics
    (dystonia, akathisia, EPS)</li>
<li>Can use alone or in addition to antipsychotic agent</li>
<li>Can worsen delirium, disinhibit patients with
    neurocognitive-related agitation</li>
<li>Preferred for agitation related to intoxication/withdrawal of
    sedatives<ul>
<li>Lorazepam preferentially used due to PO, IV and IM
    availabilit</li>
<li>Lorazepam 2mg PO/IM/IV q6h prn typical starting dose (1mg if
    older/frail)<ul>
<li>Can increase frequency if warranted though monitor
    respiratory suppression when combined with other
    respiratory suppressing agents</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>If severe agitation not responsive to above, may require sedation
    with infusion:<ul>
<li>Dexmedetomidine, Propofol or Midazolam</li>
</ul>
</li>
</ul>
<p>Maintenance medications:</p>
<ul>
<li>Antipsychotics<ul>
<li>Reserve antipsychotics for severe aggression that pose
    significant risk</li>
<li>Aim to wean as soon as safely possible</li>
<li>Adverse effects: metabolic, EPS, increased mortality in dementia</li>
<li>Most commonly used: Olanzapine, Quetiapine, Risperidone</li>
</ul>
</li>
<li>Antiepileptic
    agents<ul>
<li>May be effective in reduction of impulsive aggression</li>
<li>Most commonly used: Depakote<ul>
<li><strong>​​​​​​​​​​​​​​​​​​​​​​​​​​​​</strong> Levetiracetam could worsen
    aggression/agitation</li>
</ul>
</li>
</ul>
</li>
<li>Beta Blockers and Alpha Agonists<ul>
<li>Noradrenergic over-activity implicated in aggression expression</li>
<li>Commonly Used: Propranolol, Clonidine, Guanfacine</li>
</ul>
</li>
<li>Serotonergic agents: SSRI/SNRI/Buspar<ul>
<li>Some studies supporting use, though weeks to benefit</li>
<li>Useful if co-occurring depression/anxiety disorders</li>
</ul>
</li>
</ul>
<p>Agitation/Aggression due to personality disorder/secondary gain:</p>
<ul>
<li>Behavioral plan development (see Borderline Personality Disorder
    chapter)</li>
<li>Environmental safety precautions and medication management as
    outlined above</li>
<li>If continued disruptions, may require multidisciplinary team meeting
    with treating team(s) &plusmn; ethics, psychiatry, palliative care to
    determine appropriateness of administrative discharge vs. enforced
    treatment</li>
</ul>
<p>​​​​​​​</p></section><section class="print-page" id="psychiatry-psychiatry-inpatient-insomnia"><h1 id="psychiatry-psychiatry-inpatient-insomnia-inpatient-insomnia">Inpatient Insomnia<a class="headerlink" href="#psychiatry-psychiatry-inpatient-insomnia-inpatient-insomnia" title="Permanent link">&para;</a></h1>
<p>Inpatient Insomnia – Julian Raffoul, Jose Alberto Arriola Vigo</p>
<p>Background</p>
<ul>
<li>Sleep disturbances in the hospital are multifactorial</li>
<li>Consequences of sleep disturbances in the hospital include changes
    in cognition, behavior, anxiety, pain perception, respiratory
    function, inflammation, and metabolism</li>
<li>Goals while inpatient: optimize sleep environment, minimize
    stimulating or sleep-related side effects of concomitant
    medications, utilizing non-pharmacologic strategies</li>
</ul>
<p>Management</p>
<ul>
<li>Non-pharmacologic interventions:<ul>
<li>Noise reduction:
    use of ear protection, sound masking (white noise), sound
    proofing acoustic materials, and behavioral modifications (or
    "quiet time" protocols)</li>
<li>Light therapy
    : Use of eye masks in conjunction with ear plugs will improve
    sleep, however, nocturnal light appears to be less of an issue
    compared with inadequate daytime light exposure, which improves
    circadian rhythms, nocturnal sleep, and minimizes delirium<ul>
<li>Light exposure typically consists of two to five hours of
    daytime to early evening light in the range of 2000 to 5000
    lux</li>
</ul>
</li>
<li>Reducing nighttime interruptions:
    Alter workflow/lab draws, if possible, to permit 8-hr nocturnal
    "quiet time"</li>
<li>Relaxation techniques:
    Music or white noise may
    ↑
    subjective sleep quality and duration</li>
<li>Equipment:
    for severely ill pts, minimize hardware and tubes that can alter
    sleep due to physical presence and alarms</li>
</ul>
</li>
<li>Pharmacotherapy:<ul>
<li>Melatonin:
    1-5 mg PO qhs; (dosing is not standardized); the best first-line
    choice based on mild side-effect profile, low potential for
    drug-drug interactions, and improves circadian rhythms; Most
    effective 2-3hrs before bedtime</li>
<li>Ramelteon:
    8 mg PO qhs; a melatonin-receptor agonist; May also play a role
    in preventing delirium in older adult inpatients</li>
<li>Trazodone:
    25-50 mg PO qhs (max 200 mg/day); a serotonin modulator w/
    significant sedation as a side effect, also headache, dry mouth,
    and nausea are common<ul>
<li>Monitor for orthostasis and infrequent atrial arrhythmias;
    use lowest effective dose</li>
</ul>
</li>
<li>Mirtazapine:
    7.5-15 mg PO qHS; a primary alpha-2 antagonist with 5-HT2 and H1
    antagonism, consider when insomnia appears to be related to
    primary depression<ul>
<li>Advise that appetite and weight gain may also occur</li>
</ul>
</li>
<li>Minimize
    medications such as vasopressors, sedatives/hypnotics, opioids,
    glucocorticoids, beta blockers, and certain antibiotics that
    disturb sleep architecture</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Avoid the following in the inpatient setting:<ul>
<li>Benzodiazepines
    :  While effective at reducing sleep latency and increasing
    total sleep time, benzodiazepines are associated with
    significant adverse effects, particularly in older adults, e.g.,
    respiratory depression, cognitive decline, delirium, daytime
    sleepiness, and falls, particularly in hospitalized adults</li>
<li>Non
    -
    benzodiazepines
    : Benzodiazepine receptor agonists (e.g., zolpidem,
    eszopiclone/zopiclone, zaleplon) are effective in the outpatient
    setting and commonly used in the inpatient setting; however,
    they may be associated with cognitive dysfunction, delirium, and
    falls in hospitalized patients</li>
<li>Diphenhydramine
    : Trials evaluating their effectiveness as sleep aids are
    limited and show mixed results w/ many potential side effects
    that are enhanced in the inpatient setting: <em>impaired cognition</em>
    , <em>anticholinergic effects</em> (constipation, urinary retention)</li>
<li>Others
    : ( <strong>anticonvulsants</strong> , <strong>antidepressants</strong> ,
    <strong>antipsychotics</strong> , <strong>barbiturates</strong> ) are usually used in
    outpatient setting, but have not been well studied in the
    inpatient setting</li>
</ul>
</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-medical-decision-making-capacity"><h1 id="psychiatry-psychiatry-medical-decision-making-capacity-medical-decision-making-capacity">Medical Decision-Making Capacity<a class="headerlink" href="#psychiatry-psychiatry-medical-decision-making-capacity-medical-decision-making-capacity" title="Permanent link">&para;</a></h1>
<p>Medical Decision-Making Capacity – Chelsea Sprick, Neil Phillips,
Jonathan Smith</p>
<ul>
<li>Capacity can be assessed by any physician regarding a pt’s ability
    to make a <strong><em>specific</em></strong> medical decision at a <strong><em>specific</em></strong> point
    in time</li>
<li>Competency:
    “global decision-making capacity,” a legal determination made by a
    judge</li>
<li>If the patient does not have medical decision-making capacity:<ul>
<li>Identify and remedy cause of impairment if possible (if decision
    is non-urgent)</li>
<li>Identify surrogate decision maker</li>
</ul>
</li>
</ul>
<p>Assessing medical decision-making capacity</p>
<ul>
<li>Choice: patient must clearly indicate a consistent choice<ul>
<li>“Have you decided whether to follow the recommendation for the
    treatment?”</li>
<li>“Can you tell me what your decision is?”</li>
</ul>
</li>
<li>Understand
    : pt must grasp the fundamental meaning of the information
    communicated by the medical team<ul>
<li>“Please tell me in your own words what you were told about:<ul>
<li>The problem with (1) your health now and (2) the recommended
    treatment</li>
<li>The risks/benefits of (3) treatment, (4) alternative
    treatments and (5) no treatment”</li>
</ul>
</li>
</ul>
</li>
<li>Appreciate: the medical condition and likely consequences of
    treatment options<ul>
<li>“What do you believe is wrong with your health now?”</li>
<li>“What is treatment likely to do for you?”</li>
<li>“Do you believe you need treatment?”</li>
<li>“What do you believe will happen if you’re not treated”</li>
<li>“Why do you think this treatment was recommended?”</li>
</ul>
</li>
<li>Reason: patient must rationally manipulate relevant information<ul>
<li>“What makes the chosen option better than the alternative?”</li>
<li>“How did you decide to accept or reject the recommended
    treatment?”</li>
</ul>
</li>
</ul>
<p>Documenting medical decision-making capacity:</p>
<p>Use</p>
<p>a <strong>dot phrase .Capacity that lists the four components</strong> and document
your thought process citing evidence from your interview</p></section><section class="print-page" id="psychiatry-psychiatry-medical-hold"><h1 id="psychiatry-psychiatry-medical-hold-medical-hold">Medical Hold<a class="headerlink" href="#psychiatry-psychiatry-medical-hold-medical-hold" title="Permanent link">&para;</a></h1>
<p>Medical Hold – Chelsea Sprick, Barrington Hwang</p>
<p>Background</p>
<ul>
<li>6404: applies when there is a need for psychiatric hospitalization<ul>
<li>Can only be completed by a licensed physician<ul>
<li>Psychiatry residents can write these due to their special
    training licenses</li>
</ul>
</li>
</ul>
</li>
<li>No AMA Medical Hold: useful when a pt does not have capacity to
    leave the hospital against medical advice and needs to remain in the
    hospital<ul>
<li>Can be ordered by any physician</li>
</ul>
</li>
<li>6401 vs. 6404: Tennessee Title 33, Chapter 6, Part 4 is the legal
    code<ul>
<li>"6401": the form needed for emergency detention, examination and
    admissio<ul>
<li>One person completes this</li>
</ul>
</li>
</ul>
</li>
<li>"6404": the certificates for emergency involuntary admission<ul>
<li>The first 6404 is needed to transport a patient to a psychiatric
    facility and the second 6404 is needed for an involuntary
    admission</li>
<li>Pt must have mental illness or serious emotional disturbance,
    excluding intellectual/developmental disabilities and pose an
    immediate substantial likelihood of serious harm because of
    this, as evidenced by current/past SI/HI/SIB or deterioration at
    point of inability to care for self at significant risk to self
    or others</li>
<li>Treatment must be necessary for symptom reduction and lack of
    treatment would lead to deterioration, with no less drastic
    alternative to inpatient hospitalization.</li>
<li>Two different qualified persons must each complete a form</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>VUH-specific procedures<ul>
<li>A physical copy of (at least) the first 6404 is required to
    accompany the patient when they are transported to a psychiatric
    facility after medical discharge</li>
<li>Once completed, 6404s should be given to the medical
    receptionist on the unit for scanning into the medical record
    and for safe-keeping</li>
</ul>
</li>
<li>Consider whether a pt has a conservator or activated healthcare POA</li>
<li>If the conservator/POA is willing and able to complete the consent
    for admission, the pt can be admitted voluntarily<ul>
<li>The first 6404 would still be necessary for transportation to a
    psychiatric facility</li>
</ul>
</li>
<li>Unless the pt has a mental health-related condition or qualifies
    under the criteria above, pt is NOT committable under the
    involuntary admission</li>
<li>Just because someone wants to leave to use substances does not in
    itself mean they are committable, even if it does not seem like a
    good decision</li>
<li>While this may seem obvious, a 6404 or No AMA/Medical Hold takes
    away the personal liberties of an individual and this is a serious
    decision</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-motivational-interviewing"><h1 id="psychiatry-psychiatry-motivational-interviewing-motivational-interviewing">Motivational Interviewing<a class="headerlink" href="#psychiatry-psychiatry-motivational-interviewing-motivational-interviewing" title="Permanent link">&para;</a></h1>
<p>Motivational Interviewing (MI) – Barrington Hwang, <span
id="_Hlk41769139">Jose Arriola Vigo</span></p>
<p>Background</p>
<ul>
<li>MI:  an evidence-based form of non-judgmental, pt-centered
    counseling that elicits change in pt behavior by guiding pt through
    own motivations for change</li>
<li>For inpatients, MI is most useful for encouraging medication
    compliance before discharge or substance use cessation</li>
<li>Assumptions/principles:<ul>
<li>Pt is in state of ambivalence, whether outwardly expressed or
    not</li>
<li>Ambivalence is expressed with conflict between multiple courses
    of action</li>
</ul>
</li>
<li>Pt may go between stages of change at any given time, some pts may
    benefit from explaining this model of behavior change</li>
<li>Techniques to identify ambivalence:<ul>
<li>Focus
    on reasons to change ("why") as opposed to specific actions
    ("how")</li>
<li>Express empathy: discussion about values, hopes, emotions, and
    goals surrounding behavior</li>
<li>Empower self-efficacy: ask about other times they have made
    changes in life</li>
<li>Develop discrepancy - between current and desired behavior</li>
<li>Avoid argument and authoritarian mentality - consider "asking"
    for permission to give your own thoughts, don't "give advice"</li>
<li>Defuse resistance to change - emphasize pt autonomy and reflect
    on resistance</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Stages of behavior change:<ul>
<li>Precontemplation - pt does not intend to change and has not
    taken action toward behavior change; could be related to
    demoralization from prior attempts</li>
<li>Contemplation - pt intends to change, but has not taken action,
    usually related to awareness of risks vs benefits of change</li>
<li>Preparation - pt intends to change, has taken steps to create
    plan and mental action, but no current physical action toward
    behavior change</li>
<li>Action - pt intends to change, currently following through on
    plan</li>
<li>Maintenance - pt intends to change, has changed, and is taking
    steps to prevent relapse</li>
</ul>
</li>
<li>Continuing the Conversation:<ul>
<li>May be effective to have SMART goal-setting if pt is in any
    stage except precontemplation: Specific, Measurable, Attainable,
    Realistic, Time-limited</li>
<li>Pts may benefit from discussion on specific defense mechanisms</li>
<li>"OARS" interviewing skills: Open-ended questions, Affirm,
    Reflect, Summarize</li>
<li>Most effective in conjunction with other treatments, when pts
    are willing, and when pts express ideas for change themselves</li>
<li>Least effective in
    group format and when pt feels change comes from authority</li>
</ul>
</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-personality-disorders"><h1 id="psychiatry-psychiatry-personality-disorders-personality-disorders">Personality Disorders<a class="headerlink" href="#psychiatry-psychiatry-personality-disorders-personality-disorders" title="Permanent link">&para;</a></h1>
<p>Personality Disorders – Jonathan Constant, Jonathan Smith</p>
<p>Background</p>
<ul>
<li>Caring for pts with personality disorder symptoms can result in pt
    and provider frustration, delays in treatment and at times,
    sub-optimal care and AMA discharges</li>
<li>An understanding of personality disorders can mitigate some of these
    barriers</li>
<li>How do personality disorders develop?<ul>
<li>Genetic/temperament component, early traumatizing and shaping
    experiences</li>
<li>Development of maladaptive perceptions and responses to other
    individuals</li>
<li>Pathological interaction styles and response to stressors (fear
    of abandonment, dependence, rejection) are developed and become
    self-fulfilling and re-enforced leading to pervasive
    interpersonal difficulties</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Borderline Personality Disorder:<ul>
<li>Unstable and intense relationships; “splitting” between
    idealization and devaluation</li>
<li>Frantic efforts to avoid real or imagined abandonment</li>
<li>Impulsivity: substance use, binge eating, reckless behavior</li>
<li>Recurrent suicidal behavior or gestures</li>
<li>Mood instability: quick onset and short-lived intense dysphoria,
    irritability, anxiety</li>
<li>Difficulty controlling anger (displays of temper, aggression)</li>
</ul>
</li>
<li>Narcissistic Personality Disorder:<ul>
<li>Grandiosity: exaggerates achievements and expects to be
    recognized as superior</li>
<li>Preoccupied with unlimited power, success, brilliance</li>
<li>Sense of entitlement: expects favorable treatment and compliance
    with expectations</li>
<li>Exploits others and lacks empathy</li>
</ul>
</li>
<li>Antisocial personality disorder:<ul>
<li>Failure to conform to social norms with respect to lawful
    behavior</li>
<li>Deceitfulness, lying, conning others for personal profit or
    pleasure</li>
<li>Impulsivity and reckless disregard for others</li>
<li>Irritability, aggressiveness and lack of remorse</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Consult Psychiatry</li>
<li>Create a behavioral plan<ul>
<li>Outline the pt, as well as the team’s, responsibilities and
    goals of care with identification of the concerning behavior and
    a firm plan for if the agreement is broken</li>
<li>Ideally, the pt should sign this plan and consider it as a
    contract</li>
<li>Dot Phrase/Sample:
    .IMBehavioralPlan (go to dot phrases under user Joseph Quintana)<ul>
<li>Adjust, add and remove content based on patient</li>
</ul>
</li>
</ul>
</li>
<li>Behavioral interventions:<ul>
<li>Aim for consistency w/ providers &amp; nursing; limit consultants to
    ↓
    splitting behaviors</li>
<li>Acknowledge pt's grievance/frustrations and shift focus on how
    to solve the problem</li>
<li>Align goals by emphasizing common ground and find ways to make
    small concessions</li>
<li>Be aware of progress and know when to disengage (if behaviors
    are escalating)</li>
<li>Monitor countertransference (the emotions the pt is eliciting in
    the provider): irresponsible and child-like behavior may prompt
    the provider to become angry or act in ways to limit the pt's
    control in their care, further perpetuating the behavior</li>
</ul>
</li>
<li>Gold standard = Psychotherapy<ul>
<li>Dialectical Behavioral therapy, Cognitive behavioral therapy,
    Psychodynamic</li>
<li>If the patient is willing, SW should assist with establishing at
    discharge</li>
</ul>
</li>
<li>Pharmacotherapy <strong>:</strong><ul>
<li>Unclear benefit in pharmacological management of Personality
    Disorder</li>
<li>Treatment of comorbid psychiatric disorders if present would be
    most appropriate</li>
</ul>
</li>
</ul></section><section class="print-page" id="psychiatry-psychiatry-substance-use-disorder"><h1 id="psychiatry-psychiatry-substance-use-disorder-substance-use-disorder">Substance Use Disorder<a class="headerlink" href="#psychiatry-psychiatry-substance-use-disorder-substance-use-disorder" title="Permanent link">&para;</a></h1>
<p>Substance Use Disorder (SUD)– Barrington Hwang, Kristopher Kast</p>
<p>Background</p>
<ul>
<li>SUDs are common, complex, and chronic neuropsychiatric
    disorders
    with well-described inherited risk, dysregulated neurophysiology,
    and multiple effective treatment modalities</li>
<li>Pts w/SUD
    face significant stigma, prior traumatic experiences in healthcare
    environments</li>
<li>Approaching pts respectfully and fostering partnership is important
    to quality care</li>
<li>Using
    the term “abuse” undermines the disease model of addiction,
    connoting volitional “bad” behavior driving recurrent substance use</li>
<li>Person
    -centered, specific terminology: “person with opioid and alcohol use
    disorders”</li>
<li>Avoid the qualifier “Polysubstance,” suggests the specific diagnoses
    are less important data</li>
<li>Clarify specific diagnoses for each substance category:<ul>
<li>Identify
    the
    current substance exposures and distinguish use
    disorder
    from unhealthy use and episodic use</li>
</ul>
</li>
<li>DSM 5 Criteria (same for most substance categories): Requires 2+
    criteria met in past year; use must cause clinically significant
    impairment and/or distress:<ul>
<li>Loss of control – larger amounts, longer time, ongoing use
    despite consequences, efforts/desire to reduce use</li>
<li>Physiologic changes -- tolerance, withdrawal (these 2 alone do
    not necessarily imply a disorder if they result from prescribed
    therapy), craving</li>
<li>Consequences – hazardous use, interpersonal problems, medical
    problems, failed role obligations, lost activities</li>
</ul>
</li>
<li>In the general hospital, SUD management first requires identifying
    and stabilizing withdrawal states to mitigate risks of severe
    sequelae (seizure, delirium), unintended iatrogenic harm (opioid
    abstinence leading to lost tolerance and post-discharge overdose),
    and distress-driven AMA discharge</li>
</ul>
<p>General Management:</p>
<ul>
<li>Consider Addiction Psychiatry consultation for management of complex
    withdrawal states, substance use disorders and co-occurring
    psychiatric diagnoses, assistance with risk stratification for
    hospital misuse and/or hospital discharge with PICC lines for
    outpatient antibiotics, and differentiation of pain requiring opioid
    therapy and opioid use disorder<ul>
<li>At VUMC: In Epic, “Inpatient Consult to Psychiatry, Addiction
    Medicine”</li>
<li>Team consists of addiction psychiatrists, nurse practitioners,
    fellows/residents, social workers, and recovery coaches</li>
</ul>
</li>
<li>If in the emergency room and not admitted, consult PAS</li>
</ul>
<p>Opioid</p>
<p>Use Disorder – Rita Hurd, David Marcovitz</p>
<p>Background</p>
<ul>
<li>Standard
    of care is opioid stabilization with buprenorphine or methadone (in
    OUD) or other full agonist opioids (in chronic opioid therapy)</li>
<li>Methadone
    and buprenorphine can be ordered by any physician for inpatients</li>
<li>Maintenance
    agonist therapy should be offered to every patient, with preference
    for an “opt-out” approach (even for uninsured patients through state
    grant funding)</li>
</ul>
<p>Presentation (Withdrawal)</p>
<ul>
<li>Restlessness
    /psychomotor activation, anxiety, irritability, nausea, abdominal
    cramping, loose stool, diffuse musculoskeletal pain, chills,
    Insomnia, yawning</li>
<li>Pupillary
    dilation, piloerection, tearing, nasal congestion, diaphoresis,
    restless legs</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Clinical
    Opioid Withdrawal Scale (COWS): quantifies severity of opioid
    withdrawal and allows for safer buprenorphine inductions</li>
<li>Asking
    about opioid exposure: “You’re uncomfortable. I work with a lot of
    people in the hospital, and some come with regular exposure to
    opioids from a lot of different places (their doctors, friends),
    should we be treating any withdrawal for you?”</li>
</ul>
<p>Medications for Opioid Use Disorder (MOUD)</p>
<p>Buprenorphine</p>
<ul>
<li>Partial
    agonist at the mu opioid receptor with high binding affinity</li>
<li>Long
    half-life (24-36 hours) allows for daily dosing</li>
<li>TID
    dosing is more effective for <strong>acute pain</strong> (as the analgesic effect
    is shorter-lived)</li>
<li>OK
    to use in renal failure/HD; may reduce dose in hepatic injury</li>
<li>All non-pregnant pts should receive buprenorphine-naloxone (e.g.
    Suboxone)
    formulations
    to mitigate risk of diversion/injection</li>
<li>Induction
    :<ul>
<li>Hold all opioid medication 12+ hours prior to first
    buprenorphine dose (typically, this opioid-free period is
    overnight from 9 PM to 9 AM), with a recorded COWS score &gt;8-10;</li>
<li>4 mg is given SL, monitoring for oversedation; additional 4 mg
    is given in 1 hour, and final 4 mg at 4 hours (total of 12 mg in
    first day)<ul>
<li>Only sedation or hypopnea should prevent a full 12 mg dose</li>
</ul>
</li>
<li>Typical
    starting
    dose: 12-16 mg/day</li>
</ul>
</li>
<li>Maintenance
    :
    4-32 mg daily; 16mg and above to suppress opioid use<ul>
<li>Requires waivered-provider</li>
</ul>
</li>
<li>Acute
    Pain Management in pts using Buprenorphine:<ul>
<li>There is no contraindication to full-agonist opioid analgesia
    for breakthrough pain<ul>
<li>If the etiology of pts pain would require opioid therapy in
    a non-OUD patient, do not avoid opioids; these may be used
    safely in the hospital</li>
</ul>
</li>
<li>Peri-operative pain management: continue buprenorphine at
    reduced and split doses (4 mg BID or TID); will prevent
    withdrawal and cravings, but NOT manage new pain</li>
<li>Post-operatively: reduce opioid requirements and increase
    buprenorphine to home dose<ul>
<li>If buprenorphine was discontinued, will require induction
    procedure</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Methadone</p>
<ul>
<li>Full mu opioid agonist with additional NMDA-receptor activity</li>
<li>FDA-approved for OUD when dispensed from a licensed opioid treatment
    program</li>
<li>Better option for individuals who cannot tolerate the buprenorphine
    induction procedure, with significant chronic or escalating pain<ul>
<li>Long t <sup>1/</sup> <sub>2</sub> : 12-36 hrs; max 10 mg/d q7d,
    to prevent dose-stacking and delayed overdose</li>
</ul>
</li>
<li>Safe in renal failure; dose reduction for hepatic injury</li>
<li>Potential for QT prolongation at higher doses, warrants QTc
    monitoring</li>
<li>Induction
    :<ul>
<li>In the hospital, start at 10 mg TID, holding doses for sedation
    or hypopnea; lower doses if concerned for respiratory compromise
    or concurrent CNS depressant therapy</li>
<li>Limit 40 mg in first 24 hours; then titrate 5 mg/d q3d while
    admitted</li>
</ul>
</li>
<li>Maintenance
    :<ul>
<li>Must confirm dose with methadone clinic before restarting
    outpatient dose; until then, do not give more than initial doses
    (30 mg in single dose, 40 mg in first 24 hours)</li>
<li>After confirming home dose, continue as single daily dose</li>
</ul>
</li>
</ul>
<p>Naltrexone</p>
<ul>
<li>Mu opioid antagonist; Half-life oral ~4 hours but clinically active
    ~24 hrs</li>
<li>IM maintains clinically effective levels up to 30 days</li>
<li>High affinity for mu receptor &rarr; CAN precipitate withdrawal
    requiring 7-10 days opioid abstinence prior to initiation</li>
<li>If due for monthly injection while admitted, may substitute oral
    formulation until discharged to outpatient provider to receive
    injection</li>
</ul>
<p>Additional Information</p>
<ul>
<li>Psychosocial Interventions that complement MOUD:<ul>
<li>Consider referral to SUD counseling, mutual help (self-help,
    12-step, AA), intensive outpatient, and short- or long-term
    residential treatment</li>
<li>Use of other drugs NOT a contraindication to MOUD, however
    should encourage abstinence from other drugs during therapy
    (especially benzodiazepines)</li>
</ul>
</li>
<li>Prescribe intranasal naloxone for overdose prevention to all OUD
    patients discharging from hospital, regardless of MOUD status</li>
</ul>
<p>Alcohol Use Disorder – Barrington Hwang , Kristopher Kast</p>
<p>Background</p>
<ul>
<li>50% of hospitalized pts drink alcohol; at-risk alcohol use is &gt;14
    drinks/week or &gt;5 drinks in a sitting (for men; for women and
    men &gt;65, 7 per week, &gt;4 per sitting)</li>
<li>Alcohol
    withdrawal onset occurs 6-12 hours after last drink, with 90% having
    non-severe course; CIWA score \&lt;10 at 24-48 hours indicates low risk
    of worsening symptoms</li>
<li>Risk
    of seizures greatest at 12-24 hrs, occurring in ~3% of pts; risk of
    delirium greatest at 48-72 hrs, occurring in ~5%</li>
<li>Risk
    assessment<ul>
<li>RF: prior seizures/delirium, co-substance use (especially
    benzodiazepines), no abstinent days in past month, presenting
    BAL &gt;200, dysautonomia</li>
<li>CIWA symptom-triggered protocol appropriate for pts at <strong>low</strong>
    <strong>risk</strong> of severe withdrawal</li>
<li>For non-low risk pts, consider benzodiazepine/barbiturate load
    and standing taper;</li>
</ul>
</li>
<li>Indications
    for
    admission: prior severe withdrawal (withdrawal seizures or
    delirium), comorbidities (medical and psychiatric illness),
    pregnancy, significant impairment in social/occupational
    functioning, communication barriers, social barriers</li>
</ul>
<p>Presentation</p>
<ul>
<li>Acute
    intoxication: disinhibition, slurred speech, ataxia, nystagmus</li>
<li>Acute
    Withdrawal:  nausea, vomiting, anxiety, agitation, audio-visual and
    tacticle
    hallucinations
    , headache, diaphoresis, fine motor tremor while arms and fingers
    outstretched, autonomic hyperactivity</li>
<li>Chronic
    heavy use:<ul>
<li>Sequelae of chronic liver disease &amp; malnutrition, including
    thiamine deficiency</li>
</ul>
</li>
<li>Caine
    criteria for Wernicke’s encephalopathy:<ul>
<li>2 or more: (1) malnutrition, (2) ataxia, (3) oculomotor
    abnormalities, (4) AMS</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Identify
    last use, quantity per day/week, other sedative-hypnotic use,
    history of withdrawal, social/occupational dysfunction, other toxic
    forms of alcohol compounds including methanol, ethylene glycol</li>
<li>Acute
    Alcohol
    Withdrawal<ul>
<li>Labs: Blood alcohol level, urine toxicology (&plusmn; ethyl
    glucuronide to detect use in prior 3 days), BMP, CBC, HFTs
    (AST:ALT elevation 2:1), CK and
    β
    - hCG</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>CIWA
    score quantifies severity, though subject to inflation by subjective
    symptoms</li>
<li>Objective Alcohol Withdrawal Scale (OAWS) is an alternative for pts
    at risk of over-reporting symptoms</li>
</ul>
<p>Management</p>
<p>Acute Alcohol Withdrawal</p>
<ul>
<li>Most patients are appropriate for diazepam-based protocols:<ul>
<li>CIWA-based symptom-triggered for low-risk patients</li>
<li>Diazepam load + standing taper for non-low risk patients</li>
</ul>
</li>
<li>Substitute lorazepam for pts with hepatic impairment (risk of long
    acting accumulation)</li>
<li>Benzodiazepine resistance: likely due to poor cross-tolerance, these
    pts  require phenobarbital load ( 8-12 mg/kg (up to 15 mg/kg)
    divided into 3 doses 3 hours apart)</li>
<li>Add folate, multivitamin, and electrolyte repletion</li>
<li>If &gt;2 Caine criteria, treat empirically for Wernicke’s
    encephalopathy with high-dose IV thiamine (500 mg TID IV x 3-5 days)</li>
</ul>
<p>-      Consider Addiction Psychiatry consultation for complex
presentations</p>
<p>Alcohol Use Disorder</p>
<ul>
<li>After withdrawal stabilization, engage pt in discussion around use
    and educate on connection between use and presenting medical
    problems</li>
<li>All patients with AUD should be initiated on pharmacotherapy (MAUD)
    prior to discharge to mitigate risk of relapse, if consistent with
    patient’s goals</li>
<li>Additional psychosocial treatments effective for AUD include
    motivational interviewing, 12-step groups (AA, SMART Recovery),
    cognitive behavioral therapy, sober living facilities, family
    therapy, contingency management, and IOP/residential facilities</li>
<li>If patient does not have abstinence goal, reduced or controlled
    drinking may allow for harm reduction; naltrexone and topiramate
    have evidence for non-abstinence outcomes</li>
</ul>
<!-- -->

<ul>
<li>Pharmacologic
    Interventions:<ul>
<li>Naltrexone
    (cannot be on opioid agonist):<ul>
<li>Need 7-10 days since last opioid before starting</li>
<li>25 mg x1 day, then titrate up to 50 mg daily; also available
    in q30d IM</li>
<li>Monitor liver enzymes; AST/ALT must be \&lt; 3-5x ULN</li>
</ul>
</li>
<li>Acamprosate
    (cannot be used in severe renal impairment)<ul>
<li>Head-to-head, inferior to naltrexone (see COMBINE trial)</li>
<li>333 mg TID, titrating to 666 mg TID dosing</li>
<li>Difficult TID dosing may be helpful if framed as
    commitment/mindfulness practice</li>
</ul>
</li>
<li>Disulfiram<ul>
<li>Infrequently used outside of extreme motivation (e.g.
    professional under monitoring); would not use outside
    specialist care</li>
<li>Must abstain from alcohol ~2 weeks after last dose, given
    risk of disulfiram-ethanol reaction (DER), which can be
    fatal depending upon disulfiram and ethanol doses</li>
</ul>
</li>
<li>Topiramate<ul>
<li>Not FDA-approved for AUD, but has significant supporting
    evidence</li>
<li>Useful for individuals without abstinence goal</li>
<li>Titrate slowly over 8 weeks to 200-300 mg/d</li>
</ul>
</li>
<li>Gabapentin
    :<ul>
<li>Not FDA-approved for AUD, but with some evidence</li>
<li>Useful for post-acute withdrawal anxiety, insomnia, or
    co-occurring neuropathy</li>
<li>Titrate to 900-1800 mg/d divided into TID dosing, monitoring
    for sedation</li>
<li>Risk
    of sedation/apnea if concomitant alcohol use; ensure pt
    educated about risk</li>
</ul>
</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Psychiatry</h1>
                        <h1 class='nav-section-title' id='section-pulmonary'>
                            Pulmonary <a class='headerlink' href='#section-pulmonary' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="pulmonary-main"><p>Hypoxia – Henry Brems</p>
<p>Background</p>
<ul>
<li>
<p>Two major ways to measure oxygenation, which are similar but
    distinct:</p>
</li>
<li>
<p>SpO2 or "pulse ox" - most common, measures the O2 saturation of Hgb
    at capillary level</p>
<ul>
<li>\&lt;95% is abnormal, but do not need supplemental O2 unless
    \&lt;90-92% in most pts</li>
</ul>
</li>
<li>
<p>PaO2 - the partial pressure of oxygenation measured on an ABG</p>
<ul>
<li>\&lt;80 mmHg is abnormal</li>
</ul>
</li>
<li>
<p>The relationship between SpO2 and PaO2 is the classic S-shaped
    curve.</p>
<ul>
<li>SpO2 of \&lt;88% PaO2 begins to fall off dangerously fast</li>
</ul>
</li>
</ul>
<p>Mechanisms of Hypoxia</p>
<table>
<colgroup>
<col style="width: 29%" />
<col style="width: 70%" />
</colgroup>
<thead>
<tr class="header">
<th>Mechanism</th>
<th>Pathophysiology</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Decreased barometric pressure</td>
<td><p>Normal A-a gradient</p>
<p>Unlikely to be seen except at high altitudes</p></td>
</tr>
<tr class="even">
<td>Hypoventilation</td>
<td><p>Normal A-a gradient</p>
<p>Hypoxia easily correctable with supplemental O2</p></td>
</tr>
<tr class="odd">
<td>V/Q Mismatch</td>
<td><p>Increased A-a gradient</p>
<p>Processes that lead to areas of lung where V/Q &lt;1</p>
<p>Common examples include PNA, ARDS, pulmonary edema</p></td>
</tr>
<tr class="even">
<td>Right-to-left Shunt</td>
<td><p>Increased A-a gradient</p>
<p>Can be anatomic (e.g. intracardiac, AVMs) or physiologic
(water/pus/blood filling alveoli)</p>
<p>Classically does not easily correct with supplemental O2</p></td>
</tr>
<tr class="odd">
<td>Diffusion Limitation</td>
<td><p>Increased A-a gradient</p>
<p>Often related to diseases affecting the interstitium -- e.g.,
ILD</p></td>
</tr>
</tbody>
</table>

<p>Differential diagnosis for hypoxia based on anatomical location</p>
<table>
<colgroup>
<col style="width: 29%" />
<col style="width: 70%" />
</colgroup>
<thead>
<tr class="header">
<th>Anatomical Location</th>
<th>Differential Diagnosis</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Airways</td>
<td><p>COPD most common, Asthma in very severe cases</p>
<p>CF, bronchiectasis in patients with appropriate history</p></td>
</tr>
<tr class="even">
<td>Alveoli</td>
<td><p>Blood</p>
<p>Pus: infection from bacterial, viral, fungal agents</p>
<p>Water: pulmonary edema</p>
<p>Protein/Cells/Other: ARDS, pneumonitis (e.g., aspiration,
drug-induced)</p></td>
</tr>
<tr class="odd">
<td>Interstitium/Parenchyma</td>
<td>Interstitial Lung Disease</td>
</tr>
<tr class="even">
<td>Vascular</td>
<td><p>Pulmonary Emboli</p>
<p>Suspect in patients with significant hypoxia and a clear CXR</p></td>
</tr>
<tr class="odd">
<td><p>Pleural Space and</p>
<p>Chest Wall</p></td>
<td><p>Pleural Effusions, Pneumothorax, Neuromuscular weakness, tense
ascites</p>
<p>More likely to cause dyspnea, need to be severe to cause
hypoxia</p></td>
</tr>
</tbody>
</table>

<p>Evaluation</p>
<ul>
<li>
<p>Confirm true hypoxia with good pleth</p>
</li>
<li>
<p>CXR</p>
</li>
<li>
<p>Labs: CBC, BMP, BNP, troponin, ABG/VBG</p>
</li>
<li>
<p>EKG</p>
</li>
<li>
<p>TTE: obtain with bubble if shunt on ddx</p>
</li>
<li>
<p>Lung US: B lines, lung sliding, effusions, consolidations
    (hepatization), diaphragm paralysis</p>
</li>
<li>
<p>Chest CT without contrast for evaluation of lung parenchyma</p>
</li>
<li>
<p>CTA chest if suspicion for PE (see PE section)</p>
</li>
<li>
<p>Outpatient PFTs if suspected obstructive or restrictive disease</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Should be directed at underlying cause</p>
</li>
<li>
<p>If acutely decompensating, Duonebs, IV lasix, antibiotics depending
    on clinical picture</p>
</li>
<li>
<p>Supplemental O2 for goal SpO2:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>>90-92% for most patients (There is generally no need to make SpO2
    100%)</p>
</li>
<li>
<p>Between 88-92% for patients with chronic hypoxia from COPD (i.e., on
    home O2)</p>
</li>
</ul>
<p>Pulmonary Function Tests (PFTs) – Peter Edmonds</p>
<p>Full PFTs include:</p>
<ul>
<li>Spirometry: FVC, FEV1, with or without bronchodilator</li>
</ul>
<!-- -->

<ul>
<li>Patients with new shortness of breath, chronic cough, or upper
    airway obstruction</li>
</ul>
<!-- -->

<ul>
<li>Plethysmography: TLC, RV</li>
</ul>
<!-- -->

<ul>
<li>Evaluation of restrictive diseases (ILD, neuromuscular) or
    hyperinflation (COPD, asthma)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Diffusion (DLCO) can be added to plethysmography</p>
</li>
<li>
<p>'Full PFTs' = Spirometry + Plethysmography + DLCO</p>
</li>
</ul>
<p>Tips for ordering:</p>
<ul>
<li>
<p>Initial diagnostic workup: Full PFTs with bronchodilator challenge</p>
</li>
<li>
<p>Chronic Lung disease: Spirometry to track FEV1/FVC over time &plusmn;
    DLCO to evaluate ILD</p>
</li>
</ul>
<p>Interpretation:</p>
<ul>
<li>Distinguish between obstructive and restrictive disease</li>
</ul>
<!-- -->

<ul>
<li>
<p>FEV1/FVC \&lt; 0.7 indicates obstructive disease</p>
<ul>
<li>Normal to increased FVC &amp; TLC is consistent with isolated
    obstructive disease</li>
</ul>
</li>
<li>
<p>TLC \&lt; 80% is diagnostic of restrictive disease</p>
<ul>
<li>
<p>Reduced FVC is suggestive, but not diagnostic of restrictive
    disease</p>
</li>
<li>
<p>FEV1 commonly too but FEV1/FVC ratio is normal in isolated
    restrictive disease</p>
</li>
</ul>
</li>
<li>
<p>Decreased FEV1/FVC and TLC suggests a mixed obstructive and
    restrictive picture</p>
</li>
</ul>
<!-- -->

<ul>
<li>Assess DLCO -- abnormal is \&lt;75%</li>
</ul>
<!-- -->

<ul>
<li>Decreased DLCO can help differentiate between causes of obstructive
    or restrictive PFTs</li>
</ul>
<p>Causes of common abnormalities:</p>
<ul>
<li>Obstruction</li>
</ul>
<!-- -->

<ul>
<li>
<p>Decreased DLCO: COPD, CF, bronchiectasis</p>
</li>
<li>
<p>Normal DLCO: asthma, early stages of COPD or CF</p>
<ul>
<li>Asthma: spirometry may be normal, +bronchodilator response (an
    increase in FEV1 by 12% and 200ml after bronchodilator),
    +methacholine challenge</li>
</ul>
</li>
<li>
<p>Though we use FEV1/FVC to diagnose, we track disease severity using
    FEV1</p>
</li>
</ul>
<!-- -->

<ul>
<li>Restriction:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Decreased DLCO: ILD</p>
</li>
<li>
<p>Normal DLCO: pleural disease, chest wall (obesity, scoliosis),
    neuromuscular disorders</p>
</li>
</ul>
<!-- -->

<ul>
<li>Decreased DLCO: If PFTs otherwise normal consider pulmonary vascular
    disease, pulmonary edema, or mixed obstructive/restrictive disease
    (pseudo-normalization of PFTs)</li>
</ul>
<p>Basics of Blood Gases – Lexi Haugh</p>
<p>Did you order an ABG or VBG?</p>
<ul>
<li>
<p>Need to assess oxygenation ABG</p>
</li>
<li>
<p>Need to assess hypoventilation May use VBG. ABG if shock, severe
    hypercapnia</p>
</li>
<li>
<p>pH VBG usually correlates with an ABG (venous pH is ~0.04 lower
    than arterial pH)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Less accurate in shock or severe acid-base disturbance</li>
</ul>
<!-- -->

<ul>
<li>
<p>ABGs are obtained by respiratory both at VUMC and the VA</p>
</li>
<li>
<p>VBGs can be ordered like other labs on the floor. Ran as point of
    care test (iSTAT) in the ICU</p>
</li>
</ul>
<p>Assessing Oxygenation:</p>
<ul>
<li>A-a gradient = PAO2 (alveolar O2) – PaO2 (arterial O2)</li>
</ul>
<!-- -->

<ul>
<li>
<p>PAO2 = FiO2 (Pbarom - PH2O) - PaCO2/R</p>
<ul>
<li>
<p>FiO2 = 0.21 on room air otherwise obtain from ventilator</p>
</li>
<li>
<p>Pbarom = 760, PH2O = 47</p>
</li>
<li>
<p>R (respiratory quotient) = 0.8</p>
</li>
<li>
<p>PaCO2 = arterial CO2 measured on ABG</p>
</li>
<li>
<p>Normal A-a gradient = (Age +10)/4</p>
</li>
</ul>
</li>
<li>
<p>See hypoxia section for ddx of increased A-a gradient</p>
</li>
</ul>
<p>Assessing Acid/Base Status and Ventilation:</p>
<ul>
<li>
<p>Look at the pH (normal = 7.35 – 7.45): pH \&lt; 7.35 = acidosis; pH >
    7.45 = alkalosis</p>
</li>
<li>
<p>Look at the pCO2 (normal = 35-45 mmHg)</p>
</li>
</ul>
<table>
<thead>
<tr>
<th>Primary Disorder</th>
<th>pH</th>
<th>pCO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Acidosis</td>
<td>\&lt; 7.35</td>
<td>>45</td>
</tr>
<tr>
<td>Respiratory Alkalosis</td>
<td>> 7.45</td>
<td>\&lt;35</td>
</tr>
<tr>
<td>Metabolic Acidosis</td>
<td>\&lt; 7.35</td>
<td>\&lt;45</td>
</tr>
<tr>
<td>Metabolic Alkalosis</td>
<td>> 7.45</td>
<td>>35</td>
</tr>
</tbody>
</table>
<ul>
<li>
<p>Is the primary disorder acute vs. chronic?</p>
</li>
<li>
<p>Is the primary disorder appropriately compensated?</p>
</li>
<li>
<p>If not appropriately compensated, what additional process is
    present?</p>
</li>
</ul>
<p>Primary Respiratory Acidosis:</p>
<ul>
<li>Acute versus chronic</li>
</ul>
<!-- -->

<ul>
<li>
<p>Acute respiratory acidosis and hypercarbia will often present with
    somnolence or AMS</p>
</li>
<li>
<p>Similarly, if a PCO2 is 80, and the patient is talking to you, it is
    most likely chronic</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Acute Causes: Decreased respiratory drive (opiates, intoxication),
    respiratory muscle weakness (i.e., myasthenia gravis)</p>
</li>
<li>
<p>Chronic Causes: COPD, sleep apnea</p>
</li>
</ul>
<p>Primary Respiratory Alkalosis</p>
<ul>
<li>
<p>Acute Causes: Mechanical ventilation, anxiety/panic attack, pain, PE</p>
</li>
<li>
<p>Chronic Causes: Pregnancy, CNS disorder, hormones (thyroid,
    progesterone)</p>
</li>
</ul>
<p>Compensation for primary respiratory disorders</p>
<table>
<thead>
<tr>
<th></th>
<th>Respiratory Acidosis</th>
<th>Respiratory alkalosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute</td>
<td>10:1</td>
<td>10:2</td>
</tr>
<tr>
<td>Chronic</td>
<td>10:3.5</td>
<td>10:4</td>
</tr>
<tr>
<td></td>
<td>For every ↑of 10 in pCO2, HCO3 ↑ by 1 or 3.5</td>
<td>For every ↓ of 10 in pCO2 HCO3 ↓ by 2 or 4</td>
</tr>
</tbody>
</table>
<p>Primary Metabolic Alkalosis</p>
<ul>
<li>Appropriate Respiratory Compensation?</li>
</ul>
<!-- -->

<ul>
<li>Expected pCO2 = 0.7*(HCO3) + 20 (&plusmn;5)</li>
</ul>
<!-- -->

<ul>
<li>Etiologies: Associated with high aldosterone (either appropriate or
    inappropriate)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Chloride Responsive = appropriate hyperaldosteronism, can usually be
    fixed with Cl administration/ volume resuscitation</p>
<ul>
<li>
<p>Etiologies: Volume contraction i.e., vomiting, over-diuresis)</p>
</li>
<li>
<p>Urine Cl \&lt;20</p>
</li>
</ul>
</li>
<li>
<p>Chloride Unresponsive = inappropriate hyperaldosteronism, cannot fix
    with NaCl administration/ volume resuscitation</p>
<ul>
<li>
<p>Etiologies: Steroids, Cushing’s, Conn’s, RAS, CHF, cirrhosis</p>
</li>
<li>
<p>Urine Cl >20</p>
</li>
</ul>
</li>
</ul>
<p>Primary Metabolic Acidosis: See nephrology section, “Metabolic Acidosis”</p>
<p>Interstitial Lung Disease – Pakinam Mekki</p>
<p>Background</p>
<ul>
<li>Heterogenous group of parenchymal lung diseases that involve
    scarring or fibrosis, affecting the lung interstitium, alveoli, and
    pulmonary capillaries</li>
</ul>
<!-- -->

<ul>
<li>Leads to loss of lung volume and compliance and impaired gas
    exchange</li>
</ul>
<p>Etiologies</p>
<ul>
<li>
<p>ILD is divided into primary (idiopathic) causes and secondary causes</p>
</li>
<li>
<p>Idiopathic: idiopathic pulmonary fibrosis, eosinophilic pneumonia,
    idiopathic NSIP, organizing pneumonia, acute interstitial pneumonia,
    etc</p>
</li>
<li>
<p>Secondary</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Systemic:</p>
<ul>
<li>
<p>Connective tissue disease: RA, Sjogrens, dermatomyositis,
    polymyositis SLE, MCTD, scleroderma</p>
</li>
<li>
<p>Granulomatous disease: sarcoidosis, TB</p>
</li>
<li>
<p>Vasculitis: granulomatosis with polyangiitis, eosinophilic
    granulomatosis with polyangiitis, amyloidosis,
    lymphangioleiomyomatosis</p>
</li>
</ul>
</li>
<li>
<p>Exposure</p>
<ul>
<li>
<p>Pneumoconiosis (inorganic) – exposure to coal mines, silica,
    asbestos, organic solvents, heavy metals, solder, hair dressing
    chemicals</p>
</li>
<li>
<p>Hypersensitivity pneumonitis (organic)- farm exposures, chicken
    coops, pesticide, stored grains, mold (ex: water damage in home,
    hot tubs)</p>
</li>
<li>
<p>Iatrogenic – amiodarone, immunotherapies, TKI, TNF-a inhibitors,
    nitrofurantoin, radiation</p>
</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Dry cough is the most common symptom of ILD. Productive coughs are
    uncharacteristic</p>
</li>
<li>
<p>History:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Duration, timing, severity of respiratory symptoms</p>
</li>
<li>
<p>Exposures – pets, occupation, residence, smoking, drugs, travel,
    hobbies, dust, hay, grass,</p>
</li>
<li>
<p>Screen for autoimmune symptoms (arthritis, myalgia, rash, Raynaud’s
    phenomenon</p>
</li>
<li>
<p>Screen for vasculitis symptoms: hematuria, hemoptysis, mononeuritis
    multiplex</p>
</li>
<li>
<p>Medication history</p>
</li>
<li>
<p>Family history – premature aging, myelodysplastic syndrome (most
    common familial IPF association with telomerase mutations)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Chest Imaging:</li>
</ul>
<!-- -->

<ul>
<li>
<p>CXR – could find peripheral reticular opacities</p>
</li>
<li>
<p>HRCT protocol is used for diagnosis: evaluates the lung parenchyma
    while pt is supine, prone, with inspiratory and expiratory cuts</p>
</li>
<li>
<p>There are two morphologic features on HRCT</p>
<ul>
<li>
<p>Usual Interstitial Pneumonia (UIP): basilar predominant
    fibrosis, honey combing, and traction bronchiectasis. Minimal
    GGOs. Pattern seen in IPF.</p>
</li>
<li>
<p>Non-Specific Interstitial Pneumonia (NSIP): Marked by subpleural
    sparing, increased reticular patterns, and mosaic attenuation
    due to air trapping. Minimal or absent honeycombing</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Labs</li>
</ul>
<!-- -->

<ul>
<li>
<p>Rule out infection: CBC, RVP, sputum Cx, Histo antigen, Blasto
    antigen, Aspergillus galactomannan, 1,3-β-D-Glucan, sputum GMS,
    consider NTM, HIV</p>
</li>
<li>
<p>Rheumatologic workup: ANA w/ reflex ENA, ESR, CRP, CK, aldolase,
    consider full myositis panel, RF, anti-CCP</p>
</li>
</ul>
<!-- -->

<ul>
<li>Bronchoscopy</li>
</ul>
<!-- -->

<ul>
<li>
<p>BAL is not diagnostic ILD (except eosinophilic PNA), may be helpful
    to rule out infection</p>
</li>
<li>
<p>Transbronchial biopsy is the gold standard for diagnosis. Surgical
    lung biopsy may be helpful in cases where the clinical evaluation
    and imaging are not effective (uncommon)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Misc:</li>
</ul>
<!-- -->

<ul>
<li>
<p>PFTs with 6-minute walk test (prognostic value)</p>
</li>
<li>
<p>TTE to evaluate for pHTN</p>
</li>
<li>
<p>SLP evaluation for indolent aspiration</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Acute flare – all non- UIP = may respond to steroids. Consult
    rheumatology if CTD origin for further options.</p>
</li>
<li>
<p>Chronic therapy</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consider tyrosine kinase inhibitor (nintedanib; INPULSIS trial) and
    antifibrotics (pirfenidone; ASCEND trial) – reduces FVC decline but
    no change in mortality</p>
</li>
<li>
<p>There is increased mortality in IPF with azathioprine/pred/NAC
    (PANTHER-IPF); steroids are not indicated</p>
</li>
<li>
<p>Immunosuppression for autoimmune related ILD</p>
</li>
<li>
<p>Antigen avoidance for hypersensitivity pneumonitis</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consider lung transplant evaluation for severe disease</li>
</ul>
<p>Acute Asthma Exacerbation – Stacy Blank</p>
<p>Presentation</p>
<ul>
<li>
<p>History of asthma or a history concerning for asthma</p>
</li>
<li>
<p>Progressive worsening of symptoms: dyspnea, chest tightness,
    wheezing, and cough</p>
</li>
<li>
<p>Physical exam with wheezing, poor air movement, tachypnea, increased
    work of breathing, hypoxemia</p>
</li>
<li>
<p>Often use of peak flows is cited in the literature (PEF \&lt;200 L/min
    or PEF \&lt;50% predicted indicates severe obstruction, PEF \&lt;70%
    predicted indicates moderate exacerbation)</p>
</li>
</ul>
<!-- -->

<ul>
<li>May be useful although often does not change management acutely</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Generally aimed at ruling out causes for exacerbation and other
    diagnoses; these are not required but should be considered in pts
    being admitted for inpatient management:</li>
</ul>
<!-- -->

<ul>
<li>
<p>EKG, trop, BNP, D-dimer to assess for cardiac cause (ACS, CHF, PE)</p>
</li>
<li>
<p>CXR to rule out underlying process (PNA, PTX, atelectasis)</p>
</li>
<li>
<p>ABG/VBG not routinely needed unless ill-appearing, tachypneic, or
    lethargic/altered</p>
</li>
</ul>
<!-- -->

<ul>
<li>Dangerous signs and possible ICU if:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Tachypnea >30 and/or significantly increased work-of-breathing</p>
</li>
<li>
<p>Hypercapnia or even normocapnia (these pts are usually
    hyperventilating; a normal CO2 in a severe asthma exacerbation could
    indicate impending respiratory failure)</p>
</li>
<li>
<p>Altered mental status</p>
</li>
<li>
<p>Requiring continuous nebulizers</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Continuous pulse ox with oxygen therapy to maintain O2 >92 %</p>
</li>
<li>
<p>Continuous albuterol nebulizer or Duonebs until able to space to
    q1h>>q2h, etc</p>
</li>
<li>
<p>Steroids with dosing based on severity of illness (there is no data
    behind exact dosing of steroids).</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Start with IV methylpred 125mg q6h in severe exacerbation/ICU
    patients</p>
</li>
<li>
<p>Can start with oral prednisone 60mg q12h in less severe
    exacerbation/floor pts</p>
</li>
<li>
<p>Plan to transition from IV to PO and then likely to send pt home to
    finish course of 40-60 mg pred daily for 5-7 days.</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>IV mag sulfate 4g over 20 minutes for severe exacerbation</p>
</li>
<li>
<p>Keep pt NPO until off continuous nebs/respiratory effort is
    improved. Consider IV fluids with pt’s comorbidities (HFrEF, renal
    disease) vs. increased insensible losses with resp effort</p>
</li>
<li>
<p>If pt is not responding to therapies, has worsening respiratory
    status, or blood gas concerning for respiratory acidosis needs ICU
    care for BiPAP vs mechanical ventilation</p>
</li>
<li>
<p>Note: We do not start empiric antibiotics unless there is concern
    for bacterial infection</p>
</li>
</ul>
<p>Prior to discharge:</p>
<ul>
<li>
<p>Ensure that pt is on appropriate controller medications (see
    outpatient management)</p>
</li>
<li>
<p>Evaluate for causes of acute exacerbation to prevent future events
    (noncompliance, resp viruses, allergies, exposures, etc.)</p>
</li>
</ul>
<p>COPD Exacerbation – Taylor Coston</p>
<p>Background</p>
<ul>
<li>
<p>Presentation: increased dyspnea, cough, and sputum production or
    purulence, diffuse wheezing, distant breath sounds, tachypnea,
    tachycardia</p>
</li>
<li>
<p>Severe respiratory insufficiency: accessory muscle use, fragmented
    speech, inability to lie supine, profound diaphoresis, agitation,
    asynchrony between chest and abdominal wall with respiration,
    failure to improve with initial emergency treatment</p>
</li>
<li>
<p>Impending respiratory arrest: Inability to maintain respiratory
    effort, cyanosis, hemodynamic instability, and depressed mental
    status</p>
</li>
<li>
<p>Remember that patients with COPD can have other causes of
    respiratory distress including acute coronary syndrome,
    decompensated heart failure, PE, PNA, PTX, sepsis, acidosis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Initial Assessment: ABCs</li>
</ul>
<!-- -->

<ul>
<li>
<p>Airway/Breathing: Ensure patient is protecting airway</p>
<ul>
<li>
<p>If obtunded or in severe respiratory distress intubation</p>
</li>
<li>
<p>BiPAP typically appropriate for severe COPD exacerbation unless
    contraindication (vomiting, obtundation, facial trauma)</p>
<ul>
<li>BiPAP is ordered as IPAP and EPAP, 12/5 is often a good
    start</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Circulation</p>
<ul>
<li>For hemodynamic instability immediate rapid sequence intubation.
    Pt’s can be hypotensive for a host of reasons (pneumothorax,
    sepsis, circulatory collapse from hypoxia and bradycardia, etc)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Subsequent Workup:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Continuous pulse oximetry, ABG/VBG, EKG, CXR, CBC, BMP, troponin,
    BNP, sputum cx, RPP, blood cultures if hemodynamically unstable</p>
</li>
<li>
<p>Lung ultrasound to differentiate COPD from pulmonary edema when a pt
    presents with wheezing and respiratory failure (pulmonary edema will
    have B lines)</p>
</li>
<li>
<p>Consider trigger: viral infection (70%), PNA, PE (have a high index
    of suspicion for PE)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Bronchodilators</li>
</ul>
<!-- -->

<ul>
<li>
<p>Order “Respiratory Care Therapy Management Protocol” at VUMC</p>
<ul>
<li>RT evaluates the pt and based on physical exam will give a
    duoneb. Continues to assess the pt and treats based on severity
    of the exacerbation</li>
</ul>
</li>
<li>
<p>If ordering bronchodilators individually:</p>
<ul>
<li>
<p>Albuterol 2.5 mg diluted to 3 mL via nebulizer or 4 to 8
    inhalations from MDI every 4 hours while awake (RT) or more
    frequently if needed</p>
</li>
<li>
<p>Ipratropium 500 mcg via nebulizer, or 4-8 inhalations from MDI
    q4 hrs while awake</p>
</li>
<li>
<p>Can additionally order Duoneb (albuterol and ipratroprium) q4-6
    hours at VUMC</p>
</li>
<li>
<p>There is no respiratory order protocol at the VA, order
    individually as above</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Steroids</li>
</ul>
<!-- -->

<ul>
<li>
<p>For severe exacerbation give methylprednisolone 125 mg IV BID (or
    60mg IV q6h)</p>
</li>
<li>
<p>For moderate to mild COPD exacerbations give prednisone 40mg PO
    daily for 5 days (including the initial IV dose if pt received one
    in the ER)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Antibiotics</li>
</ul>
<!-- -->

<ul>
<li>
<p>For moderate to severe exacerbations</p>
</li>
<li>
<p>Azithromycin (500mg x 1 then 250mg daily x 4 or 500mg daily x 3) or
    doxycycline 200 mg BID if concern for QT prolongation. Can consider
    respiratory fluroquinolone in certain high-risk patients but
    typically too broad</p>
</li>
<li>
<p>Refer to Pneumonia in Infection Disease chapter if treating
    concomitant pneumonia</p>
</li>
</ul>
<!-- -->

<ul>
<li>Discharge Planning:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Controller medications/inhalers (see COPD in Outpatient chapter)</p>
<ul>
<li>
<p>Make sure any new inhalers are covered by insurance prior to
    discharge</p>
</li>
<li>
<p>Provide inhaler education and consider use of a spacer</p>
</li>
</ul>
</li>
<li>
<p>Vaccinations (influenza, COVID, pneumococcal)</p>
</li>
</ul>
<p>Cystic Fibrosis (CF) Exacerbation</p>
<p>Background</p>
<ul>
<li>Presentation: acute worsening of pulmonary symptoms such as
    new/increased cough, sputum production (or change in sputum
    quality), dyspnea. May have constitutional symptoms including
    fatigue, poor appetite</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>“Cystic Fibrosis” Admission order set in epic is useful and contains
    most of the work-up and management listed below</p>
</li>
<li>
<p>Labs: Sputum culture (specify CF culture), RPP</p>
</li>
<li>
<p>CXR PA and lateral</p>
</li>
<li>
<p>Always ask about coughing up blood and amount -- see 'Hemoptysis'
    section if present</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>All patients need a cystic fibrosis pulmonary consult (unless on
    Rogers Pulmonary if attending specializes in CF). FYI there is no
    fellow so don’t worry when you have to page an attending</p>
</li>
<li>
<p>All CF pts are placed on contact precautions</p>
</li>
<li>
<p>Antibiotics</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Check CF notes, recent hospitalizations, culture data – MRSA, MSSA,
    and Pseudomonas are the most common</p>
</li>
<li>
<p>If they were recently admitted and improved on that antibiotic
    regimen, it is usually a good empiric choice. CF team will
    ultimately guide regimen</p>
</li>
<li>
<p>General coverage:</p>
<ul>
<li>MRSA vancomycin (Bactrim or linezolid for allergies)</li>
</ul>
</li>
<li>
<p>Pseudomonas Penicillin class (cephalosporin, carbapenem, extended
    penicillin) AND aminoglycoside or Ciprofloxacin (double coverage)</p>
</li>
<li>
<p>Be aware that the antibiotic doses are not the typical doses used
    for other indications. Use Epic Order Adult Cystic Fibrosis order
    set for Antibiotic/dosing (or consult with CF team, pharmacy)</p>
</li>
<li>
<p>Continue tobramycin nebs (if on that month) and MWF Azithromycin
    unless otherwise contraindicated if they are on these therapies at
    home</p>
</li>
</ul>
<!-- -->

<ul>
<li>Airway/sputum clearance</li>
</ul>
<!-- -->

<ul>
<li>Albuterol nebs, pulmozyme (if on at home), hypertonic saline (if on
    at home), Vest, positive end expiratory pressure valve (PEP, ex:
    Flutter, Acapella), chest percussive devices (the wand) as last
    choice (not as effective)</li>
</ul>
<!-- -->

<ul>
<li>
<p>CF modulators (e.g., ivacaftor/tezacaftor/elaxacaftor): continue if
    on at home, needs a non-formulary order so pt can use own supply;
    time with fat rich meal for absorption</p>
</li>
<li>
<p>Nutrition/GI</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pancreatic enzymes (most pts are on them), order at bedside for pt
    administration</p>
</li>
<li>
<p>Always continue ADEK vitamins</p>
</li>
<li>
<p>Daily to 3 times a week weight checks</p>
</li>
<li>
<p>Nutrition consult</p>
</li>
</ul>
<p>DIOS - Distal Intestinal Obstruction Syndrome</p>
<ul>
<li>
<p>Acute obstruction (complete or incomplete) in ileocecum by
    inspissated intestinal contents. Presents with abdominal
    pain/distension, constipation, poor appetite, possibly vomiting
    often looks like mechanical obstruction</p>
</li>
<li>
<p>Treat with Miralax and/or Golytely</p>
</li>
<li>
<p>RARELY surgery, try medical management first</p>
</li>
</ul>
<p>Pulmonary Hypertension – Pakinam Mekki</p>
<p>Background</p>
<ul>
<li>
<p>Symptoms: insidious dyspnea, exertional chest pain, orthopnea, PND,
    edema</p>
</li>
<li>
<p>Exam: JVD, increased P2, split S2, RV heave, TR murmur,
    hepatomegaly, ascites, edema</p>
</li>
<li>
<p>Signs of RV failure: low cardiac output (hypotension, renal failure,
    hepatic congestion), arrhythmias, refractory hypoxemia (R→L shunt),
    effusions (pericardial > pleural) </p>
</li>
<li>
<p>WHO Groups and Causes: </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Group 1: Pulmonary arterial hypertension (PAH): obliteration of
    blood vessels in the lung </p>
<ul>
<li>
<p>Idiopathic, heritable </p>
</li>
<li>
<p>Drugs/toxins (methamphetamine) </p>
</li>
<li>
<p>Associated with CTD, HIV, portal HTN, congenital heart disease,
    schistosomiasis </p>
</li>
<li>
<p>Pulmonary veno-occlusive disease (PVOD), pulmonary capillary
    hemangiomatosis </p>
</li>
</ul>
</li>
<li>
<p>Group 2: Left heart disease: back pressure and passive congestion </p>
<ul>
<li>HFrEF, HFpEF, valvular disease, LA stiffness </li>
</ul>
</li>
<li>
<p>Group 3: Chronic lung disease: chronic hypoxemia, chronic pulmonary
    vasoconstriction </p>
<ul>
<li>COPD, ILD, OSA, chronic high-altitude, developmental lung
    disorders </li>
</ul>
</li>
<li>
<p>Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) </p>
</li>
<li>
<p>Group 5: Multifactorial</p>
<ul>
<li>Hematologic disorders, chronic hemolytic anemia, sarcoidosis,
    pulmonary Langerhans cell histiocytosis, fibrosing
    mediastinitis, metabolic disorders </li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Most common reason for admission with a known diagnosis of pHTN is
    volume overload/RV failure and hypoxia</li>
</ul>
<!-- -->

<ul>
<li>Consider etiology of decompensation: Progression of underlying
    disease, medication/dietary nonadherence, infection, arrhythmia,
    myocardial infarction/RV ischemia, shunting via opening a PFO as a
    release valve, pulmonary embolism</li>
</ul>
<!-- -->

<ul>
<li>
<p>Consult pulmonary hypertension with any questions or assistance with
    workup</p>
</li>
<li>
<p>Studies to consider ordering to determine etiology of pulmonary
    hypertension</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Labs: BNP, liver enzymes, rheumatologic serologies (ANA w/ reflex
    ENA, RF/CCP, ANCA, Scl-70, Ro/LA)</p>
</li>
<li>
<p>EKG: R-axis deviation, RBBB, increased P wave in lead II</p>
</li>
<li>
<p>CXR: increased PA and R heart border, vascular pruning</p>
</li>
<li>
<p>TTE w bubble: RVSP >35-40, RV dilation and dysfunction, RA
    dilation, septal flattening, pericardial effusion, evaluate for L
    heart disease and shunt</p>
</li>
<li>
<p>PFT (outpatient): isolated decrease in DLCO in group I PH, TLC \&lt;
    50%, FEV/FVC \&lt; 70%</p>
</li>
<li>
<p>V/Q scan or CTA chest to evaluate for CTEPH</p>
</li>
<li>
<p>6-minute walk test is prognostic, can be used to monitor response to
    therapy</p>
</li>
<li>
<p>&plusmn; CT chest to evaluate for parenchymal lung disease</p>
</li>
<li>
<p>&plusmn; sleep study to evaluate for OSA</p>
</li>
<li>
<p>Right heart catheterization (RHC) is the gold standard test for PH
    diagnosis and determines pre-vs post-capillary HTN (See RHC section
    in Cardiology)  </p>
<ul>
<li>
<p>Nitric oxide challenge to assess for drug response</p>
</li>
<li>
<p>Fluid challenge with 500cc LR to assess left heart compliance
    `</p>
</li>
</ul>
</li>
</ul>
<table>
<colgroup>
<col style="width: 33%" />
<col style="width: 40%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr class="header">
<th>Definitions</th>
<th>Characteristics</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Pre-capillary PH</td>
<td><p>mPAP &gt; 20 mmHg</p>
<p>PAWP ≤ 15 mmHg</p>
<p>PVR ≥ 3 WU</p></td>
<td>Groups 1, 3, 4, 5</td>
</tr>
<tr class="even">
<td>Post-capillary PH</td>
<td><p>mPAP &gt; 20 mmHg</p>
<p>PAWP &gt; 15 mmHg</p>
<p>PVR &lt; 3 WU</p></td>
<td>Group 2</td>
</tr>
<tr class="odd">
<td><p>Combined pre- and post-</p>
<p>capillary PH</p></td>
<td><p>mPAP &gt; 20 mmHg</p>
<p>PAWP &gt; 15 mmHg</p>
<p>PVR ≥ 3 WU</p></td>
<td>Group 2, 5</td>
</tr>
</tbody>
</table>

<p>Poor Prognostic Indicators for pHTN</p>
<ul>
<li>
<p>NYHA Functional Class (FC III-IV) - 6-minute walk test \&lt; 300</p>
</li>
<li>
<p>AKI - Hyponatremia</p>
</li>
<li>
<p>Low SBP (SBP \&lt; 90) - CTD or liver disease as etiology</p>
</li>
<li>
<p>Poor hemodynamics on RHC (RAP > 20; cardiac index \&lt; 2)</p>
</li>
<li>
<p>TTE findings - TAPSE \&lt; 1.8, pericardial effusion, severe RV
    dysfunction</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Goal of hospitalization is to understand and optimize hemodynamics</p>
</li>
<li>
<p>Overall goal- improve NYHA functional class, RV function, 6-minute
    walk test, quality of life</p>
</li>
<li>
<p>General management: treat underlying cause, diuretics for right
    heart failure, goal SpO2>90%</p>
</li>
<li>
<p>PAH medicines: Consult pulmonary hypertension if considering
    starting of changing meds</p>
</li>
<li>
<p>Oral treatments may be used as monotherapy or in combination </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Calcium-channel blockers → patients with + vasoreactive challenge </p>
</li>
<li>
<p>NO-cGMP enhancers: PDE5-inhibitors sildenafil or tadalafil,
    riociguat </p>
</li>
<li>
<p>Endothelin receptor antagonists (ERAs): Bosentan, macitenatan,
    ambrisentan –</p>
</li>
<li>
<p>Prostacyclin analogs</p>
<ul>
<li>
<p>Prostacyclin analogs increase cAMP-mediated pulmonary
    vasodilation. Side effects include jaw pain, flushing,
    arthralgia, diarrhea.</p>
</li>
<li>
<p>IV formulations are administered through a continuous pump.
    Never stop IV prostacyclins, even brief pauses can cause rebound
    vasoconstriction and death. In an emergency, can run temporarily
    through PIV</p>
<ul>
<li>
<p>Epoprostenol: IV (Veletri) or inhaled (Flolan), half-life 4
    minutes.</p>
</li>
<li>
<p>Treprostinil: IV/subcutaneous/inhaled/PO, half-life 4 hours </p>
</li>
<li>
<p>Iloprost: inhaled, half-life minutes </p>
</li>
<li>
<p>Selexipag (Uptravi): PO, half-life hours </p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Treatment based on NYHA functional classification: </li>
</ul>
<!-- -->

<ul>
<li>
<p>Class I: no treatment or monotherapy </p>
</li>
<li>
<p>Class II: monotherapy or combination oral therapy </p>
</li>
<li>
<p>Class III: combination oral therapy or prostacyclin </p>
</li>
<li>
<p>Class IV: prostacyclin &plusmn; oral therapy </p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Lung transplant for patients who are candidates and failing maximal
    medical therapy </p>
</li>
<li>
<p>VA ECMO can be used as bridge to medical therapy or lung transplant </p>
</li>
<li>
<p>Atrial septostomy- serves as “pop-off” valve and allows for
    decompression of failing RV; used as definitive palliative procedure
    or bridge to transplant </p>
</li>
</ul>
<p>Hemoptysis – Henry Brems</p>
<p>Background</p>
<ul>
<li>
<p>Distinguish between massive (>600cc/24hr or >100cc/hr) and
    non-massive hemoptysis. Can be difficult to quantify expectorated
    blood volume and volume that is retained in lungs</p>
</li>
<li>
<p>Massive is potentially life-threatening due to impaired ventilation</p>
</li>
<li>
<p>Remember UGIB (hematemesis) and nasopharyngeal bleeds can easily
    mimic hemoptysis</p>
</li>
<li>
<p>Presentation based on source of bleed:</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 79%" />
</colgroup>
<thead>
<tr class="header">
<th>Structure</th>
<th>Etiologies</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Airways</td>
<td>Bronchitis (common cause of non-massive), bronchiectasis (especially
in CF pts), neoplasm</td>
</tr>
<tr class="even">
<td><p>Alveolar/</p>
<p>Parenchymal</p></td>
<td>Infectious (bacterial PNA, abscess, TB, fungal, aspergilloma),
Rheumatic (Goodpasture’s, GPA, Behcet’s)</td>
</tr>
<tr class="odd">
<td>Vascular</td>
<td>PE, AVM, CHF, mitral stenosis</td>
</tr>
<tr class="even">
<td>Other</td>
<td>Coagulopathy, traumatic, foreign-body, iatrogenic,
cocaine-induced</td>
</tr>
</tbody>
</table>

<p>Evaluation</p>
<ul>
<li>
<p>Check for anticoagulation on med list</p>
</li>
<li>
<p>Labs: CBC, BMP, Coags, UA (for hematuria), ABG (evaluate
    oxygenation), type and screen</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consider ANA, ANCA, Anti-GBM, sputum culture (bacteria, fungal,
    AFB), sputum cytology depending on clinical context</li>
</ul>
<!-- -->

<ul>
<li>
<p>Imaging: CXR first (to evaluate etiology and to localize the source
    to a side). Chest CT depending on prior workup, severity of bleed,
    and stability of patient</p>
</li>
<li>
<p>Bronchoscopy is sometimes indicated to localize bleeding source</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Urgent evaluation if any hemodynamic compromise, hypoxia,
    hypercarbia, or respiratory distress</p>
</li>
<li>
<p>Ensure a secure airway: massive hemoptysis may require intubation
    and MICU transfer</p>
</li>
<li>
<p>Reverse underlying coagulopathy if present. Consider trending HCT</p>
</li>
<li>
<p>If unilateral bleed, place bleeding lung down (i.e. if the source is
    left lung, place pt on left side) to prevent filling 'good' lung
    with blood (include this info in sign-out if known)</p>
</li>
<li>
<p>Urgent pulmonary consult if clinical instability: Bronchoscopy is
    diagnostic and therapeutic</p>
</li>
<li>
<p>Obtain CT Bronchial Artery Protocol if concern for bronchial artery
    source (especially in CF patients) so embolization can be planned</p>
</li>
</ul>
<!-- -->

<ul>
<li>Order this at VUMC with a CTA Chest (NOT a CTA PE as that will be
    timed incorrectly) and include "bronchial artery protocol" in
    comments for the study</li>
</ul>
<!-- -->

<ul>
<li>Consider IR consult for angiography as diagnostic and therapeutic
    option</li>
</ul>
<!-- -->

<ul>
<li>Consult early if there is massive hemoptysis; If bronchoscopy is
    attempted but fails to stop the bleed, they can get to angiography
    fastest if IR has already been made aware</li>
</ul>
<p>Pleural Effusions – Eddie Qian</p>
<p>Background</p>
<ul>
<li>
<p>There is a normal influx of fluid into the pleural space due to
    leaky capillary membranes and the pleural space’s negative pressure.
    This fluid is constantly reabsorbed by lymphatics. An imbalance in
    the system will result in accumulation.</p>
</li>
<li>
<p>Some examples:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Increased influx: increased filtration from the capillaries from
    high intravascular hydrostatic pressure (i.e., heart failure, renal
    failure) or low intravascular oncotic pressure</p>
</li>
<li>
<p>Other liquid entry into the pleural space through anatomic deficits:
    CSF, chyle, urine, blood, ascites (the diaphragm is naturally
    porous)</p>
</li>
<li>
<p>Decreased efflux: obstruction of the parietal pleural stoma (from
    protein or cellular debris in exudative pleural effusions)</p>
</li>
<li>
<p>Increased systemic venous pressure (lymphatic system drains into the
    systemic venous circulation so high venous pressure prevents
    lymphatics from draining appropriately)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Imaging:</li>
</ul>
<!-- -->

<ul>
<li>
<p>CXR: lateral decubitus position (if effusion moves with gravity,
    suggests free flowing)</p>
</li>
<li>
<p>Ultrasound: assess size, location, loculations</p>
</li>
<li>
<p>CT Chest with contrast (not always indicated; helpful to eval
    septations)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Thoracentesis (see Procedures section):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Will it change management?</p>
</li>
<li>
<p>Pleural LDH, protein, cell count/diff, culture (don’t forget to
    order serum LDH &amp; protein)</p>
</li>
<li>
<p>Consider: pleural cytology, hematocrit, triglycerides, glucose,
    amylase</p>
</li>
<li>
<p>If septated or empyema, consider pulm consult for chest tube</p>
</li>
</ul>
<!-- -->

<ul>
<li>Interpretation of pleural studies:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Lights criteria: 1 of the following to be considered an exudative
    effusion</p>
<ul>
<li>
<p>Pleural to serum protein ratio > 0.5</p>
</li>
<li>
<p>Pleural to serum LDH ratio > 0.6</p>
</li>
<li>
<p>Pleural LDH > &#8532; upper limit of normal range of serum LDH</p>
</li>
</ul>
</li>
<li>
<p>Transudative: CHF exacerbation, hepatic hydrothorax, atelectasis
    (caused by increased intrapleural negative pressure),
    hypoalbuminemia, renal failure</p>
</li>
<li>
<p>Exudative: infections (bacterial, TB, fungal), malignant,
    rheumatologic, PE</p>
</li>
<li>
<p>Other tips:</p>
<ul>
<li>
<p>Protein: >5 think TB or malignancy, \&lt; 0.5 think urine, CSF,
    peritoneal dialysate</p>
</li>
<li>
<p>Glucose: \&lt; 60 think about malignancy, TB, or rheumatologic,
    less likely hemothorax or parapneumonic</p>
</li>
<li>
<p>Cell count/differential: polys represent an acute process,
    monocytes represent a chronic process, lymphocytes think about
    TB or malignancy, eosinophils think about air/blood, TB,
    malignancy, asbestos, drugs</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Two separate processes may co-occur, and a transudate may mask an
    exudative effusion; if concerned for this and you have clinical
    stability, trial diuresis prior to thoracentesis</li>
</ul>
<p>Lung Masses – Chandler Montgomery</p>
<p>Background</p>
<ul>
<li>Definitions: lesion \&lt; 3 cm = pulmonary nodule. Lesion > 3 cm =
    lung mass</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pulmonary nodules are common and often benign, but presence of lung
    mass (>3cm) should prompt workup as chance of malignancy is high
    (>50%)</p>
</li>
<li>
<p>For nodules, refer to the Fleischner Society guidelines (incidental
    nodules) or Lung-RADS (detected on lung cancer screening) for
    surveillance/management recommendations</p>
</li>
<li>
<p>Note that in TN, prior histoplasmosis is a very common cause of
    pulmonary nodules</p>
</li>
</ul>
<!-- -->

<ul>
<li>Differential diagnosis:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Malignant:</p>
<ul>
<li>
<p>Primary non-small cell lung cancer (NCSLC): adenocarcinoma,
    squamous cell (SCC), large cell carcinoma</p>
</li>
<li>
<p>Metastatic: commonly melanoma, sarcoma, colon, breast, renal,
    testicular</p>
<ul>
<li>Often multiple nodules/masses (e.g., cannonball) </li>
</ul>
</li>
<li>
<p>Neuroendocrine: small cell lung cancer (SCLC), carcinoid, large
    cell neuroendocrine</p>
</li>
</ul>
</li>
<li>
<p>Infectious:</p>
<ul>
<li>
<p>Granulomatous: TB, non-TB mycobacterium, endemic fungal (histo,
    blasto, coccidio)</p>
<ul>
<li>May have component of calcification</li>
</ul>
</li>
<li>
<p>Abscess: Staph aureus, Klebsiella, anaerobes, polymicrobial
    (aspiration)</p>
</li>
<li>
<p>Septic emboli, hydatid cyst, aspergilloma</p>
</li>
</ul>
</li>
<li>
<p>Other: hamartoma, AVM, pulmonary infarct, inflammatory nodule (GPA,
    RA), sarcoidosis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>History: smoking, cough, hemoptysis, dyspnea, chest pain, weight
    loss, fevers, night sweats, hoarseness, bone pain, neuro deficits</li>
</ul>
<!-- -->

<ul>
<li>Lung cancer should always be considered in a patient with smoking
    history &amp; new cough or hemoptysis</li>
</ul>
<!-- -->

<ul>
<li>
<p>Exam: cachexia, lymphadenopathy, bone pain, hepatomegaly, neuro
    deficits</p>
</li>
<li>
<p>Imaging:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>CXR has poor sensitivity for lung nodules, may show large mass or
    malignant effusion</p>
</li>
<li>
<p>CT chest (with contrast if possible - better evaluation of
    mediastinum/LNs)</p>
<ul>
<li>
<p>Review prior chest imaging to assess age and growth pattern of
    lesion(s)</p>
</li>
<li>
<p>Benign features: small (sub-centimeter), calcified, fat
    attenuation, stable over 2 years, multiple nodules</p>
</li>
<li>
<p>Concerning features: large, growth, spiculation, upper lobe
    location, thick-walled cavitation, mediastinal invasion</p>
</li>
<li>
<p>Location- adenocarcinoma often more peripheral, SCC often more
    central, SCLC associated with massive LAD, mediastinal invasion,
    large hilar masses</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Look for paraneoplastic syndromes:</li>
</ul>
<!-- -->

<ul>
<li>
<p>SCLC: SIADH, Lambert-Eaton, Cushing’s syndrome</p>
</li>
<li>
<p>SCC: hypercalcemia (PTHrP)</p>
</li>
<li>
<p>Dermatomyositis, polymyositis, hypertrophic osteoarthropathy</p>
</li>
</ul>
<p>Staging/Diagnosis</p>
<ul>
<li>
<p>Imaging: CT chest (with contrast if possible)m CTAP w/contrast vs.
    PET/CT to assess for metastasis, consider MRI brain if clinical
    stage III or IV disease</p>
</li>
<li>
<p>Biopsy: careful planning is key</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>For metastatic disease, obtain tissue from least invasive site</p>
<ul>
<li>FNA or excision of palpable lymph node (cytology department,
    US-guided procedure, or EGS)</li>
</ul>
</li>
<li>
<p>If uncertain how to best obtain tissue, consult IR, interventional
    pulm, and/or oncology to discuss approach</p>
<ul>
<li>
<p>Surgical Bx: Wedge resection/lobectomy often preferred if
    solitary nodule amenable to both diagnostic and therapeutic
    resection in good surgical candidate</p>
</li>
<li>
<p>Bronchoscopy with EBUS (endobronchial US) often used to obtain
    biopsy of mediastinal tissue or central/peri-bronchial lesion</p>
</li>
<li>
<p>Trans-thoracic needle aspiration (TTNA): peripheral lesions not
    amenable to bronchoscopy</p>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Planning is complex, usually discussed at multidisciplinary tumor
    board</p>
</li>
<li>
<p>NSCLC</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Stage I/II: surgical resection &plusmn; adjuvant chemotherapy</p>
</li>
<li>
<p>Stage III: more complex requiring multidisciplinary approach</p>
</li>
<li>
<p>Stage IV: chemo &plusmn; targeted therapy depending on PD-L1 expression,
    presence of driver mutations for EGFR, ALK, ROS-1, BRAF, MET, RET,
    others</p>
</li>
</ul>
<!-- -->

<ul>
<li>SCLC: usually widely metastatic at time of diagnosis, treated with
    systemic chemo/radiation</li>
</ul>
<p>Inhaler Therapy – Patrick Barney</p>
<p>Inhaler therapy</p>
<ul>
<li>Current inhaler device delivery options</li>
</ul>
<!-- -->

<ul>
<li>
<p>MDI – typical handheld inhaler</p>
<ul>
<li>
<p>Pro is same dose of medicine each time you use them – if used
    correctly.</p>
</li>
<li>
<p>Con is that it requires coordination. Patient must be able to
    time 3-5s slow inhalation and 5-10s breath hold w/ release of
    medicine, can be helped w/ spacer.</p>
</li>
</ul>
</li>
<li>
<p>SMI – “soft mist inhaler,” handheld. Creates cloud of medicine that
    is inhaled without propellant.</p>
<ul>
<li>Pros are more medicine gets into lungs than w/ MDI so lower dose
    can be used, does not require coordination.</li>
</ul>
</li>
<li>
<p>DPI - handheld inhaler, delivers medicine whenever patient breathes
    in through the device, requiring less coordination.</p>
<ul>
<li>Pro is lack of need to coordinate breath; Con is inconsistent
    dose delivery.</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Nebulizers</li>
</ul>
<!-- -->

<ul>
<li>
<p>Saline</p>
<ul>
<li>Hypertonic saline, NS, 3% and 7%. Can be used to thin secretions
    and produce deep cough in patients who need to expectorate as
    part of treatment. For CF, chronic tracheostomy, NM weakness. No
    evidence for benefit in COPD.</li>
</ul>
</li>
<li>
<p>Enzymatic Agents</p>
<ul>
<li>Dornase alpha – Pulmozyme – “DNAse’ - enzyme that breaks down
    polymerized DNA in high concentrations in CF airways, indicated
    specifically for patients with CF</li>
</ul>
</li>
<li>
<p>Anticholinergics</p>
<ul>
<li>
<p>COPD exacerbation, asthma exacerbation – bronchodilation and
    secretion inhibition in acute setting</p>
</li>
<li>
<p>Ipratropium (Atrovent) intermittent nebulizer or
    Ipratropium-albuterol (Duo-Neb) intermittent or continuous
    nebulizer</p>
</li>
</ul>
</li>
<li>
<p>Disulfide Disrupters</p>
<ul>
<li>
<p>Sever disulfide bonds of glycoproteins in mucus, lowering its
    viscosity and making it more amenable to suction, expectoration</p>
</li>
<li>
<p>N-acetylcysteine (Mucomyst) - nebulized form available in “adult
    burn inhalation injury protocol” when search “mucomyst”</p>
</li>
</ul>
</li>
<li>
<p>Antibiotics</p>
<ul>
<li>
<p>May be indicated in patients w/ CF, non-CF bronchiectasis, VAP
    as salvage therapy</p>
</li>
<li>
<p>Tobramycin – only nebulized antibiotic available at VUMC</p>
</li>
</ul>
</li>
</ul>
<p>Categories of inhaled medications</p>
<ul>
<li>
<p>Short-acting beta agonist (SABA): beta-2 agonism of bronchial smooth
    muscle to achieve bronchodilation; also decrease mast cell mediator
    release. Ex: albuterol, levalbuterol</p>
</li>
<li>
<p>Long-acting beta agonist (LABA): - beta-2 agonists, same as SABAs
    but have lipophilic side chains that allow longer binding but also
    slow the onset of action. Ex: formoterol, salmeterol, olodaterol</p>
</li>
<li>
<p>Long-acting muscarinic antagonist (LAMA): - non-specific muscarinic
    receptor antagonists, leads to bronchodilation and reduced
    secretions. Ex: tiotropium, umeclidinium, glycopyrrolate</p>
</li>
<li>
<p>Inahled corticosteroid (ICS): - suppress airway inflammation. Ex:
    budesonide, fluticasone, mometasone</p>
</li>
</ul>
<p>VUMC Inpatient Options</p>
<ul>
<li>
<p>SABA : Albuterol (Proventil/Ventolin/Proair) - MDI, neb, continuous
    aerosol available</p>
</li>
<li>
<p>SABA/SAMA: Ipratropium-albuterol (Duo-Neb) - neb and continuous neb
    available</p>
</li>
<li>
<p>LABA – only available in combination w/ ICS. LABA/ICS:
    vilanterol-fluticasone (Breo Ellipta), salmeterol-fluticasone
    (Advair Diskus/HFA)</p>
</li>
<li>
<p>LAMA: Tiotropium (Spiriva Respimat)</p>
</li>
<li>
<p>ICS: Budesonide inhaler (Pulmicort) or neb, fluticasone furoate
    (Arnuity Ellipta)</p>
</li>
</ul>
<p>Airway Clearance Therapy – Patrick Barney</p>
<ul>
<li>Indications</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cystic fibrosis, advanced COPD, chronic bronchitis, bronchiectasis,
    chronic neuromuscular weakness, prolonged ventilator-dependence</p>
</li>
<li>
<p>Goal is to assist patients with removing/expectorating mucus from
    lungs to decrease risk of atelectasis, mucus plug, increased airway
    resistance, infection</p>
</li>
</ul>
<!-- -->

<ul>
<li>Chest Physiotherapy (CPT)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Use: pathologies w/ retained secretions and mucous plugging (CF,
    bronchiectasis)</p>
</li>
<li>
<p>RT helps patient go through sequence of positions aimed at
    “draining” each of the lobes of the lung by gravity. Sometimes
    combined with percussion.</p>
</li>
<li>
<p>Finding in Epic: chest physiotherapy > CPPD panel – will initiate
    RT bronchial hygiene protocol and order TID CPT</p>
</li>
</ul>
<!-- -->

<ul>
<li>High Frequency Chest Wall Compression (HFCWC)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Use: pathologies w/ retained secretions (CF, bronchiectasis, chronic
    bronchitis) or mucociliary clearance problems (lung transplant)</p>
</li>
<li>
<p>RT wraps patient in inflatable vest, compressor rapidly inflates and
    deflates vest to “break up” thickened mucus from airway wall so it
    can be suctioned or expectorated</p>
</li>
<li>
<p>Finding in Epic: vest > Facility List > vest physiotherapy or vest
    physiotherapy for CF under Procedures</p>
</li>
</ul>
<!-- -->

<ul>
<li>Positive Expiratory Pressure (PEP)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Use: pathologies w/ retained secretions as discussed above</p>
</li>
<li>
<p>Patient exhales against fixed or fluttering resistor that allows air
    to get behind mucus, helps move mucus from airway walls, and holds
    airways open longer for improved ventilation</p>
</li>
<li>
<p>Trade names- Flutter, Acapella, AerobikA</p>
</li>
<li>
<p>Finding in Epic: PEP > Facility List > PEP therapy panel or
    Oscillatory PEP therapy panel under Order Sets</p>
<ul>
<li>Can also find in a supply closet on 8S and bring to patient, be
    sure to teach them how to use it</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Cough Assist</li>
</ul>
<!-- -->

<ul>
<li>
<p>Use: most effective in patients with neuromuscular weakness
    affecting diaphragmatic strength – muscular dystrophy, myasthenia
    gravis, spinal cord lesions, SMA</p>
</li>
<li>
<p>Via mask or trach/vent connection – applies positive pressure to
    fill the lungs, then quickly switches to negative pressure to
    produce a high expiratory flow rate to simulate a cough that is
    intended to produce expectorant</p>
</li>
<li>
<p>Finding in Epic: cough assist > Facility List > cough assist
    treatment panel under Order Sets</p>
</li>
</ul>
<p>Chest Tubes – Pakinam Mekki</p>
<p>Background</p>
<ul>
<li>
<p>Nomenclature: Small bore chest tubes= Pigtail Catheters (Often 8-12
    Fr) placed via Seldinger technique. “Chest Tube” technically denotes
    a large bore, surgical thoracostomy tube (Often 24-40 Fr)</p>
</li>
<li>
<p>Indications: Pneumothorax, hemothorax (more often surgical chest
    tubes), empyema, malignant effusion (patient specific), chylothorax,
    penetrating chest trauma</p>
</li>
<li>
<p>Contraindications: No absolute contraindications. Relative
    contraindications include hepatic hydrothorax, large emphysematous
    blebs, and anticoagulation or coagulopathy</p>
</li>
</ul>
<p>Procedure</p>
<ul>
<li>
<p>Consult pulmonology for patients who may need pigtail chest tube</p>
</li>
<li>
<p>Placement and Sizing</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>The location and size of the chest tube is related to the pathology</p>
<ul>
<li>
<p>Pneumothorax anterior near the apex of the lung in the 2<sup>nd</sup>
    intercostal space, midaxillary line</p>
</li>
<li>
<p>Fluid (water, pus, blood), posterior near the base of the lung
    (fifth or sixth intercostal space, midaxillary line</p>
</li>
<li>
<p>Hemothorax surgical chest tube is placed to prevent clot
    formation</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Potential complications: Laceration of an intercostal vessel, organ
    perforation (lung, heart, diaphragm, intraabdominal), trauma of the
    intercostal neurovascular bundle, subcutaneous emphysema,
    pneumothorax, infection, re-expansion pulmonary edema.</li>
</ul>
<!-- -->

<ul>
<li>Smaller size results in less tissue disruption but more likely to
    clog or kink</li>
</ul>
<p><strong>Understanding the Atrium:</strong> After the chest tube is placed, it is
connected to the Atrium which can be connected to the wall for suction.
(See Diagram below)</p>
<p><img src="../pulmonary/main/output/media/image29.png"
style="width:2.78846in;height:2.62167in"
alt="A picture containing text, electronics Description automatically generated" /></p>
<p><u>(A) Dry suction control-</u> determines the level of suction out of
the chest tube and is set by the provider. It is important to note that
while the atrium is linked to the wall suction via suction port (F) the
level of wall suction is determined by (A)</p>
<p><u>(B) Water seal chamber-</u> if the atrium is disconnected from the
wall suction, it is on “water seal” (i.e., to gravity). This allows for
the one-way flow of pleural space contents out of the chest.</p>
<p><u>(C) Air leak monitor-</u> if air bubbles are present in the water
seal chamber, then that indicates the presence of air in the pleural
space. The presence of air is different from normal “tidaling,” within
the water seal and requires troubleshooting (see below). Tidaling is
normal; it is the movement with respiratory variation in water seal
chamber. The water should rise with inspiration and fall with
expiration.</p>
<p><u>(D) Collection chamber-</u> drains the pleural fluid contents via the
chest tube.</p>
<p><u>(E) Suction verification window</u>- will be orange if suction is on
and atrium is functioning appropriately</p>
<p>Troubleshooting</p>
<ul>
<li>Air leaks: If bubbles are present in the water seal chamber, this
    indicates air in the pleural space. This is an expected finding in a
    pneumothorax; over time, the air leak should disappear as the lung
    re-expands. This contrasts with normal tidaling present with
    respiratory variation</li>
</ul>
<!-- -->

<ul>
<li>
<p>There are two major causes of air leaks:</p>
<ul>
<li>
<p>Persistent air in the pleural space, seen in alveolar-pleural
    fistula or pneumothorax (new or old)</p>
</li>
<li>
<p>Leak in the chest tubing at its insertion site or in the tubing
    system. To identify the etiology of a new air leak, try clamping
    the chest tube at various points, obtain a CXR</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Clogging: Would see debris in the collection chamber and lack of
    tidaling in the water seal camber</li>
</ul>
<!-- -->

<ul>
<li>
<p>In patients with viscous fluid output (ex- empyema), important to
    flush the chest tube with normal saline flushes at least twice daily
    to prevent clogging</p>
</li>
<li>
<p>For clog- try flushing 10cc of sterile saline toward the pt or
    “stripping” the chest tube by pressing the chest tube with your
    fingers and pulling towards the drainage system.</p>
</li>
<li>
<p>May require tPA or dornase for fibrinolysis, discuss with team that
    placed the tube</p>
</li>
</ul>
<p>Chest tube removal</p>
<ul>
<li>
<p>Generally, chest tubes are removed when there is \&lt; 150cc of
    drainage in 24 hrs (if placed for pleural effusion)</p>
</li>
<li>
<p>For pneumothorax, there is typically a step-wise approach to
    removal. The team that placed the chest tube will guide removal</p>
</li>
</ul>
<!-- -->

<ul>
<li>Suctionwater seal &plusmn; clamp trial. CXR obtain after each transition
    to monitor for reaccumulation</li>
</ul>
<!-- -->

<ul>
<li>Chest tube should be removed while patient hums (to prevent
    inhalation during removal that could introduce air into pleural
    space). Pigtail catheters have to be “unlocked” prior to removal to
    release the pigtail</li>
</ul>
<p>Home Oxygen Therapies – Mackenzie Samson</p>
<p>Summary of Medicare Part B Guidelines for Home Oxygen:</p>
<ul>
<li>Conditions for which oxygen therapy may be covered</li>
</ul>
<!-- -->

<ul>
<li>
<p>Severe lung disease including COPD and ILD, CF, bronchiectasis,
    widespread neoplasms</p>
</li>
<li>
<p>Hypoxia related symptoms or findings expected to improve with O2:
    pulmonary hypertension, cor pulmonale, erythrocytosis, impaired
    cognition, nocturnal restlessness, morning headache</p>
</li>
</ul>
<!-- -->

<ul>
<li>Qualifying Tests and Requirements:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Testing must be performed with a pt in chronic stable condition or
    within two days of discharge from an inpatient hospital stay (after
    treatment of acute exacerbating conditions)</p>
</li>
<li>
<p>Criteria: Resting SpO2 ≤ 88% (or PaO2 &lt;55) or SpO2 &lt;88%
    with ambulation</p>
<ul>
<li>Must be documented in chart</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Special Considerations:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Medicare requires an additional walk on 4L/min showing desaturation
    if the patient needs a flow rate of 5L/min or higher</p>
</li>
<li>
<p>Because of the risk of desaturation with exertion and the intrinsic
    error in the pulse ox (around 3%), patients with resting SpO2 ≤ 92%
    should have amb sats checked</p>
</li>
<li>
<p>Patients with Raynaud’s or poor circulation may have inaccurate
    finger pulse oximeter readings. Consider using a head saturation
    monitor</p>
</li>
</ul>
<!-- -->

<ul>
<li>VA Specific Guidance: Will need to document ambulatory saturations
    in notes as above. Call the Oxygen Clinic (number listed in all team
    rooms) and talk with your case manager</li>
</ul>
<p>Summary of Medicare Part C Guidelines for Home Respiratory Assist
Devices i.e. CPAP/BiPAP:</p>
<ul>
<li>Restrictive thoracic disorders, covered if the following criteria
    are met:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Documentation of a neuromuscular disease/severe thoracic cage
    abnormality AND one of the following:</p>
<ul>
<li>
<p>PaCO2 ≥ 45mmHg on ABG, performed while awake and on home O2
    requirement</p>
</li>
<li>
<p>Sleep oximetry demonstrates oxygen saturation ≤ 88% for ≥ 5
    minutes of nocturnal recording time performed while on home O2
    requirement</p>
</li>
<li>
<p>For a neuromuscular disease (only), either: Maximal inspiratory
    pressure \&lt; 60cm H2O or forced vital capacity \&lt; 50% predicted
    and COPD may not contribute significantly</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Severe COPD, covered if the following criteria are met:</li>
</ul>
<!-- -->

<ul>
<li>
<p>PaCO2 ≥ 52mmHg on ABG, performed while awake and on patient’s
    prescribed home O2</p>
</li>
<li>
<p>Sleep oximetry demonstrates oxygen saturation ≤ 88% for ≥ 5 minutes
    of nocturnal recording time, performed while breathing oxygen at
    2LPM or patient’s prescribed FiO2 (whichever is higher). Also
    requires that OSA had been considered and ruled out (formal sleep
    testing not required)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Hypoventilation Syndrome: covered if criteria 1, 2, AND either 3 or
    4 are met:</li>
</ul>
<!-- -->

<ul>
<li>
<p>PaCO2 ≥45 mm Hg on ABG, performed while awake and on home O2
    requirement, AND</p>
</li>
<li>
<p>Spirometry shows an FEV1/FVC ≥ 70% AND</p>
</li>
<li>
<p>ABG PaCO2, performed during sleep or immediately upon awakening that
    demonstrates worsening PaCO2 of ≥ 7mm Hg compared to the original
    result in criterion 1 OR</p>
</li>
<li>
<p>A facility-based PSG or HST demonstrates oxygen saturation ≤ 88% for
    ≥ 5 minutes of nocturnal recording time that is not caused by
    obstructive upper airway events</p>
</li>
</ul>
<!-- -->

<ul>
<li>OSA:</li>
</ul>
<!-- -->

<ul>
<li>
<p>An initial screening for OSA in the hospital is nocturnal pulse
    oximetry. The distinct “saw-tooth” pattern representing intermittent
    hypoxia is suggestive of OSA, and a formal NPSG or home sleep test
    is recommended to evaluate for OSA.  This is done on an outpatient
    basis only once acute issues have fully resolved</p>
</li>
<li>
<p>Home CPAP/BiPAP covered IF:</p>
<ul>
<li>
<p>The diagnosis of central sleep apnea or complex sleep apnea and</p>
</li>
<li>
<p>Significant improvement of the sleep-associated hypoventilation
    occurs with the use of the device</p>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-acute-asthma-exacerbation"><h1 id="pulmonary-pulmonary-acute-asthma-exacerbation-acute-asthma-exacerbation">Acute Asthma Exacerbation<a class="headerlink" href="#pulmonary-pulmonary-acute-asthma-exacerbation-acute-asthma-exacerbation" title="Permanent link">&para;</a></h1>
<p>Acute Asthma Exacerbation – Stacy Blank</p>
<p>Background</p>
<ul>
<li>History of asthma or a history concerning for asthma</li>
<li>Progressive worsening of symptoms:  dyspnea, chest tightness,
    wheezing, and cough</li>
<li>Physical exam with wheezing, poor air movement (if severe
    obstruction may just not hear good breath sounds, which is worse
    than wheezing), tachypnea, increased work of breathing (accessory
    muscle use), hypoxemia</li>
<li>Often use of peak flows is cited in the literature (PEF \&lt;200 L/min
    or PEF \&lt;50% predicted indicates severe obstruction, PEF \&lt;70%
    predicted indicates moderate exacerbation)<ul>
<li>These can be ordered as an RT order and may be useful; although
    often does not change management acutely</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Generally aimed at ruling out causes for exacerbation and other
    diagnoses; these are not required but should be considered in pts
    being admitted for inpatient management:<ul>
<li>EKG, trop, BNP, D-dimer to assess for cardiac cause (ACS, HF,
    PE)</li>
<li>CXR to rule out underlying process (PNA, PTX, atelectasis)</li>
<li>ABG/VBG not routinely needed but if pt ill-appearing,
    tachypneic, or lethargic/altered</li>
</ul>
</li>
<li>Dangerous signs and possible ICU if:<ul>
<li>Tachypnea &gt;30 and/or significantly increased work-of-breathing</li>
<li>Hypercapnia or even normocapnia (these pts are usually
    hyperventilating; a normal CO2 in a severe asthma exacerbation
    could indicate impending respiratory failure)</li>
<li>Altered mental status</li>
<li>Requiring continuous nebulizers</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Continuous pulse ox with oxygen therapy to maintain O2 &gt;92 %</li>
<li>Continuous albuterol nebulizer or Duonebs until able to space to
    q1h&gt;>q2h, etc (ED almost always starts with continuous if pt is
    severe enough to warrant inpatient management)</li>
<li>Steroids with dosing base on severity of illness (there is no data
    behind exact dosing of steroids).  Start with IV methylpred 125mg
    q6h in severe exacerbation/ICU patients. Can start with oral
    prednisone 60mg q12h in less severe exacerbation/floor pts. Plan to
    transition from IV to PO and then likely to send pt home to finish
    course of 40-60 mg pred daily for 5-7 days.</li>
<li>IV mag sulfate 4g over 20 minutes for severe exacerbation (anyone
    going to the ICU)</li>
<li>Keep pt NPO until off continuous nebs/respiratory effort is improved
    to safely swallow, consider IV fluids with pt’s comorbidities
    (HFrEF, renal disease) vs. increased insensible losses with resp
    effort</li>
<li>If pt is not responding to therapies, has worsening respiratory
    status or blood gas concerning for respiratory acidosis: use BiPAP
    in patients whose mental status is appropriate vs. intubation/MV
    (i.e., it’s time to call your MICU fellow)</li>
<li>Note:  We do not start empiric antibiotics unless there is concern
    for bacterial infection</li>
</ul>
<p>Prior to discharge:</p>
<ul>
<li>Ensure that pt is on appropriate controller medications (see
    outpatient management)</li>
<li>Evaluate for causes of acute exacerbation to prevent future events
    (noncompliance, resp viruses, allergies, exposures, etc.)</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-blood-gases"><h1 id="pulmonary-pulmonary-blood-gases-blood-gases">Blood Gases<a class="headerlink" href="#pulmonary-pulmonary-blood-gases-blood-gases" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basics of Blood Gases – Lexi Haugh</td>
</tr>
</tbody>
</table>
<p>Did you order an ABG or VBG?</p>
<ul>
<li>If you need to assess oxygenation (PaO2), then must order an ABG. An
    ABG is also the most accurate way to assess PaCO2 and pH</li>
<li>If you want to assess hypoventilation, a VBG is informative and
    usually similar, but it may be inaccurate in some cases such as
    shock or severe hypercapnia</li>
<li>The pH on a VBG usually correlates with an ABG (i.e. venous pH is
    ~0.05 lower than arterial pH), but this is less accurate in shock
    or severe acid-base disturbance</li>
<li>ABGs are obtained by respiratory both at VUMC and the VA. VBGs can
    be ordered the same as any other lab. Alternatively the nurses can
    obtain a VBG (+lactate) with the iSTAT in the ICU at either VUMC or
    VA, which will return considerably faster<ul>
<li>To order iSTAT at VUMC, order "Respiratory Lab Panel" and choose
    selections</li>
<li>To order VBG at VA, order POC CG4+ (standard), POC CG8+ (loaded
    VBG), or simply enter a free text order "please obtain VBG"</li>
</ul>
</li>
</ul>
<p>Assessing Oxygenation:</p>
<p>On an ABG, can use the arterial PaO2 (measurement of O2 dissolved in
plasma) to assess oxygenation and calculate the A-a gradient.</p>
<p>A-a gradient = PAO2 (alveolar O2) – PaO2 (arterial O2)</p>
<ul>
<li>P <sub>A</sub> O <sub>2</sub> = FiO <sub>2</sub> (P
    <sub>barom</sub> - P <sub>H2O</sub> ) - PaCO <sub>2</sub> /R<ul>
<li>FiO2 = 0.21 on room air otherwise obtain from ventilator</li>
<li>P <sub>barom</sub> = 760, P <sub>H2O =</sub> 47</li>
<li>R (respiratory quotient) = 0.8</li>
<li>PaCO <sub>2</sub> = arterial CO2 measured on ABG</li>
<li>Normal A-a gradient = (Age +10)/4</li>
</ul>
</li>
<li>Common Reasons for an Increased A-a Gradient:<ul>
<li>V/Q Mismatch: PE, atelectasis, PNA, pulmonary edema,
    pneumothorax, ILD, COPD</li>
<li>Diffusion limitation: interstitial lung disease</li>
<li>R
    à
    L Shunt Physiology:<ul>
<li>Cardiac: PFO, VSD, ASD, AVMs</li>
<li>Pulmonary: blood, pus, water(edema), cells, protein in the
    Alveoli</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Assessing Acid/Base Status and Ventilation:</p>
<ul>
<li>Look at the pH (normal = 7.35 – 7.45)<ul>
<li>pH \&lt; 7.35 = acidosis</li>
<li>pH &gt; 7.45 = alkalosis<ul>
<li>Look at the pCO2 (normal = 35-45 mmHg <em>)</em></li>
</ul>
</li>
</ul>
</li>
</ul>
<table>
<thead>
<tr>
<th>Primary Disorder</th>
<th>pH</th>
<th>pCO2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory Acidosis</td>
<td>\&lt; 7.35</td>
<td>>45</td>
</tr>
<tr>
<td>Respiratory Alkalosis</td>
<td>> 7.45</td>
<td>\&lt;35</td>
</tr>
<tr>
<td>Metabolic Acidosis</td>
<td>\&lt; 7.35</td>
<td>\&lt;45</td>
</tr>
<tr>
<td>Metabolic Alkalosis</td>
<td>> 7.45</td>
<td>>35</td>
</tr>
</tbody>
</table>
<ul>
<li>Is the primary disorder acute vs. chronic?</li>
<li>Is the primary disorder appropriately compensated?</li>
<li>If not appropriately compensated, what additional process is
    present?</li>
</ul>
<p>Primary Respiratory Acidosis:</p>
<ul>
<li>Assess patient’s history: Is this acute or chronic?<ul>
<li>Acute respiratory acidosis and hypercarbia will often present
    with somnolence or AMS</li>
<li>Similarly, if a PCO2 is 80, and the patient is talking to you,
    it is most likely chronic</li>
</ul>
</li>
<li>Common Acute Causes: Decreased respiratory drive (opiates,
    intoxication) or respiratory muscle weakness (i.e. myasthenia gravis
    exacerbation)</li>
<li>Common Chronic Causes: COPD, sleep apnea</li>
<li>Appropriate metabolic compensation?<ul>
<li>If acute, every 10 mmHg increase in pCO2 above normal (40)
    should raise HCO3 by 1<ul>
<li>Expected HCO3 = 24 + ((pCO2 -40)/10))
    If chronic, every 10 mm Hg
    ↑
    in pCO2 above normal (40) should raise HCO3 by 3.5</li>
<li>Expected HCO3 = 24 + 3.5 ((pCO2-40/10)).</li>
</ul>
</li>
</ul>
</li>
<li>If HCO3 higher than expected
    à
    additional metabolic alkalosis</li>
<li>If HCO3 lower than expected
    à
    additional metabolic acidosis</li>
</ul>
<p>Primary Respiratory Alkalosis</p>
<ul>
<li>Assess patient’s history: Is this acute or chronic?<ul>
<li>Common Acute Causes: Mechanical ventilation, anxiety/panic
    attack, pain, PE</li>
<li>Common Chronic Causes: Pregnancy, CNS disorder, hormones
    (thyroid, progesterone)</li>
</ul>
</li>
<li>Appropriate metabolic compensation?<ul>
<li>If acute, every 10 mmHg change in pCO2 should decrease the HCO3
    by 2<ul>
<li>Expected HCO3 = 24 – 2*((40-pCO2/10)</li>
</ul>
</li>
<li>If chronic, every 10 mmHg change in pCO2 should decrease the
    HCO3 by 4<ul>
<li>Expected HCO3 = 24 – 4*((40-pC02)/10)</li>
</ul>
</li>
</ul>
</li>
<li>If HCO3 higher than expected
    à
    additional metabolic alkalosis</li>
<li>If HCO3 lower than expected
    à
    additional metabolic acidosis</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaN</td>
<td>Respiratory Acidosis</td>
<td>Respiratory alkalosis</td>
</tr>
<tr>
<td>Acute</td>
<td>10:1</td>
<td>10:2</td>
</tr>
<tr>
<td>Chronic</td>
<td>10:3.5</td>
<td>10:4</td>
</tr>
<tr>
<td>NaN</td>
<td>For every ↑of 10 in pCO2, HCO3 ↑ by 1 or 3.5</td>
<td>For every ↓ of 10 in pCO2 HCO3 ↓ by 2 or 4</td>
</tr>
</tbody>
</table>
<p>Primary Metabolic Alkalosis</p>
<ul>
<li>Appropriate Respiratory Compensation?<ul>
<li>Expected pCO2 = 0.7*(HCO3) + 20 (&plusmn;5)</li>
</ul>
</li>
<li>Etiologies: Majority of causes are associated with high aldosterone
    (either appropriate or inappropriate)<ul>
<li>Chloride Responsive
    = appropriate hyperaldosteronism, can usually be fixed with NaCl
    administration/ volume resuscitation<ul>
<li>Etiologies: Volume contraction i.e vomiting, over-diuresis
    which stimulates kidneys to reabsorb Na (and Cl absorbed
    with Na)</li>
<li>Urine Cl \&lt;20</li>
</ul>
</li>
</ul>
</li>
<li>Chloride Unresponsive
    = inappropriate hyperaldosteronism, cannot fix with NaCl
    administration/ volume resuscitation as already likely volume
    overloaded<ul>
<li>
<ul>
<li>Etiologies: Steroids, Cushing’s, Conn’s, RAS, CHF, cirrhosis</li>
<li>Urine Cl &gt;20.</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Primary Metabolic Acidosis</p>
<ul>
<li>See nephrology section, “Metabolic Acidosis”</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-cf-exacerbation"><h1 id="pulmonary-pulmonary-cf-exacerbation-cf-exacerbation">CF Exacerbation<a class="headerlink" href="#pulmonary-pulmonary-cf-exacerbation-cf-exacerbation" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystic Fibrosis (CF) Exacerbation</td>
</tr>
</tbody>
</table>
<p>All admissions:</p>
<ul>
<li>“Cystic Fibrosis” Admission order set in epic, contains most orders
    and labs below</li>
<li>Enter “Pulmonary, Cystic Fibrosis” Consult in Epic, exception is on
    Rogers Pulmonary if the attending specializes in CF</li>
<li>Pancreatic enzymes (most pts are on them), order at bedside for pt
    administration</li>
<li>Always continue ADEK vitamins</li>
<li>Consult nutrition (There is a specific Radio Button in the nutrition
    consult order for CF)</li>
<li>Send sputum culture for bacterial, AFB and Fungus if not sent from
    clinic<ul>
<li>Specify “CF Resp” when prompted</li>
</ul>
</li>
<li>CXR PA and Lat – especially if new sharp chest pains</li>
<li>Order all home inhaler and airway clearance (AWC) therapies (See
    Sputum Clearance below), ask about compliance with these therapies
    at home</li>
<li>All CF pts are placed on contact precautions</li>
<li>Always ask about coughing up blood and amount -- see 'Hemoptysis'
    section if present</li>
<li>Sputum clearance: albuterol nebs, pulmozyme (if on at home),
    hypertonic saline (if on at home), Vest and/or Acapella, CPD as last
    choice since not as effective (pts like it)</li>
<li>CF modulators (e.g., ivacaftor/tezacaftor/elaxacaftor): continue if
    on at home;  place non-formulary order so pt can use own supply;
    time with fat rich meal for absorption</li>
</ul>
<p>Malnutrition:</p>
<ul>
<li>Common and improves with treatment of infectious exacerbation</li>
<li>Daily to 3 times a week weight checks</li>
<li>Nutrition consult as above</li>
</ul>
<p>DIOS - Distal Intestinal Obstruction Syndrome:</p>
<ul>
<li>Treat with Miralax and/or Golytely</li>
<li>Often looks like mechanical obstruction</li>
<li>RARELY surgery, try medical management first</li>
</ul>
<p>CF Pneumonia admission:</p>
<ul>
<li>Continue tobramycin nebs (if on that month) and MWF Azithromycin
    unless otherwise contraindicated if they are on these therapies at
    home</li>
<li>Check RVP, and treat with oseltamivir if flu+</li>
<li>Use Epic Order Adult Cystic Fibrosis order set for Antibiotic/dosing</li>
<li>Look at last admission, last CF note, culture data – MRSA, MSSA, and
    Pseudomonas are by far the most common<ul>
<li>If they were recently admitted and improved on that antibiotic
    regimen, it is usually a good empiric choice</li>
</ul>
</li>
<li>If MRSA then Vancomycin 1G q8h (okay to consult Pharm for dosing)<ul>
<li>if Vanc allergic then Bactrim DS-2 TID or Linezolid</li>
</ul>
</li>
<li>Assume all pts are colonized with Pseudomonas. Empirically double
    cover with:<ul>
<li>Something from Penicillin class (Cephalosporin, carbapenem,
    extended penicillin)</li>
<li>Aminoglycoside or Ciprofloxacin</li>
</ul>
</li>
<li>CF team -- there is no fellow for this, so don’t worry when you have
    to page an attending<ul>
<li>They will guide all antibiotics decisions following admission
    (check outpt clinic note)</li>
<li>Doses are not normal, do not use Sanford:<ul>
<li>Aztreonam: 2 gm q 6 hours (good for Pen allergic)</li>
<li>Cefepime 2 gm q 8 hours</li>
<li>Ceftazidime 4 gms q 8 hours</li>
<li>Cipro 750 mg po bid or 400 mg IV q 8</li>
<li>Imipenem 1 gm q 6-8 hours</li>
<li>Meropenem 2 gm q 8 hours 2 hr infusion</li>
<li>Doripenem 1 gm q 8 hours 2 hr infusion</li>
<li>Piperacillin/tazo (Zosyn) 4.750 gm q 6 hours 4 h infusion</li>
<li>Tobramycin 10mg/kg q 24 hours</li>
<li>Can consult pharmacy for Tobramycin dosing, but check renal
    function first</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-copd-exacerbation-management"><h1 id="pulmonary-pulmonary-copd-exacerbation-management-copd-exacerbation-management">COPD Exacerbation Management<a class="headerlink" href="#pulmonary-pulmonary-copd-exacerbation-management-copd-exacerbation-management" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD Exacerbation – Taylor Coston</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Diffuse wheezing, distant breath sounds, barrel-shaped chest,
    tachypnea, tachycardia, smoking &gt;20 pack years</li>
<li>Features of severe respiratory insufficiency: accessory muscle use;
    fragmented speech; inability to lie supine; profound diaphoresis;
    agitation; asynchrony between chest and abdominal motion with
    respiration; failure to improve with initial emergency treatment</li>
<li>Features of impending respiratory arrest: Inability to maintain
    respiratory effort, cyanosis, hemodynamic instability, and depressed
    mental status</li>
<li>Remember: Patients with COPD can have other causes of respiratory
    distress including acute coronary syndrome, decompensated heart
    failure, PE, PNA, PTX, sepsis, acidosis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Initial Assessment: ABCs<ul>
<li>Airway/Breathing<ul>
<li>Ensure patient is protecting airway. If obtunded or in
    severe respiratory distress (see above) call anesthesia
    early for consideration of endotracheal intubation. <em>(If in
    the</em> MICU during the day, just call the MICU fellow)<ul>
<li>Noninvasive ventilation (NIV), particularly BiPAP:
    Appropriate for most patients with severe COPD
    exacerbation unless immediate intubation is needed or
    other contraindication (vomiting, too obtunded to take
    off mask if necessary, facial trauma). Necessitates MICU
    admission</li>
<li>Remember: BiPAP is ordered as IPAP and EPAP. I.e. if the
    pt is on 12/5 the mask will deliver a pressure of 12
    when breathing in and 5 when breathing out.</li>
<li>12/5 is a good start, in comments write “auto-titrate”
    and the RT will have some leeway to change settings</li>
</ul>
</li>
<li>Immediate pharmacotherapy, in tandem with diagnostics and
    airway mgmt</li>
</ul>
</li>
<li>Circulation<ul>
<li>For hemodynamic instability, HR \&lt; 50, call anesthesia for
    immediate rapid sequence intubation (RSI). Pt’s can be
    hypotensive for a host of reasons including pneumothorax,
    sepsis, circulatory collapse from hypoxia and bradycardia,
    etc.</li>
</ul>
</li>
</ul>
</li>
<li>Subsequent Workup:<ul>
<li>Continuous pulse oximetry, ABG/VBG, EKG, CXR, CBC, BMP,
    troponin, BNP (if considering HF dx), Sputum cx, consider blood
    cx if concern for sepsis, rapid flu.</li>
<li>Lung Ultrasound to differentiate COPD from pulmonary edema when
    a pt presents with wheezing and respiratory failure (pulmonary
    edema will have Kerley B lines)</li>
<li>During evaluation, consider triggers for COPD exacerbation:
    viral infection (70%), PNA, PE. <strong>Have a high index of suspicion
    for PE in these pts</strong> .</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Manage airway
    as above - many pts will need BiPAP if severe respiratory distress
    or hypercapnia are present</li>
<li>Bronchodilators<ul>
<li>Order “Respiratory Care Therapy Management Protocol” at VUMC</li>
<li>When ordered, an RT evaluates the pt and based on physical exam
    will give a duoneb</li>
<li>The RT will then continue to assess the pt based on severity of
    the exacerbation</li>
<li>If ordering bronchodilators individually (this is discouraged)
    order:<ul>
<li>Albuterol 2.5 mg diluted to 3 mL via nebulizer or 4 to 8
    inhalations from MDI every 4 hours while awake (RT), or more
    frequently if needed</li>
<li>Ipratropium 500 mcg via nebulizer, or 4-8 inhalations from
    MDI q 4 hrs while awake</li>
<li>Can additionally order "duoneb" at VUMC</li>
<li>There is no respiratory order protocol at the VA, order
    individually as above. RT is available to assess if needed</li>
</ul>
</li>
</ul>
</li>
<li>Steroids<ul>
<li>For severe exacerbation give methylprednisolone 125 mg IV BID
    (or 60mg IV q6h)</li>
<li>For moderate to mild COPD exacerbations give prednisone 40mg PO
    daily for 5 days (including the initial IV dose if pt received
    one in the ER)</li>
</ul>
</li>
<li>Antibiotics<ul>
<li>Benefit less clear in mild to moderate exacerbations</li>
<li>Azithromycin 500mg x 1 then 250mg daily for 4 days or
    doxycycline 200 mg BID if concern for QT prolongation. Can also
    consider Levaquin 750mg PO daily for 5 days, however this is
    often too broad for a standard COPD exacerbation.</li>
<li>Refer to “Pneumonia” if treating a separate PNA in addition to
    COPD</li>
</ul>
</li>
<li>Discharge Planning:<ul>
<li>Teaching on medication compliance and appropriate use. Ensure pt
    has a spacer</li>
<li>Pulmonary Rehab</li>
<li>Vaccinations (see outpatient management COPD in handbook)</li>
<li>Controller medications/inhalers (see outpatient management COPD
    in handbook)</li>
<li>Exacerbation Action plans: No consensus as to what the
    components should be, but instead a patient-specific plan can be
    made should the pt’s symptoms recur</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-cxrs"><h1 id="pulmonary-pulmonary-cxrs-cxrs">CXRs<a class="headerlink" href="#pulmonary-pulmonary-cxrs-cxrs" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>How to Interpret Chest Radiographs (CXR) – Gautam Babu</td>
</tr>
</tbody>
</table>
<p>An X-ray is a density-gram where “white” is “dense” and “black” is “not
dense”.  Determine a systematic method you use every time you interpret
a CXR to ensure you don’t miss anything.</p>
<ul>
<li>
<p>Start every CXR you interpret by assessing the quality of the film:</p>
<ul>
<li>Penetration: You should be able to see vertebral bodies through
    the cardiac silhouette but not into the abdomen. If you cannot
    see them through the heart the film is “under-penetrated” and
    everything will appear more “white.” If you can see them through
    the abdomen the film is “over-penetrated” and everything will
    appear more “black”</li>
<li>Rotation: The spinous processes should be in the middle of the
    clavicular heads, if not then the film is rotated</li>
</ul>
</li>
<li>
<p>Two Different Systematic Methods:</p>
<ul>
<li>ABCDE method<ul>
<li>Airway – Trachea midline and patent</li>
<li>Bones – Bone density and obvious fractures</li>
<li>Cardiac Silhouette – You should be able to see the L and R
    heart border, if not there may be an adjacent opacity (Right
    Middle Lobe, Lingula)</li>
<li>Cardiomegaly defined as heart size
    ≥
    &frac12; width of the hemithorax <em>on a PA film</em></li>
<li>Diaphragm – Look for pleural effusions at the costo-phrenic
    angle. If you cannot see the diaphragm along the way there
    may be an adjacent opacity (Lower Lobe)</li>
<li>“Everything else” – Refers to the lung fields but if you
    wanted to continue the alphabet mnemonic</li>
<li>Extra-Thoracic Soft Tissue – Subcutaneous emphysema</li>
<li>Fields and Fissures –lung fields should appear symmetric and
    “black.” Asymmetry suggests there is an issue on one side.</li>
<li>Great Vessels – Tortuosity of the aorta and the outlines of
    the pulmonary vessels</li>
<li>Hilum – Hilar masses, LAD and pulmonary arteries, the left
    hila is higher than the right normally because of the heart</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Working around the film method:</p>
<ul>
<li>Imagine the entire CXR film as a square and an inner “box” as
    the pleural lining</li>
</ul>
</li>
<li>
<ul>
<li>Outside the box: Looking for lines, tubes, EKG/tele leads,
        subcutaneous emphysema, stomach bubble, sub diaphragmatic air</li>
<li>The edge of the box: Looking for pleural thickening, pleural
    effusion, pneumothorax, visualization of the diaphragm</li>
<li>The middle of the box: aka Mediastinum -&gt; trachea, vascular
    pedicle, hila, heart borders, great vessels, retrocardiac space</li>
<li>The lung fields</li>
</ul>
</li>
</ul>
<p>One important concept to know is the <strong>silhouette sign:</strong> Two things of
different densities will show a clear border on a chest x-ray. In the
contrapositive, the loss of a border you expect to see suggests there
has been</p>
<p>a change in density of one of the structures. For example, the heart and
the lung are different densities and as such you have a sharp border.
Loss of this border suggests that the adjacent lung “increased” in
density from a PNA (in the right clinical scenario).</p>
<ul>
<li>Often try to distinguish PNA from pulmonary edema, as these are two
    of the most common causes of abnormal opacities seen on CXR<ul>
<li>PNA<ul>
<li>"fluffy" opacities and air bronchograms frequently indicate
    alveolar filling</li>
<li>typically asymmetric</li>
</ul>
</li>
<li>Pulmonary Edema<ul>
<li>linear opacities, fluid in the fissure, Kerley B lines,
    cephalization, bilateral pleural effusions</li>
<li>Typically symmetric</li>
<li>atypical or viral PNA can similarly present with linear
    opacities</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Web Resources:</p>
<ul>
<li>UVA Department of Radiology “Introduction to Chest Radiology”<ul>
<li><a href="https://www.med-ed.virginia.edu/courses/rad/cxr/index.html">https://www.med-ed.virginia.edu/courses/rad/cxr/index.html</a></li>
<li>Website includes specific examples of lung pathology as well as
    CXR interpretation exercises in the “post test” section</li>
</ul>
</li>
<li>Life in the Fast Lane CXR Self-Assessment Quiz:
    <a href="https://litfl.com/top-100/cxr/">https://litfl.com/top-100/cxr/</a></li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-hemoptysis"><h1 id="pulmonary-pulmonary-hemoptysis-hemoptysis">Hemoptysis<a class="headerlink" href="#pulmonary-pulmonary-hemoptysis-hemoptysis" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoptysis – Henry Brems</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Distinguish between massive (&gt;600cc/24hr or &gt;100cc/hr) and
    non-massive hemoptysis; however, due to practical difficulties
    quantifying expectorated blood and limitations in quantifying blood
    in lungs that is not expectorated, verbiage is falling out of favor</li>
<li>Massive is potentially life-threatening due to impaired ventilation
    not necessarily due to hemodynamic compromise</li>
<li>Remember UGIB (hematemesis) and nasopharyngeal bleeds can easily
    mimic hemoptysis and require different management</li>
<li>Presentation based on source of bleed:</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structure</td>
<td>Etiologies</td>
</tr>
<tr>
<td>Airways</td>
<td>Bronchitis (common cause of non-massive), bronchiectasis (especially in CF pts), neoplasm</td>
</tr>
<tr>
<td>Alveolar/ Parenchymal</td>
<td>Infectious (bacterial PNA, abscess, TB, fungal, aspergilloma), Rheumatic (Goodpasture’s, GPA, Behcet’s)</td>
</tr>
<tr>
<td>Vascular</td>
<td>PE, AVM, CHF, mitral stenosis</td>
</tr>
<tr>
<td>Other</td>
<td>Coagulopathy, traumatic, foreign-body, iatrogenic, cocaine-induced</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Assess anticoagulation status</li>
<li>Labs: CBC, BMP, Coags, UA (for hematuria), ABG (evaluate
    oxygenation), type and screen<ul>
<li>Also consider ANA, ANCA, Anti-GBM, sputum culture (bacteria,
    fungal, AFB), sputum cytology as indicated to further evaluate
    etiology</li>
</ul>
</li>
<li>Imaging: CXR first (to evaluate etiology and to localize the source
    to a side). May likely require Chest CT pending prior workup,
    severity of bleed, and stability of patient</li>
<li>Bronchoscopy is sometimes indicated to localize bleeding source</li>
</ul>
<p>Management</p>
<ul>
<li>Hemoptysis that is non-massive and does not impair ventilation can
    generally be evaluated and treated non-urgently</li>
<li>Urgent evaluation needed if there is any hemodynamic compromise,
    hypoxia, hypercarbia, or respiratory distress</li>
<li>Reverse underlying coagulopathy if present. Consider trending HCT</li>
<li>Make NPO</li>
<li>If unilateral bleed, place <strong>bleeding lung down</strong> (i.e. if the
    source is left lung, place pt on left side) to prevent filling
    'good' lung with blood ( <strong>Include this info in sign-out</strong> if known)</li>
<li>Ensure a secure airway: Massive hemoptysis may require intubation
    and MICU transfer</li>
<li>Urgent pulmonary consult if clinical instability: Bronchoscopy is
    diagnostic and therapeutic</li>
<li>Obtain CT Bronchial Artery Protocol if concern for bronchial artery
    source (especially in CF patients) so embolization can be planned<ul>
<li>Order this at VUMC with a CTA Chest (NOT a CTA PE as that will
    be timed incorrectly) and include "bronchial artery protocol" in
    comments for the study</li>
</ul>
</li>
<li>Consider IR consult for angiography as diagnostic and therapeutic
    option<ul>
<li>Consult early if there is massive hemoptysis; If bronchoscopy is
    attempted but fails to stop the bleed, they can get to
    angiography fastest if IR has already been made aware</li>
</ul>
</li>
<li>Consider GI and/or ENT evaluation if source of bleed is unclear</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-home-oxygen-therapies"><h1 id="pulmonary-pulmonary-home-oxygen-therapies-home-oxygen-therapies">Home Oxygen Therapies<a class="headerlink" href="#pulmonary-pulmonary-home-oxygen-therapies-home-oxygen-therapies" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home Oxygen Therapies – Taryn Boyle</td>
</tr>
</tbody>
</table>
<p>Summary of Medicare Part B Guidelines for Home Oxygen:</p>
<ul>
<li>Conditions for Which Oxygen Therapy May Be Covered:<ul>
<li>Severe lung disease including COPD and ILD (regardless of known
    etiology), CF, bronchiectasis, widespread pulmonary neoplasms</li>
<li>Hypoxia related symptoms or findings expected to improve with
    O2: pulmonary hypertension, recurring CHF secondary to chronic
    cor pulmonale, erythrocytosis, impaired cognition, nocturnal
    restlessness, morning headache</li>
</ul>
</li>
<li>Qualifying Tests and Requirements:<ul>
<li>Testing must be performed with a pt in chronic stable condition
    (i.e. outpatient clinic) or within two days of discharge from an
    inpatient hospital stay (after treatment of acute exacerbating
    conditions have been trialed, ie. infection, bronchospasm)</li>
<li>Medicare requires that test results must be documented in a pt’s
    medical record and made available to the oxygen provider</li>
</ul>
</li>
<li>Patient can be tested under either of these conditions:<ul>
<li>At rest: SpO2 ≤ 88% (or PaO2 \&lt;55)</li>
<li>If no hypoxia at rest, perform with exercise (“Ambulatory Sats”)<ul>
<li>Ask RN or RT to perform and document in Epic—they have a
    template:<ul>
<li>SpO2 at rest</li>
<li>SpO2 on room air with ambulation (must desat ≤ 88%)</li>
<li>Amount of O2 (in L) required to maintain SpO2 &gt; 89%</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Special Considerations:<ul>
<li>Medicare requires an additional walk on 4L/min showing
    desaturation if the patient needs a flow rate of  5L/min or
    higher</li>
<li>Because of the risk of desaturation with exertion and the
    intrinsic error in the pulse ox (around 3%), patients with
    resting saturations of ≤ 92% should be walked to assess O2 needs</li>
<li>Be aware that if the patient has Raynaud’s or poor circulation,
    a finger pulse oximeter reading may be inaccurate and read lower
    than the patient’s actual saturations.  A head saturation
    monitor should be used in these circumstances</li>
</ul>
</li>
<li>Try to perform any of these diagnostic tests 1-2 days prior to
    anticipated discharge. Be sure to touch base with your CM about the
    need for home oxygen, as they will help arrange</li>
<li>VA Specific Guidance: Will need to document ambulatory saturations
    in notes as above. Call the Oxygen Clinic (number listed in all team
    rooms) and talk with your case manager</li>
</ul>
<p>Summary of Medicare Part C Guidelines for Home Respiratory Assist
Devices i.e CPAP/BiPAP:</p>
<ul>
<li>Restrictive Thoracic Disorders: Covered if the following criteria
    are met:<ul>
<li>There is documentation in the MR of a neuromuscular disease or a
    severe thoracic cage abnormality and one of the following:<ul>
<li>An arterial blood gas PaCO2 ≥ 45mmHg, performed while awake
    and on home O2 requirement, OR</li>
<li>Sleep oximetry demonstrates oxygen saturation ≤ 88%, for ≥ 5
    minutes of nocturnal recording time (minimum recording time
    of 2 hours), performed while on home O2 requirement, OR</li>
<li>For a neuromuscular disease (only), either:<ul>
<li>Maximal inspiratory pressure \&lt; 60cm H2O or</li>
<li>Forced vital capacity \&lt; 50% predicted and</li>
</ul>
</li>
<li>COPD may not contribute significantly to the patient’s
    limitations</li>
</ul>
</li>
</ul>
</li>
<li>Severe COPD: Covered if the following criteria are met:<ul>
<li>An arterial blood gas PaCO2 ≥ 52mmHg, performed while awake and
    on patient’s prescribed home O2</li>
</ul>
</li>
<li>Sleep oximetry demonstrates oxygen saturation ≤ 88% for ≥ 5 minutes
    of nocturnal recording time (minimum recording time of 2 hours),
    performed while breathing oxygen at 2LPM or patient’s prescribed
    FIO2 (whichever is higher), AND<ul>
<li>Prior to initiating therapy, sleep apnea and treatment with a
    continuous positive airway pressure (CPAP) device has been
    considered and ruled out (formal sleep testing not required)</li>
</ul>
</li>
<li>Hypoventilation Syndrome: covered if criteria 1, 2, AND either 3 or
    4 are met:<ul>
<li>An initial arterial blood gas PaCO2 ≥45 mm Hg, performed while
    awake and on home O2 requirement, AND</li>
<li>Spirometry shows an FEV1/FVC ≥ 70% AND</li>
<li>An arterial blood gas PaCO2, performed during sleep or
    immediately upon awakening that demonstrates worsening PaCO2 of
    ≥ 7mm Hg compared to the original result in criterion 1 OR</li>
<li>A facility-based PSG or HST demonstrates oxygen saturation ≤ 88%
    for ≥ 5 minutes of nocturnal recording time (minimum recording
    time of 2 hours) that is not caused by obstructive upper airway
    events, i.e., AHI \&lt;5</li>
</ul>
</li>
<li>OSA:<ul>
<li>An initial screening for OSA in the hospital is nocturnal pulse
    oximetry. The distinct “saw-tooth” pattern representing
    intermittent hypoxia is suggestive of OSA, and a formal NPSG or
    home sleep test is recommended to evaluate for OSA.  This is
    done on an outpatient basis only once acute issues have fully
    resolved</li>
<li>Home CPAP/BiPAP covered IF:<ul>
<li>The diagnosis of central sleep apnea or complex sleep apnea
    and</li>
<li>Significant improvement of the sleep-associated
    hypoventilation occurs with the use of the device</li>
</ul>
</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-hypoxia"><h1 id="pulmonary-pulmonary-hypoxia-hypoxia">Hypoxia<a class="headerlink" href="#pulmonary-pulmonary-hypoxia-hypoxia" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypoxia – Henry Brems</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Two major ways to measure oxygenation, which are similar but
    distinct:<ul>
<li>SpO2 or "pulse ox" - most common measurement in the hospital or
    clinic, which measures the O2 saturation of Hgb at capillary
    level<ul>
<li>\&lt;95% is abnormal, but may not need supplemental O2 until
    \&lt;90-92% in most pts</li>
</ul>
</li>
<li>PaO2 -- the partial pressure of oxygenation measured on an ABG<ul>
<li>\&lt;80 mmHg is abnormal</li>
</ul>
</li>
</ul>
</li>
<li>The relationship between SpO2 and PaO2 is the classic S-shaped
    curve.</li>
<li>Below an SpO2 of ~88%, PaO2 begins to fall off dangerously fast
    thus necessitating quick intervention for pts with SpO2 below this
    level</li>
</ul>
<p>Mechanisms of Hypoxia:</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism</td>
<td>Pathophysiology</td>
</tr>
<tr>
<td>Decreased barometric pressure</td>
<td>- Normal A-a gradient - This is unlikely to be seen except at high altitudes</td>
</tr>
<tr>
<td>Hypoventilation</td>
<td>- Normal A-a gradient - Hypoxia easily correctable with supplemental O2</td>
</tr>
<tr>
<td>V/Q Mismatch</td>
<td>- Increased A-a gradient - Processes that lead to areas of lung where V/Q \&lt;1, i.e. where there is relatively less ventilation than perfusion. - Common examples include PNA, ARDS, pulmonary edema</td>
</tr>
<tr>
<td>Right-to-left Shunt</td>
<td>- Increased A-a gradient - Can be anatomic (e.g intracardiac, AVMs) or physiologic (water/pus/blood filling alveoli) - Classically does not easily correct with supplemental O2</td>
</tr>
<tr>
<td>Diffusion Limitation</td>
<td>- Increased A-a gradient - Often related to diseases affecting interstitium -- e.g., ILD</td>
</tr>
</tbody>
</table>
<p>Differential diagnosis for hypoxia based on anatomical location:</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anatomical Location</td>
<td>Differential Diagnosis</td>
</tr>
<tr>
<td>Airways</td>
<td>- COPD most common, Asthma in very severe cases - CF, bronchiectasis in patients with appropriate history</td>
</tr>
<tr>
<td>Alveoli</td>
<td>- Any process that fills the alveoli with: Blood Pus -- infection from bacterial, viral, fungal agents Water -- pulmonary edema Protein/Cells/Other -- ARDS, pneumonitis (e.g. aspiration, drug-induced)</td>
</tr>
<tr>
<td>Interstitium/Parenchyma</td>
<td>- Interstitial Lung Diseases (see section)</td>
</tr>
<tr>
<td>Vascular</td>
<td>- Pulmonary Emboli - particularly suspect these in patients with significant hypoxia and a clear CXR</td>
</tr>
<tr>
<td>Pleural Space and Chest Wall</td>
<td>- Pleural Effusions, Pneumothorax, Neuromuscular weakness, tense ascites - These are more likely to cause significant dyspnea and usually need to be quite severe to cause hypoxia</td>
</tr>
</tbody>
</table>
<p>Evaluation</p>
<ul>
<li>Confirm true hypoxia with good pleth. Can press pulse-ox on pt’s
    finger for better transmission</li>
<li>CXR is almost always the first step</li>
<li>Other common initial workup: CBC, BMP, BNP, troponin, EKG, ABG/VBG</li>
<li>TTE -- particularly useful if suspected new pulmonary edema or
    pulmonary HTN<ul>
<li>Obtain with 'bubble study' if any concern for shunt</li>
<li>Obtain “limited” if patient had recent “complete” TTE</li>
</ul>
</li>
<li>Chest CT<ul>
<li>Order CTA ('CTA PE' in Epic) if concerned for PE<ul>
<li>V/Q scan if unable to receive IV contrast</li>
</ul>
</li>
<li>CT Chest without contrast otherwise generally preferred for
    evaluation of lung parenchyma</li>
</ul>
</li>
<li>PFTs are useful if there is suspected obstructive (e.g. COPD) or
    restrictive disease (e.g. ILD), or if the cause remains otherwise
    unknown after initial workup<ul>
<li>These are almost always done as an outpatient</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Should be directed at underlying cause. See other sections for
    information relevant to particular diagnoses</li>
<li>If acutely decompensating, Duonebs, IV lasix, Antibiotics depending
    on clinical picture</li>
<li>Supplemental O2 for goal SpO2:<ul>
<li>>90-92% for most patients (There is generally no need to make
    SpO2 100%)</li>
<li>Between 88-92% for patients with chronic hypoxia from COPD
    (i.e., on home O2)</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-ild"><h1 id="pulmonary-pulmonary-ild-ild">ILD<a class="headerlink" href="#pulmonary-pulmonary-ild-ild" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interstitial Lung Disease – Gaby Schroeder</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>MANY CAUSES, one mnemonic to use:<ul>
<li>S
    arcoidosis</li>
<li>H
    ypersensitivity Pneumonitis</li>
<li>I
    diopathic Interstitial Pneumonias (IIPs- UIP/IPF, NSIP, OP,
    RB-ILD, DIP, LIP, AIP)</li>
<li>T
    uberculosis</li>
<li>F
    ungal</li>
<li>A
    spiration/ Asbestosis (and other Pneumoconiosis)</li>
<li>C
    onnective Tissue Disease + Cancer</li>
<li>E
    osinophilic Pneumonia</li>
<li>D
    rugs</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>History: Ask about 1) Duration, timing, severity of primary
    respiratory symptoms 2) Exposures: Pets, Occupation, Residence,
    Mold, Feathers, Smoking, Illicits, Travel, Hobbies, Medications
    (especially amiodarone, nitrofurantoin and chemotherapies) 3)
    Symptoms of systemic autoimmune disease 4) Family history</li>
<li>Chest Imaging: HRCT is best for characterization, but often not
    achievable or desirable in inpatient setting when patients are
    critically ill.</li>
<li>Labs:<ul>
<li>Rule out fungal infection: Histo Antigen, Blasto Antigen,
    Aspergillus Galactomannan, 1,3-
    β
    -D-Glucan, sputum GMS (orderable as 'Cytology/Pneumocystis
    Stain')</li>
<li>Rheumatologic Work Up: ANA w/ Reflex, CK, Aldolase, consider
    full myositis panel<ul>
<li>
<ul>
<li>RA: RF, Anti-CCP</li>
<li>Scleroderma: Anticentromere, Anti-SCL-70</li>
<li>Mixed Connective Tissue Disease: Anti-ribonuclear
    protein</li>
<li>DM/PM: Anti-Jo</li>
<li>SLE: Anti-ds DNA, Anti-sm, APL</li>
<li>Sjogren: Anti-SS-A (Ro), Anti-SS-B (La)</li>
</ul>
</li>
</ul>
</li>
<li>If risk factors present: Sputum AFB, Hypersensitivity Panel</li>
</ul>
</li>
<li>PFTs, 6-minute walk test</li>
<li>Bronchoscopy: BAL (Cell counts, cultures, cytology) + Tissue Biopsy
    (Transbronchial vs. Cryobiopsy vs. surgical/VATS)</li>
</ul>
<p>Management</p>
<ul>
<li>Treat underlying condition</li>
<li>In the inpatient setting, often determine if a patient would benefit
    from immunosuppression therapy (i.e. steroids) initially, but will
    need to rule out to infection first</li>
<li>Consider lung transplantation for rapidly progressive or refractory
    cases in appropriate candidate</li>
</ul>
<p>Primary Respiratory Acidosis:</p>
<ul>
<li>Assess patient’s history: Is this acute or chronic?<ul>
<li>Acute respiratory acidosis and hypercarbia will often present
    with somnolence or AMS</li>
<li>Similarly, if a PCO2 is 80, and the patient is talking to you,
    it is most likely chronic</li>
</ul>
</li>
<li>Common Acute Causes: Decreased respiratory drive (opiates,
    intoxication) or respiratory muscle weakness (i.e. myasthenia gravis
    exacerbation)</li>
<li>Common Chronic Causes: COPD, sleep apnea</li>
<li>Appropriate metabolic compensation?</li>
<li>If acute, every 10 mmHg increase in pCO2 above normal (40) should
    raise HCO3 by 1<ul>
<li>Expected HCO3 = 24 + ((pCO2 -40)/10))</li>
</ul>
</li>
<li>If chronic, every 10 mm Hg
    ↑
    in pCO2 above normal (40) should raise HCO3 by 3.5<ul>
<li>Expected HCO3 = 24 + 3.5 ((pCO2-40/10)).</li>
</ul>
</li>
<li>If HCO3 higher than expected
    à
    additional metabolic alkalosis</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-pfts"><h1 id="pulmonary-pulmonary-pfts-pfts">PFTs<a class="headerlink" href="#pulmonary-pulmonary-pfts-pfts" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Function Tests (PFTs) – Peter Edmonds</td>
</tr>
</tbody>
</table>
<p>PFTs should rarely be ordered in inpatient setting as acute illness can
lead to suboptimal results.</p>
<p>Full PFTs include and can be ordered as the following:</p>
<ul>
<li>Spirometry: FVC, FEV1, with or without bronchodilator<ul>
<li>Outpatient evaluation of patients with new shortness of breath,
    chronic cough, or upper airway obstruction</li>
</ul>
</li>
<li>Plethysmography: TLC, RV<ul>
<li>Evaluation of restrictive diseases (ILD, neuromuscular disease)
    and/or hyperinflation (COPD, asthma)</li>
</ul>
</li>
<li>Diffusion (DLCO) can be added to plethysmography.<ul>
<li>Full PFTs' = Spirometry + Plethysmography + DLCO</li>
</ul>
</li>
</ul>
<p>Tips for ordering:</p>
<ul>
<li>Initial diagnostic workup<ul>
<li>Order full PFTs with bronchodilator challenge</li>
</ul>
</li>
<li>Chronic Lung disease:<ul>
<li>Order spirometry only to track FEV1/FVC over time &plusmn; DLCO to
    evaluate ILD</li>
</ul>
</li>
</ul>
<p>Interpretation:</p>
<ul>
<li>Distinguish between Obstructive and Restrictive Disease<ul>
<li>FEV1/FVC \&lt; 0.7 indicates obstructive disease<ul>
<li>Normal to increased FVC &amp; TLC is consistent with isolated
    obstructive disease</li>
</ul>
</li>
<li>TLC \&lt; 80% is diagnostic of restrictive disease<ul>
<li>Reduced FVC is suggestive, but not diagnostic of restrictive
    disease</li>
<li>FEV1 commonly reduced as well, but FEV1/FVC ratio should be
    normal in isolated restrictive disease</li>
</ul>
</li>
<li>Decreased FEV1/FVC and TLC suggests a mixed obstructive and
    restrictive picture</li>
</ul>
</li>
<li>Assess DLCO -- abnormal is \&lt;75%</li>
<li>Decreased DLCO can help differentiate between causes of Obstructive
    or Restrictive PFTs</li>
</ul>
<p>Causes of common abnormalities:</p>
<ul>
<li>Obstruction<ul>
<li>DDx if DLCO decreased: COPD, CF, bronchiectasis</li>
<li>DDx if DLCO normal: asthma, early stages of COPD or CF</li>
<li>Asthma: spirometry may be normal, +bronchodilator response (an
    increase in FEV1 by 12% and 200ml after bronchodilator),
    +methacholine challenge</li>
<li>Though we use FEV1/FVC to <strong>diagnose</strong> , we track <strong>disease
    severity</strong> using FEV1</li>
</ul>
</li>
<li>Restriction:<ul>
<li>DDx if DLCO decreased:  ILD</li>
<li>DDx if DLCO normal: pleural disease, chest wall (e.g. obesity,
    scoliosis), Neuromuscular disorders</li>
</ul>
</li>
<li>Decreased DLCO:<ul>
<li>If PFTs otherwise normal, DDx includes pulmonary vascular
    disease, pulmonary edema, or mixed obstructive/restrictive
    disease (with pseudo-normalization of other PFTs)</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-pleural-effusions"><h1 id="pulmonary-pulmonary-pleural-effusions-pleural-effusions">Pleural Effusions<a class="headerlink" href="#pulmonary-pulmonary-pleural-effusions-pleural-effusions" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pleural Effusions – Eddie Qian</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>There is a normal influx of fluid into the pleural space due to
    leaky capillary membranes and the pleural space’s negative pressure.
    This fluid is constantly reabsorbed by lymphatics. An imbalance in
    the system will result in accumulation.</li>
<li>Some examples:<ul>
<li>Increased Influx: increased filtration from the capillaries from
    high intravascular hydrostatic pressure (i.e., heart failure,
    renal failure, volume overload) or low intravascular oncotic
    pressure</li>
<li>Other liquid entry into the pleural space through anatomic
    deficits: CSF, chyle, urine, blood, ascites (the diaphragm is
    naturally porous and you will not uncommonly see pleural
    effusions with ascites)</li>
<li>Decreased Efflux: obstruction of the parietal pleural stoma
    (from protein or cellular debris in exudative pleural effusions)</li>
<li>Increased systemic venous pressure (lymphatic system drains into
    the systemic venous circulation so if there is high venous
    pressure this prevents the lymphatics from draining
    appropriately)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Imaging:<ul>
<li>CXR: lateral decubitus position (if effusion moves with gravity,
    suggests free flowing)</li>
<li>Ultrasound: assess size, location, loculations (fibrinous
    septations which may prevent simple drainage)</li>
<li>CT Chest with contrast (not always indicated; helpful to eval
    septations)</li>
</ul>
</li>
<li>Thoracentesis (see Procedures section):<ul>
<li>Will it change management?</li>
<li>Pleural LDH, protein, cell count/diff, culture</li>
<li>Consider: pleural cytology, hematocrit, triglycerides, glucose,
    amylase</li>
<li>Don’t forget serum LDH &amp; protein!</li>
<li>If septated or empyema,  consider pulm consult for chest tube</li>
</ul>
</li>
<li>
<p>Interpretation:</p>
<ul>
<li>
<p>Lights criteria: 1 of  the following to be considered an
    exudative effusion</p>
</li>
<li>
<ul>
<li>Pleural to serum protein ratio &gt; 0.5</li>
<li>Pleural to serum LDH ratio &gt; 0.6</li>
<li>Pleural LDH &gt; &#8532; upper limit of normal range of serum LDH</li>
</ul>
</li>
<li>
<p>Transudative: CHF exacerbation, hepatic hydrothorax, atelectasis
    (caused by increased intrapleural negative pressure),
    hypoalbuminemia, renal failur</p>
</li>
<li>
<p>Exudative: infections (bacterial, TB, fungal), malignant,
    rheumatologic, PE</p>
</li>
<li>
<p>Pearls about your initial tests:</p>
<ul>
<li>Protein: &gt;5 think TB or malignancy, \&lt; 0.5 think urine, CSF,
    peritoneal dialysate<ul>
<li>Glucose: \&lt; 60 think about malignancy, TB,
    rheumatologic, and less specific hemothorax or
    parapneumonic</li>
<li>Cell count/differential: polys represent an acute
    process, monocytes represent a chronic process,
    lymphocytes think about TB or malignancy, eosinophils
    think about air/blood, TB, malignancy, asbestos, drugs</li>
</ul>
</li>
</ul>
</li>
<li>Two separate process may co-occur and a transudate may mask an
exudative effusion; if  concerned for this and you have clinical
stability, trial diuresis prior to thoracentesis</li>
</ul>
</li>
</ul></section><section class="print-page" id="pulmonary-pulmonary-pulmonary-hypertension"><h1 id="pulmonary-pulmonary-pulmonary-hypertension-pulmonary-hypertension">Pulmonary Hypertension<a class="headerlink" href="#pulmonary-pulmonary-pulmonary-hypertension-pulmonary-hypertension" title="Permanent link">&para;</a></h1>
<table>
<thead>
<tr>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary Hypertension – Kaele Leonard</td>
</tr>
</tbody>
</table>
<p>Background</p>
<ul>
<li>Symptoms: dyspnea, exertional chest pain, fatigue, edema (legs,
    abdomen), exertional lightheadedness or syncope, palpitation</li>
<li>Exam: JVD, increased P2, split S2, RV heave, TR murmur,
    hepatomegaly, ascites, edema</li>
<li>Signs of RV failure: low cardiac output (hypotension, renal failure,
    hepatic congestion), arrhythmias, refractory hypoxemia (R→L shunt),
    effusions (pericardial &gt; pleural)</li>
<li>
<p>WHO Groups and Causes:</p>
</li>
<li>
<p>Pulmonary arterial hypertension (PAH): obliteration of blood vessels
    in the lung</p>
<ul>
<li>Idiopathic, heritable</li>
<li>Drugs/toxins (methamphetamine)</li>
<li>Associated with CTD, HIV, portal HTN, congenital heart disease,
    schistosomiasis</li>
<li>Pulmonary veno-occlusive disease (PVOD), pulmonary capillary
    hemangiomatosis</li>
</ul>
</li>
<li>Left heart disease: back pressure and passive congestion<ul>
<li>HFrEF, HFpEF, valvular disease, LA stiffness</li>
</ul>
</li>
<li>Chronic lung disease: chronic hypoxemia
    à
    chronic pulmonary vasoconstriction<ul>
<li>COPD, ILD, OSA, chronic high-altitude, developmental lung
    disorders</li>
</ul>
</li>
<li>Pulmonary artery obstruction and thrombi: obstruction due to chronic
    clot material<ul>
<li>Chronic thromboembolic pulmonary hypertension (CTEPH)</li>
</ul>
</li>
<li>Unclear or multifactorial mechanisms<ul>
<li>Hematologic disorders, chronic hemolytic anemia, sarcoidosis,
    pulmonary Langerhans cell histiocytosis, fibrosing
    mediastinitis, metabolic disorders</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Consult pulmonary hypertension with any questions or assistance with
    workup. Below are studies to consider ordering to determine
    etiology/group of pulmonary hypertension</li>
<li>Labs: BNP, rheumatologic studies (ANA, RF), HIV</li>
<li>CXR: increased right heart border, increased PA</li>
<li>EKG: RVH
    , RAD</li>
<li>TTE w/ bubble: RVSP &gt;35-40, RV dilation and dysfunction, RA
    dilation, septal flattening, pericardial effusion, evaluate for L
    heart disease and shunt</li>
<li>PFTs: decreased DLCO in PH, evaluate for parenchymal lung disease</li>
<li>VQ scan
    or CTA chest: evaluate for CTEPH<ul>
<li>Pulmonary angiogram (evaluate for surgical candidacy for
    pulmonary endarterectomy)</li>
</ul>
</li>
<li>+
    CT chest: evaluate for parenchymal lung disease</li>
<li>+
    ABG: evaluate for hypoxemia or hypercarbia</li>
<li>+
    Sleep
    study: evaluate for OSA</li>
</ul>
<p>Right heart catheterization (RHC): diagnose PH and determine pre- vs
post-capillary</p>
<ul>
<li>See RHC section for hemodynamic assessment</li>
<li>Nitric oxide challenge assess for drug response</li>
<li>Fluid challenge
    →
    assess left heart compliance</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitions</td>
<td>Characteristics</td>
<td>Causes</td>
</tr>
<tr>
<td>Pre-capillary PH</td>
<td>mPAP > 20 mmHg PAWP ≤ 15 mmHg PVR ≥ 3 WU</td>
<td>Groups 1, 3, 4, 5</td>
</tr>
<tr>
<td>Post-capillary PH</td>
<td>mPAP > 20 mmHg PAWP > 15 mmHg PVR \&lt; 3 WU</td>
<td>Group 2</td>
</tr>
<tr>
<td>Combined pre- and post- capillary PH</td>
<td>mPAP > 20 mmHg PAWP > 15 mmHg PVR ≥ 3 WU</td>
<td>Group 2, 5</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>General: treat underlying cause; Diuretics for right heart failure;
    Oxygen goal SpO2 &gt; 90%</li>
<li>PAH medicines: Consult pulmonary hypertension for consideration to
    start or change thes<ul>
<li>Oral treatments may be used as monotherapy or in combination<ul>
<li>Calcium-channel blockers
    →
    patients with + vasoreactive challenge</li>
<li>NO-cGMP enhancers: PDE5-inhibitors sildenafil or tadalafil,
    riociguat</li>
<li>Endothelin receptor antagonists (ERAs): bosentan,
    macitentan, ambrisenta</li>
<li>Prostacyclins:</li>
<li>Epoprostenol: IV (Veletri) or inhaled (Flolan), half-life 4
    minutes</li>
<li>Treprostinil: IV/subcutaneous/inhaled/PO, half-life 4 hours</li>
<li>Iloprost: inhaled, half-life minutes</li>
<li>Selexipag (Uptravi): PO, half-life hours</li>
<li>Side effects: headache, jaw pain, flushing, diarrhea,
    arthralgias</li>
</ul>
</li>
</ul>
</li>
<li>Treatment based on NYHA functional classification:<ul>
<li>Class I: no treatment or monotherapy</li>
<li>Class II: monotherapy or combination oral therapy</li>
<li>Class III: combination oral therapy or prostacyclin</li>
<li>Class IV: prostacyclin &plusmn; oral therapy</li>
</ul>
</li>
<li>Lung transplant for patients who are candidates and failing maximal
    medical therapy</li>
<li>V-A ECMO can be used as bridge to medical therapy or lung transplant</li>
<li>Palliative
    measures<ul>
<li>Atrial septostomy – serves as “pop-off” valve and allows for
    decompression of failing RV; used as definitive palliative
    procedure or bridge to lung transplant</li>
</ul>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Pulmonary</h1>
                        <h1 class='nav-section-title' id='section-radiology'>
                            Radiology <a class='headerlink' href='#section-radiology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="radiology-radiology-consults-radiology-procedures"><h1 id="radiology-radiology-consults-radiology-procedures-consults-for-radiology-procedures">Consults for Radiology Procedures<a class="headerlink" href="#radiology-radiology-consults-radiology-procedures-consults-for-radiology-procedures" title="Permanent link">&para;</a></h1>
<ul>
<li>Radiology Procedures are performed by 3 separate consult services
    depending on the procedure requested.</li>
<li>These pagers are covered 24/7, often by the same person for up to a
    week at a time (home call, not night float), so kindly reserve
    overnight pages for true urgent/emergent indications and save
    non-emergent communications until the morning</li>
</ul>
<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 27%" />
<col style="width: 25%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th>Consult Service</th>
<th>Vascular IR</th>
<th>CT/US Procedures</th>
<th>Fluoro/Neuro/MSK fluoroscopy</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>EPIC Order</td>
<td>“Inpatient Consult to Interventional Radiology”</td>
<td>“Inpatient Consult for Adult Image-Guided Procedures (CT/US)”</td>
<td>Call 20878 (Fluoroscopy) for scheduling &amp; orders.</td>
</tr>
<tr class="even">
<td>Contact Number (weekdays)</td>
<td><p>#20840</p>
<p>(MD desk)</p></td>
<td><p>#20120</p>
<p>(MD desk)</p></td>
<td><p>#20878</p>
<p>(Fluoro techs)</p></td>
</tr>
<tr class="odd">
<td>Contact Number (nights &amp; weekends)</td>
<td>Pager only</td>
<td>Pager only</td>
<td><p>#37185</p>
<p>(ER reading room)</p></td>
</tr>
<tr class="even">
<td>Service Pager</td>
<td><strong>835-5105</strong></td>
<td><strong>835-0770</strong></td>
<td>N/A</td>
</tr>
<tr class="odd">
<td>Procedure Requested</td>
<td><p>-Active bleeding Embolizations</p>
<p>-Cholecystostomy</p>
<p>-PTC (biliary drains)</p>
<p>-Nephrostomy</p>
<p>-Tunneled lines</p>
<p>-Dialysis interventions</p>
<p>-G-tube placement</p>
<p>-IVC Filter</p>
<p>-Drain repositioning</p></td>
<td><p>-Abscess drainage</p>
<p>-Biopsies</p>
<p>-Paracentesis**</p>
<p>-Thoracentesis**</p></td>
<td><p>-Dobhoff tube placements**</p>
<p>-Lumbar punctures**</p>
<p>-Joint injections / aspirations</p>
<p>-Esophograms</p>
<p>-Upper GI Series</p>
<p>-Small bowel follow-through</p>
<p>-Contrast enemas</p></td>
</tr>
</tbody>
</table>

<p>**Requires failed bedside/Inpatient medicine procedures service
attempt</p>
<p>Specific Procedural Questions</p>
<p>Pre-Procedure (contact consult services for case-specific requirements,
guidelines below):</p>
<ul>
<li>
<p>NPO @ MN prior to procedure if sedation is to be used (majority of
    cases). Local only cases do not require patient to be NPO (see IR or
    CT/US procedures consult note for details).</p>
</li>
<li>
<p>Labs required within 1 month of procedure or sooner if there is a
    clinical situation that can affect those lab values. Think Warfarin
    and INR, for example.</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>INR (\&lt;1.5 for most procedures)</p>
</li>
<li>
<p>Platelets (>50K)</p>
</li>
</ul>
<!-- -->

<ul>
<li>Anticoagulation</li>
</ul>
<!-- -->

<ul>
<li>
<p>Google “SIR anticoagulation guidelines 2019”</p>
</li>
<li>
<p>VUMC IR guidelines based on SIR 2019 guidelines are included at end
    of section</p>
</li>
</ul>
<p>Inpatient biopsies for malignancy: Inpatient biopsies are lowest
priority on the CT/US procedures service given resource availability and
will more than likely get bumped. <strong>We recommend that these get
scheduled outpatient.</strong></p>
<ul>
<li>Place an outpatient consult to image guided procedures at time of
    discharge/through discharge tab in EPIC to facilitate outpatient
    biopsies.</li>
</ul>
<p>Drain Management</p>
<ul>
<li>Best to discuss directly with service that placed the drain (IR vs.
    CT/US vs. surgery)</li>
</ul>
<!-- -->

<ul>
<li>Flush with 10 mL sterile saline q shift while inpatient (flush into
    drain towards the patient and then place back to gravity or
    accordion suction bag)</li>
</ul>
<!-- -->

<ul>
<li>If drain output decreases, either:</li>
</ul>
<!-- -->

<ul>
<li>
<p>The collection (e.g., abscess) has been drained</p>
</li>
<li>
<p>The drain is clogged/malfunctioning/mispositioned</p>
<ul>
<li>
<p>Start with making sure there are no kinks in the drain, the 3
    way is not clogged, and that the accordion drain is functioning.</p>
</li>
<li>
<p>Next, ensure the drain flushes appropriately. What this means
    is: you can flush the drain with 10 ml of saline and when you
    place back to gravity/accordion drainage bag you get back what
    you flushed in. There should be no leakage around the drain at
    the skin at baseline or during flushing.</p>
</li>
<li>
<p>If the drain is functioning, and there is still no output,
    obtain a CT w/ IV contrast to evaluate the collection and
    ongoing need for drainage,</p>
</li>
<li>
<p>If the collection remains, and drain is appropriately positioned
    within the drain, it is likely clogged/malfunctioning. First
    ensure proper suction/3-way direction. If this is not the issue,
    you can consider instilling tPA into the catheter for 2 hours</p>
<ul>
<li>
<p>Would avoid in the setting of therapeutic anticoagulation
    given increased risk of bleeding unless discussed with
    procedural service).</p>
</li>
<li>
<p>Epic order: Alteplase (TPA) injection/infusion options
    Percutaneous drainage 2mg or 4mg</p>
</li>
</ul>
</li>
<li>
<p>If this doesn't improve output in 48 hours, consider
    repositioning drain (VIR consult)</p>
</li>
</ul>
</li>
</ul>
<h2 id="radiology-radiology-consults-radiology-procedures-anticoagulation-for-ir-procedures">Anticoagulation for IR Procedures<a class="headerlink" href="#radiology-radiology-consults-radiology-procedures-anticoagulation-for-ir-procedures" title="Permanent link">&para;</a></h2>
<p>Based on 2019 SIR Consensus Guidelines. JVIR 2019; 1168-1184. The length
of time anticoagulation is held may differ from these guidelines in
certain clinical circumstances at the discretion of the proceduralist.
Generally, may resume anticoagulation 24 hours after the procedure.</p>
<p><strong>Low Risk Procedures</strong></p>
<ul>
<li>Screening coagulation laboratory tests</li>
</ul>
<!-- -->

<ul>
<li>PT/INR, platelet count, Hgb not routinely needed</li>
</ul>
<!-- -->

<ul>
<li>Suggested laboratory thresholds for most patients</li>
</ul>
<!-- -->

<ul>
<li>
<p>INR: correct to \&lt;3.0</p>
</li>
<li>
<p>Platelets: transfuse if \&lt;20,000</p>
</li>
</ul>
<!-- -->

<ul>
<li>Suggested laboratory thresholds in patients with chronic liver
    disease</li>
</ul>
<!-- -->

<ul>
<li>
<p>INR: n/a</p>
</li>
<li>
<p>Platelets: transfuse if \&lt;20,000</p>
</li>
<li>
<p>Fibrinogen: cryoprecipitate if \&lt;100</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 38%" />
<col style="width: 30%" />
<col style="width: 31%" />
</colgroup>
<thead>
<tr class="header">
<th>List of Low-Risk Procedures</th>
<th>Medication</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td rowspan="25"><p><strong>Vascular</strong></p>
<p>- Central venous catheter non-tunneled/tunneled line placement,
removal and exchanges (e.g. port)</p>
<p>- Dialysis assess interventions (e.g. shuntograms)</p>
<p>- Gonadal vein embolization</p>
<p>- IVC filter placement and retrieval</p>
<p>- Laser ablation and phlebectomy</p>
<p>- Lymphangiogram</p>
<p>- Sclerotherapy for venous malformation</p>
<p>- Transjugular liver biopsy</p>
<p>- Venography and select venous interventions (e.g. adrenal vein
sampling)</p>
<p><strong>Nonvascular</strong></p>
<p>- Superficial abscess drainage</p>
<p>- Catheter exchanges (e.g. biliary, nephrostomy, abscess)</p>
<p>- FNA/superficial biopsy</p>
<p>- Gastrostomy and GJ exchanges</p>
<p>- Appendicular skeleton bone biopsy, joint injections, peripheral
nerve blocks</p>
<p>- Thoracentesis</p>
<p>- Paracentesis</p>
<p>- Tunneled drainage catheter placement</p></td>
<td colspan="2"><strong>Anticoagulants</strong></td>
</tr>
<tr class="even">
<td>Warfarin (Coumadin)</td>
<td>Target INR &lt;3.0. Withhold 5 days for MSK procedures only.
Bridging per PCP/cardiology</td>
</tr>
<tr class="odd">
<td>Heparin (unfractionated)</td>
<td>Do not withhold</td>
</tr>
<tr class="even">
<td>LMWH (therapeutic)</td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td>LMWH (prophylactic)</td>
<td>Do not withhold</td>
</tr>
<tr class="even">
<td>Rivaroxaban (Xarelto)</td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td>Edoxaban (Savaysa)</td>
<td>Do not withhold</td>
</tr>
<tr class="even">
<td>Fundaparinux (Arixtra)</td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td>Apixaban (Eliquis)</td>
<td>Do not withhold</td>
</tr>
<tr class="even">
<td>Argatroban</td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td>Bivalirudin (Angiomax)</td>
<td>Do not withhold</td>
</tr>
<tr class="even">
<td>Dabigatran (Pradaxa)</td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td colspan="2"><strong>Antiplatelets</strong></td>
</tr>
<tr class="even">
<td>Aspirin (81 or 325 mg)</td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td>Clopidogrel (Plavix)</td>
<td>Do not withhold</td>
</tr>
<tr class="even">
<td>Prasugrel (Effient)</td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td>Ticagrelor (Brilinta)</td>
<td>Do not withhold</td>
</tr>
<tr class="even">
<td>Cangrelor (Kengreal)</td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td colspan="2"><strong>NSAIDs</strong></td>
</tr>
<tr class="even">
<td><p>Short-acting</p>
<p>- Ibuprofen</p>
<p>- Diclofenac</p>
<p>- Ketoprofen</p>
<p>- Indomethacin</p></td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td><p>Intermediate-acting</p>
<p>- Ibuprofen</p>
<p>- Diclofenac</p>
<p>- Ketoprofen</p>
<p>- Indomethacin</p></td>
<td>Do not withhold</td>
</tr>
<tr class="even">
<td><p>Long-acting</p>
<p>-Meloxicam</p></td>
<td>Do not withhold</td>
</tr>
<tr class="odd">
<td colspan="2"><strong>Glycoprotein IIb/IIIa Inhibitors</strong></td>
</tr>
<tr class="even">
<td><p>Long-acting</p>
<p>- Abciximab (ReoPro)</p></td>
<td>Withhold 24 hours</td>
</tr>
<tr class="odd">
<td><p>Short-acting</p>
<p>- Eptifibatide (Integrilin)</p>
<p>- Tirofiban (Aggrastat)</p></td>
<td>Withhold 4 hours</td>
</tr>
</tbody>
</table>

<p><strong>High Risk Procedures</strong></p>
<ul>
<li>Screening coagulation laboratory tests</li>
</ul>
<!-- -->

<ul>
<li>PT/INR, platelet count, Hgb</li>
</ul>
<!-- -->

<ul>
<li>Suggested laboratory thresholds for most patients</li>
</ul>
<!-- -->

<ul>
<li>
<p>INR: correct to \&lt;1.8 (\&lt;1.5 if neuro procedure)</p>
</li>
<li>
<p>Platelets: transfuse if \&lt;50,000</p>
</li>
</ul>
<!-- -->

<ul>
<li>Suggested laboratory thresholds in patients with chronic liver
    disease</li>
</ul>
<!-- -->

<ul>
<li>
<p>INR: \&lt;2.5. (\&lt;1.5 if neuro procedure)</p>
</li>
<li>
<p>Platelets: transfuse if \&lt;30,000</p>
</li>
<li>
<p>Fibrinogen: cryoprecipitate if \&lt;100</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 38%" />
<col style="width: 30%" />
<col style="width: 31%" />
</colgroup>
<thead>
<tr class="header">
<th>List of High-Risk Procedures</th>
<th>Medication</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td rowspan="25"><p><strong>Vascular</strong></p>
<p>- Angiography and arterial interventions (e.g. chemoembolization,
renal embolization, uterine embolization)</p>
<p>- BRTO/BATO</p>
<p>- Catheter directed thrombolysis (e.g. DVT, PE, portal vein)</p>
<p>- Complex IVC filter removal</p>
<p>- Lymphangiogram with thoracic duct embolization</p>
<p>- Portal vein interventions</p>
<p>- Pulmonary artery malformation embolization</p>
<p>- Transjugular intrahepatic portosystemic shunt (TIPS)</p>
<p><strong>Nonvascular</strong></p>
<p>- Ablations (e.g. cryoablation, microwave ablation, radiofrequency
ablation)</p>
<p>- Deep abscess drainage</p>
<p>- Biliary interventions (new placement e.g. cholecystostomy)</p>
<p>- Deep non-organ biopsy (e.g. retroperitoneal, pelvic,
intra-abdominal)</p>
<p>- New Gastrostomy and GJ tube placement</p>
<p>- Axial skeleton biopsy, bone marrow biopsy</p>
<p>- Neuro: epidural injection, facet block, LP, myelogram, vertebral
biopsy</p>
<p>- Solid organ biopsy (e.g. liver, kidney, lung)</p>
<p>- Spine procedures</p>
<p>- Urinary tract interventions (nephrostomy tube placement, ureteral
dilation)</p></td>
<td colspan="2"><strong>Anticoagulants</strong></td>
</tr>
<tr class="even">
<td>Warfarin (Coumadin)</td>
<td>Withhold 5 days, goal INR &lt;1.8. Bridging per PCP/cardiology</td>
</tr>
<tr class="odd">
<td>Heparin (unfractionated)</td>
<td><p>Withhold IV for 4 hours</p>
<p>Withhold SQ for 6 hours</p></td>
</tr>
<tr class="even">
<td>LMWH (therapeutic)</td>
<td>Withhold for 24 hours</td>
</tr>
<tr class="odd">
<td>LMWH (prophylactic)</td>
<td>Withhold for 12 hours</td>
</tr>
<tr class="even">
<td>Rivaroxaban (Xarelto)</td>
<td><p>Withhold:</p>
<p>2 days (CrCl&gt;30)</p>
<p>3 days (CrCl&lt;30)</p></td>
</tr>
<tr class="odd">
<td>Edoxaban (Savaysa)</td>
<td>Withhold 2 days</td>
</tr>
<tr class="even">
<td>Fundaparinux (Arixtra)</td>
<td><p>Withhold:</p>
<p>2 days (CrCl&gt;50)</p>
<p>3 days (CrCl&lt;50)</p></td>
</tr>
<tr class="odd">
<td>Apixaban (Eliquis)</td>
<td><p>Withhold:</p>
<p>2 days (CrCl&gt;50)</p>
<p>3 days (CrCl&lt;50)</p></td>
</tr>
<tr class="even">
<td>Argatroban</td>
<td>Withhold for 2 hours</td>
</tr>
<tr class="odd">
<td>Bivalirudin (Angiomax)</td>
<td>Withhold for 2 hours</td>
</tr>
<tr class="even">
<td>Dabigatran (Pradaxa)</td>
<td><p>Withhold:</p>
<p>2 days (CrCl&gt;50)</p>
<p>3 days (CrCl&lt;50)</p></td>
</tr>
<tr class="odd">
<td colspan="2"><strong>Antiplatelets</strong></td>
</tr>
<tr class="even">
<td>Aspirin (81 or 325 mg)</td>
<td><p>81mg: Do not withhold</p>
<p>325mg: Withhold 5 days unless angiography or neuro procedure</p></td>
</tr>
<tr class="odd">
<td>Clopidogrel (Plavix)</td>
<td>Withhold 5 days unless angiography/embolization</td>
</tr>
<tr class="even">
<td>Prasugrel (Effient)</td>
<td>Withhold 7 days</td>
</tr>
<tr class="odd">
<td>Ticagrelor (Brilinta)</td>
<td>Withhold 5 days</td>
</tr>
<tr class="even">
<td>Cangrelor (Kengreal)</td>
<td>Avoid; if emergent withhold 1 hour</td>
</tr>
<tr class="odd">
<td colspan="2"><strong>NSAIDs</strong></td>
</tr>
<tr class="even">
<td><p>Short-acting</p>
<p>- Ibuprofen</p>
<p>- Diclofenac</p>
<p>- Ketoprofen</p>
<p>- Indomethacin</p></td>
<td>No recommendation</td>
</tr>
<tr class="odd">
<td><p>Intermediate-acting</p>
<p>- Ibuprofen</p>
<p>- Diclofenac</p>
<p>- Ketoprofen</p>
<p>- Indomethacin</p></td>
<td>No recommendation</td>
</tr>
<tr class="even">
<td><p>Long-acting</p>
<p>-Meloxicam</p></td>
<td>No recommendation</td>
</tr>
<tr class="odd">
<td colspan="2"><strong>Glycoprotein IIb/IIIa Inhibitors</strong></td>
</tr>
<tr class="even">
<td><p>Long-acting</p>
<p>- Abciximab (ReoPro)</p></td>
<td>Withhold 24 hours</td>
</tr>
<tr class="odd">
<td><p>Short-acting</p>
<p>- Eptifibatide (Integrilin)</p>
<p>- Tirofiban (Aggrastat)</p></td>
<td>Withhold 4 hours</td>
</tr>
</tbody>
</table>

<h2 id="radiology-radiology-consults-radiology-procedures-contrast-allergies-or-extravasation">Contrast Allergies or Extravasation<a class="headerlink" href="#radiology-radiology-consults-radiology-procedures-contrast-allergies-or-extravasation" title="Permanent link">&para;</a></h2>
<p>See ACR contrast manual for additional Information
(<a href="https://www.acr.org/Clinical-Resources/Contrast-Manual">https://www.acr.org/Clinical-Resources/Contrast-Manual</a>)</p>
<!--
<img src="../radiology/radiology-consults-radiology-procedures/output/media/image34.png"
style="width:3.56291in;height:4.31726in"
alt="Text Description automatically generated" />
--></section><section class="print-page" id="radiology-radiology-cxr"><h1 id="radiology-radiology-cxr-basic-chest-x-ray-interpretation">Basic Chest X-ray Interpretation<a class="headerlink" href="#radiology-radiology-cxr-basic-chest-x-ray-interpretation" title="Permanent link">&para;</a></h1>
<p>Gautam Babu</p>
<hr />
<p>An X-ray is a density-gram where “white” is “dense” and “black” is “not
dense.” Determine a systematic method you use every time you interpret a
CXR to ensure you don’t miss anything</p>
<ul>
<li>Start every CXR you interpret by assessing the quality of the film:</li>
<li>Penetration:<ul>
<li>Should see vertebral bodies through the cardiac silhouette but
    not into the abdomen</li>
<li>If you cannot see them through the heart, the film is
    “under-penetrated,” and everything will appear more “white.”</li>
<li>If you can see them through the abdomen the film is
    “over-penetrated” and everything will appear more “black.”</li>
</ul>
</li>
<li>Rotation: Spinous processes should be in the middle of the
    clavicular heads</li>
<li>Two Different Systematic Methods:</li>
<li>
<p>ABCDE method</p>
<ul>
<li>Airway – Trachea midline and patent</li>
<li>Bones – Bone density and obvious fractures</li>
<li>Cardiac Silhouette – Should see L &amp; R heart border, if not there
    may be an adjacent opacity (Right Middle Lobe, Lingula)<ul>
<li>Cardiomegaly = heart size ≥ &frac12; the width of the hemithorax
    on a PA film</li>
</ul>
</li>
<li>Diaphragm – Look for pleural effusions at the costo-phrenic
    angle. If you cannot see the diaphragm along the way, there may
    be an adjacent opacity (Lower Lobe)</li>
<li>“Everything else” – Refers to the lung fields<ul>
<li>Extra-Thoracic Soft Tissue – Subcutaneous emphysema</li>
<li>Fields and Fissures –lung fields should appear symmetric and
    “black”</li>
<li>Great Vessels – Tortuosity of the aorta and the outlines of
    the pulmonary vessels</li>
<li>Hilum – Hilar masses, LAD and pulmonary arteries</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Working around the film method:</p>
<ul>
<li>Imagine the entire CXR film as a square and an inner “box” as
    the pleural lining</li>
<li>Outside the box: Lines/tubes, subq emphysema, gastric bubble,
    subdiaphragmatic air</li>
<li>Edge of the box: Look for pleural thickening, pleural effusion,
    pneumothorax, visualization of the diaphragm</li>
<li>Middle of the box: Trachea, vascular pedicle, hila, heart
    borders, great vessels, retrocardiac space</li>
<li>The lung fields</li>
</ul>
</li>
</ul>
<p>Silhouette sign</p>
<ul>
<li>Two things of different densities will show a clear
    border on a chest x-ray</li>
<li>Loss of a border you expect to see suggests a change in density of
    one of the structures.</li>
<li>Ex: heart &amp;l lung have different densities with sharp border. Loss
    of this border suggests that the lung “increased” in density<ul>
<li>Ex: Pneumonia (fluffy opacities, air bronchograms, asymmetric)
    and pulmonary edema (linear opacities, fluid in fissures, Kerley
    B lines, cephalization)</li>
</ul>
</li>
</ul>
<!--
<img src="../radiology/radiology-cxr/output/media/image30.jpeg"
style="width:1.89623in;height:2.30208in"
alt="Diagram Description automatically generated" /><img src="../radiology/radiology-cxr/output/media/image31.jpeg"
style="width:1.64653in;height:2.30694in"
alt="A picture containing indoor, tattoo, plant Description automatically generated" />


- 1,2-10: first rib, posterior aspect of ribs 2 to 10

- AK: aortic knob

- APW: aortopulmonary window

- BS: breast shadow

- C, T: carina, tracheal air column

- CA, GA: colonic air, gastric air

- CPA: costophrenic angle

- DA: descending aorta

- LHB: left heart border (most of which represents the left ventricle,
    the superior aspect represents the left atrial appendage)

- LPA: left pulmonary artery

- RC: right clavicle

- RHB: right heart border (represents the right atrium)

- PHB: posterior heart border

- RHD, LHD: right hemidiaphragm, left hemidiaphragm

- RPA: right pulmonary artery

- S: scapula

- RA: retrosternal space

- RMF: right lung fissure (left major and minor fissures are not
    always visualized)

Chapter 15. Imaging Studies. Gomella L.G., & Haist S.A. (Eds.), (2007).
Clinician's Pocket Reference: The Scut Monkey, 11e. McGraw Hill.
<https://accessmedicine.mhmedical.com/content.aspx?bookid=365&sectionid=43074924>

--></section><section class="print-page" id="radiology-radiology-kub"><h1 id="radiology-radiology-kub-basic-abdominal-x-ray-interpretation">Basic Abdominal X-ray Interpretation<a class="headerlink" href="#radiology-radiology-kub-basic-abdominal-x-ray-interpretation" title="Permanent link">&para;</a></h1>
<p>Gautam Babu</p>
<hr />
<p>As with chest radiographs, use a systematic approach. Here are some
important reminders:</p>
<ul>
<li>Patient positioning (marked by tech):</li>
</ul>
<!-- -->

<ul>
<li>
<p>Supine films poorly evaluate for free air, but are fine for
    evaluating bowel gas pattern, tube positioning</p>
</li>
<li>
<p>Upright or left lateral decubitus are more sensitive for free air</p>
</li>
</ul>
<!-- -->

<ul>
<li>NGT films</li>
</ul>
<!-- -->

<ul>
<li>
<p>Film will not include the lower abdomen so cannot fully evaluate
    bowel gas pattern. If you don't see your NGT, confirm that the tube
    is not coiled in the oropharynx, esophagus or airway (check CXR if
    necessary).</p>
</li>
<li>
<p>Post pyloric placement should be to the right of the midline with
    the tube resembling the “C-loop” of the duodenum.</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Bowel caliber – small bowel distension more than 3cm caliber may be
    abnormal, is there distal gas? Recent operative intervention?
    Differential: ileus vs SBO</p>
</li>
<li>
<p>Colon – identify by haustration. Cecum and rectum can be distended
    up to 9cm. Remainder of colon should be under 6cm. Stool burden?
    Twist/volvulus?</p>
</li>
<li>
<p>Gas (where it shouldn't be) – look for lucency against straight
    lines (diaphragm, liver, falciform).</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Large volume air can also outline bowel wall against intraluminal
    air</p>
</li>
<li>
<p>Bowel wall shouldn't have gas (pneumatosis)</p>
</li>
<li>
<p>Liver gas can be pneumobilia (prior ERCP/stent) or portal venous gas
    (from ischemic bowel)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Bladder – foley projecting in right location?</p>
</li>
<li>
<p>Soft tissues – may faintly see kidney margins, psoas. No big/obvious
    soft tissue mass?</p>
</li>
<li>
<p>Bones – rib fractures, spine compression deformities, pelvic/hip
    fractures</p>
</li>
</ul>
<!--
    <img src="../radiology/radiology-kub/output/media/image32.jpeg"
    style="width:3.02847in;height:2.85486in" />
--></section><section class="print-page" id="radiology-radiology-radiology-exams-diagnosis"><h1 id="radiology-radiology-radiology-exams-diagnosis-common-radiology-exams-by-suspected-diagnosis">Common Radiology Exams by Suspected Diagnosis<a class="headerlink" href="#radiology-radiology-radiology-exams-diagnosis-common-radiology-exams-by-suspected-diagnosis" title="Permanent link">&para;</a></h1>
<p>Ryan Adams, Leah Brown</p>
<hr />
<table>
<colgroup>
<col style="width: 37%" />
<col style="width: 62%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="2">Musculoskeletal</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Fracture</td>
<td>X-rays, CT (extremity) without contrast</td>
</tr>
<tr class="even">
<td>Soft tissue infection</td>
<td><p>CT (extremity) with contrast</p>
<p>MRI (extremity) with and without contrast</p></td>
</tr>
<tr class="odd">
<td>Osteomyelitis</td>
<td><p>X-ray (extremity)</p>
<p>MRI (extremity) with and without contrast</p></td>
</tr>
<tr class="even">
<td>Bone or soft tissue tumors</td>
<td>MRI (extremity) with and without contrast</td>
</tr>
<tr class="odd">
<td>DVT</td>
<td>Ultrasound doppler (extremity) venous (laterality)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chest</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary embolism</td>
<td>CT angiogram chest pulmonary embolism with contrast</td>
</tr>
<tr>
<td>Lung mass, metastases</td>
<td>CT chest with contrast</td>
</tr>
<tr>
<td>Pulmonary nodule</td>
<td>CT chest without contrast</td>
</tr>
<tr>
<td>Pneumothorax</td>
<td>X-ray chest portable (or 2 view), SPECIFY UPRIGHT</td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 34%" />
<col style="width: 65%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="2">Abdomen/Pelvic</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Cholecystitis</td>
<td>Ultrasound abdomen limited (specify cholecystitis)</td>
</tr>
<tr class="even">
<td>Pancreatitis</td>
<td>CT abdomen pelvis with contrast</td>
</tr>
<tr class="odd">
<td>Appendicitis</td>
<td>CT abdomen pelvis with contrast</td>
</tr>
<tr class="even">
<td>Bowel obstruction</td>
<td>X-ray abdomen 1 view, CT abdomen pelvis with contrast</td>
</tr>
<tr class="odd">
<td>HCC</td>
<td><p>CT abdomen with contrast, specify HCC in comments</p>
<p>MRI abdomen with contrast, specify HCC in comments</p></td>
</tr>
<tr class="even">
<td>Mesenteric ischemia/AAA</td>
<td>CT angiogram abdomen and pelvis</td>
</tr>
<tr class="odd">
<td>Crohn’s/IBD</td>
<td>CT abdomen pelvis enterography with contrast</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Neurologic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain mass/metastases</td>
<td>MRI brain with and without IV contrast</td>
</tr>
<tr>
<td>Stroke</td>
<td>MRI brain without contrast</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>MRI brain with and without contrast</td>
</tr>
<tr>
<td>Aneurysm or vascular injury</td>
<td>CT angiogram head and neck with and without contrast</td>
</tr>
<tr>
<td>Dural venous sinus thrombosis</td>
<td>CT venogram head</td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td>CT head without contrast</td>
</tr>
<tr>
<td>Spine trauma</td>
<td>CT (c/t/l) spine without contrast, MRI spine wo contrast</td>
</tr>
<tr>
<td>Spine tumor, infection, post-op</td>
<td>MRI (C/T/L) spine with and without contrast</td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col style="width: 35%" />
<col style="width: 64%" />
</colgroup>
<thead>
<tr class="header">
<th colspan="2">Urogenital</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Ovarian/testicular torsion</td>
<td><p>Ultrasound scrotal with complete doppler</p>
<p>Ultrasound pelvic transvaginal</p></td>
</tr>
<tr class="even">
<td>Ectopic pregnancy</td>
<td>Ultrasound transvaginal and pelvic</td>
</tr>
<tr class="odd">
<td>Kidney stones</td>
<td><p>Ultrasound renal</p>
<p>CT abdomen pelvis without contrast</p></td>
</tr>
<tr class="even">
<td>Pyelonephritis</td>
<td><p>Ultrasound renal</p>
<p>CT abdomen pelvis with contrast</p></td>
</tr>
</tbody>
</table>

<p>See ACR appropriateness criteria for additional Information.
(<a href="https://www.acr.org/Clinical-Resources/ACR-Appropriateness-Criteria">https://www.acr.org/Clinical-Resources/ACR-Appropriateness-Criteria</a>)</p></section><h1 class='nav-section-title-end'>Ended: Radiology</h1>
                        <h1 class='nav-section-title' id='section-rheumatology'>
                            Rheumatology <a class='headerlink' href='#section-rheumatology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="rheumatology-main"><p>Rheumatology Lab Testing – Raeann Whitney</p>
<table>
<thead>
<tr>
<th>Lab Test</th>
<th>Quick Associations</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANA</td>
<td>SLE, many others (NOT specific)</td>
</tr>
<tr>
<td>dsDNA</td>
<td>SLE</td>
</tr>
<tr>
<td>Anti-Smith</td>
<td>SLE</td>
</tr>
<tr>
<td>Anti-SSA / Ro</td>
<td>Sjogrens (fetal heart block)</td>
</tr>
<tr>
<td>Anti-SSB / La</td>
<td>Sjogrens</td>
</tr>
<tr>
<td>Anti-RNP</td>
<td>Mixed Connective Tissue Disease</td>
</tr>
<tr>
<td>Anti-Scl70</td>
<td>Scleroderma (diffuse)</td>
</tr>
<tr>
<td>Anti-Centromere</td>
<td>Scleroderma (limited)</td>
</tr>
<tr>
<td>Anti-Jo</td>
<td>Dermatomyositis</td>
</tr>
<tr>
<td>Anti-histone</td>
<td>Drug-induced lupus</td>
</tr>
<tr>
<td>RF</td>
<td>RA (not specific; also HBV/HCV, cryoglobulinemia, etc.)</td>
</tr>
<tr>
<td>Anti-CCP</td>
<td>RA</td>
</tr>
<tr>
<td>C3/C4</td>
<td>SLE (hypocomplementemia)</td>
</tr>
<tr>
<td>ANCA</td>
<td>Granulomatosis with polyangiitis, microscopic polyangiitis</td>
</tr>
</tbody>
</table>
<p>Serologic testing must be interpreted in the clinical context. ANA,
ANCA, and even specific antibodies without typical manifestations of the
disease are of unclear clinical significance</p>
<p>Anti-nuclear Antibodies (ANA)</p>
<ul>
<li>Always send with reflex (if ≥ 1:80, will check for dsDNA, Sm, SSA,
    SSB, Scl70, RNP)</li>
</ul>
<!-- -->

<ul>
<li>
<p>At VUMC, 1:80 is considered “positive”; a higher titer is more
    specific for ANA-associated rheumatologic disease</p>
<ul>
<li>~30% of the general population has a “positive” ANA at 1:40,
    most clinically significant ANAs are at least 1:160</li>
</ul>
</li>
<li>
<p>Common Patterns</p>
<ul>
<li>
<p>Smooth/homogenous – associated with Anti-dsDNA and Anti-histone
    antibodies</p>
</li>
<li>
<p>Speckled – associated with Anti-RNP, Anti-Smith, Anti-SSA/Ro,
    Anti-SSB/La</p>
</li>
<li>
<p>Nucleolar – associated with Anti-Scl-70</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Specific types of ANAs:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Anti-dsDNA: High levels (>150) are usually specific for SLE. Can
    correlate with disease activity, a/w renal disease</p>
</li>
<li>
<p>Anti-Smith (Qualitative): Very specific for SLE but not sensitive</p>
</li>
<li>
<p>Anti-SSA/Ro</p>
<ul>
<li>
<p>Classic for Sjogren’s but non-specific; can also be seen in SLE,
    MCTD, myositis, etc</p>
</li>
<li>
<p>Maternal positivity for SSA is associated with congenital heart
    block in infants</p>
</li>
</ul>
</li>
<li>
<p>Anti-SSB/La: Similar profile to Anti-SSA/Ro but less common</p>
</li>
<li>
<p>Anti-Scl-70: Specific for systemic sclerosis, most associated with
    diffuse cutaneous disease</p>
</li>
<li>
<p>Anti-RNP: Required for MCTD diagnosis, can also be seen in SLE</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Anti-histone: drug-induced lupus</p>
</li>
<li>
<p>Anti-centromere: limited scleroderma, a/w pulmonary HTN</p>
</li>
<li>
<p>Anti-RNA polymerase III: increased risk of scleroderma renal disease</p>
</li>
</ul>
<p>Anti-neutrophil Cytoplasmic Antibodies (ANCA)</p>
<ul>
<li>
<p>Qualitative: p-ANCA, c-ANCA, negative, or indeterminate</p>
</li>
<li>
<p>Quantitative titers: anti-proteinase 3 (PR3), anti-myeloperoxidase
    (MPO) IgG antibodies</p>
</li>
<li>
<p>See vasculitis section for further details</p>
</li>
</ul>
<p>C3 and C4</p>
<ul>
<li>
<p>Hypocomplementemia in active SLE (due to increased consumption)</p>
</li>
<li>
<p>Complement may also be low in diseases that decreases the liver’s
    synthetic function</p>
</li>
<li>
<p>↓ C3/C4 in other diseases that form immune complexes, activating the
    classic complement pathway: mixed cryoglobulinemia, Sjogren’s, MPGN,
    and antiphospholipid syndrome</p>
</li>
</ul>
<p>C-reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)</p>
<ul>
<li>
<p>Both tests are non-specific markers of inflammation</p>
</li>
<li>
<p>CRP measures a specific acute phase protein made by the liver</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>IL-6 dependent (pts anti-IL6 therapy will have falsely decreased
    CRP)</p>
</li>
<li>
<p>Typically changes more rapidly than ESR as it is a direct measure of
    acute phase reactant</p>
</li>
</ul>
<!-- -->

<ul>
<li>ESR is the rate at which RBCs settle to the bottom of a test tube</li>
</ul>
<!-- -->

<ul>
<li>
<p>Presence of positively charged proteins disrupt the self-repelling
    negative charges of RBCs clumping (rouleaux formation) increased
    rate of sedimentation</p>
<ul>
<li>ESR will increase in states with increased antibodies, acute
    phase proteins, etc</li>
</ul>
</li>
<li>
<p>Falsely low ESR: low fibrinogen states (DIC, HLH), sickle cell,
    polycythemia</p>
</li>
</ul>
<p>Creatinine Kinase (CK)</p>
<ul>
<li>
<p>CK can be elevated by vigorous exercise, rhabdomyolysis,
    endocrinopathy, cardiac disease, renal disease, malignancy,
    medication effect, neuromuscular disease, connective tissue disease</p>
</li>
<li>
<p>Consider inflammatory myopathies if there is elevated CK and
    objective proximal muscle weakness</p>
</li>
<li>
<p>Notably, CK is normal in polymyalgia rheumatica</p>
</li>
</ul>
<p>Extended Myositis Panel</p>
<ul>
<li>
<p>Ordered as “Myositis extended Pnl-ARUP”; includes 19 separate Abs</p>
</li>
<li>
<p>Can be sent when suspecting various forms of myositis such as
    dermatomyositis, polymyositis, anti-synthetase syndrome (ex- ILD
    work-up)</p>
</li>
</ul>
<p>Cryoglobulins</p>
<ul>
<li>
<p>Cryoglobulins are immunoglobulins that spontaneously precipitate at
    low temperatures and become soluble again with rewarming</p>
</li>
<li>
<p>Reported as qualitative (positive or negative) and quantitative
    (percentage = “cryocrit”)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cryoglobulin last test is highly prone to collection error; must be
    collected in pre-warmed tubes and maintained at body temperature
    during collection and delivery to the lab;</p>
</li>
<li>
<p>At VUMC can only be obtained at certain times M-F; lab &amp; nursing
    staff can coordinate</p>
</li>
</ul>
<!-- -->

<ul>
<li>Cryoglobulins are classified into three types: Type I, II, and III</li>
</ul>
<!-- -->

<ul>
<li>
<p>Type I Cryoglobulins: Monoclonal immunoglobulins (IgM or IgG)</p>
<ul>
<li>A/w lymphoproliferative disorders (Waldenström’s, MM, CLL, B
    cell lymphomas)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Types II and III are Mixed Cryoglobulins (they contain polyclonal
    components)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Essentially all mixed cryoglobulinemias will be RF+ *</p>
</li>
<li>
<p>Commonly associated with HCV (~90%); also CTD</p>
</li>
<li>
<p>Type II: <em>monoclonal</em> Ig with RF activity against <em>polyclonal</em> Igs</p>
</li>
<li>
<p>Type III: <em>polyclonal</em> Ig with RF against <em>polyclonal</em> Igs</p>
<p>*RF activity by definition is the reactivity of an IgM component
with the Fc portion of an IgG</p>
</li>
</ul>
<!-- -->

<ul>
<li>Cryoglobulinemic vasculitis: small vessel vasculitis, vascular
    deposition of cryoprecipitates</li>
</ul>
<!-- -->

<ul>
<li>
<p>Skin most common: palpable purpura, usually in lower extremities
    (colder areas), immune-complex mediated leukocytoclastic vasculitis
    on biopsy</p>
</li>
<li>
<p>Additional manifestations include: Arthralgias, peripheral motor or
    sensory neuropathy, sicca, glomerulonephritis (usually MPGN)</p>
</li>
</ul>
<p>Rheumatoid Arthritis – Raeann Whitney</p>
<p>Background</p>
<ul>
<li>
<p>Inflammation and proliferation of synovial tissue, loss of articular
    cartilage, erosion of juxtarticular bone</p>
</li>
<li>
<p>Female predominant (~3:1), mostly child-bearing age at onset</p>
</li>
<li>
<p>Chronic, inflammatory polyarthritis affecting the small joints of
    the hands (MCPs, PIPs, classically spares DIPs), wrists, feet,
    ankles - typically <em>symmetric</em></p>
</li>
<li>
<p>Ulnar deviation, swan neck, boutonniere deformities are late
    findings of untreated disease</p>
</li>
<li>
<p>Morning stiffness lasting >30 min (often 1 hr+) suggests
    inflammatory arthritis (not specific)</p>
</li>
<li>
<p>Extra-articular manifestations include: sicca symptoms, scleritis,
    ILD, pulm nodules, serositis, constrictive pericarditis, anemia,
    mononeuritis multiplex, rheumatoid nodules, rheumatoid vasculitis.
    Increased risk of lymphoma, osteoporosis</p>
</li>
<li>
<p>C1-C2 instability: pts need evaluation with imaging prior to
    surgical procedure/intubation</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Clinical diagnosis + positive RF, anti-CCP. Note up to 15-20%
    patients have seronegative RA</li>
</ul>
<!-- -->

<ul>
<li>
<p>RF is more sensitive but not specific; can be + in HBV/HCV,
    cryoglobulinemia</p>
</li>
<li>
<p>CCP is less sensitive but more specific</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>CBC, CMP, CRP, ESR, HIV, Hepatitis B and C screening; Quantiferon
    Gold (biologics)</p>
</li>
<li>
<p>Obtain hand and foot films to assess for periarticular osteopenia &amp;
    typical marginal erosions</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>The majority of joint damage occurs early in the disease so early
    treatment paramount</p>
</li>
<li>
<p>DMARDs: typically start with MTX; may require biologics such as TNF
    inhibitors</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>MTX dosed weekly; required daily 1 mg folic acid supplement</p>
<ul>
<li>Toxicities: oral ulcers, bone marrow suppression, liver
    toxicity, pneumonitis, teratogenic (contraception required)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Symptomatic/Flare treatment (no impact on disease progression):</li>
</ul>
<!-- -->

<ul>
<li>Steroids at low-moderate dosage (e.g., prednisone 15-20mg/day);
    NSAIDs (high doses required for anti-inflammatory effects)</li>
</ul>
<p>Systemic Lupus Erythematous – Eva Niklinska</p>
<p>Background</p>
<ul>
<li>
<p>Characterized by multisystem inflammation, activation of complement,
    autoantibody formation</p>
</li>
<li>
<p>Presentation:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Constitutional: fatigue, fevers, weight loss</p>
</li>
<li>
<p>Neurologic: cerebritis, myelitis, mononeuritis multiplex, psychosis</p>
</li>
<li>
<p>Skin: malar rash (spares nasolabial folds), discoid lesions
    (scarring), photosensitivity</p>
</li>
<li>
<p>Hematologic: leukopenia, anemia, thrombocytopenia</p>
</li>
<li>
<p>Pulmonary: pleuritis, pleural effusion, ILD</p>
</li>
<li>
<p>Cardiac: pericarditis/myocarditis, increased risk for CAD,
    Libman-Sacks endocarditis</p>
</li>
<li>
<p>Renal: nephritic/nephrotic syndrome</p>
</li>
<li>
<p>MSK: arthralgias, myalgias, arthritis (nonerosive, often symmetric)</p>
</li>
<li>
<p>Ophtho: keratoconjunctivitis sicca 2/2 concurrent Sjogren’s</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Labs to check upon admission: dsDNA (don’t re-send ANA/ENA panel if
    known ddx), C3/C4, ESR, CRP, CBC w/ diff, CMP, UPC</p>
</li>
<li>
<p>2019 EULAR/ACR classification criteria for diagnosis:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>ANA (≥ 1:80) + additive scoring (classify as SLE if score is 10+)</p>
</li>
<li>
<p>Do not count criteria if there is a more likely explanation for it</p>
</li>
<li>
<p>Occurrence of a criterion on one occasion is sufficient. Criteria do
    not need to occur simultaneously. At least one criterion must be
    clinical</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ddx: RA, MCTD, SS, Sjogren’s, Vasculitis (Behcet’s), PM/DM,
    Fibromyalgia </p>
</li>
<li>
<p>* Note + ANA is now entry criteria [ANA only needs to be + once]</p>
</li>
</ul>
<table>
<colgroup>
<col style="width: 46%" />
<col style="width: 9%" />
<col style="width: 31%" />
<col style="width: 11%" />
</colgroup>
<thead>
<tr class="header">
<th>Clinical Criteria</th>
<th>Weight</th>
<th>Laboratory Criteria</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p><em>Constitutional</em></p>
<p>Fever</p></td>
<td>2</td>
<td><p><em><strong>Antiphospholipid antibodies</strong></em></p>
<p>(Lupus AC, CL, β2GP1)</p></td>
<td>2</td>
</tr>
<tr class="even">
<td><p><em>Hematologic</em></p>
<p>Leukopenia</p>
<p>Thrombocytopenia</p>
<p>Autoimmune hemolysis</p></td>
<td><p>3</p>
<p>4</p>
<p>4</p></td>
<td><p><em><strong>Complement proteins</strong></em></p>
<p>Low C3 OR C4</p>
<p>Low C3 AND C4</p>
<p><em><strong>SLE-specific antibodies</strong></em></p></td>
<td><p>3</p>
<p>4</p></td>
</tr>
<tr class="odd">
<td><p><em>Neuropsychiatric</em></p>
<p>Delirium</p>
<p>Psychosis</p>
<p>Seizure</p></td>
<td><p>2</p>
<p>3</p>
<p>4</p></td>
<td><p>Anti-dsDNA OR</p>
<p>Anti-Smith</p></td>
<td>6</td>
</tr>
<tr class="even">
<td><p><em>Mucocutaneous</em></p>
<p>Non-scarring alopecia</p>
<p>Oral ulcers</p>
<p>Subacute cutaneous OR discoid lupus</p>
<p>Acute cutaneous lupus</p></td>
<td><p>2</p>
<p>2</p>
<p>4</p>
<p>6</p></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><em>Serosal</em></p>
<p>Pleural or pericardial effusion</p>
<p>Acute pericarditis</p></td>
<td><p>5</p>
<p>6</p></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><p><em>Musculoskeletal</em></p>
<p>Joint involvement (2+ joints)</p></td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><em>Renal</em></p>
<p>Proteinuria (&gt;0.5g/24h)</p>
<p>Renal Bx Class II or V lupus nephritis</p>
<p>Renal Bx Class III or IV lupus nephritis</p></td>
<td><p>4</p>
<p>8</p>
<p>10</p></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>Management</p>
<ul>
<li>Hydroxychloroquine mainstay of treatment, 200-400 mg/day; dose 5
    mg/kg/day for long term to decrease risk of retinal toxicity</li>
</ul>
<!-- -->

<ul>
<li>
<p>Safe in pregnancy; decreases VTE/HLD risk </p>
</li>
<li>
<p>Annual ophtho exam for retinal toxicity </p>
</li>
<li>
<p>NOT immunosuppressive</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Glucocorticoids for flares: Usually started with hydroxychloroquine
    and tapered once hydroxychloroquine has taken effect</p>
</li>
<li>
<p>Other immunosuppressive medications (MTX, MMF, AZA, RTX) used with
    rheumatology consultation: MMF, cyclophosphamide or other advanced
    therapies used in SLE with renal involvement or severe end organ
    involvement</p>
</li>
</ul>
<p>Scleroderma (Systemic Sclerosis) – Eva Niklinska and Raeann Whitney</p>
<p>Background</p>
<ul>
<li>
<p>Distinguish from localized scleroderma (morphea or linear
    scleroderma) = dermal fibrosis w/o internal organ involvement)</p>
</li>
<li>
<p>2 Major Subtypes of Generalized / Systemic Scleroderma (SSc):</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Limited Cutaneous (lcSSc): skin thickening limited to the neck,
    face, or distal to elbows and knees; spares the truck and proximal
    extremities</p>
<ul>
<li>
<p>Limited does not equal mild, limited refers to distribution of
    skin involvement</p>
</li>
<li>
<p>Renal crisis is rare</p>
</li>
<li>
<p>Patients with + ACA (anticentromere Ab) are at high risk for
    developing PAH</p>
</li>
<li>
<p>Patients with + Anti-Scl-70 Ab are also at high risk for
    progressive ILD</p>
</li>
</ul>
</li>
<li>
<p>Diffuse Cutaneous: skin thickening extends proximal to the
    elbows/knees or trunk</p>
<ul>
<li>
<p>Typically more abrupt onset and rapid progression compared to
    lcSSc</p>
</li>
<li>
<p>High risk for progressive ILD</p>
</li>
<li>
<p>+ RNA polymerase III Ab = high risk of renal crisis, higher
    risk for malignancy</p>
</li>
</ul>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>CREST: Calcinosis cutis, Raynaud phenomenon, Esophageal dysmotility,
    Sclerodactyly, Telangiectasia (CREST syndrome is no longer a
    discrete diagnosis)</p>
</li>
<li>
<p>Systemic: fatigue, weight loss</p>
</li>
<li>
<p>Vascular: Raynaud’s &plusmn; digital tip ulcers, telangiectasias,
    nailfold capillaroscopy w/ dilated capillary loops</p>
</li>
<li>
<p>Skin: Loss of facial wrinkles, decreased oral aperture</p>
</li>
<li>
<p>MSK: arthralgias, myalgias, flexion contractures</p>
</li>
<li>
<p>GI: Esophageal or intestinal dysmotility, GERD, GAVE (watermelon
    stomach)</p>
</li>
<li>
<p>Pulm: ILD (NSIP, UIP), pulmonary arterial hypertension (PAH)</p>
</li>
<li>
<p>Cardiac: pericardial effusions, myocarditis, cardiomyopathy,
    conduction system disease</p>
</li>
<li>
<p>Renal: renal crisis (onset of malignant HTN, greatest risk in first
    5 years)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>2013 ACR/EULAR Classification Criteria weight-based symptom
    scoring  </li>
</ul>
<table>
<colgroup>
<col style="width: 59%" />
<col style="width: 29%" />
<col style="width: 11%" />
</colgroup>
<thead>
<tr class="header">
<th>Items</th>
<th>Sub-items</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Skin thickening of fingers of both hands extending proximal to
metacarpophalangeal (MCP) joints</td>
<td></td>
<td>9</td>
</tr>
<tr class="even">
<td>Skin thickening of fingers (only count the highest score)</td>
<td>Puffy fingers<br />
Whole finger, distal to MCP</td>
<td>2<br />
4</td>
</tr>
<tr class="odd">
<td>Fingertip lesions (only count the highest score)</td>
<td>Digital tip ulcers<br />
Pitting scars</td>
<td>2<br />
3</td>
</tr>
<tr class="even">
<td>Telangiectasia</td>
<td></td>
<td>2</td>
</tr>
<tr class="odd">
<td>Abnormal nailfold capillaries</td>
<td></td>
<td>2</td>
</tr>
<tr class="even">
<td>Pulmonary arterial hypertension and/or interstitial lung
disease</td>
<td></td>
<td>2</td>
</tr>
<tr class="odd">
<td>Raynaud’s phenomenon</td>
<td></td>
<td>3</td>
</tr>
<tr class="even">
<td>Scleroderma-related antibodies (any of anti-centromere,
anti-topoisomerase I [anti-cL 70], anti-RNA polymerase III)</td>
<td></td>
<td>3</td>
</tr>
<tr class="odd">
<td colspan="3"><em>Patients with a total score of ≥9 are classified as
having definite systemic sclerosis (sensitivity 91%, specificity
92%)</em></td>
</tr>
</tbody>
</table>

<ul>
<li>
<p>Labs: ANA w/ Reflex, Scl70, anticentromere, RNA pol III (separate
    order in Epic)</p>
</li>
<li>
<p>Imaging/Procedures: Baseline PFTs, Lung HRCT, TTE, EKG, 6-minute
    walk test</p>
</li>
<li>
<p>Skin biopsy: Not often used for dx, may be required to differentiate
    other rare disorders (eosinophilic fasciitis, scleroderma,
    scleromyxedema)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Organ-Based Symptomatic Therapy</li>
</ul>
<!-- -->

<ul>
<li>
<p>Raynauds: CCB (amlodipine, nifedipine), topical nitroglycerin</p>
</li>
<li>
<p>GERD: PPI</p>
</li>
<li>
<p>Renal: Monitor BP; Cr</p>
</li>
<li>
<p>ILD: Periodic PFTs, monitor for new respiratory symptoms, pulm
    referral</p>
</li>
<li>
<p>Cardiac/PAH: annual TTE, cardiology referral</p>
</li>
</ul>
<!-- -->

<ul>
<li>Systemic Immunosuppression (if progressive skin thickening or organ
    involvement)</li>
</ul>
<!-- -->

<ul>
<li>MTX, MMF, cyclophosphamide, if refractory rituximab, IVIG </li>
</ul>
<p>Scleroderma Renal Crisis</p>
<ul>
<li>
<p>Typically presents early in disease course (can even precede skin
    thickening)</p>
</li>
<li>
<p>Abrupt onset of hypertension and renal dysfunction</p>
</li>
<li>
<p>Labs: Elevated Cr, proteinuria, microangiopathic hemolytic anemia,
    elevated renin</p>
</li>
<li>
<p>Treatment: short acting ACE (captopril or enalapril, titratable),
    may require HD</p>
</li>
</ul>
<p>Anti-Phospholipid Syndrome – Gautam Babu</p>
<p>Background</p>
<ul>
<li>
<p>Antiphospholipid antibodies (aPLs) = a heterogenous group of
    autoantibodies which interact with endothelial cells through binding
    of β2GPI receptor</p>
</li>
<li>
<p>APLs induce a procoagulant and proinflammatory endothelial phenotype
    arterial, venous, small vessel thromboembolic events, or pregnancy
    losses</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>Unexplained/recurrent venous, arterial, and/or small vessel
    thromboembolic events</li>
</ul>
<!-- -->

<ul>
<li>
<p>Venous: DVT most common</p>
</li>
<li>
<p>Arterial: cerebral, renal, mesenteric, coronary, PE</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Pregnancy morbidity: recurrent, unexplained spontaneous abortions,
    fetal loss, preterm birth due to preeclampsia, placental
    insufficiency</p>
</li>
<li>
<p>Other features: nonbacterial vegetations (Libman-Sachs
    endocarditis), thrombocytopenia, livedo reticularis</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Revised Sapporo classification criteria: At least one of the
    clinical criteria and one of the laboratory criteria are met:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Vascular thrombosis (arterial, small vessel, or venous)</p>
</li>
<li>
<p>Pregnancy morbidity</p>
</li>
<li>
<p>Antiphospholipid lab testing: must be present on two or more
    occasions at least 12 weeks apart (NOT TESTED INPATIENT) Lupus
    anticoagulant, anticardiolipin antibody (IgG or IgM, medium or high
    titer) anti-beta-2 glycoprotein-I antibody (IgG or IgM)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Mainstay is anticoagulation for treatment and secondary prevention</p>
</li>
<li>
<p>Acute thromboembolism: Heparin gtt with bridge to warfarin</p>
</li>
<li>
<p>Secondary thrombosis prevention, anticoagulation with warfarin is
    preferred</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Studies suggest that DOACs are less effective than warfarin</p>
</li>
<li>
<p>Goal INR 2-3 regardless of whether arterial or venous
    thromboembolism present</p>
</li>
</ul>
<!-- -->

<ul>
<li>ASA 81 mg + warfarin for pts w/arterial events and risks for ASCVD</li>
</ul>
<p>Catastrophic Anti-phospholipid Syndrome (CAPS) – Gautam Babu</p>
<p>Background</p>
<ul>
<li>Rapid development of thromboses in multiple small blood vessels in
    various organs resulting in multi-organ failure. Occurs in a small
    subset of patients with APS</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Similar presentation to APS, but multiple organs are involved in a
    short period of time</p>
</li>
<li>
<p>Renal (hypertension, proteinuria, hematuria, acute renal failure),
    Pulmonary (ARDS, PE), Central Nervous System (encephalopathy,
    stroke, cerebral venous thrombosis), Cardiac (coronary thrombosis),
    and Cutaneous (livedo reticularis, acrocyanosis, purpura,
    ecchymosis, splinter hemorrhages, and necrosis resulting in
    ulceration)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Exclude other causes of small vessel occlusion: HIT, DIC or TMA</p>
</li>
<li>
<p>Definite dx= all 4 criteria met, probable dx=combination of criteria
    present</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Evidence of involvement of three or more organs, systems, and/or
    tissues</p>
</li>
<li>
<p>Development of manifestations simultaneously or in less than a week</p>
</li>
<li>
<p>Confirmation by histopathology of small vessel occlusion in at least
    one organ or tissue</p>
</li>
<li>
<p>Laboratory confirmation of the presence of antiphospholipid
    antibodies</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Anticoagulation: Heparin acutely. Warfarin once stable &amp; no bleeding
    or recurrent thromboses</p>
</li>
<li>
<p>Pulse steroids with methylprednisolone x 3 days followed by
    prednisone</p>
</li>
<li>
<p>Severe cases may require PLEX/IVIG. Refractory CAPS may require
    rituximab or eculizumab</p>
</li>
</ul>
<p>Sarcoidosis – Jared Freitas</p>
<p>Background</p>
<ul>
<li>
<p>Multisystem disordered defined by forming noncaseating granulomas in
    different tissues</p>
</li>
<li>
<p>Cardiac and neuro manifestations can be isolated</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Constitutional symptoms: fatigue, night sweats, weight loss, fevers,
    arthralgias, myalgias</p>
</li>
<li>
<p>Pulmonary symptoms (most common): dyspnea, cough, and wheezing</p>
</li>
<li>
<p>Extrapulmonary manifestations:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cutaneous: Highly variable, but present in 25% of patients</p>
<ul>
<li>
<p>Papules, macules, or plaques commonly involving neck, upper
    back, extremities</p>
</li>
<li>
<p>Lupus pernio: indurated, violaceous bumps on nose, lips, cheeks,
    ears</p>
</li>
<li>
<p>Erythema nodosum</p>
</li>
</ul>
</li>
<li>
<p>Neuro</p>
<ul>
<li>
<p>Affects 5-10% pts; involving any part of CNS or PNS</p>
</li>
<li>
<p>CN palsies, hypothalamic/pituitary dysfunction, seizures,
    myelopathy or radiculopathy, hydrocephalus, aseptic meningitis</p>
</li>
</ul>
</li>
<li>
<p>Cardiac</p>
<ul>
<li>Granulomas can affect pericardium, myocardium and endocardium
    resulting in valvular disorders, conduction system and
    cardiomyopathy</li>
</ul>
</li>
<li>
<p>Liver/Spleen</p>
<ul>
<li>Granulomas in liver and spleen can lead to elevated LFTs,
    cirrhosis, anemia, leukopenia and thrombocytopenia (splenic
    sequestration)</li>
</ul>
</li>
<li>
<p>Ocular</p>
<ul>
<li>Uveitis, secondary glaucoma, retinal vasculitis,
    keratoconjunctivitis</li>
</ul>
</li>
</ul>
<p>Work Up</p>
<ul>
<li>Combination of clinical features, radiographic manifestations,
    exclusion of other similarly presenting diseases, and noncaseating
    granulomas on pathology</li>
</ul>
<!-- -->

<ul>
<li>
<p>CXR: hilar and mediastinal lymphadenopathy ± pulmonary infiltrates</p>
</li>
<li>
<p>High-Resolution Chest CT</p>
<ul>
<li>Lymphadenopathy (bilateral and symmetric), with micro or
    macronodules, fibrotic changes (reticular opacities, traction
    bronchiectasis, volume loss)</li>
</ul>
</li>
<li>
<p>PFTs</p>
<ul>
<li>May show restrictive disease (decreased TLC &amp; VC) and diffusion
    impairment (reduced DLCO). Occasionally obstructive with
    endobronchial disease.</li>
</ul>
</li>
<li>
<p>Labs: CBC w/ diff, CMP, UA, quant-gold for TB. ACE level is of
    limited clinical use</p>
</li>
<li>
<p>Biopsy</p>
<ul>
<li>
<p>Important to rule out mimics. The differential for “noncaseating
    granulomas” is extensive, including lymphoma and fungal
    infections.</p>
</li>
<li>
<p>Not required for pts w/ asymptomatic bilateral hilar adenopathy
    or Lofgren syndrome (fever, erythema nodosum, arthralgias, and
    bilateral hilar LAD)</p>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Most pts do not require therapy: monitor symptoms, CXR, PFTs at 3-6
    month intervals</p>
</li>
<li>
<p>Indications for treatment: progressive disease or severe disease at
    presentation</p>
</li>
<li>
<p>Mainstay of treatment is oral steroids:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Dosing usually 0.3-0.6 mg/kg daily for 4-6 weeks</p>
</li>
<li>
<p>If only symptoms is cough, could consider inhaled glucocorticoids</p>
</li>
</ul>
<!-- -->

<ul>
<li>If unresponsive or unable to tolerate steroids may require
    alternative agents (MTX, AZA)</li>
</ul>
<p>Crystalline Arthropathies – Thomas Horton</p>
<p>Gout</p>
<p>Presentation</p>
<ul>
<li>
<p>Red, hot, swollen joint (classically affects 1<sup>st</sup> metatarsal
    phalangeal joint [podagra])</p>
</li>
<li>
<p>May progress to involve ankles, knees, elbows, and small joints of
    hand if untreated</p>
</li>
</ul>
<!-- -->

<ul>
<li>Flares may also become polyarticular over time</li>
</ul>
<!-- -->

<ul>
<li>
<p>Gout is diagnosed with combination of clinical presentation and
    arthrocentesis results</p>
</li>
<li>
<p>Lifestyle factors:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Protective: Low fat dairy, hydration, weight loss, smoking cessation</p>
</li>
<li>
<p>Promoting: Meat, seafood, alcohol, high fructose corn syrup,
    medications that lead to hyperuricemia (ex: thiazides)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Synovial Fluid Analysis: </li>
</ul>
<!-- -->

<ul>
<li>
<p>Cell count and differential: WBC 20,000-100,000, > 50% neutrophils</p>
</li>
<li>
<p>Order gram stain/culture (It is possible to have septic arthritis
    and gout)</p>
</li>
<li>
<p>Examination for crystals under polarizing light microscopy: (order
    “Synovial Fluid Eval” so the lab knows to look for crystals)</p>
<ul>
<li>Monosodium urate crystals: needle-shaped and negatively
    birefringent and appear yellow when parallel to the polarizer</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Imaging: generally unnecessary</li>
</ul>
<!-- -->

<ul>
<li>
<p>MSK ultrasound: "Double contour sign" (hyperechoic band = urate
    crystals deposits)</p>
</li>
<li>
<p>Radiographs: Punched out erosions or lytic areas with overhanging
    edges</p>
</li>
<li>
<p>Dual energy CT scan: gout crystal aggregates appear green. Not
    routinely necessary; Do not order without rheumatology consult</p>
</li>
</ul>
<p>Management</p>
<p>Acute:</p>
<ul>
<li>
<p>Do not discontinue allopurinol during an acute gout attack</p>
</li>
<li>
<p>NSAIDs (if not contraindicated): Short course (2-5 days) at full
    anti-inflammatory dose: ibuprofen 800 mg TID, indomethacin 50 mg
    TID, naproxen 500 mg BID</p>
</li>
<li>
<p>Colchicine (avoid if GFR \&lt;10 mL/min. Dose reduce by 50% if GFR \&lt;50
    mL/min)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Best if used within the first 36 hours of an attack. Much less
    effective if started later.</p>
</li>
<li>
<p>Dosing: 1.2 mg then 0.6 mg one hour later, then 0.6 mg daily until
    clinical improvement</p>
<ul>
<li>Note drug interactions that may require dose adjustment of
    colchicine: Statins, diltiazem, fluconazole, cyclosporine,
    tacrolimus, clarithromycin, etc.</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Steroids:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Ideally intra-articular if single joint affected and infection has
    been ruled out</p>
</li>
<li>
<p>Oral prednisone, dose 0.5mg/kg/day until clinical improvement then
    taper over 7-14 days</p>
</li>
</ul>
<!-- -->

<ul>
<li>Anakinra (IL-1 receptor antagonist): 100mg once daily for three days
    (or QOD for CrCl \&lt;30). Requires rheumatology consult. For patients
    with contraindications to all other treatments</li>
</ul>
<p>Chronic:</p>
<ul>
<li>Urate Lowering Therapy (ULT)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Indications: Strong: >2 attacks/year, one or more subcutaneous
    tophi, radiologic changes. Conditional: CKD 3 or worse,
    urolithiasis, serum urate >9</p>
</li>
<li>
<p>Goal serum urate: \&lt;6.0 mg/dL, or \&lt;5.0 mg/dL in patients with tophi</p>
</li>
<li>
<p>ULT can precipitate an acute gout flare and should always be started
    with low-dose NSAIDs, colchicine (0.6 mg) or prednisone (5 mg daily
    or QOD)</p>
<ul>
<li>Prophylaxis should be continued for at least 6 months until uric
    acid is at goal and tophi have resolved</li>
</ul>
</li>
<li>
<p>Allopurinol (xanthine oxidase inhibitor): Start low at 100 mg per
    day (sometimes even 50mg daily in those with advanced CKD) and
    increase as needed for target uric acid \&lt;6 (most patients will need
    400-800 mg daily)</p>
<ul>
<li>
<p>Adjust dose monthly (3-4 weeks). In kidney dysfunction go
    slower.</p>
</li>
<li>
<p>Titration of allopurinol ↓ both the risk of acute gout attacks
    and DRESS syndrome</p>
</li>
<li>
<p>Genetic testing (HLA-B*5801) recommended prior to starting for
    pts of Asian and African descent given ↑ incidence of
    allopurinol hypersensitivity if + positive allele</p>
</li>
</ul>
</li>
<li>
<p>Febuxostat: alternative xanthine oxidase inhibitor that is
    metabolized by the liver for pts at risk for DRESS or SJS related to
    allopurinol. Black box warning for ↑ cardiovascular risk; more
    expensive than allopurinol</p>
</li>
</ul>
<!-- -->

<ul>
<li>Consider Rheumatology consult for patients with refractory serum
    urate levels >6.0 on XOI</li>
</ul>
<p>Additional pearls</p>
<ul>
<li>
<p>There is a microscope in the rheumatology clinic at VUMC (TVC 2);
    You can page the rheumatology fellow and they are happy to help you
    use it</p>
</li>
<li>
<p>Uric acid level is often normal during acute gout flare</p>
</li>
<li>
<p>Shifts in uric acid may be the trigger of the flare: Diuresis,
    dietary changes, hospital stays</p>
</li>
<li>
<p>Eliminating uric acid from the diet only reduces uric acid by ~1
    mg/dL. Urate lowering therapy will be needed in most patients even
    if diet changed</p>
</li>
<li>
<p>VA specific guidance:</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Colchicine is non-formulary but is easily approved</p>
</li>
<li>
<p>For steroid intra-articular injections triamcinolone is the
    formulary option</p>
</li>
</ul>
<p>Pseudogout- Calcium pyrophosphate dihydrate crystal deposition disease
(CPPD)</p>
<p>Presentation</p>
<ul>
<li>
<p>Red, hot, swollen joint usually in the wrists, knees, or MCP joints</p>
</li>
<li>
<p>Cannot distinguish from gout based on clinical features alone. Like
    gout, diagnosis is based on exam and arthrocentesis</p>
</li>
<li>
<p>More prevalent in the elderly populations</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Synovial Fluid:</li>
</ul>
<!-- -->

<ul>
<li>
<p>Cell count and differential: WBC 20,000 to 100,000, >50%
    neutrophils</p>
</li>
<li>
<p>Order gram stain/culture (It is possible to have septic arthritis
    and CPPD)</p>
</li>
<li>
<p>Examination for crystals under polarizing light microscopy</p>
<ul>
<li>CPPD crystals: rhomboid-shaped, weakly positively birefringent
    and appear blue when parallel to the polarizer</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Imaging: </li>
</ul>
<!-- -->

<ul>
<li>XR: chondrocalcinosis (thin calcified line present in
    fibrocartilage) in the joint space (easiest to see in knee and
    wrists)</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Typically follows the same treatment used for acute gout attacks
    (see above, little evidence)</p>
</li>
<li>
<p>Some patients may develop Chronic CPP Crystal Inflammatory
    Arthritis.</p>
<ul>
<li>
<p>Resembles RA in presentation</p>
</li>
<li>
<p>Treatment base on symptoms and ranges from NSAIDs (1<sup>st</sup> line) to
    &gt; Colchicine, HCQ, and steroids. Can also use anakinra in acute
    &gt; cases, with consult to rheumatology</p>
<p>Additional Information</p>
</li>
</ul>
</li>
<li>
<p>CPPD can be associated with other disorders: hyperparathyroidism,
    hemochromatosis, hypomagnesemia, hypophosphatemia, and familial
    hypocalciuric hypercalcemia</p>
<ul>
<li>Consider further workup for these conditions, especially in a
    &gt; younger patient.</li>
</ul>
</li>
</ul>
<p>Vasculitis – Hannah Angle</p>
<p>Background</p>
<ul>
<li>Large vessel vasculitis (aorta and its major branches)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Takayasu arteritis:</p>
<ul>
<li>
<p>Most commonly \&lt;30 years old, 80-90% cases in females, greatest
    prevalence in Asia</p>
</li>
<li>
<p>Branches of aorta/aortic arch (subclavian, innominate, carotid
    arteries)</p>
</li>
</ul>
</li>
<li>
<p>Giant cell Arteritis:</p>
<ul>
<li>
<p>Most commonly >50 years old, slight F > M predominance</p>
</li>
<li>
<p>Cranial arteries (temporal artery), aorta and its branches</p>
</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Medium vessel vasculitis (muscular arteries that supply visceral
    organs)</li>
</ul>
<!-- -->

<ul>
<li>
<p>Polyarteritis nodosa (PAN):</p>
<ul>
<li>
<p>Most often middle age/older adults (peaks in 5<sup>th</sup> decade of life)</p>
</li>
<li>
<p>Necrotizing vasculitis of muscular arteries (renal, mesenteric,
    arteries supplying neurons and skin)</p>
</li>
</ul>
</li>
<li>
<p>Kawasaki’s: not addressed here- most often children</p>
</li>
</ul>
<!-- -->

<ul>
<li>Small Vessel Vasculitis (arterioles, capillaries, and venules)</li>
</ul>
<!-- -->

<ul>
<li>ANCA-associated vasculitis:</li>
</ul>
<!-- -->

<ul>
<li>
<p>GPA: granulomatous; classically involves nasopharynx, lungs, kidneys</p>
</li>
<li>
<p>MPA: affects multiple organs but predilection for lungs and kidneys;
    &gt; in contrast to GPA, no nasopharynx involvement or granulomas</p>
</li>
<li>
<p>EGPA: granulomatous; predilection for heart and lungs; associated
    &gt; with eosinophilia, chronic rhinosinusitis, asthma; uncommon > 65
    &gt; years old</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Immune-complex vasculitis: not addressed here</p>
<ul>
<li>
<p>Cryoglobulinemic vasculitis (see lab section)</p>
</li>
<li>
<p>IgA vasculitis</p>
</li>
<li>
<p>Anti-GBM disease</p>
</li>
</ul>
</li>
</ul>
<p>Takayasu's Arteritis</p>
<p>Presentation</p>
<ul>
<li>
<p>Subacute constitutional symptoms (fevers, arthralgias, myalgias,
    rash, weight loss), limb claudication, neuro symptoms from
    carotid/vertebral arteritis (vertigo, headaches, syncope, strokes),
    GI symptoms from mesenteric ischemia, angina from coronary arteritis</p>
</li>
<li>
<p>HTN (renal artery involvement), discrepant BP between arms (arterial
    stenosis), diminished or absent pulses (“pulseless disease”),
    arterial bruits, carotidynia (tenderness of carotid artery)</p>
<p>Evaluation</p>
</li>
<li>
<p>ESR/CRP (often elevated, though can be normal during active disease)</p>
</li>
<li>
<p>Arteriography: MRA or CTA of head/neck, chest, and abdomen/pelvis</p>
<p>Management</p>
</li>
<li>
<p>New arterial stenosis or aorta/carotid artery involvement: 1mg/kg
    prednisone daily (max 60-80mg) for 2-4 weeks followed by steroid
    taper</p>
</li>
<li>
<p>Organ threatening disease (coronary artery involvement, critical
    stenosis of carotid/vertebral arteries): 500-1000mg IV
    methylprednisolone daily for 1-3 days, then 1mg/kg prednisone daily
    for 2-4 weeks followed by steroid taper</p>
</li>
</ul>
<p>Giant Cell Arteritis</p>
<p>Presentation</p>
<ul>
<li>
<p>Always consider in pts >50 years old with new headache, abrupt
    vision changes (diplopia, amaurosis fugax), jaw claudication,
    temporal artery tenderness</p>
</li>
<li>
<p>Polymyalgia rheumatica will often accompany GCA; classically with
    bilateral shoulder and hip pain/stiffness (with elevated ESR, but
    normal CK)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>ESR/CRP (almost always elevated), CK, TSH</p>
</li>
<li>
<p>Evaluate for any temporal artery abnormalities (tenderness to
    palpation, presence of nodules)</p>
</li>
<li>
<p>Ophthalmology evaluation if any concern for ocular involvement</p>
</li>
<li>
<p>Temporal artery biopsy by vascular surgery</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Start glucocorticoids as soon as GCA is suspected, do not delay
    while awaiting biopsy</p>
<ul>
<li>
<p>No vision loss: prednisone 1mg/kg daily (max 60 mg) for 2-4
    &gt; weeks followed by steroid taper</p>
</li>
<li>
<p>Vision loss/diplopia: 500-1000mg IV methylprednisolone daily for
    &gt; 3 days, followed by prednisone 1mg/kg daily (max 60mg) for 2-4
    &gt; weeks followed by steroid taper  </p>
</li>
</ul>
</li>
</ul>
<p>Polyarteritis Nodosa (PAN)</p>
<p>Presentation</p>
<ul>
<li>
<p>Constitutional symptoms: fatigue, weakness, fevers, arthralgias,
    myalgias, rash, weight loss</p>
</li>
<li>
<p>Evidence of multisystem involvement:</p>
<ul>
<li>
<p>Asymmetric polyneuropathy with motor and sensory deficits (foot
    &gt; drop, radial/ulnar neuropathy)</p>
</li>
<li>
<p>Skin manifestations: livedo reticularis, palpable purpura,
    &gt; ulcers, tender erythematous nodules, bullae, vesicles</p>
</li>
<li>
<p>HTN (renal arteritis)</p>
</li>
<li>
<p>Abdominal pain and melena (mesenteric arteritis)</p>
</li>
<li>
<p>Ischemic cardiomyopathy (coronary arteritis)</p>
</li>
<li>
<p>Testicular pain (orchitis)</p>
</li>
</ul>
</li>
<li>
<p>Classically spares the lungs (consider other dx if pulmonary
    complaints)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>ESR/CRP, CK, TSH</p>
</li>
<li>
<p>Hepatitis panel (HBV/HCV can cause secondary PAN)</p>
</li>
<li>
<p>Arteriography: MRI, CT, or angiogram with classic “string of pearls”
    appearance </p>
</li>
<li>
<p>Biopsy: segmental transmural inflammation of muscular arteries,
    fibrinoid necrosis of arterial wall (no granulomas, presence
    suggests another process)</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Mild disease (ex: isolated cutaneous disease): prednisone 1mg/kg
    daily (max 60-80mg) for 4 weeks followed by steroid taper</p>
</li>
<li>
<p>Moderate disease: cyclophosphamide + prednisone 1mg/kg daily (max
    60-80mg) for 4 weeks followed by steroid taper</p>
</li>
<li>
<p>Severe/life-threatening disease (renal failure, significant
    proteinuria, GI/cardiac/neurologic involvement): cyclophosphamide +
    500-1000mg IV methylprednisolone daily for 3 days, followed by
    prednisone 1mg/kg daily (max 60mg) for 4 weeks followed by steroid
    taper  </p>
</li>
</ul>
<p>Granulomatosis with Polyangiitis (GPA)</p>
<p>Presentation</p>
<ul>
<li>
<p>Constitutional symptoms (fevers, fatigue, weight loss) + evidence of
    glomerulonephritis (hematuria, proteinuria), upper respiratory tract
    involvement (nasal crusting, rhinorrhea, epistaxis, sinusitis), and
    pulmonary involvement (dyspnea, cough, hemoptysis)</p>
</li>
<li>
<p>Less commonly affects eyes (scleritis), skin (palpable purpura), and
    peripheral nerves (mononeuritis multiplex)</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>ANCA + (typically PR3-cANCA)</p>
</li>
<li>
<p>ESR/CRP, ANA, anti-GBM, C3/C4, cryoglobulins, HBV/HCV, HIV</p>
</li>
<li>
<p>UA with microscopy (hematuria, proteinuria, RBC casts, dysmorphic
    RBCs)</p>
</li>
<li>
<p>CT chest if pulmonary symptoms</p>
</li>
<li>
<p>Biopsy: necrotizing granulomatous vasculitis, pauci-immune
    glomerulonephritis</p>
</li>
<li>
<p>Clinical Pearl: If you suspect renal disease based (elevated Cr,
    hematuria) ask renal fellow or rheum fellow to help spin the urine
    to evaluate for RBC casting or dysmorphic cells. Quick way to
    confirm active GN, renal biopsy takes time to arrange</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Mild-moderate disease: MTX + prednisone 0.5 mg/kg/day followed by
    steroid taper</p>
</li>
<li>
<p>Severe disease: rituximab or cyclophosphamide + prednisone
    1mg/kg/day (60-80mg max)</p>
<ul>
<li>For pts with RPGN, pulmonary hemorrhage, mononeuritis multiplex,
    &gt; or optic neuritis: IV methylprednisolone 7-15mg/kg/day (1000mg
    &gt; max) x 3 days for induction therapy</li>
</ul>
</li>
<li>
<p>DVT ppx (high risk for DVT/PE)</p>
</li>
</ul>
<p>Microscopic Polyangiitis (MPA)</p>
<p>Presentation</p>
<ul>
<li>Similar to GPA, but without upper respiratory tract involvement;
    classically only involves lungs and kidneys</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>ANCA + (typically MPO-pANCA)</p>
</li>
<li>
<p>ESR/CRP, ANA, anti-GBM, C3/C4, cryoglobulins, HBV/HCV, HIV</p>
</li>
<li>
<p>UA with microscopy (hematuria, proteinuria, RBC casts, dysmorphic
    RBCs)</p>
</li>
<li>
<p>CT chest if pulmonary symptoms</p>
</li>
<li>
<p>Biopsy: necrotizing vasculitis (no granulomas), pauci-immune
    glomerulonephritis</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>Same as GPA, see above</li>
</ul>
<p>Eosinophilic Granulomatosis with Polyangiitis (EGPA)</p>
<p>Presentation</p>
<ul>
<li>
<p>Similar to GPA/MPA + atopic symptoms such as asthma (>90%),
    rhinosinusitis, and peripheral eosinophilia</p>
</li>
<li>
<p>Cardiac involvement (accounts for 50% deaths from EGPA): coronary
    arteritis, myocarditis, heart failure, arrhythmias</p>
</li>
<li>
<p>Skin involvement (>50%): tender subcutaneous nodules</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>ANCA + (typically MPO-pANCA), peripheral eosinophilia</p>
</li>
<li>
<p>IgE, ANA, RF, C3/C4</p>
</li>
<li>
<p>Biopsy: necrotizing granulomatous vasculitis, eosinophilic
    infiltrates with fibrinoid necrosis, pauci-immune glomerulonephritis</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Mild-moderate disease: prednisone 0.5-1 mg/kg/day for 6-12 weeks
    followed by steroid taper</p>
</li>
<li>
<p>Severe disease: cyclophosphamide + prednisone 0.5-1 mg/kg/day for
    6-12 weeks followed by steroid taper</p>
<ul>
<li>For pts with life-threatening multiorgan involvement (cardiac,
    &gt; pulmonary, renal, neurologic): IV methylprednisolone 1000mg
    &gt; daily x 3 days for induction therapy</li>
</ul>
</li>
<li>
<p>DVT ppx (high risk for DVT/PE)</p>
</li>
</ul>
<p>Inflammatory Myopathies – Greg Jackson</p>
<p>Background</p>
<ul>
<li>
<p>Inflammation and damage of skeletal muscle primarily leading to
    weakness</p>
</li>
<li>
<p>Subtypes: Dermatomyositis, polymyositis, antisynthetase antibody
    syndrome associated myositis, immune-mediated necrotizing myositis,
    inclusion body myositis</p>
</li>
<li>
<p>Additional myopathies: statin-induced myopathy, metabolic
    (hypothyroid, electrolyte), viral/infection myositis, diabetic
    myonecrosis</p>
</li>
<li>
<p>Important point: PMR= painful, preserved strength vs inflammatory
    myopathy = painless weakness</p>
</li>
<li>
<p>Hypomyopathic (or amyopathic) variants: skin and/or lungs are
    affected >> muscles</p>
</li>
</ul>
<p>Presentation</p>
<ul>
<li>
<p>Proximal, symmetric muscle weakness in upper and lower extremities
    in all but inclusion body myositis which is typically more distal
    and asymmetric</p>
</li>
<li>
<p>Dermatomyositis: skin involvement can include heliotrope rash of
    upper eyelids, Gottron’s papules (on MCP, PIP), “mechanic’s hands,”
    and shawl sign</p>
</li>
<li>
<p>Raynaud’s and arthralgias can also be present</p>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>
<p>Labbs: BMP, TSH, CK level, anti Jo-1 antibody</p>
</li>
<li>
<p>EMG: findings indicate myopathy</p>
</li>
<li>
<p>MRI extremity/affected muscle group: muscle edema</p>
</li>
<li>
<p>Skin biopsy in dermatomyositis: “interface dermatitis.”</p>
</li>
<li>
<p>Muscle biopsy (do not do biopsy in same muscle as EMG done)</p>
</li>
</ul>
<!-- -->

<ul>
<li>
<p>Polymyositis, inclusion body myositis: T cell mediated muscle injury</p>
</li>
<li>
<p>Dermatomyositis: immune complex/B cell mediated muscle injury</p>
</li>
</ul>
<p>Management</p>
<ul>
<li>
<p>Prednisone 1 mg/kg/day for 4-6 weeks with subsequent taper</p>
</li>
<li>
<p>Consult Rheumatology</p>
</li>
<li>
<p>MTX or AZA used if refractory to steroids, may need IVIG, rituximab</p>
</li>
<li>
<p>If statin induced: stop statin or switch to lower intensity</p>
</li>
<li>
<p>If dermatomyositis: evaluate for underlying malignancy</p>
</li>
</ul>
<p>Arthrocentesis Quick Look – Raeann Whitney</p>
<p>When in doubt, tap it!</p>
<ul>
<li>
<p>Send synovial fluid for Gram stain/culture and cell count</p>
</li>
<li>
<p>Beware: Inflammatory / crystal arthropathies can have very high
    leukocyte counts!</p>
</li>
</ul>
<!-- -->

<ul>
<li>The presence of crystals does NOT exclude septic arthritis</li>
</ul>
<!-- -->

<ul>
<li>
<p>A fever or concern for infection in a prosthetic joint is a surgical
    emergency; ortho will come in the middle of the night to tap a joint</p>
</li>
<li>
<p>Contraindications to tap: overlying cellulitis or psoriatic plaque</p>
</li>
</ul>
<!-- -->

<ul>
<li>Anticoagulation / DVT ppx is OK (no need to hold)</li>
</ul>
<table>
<thead>
<tr>
<th>​Arthritis Type</th>
<th>Appearance ​</th>
<th>Total WBC ​</th>
<th>PMNs ​</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-inflammatory ​</td>
<td>Straw like / yellow ​</td>
<td>\&lt;2000​</td>
<td>\&lt;25%​</td>
</tr>
<tr>
<td>Inflammatory / Crystalopathies ​</td>
<td>Yellow / cloudy ​</td>
<td>>2000​ (often 20-50K+)</td>
<td>>50%​</td>
</tr>
<tr>
<td>Septic ​</td>
<td>Purulent ​</td>
<td>>50,000​ (often >100K)</td>
<td>>75%​</td>
</tr>
</tbody>
</table>
<p>Crystals</p>
<ul>
<li>Monosodium urate: needle-shaped, negatively birefringent</li>
</ul>
<!-- -->

<ul>
<li>Sensitivity is generally good (>90s%)</li>
</ul>
<!-- -->

<ul>
<li>Calcium pyrophosphate dihydrate: rhomboid-shaped, positively
    birefringent (weakly)</li>
</ul>
<!-- -->

<ul>
<li>Weak birefringence significantly reduced sensitivity</li>
</ul>
<p>Biologic Overview – Hannah Lomzenski</p>
<p>Background</p>
<ul>
<li>
<p>"-cept" refers to fusion of a receptor to the Fc part of human
    immunoglobulin G1 (IgG1)</p>
</li>
<li>
<p>"-mab" indicates a monoclonal antibody (mAb)</p>
</li>
<li>
<p>"-ximab" indicates a chimeric mAb</p>
</li>
<li>
<p>"-zumab" indicates a humanized mAb</p>
</li>
<li>
<p>"-umab" indicates a fully human mAb</p>
</li>
<li>
<p>“-tinib” indicates a tyrosine kinase inhibitor (small molecule
    inhibitors, not true biologics)</p>
</li>
</ul>
<p>Selected biologics</p>
<p>Kinase inhibition</p>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 22%" />
<col style="width: 22%" />
<col style="width: 35%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Tofacitinib</p>
<p>(Xeljanz)</p></td>
<td>JAK-1 and JAK-3 inhibitor</td>
<td>RA, UC, JIA, psoriatic arthritis</td>
<td>nasopharyngitis, skin rash, GI sx, GU sx; &lt;1% lymphoma</td>
</tr>
<tr class="even">
<td><p>Baracitinib</p>
<p>(Olumiant)</p></td>
<td>JAK-1 and JAK-2 inhibitor</td>
<td>RA; off-label: COVID-19</td>
<td>URI, nausea, ⇑AST/ALT; &lt;1% lymphoma</td>
</tr>
<tr class="odd">
<td><p>Upadacitinib</p>
<p>(Rinvoq)</p></td>
<td>non-specific JAK inhibitor</td>
<td>RA</td>
<td>URI, nausea, neutropenia, ⇑AST, ⇑CPK</td>
</tr>
</tbody>
</table>

<p>IL-1 inhibition</p>
<table>
<colgroup>
<col style="width: 17%" />
<col style="width: 16%" />
<col style="width: 35%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Anakinra</p>
<p>(Kineret)</p></td>
<td>IL-1 receptor antagonist</td>
<td>IL-1 receptor antagonist deficiency, gout flares, FMF, HLH</td>
<td>HA, vomiting, infections, nasopharyngitis, Ab development; in RA:
eosinophilia, decreased WBC</td>
</tr>
<tr class="even">
<td><p>Canakinumab</p>
<p>(Ilaris)</p></td>
<td>mAb against IL-1β</td>
<td>Cryoporin-associated periodic syndromes (CAPS), FMF,
hyperimmunoglobin D syndrome, TRAPS; off-label: gout flare</td>
<td>Weight gain, GI sx, HA, vertigo, serious infections</td>
</tr>
</tbody>
</table>

<p>IL-17 inhibition</p>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 25%" />
<col style="width: 16%" />
<col style="width: 38%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Secukinumab</p>
<p>(Cosentyx)</p></td>
<td>human IgG1 mAb against IL-17A</td>
<td>AS, psoriasis</td>
<td>nasopharyngitis, GI, IBD (&lt;1%)</td>
</tr>
<tr class="even">
<td><p>Ixekizumab</p>
<p>(Taltz)</p></td>
<td>human IgG4 mAb against IL-17A</td>
<td>AS, psoriasis</td>
<td>neutropenia, Ab development, URI, Crohn’s (&lt;1%)</td>
</tr>
</tbody>
</table>

<p>IL-6 inhibition</p>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 26%" />
<col style="width: 24%" />
<col style="width: 29%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Tocilizumab</p>
<p>(Actemra)</p></td>
<td>IL-6 receptor antagonist</td>
<td>cytokine release syndrome, giant cell arteritis, RA, JIA</td>
<td>⇑ serum cholesterol, ⇑ AST/ALT, infusion rxn, HSV infection
(&lt;2%)</td>
</tr>
<tr class="even">
<td><p>Sarilumab</p>
<p>(Kevzara)</p></td>
<td>IL-6 receptor antagonist (soluble + membrane-bound)</td>
<td>RA</td>
<td>⇑ AST/ALT, HSV infection (&lt;2%)</td>
</tr>
</tbody>
</table>

<p>IL-12/23 inhibition</p>
<table>
<colgroup>
<col style="width: 20%" />
<col style="width: 23%" />
<col style="width: 28%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Ustekinumab</p>
<p>(Stelara)</p></td>
<td>mAb against IL-12 + IL-23</td>
<td>IBD, psoriasis</td>
<td>nasopharyngitis, Ab development, acne vulgaris, GI sx, GU sx</td>
</tr>
<tr class="even">
<td><p>Guselkumab</p>
<p>(Tremfya)</p></td>
<td>human IgG1 mAb against IL-23</td>
<td>psoriasis</td>
<td>URI, tinea, GI sx</td>
</tr>
</tbody>
</table>

<p>Costimulation blockade</p>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 38%" />
<col style="width: 14%" />
<col style="width: 27%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Abatacep</p>
<p>(Orencia)</p></td>
<td>inhibits T-cell activation by binding CD80 and CD86 on APCs, thus
blocking the required CD28 ixn between APCs and T cells.</td>
<td>RA, psoriasis, JIA</td>
<td>nausea, UTI, HA, URI, Ab development</td>
</tr>
</tbody>
</table>

<p>B-cell depletion and inhibition</p>
<table style="width:100%;">
<colgroup>
<col style="width: 18%" />
<col style="width: 25%" />
<col style="width: 28%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Rituximab</p>
<p>(Rituxan)</p></td>
<td>mAb against the CD20 antigen on surface of B-lymphocytes</td>
<td>CLL, Non-Hodgkin lymphomas, GPA, microscopic polyangiitis, pemphigus
vulgaris, RA; many off-label uses (GvHD, lupus nephritis, MG,
neuromyelitis optica)</td>
<td>HTN, peripheral edema, night sweats, fever, weight gain, angioedema,
arthralgias, ⇑ ALT, hypophosphatemia, hematologic abnormalities</td>
</tr>
<tr class="even">
<td><p>Belimumab</p>
<p>(Benlysta)</p></td>
<td>IgG1-lambda mAb that prevents survival of B-lymphocytes by blocking
the binding of soluble human B lymphocyte stimulator protein (BLyS) to
receptors on B lymphocytes</td>
<td>lupus nephritis, SLE</td>
<td>GI symptoms, hypersensitivity reaction, infections, psychiatric
disturbances</td>
</tr>
</tbody>
</table>

<p>TNF-inhibition</p>
<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 28%" />
<col style="width: 25%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr class="header">
<th><p>Generic Name</p>
<p>(Brand Name)</p></th>
<th>Mechanism of Action</th>
<th>Common Uses</th>
<th>Common Side Effects</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p>Adalilumab</p>
<p>(Humira)</p></td>
<td>mAb against TNFα</td>
<td>RA, IBD, AS, psoriasis, uveitis, hidradenitis suppurativa</td>
<td>skin rash, HA, URI, ⇑ CPK, +ANA titer (12%), Ab development
(3-26%)</td>
</tr>
<tr class="even">
<td><p>Certolizumab</p>
<p>(Cimzia)</p></td>
<td>humanized mAb Fab fragment against TNFα</td>
<td>RA, Crohn’s, AS, psoriasis; \*approved for use during pregnancy</td>
<td>skin rash, nausea, URI</td>
</tr>
<tr class="odd">
<td><p>Etanercept</p>
<p>(Enbrel)</p></td>
<td>tumor necrosis factor receptor linked to Fc portion of IgG1; binds
TNF</td>
<td>RA, AS, psoriasis, JIA</td>
<td><p>skin rash, diarrhea,</p>
<p>+ANA titer (11%)</p></td>
</tr>
<tr class="even">
<td><p>Infliximab</p>
<p>(Remicade)</p></td>
<td>chimeric mAb against TNFα</td>
<td>RA, IBD, AS, psoriasis</td>
<td>abd pain, URI sx, anemia, ⇑ ALT, Ab development (10-50%)</td>
</tr>
<tr class="odd">
<td><p>Golimumab</p>
<p>(Simponi)</p></td>
<td>mAb against TNFα</td>
<td>RA, UC, AS, psoriasis, JIA</td>
<td>URI, Ab development (16-38%), +ANA titer (4-17%)</td>
</tr>
</tbody>
</table></section><section class="print-page" id="rheumatology-rheumatology-biologic-overview"><h1 id="rheumatology-rheumatology-biologic-overview-biologic-overview">Biologic Overview<a class="headerlink" href="#rheumatology-rheumatology-biologic-overview-biologic-overview" title="Permanent link">&para;</a></h1>
<p>Biologic Overview – Hannah Lomzenski</p>
<p>Background</p>
<ul>
<li>"-cept" refers to fusion of a receptor to the Fc part of human
    immunoglobulin G1 (IgG1)</li>
<li>"-mab" indicates a monoclonal antibody (mAb)</li>
<li>"-ximab" indicates a chimeric mAb</li>
<li>"-zumab" indicates a humanized mAb</li>
<li>"-umab" indicates a fully human mAb</li>
<li>“-tinib” indicates a tyrosine kinase inhibitor (TKIs are small
    molecule inhibitors rather than true biologics)</li>
</ul>
<p>​​​​​​​</p>
<p>Kinase inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Xeljanz</td>
<td>JAK-1 and JAK-3 inhibitors</td>
<td>RA, UC, JIA, psoriatic arthritis</td>
<td>infections, nasopharyngitis, skin rash, GI sx, GU sx; \&lt;1% lymphoma</td>
</tr>
<tr>
<td>Baracitinib</td>
<td>Olumiant</td>
<td>JAK-1 and JAK-2 inhibitor</td>
<td>RA; off-label: COVID-19</td>
<td>infections, URI, nausea, ÝAST/ALT; \&lt;1% lymphoma</td>
</tr>
<tr>
<td>Upadacitinib</td>
<td>Rinvoq</td>
<td>non-specific JAK inhibitor</td>
<td>RA</td>
<td>URI, nausea, neutropenia, ÝAST, ÝCPK</td>
</tr>
</tbody>
</table>
<p>IL-1 inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Anakinra</td>
<td>Kineret</td>
<td>IL-1 receptor antagonist</td>
<td>IL-1 receptor antagonist deficiency, neonatal multi-system inflammatory Dz, RA; off-label: gout flares, FMF, recurrent pericarditis, HLH</td>
<td>HA, vomiting, infections, nasopharyngitis, Ab development; in RA: eosinophilia, decreased WBC</td>
</tr>
<tr>
<td>Canakinumab</td>
<td>Ilaris</td>
<td>mAb against IL-1β</td>
<td>cryoporin-associated periodic syndromes (CAPS), FMF, hyperimmunoglobin D syndrome, TRAPS; off-label: gout flare</td>
<td>weight gain, GI sx, HA, vertigo, serious infections</td>
</tr>
<tr>
<td>Rilonacept</td>
<td>Arcalyst</td>
<td>binds to IL-1β (some binding of IL-1α and IL-1 receptor antagonist)</td>
<td>CAPS, deficiency of IL-1 receptor antagonist</td>
<td>URI, infections, hypoesthesia, Ab development</td>
</tr>
</tbody>
</table>
<p>TNF-inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Adalilumab</td>
<td>Humira</td>
<td>mAb against TNFα</td>
<td>RA, IBD, AS, psoriasis, uveitis, hidradenitis suppurativa</td>
<td>skin rash, HA, URI, infections, Ý CPK, +ANA titer (12%), Ab development (3-26%)</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>Cimzia</td>
<td>humanized mAb Fab fragment against TNFα</td>
<td>RA, Crohn’s, AS, psoriasis; *approved for use during pregnancy</td>
<td>skin rash, nausea, URI, infections</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Enbrel</td>
<td>tumor necrosis factor receptor linked to Fc portion of IgG1; binds TNF</td>
<td>RA, AS, psoriasis, JIA</td>
<td>skin rash, diarrhea, infections, +ANA titer (11%)</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Remicade</td>
<td>chimeric mAb against TNFα</td>
<td>RA, IBD, AS, psoriasis</td>
<td>abd pain, URI sx, anemia, Ý ALT, Ab development (10-50%), infections</td>
</tr>
<tr>
<td>Golimumab</td>
<td>Simponi</td>
<td>mAb against TNFα</td>
<td>RA, UC, AS, psoriasis, JIA</td>
<td>URI, infections, Ab development (16-38%), +ANA titer (4-17%)</td>
</tr>
</tbody>
</table>
<p>IL-17 inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>Cosentyx</td>
<td>human IgG1 mAb against IL-17A</td>
<td>AS, psoriasis</td>
<td>infections, nasopharyngitis, GI, IBD (\&lt;1%)</td>
</tr>
<tr>
<td>Ixekizumab</td>
<td>Taltz</td>
<td>human IgG4 mAb against IL-17A</td>
<td>AS, psoriasis</td>
<td>neutropenia, Ab development, infections, URI, Crohn’s (\&lt;1%)</td>
</tr>
</tbody>
</table>
<p>Costimulation blockade</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Abatacept</td>
<td>Orencia</td>
<td>inhibits T-cell activation by binding CD80 and CD86 on APCs, thus blocking the required CD28 ixn between APCs and T cells.</td>
<td>RA, psoriasis, JIA</td>
<td>nausea, UTI, HA, infections, URI, Ab development</td>
</tr>
</tbody>
</table>
<p>B-cell depletion and inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Rituxan</td>
<td>mAb against the CD20 antigen on surface of B-lymphocytes</td>
<td>CLL, Non-Hodgkin lymphomas, GPA, microscopic polyangiitis, pemphigus vulgaris, RA; many off-label uses (GvHD, lupus nephritis, MG, neuromyelitis optica)</td>
<td>HTN, peripheral edema, night sweats, fever, weight gain, angioedema, arthralgias, Ý ALT, infections, hypophosphatemia, hematologic abnormalities</td>
</tr>
<tr>
<td>Belimumab</td>
<td>Benlysta</td>
<td>IgG1-lambda mAb that prevents survival of B-lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to receptors on B lymphocytes</td>
<td>lupus nephritis, SLE</td>
<td>GI sx, hypersensitivity rxn, infections, psychiatric disturbances</td>
</tr>
</tbody>
</table>
<p>IL-6 inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>Actemra</td>
<td>IL-6 receptor antagonist</td>
<td>cytokine release syndrome, giant cell arteritis, RA, JIA</td>
<td>Ý serum cholesterol, Ý AST/ALT, infusion rxn, HSV infection (\&lt;2%)</td>
</tr>
<tr>
<td>Sarilumab</td>
<td>Kevzara</td>
<td>IL-6 receptor antagonist (soluble + membrane-bound)</td>
<td>RA</td>
<td>Ý AST/ALT, HSV infection (\&lt;2%)</td>
</tr>
</tbody>
</table>
<p>IL-12/23 inhibition</p>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Mechanism of Action</td>
<td>Common Uses</td>
<td>Common Side Effects</td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Stelara</td>
<td>mAb against IL-12 + IL-23</td>
<td>IBD, psoriasis</td>
<td>infections, nasopharyngitis, Ab development, acne vulgaris, GI sx, GU sx</td>
</tr>
<tr>
<td>Guselkumab</td>
<td>Tremfya</td>
<td>human IgG1 mAb against IL-23</td>
<td>psoriasis</td>
<td>infections, URI, tinea, GI sx</td>
</tr>
</tbody>
</table></section><section class="print-page" id="rheumatology-rheumatology-common-rheumatologic-diseases"><h1 id="rheumatology-rheumatology-common-rheumatologic-diseases-common-rheumatologic-diseases">Common Rheumatologic Diseases<a class="headerlink" href="#rheumatology-rheumatology-common-rheumatologic-diseases-common-rheumatologic-diseases" title="Permanent link">&para;</a></h1>
<p>Common Rheumatologic Diseases</p>
<p>Rheumatoid Arthritis – Greg Jackson</p>
<p>Background</p>
<ul>
<li>Proliferation of synovial tissue, mediated by TNF, IL-1, IL-6
    leading to joint destruction</li>
<li>Chronic, inflammatory polyarthritis affecting the small joints of
    the hands, wrists, and feet</li>
<li>Pain and swelling of joints, typically symmetric MCP, wrists, MTP
    affected</li>
<li>Ulnar deviation, swan neck, boutonniere deformities are late
    manifestations of untreated disease</li>
<li>Morning stiffness lasting &gt;1 hr suggests inflammatory arthritis like
    RA, but is not specific</li>
<li>C1-C2 instability: pts need evaluation with imaging prior to
    surgical procedure/intubation</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Clinical diagnosis and positive RF, anti-CCP (as described in labs
    section above), though up to 30% patients have seronegative RA ,
    elevated ESR and CRP</li>
<li>CBC, CMP, HIV, Hepatitis B and C screening; Quantiferon Gold (for
    possible biologics)</li>
<li>Obtain hand films to assess for osteopenia &amp; erosions</li>
</ul>
<p>Management</p>
<ul>
<li>The majority of joint damage occurs early in the disease so early
    treatment paramount</li>
<li>DMARDs: start with MTX; if inadequate response, add biologic such as
    TNF inhibitors<ul>
<li>Dosing
    : MTX 7.5-20 mg weekly; need to supplement with folic acid 1 mg
    daily</li>
<li>Requires
    routine lab monitoring for bone marrow suppression, lung and
    liver toxicity</li>
<li>Contraception
    must be used in women of childbearing age on MTX</li>
</ul>
</li>
<li>Symptomatic/Flare treatment (no impact on disease progression):<ul>
<li>NSAIDs
    : high doses required for anti-inflammatory effects (ie
    ibuprofen 3200 mg/day or 1000 mg/day naproxen), usually treat
    for 2 wks to achieve maximum analgesic effect</li>
<li>Prednisone
    5-10 mg/day for 2 weeks and then slow wean off or low-dose (5 mg
    or less)</li>
</ul>
</li>
</ul>
<p>Anti-Phospholipid Syndrome – Gautam Babu</p>
<p>Background</p>
<ul>
<li>Development of antiphospholipid antibodies (aPLs) = a heterogenous
    group of autoantibodies, which interact with endothelial
    cells through binding of
    β
    2GPI receptor</li>
<li>APLs induce a procoagulant and proinflammatory
    endothelial phenotype, resulting in arterial, venous, or small
    vessel thromboembolic events and/or pregnancy losses</li>
</ul>
<p>Presentation</p>
<ul>
<li>Common features: DVTs, thrombocytopenia, and livedo reticularis</li>
<li>Arterial thromboses: renal, mesenteric, coronary and cerebral
    vasculature</li>
<li>Pulmonary embolism, CTEPH, nonbacterial vegetations (Libman-Sacks
    endocarditis)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Revised Sapporo classification criteria are used to diagnose
    patients with APS</li>
<li>At least one of the clinical criteria and one of the laboratory
    criteria are met:<ul>
<li>Vascular thrombosis (arterial, small vessel, or venous)</li>
<li>Pregnancy morbidity</li>
<li>LA (lupus anticoagulant) present, on 2 or more occasions at
    least 12 weeks apart</li>
<li>aCL (anticardiolipin antibody) of IgG and/or IgM isotype in
    serum or plasma, present in medium or high titer, on two or more
    occasions, at least 12 weeks apart</li>
<li>Anti-beta-2 glycoprotein-I antibody of IgG and/or IgM isotype in
    serum or plasma, present on two or more occasions, at least 12
    weeks apart</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Mainstay is anticoagulation for treatment and secondary prevention</li>
<li>Do not use (ASA or AC) for primary thrombosis prevention</li>
<li>Acute thromboembolism: Heparin gtt with bridge to warfarin</li>
<li>Secondary thrombosis prevention, anticoagulation with warfarin is
    preferred<ul>
<li>Studies
    suggest that DOACs are less effective than warfarin</li>
<li>Goal INR 2-3 regardless of whether arterial or venous
    thromboembolism present</li>
</ul>
</li>
<li>ASA 81 mg + warfarin for pts w/arterial events and risks for ASCVD</li>
</ul>
<p>Systemic Lupus Erythematous</p>
<p>– Greg Jackson</p>
<p>Presentation</p>
<ul>
<li>Characterized by multisystem inflammation, precise etiology of
    disease unknown</li>
<li>Constitutional: fatigue, fevers, weight loss</li>
<li>Neurologic: cerebritis, myelitis, psychosis</li>
<li>Skin: malar rash, discoid rash, photosensitive rashes</li>
<li>Hematologic: leukopenia, anemia, thrombocytopenia</li>
<li>Pulmonary: pleuritis, pleural effusion, ILD</li>
<li>Cardiac: pericarditis/myocarditis (also due to underlying
    inflammatory condition have increased risk for coronary artery
    disease, similar to RA); Libman-Sacks endocarditis</li>
<li>Renal: nephritic/nephrotic syndrome</li>
<li>MSK: arthralgias/myalgias/arthritis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>See section on rheumatology labs for specific
    sensitivity/specificity of tests</li>
<li>SLICC criteria not initially developed to diagnose SLE but often
    used:  need &gt;/= 4/17 of SLICC criteria with &gt;/=1 clinical and &gt;/= 1
    immunologic</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory Criteria</td>
<td>Laboratory Criteria</td>
</tr>
<tr>
<td>Acute cutaneous rash (is Malar rash, etc.)</td>
<td>Elevated ANA</td>
</tr>
<tr>
<td>Chronic cutaneous Rash (i.e. Discoid rash, etc.)</td>
<td>Elevated anti-dsDNA</td>
</tr>
<tr>
<td>Alopecia, non-scarring</td>
<td>Positive Anti-Sm</td>
</tr>
<tr>
<td>Joint disease (Two or more joints with inflammatory characteristics)</td>
<td>Positive Anti-phospholipid Screen</td>
</tr>
<tr>
<td>Oral/nasal ulcers</td>
<td>Low C3/C4</td>
</tr>
<tr>
<td>Serositis (usually pleural or pericardial)</td>
<td>NaN</td>
</tr>
<tr>
<td>Neurologic (seizures, psychosis, AMS)</td>
<td>NaN</td>
</tr>
<tr>
<td>Anemia, leukopenia (\&lt;1000), thrombocytopenia (\&lt;100,000)</td>
<td>NaN</td>
</tr>
</tbody>
</table>
<p>Management</p>
<ul>
<li>Hydroxychloroquine mainstay of treatment, 200-400 mg/day, dose 5
    mg/kg/day for long term to decrease risk of retinal toxicity<ul>
<li>Monitor
    for retinal toxicity with yearly retinal exam</li>
</ul>
</li>
<li>Glucocorticoids for flares (Similar dosing to RA)<ul>
<li>Usually
    started with hydroxychloroquine and tapered once
    hydroxychloroquine has taken effect for symptom control</li>
</ul>
</li>
<li>Other immunosuppressive medications (MTX, MMF, AZA, RTX) used with
    rheumatology consultation: MMF, cyclophosphamide used in SLE with
    renal involvement</li>
</ul>
<p>Catastrophic Anti-phospholipid Syndrome (CAPS) – Gautam Babu</p>
<p>Background</p>
<ul>
<li>Occurs in a small subset of patients with APS</li>
<li>Rapid development of thromboses in multiple small blood vessels in
    various organs resulting in multiorgan failure</li>
</ul>
<p>Presentation</p>
<ul>
<li>Similar presentation to APS, but multiple organs are involved in a
    short period of time</li>
<li>Renal (hypertension, proteinuria, hematuria, acute renal failure),
    Pulmonary (ARDS, PE), Central Nervous System (encephalopathy,
    stroke, cerebral venous thrombosis), Cardiac (coronary thrombosis),
    and Cutaneous (livedo reticularis, acrocyanosis, purpura,
    ecchymosis, splinter hemorrhages, and necrosis resulting in
    ulceration)</li>
<li>Pts can develop systemic inflammatory response syndrome 2/2
    extensive tissue damage</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Exclude other causes of small vessel occlusion: HIT, DIC or TMA</li>
<li>Definite
    diagnosis of CAPS is made when all four diagnostic criteria are
    present</li>
<li>Diagnosis is <strong>probable</strong> when a combination of these criteria is
    present<ul>
<li>Evidence
    of involvement of three or more organs, systems, and/or tissues</li>
<li>Development
    of manifestations simultaneously or in less than a week</li>
<li>Confirmation
    by histopathology of small vessel occlusion in at least one
    organ or tissue</li>
<li>Laboratory
    confirmation of the presence of antiphospholipid antibodies:</li>
</ul>
</li>
<li>Lupus anticoagulant, anticardiolipin antibodies, and/or
    anti-beta2-glycoprotein I</li>
</ul>
<p>Management</p>
<ul>
<li>Anticoagulation
    : Heparin gtt acutely</li>
<li>Transition
    to warfarin:
    If hemodynamically stable; no
    bleeding or
    recurrent thromboses</li>
<li>Immunosuppression: methylprednisolone 0.5 to 1 g intravenously daily
    for 3 days, subsequently followed by oral prednisone therapy at 1
    mg/kg/day</li>
<li>Severe cases may require PLEX &plusmn; IVIG</li>
<li>Refractory CAPS may require rituximab or eculizumab</li>
</ul>
<p>Sarcoidosis – Jared Freitas</p>
<p>Background</p>
<ul>
<li>Multisystem
    disordered defined by forming noncaseating granulomas in different
    tissues</li>
<li>Cardiac
    and neuro manifestations can be isolated</li>
</ul>
<p>Presentation</p>
<ul>
<li>Constitutional
    symptoms: fatigue, night sweats, weight loss, fevers, arthralgias,
    myalgias</li>
<li>Pulmonary
    symptoms (most common): dyspnea, cough, and wheezing</li>
<li>Extrapulmonary
    manifestations:<ul>
<li>Cutaneous<ul>
<li>Highly variable, but present in 25% of patients</li>
<li>Papules, macules, plaques that can be isolated or in groups,
    commonly involving neck, upper back, extremities; in African
    Americans can leave scars and depigmented areas</li>
<li>Lupus pernio: indurated, violaceous bumps on nose, lips,
    cheeks, ears</li>
<li>Erythema nodosum</li>
</ul>
</li>
</ul>
</li>
<li>Neuro<ul>
<li>Affects 5-10% pts; involving any part of CNS or PNS, causing CN,
    hypothalamic, seizures, myelopathy or radiculopathy,
    hydrocephalus, aseptic meningitis</li>
</ul>
</li>
<li>Cardiac<ul>
<li>Granulomas can affect pericardium, myocardium and endocardium
    resulting in valvular disorders, conduction system and
    cardiomyopathy</li>
</ul>
</li>
<li>Liver/Spleen<ul>
<li>Granulomas in liver and spleen can lead to elevated LFTs,
    cirrhosis, anemia, leukopenia and thrombocytopenia (splenic
    sequestration)</li>
</ul>
</li>
<li>Ocular<ul>
<li>Photophobia, red eye, pain, blurry vision</li>
<li>Pts need eye exams to look for ocular involvement: uveitis
    (anterior and posterior), secondary glaucoma, retinal
    vasculitis, keratoconjunctivitis</li>
</ul>
</li>
</ul>
<p>Work Up</p>
<ul>
<li>Requires
    combination of clinical presentation, radiographic manifestations,
    exclusion of other similarly presenting diseases, and noncaseating
    granulomas on pathology</li>
<li>CXR: hilar and mediastinal lymphadenopathy
    ±
    pulmonary infiltrates</li>
<li>High-Resolution Chest CT<ul>
<li>Lymphadenopathy (bilateral and symmetric), with micro or
    macronodules, fibrotic changes (reticular opacities, traction
    bronchiectasis, volume loss)</li>
</ul>
</li>
<li>PFTs<ul>
<li>Typical findings: most sensitive is reduced DLCO, followed by
    reduced TLC, and then reduced VC (need to do full PFTs not just
    spirometry)</li>
</ul>
</li>
<li>Labs:<ul>
<li>CBC w/ diff, CMP, and urinalysis</li>
<li>ACE level is of limited clinical use</li>
<li>Testing for TB: Quant-Gold</li>
</ul>
</li>
<li>Biopsy<ul>
<li>Important to rule out mimics. The differential for “noncaseating
    granulomas” is extensive, including lymphoma and fungal
    infections</li>
<li>Not required for pts w/ asymptomatic bilateral hilar adenopathy
    or <strong>Lofgren syndrome</strong> (fever, erythema nodosum, arthralgias,
    and bilateral hilar LAD)</li>
<li>Target accessible lesions, like skin lesions or lymph nodes. May
    need bronchoscopy</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Most
    pts do not require therapy<ul>
<li>Monitor symptoms, CXR, PFTs at 3-6 month intervals</li>
</ul>
</li>
<li>Indications for treatment
    : progressive disease or severe disease at presentation</li>
<li>Mainstay of treatment is oral steroids:<ul>
<li>Dosing usually 0.3-0.6 mg/kg daily for 4-6 weeks</li>
<li>If only symptoms is cough, could consider inhaled
    glucocorticoids</li>
</ul>
</li>
<li>If unresponsive or unable to tolerate steroids may require
    alternative agents (MTX, AZA)</li>
</ul></section><section class="print-page" id="rheumatology-rheumatology-crystal-arthropathy"><h1 id="rheumatology-rheumatology-crystal-arthropathy-crystal-arthropathy">Crystal Arthropathy<a class="headerlink" href="#rheumatology-rheumatology-crystal-arthropathy-crystal-arthropathy" title="Permanent link">&para;</a></h1>
<p>Crystalline Arthropathies – Arissa Young</p>
<p>Gout</p>
<p>Presentation</p>
<ul>
<li>Red, hot, swollen joint (Classically affects 1 <sup>st</sup>
    metatarsal phalangeal joint [podagra])</li>
<li>May evolve
    to involve knees, elbows, and small joints of hand if untreated</li>
<li>Flares
    may
    become polyarticular over time</li>
<li>Gout is diagnosed with combination of clinical
    presentation and arthrocentesis results</li>
<li>Lifestyle factors:<ul>
<li>Protective: Low fat dairy, hydration</li>
<li>Promoting:  Meat, seafood, alcohol, high fructose corn syrup,
    medications that lead to hyperuricemia (consider discontinuing
    diuretics when using as antihypertensive)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Synovial Fluid Analysis:<ul>
<li>Order cell count and differential<ul>
<li>WBC 20,000-100,000, &gt; 50% neutrophils</li>
</ul>
</li>
<li>Order gram stain/culture (It is possible to have septic
    arthritis and gout)</li>
<li>Examination for crystals under polarizing light microscopy:
    (order “Synovial Fluid Eval” so the lab knows to look for
    crystals)<ul>
<li>Monosodium urate crystals: needle-shaped and negatively
    birefringent and appear yellow when parallel to the
    polarizer</li>
</ul>
</li>
</ul>
</li>
<li>Imaging: generally unnecessary<ul>
<li>MSK ultrasound: Double contour sign (hyperechoic band = urate
    crystals deposits)</li>
<li>Dual energy CT scan: gout crystal aggregates appear green<ul>
<li>Not routinely necessary; Do not order without rheumatology
    consult</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Management</p>
<p>Acute:</p>
<ul>
<li>Do not discontinue allopurinol during an acute gout attack</li>
<li>NSAIDs (if not contraindicated):<ul>
<li>Short course of any at full anti-inflammatory dose: ibuprofen
    800 mg TID, indomethacin 50 mg TID, naproxen 500 mg BID</li>
</ul>
</li>
<li>Colchicine (only for use in patients without CKD):<ul>
<li>Best if used within the first 36 hours of an attack. Much less
    effective if started later</li>
<li>Dosing: 1.2 mg then 0.6 mg one hour later, then 0.6 mg daily
    until clinical improvement<ul>
<li>Important drug interactions (may require dose adjustment of
    colchicine): CYP3A4 inhibitors and P-glycoprotein/ABCB1
    inhibitors</li>
<li>E.g. statins, diltiazem, fluconazole, cyclosporine,
    tacrolimus, clarithromycin</li>
</ul>
</li>
</ul>
</li>
<li>Steroids: Ideally intra-articular if single joint affected and
    infection has been ruled out<ul>
<li>Oral prednisone - moderate dose 0.5mg/kg/day until clinical
    improvement and then taper over 7-14 days</li>
</ul>
</li>
<li>Anakinra (Requires Rheumatology consult): once daily for three days<ul>
<li>Reserved for patients who have contraindications to all other
    treatments</li>
</ul>
</li>
</ul>
<p>Chronic:</p>
<ul>
<li>Urate Lowering Therapy (ULT)<ul>
<li>Indications: 2-3 attacks/year, tophi, radiologic changes, gout
    with CKD, urolithiasis</li>
<li>Goal serum urate: \&lt;6.0 mg/dL or \&lt;5.0 mg/dL in patients with
    tophi</li>
<li>ULT can precipitate an acute gout flare, thus it should always
    be started with: low-dose NSAIDs, low-dose colchicine (0.6 mg)
    or low-dose prednisone (5 mg daily)<ul>
<li>Prophylaxis should be continued for 3-6 months after
    initiation of urate-lowering therapy (Can stop once uric
    acid is \&lt;6 for 6 months on a constant ULT dose)</li>
</ul>
</li>
<li>Allopurinol (xanthine oxidase inhibitor): Start low at 100 mg
    per day and increase as needed for target uric acid \&lt;6 (most
    patients will need 400-800 mg daily)<ul>
<li>Adjust dose monthly (in kidney dysfunction go slower)</li>
<li>Can be used in patients with kidney dysfunction: 50 mg/day,
    then
    ↑
    by 50 mg</li>
<li>Titration of allopurinol
    ↓
    both the risk of acute gout attacks and DRESS syndrome</li>
<li>Genetic testing (HLA-B*5801) recommended prior to starting
    for pts of Asian and African descent given
    ↑
    incidence of DRESS among pts with positive allel</li>
</ul>
</li>
<li>Febuxostat: alternative xanthine oxidase inhibitor that is
    metabolized by the liver for pts at risk for or with a history
    of DRESS or SJS related to allopurinol<ul>
<li>Has black box warning for
    ↑
    cardiovascular risk; more expensive than allopurinol</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Additional Information</p>
<ul>
<li>VUMC guidance: there is a microscope in the rheumatology clinic (TVC
    2);  You can page the rheumatology fellow and they are happy to help
    you use it</li>
<li>VA specific guidance:<ul>
<li>Dr. Birchmore is excellent at teaching residents how to use the
    polarizing microscope</li>
<li>Colchicine is non-formulary but is easily approved</li>
<li>For steroid intra-articular injections triamcinolone is the
    formulary option</li>
</ul>
</li>
<li>Uric acid level is often normal during acute gout flare</li>
<li>Shifts in uric acid may be the trigger of the flare: Diuresis,
    dietary changes, hospital stays</li>
<li>Eliminating uric acid from the diet will only reduce uric acid by
    ~1 mg/dL, so urate lowering therapy will be needed in most patients
    even if diet changed</li>
</ul>
<p>Pseudogout</p>
<p>Presentation</p>
<ul>
<li>Red, hot, swollen joint usually in the wrists, knees, or MCP joints</li>
<li>Cannot distinguish from gout based on clinical features alone</li>
<li>Like gout, diagnosis is based on exam and arthrocentesis</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Synovial Fluid:<ul>
<li>Order cell count and differential</li>
<li>WBC 20,000 to 100,000, &gt;50% neutrophils</li>
</ul>
</li>
<li>Order gram stain/culture (It is possible to have septic arthritis
    and CPPD)</li>
<li>Examination for crystals under polarizing light microscopy</li>
<li>CPPD crystals: rhomboid-shaped, weakly positively birefringent and
    appear blue when parallel to the polarizer</li>
<li>Imaging:<ul>
<li>XR: chondrocalcinosis in knee and wrists (thin calcified line
    present in fibrocartilage)</li>
</ul>
</li>
</ul>
<p>Management</p>
<p>Typically follows the same treatment used for acute gout attacks (see
above, little evidence)</p></section><section class="print-page" id="rheumatology-rheumatology-inflammatory-myopathies"><h1 id="rheumatology-rheumatology-inflammatory-myopathies-inflammatory-myopathies">Inflammatory Myopathies<a class="headerlink" href="#rheumatology-rheumatology-inflammatory-myopathies-inflammatory-myopathies" title="Permanent link">&para;</a></h1>
<p>Inflammatory Myopathies – Greg Jackson</p>
<p>Background</p>
<ul>
<li>Inflammation and damage of skeletal muscle primarily leading to
    weakness</li>
<li>Subtypes: Dermatomyositis, polymyositis, statin-induced myositis,
    inclusion body myositis, metabolic (hypothyroid, electrolyte)
    myositis, viral/infection myositis, diabetic myonecrosis</li>
<li>Important point: this differs from PMR in that myopathy presentation
    is usually painless weakness whereas PMR will have myalgias with
    preserved strength</li>
<li>Hypomyopathic (or amyopathic) variants: skin and/or lungs are
    affected &gt;> muscles</li>
</ul>
<p>Presentation</p>
<ul>
<li>Proximal, symmetric muscle weakness in upper and lower extremities
    in all but inclusion body myositis which is typically more distal
    and asymmetric</li>
<li>Dermatomyositis: skin involvement can include heliotrope rash of
    upper eyelids, Gottron’s papules (on MCP, PIP), “mechanic’s hands,”
    and shawl sign</li>
<li>Raynaud’s and arthralgias can also be present</li>
</ul>
<p>Evaluation</p>
<ul>
<li>BMP &amp; TSH ; CK level</li>
<li>Anti Jo-1 most common specific antibody</li>
<li>EMG: findings indicate myopathy</li>
<li>MRI extremity/affected muscle group: muscle edema</li>
<li>Skin biopsy in dermatomyositis: “interface dermatitis.”</li>
<li>Muscle biopsy (do not do biopsy in same muscle as EMG done)<ul>
<li>Polymyositis, inclusion body myositis: T cell mediated muscle
    injury</li>
<li>Dermatomyositis: immune complex/B cell mediated muscle injury</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>Prednisone 1 mg/kg/day for 4-6 weeks with subsequent taper</li>
<li>Consult Rheumatology</li>
<li>MTX or AZA used if refractory to steroids, may need IVIG, rituximab</li>
<li>If statin induced: stop statin or switch to lower intensity</li>
<li>If dermatomyositis: evaluate for underlying malignancy</li>
</ul></section><section class="print-page" id="rheumatology-rheumatology-rheumatology-lab-testing"><h1 id="rheumatology-rheumatology-rheumatology-lab-testing-rheumatology-lab-testing">Rheumatology Lab Testing<a class="headerlink" href="#rheumatology-rheumatology-rheumatology-lab-testing-rheumatology-lab-testing" title="Permanent link">&para;</a></h1>
<p>Rheumatology Lab Testing – Ben Boone</p>
<ul>
<li>Rheumatologic labs must be interpreted in the context of the
    clinical situation</li>
<li>It is challenging to interpret positive/abnormal labs with low
    pretest probability</li>
<li>Sensitivities and specificities referenced below refer to scenarios
    with moderate-to-high probability clinical situations</li>
</ul>
<p>Rheumatoid Factor (RF)</p>
<ul>
<li>A group of antibodies targeted against the Fc region of IgG</li>
<li>When positive in RA patients, called “seropositive RA” (typically
    more symptomatic)</li>
<li>A higher RF level is more specific for RA</li>
<li>70 - 80% sensitive for RA, but not very specific<ul>
<li>Present in 5-15% of healthy people</li>
<li>Commonly positive in Sjogren’s, Mixed Connective Tissue Disease
    (MCTD), Mixed Cryoglobulinemia, SLE, and rarely inflammatory
    myopathies</li>
<li>Can be positive some infectious diseases (i.e. malaria, hep B/C,
    rubella)</li>
<li>Often positive in RA patients before Anti-CCP and even before
    symptoms/diagnosis</li>
<li>Can be used as a surrogate when mixed cryoglobulinemia is
    suspected, since cryoglobulins can take up to a week to result
    and RF results in \&lt;48 hour</li>
</ul>
</li>
</ul>
<p>Anti-cyclic Citrullinated Peptides (Anti-CCP)</p>
<ul>
<li>Very specific for RA (&gt;95%); only 70% sensitive for RA</li>
<li>When positive in RA patients, called “seropositive RA” (typically
    more symptomatic)</li>
<li>A high titer is associated with more aggressive disease in RA</li>
</ul>
<p>Anti-nuclear Antibodies (ANA)</p>
<ul>
<li>Don't order for nonspecific symptoms – High Value Rheumatology Care
    Recommendation</li>
<li>Should always be ordered with the reflex survey <strong>(ANA w/ Rfx
    ENA/DNA)</strong></li>
<li>Reported as both a titer and a pattern<ul>
<li>Titer<ul>
<li>At VUMC, 1:80 is considered “positive”; however, a higher
    titer is more specific (albeit less sensitive) for
    ANA-associated rheumatologic disease</li>
<li>~30% of the general population has a “positive” ANA at
    1:40, whereas only ~1% of people have a true ANA-associated
    rheumatologic disease</li>
</ul>
</li>
<li>Pattern
    (three clinically significant ones)<ul>
<li>Smooth/homogenous – associated with Anti-dsDNA and
    Anti-histone antibodies</li>
<li>Speckled – associated with Anti-RNP, Anti-Smith,
    Anti-SSA/Ro, Anti-SSB/La</li>
<li>Nucleolar – associated with Anti-Scl-70</li>
</ul>
</li>
</ul>
</li>
<li>If ANA is
    ≥
    1:80 the following studies will be sent:<ul>
<li>Anti-dsDNA (Quantitative and Qualitative)<ul>
<li>Classical teaching is
    anti-dsDNA antibodies are specific for SLE. However, this
    depends on lab methodology; VUMC uses ELISA assay (less
    specific)</li>
<li>In some pts, dsDNA varies with disease activity</li>
<li>If dsDNA is positive, there is an increased risk of renal
    lupus</li>
</ul>
</li>
<li>Positive
    if <u>></u> 25 IU/mL ~70% sensitive and specific for SLE</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>
<ul>
<li>Anti-SSA/Ro (Qualitative)
        -   Non-specific; ~70% sensitive for Sjogren’s; present in
            ~30% of SLE and MCTD pts
        -   Present in ~20% of RA and idiopathic inflammatory myopathy
            pts
        -   Maternal positivity for SSA is associated with congenital
            heart block in infants</li>
<li>Anti-SSB/La (Qualitative)</li>
</ul>
</li>
</ul>
<!-- -->

<ul>
<li>Similar profile to Anti-SSA/Ro but less common</li>
<li>~50% of Sjogren’s and ~20% of SLE/MCTD pts</li>
<li>Very rare to have Anti-SSB w/o Anti-SSA in a pt with true Sjogren’s
    disease<ul>
<li>Anti-Scl-70 (Qualitative)<ul>
<li>Very specific for systemic sclerosis (&gt;99%); 20-60%
    sensitive for systemic sclerosis</li>
<li>~70% sensitive for diffuse cutaneous systemic sclerosis</li>
<li>Only ~10% sensitive for CREST syndrome</li>
</ul>
</li>
<li>Anti-Smith (Qualitative)</li>
</ul>
</li>
<li>Very specific &gt;99% for SLE; but only ~20% sensitive for SLE<ul>
<li>Anti-RNP (Qualitative)</li>
</ul>
</li>
<li>Required for MCTD diagnosis; present in ~40% of SLE; rarely in
    systemic sclerosis</li>
</ul>
<p>Other notable ANAs</p>
<ul>
<li>Anti-histone: Associated w/drug-induced lupus (VUMC order: <strong>Histone
    IgG-ARUP</strong> )</li>
<li>Anti-centromere: Seen in limited scleroderma (CREST syndrome)</li>
<li>Anti-neutrophil Cytoplasmic Antibodies (ANCA)<ul>
<li>Qualitative: p-ANCA, c-ANCA, negative, or indeterminate</li>
<li>Quantitative titers: anti-proteinase 3 (PR3),
    anti-myeloperoxidase (MPO) IgG antibodies</li>
</ul>
</li>
</ul>
<p>C3 and C4</p>
<ul>
<li>Complement
    levels should be checked in any pt in whom you suspect active SLE</li>
<li>Complement may also be low in diseases that decreases the liver’s
    synthetic function</li>
<li>↓
    C3
    /C4 in diseases that form immune complexes, activating the classic
    complement pathway: mixed cryoglobulinemia, Sjogren’s, MPGN, and
    antiphospholipid syndrome</li>
</ul>
<p>C-reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR)</p>
<ul>
<li>
<ul>
<li>Both tests are non-specific markers of inflammation</li>
<li>Should be ordered alongside other rheumatology labs to
    corroborate disease activity</li>
</ul>
</li>
<li>
<p>CRP
    measures a specific protein made by the liver that activates the
    complement pathway</p>
<ul>
<li>CRP is IL-6 dependent</li>
<li>↓
    IL-6 (pts on tocilizumab or tofacitinib) results in
    ↓
    CRP regardless of disease activity</li>
</ul>
</li>
<li>
<p>ESR is the rate that RBCS settle in a standardized tube in one hour</p>
<ul>
<li>Fibrinogen is the primary driver of the ESR</li>
<li>The positive fibrinogen binds to the negatively-charged RBCs,
    allowing them to settle faster in the tube as RBCs no longer
    repel each other (both negatively charged)</li>
<li>Both Low fibrinogen (DIC or HLH) and anemia falsely lower the
    ESR</li>
</ul>
</li>
</ul>
<p>Creatinine Kinase (CK)</p>
<ul>
<li>CK can be elevated by exercise, rhabdomyolysis, endocrinopathy,
    cardiac disease, renal disease, malignancy, medication effect,
    neuromuscular disease, connective tissue disease<ul>
<li>Vigorous exercise can elevate CK up to 30-times the upper limit
    of normal</li>
</ul>
</li>
<li>CK can be elevated in asymptomatic pts (should be rechecked in 1 wk
    to ensure resolution)</li>
<li>Elevated
    CK in pts with objective proximal muscle weakness can direct the
    differential diagnosis to inflammatory myopathies (dermatomyositis,
    inclusion body myositis, polymyositis, and immune-mediated
    necrotizing myopathy)<ul>
<li>Notably, CK is normal in polymyalgia rheumatica</li>
</ul>
</li>
</ul>
<p>Cryoglobulin Evaluation</p>
<ul>
<li>Clinical context drives interpretation of the test:<ul>
<li>The presence of detectable cryoglobulins
    ≠
    cryoglobulinemic vasculitis</li>
</ul>
</li>
<li>Reported
    as qualitative (positive or negative) and quantitative (percentage =
    “cryocrit”)<ul>
<li>This test is highly prone to collection error</li>
<li>To perform this test, you need 6 full red-top tubes, kept
    between 37-39°C from the moment they are collected. This is
    accomplished using a thermos with a thermometer aka the “Cryo
    Kit”. At VUMC, this kit can be found in the immunopathology lab
    on the 4<sup>th</sup> floor. Place water at 39°C in the kit, then collect
    the blood at bedside with a nurse, placing each labeled tube
    directly into the water. Once all 6 tubes are collected, take
    the Cryo Kit back to the lab. If the temperature is less than
    37°C, the lab won’t accept it</li>
</ul>
</li>
<li>Essential Cryoglobulinemia (rare ~ 10%): cryoglobulinemia w/o
    associated disease</li>
<li>Cryoglobulinemic
    vasculitis: small vessel vasculitis with a highly variable
    presentation<ul>
<li>Arthralgias, peripheral neuropathy and renal disease (usually
    MPGN) are common</li>
<li>Skin involvement (purpura and erythematous macules, usually in
    colder areas of the body like the lower extremities)</li>
</ul>
</li>
<li>Type
    I Cryoglobulins<ul>
<li>Monoclonal immunoglobulins (Igs); usually IgG or IgM; rarely IgA
    or light chains</li>
<li>Classically associated with digital ischemia, skin necrosis, and
    livedo reticularis</li>
<li>Associated with Waldenström macroglobulinemia, multiple myeloma,
    MGUS, and CLL</li>
</ul>
</li>
<li>Mixed Cryoglobulins (these do not produce a single monoclonal
    antibody like Type I)<ul>
<li>Type II<ul>
<li>A mixture of a monoclonal Ig (IgG, IgM, or IgA) combined
    with polyclonal Igs</li>
<li>Associated with chronic viral infections HCV (most common),
    HBV, and HIV</li>
<li>Less commonly seen in autoimmune diseases like SLE and
    Sjogren’s</li>
</ul>
</li>
<li>Type III<ul>
<li>A mixture of polyclonal IgG and polyclonal IgM</li>
<li>Associated with the reverse profile of Type II; most
    commonly with autoimmune diseases; less commonly with
    infections</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Extended Myositis Panel</p>
<ul>
<li>Can be sent when suspecting various forms of myositis such as
    dermatomyositis, polymyositis, anti-synthetase syndrome, etc.</li>
<li>Ordered as “ <strong>Myositis extended Pnl-ARUP</strong> ”<ul>
<li>Includes 19 separate antibodies with a summary interpretation
    provided at the end</li>
</ul>
</li>
<li>P155 (TIF1-gamma) and P140 (NXP-2) antibodies are particularly
    associated with malignancy in pts &gt; 30 y/o (ensure age-appropriate
    cancer screening)<ul>
<li>PET/CT and pelvic U/S in female patients should be pursued to
    search for malignancy</li>
</ul>
</li>
</ul></section><section class="print-page" id="rheumatology-rheumatology-vasculitis"><h1 id="rheumatology-rheumatology-vasculitis-vasculitis">Vasculitis<a class="headerlink" href="#rheumatology-rheumatology-vasculitis-vasculitis" title="Permanent link">&para;</a></h1>
<p>Vasculitides – Trever Stevens and Greg Jackson</p>
<p>Background</p>
<ul>
<li>Large
    vessel vasculitides
    - affect the Aorta and its major branches:<ul>
<li>Takayasu's
    Arteritis: most commonly affects \&lt;50 years old and young Asian
    Females<ul>
<li>Branches of the aorta and aortic arch (subclavian,
    innominate, and carotid arteries)</li>
</ul>
</li>
<li>Giant
    Cell: most commonly affects adults &gt;50 years old<ul>
<li>Almost never seen under the age of 50; and affects F&gt;M
    slightly</li>
<li>Cranial arteries like the temporal artery, although can
    involve aorta and its branches</li>
</ul>
</li>
</ul>
</li>
<li>Medium
    vessel vasculitides
    - affect the muscular arteries that supply visceral organs:<ul>
<li>PAN: Necrotizing vasculitis, involves muscular arteries
    including the renal arteries, mesenteric artery, and arteries
    that supply neurons and the skin<ul>
<li>PAN <strong>spares the lung</strong> (consider other process if pulmonary
    complaints)</li>
<li>Affects middle age to older adults (peaks at 5<sup>th</sup> decade of
    life)</li>
<li>Can be associated with HBV infection and HBsAg</li>
</ul>
</li>
<li>Kawasaki’s: most commonly affects children (not addressed here)</li>
</ul>
</li>
<li>Small
    Vessel Vasculitides
    - affect arterioles, capillaries, and venules<ul>
<li>Cryoglobulinemic vasculitis and Henoch Schonlein Purpura - not
    discussed here</li>
<li>GPA
    : Necrotizing and granulomatous; involves the nasopharynx,
    lungs, and kidneys</li>
<li>MPA
    :
    Necrotizing
    ; affects multiple organs, predilection for lungs and kidneys<ul>
<li>Nasopharyngeal involvement and granulomas are <strong>absent</strong>
    (contrast to GPA)</li>
</ul>
</li>
<li>EGPA: Granulomatous
    necrotizing inflammation with eosinophilia<ul>
<li>Uncommon over the age of 65; predilection for heart and
    lungs</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Takayasu's Arteritis</p>
<p>Presentation</p>
<ul>
<li>Unequal pulses, arterial bruits, or different BP in both arms (known
    as “pulseless disease”)</li>
<li>Constitutional symptoms: fevers, arthralgias, myalgias, rash, weight
    loss</li>
<li>Can also cause carotidynia (tenderness of carotid artery),
    lightheadedness, vertigo, headaches, syncope, and strokes due to
    involvement of carotid arteries</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Inflammatory markers: ESR &amp; CRP (usually elevated)</li>
<li>Arteriography: MRA or CTA of head/neck, chest, and abdomen</li>
</ul>
<p>Management</p>
<ul>
<li>If signs of aortitis/carotidynia or arterial stenosis: 1mg/kg
    prednisone daily (max 60-80mg/kg) for 2-4 weeks followed by steroid
    taper</li>
<li>Organ threatening disease or ischemia: 500-1000 mg IV
    methylprednisolone (1-3 days) then 1mg/kg prednisone daily (2-4
    weeks) followed by steroid taper</li>
<li>MTX, immunomodulators</li>
</ul>
<p>Giant Cell Arteritis</p>
<p>Presentation</p>
<ul>
<li>In a pt &gt;65 with headache and vision changes (diplopia or amaurosis
    fugax) this needs to be ruled out!</li>
<li>Classically presents as headache, jaw claudication, tenderness to
    palpation of scalp in addition to constitutional symptoms</li>
<li>Polymyalgia rheumatica will often accompany GCA<ul>
<li>B/l shoulder and hip pain and stiffness (elevated ESR but normal
    CK)</li>
</ul>
</li>
</ul>
<p>Evaluation</p>
<ul>
<li>Order ESR, CRP, CK level, TSH</li>
<li>Detailed vascular exam for (4 limb blood pressures with attention to
    symmetry, abdominal/neck/chest auscultation for bruit)</li>
<li>Ophthalmology eval if there is ocular involvement.</li>
<li>Temporal artery biopsy – evaluating for evidence of vasculitis or
    giant cells<ul>
<li>(Vascular surgery can assist with timely biopsy)</li>
</ul>
</li>
</ul>
<p>Management</p>
<ul>
<li>If ESR is elevated in a moderate to high probability setting, give
    steroids without delay (biopsy results will be unaffected if done
    within ~2 weeks)</li>
<li>Without visual loss: prednisone 1mg/kg (max of 60 mg) daily</li>
<li>With visual loss or diplopia: 100-1000mg of IV methylprednisolone
    daily for 3 days, followed by prednisone 1mg/kg daily (max of 60mg)</li>
<li>Duration: daily high-dose steroids as above for 2-4 weeks, then
    begin to taper steroids</li>
</ul>
<p>Polyarteritis Nodosa (PAN)</p>
<p>Presentation</p>
<ul>
<li>Constitutional symptoms: fevers, arthralgias, myalgias, rash, weight
    loss</li>
<li>Asymmetric polyneuropathy (most common symptom) &amp; <strong>both</strong> motor and
    sensory deficits</li>
<li>Foot drop, radial and ulnar neuropathies</li>
<li>Hypertension if renal artery involvement</li>
<li>Abdominal pain and melena if mesenteric artery inflammation</li>
<li>Skin manifestations: livedo reticularis, palpable purpura, or tender
    erythematous nodules</li>
</ul>
<p>Evaluation</p>
<ul>
<li>ESR, CRP, CK level, TSH</li>
<li>Arteriography: MRI or CT or catheter based angiogram - “string of
    pearls” appearance</li>
<li>Histology: fibrinoid necrosis and vasculitis in target tissue</li>
</ul>
<p>Management</p>
<ul>
<li>Hepatitis screening if not previously done to evaluate for HBsAg</li>
<li>Mild disease or isolated cutaneous disease: Glucocorticoids</li>
<li>Moderate disease: Up to 1mg/kg prednisone daily (up to 60-80mg max)
    for 2-4 weeks followed by steroid taper &plusmn; DMARD</li>
<li>Severe disease or life threatening disease (evidence of renal
    insufficiency, significant proteinuria, gastrointestinal, cardiac,
    or neurologic involvement): 500-1000mg IV methylprednisolone daily
    for up to 3 doses followed by prednisone as above for 4 weeks with
    taper plus cyclophosphamide</li>
</ul>
<p>Granulomatosis with Polyangiitis (GPA)</p>
<p>Presentation</p>
<ul>
<li>Sinus and respiratory symptoms, sinusitis/ulcers, hemoptysis</li>
<li>Renal involvement – elevated Cr, hematuria, or proteinuria from RPGN</li>
<li>Less commonly affects eyes (scleritis: red, painful, light
    sensitive), skin (palpable purpura), peripheral nerves (mononeuritis
    multiplex)</li>
</ul>
<p>Evaluation</p>
<ul>
<li>ANCA + (Usually PR3-cANCA &gt; MPO-pANCA)</li>
<li>U/A with urine microscopy: need to spin the urine to evaluate for
    active renal disease</li>
<li>Biopsy of a site of suspected disease activity (necrotizing
    granulomatous vasculitis)</li>
</ul>
<p>Management</p>
<ul>
<li>If treating inpatient, has 20x increase risk of DVT/PE – ensure DVT
    ppx</li>
<li>Mild to moderate disease: MTX + glucocorticoids</li>
<li>Severe disease: rituximab or cyclophosphamide, then maintenance w/
    Rituxan or DMARD</li>
</ul>
<p>Microscopic Polyangiitis (MPA)</p>
<p>Presentation</p>
<ul>
<li>Similar to GPA but will only involve kidneys and lungs (less sinus
    involvement)</li>
<li>Hemoptysis with bilateral nodular lung involvement and
    hematuria/proteinuria common</li>
</ul>
<p>Evaluation</p>
<ul>
<li>ANCA +, typically MPO-pANCA</li>
<li>U/A with urine microscopy: need to spin the urine to evaluate for
    active renal disease</li>
<li>Biopsy of a site of suspected diseased activity</li>
</ul>
<p>Management</p>
<ul>
<li>DVT ppx is important as patients are at higher risk for DVTs/PE</li>
<li>Mild to moderate disease: MTX (or similar DMARD) + glucocorticoids</li>
<li>Severe disease: rituximab or cyclophosphamide, then maintenance
    w/Rituxan or DMARD</li>
</ul>
<p>Eosinophilic Granulomatosis with Polyangiitis (EGPA or Churg-Strauss
Syndrome)</p>
<p>Presentation</p>
<ul>
<li>Similar to MPA and GPA; unique symptoms include atopic symptoms
    (asthma, etc.)<ul>
<li>Asthma is the most common symptom with involvement in over 90%
    of patients</li>
</ul>
</li>
<li>Can have Peripheral eosinophilia</li>
<li>More likely small vessel vasculitis to cause cardiac tissue
    involvement: Coronary arteritis, myocarditis, heart failure and
    arrhythmias</li>
<li>Skin lesions: tender subcutaneous nodules</li>
<li>Renal involvement: hematuria and proteinuria</li>
</ul>
<p>Evaluation</p>
<ul>
<li>ANCA + (typically MPO-pANCA) and peripheral eosinophilia</li>
<li>Histology: Eosinophilic infiltrates with fibrinoid necrosis</li>
</ul>
<p>Management</p>
<ul>
<li>DVT prophylaxis as patients are high risk for DVTs/PE</li>
<li>Mild to moderate disease: MTX (or similar DMARD) + glucocorticoids</li>
<li>Severe disease (cardiac or neurologic involvement): cyclophosphamide
    induction with maintenance DMARD, Rituximab</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Rheumatology</h1>
                        <h1 class='nav-section-title' id='section-toxicology'>
                            Toxicology <a class='headerlink' href='#section-toxicology' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="toxicology-toxicology-brown-recluse-loxoscelism"><h1 id="toxicology-toxicology-brown-recluse-loxoscelism-brown-recluse-bites-loxoscelism">Brown Recluse Bites (Loxoscelism)<a class="headerlink" href="#toxicology-toxicology-brown-recluse-loxoscelism-brown-recluse-bites-loxoscelism" title="Permanent link">&para;</a></h1>
<p>Ashley Zeoli</p>
<hr />
<h2 id="toxicology-toxicology-brown-recluse-loxoscelism-background">Background<a class="headerlink" href="#toxicology-toxicology-brown-recluse-loxoscelism-background" title="Permanent link">&para;</a></h2>
<ul>
<li>Only a handful of spiders are truly harmful to humans</li>
<li>The brown recluse (a member of the Loxoceles genus) is widespread in
    the South, West, and Midwest US</li>
<li>They are often found in homes (attics, basements, cupboards) and
    outdoors (rock piles and under tree bark)</li>
<li>Their numbers increase in association with humans (i.e.
    synanthropic)</li>
<li>Appearance/identification:<ul>
<li>Brown recluses have three pairs of eyes, a monochromatic abdomen and
legs, and very fine hairs on its legs</li>
<li>Using the “violin” pattern on its body is a poor way to identify
this spider, as other harmless spiders can have similar markings.</li>
</ul>
</li>
<li>Loxocelism is the medical manifestation of the brown recluse spider
    bite</li>
<li>Venom contains insecticidal toxins, metalloproteases, and
    phospholipases</li>
</ul>
<h2 id="toxicology-toxicology-brown-recluse-loxoscelism-presentation">Presentation<a class="headerlink" href="#toxicology-toxicology-brown-recluse-loxoscelism-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Bites are most common on the upper arm, thorax, or inner thigh</li>
<li>Local signs:<ul>
<li>Sometimes painless, but can cause burning sensation with two small
cutaneous puncture marks with surrounding erythema. Pain can
increase over the first 8 hours</li>
<li>Usually appears as a red plaque or papule with central pallor and
can sometimes present with vesiculation</li>
<li>Usually self-resolves in 1 week</li>
</ul>
</li>
<li>Skin necrosis:<ul>
<li>In some, skin lesion can progress to necrosis overall several days</li>
<li>An eschar will form that eventually ulcerates</li>
<li>Usually will heal over several weeks to months</li>
</ul>
</li>
<li>Systemic signs:<ul>
<li>The degree of systemic effects does not correlate with the
appearance of the bite</li>
<li>Symptoms may develop over several days, and include nausea,
vomiting, fever, rhabdomyolysis, malaise, acute hemolytic anemia,
significant swelling from head/neck bites that can compromise the
airway, DIC and renal failure</li>
</ul>
</li>
</ul>
<h2 id="toxicology-toxicology-brown-recluse-loxoscelism-evaluation">Evaluation<a class="headerlink" href="#toxicology-toxicology-brown-recluse-loxoscelism-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Presumptive diagnosis is based clinical presentation of the
    bite/wound</li>
<li>DDx includes vasculitis, pyoderma gangrenosum, cellulitis, or other
    arthropod bites</li>
<li>Definitive diagnosis is based upon observing a spider bite in
    combination identification by an entomologist. There is an assay for
    Loxoceles venom, but it is not commercially available</li>
<li>Patients with local symptoms do not need any further workup</li>
<li>Patient with any systemic symptoms require lab evaluation for more
    serious disease:<ul>
<li>CBC, UA to eval for blood, CMP, CK</li>
<li>If anemia: Type and Screen, peripheral smear, reticulocyte count,
LDH, haptoglobin, coags to evaluate for hemolysis or DIC</li>
</ul>
</li>
</ul>
<!-- 
<img src="../toxicology/toxicology-brown-recluse-loxoscelism/output/media/image35.png"
style="width:3.66923in;height:2.52573in"
alt="Diagram Description automatically generated" />
-->

<h2 id="toxicology-toxicology-brown-recluse-loxoscelism-management">Management<a class="headerlink" href="#toxicology-toxicology-brown-recluse-loxoscelism-management" title="Permanent link">&para;</a></h2>
<ul>
<li>Local signs:<ul>
<li>Wound care (soap/water, elevation)</li>
<li>Pain management</li>
<li>Tetanus vaccine/prophylaxis if indicated</li>
<li>Antibiotics only if signs of concurrent cellulitis</li>
</ul>
</li>
<li>Skin necrosis:<ul>
<li>Symptomatic and supportive care</li>
<li>Surgical intervention can worsen cosmetic outcomes and is rarely
indicated in the acute care setting. Skin grafting is occasionally
needed for a very large ulcerative wound that is not healing.
Infection is rare, Furthermore, the ulcerative base of the wounds
often have a yellow stringy material that is not pus or infection.
Please call Toxicology with any questions regarding brown recluse
bites</li>
</ul>
</li>
<li>Systemic signs: Targeted at treatment of symptoms that develop (Consult toxicology)<ul>
<li>Hemolytic anemia: transfuse for Hgb &lt;10 + consult heme</li>
<li>Rhabdomyolysis: LR for UOP &gt;200-300cc/hr</li>
<li>If patient develops chest pain, obtain EKG and check a troponin; if
    either is abnormal please obtain echo and call Toxicology as heart
    effects (i.e. myocarditis) is something we have been seeing at VUMC</li>
<li>DIC: supportive care</li>
</ul>
</li>
</ul></section><section class="print-page" id="toxicology-toxicology-overdose-management"><h1 id="toxicology-toxicology-overdose-management-management-of-specific-overdoses">Management of Specific Overdoses<a class="headerlink" href="#toxicology-toxicology-overdose-management-management-of-specific-overdoses" title="Permanent link">&para;</a></h1>
<p>Lauren Chen</p>
<hr />
<h2 id="toxicology-toxicology-overdose-management-overview">Overview<a class="headerlink" href="#toxicology-toxicology-overdose-management-overview" title="Permanent link">&para;</a></h2>
<p>There are 5 main classes of drugs/toxins that induce bradycardia and
hypotension (ABCDO)</p>
<ul>
<li>Alpha-2 agonist</li>
<li>Beta-blockers</li>
<li>Calcium channel blockers</li>
<li>Digoxin and cardiac glycosides</li>
<li>Acetylcholinesterase inhibitors (Organophosphates)</li>
</ul>
<p>Key Points:</p>
<ul>
<li>Physical exam, labs, and ECG can be helpful in determining the class
    of drug/toxicant</li>
<li>Ensure physical exam includes vitals (including RR) pupils,
    heart/lung exam, abdominal exam including bowel sounds, and
    peripheral pulses</li>
<li>Obtain a blood glucose to differentiate beta blocker (hypoglycemia
    or normoglycemia) versus calcium channel blocker (hyperglycemia)
    toxicity</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-alpha-2-agonists">Alpha-2 Agonists<a class="headerlink" href="#toxicology-toxicology-overdose-management-alpha-2-agonists" title="Permanent link">&para;</a></h2>
<h3 id="toxicology-toxicology-overdose-management-background">Background<a class="headerlink" href="#toxicology-toxicology-overdose-management-background" title="Permanent link">&para;</a></h3>
<ul>
<li>Examples: Clonidine, dexmedetomidine, guanfacine, tizanidine,
    methyldopa</li>
<li>Mechanism: Centrally acting inhibition of norepinephrine release
    decreased noradrenergic activity</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-evaluation">Evaluation<a class="headerlink" href="#toxicology-toxicology-overdose-management-evaluation" title="Permanent link">&para;</a></h3>
<ul>
<li>Physical Exam: Early/transient HTN, attenuated sympathetic response
    (decreased HR, BP), opioid toxidrome (pinpoint pupils, CNS
    depression, respiratory depression)</li>
<li>Laboratory abnormalities: None associated with overdose</li>
<li>ECG: Sinus bradycardia</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-management">Management<a class="headerlink" href="#toxicology-toxicology-overdose-management-management" title="Permanent link">&para;</a></h3>
<ul>
<li>IVF and high dose naloxone</li>
<li>Naloxone may reverse the CNS and respiratory depression as well as
    hypotension</li>
<li>Vasopressors such as norepinephrine/epinephrine are used if naloxone
    does not work</li>
</ul>
<p>Quick dosing reference:</p>
<ul>
<li>Naloxone 10mg IVP followed by 5 mg/hr if there is no response</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-beta-blockers-bbs">Beta blockers (BB’s)<a class="headerlink" href="#toxicology-toxicology-overdose-management-beta-blockers-bbs" title="Permanent link">&para;</a></h2>
<h3 id="toxicology-toxicology-overdose-management-background_1">Background<a class="headerlink" href="#toxicology-toxicology-overdose-management-background_1" title="Permanent link">&para;</a></h3>
<ul>
<li>Mechanism: Competitively block catecholamines at beta-adrenergic
    receptors decreased inotropy and chronotropy; impaired
    gluconeogenesis and glycogenolysis</li>
<li>Lipophilic BB’s (propranolol, metoprolol): Cross the blood brain
    barrier -&gt; CNS depression</li>
<li>Membrane stabilizing BB’s (propranolol): QRS prolongation,
    dysrhythmias, and seizures</li>
<li>Sotalol: Potassium channel blocking properties QTc prolongation and
    dysrhythmias</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-evaluation_1">Evaluation<a class="headerlink" href="#toxicology-toxicology-overdose-management-evaluation_1" title="Permanent link">&para;</a></h2>
<ul>
<li>Physical Exam: CNS depression, seizures, myocardial depression,
    respiratory depression</li>
<li>Laboratory abnormalities: Hypoglycemia or normoglycemia</li>
<li>ECG: Sinus bradycardia, AV block (low grade), QRS widening
    (propranolol), QTc prolongation (sotalol)</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-management_1">Management<a class="headerlink" href="#toxicology-toxicology-overdose-management-management_1" title="Permanent link">&para;</a></h2>
<ul>
<li>IVF, Calcium</li>
<li>Glucagon: Stimulates adenylcyclase increased cAMP increase HR and BP</li>
<li>Epinephrine or Norepinephrine should be first line vasopressors</li>
<li>Intralipid infusion if refractory HoTN or pt codes from a lipophilic
    BB (i.e. Propranolol)</li>
<li>BB induced arrhythmias: Sodium bicarbonate (adjunct QRS widening)
    and Mg for QTc prolongation induced Torsades de pointes</li>
<li>Hemodialysis for significant sotalol toxicity</li>
</ul>
<p>Quick dosing reference:</p>
<ul>
<li>Calcium: 3g calcium gluconate</li>
<li>Glucagon:<ul>
<li>10 mg over 10 min (vomiting occurs if administered too
fast)</li>
<li>Infusion 3-5 mg/h (need infusion as half-life is 6 minutes)</li>
</ul>
</li>
<li>Atropine: 0.5-1mg q3-5min</li>
<li>Intralipid (Lipid Emulsion) 20% infusions: 1.5 cc/kg bolus followed
    by 0.25 cc/kg/min for 60 minutes (for 70 kg adult: 1 liter over 1
    hour) for refractory hypotension or if patient codes), max dose is
    10 ml/kg or 1200 ml whichever is greater however, there is limited
    guidance on a max dose - if using lipid emulsion therapy, please
    call Toxicology or Poison Control immediately</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-calcium-channel-blockers-ccbs">Calcium channel blockers (CCB’s)<a class="headerlink" href="#toxicology-toxicology-overdose-management-calcium-channel-blockers-ccbs" title="Permanent link">&para;</a></h2>
<h3 id="toxicology-toxicology-overdose-management-background_2">Background<a class="headerlink" href="#toxicology-toxicology-overdose-management-background_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Two categories: Dihydropyridines (DHP) and non-dihydropyridines
    (Non-DHP)</li>
<li>DHP (amlodipine, nifedipine): Peripheral > central channels,
    selectivity is lost in overdose</li>
<li>Non-DHP (diltiazem, verapamil): Primarily cardiac calcium channels</li>
<li>Mechanism:<ul>
<li>DHP: arterial vasodilation reflex tachycardia</li>
<li>Non-DHP: peripheral vasodilation, decreased inotropy, bradycardia.
Calcium mediated insulin inhibition in the pancreas hyperglycemia</li>
</ul>
</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-evaluation_2">Evaluation<a class="headerlink" href="#toxicology-toxicology-overdose-management-evaluation_2" title="Permanent link">&para;</a></h3>
<ul>
<li>Physical Exam: Markedly preserved mental status until patient is
    about to code</li>
<li>Labs: Hyperglycemia (elevated serum glucose concentrations are
    associated with severe overdose and sequelae)</li>
<li>ECG: Bradyarrhythmia, high-degree heart block (3<sup>rd</sup> degree)</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-management_2">Management<a class="headerlink" href="#toxicology-toxicology-overdose-management-management_2" title="Permanent link">&para;</a></h3>
<ul>
<li>IVF, vasopressors if needed</li>
<li>Bradycardia: Atropine (not effective for second- or third-degree
    block), calcium, glucagon</li>
<li>Hypotension + bradycardia:<ul>
<li>High dose insulin/euglycemic therapy (HIE)</li>
<li>Give with dextrose. Titrate insulin like a pressor. Blood
    pressure may take up to 20 minutes to change</li>
<li>May increase contractility through increasing the cardiac
    utilization of glucose. Not likely to help with vasodilation or
    bradycardia</li>
</ul>
</li>
<li>Vasopressors (norepinephrine or epinephrine). May consider
    phenylephrine for DHT induced vasoplegic shock with tachycardia</li>
<li>Intralipid should be used in code/refractory hypotensive situations
    for lipophilic CCB’s (verapamil, amlodipine, diltiazem)</li>
<li>Methylene blue for refractory distributive shock can be considered,
    but consult toxicology prior to using</li>
</ul>
<p>Quick dosing reference:</p>
<ul>
<li>Calcium: 3g calcium gluconate</li>
<li>Glucagon<ul>
<li>10 mg over 10 min (vomiting occurs if administered too
fast; max 10 mg/hr)</li>
<li>Infusion 3-5 mg/h (need infusion as half-life is 6 minutes)</li>
</ul>
</li>
<li>Atropine: 0.5-1mg q3-5min</li>
<li>If hypotensive and bradycardic:<ul>
<li>High-dose insulin 0.5-1 unit/kg bolus followed by 0.5-1
    unit/kg/hour infusion titrated to up to 10 units/kg/ hour.
    Call Toxicology immediately if exceeding 3 units/kg/hour.</li>
<li>Intralipid infusions: 20% infusions: 1.5 cc/kg bolus followed by
    0.25 cc/kg/min for 60 minutes (for 70 kg adult: 1 liter over 1
    hour) for refractory hypotension or if patient codes), max
    dose is 10 ml/kg or 1200 ml whichever is greater however,
    there is limited guidance on a max dose - if using lipid
    emulsion therapy, please call Toxicology or Poison Control
    immediately.</li>
</ul>
</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-digoxin-and-cardiac-glycosides">Digoxin and Cardiac Glycosides<a class="headerlink" href="#toxicology-toxicology-overdose-management-digoxin-and-cardiac-glycosides" title="Permanent link">&para;</a></h2>
<h3 id="toxicology-toxicology-overdose-management-background_3">Background<a class="headerlink" href="#toxicology-toxicology-overdose-management-background_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Examples: Digoxin, yellow oleander, lanatoside C, foxglove, lily of
    the valley, bufo toads</li>
<li>Mechanism: Blockade of Na/K ATPase increased intracellular calcium
    increased contractility and may delay after depolarizations/shorten
    repolarization of the atria and ventricles trigger arrhythmias;
    increased vagal tone</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-evaluation_3">Evaluation<a class="headerlink" href="#toxicology-toxicology-overdose-management-evaluation_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Physical Exam: Lethargy, nausea, vomiting, reported yellow halos in
    visual fields (chronic)</li>
<li>Laboratory abnormalities: Hyperkalemia (marker of acute toxicity
    although does not cause; correlates with mortality)</li>
<li>ECG: Any abnormality (though Afib RVR is unlikely, more likely to
    have a regular pulse due to 3<sup>rd</sup> degree block in the
    setting of Afib), biventricular tachycardia is classic but rarely
    seen</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-management_3">Management<a class="headerlink" href="#toxicology-toxicology-overdose-management-management_3" title="Permanent link">&para;</a></h3>
<ul>
<li>Digoxin fab fragments<ul>
<li>Indications: Hemodynamic instability, significant unstable
arrhythmia, end organ damage secondary to hypoperfusion (renal
failure), or potassium ≥5.0 mEq/L</li>
<li>It can also be indicated for pts with high post distribution digoxin
levels even if they are asymptomatic. However, please contact poison
control/toxicology for guidance.</li>
</ul>
</li>
<li>For pts with severe symptomatic bradycardia when digoxin fab
    fragments are not available, atropine is recommended but will likely
    not be effective</li>
<li>Given the sensitivity of the myocardium with digoxin, pacers can
    trigger significant dysrhythmias and only recommended if no access
    to digoxin fab fragments or fab fragment failure</li>
</ul>
<p>Quick reference dosing:</p>
<ul>
<li>Digoxin fab fragments: Number of vials = [(serum level times the
    weight of the patient)/100] rounded up. Empiric treatment 10 vials.
    NOTE: In acute on chronic toxicity or chronic toxicity, please
    contact the Poison Center or Medical Toxicology for guidance as less
    vials may be recommended to try to avoid adverse events from
    worsening heart failure or atrial fibrillation<ul>
<li>Unclear dosing for natural toxins (often empirically 10 vials for an
adult)</li>
</ul>
</li>
<li>Atropine (if digoxin fab fragments are not available): 0.5-1mg
    q3-5min</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-acetylcholinesterase-inhibitors">Acetylcholinesterase Inhibitors<a class="headerlink" href="#toxicology-toxicology-overdose-management-acetylcholinesterase-inhibitors" title="Permanent link">&para;</a></h2>
<h3 id="toxicology-toxicology-overdose-management-background_4">Background<a class="headerlink" href="#toxicology-toxicology-overdose-management-background_4" title="Permanent link">&para;</a></h3>
<ul>
<li>Examples: Organophosphates (e.g. insecticides), carbamates,
    physostigmine, rivastigmine, donepezil</li>
<li>Mechanism: Inhibition of the breakdown of acetylcholine increased
    acetylcholine stimulation of muscarinic and nicotinic receptors</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-evaluation_4">Evaluation<a class="headerlink" href="#toxicology-toxicology-overdose-management-evaluation_4" title="Permanent link">&para;</a></h3>
<ul>
<li>Physical Exam:<ul>
<li>Muscarinic: Diarrhea/Diaphoresis, Urination, Miosis,
Bronchorrhea/Bronchospasm, Bradycardia, Miosis, Emesis, Lacrimation,
Salivation (DUMBBELS mnemonic)</li>
<li>Nicotinic: Fasciculations, muscle weakness, and/or muscle paralysis</li>
<li>Intermediate syndrome: Neurologic syndrome after resolution of
cholinergic excess, decreased DTR, proximal muscle weakness,
respiratory insufficiency, neck flexion weakness, CN abnormalities</li>
</ul>
</li>
<li>Laboratory abnormalities: Standard lab tests are not helpful.</li>
<li>ECG: Sinus bradycardia, QTc prolongation</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-management_4">Management<a class="headerlink" href="#toxicology-toxicology-overdose-management-management_4" title="Permanent link">&para;</a></h3>
<ul>
<li>Atropine, Pralidoxime, Benzodiazepines</li>
<li>Secretions: Titrate atropine to dry secretions (can require large
    amounts i.e. 50 mg).</li>
<li>Bronchorrhea: Atropine as below; excessive watery mucous from the
    lungs can cause patients to drown in their own secretions</li>
<li>Organophosphate poisoning: Pralidoxime to reactivate the
    acetylcholinesterase enzyme</li>
<li>Seizures: Benzodiazepines</li>
</ul>
<p>Quick dosing reference</p>
<ul>
<li>Atropine: 1-2 mg (mild-moderate symptoms) vs 3-5mg (severe) IV
    repeated every 2-20 minutes or 1mg followed by doubling doses every
    5 minutes until bronchorrhea is no longer present followed by an
    infusion 10-20% of the loading dose per hour (max 2 mg/hour)</li>
<li>Pralidoxime: 30mg/kg (max 2g) loading dose followed by 8-10 mg/kg/hr
    (max 650mg/hr); WHO dosing is 2000 mg bolus followed by 500 mg/hr
    infusion. Pralidoxime use for other acetylcholinesterase inhibitors
    should be used only with Poison Control/Medical Toxicology guidance</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-alcohol">Alcohol<a class="headerlink" href="#toxicology-toxicology-overdose-management-alcohol" title="Permanent link">&para;</a></h2>
<h3 id="toxicology-toxicology-overdose-management-background_5">Background<a class="headerlink" href="#toxicology-toxicology-overdose-management-background_5" title="Permanent link">&para;</a></h3>
<ul>
<li>One standard drink = 12oz regular beer = 5oz wine = 1.5oz 80%
    distilled spirit</li>
<li>Absorption primarily in duodenum/small intestine (80%) with 80-90%
    of absorption in \&lt;60 min in ideal conditions (i.e. empty stomach)</li>
<li>Mechanism: Metabolism via alcohol dehydrogenase. Withdrawal due to
    CNS overactivity from decreased inhibitory tone (GABA) and
    unregulated excess excitation (glutamate binding to NMDA, dopamine)</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-evaluation_5">Evaluation<a class="headerlink" href="#toxicology-toxicology-overdose-management-evaluation_5" title="Permanent link">&para;</a></h3>
<ul>
<li>Physical Exam:<ul>
<li>Intoxication: Slurred speech, disinhibition, incoordination,
unsteady gait, memory impairment, nystagmus, stupor, coma,
hypotension, tachycardia</li>
<li>Wernicke encephalopathy: Encephalopathy, oculomotor dysfunction,
gait ataxia</li>
<li>Withdrawal: Anxiety, agitation, restlessness, insomnia, tremor,
diaphoresis, palpitations, HA, n/v, hallucinations (onset 12-24h
after last drink), seizures (12-48hr), DTs (72-96hr)</li>
</ul>
</li>
<li>Laboratory abnormalities: EtOH level, Peth, UDS, hypoglycemia,
    hyperlactatemia, hypoK, hypoMg, hypoCa, hypophos</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-management_5">Management<a class="headerlink" href="#toxicology-toxicology-overdose-management-management_5" title="Permanent link">&para;</a></h3>
<ul>
<li>Intoxication: Supportive care</li>
<li>Withdrawal: Thiamine, folate, multivitamin, IV fluid for
    intravascular depletion</li>
<li>Psychomotor agitation: Benzodiazepines (long-acting preferred)
    including diazepam, lorazepam, and chlordiazepoxide. Lorazepam for
    acute alcoholic hepatitis/liver dysfunction.</li>
<li>Seizures: CIWA scoring and benzodiazepines. If h/o DTs, consider
    phenobarbital taper. If status, consider escalation to propofol</li>
</ul>
<p>Quick dosing reference:</p>
<ul>
<li>Diazepam: 5-10mg IV every 5-10min until appropriate sedation
    (severe) or per CIWA protocol</li>
<li>Lorazepam: 2-4mg IV every 15-20min or per CIWA protocol</li>
<li>Thiamine: Administer before glucose containing fluids. WE prevention
    100mg IV QD x3d. For WE 500mg IV TID x3d followed by 250mg QD x3d,
    then 100mg QD.</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-opioids">Opioids<a class="headerlink" href="#toxicology-toxicology-overdose-management-opioids" title="Permanent link">&para;</a></h2>
<h3 id="toxicology-toxicology-overdose-management-background_6">Background<a class="headerlink" href="#toxicology-toxicology-overdose-management-background_6" title="Permanent link">&para;</a></h3>
<ul>
<li>Examples: Natural opiates (morphine, codeine), semi-synthetic
    (hydrocodone, hydromorphone, oxycodone, oxymorphone, heroin,
    buprenorphine), synthetic opioids (fentanyl, meperidine, tramadol)</li>
<li>Mechanism: Multiple receptors with wide range of clinical effects
    including sedation, analgesia, respiratory depression, GI
    dysmotility, bradycardia, miosis, anxiolysis</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-evaluation_6">Evaluation<a class="headerlink" href="#toxicology-toxicology-overdose-management-evaluation_6" title="Permanent link">&para;</a></h3>
<ul>
<li>Physical Exam<ul>
<li>Intoxication: AMS, miosis, hypoventilation, decreased bowel
    sounds, seizures, coma</li>
<li>Withdrawal: Mydriasis, yawning, piloerection, diaphoresis,
    rhinorrhea, increased BS</li>
</ul>
</li>
<li>Laboratory abnormalities: None specific to opioid toxicity</li>
<li>ECG: QT prolongation (loperamide, methadone, very large doses of
    oxycodone), QRS widening (loperamide)</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-management_6">Management<a class="headerlink" href="#toxicology-toxicology-overdose-management-management_6" title="Permanent link">&para;</a></h3>
<ul>
<li>Intoxication: Supplemental oxygenation/ventilation support,
    naloxone, ACLS<ul>
<li>IV naloxone preferable. However, if no IV access, apneic, or
    patient in critical condition, can use intranasally or IM.
    Switch to IV when able</li>
<li>Consider alternative etiologies of respiratory depression if no
    response after 10mg</li>
</ul>
</li>
<li>Withdrawal: COWs scoring and protocol<ul>
<li>Symptom control: ondansetron (nausea, vomiting), loperamide
    (diarrhea), hydroxyzine (anxiety), methocarbamol (cramps),
    dicyclomine (abdominal cramps)</li>
<li>Acute, severe: Methadone or buprenorphine, do NOT use for
    iatrogenic withdrawal (i.e following naloxone administration)</li>
<li>Iatrogenic or patients trying to overcome addition: Clonidine
    taper</li>
</ul>
</li>
</ul>
<p>Quick dosing reference</p>
<ul>
<li>Intranasal naloxone: 4 or 8mg as single dose in one nostril. Repeat
    q2-3min, alternating nostrils</li>
<li>IV naloxone: 0.4-2mg q2-3min. Consider initial lower dose
    (0.04-0.2mg) in patients with opioid dependence to avoid withdrawal
    or if concerned for concomitant stimulant overdose. However, if
    apneic, use higher doses, if mildly bradypneic in a known chronic
    user, can try smaller doses repeated every 2 minutes until patient
    is breathing at a normal rate while using bag mask ventilation to
    support the patient</li>
<li>Methadone 10mg IM or 20mg PO. Usually need to discuss with psych to
    give.</li>
<li>Buprenorphine 4-8mg sublingual. If symptoms persist after 60min, can
    give subsequent dose. Maximum 24mg in 24hr. Usually need to discuss
    with psych to give.</li>
<li>Clonidine 0.1-0.3mg every hour until symptom resolution, maximum
    0.8mg per 24hr</li>
</ul>
<h2 id="toxicology-toxicology-overdose-management-sodium-channel-blockers">Sodium Channel Blockers<a class="headerlink" href="#toxicology-toxicology-overdose-management-sodium-channel-blockers" title="Permanent link">&para;</a></h2>
<h3 id="toxicology-toxicology-overdose-management-background_7">Background<a class="headerlink" href="#toxicology-toxicology-overdose-management-background_7" title="Permanent link">&para;</a></h3>
<ul>
<li>Examples: Class I antiarrhythmics, tricyclic antidepressants
    (amitriptyline, imipramine) anticonvulsants (carbamazepine,
    lamotrigine), cocaine, insecticides</li>
<li>Mechanism: decreases depolarization of non-nodal cardiac myocytes</li>
<li>Consider other concomitant effects (e.g. TCA with anticholinergic
    and K channel blockade)</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-evaluation_7">Evaluation<a class="headerlink" href="#toxicology-toxicology-overdose-management-evaluation_7" title="Permanent link">&para;</a></h3>
<ul>
<li>Physical Exam: Depends on ingestion</li>
<li>Pure Na channel blockade: classically bradycardia but sodium channel
    blocking drugs often have anticholinergic properties resulting in
    tachycardia</li>
<li>TCAs: typically tachycardia, cardiogenic shock, hypotension, AMS,
    seizures, respiratory depression, anticholinergic symptoms</li>
<li>Laboratory abnormalities: No specific abnormalities</li>
<li>ECG: QRS widening, QTc prolongation, ventricular dysrhythmia (Vfib,
    Vtach, TdP), new right axis deviation</li>
</ul>
<h3 id="toxicology-toxicology-overdose-management-management_7">Management<a class="headerlink" href="#toxicology-toxicology-overdose-management-management_7" title="Permanent link">&para;</a></h3>
<ul>
<li>Sodium bicarbonate (mainstay)<ul>
<li>Indications: hypotension, QTC >100ms, QT prolongation</li>
<li>Mechanism: increases serum pH and extracellular Na to help offload
Na channels</li>
<li>Goal pH: 7.5-7.55</li>
</ul>
</li>
<li>Magnesium if arrhythmias refractory to sodium bicarb</li>
<li>IVF and vasopressor support as needed</li>
<li>TCA toxicity: consider lipid emulsion (discuss with poison control
    prior)</li>
</ul>
<p>Quick dosing reference</p>
<ul>
<li>Sodium bicarb: Initial 1-2mEq/kg bolus q5min until pH is 7.45 to
    7.55, QRS will hopefully narrow to less than 120 msec at this pH but
    it may remain prolonged. Then recommend infusion 150mEq in 1L D5W at
    150ml/h (contact poison control or toxicology for guidance on
    discontinuation</li>
<li>Intralipid infusions: 20% infusions: 1.5 cc/kg bolus followed by
    0.25 cc/kg/min for 60 minutes (for 70 kg adult: 1 liter over 1 hour)
    for refractory hypotension or if patient codes), max dose is 10
    ml/kg or 1200 ml whichever is greater however, there is limited
    guidance on a max dose - if using lipid emulsion therapy, please
    call Toxicology or Poison Control immediately</li>
</ul></section><section class="print-page" id="toxicology-toxicology-qtc"><h1 id="toxicology-toxicology-qtc-drug-induced-qtc-prolongation">Drug-Induced QTc Prolongation<a class="headerlink" href="#toxicology-toxicology-qtc-drug-induced-qtc-prolongation" title="Permanent link">&para;</a></h1>
<p>Mohamed Salih</p>
<hr />
<h2 id="toxicology-toxicology-qtc-background">Background<a class="headerlink" href="#toxicology-toxicology-qtc-background" title="Permanent link">&para;</a></h2>
<ul>
<li>QT is measured from the start of the Q-wave to the end of the T-wave
    (use the lead with the longest measurement) and is the time of
    ventricular depolarization + repolarization</li>
<li>QTc is the corrected estimate of QT assuming a rate of 60 bpm since
    QT decreases with tachycardia and increases with bradycardia</li>
<li>QTcF (Fridericia) + QTcB (Bazett) on ECG are different equations and
    either may be used</li>
<li>QTcB tends to overestimate QT</li>
<li>A 2016 Meta-analysis (PMID 27317349) recommended QTcF over QTcB</li>
<li>Prolongation is defined as a QT &gt; 440 ms in males or &gt;460 in
    females</li>
<li>Usually not very high concern until QTcF &gt; 500 ms.</li>
<li>Life threatening risk of prolonged QTcF &gt;500ms = Torsades de pointes
    (TdP) (see “Wide Complex Tachycardias” in the Cardiology section for
    evaluation and management of TdP).</li>
<li>Two main causes of prolonged QT:<ul>
<li>Congenital/Hereditary (long QT syndrome/channelopathies)</li>
<li>Acquired (Drug induced, anorexia, bradycardia, MI/BBB, hypothermia,
hypothyroidism, hypokalemia, hypomagnesemia, hypocalcemia, increased
ICP)</li>
<li>Think of ABCDE for common offenders:<ul>
<li>A: Anti”A”rrythmics (think class IA (procainamide,
    disopyramide) and class III (amiodarone, sotalol,
    dofetilide))</li>
<li>B: Anti”B”iotics: (azoles, macrolides, quinolones)</li>
<li>C: Anti”C”ychotics: 1<sup>st</sup> gen>2<sup>nd</sup> gen (chlorpromazine,
    haloperidol, risperidone)</li>
<li>D: Anti “D”epressants: SSRIs, TCAs</li>
<li>E: Anti”E”metics: (5-HT3 antagonists) ondansetron, also
    droperidol</li>
</ul>
</li>
<li>Other high risk medications: methadone, Arsenic (chemo),
    quinines (antimalarials), hydroxychloroquine</li>
<li>Special note on ondansetron (Zofran): Risk IV &gt; PO (ODT). Risk
    is greater if using IV dose &gt; 16mg, concomitant QT prolonging
    meds, concomitant other congenital and/or acquired QT
    prolongation condition</li>
<li>Conclusion: Single dosing of IV/PO Zofran without additional
    risk factors is safe, but if the patient is on other QTc
    prolonged medications or has risk factors for QTc prolongation,
    would get ECG prior to giving or before giving another dose of
    Zofran <em>within 2 hours</em></li>
</ul>
</li>
</ul>
<h2 id="toxicology-toxicology-qtc-presentation">Presentation<a class="headerlink" href="#toxicology-toxicology-qtc-presentation" title="Permanent link">&para;</a></h2>
<ul>
<li>Most commonly asymptomatic</li>
<li>Other symptoms include palpitations, seizure, syncope, SCD</li>
</ul>
<h2 id="toxicology-toxicology-qtc-evaluation">Evaluation<a class="headerlink" href="#toxicology-toxicology-qtc-evaluation" title="Permanent link">&para;</a></h2>
<ul>
<li>Always evaluate with a recent EKG</li>
<li>If pt is at high risk; ie: receiving antibiotics &plusmn; antiemetics
    while inpatient with QT &gt;500, can monitor with EKG q 2-3 days</li>
<li>It important to add QTc for crossover resident in your handoff</li>
</ul>
<h2 id="toxicology-toxicology-qtc-management">Management<a class="headerlink" href="#toxicology-toxicology-qtc-management" title="Permanent link">&para;</a></h2>
<ul>
<li>If stable:<ul>
<li>Stop the offending medication (see ABCDE’s above)</li>
<li>Aggressive electrolyte repletion (K and Mg especially)</li>
<li>Serial EKG monitoring &plusmn; monitor on telemetry</li>
<li>If offending medication is needed, think of alternatives regimens
(zofran scopolamine patch/alcohol wipe sniff; neutropenic ppx
LVQ/fluconazole cefdinir/micafungin, etc.)</li>
</ul>
</li>
<li>If unstable:<ul>
<li>ABCs</li>
<li>Defibrillation if pulseless</li>
<li>Empiric IV magnesium</li>
<li>If drug induced, contact cardiology for overdrive pacing as IV
magnesium does not work</li>
<li>Refer to ACLS protocol</li>
</ul>
</li>
</ul></section><section class="print-page" id="toxicology-toxicology-toxidrome-overview"><h1 id="toxicology-toxicology-toxidrome-overview-toxidrome-overview">Toxidrome Overview<a class="headerlink" href="#toxicology-toxicology-toxidrome-overview-toxidrome-overview" title="Permanent link">&para;</a></h1>
<p>Quinton Taylor</p>
<hr />
<table>
<colgroup>
<col style="width: 21%" />
<col style="width: 23%" />
<col style="width: 31%" />
<col style="width: 23%" />
</colgroup>
<thead>
<tr class="header">
<th>Toxidrome</th>
<th>Agent</th>
<th>Symptoms</th>
<th>Antidote</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Cholinergic</td>
<td><p>Insecticides (e.g. organophosphates)</p>
<p>physostigmine, neostigmine, pyridostigmine, pilocarpine,</p>
<p>nerve agents (e.g. Sarin)</p></td>
<td><p>Muscarinic: Defecation, Urination, Miosis, Bradycardia,
Bronchosecretions, Emesis, Lacrimation, Salivation, Sweating
(DUMBBELLS)</p>
<p>Nicotinic: Mydriasis, Tachycardia, Weakness, Hypertension,
Fasciculations (MTWtHF)</p></td>
<td>Atropine (with pralidoxime if organophosphate poisoning)</td>
</tr>
<tr class="even">
<td>Anticholinergic</td>
<td>Antihistamines, antipsychotics, antidepressants (TCAs),
anti-parkinsons, atropine, scopolamine</td>
<td>Hyperthermia, dry skin, mydriasis, delirium, hallucinations,
tachycardia, urinary retention, seizures (“Hot as a hare, red as a beet,
dry as a bone, blind as a bat, mad as a hatter”)</td>
<td><p>Supportive care, consider</p>
<p>physostigmine with toxicology</p></td>
</tr>
<tr class="odd">
<td>Sympathomimetic</td>
<td>Cocaine, amphetamines, bath salts, synthetic cannabinoids,
sedative/hyponotic withdrawal, pseudoephedrine, caffeine</td>
<td>Hyperthermia, mydrasis, diaphoresis, tachycardia, arrythmias,
hypertension, seizures</td>
<td>None, supportive care; benzodiazepines as needed\*</td>
</tr>
<tr class="even">
<td>Opioid</td>
<td>Morphine, heroin, hydromorphone, fentanyl</td>
<td>Miosis, hypoventilation, somnolence, comatose, bradycardia,
hypotension</td>
<td>Naloxone</td>
</tr>
<tr class="odd">
<td>Sedative-hypnotic</td>
<td>Benzos, barbiturates, alcohol, zolpidem</td>
<td>CNS depression, confusion, stupor, coma</td>
<td>None, supportive care only</td>
</tr>
<tr class="even">
<td>Hallucinogenic</td>
<td>Phencyclidine, LSD, MDMA “Ecstasy”</td>
<td>Hallucinations, depersonalization, agitation, mydriasis (usually),
tachycardia, hypertension, nystagmus</td>
<td>None, supportive care only</td>
</tr>
<tr class="odd">
<td>Serotonin syndrome</td>
<td>SSRIs, SNRIs, MOAIs</td>
<td>Hyperreflexia, myoclonus, diaphoresis, flushing, diarrhea,
hyperthermia, tachycardia, confusion, agitation, coma</td>
<td>Supportive care; benzodiazepines as needed\*; contact toxicology
prior to using cyproheptadine</td>
</tr>
<tr class="even">
<td colspan="4"><em>*for treatment of seizures, tachycardia,
hypertension, agitation, and hyperthermia</em></td>
</tr>
</tbody>
</table>

<p>General Workup</p>
<ul>
<li>
<p>ABCs, evaluate vital signs, mental status, pupil size, skin
    temperature and moisture</p>
</li>
<li>
<p>Pulse ox, continuous cardiac monitoring, EKG, blood glucose</p>
</li>
<li>
<p>UDS, acetaminophen/salicylate levels, ethanol levels, UA, BMP,
    hepatic function panel, blood gas</p>
</li>
</ul>
<p>General Management</p>
<ul>
<li>
<p>Decontamination for topical exposures</p>
</li>
<li>
<p>Antidotes if known ingestions/fits appropriate toxidrome</p>
</li>
<li>
<p>Supportive care</p>
</li>
<li>
<p>Discuss with toxicology, may be ways to enhance elimination of the
    toxin (e.g. diuresis, alkalinization, dialysis, etc.)</p>
</li>
</ul></section><h1 class='nav-section-title-end'>Ended: Toxicology</h1>
                        <h1 class='nav-section-title' id='section-zcbh'>
                            zCBH <a class='headerlink' href='#section-zcbh' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="zcbh-cprs"><h1 id="zcbh-cprs-cprs">CPRS<a class="headerlink" href="#zcbh-cprs-cprs" title="Permanent link">&para;</a></h1>
<p>FYI, the Cerner transition has a goal completion date of 2028.</p>
<p>This is a <em>goal</em> completion date, and this is a project of the US Government.</p>
<p>CPRS skills are likely to be useful for a good while yet.</p>
<h2 id="zcbh-cprs-shortcuts">Shortcuts<a class="headerlink" href="#zcbh-cprs-shortcuts" title="Permanent link">&para;</a></h2>
<p>CPRS has a rather staggering amount of keyboard shortcuts.</p>
<p>The full list is available in this
<a href="http://www.va.gov/vdl/documents/Clinical/Comp_Patient_Recrd_Sys_(CPRS)/cprsguium.pdf">pdf</a>.</p>
<h2 id="zcbh-cprs-task-management">Task management<a class="headerlink" href="#zcbh-cprs-task-management" title="Permanent link">&para;</a></h2>
<p>One of the beautiful and awful things
about CPRS is that it is self-contained.</p>
<p>It does not interface with the outside world -
no push notifications,
no easy way to check things on your phone.</p>
<p>Within its walled garden,
it is also not easy to figure out
what has been done and what needs doing.</p>
<p>There are a few approaches to task management
more-or-less built into CPRS.</p>
<h3 id="zcbh-cprs-tracker-reminder-notes">Tracker Reminder Notes<a class="headerlink" href="#zcbh-cprs-tracker-reminder-notes" title="Permanent link">&para;</a></h3>
<p>One of the available note types
is called "Tracker Reminder."
These are unsignable notes (try to sign one and it will fail),
that remain in your inbox until deleted.
They are a great way to prechart,
and you can use them to make notes to yourself about whatever.</p>
<p>No one else, including your preceptor, can see what's in them
(maybe there's some way for some admin to introspect them,
but I haven't heard of anyone who both knows how to do this and cares to look at your personal scribblings).</p>
<p>I used to also use them as a general to-do list,
and I know some residents live by them throughout training.
I don't use them as a catch-all anymore (instead preferring Ticklers, outlined below),
and now essentially only use them for pre-charting.
In your inbox,
all you can see is the patient for whom you have a Tracker Reminder,
and the note title ("UNSIGNED Tracker Reminder") -
there is no good way to differentiate between a precharted note,
a to-do item,
or anything else you may have written.</p>
<p>CPRS is very slow,
so clicking into each Tracker Reminder
to see what's in there is much too expensive in terms of time.</p>
<h3 id="zcbh-cprs-ticklers">Ticklers<a class="headerlink" href="#zcbh-cprs-ticklers" title="Permanent link">&para;</a></h3>
<p>Yes, self-assigned alerts in CPRS are called "Ticklers."
Because "Alerts" is not nearly descriptive enough.</p>
<p>To set up Ticklers for yourself, get into a new note or make an addendum.</p>
<p>(shout out to Paige, RN extraordinaire, for showing me her approach -
it's A-OK to make an addendum with the content of only "setting alert")</p>
<p>Click "Templates" on the bottom left.
The first "Shared Template" should have the word "Tickler."
Double-click it,
and it will open up a simple dialogue
that asks you when you want to be alerted,
and any text you would like within the alert.</p>
<p>Then, when the time comes for that alert,
it will show up in your universal CPRS inbox.
When you click into it,
it will show you the text you entered,
and give you three options -
copy the text of the alert to the clipboard,
renew the alert,
or close it out.</p>
<p>One advantage to this approach over
a huge list of Tracker Reminder notes
is that your inbox does not become nearly as cluttered,
and you can tell more easily what is time-sensitive.
I also prefer it over some third-party solution,
such as a OneNote page, Word doc, or Excel sheet
(all HIPAA-compliant if using your institutional OneDrive account),
because all of my VA work and data lives in a single system,
so I don't have something else to (forget to) check.</p>
<h3 id="zcbh-cprs-leave-one-behind-alert-method">Leave-one-behind alert method<a class="headerlink" href="#zcbh-cprs-leave-one-behind-alert-method" title="Permanent link">&para;</a></h3>
<p>The most common scenario:
see a patient, order some studies.
Study results roll in,
you need to discuss next steps with the patient.
Something is still processing,
and/or you don't have time right now to have a phone call.
Instead of leaving 6 or 7 alerts for the same person cluttering your inbox,
remove all but one
(highlight the alerts you want to get rid of and click "Remove").
That lone remaining alert functions as a reminder.
When the stars align, click into that alert,
go through all the recent results,
and communicate however makes sense for the situation.</p>
<h2 id="zcbh-cprs-remote-access-qol">Remote Access QoL<a class="headerlink" href="#zcbh-cprs-remote-access-qol" title="Permanent link">&para;</a></h2>
<h3 id="zcbh-cprs-text-expansion">Text expansion<a class="headerlink" href="#zcbh-cprs-text-expansion" title="Permanent link">&para;</a></h3>
<p>One of the best categories of quality-of-life improvements
you can make for using CPRS remotely
is text expansion/macros.</p>
<p>On Windows, PhraseExpress is great.
On Mac, aText is also great.</p>
<p>Set up an expansion to [enter your passcode (123456) and hit "Enter"].</p>
<p>I have it set to <code>,c</code>. (I have <code>,e</code> mapped to my Epic password).</p>
<p>This saves so much time and hassle.
For example, to sign a note,
I hit <code>Ctrl+Shift+g</code> to open the "Sign Note" dialog (this is a built-in CPRS shortcut),
then I tap <code>,c</code>, and the note is signed.
Takes far less than a second,
fingers stay close to home row.</p>
<p>The VA made their own tool to do this,
called "CPRSBooster" (it's somewhere under the Star folder on every desktop).
It works.</p>
<p><img alt="totally works" src="https://media.giphy.com/media/l2JI8Ao9q7hkqWuD6/giphy.gif" /></p>
<p>The main utility of CPRSBooster
is to give you ideas for other text expansions you could set up,
such as your nurse's name for tagging on notes.</p>
<h2 id="zcbh-cprs-vista">VistA<a class="headerlink" href="#zcbh-cprs-vista" title="Permanent link">&para;</a></h2>
<p>VistA is the (rather insane) software and database system that undergirds CPRS.
I get the sense that the deepest magicks rest in VistA,
waiting for the intrepid explorer,
seeking a grail filled with
automated data extraction and sane clinical workflows.</p>
<p>The documentation is scattered.
<a href="https://www.va.gov/vdl/">This</a> is one of the official sources.
I've only taken a cursory look, but it seems less technical and mostly snarky.</p>
<p>There's also a <a href="http://www.vistapedia.com/index.php/Main_Page#VistApedia">wiki</a> devoted to VistA,
though it is not restricted to the official USGovt version
(since the software is federally mandated to be open source,
it has been forked and developed in several countries worldwide).</p>
<p>If you have been inducted into the cult of VistA,
and need an acolyte,
let me know.
I make pretty kickass chocolate chip cookies.</p></section><section class="print-page" id="zcbh-va-notes"><h1 id="zcbh-va-notes-va-notes">VA notes<a class="headerlink" href="#zcbh-va-notes-va-notes" title="Permanent link">&para;</a></h1>
<h2 id="zcbh-va-notes-tricks">tricks<a class="headerlink" href="#zcbh-va-notes-tricks" title="Permanent link">&para;</a></h2>
<h3 id="zcbh-va-notes-cleaning-up-old-orders">Cleaning up old orders<a class="headerlink" href="#zcbh-va-notes-cleaning-up-old-orders" title="Permanent link">&para;</a></h3>
<p><em>Shout out to the BMT nurses for showing me this trick</em></p>
<p>Some folks have literally years
of old nursing orders and administrative mumbo jumbo
in their orders tab that is not only useless,
it is dangerous, because it makes it harder for everyone
(nurses included) to see current, relevant orders.</p>
<p>Cleaning out old orders is easy.
Highlight all the orders you want
(CTRL-click is better than SHIFT-click,
bc you can drag a CTRL-click and skip some,
then drag some more),
right click,
select "Discontinue,"
then click "Duplicate Order."</p>
<p>After you sign these,
they should disappear from the chart immediately.</p>
<p>Oddities:</p>
<p>For some reason,
no orders from 2008 or earlier are able to be deleted.
If you figure out how to fix this, let me know.</p>
<p>Most old "pending" lab orders can be deleted,
but "active" ones (even if super old)
stick around like peanut butter stains.</p>
<h2 id="zcbh-va-notes-orders-of-much-consternation">orders of much consternation<a class="headerlink" href="#zcbh-va-notes-orders-of-much-consternation" title="Permanent link">&para;</a></h2>
<ul>
<li>Coombs/DAT: (not in Lab Tests...) Blood Bank Orders (VBECS) -&gt; Blood Bank Orders -&gt; Diagnostic Tests -&gt; Direct Antiglobulin Test</li>
<li>topical TXA: Meds: Inpatient -&gt;  tranexamic acid inj -&gt; the option that says *VL*, also specify topical in the comments (thanks inpt pharm!)</li>
<li>procedure service: not available at the VA</li>
</ul></section><h1 class='nav-section-title-end'>Ended: zCBH</h1>
                        <h1 class='nav-section-title' id='section-appendices'>
                            Appendices <a class='headerlink' href='#section-appendices' title='Permanent link'>↵</a>
                        </h1>
                        <section class="print-page" id="appendices-appendices-how-discharges-va"><h1 id="appendices-appendices-how-discharges-va-how-to-on-discharges-at-va">"How to" on Discharges at VA<a class="headerlink" href="#appendices-appendices-how-discharges-va-how-to-on-discharges-at-va" title="Permanent link">&para;</a></h1>
<p>Complete the following steps <em>in this order</em> to ensure info will be
accurately reflected on the DIPN.</p>
<ul>
<li>Medication reconciliation<ul>
<li>The list of outpatient medications at the end of your
    reconciliation is the final medication discharge list.</li>
<li>In the medication tab, transfer new inpatient medications to the
    outpatient medication list by right-clicking and select
    ‘Transfer’</li>
<li>Select “Pick up at window,” as this will ensure the patient will
    have the medication prior to leaving the hospital</li>
<li>Review the existing outpatient medications to determine if they
    need to be continued and if the pt has an adequate supply at
    home - refill meds if necessary</li>
<li>Discontinue any outpatient medications that you do not want the
    pt to continue taking. Right-click and select ‘Discontinue’</li>
</ul>
</li>
</ul>
<p>-</p>
<p>​​​​​ <strong>Return to clinic (Primary care)</strong></p>
<ul>
<li>
<ul>
<li>Look at the pt banner to determine where he/she receives primary
        care (top of screen)</li>
<li>PCC codes should start with a location (ex. NA, MU, CA etc)
    followed by the MD and number which designates the proper
    primary care physician</li>
<li>Place an order for ‘Return to clinic’ with the appropriate
    physician and be sure to select the date of follow-up</li>
<li>PCP, consultants, and office coordinators (RNs) can be cc’d to
    DC summary by resident</li>
</ul>
</li>
</ul>
<p>-</p>
<p><strong>Complete DIPN</strong></p>
<ul>
<li>The DIPN contains all of the discharge instructions</li>
<li>Start a new note and select ‘DIPN’ template. This will open a
    pre-templated note - follow the prompts and select finish. All
    sections need to be addressed to proceed.</li>
<li>Discharge related orders will generate after you finish the DIPN
    prompts, which includes vaccinations, removing IV, removing Foley
    catheter, etc.</li>
<li>The DIPN is valid for 24 hrs; thus the DIPN may be pre-signed one
    day prior. If DIPN is pre-signed, final changes to pt instructions
    and medications need to be addended.</li>
</ul>
<p>-</p>
<p><strong>Sign the DFF (discharge from facility) order</strong></p>
<ul>
<li>The DFF order is found under the “Discharge Orders” tab in CPRS
    orders</li>
<li>Once all steps are completed, DFF can be signed and pt will be
    discharged from facility</li>
</ul></section><section class="print-page" id="appendices-appendices-how-discharges-vumc"><h1 id="appendices-appendices-how-discharges-vumc-how-to-on-discharges-at-vumc">"How to" on Discharges at VUMC<a class="headerlink" href="#appendices-appendices-how-discharges-vumc-how-to-on-discharges-at-vumc" title="Permanent link">&para;</a></h1>
<ul>
<li>Verify the correct pharmacy with the pt and if refills of existing
    medications are needed</li>
<li>Select ‘Transfer-Discharge’ on the navigator panel on eStar</li>
<li>Select ‘Discharge’ tab on the top of the page</li>
<li>Select ‘Rx Routing’ on the left panel. Choose one of the three
    options. This choice will set the default prescribing choice for new
    medications at discharge or refilled medications. This can be
    changed manually within each Rx order.<ul>
<li>Default = will e-prescribe to pt’s pharmacy</li>
<li>Print = will print all Rx’s and not e-prescribe (printed to
    nursing station on pt’s floor)</li>
<li>Do not print and do not e-prescribe (This is used for pt going
    to SNF or IPR)</li>
</ul>
</li>
<li>Select ‘Discharge Orders’ on the left panel. This will open a
    reconciliation navigator.</li>
<li>Reconcile the home medications with the current inpatient
    medications. The red tab on the right side of the screen will become
    green when all medications are addressed.<ul>
<li>For new medications or refills, make sure the ‘Class’ in the
    prescription is set to ‘Normal’ for electronic prescriptions.
    Otherwise, to add the medication to the list without a
    prescription, choose ‘No Print’.</li>
<li>The medications will e-prescribe to the pharmacy selected at the
    bottom of the order panel on the right side of your screen.</li>
<li>To send to multiple pharmacies, select the primary pharmacy at
    the bottom of the order panel on the right side of your screen,
    then choose ‘Send to Multiple Pharmacies’.</li>
</ul>
</li>
<li>Next, select ‘Order Sets’ at the top of the Discharge Orders panel</li>
<li>In the order box on the right, type “Adult General Discharge”<ul>
<li>Right-click on the option and select “Add to Favorites”. Now,
    this option will be available on the Order Set page for future
    patients.</li>
<li>Open Adult General Discharge order set<ul>
<li>Select the appropriate choices pertinent to current pt</li>
<li>On the right side of the screen, you can add Ad Hoc orders
    such as:</li>
</ul>
</li>
<li>Hospital Follow-up with "X" service</li>
<li>Ambulatory Referrals</li>
<li>Post-discharge labs</li>
<li>*Important for ID labs in addition to INR checks, place fax
    number for which provider that will be following up results in
    the comments section. If labs will be done outside of Vanderbilt
    system, must select "External Non-VMG"</li>
<li>Medications not listed on reconciliation list</li>
</ul>
</li>
<li>When all sections are completed, click ‘Sign – Print and/or
    E-prescribe Now’</li>
<li>Select ‘Follow-up Providers’ on the left panel.<ul>
<li>Select the providers that you want to receive the discharge
    summary.</li>
</ul>
</li>
<li>[Optional but strongly recommended] Providing personal
    instructions to the patient<ul>
<li>Select ‘Instructions’ on the left-hand panel</li>
<li>Free-text your personal comments and instructions to the
    patient, such as:<ul>
<li>A simple statement for why the pt was admitted</li>
<li>Changes made to pt’s medications that you feel are important
    to highlight</li>
<li>Home instructions (daily weights, diet changes, wound care,
    etc)</li>
</ul>
</li>
<li>This section appears FIRST in the pt’s printed AVS</li>
</ul>
</li>
</ul></section><section class="print-page" id="appendices-appendices-interns-guide-rotations-va"><h1 id="appendices-appendices-interns-guide-rotations-va-interns-guide-to-rotations-at-va">Interns' Guide to Rotations at VA<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-va-interns-guide-to-rotations-at-va" title="Permanent link">&para;</a></h1>
<p>VA: Veterans Affairs Rotations</p>
<p>Always make sure that your VA login works a few days before you are
scheduled to start!</p>
<p><strong>Conference Schedule</strong></p>
<p>VA Morning Report: Mon-Tues-Wed-Fri (just like VU except Tuesday also
has CXR rounds)</p>
<p>Noon Conference – Mon, Wed &amp; Friday on 7T; 12:00 – 1:00: Lunch with
various lectures.</p>
<p>Fox and Hedgehog – Light Hall 208; Tuesdays 12:00 – 1:00; Chief Resident
Conference</p>
<p><strong>VA General Wards (1A – 6B)</strong></p>
<ul>
<li><strong>Team</strong> : 1 Res, 2 Interns with patient cap of 8 each (16 total)</li>
<li>Pick up list 6:30 AM; Admit every other day; Can sign-out on
    non-admit days at 2 PM</li>
<li><strong>Rounds</strong> alternates at 7 AM on admitting days, 8 AM on
    non-admitting days, meet at workrooms<ul>
<li>Workroom:<ul>
<li>Teams 1-3 on 2N</li>
<li>Team 4 at 2<sup>nd</sup> floor main elevators</li>
<li>Team 5 on 3N</li>
<li>Team 6 2<sup>nd</sup> floor off ICU hallway</li>
</ul>
</li>
</ul>
</li>
<li><strong>Conferences</strong> : VA Morning Report; Noon conference, Fox; don’t
    forget CXR rounds on Tuesdays!</li>
<li><strong>Review</strong> : Many admissions for falls (review Geriatrics sections),
    chest pain, ACS/NSTEMI, syncope (review cardiology), COPD
    exacerbation, Pneumonia (ID), Skin and Soft Tissue Infections (ID),
    diabetic foot infections.</li>
<li><strong>Tips</strong> : Admission days can be very busy and anything you can get
    done on the non-admitting days will make your life easier
    (especially DIPNs for people leaving the next day); start your own
    patient list in a word document to use as your pre-rounding sheet as
    well as sign-out; Roll your pagers via Vanderbilt operator (same as
    at VU); ensure all orders on patients still in the ED are “Delayed”
    or they will disappear once on the floor (ask your resident); All
    consults must be accompanied by page to the covering fellow (see
    synergy for medicine subspecialties, TVHS website for surgery/other)</li>
</ul>
<p><strong>VA MICU</strong></p>
<ul>
<li>Team: 3 Res, 3 Interns, no specific patient cap (typically 10-12)</li>
<li>Day Intern: 7 AM - 9 PM; Night Intern 8 PM - 10 AM; MICU is on 2<sup>nd</sup>
    floor between 2N and 2G<ul>
<li>Night intern presents the old patients on morning rounds</li>
</ul>
</li>
<li>Excused from Conferences</li>
<li><strong>Review</strong> : ARDS, Vent Settings, Modes of Oxygen Delivery, Sepsis,
    Management of Shock, MICU/CCU Drips, Basics of blood gases (Pulm)
    Stress Dose Steroids (Endo), Cirrhosis (Hep)</li>
<li><strong>Tips</strong> : Night intern presents all of the old patients in the
    morning and signs the notes. The day intern owns the A&amp;P of the
    notes by keeping them updated. Never hesitate to relay information
    to your resident overnight if you are concerned</li>
</ul>
<p><strong>VA Nights</strong></p>
<ul>
<li><strong>Team</strong> : 1 Res, 2 Interns, total of 10 admissions overnight</li>
<li>Start at 7 PM, Admit until 5:30 AM, present new patients to teams at
    7 AM, leave by 8 AM</li>
<li><strong>Start on Sunday night</strong> ; Off day is Saturday night for interns</li>
<li><strong>Tips</strong> : Admissions typically bolus at the start of shift and stop
    later in the night, so worry about seeing patients, formulating
    plans with resident and putting in orders as the notes can be
    finished once it slows downs; the cafeteria at VU closes at 2 AM;
    communicate everything you do with your resident who is supervising
    a second intern as well; ensure all orders on patients still in the
    ED are “Delayed” or they will disappear once on the floor (ask your
    resident)</li>
</ul></section><section class="print-page" id="appendices-appendices-interns-guide-rotations-vumc"><h1 id="appendices-appendices-interns-guide-rotations-vumc-interns-guide-to-rotations">Interns' Guide to Rotations<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-interns-guide-to-rotations" title="Permanent link">&para;</a></h1>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-structure-overview">Structure Overview<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-structure-overview" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Teaching Service</th>
<th>Structure</th>
<th>Patient Cap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morgan 1-6</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>Geriatrics</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>Rogers (Hep, ID, Pulm, Renal)</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>Heart Failure (CHF 1 &amp; 2 ) (one team)</td>
<td>1 resident, 2 interns</td>
<td>8 per intern (16 total)</td>
</tr>
<tr>
<td>Cardiology (Harrison 1 &amp; 2) (two teams)</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>Hematology (Brittingham A &amp; B) (one team)</td>
<td>1 resident, 2 interns</td>
<td>8 per intern (16 total)</td>
</tr>
<tr>
<td>Oncology (Onc A &amp; B)  (two teams)</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>VU MICU 1 &amp; 2   (two teams)</td>
<td>3 residents, 3 interns</td>
<td>no cap (typically 10-12)</td>
</tr>
<tr>
<td>VU Night: Admitting Morgan/Rogers</td>
<td>1 resident, 2 interns</td>
<td>10</td>
</tr>
<tr>
<td>VU Night: Admitting Harrison/Heme/Onc</td>
<td>1 resident, 1 intern</td>
<td>10</td>
</tr>
<tr>
<td>VU Night: Crosscover</td>
<td>1 resident, 1 intern</td>
<td>N/A</td>
</tr>
<tr>
<td>VA Wards 1-5</td>
<td>1 resident, 2 interns</td>
<td>8 per intern (16 total)</td>
</tr>
<tr>
<td>VA Wards 6</td>
<td>2 residents</td>
<td>8 per resident (16 total)</td>
</tr>
<tr>
<td>VA MICU</td>
<td>3 residents, 3 interns</td>
<td>no cap (typically 10-12)</td>
</tr>
<tr>
<td>VA Night: Admitting</td>
<td>1 resident, 2 interns</td>
<td>10</td>
</tr>
<tr>
<td>VA Night: Crosscover</td>
<td>1 resident</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-service-details">Service Details<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-service-details" title="Permanent link">&para;</a></h2>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-morgan-1-6">Morgan (1 –  6)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-morgan-1-6" title="Permanent link">&para;</a></h2>
<ul>
<li>Pick up list at 6 - 6:30 AM, admit until 5:30 PM, sign-out 6 PM</li>
<li>Admitting: Teams 1-3-5 &amp; 2-4-6 alternate admitting days (just
        like VA)</li>
<li>Non-admitting teams can sign-out at 2PM on weekdays and 12PM on
        weekends</li>
<li>Rounds at 8 AM, teams usually meet at 8N Nursing stations; coordinate with
    attendings</li>
<li>Workroom: team-specific rooms on hall behind 7N Nursing station
        (Code 24300)</li>
<li>Review: read about each pt as you admit them, you will see a variety of
    different diseases</li>
<li>Tips: Call consults as soon as possible; keep a column on your pt list
    for Labs and New Notes easily track updates without entering chart
    to check; Your team pharmacist is a valuable resource, get her/his
    number the first day; Close communication with your team SW and CM
    help with discharges (upper level’s responsibility); Enter
    meds-2-beds ASAP</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-geriatrics">Geriatrics<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-geriatrics" title="Permanent link">&para;</a></h2>
<ul>
<li>Rounds at 8 AM, team meets in the Round Wing workroom 7434<ul>
<li>Workroom: 7434</li>
</ul>
</li>
<li>Review: Geriatrics Section, Altered mental status (Neuro), genitourinary
    infection (ID)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-rogers-subspecialty-services">Rogers (Subspecialty Services)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-subspecialty-services" title="Permanent link">&para;</a></h2>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-all-rogers-services">All Rogers services<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-all-rogers-services" title="Permanent link">&para;</a></h3>
<ul>
<li>Team: 1 Res, 1 Intern with patient cap of 10</li>
<li>Pick up list at 6 - 6:30 AM, admit daily until 5:30 PM, sign-out 6
    PM</li>
<li>Each HPI usually requires special info about the patient’s
    subspecialty diagnosis (See Tips)</li>
</ul>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-rogers-hepatology">Rogers Hepatology<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-hepatology" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets on 6MCE</li>
<li>Work room: 6MCE, 6755 – north end (No Code)</li>
<li>Review: Hepatology Section, Paracentesis (Procedures)</li>
<li>Tips: Present pts as “Cirrhosis secondary to ____ decompensated by
    ___ (EVs, Ascites, SBP, HE, HRS)”; use the MELD-Na dot phrase;
    almost never should give cirrhosis patient crystalloid, consider
    albumin instead (25%, not 5%), consult procedure service during
    rounds to get your pts on the list for therapeutic paracenteses</li>
</ul>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-rogers-id">Rogers ID<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-id" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets in Resident Library (8N)</li>
<li>Work room: 6 Round Wing, 2 <sup>nd</sup> door on left after
        coming out of elevator (No Code)</li>
<li>Review
    : Infectious Diseases Section, specifically HIV and ART General
    Concepts</li>
<li>Tips
    : Each HPI for pt with HIV should include most recent CCC provider,
    CD4/Viral Load, prior AIDS-defining illnesses and compliance to ART;
    Use ‘Notifications’ tab on main screen in Epic to keep track of lab
    orders as patients can have long stays with send-out labs that can
    take up to two weeks to result (can also hit ‘Notify Me’ in dropdown
    box of Order); consider doxy in lieu of Azithro for CAP in HIV/AIDS
    (MAC Coverage)</li>
</ul>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-rogers-pulmonology">Rogers Pulmonology<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-pulmonology" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets at 8N nursing station</li>
<li>Workroom: 8South 8216 (Code 2430)</li>
<li>Review: Pulmonary Section, specifically Home Oxygen Therapies</li>
<li>Tips: Each HPI should include most recent PFTs (FEV1%most important,
    include other relevant data or recent changes); For CF, Use the CF
    admission order set, know typical organisms in patient’s sputum (ex:
    MDR Pseudomonas, Burkholderia, MRSA) and consult CF team; for PH
    know the therapies they are on (typically Flolan or Veletri)</li>
</ul>
<h3 id="appendices-appendices-interns-guide-rotations-vumc-rogers-renal">Rogers Renal<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-rogers-renal" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically start 7-7:30 AM, team meets at resident/fellow work room
    on 6MCE</li>
<li>Workroom: 6MCE 6772, behind nursing station with renal fellows
        (No Code)</li>
<li>Review: Nephrology section, specifically Renal Transplant</li>
<li>Tips: Each HPI should have renal transplant history with year, type of
    tpx, PRA, Ag MM, CMV D/R; 6MCE charge nurse can get pts transferred
    there; alert the night resident to patients with renal biopsy and
    low threshold to contact renal fellow; transplant pts should have
    daily tacro level one hour before AM tacro dose (5:00 am),
    regardless of pt’s home schedule and be cautious with first dose
    timing of IS to keep things on schedule</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-heart-failure-chf-1-2">Heart Failure (CHF 1 &amp; 2)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-heart-failure-chf-1-2" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 2 Interns on one team with pt cap of 8 per intern (16
    total)</li>
<li>Pick up list at 6 AM, admit until 5PM (alternate admissions,
    resident to help assign)</li>
<li>Rounds typically at 7 AM, team meets at 7MCE nursing station</li>
<li>Workroom: 7N 7024 right before bridge to 7MCE. (Code 145)</li>
<li>Review: Advanced heart failure; RHC and swan numbers (useful in assessing
    volume status in hard to examine pts, and CCU transfers), post-cath
    care, valvular disease</li>
<li>Tips: Know each patient’s dry weight (usually found in outpatient cards
    notes or at last discharge), Know current outpatient diuretic
    regimen and most recent TTE (weight at the time helps too); order
    strict I&Os; Daily <strong><em><u>Standing</u></em></strong> Weights, and fluid
    restriction of 2L/day; Always assess JVP before rounds</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-harrison-1-2">Harrison (1 &amp; 2)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-harrison-1-2" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 1 Intern on each team with patient cap of 10</li>
<li>Pick up list at 6 AM, admit until 5 PM (Long) or 2 PM (Short)
    alternating with other team</li>
<li>Weekends: Only long team admits new patients</li>
<li>Rounds typically at 7 AM, team meets at 7MCE Nursing station</li>
<li>Workroom: 5MCE 5181 (Code 0701); hard to hear stats so keep door
        propped</li>
<li>Review: post-cath care, ACS, chest pain, valvular disease, arrhytmia’s,
    PE’s.</li>
<li>Tips: To order heart cath, must be in the cardiology context in Epic
    “VUMC Cardiology VIR” (order listed as “Case Request Cath Lab” and
    use provider “Surgeon, Generic”)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-hematology-brittingham">Hematology (Brittingham)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-hematology-brittingham" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 2 Interns with patient cap of 8 per intern (16 total)</li>
<li>Pick up list at 6 AM, admit until 5 PM (alternate admissions with
    second intern)</li>
<li>Rounds at 8 AM, team meets on 10T</li>
<li>Workroom: Brittingham</li>
<li>Review: Neutropenic Fever, TLS, DIC, Acute Leukemia, Lymphoma, Plasma Cell
    Dyscrasia</li>
<li>Tips: Each HPI should include malignancy history (dx, prior tx, current
    tx); know the febrile neutropenia algorithm; if possible, enter
    orders/write notes while the other intern and attending are at
    bedside; low threshold to work any complaints up as bleeds and
    infections are common and can be rapidly lethal.</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-oncology-onc-a-b">Oncology (Onc A &amp; B)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-oncology-onc-a-b" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 1 Intern on each team with patient cap of 10</li>
<li>Pick up list at 6 AM, admit daily 6 AM until 5 PM, sign-out 6 PM</li>
<li>Rounds at 8 AM, team meets on 11N at nursing station</li>
<li>Workroom: No assigned room, typically library, 11N or 10T, or 7MCE Conference room</li>
<li>Review: Opiates (Pain &amp; Palliative Care), Oncologic emergencies,
    Paraneoplastic Syndromes, Chemotherapy Toxicity/Side Effects</li>
<li>Tips: Each HPI should have Onc history (Dot Phrase “.onchist”) including
    dx, prior treatments, most recent imaging; 10T and 11N charge nurse
    can get pts transferred there, you can write delayed admission
    orders for pts seen in infusion clinic (ask your resident)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-vu-micu">VU MICU<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-vu-micu" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 3 Res, 3 Interns, no specific patient cap (typically 10-12)</li>
<li>Day Intern: 8 AM - 10 PM; Night Intern 9 PM - 11 AM; MICU is on 8T</li>
<li>Review: ARDS, Vent Settings, Modes of Oxygen Delivery, Sepsis, Management
    &amp; Types of Shock, MICU/CCU Drips, ABGs (Pulm) Stress Dose Steroids
    (Endo), Cirrhosis, ACLS</li>
<li>Tips: Night intern presents all the old patients in the morning and
    signs the notes. The day intern owns the A&amp;P of the notes by keeping
    them updated. Trust the nurses and never hesitate to relay info to
    your resident overnight if you’re concerned (wake him/her up!)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-vu-nights">VU Nights<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-vu-nights" title="Permanent link">&para;</a></h2>
<ul>
<li>Start on Sunday night for interns, Wednesday night for residents; off Saturday
    night</li>
<li>Harrison/Heme/Onc: Start at 6 PM, admit until 5 AM, sign-out by 6 AM</li>
<li>Morgan/Rogers: Start at 6:30 PM, admit until 5:30 AM, sign-out by 6:30 AM</li>
<li>Cross cover: Start at 6 PM (Be on time!) sign-out 6:30 AM</li>
<li>Tips: ensure you communicate all orders and plans with the resident;
    Writing “To do” boxes on the first pages of each printed H&amp;P might
    help you communicate the important aspects of each plan to the day
    intern when they arrive the next morning; cafeteria closes at 2 AM.
    For cross cover, make sure to document any significant events in
    Epic. Useful to follow-up on pts admitted previous nights to reflect
    on your diagnosis and workups</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-va-general-wards-1a-6b">VA General Wards (1A – 6B)<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-va-general-wards-1a-6b" title="Permanent link">&para;</a></h2>
<ul>
<li>Always make sure that your VA login works a few days before you are
    scheduled to start!</li>
<li>Team: 1 Res, 2 Interns with patient cap of 8 each (16 total)</li>
<li>Pick up list by 6:30 AM; Admit every other day; Can sign-out on
    non-admit days at 2 PM</li>
<li>Rounds alternate at 7 AM on admitting days, 8 AM on non-admitting days,
    meet at workrooms; night admitting team presents to attendings at 7
    AM (depending on team)</li>
<li>Workrooms:</li>
<li>Team 1 – pulm &amp; ID fellow workroom outside MICU on 2G</li>
<li>Teams 3 on 2N</li>
<li>Team 4 at 2<sup>nd</sup> floor main elevators</li>
<li>Team 5 on 3N</li>
<li>Team 6 – 2N hallway (Old team 1 workroom)</li>
<li>Review:  Geriatrics, chest pain, CHF, ACS/NSTEMI, syncope , COPD
    exacerbation, Pneumonia, Skin and Soft Tissue Infections, diabetic
    foot infections, AMS</li>
<li>Tips: Admission days can be very busy and anything you can get done on
    the non-admitting days will make your life easier (especially DIPNs
    for people leaving the next day); start your own patient list in a
    word document to use as your pre-rounding sheet as well as sign-out;
    Roll your pagers via Vanderbilt operator (same as at VU); ensure all
    orders on patients still in the ED are “Delayed” or they will
    disappear once on the floor (ask your resident); All consults must
    be accompanied by page to the covering fellow (see synergy for
    medicine subspecialties, TVHS website for surgery/other)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-va-micu">VA MICU<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-va-micu" title="Permanent link">&para;</a></h2>
<ul>
<li>Combined CCU and MICU; 7AM CCU rounds followed by 8AM MICU rounds</li>
<li>Day Intern: 7 AM - 9 PM; Night Intern 8 PM - 10 AM; MICU between 2N
    and 2G (2 <sup>nd</sup> floor)</li>
<li>Review
    : ARDS, Vent Settings, Modes of Oxygen Delivery, Sepsis, Management
    of Shock, MICU/CCU Drips, ABGs (Pulm) Stress Dose Steroids (Endo),
    Cirrhosis (Hep), ACLS</li>
<li>Tips
    : Night intern presents all of the old patients in the morning and
    signs the notes. The day intern owns the A&amp;P of the notes by keeping
    them updated. Never hesitate to relay information to your resident
    overnight if you are concerned (wake him/her up!)</li>
</ul>
<h2 id="appendices-appendices-interns-guide-rotations-vumc-va-nights">VA Nights<a class="headerlink" href="#appendices-appendices-interns-guide-rotations-vumc-va-nights" title="Permanent link">&para;</a></h2>
<ul>
<li>Start at 7 PM, Admit until 5:30 AM, present new patients to teams at
    7 AM, leave by 8 AM</li>
<li>Start Sunday night for interns, Wednesday night for residents; Off day is Saturday night for interns/cross-cover resident
    (covered by clinic resident), Friday night for admitting resident
    (covered by BMT resident)</li>
<li>Tips: Admissions typically bolus at the start of shift and stop later in
    the night, so worry about seeing pts, formulating plans with
    resident and putting in orders as notes can be finished once it
    slows down; cafeteria at VU closes at 2 AM; communicate everything
    you do with your resident who is supervising a second intern as
    well; ensure all orders on pts still in the ED are “Delayed” or they
    will disappear once on the floor (ask your resident)</li>
</ul></section><section class="print-page" id="appendices-appendices-staging-wounds"><h1 id="appendices-appendices-staging-wounds-staging-wounds">Staging Wounds<a class="headerlink" href="#appendices-appendices-staging-wounds-staging-wounds" title="Permanent link">&para;</a></h1>
<p>Wound Staging adapted from Dr. Duggan's Geriatrics Guide</p>
<p>Wound Care by Amanda Bailey, NP</p>
<ul>
<li>Document ALL wounds that are present on admission. This affects
    reimbursement.</li>
<li>Use the Haiku app on your cellphone to document images of wounds in
    pt chart</li>
</ul>
<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feature</td>
<td>Deep Tissue Injury</td>
<td>Stage 1</td>
<td>Stage 2</td>
<td>Stage 3</td>
<td>Stage 4</td>
</tr>
<tr>
<td>Skin Consistency</td>
<td>Boggy</td>
<td>Boggy</td>
<td>Variable</td>
<td>NaN</td>
<td>NaN</td>
</tr>
<tr>
<td>Skin color/nature of lesion</td>
<td>Non-blanching purple or maroon, may appear as blood-filled blister</td>
<td>Non-blanching erythema</td>
<td>Abrasion, blister, or shallow crater</td>
<td>Variable</td>
<td>Variable. If eschar, must be removed in order to stage, or is unstageable</td>
</tr>
<tr>
<td>Depth</td>
<td>Epidermis intact</td>
<td>Epidermis intact</td>
<td>Through surface of epidermis and outer dermis</td>
<td>SQ tissue to, but not through, fascia</td>
<td>Full-thickness loss w/ destruction, necrosis, or damage to muscle, bone, supporting structures</td>
</tr>
</tbody>
</table>
<p><img src="/sites/default/files/inline-images/Pressure%20Ulcer%20Stages.jpg" data-entity-type="file" data-entity-uuid="0f963d7f-b572-42a2-946a-66fd4dc6e89b" alt="Pressure Ulcer Stages" /></p>
<p>Recall other types of ulcers to consider in your differential:</p>
<ul>
<li>Arterial
    : shallow, well-defined borders, pale/necrotic wound bed, minimal
    exudate due to poor blood flow, cramping pain or a constant deep
    ache</li>
<li>Diabetic
    : Plantar surface of foot, callused wound margins; usually painless
    due to neuropathy</li>
<li>Venous
    : medial malleolus, irregular edges, ruddy red with yellow slough
    and copious exudate</li>
</ul>
<p>Non Acute Wound</p>
<ul>
<li>Order “Inpatient Consult to Adult <strong>Simple</strong> Wound Ostomy VUH” for:<ul>
<li>Pressure Injuries – stage 1, stage 2, deep tissue injury</li>
<li>Skin tears – partial thickness</li>
<li>Moisture Associated Skin Damage – diarrhea, tube drainage, skin
    folds</li>
<li>Partial thickness wounds – other</li>
<li>Peri-tube skin problems – peg, trach skin issues</li>
<li>Fistulas</li>
</ul>
</li>
<li>Order “Inpatient Consult to <strong>Complex</strong> Wound” for:<ul>
<li>Pressure injuries – stage 3, 4, unstageable</li>
<li>Wounds with pathology<ul>
<li>Diabetic – areas of pressure<ul>
<li>For routine diabetic foot wounds even if they need
    debridement but are not frankly infected, consult
    COMPLEX WOUND</li>
<li>Caveat
    : If frank pus or erythema is spreading up leg, consult
    “Ortho foot-ankle”</li>
<li>Caveat
    : If pt is being followed by Drs. Hicks, Trenner or
    Deeter, consult “Ortho Foot-Ankle.” Use the Epic search
    tool to determine this</li>
</ul>
</li>
</ul>
</li>
<li>Arterial – distal on digit</li>
<li>Venous – gravity dependent areas</li>
<li>Calciphylaxis</li>
<li>Pyoderma Gangrenosum</li>
<li>Fungating Lesion</li>
<li>Vasculitis</li>
<li>Abscess ( <strong><em>already</em></strong> drained, just needs packing
    instructions)</li>
<li>Surgical wounds (for pts <strong><em>without</em></strong> VUMC surgeon)</li>
<li>If pt has VUMC surgeon, consult appropriate surgical team (see
    below)</li>
<li>Hematoma with no active bleeding but with overlying skin
    necrosis/wound</li>
<li>Wound with underlying osteomyelitis</li>
<li>IV infiltrate –contact team pharmacist or inpatient pharmacy
    (615-875-6337) for protocol</li>
</ul>
</li>
</ul>
<p>Acute Wound</p>
<ul>
<li>Abscess, Hematoma, Osteomyelitis with overlying wound<ul>
<li>Whom to consult for drainage/debridement:<ul>
<li>Face – Face</li>
<li>Chest/Sternum – CT surgery</li>
<li>Breast – General Surgery</li>
<li>Spine – Spine</li>
<li>Arm (hand to elbow) – Hand</li>
<li>Lower leg (foot to knee) – Ortho</li>
<li>Labial – OB/GYN</li>
<li>Scrotal – Urology</li>
<li>Buttock, thigh (knee to hip), arm (elbow to shoulder)– EGS
    consult</li>
<li>Perirectal/Rectal<ul>
<li>Acute abscess – EGS</li>
<li>Chronic due to IBD – Colorectal surgery</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<p>Necrotizing Fasciitis</p>
<ul>
<li>Whom to consult for URGENT/EMERGENT surgical eval:<ul>
<li>Genitalia – Urology</li>
<li>Buttocks, perineum, abdomen – EGS</li>
<li>Upper extremity (shoulder to hand) – Hand</li>
<li>Lower extremity (hip to toes) – Ortho</li>
</ul>
</li>
</ul>
<p>Pressure Injury</p>
<ul>
<li>If concerned for sepsis, consult EGS</li>
<li>If EGS deems no URGENT or EMERGENT surgical needs, consult Complex
    Wound</li>
<li>If EGS recommends consult to plastic surgery for “flap, debridement,
    wound care, etc.” and there are no URGENT or EMERGENT surgical
    needs, consult Complex Wound</li>
</ul>
<p>Simple and Complex Wound Service Hours:</p>
<ul>
<li>Both services are Monday through Friday</li>
<li>Consults placed on weekends and holidays are addressed on the next
    business day</li>
<li>If there is an urgent/emergent wound need i.e. needs surgery for
    debridement or I&amp;D then consult the appropriate surgical service</li>
<li>While awaiting consultation, utilize the wound orders below to
    initiate topical care</li>
</ul>
<p>Order Wound Care Until Consult Complete:</p>
<ul>
<li>Superficial wounds<ul>
<li>Stage 1 or 2 Pressure injuries, Moisture Associated Skin Damage,
    Skin Tears<ul>
<li>Order “Adult skin Care Guidelines” and use the order set to
    guide you</li>
</ul>
</li>
<li>Shallow Stage 3 (i.e., \&lt;1cm deep), diabetic foot ulcers<ul>
<li>Order “Wound Care”: Frequency 2x weekly and prn; Cleanse
    with NS; Protect periwound with Mepilex foam (type in
    comments)</li>
</ul>
</li>
</ul>
</li>
<li>Painful superficial wounds no infection (i.e. vasculitis, PG,
    calciphylaxis)<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS;
    Apply Vaseline; Protect periwound with Xeroform and dry gauze
    (type in comments)<ul>
<li>If wound is on the hand, arm, foot, or lower leg consider
    wrapping in Kerlix</li>
<li>If wound is on the trunk (i.e., abdomen or buttocks),
    consider covering with an ABD pad and secure with medipore
    tape</li>
</ul>
</li>
</ul>
</li>
<li>Infected superficial wounds<ul>
<li>NOTE
    : Odor alone is NOT infection; wounds with necrotic tissue may
    have odor</li>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS,
    Apply Silvadene; Protect periwound with Xeroform and dry gauze
    (type in comments)<ul>
<li>If wound is on hand, arm, foot, or lower leg consider
    wrapping in a Kerlix</li>
<li>If wound is on the trunk (i.e., abdomen or buttocks),
    consider covering with an ABD pad and secure with medipore
    tape</li>
</ul>
</li>
<li>Medication order required: Silvadene q12h; in Admin Inst put
    “per wound care orders”</li>
</ul>
</li>
<li>All Deep wounds &gt; 1cm deep (i.e., deep stage 3, 4 or deep diabetic
    foot wound)<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with NS,
    pack with Dakin’s 0.025% (1/20 strength) soaked continuous
    Kerlix roll; Protect Periwound with ABD pad &amp; medipore tape
    (type in comments).</li>
<li>If wound care is painful, consider changing to daily dressing
    changes</li>
<li>Medication order required: Dakin’s 0.025% solution q12h; in
    Admin Inst put “per wound care orders”</li>
</ul>
</li>
<li>Deep tissue injury Pressure injury<ul>
<li>Medication order required: Venelex (balsam peru- castor oil)
    ointment q4h; in Admin Inst put location to apply ointment and
    put “no dressing”</li>
</ul>
</li>
<li>Fungating mass<ul>
<li>Order “Wound Care”: Frequency 2 times daily; Cleanse with baby
    shampoo and water, NS, Metrogel (type in comments); Protect with
    Xeroform, ABD pad, medipore tape</li>
<li>Medication order required: metrogel q12h; in Admin Inst put “per
    wound care orders”</li>
</ul>
</li>
<li>Wound VAC present<ul>
<li>Vanderbilt surgeon – consult Vanderbilt provider to provide care<ul>
<li>Ensure connected to VUMC wound VAC. Pt shouldn’t use home
    unit while admitted</li>
<li>Order “nursing communication” to “Obtain wound VAC hospital
    machine and canister from service center to connect pt to
    hospital machine.”</li>
<li>Wound VAC should not be left without suction for more than 2
    hours</li>
<li>Settings: 125 mmHg continuous</li>
</ul>
</li>
<li>Non VUMC surgeon (i.e., gets wound care at outside
    hospital/wound care center)<ul>
<li>Discontinue wound VAC as soon as possible</li>
<li>Remove all of the clear plastic drape just like you would
    remove tape</li>
<li>Remove all of the sponge just like you would remove gauze
    packing</li>
<li>Examine the wound to ensure no residual sponge by gently
    probing site</li>
<li>Rinse with saline, initiate care based wound type as above</li>
</ul>
</li>
</ul>
</li>
<li>Leg Wrap present (i.e., Unna’s boot, ACE and 2, 3, or 4 layer
    compression)<ul>
<li>Remove by cutting the wrap off</li>
<li>Assess the wound and order dressing based on type of wound as
    above</li>
<li>Order ACE bandage wrapped toe-to-knee. Remove q12h to assess
    skin</li>
</ul>
</li>
<li>Debridement Needed<ul>
<li>Complex wound care can provide non-urgent/non-emergent bedside
    debridement</li>
<li>The presence of necrotic, odorous, black, grey, yellow or loose
    dead debris does not require emergent or urgent debridement by a
    surgical service and in most cases can be managed with dressings
    described above until wound consult team can assess pt</li>
</ul>
</li>
</ul></section><section class="print-page" id="appendices-appendices-uploading-records"><h1 id="appendices-appendices-uploading-records-uploading-records-to-epic">Uploading Records to EPIC<a class="headerlink" href="#appendices-appendices-uploading-records-uploading-records-to-epic" title="Permanent link">&para;</a></h1>
<ul>
<li>Request outside records to your Doximity account fax</li>
<li>Open Doximity in Epic virtual desktop browser window (internet
    explorer)</li>
<li>Open faxed documents, and save your document as PDF to desktop of
    the virtual desktop</li>
<li>Return to Epic</li>
<li>Click the "Epic" dropdown menu (the same one where you "Change
    Context")</li>
<li>Hover over “Patient Care” than click "Media Manager" (pin to avoid
    extra clicks next time)</li>
<li>Select your pt</li>
<li>Click "Scan;" a popup window will appear</li>
<li>On the popup window, click "File" > "Import File"</li>
<li>In the bottom right-hand corner, change the file type from "Image
    Files" to "PDF Files"</li>
<li>Search for your saved document under "Downloads" or “Desktop” and
    select "Open"</li>
<li>The documents should appear in the popup window. On the right-hand
    side, under "Store Images As:" scroll down and select "Outside
    Medical Records"</li>
<li>Click "Upload Images;" name them as you choose</li>
<li>Exit out of Media Manager and refresh chart</li>
</ul></section><section class="print-page" id="appendices-appendices-va-phone-numbers"><h1 id="appendices-appendices-va-phone-numbers-va-phone-numbers">VA Phone Numbers<a class="headerlink" href="#appendices-appendices-va-phone-numbers-va-phone-numbers" title="Permanent link">&para;</a></h1>
<h2 id="appendices-appendices-va-phone-numbers-administrative-numbers">Administrative Numbers<a class="headerlink" href="#appendices-appendices-va-phone-numbers-administrative-numbers" title="Permanent link">&para;</a></h2>
<ul>
<li>AOD: 67010</li>
<li>NOD (text or call): 615-456-0362</li>
<li>Flow coordinator (text or call): 615-712-5316</li>
<li>Transfer coordinator: 22516 (6:30a-4:45p)</li>
<li>VA inpatient chief office: 67112</li>
<li>VA outpatient chief office: 615-936-7080</li>
<li>IT Help Desk: 26500</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-resident-team-work-roomsareas">Resident Team Work Rooms/Areas<a class="headerlink" href="#appendices-appendices-va-phone-numbers-resident-team-work-roomsareas" title="Permanent link">&para;</a></h2>
<ul>
<li>Team 1: 68628/67147/66091</li>
<li>Team 2: 67146/68128/66090</li>
<li>Team 3: 66088/66089/66087</li>
<li>Team 4: 67662/68637/66081</li>
<li>Team 5: 66826/68427/66563</li>
<li>Team 6: 68687/67115/68696</li>
<li>BMT (Team 7): 67979</li>
<li>MICU/CCU: 67599</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-team-pager-numbers">Team Pager Numbers<a class="headerlink" href="#appendices-appendices-va-phone-numbers-team-pager-numbers" title="Permanent link">&para;</a></h2>
<ul>
<li>Team 1 Resident: 317-1303</li>
<li>Team 1 Intern A: 317-1201</li>
<li>Team 1 Intern B: 317-1205</li>
<li>Team 2 Resident: 317-1245</li>
<li>Team 2 Intern A: 317-1207</li>
<li>Team 2 Intern B: 317-1209</li>
<li>Team 3 Resident: 317-1304</li>
<li>Team 3 Intern A: 317-1213</li>
<li>Team 3 Intern B: 317-1206</li>
<li>Team 4 Resident: 317-1307</li>
<li>Team 4 Intern A: 317-1225</li>
<li>Team 4 Intern B: 317-1226</li>
<li>Team 5 Resident: 317-1261</li>
<li>Team 5 Intern A: 317-1216</li>
<li>Team 5 Intern B: 317-1144</li>
<li>Team 6 Resident: 317-1210</li>
<li>Team 6 Intern A: 317-1223</li>
<li>Team 6 Intern B: 317-1150</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-hospital-unit-secretariesreceptionists">Hospital Unit Secretaries/Receptionists<a class="headerlink" href="#appendices-appendices-va-phone-numbers-hospital-unit-secretariesreceptionists" title="Permanent link">&para;</a></h2>
<ul>
<li>2N: 68030</li>
<li>3N: 68040</li>
<li>2G: 68010</li>
<li>MICU/CCU: 67470</li>
<li>SICU: 67930</li>
<li>PACU: 67746</li>
<li>Dialysis: 66860</li>
<li>VA triage charge RN: 66849</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-va-consult-team-numbers-ppager">VA Consult Team Numbers (p=pager)<a class="headerlink" href="#appendices-appendices-va-phone-numbers-va-consult-team-numbers-ppager" title="Permanent link">&para;</a></h2>
<p>Most of the surgical/procedural services maintain
an Excel spreadsheet of on-call clinicians,
updated monthly,
available for download on the VA Intranet.</p>
<p>The main on-call page is available <a href="https://vaww.v09.va.gov/tennessee-valley/Clinical/On-Call-Schedules-Contacts">here</a>,
and individual on-call pages are linked below.</p>
<p>Cardiac and thoracic surgery have NPs
that field most of the consults, their pagers are included below as well.</p>
<ul>
<li>Cardiac Surgery: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Cardiac">VA website</a>; Bo Mistak, NP (p): 831-4101</li>
<li>Cardiology (24/7 p): 317-0520</li>
<li>Dermatology: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Dermatology">VA website</a></li>
<li>ENT: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-ENT">VA website</a></li>
<li>General Surgery (p): 835-7338</li>
<li>Hepatology transplant (Dr. Awad’s pager): 835-4967</li>
<li>IR: 68552 (call before placing orders)</li>
<li>Neurology (p): 835-5137</li>
<li>Neurosurgery: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Neurosurgery">VA website</a></li>
<li>Ophthalmology: call eye clinic 67279 (7a-5p); night/weekend (p): 831-4433</li>
<li>Oral Surgery (p): 317-0571</li>
<li>Orthopedic Surgery: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Orthopaedic">VA website</a></li>
<li>Palliative Care (p): 317-3040</li>
<li>Podiatry: 68425 (RN, first call); 615-708-5658 (Dr. Sieber’s cell, second call)</li>
<li>Plastic Surgery: [VA website]</li>
<li>Psychiatry (p): 317-1506 (first call); 615-476-9004 (Emergencies/second call)</li>
<li>SATP: 67880</li>
<li>Thoracic Surgery: <a href="https://vaww.v09.va.gov/Tennessee-Valley/Clinical-Resources/On-Call-Schedules-Contacts/On-call-Schedule-Plastic-Surgery">VA website</a>; Pinkerman, NP (p): 317-3138</li>
<li>Urologic Surgery (p): 831-8038</li>
<li>Vascular Surgery (p): 835-7358</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-va-triageer">VA Triage/ER<a class="headerlink" href="#appendices-appendices-va-phone-numbers-va-triageer" title="Permanent link">&para;</a></h2>
<ul>
<li>MD areas: 66892/67173/68192/68199</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-other-services">Other Services<a class="headerlink" href="#appendices-appendices-va-phone-numbers-other-services" title="Permanent link">&para;</a></h2>
<ul>
<li>Anti-coagulation Clinic: 66772</li>
<li>Blood Bank: 67025 (supervisor: 67029)</li>
<li>Cardiology Services</li>
<li>Cath lab: 68057/68283/68325/68358</li>
<li>Echo: 67982 (66705 for reading room)</li>
<li>Heart station (including EKG’s): 67370/66025</li>
<li>Stress test results: 66811 (nuc med reading room)</li>
<li>Nutrition Consult:</li>
<li>2N, MICU: 66730</li>
<li>3N, SICU: 67471</li>
<li>2G, PCU: 67613</li>
<li>Chaplain: 66983</li>
<li>Dental Clinic: 67120</li>
<li>Diabetes Educator: 67518, (p) 317-3210</li>
<li>Dietary: 66996</li>
<li>GI lab: 67240</li>
<li>Home Oxygen: 68402</li>
<li>Infection Control: 66759</li>
<li>Infusion Clinic: 67318</li>
<li>Medical Records: 67830</li>
<li>Physical Therapy (inpt): 67690</li>
<li>PICC (third-party, Lee Medical): 866-599-3819</li>
<li>Police: 67740</li>
<li>Prosthetics: 67770</li>
<li>Pulmonary Function Tests (PFT): 67780</li>
<li>Respiratory Therapy</li>
<li>Wards: 615-651-3939 (supervisor at 651-3583)</li>
<li>MICU: 615-651-9923</li>
<li>Social work: varies per team</li>
<li>Speech pathology: 67193</li>
<li>Telemetry: 67377</li>
<li>TPN: 67164</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-labs">Labs<a class="headerlink" href="#appendices-appendices-va-phone-numbers-labs" title="Permanent link">&para;</a></h2>
<ul>
<li>Chemistry: 67004</li>
<li>Hematology/Serology/Coag/Urine: 67045/66948</li>
<li>Microbiology: 67049 (supervisor at 66982)</li>
<li>Specimen processing: 66975</li>
<li>Cytology: 67062</li>
<li>Surgical pathology: 67064</li>
<li>Hematopathology: 68588</li>
<li>Occupational Therapy (inpt): 67560</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-pharmacy">Pharmacy<a class="headerlink" href="#appendices-appendices-va-phone-numbers-pharmacy" title="Permanent link">&para;</a></h2>
<ul>
<li>Inpatient: 67660</li>
<li>Outpatient: 67680</li>
<li>2N med rec room: 66093</li>
<li>3N med rec room: 68223</li>
</ul>
<h2 id="appendices-appendices-va-phone-numbers-radiology">Radiology<a class="headerlink" href="#appendices-appendices-va-phone-numbers-radiology" title="Permanent link">&para;</a></h2>
<ul>
<li>XR: 67810</li>
<li>CT: 67007</li>
<li>MRI: 66366</li>
<li>Nuclear Medicine: 66813</li>
<li>PET: 67615</li>
<li>Ultrasound: 67550</li>
</ul></section><section class="print-page" id="appendices-appendices-vumc-phone-directory"><h1 id="appendices-appendices-vumc-phone-directory-vumc-phone-directory">VUMC Phone Directory<a class="headerlink" href="#appendices-appendices-vumc-phone-directory-vumc-phone-directory" title="Permanent link">&para;</a></h1>
<p>Shorthand</p>
<p>1xxxx</p>
<p>– 615-421-xxxx</p>
<p>2xxxx</p>
<p>– 615-322-xxxx</p>
<p>3xxxx</p>
<p>– 615-343-xxxx</p>
<p>5xxxx</p>
<p>– 615-875-xxxx</p>
<p>6xxxx</p>
<p>– 615-936-xxxx</p>
<p>Labs</p>
<p>Blood Bank</p>
<p>– 22233</p>
<p>Cytology Lab</p>
<p>– 22721</p>
<p>Flow Cytometry Lab</p>
<p>– 39081</p>
<p>Hematology Lab</p>
<p>– 39125</p>
<p>Hematology Smear Lab</p>
<p>– 33905</p>
<p>Lab Operator</p>
<p>– 55227</p>
<p>Microbiology Lab</p>
<p>– 23406</p>
<p>Cardiology</p>
<p>Cardiac Access Center</p>
<p>– 33255</p>
<p>Cardiac MRI</p>
<p>– 68111</p>
<p>Cath Lab</p>
<p>– 34808</p>
<p>Echo Lab</p>
<p>– 20624</p>
<p>Echo Reading Room</p>
<p>– 60705</p>
<p>EP Lab</p>
<p>– 35036</p>
<p>TEE</p>
<p>– 67431</p>
<p>Telemetry</p>
<p>– 65945</p>
<p>Neurology</p>
<p>831</p>
<p>- <strong>4790</strong> – Page this to discuss a patient admitted to the neurology
general service</p>
<p>831</p>
<p>- <strong>4792</strong> – Page this to discuss a patient admitted to the neurology
stroke service</p>
<p>835</p>
<p>- <strong>5137</strong> – Page this for any neurology issues/questions at the
Nashville VA</p>
<p>831</p>
<p>- <strong>4793</strong> – Page this to for any other neurology question (When in
doubt, pager this #)</p>
<p>Units</p>
<p>A Pod</p>
<p>– 35914</p>
<p>B Pod</p>
<p>– 27173</p>
<p>C Pod</p>
<p>–64593</p>
<p>TCU</p>
<p>–34893</p>
<p>3 Round Wing</p>
<p>– 25120</p>
<p>4 North</p>
<p>– 22255</p>
<p>4 Round Wing</p>
<p>– 22244</p>
<p>4 South</p>
<p>– 32736</p>
<p>5 North</p>
<p>– 35030</p>
<p>5 Round Wing</p>
<p>– 23895</p>
<p>5 South</p>
<p>– 24710</p>
<p>6 North</p>
<p>– 32482</p>
<p>6 Round Wing</p>
<p>– 28900</p>
<p>6 South</p>
<p>– 22000</p>
<p>6 Tower</p>
<p>– 35232</p>
<p>7 East -</p>
<p>56801</p>
<p>7 North</p>
<p>– 20942</p>
<p>7 Round Wing</p>
<p>– 35302</p>
<p>7 South</p>
<p>– 32271</p>
<p>7 Tower</p>
<p>– 20911</p>
<p>8 East</p>
<p>– 53700</p>
<p>8 North</p>
<p>– 20948</p>
<p>8 South</p>
<p>– 20946</p>
<p>8 Tower</p>
<p>– 20938</p>
<p>9 North</p>
<p>– 20918</p>
<p>9 South</p>
<p>– 20916</p>
<p>9 Tower</p>
<p>– 20988</p>
<p>10 North</p>
<p>– 30398</p>
<p>10 South</p>
<p>– 28920</p>
<p>10 Tower</p>
<p>– 24545</p>
<p>11 North</p>
<p>– 55333</p>
<p>11 South</p>
<p>– 24590</p>
<p>Radiology</p>
<p>Body Reading Room</p>
<p>– 26011</p>
<p>Chest Reading Room</p>
<p>– 28485</p>
<p>CT Scanner A Pod</p>
<p>– 36055</p>
<p>CT Tech</p>
<p>– 38074</p>
<p>CTA Reading Room</p>
<p>– 32162</p>
<p>ED Reading Room</p>
<p>– 37185</p>
<p>Fluoroscopy Reading Room</p>
<p>– 30951</p>
<p>Fluoroscopy Tech</p>
<p>– 20878</p>
<p>IR Reading Room</p>
<p>– 20840</p>
<p>MRI Tech</p>
<p>– 34557</p>
<p>Nuclear Med Reading Room</p>
<p>– 31577</p>
<p>Nuclear Med Tech</p>
<p>– 20893</p>
<p>Neuroradiology Reading Room</p>
<p>– 30900</p>
<p>PET Reading Room</p>
<p>– 37523</p>
<p>Radiology Library</p>
<p>– 20866</p>
<p>Ultrasound Reading Room</p>
<p>– 20853</p>
<p>Ultrasound Tech</p>
<p>– 34970</p>
<p>Vascular Lab</p>
<p>– 39205</p>
<p>X-ray Tech ED</p>
<p>– 28804</p>
<p>X-ray Tech Floor Pager</p>
<p>– 615-835-5647</p>
<p>X-ray Tech Tower Pager</p>
<p>– 615-835-5597</p>
<p>Miscellaneous</p>
<p>Admitting</p>
<p>– 30179</p>
<p>Anesthesia STAT Phone</p>
<p>– 615-887-7369</p>
<p>Bed Management (Option 5)</p>
<p>– 54000</p>
<p>Bronchoscopy Lab</p>
<p>– 39647</p>
<p>Dialysis</p>
<p>– 20912</p>
<p>EEG Tech Pager</p>
<p>– 615-835-8847</p>
<p>GI Lab</p>
<p>– 39716</p>
<p>Inpatient Pharmacy</p>
<p>– 56337</p>
<p>Language Line</p>
<p>– (866) 874-3972 (218443)</p>
<p>Meds to Beds</p>
<p>– 20804</p>
<p>Nutrition Services</p>
<p>– 39761</p>
<p>PICC Service</p>
<p>– 22772</p>
<p>Resident Library</p>
<p>– 56205</p>
<p>Service Center</p>
<p>– 39600</p>
<p>The MAC</p>
<p>– 615-540-4213</p>
<p>Transfer Center</p>
<p><strong>(Option 4)</strong> – 54000</p>
<p>Vanderbilt Operator</p>
<p>– 615-322-5000 or 0</p>
<p>Vanderbilt Inpatient Team Pagers</p>
<p>Brittingham (Heme) 1: 831-4785</p>
<p>Brittingham (Heme) 2: 831-4788</p>
<p>CHF-A: 831-6485</p>
<p>CHF-B: 831-6486</p>
<p>Harrison 1: 831-4769</p>
<p>Harrison 2: 831-4770</p>
<p>Morgan 1: 831-4765</p>
<p>Morgan 2: 831-4766</p>
<p>Morgan 3: 831-4767</p>
<p>Morgan 4: 831-4768</p>
<p>Morgan 5: 831-8481</p>
<p>Morgan 6: 831-4781</p>
<p>Oncology A: 831-4786</p>
<p>Oncology B: 831-4787</p>
<p>Rogers Hepatology: 831-4782</p>
<p>Rogers ID: 831-4779</p>
<p>Rogers Pulmonary: 831-4777</p>
<p>Rogers Renal: 831-4783</p></section><section class="print-page" id="appendices-main"><h1 id="appendices-main-vumc-rotations">VUMC Rotations<a class="headerlink" href="#appendices-main-vumc-rotations" title="Permanent link">&para;</a></h1>
<h2 id="appendices-main-morgan-1-6">Morgan (1 – 6)<a class="headerlink" href="#appendices-main-morgan-1-6" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 1 Intern with patient cap of 10</li>
<li>Pagers: Morgan 1: 831-4765, Morgan 2: 831-4766, Morgan 3: 831-4767,
    Morgan 4: 831-4768, Morgan 5: 831-8481, Morgan 6: 831-4781</li>
<li>Pick up list at 6 AM in res library on 8N (code 431), admit until
    5:30 PM, sign-out 6 PM</li>
<li>Admitting: Teams 1-3-5 &amp; 2-4-6 alternate admitting days (just like
    VA)</li>
<li>Non-admitting teams can sign out once their work is complete as
    early as 2PM on weekdays and 12PM on weekends</li>
<li>Rounding time and meeting location varies by attending (typically
    between 7 to 8 AM)</li>
<li>Work room: team-specific rooms labelled on hall behind 7N Nursing
    station (Code 24300)<ul>
<li>Morgan 5, 6 7755 (no code)</li>
</ul>
</li>
<li>Huddle<ul>
<li>Morgan 1</li>
<li>Morgan 2</li>
<li>Morgan 3</li>
<li>Morgan 4</li>
<li>Morgan 5 - 1340 on Teams</li>
<li>Morgan 6 - 1350 on Teams</li>
</ul>
</li>
<li>Tips: get pharmacist's phone number 1<sup>st</sup> day, get case
    management/social work phone numbers, place consults as soon as
    possible (preferably before rounds once consult teams arrive at 7
    AM)</li>
</ul>
<h2 id="appendices-main-geriatrics">Geriatrics<a class="headerlink" href="#appendices-main-geriatrics" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 1 Intern with patient cap of 10</li>
<li>Rounds at 8 AM, team meets in the Round Wing workroom</li>
<li>Work room: 7434</li>
</ul>
<h2 id="appendices-main-rogers-subspecialty-services">Rogers (Subspecialty Services)<a class="headerlink" href="#appendices-main-rogers-subspecialty-services" title="Permanent link">&para;</a></h2>
<h3 id="appendices-main-all-rogers-services">All Rogers services<a class="headerlink" href="#appendices-main-all-rogers-services" title="Permanent link">&para;</a></h3>
<ul>
<li>Team: 1 Res, 1 Intern with patient cap of 10</li>
<li>Pick up list at 6 AM, admit daily until 5:30 PM, sign-out 6 PM</li>
<li>Each HPI usually requires special info about the patient’s
    subspecialty diagnosis; refer to primer documents that are available
    for most subspecialty services in the chief's "welcome to the wards"
    email, and see tips below</li>
</ul>
<h3 id="appendices-main-rogers-hepatology">Rogers Hepatology<a class="headerlink" href="#appendices-main-rogers-hepatology" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets on 6MCE</li>
<li>Pager: 831-4782</li>
<li>Work room: 6MCE, room 6755 near the elevators (no code)</li>
<li>Review: Hepatology Section, Paracentesis (Procedures), and
    'Surviving Rogers Hep' primer</li>
<li>Tips: structure one-liner as “cirrhosis secondary to ___
    decompensated by ___ (EV bleed, ascites, SBP, HE, or HRS) who
    follows with ___ (hepatologist) and is ___ (listed /
    undergoing workup for / not listed) for transplant”; know patient
    MELD-Na scores (use the MELD-Na dot phrase or patient list column);
    anticipate at least diagnostic paracentesis on admission if any
    concern for SBP (abdominal pain, AMS, etc.)</li>
</ul>
<h3 id="appendices-main-rogers-id">Rogers ID<a class="headerlink" href="#appendices-main-rogers-id" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets in Resident Library (8N)</li>
<li>Pager: 831-4779</li>
<li>Work room: 6 Round Wing, 2<sup>nd</sup> door on left after coming out of
    elevator (no code)</li>
<li>Tips: Each HPI for pt with HIV should include most recent CCC
    provider, CD4/Viral Load, prior AIDS-defining illnesses and
    compliance to ART; Use ‘Notifications’ tab on main screen in Epic to
    keep track of lab orders as patients can have long stays with
    send-out labs that can take up to two weeks to result (can also hit
    ‘Notify Me’ in dropdown box of Order)</li>
</ul>
<h3 id="appendices-main-rogers-pulmonology">Rogers Pulmonology<a class="headerlink" href="#appendices-main-rogers-pulmonology" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically at 8 AM, team meets at 8N nursing station</li>
<li>Pager: 831-4777</li>
<li>Work room: 8 South 8216 (code 2430)</li>
<li>Tips: Each HPI should include most recent PFTs (FEV1% most
    important, include other relevant data or recent changes); For CF,
    Use the CF admission order set, know typical organisms in patient’s
    sputum (ex: MDR Pseudomonas, Burkholderia, MRSA) and consult CF
    team; for PH know the therapies they are on (typically Flolan or
    Veletri)</li>
</ul>
<h3 id="appendices-main-rogers-renal">Rogers Renal<a class="headerlink" href="#appendices-main-rogers-renal" title="Permanent link">&para;</a></h3>
<ul>
<li>Rounds typically start 7-7:30 AM, team meets at resident/fellow work
    room on 6MCE</li>
<li>Pager: 831-4783</li>
<li>Work room: 6MCE 6772, behind nursing station with renal fellows (no
    code)</li>
<li>Tips: Each HPI should have renal transplant history with year, type
    of transplant, PRA, Ag MM, CMV D/R; 6MCE charge nurse can get pts
    transferred there; alert the night cross-cover resident to patients
    with recent renal biopsy and low threshold to contact renal fellow;
    transplant pts should have daily tacro level one hour before AM
    tacro dose (5:00 am), regardless of pt’s home schedule and be
    cautious with first dose timing of immunosuppression to keep on
    schedule</li>
</ul>
<h2 id="appendices-main-cardiology-services-chf-harrison-and-ccu">Cardiology Services (CHF, Harrison, and CCU)<a class="headerlink" href="#appendices-main-cardiology-services-chf-harrison-and-ccu" title="Permanent link">&para;</a></h2>
<h3 id="appendices-main-chf-heart-failure-1-2">CHF - Heart Failure (1 &amp; 2)<a class="headerlink" href="#appendices-main-chf-heart-failure-1-2" title="Permanent link">&para;</a></h3>
<ul>
<li>Team: 1 Res, 2 Interns on one team with pt cap of 8 per intern (16
    total)</li>
<li>Pagers: CHF-A: 831-6485, CHF-B: 831-6486</li>
<li>Pick up list at 6 AM, admit daily until 5PM (alternate admissions,
    resident to help assign)</li>
<li>Rounds typically at 7 AM, team meets at 7MCE nursing station</li>
<li>Workroom: 7N room 7024 right before bridge to 7MCE (code 145)</li>
<li>Tips: Know each patient’s dry weight (usually found in outpatient
    cards notes or at last discharge), know current outpatient diuretic
    regimen, know most recent TTE, RHC, and LHC results (keep this info
    accessible on rounds), order strict I&Os; Daily Standing Weights,
    and fluid restriction of 2L/day, obtain iron studies to assess need
    for IV iron, perform volume exams on patients before rounds</li>
</ul>
<h3 id="appendices-main-harrison-1-2">Harrison (1 &amp; 2)<a class="headerlink" href="#appendices-main-harrison-1-2" title="Permanent link">&para;</a></h3>
<ul>
<li>Team: 1 Res, 1 Intern on each team with patient cap of 10</li>
<li>Pagers: Harrison 1: 831-4769, Harrison 2: 831-4770</li>
<li>Pick up list at 6 AM, admit until 5 PM (Long) or 2 PM (Short)</li>
<li>Alternate long and short days with other Harrison team</li>
<li>Weekends: Only long team admits new patients</li>
<li>Rounds typically at 7 AM, team meets at 7MCE Nursing station</li>
<li>Work room: 5MCE 5181 (code 0701); hard to hear stats so keep door
    propped</li>
<li>Tips: To order heart cath, must be in the cardiology context in Epic
    “VUMC Cardiology VIR” (order listed as “Case Request Cath Lab” and
    use provider “Surgeon, Generic”)</li>
</ul>
<h3 id="appendices-main-ccu">CCU<a class="headerlink" href="#appendices-main-ccu" title="Permanent link">&para;</a></h3>
<ul>
<li>Team: 3 Res, dedicated cards fellow, no specific patient cap</li>
<li>Pager: 831-6487</li>
<li>Rounds start at 7 AM on 5N with Interventional rounds, then Advanced
    Heart Failure rounds</li>
<li>Call room: 5229AA, on 5S behind the nursing station (code 1234#)</li>
<li>Supply room: on 5N (code 512), equipment/US room: on 5N (code 512)</li>
<li>Tips: make sure you have access to the Swan sheet folder, have
    someone show you how to fill in Swan numbers, make a new Swan
    document daily, make a schedule so you stay on top of q4h Swan
    numbers and frequent I/O assessments, familiarize yourself with IABP
    monitors and Impella care, have pre-call update any hospital courses
    the post-call resident wasn't able to do since post-call is busy
    presenting on rounds</li>
</ul>
<h2 id="appendices-main-hematology-brittingham-oncology">Hematology (Brittingham) &amp; Oncology<a class="headerlink" href="#appendices-main-hematology-brittingham-oncology" title="Permanent link">&para;</a></h2>
<h3 id="appendices-main-hematology-brittingham">Hematology (Brittingham)<a class="headerlink" href="#appendices-main-hematology-brittingham" title="Permanent link">&para;</a></h3>
<ul>
<li>Team: 1 Res, 2 Interns with patient cap of 8 per intern (16 total)</li>
<li>Pagers: Brittingham 1: 831-4785, Brittingham 2: 831-4788</li>
<li>Pick up list at 6 AM, admit daily until 5 PM (alternate admissions
    between interns)</li>
<li>Rounds at 8 AM, team meets on 10T</li>
<li>Work room: 7MCE conference room (code 0701)</li>
<li>Tips: Each HPI should include malignancy history (dx, prior tx,
    current tx), utilize the 'treatment' tab to keep on track with chemo
    cycle/day, know the febrile neutropenia algorithm, if possible,
    enter orders/write notes while the other intern and attending are at
    bedside, low threshold to work any complaints up as bleeds,
    infections, and fevers are common and can be rapidly lethal</li>
</ul>
<h3 id="appendices-main-oncology-a-b">Oncology (A &amp; B)<a class="headerlink" href="#appendices-main-oncology-a-b" title="Permanent link">&para;</a></h3>
<ul>
<li>Team: 1 Res, 1 Intern on each team with patient cap of 10</li>
<li>Pagers: Oncology A: 831-4786, Oncology B: 831-4787</li>
<li>Pick up list at 6 AM, admit daily until 5 PM, sign-out 6 PM</li>
<li>Rounds at 8 AM, team meets on 11N at nursing station</li>
<li>Workroom: Varied; typically resident library, 11N or 10T, or 7MCE
    Conference room</li>
<li>Tips: Each HPI should have Onc history (Dot Phrase “.onchist”)
    including dx, prior treatments, most recent imaging; 10T and 11N
    charge nurse can get pts transferred there, know that patients
    admitted from infusion clinic must be seen and have orders placed
    (write delayed admission orders in advance of their arrival to floor
    bed)</li>
</ul>
<h2 id="appendices-main-vu-micu">VU MICU<a class="headerlink" href="#appendices-main-vu-micu" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 3 Res, 3 Interns, no specific patient cap</li>
<li>Pagers: MICU 1 Intern Pager: 831-4759, MICU 2 Intern Pager:
    831-4757. Need to also carry the team phone</li>
<li>Day Intern: 8 AM - 10 PM; Night Intern 9 PM - 11 AM</li>
<li>Rounds at 8 AM (start with half hour teaching most days)</li>
<li>Work areas: team 1 sits at computers across from pt room 8641; team
    2 sits at computers across from pt room 8613; ultrasound/equipment
    room code is 4321#; break room code 4321</li>
<li>Tips: Day 1, figure out if you're the code team and where the I/O
    kit is. Night intern presents all the old patients in the morning
    and signs the notes. The day intern owns the A&amp;P of the notes by
    keeping them updated. Trust the nurses and never hesitate to relay
    info to your resident overnight if you’re concerned (wake him/her
    up!)</li>
</ul>
<h2 id="appendices-main-vu-nights">VU Nights<a class="headerlink" href="#appendices-main-vu-nights" title="Permanent link">&para;</a></h2>
<ul>
<li>Start on Sunday night for interns, Wednesday night for residents;
    off Saturday night</li>
<li>Team: 1 Res, 2 Interns with patient cap of 10 for Morgan/Rogers
    admitting; 1 Res + 1 Intern w/ cap of 10 for Harrison/Heme/Onc (Res
    and Intern split admissions)</li>
<li>Harrison/Heme/Onc: Start at 6 PM, admit until 5 AM, sign-out by 6 AM</li>
<li>Morgan/Rogers: Start at 6:30 PM, admit until 5:30 AM, sign-out by
    6:30 AM</li>
<li>Cross cover: Start at 6 PM (Be on time!), sign-out 6:30 AM</li>
<li>Tips: ensure you communicate all orders and plans with the resident,
    writing “To do” boxes on the first pages of each printed H&amp;P might
    help you communicate the important aspects of each plan to the day
    intern when they arrive the next morning, cafeteria closes at 2 AM.
    For cross cover, make sure to document any significant events in
    Epic. Useful to follow-up on pts admitted previous nights to reflect
    on your diagnosis and workups.</li>
</ul>
<h1 id="appendices-main-va-veterans-affairs-rotations">VA: Veterans Affairs Rotations<a class="headerlink" href="#appendices-main-va-veterans-affairs-rotations" title="Permanent link">&para;</a></h1>
<h2 id="appendices-main-va-general-wards-1a-6b">VA General Wards (1A – 6B)<a class="headerlink" href="#appendices-main-va-general-wards-1a-6b" title="Permanent link">&para;</a></h2>
<ul>
<li>Always make sure that your VA login works a few days before you are
    scheduled to start!</li>
<li>Team: 1 Res, 2 Interns with soft patient cap of 8 each (16 total)</li>
<li>Pagers: See VA Phone/Pager Directory Section for pager numbers</li>
<li>Pick up list by 6:30 AM In the pulm/ID fellows workroom on the 2<sup>nd</sup>
    floor (between team 4 workroom and the MICU), sign-out at 6 PM</li>
<li>Admitting: Teams 1-3-5 &amp; 2-4-6 alternate admitting days and admit
    until 5:30 PM</li>
<li>Non-admitting teams can sign out once their work Is complete as
    early as 2PM on weekdays and 12PM on weekends</li>
<li>Rounds alternate at 7 AM on admitting days, 8 AM on non-admitting
    days, meet at workrooms; night admitting team presents to attendings
    at 7 AM (depending on team)</li>
<li>Work rooms:<ul>
<li>Team 1 on 2N hallway, past RN station</li>
<li>Team 2 on 2N hallway, past RN station</li>
<li>Team 3 on 2N hallway, between main elevators and RN station</li>
<li>Team 4 at 2<sup>nd</sup> floor adjacent to main elevators</li>
<li>Team 5 on 3N hallway</li>
<li>Team 6 in pulm &amp; ID fellow workroom outside MICU on 2G</li>
</ul>
</li>
<li>Tips: Admission days can be very busy and anything you can get done
    on the non-admitting days will make your life easier (ex: DIPNs).
    Ensure that you tag PCP on EVERY H&amp;P so they know patient is
    admitted (right click signed H&amp;P -> dropdown menu -> "identify
    additional co-signer"), make documents in OneDrive (it's
    HIPAA-compliant!) to use as your pre-rounding sheet and sign-out
    sheet and share these with your team (for days off); roll your
    pagers via Vanderbilt operator (same as at VU); ensure all orders on
    patients still in the ED are “delayed” or they will disappear once
    on the floor (ask your resident); all consults must be accompanied
    by page to the covering fellow (use Synergy for medicine
    subspecialties consult schedule, TVHS website for surgery/other),
    beware that medications disappear after 1 month of admission (your
    pharmacist can help!), beware that diets disappear when converting
    obs to inpatient, enjoy a complimentary VA square!</li>
</ul>
<h2 id="appendices-main-va-micu">VA MICU<a class="headerlink" href="#appendices-main-va-micu" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 3 Res, 3 Interns, no specific patient cap</li>
<li>Combined CCU and MICU; 7AM CCU rounds followed by 8AM MICU rounds</li>
<li>Day Intern: 7 AM - 9 PM; Night Intern 8 PM - 10 AM; MICU between 2N
    and 2G (2<sup>nd</sup> floor)</li>
<li>Tips: Night intern presents all of the old patients in the morning
    and signs the notes. The day intern owns the A&amp;P of the notes by
    keeping them updated. Never hesitate to relay information to your
    resident overnight if you are concerned (wake him/her up!)</li>
</ul>
<h2 id="appendices-main-va-nights">VA Nights<a class="headerlink" href="#appendices-main-va-nights" title="Permanent link">&para;</a></h2>
<ul>
<li>Team: 1 Res, 2 Interns, total of 10 admissions overnight</li>
<li>Pager: NIGHT ADMIT RESIDENT must roll the night admitting pager
    317-0227</li>
<li>Start at 7 PM, Admit until 5 AM, present new patients to teams at 7
    AM, leave by 8 AM</li>
<li>Start Sunday night for interns, Wednesday night for residents; off
    day is Saturday night for interns/cross-cover resident (covered by
    clinic resident), Friday night for admitting resident (covered by
    BMT resident)</li>
<li>Tips: Admissions typically bolus at the start of shift and slow
    later in the night, so worry about seeing pts, formulating plans
    with resident and putting in orders first as notes can be finished
    once it slows down, cafeteria at VU closes at 2 AM, communicate
    everything you do with your resident who is supervising a second
    intern as well, ensure all orders on pts still in the ED are
    “delayed” or they will disappear once on the floor (ask your
    resident), enjoy a complimentary VA square for breakfast!</li>
</ul>
<h1 id="appendices-main-how-to-discharge-a-patient-at-vumc">How to Discharge a Patient at VUMC<a class="headerlink" href="#appendices-main-how-to-discharge-a-patient-at-vumc" title="Permanent link">&para;</a></h1>
<ul>
<li>Verify the correct pharmacy with the patient (Vanderbilt MCE
    pharmacy if using meds-to-beds) and if refills of existing
    medications are needed</li>
<li>Select ‘Transfer-Discharge’ on the navigator panel on eStar select
    ‘Discharge’ tab on the top of the page</li>
<li>Select ‘Rx Routing’ on the left panel. Choose one of the three
    options. This choice will set the default prescribing choice for new
    medications at discharge or refilled medications. This can be
    changed manually within each Rx order</li>
<li>Default = will e-prescribe to pt’s pharmacy</li>
<li>Print = will print all Rx’s and not e-prescribe (printed to nursing
    station on pt’s floor)</li>
<li>Do not print and do not e-prescribe (This is used for pt going to
    SNF or IPR)</li>
<li>Select ‘Discharge Orders’ on the left panel. This will open a
    reconciliation navigator</li>
<li>Reconcile the home medications with the current inpatient
    medications. The red tab on the right side of the screen will become
    green when all medications are addressed</li>
<li>For new medications or refills, make sure the ‘Class’ in the
    prescription is set to ‘Normal’ for electronic prescriptions.
    Otherwise, to add the medication to the list without a prescription,
    choose ‘No Print’</li>
<li>The medications will e-prescribe to the pharmacy selected at the
    bottom of the order panel on the right side of your screen</li>
<li>To send to multiple pharmacies, select the primary pharmacy at the
    bottom of the order panel on the right side of your screen, then
    choose ‘Send to Multiple Pharmacies’</li>
<li>Note that meds-to-beds will arrange to deliver meds AFTER the
    "discharge" order is signed; if discharge is time-sensitive, can
    call to ask if meds can be delivered in advance</li>
<li>Next, select ‘Order Sets’ at the top of the Discharge Orders panel</li>
<li>In the order box on the right, type “Adult General Discharge”</li>
<li>Right-click on the option and select “Add to Favorites”. Now, this
    option will be available on the Order Set page for future patients.</li>
<li>Open Adult General Discharge order set<ul>
<li>Select the appropriate choices pertinent to current pt<ul>
<li>For SNF/LTC, include RN orders like diet, activity
    order/restriction, wound care, etc.</li>
</ul>
</li>
<li>On the right side of the screen, you can add Ad Hoc orders such
    as:<ul>
<li>Hospital Follow-up with "X" service (place these as soon as
    you know!)</li>
<li>Ambulatory Referrals</li>
<li>Post-discharge labs</li>
<li>Important for ID labs in addition to INR checks, place fax
    number for which provider that will be following up results
    in the comments section. If labs will be done outside of
    Vanderbilt system, must select "External Non-VMG"</li>
<li>Medications not listed on reconciliation list</li>
</ul>
</li>
</ul>
</li>
<li>When all sections are completed, click ‘Sign – Print and/or
    E-prescribe Now’</li>
<li>Select ‘Follow-up Providers’ on the left panel.</li>
<li>Select the providers that you want to receive the discharge summary.
    Provide personal instructions to the patient</li>
<li>Select ‘Instructions’ on the left-hand panel</li>
<li>Free-text your personal comments and instructions to the patient,
    such as:<ul>
<li>A simple statement for why the pt was admitted</li>
<li>Changes made to pt’s medications that you feel are important to
    highlight</li>
<li>Home instructions (daily weights, diet changes, wound care, etc)</li>
<li>Key follow-up plans (main appointments, labs, or tests)</li>
</ul>
</li>
<li>This section appears FIRST in the pt’s printed AVS</li>
</ul>
<h1 id="appendices-main-how-to-discharge-a-patient-at-va">How to Discharge a Patient at VA<a class="headerlink" href="#appendices-main-how-to-discharge-a-patient-at-va" title="Permanent link">&para;</a></h1>
<p>Complete the following steps in this order to ensure info will be
accurately reflected on the DIPN.</p>
<ul>
<li>Medication reconciliation<ul>
<li>The list of outpatient medications at the end of your reconciliation
    is the final medication discharge list.</li>
<li>In the medication tab, transfer new inpatient medications to the
    outpatient medication list by right-clicking and select ‘Transfer’</li>
<li>Select “Pick up at window,” as this will ensure the patient will
    have the medication prior to leaving the hospital</li>
<li>Order new supplies (wound care, tube feeds, etc) by placing new
    outpatient "med" order</li>
<li>Review the existing outpatient medications to determine if they need
    to be continued and if the pt has an adequate supply at home -
    refill meds if necessary</li>
<li>Discontinue any outpatient medications that you do not want the pt
    to continue taking. Right-click and select ‘Discontinue’</li>
</ul>
</li>
<li>Return to clinic (Primary care)</li>
<li>Critical to tag PCP on discharge summary to ensure they are alerted
    to hospital stay. Can also tag consultants and office coordinators
    (RNs) can be cc’d to DC summary by resident</li>
<li>For PCP follow-up, no longer need to place an RTC, will be
    coordinated by PACT on the clinic side</li>
<li>Ask VA Inpatient Chief for "welcome to VA wards" info with
    instructions to place subspecialty hospital follow up appts, as
    there is variation (page fellow vs e-consult vs RTC)</li>
<li>Complete DIPN<ul>
<li>The DIPN contains all of the discharge instructions</li>
<li>Start a new note and select ‘DIPN’ template. This will open a
    pre-templated note - follow the prompts and select finish. All
    sections need to be addressed to proceed.</li>
<li>Discharge related orders will generate after you finish the DIPN
    prompts, which includes vaccinations, removing IV, removing Foley
    catheter, etc.</li>
<li>The DIPN is valid for 24 hrs; thus the DIPN may be pre-signed one
    day prior. If DIPN is pre-signed, final changes to pt instructions
    and medications need to be addended.</li>
<li>[Optional but strongly recommended] Provide personal instructions
    to the patient at the top of the DIPN (coach your interns to do
    this!), such as:<ul>
<li>A simple statement for why the pt was admitted</li>
<li>Changes made to pt’s medications that you feel are important to
    highlight</li>
<li>Home instructions (daily weights, diet changes, wound care, etc)</li>
<li>Key follow-up plans (main appointments, labs, or tests)</li>
</ul>
</li>
</ul>
</li>
<li>Sign the DFF (discharge from facility) order<ul>
<li>The DFF order is found under the “Discharge Orders” tab in CPRS
    orders</li>
<li>Once all steps are completed, DFF can be signed and pt will be
    discharged from facility</li>
</ul>
</li>
<li>Discharge summary: right click dropdown menu "identify additional
    cosigner" ALWAYS add the patient's PCP, may add other consultants or
    subspecialists for continuity</li>
</ul>
<h1 id="appendices-main-vumc-and-va-door-codes-and-ultrasound-locations">VUMC and VA Door Codes and Ultrasound Locations<a class="headerlink" href="#appendices-main-vumc-and-va-door-codes-and-ultrasound-locations" title="Permanent link">&para;</a></h1>
<h2 id="appendices-main-vumc">VUMC<a class="headerlink" href="#appendices-main-vumc" title="Permanent link">&para;</a></h2>
<p>Resident Library – 431</p>
<p>Morgan Team Rooms – 24300</p>
<p>Brittingham – 0701#</p>
<p>Rogers Pulm – 2430</p>
<p>GME Lounge – 215</p>
<p>7MCE Conference Room – 4321</p>
<p>CHF Room – 145</p>
<p>CCU Resident Call Room – 1234#</p>
<p>CCU Supply Room for US – 512</p>
<p>MICU Resident Call Room – 2430</p>
<p>MICU Break Room – 4321</p>
<p>MICU Supply Room for US – 4321#</p>
<p>11N Supply Room – 123</p>
<p>8South Supply Room – 512</p>
<p>GME Resident Lounge (TVC, 2806) – 215</p>
<p>Many door entries at VUMC – 016 or 0160</p>
<h2 id="appendices-main-vumc-us-locations">VUMC US Locations<a class="headerlink" href="#appendices-main-vumc-us-locations" title="Permanent link">&para;</a></h2>
<p>8N behind RN station</p>
<p>8S, ask medical receptionist to sign out</p>
<p>6MCE behind RN station</p>
<p>Please don't take MICU or CCU ultrasounds off the units!</p>
<h2 id="appendices-main-va">VA<a class="headerlink" href="#appendices-main-va" title="Permanent link">&para;</a></h2>
<p>Team Rooms – 531</p>
<p>Richard Frances Conference Room – code is written above the door</p>
<p>VA Supply rooms – 541. VA MICU Supply Room – 541#</p>
<h2 id="appendices-main-va-ultrasound-location">VA Ultrasound Location<a class="headerlink" href="#appendices-main-va-ultrasound-location" title="Permanent link">&para;</a></h2>
<p>Internal Medicine office suite on 2G, in the hospitalist work room
(across hall from chief office) - the hospitalist on call can unlock if
needed. Please don't take MICU ultrasound off the unit!</p>
<h1 id="appendices-main-vumc-phone-and-pager-directory">VUMC Phone and Pager Directory<a class="headerlink" href="#appendices-main-vumc-phone-and-pager-directory" title="Permanent link">&para;</a></h1>
<p>From Ben Boone’s QI Project</p>
<hr />
<p>FedEx #: 2008-1658-7</p>
<h2 id="appendices-main-shorthand">Shorthand<a class="headerlink" href="#appendices-main-shorthand" title="Permanent link">&para;</a></h2>
<p>1xxxx – 615-421-xxxx</p>
<p>2xxxx – 615-322-xxxx</p>
<p>3xxxx – 615-343-xxxx</p>
<p>5xxxx – 615-875-xxxx</p>
<p>6xxxx – 615-936-xxxx</p>
<h2 id="appendices-main-labs">Labs<a class="headerlink" href="#appendices-main-labs" title="Permanent link">&para;</a></h2>
<p>Blood Bank – 22233</p>
<p>Cytology Lab – 22721</p>
<p>Flow Cytometry Lab – 39081</p>
<p>Hematology Lab – 39125</p>
<p>Hematology Smear Lab – 33905</p>
<p>Lab Operator – 55227</p>
<p>Microbiology Lab – 23406</p>
<h2 id="appendices-main-cardiology">Cardiology<a class="headerlink" href="#appendices-main-cardiology" title="Permanent link">&para;</a></h2>
<p>Cardiac Access Center – 33255</p>
<p>Cardiac MRI – 68111</p>
<p>Cath Lab – 34808</p>
<p>Echo Lab – 20624</p>
<p>Echo Reading Room – 60705</p>
<p>EP Lab – 35036</p>
<p>TEE – 67431</p>
<p>Telemetry – 65945</p>
<h2 id="appendices-main-units">Units<a class="headerlink" href="#appendices-main-units" title="Permanent link">&para;</a></h2>
<p>A Pod – 35914</p>
<p>B Pod – 27173</p>
<p>C Pod – 20116</p>
<p>G Pod – 50607</p>
<p>TCU – 34893</p>
<p>3 Round Wing – 25120</p>
<p>4 North – 22255</p>
<p>4 Round Wing – 22244</p>
<p>4 South – 32736</p>
<p>5 North – 35030</p>
<p>5 Round Wing – 23895</p>
<p>5 South – 24710</p>
<p>6 MCE – 20910</p>
<p>6 North – 32482</p>
<p>6 Round Wing – 28900</p>
<p>6 South – 22000</p>
<p>6 Tower – 35232</p>
<p>7 MCE - 56801</p>
<p>7 North – 20942</p>
<p>7 Round Wing – 35302</p>
<p>7 South – 32271</p>
<p>7 Tower – 20911</p>
<p>8 MCE – 53700</p>
<p>8 North – 20948</p>
<p>8 South – 20946</p>
<p>8 Tower – 20938</p>
<p>9 North – 20918</p>
<p>9 South – 20916</p>
<p>9 Tower – 20988</p>
<p>10 North – 30398</p>
<p>10 South – 28920</p>
<p>10 Tower – 24545</p>
<p>11 North – 55333</p>
<p>11 South – 24590</p>
<h2 id="appendices-main-radiology">Radiology<a class="headerlink" href="#appendices-main-radiology" title="Permanent link">&para;</a></h2>
<p>Body Reading Room – 26011</p>
<p>Chest Reading Room – 28485</p>
<p>CT Scanner A Pod – 36055</p>
<p>CT Tech – 38074</p>
<p>CTA Reading Room – 32162</p>
<p>ED Reading Room – 37185</p>
<p>Fluoroscopy Reading Room – 30951</p>
<p>Fluoroscopy Tech – 20878</p>
<p>IR Reading Room – 20840</p>
<p>MRI Tech – 34557</p>
<p>Nuclear Med Reading Room – 31577</p>
<p>Nuclear Med Tech – 20893</p>
<p>Neuroradiology Reading Room – 30900</p>
<p>PET Reading Room – 37523</p>
<p>Radiology Library – 20866</p>
<p>Ultrasound Reading Room – 20853</p>
<p>Ultrasound Tech – 34970</p>
<p>Vascular Lab – 39205</p>
<p>X-ray Tech ED – 28804</p>
<p>X-ray Tech Floor Pager – 615-835-5647</p>
<p>X-ray Tech Tower Pager – 615-835-5597</p>
<h2 id="appendices-main-miscellaneous">Miscellaneous<a class="headerlink" href="#appendices-main-miscellaneous" title="Permanent link">&para;</a></h2>
<p>Admitting – 30179</p>
<p>Anesthesia STAT Phone – 615-887-7369</p>
<p>Bed Management (Option 5) – 54000</p>
<p>Bronchoscopy Lab – 39647</p>
<p>Dialysis – 20912</p>
<p>EEG Tech Pager – 615-835-8847</p>
<p>GI Lab – 39716</p>
<p>Inpatient Pharmacy – 56337</p>
<p>Language Line – (866) 874-3972 (218443)</p>
<p>Meds to Beds / Discharge Pharmacy – 20804</p>
<p>Nutrition Services – 39761</p>
<p>PICC Service – 22772</p>
<p>Resident Library – 56205</p>
<p>Service Center – 39600</p>
<p>The MAC – 615-540-4213</p>
<p>Transfer Center (Option 4) – 54000</p>
<p>Vanderbilt Operator – 615-322-5000 or 0</p>
<h2 id="appendices-main-vanderbilt-inpatient-team-pagers">Vanderbilt Inpatient Team Pagers<a class="headerlink" href="#appendices-main-vanderbilt-inpatient-team-pagers" title="Permanent link">&para;</a></h2>
<p>Brittingham (Heme) 1: 831-4785</p>
<p>Brittingham (Heme) 2: 831-4788</p>
<p>CHF-A: 831-6485</p>
<p>CHF-B: 831-6486</p>
<p>Harrison 1: 831-4769</p>
<p>Harrison 2: 831-4770</p>
<p>Morgan 1: 831-4765</p>
<p>Morgan 2: 831-4766</p>
<p>Morgan 3: 831-4767</p>
<p>Morgan 4: 831-4768</p>
<p>Morgan 5: 831-8481</p>
<p>Morgan 6: 831-4781</p>
<p>Oncology A: 831-4786</p>
<p>Oncology B: 831-4787</p>
<p>Rogers Hepatology: 831-4782</p>
<p>Rogers ID: 831-4779</p>
<p>Rogers Pulmonary: 831-4777</p>
<p>Rogers Renal: 831-4783</p>
<p>MICU 1 Intern Pager: 831-4759</p>
<p>MICU 2 Intern Pager: 831-4757</p>
<p>CCU Pager: 831-6487</p>
<p>Chief-On-Call Pager: 831-6489</p>
<h2 id="appendices-main-neurology-pagers">Neurology Pagers<a class="headerlink" href="#appendices-main-neurology-pagers" title="Permanent link">&para;</a></h2>
<p>831-4790 – Page this to discuss a patient admitted to the neurology
general service</p>
<p>831-4792 – Page this to discuss a patient admitted to the neurology
stroke service</p>
<p>835-5137 – Page this for any neurology issues/questions at the Nashville
VA</p>
<p>831-4793 – Page this to for any other neurology question (When in doubt,
page this #)</p>
<p>VA Phone and Pager Directory</p>
<h2 id="appendices-main-administrative-numbers">Administrative Numbers<a class="headerlink" href="#appendices-main-administrative-numbers" title="Permanent link">&para;</a></h2>
<p>AOD: 67010</p>
<p>NOD: 615-456-0362</p>
<p>Flow coordinator: 615-712-5316</p>
<p>Transfer coordinator: 22516 (6:30a-4:45p), 615-225-4725</p>
<p>IT Help Desk: 26500, 615-225-6500; local IT = 1-855-673-4357</p>
<h2 id="appendices-main-va-triageer">VA Triage/ER<a class="headerlink" href="#appendices-main-va-triageer" title="Permanent link">&para;</a></h2>
<p>MD areas: 67990/ 66892/ 67173/ 68192/ 68199</p>
<h2 id="appendices-main-resident-team-work-rooms">Resident Team Work Rooms<a class="headerlink" href="#appendices-main-resident-team-work-rooms" title="Permanent link">&para;</a></h2>
<p>Team 1: 68628/ 67147/ 66091</p>
<p>Team 2: 67146/ 68128/ 66090</p>
<p>Team 3: 66088/ 66089/ 66087</p>
<p>Team 4: 67662/ 68637/ 66081</p>
<p>Team 5: 66826/ 68427/ 66563</p>
<p>Team 6 (2G ID/Pulm Room): 68687/ 67115/ 68696/ 68167</p>
<p>BMT: 67976, 67977</p>
<p>MICU/CCU: 67599</p>
<h2 id="appendices-main-hospital-unit-ward-clerks">Hospital Unit Ward Clerks<a class="headerlink" href="#appendices-main-hospital-unit-ward-clerks" title="Permanent link">&para;</a></h2>
<p>Vocera: 66480</p>
<p>2N: 68030</p>
<p>3N: 68040</p>
<p>2G: 68010</p>
<p>MICU/CCU: 67470</p>
<p>SICU: 67930</p>
<p>PACU: 67746, 67747</p>
<p>Dialysis: 66860, 68132</p>
<p>VA triage charge RN: 66849, 67990</p>
<p>2N Fax: 615-873-8021</p>
<p>3N Fax: 615-873-8051</p>
<p>MICU Fax: 615-873-8161</p>
<h2 id="appendices-main-va-consult-team-numbers-p-pager">VA Consult Team Numbers: (p= pager)<a class="headerlink" href="#appendices-main-va-consult-team-numbers-p-pager" title="Permanent link">&para;</a></h2>
<p>Addiction Tx Services (ATS): Angela Burcham (p) 317-1751, x26363; alt
(p) 317-1359, x67870</p>
<p>Anesthesia Service (p): 615-317-3222</p>
<p>Cardiac Surgery: look on VA website; OR Bo Mistak NP (p): 831-4101,
Sherry PA (p): 317-4192</p>
<p>Cardiology (p): 317-0520</p>
<p>Dermatology (p): 317-1683 (days) or 835-8620 (nights)</p>
<p>Endocrine (p): 835-5232</p>
<p>ENT: look on VA website</p>
<p>GI (p): 831-4711</p>
<p>Geriatrics (p): 317-1282, 317-3046</p>
<p>General Surgery (p): 835-7338</p>
<p>Hepatology transplant (Dr. Awad's pager): 835-4967</p>
<p>IR: 68552 (call 1<sup>st</sup> before placing orders)</p>
<p>Nephrology (p): 835-9945</p>
<p>Neurology (p): 835-5137</p>
<p>Neurosurgery: look on VA website</p>
<p>Ophthalmology: call eye clinic 67279 (7a-5p): Night/weekend ONLY (p):
831-4433</p>
<p>Oral Surgery (p): 317-0571</p>
<p>Orthopedic Surgery: look on VA website</p>
<p>Palliative Care (p): 317-3040</p>
<p>Podiatry: 68425 (RN, 1<sup>st</sup> call)</p>
<p>Plastic Surgery: look on VA website</p>
<p>Psychiatry (p): 317-1506 (1<sup>st</sup> call); Emergencies/2<sup>nd</sup> call: 615-476-9004
or 615-476-1341</p>
<p>Thoracic Surgery: look on VA website, or page Pinkerman NP (p): 317-3138</p>
<p>Urologic Surgery (p): 831-8038</p>
<p>Vascular Surgery (p): 835-7358</p>
<h2 id="appendices-main-other-va-services">Other VA Services<a class="headerlink" href="#appendices-main-other-va-services" title="Permanent link">&para;</a></h2>
<p>Anti-coagulation Clinic: 66772</p>
<p>Audiology Clinic (same as outpatient SLP): 67310</p>
<p>Blood Bank: 67025 (supervisor at 67029)</p>
<p>Cardiology Services</p>
<ul>
<li>Cath lab: 68057, 68283, 68325, 68358</li>
<li>Echo: 67982 (66705 for reading room)</li>
<li>Heart station (including EKG’s): 67370/ 66025</li>
<li>Stress test results: 66811 (nuc med reading room)</li>
<li>Stress test lab: 67982</li>
</ul>
<p>Chaplain: 66983</p>
<p>Community Health: Patricia Elliott 615-225-3799, Myra Golden
615-225-3802</p>
<p>Dental Clinic: 67120</p>
<p>Derm Clinic: 67130</p>
<p>Diabetes Educator: 67518, (p) 317-3210</p>
<p>Dietary: 66996</p>
<p>EMG: 67450</p>
<p>EEG: 67300</p>
<p>GI lab: 67240</p>
<p>Housekeeping/Environmental Services: 67198, 68689</p>
<p>Home Oxygen: 68402</p>
<p>Infection Control: 66759</p>
<p>Infusion Clinic: 67318</p>
<p>Lab:</p>
<ul>
<li>Chemistry: 67004</li>
<li>Hematology/Serology/Coag/Urine: 67045, 66948</li>
<li>Microbiology: 67049, 67051 (supervisor at 66982)</li>
<li>Specimen processing: 66975</li>
<li>Cytology: 67062, 67063</li>
<li>Surgical pathology: 67064</li>
<li>Hematopathology: 68588</li>
</ul>
<p>Logistics: 68747/ 68748</p>
<p>Medical Records: 67830</p>
<p>Nutrition Consult:</p>
<ul>
<li>2N, MICU: 66730</li>
<li>3N, SICU: 67471</li>
<li>2G, PCU: 67613</li>
</ul>
<p>Occupational Therapy, Inpatient: 67560</p>
<p>Pain Clinic: 67003</p>
<p>Palliative: 66773 or (p) 428-7832</p>
<p>Phlebotomy: 67397</p>
<p>Pharmacy</p>
<ul>
<li>Inpatient: 67660</li>
<li>Outpatient: 67680</li>
<li>Discharge: 66093</li>
<li>2N med rec room: 66093</li>
<li>3N med rec room: 68223</li>
</ul>
<p>Physical Therapy (inpatient): 67690</p>
<p>PICC (3<sup>rd</sup> party ePICC): alert charge RN PICC order placed; NOD calls
PICC company to place it 24/7</p>
<p>Police: 67740</p>
<p>Prosthetics: 67770, 67760</p>
<p>Pulmonary Function Tests (PFT): 67780, 67310 or weekdays (9A-3P)
636-675-3060</p>
<p>Radiology</p>
<ul>
<li>Main line: 67810 (call here to be directed to radiology reading
rooms); 68811</li>
<li>Angio/IR: 68552</li>
<li>Fluoro: 67271</li>
<li>XR: 67810</li>
<li>CT: 67007, 68449</li>
<li>MRI: 66366</li>
<li>Nuclear Medicine: 67550, 66813</li>
<li>PET: 67615</li>
<li>Ultrasound: 67550</li>
<li>VetMED (after hours reads): 1-844-VMG-RADS (864-7237) or 646-827-9492</li>
</ul>
<p>Respiratory Therapy</p>
<ul>
<li>
<p>Wards: 615-651-3939 (supervisor at 651-3583)</p>
</li>
<li>
<p>MICU: 615-651-9923</p>
</li>
</ul>
<p>Social work: varies per team (weekday); Deb Flowers 615-289-3722
(weekend)</p>
<p>Speech pathology: 67193 (back room), 67970 (clinic front desk)</p>
<p>Telemetry: 67377</p>
<p>TPN: 67164</p>
<p>Wound Care: 66126, or call general surgery</p>
<h2 id="appendices-main-nashville-va-team-pager-numbers">Nashville VA Team Pager Numbers<a class="headerlink" href="#appendices-main-nashville-va-team-pager-numbers" title="Permanent link">&para;</a></h2>
<p>Team 1 Resident: 317-1303</p>
<p>Team 1 Intern A: 317-1201</p>
<p>Team 1 Intern B: 317-1205</p>
<p>Team 2 Resident: 317-1245</p>
<p>Team 2 Intern A: 317-1207</p>
<p>Team 2 Intern B: 317-1209</p>
<p>Team 3 Resident: 317-1304</p>
<p>Team 3 Intern A: 317-1213</p>
<p>Team 3 Intern B: 317-1206</p>
<p>Team 4 Resident: 317-1307</p>
<p>Team 4 Intern A: 317-1225</p>
<p>Team 4 Intern B: 317-1226</p>
<p>Team 5 Resident: 317-1261</p>
<p>Team 5 Intern A: 317-1216</p>
<p>Team 5 Intern B: 317-1144</p>
<p>Team 6 Resident: 317-1210</p>
<p>Team 6 Intern A: 317-1223</p>
<p>Team 6 Intern B: 317-1150</p>
<p>Night Admit Resident: 317-0227</p>
<p>BMT Resident: 317-0144</p></section><h1 class='nav-section-title-end'>Ended: Appendices</h1></div>

              
            </article>
            
          </div>
        </div>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
    <div class="md-copyright__highlight">
      Copyright &copy; 2022 Vanderbilt University Medical Center <br>
Vanderbilt University Medical Center is committed to principles of equal opportunity and affirmative action. <br>
EOE/AA/Women/Minority/Vets/Disabled <br>

    </div>
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    <script id="__config" type="application/json">{"base": "/", "features": ["search.suggest", "search.highlight", "search.share"], "search": "../assets/javascripts/workers/search.85cb4492.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.config.lang": "en", "search.config.pipeline": "trimmer, stopWordFilter", "search.config.separator": "[\\s\\-]+", "search.placeholder": "Search", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version.title": "Select version"}}</script>
    
    
      <script src="../assets/javascripts/bundle.a877e258.min.js"></script>
      
        <script src="../js/print-site.js"></script>
      
    
  </body>
</html>